FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yu, SE
   Park, SH
   Jang, YK
AF Yu, Seung Eun
   Park, Su Hyung
   Jang, Yeun Kyu
TI Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during
   progression to breast cancer
SO MOLECULES AND CELLS
LA English
DT Article
DE co-stimulatory molecules; DNA methylation; epigenetic silencing;
   isogenic human breast cancer cell lines; TNFSF7(CD70)
ID MCF10 MODEL; CELL-LINES; T-CELL; EXPRESSION; GENE; APOPTOSIS;
   5-AZA-2'-DEOXYCYTIDINE; TRANSFORMATION; ACTIVATION; INDUCTION
AB To escape the immune system, tumor cells may remove surface molecules such as the major histocompatibility complex (MHC) and co-stimulatory molecules, which are essential for recognition by lymphocytes. Down-regulation of the co-stimulatory molecules CD70 (TNFSF7) and CD80 may contribute to tumor cell survival; however, the mechanism of down-regulation of the TNFSF7 gene during tumorigenesis is poorly understood. Here we present evidence indicating that TNFSF7 gene expression is epigenetically down-regulated via DNA hypermethylation within its promoter region during progression in breast cancer cells in the isogenic MCF10 model. Bisulfite sequencing revealed that the CpG pairs at the proximal region of the TNFSF7 promoter are heavily methylated during progression of breast cancer cells but that methylation of the more distal sequences was not changed considerably. Thus, this epigenetic silencing of the TNFSF7 gene via hypermethylation of its proximal region may allow the benign and invasive MCF10 variants to escape immune surveillance.
C1 [Yu, Seung Eun; Park, Su Hyung; Jang, Yeun Kyu] Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea.
   [Yu, Seung Eun; Park, Su Hyung; Jang, Yeun Kyu] Yonsei Univ, Yonsei Biomol Res Initiat, Seoul 120749, South Korea.
C3 Yonsei University; Yonsei University
RP Jang, YK (通讯作者)，Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea.
EM ykjang@yonsei.ac.kr
RI Yu, Seung Eun/AER-8889-2022
OI Yu, Seung Eun/0000-0002-9690-8739
FU Korea Food and Drug Administration in 2009 [09162KFDA565]
FX We thank Fred Miller and S. J. Santner for providing human breast cell
   lines kindly. This work was supported by a grant (09162KFDA565) from
   Korea Food and Drug Administration in 2009.
CR Baylin S.B., 2007, Epigenetics, P457
   Borst J, 2005, CURR OPIN IMMUNOL, V17, P275, DOI 10.1016/j.coi.2005.04.004
   Choi B, 2007, EXP MOL MED, V39, P796, DOI 10.1038/emm.2007.86
   Cormary C, 2004, CANCER GENE THER, V11, P497, DOI 10.1038/sj.cgt.7700708
   Diegmann J, 2006, NEOPLASIA, V8, P933, DOI 10.1593/neo.06451
   Douin-Echinard V, 2003, INT IMMUNOL, V15, P359, DOI 10.1093/intimm/dxg038
   Douin-Echinard V, 2000, CANCER GENE THER, V7, P1543, DOI 10.1038/sj.cgt.7700268
   Huang YH, 2002, CANCER RES, V62, P2913
   Hurst DR, 2009, CLIN EXP METASTAS, V26, P89, DOI 10.1007/s10585-008-9216-9
   Kim JH, 2005, MOL CELLS, V19, P279
   Lu QJ, 2005, J IMMUNOL, V174, P6212, DOI 10.4049/jimmunol.174.10.6212
   Marella NV, 2009, CANCER RES, V69, P5946, DOI 10.1158/0008-5472.CAN-09-0420
   Motegi K, 2005, LAB INVEST, V85, P342, DOI 10.1038/labinvest.3700234
   Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525
   Park HY, 2007, EXP MOL MED, V39, P195, DOI 10.1038/emm.2007.22
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   Rhee DK, 2008, GENOMICS, V92, P419, DOI 10.1016/j.ygeno.2008.08.005
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Song JH, 2006, LIFE SCI, V79, P193, DOI 10.1016/j.lfs.2005.12.054
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Zhu JQ, 2008, MOL CELLS, V25, P211
NR 23
TC 20
Z9 21
U1 0
U2 7
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD FEB
PY 2010
VL 29
IS 2
BP 217
EP 221
DI 10.1007/s10059-010-0052-9
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 563IW
UT WOS:000275123100015
PM 20119871
OA hybrid
DA 2025-01-12
ER

PT J
AU Paluszczak, J
   Krajka-Kuzniak, V
   Baer-Dubowska, W
AF Paluszczak, Jaroslaw
   Krajka-Kuzniak, Violetta
   Baer-Dubowska, Wanda
TI The effect of dietary polyphenols on the epigenetic regulation of gene
   expression in MCF7 breast cancer cells
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Chemoprevention; DNA methylation; Epigenetics; Histone methylation;
   Polyphenols
ID CATECHOL-O-METHYLTRANSFERASE; DNA METHYLATION; INHIBITION; GENISTEIN;
   HYPERMETHYLATION; LOCALIZATION; MODULATION
AB The CpG island methylator phenotype is characterized by DNA hypermethylation in the promoters of several suppressor genes associated with the inactivation of various pathways involved in tumorigenesis. DNA methylation is catalyzed by specific DNA methyltransferases (DNMTs). Dietary phytochemicals particularly catechol-containing polyphenols were shown to inhibit these enzymes and reactivate epigenetically silenced genes.
   The aim of this study was to evaluate the effect of a wide range of dietary phytochemicals on the activity and expression of DNMTs in human breast cancer MCF7 cell line and their effect on DNA and histone H3 methylation. All phytochemicals inhibited the DNA methyltransferase activity with betanin being the weakest while rosmarinic and ellagic acids were the most potent modulators (up to 88% inhibition). While decitabine led to a partial demethylation and reactivation of the genes, none of the tested phytochemicals affected the methylation pattern or the expression of RASSF1A, GSTP1 or HIN1 in MCF7 cells. The global methylation of histone H3 was not affected by any of the tested phytochemicals or decitabine. The results of our study may suggest that non-nucleoside agents are not likely to be effective epigenetic modulators, in our experimental model at least. However, a long-term exposure to these chemicals in diet might potentially lead to an effect, which can be sufficient for cancer chemoprevention. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Paluszczak, Jaroslaw; Krajka-Kuzniak, Violetta; Baer-Dubowska, Wanda] Poznan Univ Med Sci, Dept Pharmaceut Biochem, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences
RP Baer-Dubowska, W (通讯作者)，Poznan Univ Med Sci, Dept Pharmaceut Biochem, Ul Swiecickiego 4, PL-60781 Poznan, Poland.
EM baerw@ump.edu.pl
RI Baer-Dubowska, Wanda/AGN-3671-2022; Paluszczak, Jaroslaw/IZE-4347-2023
OI Paluszczak, Jaroslaw/0000-0002-6187-7549; Baer-Dubowska,
   Wanda/0000-0002-6625-5343; Krajka-Kuzniak, Violetta/0000-0001-7275-0298
FU Polish Ministry of Science and Higher Education [N405 048 31/3338]
FX This research was supported by the Polish Ministry of Science and Higher
   Education (grant No. N405 048 31/3338).
CR Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baer-Dubowska W, 1998, XENOBIOTICA, V28, P735, DOI 10.1080/004982598239155
   Balch C, 2007, BIOESSAYS, V29, P842, DOI 10.1002/bies.20619
   Byun HM, 2008, CANCER LETT, V266, P238, DOI 10.1016/j.canlet.2008.02.069
   Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172
   CIU Y, 2008, LIFE SCI, V82, P247
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fini L, 2007, J NUTR, V137, P2622, DOI 10.1093/jn/137.12.2622
   Heeres JT, 2007, CURR OPIN CHEM BIOL, V11, P644, DOI 10.1016/j.cbpa.2007.08.038
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109
   Krop I, 2004, MOL CANCER RES, V2, P489
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124/jpet.108.147934
   LOWRY OH, 1951, J BIOL CHEM, V193, P230
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Ulmanen I, 1997, EUR J BIOCHEM, V243, P452, DOI 10.1111/j.1432-1033.1997.0452a.x
   Valinluck V, 2007, CANCER RES, V67, P5583, DOI 10.1158/0008-5472.CAN-07-0846
   Weisz J, 2000, AM J PATHOL, V156, P1841, DOI 10.1016/S0002-9440(10)65057-2
NR 29
TC 153
Z9 168
U1 0
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD FEB 1
PY 2010
VL 192
IS 2
BP 119
EP 125
DI 10.1016/j.toxlet.2009.10.010
PG 7
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 558LH
UT WOS:000274743300007
PM 19840838
DA 2025-01-12
ER

PT J
AU Ramos, EAS
   Camargo, AA
   Braun, K
   Slowik, R
   Cavalli, IJ
   Ribeiro, EMSF
   Pedrosa, FD
   de Souza, EM
   Costa, FF
   Klassen, G
AF Ramos, Edneia A. S.
   Camargo, Anamaria A.
   Braun, Karin
   Slowik, Renata
   Cavalli, Iglenir J.
   Ribeiro, Enilze M. S. F.
   Pedrosa, Fabio de O.
   de Souza, Emanuel M.
   Costa, Fabricio F.
   Klassen, Giseli
TI Simultaneous <i>CXCL12</i> and <i>ESR1</i> CpG island hypermethylation
   correlates with poor prognosis in sporadic breast cancer
SO BMC CANCER
LA English
DT Article
ID DNA HYPERMETHYLATION; ER-ALPHA; ESTROGEN; METHYLATION; EXPRESSION
AB Background: CXCL12 is a chemokine that is constitutively expressed in many organs and tissues. CXCL12 promoter hypermethylation has been detected in primary breast tumours and contributes to their metastatic potential. It has been shown that the oestrogen receptor alpha (ESR1) gene can also be silenced by DNA methylation. In this study, we used methylation-specific PCR (MSP) to analyse the methylation status in two regions of the CXCL12 promoter and ESR1 in tumour cell lines and in primary breast tumour samples, and correlated our results with clinicopathological data.
   Methods: First, we analysed CXCL12 expression in breast tumour cell lines by RT-PCR. We also used 5-aza-2'-deoxycytidine (5-aza-CdR) treatment and DNA bisulphite sequencing to study the promoter methylation for a specific region of CXCL12 in breast tumour cell lines. We evaluated CXCL12 and ESR1 methylation in primary tumour samples by methylation-specific PCR (MSP). Finally, promoter hypermethylation of these genes was analysed using Fisher's exact test and correlated with clinicopathological data using the Chi square test, Kaplan-Meier survival analysis and Cox regression analysis.
   Results: CXCL12 promoter hypermethylation in the first region ( island 2) and second region ( island 4) was correlated with lack of expression of the gene in tumour cell lines. In the primary tumours, island 2 was hypermethylated in 14.5% of the samples and island 4 was hypermethylated in 54% of the samples. The ESR1 promoter was hypermethylated in 41% of breast tumour samples. In addition, the levels of ER alpha protein expression diminished with increased frequency of ESR1 methylation (p < 0.0001). This study also demonstrated that CXCL12 island 4 and ESR1 methylation occur simultaneously at a high frequency (p = 0.0220).
   Conclusions: This is the first study showing a simultaneous involvement of epigenetic regulation for both CXCL12 and ESR1 genes in Brazilian women. The methylation status of both genes was significantly correlated with histologically advanced disease, the presence of metastases and death. Therefore, the methylation pattern of these genes could be used as a molecular marker for the prediction of breast cancer outcome.
C1 [Ramos, Edneia A. S.; Braun, Karin; Slowik, Renata; Klassen, Giseli] Univ Fed Parana, Dept Basic Pathol, BR-80060000 Curitiba, Parana, Brazil.
   [Camargo, Anamaria A.] Ludwig Inst Canc Res, Lab Mol Biol & Genom, Sao Paulo, Brazil.
   [Cavalli, Iglenir J.; Ribeiro, Enilze M. S. F.] Univ Fed Parana, Dept Genet, BR-80060000 Curitiba, Parana, Brazil.
   [Pedrosa, Fabio de O.; de Souza, Emanuel M.] Univ Fed Parana, Dept Biochem & Mol Biol, BR-80060000 Curitiba, Parana, Brazil.
   [Costa, Fabricio F.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Costa, Fabricio F.] Childrens Mem Res Ctr, Canc Biol & Epigenom Program, Chicago, IL USA.
C3 Universidade Federal do Parana; Ludwig Institute for Cancer Research;
   Universidade Federal do Parana; Universidade Federal do Parana;
   Northwestern University; Feinberg School of Medicine
RP Klassen, G (通讯作者)，Univ Fed Parana, Dept Basic Pathol, BR-80060000 Curitiba, Parana, Brazil.
EM giseli@ufpr.br
RI Braun-Prado, Karin/C-4282-2014; Ribeiro, Enilze/K-7319-2012; Cavalieri,
   Edneia/Q-9636-2019; Costa, Fabricio/M-5309-2017; Pedrosa,
   Fabio/C-1938-2013; Klassen, Giseli/F-8753-2012; Aranha Camargo,
   Anamaria/E-9388-2012; Souza, Emanuel/C-1920-2013
OI Klassen, Giseli/0000-0001-5336-6178; Aranha Camargo,
   Anamaria/0000-0002-6076-9597; braun prado, Karin/0000-0002-9652-0566;
   ASR Cavalieri, Edneia/0000-0002-8855-5988; Souza,
   Emanuel/0000-0003-1546-9218
FU Brazilian Research Council (CNPq); CAPES; Maeve McNicholas Memorial
   Foundation
FX We thank Roseli Prado, Valter Baura and Julieta Pie for technical
   assistance. Thanks also to Dr. Rubens Silveira de Lima for providing
   patient material and clinicopathological data. This work was supported
   by the Brazilian Research Council (CNPq) and CAPES. FFC is supported by
   the Maeve McNicholas Memorial Foundation.
CR Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Costa FF, 2006, CANCER GENET CYTOGEN, V165, P135, DOI 10.1016/j.cancergencyto.2005.07.023
   Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002
   García-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008
   Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438
   Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742-4658.2006.05343.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kishimoto H, 2005, CARCINOGENESIS, V26, P1706, DOI 10.1093/carcin/bgi137
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   SAMBROOK J, 1995, GENOMICS, V28, P495
   Senior K, 2009, LANCET INFECT DIS, V9, P80, DOI 10.1016/S1473-3099(09)70008-8
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616
   Veronesi U, 2006, BREAST, V15, P3, DOI 10.1016/j.breast.2005.11.011
   Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhao L, 2008, BREAST CANC RES TREA
   Zhou W, 2009, J CANCER RES CLIN, V135, P91, DOI 10.1007/s00432-008-0435-x
NR 34
TC 55
Z9 59
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 28
PY 2010
VL 10
AR 23
DI 10.1186/1471-2407-10-23
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 569BJ
UT WOS:000275570600001
PM 20109227
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Galluzzi, L
   Morselli, E
   Kepp, O
   Maiuri, MC
   Kroemer, G
AF Galluzzi, Lorenzo
   Morselli, Eugenia
   Kepp, Oliver
   Maiuri, Maria Chiara
   Kroemer, Guido
TI Defective autophagy control by the p53 rheostat in cancer
SO CELL CYCLE
LA English
DT Article
DE Bax; BH3-only proteins; DRAM; PI3K; TSC; TIGAR
ID MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; WILD-TYPE P53; BCL-X-L; NUCLEAR
   EXCLUSION; CELL-DEATH; BREAST-CANCER; TARGET GENES; BECLIN 1; APOPTOSIS;
   MDM2
AB Autophagy is a finely regulated, lysosomal catabolic pathway that contributes to the turnover of long-lived proteins and to the elimination of old/ damaged organelles. Autophagy exerts bona fide oncosuppressive functions by: (1) limiting chromosomal instability; (2) reducing potentially mutagenic oxidative stress; and (3) restraining intratumoral necrosis and local inflammation. Defective autophagy constitutes a hallmark of cancer cells together with: (1) provision of autonomous growth signals;, (2) insensitivity to antiproliferative stimuli; (3) disabled apoptosis; (4) limitless replication; (5) production of angiogenic factors; (6) tissue invasion with metastasis; (7) avoidance of the immune response; and (8) enhanced anabolism. p53 is the best-known human oncosuppressor protein, and its genetic/epigenetic inactivation has been observed in more than 50% of all human cancers. p53 mostly mediates tumor suppression by transactivating pro-apoptotic and cell cycle arresting genes, but also by favoring mitochondrial apoptosis in a transcription-independent fashion, by modulating metabolic circuitries and by regulating autophagy. p53 mutations (or epigenetic changes) that simultaneously abolish its pro-apoptotic and autophagy-inhibitory functions behave as "multi-hit" events, as opposed to "single-hit" mutations that only affect the classical (pro-apoptotic and/or cell cycle-arresting) functions of the p53 system. We speculate that, in this latter case, additional genetic/epigenetic events resulting in disabled autophagy are likely to contribute to accelerated oncogenesis.
C1 [Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France.
   Univ Paris 11, Villejuif, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UNICANCER; Gustave Roussy; Universite Paris Saclay
RP Kroemer, G (通讯作者)，Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France.
EM kroemer@orange.fr
RI Moruno-Manchon, Jose Felix/AAC-5958-2022; Galluzzi,
   Lorenzo/AAG-6432-2019; Kroemer, Guido/B-4263-2013; Kepp,
   Oliver/N-2763-2017
OI Kroemer, Guido/0000-0002-9334-4405; Morselli,
   Eugenia/0000-0002-7840-8351; Kepp, Oliver/0000-0002-6081-9558
FU Ligue Nationale contre le Cancer (Equipe labellisee); Agence Nationale
   pour la Recherche (ANR); European Commission; ApoSys; ChemoRes;
   ApopTrain; Fondation pour la Recherche Medicale (FRM); Institut National
   du Cancer (INCa); Cancerople Ile-de-France; European Union; EMBO
FX G. K. is supported by the Ligue Nationale contre le Cancer (Equipe
   labellisee), Agence Nationale pour la Recherche (ANR), European
   Commission (ApoSys, ChemoRes, ApopTrain, Active p53), Fondation pour la
   Recherche Medicale (FRM), Institut National du Cancer (INCa) and
   Cancerople Ile-de-France. L. G. is supported by the Apo-Sys consortium
   of the European Union. E. M. is funded by a Ph.D. student grant from
   ApopTrain. O.K. receives a post-doctoral fellowship from EMBO.
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   Ahmed M, 2006, ONCOGENE, V25, P5906, DOI 10.1038/sj.onc.1209873
   Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251
   Bensaad K., 2009, EMBO J
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Christoph F, 2007, CANCER LETT, V247, P137, DOI 10.1016/j.canlet.2006.03.028
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   Galluzzi L, 2008, CELL CYCLE, V7, P1949, DOI 10.4161/cc.7.13.6222
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221
   Harrison B, 2008, J BIOL CHEM, V283, P9999, DOI 10.1074/jbc.M706040200
   Hurt EM, 2006, CANCER BIOL THER, V5, P1154, DOI 10.4161/cbt.5.9.3001
   Iwakuma T, 2003, MOL CANCER RES, V1, P993
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li H, 2009, J BIOL CHEM, V284, P1748, DOI 10.1074/jbc.M807821200
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   MAIURI MC, 2009, CURR OPIN C IN PRESS
   Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007
   MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407
   MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262
   MORSELLI E, 2009, BIOCH BIOPHYS ACTA
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Morselli E, 2008, CELL RES, V18, P708, DOI 10.1038/cr.2008.77
   Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200
   Onel K, 2004, MOL CANCER RES, V2, P1
   Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135
   Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141
   Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530
   Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X
   Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280
   Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Teodoro JG, 2006, SCIENCE, V313, P968, DOI 10.1126/science.1126391
   Vahteristo P, 2001, CANCER RES, V61, P5718
   Valgañón M, 2005, BRIT J HAEMATOL, V129, P53, DOI 10.1111/j.1365-2141.2005.05405.x
   Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715
   WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   ZHANG XD, 2009, AUTOPHAGY, P5
NR 73
TC 34
Z9 38
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD JAN 15
PY 2010
VL 9
IS 2
BP 250
EP 255
DI 10.4161/cc.9.2.10493
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 550PG
UT WOS:000274139800020
PM 20023384
OA Bronze
DA 2025-01-12
ER

PT J
AU Fortunati, N
   Bertino, S
   Costantino, L
   De Bortoli, M
   Compagnone, A
   Bandino, A
   Catalano, MG
   Boccuzzi, G
AF Fortunati, N.
   Bertino, S.
   Costantino, L.
   De Bortoli, M.
   Compagnone, A.
   Bandino, A.
   Catalano, M. G.
   Boccuzzi, G.
TI Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative
   breast cancer cells
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Breast cancer; ER alpha; HD1; VPA; Antiestrogen
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITION; LUMINAL
   SUBTYPE; GENE-EXPRESSION; FOXA1; TAMOXIFEN; REVEALS; TARGET;
   TRANSCRIPTION; METHYLATION
AB Histone deacetylase inhibitors (HDIs) are valuable drugs in breast cancer where estrogen receptor a (ER alpha) can be silenced by epigenetic modifications. We report the effect of the clinically available HDI, valproic acid (VPA), on ER alpha expression and function in ER-negative breast cancer cells, MDA-MB-231. VPA induced ER(x mRNA and protein, while did not modify ER beta. In VPA-treated cells, we also observed: (1) a correct transcriptional response to estradiol after transfection with the luciferase gene under the control of an estrogen-responsive minimal promoter (ERE-TKluc); (2) increased expression of the ER-related transcription factor FoxA1; (3) estradiol-induced up-regulation of several estrogen-regulated genes (e.g. pS2, progesterone receptor); (4) inhibitory effect of tamoxifen on cell growth. In conclusion, the HDI VPA, inducing ER alpha and FoxA1, confers to MDA-MB 231 cells an estrogen-sensitive "phenotype", restoring their sensitivity to antiestrogen therapy. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Bertino, S.; Costantino, L.; Catalano, M. G.; Boccuzzi, G.] Univ Turin, Dept Clin Physiopathol, I-10126 Turin, Italy.
   [Fortunati, N.; Boccuzzi, G.] AUO San Giovanni Battista, Turin, Italy.
   [De Bortoli, M.] Univ Turin, Dept Oncol Sci, I-10126 Turin, Italy.
   [De Bortoli, M.] Univ Turin, Ctr Complex Syst Mol Biol & Med, I-10126 Turin, Italy.
   [Compagnone, A.; Bandino, A.] Univ Turin, Dept Expt Med & Oncol, Biochem Sect, I-10126 Turin, Italy.
C3 University of Turin; A.O.U. Citta della Salute e della Scienza di
   Torino; AOU San Giovanni Battista-Molinette; University of Turin;
   University of Turin; University of Turin
RP Boccuzzi, G (通讯作者)，Univ Turin, Dept Clin Physiopathol, Via Genova 3, I-10126 Turin, Italy.
EM giuseppe.boccuzzi@unito.it
RI boccuzzi, giuseppe/A-6707-2012; De Bortoli, Michele/B-5418-2013;
   CATALANO, Maria Graziella/J-4320-2016; Fortunati, Nicoletta/K-3081-2016
OI CATALANO, Maria Graziella/0000-0002-1170-8245; Fortunati,
   Nicoletta/0000-0001-8069-9621
FU MIUR; Regione Piemonte
FX This project was supported by the Special Project "Oncology", Compagnia
   di San Paolo, Turin, by MIUR and by Regione Piemonte. The authors thanks
   Alessandro Weisz, Dipartimento di Patologia Generale, Seconda UniversitA
   degli Studi di Napoli, Napoli, Italy, for providing the ERE-TKIuc
   plasmid used for luciferase transcription assay.
CR Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Biçaku E, 2008, CANCER RES, V68, P1513, DOI 10.1158/0008-5472.CAN-07-2822
   Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Catalano MG, 2007, ENDOCR-RELAT CANCER, V14, P839, DOI 10.1677/ERC-07-0096
   CHAPMAN A, 1982, PROG NEUROBIOL, V19, P315, DOI 10.1016/0301-0082(82)90010-7
   Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719
   Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X
   DeVane C Lindsay, 2003, Psychopharmacol Bull, V37 Suppl 2, P25
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kininis Miltiadis, 2008, Nucl Recept Signal, V6, pe005, DOI 10.1621/nrs.06005
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Robyr D, 2000, J BIOL CHEM, V275, P28291
   Santos MDL, 2007, ENDOCR-RELAT CANCER, V14, P1021, DOI 10.1677/ERC-07-0144
   Scafoglio C, 2006, J CELL BIOCHEM, V98, P1163, DOI 10.1002/jcb.20820
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431
   Yamaguchi N, 2008, BIOCHEM BIOPH RES CO, V365, P711, DOI 10.1016/j.bbrc.2007.11.064
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 31
TC 31
Z9 36
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 15
PY 2010
VL 314
IS 1
BP 17
EP 22
DI 10.1016/j.mce.2009.09.011
PG 6
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 523VC
UT WOS:000272101700002
PM 19772891
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Andrews, J
   Kennette, W
   Pilon, J
   Hodgson, A
   Tuck, AB
   Chambers, AF
   Rodenhiser, DI
AF Andrews, Joseph
   Kennette, Wendy
   Pilon, Jenna
   Hodgson, Alexandra
   Tuck, Alan B.
   Chambers, Ann F.
   Rodenhiser, David I.
TI Multi-Platform Whole-Genome Microarray Analyses Refine the Epigenetic
   Signature of Breast Cancer Metastasis with Gene Expression and Copy
   Number
SO PLOS ONE
LA English
DT Article
ID CARCINOMA CELL-LINES; DNA METHYLATION; WIDE; THERAPY; MODEL;
   14-3-3-SIGMA; VALIDATION; MDA-MB-468; REVEALS; VARIANT
AB Background: We have previously identified genome-wide DNA methylation changes in a cell line model of breast cancer metastasis. These complex epigenetic changes that we observed, along with concurrent karyotype analyses, have led us to hypothesize that complex genomic alterations in cancer cells (deletions, translocations and ploidy) are superimposed over promoter-specific methylation events that are responsible for gene-specific expression changes observed in breast cancer metastasis.
   Methodology/Principal Findings: We undertook simultaneous high-resolution, whole-genome analyses of MDA-MB-468GFP and MDA-MB-468GFP-LN human breast cancer cell lines (an isogenic, paired lymphatic metastasis cell line model) using Affymetrix gene expression (U133), promoter (1.0R), and SNP/CNV (SNP 6.0) microarray platforms to correlate data from gene expression, epigenetic (DNA methylation), and combination copy number variant/single nucleotide polymorphism microarrays. Using Partek Software and Ingenuity Pathway Analysis we integrated datasets from these three platforms and detected multiple hypomethylation and hypermethylation events. Many of these epigenetic alterations correlated with gene expression changes. In addition, gene dosage events correlated with the karyotypic differences observed between the cell lines and were reflected in specific promoter methylation patterns. Gene subsets were identified that correlated hyper (and hypo) methylation with the loss (or gain) of gene expression and in parallel, with gene dosage losses and gains, respectively. Individual gene targets from these subsets were also validated for their methylation, expression and copy number status, and susceptible gene pathways were identified that may indicate how selective advantage drives the processes of tumourigenesis and metastasis.
   Conclusions/Significance: Our approach allows more precisely profiling of functionally relevant epigenetic signatures that are associated with cancer progression and metastasis.
C1 [Andrews, Joseph; Kennette, Wendy; Pilon, Jenna; Hodgson, Alexandra; Tuck, Alan B.; Chambers, Ann F.; Rodenhiser, David I.] London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada.
   [Pilon, Jenna; Hodgson, Alexandra; Rodenhiser, David I.] Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON, Canada.
   [Tuck, Alan B.; Chambers, Ann F.; Rodenhiser, David I.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Oncol, London, ON, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Paediat, London, ON, Canada.
   [Tuck, Alan B.; Chambers, Ann F.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Pathol, London, ON, Canada.
   [Rodenhiser, David I.] Childrens Hlth Res Inst, EpiGenWestern Res Grp, London, ON, Canada.
C3 Western University (University of Western Ontario); London Health
   Sciences Centre; Western University (University of Western Ontario);
   Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Andrews, J (通讯作者)，London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada.
EM drodenhi@uwo.ca
RI Chambers, Ann/L-6285-2015
OI Chambers, Ann/0000-0002-9509-5123
FU Canadian Breast Cancer Research Alliance [016506]; Canadian Breast
   Cancer Foundation; Cancer Research Society
FX Financial support gratefully acknowledged by grant #016506 from the
   Canadian Breast Cancer Research Alliance, with special funding support
   from the Canadian Breast Cancer Foundation and the Cancer Research
   Society. AFC is Canada Research Chair in Oncology, supported by the
   Canada Research Chairs Program. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR *AFF, AFF NETTF TOOL
   Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   Carter NP, 2007, NAT GENET, V39, pS16, DOI 10.1038/ng2028
   Chari R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-324
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Chi B, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-243
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   de Tayrac M, 2009, GENE CHROMOSOME CANC, V48, P55, DOI 10.1002/gcc.20618
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fadlelmola FM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-2
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   FENG Y, 2006, BREAST CANC RES TREA
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Horie-Inoue K, 2006, SEMIN CANCER BIOL, V16, P235, DOI 10.1016/j.semcancer.2006.03.006
   Johnson N, 2008, BREAST CANCER RES TR, V111, P55, DOI 10.1007/s10549-007-9758-6
   Juric Dejan, 2007, Methods Mol Biol, V377, P187
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lodygin D, 2006, SEMIN CANCER BIOL, V16, P214, DOI 10.1016/j.semcancer.2006.03.008
   MARGARETO J, 2009, CANC INVEST, P1
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462
   Pusztai L, 2006, CLIN CANCER RES, V12, P7209, DOI 10.1158/1078-0432.CCR-06-2649
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   RODENHISER DI, 2008, CLIN EXP METASTASIS
   Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   Welch DR, 2004, BREAST CANCER RES, V6, P61, DOI 10.1186/bcr736
   Woelfle U, 2003, CANCER RES, V63, P5679
   Xu J, 2008, CANCER GENET CYTOGEN, V181, P1, DOI 10.1016/j.cancergencyto.2007.05.030
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yuan E, 2006, CANCER RES, V66, P3443, DOI 10.1158/0008-5472.CAN-05-3739
   ZHANG RD, 1991, INVAS METAST, V11, P204
   EXONPRIMER SOFTWARE
   PRIMERQUEST SOFTWARE
NR 47
TC 41
Z9 50
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 13
PY 2010
VL 5
IS 1
AR e8665
DI 10.1371/journal.pone.0008665
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 543EV
UT WOS:000273554600018
PM 20084286
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Vrba, L
   Jensen, TJ
   Garbe, JC
   Heimark, RL
   Cress, AE
   Dickinson, S
   Stampfer, MR
   Futscher, BW
AF Vrba, Lukas
   Jensen, Taylor J.
   Garbe, James C.
   Heimark, Ronald L.
   Cress, Anne E.
   Dickinson, Sally
   Stampfer, Martha R.
   Futscher, Bernard W.
TI Role for DNA Methylation in the Regulation of miR-200c and miR-141
   Expression in Normal and Cancer Cells
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN PROSTATIC-CARCINOMA;
   BREAST-CANCER; HISTONE METHYLTRANSFERASE; GENE-EXPRESSION;
   DOWN-REGULATION; CPG ISLANDS; E-CADHERIN; LINES; INVASION
AB Background: The microRNA-200 family participates in the maintenance of an epithelial phenotype and loss of its expression can result in epithelial to mesenchymal transition (EMT). Furthermore, the loss of expression of miR-200 family members is linked to an aggressive cancer phenotype. Regulation of the miR-200 family expression in normal and cancer cells is not fully understood.
   Methodology/Principal Findings: Epigenetic mechanisms participate in the control of miR-200c and miR-141 expression in both normal and cancer cells. A CpG island near the predicted mir-200c/mir-141 transcription start site shows a striking correlation between miR-200c and miR-141 expression and DNA methylation in both normal and cancer cells, as determined by MassARRAY technology. The CpG island is unmethylated in human miR-200/miR-141 expressing epithelial cells and in miR-200c/miR-141 positive tumor cells. The CpG island is heavily methylated in human miR-200c/miR-141 negative fibroblasts and miR-200c/miR-141 negative tumor cells. Mouse cells show a similar inverse correlation between DNA methylation and miR-200c expression. Enrichment of permissive histone modifications, H3 acetylation and H3K4 trimethylation, is seen in normal miR-200c/miR-141-positive epithelial cells, as determined by chromatin immunoprecipitation coupled to real-time PCR. In contrast, repressive H3K9 dimethylation marks are present in normal miR-200c/miR-141-negative fibroblasts and miR-200c/miR-141 negative cancer cells and the permissive histone modifications are absent. The epigenetic modifier drug, 5-aza-2'-deoxycytidine, reactivates miR-200c/miR-141 expression showing that epigenetic mechanisms play a functional role in their transcriptional control.
   Conclusions/Significance: We report that DNA methylation plays a role in the normal cell type-specific expression of miR-200c and miR-141 and this role appears evolutionarily conserved, since similar results were obtained in mouse. Aberrant DNA methylation of the miR-200c/141 CpG island is closely linked to their inappropriate silencing in cancer cells. Since the miR-200c cluster plays a significant role in EMT, our results suggest an important role for DNA methylation in the control of phenotypic conversions in normal cells.
C1 [Vrba, Lukas; Jensen, Taylor J.; Heimark, Ronald L.; Cress, Anne E.; Dickinson, Sally; Stampfer, Martha R.; Futscher, Bernard W.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
   [Jensen, Taylor J.; Futscher, Bernard W.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   [Garbe, James C.; Stampfer, Martha R.] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA USA.
   [Vrba, Lukas] ASCR, Ctr Biol, Vvi, Inst Plant Mol Biol, Ceske Budejovice, Czech Republic.
C3 Arizona Center Cancer Care; University of Arizona; University of
   Arizona; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; Czech Academy of Sciences; Biology Centre of the
   Czech Academy of Sciences
RP Vrba, L (通讯作者)，Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
EM bfutscher@azcc.arizona.edu
RI Cress, Anne/V-6527-2019; Vrba, Lukas/J-9268-2015
OI Vrba, Lukas/0000-0003-3042-6275; Cress, Anne/0000-0001-6194-0061
FU BIO5 interdisciplinary biotechnology center; NIH [U54 CA112970]; DOD
   [BCRP BC060444, DE-AC03-76SF00098];  [R01CA65662];  [P30ES06694]; 
   [P30CA023074]
FX Grants R01CA65662 to B. W. F supported this work. Center Grants
   P30ES06694 and P30CA023074, and the BIO5 interdisciplinary biotechnology
   center at the UA supported the Genomics Shared Service. J.C.G. and M. R.
   S. were supported by NIH U54 CA112970, DOD BCRP BC060444, and the Office
   of Energy Research, Office of Health and Biological Research, U. S.
   Department of Energy under Contract No. DE-AC03-76SF00098. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Du Y, 2009, J GASTROENTEROL, V44, P556, DOI 10.1007/s00535-009-0037-7
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063
   Hackenberg M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-446
   HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
   Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189
   Irizarry RA, 2009, MAMM GENOME
   JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969
   Jensen TJ, 2008, CARCINOGENESIS, V29, P1500, DOI 10.1093/carcin/bgn102
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101
   Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731
   Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Oshiro MM, 2005, NEOPLASIA, V7, P799, DOI 10.1593/neo.05274
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907
   PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918
   Sharbati-Tehrani S, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-34
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305
   TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299
   Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2
   VALERI N, 2009, MAMM GENOME
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Vrba L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-486
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
NR 46
TC 242
Z9 283
U1 0
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 13
PY 2010
VL 5
IS 1
AR e8697
DI 10.1371/journal.pone.0008697
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 543EV
UT WOS:000273554600042
PM 20084174
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Barton, CA
   Gloss, BS
   Qu, W
   Statham, AL
   Hacker, NF
   Sutherland, RL
   Clark, SJ
   O'Brien, PM
AF Barton, C. A.
   Gloss, B. S.
   Qu, W.
   Statham, A. L.
   Hacker, N. F.
   Sutherland, R. L.
   Clark, S. J.
   O'Brien, P. M.
TI Collagen and calcium-binding EGF domains 1 is frequently inactivated in
   ovarian cancer by aberrant promoter hypermethylation and modulates cell
   migration and survival
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE ovarian cancer; CCBE1; tumour suppressor
ID ASPARAGINYL-BETA-HYDROXYLASE; COMPARATIVE GENOMIC HYBRIDIZATION;
   GROWTH-FACTOR; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; VITELLOGENIN
   RECEPTOR; DNA METHYLATION; OVEREXPRESSION; CHOLANGIOCARCINOMA;
   ASSOCIATION
AB BACKGROUND: Collagen and calcium-binding EGF domains 1 (CCBE1) is an uncharacterised gene that has down-regulated expression in breast cancer. As CCBE1 maps to 18q21.32, a region frequently exhibiting loss of heterozygosity in ovarian cancer, the aim of this study was to determine the expression and function of CCBE1 in ovarian cancer.
   METHODS: Expression and methylation patterns of CCBE1 were determined in ovarian cancer cell lines and primary tumours. CCBE1 contains collagen repeats and an aspartic acid/asparagine hydroxylation/EGF-like domain, suggesting a function in extracellular matrix remodelling and migration, which was determined using small-interfering RNA (siRNA)-mediated knockdown and over-expression of CCBE1 in cell lines.
   RESULTS: CCBE1 is expressed in normal ovary, but is reduced in ovarian cancer cell lines and primary carcinomas. Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer. CCBE1 promoter hypermethylation was detected in 6/11 (55%) ovarian cancer cell lines and 38/81 (41%) ovarian carcinomas. siRNA-mediated knockdown of CCBE1 in ovarian cancer cell lines enhanced their migration; conversely, re-expression of CCBE1 reduced migration and survival. Hence, loss of CCBE1 expression may promote ovarian carcinogenesis by enhancing migration and cell survival.
   CONCLUSIONS: These data suggest that CCBE1 is a new candidate tumour suppressor in ovarian cancer. British Journal of Cancer (2010) 102, 87-96. doi:10.1038/sj.bjc.6605429 www.bjcancer.com Published online 24 November 2009 (C) 2010 Cancer Research UK
C1 [Barton, C. A.; Gloss, B. S.; Qu, W.; Statham, A. L.; Hacker, N. F.; Sutherland, R. L.; Clark, S. J.; O'Brien, P. M.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia.
   [Hacker, N. F.] Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia.
   [Hacker, N. F.; Sutherland, R. L.; Clark, S. J.; O'Brien, P. M.] Univ NSW, Fac Med, Sydney, NSW 2031, Australia.
C3 Garvan Institute of Medical Research; NSW Health; St Vincents Hospital
   Sydney; NSW Health; South Eastern Sydney Local Health District; The
   Royal Hospital for Women; University of New South Wales Sydney
RP O'Brien, PM (通讯作者)，St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
EM p.obrien@garvan.org.au
RI Sutherland, Robert/A-8378-2008; Clark, Susan/B-2272-2008
OI Gloss, Brian/0000-0001-7695-4394; Clark, Susan/0000-0001-5925-5030;
   Hacker, Neville/0000-0002-1445-2302
FU Ovarian Cancer Project; Royal Hospital for Women Foundation, Sydney,
   Australia; Cancer Institute New South Wales; RT Hall Trust; National
   Health & Medical Research Council (NH&MRC) of Australia
FX We thank Ms Alison Smith and Ms Cheryl Paul, the staff of the
   Gynaecological Cancer Centre, Royal Hospital for Women and the
   Australian Cancer Research Foundation (ACRF) Unit for Molecular Genetics
   of Cancer at the Garvan Institute for their professional support. This
   study was carried out by the Ovarian Cancer Project, a collaboration
   between the Gynaecological Cancer Centre, Royal Hospital for Women and
   the Cancer Research Program, Garvan Gynaecological Oncology (GO)
   Research Fund of the Royal Hospital for Women Foundation, Sydney,
   Australia; the Cancer Institute New South Wales; the RT Hall Trust and
   the National Health & Medical Research Council (NH&MRC) of Australia.
   Susan J Clark is an NH&MRC Principal Research Fellow and Robert L
   Sutherland is a Senior Principal Research Fellow of the NH&MRC.
CR Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Cantarini MC, 2006, HEPATOLOGY, V44, P446, DOI 10.1002/hep.21272
   Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   de la Monte SM, 2006, J HEPATOL, V44, P971, DOI 10.1016/j.jhep.2006.01.038
   Dinchuk JE, 2002, J BIOL CHEM, V277, P12970, DOI 10.1074/jbc.M110389200
   Dinchuk JE, 2000, J BIOL CHEM, V275, P39543, DOI 10.1074/jbc.M006753200
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6
   GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609
   Hauptmann S, 2002, HUM PATHOL, V33, P632, DOI 10.1053/hupa.2002.124913
   Heinzelmann-Schwarz VA, 2006, BRIT J CANCER, V94, P904, DOI 10.1038/sj.bjc.6603003
   Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hutchinson E, 2001, LANCET ONCOL, V2, P642, DOI 10.1016/S1470-2045(01)00524-1
   Ince N, 2000, CANCER RES, V60, P1261
   JEMAL A, 2008, CA-CANCER J CLIN, V96, P58, DOI DOI 10.3322/CA.2007.0010
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681
   Lassus H, 2001, AM J PATHOL, V159, P35, DOI 10.1016/S0002-9440(10)61670-7
   Lavaissiere L, 1996, J CLIN INVEST, V98, P1313, DOI 10.1172/JCI118918
   LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9
   Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409
   Maeda T, 2003, J HEPATOL, V38, P615, DOI 10.1016/S0168-8278(03)00052-7
   MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6
   Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200
   Rand KN, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni120
   SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485
   Schonbaum CP, 2000, MOL BIOL CELL, V11, P511, DOI 10.1091/mbc.11.2.511
   Sepe PS, 2002, LAB INVEST, V82, P881, DOI 10.1097/01.LAB.0000020406.91689.7F
   Shyamsundar R, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-r22
   Takakura S, 1999, GENE CHROMOSOME CANC, V24, P264, DOI 10.1002/(SICI)1098-2264(199903)24:3<264::AID-GCC12>3.0.CO;2-Y
   TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184
   van Kempen LCLT, 2003, EUR J CELL BIOL, V82, P539, DOI 10.1078/0171-9335-00346
   Yamamoto F, 2007, ELECTROPHORESIS, V28, P1882, DOI 10.1002/elps.200700093
NR 38
TC 34
Z9 50
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JAN 5
PY 2010
VL 102
IS 1
BP 87
EP 96
DI 10.1038/sj.bjc.6605429
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 543HE
UT WOS:000273563800013
PM 19935792
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Chen, XB
   Cao, XG
   Dong, WJ
   Xia, M
   Luo, SX
   Fan, QX
   Xie, J
AF Chen, Xiaobing
   Cao, Xinguang
   Dong, Wenjie
   Xia, Microgene
   Luo, Suxia
   Fan, Qingxia
   Xie, Jing
TI Cystatin M expression is reduced in gastric carcinoma and is associated
   with promoter hypermethylation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Cystatin M; Gastric cancer; Hypermethylation
ID TUMOR-SUPPRESSOR GENE; BREAST-CANCER; EPIDERMAL CORNIFICATION;
   CERVICAL-CANCER; METHYLATION; CELLS; CST6; HYBRIDIZATION; INACTIVATION;
   PROGRESSION
AB Cystatin M is a secreted inhibitor of lysosomal cysteine proteases and increasing evidences indicate that it is a novel target for epigenetic silencing during mammary tumorigenesis. Aberrant promoter methylation is a well-known mechanism that participates in cystatin M silencing in breast cancer. However, the role of cystatin M in the gastric cancer remains to be elucidated. Immumohistochemistry was used to investigate the expression of cystatin M in 60 gastric carcinomas. Hypermethylation of cystatin M promoter was evaluated by the methylation-specific PCR (MSP) method in gastric carcinomas (tumor and paired adjacent non-tumor tissues). Reverse-transcriptase PCR and BSP were also performed on gastric cancer cell lines before and after treatment with 5-aza-2'-deoxycytidine (5-Aza-dC). Lost expression of cystatin M was observed in 42 of 60 (70%) gastric carcinomas. 55% (33 of 60) of primary tumors analyzed displayed cystatin M promoter hypermethylation, indicating that this aberrant characteristic is common in gastric malignancies. Moreover, a statistically significant inverse association was found between cystatin M methylation status and expression of the cystatin M protein in tumor tissues (p = 0.027). We also found that patients with cystatin M promoter methylation had a significantly shorter survival time than those without this methylation (p = 0.020). These results suggest that cystatin M promoter hypermethylation is one of the molecular mechanisms that accounts for reduced cystatin M gene expression in gastric carcinomas. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Chen, Xiaobing; Fan, Qingxia] Zhengzhou Univ, Affiliated Hosp 1, Dept Internal Med Oncol, Zhengzhou 450052, Peoples R China.
   [Chen, Xiaobing; Cao, Xinguang; Luo, Suxia] Henan Tumor Hosp, Dept Internal Med Oncol, Zhengzhou, Peoples R China.
   [Dong, Wenjie] Shanghai Jiao Tong Univ, Dept Gastroenterol, Sch Med, Rui Jin Hosp, Shanghai 200030, Peoples R China.
   [Xia, Microgene] Univ Hong Kong, Integrat Lab, Pokfulam, Hong Kong, Peoples R China.
   [Xie, Jing] Shanghai Jiao Tong Univ, Dept Pathol, Rui Jin Hosp, Shanghai 200030, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; Shanghai Jiao Tong
   University; University of Hong Kong; Shanghai Jiao Tong University
RP Fan, QX (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Internal Med Oncol, 1 Western Jianshe Rd, Zhengzhou 450052, Peoples R China.
EM qingxiafanzdyxy@163.com
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Anlauf M, 2007, Verh Dtsch Ges Pathol, V91, P320
   D'Adda T, 1999, LAB INVEST, V79, P671
   Keppler D, 2006, CANCER LETT, V235, P159, DOI 10.1016/j.canlet.2005.04.001
   Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Kioulafa M, 2009, INT J CANCER, V125, P2887, DOI 10.1002/ijc.24686
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Pulukuri SM, 2009, ONCOGENE, V28, P2829, DOI 10.1038/onc.2009.134
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   SINICROPE FA, 1995, CANCER RES, V55, P237
   Song J, 2006, BIOCHEM BIOPH RES CO, V340, P175, DOI 10.1016/j.bbrc.2005.11.171
   Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698
   Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512
   Vauhkonen H, 2006, CANCER GENET CYTOGEN, V170, P133, DOI 10.1016/j.cancergencyto.2006.06.001
   Veena MS, 2008, GENE CHROMOSOME CANC, V47, P740, DOI 10.1002/gcc.20576
   Vigneswaran N, 2006, LIFE SCI, V78, P898, DOI 10.1016/j.lfs.2005.05.096
   Vigneswaran N, 2005, PATHOL RES PRACT, V200, P753, DOI 10.1016/j.prp.2004.09.005
   Zeeuwen PLJM, 2004, HUM MOL GENET, V13, P1069, DOI 10.1093/hmg/ddh115
   Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
NR 24
TC 15
Z9 16
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2010
VL 391
IS 1
BP 1070
EP 1074
DI 10.1016/j.bbrc.2009.12.022
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 544AV
UT WOS:000273624500189
PM 20004178
DA 2025-01-12
ER

PT J
AU Pietkiewicz, PP
   Lutkowska, A
   Lianeri, M
   Jagodzinski, PP
AF Pietkiewicz, P. P.
   Lutkowska, A.
   Lianeri, M.
   Jagodzinski, P. P.
TI Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast
   cancer cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE CXCL12; Tamoxifen; Breast cancer
ID PROMOTER HYPERMETHYLATION; CHEMOKINE RECEPTORS; DNA METHYLATION;
   DOWN-REGULATION; FACTOR-1 SDF-1; FACTOR-I; METASTASIS; ASSOCIATION;
   CARCINOMAS; MIGRATION
AB The CXCL12 chemokine binds to the CXCR4 receptor and contributes to survival, proliferation, and migration of malignant cells. Recent reports indicate that breast cancer cells lacking expression of CXCL12 but exhibiting CXCR4 can metastasize to target organs that secrete CXCL12. We observed that Tamoxifen (Tam), similarly to 5-dAzaC, results in significantly increased levels of CXCL12 transcript and protein in MCF-7 breast cancer cells. Bisulfite sequencing suggests that Tam, similarly to 5-dAzaC, may increase CXCL12 expression via reduction in methylation of cytosine in the cytosine-guanosine (CpG) dinucleotide island of the CXCL12 promoter of MCF-7 cells. Our results, together with findings of other researches, may suggest that Tam epigenetically activates CXCL12 expression in breast cancer cells and can make these cells less susceptible to attraction by exogenous CXCL12 to metastasis sites. (C) 2009 Elsevier Masson SAS. All rights reserved.
C1 [Pietkiewicz, P. P.; Lutkowska, A.; Lianeri, M.; Jagodzinski, P. P.] Karol Marcinkowski Univ Med Sci, Dept Biochem & Mol Biol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences
RP Jagodzinski, PP (通讯作者)，Karol Marcinkowski Univ Med Sci, Dept Biochem & Mol Biol, 6 Swiecickiego St, PL-60781 Poznan, Poland.
EM pjagodzi@am.poznan.pl
RI Pietkiewicz, Pawel/J-6074-2012; Jagodzinski, Pawel/KWV-0637-2024
OI Pietkiewicz, Pawel/0000-0001-7262-2456; Jagodzinski,
   Pawel/0000-0002-9046-6802
FU Poznan University of Medical Sciences [502-01-01124182-07474]
FX Supported by a grant No. 502-01-01124182-07474, Poznan University of
   Medical Sciences.
CR Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269
   Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539
   Hassan S, 2008, CLIN CANCER RES, V14, P446, DOI 10.1158/1078-0432.CCR-07-1189
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163
   Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022
   KUBAREK I, BIOMED PHARMACOTHER, DOI DOI 10.1016/J.BIOPHA.2008.10.007
   Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021
   McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Szabo A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r59
   Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Yong K, 1999, BRIT J HAEMATOL, V107, P441, DOI 10.1046/j.1365-2141.1999.01714.x
   Zhou W, 2008, J NEUROSCI RES, V86, P3002, DOI 10.1002/jnr.21746
   Zhou W, 2009, J CANCER RES CLIN, V135, P91, DOI 10.1007/s00432-008-0435-x
NR 27
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2010
VL 64
IS 1
BP 54
EP 57
DI 10.1016/j.biopha.2009.04.041
PG 4
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 550BI
UT WOS:000274101100009
PM 19748759
DA 2025-01-12
ER

PT J
AU Akhoondi, S
   Lindström, L
   Widschwendter, M
   Corcoran, M
   Bergh, J
   Spruck, C
   Grandér, D
   Sangfelt, O
AF Akhoondi, Shahab
   Lindstrom, Linda
   Widschwendter, Martin
   Corcoran, Martin
   Bergh, Jonas
   Spruck, Charles
   Grander, Dan
   Sangfelt, Olle
TI Inactivation of <i>FBXW7</i>/<i>hCDC4</i>-β expression by promoter
   hypermethylation is associated with favorable prognosis in primary
   breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENES; CYCLIN-E;
   CELL-CYCLE; UBIQUITIN LIGASES; OVARIAN-CANCER; METHYLATION; HCDC4;
   FBXW7; P53
AB Introduction: Mutational inactivation of the FBXW7/hCDC4 tumor suppressor gene (TSG) is common in many cancer types, but infrequent in breast cancers. This study investigates the presence and impact of FBXW7/hCDC4 promoter methylation in breast cancer.
   Methods: FBXW7/hCDC4-beta expression and promoter methylation was assessed in 161 tumors from two independent breast cancer cohorts. Associations between methylation status and clinicopathologic characteristics were assessed by Fisher's exact test. Survival was analyzed using the Kaplan-Meier method in addition to modeling the risk by use of a multivariate proportional hazard (Cox) model adjusting for possible confounders of survival.
   Results: Methylation of the promoter and loss of mRNA expression was found both in cell lines and primary tumors (43% and 51%, respectively). Using Cox modeling, a trend was found towards decreased hazard ratio (HR) for death in women with methylation of FBXW7/hCDC4-beta in both cohorts (HR 0.53 (95% CI 0.23 to 1.23) and HR 0.50 (95% CI 0.23 to 1.08), respectively), despite an association between methylation and high-grade tumors (P = 0.017). Interestingly, in subgroups of patients whose tumors are p53 mutated or lymph-node positive, promoter methylation identified patients with significantly improved survival (P = 0.048 and P = 0.017, respectively).
   Conclusions: We demonstrate an alternative mechanism for inactivation of the TSG FBXW7/hCDC4, namely promoter specific methylation. Importantly, in breast cancer, methylation of FBXW7/hCDC4-beta is related to favorable prognosis despite its association with poorly differentiated tumors. Future work may define whether FBXW7/hCDC4 methylation is a biomarker of the response to chemotherapy and a target for epigenetic modulation therapy.
C1 [Akhoondi, Shahab; Sangfelt, Olle] Karolinska Inst, Dept Cell, S-17177 Stockholm, Sweden.
   [Akhoondi, Shahab; Sangfelt, Olle] Karolinska Inst, Dept Mol Biol, S-17177 Stockholm, Sweden.
   [Akhoondi, Shahab; Lindstrom, Linda; Corcoran, Martin; Bergh, Jonas; Grander, Dan; Sangfelt, Olle] Karolinska Hosp & Inst, Radiumhemmet, Canc Ctr Karolinska, Dept Oncol, S-17176 Stockholm, Sweden.
   [Akhoondi, Shahab; Lindstrom, Linda; Corcoran, Martin; Bergh, Jonas; Grander, Dan; Sangfelt, Olle] Karolinska Hosp & Inst, Radiumhemmet, Canc Ctr Karolinska, Dept Pathol, S-17176 Stockholm, Sweden.
   [Bergh, Jonas] Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England.
   [Widschwendter, Martin] UCL, EGA Hosp, Inst Womens Hlth, Dept Gynecol Oncol, London WC1E 6DH, England.
   [Spruck, Charles] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska University Hospital; Karolinska Institutet; Karolinska
   University Hospital; Christie NHS Foundation Trust; Christie Hospital;
   University of Manchester; University of London; University College
   London; Sanford Burnham Prebys Medical Discovery Institute
RP Sangfelt, O (通讯作者)，Karolinska Inst, Dept Cell, Berzeliusvag 35,Box 285, S-17177 Stockholm, Sweden.
EM olle.sangfelt@ki.se
RI Sangfelt, Olle/ISU-9627-2023; Lindstrom, Linda/J-3215-2012
OI Lindstrom, Linda Sofie/0000-0002-7722-7532; Corcoran,
   Martin/0000-0002-2774-0936; Widschwendter, Martin/0000-0002-7778-8380;
   Bergh, Jonas/0000-0001-5526-1847
FU Cancer Society in Stockholm; Swedish Cancer Society; Swedish Research
   Council; Gustaf V Jubilee Foundation; Swedish Breast Cancer Group;
   ALF/FOU; Stockholm County Council; Linne Foundation; Marit & Hans
   Rausing initiative against Breast Cancer; Department of Defense;
   Department of Health NIHR Biomedical Research Centres
FX Grant support: S. Akhoondi is an MD and Scholar in experimental oncology
   funded by the Cancer Society in Stockholm. This work was also supported
   by grants from the Swedish Cancer Society (O.S., DG, J.B), the Swedish
   Research Council (OS, DG, JB), the Cancer Society in Stockholm (OS, JB),
   the Gustaf V Jubilee Foundation (DG, JB), the Swedish Breast Cancer
   Group (JB), ALF/FOU (J.B), Stockholm County Council (JB), Linne
   Foundation (JB), Marit & Hans Rausing initiative against Breast Cancer
   (JB), and the Department of Defense Breast Cancer Research Program (DOD
   BCRP) (CS). Part of this work has been undertaken at UCLH/UCL who
   received a proportion of funding from the Department of Health NIHR
   Biomedical Research Centres funding scheme (MW).
CR Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320
   [Anonymous], IMAGE J SOFTWARE
   Asnafi V, 2009, BLOOD, V113, P3918, DOI 10.1182/blood-2008-10-184069
   BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029
   Braggio E, 2010, INT J HEMATOL, V91, P87, DOI 10.1007/s12185-009-0459-2
   Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Fiegl H, 2008, CLIN CANCER RES, V14, P3494, DOI 10.1158/1078-0432.CCR-07-4557
   Finkin S, 2008, ONCOGENE, V27, P4411, DOI 10.1038/onc.2008.77
   Gonzalez-Angulo AM, 2010, J CLIN ONCOL, V28, pE20, DOI 10.1200/JCO.2009.25.8491
   Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106
   HOLZNER E, 2002, CANCER RES, V62, P4535
   Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879
   Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x
   Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8
   Kwak EL, 2005, GYNECOL ONCOL, V98, P124, DOI 10.1016/j.ygyno.2005.04.007
   Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x
   Maier Sabine, 2005, Per Med, V2, P339, DOI 10.2217/17410541.2.4.339
   Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381
   Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155
   Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981
   Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5
   Park MJ, 2009, BRIT J HAEMATOL, V145, P198, DOI 10.1111/j.1365-2141.2009.07607.x
   Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804
   Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313
   Sangfelt O, 2008, CELL CYCLE, V7, P1075, DOI 10.4161/cc.7.8.5648
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Spruck C, 2006, CANCER RES, V66, P7355, DOI 10.1158/0008-5472.CAN-05-3240
   Sterian A, 2006, ONCOLOGY-BASEL, V70, P168, DOI 10.1159/000094444
   Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076
   Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172
   Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036
   Tovey S, 2005, CLIN CANCER RES, V11, P4835, DOI 10.1158/1078-0432.CCR-05-0196
   van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020
   Verma M, 2006, MOL DIAGN THER, V10, P1
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719
   Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yamasaki L, 2004, CURR OPIN CELL BIOL, V16, P623, DOI 10.1016/j.ceb.2004.08.005
   Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846
   Zilberman D, 2007, DEVELOPMENT, V134, P3959, DOI 10.1242/dev.001131
NR 53
TC 70
Z9 81
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2010
VL 12
IS 6
AR R105
DI 10.1186/bcr2788
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 739WJ
UT WOS:000288751500016
PM 21122106
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Bediaga, NG
   Acha-Sagredo, A
   Guerra, I
   Viguri, A
   Albaina, C
   Diaz, IR
   Rezola, R
   Alberdi, MJ
   Dopazo, J
   Montaner, D
   de Renobales, M
   Fernández, AF
   Field, JK
   Fraga, MF
   Liloglou, T
   de Pancorbo, MM
AF Bediaga, Naiara G.
   Acha-Sagredo, Amelia
   Guerra, Isabel
   Viguri, Amparo
   Albaina, Carmen
   Ruiz Diaz, Irune
   Rezola, Ricardo
   Jesus Alberdi, Maria
   Dopazo, Joaquin
   Montaner, David
   de Renobales, Mertxe
   Fernandez, Agustin F.
   Field, John K.
   Fraga, Mario F.
   Liloglou, Triantafillos
   de Pancorbo, Marian M.
TI DNA methylation epigenotypes in breast cancer molecular subtypes
SO BREAST CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; EMBRYONIC STEM-CELLS; MAMMARY EPITHELIAL-CELLS;
   PROMOTER METHYLATION; CPG ISLAND; EPIGENETIC REGULATION; ASSOCIATION;
   HYPERMETHYLATION; EXPRESSION; HYPOMETHYLATION
AB Introduction: Identification of gene expression-based breast cancer subtypes is considered a critical means of prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes occurring in breast cancer. So far, these epigenetic contributions to sporadic breast cancer subtypes have not been well characterized, and only a limited understanding exists of the epigenetic mechanisms affected in those particular breast cancer subtypes. The present study was undertaken to dissect the breast cancer methylome and to deliver specific epigenotypes associated with particular breast cancer subtypes.
   Methods: By using a microarray approach, we analyzed DNA methylation in regulatory regions of 806 cancer-related genes in 28 breast cancer paired samples. We subsequently performed substantial technical and biologic validation by pyrosequencing, investigating the top qualifying 19 CpG regions in independent cohorts encompassing 47 basal-like, 44 ERBB2+ overexpressing, 48 luminal A, and 48 luminal B paired breast cancer/adjacent tissues. With the all-subset selection method, we identified the most subtype-predictive methylation profiles in multivariable logistic regression analysis.
   Results: The approach efficiently recognized 15 individual CpG loci differentially methylated in breast cancer tumor subtypes. We further identified novel subtype-specific epigenotypes that clearly demonstrate the differences in the methylation profiles of basal-like and human epidermal growth factor 2 (HER2)-overexpressing tumors.
   Conclusions: Our results provide evidence that well-defined DNA methylation profiles enable breast cancer subtype prediction and support the utilization of this biomarker for prognostication and therapeutic stratification of patients with breast cancer.
C1 [Bediaga, Naiara G.; de Pancorbo, Marian M.] Univ Basque Country UPV EHU, BIOMICs Res Grp, Ctr Invest & Estudios Avanzados Lucio Lascaray, Vitoria, Spain.
   [Acha-Sagredo, Amelia] Univ Basque Country UPV EH, Oral Med & Pathol Unit, Fac Med & Dent, E-48940 Leioa, Vizcaya, Spain.
   [Guerra, Isabel; Viguri, Amparo; Albaina, Carmen] Hosp Txagorritxu, Serv Anat Pathol, E-01009 Vitoria, Alava, Spain.
   [Ruiz Diaz, Irune] Hosp Donostia, Serv Anat Pathol, E-20014 San Sebastian, Guipuzcoa, Spain.
   [Rezola, Ricardo; Jesus Alberdi, Maria] Inst Oncol, Serv Anat Pathol, E-20012 San Sebastian, Spain.
   [Dopazo, Joaquin; Montaner, David] Ctr Invest Principe Felipe, Dept Bioinformat & Genom, E-6012 Valencia, Spain.
   [de Renobales, Mertxe] Univ Basque Country UPV EHU, Fac Pharm, E-01006 Vitoria, Spain.
   [Fernandez, Agustin F.] Univ Oviedo, Canc Epigenet Lab, IUOPA, HUCA, E-33006 Oviedo, Spain.
   [Field, John K.; Liloglou, Triantafillos] Univ Liverpool Canc, Liverpool CR UK Canc Res Ctr, Sch Canc Studies, Liverpool L3 9TA, Merseyside, England.
   [Fraga, Mario F.] CNB CSIC, Dept Immunol & Oncol, Natl Biotechnol Ctr, E-28049 Madrid, Spain.
C3 University of Basque Country; University of Basque Country; University
   Hospital of Araba; University Hospital Donostia; Prince Felipe Research
   Center; University of Basque Country; Central University Hospital
   Asturias; University of Oviedo; Instituto Universitario de Oncologia de
   Asturias; University of Liverpool; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)
RP de Pancorbo, MM (通讯作者)，Univ Basque Country UPV EHU, BIOMICs Res Grp, Ctr Invest & Estudios Avanzados Lucio Lascaray, Miguel de Unamuno 3,1006, Vitoria, Spain.
EM marianpancorbo@gmail.com
RI Acha-Sagredo, Amelia/AAE-5699-2020; Liloglou,
   Triantafillos/KTI-2202-2024; Bediaga, Naiara/AAD-6062-2020; Field,
   John/AAD-5674-2020; Fernandez, Agustin/N-7302-2014; Dopazo,
   Joaquin/A-9270-2014; Montaner, David/A-9362-2014; Fraga,
   Mario/H-7824-2017
OI M. de Pancorbo, Marian/0000-0002-8081-0702; Fernandez,
   Agustin/0000-0002-3792-4085; Dopazo, Joaquin/0000-0003-3318-120X;
   Liloglou, Triantafillos/0000-0003-0460-1404; Acha-Sagredo,
   Amelia/0000-0001-8265-8604; MARTINEZ DE PANCORBO, MARIA DE LOS
   ANGELES/0000-0002-7408-6068; G. Bediaga, Naiara/0000-0002-7363-0068;
   Montaner, David/0000-0002-2484-3278; Field, John/0000-0003-3951-6365;
   Fraga, Mario/0000-0001-8450-2603
FU MICINN [CGL2008-01131, S-PE08UN45, PE09BF02, BIO2008-04212,
   RD06/0020/1019]; Basque Government (Departamento de Educacion,
   Universidades e Investigacion)
FX This work was supported by grants from project CGL2008-01131
   (Departamento de Sanidad del Gobierno Vasco), S-PE08UN45 and PE09BF02
   (Departamento de Ciencia y Tecnologia del Gobierno Vasco),
   BIO2008-04212, and RD06/0020/1019 (Red Tematica de Investigacion
   Cooperativa en Cancer, RTICC) from the MICINN. The CIBER de Enfermedades
   Raras is an initiative of the ISCIII. NGB had a doctoral fellowship from
   the Basque Government (Departamento de Educacion, Universidades e
   Investigacion).
CR Altun G, 2010, J CELL BIOCHEM, V109, P1, DOI 10.1002/jcb.22374
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Bertolo C, 2008, AM J CLIN PATHOL, V130, P414, DOI 10.1309/J3QV9763DYPV338D
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005
   Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bloushtain-Qimron N, 2009, CELL CYCLE, V8, P809, DOI 10.4161/cc.8.6.7938
   Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Christensen BC, 2009, CANCER RES, V69, P6315, DOI 10.1158/0008-5472.CAN-09-1073
   Dammann R, 2001, CANCER RES, V61, P3105
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Du Y, 2001, CANCER RES, V61, P8094
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113
   Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204
   Geli J, 2008, CLIN CANCER RES, V14, P2551, DOI 10.1158/1078-0432.CCR-07-1867
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hu XC, 2002, LIFE SCI, V71, P1397, DOI 10.1016/S0024-3205(02)01843-X
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Konishi K, 2007, GASTROENTEROLOGY, V132, P1254, DOI 10.1053/j.gastro.2007.01.035
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683
   Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Terada K, 2009, CARCINOGENESIS, V30, P466, DOI 10.1093/carcin/bgp021
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Yuan JH, 2003, CANCER RES, V63, P4174
NR 43
TC 138
Z9 163
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2010
VL 12
IS 5
AR R77
DI 10.1186/bcr2721
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 697IG
UT WOS:000285506100012
PM 20920229
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Muggerud, AA
   Ronneberg, JA
   Wärnberg, F
   Botling, J
   Busato, F
   Jovanovic, J
   Solvang, H
   Bukholm, I
   Borresen-Dale, AL
   Kristensen, VN
   Sorlie, T
   Tost, J
AF Muggerud, Aslaug Aa
   Ronneberg, Jo Anders
   Warnberg, Fredrik
   Botling, Johan
   Busato, Florence
   Jovanovic, Jovana
   Solvang, Hiroko
   Bukholm, Ida
   Borresen-Dale, Anne-Lise
   Kristensen, Vessela N.
   Sorlie, Therese
   Tost, Joerg
TI Frequent aberrant DNA methylation of <i>ABCB1</i>, <i>FOXC1</i>,
   <i>PPP2R2B</i> and <i>PTEN</i> in ductal carcinoma in situ and early
   invasive breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID HORMONE-RECEPTOR STATUS; CPG ISLAND METHYLATION; PROMOTER
   HYPERMETHYLATION; ESTROGEN-RECEPTOR; REFERENCE GENES; RT-PCR;
   EXPRESSION; PROFILES; RASSF1A; INSTABILITY
AB Introduction: Ductal carcinoma in situ (DCIS) is a non-invasive lesion of the breast that is frequently detected by mammography and subsequently removed by surgery. However, it is estimated that about half of the detected lesions would never have progressed into invasive cancer. Identifying DCIS and invasive cancer specific epigenetic lesions and understanding how these epigenetic changes are involved in triggering tumour progression is important for a better understanding of which lesions are at risk of becoming invasive.
   Methods: Quantitative DNA methylation analysis of ABCB1, CDKN2A/p16(INK4a), ESR1, FOXC1, GSTP1, IGF2, MGMT, MLH1, PPP2R2B, PTEN and RASSF1A was performed by pyrosequencing in a series of 27 pure DCIS, 28 small invasive ductal carcinomas (IDCs), 34 IDCs with a DCIS component and 5 normal breast tissue samples. FOXC1, ABCB1, PPP2R2B and PTEN were analyzed in 23 additional normal breast tissue samples. Real-Time PCR expression analysis was performed for FOXC1.
   Results: Aberrant DNA methylation was observed in all three diagnosis groups for the following genes: ABCB1, FOXC1, GSTP1, MGMT, MLH1, PPP2R2B, PTEN and RASSF1A. For most of these genes, methylation was already present at the DCIS level with the same frequency as within IDCs. For FOXC1 significant differences in methylation levels were observed between normal breast tissue and invasive tumours (P < 0.001). The average DNA methylation levels were significantly higher in the pure IDCs and IDCs with DCIS compared to pure DCIS (P = 0.007 and P = 0.001, respectively). Real-time PCR analysis of FOXC1 expression from 25 DCIS, 23 IDCs and 28 normal tissue samples showed lower gene expression levels of FOXC1 in both methylated and unmethylated tumours compared to normal tissue (P < 0.001). DNA methylation levels of FOXC1, GSTP1, ABCB1 and RASSF1A were higher in oestrogen receptor (ER) positive vs. ER negative tumours; whereas methylation levels of FOXC1, ABCB1, PPP2R2B and PTEN were lower in tumours with a TP53 mutation.
   Conclusions: Quantitative methylation analysis identified ABCB1, FOXC1, PPP2R2B and PTEN as novel genes to be methylated in DCIS. In particular, FOXC1 showed a significant increase in the methylation frequency in invasive tumours. Low FOXC1 gene expression in both methylated and unmethylated DCIS and IDCs indicates that the loss of its expression is an early event during breast cancer progression.
C1 [Muggerud, Aslaug Aa; Ronneberg, Jo Anders; Solvang, Hiroko; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.; Sorlie, Therese] Oslo Univ Hosp, Dept Genet, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway.
   [Muggerud, Aslaug Aa; Ronneberg, Jo Anders; Borresen-Dale, Anne-Lise] Univ Oslo, Div Norwegian Radium Hosp, Fac Med, N-0310 Oslo, Norway.
   [Warnberg, Fredrik] Univ Uppsala Hosp, Dept Surg, SE-75185 Uppsala, Sweden.
   [Botling, Johan] Univ Uppsala Hosp, Dept Genet & Pathol, SE-75185 Uppsala, Sweden.
   [Jovanovic, Jovana; Kristensen, Vessela N.] Univ Oslo, Div Akershus Univ Hosp, Fac Med, Inst Clin Epidemiol & Mol Biol EpiGen, N-1474 Nordbyhagen, Norway.
   [Bukholm, Ida] Univ Oslo, Akershus Univ Hosp, Dept Surg, N-1474 Nordbyhagen, Norway.
   [Kristensen, Vessela N.] Div Akershus Univ Hosp, Fac Med, N-1474 Nordbyhagen, Norway.
   [Sorlie, Therese] Univ Oslo, Biomed Res Grp, Dept Informat, N-0316 Oslo, Norway.
   [Busato, Florence; Tost, Joerg] CEA, Lab Epigenet, Ctr Natl Genotypage, Inst Genom, F-91000 Evry, France.
   [Solvang, Hiroko] Univ Oslo, Dept Biostat, Inst Basic Med Sci, N-0317 Oslo, Norway.
C3 University of Oslo; University of Oslo; Uppsala University; Uppsala
   University Hospital; Uppsala University; Uppsala University Hospital;
   University of Oslo; University of Oslo; University of Oslo; CEA;
   Universite Paris Saclay; University of Oslo
RP Kristensen, VN (通讯作者)，Oslo Univ Hosp, Dept Genet, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway.
EM vessela.kristensen@medisin.uio.no
RI Sørlie, Therese/B-1413-2015; Busato, Fabio/LIC-8043-2024; Botling,
   Johan/ABA-2586-2020; Tost, Jorg/H-7129-2019
OI Tost, Jorg/0000-0002-2683-0817; Botling, Johan/0000-0003-2226-3517;
   Warnberg, Fredrik/0000-0002-0130-7296
FU Norwegian Cancer Society [PR-2006-0332, D-03067]; Norwegian Research
   Council [163027/V409]; French-Norwegian cooperation program [15842WE];
   Swedish Cancer Society [4920-B06-03PCD]
FX This study was supported by the Norwegian Cancer Society (PR-2006-0332
   to TS and D-03067 to VNK), the Norwegian Research Council (163027/V409
   to TS), the French-Norwegian cooperation program Aurora grant 15842WE
   (to VNK and JT) and the Swedish Cancer Society (4920-B06-03PCD to FW).
   AAM is a fellow of the Norwegian Cancer Society. JAR is a fellow of the
   Faculty of Medicine, University of Oslo.
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Atalay C, 2008, J CHEMOTHERAPY, V20, P734, DOI 10.1179/joc.2008.20.6.734
   Batistatou A, 2004, IN VIVO, V18, P661
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Boda E, 2009, J MOL NEUROSCI, V37, P238, DOI 10.1007/s12031-008-9128-9
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Done SJ, 2001, J NATL CANCER I, V93, P700, DOI 10.1093/jnci/93.9.700
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Hannemann J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1613
   HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Khilko N, 2007, INT J SURG PATHOL, V15, P233, DOI 10.1177/1066896907302116
   Kuijk EW, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-58
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lukas J, 2000, AM J PATHOL, V156, P183, DOI 10.1016/S0002-9440(10)64718-9
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Pinto AE, 2006, J CLIN PATHOL, V59, P367, DOI 10.1136/jcp.2005.027722
   Porter D, 2003, MOL CANCER RES, V1, P362
   Reed K, 2008, EPIGENETICS-US, V3, P270, DOI 10.4161/epi.3.5.6868
   Rodriguez J, 2006, CANCER RES, V66, P8462, DOI 10.1158/0008-5472.CAN-06-0293
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610
   Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Viswanathan M., 2006, Indian Journal of Experimental Biology, V44, P115
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wiechmann L, 2008, CANCER-AM CANCER SOC, V112, P2130, DOI 10.1002/cncr.23430
   Yan PS, 2003, CANCER RES, V63, P6178
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
   ZHOU W, 2009, MOL ONCOL IN PRESS
NR 52
TC 122
Z9 146
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2010
VL 12
IS 1
AR R3
DI 10.1186/bcr2466
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 587JD
UT WOS:000276986300009
PM 20056007
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Mukhopadhyay, R
   Costes, SV
   Bazarov, AV
   Hines, WC
   Barcellos-Hoff, MH
   Yaswen, P
AF Mukhopadhyay, Rituparna
   Costes, Sylvain V.
   Bazarov, Alexey V.
   Hines, William C.
   Barcellos-Hoff, Mary Helen
   Yaswen, Paul
TI Promotion of variant human mammary epithelial cell outgrowth by ionizing
   radiation: an agent-based model supported by in vitro studies
SO BREAST CANCER RESEARCH
LA English
DT Article
ID DE-NOVO METHYLATION; CPG ISLAND; TUMOR-GROWTH; GALACTOSIDASE ACTIVITY;
   MAMMALIAN-CELLS; CYCLE CONTROL; HUMAN LUNG; GENE; SENESCENCE; EXPRESSION
AB Introduction: Most human mammary epithelial cells (HMEC) cultured from histologically normal breast tissues enter a senescent state termed stasis after 5 to 20 population doublings. These senescent cells display increased size, contain senescence associated beta-galactosidase activity, and express cyclin-dependent kinase inhibitor, p16(INK4A) (CDKN2A; p16). However, HMEC grown in a serum-free medium, spontaneously yield, at low frequency, variant (v) HMEC that are capable of long-term growth and are susceptible to genomic instability. We investigated whether ionizing radiation, which increases breast cancer risk in women, affects the rate of vHMEC outgrowth.
   Methods: Pre-stasis HMEC cultures were exposed to 5 to 200 cGy of sparsely (X- or gamma-rays) or densely (1 GeV/amu Fe-56) ionizing radiation. Proliferation (bromodeoxyuridine incorporation), senescence (senescence-associated beta-galactosidase activity), and p16 expression were assayed in subcultured irradiated or unirradiated populations four to six weeks following radiation exposure, when patches of vHMEC became apparent. Long-term growth potential and p16 promoter methylation in subsequent passages were also monitored. Agent-based modeling, incorporating a simple set of rules and underlying assumptions, was used to simulate vHMEC outgrowth and evaluate mechanistic hypotheses.
   Results: Cultures derived from irradiated cells contained significantly more vHMEC, lacking senescence associated beta-galactosidase or p16 expression, than cultures derived from unirradiated cells. As expected, post-stasis vHMEC cultures derived from both unirradiated and irradiated cells exhibited more extensive methylation of the p16 gene than pre-stasis HMEC cultures. However, the extent of methylation of individual CpG sites in vHMEC samples did not correlate with passage number or treatment. Exposure to sparsely or densely ionizing radiation elicited similar increases in the numbers of vHMEC compared to unirradiated controls. Agent-based modeling indicated that radiation-induced premature senescence of normal HMEC most likely accelerated vHMEC outgrowth through alleviation of spatial constraints. Subsequent experiments using defined co-cultures of vHMEC and senescent cells supported this mechanism.
   Conclusions: Our studies indicate that ionizing radiation can promote the outgrowth of epigenetically altered cells with pre-malignant potential.
C1 [Mukhopadhyay, Rituparna; Costes, Sylvain V.; Hines, William C.; Barcellos-Hoff, Mary Helen; Yaswen, Paul] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Bazarov, Alexey V.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Barcellos-Hoff, Mary Helen] NYU, Sch Med, Dept Radiat Oncol, New York, NY 10016 USA.
C3 University of California System; University of California Berkeley;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   San Francisco; New York University
RP Yaswen, P (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
EM P_Yaswen@lbl.gov
RI Costes, Sylvain/D-2522-2013
OI Costes, Sylvain/0000-0002-8542-2389; Hines, William/0000-0002-0707-3160
FU NIEHS NIH HHS [U01 ES012801] Funding Source: Medline
CR ALPEN EL, 1993, RADIAT RES, V136, P382, DOI 10.2307/3578551
   Andarawewa KL, 2007, CANCER RES, V67, P8662, DOI 10.1158/0008-5472.CAN-07-1294
   Barcellos-Hoff MH, 2006, MUTAT RES-FUND MOL M, V597, P32, DOI 10.1016/j.mrfmmm.2005.09.008
   Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776
   Belinsky SA, 2004, CARCINOGENESIS, V25, P1063, DOI 10.1093/carcin/bgh096
   Bonabeau E, 2002, P NATL ACAD SCI USA, V99, P7280, DOI 10.1073/pnas.082080899
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Chao DL, 2008, P NATL ACAD SCI USA, V105, P15034, DOI 10.1073/pnas.0802211105
   Chen S, 2004, P ANN INT IEEE EMBS, V26, P691
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Dicello JF, 2004, PHYS MED BIOL, V49, P3817, DOI 10.1088/0031-9155/49/16/024
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dormann Sabine, 2002, In Silico Biology, V2, P393
   Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3
   Enderling H, 2009, MATH MODEL NAT PHENO, V4, P117, DOI 10.1051/mmnp/20094305
   FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Holst CR, 2003, CANCER RES, V63, P1596
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980
   Kansal AR, 2000, J THEOR BIOL, V203, P367, DOI 10.1006/jtbi.2000.2000
   Kansal AR, 2000, BIOSYSTEMS, V55, P119, DOI 10.1016/S0303-2647(99)00089-1
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Markus M, 1999, MATH BIOSCI, V156, P191, DOI 10.1016/S0025-5564(98)10066-4
   McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051
   NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603
   Nonet GH, 2001, CANCER RES, V61, P1250
   Park CC, 2003, P NATL ACAD SCI USA, V100, P10728, DOI 10.1073/pnas.1832185100
   Peterson EJ, 2003, CANCER RES, V63, P6579
   Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201
   Romanenko A, 2004, VIRCHOWS ARCH, V445, P298, DOI 10.1007/s00428-004-1056-7
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021
   Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514
   Sudo H, 2008, RADIAT RES, V170, P23, DOI 10.1667/RR1317.1
   Sun T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002129
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168
   Tsai KKC, 2005, CANCER RES, V65, P6734, DOI 10.1158/0008-5472.CAN-05-0703
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   Yang NC, 2004, ANAL BIOCHEM, V325, P337, DOI 10.1016/j.ab.2003.11.012
   Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X
   Yates PA, 2003, MOL CELL BIOL, V23, P4461, DOI 10.1128/MCB.23.13.4461-4470.2003
NR 48
TC 20
Z9 24
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2010
VL 12
IS 1
AR R11
DI 10.1186/bcr2477
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 587JD
UT WOS:000276986300017
PM 20146798
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Avraham, A
   Sandbank, J
   Yarom, N
   Shalom, A
   Karni, T
   Pappo, I
   Sella, A
   Fich, A
   Walfisch, S
   Gheber, L
   Evron, E
AF Avraham, Ayelet
   Sandbank, Judith
   Yarom, Nirit
   Shalom, Avshalom
   Karni, Tami
   Pappo, Itzhak
   Sella, Avishay
   Fich, Alexander
   Walfisch, Shlomo
   Gheber, Larisa
   Evron, Ella
TI A similar cell-specific pattern of HOXA methylation in normal and in
   cancer tissues
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; HOX genes; breast cancer; cell type specific
   methylation; genome-wide methylation array
ID DE-NOVO METHYLATION; DNA METHYLATION; GENE; BREAST; EXPRESSION;
   ACTIVATION; HISTONE; CLUSTER
AB HOX genes are developmental genes that determine anterior-posterior embryonic pattern and govern the process of differentiation. Inappropriate expression of HOX genes has been implicated in developmental abnormalities and hematopoietic malignancies. In addition, HOX genes silencing by DNA methylation has been reported in cancers and related to disease aggressiveness and outcome. On the other hand, accumulating evidence suggests that epigenetic changes at HOX genes are linked to normal development and differentiation. To better understand the relationship between HOXA methylation and cancer, we analyzed the methylation pattern of HOXA genes in human primary breast and colon carcinomas, normal tissues, and normal white blood cells. Genome-wide methylation arrays of breast cancers and white blood cells demonstrated similar methylation patterns. Quantitative methylation analysis of seven representative HOXA genes revealed various levels of methylation in both normal tissues and cancers. Analysis of epithelial-enriched normal breast tissue and stroma indicated that the stroma was the major origin of HOXA methylation. Furthermore, in selected dense breast cancers, minimal increase in methylation of several HOXA genes did not correlate with the predominance of malignant epithelial cells in these tumors. Our results suggest that methylation of the HOXA cluster may be a normal developmental and cell type specific process rather than a cancer specific mechanism.
C1 [Avraham, Ayelet; Yarom, Nirit; Sella, Avishay; Evron, Ella] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Oncol, Zerifin, Israel.
   [Sandbank, Judith] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Pathol, Zerifin, Israel.
   [Shalom, Avshalom] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Plast Surg, Zerifin, Israel.
   [Karni, Tami; Pappo, Itzhak] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Surg, Zerifin, Israel.
   [Fich, Alexander; Walfisch, Shlomo] Soroka Univ, Med Ctr, Dept Gastroenterol, Beer Sheva, Israel.
   [Fich, Alexander; Walfisch, Shlomo] Soroka Univ, Med Ctr, Colorectal Unit, Beer Sheva, Israel.
   [Gheber, Larisa] Ben Gurion Univ Negev, Dept Chem, Beer Sheva, Israel.
C3 Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv
   University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University;
   Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir
   Medical Center (Assaf Harofeh); Ben Gurion University; Soroka Medical
   Center; Ben Gurion University; Soroka Medical Center; Ben Gurion
   University
RP Avraham, A (通讯作者)，Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Oncol, Zerifin, Israel.
EM ayeleta@asaf.health.gov.il
OI Evron, Ella/0000-0002-1003-5042
FU Israeli Cancer Association [C20070015]; ISF [1043/09]; BSF [2003141]
FX This study was supported by the Israeli Cancer Association grant no.
   C20070015 and partially by ISF grant no. 1043/09 and BSF grant no.
   2003141 awarded to L. G.
CR Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760
   Atkinson SP, 2008, STEM CELLS, V26, P1174, DOI 10.1634/stemcells.2007-0497
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fiegl H, 2008, INT J CANCER, V123, P725, DOI 10.1002/ijc.23563
   Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162
   Han L, 2007, CANCER BIOL THER, V6, P1284
   Henderson GS, 2006, CELL ONCOL, V28, P305
   Hershko AY, 2003, GENE, V302, P65, DOI 10.1016/S0378111902010910
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161
   Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Shen HCJ, 2008, ENDOCR-RELAT CANCER, V15, P267, DOI 10.1677/ERC-07-0191
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453
   Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436
   Strathdee G, 2007, CARCINOGENESIS, V28, P299, DOI 10.1093/carcin/bgl133
   Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103
   Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608
   Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056
NR 32
TC 13
Z9 15
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JAN 1
PY 2010
VL 5
IS 1
BP 41
EP 46
DI 10.4161/epi.5.1.10724
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 559AA
UT WOS:000274790700008
PM 20083893
OA Bronze
DA 2025-01-12
ER

PT J
AU Fu, DY
   Wang, ZM
   Wang, BL
   Chen, L
   Yang, WT
   Shen, ZZ
   Huang, W
   Shao, ZM
AF Fu, De-Yuan
   Wang, Zhi-Min
   Wang, Bei-Lan
   Chen, Li
   Yang, Wen-Tao
   Shen, Zhen-Zhou
   Huang, Wei
   Shao, Zhi-Ming
TI Frequent epigenetic inactivation of the receptor tyrosine kinase
   <i>EphA5</i> by promoter methylation in human breast cancer
SO HUMAN PATHOLOGY
LA English
DT Article
DE Breast cancer; DNA methylation; EphA5; Epigenetic inactivation
ID DNA METHYLATION; ESTROGEN-RECEPTOR; CARCINOMA CELLS; EXPRESSION;
   HYPERMETHYLATION; OVEREXPRESSION; PROGRESSION; MECHANISMS
AB EphA5 is a member of the Eph receptor tyrosine kinase family, which plays a critical role in the regulation of carcinogenesis. Our previous DNA methylation microarray results suggested that the CpG islands in the EphA5 promoter exhibited higher methylation levels in breast cancer tissues. In this study, we further analyzed EphA5 gene expression profiles, methylation status, and clinical implications in breast cancer. We found that the level of EphA5 mRNA was dramatically decreased in 5 different breast cancer cell lines. After treating the cell lines with 5-aza-2'-deoxycytidine (5-aza-dC, a demethylation agent), the levels of EphA5 mRNA and protein were significantly increased. Bisulfite sequencing and methylation-specific polymerase chain reaction detection showed that decreased expression of EphA5 was associated with its methylation status. We also found a significant correlation (P = .017) between the reduction of EphA5 mRNA levels and aberrant methylation of EphA5 in 31 paired tissue samples. In clinical samples, EphA5 methylation was detected in 64.1% (75/117) of breast tumors and 28.2% (33/117) of paired normal tissues (P < .001), which was associated with higher tumor grade (P = .024), lymph node metastasis (P = .004), and progesterone receptor negative status (P = .008). Our data indicate that Eph45 might be a potential target for epigenetic silencing in primary breast cancer and a valuable molecular marker for breast cancer carcinogenesis and progression. (c) 2010 Elsevier Inc. All rights reserved.
C1 [Wang, Zhi-Min; Wang, Bei-Lan; Huang, Wei] Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China.
   [Fu, De-Yuan; Chen, Li; Shen, Zhen-Zhou; Shao, Zhi-Ming] Fudan Univ, Inst Biomed Sci, Shanghai Med Coll, Dept Oncol,Canc Hosp,Breast Canc Inst, Shanghai 200032, Peoples R China.
   [Fu, De-Yuan] Subei Peoples Hosp Jiangsu Prov, Dept Breast Surg, Yangzhou 225001, Peoples R China.
   [Yang, Wen-Tao] Fudan Univ, Inst Biomed Sci, Shanghai Med Coll, Dept Oncol,Canc Hosp,Dept Pathol, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University
RP Huang, W (通讯作者)，Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China.
EM huangwei@chgc.sh.cn; zhimingshao@yahoo.com
RI Huang, Wei/L-7090-2019
FU National Basic Research Program of China [2006CB910501]; National
   Natural Science Foundation of China [30371580, 30572109]; Shanghai
   Science and Technology Committee [03J14019, 06DJ14004, 06DZ19504]
FX This research was supported in part by the grants from the National
   Basic Research Program of China (2006CB910501), National Natural Science
   Foundation of China (30371580, 30572109), and Shanghai Science and
   Technology Committee (03J14019, 06DJ14004, 06DZ19504).
CR ANDRES AC, 1994, ONCOGENE, V9, P1461
   Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937
   Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dawson DW, 2007, ONCOGENE, V26, P4243, DOI 10.1038/sj.onc.1210211
   Dottori M, 1999, BLOOD, V94, P2477, DOI 10.1182/blood.V94.7.2477.419k13_2477_2486
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Fox BP, 2006, BIOCHEM BIOPH RES CO, V340, P268, DOI 10.1016/j.bbrc.2005.11.174
   Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577
   Holst CR, 2003, CANCER RES, V63, P1596
   Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780
   Kinch MS, 2003, CLIN CANCER RES, V9, P613
   Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122
   Lu M, 2003, CANCER RES, V63, P3425
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Merlos-Suárez A, 2008, CURR OPIN CELL BIOL, V20, P194, DOI 10.1016/j.ceb.2008.01.011
   MOLINO A, 1995, BREAST CANCER RES TR, V34, P221, DOI 10.1007/BF00689713
   Nass SJ, 2000, CANCER RES, V60, P4346
   Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T
   Wang JD, 2005, ONCOGENE, V24, P5637, DOI 10.1038/sj.onc.1208720
   Wang JD, 2007, HUM PATHOL, V38, P1649, DOI 10.1016/j.humpath.2007.01.030
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Yue Y, 2002, P NATL ACAD SCI USA, V99, P10777, DOI 10.1073/pnas.162354599
NR 33
TC 53
Z9 56
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD JAN
PY 2010
VL 41
IS 1
BP 48
EP 58
DI 10.1016/j.humpath.2009.06.007
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 581AT
UT WOS:000276493300007
PM 19733895
DA 2025-01-12
ER

PT J
AU Luo, J
   Li, YN
   Wang, F
   Zhang, WM
   Geng, X
AF Luo, Jin
   Li, Yan-Ni
   Wang, Fei
   Zhang, Wei-Ming
   Geng, Xin
TI S-Adenosylmethionine Inhibits the Growth of Cancer Cells by Reversing
   the Hypomethylation Status of <i>c</i>-<i>myc</i> and H-ras in Human
   Gastric Cancer and Colon Cancer
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE S-Adenosylmethionine; epigenetics; hypomethylation; gastric cancer;
   cancer therapy
ID GLOBAL DNA HYPOMETHYLATION; PROSTATE-CANCER; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; METHYLATION STATUS; PROMOTER REGION; IN-VIVO;
   DEMETHYLATION; GENE; EXPRESSION
AB A global DNA hypomethylation might activate oncogene transcription, thus promoting carcinogenesis and tumor development. S-Adenosylmethionine (SAM) serves as a major methyl donor in biological transmethylation events. The object of this study is to explore the influence of SAM on the status of methylation at the promoter of the oncogenes c-my, H-ras and tumor-suppressor gene p16 (INK4a), as well as its inhibitory effect on cancer cells. The results indicated that SAM treatment inhibited cell growth in gastric cancer cells and colon cancer cells, and the inhibition efficiency was significantly higher than that in the normal cells. Under standard growth conditions, C-myc and H-ras promoters were hypomethylated in gastric cancer cells and colon cancer cells. SAM treatment resulted in a heavy methylation of these promoters, which consequently downregulated mRNA and protein levels. In contrast, there was no significant difference in mRNA and protein levels of p16 (INK4a) with and without SAM treatment. SAM can effectively inhibit the tumor cells growth by reversing the DNA hypomethylation on promoters of oncogenes, thus down-regulating their expression. With no influence on the expression of the tumor suppressor genes, such as P16, SAM could be used as a potential drug for cancer therapy.
C1 [Luo, Jin; Zhang, Wei-Ming; Geng, Xin] Tianjin Med Univ, Dept Biochem, Tianjin 300070, Peoples R China.
   [Li, Yan-Ni] Tianjin Stomatol Hosp, Tianjin, Peoples R China.
   [Wang, Fei] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Geng, X (通讯作者)，Tianjin Med Univ, Dept Biochem, Tianjin 300070, Peoples R China.
EM gengxin111@126.com
RI Zhang, Wei-Ming/L-5761-2017
FU Chinese National Natural Science Foundation [30901703]; Tianjin
   Education Committee Technology Development [20080107]; Tianjin Medical
   University Natural Science [2008ky02]
FX We are grateful to Dr. Yong Zhao (The university of Texas Southwestern
   Medical Center, USA) and Dr. Phillip Smiraldo (The university of Texas
   Southwestern Medical Center, USA) for critical review of the manuscript.
   This work was supported by Chinese National Natural Science Foundation
   Grant (No. 30901703), Tianjin Education Committee Technology Development
   Grant (No. 20080107) and Tianjin Medical University Natural Science
   Grant (No. 2008ky02).
CR Bale S, 2010, AMINO ACIDS, V38, P451, DOI 10.1007/s00726-009-0404-y
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048
   Daura-Oller E, 2009, BIOINFORMATION, V3, P340, DOI 10.6026/97320630003340
   Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200
   Escoubet-Lozach L, 2009, CANCER RES, V69, P7347, DOI 10.1158/0008-5472.CAN-08-4898
   Gonzalo V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008777
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Lee YM, 2006, CANCER SCI, V97, P1205, DOI 10.1111/j.1349-7006.2006.00320.x
   Li Ning, 2002, Hepatobiliary Pancreat Dis Int, V1, P96
   Li TWH, 2009, MOL PHARMACOL, V76, P192, DOI 10.1124/mol.108.054411
   Liu ZX, 2008, ONCOL REP, V20, P151
   Lu SC, 2008, J GASTROEN HEPATOL, V23, pS73, DOI 10.1111/j.1440-1746.2007.05289.x
   Luka Z, 2009, J BIOL CHEM, V284, P22507, DOI 10.1074/jbc.R109.019273
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Pulukuri SMK, 2007, CANCER RES, V67, P930, DOI 10.1158/0008-5472.CAN-06-2892
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Ramani K, 2010, HEPATOLOGY, V51, P986, DOI 10.1002/hep.23411
   Richards KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004941
   Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Schaller JL, 2004, EUR CHILD ADOLES PSY, V13, P332, DOI 10.1007/s00787-004-0396-9
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Silveri MM, 2003, BIOL PSYCHIAT, V54, P833, DOI 10.1016/S0006-3223(03)00064-7
   Szyf M, 2008, CURR ONCOL, V15, P72
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Taghavi N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-138
   Tomita H, 2010, CARCINOGENESIS, V31, P1627, DOI 10.1093/carcin/bgq129
   Turner JD, 2008, NUCLEIC ACIDS RES, V36, P7207, DOI 10.1093/nar/gkn897
   Vanyushin BF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P488, DOI 10.1007/s10541-005-0143-y
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   Wang ZH, 2010, ARCH MED RES, V41, P1, DOI 10.1016/j.arcmed.2009.11.001
   Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236
   Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917
   Ye L, 2005, J ENDOCRINOL, V185, P337, DOI 10.1677/joe.1.05963
   Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622
   Zhao Ye, 2010, Chin J Cancer, V29, P752
NR 43
TC 95
Z9 108
U1 0
U2 17
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2010
VL 6
IS 7
BP 784
EP 795
PG 12
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA 700UU
UT WOS:000285770600017
PM 21152119
DA 2025-01-12
ER

PT J
AU Ji, Q
   Karnak, D
   Hao, P
   Wang, RQ
   Xu, L
AF Ji, Qing
   Karnak, David
   Hao, Ping
   Wang, Rongquan
   Xu, Liang
TI No small matter: microRNAs - key regulators of cancer stem cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE microRNAs; stem cells; cancer; regulators; oncogene
ID BREAST-CANCER; PROSPECTIVE IDENTIFICATION; SELF-RENEWAL; OVEREXPRESSION;
   METASTASIS; APOPTOSIS; MIR-21; TARGET; PDCD4; BCL-2
AB Emerging evidence demonstrates that both tumor suppressor and oncogenic miRNAs play an essential role in stem cell self-renewal and differentiation by negatively regulating the expression of certain key genes in stem cells. It seems logical that they may also be critical players in cancer stem cells. Though small in size, miRNAs play a key role in the epigenetic regulation of cancer stem cells. Specifically, the imbalance of oncogenic vs. tumor suppressor miRNAs may lead to dysregulation of cancer stem cells, thus causing excessive self-renewal and survival of cancer stem cells, and resistance to chemo/radiotherapy. We postulate that restoring the balance of miRNAs will correct this dysregulation via the direct and simultaneous modulation of downstream stem cell pathways involved in cancer stem cell self-renewal and/or differentiation. The resultant restoration of key regulatory pathways could improve therapeutic response. Restoring tumor suppressor miRNAs and/or inhibiting oncogenic miRNAs may provide a novel molecular therapy for human cancers, potentially via modulating cancer stem cells.
C1 [Ji, Qing; Wang, Rongquan] Third Mil Med Univ, Affiliated Hosp 1, Dept Digest Dis, Chongqing 400038, Peoples R China.
   [Hao, Ping] Third Mil Med Univ, Affiliated Hosp 2, Dept Oncol, Chongqing 400038, Peoples R China.
   [Ji, Qing; Karnak, David; Xu, Liang] Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
C3 Army Medical University; Army Medical University; University of Michigan
   System; University of Michigan
RP Ji, Q (通讯作者)，Third Mil Med Univ, Affiliated Hosp 1, Dept Digest Dis, Chongqing 400038, Peoples R China.
EM qingji@hotmail.com; li-angxu@umich.edu
RI Xu, Liang/F-6914-2015; Hao, Ping/H-4471-2012
OI Wang, Rongquan/0000-0001-5307-0086
FU China TMMU Natural Science Foundation [2009XHG10]; Chongqing Natural
   Science Foundation (CSTC) [2009BB5022]; United States NIH [R01
   CA121830(S1), R01 CA134655]
FX This work was supported in part by China TMMU Natural Science Foundation
   (2009XHG10) and Chongqing Natural Science Foundation (CSTC, 2009BB5022)
   (to Q. J.), and United States NIH grants R01 CA121830(S1) and R01
   CA134655 (to L. X.).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947
   Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60
   Clarke MF, 2005, CANCER CHEMOTH PHARM, V56, pS64, DOI 10.1007/s00280-005-0097-1
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Desano JT, 2009, AAPS J
   Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253
   Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
   Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Hatfield S, 2008, CELL TISSUE RES, V331, P57, DOI 10.1007/s00441-007-0530-3
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Lowery AJ, 2008, CLIN CANCER RES, V14, P360, DOI 10.1158/1078-0432.CCR-07-0992
   Lu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003420
   Papagiannakopoulos T, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-15
   Peacock CD, 2008, J CLIN ONCOL, V26, P2883, DOI 10.1200/JCO.2007.15.2702
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Tang DG, 2007, MOL CARCINOGEN, V46, P1, DOI 10.1002/mc.20255
   Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436
   Wicha MS, 2007, STEM CELL REV, V3, P110, DOI 10.1007/s12015-007-0016-4
   Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537
   Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002
   Yi SY, 2008, CANCER BIOL THER, V7, P325, DOI 10.4161/cbt.7.3.5527
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
NR 36
TC 10
Z9 11
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2010
VL 3
IS 1
BP 84
EP 87
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V28SP
UT WOS:000208700800009
PM 20369043
DA 2025-01-12
ER

PT J
AU Zhao, ZJ
   Wu, QX
   Cheng, JA
   Qiu, XM
   Zhang, JQ
   Fan, H
AF Zhao, Zhujiang
   Wu, Qingxiang
   Cheng, Jian
   Qiu, Xuemei
   Zhang, Jianqiong
   Fan, Hong
TI Depletion of <i>DNMT3A</i> Suppressed Cell Proliferation and Restored
   <i>PTEN</i> in Hepatocellular Carcinoma Cell
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
ID DNA METHYLTRANSFERASE EXPRESSION; INTERFERENCE-MEDIATED KNOCKDOWN; CPG
   ISLAND HYPERMETHYLATION; PROMOTER METHYLATION; MULTISTEP
   HEPATOCARCINOGENESIS; GENE REEXPRESSION; BREAST-CANCER; INSTABILITY;
   AKT/PKB; 3A
AB Promoter hypermethylation mediated by DNA methyltransferases (DNMTs) is the main reason for epigenetic inactivation of tumor suppressor genes (TSGs). Previous studies showed that DNMT1 and DNMT3B play an important role in CpG island methylation in tumorigenesis. Little is known about the role of DNMT3A in this process, especially in hepatocellular carcinoma (HCC). In the present study, increased DNMT3A expression in 3 out of 6 HCC cell lines and 16/25 (64%) HCC tissues implied that DNMT3A is involved in hepatocellular carcinogenesis. Depletion of DNMT3A in HCC cell line SMMC-7721 inhibited cell proliferation and decreased the colony formation (about 65%). Microarray data revealed that 153 genes were upregulated in DNMT3A knockdown cells and that almost 71% (109/153) of them contain CpG islands in their 5' region. 13 of them including PTEN, a crucial tumor suppressor gene in HCC, are genes involved in cell cycle and cell proliferation. Demethylation of PTEN promoter was observed in DNMT3A-depleted cells implying that DNMT3A silenced PTEN via DNA methylation. These results provide insights into the mechanisms of DNMT3A to regulate TSGs by an epigenetic approach in HCC.
C1 [Zhao, Zhujiang; Wu, Qingxiang; Qiu, Xuemei; Zhang, Jianqiong; Fan, Hong] Southeast Univ, Minist Educ, Key Lab Dev Genes & Human Dis, Nanjing 210009, Peoples R China.
   [Zhao, Zhujiang; Fan, Hong] Southeast Univ, Inst Life Sci, Nanjing 210009, Peoples R China.
   [Cheng, Jian] Nanjing Matern & Child Hlth Care Hosp, Prenatal Diag Ctr, Nanjing 210009, Peoples R China.
C3 Southeast University - China; Southeast University - China
RP Fan, H (通讯作者)，Southeast Univ, Minist Educ, Key Lab Dev Genes & Human Dis, Nanjing 210009, Peoples R China.
EM fanh@seu.edu.cn
RI Fan, Hong/KMA-7361-2024
FU National Natural Science Foundation of China [30470950, 30971605]
FX This work was supported by The National Natural Science Foundation of
   China, no. 30470950 and no. 30971605. The authors are grateful to
   Professor Dianqing WU in UConn Health Center USA for providing siRNA
   expression vector. They also thank Dr. Sen Lu, and Dr. Chuanjun Wen for
   their assistance in collecting samples.
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685
   Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5
   Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185
   Deng T, 2009, BIOCHEM BIOPH RES CO, V387, P611, DOI 10.1016/j.bbrc.2009.07.093
   Eads CA, 1999, CANCER RES, V59, P2302
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018
   Hata K, 2002, DEVELOPMENT, V129, P1983
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jun Xu, 2005, Acta Genetica Sinica, V32, P1115
   Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633
   KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594
   Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Nagai M, 2003, HEPATOL RES, V26, P186, DOI 10.1016/S1386-6346(03)00091-3
   Oh BK, 2007, INT J MOL MED, V20, P65
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Samuel MS, 2009, GASTROENTEROLOGY, V137, P902, DOI 10.1053/j.gastro.2009.05.042
   Shafiei F, 2008, ONCOGENE, V27, P2602, DOI 10.1038/sj.onc.1210917
   Shulkla S, 2007, INT J CANCER, V121, P1424, DOI 10.1002/ijc.22862
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Wang J, 2007, CANCER RES, V67, P10647, DOI 10.1158/0008-5472.CAN-07-1337
   Wang L, 2007, HEPATOL RES, V37, P389, DOI 10.1111/j.1872-034X.2007.00042.x
   Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
NR 44
TC 55
Z9 57
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110-7243
EI 1110-7251
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PY 2010
AR 737535
DI 10.1155/2010/737535
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 606YA
UT WOS:000278463700001
OA Green Published, Green Submitted, Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Huang, J
   Zheng, DL
   Qin, FS
   Cheng, N
   Chen, H
   Wan, BB
   Wang, YP
   Xiao, HS
   Han, ZG
AF Huang, Jian
   Zheng, Da-Li
   Qin, Feng-Song
   Cheng, Na
   Chen, Hui
   Wan, Bing-Bing
   Wang, Yu-Ping
   Xiao, Hua-Sheng
   Han, Ze-Guang
TI Genetic and epigenetic silencing of <i>SCARA5</i> may contribute to
   human hepatocellular carcinoma by activating FAK signaling
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID FOCAL-ADHESION KINASE; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE;
   COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND HYPERMETHYLATION;
   CHROMOSOME ARM 8P; FREQUENT LOSS; DOWN-REGULATION; BREAST-CANCER;
   LIVER-CANCER
AB The epigenetic silencing of tumor suppressor genes is a crucial event during carcinogenesis and metastasis. Here, in a human genome-wide survey, we identified scavenger receptor class A, member 5 (SCARA5) as a candidate tumor suppressor gene located on chromosome 8p. We found that SCARA5 expression was frequently downregulated as a result of promoter hypermethylation and allelic imbalance and was associated with vascular invasion in human hepatocellular carcinoma (HCC). Furthermore, SCARA5 knockdown via RNAi markedly enhanced HCC cell growth in vitro, colony formation in soft agar, and invasiveness, tumorigenicity, and lung metastasis in vivo. By contrast, SCARA5 overexpression suppressed these malignant behaviors. Interestingly, SCARA5 was found to physically associate with focal adhesion kinase (FAK) and inhibit the tyrosine phosphorylation cascade of the FAK-Src-Cas signaling pathway. Conversely, silencing SCARA5 stimulated the signaling pathway via increased phosphorylation of certain tyrosine residues of FAK, Src, and p130Cas; it was also associated with activation of MMP9, a tumor metastasis-associated enzyme. Taken together, these data suggest that the plasma membrane protein SCARA5 can contribute to HCC tumorigenesis and metastasis via activation of the FAK signaling pathway.
C1 [Huang, Jian; Zheng, Da-Li; Qin, Feng-Song; Cheng, Na; Chen, Hui; Wan, Bing-Bing; Wang, Yu-Ping; Han, Ze-Guang] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Dis & Hlth Genom, Shanghai 201203, Peoples R China.
   [Huang, Jian; Zheng, Da-Li; Qin, Feng-Song; Cheng, Na; Wang, Yu-Ping; Han, Ze-Guang] Shanghai Jiao Tong Univ, Sch Med, Natl Human Genome Ctr, Shanghai 200030, Peoples R China.
   [Xiao, Hua-Sheng] Natl Engn Ctr Biochip Shanghai, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Han, ZG (通讯作者)，Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Dis & Hlth Genom, 351 Guo Shou Jing Rd, Shanghai 201203, Peoples R China.
EM hanzg@chgc.sh.cn
RI Zheng, Dali/J-2973-2019; Zhu, Yuyan/ABE-4176-2021
OI Wan, Bingbing/0000-0001-8629-0616; Han, Ze-Guang/0000-0002-1018-1752;
   Zheng, Dali/0000-0003-2345-4040
FU China National Key Projects for Infectious Disease [2008ZX10002-021,
   2008ZX10002-020]; Chinese National Key Program on Basic Research
   [2010CB529200, 2006CB910402]; International Scientific Collaborative
   Project [20072901]; Shanghai Commission for Science and Technology
   [08JC1416400, 06ZR14069, 06DZ22903]; China Postdoctoral Science
   Foundation [20070420097]; Shanghai Postdoctoral Science Foundation
   [07R214138]
FX We gratefully acknowledge support from the China National Key Projects
   for Infectious Disease (2008ZX10002-021 and 2008ZX10002-020), the
   Chinese National Key Program on Basic Research (2010CB529200 and
   2006CB910402), International Scientific Collaborative Project
   (20072901), the Shanghai Commission for Science and Technology
   (08JC1416400, 06ZR14069, and 06DZ22903), the China Postdoctoral Science
   Foundation (20070420097), and the Shanghai Postdoctoral Science
   Foundation (07R214138).
CR Adams J, 2005, CANCER RES, V65, P66
   Guervsós MA, 2007, CELL ONCOL, V29, P327
   Becker SA, 1996, CANCER RES, V56, P5092
   Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Cance WG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.120pe22
   Chan KL, 2002, CANCER, V94, P3179, DOI 10.1002/cncr.10612
   Chang BL, 2007, CANCER RES, V67, P4098, DOI 10.1158/0008-5472.CAN-06-4570
   Coon SW, 2004, INT J CANCER, V111, P206, DOI 10.1002/ijc.20254
   Cooper WN, 2008, ONCOGENE, V27, P1805, DOI 10.1038/sj.onc.1210805
   Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345
   Dai HY, 2008, MOL CARCINOGEN, V47, P956, DOI 10.1002/mc.20448
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307
   Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811
   Fujii T, 2004, J HEPATOL, V41, P104, DOI 10.1016/j.jhep.2004.03.029
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-126
   Huang J, 2007, CARCINOGENESIS, V28, P1094, DOI 10.1093/carcin/bgl215
   Huang J, 2006, FEBS LETT, V580, P3571, DOI 10.1016/j.febslet.2006.05.032
   ILLC D, 1995, NATURE, V377, P539
   Itoh S, 2004, CLIN CANCER RES, V10, P2812, DOI 10.1158/1078-0432.CCR-1046-03
   Jiang Y, 2006, J BIOL CHEM, V281, P9058, DOI 10.1074/jbc.M507874200
   Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384
   Kubo T, 2004, CANCER RES, V64, P5172, DOI 10.1158/0008-5472.CAN-03-3314
   Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367
   Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138
   Lu T, 2007, WORLD J GASTROENTERO, V13, P1090, DOI 10.3748/wjg.v13.i7.1090
   Lu W, 2006, GENE CHROMOSOME CANC, V45, P509, DOI 10.1002/gcc.20314
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647
   Midorikawa Y, 2006, ONCOGENE, V25, P5581, DOI 10.1038/sj.onc.1209537
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Mitsuhashi N, 2003, HEPATOLOGY, V37, P1105, DOI 10.1053/jhep.2003.50204
   Morikawa A, 2005, BREAST CANCER RES, V7, pR1051, DOI 10.1186/bcr1349
   Patil MA, 2005, CARCINOGENESIS, V26, P2050, DOI 10.1093/carcin/bgi178
   Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538
   Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648
   Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014
   Qin LX, 1999, CANCER RES, V59, P5662
   Rubio-Moscardo F, 2005, BLOOD, V106, P3214, DOI 10.1182/blood-2005-05-2013
   Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008
   Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750
   Shih YL, 2006, CANCER, V107, P579, DOI 10.1002/cncr.22023
   Song Li-jie, 2005, Zhonghua Gan Zang Bing Za Zhi, V13, P428
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Sugimachi K, 2003, J CLIN PATHOL, V56, P854, DOI 10.1136/jcp.56.11.854
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Swalwell JI, 2002, GENE CHROMOSOME CANC, V33, P201, DOI 10.1002/gcc.10015
   Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891
   Teodoridis JM, 2008, CANCER LETT, V268, P177, DOI 10.1016/j.canlet.2008.03.022
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002
   van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011
   Venter DJ, 2005, CANCER GENET CYTOGEN, V160, P134, DOI 10.1016/j.cancergencyto.2004.12.007
   Wistuba II, 1999, CANCER RES, V59, P1973
   Wong CM, 2007, HEPATOLOGY, V45, P1129, DOI 10.1002/hep.21578
   Wong CM, 2003, CANCER RES, V63, P7646
   Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318
   Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608
   Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Ye H, 2007, CANCER GENET CYTOGEN, V176, P100, DOI 10.1016/j.cancergencyto.2007.04.003
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5
   Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4
   Zhou X, 2008, INT J ONCOL, V32, P1285
   Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 75
TC 115
Z9 162
U1 0
U2 15
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 2010
VL 120
IS 1
BP 223
EP 241
DI 10.1172/JCI38012
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 542LU
UT WOS:000273495700027
PM 20038795
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Chalabi, N
   Coxam, V
   Satih, S
   Davicco, MJ
   Lebecque, P
   Fontana, L
   Bignon, YJ
   Bernard-Gallon, DJ
AF Chalabi, Nassera
   Coxam, Veronique
   Satih, Samir
   Davicco, Marie-Jeanne
   Lebecque, Patrice
   Fontana, Luc
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique J.
TI Gene signature of rat mammary glands: Influence of lifelong soy
   isoflavones consumption
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE females Wistar; mammary glands; microarrays; soy isoflavone diets
ID ESTROGEN-RECEPTORS ALPHA; GROWTH-FACTOR-I; BREAST-CANCER; GENISTEIN;
   RISK; BETA; PHYTOESTROGENS; VEGF
AB Epidemiological studies have indicated that phytoestrogen has a preventive effect on breast cancer development. However, controversial results have been reported suggesting these compounds have ambivalent effects on breast tissue. Here, we report a transgenerational study conducted on female Wistar rats fed a diet enriched with phytoestrogen. Using a pangenomic microarray approach, a transcriptomic study was performed on mammary glands extracted from the animals. Gene expression was examined at 3 ages: 3, 18 and 24 months. The F, generation did not express the same genes as the F-0 control generation fed the same diet. This effect increased with animal age: in 3-, 18- and 24-month-old rats, 293, 441 and 2868 differentially expressed genes were respectively observed. These results suggest that long-term exposure to isoflavones may play a key role in gene regulation. Additionally, epigenetic patterns were found to be affected by DNA-methyltransferase and histone-deacetylase expression.
C1 [Chalabi, Nassera; Satih, Samir; Bignon, Yves-Jean; Bernard-Gallon, Dominique J.] Ctr Jean Perrin, Dept Oncogenet, CBRV, F-63011 Clermont Ferrand, France.
   [Fontana, Luc] CHU, Serv Med Travail & Pathol Profess, F-63001 Clermont Ferrand 01, France.
   [Chalabi, Nassera; Satih, Samir; Bignon, Yves-Jean; Bernard-Gallon, Dominique J.] CRNH, F-63009 Clermont Ferrand 01, France.
   [Coxam, Veronique; Davicco, Marie-Jeanne; Lebecque, Patrice] UNH, INRA Clermont Ferrand Theix, Equipe Alimentat Squelette & Metab, UMR 1019, F-63122 St Genes Champanelle, France.
C3 UNICANCER; Centre Jean Perrin; CHU Clermont Ferrand; INRAE
RP Bignon, YJ (通讯作者)，Ctr Jean Perrin, Dept Oncogenet, CBRV, 58 Rue Montalembert,BP 392, F-63011 Clermont Ferrand, France.
EM yves-jean.bignon@cjp.fr
RI Bernard-Gallon, Dominique/L-6079-2015; FONTANA, LUC/AAK-2701-2020
OI FONTANA, LUC/0000-0003-1870-3671
FU La Ligue Nationale Francaise de Lutte Contre le Cancer; Le Comite du
   Puy-de-Dome
FX This work was supported by grants from La Ligue Nationale Francaise de
   Lutte Contre le Cancer and Le Comite du Puy-de-Dome. N. Chalabi is a
   post-graduate of the Canceropole Lyon-Auvergne-Rhone-Alpes (CLARA),
   France. We thank Timothy Gunnels for facilitating the English
   translation.
CR Arends N, 2002, J CLIN ENDOCR METAB, V87, P2720, DOI 10.1210/jc.87.6.2720
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Ferrari G, 2006, P NATL ACAD SCI USA, V103, P17260, DOI 10.1073/pnas.0605556103
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1
   Hertrampf T, 2006, PLANTA MED, V72, P304, DOI 10.1055/s-2005-916229
   Holly J, 1998, LANCET, V352, P1388, DOI 10.1016/S0140-6736(05)60781-7
   Kim HA, 2007, MOL CELL BIOCHEM, V301, P201, DOI 10.1007/s11010-007-9412-y
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Linos Eleni, 2007, Curr Oncol Rep, V9, P31, DOI 10.1007/BF02951423
   Mardon J, 2008, EXP BIOL MED, V233, P229, DOI 10.3181/0707-RM-202
   MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541
   Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097
   Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rimoldi G, 2007, ENVIRON HEALTH PERSP, V115, P62, DOI 10.1289/ehp.9367
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Satih S, 2008, CURR NUTR FOOD SCI, V4, P259, DOI 10.2174/157340108786263658
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637
   Su Y, 2007, PHYSIOL GENOMICS, V30, P8, DOI 10.1152/physiolgenomics.00023.2007
   Totta P, 2005, J NUTR, V135, P2687, DOI 10.1093/jn/135.11.2687
   WAN XJ, 2006, TOXICOL SCI, V91, P93
   Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449
   Wu AH, 1996, CANCER EPIDEM BIOMAR, V5, P901
   Yang EB, 1996, BIOCHEM BIOPH RES CO, V224, P309, DOI 10.1006/bbrc.1996.1026
NR 31
TC 4
Z9 6
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN-FEB
PY 2010
VL 3
IS 1
BP 75
EP 81
DI 10.3892/mmr_00000221
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 532MU
UT WOS:000272753700011
PM 21472203
OA Bronze
DA 2025-01-12
ER

PT J
AU Santarius, T
   Shipley, J
   Brewer, D
   Stratton, MR
   Cooper, CS
AF Santarius, Thomas
   Shipley, Janet
   Brewer, Daniel
   Stratton, Michael R.
   Cooper, Colin S.
TI EPIGENETICS AND GENETICS A census of amplified and overexpressed human
   cancer genes
SO NATURE REVIEWS CANCER
LA English
DT Article
ID GERM-CELL TUMORS; IMPROVED SURVIVAL PROBABILITY; HUMAN BREAST-CANCER;
   EXPRESSION ANALYSIS; BLADDER-CANCER; AMPLIFICATION; AMPLICON;
   IDENTIFICATION; NEUROBLASTOMA; ADOLESCENTS
AB Integrated genome-wide screens of DNA copy number and gene expression in human cancers have accelerated the rate of discovery of amplified and overexpressed genes. However, the biological importance of most of the genes identified in such studies remains unclear. In this Analysis, we propose a weight-of-evidence based classification system for identifying individual genes in amplified regions that are selected for during tumour development. In a census of the published literature we have identified 77 genes for which there is good evidence of involvement in the development of human cancer.
C1 [Santarius, Thomas; Stratton, Michael R.] Wellcome Trust Sanger Ctr, Cambridge CB10 1SA, England.
   [Shipley, Janet; Brewer, Daniel] Inst Canc Res, Sutton SM2 5NG, Surrey, England.
C3 Wellcome Trust Sanger Institute; University of London; Institute of
   Cancer Research - UK
EM colin.cooper@icr.ac.uk
RI Lee, Ian/R-7298-2019; Lawrence, Michael/AAC-8202-2020; Brewer,
   Daniel/D-6201-2018
OI Santarius, Thomas/0000-0002-1416-9566; Stratton,
   Michael/0000-0001-6035-153X; Brewer, Daniel/0000-0003-4753-9794;
   Shipley, Janet/0000-0001-6748-8678
FU National Cancer Research Institute; Grand Charity of Freemasons;
   Prostate Cancer Charity; Bob Champion Cancer Trust; Prostate Cancer
   Research Foundation; Wellcome Trust
FX The authors thank the National Cancer Research Institute, the Grand
   Charity of Freemasons, the Prostate Cancer Charity, the Bob Champion
   Cancer Trust, the Prostate Cancer Research Foundation, and the Wellcome
   Trust for Support.
CR Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007
   Bignell GR, 2007, GENOME RES, V17, P1296, DOI 10.1101/gr.6522707
   Bourdon V, 2002, CANCER RES, V62, P6218
   Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   CORDONCARDO C, 1994, CANCER RES, V54, P794
   De Preter K, 2005, J CLIN ONCOL, V23, P3167, DOI 10.1200/JCO.2005.05.346
   Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274
   Fix A, 2008, GENE CHROMOSOME CANC, V47, P819, DOI 10.1002/gcc.20583
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741
   Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445
   Kaneko S, 2007, J CANCER RES CLIN, V133, P185, DOI 10.1007/s00432-006-0156-y
   Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339
   Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026
   McIntyre A, 2005, CANCER RES, V65, P8085, DOI 10.1158/0008-5472.CAN-05-0471
   Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045
   Natrajan R, 2006, CLIN CANCER RES, V12, P7284, DOI 10.1158/1078-0432.CCR-06-1567
   Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082
   Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749
   Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204
   Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022
   Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164
   Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302
   Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4
   Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126
   SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719
   Weber A, 2004, J CLIN ONCOL, V22, P2681, DOI 10.1200/JCO.2004.07.192
   WeberHall S, 1996, GENE CHROMOSOME CANC, V17, P7, DOI 10.1002/(SICI)1098-2264(199609)17:1<7::AID-GCC2>3.0.CO;2-0
   Zafarana G, 2003, ONCOGENE, V22, P7695, DOI 10.1038/sj.onc.1207011
   Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030
NR 32
TC 431
Z9 504
U1 1
U2 47
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-175X
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD JAN
PY 2010
VL 10
IS 1
BP 59
EP 64
DI 10.1038/nrc2771
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 546KF
UT WOS:000273809000014
PM 20029424
DA 2025-01-12
ER

PT J
AU Lasabova, Z
   Tilandyova, P
   Kajo, K
   Zubor, P
   Burjanivova, T
   Danko, J
   Plank, L
AF Lasabova, Z.
   Tilandyova, P.
   Kajo, K.
   Zubor, P.
   Burjanivova, T.
   Danko, J.
   Plank, L.
TI Hypermethylation of the GSTP1 promoter region in breast cancer is
   associated with prognostic clinicopathological parameters
SO NEOPLASMA
LA English
DT Article
DE breast cancer; prognostic factors; hypermethylation; GSTP1;
   methylation-specific PCR
ID DNA METHYLATION; EXPRESSION; MARKERS; GENES; ASSAY
AB Breast cancer is one of the most common cancer affecting women and the recent research is focused on identifying new genetic and epigenetic prognostic and predictive factors. Glutathione S-transferase P1 (GSTP1) is a biotransformation enzyme expressed in normal breast epithelial cells which can be epigenetically inactivated in breast cancer. We have shown, that application of nested two-stage methylation-specific PCR (MSP) is a suitable method for analysis of epigenetically silenced GSTP1 in formalin-fixed paraffin-embedded (FFPE) tissues from breast cancer patients. Of45 breast tumors, 11 (24, 4%) were found to have methylated GSTP 1 promoter region. We were able to demonstrate the correlation between the hypermethylation of the GSTP1 promoter region and histological grade of the tumor (p <0.01), Nottingham Prognostic Index (p < 0.01) and lymph node metastasis (p < 0.05). Our results indicate that the GSTP1 hypermethylation is putative prognostic factor in breast cancer but a confirmation of its prognostic value is desirable in larger studies.
C1 [Lasabova, Z.; Burjanivova, T.] Comenius Univ, Jessenius Fac Med, Dept Mol Biol, Martin, Slovakia.
   [Tilandyova, P.; Kajo, K.; Plank, L.] Comenius Univ, Jessenius Fac Med, Dept Pathol, Martin, Slovakia.
   [Zubor, P.] Comenius Univ, Jessenius Fac Med, Dept Obstet & Gynecol, Martin, Slovakia.
   Fac Hosp, Martin, Slovakia.
C3 Comenius University Bratislava; Comenius University Bratislava; Comenius
   University Bratislava
RP Lasabova, Z (通讯作者)，Comenius Univ, Jessenius Fac Med, Dept Mol Biol, Martin, Slovakia.
EM lasabova@jfined.uniba.sk
RI Zubor, Pavol/X-8191-2018; Kajo, Karol/HJZ-4538-2023; Lasabova,
   Zora/X-8254-2018
OI Zubor, Pavol/0009-0003-1423-5556; Kajo, Karol/0000-0002-8178-1093;
   Lasabova, Zora/0000-0003-2530-3991
FU VEGA [1/3373/06]; Slovak Ministry of Health [2005/14-MFN-06]
FX This work was supported by a VEGA grant 1/3373/06 and in part by grant
   no. 2005/14-MFN-06 from Slovak Ministry of Health. The authors thank
   Mrs. A.Vanochova and Mrs. Z.Kwiatkovska for excellent technical
   assistance.
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Arai T, 2008, EJSO-EUR J SURG ONC, V34, P734, DOI 10.1016/j.ejso.2007.07.008
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Blamey RW, 2007, EUR J CANCER, V43, P1548, DOI 10.1016/j.ejca.2007.01.016
   CAIRNS J, 1992, J PATHOL, V166, P19, DOI 10.1002/path.1711660105
   Ellis IO., 2003, Pathology and genetics of tumours of the breast and female genital organs, P13
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 1998, CANCER RES, V58, P4515
   Fucito A, 2008, INT J BIOCHEM CELL B, V40, P565, DOI 10.1016/j.biocel.2007.10.018
   Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082
   Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   House MG, 2003, CARCINOGENESIS, V24, P193, DOI 10.1093/carcin/24.2.193
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jeronimo C, 2008, BREAST CANCER RES TR, V109, P27, DOI 10.1007/s10549-007-9620-x
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   LASABOVA Z, 2008, ACTA MED MART, V2, P16
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   ONDRUSOVA M, 2007, COMPREHENSIVE ANAL I
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Payne SJL, 2008, HISTOPATHOLOGY, V52, P82, DOI 10.1111/j.1365-2559.2007.02897.x
   Pusztai L, 2008, M D ANDERSON CANCER, P323, DOI 10.1007/978-0-387-34952-7_11
   Rybárová S, 2006, NEOPLASMA, V53, P128
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Volpi A, 2004, MODERN PATHOL, V17, P1038, DOI 10.1038/modpathol.3800161
   Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
NR 36
TC 17
Z9 19
U1 0
U2 6
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2010
VL 57
IS 1
BP 35
EP 40
DI 10.4149/neo_2010_01_035
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 592WM
UT WOS:000277412400006
PM 19895170
DA 2025-01-12
ER

PT J
AU Zhang, YW
   Miao, YF
   Yi, J
   Geng, J
   Wang, R
   Chen, LB
AF Zhang, Y. W.
   Miao, Y. F.
   Yi, J.
   Geng, J.
   Wang, R.
   Chen, L. B.
TI Transcriptional inactivation of secreted frizzled-related protein 1 by
   promoter hypermethylation as a potential biomarker for non-small cell
   lung cancer
SO NEOPLASMA
LA English
DT Article
DE SFRP 1; DNA methylation; biomarker; non-small cell lung cancer
ID FREQUENT EPIGENETIC INACTIVATION; ABERRANT METHYLATION; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; DNA METHYLATION;
   BLADDER-CANCER; BETA-CATENIN; WNT PATHWAY; SFRP GENES
AB Epigenetic silencing of secreted frizzled-related protein (SFRP) genes, antagonists of the WNT pathway, contributes to the pathogenesis of several cancers including non-small cell lung cancer (NSCLC). We hypothesize that methylation analysis of SFRPs family could improve their use as a panel of biomarkers for diagnosing and staging of NSCLC in China. The expression of four SFRP members (SFRP1, 2, 4, and 5) in NSCLC samples was screened by RT-PCR and quantitative real-time PCR. Only SFRP I was significantly downregulated in NSCLC, as compared to adjacent normal tissues and benign pulmonary disease tissues (P=0.006). Promoter hypermethylation of SFRP1 was found in 32.1% (25/78) NSCLC specimens and was closely correlated with loss of expression, besides SFRP I hypermethylation was associated with lymph metastasis (P=0.039) and disease progression within one year (P=0.027). Furthermore, methylated SFRP1 was detected in 28.2% (22/78) of plasma samples from NSCLC patients while only 4% (2/50) in cancer-free controls, and the concordance of SFRP I methylation status in tumor tissues and corresponding plasmas was satisfactory (P<0.001). In conclusion, epigenetic inactivation of SFRP I is a common event contributing to lung carcinogenesis and maybe used as a potential biomarker for NSCLC in Chinese population.
C1 [Zhang, Y. W.; Miao, Y. F.; Geng, J.; Wang, R.; Chen, L. B.] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing 210002, Peoples R China.
   [Yi, J.] Jinling Hosp, Dept Cardiothorac Surg, Nanjing 210002, Peoples R China.
C3 Nanjing University
RP Zhang, YW (通讯作者)，Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing 210002, Peoples R China.
EM chenlongbang@yeah.net
RI miao, yufeng/GXH-5812-2022
CR Anglim PP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-81
   Awakura Y, 2008, ONCOL REP, V20, P1257, DOI 10.3892/or_00000138
   Belinsky SA, 2007, BRIT J CANCER, V96, P1278, DOI 10.1038/sj.bjc.6603721
   Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Han QF, 2006, CANCER LETT, V231, P129, DOI 10.1016/j.canlet.2005.01.026
   Henschke CI, 2006, NEW ENGL J MED, V355, P1763, DOI 10.1056/NEJMoa060476
   Hrzenjak A, 2004, J PATHOL, V204, P19, DOI 10.1002/path.1616
   Hsu HS, 2007, CANCER-AM CANCER SOC, V110, P2019, DOI 10.1002/cncr.23001
   Huang J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-126
   Jahr S, 2001, CANCER RES, V61, P1659
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   MARIST CJ, 2006, CANCER RES, V66, P10621, DOI DOI 10.1158/0008-5472.CAN-06-1687
   Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Román-Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043
   Shi Y, 2007, ACTA PHARMACOL SIN, V28, P1499, DOI 10.1111/j.1745-7254.2007.00692.x
   Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Toyota M, 2009, CANCER SCI, V100, P787, DOI 10.1111/j.1349-7006.2009.01095.x
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wang Y, 2008, CANCER-AM CANCER SOC, V112, P1325, DOI 10.1002/cncr.23312
   Wang YC, 2007, LUNG CANCER, V56, P289, DOI 10.1016/j.lungcan.2006.12.007
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 36
TC 35
Z9 38
U1 0
U2 2
PU VEDA, SLOVAK ACAD SCIENCES
PI BRASTISLAVA
PA DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA
SN 0028-2685
J9 NEOPLASMA
JI Neoplasma
PY 2010
VL 57
IS 3
BP 228
EP 233
DI 10.4149/neo_2010_03_228
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 592WQ
UT WOS:000277412800006
PM 20353273
DA 2025-01-12
ER

PT J
AU Hiard, S
   Charlier, C
   Coppieters, W
   Georges, M
   Baurain, D
AF Hiard, Samuel
   Charlier, Carole
   Coppieters, Wouter
   Georges, Michel
   Baurain, Denis
TI Patrocles: a database of polymorphic miRNA-mediated gene regulation in
   vertebrates
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID MICRORNA-BINDING-SITES; COPY-NUMBER; TOURETTE-SYNDROME; MESSENGER-RNA;
   HUMAN CANCER; TARGET SITE; EPIGENETIC ALTERATIONS; UNTRANSLATED REGION;
   SEQUENCE VARIATIONS; BREAST-CANCER
AB The Patrocles database (http://www.patrocles.org/) compiles DNA sequence polymorphisms (DSPs) that are predicted to perturb miRNA-mediated gene regulation. Distinctive features include: (i) the coverage of seven vertebrate species in its present release, aiming for more when information becomes available, (ii) the coverage of the three compartments involved in the silencing process (i. e. targets, miRNA precursors and silencing machinery), (iii) contextual information that enables users to prioritize candidate 'Patrocles DSPs', including graphical information on miRNA-target coexpression and eQTL effect of genotype on target expression levels, (iv) the inclusion of Copy Number Variants and eQTL information that affect miRNA precursors as well as genes encoding components of the silencing machinery and (v) a tool (Patrocles finder) that allows the user to determine whether her favorite DSP may perturb miRNA-mediated gene regulation of custom target sequences. To support the biological relevance of Patrocles' content, we searched for signatures of selection acting on 'Patrocles single nucleotide polymorphisms (pSNPs)' in human and mice. As expected, we found a strong signature of purifying selection against not only SNPs that destroy conserved target sites but also against SNPs that create novel, illegitimate target sites, which is reminiscent of the Texel mutation in sheep.
C1 [Charlier, Carole; Coppieters, Wouter; Georges, Michel; Baurain, Denis] Univ Liege, Unit Anim Genom, GIGA R, B-4000 Liege, Belgium.
   [Hiard, Samuel] Univ Liege, Syst & Modeling Montefiore Inst, B-4000 Liege, Belgium.
   [Charlier, Carole; Coppieters, Wouter; Georges, Michel; Baurain, Denis] Univ Liege, Fac Vet Med, B-4000 Liege, Belgium.
C3 University of Liege; University of Liege; University of Liege
RP Georges, M (通讯作者)，Univ Liege, Unit Anim Genom, GIGA R, B-4000 Liege, Belgium.
EM michel.georges@ulg.ac.be
RI Baurain, Denis/S-4048-2019; Coppieters, Wouter/AAF-5030-2021
OI BAURAIN, Denis/0000-0003-2388-6185; Georges, Michel/0000-0003-4124-2375;
   Charlier, Carole/0000-0002-9694-094X
FU European Union; Belgian Science Policy organisation; Belgian Fonds
   National de la Recherche Scientifique; Communaute Francaise de Belgique;
   University of Liege
FX European Union's Framework 6 (Callimir STREP, Epigenome NoE, Eadgene
   NoE); Belgian Science Policy organisation (SSTC Genefunc, BioMAGNet
   PAI); Belgian Fonds National de la Recherche Scientifique; Communaute
   Francaise de Belgique (Game, BIOMOD ARC); University of Liege. C.C. is
   Chercheur Qualifie of the Fonds National de la Recherche Scientifique.
CR Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502
   Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Arisawa T, 2007, DIGEST DIS SCI, V52, P1691, DOI 10.1007/s10620-006-9648-5
   Arndt PF, 2005, BIOINFORMATICS, V21, P2322, DOI 10.1093/bioinformatics/bti376
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Beetz C, 2008, BRAIN, V131, P1078, DOI 10.1093/brain/awn026
   Brendle A, 2008, CARCINOGENESIS, V29, P1394, DOI 10.1093/carcin/bgn126
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910
   Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244
   Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170
   Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129
   Chou IC, 2007, PEDIATR NEUROL, V37, P404, DOI 10.1016/j.pediatrneurol.2007.06.017
   Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810
   Deng H, 2006, ACTA NEUROL SCAND, V114, P400, DOI 10.1111/j.1600-0404.2006.00706.x
   Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537
   Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109
   Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062
   Fabbrini G, 2007, MOVEMENT DISORD, V22, P2229, DOI 10.1002/mds.21697
   Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158
   Ge B, 2005, GENOME RES, V15, P1584, DOI 10.1101/gr.4023805
   Gennarino VA, 2009, GENOME RES, V19, P481, DOI 10.1101/gr.084129.108
   Georges M, 2007, CURR OPIN GENET DEV, V17, P166, DOI 10.1016/j.gde.2007.04.005
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Göring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Guryev V, 2008, NAT GENET, V40, P538, DOI 10.1038/ng.141
   Hansen T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000873
   Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334
   HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163
   Hubbard TJP, 2009, NUCLEIC ACIDS RES, V37, pD690, DOI 10.1093/nar/gkn828
   Hwang DG, 2004, P NATL ACAD SCI USA, V101, P13994, DOI 10.1073/pnas.0404142101
   Iwai N, 2005, BIOCHEM BIOPH RES CO, V331, P1439, DOI 10.1016/j.bbrc.2005.04.051
   Jensen KP, 2009, MOL PSYCHIATR, V14, P381, DOI 10.1038/mp.2008.15
   Kapeller J, 2008, HUM MOL GENET, V17, P2967, DOI 10.1093/hmg/ddn195
   Keen-Kim D, 2006, HUM MOL GENET, V15, P3324, DOI 10.1093/hmg/ddl408
   Kim J, 2009, NAT BIOTECHNOL, V27, P472, DOI 10.1038/nbt.1540
   Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   Kuhn RM, 2009, NUCLEIC ACIDS RES, V37, pD755, DOI 10.1093/nar/gkn875
   Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040
   Landi D, 2008, CARCINOGENESIS, V29, P579, DOI 10.1093/carcin/bgm304
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lewis MA, 2009, NAT GENET, V41, P614, DOI 10.1038/ng.369
   Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102
   McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238
   Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104
   Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Pant PVK, 2006, GENOME RES, V16, P331, DOI 10.1101/gr.4559106
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Scharf JM, 2008, NEUROLOGY, V70, P1495, DOI 10.1212/01.wnl.0000296833.25484.bb
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004
   Sethupathy P, 2007, AM J HUM GENET, V81, P405, DOI 10.1086/519979
   She XW, 2008, NAT GENET, V40, P909, DOI 10.1038/ng.172
   Siepel A, 2004, MOL BIOL EVOL, V21, P468, DOI 10.1093/molbev/msh039
   Siva Nayanah, 2008, Nat Biotechnol, V26, P256, DOI 10.1038/nbt0308-256b
   Spielman RS, 2007, NAT GENET, V39, P226, DOI 10.1038/ng1955
   Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023
   Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142
   Stranger BE, 2005, PLOS GENET, V1, P695, DOI 10.1371/journal.pgen.0010078
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200
   Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018
   Wang G, 2008, AM J HUM GENET, V82, P283, DOI 10.1016/j.ajhg.2007.09.021
   Wong KK, 2007, AM J HUM GENET, V80, P91, DOI 10.1086/510560
   Wu MQ, 2008, CARCINOGENESIS, V29, P1710, DOI 10.1093/carcin/bgn073
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   Yang HS, 2008, CANCER RES, V68, P2530, DOI 10.1158/0008-5472.CAN-07-5991
   Yang J, 2008, MUTAT RES-FUND MOL M, V638, P205, DOI 10.1016/j.mrfmmm.2007.08.007
   Yang N, 2008, INT J CANCER, V122, P963, DOI 10.1002/ijc.23325
   Zhang J, 2006, CYTOGENET GENOME RES, V115, P205, DOI 10.1159/000095916
   Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105
   Zuchner S, 2006, AM J HUM GENET, V79, P365, DOI 10.1086/505361
NR 79
TC 115
Z9 124
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN
PY 2010
VL 38
SU 1
BP D640
EP D651
DI 10.1093/nar/gkp926
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 579TV
UT WOS:000276399100102
PM 19906729
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Metge, BJ
   Liu, S
   Riker, AI
   Fodstad, O
   Samant, RS
   Shevde, LA
AF Metge, Brandon J.
   Liu, Suhu
   Riker, Adam I.
   Fodstad, Oystein
   Samant, Rajeev S.
   Shevde, Lalita A.
TI Elevated Osteopontin Levels in Metastatic Melanoma Correlate with
   Epigenetic Silencing of Breast Cancer Metastasis Suppressor 1
SO ONCOLOGY
LA English
DT Article
DE Melanoma; Metastasis; Epigenetic modification; Breast cancer metastasis
   suppressor 1; Osteopontin; RNA silencing
ID NF-KAPPA-B; GENE-EXPRESSION; TUMOR PROGRESSION; DEACETYLASE INHIBITION;
   CARCINOMA METASTASIS; MALIGNANT-MELANOMA; IN-VIVO; BRMS1; CELLS;
   TRANSCRIPTION
AB Objective: Breast cancer metastasis suppressor 1 (BRMS1) has been shown to functionally reduce the metastatic potential of melanoma. We also previously reported that BRMS1 negatively regulates the expression of the oncoprotein osteopontin (OPN). This study was carried out to assess the clinical relevance of BRMS1 and OPN in melanoma. Methods: Epigenetic regulation of BRMS1 was assessed by treating clinically derived melanoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (DAC) and the histone deacetylase inhibitor trichostatin A (TSA), followed by sodium bisulfite modification and methylation-specific PCR. Assessments of BRMS1 and OPN levels were performed using immunoblotting, quantitative real-time RT-PCR or reporter assays. RNA silencing was employed to abrogate the expression of OPN in melanoma-derived cell lines. The in vivo relevance of our findings was determined with experiments using athymic nude mice. Results: The reduced expression of BRMS1 in surgically excised melanoma specimens correlated with increased OPN expression during the progression from primary to metastatic melanoma. Treatment with DAC and TSA elevated BRMS1 levels, but caused an inconsistent change in OPN gene expression. Abrogating the expression of OPN in BRMS1-deficient metastatic melanoma-derived cell lines retarded the growth of melanoma tumor xeno-grafts in athymic nude mice. Conclusion: While treatment with DAC and TSA may not be a universally applicable treatment alternative in melanoma, silencing the expression of OPN in metastatic melanomas that have lost expression of BRMS1 is a potential option for therapeutic intervention. Copyright (C) 2010 S. Karger AG, Basel
C1 [Metge, Brandon J.; Liu, Suhu; Fodstad, Oystein; Samant, Rajeev S.; Shevde, Lalita A.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA.
   [Riker, Adam I.] Ochsner Canc Inst, New Orleans, LA USA.
   [Fodstad, Oystein] Univ Oslo, Rikshosp, Univ Hosp, Norwegian Radium Hosp,Fac Div, N-0027 Oslo, Norway.
C3 University of South Alabama; Ochsner Health System; University of Oslo;
   National Hospital Norway
RP Shevde, LA (通讯作者)，Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.
EM lsamant@usouthal.edu
OI Samant, Rajeev/0000-0001-5681-4976
CR Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bruserud O, 2007, CURR PHARM BIOTECHNO, V8, P388, DOI 10.2174/138920107783018417
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chang PL, 2008, J HISTOCHEM CYTOCHEM, V56, P57, DOI 10.1369/jhc.7A7325.2007
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660
   Chen LF, 2005, METHODS, V36, P368, DOI 10.1016/j.ymeth.2005.03.011
   Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005
   Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139
   Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105
   Denhardt D, 2005, J INVEST DERMATOL, V124, pXVI, DOI 10.1111/j.0022-202X.2005.23708.x
   DeWald DB, 2005, CANCER RES, V65, P713
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Esteller M, 2006, E SCHERING RES FDN W, V57, P115
   Florenes VA, 2004, MELANOMA RES, V14, P173, DOI 10.1097/01.cmr.0000129579.49313.26
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Gogas HJ, 2007, CANCER-AM CANCER SOC, V109, P455, DOI 10.1002/cncr.22427
   Hayashi C, 2007, J CELL BIOCHEM, V101, P979, DOI 10.1002/jcb.21298
   Hedley BD, 2008, CLIN EXP METASTAS, V25, P727, DOI 10.1007/s10585-008-9184-0
   Hedley BD, 2008, INT J CANCER, V123, P526, DOI 10.1002/ijc.23542
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Hsieh YH, 2006, CANCER RES, V66, P7119, DOI 10.1158/0008-5472.CAN-06-1002
   Ito T, 2006, CLIN CANCER RES, V12, P1308, DOI 10.1158/1078-0432.CCR-05-1611
   Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820
   Kolb A, 2005, CANCER BIOL THER, V4, P740, DOI 10.4161/cbt.4.7.1821
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li Xiaoyu, 2008, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V22, P241
   Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06
   MacDonald IC, 2002, BIOESSAYS, V24, P885, DOI 10.1002/bies.10156
   Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Peltonen K, 2005, PIGM CELL RES, V18, P196, DOI 10.1111/j.1600-0749.2005.00225.x
   Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200
   Rangel J, 2008, CANCER-AM CANCER SOC, V112, P144, DOI 10.1002/cncr.23147
   Reiniger IW, 2007, AM J OPHTHALMOL, V143, P705, DOI 10.1016/j.ajo.2006.11.040
   Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13
   Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008
   Rothhammer T, 2007, PIGM CELL RES, V20, P92, DOI 10.1111/j.1600-0749.2007.00367.x
   Sakata R, 2004, BIOCHEM BIOPH RES CO, V315, P959, DOI 10.1016/j.bbrc.2004.01.152
   Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6
   Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690
   Saunders MM, 2001, CANCER RES, V61, P1765
   Schwabe M, 2007, CURR PHARM BIOTECHNO, V8, P382, DOI 10.2174/138920107783018372
   Seraj MJ, 2000, CANCER RES, V60, P2764
   Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452
   Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2
   Soikkeli J, 2007, J PATHOL, V213, P180, DOI 10.1002/path.2229
   Sollars VE, 2005, FRONT BIOSCI, V10, P1635, DOI 10.2741/1647
   Sturm RA, 2005, J INVEST DERMATOL, V124, pxiv, DOI 10.1111/j.0022-202X.2005.23741.x
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520
   Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435
   Wang KX, 2008, CYTOKINE GROWTH F R, V19, P333, DOI 10.1016/j.cytogfr.2008.08.001
   Zhang S, 2006, INT J GYNECOL CANCER, V16, P522, DOI 10.1111/j.1525-1438.2006.00547.x
   Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347
   Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x
NR 58
TC 15
Z9 20
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2010
VL 78
IS 1
BP 75
EP 86
DI 10.1159/000292363
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 566GC
UT WOS:000275357100012
PM 20215788
DA 2025-01-12
ER

PT J
AU McClendon, AK
   Dean, JL
   Ertel, A
   Knudsen, ES
AF McClendon, A. Kathleen
   Dean, Jeffry L.
   Ertel, Adam
   Knudsen, Erik S.
TI Differential Impact of Tumor Suppressor Pathways on DNA Damage Response
   and Therapy-Induced Transformation in a Mouse Primary Cell Model
SO PLOS ONE
LA English
DT Article
ID LI-FRAUMENI-SYNDROME; LONG-TERM SURVIVORS; RETINOBLASTOMA SURVIVORS;
   P53-DEFICIENT MICE; PROSTATE-CANCER; BREAST-CANCER; CYCLE CONTROL; P53;
   RB; GENE
AB The RB and p53 tumor suppressors are mediators of DNA damage response, and compound inactivation of RB and p53 is a common occurrence in human cancers. Surprisingly, their cooperation in DNA damage signaling in relation to tumorigenesis and therapeutic response remains enigmatic. In the context of individuals with heritable retinoblastoma, there is a predilection for secondary tumor development, which has been associated with the use of radiation-therapy to treat the primary tumor. Furthermore, while germline mutations of the p53 gene are critical drivers for cancer predisposition syndromes, it is postulated that extrinsic stresses play a major role in promoting varying tumor spectrums and disease severities. In light of these studies, we examined the tumor suppressor functions of these proteins when challenged by exposure to therapeutic stress. To examine the cooperation of RB and p53 in tumorigenesis, and in response to therapy-induced DNA damage, a combination of genetic deletion and dominant negative strategies was employed. Results indicate that loss/inactivation of RB and p53 is not sufficient for cellular transformation. However, these proteins played distinct roles in response to therapy-induced DNA damage and subsequent tumorigenesis. Specifically, RB status was critical for cellular response to damage and senescence, irrespective of p53 function. Loss of RB resulted in a dramatic evolution of gene expression as a result of alterations in epigenetic programming. Critically, the observed changes in gene expression have been specifically associated with tumorigenesis, and RB-deficient, recurred cells displayed oncogenic characteristics, as well as increased resistance to subsequent challenge with discrete therapeutic agents. Taken together, these findings indicate that tumor suppressor functions of RB and p53 are particularly manifest when challenged by cellular stress. In the face of such challenge, RB is a critical suppressor of tumorigenesis beyond p53, and RB-deficiency could promote significant cellular evolution, ultimately contributing to a more aggressive disease.
C1 [McClendon, A. Kathleen; Dean, Jeffry L.; Ertel, Adam; Knudsen, Erik S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA.
C3 Thomas Jefferson University
RP McClendon, AK (通讯作者)，Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA.
EM eknudsen@kimmelcancercenter.org
OI Dean, Jeff/0009-0002-1395-843X
FU NCI NIH HHS [CA106471, R01 CA106471] Funding Source: Medline; NIEHS NIH
   HHS [T32 ES07250-16, T32 ES007250] Funding Source: Medline
CR Ajioka I, 2008, CELL CYCLE, V7, P735, DOI 10.4161/cc.7.6.5612
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817
   Bettuzzi Saverio, 2003, Acta Biomed, V74, P101
   Bosco EE, 2005, NUCLEIC ACIDS RES, V33, P1581, DOI 10.1093/nar/gki283
   Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803
   Burke L, 2005, CLIN CANCER RES, V11, P232
   ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775
   Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006
   Incassati A, 2006, ONCOGENE, V25, P2444, DOI 10.1038/sj.onc.1209276
   Jänicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaye FJ, 2004, J NATL CANCER I, V96, P342, DOI 10.1093/jnci/djh080
   KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66
   Khan SH, 1998, CANCER RES, V58, P396
   Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054
   KNUDSEN ES, 2008, TAILORING RB TUMOUR
   Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200
   Limacher JM, 2001, INT J CANCER, V96, P238, DOI 10.1002/ijc.1021
   LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Mammas IN, 2008, PATHOL ONCOL RES, V14, P345, DOI 10.1007/s12253-008-9056-6
   Markey MP, 2007, ONCOGENE, V26, P6307, DOI 10.1038/sj.onc.1210450
   Markey MP, 2002, CANCER RES, V62, P6587
   Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019
   Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025
   Mayhew Christopher N, 2004, Methods Mol Biol, V281, P3
   MAYHEW CN, 2005, CANC RES IN PRESS
   McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973
   Mimeault M, 2008, CLIN PHARMACOL THER, V83, P673, DOI 10.1038/sj.clpt.6100296
   Miyamoto H, 1996, CANCER GENET CYTOGEN, V88, P181, DOI 10.1016/0165-4608(95)00292-8
   Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699
   Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315
   Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   Seoane M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003632
   Sharma A, 2007, CANCER RES, V67, P6192, DOI 10.1158/0008-5472.CAN-06-4424
   Sheard MA, 2003, CANCER RES, V63, P7176
   Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2
   Siddiqui H, 2007, J CELL PHYSIOL, V211, P131, DOI 10.1002/jcp.20913
   Srinivasan SV, 2007, J BIOL CHEM, V282, P23867, DOI 10.1074/jbc.M700542200
   Stengel KR, 2008, CELL CYCLE, V7, DOI 10.4161/cc.7.8.5737
   Tabori U, 2008, CANCER RES, V68, P2053, DOI 10.1158/0008-5472.CAN-07-2091
   Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010
   Yoshioka N, 2000, J VIROL, V74, P1008, DOI 10.1128/JVI.74.2.1008-1013.2000
   Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753
   Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486
NR 61
TC 3
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 1
PY 2010
VL 5
IS 1
AR e8558
DI 10.1371/journal.pone.0008558
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 539AG
UT WOS:000273225000019
PM 20049321
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ellinger, J
   Kahl, P
   von der Gathen, J
   Rogenhofer, S
   Heukamp, LC
   Gütgemann, I
   Walter, B
   Hofstädter, F
   Büttner, R
   Müller, SC
   Bastian, PJ
   von Ruecker, A
AF Ellinger, Joerg
   Kahl, Philip
   von der Gathen, Johannes
   Rogenhofer, Sebastian
   Heukamp, Lukas C.
   Guetgemann, Ines
   Walter, Bernhard
   Hofstaedter, Ferdinand
   Buettner, Reinhard
   Mueller, Stefan C.
   Bastian, Patrick J.
   von Ruecker, Alexander
TI Global Levels of Histone Modifications Predict Prostate Cancer
   Recurrence
SO PROSTATE
LA English
DT Article
DE histone; methylation; prognosis; prostate cancer; epigenetics
ID RADICAL PROSTATECTOMY; BREAST-CANCER; GENE LOCI; HYPERMETHYLATION;
   EXPRESSION; ADENOCARCINOMA; HYPOMETHYLATION; DEMETHYLASES; ACETYLATION;
   PROGNOSIS
AB PURPOSE. Epigenetic alterations such as DNA methylation and histone modifications play important roles in carcinogenesis. It was reported that global histone modification patterns are predictors of cancer recurrence in various tumor entities. Our study was performed to evaluate histone lysine (H(x)K(y)) and histone acetyl (H(x)Ac) modifications in prostate tissue.
   MATERIALS AND METHODS. A tissue microarray with 113 prostate cancer (PCA), 23 non-malignant prostate tissues was stained with antibodies against H3K4 mono-(H3K4mel), di-(H3K4me2), tri-(H3K4me3) methylation, H3K9mel, H3K9me2, H3K9me3, H3 and H4 panacetylation (H3Ac, H4Ac). We also analyzed H3K4 methylation in patients with advanced PCA (hormone-refractory PCA-HRPC, n = 34; hormone-dependent PCA, n = 30). Sections were scored according the staining intensity and the proportion of epithelial cells showing nuclear staining.
   RESULTS. H3K4mel, H3K9me2, H3K9me3, H3Ac, and H4Ac were significantly reduced in PCA compared to non-malignant prostate tissue. H3Ac and H3K9me2 levels allowed discrimination of PCA and non-malignant prostate tissue highly specifically (> 91%) and sensitively (> 78%) as determined via ROC analyses (AUC > 0.91). Histone lysine methylation and histone acetylation marks were correlated with clinical-pathological parameters (i.e., digital rectal examination, preoperative PSA, pT-stage, lymph node metastasis, Gleason score). In addition, H3K4mel was a significant predictor of PSA recurrence following radical prostatectomy. H3K4mel, H3K4me2, and H3K4me3 levels were significantly increased in HRPC.
   CONCLUSIONS. Global histone modification levels may help to identify patients with adverse prognosis, and represent a target for the future therapy of PCA. Prostate 70: 61-69, 2010. (c) 2009 Wiley-Liss, Inc.
C1 [Ellinger, Joerg; von der Gathen, Johannes; Rogenhofer, Sebastian; Mueller, Stefan C.] Univ Klinikum Bonn, Klin & Poliklin Urol, D-53105 Bonn, Germany.
   [Kahl, Philip; Heukamp, Lukas C.; Guetgemann, Ines; Buettner, Reinhard; von Ruecker, Alexander] Univ Klinikum Bonn, Inst Pathol, D-53105 Bonn, Germany.
   [Walter, Bernhard] Univ Klinikum Erlangen, Urol Univ Klin, Erlangen, Germany.
   [Hofstaedter, Ferdinand] Univ Regensburg, Inst Pathol, Regensburg, Germany.
   [Bastian, Patrick J.] Univ Klinikum Grosshadern, Urol Klin & Poliklin, Munich, Germany.
C3 University of Bonn; University of Bonn; University of Erlangen
   Nuremberg; University of Regensburg; University of Munich
RP Ellinger, J (通讯作者)，Univ Klinikum Bonn, Klin & Poliklin Urol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM joerg.ellinger@ukb.uni-bonn.de
RI Gütgemann, Ines/ABH-6426-2020; Heukamp, Lukas/A-8338-2013; Ellinger,
   Jorg/D-8389-2011; Heukamp, Lukas/G-9967-2012
OI Ellinger, Jorg/0000-0002-7526-0857; Heukamp, Lukas/0000-0002-3388-3482
FU North-Rhine Westphalian Association of Urology; Reinhard Nagel
   Foundation of the German Association of Urology
FX Grant sponsor: North-Rhine Westphalian Association of Urology; Grant
   sponsor: Reinhard Nagel Foundation of the German Association of Urology.
CR Barbisan F, 2008, INT J IMMUNOPATH PH, V21, P615, DOI 10.1177/039463200802100315
   Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bastian PJ, 2007, EUR UROL, V51, P665, DOI 10.1016/j.eururo.2006.08.008
   Bastian PJ, 2005, CLIN CANCER RES, V11, P4097, DOI 10.1158/1078-0432.CCR-04-1832
   Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1
   Florl AL, 2004, BRIT J CANCER, V91, P985, DOI 10.1038/sj.bjc.6602030
   Freedland SJ, 2007, J CLIN ONCOL, V25, P1765, DOI 10.1200/JCO.2006.08.0572
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   Mohamed M, 2009, BJU INT, V103, P391, DOI 10.1111/j.1464-410X.2008.08063.x
   Mohamed MA, 2007, BJU INT, V99, P908, DOI 10.1111/j.1464-410X.2006.06704.x
   Orr JA, 2007, ANAL QUANT CYTOL, V29, P17
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
NR 29
TC 167
Z9 196
U1 0
U2 14
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD JAN 1
PY 2010
VL 70
IS 1
BP 61
EP 69
DI 10.1002/pros.21038
PG 9
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 542DM
UT WOS:000273471800007
PM 19739128
DA 2025-01-12
ER

PT J
AU Bulun, SE
   Cheng, YH
   Pavone, ME
   Xue, Q
   Attar, E
   Trukhacheva, E
   Tokunaga, H
   Utsunomiya, H
   Yin, P
   Luo, X
   Lin, ZH
   Imir, G
   Thung, S
   Su, EJ
   Kim, JJ
AF Bulun, Serdar E.
   Cheng, You-Hong
   Pavone, Mary Ellen
   Xue, Qing
   Attar, Erkut
   Trukhacheva, Elena
   Tokunaga, Hideki
   Utsunomiya, Hiroki
   Yin, Ping
   Luo, Xia
   Lin, Zhihong
   Imir, Gonca
   Thung, Stephen
   Su, Emily J.
   Kim, J. Julie
TI Estrogen Receptor-β, Estrogen Receptor-α, and Progesterone Resistance in
   Endometriosis
SO SEMINARS IN REPRODUCTIVE MEDICINE
LA English
DT Article
DE ER-beta; ER-alpha; PR; progesterone resistance; DNA methylation;
   epigenetic; promoter; gene regulation; transcription
ID MESSENGER-RIBONUCLEIC-ACID; BREAST-CANCER CELLS; ELEMENT HALF-SITE;
   ACTIVATOR PROTEIN-1; BINDING-SITES; STROMAL CELLS; SP1 SITES; GENE;
   EXPRESSION; PROMOTER
AB Loss of progesterone signaling in the endometrium may be a causal factor in the development of endometriosis, and progesterone resistance is commonly observed in women with this disease. In endometriotic stromal cells, the levels of progesterone receptor (PR), particularly the PR-B isoform, are significantly decreased, leading to a loss of paracrine signaling. PR deficiency likely underlies the development of progesterone resistance in women with endometriosis who no longer respond to progestin therapy. Here we review the complex epigenetic and transcriptional mechanisms leading to PR deficiency. The initial event may involve deficient methylation of the estrogen receptor (ER)beta promoter resulting in pathologic overexpression of ER beta in endometriotic stromal cells. We speculate that alterations in the relative levels of ER beta and ER alpha in endometrial tissue dictate E2-regulated PR expression, such that a decreased ER alpha-ER beta ratio may result in suppression of PR. In this review, we propose a molecular model that may be responsible for changes in ER beta and ER alpha leading to PR loss and progesterone resistance in endometriosis.
C1 [Bulun, Serdar E.; Cheng, You-Hong; Pavone, Mary Ellen; Trukhacheva, Elena; Yin, Ping; Luo, Xia; Lin, Zhihong; Su, Emily J.; Kim, J. Julie] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Reprod Biol Res, Chicago, IL 60611 USA.
   [Xue, Qing] Peking Univ, Hosp 1, Dept Obstet & Gynecol, Beijing 100871, Peoples R China.
   [Attar, Erkut] Istanbul Univ, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Capa Sch Med, Istanbul, Turkey.
   [Tokunaga, Hideki; Utsunomiya, Hiroki] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan.
   [Imir, Gonca] Cumhuriyet Univ, Sch Med, Dept Obstet & Gynecol, Sivas, Turkey.
   [Thung, Stephen] Yale Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, New Haven, CT 06510 USA.
C3 Northwestern University; Feinberg School of Medicine; Peking University;
   Istanbul University; Tohoku University; Cumhuriyet University; Yale
   University
RP Bulun, SE (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Reprod Biol Res, 303 E Super St,4-123, Chicago, IL 60611 USA.
EM s-bulun@northwestern.edu
RI Tokunaga, Hideki/H-1672-2014
OI Pavone, Mary Ellen/0000-0001-9682-6381; Kim, J Julie/0000-0001-9834-8213
FU NICHD [HD040093]; Friends of Prentice
FX This article was supported by grants from the NICHD (HD040093) and
   Friends of Prentice ( both to S. E. B.).
CR Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897
   BERGMAN MD, 1992, ENDOCRINOLOGY, V130, P1923, DOI 10.1210/en.130.4.1923
   Brandenberger AW, 1999, MOL HUM REPROD, V5, P651, DOI 10.1093/molehr/5.7.651
   Bulun SE, 2006, MOL CELL ENDOCRINOL, V248, P94, DOI 10.1016/j.mce.2005.11.041
   Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6
   DMOWSKI WP, 1981, AM J OBSTET GYNECOL, V141, P377, DOI 10.1016/0002-9378(81)90598-6
   Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8
   Fujimoto J, 1999, MOL HUM REPROD, V5, P742, DOI 10.1093/molehr/5.8.742
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Grandien K, 1996, MOL CELL ENDOCRINOL, V116, P207, DOI 10.1016/0303-7207(95)03716-0
   GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223
   GRANDIEN KFH, 1993, J MOL ENDOCRINOL, V10, P269, DOI 10.1677/jme.0.0100269
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   HALME J, 1988, J CLIN ENDOCR METAB, V66, P1044, DOI 10.1210/jcem-66-5-1044
   HALME J, 1983, AM J OBSTET GYNECOL, V145, P333, DOI 10.1016/0002-9378(83)90720-2
   Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459
   Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914
   Hornung D, 1997, J CLIN ENDOCR METAB, V82, P1621, DOI 10.1210/jc.82.5.1621
   Kao LC, 2003, ENDOCRINOLOGY, V144, P2870, DOI 10.1210/en.2003-0043
   Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   KENNEDY S, 1995, J ASSIST REPROD GEN, V12, P32, DOI 10.1007/BF02214126
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696
   Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140
   Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935
   OLIVE DL, 1993, NEW ENGL J MED, V328, P1759, DOI 10.1056/NEJM199306173282407
   Osteen KG, 2005, FERTIL STERIL, V83, P529, DOI 10.1016/j.fertnstert.2004.11.026
   Osteen KG, 2002, ANN NY ACAD SCI, V955, P37, DOI 10.1111/j.1749-6632.2002.tb02764.x
   Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369
   Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008
   Petz LN, 2004, MOL ENDOCRINOL, V18, P521, DOI 10.1210/me.2003-0105
   Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972
   READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263
   SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x
   Schultz JR, 2005, J BIOL CHEM, V280, P347, DOI 10.1074/jbc.M407879200
   Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X
   Scott REM, 1997, MOL ENDOCRINOL, V11, P1581, DOI 10.1210/me.11.11.1581
   Trukhacheva E, 2009, J CLIN ENDOCR METAB, V94, P615, DOI 10.1210/jc.2008-1466
   Vercellini P, 1996, FERTIL STERIL, V65, P299, DOI 10.1016/S0015-0282(16)58089-3
   Vercellini P, 1997, FERTIL STERIL, V68, P393, DOI 10.1016/S0015-0282(97)00193-3
   VERCELLINI P, 1993, FERTIL STERIL, V60, P75
   WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62
   Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804
   Zeitoun K, 1998, J CLIN ENDOCR METAB, V83, P4474, DOI 10.1210/jc.83.12.4474
   Zeitoun KM, 1999, FERTIL STERIL, V72, P961, DOI 10.1016/S0015-0282(99)00393-3
NR 49
TC 201
Z9 227
U1 2
U2 34
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1526-8004
J9 SEMIN REPROD MED
JI Semin. Reprod. Med.
PD JAN
PY 2010
VL 28
IS 1
BP 36
EP 43
DI 10.1055/s-0029-1242991
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 547WT
UT WOS:000273921100006
PM 20104427
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Sayed, D
   Badr, G
   Maximous, D
   Mikhail, NNH
   Abu-Tarboush, F
   Alhazza, IM
AF Sayed, D.
   Badr, G.
   Maximous, D.
   Mikhail, N. N. H.
   Abu-Tarboush, F.
   Alhazza, I. M.
TI HLA-G and its relation to proliferation index in detection and
   monitoring breast cancer patients
SO TISSUE ANTIGENS
LA English
DT Article
DE breast cancer; flow cytometry; human leukocyte antigen G; proliferation
   index
ID LEUKOCYTE-ANTIGEN-G; CLASS-I GENE; G EXPRESSION; G MOLECULES; PROGNOSTIC
   INDICATOR; DNA CYTOMETRY; CARCINOMA; MARKER; PROTEIN; PLASMA
AB Recent studies indicate an ectopic upregulation of the human leukocyte antigen G (HLA-G) in tumor cells that may favor their escape from antitumor immune responses. The role of HLA-G in breast cancer has not been defined. Other studies showed that HLA-G transcription may be silenced by epigenetic mechanisms or activated by stress. This work aimed to clarify the expression of HLA-G protein, estimate the possible prognostic role of HLA-G expression and identify if this expression is linked to the DNA index (DI) and S phase fraction (SPF) in breast cancer. HLA-G protein expression and the DNA parameters were studied by flow cytometry and serum secreted HLA-G (sHLA-G) levels were detected by enzyme-linked immunosorbent assay (ELISA) in 45 breast cancer patients and 40 female blood donors as healthy donors. Surface HLA-G was expressed on 40% and the cytoplasmic pattern with no membrane association in 24.4% of the malignant specimens. There was an increased serum sHLA-G level in patients as compared with controls. There were negative correlations between cytoplasmic HLA-G and both DI and SPF and between preoperative sHLA-G and SPF with no relations with patients' clinical outcome. We cannot establish that HLA-G protein can be a useful prognostic marker, but sHLA-G may be used as a tumor marker in breast cancer patients.
C1 [Sayed, D.] Assiut Univ, Dept Clin Pathol, S Egypt Canc Inst, Assiut 71516, Egypt.
   [Badr, G.; Abu-Tarboush, F.] King Saud Univ, Coll Sci, Dept Zool, Riyadh 11451, Saudi Arabia.
   [Maximous, D.] Assiut Univ, Dept Surg Oncol, S Egypt Canc Inst, Assiut 71516, Egypt.
   [Mikhail, N. N. H.] Assiut Univ, Dept Biostat Canc Epidemiol, S Egypt Canc Inst, Assiut 71516, Egypt.
C3 Egyptian Knowledge Bank (EKB); Assiut University; King Saud University;
   Egyptian Knowledge Bank (EKB); Assiut University; Egyptian Knowledge
   Bank (EKB); Assiut University
RP Sayed, D (通讯作者)，Assiut Univ, Dept Clin Pathol, S Egypt Canc Inst, Assiut 71516, Egypt.
EM Douaa_sayed@hotmail.com
RI Sayed, Douaa/J-1452-2019; ALHAZZA, IBRAHIM/ABB-9996-2021; Badr,
   Gamal/I-4891-2014
OI Badr, Gamal/0000-0002-6157-7319; Sayed, Douaa/0000-0002-9595-2877
FU South Egypt Cancer Institute; King Saud University [NLCP-1/2009]
FX This research was supported by South Egypt Cancer Institute and King
   Saud University through the Nobel Laureate collaboration project, number
   (NLCP-1/2009). We therefore, thank the Nobel laureate, Prof. Gunter
   Blobel (Laboratory of Cell Biology, Howard Hughes Medical Institute, The
   Rockefeller University, New York), the consultant of this project.
CR Amadori D, 1998, BREAST CANCER RES TR, V51, P267, DOI 10.1023/A:1006140629766
   Barrier BF, 2006, GYNECOL ONCOL, V103, P25, DOI 10.1016/j.ygyno.2006.01.045
   Bukur J, 2003, CANCER RES, V63, P4107
   Carosella ED, 2003, ADV IMMUNOL, V81, P199, DOI 10.1016/S0065-2776(03)81006-4
   Chassevent A, 2001, CLIN CANCER RES, V7, P909
   Creput C, 2003, NEPHROLOGIE, V24, P451
   Davidson B, 2005, GYNECOL ONCOL, V96, P42, DOI 10.1016/j.ygyno.2004.09.049
   Favier B, 2007, TISSUE ANTIGENS, V69, P207, DOI 10.1111/j.1399-0039.2006.00757.x
   GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145
   Gros F, 2006, NEOPLASIA, V8, P223, DOI 10.1593/neo.05703
   Hansel Donna E, 2005, Int J Gastrointest Cancer, V35, P15, DOI 10.1385/IJGC:35:1:015
   HEDLEY DW, 1993, CYTOMETRY, V14, P482, DOI 10.1002/cyto.990140505
   Ishigami S, 2006, ANTICANCER RES, V26, P2467
   ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947
   Kleinberg L, 2006, VIRCHOWS ARCH, V449, P31, DOI 10.1007/s00428-005-0144-7
   Lefebvre S, 2002, J PATHOL, V196, P266, DOI 10.1002/path.1039
   LeMaoult J, 2003, TISSUE ANTIGENS, V62, P273, DOI 10.1034/j.1399-0039.2003.00143.x
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Menier C, 2000, HUM IMMUNOL, V61, P1118, DOI 10.1016/S0198-8859(00)00194-4
   Moreau P, 2002, CELL MOL LIFE SCI, V59, P1460, DOI 10.1007/s00018-002-8521-8
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Nückel H, 2005, BLOOD, V105, P1694, DOI 10.1182/blood-2004-08-3335
   ONNO M, 1994, HUM IMMUNOL, V41, P79, DOI 10.1016/0198-8859(94)90089-2
   Palmisano GL, 2002, HUM IMMUNOL, V63, P969, DOI 10.1016/S0198-8859(02)00642-0
   Polakova K, 2007, NEOPLASMA, V54, P455
   Real LM, 1999, J REPROD IMMUNOL, V43, P263, DOI 10.1016/S0165-0378(99)00038-8
   Rebmann V, 2001, TISSUE ANTIGENS, V57, P15, DOI 10.1034/j.1399-0039.2001.057001015.x
   Rebmann V, 2003, SEMIN CANCER BIOL, V13, P371, DOI 10.1016/S1044-579X(03)00028-2
   Rebmann V, 1999, TISSUE ANTIGENS, V53, P14, DOI 10.1034/j.1399-0039.1999.530102.x
   RILEY RS, 1993, CLIN APPL FLOW CYTOM
   ROMAIN S, 1995, INT J CANCER, V61, P7, DOI 10.1002/ijc.2910610103
   Rosadoab S, 2008, HUM IMMUNOL, V69, P9, DOI 10.1016/j.humimm.2007.11.001
   Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097
   Rouas-Freiss N, 2003, SEMIN CANCER BIOL, V13, P325, DOI 10.1016/S1044-579X(03)00023-3
   RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520
   Rudolph P, 1999, J NATL CANCER I, V91, P271, DOI 10.1093/jnci/91.3.271
   Rudstein-Svetlicky N, 2006, TISSUE ANTIGENS, V67, P111, DOI 10.1111/j.1399-0039.2006.00540.x
   SCHMIDT CM, 1993, J IMMUNOL, V151, P2633
   Sebti Y, 2003, HUM IMMUNOL, V64, P1093, DOI 10.1016/j.humimm.2003.08.345
   SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503
   Sheu JJC, 2007, SEMIN CANCER BIOL, V17, P436, DOI 10.1016/j.semcancer.2007.06.012
   Shih IM, 2007, HUM IMMUNOL, V68, P272, DOI 10.1016/j.humimm.2007.01.010
   Singer G, 2003, CLIN CANCER RES, V9, P4460
   SOBIN LH, 1997, INT UNION CANC TNM C, P123
   VANDAM PA, 1990, J CLIN PATHOL, V43, P833, DOI 10.1136/jcp.43.10.833
   Wastowski IJ, 2009, J RHEUMATOL, V36, P1230, DOI 10.3899/jrheum.080552
   Ye SR, 2007, MODERN PATHOL, V20, P375, DOI 10.1038/modpathol.3800751
   Yie SM, 2006, HUM REPROD, V21, P2538, DOI 10.1093/humrep/del126
   Yie SM, 2004, AM J OBSTET GYNECOL, V191, P525, DOI 10.1016/j.ajog.2004.01.033
NR 49
TC 35
Z9 39
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD JAN
PY 2010
VL 75
IS 1
BP 40
EP 47
DI 10.1111/j.1399-0039.2009.01393.x
PG 8
WC Cell Biology; Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology; Pathology
GA 533PZ
UT WOS:000272838000006
PM 20196818
DA 2025-01-12
ER

PT J
AU Fernandez, SV
   Russo, J
AF Fernandez, S. V.
   Russo, J.
TI Estrogen and Xenoestrogens in Breast Cancer
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE estrogen; BPA; BBP; cell transformation; breast cancer; epigenetic
   changes; neuregulin
ID HEALTHY POSTMENOPAUSAL WOMEN; HORMONE REPLACEMENT THERAPY; BISPHENOL-A;
   IN-VITRO; DNA-METHYLTRANSFERASE; ENVIRONMENTAL ESTROGEN; PERINATAL
   EXPOSURE; PLUS PROGESTIN; CELL LINE; PHTHALATE
AB There is growing concern that estrogenic environmental compounds that act as endocrine-disrupting chemicals might potentially have adverse effects on hormone-sensitive organs such as the breast. This concern is further fueled by evidence indicating that natural estrogens, specifically 17 beta-estradiol, are important factors in the initiation and progression of breast cancer. We have developed an in vitro-in vivo model in which we have demonstrated the carcinogenicity of E2 in human breast epithelial cells MCF-10F. Hypermethylation of NRG1, STXBP6. BMP6, CSS3, SPRY1, and SNIP were found at different progression stages in this model. The use of this powerful and unique model has provided a tool for exploring whether bisphenol A and butyl benzyl phthalate have relevance in the initiation of breast cancer. These studies provide firsthand evidence that the natural estrogen 17 beta-estradiol and xenoestrogenic substances like bisphenol a are able to induce neoplastic transformation in human breast epithelial cells.
C1 [Fernandez, S. V.; Russo, J.] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.
C3 Fox Chase Cancer Center
RP Russo, J (通讯作者)，Fox Chase Canc Ctr, Breast Canc Res Lab, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM jose.russo@fccc.edu
RI Fernandez, Sandra/A-8031-2010
FU NIH, USA, [R21 ES015894, U01 ES/CA 12771]
FX Grant R21 ES015894 and U01 ES/CA 12771 from the NIH, USA, Supported this
   work. The authors thank Kara Snider and Patricia A. Russo for the
   technical work. The RLGS was done in collaboration with Dr. Christopher
   Plass from Ohio State University, and the analysis of metaphase-CGH was
   performed by Dr. Binaifer Balsara from the Research Cytogenetic and
   Genomic Facility of the Fox Chase Cancer Center.
CR Akingbemi BT, 2004, ENDOCRINOLOGY, V145, P592, DOI 10.1210/en.2003-1174
   Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476
   Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389
   Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045
   Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
   Beral Valerie, 2003, Lancet, V362, P419
   BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116
   Brede C, 2003, FOOD ADDIT CONTAM, V20, P684, DOI 10.1080/02652030210134236
   BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439
   BURRIDGE E, 2003, EUR CHEM NEWS   0414, P17
   Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534
   Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   CHUA Y, 2006, BREAST CANC RES S2, V8, P5
   Chuang CC, 2008, INT J FUZZY SYST, V10, P11
   Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D
   Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814
   Colditz GA, 2005, CLIN CANCER RES, V11, p909S
   Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606
   Ema M, 2003, REPROD TOXICOL, V17, P407, DOI 10.1016/S0890-6238(03)00037-6
   Ema M, 2002, REPROD TOXICOL, V16, P71, DOI 10.1016/S0890-6238(01)00200-3
   Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590
   Fernandez SV, 2005, INT J ONCOL, V26, P691
   FERNANDEZ SV, 2006, P AM ASSOC CANC RES, V47, P1590
   Friel PN, 2005, ALTERN MED REV, V10, P36
   Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350
   Gupta C, 2000, P SOC EXP BIOL MED, V224, P61, DOI 10.1046/j.1525-1373.2000.22402.x
   Harris CA, 1997, ENVIRON HEALTH PERSP, V105, P802, DOI 10.2307/3433697
   HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505
   HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166
   Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159
   Hong EJ, 2005, J REPROD DEVELOP, V51, P253, DOI 10.1262/jrd.16075
   Howdeshell KL, 2003, ENVIRON HEALTH PERSP, V111, P1180, DOI 10.1289/ehp.5993
   Huang Y, 2007, CANCER RES, V67, P11147, DOI 10.1158/0008-5472.CAN-07-1371
   Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   IPCS, 1999, 17 IPCS WHO
   JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Lareef MH, 2005, INT J ONCOL, V26, P423
   Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366
   Levy G, 2004, ENVIRON RES, V94, P102, DOI 10.1016/S0013-9351(03)00086-0
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254
   Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207
   Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715
   Maruyama S, 1999, ENDOCR J, V46, P513, DOI 10.1507/endocrj.46.513
   Matsumoto A, 2003, ENVIRON HEALTH PERSP, V111, P101, DOI 10.1289/ehp.5512
   Matthews JB, 2001, CHEM RES TOXICOL, V14, P149, DOI 10.1021/tx0001833
   Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932
   Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888
   Ouchi K, 2002, J CHROMATOGR B, V780, P365, DOI 10.1016/S1570-0232(02)00547-0
   PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0
   Ramos JG, 2001, BIOL REPROD, V65, P1271, DOI 10.1095/biolreprod65.4.1271
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200
   Russo J, 2002, J STEROID BIOCHEM, V80, P149, DOI 10.1016/S0960-0760(01)00183-2
   Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X
   Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com
   Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R
   Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608
   Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960-0760(98)00027-2
   SOULE HD, 1990, CANCER RES, V50, P6075
   Suzuki A, 2002, REPROD TOXICOL, V16, P107, DOI 10.1016/S0890-6238(02)00005-9
   Takao T, 1999, LIFE SCI, V65, P2351, DOI 10.1016/S0024-3205(99)00502-0
   Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100
   Yang MH, 2003, ARCH ENVIRON CON TOX, V44, P546, DOI 10.1007/s00244-002-2124-0
   YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215
   Zacharewski TR, 1998, TOXICOL SCI, V46, P282, DOI 10.1093/toxsci/46.2.282
NR 69
TC 148
Z9 173
U1 1
U2 20
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PY 2010
VL 38
IS 1
BP 110
EP 122
DI 10.1177/0192623309354108
PG 13
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Toxicology
GA 559EL
UT WOS:000274804800010
PM 19933552
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Cardiff, RD
   Borowsky, AD
AF Cardiff, Robert D.
   Borowsky, Alexander D.
TI Precancer: Sequentially Acquired or Predetermined?
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE cancer; genetically engineered mice; mammary gland; molecular pathology;
   mouse pathology; pathobiology; preneoplasia
ID MAMMARY INTRAEPITHELIAL NEOPLASIA; TUMOR-SUPPRESSOR GENE; BREAST-CANCER;
   IN-SITU; MUTATOR PHENOTYPE; MOLECULAR-BIOLOGY; MOUSE MODELS; EXPRESSION;
   PROGRESSION; CELLS
AB Recognition of focal morphological intracpithelial lesions associated Willi the eventual development of invasive cancer has long been the sine qua non of precancer. Empirically, precancers are associated With a morphological continuum from atypia to dysplasia and invasive neoplasia. Such lesions ire used as early indicators of cancer, and have dramatically reduced mortality front cancers of the colon. uterine cervix, and breast. Progression has been modeled as it linear, stepwise process. Some molecular evidence supports it linear model. However, clinical studies now suggest that preexisting cofactors Such as human papilloma virus (HPV) in cervical cancer determines the cell fate. Other clinical Studies such as bladder. prostate, and breast suggest that many intraepithelial lesions do not progress to malignancy. The more recent experimental analyses reveal thin the key molecular and genetic events even predate the emergence of visible lesions. Thus. a new nonlinear, parallel model is proposed. The parallel Model suggests all origin in putative progenitor cell that expands and invades. The clinical outcome is thus predetermined. If correct, this model Suggests that "progression" to malignancy is epigenetic. Further, future assessment of biological potential will involve identification and genetic analysis of the progenitor cell populations.
C1 [Borowsky, Alexander D.] Univ Calif Davis, Ctr Comparat Pathol, Dept Pathol & Lab Med, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Borowsky, AD (通讯作者)，Univ Calif Davis, Ctr Comparat Pathol, Dept Pathol & Lab Med, Davis, CA 95616 USA.
EM adborowsky@ucdavis.edu
RI Borowsky, Alexander/S-5404-2017
FU NCI NIH HHS [U01 CA141582, U01-CA105490] Funding Source: Medline; NCRR
   NIH HHS [U42 RR14905, K26 RR0243037] Funding Source: Medline
CR Abbey CK, 2006, J MAMMARY GLAND BIOL, V11, P137, DOI 10.1007/s10911-006-9020-6
   Alvi AJ, 2002, BREAST CANCER RES, V5, DOI [10.1186/bcr547, 10.1186/bcr563]
   [Anonymous], MAKING MICE STANDARD
   [Anonymous], 1997, Gynecol Oncol, V66, P351
   APOLANT H, 1906, ARB I EXP THER FRANK, V1, P7
   ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22
   BAILLIE M, 1806, EDINBURGH MED SURG J, V2, P382
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5
   BERENBLUM I, 1954, BRIT J CANCER, V8, P1
   BEUVING LJ, 1967, JNCI-J NATL CANCER I, V39, P423
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301
   Cardiff RD, 2000, J MAMMARY GLAND BIOL, V5, P421, DOI 10.1023/A:1009534129331
   Cardiff RD, 2002, COMPARATIVE MED, V52, P12
   CARDIFF RD, 1988, ANTICANCER RES, V8, P925
   CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3
   Cardiff RD, 2007, ADV CANCER RES, V98, P53, DOI 10.1016/S0065-230X(06)98003-8
   Cardiff RD, 2006, TOXICOL PATHOL, V34, P699, DOI 10.1080/01926230600930129
   Cardiff Robert D, 2004, Toxicol Pathol, V32 Suppl 1, P31, DOI 10.1080/01926230490424662
   Cardoso CL, 2008, REV BRAS FARMACOGN, V18, P26, DOI 10.1590/S0102-695X2008000100007
   Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Cunha GR, 1997, J MAMMARY GLAND BIOL, V2, P393, DOI 10.1023/A:1026303630843
   Damonte P, 2007, LAB INVEST, V87, P1218, DOI 10.1038/labinvest.3700683
   Damonte P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2104
   DEOME KB, 1969, CANCER, V24, P1255, DOI 10.1002/1097-0142(196912)24:6<1255::AID-CNCR2820240632>3.0.CO;2-Y
   DEOME KB, 1962, MORPHOLOGICAL PRECUR, P349
   DERINGER MK, 1962, JNCI-J NATL CANCER I, V28, P203
   Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004
   DUNN TB, 1945, S MAMM TUM MIC AM AS, P13
   Esposito I, 2007, PANCREAS, V35, P212, DOI 10.1097/mpa.0b013e31805d0190
   Euhus DM, 2002, J NATL CANCER I, V94, P858, DOI 10.1093/jnci/94.11.858
   EWING J, 1914, MED REC, V86, P951
   FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fekete E, 1938, AM J PATHOL, V14, P557
   FOULDS L, 1958, J Chronic Dis, V8, P2, DOI 10.1016/0021-9681(58)90039-0
   FOULDS L, 1954, CANCER RES, V14, P327
   FOULDS L, 1957, CANCER RES, V17, P355
   FOULDS L, 1949, BRIT J CANCER, V3, P345, DOI 10.1038/bjc.1949.40
   FOULDS L, 1959, NEOPLASTIC DEV
   Foulds L., 1975, NEOPLASTIC DEV
   FUJIMOTO K, 1992, CANCER RES, V52, P1393
   Haaland M, 1911, 4 IMP CANC RES FUND, P1
   Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270
   KNUDSON AG, 1977, CANCER, V39, P1882, DOI 10.1002/1097-0142(197704)39:4+<1882::AID-CNCR2820390821>3.0.CO;2-#
   Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006
   LOEB LA, 1991, CANCER RES, V51, P3075
   LOEB LA, 1994, CANCER RES, V54, P5059
   MACDONALD I, 1951, Surg Gynecol Obstet, V92, P443
   MACDONALD I, 1958, SURG GYNECOL OBSTET, V106, P227
   MACDONALD I, 1954, SURG GYNECOL OBSTET, V98, P148
   Maglione JE, 2004, MOL CANCER THER, V3, P941
   Maglione JE, 2001, CANCER RES, V61, P8298
   Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7
   Medina D, 2000, J MAMMARY GLAND BIOL, V5, P393, DOI 10.1023/A:1009529928422
   MUNGER K, 1992, CANCER SURV, V12, P197
   Namba R, 2004, MOL CANCER RES, V2, P453
   Namba R, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-275
   Nishidate T, 2004, INT J ONCOL, V25, P797
   NOTKIN L J, 1959, Can Med Assoc J, V81, P190
   Papanicolaou GN., 1943, DIAGNOSIS UTERINE CA
   Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9
   PITOT HC, 1982, CANCER-AM CANCER SOC, V49, P1206, DOI 10.1002/1097-0142(19820315)49:6<1206::AID-CNCR2820490623>3.0.CO;2-7
   Rekhi B, 2004, Indian J Cancer, V41, P60
   Rous P, 1941, J EXP MED, V73, P365, DOI 10.1084/jem.73.3.365
   Seth A, 2003, ANTICANCER RES, V23, P2043
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946
   SHUBIK P, 1950, CANCER RES, V10, P13
   Sontag L, 2005, J THEOR BIOL, V232, P179, DOI 10.1016/j.jtbi.2004.08.002
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Tsao JL, 1999, AM J PATHOL, V154, P1815, DOI 10.1016/S0002-9440(10)65437-5
   Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235
   Valli T, 2007, VET PATHOL, V44, P962, DOI 10.1354/vp.44-6-962
   Vasilatos SN, 2009, CANCER EPIDEM BIOMAR, V18, P901, DOI 10.1158/1055-9965.EPI-08-0875
   Wang YZ, 2005, PROSTATE, V64, P149, DOI 10.1002/pros.20225
   Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933
   WEED DL, 1985, J EPIDEMIOL COMMUN H, V39, P277, DOI 10.1136/jech.39.4.277
   WOGLOM WH, 1913, STUDY EXPT CANC RES
   Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
NR 84
TC 12
Z9 15
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PY 2010
VL 38
IS 1
BP 171
EP 179
DI 10.1177/0192623309356447
PG 9
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Toxicology
GA 559EL
UT WOS:000274804800017
PM 20019354
OA Bronze
DA 2025-01-12
ER

PT J
AU Kioulafa, M
   Balkouranidou, L
   Sotiropoulou, G
   Kaklamanis, L
   Mavroudis, D
   Georgoulias, V
   Lianidou, ES
AF Kioulafa, Magdalini
   Balkouranidou, Loanna
   Sotiropoulou, Georgia
   Kaklamanis, Loukas
   Mavroudis, Dimitris
   Georgoulias, Vassilis
   Lianidou, Evi S.
TI Methylation of cystatin M promoter is associated with unfavorable
   prognosis in operable breast cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE cystatin M; CST6; DNA methylation; operable breast cancer; epigenetic
   markers
ID CYSTEINE PROTEINASE-INHIBITOR; TUMOR-SUPPRESSOR GENE; DNA METHYLATION;
   IN-SITU; CST6; HYPERMETHYLATION; INACTIVATION; EPIGENETICS; RASSF1A;
   PROGRESSION
AB The methylation status of cystatin M (CST6) gene in breast tumors was investigated and its prognostic significance as a novel breast cancer biomarker was evaluated. Using methylation-specific PCR (MSP), CST6 promoter methylation was examined in 134 formalin fixed paraffin-em bedded tissues (FFPEs): 10 pairs of breast tumors and their surrounding normal tissues, 10 breast fibroadenomas, I I normal breast tissues and 93 breast tumors. Methylation of CST6 promoter was observed in 2/21 (9.5%) noncancerous breast tissues, 1/10 (10%) benign breast tumors (fibroadenomas) and 52 (55.9%) operable breast cancer tumor samples. CST6 was rarely methylated in the normal tissue surrounding the tumor (10%). During the follow-up period, 24 (25.8%) patients relapsed and 19 (20.4%) died. CST6 methylation was detected in 19 (79.2%) of patients who relapsed and in 15 (78.9%) of patients who died. Disease-free-interval (DFI) and overall survival (OS) were significantly associated with CST6 promoter methylation (p = 0.004 and p = 0.001 respectively). Multivariate analysis revealed that CST6 methylation is an independent prognostic factor for DFI (FIR = 3.484; 95% Cl: 1.155-10.511; p = 0.027). and OS (FIR = 9.190; 95% Cl: 1.989-42.454; p = 0.004). CST6 promoter methylation status in tumor cells seems to provide important prognostic information in operable breast cancer and merits to be further evaluated and validated in a larger cohort of patients. (C) 2009 UICC
C1 [Kioulafa, Magdalini; Balkouranidou, Loanna; Lianidou, Evi S.] Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
   [Sotiropoulou, Georgia] Univ Patras, Dept Pharm, Rion, Greece.
   [Kaklamanis, Loukas] Onassis Cardiac Surg Ctr, Dept Pathol, Athens, Greece.
   [Mavroudis, Dimitris; Georgoulias, Vassilis] Univ Gen Hosp Herakl, Dept Med Oncol, Iraklion, Greece.
C3 National & Kapodistrian University of Athens; University of Patras;
   Onassis Cardiac Surgery Center; University Hospital of Heraklion
RP Lianidou, ES (通讯作者)，Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
EM lianidou@chem.uoa.gr
OI Lianidou, Evi/0000-0002-7796-5914; BALGKOURANIDOU,
   IOANNA/0000-0003-0609-8566
FU Special Account for Research Grants (SARG) (National and Kapodistrian
   University of Athens); Greek Ministry of Health; Hellenic Oncology
   Research Group (HORG)
FX Grant sponsors: Special Account for Research Grants (SARG) (National and
   Kapodistrian University of Athens), Greek Ministry of Health, Hellenic
   Oncology Research Group (HORG).
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   CALKINS CC, 1995, BIOL CHEM H-S, V376, P71
   Dammann R, 2001, CANCER RES, V61, P3105
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fiegl H, 2008, CLIN CANCER RES, V14, P3494, DOI 10.1158/1078-0432.CCR-07-4557
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kroupis C, 2008, CLIN CHIM ACTA, V390, P141, DOI 10.1016/j.cca.2007.12.024
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   Ni J, 1997, J BIOL CHEM, V272, P10853
   Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   Veena MS, 2008, GENE CHROMOSOME CANC, V47, P740, DOI 10.1002/gcc.20576
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
NR 28
TC 27
Z9 29
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 15
PY 2009
VL 125
IS 12
BP 2887
EP 2892
DI 10.1002/ijc.24686
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 523CJ
UT WOS:000272049000017
PM 19551853
OA Bronze
DA 2025-01-12
ER

PT J
AU Bertotti, A
   Burbridge, MF
   Gastaldi, S
   Galimi, F
   Torti, D
   Medico, E
   Giordano, S
   Corso, S
   Rolland-Valognes, G
   Lockhart, BP
   Hickman, JA
   Comoglio, PM
   Trusolino, L
AF Bertotti, Andrea
   Burbridge, Mike F.
   Gastaldi, Stefania
   Galimi, Francesco
   Torti, Davide
   Medico, Enzo
   Giordano, Silvia
   Corso, Simona
   Rolland-Valognes, Gaelle
   Lockhart, Brian P.
   Hickman, John A.
   Comoglio, Paolo M.
   Trusolino, Livio
TI Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene
   Addiction
SO SCIENCE SIGNALING
LA English
DT Article
ID CELL LUNG-CANCER; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE;
   COLORECTAL-CANCER; SIGNALING PATHWAY; FACTOR PROTECTS; BREAST-CANCER;
   DNA-REPAIR; BCR-ABL; GROWTH
AB Tumor onset and progression require the accumulation of many genetic and epigenetic lesions. In some cases, however, cancer cells rely on only one of these lesions to maintain their malignant properties, and this dependence results in tumor regression upon oncogene inactivation ("oncogene addiction"). Determining which nodes of the many networks operative in the transformed phenotype specifically mediate this response to oncogene neutralization is crucial to identifying the vulnerabilities of cancer. Using the Met receptor as the major model system, we combined multiplex phospho-proteomics, genome-wide expression profiling, and functional assays in various cancer cells addicted to oncogenic receptor tyrosine kinases. We found that Met blockade affected a limited subset of Met downstream signals: Little or no effect was observed for several pathways downstream of Met; instead, only a restricted and pathway-specific signature of transducers and transcriptional effectors downstream of Ras or phosphoinositide 3-kinase (PI3K) was inactivated. An analogous signature was also generated by inhibition of epidermal growth factor receptor in a different cellular context, suggesting a stereotyped response that likely is independent of receptor type or tissue origin. Biologically, Met inhibition led to cell-cycle arrest. Inhibition of Ras-dependent signals and PI3K-dependent signals also resulted in cell-cycle arrest, whereas cells in which Met was inhibited proliferated when Ras or PI3K signaling was active. These findings uncover "dominant" and "recessive" nodes among the numerous oncogenic networks regulated by receptor tyrosine kinases and active in cancer, with the Ras and PI3K pathways as determinants of therapeutic response.
C1 [Bertotti, Andrea; Gastaldi, Stefania; Galimi, Francesco; Torti, Davide; Giordano, Silvia; Corso, Simona; Comoglio, Paolo M.; Trusolino, Livio] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, I-10060 Turin, Italy.
   [Rolland-Valognes, Gaelle; Lockhart, Brian P.] Inst Rech Servier, Div Mol Pharmacol & Pathophysiol, F-78290 Croissy Sur Seine, France.
   [Medico, Enzo] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Oncogenom Ctr,Lab Funct Genom, I-10060 Turin, Italy.
C3 IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin;
   Servier; Institut de Recherches Internationales Servier; IRCCS
   Fondazione del Piemonte per l'Oncologia; University of Turin
RP Trusolino, L (通讯作者)，Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, I-10060 Turin, Italy.
EM paolo.comoglio@ircc.it; livio.trusolino@ircc.it
RI Trusolino, Livio/A-3896-2011; Medico, Enzo/AAC-3185-2021; Comoglio,
   Paolo/G-6323-2011; GIORDANO, Silvia/J-9858-2018; Medico,
   Enzo/K-8497-2018
OI GIORDANO, Silvia/0000-0003-1854-1086; Medico, Enzo/0000-0002-3917-2438;
   Trusolino, Livio/0000-0002-6379-3365; Comoglio,
   Paolo/0000-0002-7056-5328; Bertotti, Andrea/0000-0001-8196-7608; CORSO,
   Simona/0000-0002-5069-1503; GALIMI, Francesco/0000-0002-5939-6922
FU Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
CR Albanell J, 2001, CANCER RES, V61, P6500
   Albanell J, 2001, SEMIN ONCOL, V28, P56, DOI 10.1016/S0093-7754(01)90283-0
   Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987
   Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561
   Baselga J, 2008, J CLIN ONCOL, V26, P1582, DOI 10.1200/JCO.2007.15.3700
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657
   Bowers DC, 2000, CANCER RES, V60, P4277
   Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007
   Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044
   Christensen JG, 2003, CANCER RES, V63, P7345
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566
   Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943
   Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198
   Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105
   Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506
   Herrick J, 2000, P NATL ACAD SCI USA, V97, P222, DOI 10.1073/pnas.97.1.222
   Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Kamb A, 2003, MOL BIOL CELL, V14, P2201, DOI 10.1091/mbc.E02-11-0732
   Kang S, 2008, INT J GYNECOL CANCER, V18, P1339, DOI 10.1111/j.1525-1438.2007.01172.x
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001
   Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495
   Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884
   McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104
   Meng QH, 2000, BIOCHEM BIOPH RES CO, V274, P772, DOI 10.1006/bbrc.2000.3199
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Müller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002
   Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002
   Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818
   PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2
   Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850
   Recio JA, 2002, ONCOGENE, V21, P1000, DOI 10.1038/sj.onc.1205150
   Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802
   Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567
   Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025
   Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397
   Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494
   Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907
   Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
   Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014
   Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490
   Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021
   Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005
   Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898
NR 57
TC 65
Z9 71
U1 0
U2 6
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD DEC 8
PY 2009
VL 2
IS 100
AR ra80
DI 10.1126/scisignal.2000643
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 570BK
UT WOS:000275646400004
PM 20039471
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Wong, ST
AF Wong, Serena T.
TI Emerging treatment combinations: Integrating therapy into clinical
   practice
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE Antineoplastic agents; Bevacizumab; Breast neoplasms; Combined therapy;
   Everolimus; Gefitinib; Genetics; Mechanism of action; Neoplasm
   metastasis; Paclitaxel; Resistance; Site of action; Tamoxifen; Toxicity;
   Vorinostat
ID HUMAN BREAST-CANCER; RANDOMIZED PHASE-II; TRASTUZUMAB; VORINOSTAT;
   INHIBITORS; KINASE; MTOR; EVEROLIMUS; RESISTANCE; TARGET
AB Purpose. To review data supporting the effectiveness of emerging treatment options for metastatic breast cancer.
   Summary. Recent research has focused on several signal-transduction pathways important in the pathogenesis of breast cancer. Mammalian target of rapamycin (mTOR) is a serine-threonine protein kinase that is involved in cell growth and survival. Everolimus, an orally active inhibitor of mTOR, has demonstrated promising efficacy results and a favorable safety profile in initial studies. Epidermal growth factor receptor (EGFR), a cell-surface molecule that has been implicated in the pathogenesis of breast cancer, may also be important in the emergence of resistance to endocrine therapy. Initial clinical studies have suggested that EGFR inhibitors such as gefitinib may delay the development of resistance to endocrine therapy in patients with breast cancer when given concurrently with tamoxifen or an aromatase inhibitor. Finally, considerable recent research has examined the role of epigenetic gene silencing, in which acetylation or deacetylation of DNA modifies the expression of tumor-suppressing genes. The enzyme histone deacetylase (HDAC) suppresses gene tran-scription by modifying chromatin into a more compact form. HDAC inhibitors have emerged as a potential new treatment option for several cancer types, including breast cancer. The HDAC inhibitor vorinostat has recently been examined in combination with other treatments, including cytotoxic agents and bevacizumab, for the treatment of breast cancer. In one small Phase I and II study, first-line treatment with the combination of vorinostat, paclitaxel, and bevacizumab produced objective responses (partial or complete) in more than 50% of patients with recurrent or metastatic breast cancer.
   Conclusions. Although the results of the described studies are promising, randomized controlled clinical trials are needed to better understand the efficacy and safety of emerging treatment options for patients with metastatic breast cancer.
C1 Univ Med & Dent New Jersey, Div Med Oncol, Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers Cancer Institute of New
   Jersey
RP Wong, ST (通讯作者)，Univ Med & Dent New Jersey, Div Med Oncol, Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA.
EM wongse@umdnj.edu
CR Andrade SAC, 2008, B CTR PESQUI PROC AL, V26, P41
   Chan CT, 2005, BREAST CANCER RES TR, V91, P187, DOI 10.1007/s10549-004-7715-1
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824
   Cristofanilli M, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.1012
   Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033
   FASOLO A, 2008, 31 ANN SAN ANT BREAS
   Fasolo A, 2008, EXPERT OPIN INV DRUG, V17, P1717, DOI [10.1517/13543784.17.11.1717, 10.1517/13543784.17.11.1717 ]
   Fuino L, 2003, MOL CANCER THER, V2, P971
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Ma WW, 2009, CA-CANCER J CLIN, V59, P111, DOI 10.3322/caac.20003
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509
   O'Donnell A, 2008, J CLIN ONCOL, V26, P1588, DOI 10.1200/JCO.2007.14.0988
   Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036
   Osborne K, 2007, BREAST CANCER RES TR, V106, pS107
   Pietras RJ, 2007, CLIN CANCER RES, V13, P4672, DOI 10.1158/1078-0432.CCR-07-1373
   Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540
   RAMASWAMY B, 2008, 31 ANN SAN ANT BREAS
   Richon VM, 2009, CANCER LETT, V280, P201, DOI 10.1016/j.canlet.2009.01.002
   Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   Yakes FM, 2002, CANCER RES, V62, P4132
NR 24
TC 15
Z9 18
U1 0
U2 1
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD DEC 1
PY 2009
VL 66
IS 23
SU 6
BP S9
EP S14
DI 10.2146/ajhp090439
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 523YI
UT WOS:000272110600003
PM 19923318
DA 2025-01-12
ER

PT J
AU Phipps, SMO
   Love, WK
   White, T
   Andrews, LG
   Tollefsbol, TO
AF Phipps, Sharla M. O.
   Love, William K.
   White, Teresa
   Andrews, Lucy G.
   Tollefsbol, Trygve O.
TI Retinoid-induced Histone Deacetylation Inhibits Telomerase Activity in
   Estrogen Receptor-negative Breast Cancer Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Breast cancer; retinoic acid; epigenetic; histone deacetylation;
   telomerase; hTERT
ID DNA METHYLTRANSFERASES; EPIGENETIC REGULATION; HTERT GENE;
   DIFFERENTIATION; METHYLATION; EXPRESSION; ALPHA
AB Background: Multiple mechanisms regulate cancer-associated telomerase activity at the level of human telomerase reverse transcriptase (hTERT) transcription which may serve as novel targets for anticancer approaches. Materials and Methods: The effects of prolonged all-trans retinoic acid (ATRA) exposure on hTERT regulation in estrogen receptor-negative SK-BR-3 breast cancer cells were examined. Results: ATRA had a profound effect on the morphology and proliferation rate of the SK-BR-3 cells. ATRA also hindered the ability of these cancer cells to grow independently, rendering them more like normal somatic cells. The effect of ATRA on the decrease of telomerase activity was found to be associated with a rapid decrease in histone H3-lysine 9 acetylation (H3-K9-Ac) of the hTERT promoter. Extended-exposure to ATRA in these cells also caused the initiation of a putative compensatory mechanism, counteracting the induced surge in apoptosis. Conclusion: A rapid decrease of H3-K9 acetylation at the hTERT promoter could be an important mechanism by which ATRA shuts down telomerase activity and mediates its antitumor effects in estrogen receptor-negative breast cancer cells.
C1 [Phipps, Sharla M. O.; Love, William K.; White, Teresa; Andrews, Lucy G.; Tollefsbol, Trygve O.] Univ Alabama, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama, Ctr Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama, Dept Biol, 175 Campbell Hall,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
FU NCI [R01 CA129415]; Susan G. Komen for the Cure
FX This work was supported in part by grants from the NCI (R01 CA129415)
   and Susan G. Komen for the Cure. We thank J. Tyson DeAngelis for
   assistance with the Study.
CR Casillas MA, 2003, MOL CELL BIOCHEM, V252, P33, DOI 10.1023/A:1025548623524
   Fitzgerald P, 1997, CANCER RES, V57, P2642
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Hansen NJ, 2007, INT J ONCOL, V30, P641
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511
   Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058
   Love WK, 2008, INT J ONCOL, V32, P625
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   ROMAN SD, 1992, CANCER RES, V52, P2236
   Schneider SM, 2000, CANCER RES, V60, P5479
   VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N
   Yang LM, 1999, J MAMMARY GLAND BIOL, V4, P377, DOI 10.1023/A:1018718401126
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 14
TC 20
Z9 24
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD DEC
PY 2009
VL 29
IS 12
BP 4959
EP 4964
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 540UP
UT WOS:000273365700007
PM 20044602
DA 2025-01-12
ER

PT J
AU Lu, XW
   Gu, YM
   Zhu, DL
   Tan, JX
   Liu, XR
   Zha, XM
AF Lu, Xiaowei
   Gu, Yumei
   Zhu, Dongliang
   Tan, Jianxin
   Liu, Xiaorong
   Zha, Xiaoming
TI Promoter methylation status of PTEN, SYK and survivin genes in breast
   cancer tissues derived from Chinese women
SO ASIAN BIOMEDICINE
LA English
DT Article
DE Breast cancer; methylation status; PTEN; SYK; survivin
ID TUMOR-SUPPRESSOR GENE; CPG ISLANDS; ALLELIC LOSS; EXPRESSION;
   CONTRIBUTE; CARCINOGENESIS; APOPTOSIS; MUTATION; DISEASE; 10Q23
AB Background. Epigenetic mechanisms of gene transcription, including inactivation of tumor suppressor genes by hypermethylation and activation of oncogenes by hypomethylation, have been shown to contribute to breast tumorigenesis. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) and Spleen tyrosine kinase (SYK) are both tumor suppressor genes and survivin is a novel member of the inhibitor of apoptosis (IAP) family which may promote tumorigenesis.
   Objective: To investigate the methylation status of PTEN, SYK, and survivin genes in breast cancer derived from Chinese women.
   Materials and methods: We examined the methylation status of these three genes in 52 paraffin-embedded breast cancer tissues using methylation-specific PCR (MSP) assay in conjunction with sequencing analysis.
   Results: PTEN and SYK were both methylated in 15.4% (8/52) of breast tumor tissues, while the survivin gene was all demethylated in the examined samples. Random selection of MSP products sequence analyses to three genes all revealed a homogenous methylation status in the CpG sites.
   Conclusion: The present Study showed a moderate methylation status of PTEN and SYK, and an unmethylation status of survivin in breast tumor tissues derived from Chinese women, which suggested methylation mechanisms might be involved in the aberrant expression of these three genes in breast cancer development.
C1 [Zha, Xiaoming] Nanjing Med Univ, Affiliated Hosp 1, Dept Breast Surg, Nanjing 210029, Peoples R China.
   [Lu, Xiaowei] Maternal & Child Hlth Hosp Wuxi City, Dept Breast Surg, Wuxi 214002, Peoples R China.
   [Gu, Yumei; Zhu, Dongliang; Tan, Jianxin; Liu, Xiaorong] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 210029, Peoples R China.
   [Zhu, Dongliang; Liu, Xiaorong] Nanjing Med Univ, Dept Cell Biol & Med Genet, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Zha, XM (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Breast Surg, Nanjing 210029, Peoples R China.
EM zhaxm@medmail.com.cn
RI Lu, Xiaowei/AAS-6701-2020
FU National Natural Science Foundation of China [30772490]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 30772490). The authors have no conflict of
   interest to report.
CR Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940
   Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976
   Gu YM, 2008, ONCOLOGY-BASEL, V74, P61, DOI 10.1159/000139125
   Joe AK, 2001, ANTICANCER RES, V21, P3535
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   LLOYD KM, 1963, ANN INTERN MED, V58, P136, DOI 10.7326/0003-4819-58-1-136
   MALLORY SB, 1995, DERMATOL CLIN, V13, P27, DOI 10.1016/S0733-8635(18)30103-7
   Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   Rhei E, 1997, CANCER RES, V57, P3657
   Shi SR, 2002, J HISTOCHEM CYTOCHEM, V50, P1005, DOI 10.1177/002215540205000802
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   STINGH B, 1998, GENE CHROMOSOME CANC, V21, P166
   Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614
   Tanaka C, 2003, J DENT RES, V82, P607, DOI 10.1177/154405910308200807
   Tanaka K, 2000, CLIN CANCER RES, V6, P127
   Wang L, 2003, CANCER RES, V63, P4724
   Wei JJ, 2006, HUM REPROD, V21, P57, DOI 10.1093/humrep/dei309
   Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441
   Yu J, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-65
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Yuan YF, 2005, INT J CANCER, V113, P654, DOI 10.1002/ijc.20628
   Yuan YF, 2001, CANCER RES, V61, P5558
   Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4
NR 29
TC 2
Z9 2
U1 0
U2 4
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1905-7415
EI 1875-855X
J9 ASIAN BIOMED
JI Asian Biomed.
PD DEC
PY 2009
VL 3
IS 6
BP 595
EP 601
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 544JV
UT WOS:000273653700003
DA 2025-01-12
ER

PT J
AU Van der Auwera, I
   Bovie, C
   Svensson, C
   Limame, R
   Trinh, XB
   van Dam, P
   Van Laere, SJ
   Van Marck, E
   Vermeulen, PB
   Dirix, LY
AF Van der Auwera, Ilse
   Bovie, Catherine
   Svensson, Cecilia
   Limame, Ridha
   Trinh, Xuan B.
   van Dam, Peter
   Van Laere, Steven J.
   Van Marck, Eric
   Vermeulen, Peter B.
   Dirix, Luc Y.
TI Quantitative assessment of DNA hypermethylation in the inflammatory and
   non-inflammatory breast cancer phenotypes
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE inflammatory breast cancer; methylation; epigenetics;
   methylation-specific PCR; breast cancer
ID APC GENE PROMOTER; TUMOR-SUPPRESSOR GENE; ABERRANT METHYLATION;
   CPG-ISLAND; MOLECULAR-BIOLOGY; DOWN-REGULATION; PROTEIN-KINASE;
   EXPRESSION; ASSOCIATION; SURVIVAL
AB In this study, a comparative quantitative methylation profiling of inflammatory breast cancer (IBC) and non-IBC was set up for the identification of tumor-specific methylation patterns. Methylation ratios of six genes ( DAPK, TWIST, HIN-1, RASSF1A, RAR beta 2 and APC) were measured in benign breast tissues (n = 9) and in tumor samples from non-IBC ( n = 81) and IBC ( n = 19) patients using quantitative methylation-specific PCR. Median methylation ratios observed in breast cancer (n = 100) were significantly higher than those observed in benign breast tissues for 5 of 6 genes ( TWIST, HIN-1, RASSF1A, RAR beta 2 and APC). Only one of the individual genes studied, RAR beta 2, showed differential methylation ratios in IBC and non-IBC (p = 0.016). Using the maximal methylation ratio observed in benign breast tissue as a threshold, the methylation frequency of two genes, RAR beta 2 and APC, was significantly increased in IBC ( n = 19) when compared to non-IBC ( n = 81): 53% vs. 23% for RAR beta 2 ( p = 0.012) and 84% vs. 54% for APC (p = 0.017). Using hierarchical clustering, methylation patterns could not classify breast cancers according to their phenotype. The finding of differential frequencies of methylation in IBC and non-IBC for 2 out of 6 genes suggests that gene-specific patterns of methylation could provide a basis for molecular classification of IBC. Testing for additional genes could help to define the IBC phenotype based on patterns of aberrant gene promoter methylation.
C1 [Van der Auwera, Ilse; Limame, Ridha; Trinh, Xuan B.; van Dam, Peter; Van Laere, Steven J.; Van Marck, Eric; Vermeulen, Peter B.; Dirix, Luc Y.] Univ Antwerp, Univ Hosp Antwerp, Gen Hosp St Augustinus, Translat Canc Res Grp,Lab Pathol,Oncol Ctr, B-2020 Antwerp, Belgium.
   [Bovie, Catherine; Svensson, Cecilia] Ctr Hosp Univ, OncoMethylome Sci SA, Liege, Belgium.
C3 University of Antwerp; University of Liege
RP Van der Auwera, I (通讯作者)，Univ Antwerp, Univ Hosp Antwerp, Gen Hosp St Augustinus, Translat Canc Res Grp,Lab Pathol,Oncol Ctr, B-2020 Antwerp, Belgium.
EM ilse.van.der.auwera@telenet.be
RI Dirix, Luc/AAI-8880-2020; Van Laere, Steven/GQA-8872-2022
OI Van Laere, Steven/0000-0002-2640-0040; Limame, Ridha/0000-0002-9089-4858
CR Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115
   Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696
   Bièche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Chang S, 1998, CANCER, V82, P2366
   Charafe-Lauffret E, 2008, SEMIN ONCOL, V35, P41, DOI 10.1053/j.seminoncol.2007.11.015
   Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Esteller M, 2001, CANCER RES, V61, P3225
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   Gonzalez-Angulo AM, 2006, CLIN BREAST CANCER, V7, P326, DOI 10.3816/CBC.2006.n.045
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kleer CG, 2002, ONCOGENE, V21, P3172, DOI 10.1038/sj.onc.1205462
   Kleer CG, 2000, BREAST CANCER RES, V2, P423, DOI 10.1186/bcr89
   Krop I, 2005, CANCER RES, V65, P9659, DOI 10.1158/0008-5472.CAN-05-1663
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876
   Shi HD, 2003, J CELL BIOCHEM, V88, P138, DOI 10.1002/jcb.10313
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Singletary SE, 2002, J CLIN ONCOL, V20, P3628, DOI 10.1200/JCO.2002.02.026
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705
   van Golen KL, 2000, CANCER RES, V60, P5832
   Van Laere S, 2007, BRIT J CANCER, V97, P1165, DOI 10.1038/sj.bjc.6603967
   Van Laere S, 2005, BREAST CANCER RES TR, V93, P237, DOI 10.1007/s10549-005-5157-z
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yan PS, 2001, CANCER RES, V61, P8375
NR 47
TC 20
Z9 22
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD DEC 1
PY 2009
VL 8
IS 23
BP 2252
EP 2259
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 533BL
UT WOS:000272796800008
PM 19829046
DA 2025-01-12
ER

PT J
AU Kiran, M
   Chawla, YK
   Kaur, J
AF Kiran, Manjula
   Chawla, Yogesh K.
   Kaur, Jyotdeep
TI Methylation profiling of tumor suppressor genes and oncogenes in
   hepatitis virus-related hepatocellular carcinoma in northern India
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; ISLAND DNA HYPERMETHYLATION; CPG ISLANDS;
   GSTP1 GENE; BREAST-CANCER; C-MYC; HYPOMETHYLATION; EXPRESSION; LIVER;
   CIRRHOSIS
AB Hepatocellular carcinoma (HCC) is the fifth most common cancer in India, and hepatitis B virus and hepatitis C virus infections are major risk factors. DNA methylation alterations have been linked to various carcinomas in different populations. Aberrant CpG island methylation of genes has been recognized in HCC, information is limited for hepatitis virus related hepatocarcinogenesis. HCC risk has not previously been associated with gene-specific DNA methylation in India. Promoter region methylation of a panel of six tumor suppressor genes (CDKN2A, CDKN2B, CDH1, GSTP1, SOCS1, and APC) and three oncogenes (MYC, HRAS, and KRAS) was determined by methylation-specific PCR among 23 HCC samples and 20 control hepatitis samples. CDKN2B methylation frequency in HCC was double that for hepatitis, and methylation allele density of APC, GSTP1, and CDKN2B increased 2.2-, 2.3-, and 7.6-fold, respectively. Epigenetic silencing of tumor suppressor genes starts during viral infection and progresses toward HCC with the chronicity of the disease. Findings of altered methylation status support involvement of these tumor suppressor genes in HCC. MYC showed decreased methylation in HCC, relative to hepatitis. These observations on DNA methylation suggest the involvement of CDKN2B, SOCS1, CDH1, GSTP1, and MYC in pathogenesis of HCC in India and implicate altered DNA methylation in the molecular pathogenesis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Kiran, Manjula; Kaur, Jyotdeep] Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India.
   [Chawla, Yogesh K.] Postgrad Inst Med Educ & Res, Dept Hepatol, Chandigarh 160012, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh
RP Kaur, J (通讯作者)，Postgrad Inst Med Educ & Res, Dept Biochem, Sector 12, Chandigarh 160012, India.
EM jyotdeep2001@yahoo.co.in
RI Kaur, Jyotdeep/AFP-1572-2022
FU Department of Science and Technology (DST), New Delhi, India; Indian
   Council of Medical Research (ICMR), New Delhi, India
FX This work was supported by a financial grant sanctioned to J.K. from the
   Department of Science and Technology (DST), New Delhi, India. M.K. was a
   recipient of fellowship from Indian Council of Medical Research (ICMR),
   New Delhi, India.
CR AIBA N, 1989, Gastroenterologia Japonica, V24, P270
   Anzola M, 2003, LIVER INT, V23, P249, DOI 10.1034/j.1600-0676.2003.00834.x
   Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3
   But DYK, 2008, WORLD J GASTROENTERO, V14, P1652, DOI 10.3748/wjg.14.1652
   Chu HJ, 2004, J KOREAN MED SCI, V19, P83, DOI 10.3346/jkms.2004.19.1.83
   DIILIO C, 1991, CARCINOGENESIS, V12, P1471
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 1998, CANCER RES, V58, P4515
   Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028
   Gong Y, 2002, BRIT J CANCER, V86, P625, DOI 10.1038/sj.bjc.6600099
   Grant S.G., 2001, THEOR RES SOC EDUC, V29, P65, DOI 10.1080/00933104.2001.10505930
   HERMAN JG, 1998, CURR PROTOC HUM  FEB, pCH10
   HIMENO Y, 1988, LIVER, V8, P208
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   KANEKO Y, 1985, JPN J CANCER RES, V76, P1136
   Kaneto H, 2001, GUT, V48, P372, DOI 10.1136/gut.48.3.372
   Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027
   NAMBU S, 1987, JPN J CANCER RES, V78, P695
   Piotrowski A, 2006, GENE CHROMOSOME CANC, V45, P656, DOI 10.1002/gcc.20331
   Qin Y, 2004, WORLD J GASTROENTERO, V10, P1276
   Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Sato N, 2003, CANCER RES, V63, P4158
   Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639
   Tang ZY, 1998, CHINESE MED J-PEKING, V111, P313
   Tchou JC, 2000, INT J ONCOL, V16, P663
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
NR 37
TC 17
Z9 19
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD DEC
PY 2009
VL 195
IS 2
BP 112
EP 119
DI 10.1016/j.cancergencyto.2009.06.021
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 592QW
UT WOS:000277395500003
PM 19963110
DA 2025-01-12
ER

PT J
AU Sun, XL
   Li, CH
   Zhuang, CM
   Gilmore, WC
   Cobos, E
   Tao, YX
   Dai, ZH
AF Sun, Xiaolin
   Li, Chenghai
   Zhuang, Chunmei
   Gilmore, William C.
   Cobos, Everardo
   Tao, Yunxia
   Dai, Zonghan
TI Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and
   is required for invadopodia formation, extracellular matrix degradation
   and tumor growth of human breast cancer cells
SO CARCINOGENESIS
LA English
DT Article
ID SPECIALIZED SURFACE PROTRUSIONS; ALDRICH-SYNDROME PROTEIN; INVASIVE
   ACTIVITIES; PODOSOME FORMATION; SRC; MEMBRANE; COMPLEX; PHOSPHORYLATION;
   ACTIVATION; CORTACTIN
AB Abl interactor 1 (Abi1) is a key regulator of actin polymerization/depolymerization. The involvement of Abi1 in the development of abnormal cytoskeletal functions of cancer cells has recently been reported. It remains unclear, however, how Abi1 exerts its effects in tumor cells and whether it contributes to tumor progression in vivo. We report here a novel function for Abi1 in the regulation of invadopodia formation and Src-inhibitor of differentiation protein 1 (Id1)-matrix metalloproteinase (MMP)-9 pathway in MDA-MB-231 human breast cancer cells. Abi1 is found in the invadopodia of MDA-MB-231 cells. Epigenetic silencing of the Abi1 gene by short hairpin RNA in MDA-MB-231 cells impaired the formation of invadopodia and resulted in downregulation of the Src activation and Id1/MMP-9 expression. The decreased invadopodia formation and MMP-9 expression correlate with a reduction in the ability of these cells to degrade extracellular matrix. Remarkably, the knockdown of Abi1 expression inhibited tumor cell proliferation and migration in vitro and slowed tumor growth in vivo. Taken together, these results indicate that the Abi1 signaling plays a critical role in breast cancer progression and suggest that this pathway may serve as a therapeutic target for the treatment of human breast cancer.
C1 [Sun, Xiaolin; Li, Chenghai; Zhuang, Chunmei; Cobos, Everardo; Tao, Yunxia; Dai, Zonghan] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Amarillo, TX 79106 USA.
   [Sun, Xiaolin] China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing 100094, Peoples R China.
   [Zhuang, Chunmei] Shandong Univ, State Key Lab Microbial Technol, Jinan 250100, Peoples R China.
   [Gilmore, William C.] Texas Vet Med Diagnost Labs, Amarillo, TX 79106 USA.
   [Cobos, Everardo; Dai, Zonghan] Texas Tech Univ, Hlth Sci Ctr, Stem Cell Transplant Program, Lubbock, TX 79430 USA.
C3 Texas Tech University System; Texas Tech University Health Science
   Center; Texas Tech University Health Sciences Center Amarillo; China
   Agricultural University; Shandong University; Texas Tech University
   System; Texas Tech University Health Science Center
RP Dai, ZH (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, 1406 Coulter St, Amarillo, TX 79106 USA.
EM zonghan.dai@ttuhsc.edu
RI COBOS, EVERARDO/LRU-2001-2024; Sun, Xiaolin/ACX-5286-2022
OI cobos, everardo/0000-0001-5799-0074; Sun, Xiaolin/0000-0001-9709-1532
FU National Institutes of Health/National Cancer Institute [R01 CA094921,
   R21 CA133597]; National Institutes of Health/National Institute of
   Diabetes and Digestive and Kidney Diseases [K01 DK067191]; China
   Scholarship Council
FX National Institutes of Health/National Cancer Institute (R01 CA094921
   and R21 CA133597 to Z.D.); National Institutes of Health/National
   Institute of Diabetes and Digestive and Kidney Diseases (K01 DK067191 to
   Y.T.); China Scholarship Council to C.Z.
CR Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177
   Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088
   Berdeaux RL, 2004, J CELL BIOL, V166, P317, DOI 10.1083/jcb.200312168
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bharti S, 2007, MOL CELL BIOL, V27, P8271, DOI 10.1128/MCB.01781-06
   Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127
   Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.3.CO;2-S
   Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012
   Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827
   Bowden ET, 2001, METHOD CELL BIOL, V63, P613
   Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436
   Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x
   CHEN WT, 1994, BREAST CANCER RES TR, V31, P217, DOI 10.1007/BF00666155
   CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206
   Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928
   Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014
   Courtney KD, 2000, MOL CELL NEUROSCI, V16, P244, DOI 10.1006/mcne.2000.0865
   Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07-03-0227
   Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859
   Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000
   Gautreau A, 2004, P NATL ACAD SCI USA, V101, P4379, DOI 10.1073/pnas.0400628101
   Gautschi O, 2008, CANCER RES, V68, P2250, DOI 10.1158/0008-5472.CAN-07-6403
   Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005
   Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101
   Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200
   Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304
   Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105
   Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079
   Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035
   KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212
   Kelly T, 1998, CLIN EXP METASTAS, V16, P501, DOI 10.1023/A:1006538200886
   Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005
   Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102
   Li YZ, 2007, J CELL SCI, V120, P1436, DOI 10.1242/jcs.03430
   Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648
   MARCHISIO PC, 1988, BLOOD, V72, P830
   Mizutani K, 2002, CANCER RES, V62, P669
   Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959
   Nam JM, 2007, EMBO J, V26, P647, DOI 10.1038/sj.emboj.7601534
   Nieborowska-Skorska M, 2006, CANCER RES, V66, P4108, DOI 10.1158/0008-5472.CAN-05-1584
   Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318
   Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588
   Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822
   Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006
   Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7
   Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069
   Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130
   Wang K, 2007, OPTOELECTRON ADV MAT, V1, P5
   Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076
NR 51
TC 38
Z9 44
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD DEC
PY 2009
VL 30
IS 12
BP 2109
EP 2116
DI 10.1093/carcin/bgp251
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 531RE
UT WOS:000272684700019
PM 19843640
OA Green Published
DA 2025-01-12
ER

PT J
AU D'Ambrosio, J
   Fatatis, A
AF D'Ambrosio, Julia
   Fatatis, Alessandro
TI Osteoblasts modulate Ca<SUP>2+</SUP> signaling in bone-metastatic
   prostate and breast cancer cells
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Metastasis; Bone microenvironment; Osteoblast; Calcium signaling
ID MARROW STROMAL CELLS; GROWTH-FACTOR; CHEMOKINE RECEPTORS; STORE
   DEPLETION; STEM-CELLS; CALCIUM; TUMOR; APOPTOSIS; PROLIFERATION;
   MICROENVIRONMENT
AB Metastatic prostate and breast cancers display a predilection for the skeleton. The high incidence of skeletal metastasis may be a reflection of favorable reciprocal interactions between the bone microenvironment and disseminated cancer cells. Here we show that bone-metastatic PC3-ML prostate cancer cells and MDA-231 breast cancer cells-when co-cultured with human osteoblasts-down-regulate the increase in cytosolic free calcium (Ca2+) induced by agonist stimulation. This osteoblast promoted alteration of Ca2+ signaling develops and reverts in a time-dependent manner. Most importantly, the Ca2+ responses of cancer cells lacking bone metastatic potential are not affected by osteoblasts. The limited increase in cytosolic Ca2+ observed in bone-metastatic cells does not result from depleted intracellular Ca2+ stores but rather a decreased entry of Ca2+ from the extracellular space. Interestingly, the inhibition of histone deacetylase in cancer cells replicates the changes in Ca2+ signaling induced by osteoblasts, suggesting the participation of epigenetic mechanisms. Finally, cancer cells harvested from skeletal metastases induced in mice showed Ca2+ responses identical to cells co-cultured with osteoblasts. However, Ca2+ signaling in cancer cells recovered from metastases to soft-tissues was not affected, emphasizing the role of the bone microenvironment in regulating the functional behavior of bone-metastatic cells. We propose that osteoblasts protect selected malignant phenotypes from cell death caused by an excessive increase in cytosolic Ca2+, thereby facilitating their progression into macroscopic skeletal metastases.
C1 [D'Ambrosio, Julia; Fatatis, Alessandro] Drexel Univ, Dept Physiol & Pharmacol, Coll Med, Philadelphia, PA 19102 USA.
   [Fatatis, Alessandro] Drexel Univ, Dept Pathol & Lab Med, Coll Med, Philadelphia, PA 19102 USA.
C3 Drexel University; Drexel University
RP Fatatis, A (通讯作者)，Drexel Univ, Dept Physiol & Pharmacol, Coll Med, 245 N 15th St,New Coll Bldg,MS488, Philadelphia, PA 19102 USA.
EM afatatis@drexelmed.edu
FU W. W. Smith Charitable Trust Foundation; NIH [GM067892]
FX This work was supported in part by the W. W. Smith Charitable Trust
   Foundation and NIH (grant GM067892 to A. F.). The authors wish to thank
   Dr. Olimpia Meucci for critically reading the manuscript, Whitney
   Jamieson and Mike Russell in Fatatis laboratory for cancer cell
   inoculation and members of Meucci laboratory for helpful discussion.
CR Bansal G, 2007, PHARMACOL THERAPEUT, V116, P473, DOI 10.1016/j.pharmthera.2007.09.005
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849
   Berger CEM, 2001, J BONE MINER RES, V16, P2092, DOI 10.1359/jbmr.2001.16.11.2092
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180
   Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484
   Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555-007-9109-4
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Darby Peter J., 1993, Biological Signals, V2, P293
   Davis PK, 2001, BIOTECHNIQUES, V30, P1322, DOI 10.2144/01306rv01
   Dolloff NG, 2007, CANCER RES, V67, P555, DOI 10.1158/0008-5472.CAN-06-2593
   Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2
   FATATIS A, 1994, J BIOL CHEM, V269, P18021
   Fatatis A, 1997, J BIOL CHEM, V272, P4351, DOI 10.1074/jbc.272.7.4351
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Grimaldi M, 2006, J NEUROSCI RES, V84, P1738, DOI 10.1002/jnr.21064
   György H, 2006, CELL CALCIUM, V40, P553, DOI 10.1016/j.ceca.2006.08.016
   Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005-0319
   Hu M, 2008, EUR J CANCER, V44, P2760, DOI 10.1016/j.ejca.2008.09.038
   Ichikawa J, 2009, J CELL PHYSIOL, V219, P372, DOI 10.1002/jcp.21680
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lipskaia L, 2009, PFLUG ARCH EUR J PHY, V457, P673, DOI 10.1007/s00424-007-0428-7
   Malli R, 2007, CELL CALCIUM, V41, P63, DOI 10.1016/j.ceca.2006.05.001
   Mastro AM, 2004, J CELL BIOCHEM, V91, P265, DOI 10.1002/jcb.10746
   Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041
   Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
   Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901
   Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003
   Pinski J, 2001, CANCER RES, V61, P6372
   Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Russell MR, 2009, ONCOGENE, V28, P412, DOI 10.1038/onc.2008.390
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   SKRYMA R, 2000, J PHYSL, P71
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376
   Tombal B, 2000, PROSTATE, V43, P303
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008-5472.CAN-04-4188
   Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1
   Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1
   WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x
   Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019
NR 50
TC 7
Z9 10
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD DEC
PY 2009
VL 26
IS 8
BP 955
EP 964
DI 10.1007/s10585-009-9286-3
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 518VF
UT WOS:000271722400003
PM 19768662
DA 2025-01-12
ER

PT J
AU Costa, FF
   Seftor, EA
   Bischof, JM
   Kirschmann, DA
   Strizzi, L
   Arndt, K
   Bonaldo, MD
   Soares, MB
   Hendrix, MJC
AF Costa, Fabricio F.
   Seftor, Elisabeth A.
   Bischof, Jared M.
   Kirschmann, Dawn A.
   Strizzi, Luigi
   Arndt, Kelly
   Bonaldo, Maria de Fatima
   Soares, Marcelo B.
   Hendrix, Marcy J. C.
TI Epigenetically reprogramming metastatic tumor cells with an embryonic
   microenvironment
SO EPIGENOMICS
LA English
DT Article
DE DNA methylation; hESC microenvironment; Lefty; microRNAs; Nodal; Notch
ID BREAST-CANCER METASTASIS; STEM-CELLS; MICRORNA EXPRESSION; SKIN-CANCER;
   MELANOMA; PHENOTYPE
AB We have previously shown that the microenvironment of human embryonic stem cells (hESCs) is able to change and reprogram aggressive cancer cells to a less aggressive state. Some mechanisms implicated in the phenotypic changes observed after this exposure are mainly associated with the Nodal signaling pathway, which plays a key role in tumor cell plasticity. However, several other molecular mechanisms might be related directly and/or indirectly to these changes, including microRNA (miRNA) regulation and DNA methylation. Aim: To further explore the epigenetic mechanisms potentially underlying the phenotypic changes that occur after exposing metastatic melanoma cells to a hESC microenvironment. Materials & Methods: A total of 365 miRNAs were screened using the TaqMan (R) Low Density Arrays. We also evaluated whether DNA methylation could be one of the factors regulating the expression of the inhibitor of Nodal, Lefty, in hESCs (where it is highly expressed) vs melanoma cells (where it is not expressed). Results: Using these experimental approaches, we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively. We also demonstrate that Notch4 is one of the targets of miR-302a, which is upstream of Nodal. Additionally, one of the mechanisms that might explain the absence of the inhibitor of Nodal, Lefty, in cancer cells is silencing by DNA methylation, which provides new insights into the unregulated expression of Nodal in melanoma. Conclusion: These findings suggest that epigenetic changes such as DNA methylation and regulation by microRNAs might play a significant role in tumor cell plasticity and the metastatic phenotype.
C1 [Hendrix, Marcy J. C.] Childrens Mem Res Ctr, Canc Biol & Epigenom Program, Chicago, IL 60614 USA.
   Northwestern Univ, Feinberg Sch Med, Chicago, IL 60614 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Hendrix, MJC (通讯作者)，Childrens Mem Res Ctr, Canc Biol & Epigenom Program, 2300 Childrens Plaza,Box 222, Chicago, IL 60614 USA.
EM mjchendrix@childrensmemorial.org
RI Costa, Fabricio/M-5309-2017; Strizzi, Luigi/LWI-5313-2024
FU NIH [CA59702, CA 121205]; Eisenberg Scholar Research Fund; Maeve
   McNicholas Memorial Foundation
FX This work is supported by NIH grants CA59702 and CA 121205 (MJCH), the
   Eisenberg Scholar Research Fund (LS) and the Maeve McNicholas Memorial
   Foundation (FFC). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apartfrom those disclosed.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08
   CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881
   Costa FF, 2007, GENE, V386, P1, DOI 10.1016/j.gene.2006.09.028
   Costa FF, 2006, CANCER GENET CYTOGEN, V165, P135, DOI 10.1016/j.cancergencyto.2005.07.023
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Glud M, 2009, J INVEST DERMATOL, V129, P1219, DOI 10.1038/jid.2008.347
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Krebs LT, 2003, GENE DEV, V17, P1207, DOI 10.1101/gad.1084703
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8
   Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708
   Lui P, 2007, CANCER TREAT REV, V33, P665, DOI 10.1016/j.ctrv.2007.06.004
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   Morokuma J, 2008, P NATL ACAD SCI USA, V105, P16608, DOI 10.1073/pnas.0808328105
   Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105
   Postovit LM, 2007, J CELL BIOCHEM, V101, P908, DOI 10.1002/jcb.21227
   Postovit LM, 2007, EXPERT OPIN THER TAR, V11, P497, DOI 10.1517/14728222.11.4.497
   Postovit LM, 2006, STEM CELLS, V24, P501, DOI 10.1634/stemcells.2005-0459
   Rosa A, 2009, DEV CELL, V16, P517, DOI 10.1016/j.devcel.2009.02.007
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Rossi S, 2008, MAMM GENOME, V19, P526, DOI 10.1007/s00335-008-9119-8
   Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522
   Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106
   Strizzi Luigi, 2009, Expert Rev Dermatol, V4, P67, DOI 10.1586/17469872.4.1.67
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211
   Wurdinger T, 2007, PHARMACOGENOMICS J, V7, P297, DOI 10.1038/sj.tpj.6500429
NR 38
TC 65
Z9 74
U1 0
U2 11
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD DEC
PY 2009
VL 1
IS 2
BP 387
EP 398
DI 10.2217/EPI.09.25
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 604SN
UT WOS:000278298900017
PM 20495621
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Bandres, E
   Agirre, X
   Bitarte, N
   Ramirez, N
   Zarate, R
   Roman-Gomez, J
   Prosper, F
   Garcia-Foncillas, J
AF Bandres, Eva
   Agirre, Xabier
   Bitarte, Nerea
   Ramirez, Natalia
   Zarate, Ruth
   Roman-Gomez, Jose
   Prosper, Felipe
   Garcia-Foncillas, Jesus
TI Epigenetic regulation of microRNA expression in colorectal cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE microrna; epigenetic; colon; metastasis
ID DNA METHYLATION; BREAST-CANCER; CELLS; HYPERMETHYLATION;
   DIFFERENTIATION; ACTIVATION; PROFILES; TARGETS; GENES; PCR
AB In the last years, microRNAs (miRNA) have emerged as new molecular players involved in carcinogenesis. Deregulation of miRNAs expression has been shown in different human cancer but the molecular mechanism underlying the alteration of miRNA expression is unknown. To identify tumor-supressor miRNAs silenced through aberrant epigenetic events in colorectal cancer (CRC), we used a sequential approach. We first identified 5 miR-NAs down-regulated in patient with colorectal cancer samples and located around/on a CpG island. Treatment with a DNA methyltransferase inhibitor and a HDAC inhibitor restored expression of 3 of the 5 microRNAs (hsa-miR-9, hsa-miR-129 and hsa-miR-137) in 3 CRC cell lines. Expression of hsa-miR-9 was inversely correlated with methylation of their promoter regions as measure by MSP and bisulphate sequencing. Further, methylation of the hsa-miR-9-1, hsa-miR-129-2 and hsa-miR-137 CpG islands were frequently observed in CRC cell lines and in primary CRC tumors, but not in normal colonic mucosa. Finally, methylation of hsa-miR-9-1 was associated with the presence of lymph node metastasis. In summary, our results aid in the understanding of miRNA gene regulation showing that aberrant DNA methylation and histone modifications work together to induce silencing of miRNAs in CRC. (C) 2009 UICC
C1 [Bandres, Eva; Bitarte, Nerea; Ramirez, Natalia; Zarate, Ruth; Garcia-Foncillas, Jesus] Univ Navarra, Lab Pharmacogen, Div Oncol, Ctr Appl Med Res CIMA, Pamplona 31008, Navarra, Spain.
   [Agirre, Xabier; Prosper, Felipe] Univ Navarra, Div Oncol, Dept Hematol Serv, Ctr Appl Med Res CIMA, Navarra, Spain.
   [Agirre, Xabier; Prosper, Felipe] Univ Navarra, Area Cell Therapy, Ctr Appl Med Res CIMA, Navarra, Spain.
   [Roman-Gomez, Jose] Reina Sofia Hosp, Dept Hematol, Cordoba, Spain.
C3 University of Navarra; University of Navarra; University of Navarra;
   Hospital Universitario Reina Sofia - Cordoba
RP Bandres, E (通讯作者)，Univ Navarra, Lab Pharmacogen, Div Oncol, Ctr Appl Med Res CIMA, Avda Pio 12 55, Pamplona 31008, Navarra, Spain.
EM ebandres@unav.es
RI Agirre, Xabier/ABE-4110-2020; Zárate, Ruth/KWT-6859-2024;
   Garcia-Foncillas, Jesus/E-6857-2010; bandres, eva/V-6238-2018; Prosper,
   Felipe/H-6859-2017; RAMIREZ, NATALIA/M-1777-2015
OI Zarate, Ruth/0000-0002-8024-021X; Prosper, Felipe/0000-0001-6115-8790;
   J, Garcia-Foncillas/0000-0002-7591-8006; BANDRES,
   EVA/0000-0002-9497-5356; RAMIREZ, NATALIA/0000-0003-3669-1053
FU Fundacion Cientifica de la Asociacion Espaola contra el Cancer
FX The authors thank Ms. Ines Lopez and Ms. Marisol Gonzalez for their
   excellent technical assistance. Natalia Ramirez is supported by the
   Fundacion Cientifica de la Asociacion Espaola contra el Cancer.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bandrés E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Han L, 2007, CANCER BIOL THER, V6, P1284
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037
NR 36
TC 368
Z9 421
U1 1
U2 52
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2009
VL 125
IS 11
BP 2737
EP 2743
DI 10.1002/ijc.24638
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 516BK
UT WOS:000271516500031
PM 19521961
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Sun, F
   Chan, EL
   Wu, ZL
   Yang, XJ
   Marquez, VE
   Yu, Q
AF Sun, Feng
   Chan, Eli
   Wu, Zhenlong
   Yang, Xiaojing
   Marquez, Victor E.
   Yu, Qiang
TI Combinatorial pharmacologic approaches target EZH2-mediated gene
   repression in breast cancer cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; GROUP PROTEIN EZH2; DNA METHYLATION;
   DEVELOPMENTAL GENES; PATHWAY; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION;
   TRICHOSTATIN; ACTIVATION; EXPRESSION
AB Polycomb protein EZH2-mediated gene silencing is implicated in breast tumorigenesis through methylation of histone H3 on Lysine 27 (H3K27). We have previously shown that S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A can modulate histone methylation and disrupt EZH2 complex. Here, we used 3-deazaneplanocin A, together with other chromatin remodeling agents, as well as RNA interference-mediated EZH2 depletion, to probe the role of EZH2 in coordination with other epigenetic components in gene regulation in breast cancer cells. Through genome-wide gene expression analysis, coupled with extensive chromatin immunoprecipitation analysis of histone modifications, we have identified a variety of gene sets that are regulated either by EZH2 alone or through the coordinated action of EZH2 with HDAC and/or DNA methylation. We further found that tumor antigen GAGEs were regulated by distinct epigenetic mechanisms in a cell context-dependent manner, possibly reflecting mechanistic heterogeneity in breast cancer. Intriguingly, we found that EZH2 regulates a remarkable cohort of genes whose functions are highly enriched in immunoresponse and autocrine inflammation network, and that their transcriptional activation upon EZH2 perturbation is cancer specific, revealing a potential novel role of EZH2 in regulating cancer immunity. These findings show the complexity and diversity of epigenetic regulation in human cancer and underscore the importance for developing combinatorial pharmacologic approaches for effective epigenetic gene reactivation. [Mol Cancer Ther 2009;8(12):3191-202]
C1 [Sun, Feng; Wu, Zhenlong; Yang, Xiaojing; Yu, Qiang] ASTAR, Genome Inst Singapore, Singapore 138672, Singapore.
   [Sun, Feng; Chan, Eli] Natl Univ Singapore, Dept Pharm, Singapore 117548, Singapore.
   [Yu, Qiang] Natl Univ Singapore, Dept Physiol, Singapore 117548, Singapore.
   [Marquez, Victor E.] NCI, Med Chem Lab, Frederic, MD USA.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); National University of Singapore; National
   University of Singapore; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI)
RP Yu, Q (通讯作者)，ASTAR, Genome Inst Singapore, 60 Biopolis St,02-01 Genome, Singapore 138672, Singapore.
EM yuq@gis.a-star.edu.sg
RI Wu, Zhenlong/LSK-3475-2024; Yang, Xiaojing/G-9201-2012; Marquez,
   Victor/KWD-9188-2024
OI Yu, Qiang/0000-0003-2132-8278
FU A*Star [GIS/06-711101]; Research Program of the NIH, National Cancer
   Institute, Center for Cancer Research
FX Grant support: A*Star grant GIS/06-711101 (Q. Yu). V. Marquez is
   supported by the intramural Research Program of the NIH, National Cancer
   Institute, Center for Cancer Research.
CR Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bender CM, 1998, CANCER RES, V58, P95
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   De Backer O, 1999, CANCER RES, V59, P3157
   DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gjerstorff MF, 2006, BRIT J CANCER, V94, P1864, DOI 10.1038/sj.bjc.6603163
   GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4
   Hagemann T, 2007, CANCER CELL, V12, P300, DOI 10.1016/j.ccr.2007.10.005
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Nervi C, 2001, CANCER RES, V61, P1247
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   WILSON VL, 1983, CANCER RES, V43, P3493
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Yu Q, 2002, CANCER RES, V62, P5743
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102
NR 42
TC 64
Z9 75
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2009
VL 8
IS 12
BP 3191
EP 3202
DI 10.1158/1535-7163.MCT-09-0479
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 531EW
UT WOS:000272647500003
PM 19934278
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Kim, DS
   Kim, MJ
   Lee, JY
   Lee, SM
   Choi, JY
   Yoon, GS
   Na, YK
   Hong, HS
   Kim, SG
   Choi, JE
   Lee, SY
   Park, JY
AF Kim, Dong-Sun
   Kim, Min-Jin
   Lee, Ji-Yun
   Lee, Su-Man
   Choi, Jun-Young
   Yoon, Ghil-Suk
   Na, Yeon-Kyung
   Hong, Hae-Sook
   Kim, Sang-Geol
   Choi, Jin-Eun
   Lee, Shin-Yeop
   Park, Jae-Yong
TI Epigenetic Inactivation of <i>Homeobox A5</i> Gene in Nonsmall Cell Lung
   Cancer and Its Relationship With Clinicopathological Features
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE HOXA5; methylation; NSCLC
ID TUMOR-SUPPRESSOR; CPG ISLANDS; EXPRESSION; METHYLATION; HOX;
   HYPERMETHYLATION; STATISTICS
AB Promoter methylation is an important mechanism in gene silencing and is a key epigenetic event in cancer development. Homeobox A5 (HOXA5) is a master regulator of the morphogenesis and cell differentiation to be implicated as a tumor suppressor gene in breast cancer, but its role in lung cancer is still unknown. In this study, we have investigated the methylation status of the promoter region of the HOXA5 gene in nonsmall cell lung cancers (NSCLCs) using nested and standard methylation-specific PCR (MSP) and correlated the methylation status with clinicopathological features. With standard MSP analysis, HOXA5 methylation were found in 113 (81.3%) of 139 NSCLCs and 72 (51.8%) in their corresponding nonmalignant lung tissues. RT-PCR and immunohistochemical analysis showed that HOXA5 methylation correlates with gene expression. Moreover, in the patients with stage I disease, HOXA5 methylation was more frequent in smokers than in never-smokes (P=0.01). There was no influence of HOXA5 methylation on survival in all NSCLCs or at stages II-IV. However, in the patients with stage I disease, HOXA5 methylation was associated with a borderline significantly worse survival (P=0.09). These findings suggest that downregulation of the HOXA5 gene by aberrant promoter methylation occurs in the vast majority of NSCLCs and that it may play a role in the pathogenesis of NSCLC. Additional studies with larger sample sizes are required to levaluate the prognostic value of HOXA5 methylation in patients with stage I NSCLC. (C) 2009 wiley-Liss, Inc.
C1 [Choi, Jin-Eun; Lee, Shin-Yeop; Park, Jae-Yong] Kyungpook Natl Univ, Dept Internal Med, Sch Med, Taegu 702422, South Korea.
   [Kim, Dong-Sun; Kim, Min-Jin; Lee, Ji-Yun; Lee, Su-Man; Choi, Jun-Young] Kyungpook Natl Univ, Dept Anat, Taegu 702422, South Korea.
   [Yoon, Ghil-Suk] Kyungpook Natl Univ, Dept Pathol, Taegu 702422, South Korea.
   [Na, Yeon-Kyung; Hong, Hae-Sook] Kyungpook Natl Univ, Coll Nursing, Taegu 702422, South Korea.
   [Kim, Sang-Geol] Kyungpook Natl Univ, Dept Gen Surg, Taegu 702422, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Kyungpook National
   University (KNU); Kyungpook National University (KNU)
RP Park, JY (通讯作者)，Kyungpook Natl Univ, Dept Internal Med, Sch Med, 2-101 Dongin Dong, Taegu 702422, South Korea.
RI Lee, sujeong/KUD-4735-2024; Kim, Kyung/I-5501-2015; Kim,
   Dae/AAJ-7518-2021; Choi, Jun Young/IXW-9912-2023
OI Kim, Dong Sun/0000-0003-4943-0901
FU National R&D Program for Cancer Control, Ministry of Health & Welfare,
   Republic of Korea [0720550-2]; Kyungpook National University Hospital
FX This work was supported by a grant from the National R&D Program for
   Cancer Control, Ministry of Health & Welfare, Republic of Korea (grant
   no. 0720550-2) and by a Biomedical Research Institute grant from
   Kyungpook National University Hospital (2004).
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Abe M, 2006, ONCOL REP, V15, P797
   Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776
   Campling BG, 2003, MOL BIOTECHNOL, V24, P141, DOI 10.1385/MB:24:2:141
   Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004
   Duriseti S, 2006, NEOPLASIA, V8, P250, DOI 10.1593/neo.05766
   Gabrielson E, 2006, RESPIROLOGY, V11, P533, DOI 10.1111/j.1440-1843.2006.00909.x
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051
   Jee SH, 2004, CANCER CAUSE CONTROL, V15, P341, DOI 10.1023/B:CACO.0000027481.48153.97
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kouso H, 2008, J SURG ONCOL, V98, P377, DOI 10.1002/jso.21108
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014
   Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453
   Shiraishi M, 2002, ONCOGENE, V21, P3804, DOI 10.1038/sj.onc.1205454
   Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   Strathdee G, 2007, CARCINOGENESIS, V28, P299, DOI 10.1093/carcin/bgl133
   TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385
NR 32
TC 29
Z9 30
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2009
VL 48
IS 12
BP 1109
EP 1115
DI 10.1002/mc.20561
PG 7
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 529PB
UT WOS:000272528600004
PM 19554572
DA 2025-01-12
ER

PT J
AU Hughes, LAE
   van den Brandt, PA
   de Bruïne, AP
   Wouters, KAD
   Hulsmans, S
   Spiertz, A
   Goldbohm, RA
   de Goeij, AFPM
   Herman, JG
   Weijenberg, MP
   van Engeland, M
AF Hughes, Laura A. E.
   van den Brandt, Piet A.
   de Bruine, Adriaan P.
   Wouters, Kim A. D.
   Hulsmans, Sarah
   Spiertz, Angela
   Goldbohm, R. Alexandra
   de Goeij, Anton F. P. M.
   Herman, James G.
   Weijenberg, Matty P.
   van Engeland, Manon
TI Early Life Exposure to Famine and Colorectal Cancer Risk: A Role for
   Epigenetic Mechanisms
SO PLOS ONE
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; SCALE PROSPECTIVE COHORT; 1944-1945 DUTCH
   FAMINE; NETHERLANDS COHORT; BREAST-CANCER; COLON-CANCER; ADULT DISEASE;
   MICROSATELLITE INSTABILITY; ENERGY RESTRICTION; FOLLOW-UP
AB Background: Exposure to energy restriction during childhood and adolescence is associated with a lower risk of developing colorectal cancer (CRC). Epigenetic dysregulation during this critical period of growth and development may be a mechanism to explain such observations. Within the Netherlands Cohort Study on diet and cancer, we investigated the association between early life energy restriction and risk of subsequent CRC characterized by the (promoter) CpG island methylation phenotype (CIMP).
   Methodology/Principal Findings: Information on diet and risk factors was collected by baseline questionnaire (n = 120,856). Three indicators of exposure were assessed: place of residence during the Hunger Winter (1944-45) and World War II years (1940-44), and father's employment status during the Economic Depression (1932-40). Methylation specific PCR (MSP) on DNA from paraffin embedded tumor tissue was performed to determine CIMP status according to the Weisenberger markers. After 7.3 years of follow-up, 603 cases and 4631 sub-cohort members were available for analysis. Cox regression was used to calculate hazard ratios (HR) and 95% confidence intervals for CIMP+ (27.7%) and CIMP- (72.3%) tumors according to the three time periods of energy restriction, adjusted for age and gender. Individuals exposed to severe famine during the Hunger Winter had a decreased risk of developing a tumor characterized by CIMP compared to those not exposed (HR 0.65, 95%CI: 0.45-0.92). Further categorizing individuals by an index of '0-1' '2-3' or '4-7' genes methylated in the promoter region suggested that exposure to the Hunger Winter was associated with the degree of promoter hypermethylation ('0-1 genes methylated' HR = 1.01, 95%CI:0.74-1.37; '2-3 genes methylated' HR = 0.83, 95% CI:0.61-1.15; '4-7 genes methylated' HR = 0.72, 95% CI: 0.49-1.04). No associations were observed with respect to the Economic Depression and WWII years.
   Conclusions: This is the first study indicating that exposure to a severe, transient environmental condition during adolescence and young adulthood may result in persistent epigenetic changes that later influence CRC development.
C1 [Hughes, Laura A. E.; van den Brandt, Piet A.; Weijenberg, Matty P.] Maastricht Univ, Med Ctr, Dept Epidemiol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
   [de Bruine, Adriaan P.; Wouters, Kim A. D.; Hulsmans, Sarah; de Goeij, Anton F. P. M.; van Engeland, Manon] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pathol, Maastricht, Netherlands.
   [Spiertz, Angela; Goldbohm, R. Alexandra] TNO Qual Life, Dept Prevent & Hlth, Leiden, Netherlands.
   [Herman, James G.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Maastricht University; Maastricht University; Netherlands Organization
   Applied Science Research; Johns Hopkins University; Johns Hopkins
   Medicine
RP Hughes, LAE (通讯作者)，Maastricht Univ, Med Ctr, Dept Epidemiol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
EM manon.van.engeland@mumc.nl
RI Wouters, Kristien/ADM-4146-2022; van Engeland, Manon/A-7479-2009
OI van den Brandt, Piet/0000-0001-8781-8099
FU World Cancer Research Fund
FX This work was supported by the World Cancer Research Fund [2007/54 to M.
   P. W] (http://www.wcrf.org/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 1975, FAMINE HUM DEV DUTCH
   [Anonymous], 1948, Malnutrition and starvation in Western Netherlands
   [Anonymous], [No title captured]
   Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171
   BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9
   BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111
   BARKER DJP, 1992, BRIT J OBSTET GYNAEC, V99, P275, DOI 10.1111/j.1471-0528.1992.tb13719.x
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009
   de Vogel S, 2008, CARCINOGENESIS, V29, P1765, DOI 10.1093/carcin/bgn074
   DENHARTOG AP, 1983, VOEDING, V44, P92
   Derks S, 2004, CELL ONCOL, V26, P291
   Derks S, 2008, CARCINOGENESIS, V29, P434, DOI 10.1093/carcin/bgm270
   Dirx MJM, 2001, AM J EPIDEMIOL, V154, P530, DOI 10.1093/aje/154.6.530
   Dirx MJM, 2003, CANCER-AM CANCER SOC, V97, P46, DOI 10.1002/cncr.11052
   Dirx MJM, 1999, CANCER CAUSE CONTROL, V10, P189, DOI 10.1023/A:1008821524297
   Dols M. J. L., 1946, Voeding, V6, P193
   Elias SG, 2004, JNCI-J NATL CANCER I, V96, P539, DOI 10.1093/jnci/djh087
   Elias SG, 2004, INT J CANCER, V108, P628, DOI 10.1002/ijc.11584
   Ferguson LR, 2004, ENVIRON MOL MUTAGEN, V44, P36, DOI 10.1002/em.20029
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499
   GOLDBOHM RA, 1995, EUR J CLIN NUTR, V49, P420
   GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253
   Goldbohm RA., 1994, TIJDSCHR SOC GEZONDH, V72, P80
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HUGHES LAE, 2009, ENERGY RESTRICTION C
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Lumey LH, 1997, AM J EPIDEMIOL, V146, P810, DOI 10.1093/oxfordjournals.aje.a009198
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904
   Okasha M, 2002, BEST PRACT RES CL EN, V16, P225, DOI 10.1053/beem.2002.0204
   ROSE G, 1964, BRIT J PREV SOC MED, V18, P75
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104
   Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170
   Slattery ML, 2009, MUTAT RES-FUND MOL M, V660, P12, DOI 10.1016/j.mrfmmm.2008.10.001
   Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070
   Svensson E, 2005, CANCER CAUSE CONTROL, V16, P215, DOI 10.1007/s10552-004-3073-x
   Svensson E, 2002, EUR J CANCER PREV, V11, P489, DOI 10.1097/00008469-200210000-00012
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   VANDENBRANDT PA, 1990, INT J EPIDEMIOL, V19, P553
   VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E
   VANNOORD PAH, 1991, ANN HUM BIOL, V18, P57, DOI 10.1080/03014469100001402
   WACHOLDER S, 1989, BIOMETRIKA, V76, P117, DOI 10.1093/biomet/76.1.117
   Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484
   Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Waterland RA, 2006, J PEDIATR-US, V149, pS137, DOI 10.1016/j.jpeds.2006.06.064
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wong JJL, 2007, GUT, V56, P140, DOI 10.1136/gut.2005.088799
NR 54
TC 92
Z9 102
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 23
PY 2009
VL 4
IS 11
AR e7951
DI 10.1371/journal.pone.0007951
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 533MF
UT WOS:000272827300009
PM 19956740
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Ueki, T
   Park, JH
   Nishidate, T
   Kijima, K
   Hirata, K
   Nakamura, Y
   Katagiri, T
AF Ueki, Tomomi
   Park, Jae-Hyun
   Nishidate, Toshihiko
   Kijima, Kyoko
   Hirata, Koichi
   Nakamura, Yusuke
   Katagiri, Toyomasa
TI Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating
   Enzyme E2T Overexpression in Human Breast Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION PROFILES; ELEVATED EXPRESSION; TUMOR-SUPPRESSOR;
   INVOLVEMENT; BRCA1-BARD1; PATHWAY; PROTEIN; KINASE; UBCH10;
   CARCINOGENESIS
AB Breast cancer is generated through a multistep genetic and epigenetic process including activations of oncogenes and inactivations of tumor suppressor genes. Here, we report a critical role of ubiquitin-conjugating enzyme E2T (UBE2T), an E2 ubiquitin-conjugating enzyme, in mammary carcinogenesis. Immunocytochemical staining and in vitro binding assay revealed that UBE2T interacted and colocalized with the BRCA1/BRCA4-associated RING domain protein (BARD1) complex. Knocking down of UBE2T expression with small interfering RNA drastically suppressed the growth of breast cancer cells. Interestingly, in vivo ubiquitination assay indicated BRCA1 to be polyubiquitinated by incubation with wild-type UBE2T protein, but not with C86A-UBE2T protein, an E2 activity-dead mutant, in which the 86th residue of cysteine was replaced with alanine. Furthermore, knocking down of UBE2T protein induced upregulation of BRCA1 protein in breast cancer cells, whereas its overexpression caused the decrease of the BRCA1 protein. Our data imply a critical role of UBE2T in development and/or progression of breast cancer through the interaction with and the regulation of the BRCA1/BARD1 complex. [Cancer Res 2009;69(22):8752-60]
C1 [Ueki, Tomomi; Park, Jae-Hyun; Nishidate, Toshihiko; Kijima, Kyoko; Nakamura, Yusuke; Katagiri, Toyomasa] Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan.
   [Ueki, Tomomi; Nishidate, Toshihiko; Hirata, Koichi] Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido, Japan.
   [Katagiri, Toyomasa] Univ Tokushima, Inst Genome Res, Div Genome Med, Tokushima, Japan.
C3 University of Tokyo; Sapporo Medical University; Tokushima University
RP Nakamura, Y (通讯作者)，Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan.
EM yusuke@ims.u-tokyo.ac.jp
RI Katagiri, Toyomasa/I-7344-2012
CR Alpi A, 2007, MOL CELL BIOL, V27, P8421, DOI 10.1128/MCB.00504-07
   Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129
   Ashida S, 2004, CANCER RES, V64, P5963, DOI 10.1158/0008-5472.CAN-04-0020
   ATCC - AMERICAN TYPE CULTURE COLLE CTION, 2007, ATCC TECHN B, V8
   Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6
   Berlingieri MT, 2007, ONCOGENE, V26, P2136, DOI 10.1038/sj.onc.1210010
   Berlingieri MT, 2007, EUR J CANCER, V43, P2729, DOI 10.1016/j.ejca.2007.09.003
   Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100
   Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200
   Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200
   Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104
   Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853
   Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5
   Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102
   Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83
   Katagiri T, 1996, CYTOGENET CELL GENET, V74, P90, DOI 10.1159/000134389
   Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288
   Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650
   Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876
   Nishidate T, 2004, INT J ONCOL, V25, P797
   Okamoto Y, 2003, CANCER RES, V63, P4167
   PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798
   Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029
   Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200
   Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128
   Shimo A, 2008, CANCER SCI, V99, P62, DOI 10.1111/j.1349-7006.2007.00635.x
   Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x
   Shimokawa T, 2003, CANCER RES, V63, P6116
   Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200
   Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Ueki T, 2008, ONCOGENE, V27, P5672, DOI 10.1038/onc.2008.186
   Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826
   Yang YL, 2007, CANCER RES, V67, P9472, DOI 10.1158/0008-5472.CAN-07-0568
   Yang YL, 2009, CANCER SCI, V100, P24, DOI 10.1111/j.1349-7006.2008.01013.x
NR 43
TC 108
Z9 119
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2009
VL 69
IS 22
BP 8752
EP 8760
DI 10.1158/0008-5472.CAN-09-1809
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 520JC
UT WOS:000271839200029
PM 19887602
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Iliopoulos, D
   Hirsch, HA
   Struhl, K
AF Iliopoulos, Dimitrios
   Hirsch, Heather A.
   Struhl, Kevin
TI An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6
   Links Inflammation to Cell Transformation
SO CELL
LA English
DT Article
ID IN-VITRO PROPAGATION; BREAST-CANCER CELLS; SURVIVAL; STAT3;
   TUMORIGENESIS; RAS; ACTIVATION; MECHANISMS; EXPRESSION; PATHWAY
AB Inflammation is linked clinically and epidemiologically to cancer, and NF-kappa B appears to play a causative role, but the mechanisms are poorly understood. We show that transient activation of Src oncoprotein can mediate an epigenetic switch from immortalized breast cells to a stably transformed line that forms self-renewing mammospheres that contain cancer stem cells. Src activation triggers an inflammatory response mediated by NF-kappa B that directly activates Lin28 transcription and rapidly reduces let-7 microRNA levels. Let-7 directly inhibits IL6 expression, resulting in higher levels of IL6 than achieved by NF-kappa B activation. IL6-mediated activation of the STAT3 transcription factor is necessary for transformation, and IL6 activates NF-kappa B, thereby completing a positive feedback loop. This regulatory circuit operates in other cancer cells lines, and its transcriptional signature is found in human cancer tissues. Thus, inflammation activates a positive feedback loop that maintains the epigenetic transformed state for many generations in the absence of the inducing signal.
C1 [Iliopoulos, Dimitrios; Hirsch, Heather A.; Struhl, Kevin] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School
RP Struhl, K (通讯作者)，Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM kevin@hms.harvard.edu
RI Iliopoulos, Dimitrios/AAE-9106-2019
FU American Cancer Society; National Institutes of Health [CA 107486]
FX We would like to thank Richard Gregory for suggesting the idea that
   lin-28 might be involved in the process, Philip N. Tsichlis for
   providing laboratory access and materials needed for the xenograft
   experiments, Fabio Petrocca for help in designing the mammosphere and
   cell sorting experiments, Savina A. Jaeger for bioinformatic analysis
   and identification of NF-KB binding sites in let-7a and lin-28B, Joan
   Brugge for providing the MCF10A ER-Src and control cell lines, William
   Farrar for providing the pGL3-IL6 luciferace vector, George Daley for
   providing the pBabe. Puro-Lin28B vector, Joshua T. Mendell for providing
   the Lin28B-P1 luciferase vector, and Koon Ho Wong for construction of
   the mutant luciferase vectors. This work was supported by a postdoctoral
   fellowship from the American Cancer Society to H. A. H. and a research
   grant to K. S. from the National Institutes of Health (CA 107486).
CR Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417
   Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902
   Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014
   HIRSCH HA, 2009, CANC RES IN PRESS, V69
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0
   Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105
   Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001
   Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Nagel S, 2005, LEUKEMIA, V19, P841, DOI 10.1038/sj.leu.2403716
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260
   Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Ptashne M, 2009, CURR BIOL, V19, pR234, DOI 10.1016/j.cub.2009.02.015
   Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016
   Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462
   Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com
   SOULE HD, 1990, CANCER RES, V50, P6075
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040
   Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wegiel B, 2008, INT J CANCER, V122, P1521, DOI 10.1002/ijc.23261
   Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018
NR 42
TC 1174
Z9 1324
U1 4
U2 87
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 13
PY 2009
VL 139
IS 4
BP 693
EP 706
DI 10.1016/j.cell.2009.10.014
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 519EG
UT WOS:000271747200014
PM 19878981
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Vitolo, MI
   Weiss, MB
   Szmacinski, M
   Tahir, K
   Waldman, T
   Park, BH
   Martin, SS
   Weber, DJ
   Bachman, KE
AF Vitolo, Michele I.
   Weiss, Michele B.
   Szmacinski, Marta
   Tahir, Khola
   Waldman, Todd
   Park, Ben Ho
   Martin, Stuart S.
   Weber, David J.
   Bachman, Kurtis E.
TI Deletion of PTEN Promotes Tumorigenic Signaling, Resistance to Anoikis,
   and Altered Response to Chemotherapeutic Agents in Human Mammary
   Epithelial Cells
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER PATIENTS; PIK3CA MUTATIONS; EXPRESSION; METASTASIS; GENE;
   ACTIVATION; KINASE; RAS; TRANSFORMATION; CHECKPOINT
AB Many cancers, including breast cancer, harbor loss-of-function mutations in the catalytic domain of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) or have reduced PTEN expression through loss of heterozygosity and/or epigenetic silencing mechanisms. However, specific phenotypic effects of PTEN inactivation in human cancer cells remain poorly defined without a direct causal connection between the loss of PTEN function and the development or progression of cancer. To evaluate the biological and clinical relevance of reduced or deleted PTEN expression, a novel in vitro model system was generated using human somatic cell knockout technologies. Targeted homologous recombination allowed for a single and double allelic deletion, which resulted in reduced and deleted PTEN expression, respectively. We determined that heterozygous loss of PTEN in the nontumorigenic human mammary epithelial cell line MCF-10A was sufficient for activation of the phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase pathways, whereas the homozygous absence of PTEN expression led to a further increased activation of both pathways. The deletion of PTEN was able to confer growth factor-independent proliferation, which was confirmed by the resistance of the PTEN-/- MCF-10A cells to small-molecule inhibitors of the epidermal growth factor receptor. However, neither heterozygous nor homozygous loss of PTEN expression was sufficient to promote anchorage-independent growth, but the loss of PTEN did confer apoptotic resistance to cell rounding and matrix detachment. Finally, MCF-10A cells with the reduction or loss of PTEN showed increased susceptibility to the chemotherapeutic drug doxorubicin but not paclitaxel. [Cancer Res 2009;69(21):8275-83]
C1 [Vitolo, Michele I.; Weiss, Michele B.; Tahir, Khola; Martin, Stuart S.; Weber, David J.; Bachman, Kurtis E.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Weiss, Michele B.] Univ Maryland, Grad Program Mol Med, Baltimore, MD 21201 USA.
   [Szmacinski, Marta; Weber, David J.; Bachman, Kurtis E.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
   [Tahir, Khola] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.
   [Park, Ben Ho] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21205 USA.
   [Waldman, Todd] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Washington, DC USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore; Johns
   Hopkins University; Johns Hopkins Medicine; Georgetown University
RP Bachman, KE (通讯作者)，GlaxoSmithKline, 709 Swedeland Rd,UW2109, King Of Prussia, PA 19406 USA.
EM mvitolo@umaryland.edu; dweber@umaryland.edu; kurtis.e.bachman@gsk.com
RI Weber, David J./B-5349-2011
OI Weber, David J./0000-0002-8824-1110; Vitolo, Michele/0000-0001-8055-9645
FU Maryland Cigarette Restitution Fund; Susan G. Komen Breast Cancer
   Foundation [PDF104506]; National Cancer Institute [T32-DK067872,
   R01-CA115699, R01CA124704]; Breast Cancer Research Foundation; General
   Medicine/NIH [R01-CA107331, R01 GM58888]
FX Grant support: Maryland Cigarette Restitution Fund (K.E. Bachman), Susan
   G. Komen Breast Cancer Foundation grant PDF104506 (M.L. Vitolo),
   National Cancer Institute grants T32-DK067872 (M.B. Weiss), R01-CA115699
   (T. Waldman), and R01CA124704 (S.S. Martin), Breast Cancer Research
   Foundation (B.H. Park), and National Cancer Institute and General
   Medicine/NIH grants R01-CA107331 and R01 GM58888 (D.J. Weber).The costs
   of publication of this article were defrayed in part by the payment of
   page charges. This article most therefore be hereby marked advertisement
   in accordance with 18 U.S.C. Section 1734 solely to indicate this
   fact.We thank Agnes Cheung for developing the MCF-10A.Bcl2 cell line and
   Regina Harley for flow cytometry experiments.
CR Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994
   Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108
   Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371
   Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031
   Fisher B, 2001, J Natl Cancer Inst Monogr, P62
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976
   Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612
   Janssen EAM, 2007, CELL ONCOL, V29, P25
   Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048
   Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002
   Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783
   Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394
   Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0
   Lee C, 2004, CANCER RES, V64, P6906, DOI 10.1158/0008-5472.CAN-04-1767
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Marsh DJ, 1997, CANCER RES, V57, P500
   Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001
   Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595
   Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   Pinkas J, 2004, MOL CANCER RES, V2, P551
   Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621
   Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408
   Riethdorf S, 2008, INT J CANCER, V123, P1991, DOI 10.1002/ijc.23825
   Riethmüller G, 2001, SEMIN CANCER BIOL, V11, P307, DOI 10.1006/scbi.2001.0386
   Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913
   Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566
   Schmitz M, 2007, INT J CANCER, V120, P1284, DOI 10.1002/ijc.22359
   SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435
   Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6
   Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160
   VanderWeele DJ, 2004, MOL CANCER THER, V3, P1605
   Vranic S, 2007, HUM PATHOL, V38, P1425, DOI 10.1016/j.humpath.2007.03.021
   Wallgren A, 2003, J CLIN ONCOL, V21, P1205, DOI 10.1200/JCO.2003.03.130
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weinberg RA, 2008, CANCER CELL, V14, P283, DOI 10.1016/j.ccr.2008.09.009
   Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667
NR 44
TC 67
Z9 84
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2009
VL 69
IS 21
BP 8275
EP 8283
DI 10.1158/0008-5472.CAN-09-1067
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 514OA
UT WOS:000271403000009
PM 19843859
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Nevo, J
   Mattila, E
   Pellinen, T
   Yamamoto, DL
   Sara, H
   Iljin, K
   Kallioniemi, O
   Bono, P
   Heikkilä, P
   Joensuu, H
   Wärri, A
   Ivaska, J
AF Nevo, Jonna
   Mattila, Elina
   Pellinen, Teijo
   Yamamoto, Daniel L.
   Sara, Henri
   Iljin, Kristiina
   Kallioniemi, Olli
   Bono, Petri
   Heikkila, Paivi
   Joensuu, Heikki
   Warri, Anni
   Ivaska, Johanna
TI Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a
   Novel Form of Cetuximab Resistance
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CELL LUNG-CANCER; FACTOR-RECEPTOR; ACQUIRED-RESISTANCE;
   COLORECTAL-CANCER; ERBB RECEPTORS; MDGI GENE; EXPRESSION; GEFITINIB;
   THERAPY; GLAND
AB Purpose: Only few predictive factors for the clinical activity of anti-epidermal growth factor receptor (EGFR) therapy are available. Mammary-derived growth inhibitor (MDGI) is a small cytosolic protein suggested to play a role in the differentiation of epithelial cells. Here, we have investigated the effect of MDGI expression on the EGFR signaling and cetuximab responsiveness of cancer cells.
   Experimental Design: MDGI mRNA expression was investigated in clinical breast and lung cancer samples and in nontransformed and malignant cell lines. The effect of ectopic expression of MDGI on EGFR, ErbB2, and integrin function and traffic was investigated in breast and lung cancer cell lines using multiple methods. The effect of anti-EGFR agents on these cells were tested by cell proliferation measurements and by assessing tumor growth of breast cancer cells in cetuximab treated and control athymic nude mice.
   Results: Here, we show that although MDGI is absent in cultured cell lines because of epigenetic silencing, MDGI mRNA is expressed in 40% of clinical breast carcinomas and 85% of lung cancers. Ectopic expression of MDGI rendered breast and lung cancer cells resistant to the anti-EGFR antibody cetuximab in vitro and in an orthotopic breast cancer xenograft model in vivo. When expressed in cancer cells, MDGI induces intracellular accumulation of EGFR, but not ErbB2, and the internalized receptor is phosphorylated and not degraded.
   Conclusions: MDGI-driven inherent desensitization of cancer cells is a novel molecular mechanism for resistance to the anti-EGFR antibody therapy, and MDGI may be a biomarker for responsiveness to anti-EGFR antibody therapy. (Clin Cancer Res 2009;15(21):6570-81)
C1 [Nevo, Jonna; Mattila, Elina; Pellinen, Teijo; Yamamoto, Daniel L.; Iljin, Kristiina; Kallioniemi, Olli; Ivaska, Johanna] VTT Tech Res Ctr Finland, FIN-20520 Turku, Finland.
   [Nevo, Jonna; Mattila, Elina; Pellinen, Teijo; Sara, Henri; Kallioniemi, Olli; Ivaska, Johanna] Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland.
   [Nevo, Jonna; Mattila, Elina; Pellinen, Teijo; Sara, Henri; Kallioniemi, Olli; Ivaska, Johanna] Abo Akad Univ, Turku, Finland.
   [Warri, Anni] Univ Turku, Funct Foods Forum, Turku, Finland.
   [Kallioniemi, Olli] Univ Helsinki, Biomedicum, Genome Scale Biol Res Program, FIN-00014 Helsinki, Finland.
   [Kallioniemi, Olli] Univ Helsinki, Inst Mol Med Finland, FIN-00014 Helsinki, Finland.
   [Bono, Petri; Joensuu, Heikki] Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.
   [Heikkila, Paivi] Helsinki Univ Hosp, Dept Pathol, Helsinki, Finland.
C3 VTT Technical Research Center Finland; University of Turku; Abo Akademi
   University; University of Turku; University of Helsinki; University of
   Helsinki; University of Helsinki; Helsinki University Central Hospital;
   University of Helsinki; Helsinki University Central Hospital
RP Ivaska, J (通讯作者)，VTT Tech Res Ctr Finland, FIN-20520 Turku, Finland.
EM johanna.ivaska@vtt.fi
RI Kallioniemi, Olli/H-5111-2011; Kallioniemi, Olli/H-4738-2012
OI Joensuu, Heikki/0000-0003-0281-2507; Warri, Anni/0000-0002-0535-847X;
   Kallioniemi, Olli/0000-0002-3231-0332; Ivaska,
   Johanna/0000-0002-6295-6556; Iljin, Kristiina/0000-0002-5161-0584
FU Marie Curie Canceromics [MEXT-CT-2003-2728]; EU-EPITRON
   [LSHC-CT-2005-518417]; Academy of Finland; Finnish Cancer Organizations;
   Sigrid Juselius Foundation; Emil Aaltonen Foundation; Turku Graduate
   School of Biomedical Sciences; Finnish Cancer Institute
FX Marie Curie Canceromics (MEXT-CT-2003-2728) and EU-EPITRON
   (LSHC-CT-2005-518417) (O. Kallioniemi); Academy of Finland, Finnish
   Cancer Organizations, and Sigrid Juselius Foundation (O. Kallioniemi and
   J. Ivaska); Emil Aaltonen Foundation, EMBO Young Investigator program,
   and the generous donation of Tellervo Kinnunen (J. Ivaska); Turku
   Graduate School of Biomedical Sciences (J. Nevo and T. Pellinen); and
   Finnish Cancer Institute (E. Mattila).
CR BINAS B, 1995, DEV GENET, V17, P167, DOI 10.1002/dvg.1020170208
   Camp ER, 2005, CLIN CANCER RES, V11, P397
   Ceresa BP, 2006, J BIOL CHEM, V281, P1099, DOI 10.1074/jbc.M504175200
   Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Clark AJ, 2000, TRANSGENIC RES, V9, P439, DOI 10.1023/A:1026552629493
   Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008
   Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
   Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760
   Hanhoff T, 2002, MOL CELL BIOCHEM, V239, P45, DOI 10.1023/A:1020502624234
   Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823
   Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440
   Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910
   Huynh H, 1996, CANCER RES, V56, P4865
   Hyatt DC, 2008, EXP CELL RES, V314, P3415, DOI 10.1016/j.yexcr.2008.08.020
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Khan EM, 2006, J BIOL CHEM, V281, P14486, DOI 10.1074/jbc.M509332200
   Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139
   Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014
   Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t
   Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102
   Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0
   Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504
   Messersmith WA, 2008, NEW ENGL J MED, V359, P1834, DOI 10.1056/NEJMe0806778
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3
   Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019
   Phelan CM, 1996, GENOMICS, V34, P63, DOI 10.1006/geno.1996.0241
   Steiner P, 2007, CLIN CANCER RES, V13, P1540, DOI 10.1158/1078-0432.CCR-06-1887
   Thierry-Mieg D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s12
   Wang HL, 2000, ONCOGENE, V19, P2455, DOI 10.1038/sj.onc.1203575
   WHEELER DL, 2008, ONCOGENE
   Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8
   YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097
NR 37
TC 28
Z9 32
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD NOV 1
PY 2009
VL 15
IS 21
BP 6570
EP 6581
DI 10.1158/1078-0432.CCR-09-0773
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 513CP
UT WOS:000271300200014
PM 19825952
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Lucock, M
   Yates, Z
AF Lucock, Mark
   Yates, Zoe
TI Folic acid fortification: a double-edged sword
SO CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
LA English
DT Article
DE birth defects; cancer; epigenetics; folic acid; fortification;
   homocysteine; polymorphism; vascular disease
ID METHYLENETETRAHYDROFOLATE REDUCTASE GENE; FOLATE INTAKE; RISK-FACTOR;
   EPIGENETIC MODIFICATION; COGNITIVE IMPAIRMENT; HOMOCYSTEINE LEVELS;
   DOUBLE-BLIND; CANCER RISK; SUPPLEMENTATION; VITAMIN-B-12
AB Purpose of review
   To examine the impact of folic acid fortification, including its use as a functional food component, on human health.
   Recent findings
   There is a consensus view that folic acid supplementation has numerous health benefits, many of which are significant in their impact, However, emerging evidence suggests that increased population exposure to folic acid may also have a negative impact with respect to certain developmental and degenerative disorders. As examples, presently much attention is focused on the role of folic acid fortification augmenting colon cancer risk, whereas earlier in the life cycle, the vitamin may additionally influence insulin resistance. Without question, conditions that are influenced by folic acid are both diverse and many - from concerns relating to cognitive decline, breast cancer and vascular disease through to preconceptional issues where maternal folate levels might conceivably alter the phenotype of offspring via epimutations.
   Summary
   The highly complex and critical biological importance of folic acid-related molecular nutrition makes it a difficult micronutrient to deploy as a simple intervention at a population level - it has far too many biochemical spheres of influence to predict effects in a generalized way. Additionally, several gene variants and other nutrients are interactive factors. It is, therefore, hardly surprising that the scientific community does not have a true consensus view on whether mandatory fortification is appropriate as a population measure. This latter point not withstanding, any ultimate decisions on fortification should be well rooted in scientific fact rather than political expediency.
C1 [Lucock, Mark] Univ Newcastle, Fac Sci & IT, Sch Environm & Life Sci, Ourimbah, NSW 2258, Australia.
C3 University of Newcastle
RP Lucock, M (通讯作者)，Univ Newcastle, Fac Sci & IT, Sch Environm & Life Sci, POB 127,Brush Rd, Ourimbah, NSW 2258, Australia.
EM Mark.Lucock@newcastle.edu.au
CR Adams M, 2007, NEUROSCI LETT, V422, P24, DOI 10.1016/j.neulet.2007.05.025
   [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A
   Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227
   Bottiglieri T, 2005, PROG NEURO-PSYCHOPH, V29, P1103, DOI 10.1016/j.pnpbp.2005.06.021
   Boulet SL, 2008, BIRTH DEFECTS RES A, V82, P527, DOI 10.1002/bdra.20468
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   Chattopadhyay S, 2007, ONCOLOGIST, V12, P808, DOI 10.1634/theoncologist.12-7-808
   Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449
   Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351
   Cooney CA, 2002, J NUTR, V132, p2393S
   Cooney CA, 2006, P NATL ACAD SCI USA, V103, P17071, DOI 10.1073/pnas.0608653103
   Cropley JE, 2006, P NATL ACAD SCI USA, V103, P17308, DOI 10.1073/pnas.0607090103
   Czeizel AE, 1998, EUR J OBSTET GYN R B, V78, P151, DOI 10.1016/S0301-2115(98)00061-X
   Durga J, 2006, NEUROBIOL AGING, V27, P482, DOI 10.1016/j.neurobiolaging.2005.03.002
   Flynn MAT, 2008, P NUTR SOC, V67, P381, DOI 10.1017/S0029665108008720
   GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4
   GODFREY PSA, 1990, LANCET, V336, P392, DOI 10.1016/0140-6736(90)91942-4
   Haggarty P, 2008, BJOG-INT J OBSTET GY, V115, P851, DOI 10.1111/j.1471-0528.2008.01737.x
   Haggarty P, 2006, LANCET, V367, P1513, DOI 10.1016/S0140-6736(06)68651-0
   Halsted CH, 2008, FAM PRACT, V25, pI44, DOI 10.1093/fampra/cmn058
   Hirsch S, 2009, EUR J GASTROEN HEPAT, V21, P346, DOI 10.1097/MEG.0b013e328306ccdb
   Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1
   Isotalo PA, 2000, AM J HUM GENET, V67, P986, DOI 10.1086/303082
   James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366
   James SJ, 1999, AM J CLIN NUTR, V70, P495
   Jänne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606
   Johansson M, 2008, CANCER EPIDEM BIOMAR, V17, P279, DOI 10.1158/1055-9965.EPI-07-0657
   Kara I, 2003, MOL BRAIN RES, V111, P84, DOI 10.1016/S0169-328X(02)00672-1
   Kelly P, 1997, AM J CLIN NUTR, V65, P1790, DOI 10.1093/ajcn/65.6.1790
   Kempisty B, 2007, EUR PSYCHIAT, V22, P39, DOI 10.1016/j.eurpsy.2006.11.003
   Khanna D, 2005, ARTHRITIS RHEUM-US, V52, P3030, DOI 10.1002/art.21295
   Larsson SC, 2006, JNCI-J NATL CANCER I, V98, P407, DOI 10.1093/jnci/djj094
   Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382
   Lindblad B, 2005, ACTA OBSTET GYN SCAN, V84, P1055, DOI 10.1111/j.0001-6349.2005.00876.x
   Lucifero D, 2004, HUM REPROD UPDATE, V10, P3, DOI 10.1093/humupd/dmh002
   Lucock M, 2005, NAT REV GENET, V6, P235, DOI 10.1038/nrg1558
   Lucock M, 2004, BMJ-BRIT MED J, V328, P211, DOI 10.1136/bmj.328.7433.211
   Lucock M, 2008, J NUTRIGENET NUTRIGE, V1, P24, DOI 10.1159/000109872
   Lucock MD, 2006, CURR OPIN CLIN NUTR, V9, P748, DOI 10.1097/01.mco.0000247468.18790.1e
   LUCOCK MD, 1995, BIOCHEM MOL MED, V55, P43, DOI 10.1006/bmme.1995.1030
   LUCOCK MD, 1989, BIOCHEM MED METAB B, V42, P30, DOI 10.1016/0885-4505(89)90038-8
   Lucock MD, 1999, FOOD FORTIFICATION F
   Luebeck EG, 2008, CANCER EPIDEM BIOMAR, V17, P1360, DOI 10.1158/1055-9965.EPI-07-2878
   MATTHEWS RG, 1979, BIOCHEMISTRY-US, V18, P4845, DOI 10.1021/bi00589a012
   Michels A, 2008, J CRANIOFAC SURG, V19, P37, DOI 10.1097/scs.0b013e31815c8a87
   MILLS JL, 2000, AM J MED GENET, V92, P79
   Muñoz-Moran E, 1998, LANCET, V352, P1120, DOI 10.1016/S0140-6736(05)79761-0
   Muntjewerff JW, 2005, AM J MED GENET B, V135B, P69, DOI 10.1002/ajmg.b.30179
   Nelen WLDM, 2000, OBSTET GYNECOL, V95, P519, DOI 10.1016/S0029-7844(99)00610-9
   Ng XW, 2009, J NUTRIGENET NUTRIGE, V2, P1, DOI 10.1159/000160079
   Ng XW, 2008, FOOD CHEM, V106, P200, DOI 10.1016/j.foodchem.2007.05.057
   Niemitz EL, 2004, AM J HUM GENET, V74, P599, DOI 10.1086/382897
   Piyathilake CJ, 2008, NUTRITION, V24, P94, DOI 10.1016/j.nut.2007.10.007
   Quadri P, 2004, AM J CLIN NUTR, V80, P114
   Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P276, DOI 10.1055/s-2008-1065354
   Reyes-Engel A, 2002, MOL HUM REPROD, V8, P952, DOI 10.1093/molehr/8.10.952
   Rogers EJ, 2008, MED HYPOTHESES, V71, P406, DOI 10.1016/j.mehy.2008.04.013
   Salim A, 2006, BRIT J DERMATOL, V154, P1169, DOI 10.1111/j.1365-2133.2006.07289.x
   Sauer J, 2009, CURR OPIN CLIN NUTR, V12, P30, DOI 10.1097/MCO.0b013e32831cec62
   Morris MS, 2007, AM J CLIN NUTR, V85, P193, DOI 10.1093/ajcn/85.1.193
   Smith AD, 2008, AM J CLIN NUTR, V87, P517
   Sohn KJ, 2004, JNCI-J NATL CANCER I, V96, P134, DOI 10.1093/jnci/djh015
   Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895
   Tangney CC, 2009, NEUROLOGY, V72, P361, DOI 10.1212/01.wnl.0000341272.48617.b0
   Troen AM, 2006, J NUTR, V136, P189, DOI 10.1093/jn/136.1.189
   Ulrich CM, 2007, JAMA-J AM MED ASSOC, V297, P2408, DOI 10.1001/jama.297.21.2408
   Wang XB, 2007, LANCET, V369, P1876, DOI 10.1016/S0140-6736(07)60854-X
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230
   Wen SW, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.067
   Wong WY, 2002, FERTIL STERIL, V77, P491, DOI 10.1016/S0015-0282(01)03229-0
   Wright AJA, 2007, BRIT J NUTR, V98, P667, DOI 10.1017/S0007114507777140
   Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y
   Zhao RB, 2001, BIOCHEM PHARMACOL, V61, P857, DOI 10.1016/S0006-2952(01)00532-9
NR 74
TC 73
Z9 84
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1363-1950
EI 1473-6519
J9 CURR OPIN CLIN NUTR
JI Curr. Opin. Clin. Nutr. Metab. Care
PD NOV
PY 2009
VL 12
IS 6
BP 555
EP 564
DI 10.1097/MCO.0b013e32833192bc
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 513BI
UT WOS:000271296600001
PM 19726978
DA 2025-01-12
ER

PT J
AU Benton, G
   Crooke, E
   George, J
AF Benton, Gabriel
   Crooke, Elliott
   George, Jay
TI Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast
   cancer cells by inhibiting DNA methyltransferase 1 and reversing
   promoter methylation status
SO FASEB JOURNAL
LA English
DT Article
DE extracellular matrix; epigenetic; metastasis; microenvironment;
   mesenchymal to epithelial reverting transition; MErT
ID MAMMARY EPITHELIAL-CELLS; RECONSTITUTED BASEMENT-MEMBRANE; ALUI
   RESTRICTION ENZYME; GENE-EXPRESSION; MESENCHYMAL TRANSITION; SIGNALING
   PATHWAYS; TUMOR PROGRESSION; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX;
   TISSUE ARCHITECTURE
AB This study determines the role of laminin-1 in promoting metastatic colonization during breast cancer. For this purpose, human mammary epithelial cell lines representing normal (MCF-10A), adenocarcinoma (MCF-7), and malignant carcinoma (MDA-MB-231) were propagated in 3-dimensional cultures composed of laminin-1, collagen I, or mixtures of the two, and analyzed by Western blot, immunocytochemistry, semiquantitative reverse transcription polymerase chain reaction, and methylation-specific PCR. Here we demonstrate that laminin-1 decreases methylation of the E-cadherin promoter, resulting in increased mRNA and protein expression for malignant mammary epithelial cells. This decreased methylation is associated with dramatic changes in the cellular and structural morphology as well as a 70-fold decrease in DNA methyltransferase 1 (DNMT1) and a 6-fold decrease in cadherin 11 protein expression. To control for specificity of laminin-1 interactions, cells were also cultured on 2-dimensional plastic substrata and collagen I hydrogels for analysis, and the MCF-10A and MCF-7 were used as nonmalignant controls. Using a 3-dimensional model, we present evidence that laminin-1 is capable of inducing epigenetic change by inhibiting expression of DNMT1 and preventing methylation of the E-cadherin promoter, resulting in E-cadherin expression and the formation of cell-cell bonds in malignant carcinoma.-Benton, G., Crooke, E., George, J. Laminin-1 induces E-cadherin expression in 3-dimensional-cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J. 23, 3884-3895 (2009). www.fasebj.org
C1 [Benton, Gabriel; Crooke, Elliott] Georgetown Univ, Washington, DC USA.
   [Benton, Gabriel; George, Jay] Trevigen Inc, Gaithersburg, MD USA.
C3 Georgetown University
RP Benton, G (通讯作者)，8405 Helgerman Ct, Gaithersburg, MD 20877 USA.
EM gjb2@georgetown.edu
RI George, Jacob/KDN-5645-2024
OI Benton, Gabriel/0000-0003-4244-5764; George, Jacob/0000-0002-8421-5476
CR Alpaugh ML, 1999, CANCER RES, V59, P5079
   Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035
   BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849
   Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001
   Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6
   BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499
   Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016
   Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579
   BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5
   Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2
   Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e
   FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   GRAFF JR, 1995, CANCER RES, V55, P5195
   GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8
   Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hurtubise A, 2004, ANTI-CANCER DRUG, V15, P161, DOI 10.1097/01.cad.0000113334.52071.97
   Imamichi Y, 2007, CELLS TISSUES ORGANS, V185, P180, DOI 10.1159/000101319
   Ivascu A, 2007, INT J ONCOL, V31, P1403
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   KANE RE, 1995, DRUG METAB DISPOS, V23, P303
   Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953
   Kleinman H K, 2001, Surg Oncol Clin N Am, V10, P329
   KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005
   KOCAREK TA, 1993, MOL PHARMACOL, V43, P328
   Koenig A, 2006, CANCER RES, V66, P4662, DOI 10.1158/0008-5472.CAN-05-2804
   Le Beyec J, 2007, EXP CELL RES, V313, P3066, DOI 10.1016/j.yexcr.2007.04.022
   Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219
   LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136
   Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090
   Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com
   Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861
   Maniotis AJ, 2005, AM J PATHOL, V166, P1187, DOI 10.1016/S0002-9440(10)62338-3
   McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020
   Moiseeva EP, 2007, MOL CANCER THER, V6, P3071, DOI 10.1158/1535-7163.MCT-07-0117
   MONAGHAN P, 1983, P NATL ACAD SCI-BIOL, V80, P3344, DOI 10.1073/pnas.80.11.3344
   Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
   Nelson CM, 2008, J CELL BIOCHEM, V105, P25, DOI 10.1002/jcb.21821
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Olave IA, 2007, J BIOL CHEM, V282, P853, DOI 10.1074/jbc.M610404200
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071
   PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Pishvaian MJ, 1999, CANCER RES, V59, P947
   Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0
   Rahnama F, 2009, ENDOCRINOLOGY, V150, P1466, DOI 10.1210/en.2008-1142
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Rubin MA, 2001, HUM PATHOL, V32, P690, DOI 10.1053/hupa.2001.25902
   Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104
   SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302
   SEELY KA, 1991, J CELL PHYSIOL, V146, P117, DOI 10.1002/jcp.1041460116
   STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Thomlinson R H, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P105
   Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003
   Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578
   Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821
   Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494
   WARBURTON MJ, 1982, J HISTOCHEM CYTOCHEM, V30, P667, DOI 10.1177/30.7.6179984
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225
   Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1
   Wilsbacher Julie L, 2006, Cell Commun Signal, V4, P5, DOI 10.1186/1478-811X-4-5
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022
   Yates CC, 2007, BRIT J CANCER, V96, P1246, DOI 10.1038/sj.bjc.6603700
   Yates C, 2007, ADV CANCER RES, V97, P225, DOI 10.1016/S0065-230X(06)97010-9
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028
NR 84
TC 39
Z9 59
U1 0
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2009
VL 23
IS 11
BP 3884
EP 3895
DI 10.1096/fj.08-128702
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 512TC
UT WOS:000271272500024
PM 19635753
DA 2025-01-12
ER

PT J
AU Takeshima, H
   Yamashita, S
   Shimazu, T
   Niwa, T
   Ushijima, T
AF Takeshima, Hideyuki
   Yamashita, Satoshi
   Shimazu, Taichi
   Niwa, Tohru
   Ushijima, Toshikazu
TI The presence of RNA polymerase II, active or stalled, predicts
   epigenetic fate of promoter CpG islands
SO GENOME RESEARCH
LA English
DT Article
ID ABERRANT DNA METHYLATION; POLYCOMB TARGET GENES; CANCER-CELLS;
   HELICOBACTER-PYLORI; PROSTATE-CANCER; GASTRIC MUCOSAE; HUMAN GENOME;
   HYPERMETHYLATION; TRANSCRIPTION; CHROMATIN
AB Instructive mechanisms are present for induction of DNA methylation, as shown by methylation of specific CpG islands (CGIs) by specific inducers and in specific cancers. However, instructive factors involved are poorly understood, except for involvement of low transcription and trimethylation of histone H3 lysine 27 (H3K27me3). Here, we used methylated DNA immunoprecipitation (MeDIP) combined with a CGI oligonucleotide microarray analysis, and identified 5510 and 521 genes with promoter CGIs resistant and susceptible, respectively, to DNA methylation in prostate cancer cell lines. Expression analysis revealed that the susceptible genes had low transcription in a normal prostatic epithelial cell line. Chromatin immunoprecipitation with microarray hybridization (CHiP-chip) analysis of RNA polymerase II (Pol II) and histone modifications showed that, even among the genes with low transcription, the presence of Pol II was associated with marked resistance to DNA methylation (OR = 0.22; 95% CI = 0.12-0.38), and H3K27me3 was associated with increased susceptibility (OR = 11.20; 95% CI = 7.14-17.55). The same was true in normal human mammary epithelial cells for 5430 and 733 genes resistant and susceptible, respectively, to DNA methylation in breast cancer cell lines. These results showed that the presence of Pol II, active or stalled, and H3K27me3 can predict the epigenetic fate of promoter CGIs independently of transcription levels.
C1 [Takeshima, Hideyuki; Yamashita, Satoshi; Niwa, Tohru; Ushijima, Toshikazu] Natl Canc Ctr, Div Carcinogenesis, Res Inst, Tokyo 1040045, Japan.
   [Shimazu, Taichi] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Epidemiol & Prevent Div, Tokyo 1040045, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan
RP Ushijima, T (通讯作者)，Natl Canc Ctr, Div Carcinogenesis, Res Inst, Tokyo 1040045, Japan.
EM tushijim@ncc.go.jp
RI Ushijima, Toshikazu/AAP-5742-2021; Niwa, Tohru/C-2701-2011; Yamashita,
   Satoshi/KLD-0817-2024; Shimazu, Taichi/A-4470-2015
OI Shimazu, Taichi/0000-0001-6000-9830; Yamashita,
   Satoshi/0000-0002-8609-5797; Takeshima, Hideyuki/0000-0002-8552-2427;
   Ushijima, Toshikazu/0000-0003-3405-7817
FU Ministry of Health, Labour and Welfare, Japan; Ministry of Education,
   Science, Culture, and Sport, Japan; Uehara Life Science Foundation
FX We thank Hiroyuki Sasaki for his critical reading of this manuscript. H.
   T. is a recipient of Research Resident Fellowships from the Foundation
   for Promotion of Cancer Research. This study was supported by
   Grants-in-Aid for the Third-Term Comprehensive Cancer Control Strategy
   from the Ministry of Health, Labour and Welfare, Japan; for the
   Priority-area Research from the Ministry of Education, Science, Culture,
   and Sport, Japan; and a grant from Uehara Life Science Foundation.
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027
   Boumber YA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000162
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105
   Esteller M, 2001, CANCER RES, V61, P3225
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gal-Yam EN, 2006, PLOS GENET, V2, P1451, DOI 10.1371/journal.pgen.0020160
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096
   Mihara M, 2006, AM J PATHOL, V169, P1643, DOI 10.2353/ajpath.2006.060552
   Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21
   Nakajima T, 2009, INT J CANCER, V124, P905, DOI 10.1002/ijc.24018
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394
   Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Sato N, 2003, CANCER RES, V63, P3735
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   Ushijima T, 2003, GENOME RES, V13, P868, DOI 10.1101/gr.969603
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   YAMASHITA S, 2009, DNA RES IN PRESS
   Yates PA, 1999, J BIOL CHEM, V274, P36357, DOI 10.1074/jbc.274.51.36357
   Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178
   Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26
NR 51
TC 102
Z9 110
U1 0
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD NOV
PY 2009
VL 19
IS 11
BP 1974
EP 1982
DI 10.1101/gr.093310.109
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 514WK
UT WOS:000271426600006
PM 19652013
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Kato, TA
   Wilson, PF
   Nagasaw, H
   Peng, YL
   Weil, MM
   Little, JB
   Bedford, JS
AF Kato, Takamitsu A.
   Wilson, Paul F.
   Nagasaw, Hatsumi
   Peng, Yuanlin
   Weil, Michael M.
   Little, John B.
   Bedford, Joel S.
TI VARIATIONS IN RADIOSENSITIVITY AMONG INDIVIDUALS: A POTENTIAL IMPACT ON
   RISK ASSESSMENT?
SO HEALTH PHYSICS
LA English
DT Article
DE radiation protection; risk assessment; environmental assessment;
   National Council on Radiation Protection and Measurements
ID RADIATION-INDUCED LYMPHOMAS; DOSE-RATE; HEREDITARY RETINOBLASTOMA;
   GENETIC PREDISPOSITION; UNAFFECTED PARENTS; GAMMA-IRRADIATION;
   BREAST-CANCER; X-IRRADIATION; DNA-REPAIR; MICE
AB To have an impact on risk assessment for purposes of radiation protection recommendations, significantly broad variations in carcinogenic radiosensitivity would have to exist in significant proportions in the human population. Even if we knew all the genes where mutations would have major effects, individual genome sequencing does not seem useful, since we do not know all these genes, nor can we be certain of the phenotypic effect of polymorphisms discovered. Further, sequencing would not reveal epigenetic changes in gene expression. Another approach to develop phenotypic biomarkers for cells or tissues for which variations in radiation response may reflect the variations in carcinogenic sensitivity. To be useful, experimental evidence for such a correlation would be crucial, and it is also evident that correlations may be tissue or tumor specific. Some cellular markers are discussed that have shown promise in this regard. They include chromosome aberration induction and DNA repair assays that are sufficiently sensitive to measure after modest or low doses or dose rates. To this end we summarize here some of these assays and review the results of a number of experiments from our laboratory that show clear differences in DNA repair capacity reflected by gamma-H2AX foci formation in cells from a high proportion (perhaps 113) of apparently normal individuals. A low dose-rate assay was used to amplify such differences. Another promising assay combines G(2) chromosomal radiosensitivity with the above gamma-H2AX foci on mitotic chromosomes. There are other potentially useful assays as well. Health Phys. 97(5):470-480; 2009
C1 [Kato, Takamitsu A.; Wilson, Paul F.; Nagasaw, Hatsumi; Peng, Yuanlin; Weil, Michael M.; Bedford, Joel S.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA.
   [Kato, Takamitsu A.] Natl Inst Radiol Sci, Inage Ku, Chiba 260, Japan.
   [Wilson, Paul F.] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA 94551 USA.
   [Little, John B.] Harvard Univ, Sch Publ Hlth, Ctr Radiat Sci & Environm Hlth, Boston, MA 02115 USA.
C3 Colorado State University; National Institutes for Quantum Science &
   Technology; United States Department of Energy (DOE); Lawrence Livermore
   National Laboratory; Harvard University; Harvard T.H. Chan School of
   Public Health
RP Bedford, JS (通讯作者)，Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA.
EM jbedford@colostate.edu
RI Kato, Takamitsu/D-7969-2015
OI Kato, Takamitsu/0000-0002-6263-600X
FU U.S. DOE Low Dose Radiation Research Program [DE-FG02-07ER64350];
   National Aeronautics and Space Administration [NNX07AP85G]
FX This work was supported in part by grant DE-FG02-07ER64350 from the U.S.
   DOE Low Dose Radiation Research Program and grant NNX07AP85G from the
   National Aeronautics and Space Administration.
CR DESCHAVANNE PJ, 1986, INT J RADIAT BIOL, V50, P279, DOI 10.1080/09553008614550661
   Fitzek MM, 2002, INT J CANCER, V99, P764, DOI 10.1002/ijc.10401
   Flint-Richter P, 2007, LANCET ONCOL, V8, P403, DOI 10.1016/S1470-2045(07)70107-9
   KALLMAN RF, 1962, RADIAT RES, V16, P796, DOI 10.2307/3571279
   Kato TA, 2007, DNA REPAIR, V6, P818, DOI 10.1016/j.dnarep.2007.01.008
   Kato TA, 2006, RADIAT RES, V166, P443, DOI 10.1667/RR3604.1
   MOLE RH, 1983, BRIT J CANCER, V47, P285, DOI 10.1038/bjc.1983.37
   Okayasu R, 2000, CANCER RES, V60, P4342
   OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135
   OKUMOTO M, 1995, EXP ANIM TOKYO, V44, P43, DOI 10.1538/expanim.44.43
   PARSHAD R, 1983, P NATL ACAD SCI-BIOL, V80, P5612, DOI 10.1073/pnas.80.18.5612
   Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411
   Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544
   SANFORD KK, 1990, CHROMOSOMAL ABERRATI, P113
   Scott D, 1996, RADIAT RES, V145, P3, DOI 10.2307/3579189
   SCOTT D, 1994, LANCET, V344, P1444, DOI 10.1016/S0140-6736(94)90615-7
   STACKHOUSE MA, 1993, RADIAT RES, V136, P250, DOI 10.2307/3578618
   STORER JB, 1988, RADIAT RES, V114, P331, DOI 10.2307/3577229
   Szymanska H, 1999, INT J CANCER, V83, P674, DOI 10.1002/(SICI)1097-0215(19991126)83:5<674::AID-IJC18>3.0.CO;2-M
   ULLRICH RL, 1983, RADIAT RES, V93, P506, DOI 10.2307/3576029
   Wilson PF, 2008, RADIAT RES, V169, P483, DOI 10.1667/RR1333.1
NR 21
TC 23
Z9 26
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD NOV
PY 2009
VL 97
IS 5
BP 470
EP 480
DI 10.1097/HP.0b013e3181b08eee
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 506UI
UT WOS:000270801500011
PM 19820456
DA 2025-01-12
ER

PT J
AU Juckett, DA
AF Juckett, David A.
TI A 17-year oscillation in cancer mortality birth cohorts on three
   continents - synchrony to cosmic ray modulations one generation earlier
SO INTERNATIONAL JOURNAL OF BIOMETEOROLOGY
LA English
DT Article
DE Cancer mortality; Age-period-cohort analysis; Cosmic radiation;
   Evolution; Grandmother effects
ID TIME-SERIES; RADIATION; SOLAR; EXPOSURE; CYCLES
AB Cross-generational effects (grandmother effects) associated with epigenetic imprinting, environmental exposures, and lifestyle choices are beginning to be explored by various investigators. The possibility that low-level background radiation can be a driver of such effects has been suggested previously and is explored further in this study. Age-period-cohort analysis was performed on United States (US), United Kingdom (UK), and Australian (AU) female breast cancer mortality of the twentieth century, as well as on UK female total cancer mortality, to extract the high-frequency oscillations in the birth cohort time series. US fetal and infant congenital mortality were examined to extend the birth cohorts to modern times. A similar to 17-year cycle was detected in all birth cohort series, which spanned approximately 180 years from 1820 to 2000. This suggests a global, environmental cause. To mimic previous work in examining a possible link to cosmic radiation, the 17- to 18-year cycles of the cosmogenic nuclide (14)C, the sunspot double-cycle, neutron monitors, and a compilation of ground-based magnetic field observations were examined in the birth cohort and germ cell cohort time frames. Evidence is presented that optimal alignments with extraterrestrial oscillations occur in the time frame of the germ-cell cohort, one generation before the birth cohorts. Furthermore, the alignment is optimized by accounting for the changes in the maternal age distribution over time. These findings have potential importance to the mechanisms of disease as well as species adaptation and evolution.
C1 [Juckett, David A.] Barros Res Inst, Holt, MI 48842 USA.
   [Juckett, David A.] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.
C3 Michigan State University
RP Juckett, DA (通讯作者)，Barros Res Inst, 2430 Coll Rd, Holt, MI 48842 USA.
EM juckett@msu.edu
FU Barros Research Institute; Michigan State University Foundation
FX This work was supported by the Barros Research Institute and by a joint
   operating agreement grant from the Michigan State University Foundation.
CR [Anonymous], 2009, INTEGR COMP BIOL, DOI DOI 10.1093/ICB/ICP106
   [Anonymous], HLTH RISKS EXP LOW L
   [Anonymous], 2002, IARC Scientific Publication
   Castillo Enrique., 1988, EXTREME VALUE THEORY
   Chaney EK, 2005, HEALTH PHYS, V89, P322, DOI 10.1097/01.HP.0000164650.96261.9d
   Durante M, 2008, ADV SPACE RES, V42, P999, DOI 10.1016/j.asr.2007.02.014
   FREJKA T, 2004, CHILDBEARING TRENDS, P373
   Godar DE, 2001, PHOTOCHEM PHOTOBIOL, V73, P621, DOI 10.1562/0031-8655(2001)073<0621:UDOA>2.0.CO;2
   Heimers A, 1999, INT J RADIAT BIOL, V75, P691, DOI 10.1080/095530099140023
   Hoyt DV, 1998, SOL PHYS, V181, P491, DOI 10.1023/A:1005056326158
   Joyce P, 2008, GENETICS, V180, P1627, DOI 10.1534/genetics.108.088716
   Juckett DA, 1998, SOL PHYS, V183, P201, DOI 10.1023/A:1005075703810
   Juckett DA, 1997, INT J BIOMETEOROL, V40, P206, DOI 10.1007/s004840050043
   JUCKETT DA, 1993, RADIAT RES, V133, P312, DOI 10.2307/3578215
   Juckett DA, 2001, J GEOPHYS RES-SPACE, V106, P18651, DOI 10.1029/2000JA000367
   Juckett DA, 2007, INT J ASTROBIOL, V6, P307, DOI 10.1017/S1473550407003928
   Lim MK, 2002, OCCUP ENVIRON MED, V59, P428, DOI 10.1136/oem.59.7.428
   Mahmoud BH, 2008, PHOTOCHEM PHOTOBIOL, V84, P450, DOI 10.1111/j.1751-1097.2007.00286.x
   Medvedev MV, 2007, ASTROPHYS J, V664, P879, DOI 10.1086/518757
   Melott AL, 2008, J GEOPHYS RES-PLANET, V113, DOI 10.1029/2008JE003206
   *NAT ARCH UK, 1901, 69 NDADCRDA NAT ARCH
   Sliney DH, 2000, RADIAT PROT DOSIM, V91, P213, DOI 10.1093/oxfordjournals.rpd.a033204
   Sonett CP, 1997, SPACE SCI S, P67
   Stoupel EG, 2005, INT J BIOMETEOROL, V50, P1, DOI 10.1007/s00484-005-0274-2
   Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172
   THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433
   *US BUR CENS, 1945, 16 CENS US 1940 POP
   *US BUR CENS, 1940, CENS POP US
   *US BUR CENS, 1930, CENS POP US
   *US BUR CENS, 1920, CENS POP US
   *US BUR CENS, MORT STAT 1900 1938
   *US BUR CENS, 1910, CENS POP US
   *US BUR CENS, 1900, CENS POP US
   *US DHHS, VIT STAT US 1939 200
   VAUTARD R, 1992, PHYSICA D, V58, P95, DOI 10.1016/0167-2789(92)90103-T
   WILLIGAN JD, 1982, DEMOGRAPHY, V19, P161, DOI 10.2307/2061188
   WILSON PR, 1994, SOLAR STELLAR ACTIVI, P16
NR 37
TC 11
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0020-7128
J9 INT J BIOMETEOROL
JI Int. J. Biometeorol.
PD NOV
PY 2009
VL 53
IS 6
BP 487
EP 499
DI 10.1007/s00484-009-0237-0
PG 13
WC Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences;
   Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric
   Sciences; Physiology
GA 527OA
UT WOS:000272375200003
PM 19506913
DA 2025-01-12
ER

PT J
AU Radpour, R
   Sikora, M
   Grussenmeyer, T
   Kohler, C
   Barekati, Z
   Holzgreve, W
   Lefkovits, I
   Zhong, XY
AF Radpour, Ramin
   Sikora, Michal
   Grussenmeyer, Thomas
   Kohler, Corina
   Barekati, Zeinab
   Holzgreve, Wolfgang
   Lefkovits, Ivan
   Zhong, Xiao Yan
TI Simultaneous Isolation of DNA, RNA, and Proteins for Genetic,
   Epigenetic, Transcriptomic, and Proteomic Analysis
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE Column-based extraction; AllPrep method; genetic analysis;
   transcriptomic analysis; proteomic analysis; limited sample resources;
   MALDI-TOF mass spectrometry
ID PARAFFIN-EMBEDDED TISSUE; BREAST-CANCER; METHYLATION PATTERNS;
   MESSENGER-RNA; SERUM SAMPLES; HUMAN PLASMA; EXTRACTION; CELL; CLEAVAGE;
   TIME
AB Analysis of DNA, RNA, and proteins for downstream genetic, epigenetic, transcriptomic, and proteomic analysis holds an important place in the field of medical care and life science. This is often hampered by the limited availability of sample material. For this reason, there exists an increasing interest for simultaneous isolation of DNA, RNA and proteins from a single sample aliquot Several kit-systems allowing such a procedure have been introduced to the market We present an approach using the AllPrep method for simultaneous isolation of DNA, RNA and proteins from several human specimens, such as whole blood, buffy coat, serum, plasma and tissue samples. The quantification and qualification of the isolated molecular species were assessed by different downstream methods. NanoDrop for measuring concentration and purity of all molecular species; DNA and RNA LabChip for fractionation analysis of nucleic acids; quantitative PCR for quantification analysis of DNA and RNA; thymidine-specific cleavage mass array on MALDI-TOF silico-chip for epigenetic analysis; Protein LabChip and two-dimensional (2D) gel electrophoresis for proteomic analysis. With our modified method, we can simultaneously isolate DNA, RNA and/or proteins from one single sample aliquot. We could overcome to some method limitations like low quality or DNA fragmentation using reamplification strategy for performing high-throughput downstream assays. Fast and easy performance of the procedure makes this method interesting for all fields of downstream analysis, especially when using limited sample resources. The cost-effectiveness of the procedure when material is abundantly available has not been addressed. This methodological improvement enables to execute such experiments that were not performable with standard procedure, and ensures reproducible outcome
C1 [Radpour, Ramin; Sikora, Michal; Kohler, Corina; Barekati, Zeinab; Zhong, Xiao Yan] Univ Basel, Lab Prenatal Med & Gynecol Oncol, Womens Hosp, Dept Biomed, CH-4003 Basel, Switzerland.
   [Grussenmeyer, Thomas; Lefkovits, Ivan] Univ Basel Hosp, Dept Biomed, Basel, Switzerland.
   [Grussenmeyer, Thomas; Lefkovits, Ivan] Univ Basel Hosp, Dept Cardiac Surg, Basel, Switzerland.
   [Holzgreve, Wolfgang] Univ Med Ctr Freiburg, Freiburg, Germany.
C3 University of Basel; University of Basel; University of Basel;
   University of Freiburg
RP Zhong, XY (通讯作者)，Univ Basel, Lab Prenatal Med & Gynecol Oncol, Womens Hosp, Dept Biomed, CH-4003 Basel, Switzerland.
RI Kohler, Corina/KTH-9502-2024; Grussenmeyer, Thomas/B-9859-2009; Radpour,
   PD Dr. Ramin/J-4949-2014; Lefkovits, Ivan/B-9777-2009
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833; Lefkovits,
   Ivan/0000-0003-1783-8881
FU Swiss National Science Foundation [320000-119722/1]; Swiss Cancer
   League; Krebsliga Bolder Basel; Dr Hans Altschueler Stiftung
FX We thank Nicole Chiodetti and Vivian Kiefer for their help, Sheena
   Kinmry for proofreading the text and we are indebted to the patients for
   their cooperation. This work was supported in part by Swiss National
   Science Foundation (320000-119722/1) and Swiss Cancer League, Krebsliga
   Bolder Basel and Dr Hans Altschueler Stiftung. The authors declare no
   conflict of interest neither in the use of the commercially available
   kits nor any other procedures
CR Andersen CL, 2007, CARCINOGENESIS, V28, P38, DOI 10.1093/carcin/bgl086
   ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0
   Bianchi DW, 2006, ANN NY ACAD SCI, V1075, P63, DOI 10.1196/annals.1368.008
   CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532
   Coudry RA, 2007, J MOL DIAGN, V9, P70, DOI 10.2353/jmoldx.2007.060004
   Donoso P, 2007, BEST PRACT RES CL OB, V21, P157, DOI 10.1016/j.bpobgyn.2006.09.006
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   EVERSON RB, 1993, BIOTECHNIQUES, V15, P18
   Grussenmeyer T, 2008, J PROTEOME RES, V7, P5211, DOI 10.1021/pr8005292
   Hood BL, 2005, MOL CELL PROTEOMICS, V4, P1741, DOI 10.1074/mcp.M500102-MCP200
   Hummon AB, 2007, BIOTECHNIQUES, V42, P467, DOI 10.2144/000112401
   Ikeda K, 1998, J HISTOCHEM CYTOCHEM, V46, P397, DOI 10.1177/002215549804600314
   Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069
   Kirkland PA, 2006, ANAL BIOCHEM, V351, P254, DOI 10.1016/j.ab.2006.01.017
   Lee TH, 2001, TRANSFUSION, V41, P276, DOI 10.1046/j.1537-2995.2001.41020276.x
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Morse SMJ, 2006, BIOTECHNIQUES, V40, P54, DOI 10.2144/000112100
   Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.3.CO;2-H
   Noutsias M, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-3
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Sjöholm MIL, 2005, CANCER EPIDEM BIOMAR, V14, P251
   Tapio S, 2008, RADIAT ENVIRON BIOPH, V47, P183, DOI 10.1007/s00411-007-0149-5
   Tolosa JM, 2007, BIOTECHNIQUES, V43, P799, DOI 10.2144/000112594
   Torres L, 2007, BREAST CANCER RES TR, V102, P143, DOI 10.1007/s10549-006-9317-6
   Walker BA, 2006, BLOOD, V108, P1733, DOI 10.1182/blood-2006-02-005496
   Wong SCC, 2004, J CLIN PATHOL, V57, P766, DOI 10.1136/jcp.2003.007880
   Zhong XY, 2007, ANN HEMATOL, V86, P139, DOI 10.1007/s00277-006-0182-5
   Zhong Xiao Yan, 2008, V444, P269, DOI 10.1007/978-1-59745-066-9_21
NR 29
TC 28
Z9 30
U1 0
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV
PY 2009
VL 8
IS 11
BP 5264
EP 5274
DI 10.1021/pr900591w
PG 11
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 586XV
UT WOS:000276949600034
PM 19780627
DA 2025-01-12
ER

PT J
AU Dallosso, AR
   Hancock, AL
   Szemes, M
   Moorwood, K
   Chilukamarri, L
   Tsai, HH
   Sarkar, A
   Barasch, J
   Vuononvirta, R
   Jones, C
   Pritchard-Jones, K
   Royer-Pokora, B
   Lee, SB
   Owen, C
   Malik, S
   Feng, Y
   Frank, M
   Ward, A
   Brown, KW
   Malik, K
AF Dallosso, Anthony R.
   Hancock, Anne L.
   Szemes, Marianna
   Moorwood, Kim
   Chilukamarri, Laxmi
   Tsai, Hsin-Hao
   Sarkar, Abby
   Barasch, Jonathan
   Vuononvirta, Raisa
   Jones, Chris
   Pritchard-Jones, Kathy
   Royer-Pokora, Brigitte
   Lee, Sean Bong
   Owen, Ceris
   Malik, Sally
   Feng, Yi
   Frank, Marcus
   Ward, Andrew
   Brown, Keith W.
   Malik, Karim
TI Frequent Long-Range Epigenetic Silencing of Protocadherin Gene Clusters
   on Chromosome 5q31 in Wilms' Tumor
SO PLOS GENETICS
LA English
DT Article
ID GAMMA-PROTOCADHERINS; BREAST-CANCER; COLORECTAL-CANCER; SUPPRESSOR GENE;
   KIDNEY DEVELOPMENT; NEPHROGENIC RESTS; DNA METHYLATION; COMMON EVENT;
   LUNG-CANCER; CELL-LINE
AB Wilms' tumour (WT) is a pediatric tumor of the kidney that arises via failure of the fetal developmental program. The absence of identifiable mutations in the majority of WTs suggests the frequent involvement of epigenetic aberrations in WT. We therefore conducted a genome-wide analysis of promoter hypermethylation in WTs and identified hypermethylation at chromosome 5q31 spanning 800 kilobases (kb) and more than 50 genes. The methylated genes all belong to alpha-, beta-, and gamma-protocadherin (PCDH) gene clusters (Human Genome Organization nomenclature PCDHA@, PCDHB@, and PCDHG@, respectively). This demonstrates that long-range epigenetic silencing (LRES) occurs in developmental tumors as well as in adult tumors. Bisulfite polymerase chain reaction analysis showed that PCDH hypermethylation is a frequent event found in all Wilms' tumor subtypes. Hypermethylation is concordant with reduced PCDH expression in tumors. WT precursor lesions showed no PCDH hypermethylation, suggesting that de novo PCDH hypermethylation occurs during malignant progression. Discrete boundaries of the PCDH domain are delimited by abrupt changes in histone modifications; unmethylated genes flanking the LRES are associated with permissive marks which are absent from methylated genes within the domain. Silenced genes are marked with non-permissive histone 3 lysine 9 dimethylation. Expression analysis of embryonic murine kidney and differentiating rat metanephric mesenchymal cells demonstrates that Pcdh expression is developmentally regulated and that Pcdhg@ genes are expressed in blastemal cells. Importantly, we show that PCDHs negatively regulate canonical Wnt signalling, as short-interfering RNA-induced reduction of PCDHG@ encoded proteins leads to elevated beta-catenin protein, increased beta-catenin/T-cell factor (TCF) reporter activity, and induction of Wnt target genes. Conversely, over-expression of PCDHs suppresses beta-catenin/TCF-reporter activity and also inhibits colony formation and growth of cancer cells in soft agar. Thus PCDHs are candidate tumor suppressors that modulate regulatory pathways critical in development and disease, such as canonical Wnt signaling.
C1 [Dallosso, Anthony R.; Hancock, Anne L.; Szemes, Marianna; Chilukamarri, Laxmi; Tsai, Hsin-Hao; Owen, Ceris; Malik, Sally; Brown, Keith W.; Malik, Karim] Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Canc & Leukaemia Childhood Sargent Res Unit, Bristol BS8 1TD, Avon, England.
   [Moorwood, Kim; Ward, Andrew] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.
   [Sarkar, Abby; Barasch, Jonathan] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
   [Vuononvirta, Raisa; Jones, Chris; Pritchard-Jones, Kathy] Royal Marsden NHS Trust, Inst Canc Res, Sutton, Surrey, England.
   [Royer-Pokora, Brigitte] Univ Dusseldorf, Inst Human Genet & Anthropol, Dusseldorf, Germany.
   [Lee, Sean Bong] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
   [Feng, Yi] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.
   [Frank, Marcus] Univ Freiburg, Inst Biol 1, D-7800 Freiburg, Germany.
C3 University of Bristol; University of Bath; Columbia University;
   University of London; Institute of Cancer Research - UK; Royal Marsden
   NHS Foundation Trust; Heinrich Heine University Dusseldorf; National
   Institutes of Health (NIH) - USA; NIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK); University of Bristol; University
   of Freiburg
RP Dallosso, AR (通讯作者)，Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Canc & Leukaemia Childhood Sargent Res Unit, Bristol BS8 1TD, Avon, England.
EM Keith.Brown@bristol.ac.uk; k.t.a.malik@bristol.ac.uk
RI Jones, Chris/ABE-6059-2021; dallosso, anthony/A-8335-2008; Lee,
   Sean/KCK-6072-2024; Brown, Keith/C-3355-2009; Pritchard-Jones,
   Kathryn/F-4286-2014
OI Malik, Sally/0009-0006-7098-7340; Pritchard-Jones,
   Kathryn/0000-0002-2384-9475; Lee, Sean/0000-0001-6211-3498; Moorwood,
   Kim/0000-0003-0943-6161; Jones, Chris/0000-0001-8118-2296; Malik,
   Karim/0000-0002-8965-200X; Ward, Andrew/0000-0001-8311-5695; Dallosso,
   Anthony/0000-0002-1460-2550; Sarkar, Abby/0000-0001-6101-1721
FU Cancer and Leukaemia in Childhood - Sargent; Children's Leukaemia Trust;
   Kidney Research UK; MRC [G0300415] Funding Source: UKRI
FX This work was supported by Cancer and Leukaemia in Childhood - Sargent,
   the Children's Leukaemia Trust, and Kidney Research UK. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alami J, 2003, INT J CANCER, V107, P365, DOI 10.1002/ijc.11429
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   BRATTAIN MG, 1981, CANCER RES, V41, P1751
   Brown KW, 2008, MOL CANCER RES, V6, P1114, DOI 10.1158/1541-7786.MCR-08-0002
   Brunskill EW, 2008, DEV CELL, V15, P781, DOI 10.1016/j.devcel.2008.09.007
   Charles AK, 1998, AM J PATHOL, V153, P991, DOI 10.1016/S0002-9440(10)65641-6
   Chen J, 2009, J BIOL CHEM, V284, P2880, DOI 10.1074/jbc.M807417200
   Chilukamarri L, 2007, NEOPLASIA, V9, P970, DOI 10.1593/neo.07661
   Dallosso AR, 2004, HUM MOL GENET, V13, P405, DOI 10.1093/hmg/ddh038
   Daugherty RL, 2007, PHYSIOLOGY, V22, P303, DOI 10.1152/physiol.00020.2007
   Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890
   Filippova GN, 2002, CANCER RES, V62, P48
   Frank M, 2005, MOL CELL NEUROSCI, V29, P603, DOI 10.1016/j.mcn.2005.05.001
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Fukuzawa R, 2007, J CLIN PATHOL, V60, P1013, DOI 10.1136/jcp.2006.043083
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59
   Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200
   Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020
   Koesters R, 1999, CANCER RES, V59, P3880
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Liu ZY, 2008, LUNG CANCER, V62, P15, DOI 10.1016/j.lungcan.2008.02.005
   Malik K, 2000, CANCER RES, V60, P2356
   Menke AL, 2003, J PATHOL, V200, P667, DOI 10.1002/path.1390
   Morishita H, 2007, CURR OPIN CELL BIOL, V19, P584, DOI 10.1016/j.ceb.2007.09.006
   Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155
   Phillips GR, 2003, J NEUROSCI, V23, P5096
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696
   Ruteshouser EC, 2008, GENE CHROMOSOME CANC, V47, P461, DOI 10.1002/gcc.20553
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schmidt-Ott KM, 2008, KIDNEY INT, V74, P1004, DOI 10.1038/ki.2008.322
   Schmidt-Ott KM, 2007, DEVELOPMENT, V134, P3177, DOI 10.1242/dev.006544
   Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   van Buul JD, 2005, J BIOL CHEM, V280, P21129, DOI 10.1074/jbc.M500898200
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
   Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050
   Zhang SM, 2007, INT J SEMANT WEB INF, V3, P1, DOI 10.4018/jswis.2007040101
NR 55
TC 125
Z9 146
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2009
VL 5
IS 11
AR e1000745
DI 10.1371/journal.pgen.1000745
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 528CW
UT WOS:000272419500040
PM 19956686
OA Green Submitted, Green Accepted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Wang, X
   Sansam, CG
   Thom, CS
   Metzger, D
   Evans, JA
   Nguyen, PTL
   Roberts, CWM
AF Wang, Xi
   Sansam, Courtney G.
   Thom, Christopher S.
   Metzger, Daniel
   Evans, Julia A.
   Nguyen, Phuong T. L.
   Roberts, Charles W. M.
TI Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on
   Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex
SO CANCER RESEARCH
LA English
DT Article
ID CANCER CELL-LINES; ACUTE LYMPHOBLASTIC-LEUKEMIA; SOFT-TISSUE SARCOMAS;
   RHABDOID TUMORS; PROTEIN EXPRESSION; GERMLINE MUTATION; INI1 EXPRESSION;
   BREAST-CANCER; GENE; CYCLE
AB Alterations in chromatin play an important role in oncogenic transformation, although the underlying mechanisms are often poorly understood. The SWI/SNF complex contributes to epigenetic regulation by using the energy of ATP hydrolysis to remodel chromatin and thus regulate transcription of target genes. SNF5, a core subunit of the SWI/SNF complex, is a potent tumor suppressor that is specifically inactivated in several types of human cancer. However, the mechanism by which SNF5 mutation leads to cancer and the role of SNF5 within the SWI/SNF complex remain largely unknown. It has been hypothesized that oncogenesis in the absence of SNF5 occurs due to a loss of function of the SWI/SNF complex. Here, we show, however, distinct effects for inactivation of Snf5 and the ATPase subunit Brg1 in primary cells. Further, using both human cell lines and mouse models, we show that cancer formation in the absence of SNF5 does not result from SWI/SNF inactivation but rather that oncogenesis is dependent on continued presence of BRG1. Collectively, our results show that cancer formation in the absence of SNF5 is dependent on the activity of the residual BRG1-containing SWI/SNF complex. These findings suggest that, much like the concept of oncogene addiction, targeted inhibition of SWI/SNF ATPase activity may be an effective therapeutic approach for aggressive SNF5-deficient human tumors. [Cancer Res 2009; 69(20):8094-101]
C1 [Wang, Xi; Sansam, Courtney G.; Thom, Christopher S.; Evans, Julia A.; Nguyen, Phuong T. L.; Roberts, Charles W. M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
   [Wang, Xi; Sansam, Courtney G.; Thom, Christopher S.; Evans, Julia A.; Nguyen, Phuong T. L.; Roberts, Charles W. M.] Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp Boston,Div Hematol Oncol, Boston, MA USA.
   [Metzger, Daniel] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Boston Children's Hospital; Harvard Medical School; Centre National de
   la Recherche Scientifique (CNRS); Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Institut National de
   la Sante et de la Recherche Medicale (Inserm)
RP Roberts, CWM (通讯作者)，Dana Farber Canc Inst, Dept Pediat Oncol, Mayer 657,44 Binney St, Boston, MA 02115 USA.
EM charles_roberts@dfci.harvard.edu
RI Thom, Christopher/AGB-3603-2022; Roberts, Charles/N-2541-2018
OI Roberts, Charles/0000-0003-1135-1896; Sansam,
   Courtney/0000-0002-0253-8643; Metzger, Daniel/0000-0002-5555-046X
FU Garrett B. Smith Foundation; Claudia Adams Barr Foundation; Sarcoma
   Foundation of America; PHS award [R01CA113794, F32CA123776]; Flope
   Street Kids Foundation
FX Grant support: Garrett B. Smith Foundation, the Claudia Adams Barr
   Foundation, the Sarcoma Foundation of America, and PHS award R01CA113794
   (C.W.M. Roberts) and PHS awards F32CA123776 and Flope Street Kids
   Foundation (C.G. Sansam).
CR Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470
   Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706
   Biegel JA, 1999, CANCER RES, V59, P74
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1
   Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664
   Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44
   D Kaeser M, 2006, CURR OPIN GENET DEV, V16, P508, DOI 10.1016/j.gde.2006.08.001
   DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136
   Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472
   Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001
   Ho L, 2009, P NATL ACAD SCI USA, V106, P5181, DOI 10.1073/pnas.0812889106
   Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513
   Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207
   Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102
   Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006
   Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129
   Kohashi K, 2008, AM J SURG PATHOL, V32, P1168, DOI 10.1097/PAS.0b013e318161781a
   Kreiger PA, 2009, MODERN PATHOL, V22, P142, DOI 10.1038/modpathol.2008.185
   Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019
   Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071
   Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9
   McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08
   Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730
   Modena P, 2005, CANCER RES, V65, P4012, DOI 10.1158/0008-5472.CAN-04-3050
   Moloney FJ, 2009, J INVEST DERMATOL, V129, P1012, DOI 10.1038/jid.2008.319
   Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120
   Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200
   Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9
   Pottier N, 2007, HUM MOL GENET, V16, P2261, DOI 10.1093/hmg/ddm178
   Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416
   Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206
   Reisman DN, 2003, CANCER RES, V63, P560
   Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979
   Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697
   Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273
   Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833
   Trobaugh-Lotrario AD, 2009, PEDIATR BLOOD CANCER, V52, P328, DOI 10.1002/pbc.21834
   Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841
   Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212
   Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117
   Wang XM, 2004, INT J CANCER, V112, P636, DOI 10.1002/ijc.20450
   WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3
   Wong AKC, 2000, CANCER RES, V60, P6171
   Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545
   Wu JI, 2009, CELL, V136, P200, DOI 10.1016/j.cell.2009.01.009
   Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276
   Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
NR 50
TC 114
Z9 150
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2009
VL 69
IS 20
BP 8094
EP 8101
DI 10.1158/0008-5472.CAN-09-0733
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 508MM
UT WOS:000270935500026
PM 19789351
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Fluge, O
   Gravdal, K
   Carlsen, E
   Vonen, B
   Kjellevold, K
   Refsum, S
   Lilleng, R
   Eide, TJ
   Halvorsen, TB
   Tveit, KM
   Otte, AP
   Akslen, LA
   Dahl, O
AF Fluge, O.
   Gravdal, K.
   Carlsen, E.
   Vonen, B.
   Kjellevold, K.
   Refsum, S.
   Lilleng, R.
   Eide, T. J.
   Halvorsen, T. B.
   Tveit, K. M.
   Otte, A. P.
   Akslen, L. A.
   Dahl, O.
CA Norwegian Gastrointestinal Canc Gr
TI Expression of EZH2 and Ki-67 in colorectal cancer and associations with
   treatment response and prognosis
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE colorectal cancer; adjuvant chemotherapy; prediction of outcome; EZH2;
   ki-76; immunehistochemistry
ID TUMOR-CELL PROLIFERATION; ADJUVANT THERAPY; COLON-CANCER; BREAST-CANCER;
   STAGE-II; FLUOROURACIL; CHEMOTHERAPY; LEVAMISOLE; CARCINOMA; PROSTATE
AB BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation.
   METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy.
   RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P = 0.041) and high proliferation (>= 40%; P = 0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P 0.001), but not among those who were treated by surgery alone (P = 0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P = 0.046), but not in patients with low proliferation (P = 0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55).
   CONCLUSION: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer. British Journal of Cancer ( 2009) 101, 1282-1289. doi:10.1038/sj.bjc.6605333 www.bjcancer.com Published online 22 September 2009 (C) 2009 Cancer Research UK
C1 [Fluge, O.; Dahl, O.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway.
   [Gravdal, K.; Akslen, L. A.] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
   [Carlsen, E.] Ullevaal Univ Hosp, Dept Surg, Oslo, Norway.
   [Vonen, B.] Univ No Norway, Dept Surg, Tromso, Norway.
   [Kjellevold, K.] Stavanger Univ Hosp, Dept Pathol, Stavanger, Norway.
   [Refsum, S.] Lab Pathol AS, Oslo, Norway.
   [Lilleng, R.] Buskerud Cent Hosp, Dept Pathol, Drammen, Norway.
   [Eide, T. J.] Univ Oslo, Natl Hosp, Dept Pathol, Oslo, Norway.
   [Halvorsen, T. B.] St Olavs Hosp, Dept Pathol, Trondheim, Norway.
   [Tveit, K. M.] Ullevaal Univ Hosp, Dept Oncol, Oslo, Norway.
   [Otte, A. P.] Univ Amsterdam, Swammerdam Inst Life Sci, Dept Biochem, Amsterdam, Netherlands.
   [Akslen, L. A.] Univ Bergen, Gade Inst, Dept Pathol, Bergen, Norway.
   [Dahl, O.] Univ Bergen, Inst Med, Sect Oncol, Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen; Haukeland University Hospital; University of Oslo; Stavanger
   University Hospital; University of Oslo; National Hospital Norway;
   Norwegian University of Science & Technology (NTNU); University of Oslo;
   University of Amsterdam; University of Bergen; University of Bergen
RP Dahl, O (通讯作者)，Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway.
EM olav.dahl@helse-bergen.no
RI Akslen, Lars/C-1202-2017
CR Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Baak JPA, 2009, BREAST CANCER RES TR, V115, P241, DOI 10.1007/s10549-008-0126-y
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brown DC, 2002, HISTOPATHOLOGY, V40, P2, DOI 10.1046/j.1365-2559.2002.01343.x
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Chen HM, 1996, GENOMICS, V38, P30, DOI 10.1006/geno.1996.0588
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Dahl O, 2009, ACTA ONCOL, V48, P368, DOI 10.1080/02841860902755244
   de Gramont A, 2007, SEMIN ONCOL, V34, pS37, DOI 10.1053/j.seminoncol.2007.01.004
   Kimura T, 2000, INT J ONCOL, V16, P55
   LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447
   MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602
   Palmqvist R, 1999, BRIT J CANCER, V79, P577, DOI 10.1038/sj.bjc.6690091
   Salminen E, 2005, WORLD J GASTROENTERO, V11, P3245, DOI 10.3748/wjg.v11.i21.3245
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   WOLMARK N, 1988, JNCI-J NATL CANCER I, V80, P30, DOI 10.1093/jnci/80.1.30
NR 19
TC 127
Z9 138
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 13
PY 2009
VL 101
IS 8
BP 1282
EP 1289
DI 10.1038/sj.bjc.6605333
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 506HZ
UT WOS:000270767200009
PM 19773751
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Hoque, MO
   Prencipe, M
   Poeta, ML
   Barbano, R
   Valori, VM
   Copetti, M
   Gallo, AP
   Brait, M
   Maiello, E
   Apicella, A
   Rossiello, R
   Zito, F
   Stefania, T
   Paradiso, A
   Carella, M
   Dallapiccola, B
   Murgo, R
   Carosi, I
   Bisceglia, M
   Fazio, VM
   Sidransky, D
   Parrella, P
AF Hoque, Mohammad Obaidul
   Prencipe, Maria
   Poeta, Maria Luana
   Barbano, Raffaela
   Valori, Vanna Maria
   Copetti, Massimiliano
   Gallo, Antonietta Pia
   Brait, Mariana
   Maiello, Evaristo
   Apicella, Adolfo
   Rossiello, Raffaele
   Zito, Francesco
   Stefania, Tommasi
   Paradiso, Angelo
   Carella, Massimo
   Dallapiccola, Bruno
   Murgo, Roberto
   Carosi, Illuminato
   Bisceglia, Michele
   Fazio, Vito Michele
   Sidransky, David
   Parrella, Paola
TI Changes in CpG Islands Promoter Methylation Patterns during Ductal
   Breast Carcinoma Progression
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID BETA-CATENIN EXPRESSION; E-CADHERIN; IN-SITU; HYPERMETHYLATION PROFILE;
   ABERRANT METHYLATION; GENETIC ALTERATIONS; LOBULAR CARCINOMA; DNA
   METHYLATION; EARLY EVENT; CANCER
AB Aberrant promoter methylation of several known or putative tumor suppressor genes occurs frequently during carcinogenesis, and this epigenetic change has been considered as a potential molecular marker for cancer. We examined the methylation status of nine genes (APC, CDH1, CTNNB1, TIMP3, ESR1, GSTP1, MGMT, THBS1, and TMS1), by quantitative methylation specific PCR. Synchronous preinvasive lesions (atypical ductal hyperplasia and/or ductal carcinoma in situ) and invasive ductal breast carcinoma from 52 patients, together with pure lesions from 24 patients and 12 normal tissues paired to tumor and 20 normal breast distant from tumor were analyzed. Aberrant promoter methylation was detected in both preinvasive and invasive lesions for genes APC, CDH1, CTNNB1, TIMP3, ESR1, and GSTP1. However, hierarchical mixed model and Generalized Estimating Equations model analyses showed that only APC, CDH1, and CTNNB1 promoter regions showed a higher frequency and methylation levels in pathologic samples when compared with normal breast. Whereas APC and CTNNB1 did not show differences in methylation levels or frequencies, CDH1 showed higher methylation levels in invasive tumors as compared with preinvasive lesions (P < 0.04, Mann-Whitney test with permutation correction). The analysis of APC, CDH1, and CTNNB1 methylation status was able to distinguish between normal and pathologic samples with a sensitivity of 67% (95% confidence interval, 60-71%) and a specificity of 75% (95% confidence interval, 69-81%). Our data point to the direct involvement of APC, CDH1, and CTNNB1 promoter methylation in the early stages of breast cancer progression and suggest that they may represent a useful tool for the detection of tumor cells in clinical specimens. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2694-2700)
C1 [Prencipe, Maria; Barbano, Raffaela; Gallo, Antonietta Pia; Fazio, Vito Michele; Parrella, Paola] IRCCS Casa Sollievo Sofferenza, Oncol Res Lab, I-71013 San Giovanni Rotondo, FG, Italy.
   [Valori, Vanna Maria; Maiello, Evaristo] IRCCS Casa Sollievo Sofferenza, Dept Oncoemathol, I-71013 San Giovanni Rotondo, FG, Italy.
   [Copetti, Massimiliano] IRCCS Casa Sollievo Sofferenza, Biostat Unit, I-71013 San Giovanni Rotondo, FG, Italy.
   [Carella, Massimo; Dallapiccola, Bruno] IRCCS Casa Sollievo Sofferenza, Med Genet Unit, I-71013 San Giovanni Rotondo, FG, Italy.
   [Murgo, Roberto] IRCCS Casa Sollievo Sofferenza, Dept Thorac Surg, Breast Unit RM, I-71013 San Giovanni Rotondo, FG, Italy.
   [Carosi, Illuminato; Bisceglia, Michele] IRCCS Casa Sollievo Sofferenza, Dept Pathol, I-71013 San Giovanni Rotondo, FG, Italy.
   [Hoque, Mohammad Obaidul; Poeta, Maria Luana; Brait, Mariana; Sidransky, David] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
   [Poeta, Maria Luana; Fazio, Vito Michele] Univ Campus Biomed, CIR, Lab Mol Med & Biotechnol, Rome, Italy.
   [Apicella, Adolfo; Rossiello, Raffaele] Univ Naples 2, Dept Pathol L Armanni, Naples, Italy.
   [Zito, Francesco] Natl Canc Inst, Dept Pathol, Bari, Italy.
   [Stefania, Tommasi; Paradiso, Angelo] Natl Canc Inst, Clin Expt Oncol Lab, Bari, Italy.
   [Stefania, Tommasi; Paradiso, Angelo] Natl Canc Inst, Dept Donna, Bari, Italy.
C3 IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo Della
   Sofferenza; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo
   Della Sofferenza; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa
   Sollievo Della Sofferenza; Johns Hopkins University; University Campus
   Bio-Medico - Rome Italy; Universita della Campania Vanvitelli; IRCCS
   Istituto Tumori Bari Giovanni Paolo II; IRCCS Istituto Tumori Bari
   Giovanni Paolo II; IRCCS Istituto Tumori Bari Giovanni Paolo II
RP Parrella, P (通讯作者)，IRCCS Casa Sollievo Sofferenza, Oncol Res Lab, Viale Padre Pio, I-71013 San Giovanni Rotondo, FG, Italy.
EM pparrella@operapadrepio.it
RI poeta, maria/G-6014-2015; Zito, Francesco/AAQ-8972-2020; paradiso,
   angelo/J-9457-2018; Maiello, Evaristo/C-5224-2017; PARRELLA,
   PAOLA/D-8895-2011; Dallapiccola, Bruno/K-8692-2016; Tommasi,
   Stefania/J-6732-2012; Carella, Massimo/A-2804-2014; COPETTI,
   MASSIMILIANO/K-3186-2016; Barbano, Raffaela/H-3640-2016; Fazio, Vito
   Michele/H-3007-2016
OI Maiello, Evaristo/0000-0003-3890-3435; PARRELLA,
   PAOLA/0000-0001-6031-9636; POETA, Maria Luana/0000-0002-6364-727X;
   Prencipe, Maria/0000-0002-8864-1560; Dallapiccola,
   Bruno/0000-0002-5031-1013; Tommasi, Stefania/0000-0002-2157-2978;
   Carella, Massimo/0000-0002-6830-6829; COPETTI,
   MASSIMILIANO/0000-0002-7960-5947; Hoque, Mohammad
   Obaidul/0000-0001-6701-9978; Barbano, Raffaela/0000-0002-4533-4157;
   Fazio, Vito Michele/0000-0002-7751-1867; Brait,
   Mariana/0000-0002-1652-8921
FU AIRC (Associazione Italiana Ricerca sul Cancro); Italian Ministry of
   Health [RC2009, 4 RFPS-2006-2-340202.04]; UICC; Flight Attendant Medical
   Research Institute Young Clinical Scientist Award; International
   Association for the Study of Lung and Career development [P50 CA098252]
FX A grant from AIRC (Associazione Italiana Ricerca sul Cancro) and
   partially supported by grants from the Italian Ministry of Health
   (RC2009, and Progetto Integrato Oncologia Progetto no. 4
   RFPS-2006-2-340202.04). M. Prencipe was partially supported by an ICRETT
   grant from the UICC. Dr. Hoque is supported by Flight Attendant Medical
   Research Institute Young Clinical Scientist Award, International
   Association for the Study of Lung and Career development award from
   SPORE in Cervical Cancer Grants P50 CA098252. Dr. Hoque is a Paid
   consultant to Oncomethylome Sciences, SA.
CR Acs G, 2001, AM J CLIN PATHOL, V115, P85
   [Anonymous], 2001, Generalized, linear, and mixed models (wiley series in probability and statistics
   [Anonymous], 1993, An Introduction to the Bootstrap
   BARTOW SA, 1987, CANCER-AM CANCER SOC, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165
   DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   Heagerty P., 2002, Analysis of Longitudinal Data
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Karayiannakis AJ, 2001, EUR J SURG ONCOL, V27, P31, DOI 10.1053/ejso.1999.1017
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lo YMD, 1999, CANCER RES, V59, P3899
   Näthke I, 2004, J CELL SCI, V117, P4873, DOI 10.1242/jcs.01313
   Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Parrella P, 2005, CAN META BIO TREAT, V7, P81
   Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   RECHT A, 1994, EUR J CANCER, V30A, P1895, DOI 10.1016/0959-8049(94)90611-4
   Reis JS, 2003, BREAST CANCER RES, V5, P313, DOI 10.1186/bcr650
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020
   Yoshida R, 2001, INT J ONCOL, V18, P513
   Yu Q, 2009, BREAST CANCER RES TR, V114, P433, DOI 10.1007/s10549-008-0029-y
NR 44
TC 66
Z9 71
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2009
VL 18
IS 10
BP 2694
EP 2700
DI 10.1158/1055-9965.EPI-08-0821
PG 7
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 505NZ
UT WOS:000270702100017
PM 19789364
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Yazici, H
   Terry, MB
   Cho, YH
   Senie, RT
   Liao, YY
   Andrulis, I
   Santella, RM
AF Yazici, Hulya
   Terry, Mary Beth
   Cho, Yoon Hee
   Senie, Ruby T.
   Liao, Yuyan
   Andrulis, Irene
   Santella, Regina M.
TI Aberrant Methylation of <i>RASSF1A</i> in Plasma DNA Before Breast
   Cancer Diagnosis in the Breast Cancer Family Registry
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; EPIGENETIC
   INACTIVATION; CELL-FREE; LUNG; 3P21.3; SERUM; CARCINOGENESIS; MARKER;
   LOCUS
AB In addition to classic genetic mechanisms such as deletions and mutations, growth regulatory genes can be inactivated via methylation of cytosine-residues in their promoter regions. Hypermethylation of promoter CpG islands is now recognized as an important and early event in carcinogenesis. Detection of methylated DNA in serum or plasma has been suggested to be a marker for early cancer development. We examined methylation changes in RASSF1A, a growth regulatory gene in plasma DNA from blood collected before diagnosis from women with breast cancer and from controls. Samples were from two sets of subjects, 28 women with breast cancer and 10 of their unaffected siblings, and 33 women with breast cancer and 29 age- and ethnicity-matched population-based controls. Using methylation specific PCR, we found 11 of 61 (18%) cases were positive for methylation of RASSF1A in their plasma DNA collected before diagnosis. Two of 10 healthy high-risk sibling controls (20%) had plasma DNA positive for RASSF1A methylation in their plasma DNA compared with 0 of 29 (0%) population-based controls. Tumor tissue was available for 12 cases and all were positive for RASSF1A methylation. These results, if replicated, suggest that aberrant promoter hypermethylation in serum/plasma DNA may be common among high-risk women and may be present years before cancer diagnosis. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2723-5)
C1 [Yazici, Hulya; Cho, Yoon Hee; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Terry, Mary Beth; Senie, Ruby T.; Liao, Yuyan] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.
   [Andrulis, Irene] Univ Toronto, Mt Sinai Hosp, Dept Lab Med & Pathobiol, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   [Andrulis, Irene] Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada.
   [Andrulis, Irene] Ontario Canc Genet Network, Div Res, Toronto, ON, Canada.
C3 Columbia University; Columbia University; University of Toronto; Sinai
   Health System Toronto; Lunenfeld Tanenbaum Research Institute;
   University of Toronto; University of Toronto; University Health Network
   Toronto
RP Yazici, H (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 630 W 168th St, New York, NY 10032 USA.
EM hulyayazici@yahoo.com
RI Cho, Yoon/AAN-6560-2021; YAZICI, HULYA/AAU-9491-2021; Andrulis,
   Irene/E-7267-2013
OI Terry, Mary Beth/0000-0002-4106-5033
FU National Cancer Institute [CA-06-503]
FX National Cancer Institute under RFA # CA-06-503 and through cooperative
   agreements with members of the Breast Cancer Family Registry and P.I.s.
   The content of this manuscript does not necessarily reflect the views or
   policies of the National Cancer Institute or any of the collaborating
   centers in the Cancer Family Registry, nor does mention of trade names,
   commercial products, or organizations imply endorsement by the U.S.
   Government or the Cancer Family Registry.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hu XC, 2003, ONCOL REP, V10, P1811
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, CLIN CHEM, V50, P1065, DOI 10.1373/clinchem.2003.030387
   Papadopoulou E, 2006, ANN NY ACAD SCI, V1075, P235, DOI 10.1196/annals.1368.032
   Silva JM, 1999, CANCER RES, V59, P3251
   Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
   Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900
NR 21
TC 20
Z9 26
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2009
VL 18
IS 10
BP 2723
EP 2725
DI 10.1158/1055-9965.EPI-08-1237
PG 3
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 505NZ
UT WOS:000270702100021
PM 19755643
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Kure, S
   Nosho, K
   Baba, Y
   Irahara, N
   Shima, K
   Ng, K
   Meyerhardt, JA
   Giovannucci, EL
   Fuchs, CS
   Ogino, S
AF Kure, Shoko
   Nosho, Katsuhiko
   Baba, Yoshifumi
   Irahara, Natsumi
   Shima, Kaori
   Ng, Kimmie
   Meyerhardt, Jeffrey A.
   Giovannucci, Edward L.
   Fuchs, Charles S.
   Ogino, Shuji
TI Vitamin D Receptor Expression Is Associated with <i>PIK3CA</i> and
   <i>KRAS</i> Mutations in Colorectal Cancer
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; HUMAN COLONIC MUCOSA; MICROSATELLITE
   INSTABILITY; DNA METHYLATION; D SYSTEM; LINE-1 HYPOMETHYLATION; CELL
   CARCINOMAS; BRAF MUTATION; BREAST-CANCER; GROWTH
AB Vitamin D is associated with decreased risks of various cancers, including colon cancer. The vitamin D receptor (VDR) is a transcription factor, which plays an important role in cellular differentiation and inhibition of proliferation. A link between VDR and the RAS-mitogen-activated protein kinase NAM or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested. However, the prognostic role of VDR expression or its relationship with PIK3CA or KRAS mutation remains uncertain. Among 619 colorectal cancers in two prospective cohort studies, 233 (38%) tumors showed VDR overexpression by immunohistochemistry. We analyzed for PIK3CA and KRAS mutations and LINE-1 methylation by Pyrosequencing, microsatellite instability (MSI), and DNA methylation (epigenetic changes) in eight CpG island methylator phenotype (CIMP)-specific promoters [CACNA1G, CDKN2A (p16), CRAM, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1] by MethyLight (real-time PCR). VDR overexpression was significantly associated with KRAS mutation (odds ratio, 1.55; 95% confidence interval, 1.11-2.16) and PIK3CA mutation (odds ratio, 2.17; 95% confidence interval, 1.36-3.47), both of which persisted in multivariate logistic regression analysis. VDR was not independently associated with body mass index, family history of colorectal cancer, tumor location (colon versus rectum), stage, tumor grade, signet ring cells, CIMP, MSI, LINE-1 hypomethylation, BRAF, p53, p21, beta-catenin, or cyclooxygenase-2. VDR expression was not significantly related with patient survival, prognosis, or clinical outcome. In conclusion, VDR overexpression in colorectal cancer is independently associated with PIK3CA and KRAS mutations. Our data support potential interactions between the VDR, RAS-MAPK and PI3K-AKT pathways, and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR. (Cancer Epidemiol Biomarkers Prev 20091-18(10):2765-72)
C1 [Kure, Shoko; Nosho, Katsuhiko; Baba, Yoshifumi; Irahara, Natsumi; Shima, Kaori; Ng, Kimmie; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Giovannucci, Edward L.; Fuchs, Charles S.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Kure, Shoko; Nosho, Katsuhiko; Baba, Yoshifumi; Irahara, Natsumi; Shima, Kaori; Ng, Kimmie; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Brigham & Women's
   Hospital; Harvard University; Harvard Medical School
RP Ogino, S (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol,Brigham & Womens Hosp, 44 Binney St,Room JF-215C, Boston, MA 02115 USA.
EM shuji_ogino@dfci.harvard.edu
RI Giovannucci, Edward/ADE-8028-2022; kure, shoko/L-6650-2019; Shima,
   Kaori/HTO-3717-2023; Meyerhardt, Jeffrey/IAP-4528-2023
OI Ogino, Shuji/0000-0002-3909-2323
FU NIH [P01 CA87969, P01 CA55075, P50 CA127003, K07 CA122826]; Bennett
   Family Fund; Entertainment Industry Foundation National Colorectal
   Cancer Research Alliance; Japan Society for Promotion of Science;
   American Society of Clinical Oncology Cancer Foundation Young
   Investigator Award; Charles A. King Trust Fellowship Award, Bank of
   America, Co-Trustee
FX NIH grants P01 CA87969 IS. Hankinson), P01 CA55075 (W. Willett), P50
   CA127003 (C.S. Fuchs), and K07 CA122826 (S. Ogino); Bennett Family Fund;
   and Entertainment Industry Foundation National Colorectal Cancer
   Research Alliance. K. Nosho was supported by a fellowship grant from the
   Japan Society for Promotion of Science. K. Ng was supported by the
   American Society of Clinical Oncology Cancer Foundation Young
   Investigator Award and the Charles A. King Trust Fellowship Award, Bank
   of America, Co-Trustee.
CR Ally MS, 2009, CANCER EPIDEM BIOMAR, V18, P922, DOI 10.1158/1055-9965.EPI-08-0703
   Bapat B, 2009, CANCER EPIDEM BIOMAR, V18, P967, DOI 10.1158/1055-9965.EPI-08-0878
   Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388
   BEATY MM, 1993, J NUTR, V123, P144, DOI 10.1093/jn/123.1.144
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Cross HS, 2005, J STEROID BIOCHEM, V97, P121, DOI 10.1016/j.jsbmb.2005.06.005
   Cross HS, 2001, STEROIDS, V66, P287, DOI 10.1016/S0039-128X(00)00153-7
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Dunn SE, 1998, CANCER RES, V58, P3353
   EISMAN JA, 1987, CANCER RES, V47, P21
   English DR, 2008, CANCER EPIDEM BIOMAR, V17, P1774, DOI 10.1158/1055-9965.EPI-08-0091
   Figueiredo JC, 2009, CANCER EPIDEM BIOMAR, V18, P1041, DOI 10.1158/1055-9965.EPI-08-0926
   Friedrich M, 2003, RECENT RES CANCER, V164, P239
   GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7
   GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3
   Giovannucci E, 2006, JNCI-J NATL CANCER I, V98, P451, DOI 10.1093/jnci/djj101
   González-Sancho JM, 2006, ANTICANCER RES, V26, P2669
   Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583
   Hughes PJ, 2006, J CELL BIOCHEM, V98, P590, DOI 10.1002/jcb.20787
   Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5<730::AID-IJC11>3.0.CO;2-Q
   Larriba MJ, 2009, CARCINOGENESIS, V30, P1459, DOI 10.1093/carcin/bgp140
   Kawasaki T, 2007, NEOPLASIA, V9, P569, DOI 10.1593/neo.07334
   Lamprecht SA, 2001, ANN NY ACAD SCI, V952, P73, DOI 10.1111/j.1749-6632.2001.tb02729.x
   Matusiak D, 2005, CANCER EPIDEM BIOMAR, V14, P2370, DOI 10.1158/1055-9965.EPI-05-0257
   Mitschele T, 2004, LAB INVEST, V84, P693, DOI 10.1038/labinvest.3700096
   Ng K, 2008, J CLIN ONCOL, V26, P2984, DOI 10.1200/JCO.2007.15.1027
   Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336
   Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933
   Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5
   Ogino S, 2006, J PATHOL, V210, P147, DOI 10.1002/path.2030
   Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482
   Ogino S, 2005, CLIN CANCER RES, V11, P6650, DOI 10.1158/1078-0432.CCR-05-0738
   Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470
   Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082
   Ogino S, 2007, J MOL DIAGN, V9, P305, DOI 10.2353/jmoldx.2007.060170
   Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Ogino S, 2009, J CLIN ONCOL, V27, P1477, DOI 10.1200/JCO.2008.18.6544
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Ogino S, 2008, J NATL CANCER I, V100, P1734, DOI 10.1093/jnci/djn359
   Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512
   Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200
   Reichrath J, 2004, J CUTAN PATHOL, V31, P224, DOI 10.1111/j.0303-6987.2003.00183.x
   SHABAHANG M, 1994, CANCER RES, V54, P4057
   Sheinin Y, 2000, VIRCHOWS ARCH, V437, P501, DOI 10.1007/s004280000275
   Slattery ML, 2009, MUTAT RES-FUND MOL M, V660, P12, DOI 10.1016/j.mrfmmm.2008.10.001
   Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871
   Solomon C, 2001, RADIAT RES, V155, P156, DOI 10.1667/0033-7587(2001)155[0156:VDRIRT]2.0.CO;2
   Spina CS, 2007, J STEROID BIOCHEM, V103, P757, DOI 10.1016/j.jsbmb.2006.12.040
   Stedman L, 2003, NUTR CANCER, V45, P93, DOI 10.1207/S15327914NC4501_11
   Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022
   Weinstein SJ, 2008, CANCER EPIDEM BIOMAR, V17, P3233, DOI 10.1158/1055-9965.EPI-08-0459
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wu K, 2007, J NATL CANCER I, V99, P1120, DOI 10.1093/jnci/djm038
   Zhang YY, 2006, CELL CYCLE, V5, P447, DOI 10.4161/cc.5.4.2467
NR 55
TC 54
Z9 62
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2009
VL 18
IS 10
BP 2765
EP 2772
DI 10.1158/1055-9965.EPI-09-0490
PG 8
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 505NZ
UT WOS:000270702100027
PM 19789368
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Alvarez, S
   Khanwalkar, H
   Alvarez, R
   Erb, C
   Martínez, C
   Rodríguez-Barrios, F
   Germain, P
   Gronemeyer, H
   de Lera, AR
AF Alvarez, Susana
   Khanwalkar, Harshal
   Alvarez, Rosana
   Erb, Cathie
   Martinez, Claudio
   Rodriguez-Barrios, Fatima
   Germain, Pierre
   Gronemeyer, Hinrich
   de Lera, Angel R.
TI C3 Halogen and C8" Substituents on Stilbene Arotinoids Modulate Retinoic
   Acid Receptor Subtype Function
SO CHEMMEDCHEM
LA English
DT Article
DE agonists; antagonists; arotinoids; molecular modeling; retinoid
   receptors; transactivation
ID NUCLEAR HORMONE-RECEPTORS; HIV-1 REVERSE-TRANSCRIPTASE; LIGAND-BINDING
   DOMAINS; CELL LUNG-CANCER; STRUCTURAL BASIS; BREAST-CANCER; RAR-GAMMA;
   NEUTRAL ANTAGONISTS; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR
AB The synthesis and biological evaluation of the entire series of C3-halogenated derivatives and bulkier substituents at the C8 '' position of the parent stilbene-based RAR beta-selective agonist BMS641 4c was undertaken. The synthesis uses an E-selective Horner-Wadsworth-Emmons (HWE) condensation of C8-substituted C5-dimethyl dihydronaphthaldehyde and the benzylic phosphonates derived from the C3-halogenated benzoates to construct the stilbene skeleton. Transactivation studies revealed the synergistic effect of small halogen atoms at C3 (F, CI) and the moderately bulky phenyl group at C8 '' (in 4 b and 4 c) to achieve RAR beta selectivity. Our results, supported by computational studies, provide a structural rationale for the mixed agonist-antagonist activities of these arotinoids, which are potent agonists of the RAR beta subtype and antagonists of the RAR alpha paralogue. Moreover, transitions from partial agonists to inverse agonists and antagonists can be accomplished with the incorporation of the same halogen atoms into the structures of known modulators BMS701 (5a) and BMS493 (6a), which have bulkier substituents than phenyl (p-tolyl and phenylethynyl, respectively) at C8 ''. Conversely, incorporation of halogen atoms in 6 a converted the ligand from an RAR beta inverse agonist (6 b) to an antagonist (6 c) or an agonist (6 d). Amazingly, 6 a-c commonly acted as inverse agonists for RARa, while 6 d and 6 e acted as regular RAR alpha antagonists, not affecting co-repressor interaction. In the case of the mixed agonist/antagonist 5a, C3-halogenation yields inverse RAR alpha and RAR beta agonists (5 b-d) with the exception of iodinated 5 e, which is a regular antagonist for both these receptors. Because RAR beta gene expression is frequently deleted or epigenetically silenced in several tumor cells, the novel repertoire of receptor and function-selective RAR agonists, mixed agonist/antagonists, regular antagonists, and inverse agonists will be useful in the elucidation of the mechanism of tumor suppression by retinoids.
C1 [Alvarez, Susana; Alvarez, Rosana; Martinez, Claudio; Rodriguez-Barrios, Fatima; de Lera, Angel R.] Univ Vigo, Dept Quim Organ, Fac Quim, Vigo 36310, Spain.
   [Khanwalkar, Harshal; Germain, Pierre; Gronemeyer, Hinrich] ULP, Dept Canc Biol, IGBMC, CNRS,INSERM,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.
   [Germain, Pierre] CNRS, Ctr Biochim Struct, Dept Struct Canc & Virulence, INSERM,U5048,U554, F-34090 Montpellier, France.
C3 Universidade de Vigo; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; Centre National de la Recherche Scientifique
   (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier
RP Alvarez, S (通讯作者)，Univ Vigo, Dept Quim Organ, Fac Quim, Vigo 36310, Spain.
EM hg@igbmc.fr; qolero@uvigo.es
RI Rodríguez, Rosana/AAA-1998-2019; susana, alvarez rodriguez/L-9941-2015;
   Martinez, Claudio/N-7231-2015; Gronemeyer, Hinrich/G-6240-2011
OI susana, alvarez rodriguez/0000-0003-2420-4721; Martinez,
   Claudio/0000-0003-0390-9941; Rodriguez de Lera,
   Angel/0000-0001-6896-9078; Germain, Pierre/0000-0003-2962-9593;
   Gronemeyer, Hinrich/0000-0001-9454-2449
FU E.U. [QLK3-CT2002-02029, LSHM-CT-2005-018652]; Spanish MEC-FEDER
   [SAF2004-07131, SAF2007-63880]; Association for International Cancer
   Research; Ligue National Contre le Cancer
FX This work was supported by grants from the E.U. (QLK3-CT2002-02029,
   "Anticancer Retinoids"; LSHM-CT-2005-018652 "Crescendo"), the Spanish
   MEC-FEDER (SAF2004-07131, Research Contract to S.A.; SAF2007-63880, Juan
   de la Cierva Contract to FR.-B.), the Association for International
   Cancer Research (H.G.), and the Ligue National Contre le Cancer
   (laboratoire labelise) (H.G.).
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397
   Alvarez S, 2007, INT J BIOCHEM CELL B, V39, P1406, DOI 10.1016/j.biocel.2007.02.010
   Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0
   Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4
   Castillo L, 1997, CLIN CANCER RES, V3, P2137
   Chandra V, 2008, NATURE, V456, P350, DOI 10.1038/nature07413
   CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   de Lera AR, 2007, NAT REV DRUG DISCOV, V6, P811, DOI 10.1038/nrd2398
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Frisch M.J., 2001, GAUSSIAN 98 REVISION
   Géhin M, 1999, CHEM BIOL, V6, P519, DOI 10.1016/S1074-5521(99)80084-2
   Germain P, 2004, EMBO REP, V5, P877, DOI 10.1038/sj.embor.7400235
   Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a
   Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4
   Germain P, 2009, CHEM BIOL, V16, P479, DOI 10.1016/j.chembiol.2009.03.008
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551
   Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6
   Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5
   Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069
   Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7
   JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003
   Klaholz BP, 2002, STRUCTURE, V10, P1197, DOI 10.1016/S0969-2126(02)00828-6
   Klaholz BP, 2000, P NATL ACAD SCI USA, V97, P6322, DOI 10.1073/pnas.97.12.6322
   Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199
   Klaholz BP, 2000, J MOL BIOL, V302, P155, DOI 10.1006/jmbi.2000.4032
   Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692
   Laudet V., 2002, The Nuclear Receptor Facts Book
   LOELIGER P, 1980, EUR J MED CHEM, V15, P9
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Lund BW, 2009, J MED CHEM, V52, P1540, DOI 10.1021/jm801532e
   Lund BW, 2005, J MED CHEM, V48, P7517, DOI 10.1021/jm050891r
   Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Memic A, 2008, CHEMBIOCHEM, V9, P2793, DOI 10.1002/cbic.200800572
   Métivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626
   Metrangolo P, 2005, ACCOUNTS CHEM RES, V38, P386, DOI 10.1021/ar0400995
   Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209
   Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198
   Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059
   RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0
   Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243
   Rodríguez-Barrios F, 2005, J AM CHEM SOC, V127, P7570, DOI 10.1021/ja042289g
   Rodríguez-Barrios F, 2001, J MED CHEM, V44, P1853, DOI 10.1021/jm001095i
   Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590
   Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Teng M, 1997, J MED CHEM, V40, P2445, DOI 10.1021/jm9703911
   Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697
   Vuligonda V, 1999, BIOORG MED CHEM LETT, V9, P743, DOI 10.1016/S0960-894X(99)00077-3
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a
   Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624
   Xu XC, 1997, CANCER RES, V57, P4992
   Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6
NR 62
TC 24
Z9 24
U1 1
U2 19
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD OCT
PY 2009
VL 4
IS 10
BP 1630
EP 1640
DI 10.1002/cmdc.200900214
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 506IG
UT WOS:000270767900008
PM 19670208
DA 2025-01-12
ER

PT J
AU Rousseaux, S
   Khochbin, S
AF Rousseaux, Sophie
   Khochbin, Saadi
TI New hypotheses for large-scale epigenome alterations in somatic cancer
   cells: a role for male germ-cell-specific regulators
SO EPIGENOMICS
LA English
DT Article
DE biomarker; BRDT; cancer; chromatin; GAGE; histone; immunotherapy; MAGE;
   spermatogenesis; spermiogenesis; SPO11
ID CYTOLYTIC T-LYMPHOCYTES; TESTIS ANTIGENS; BREAST-CANCER; CANCER/TESTIS
   ANTIGENS; MULTIPLE-MYELOMA; IMMUNE-RESPONSES; TUMOR-CELLS; LUNG-CANCER;
   HISTONE H3; MOUSE SPERMATOGENESIS
AB Oncogenic cell transformation is consistently associated with alterations of the cell epigenome leading to aberrant gene repression and activation. Some of these events, such as the DNA-methylation-based silencing of tumor suppressor genes, are considered to be oncogenic themselves. A much less-studied consequence of these epigenetic misregulations is the abnormal activation of tissue-specific genes in precancerous and transformed cells. Here, we explore the idea that the aberrant expression of germ-cell-specific genes in somatic cancer cells could contribute to malignant cell transformation and cancer progression. Indeed, a significant number of papers have reported the abnormal activation of germ cell-specific genes in various somatic cancers (known as cancer testis [C/T] antigens or factors). Although in most cases the physiological function of these genes remains unknown, functional investigations suggest that they can act as potent genome, epigenome and cellular reorganizers. Hence, in view of the existing literature, we discuss the hypothesis that C/T activation in somatic cells is not only a consequence of global epigenetic deregulation, but also a cause of further large-scale alterations of the epigenome, which themselves have direct oncogenic consequences for the affected cells. Finally, we highlight the fact that C/T factors have the potential to serve as valuable markers for cancer detection, as well as provide promising targets for developing new therapeutical strategies.
C1 [Rousseaux, Sophie; Khochbin, Saadi] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, F-38700 Grenoble, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)
RP Khochbin, S (通讯作者)，Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, F-38700 Grenoble, France.
EM khochbin@ujf-grenoble.fr
RI Rousseaux, Sophie/G-1697-2013; Khochbin, Saadi/M-8090-2013
OI Rousseaux, Sophie/0000-0001-5246-5350; Khochbin,
   Saadi/0000-0002-0455-0857
FU ANR; ARC; Delegation a la Recherche Clinique; INCa
FX We wish to acknowledge the support of ANR programs 'EPISPERM' and
   'EMPREINTE; INCa ('CT-Lymph'), ARC ('ARECA' program) and 'Delegation a
   la Recherche Clinique'. The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript apart from those disclosed.
CR Atanackovic D, 2007, BLOOD, V109, P1103, DOI 10.1182/blood-2006-04-014480
   Atanackovic D, 2006, CANCER BIOL THER, V5, P1218, DOI 10.4161/cbt.5.9.3174
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337
   BOCKAXELSEN J, 2007, P NATL ACAD SCI US
   BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0
   Boussouar F, 2008, CELL CYCLE, V7, P3499, DOI 10.4161/cc.7.22.6975
   Caron C, 2005, PROG MOLEC, V38, P65
   Chen QY, 2004, P NATL ACAD SCI USA, V101, P9363, DOI 10.1073/pnas.0403271101
   Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919
   Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914
   Collins RE, 2005, J BIOL CHEM, V280, P5563, DOI 10.1074/jbc.M410483200
   Condomines M, 2007, J IMMUNOL, V178, P3307, DOI 10.4049/jimmunol.178.5.3307
   Cooper CDO, 2006, LEUKEMIA, V20, P2172, DOI 10.1038/sj.leu.2404424
   Costa FF, 2007, STEM CELLS, V25, P707, DOI 10.1634/stemcells.2006-0469
   D'Alessio AC, 2007, MOL CELL BIOL, V27, P7462, DOI 10.1128/MCB.01120-07
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Darcy V, 2006, CLIN CANCER RES, V12, P5978, DOI 10.1158/1078-0432.CCR-05-2731
   Davis ID, 2004, P NATL ACAD SCI USA, V101, P10697, DOI 10.1073/pnas.0403572101
   De Backer O, 1999, CANCER RES, V59, P3157
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gokul G, 2007, EPIGENETICS-US, V2, P80, DOI 10.4161/epi.2.2.3692
   Govin J, 2006, E SCHERING RES FDN W, V57, P155
   Govin J, 2005, TRENDS BIOCHEM SCI, V30, P357, DOI 10.1016/j.tibs.2005.05.001
   Govin J, 2004, EUR J BIOCHEM, V271, P3459, DOI 10.1111/j.1432-1033.2004.04266.x
   Govin J, 2007, J CELL BIOL, V176, P283, DOI 10.1083/jcb.200604141
   Greiner J, 2007, LEUKEMIA RES, V31, P1, DOI 10.1016/j.leukres.2006.05.016
   Grizzi F, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-23
   Hazzouri M, 2000, EUR J CELL BIOL, V79, P950, DOI 10.1078/0171-9335-00123
   Heidebrecht HJ, 2006, CLIN CANCER RES, V12, P4804, DOI 10.1158/1078-0432.CCR-06-0186
   Hoeppner Luke H, 2006, Cancer Immun, V6, P1
   Hoffmann MJ, 2006, BIOCHEM PHARMACOL, V72, P1577, DOI 10.1016/j.bcp.2006.06.020
   Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Jäger E, 2006, P NATL ACAD SCI USA, V103, P14453, DOI 10.1073/pnas.0606512103
   Jäger E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497
   James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678
   Kalejs M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-4
   Kang Y, 2007, ONCOGENE, V26, P4394, DOI 10.1038/sj.onc.1210218
   Karpf AR, 2007, CURR OPIN MOL THER, V9, P231
   Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0
   Kholmanskikh O, 2008, INT J CANCER, V122, P777, DOI 10.1002/ijc.23140
   Kisseleva-Romanova E, 2006, EMBO J, V25, P3576, DOI 10.1038/sj.emboj.7601235
   Kondo T, 2007, CLIN CANCER RES, V13, P4713, DOI 10.1158/1078-0432.CCR-07-0618
   Laduron S, 2004, NUCLEIC ACIDS RES, V32, P4340, DOI 10.1093/nar/gkh735
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lim JH, 2005, INT J CANCER, V116, P200, DOI 10.1002/ijc.21007
   Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   Loukinov D, 2006, J CELL BIOCHEM, V98, P1037, DOI 10.1002/jcb.20953
   Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J
   Marchand M, 2003, EUR J CANCER, V39, P70, DOI 10.1016/S0959-8049(02)00479-3
   Meklat F, 2007, BRIT J HAEMATOL, V136, P769, DOI 10.1111/j.1365-2141.2006.06484.x
   Meklat F, 2009, BRIT J HAEMATOL, V144, P660, DOI 10.1111/j.1365-2141.2008.07502.x
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103
   Natsume A, 2008, INT J CANCER, V122, P2542, DOI 10.1002/ijc.23407
   Odunsi K, 2007, P NATL ACAD SCI USA, V104, P12837, DOI 10.1073/pnas.0703342104
   Okada T, 2006, CLIN CANCER RES, V12, P191, DOI 10.1158/1078-0432.CCR-05-1206
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601
   Pavoni E, 2006, CANCER DETECT PREV, V30, P248, DOI 10.1016/j.cdp.2006.05.004
   Pivot-Pajot C, 2003, MOL CELL BIOL, V23, P5354, DOI 10.1128/MCB.23.15.5354-5365.2003
   Risinger JI, 2007, CLIN CANCER RES, V13, P1713, DOI 10.1158/1078-0432.CCR-05-2569
   Rousseaux S, 2005, GENE, V345, P139, DOI 10.1016/j.gene.2004.12.004
   Sahin U, 2000, CLIN CANCER RES, V6, P3916
   SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810
   Sahin U, 1998, INT J CANCER, V78, P387, DOI 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2
   Scanlan Matthew J, 2004, Cancer Immun, V4, P1
   Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276
   Schaefer CB, 2007, SCIENCE, V316, P398, DOI 10.1126/science.1137544
   Shang EY, 2007, DEVELOPMENT, V134, P3507, DOI 10.1242/dev.004481
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Susumu S, 2008, CANCER SCI, V99, P107, DOI 10.1111/j.1349-7006.2007.00654.x
   Szmania S, 2007, J IMMUNOTHER, V30, P847, DOI 10.1097/CJI.0b013e318158fcff
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Taylor BJ, 2005, J IMMUNOTHER, V28, P564, DOI 10.1097/01.cji.0000175685.36239.e5
   Taylor M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1749
   Türeci Ö, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2
   VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Westbrook VA, 2004, CLIN CANCER RES, V10, P101, DOI 10.1158/1078-0432.CCR-0647-3
   Woloszynska-Read Anna, 2007, Cancer Immun, V7, P21
   Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478
   Yang B, 2007, J INVEST DERMATOL, V127, P2123, DOI 10.1038/sj.jid.5700836
NR 94
TC 16
Z9 16
U1 0
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD OCT
PY 2009
VL 1
IS 1
BP 153
EP 161
DI 10.2217/EPI.09.1
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 601EM
UT WOS:000278041000019
PM 22122641
DA 2025-01-12
ER

PT J
AU Yang, ZQ
   Liu, G
   Bollig-Fischer, A
   Haddad, R
   Tarca, AL
   Ethier, SP
AF Yang, Zeng-Quan
   Liu, Gang
   Bollig-Fischer, Aliccia
   Haddad, Ramsi
   Tarca, Adi L.
   Ethier, Stephen P.
TI Methylation-associated silencing of SFRP1 with an 8p11-12 amplification
   inhibits canonical and non-canonical WNT pathways in breast cancers
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE SFRP1; amplification; DNA methylation; WNT pathway; breast cancer
ID GENE-EXPRESSION PATTERNS; MAMMARY EPITHELIAL-CELLS; ANTAGONIST SFRP1;
   AMPLICON; CARCINOMAS; TUMOR; HETEROZYGOSITY; CARCINOGENESIS;
   CHROMOSOME-8; EPIGENOMICS
AB Recently, we analysed the 8p11-12 genomic region for copy number and gene expression changes in a panel of human breast cancer cell lines and primary specimens. We found that SFRP1 (Secreted frizzled related protein 1) is frequently under expressed even in breast tumours with copy number increases in this genomic region. SFRP1 encodes a WNT signalling antagonist, and plays a role in the development of multiple solid tumour types. In this study, we analysed methylation-associated silencing of the SFRP1 gene in breast cancer cells with the 8p11-12 amplicon, and investigated the tumour suppressor properties of SFRP1 in breast cancer cells. SFRP1 expression was markedly reduced in both the breast cancer cell lines and primary tumour specimens relative to normal primary human mammary epithelial cells even when SFRP1 is amplified. Suppression of SFRP1 expression in breast cancer cells with an SFRP1 gene amplification is associated with SFRP1 promoter methylation. Furthermore, restoration of SFRP1 expression suppressed the growth of breast cancer cells in monolayer, and inhibited anchorage independent growth. We also examined the relationship between the silencing of SFRP1 gene and WNT signalling in breast cancer. Ectopic SFRP1 expression in breast cancer cells suppressed both canonical and non-canonical WNT signalling pathways, and SFRP1 expression was negatively associated with the expression of a subset of WNT responsive genes including RET and MSX2. rhus, downregulation of SFRP1 can be triggered by epigenetic and/or genetic events and may contribute to the tumourigenesis of human breast cancer through both canonical and non-canonical WNT signalling pathways. (C) 2009 UICC
C1 [Yang, Zeng-Quan; Liu, Gang; Bollig-Fischer, Aliccia; Haddad, Ramsi; Ethier, Stephen P.] Karmanos Canc Inst, Breast Canc Program, Dept Pathol, Detroit, MI USA.
   [Tarca, Adi L.] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA.
C3 Barbara Ann Karmanos Cancer Institute; Wayne State University
RP Yang, ZQ (通讯作者)，Barbara Ann Karmanos Canc Inst, 4100 John R HWCRC 815, Detroit, MI 48201 USA.
EM yangz@karmanos.org
RI Liu, Gang/AAU-3119-2020
OI Bollig-Fischer, Aliccia/0000-0003-4832-9457
FU National Institutes of Health [ROI CA 00724]; Department of Defense
   [DAMDI7-03-l-0459]
FX This work was supported by grants from the National Institutes of Health
   to Dr. Stephen P. Ethier and a grant from the Department of Defense
   Breast Cancer Program to Dr. Zeng-Quan Yang.Grant sponsor: National
   Institutes of Health; Grant number: ROI CA 00724: Grant sponsor:
   Department of Defense Breast Cancer Program; Grant number:
   DAMDI7-03-l-0459
CR Adélaïde J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218
   Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb
   Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Charafe-Jauffret E, 2002, INT J ONCOL, V21, P989
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06
   Dahiya R, 1998, INT J ONCOL, V12, P811
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007
   Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Janssen JWG, 2002, J HUM GENET, V47, P460, DOI 10.1007/s100380200065
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jung YS, 2006, CANCER RES, V66, P723, DOI 10.1158/0008-5472.CAN-05-3124
   Kestler HA, 2008, PHILOS T R SOC B, V363, P1333, DOI 10.1098/rstb.2007.2251
   Klopocki E, 2004, INT J ONCOL, V25, P641
   KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   Moffa AB, 2004, MOL CANCER RES, V2, P643
   Mohinta S, 2007, FRONT BIOSCI-LANDMRK, V12, P4020, DOI 10.2741/2368
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750
   Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570
   Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Yang CW, 2004, AM J PATHOL, V164, P1031, DOI 10.1016/S0002-9440(10)63190-2
   Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946
   Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4
NR 50
TC 34
Z9 39
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2009
VL 125
IS 7
BP 1613
EP 1621
DI 10.1002/ijc.24518
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 491GB
UT WOS:000269565400014
PM 19569235
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Marella, NV
   Bhattacharya, S
   Mukherjee, L
   Xu, JH
   Berezney, R
AF Marella, Narasimharao V.
   Bhattacharya, Sambit
   Mukherjee, Lopamudra
   Xu, Jinhui
   Berezney, Ronald
TI Cell Type Specific Chromosome Territory Organization in the Interphase
   Nucleus of Normal and Cancer Cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ORDER CHROMATIN ARRANGEMENTS; ART. NO. 44; MAMMALIAN-CELLS;
   GENE-EXPRESSION; SPATIAL-ORGANIZATION; GENOME FUNCTION; INTERCHROMOSOMAL
   ASSOCIATIONS; X-INACTIVATION; ARCHITECTURE; TRANSCRIPTION
AB Numerous studies indicate that the genome of higher eukaryotes is organized into distinct chromosome territories and that the 3-D arrangement of these territories may be closely connected to genomic function and the global regulation of gene expression. Despite this progress, the degree of non-random arrangement remains unclear and no overall model has been proposed for chromosome territory associations. To address this issue, a re-FISH approach was combined with computational analysis to analysis the pair-wise associations for six pairs of human chromosomes (chr #1, 4, 11, 12, 16, 18) in the G(0) state of normal human WI38 lung fibroblast and MCF10A epithelial breast cells. Similar levels of associations were found in WI38 and MCF10A for several of the chromosomes whereas others showed striking differences. A novel computational geometric approach, the generalized median graph (GMG), revealed a preferred probabilistic arrangement distinct for each cell line. Statistical analysis demonstrated that similar to 50% of the associations depicted in the GMG models are present in each individual nucleus. A nearly twofold increase of chromosome 4/16 associations in a malignant breast cancer cell line (MCFCAIa) compared to the related normal epithelial cell line (MCF10A) further demonstrates cancer related changes in chromosome arrangements. Our findings of highly preferred chromosome association profiles that are cell type specific and undergo alterations in cancer cells, lead us to propose a probabilistic chromosome code whereby the 3-D association profile of chromosomes contributes to the functional landscape of the cell nucleus, the global regulation of gene expression and the epigenetic state of chromatin. J. Cell. Physiol. 221: 130-138, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Marella, Narasimharao V.; Berezney, Ronald] SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.
   [Bhattacharya, Sambit] Fayetteville State Univ, Dept Math & Comp Sci, Fayetteville, NC USA.
   [Mukherjee, Lopamudra; Xu, Jinhui] SUNY Buffalo, Dept Comp Sci & Engn, Buffalo, NY 14260 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   University of North Carolina; Fayetteville State University; State
   University of New York (SUNY) System; University at Buffalo, SUNY
RP Berezney, R (通讯作者)，SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.
EM berezney@buffalo.edu
FU National Institute of Health [GM-072131]
FX This research was supported by a grant from the National Institute of
   Health (GM-072131) to R Berezney. We are thankful to Dr. Kishore
   Malyavantham for his advice in planning of some experiments and also for
   development of in house software.
CR Apostolou E, 2008, CELL, V134, P85, DOI 10.1016/j.cell.2008.05.052
   Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365
   Berezney R, 2002, ADV ENZYME REGUL, V42, P39, DOI 10.1016/S0065-2571(01)00041-3
   Berezney R, 1995, INT REV CYTOL, V162A, P1
   BEREZNEY R, 1984, CHROMOSOMAL NONHISTO
   BHATTACHARYA S, 2008, P 2008 INT C IM PROC, V2, P217
   Bin Sun H, 2000, BIOPHYS J, V79, P184, DOI 10.1016/S0006-3495(00)76282-5
   Bolzer A, 2005, PLOS BIOL, V3, P826, DOI 10.1371/journal.pbio.0030157
   Boveri T., 1909, Arch Zellforsch, V3, P181
   Boyle S, 2001, HUM MOL GENET, V10, P211, DOI 10.1093/hmg/10.3.211
   Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138
   Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104
   Cremer M, 2003, J CELL BIOL, V162, P809, DOI 10.1083/jcb.200304096
   Cremer M, 2001, CHROMOSOME RES, V9, P541, DOI 10.1023/A:1012495201697
   Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075
   Cremer T, 2004, BIOL CELL, V96, P555, DOI 10.1016/j.biolcel.2004.07.002
   Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007
   Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119
   Fedorova E, 2008, BBA-MOL CELL RES, V1783, P2174, DOI 10.1016/j.bbamcr.2008.07.018
   Folle GA, 2008, MUTAT RES-REV MUTAT, V658, P172, DOI 10.1016/j.mrrev.2007.08.005
   Gerlich D, 2003, CURR OPIN CELL BIOL, V15, P664, DOI 10.1016/j.ceb.2003.10.014
   Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2
   HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y
   Heard E, 2007, CURR OPIN CELL BIOL, V19, P311, DOI 10.1016/j.ceb.2007.04.016
   Kumaran RI, 2008, CELL, V132, P929, DOI 10.1016/j.cell.2008.03.004
   Kuroda M, 2004, J CELL SCI, V117, P5897, DOI 10.1242/jcs.01508
   Lanctôt C, 2007, NAT REV GENET, V8, P104, DOI 10.1038/nrg2041
   LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090
   Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191
   Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035
   Malyavantham KS, 2008, CHROMOSOMA, V117, P553, DOI 10.1007/s00412-008-0172-6
   Malyavantham KS, 2008, J CELL BIOCHEM, V105, P391, DOI 10.1002/jcb.21834
   MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453
   MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784
   Mateos-Langerak J, 2007, J CELL BIOCHEM, V102, P1067, DOI 10.1002/jcb.21521
   Mayer R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-44
   Meaburn KJ, 2007, NATURE, V445, P379, DOI 10.1038/445379a
   Misteli T, 2004, CELL, V119, P153, DOI 10.1016/j.cell.2004.09.035
   Misteli T, 2005, BIOESSAYS, V27, P477, DOI 10.1002/bies.20226
   Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028
   Morey C, 2007, DEVELOPMENT, V134, P909, DOI 10.1242/dev.02779
   Mukherjee L, 2009, J COMB OPTIM, V17, P21, DOI 10.1007/s10878-008-9184-7
   Nagele RG, 1999, J CELL SCI, V112, P525
   Neusser M, 2007, CHROMOSOMA, V116, P307, DOI 10.1007/s00412-007-0099-3
   Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207
   Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138
   Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Parada LA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r44
   Parada LA, 2004, EXP CELL RES, V296, P64, DOI 10.1016/j.yexcr.2004.03.013
   Parada LA, 2003, TRENDS CELL BIOL, V13, P393, DOI 10.1016/S0962-8924(03)00149-1
   Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1
   Pederson T, 2004, CURR OPIN GENET DEV, V14, P203, DOI 10.1016/j.gde.2004.02.008
   Pombo A, 1998, EMBO J, V17, P1768, DOI 10.1093/emboj/17.6.1768
   Razin SV, 2007, J MOL BIOL, V369, P597, DOI 10.1016/j.jmb.2007.04.003
   Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177
   SCHARDIN M, 1985, HUM GENET, V71, P281, DOI 10.1007/BF00388452
   Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607
   Solovei I, 2002, EXP CELL RES, V276, P10, DOI 10.1006/excr.2002.5513
   Sorensen JT, 1948, A method of establishing group of equal amplitude in plant sociobiology based on similarity of species content and its application to analyses of the vegetation on Danish commons, DOI DOI 10.1234/12345678
   Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591
   Soutoglou Evi, 2008, J Natl Cancer Inst Monogr, P16, DOI 10.1093/jncimonographs/lgn017
   Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574
   Stadler S, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-44
   Stein GS, 2008, J CELL BIOCHEM, V104, P2016, DOI 10.1002/jcb.21813
   Stein GS, 2003, TRENDS CELL BIOL, V13, P584, DOI 10.1016/j.tcb.2003.09.009
   Tanabe H, 2002, P NATL ACAD SCI USA, V99, P4424, DOI 10.1073/pnas.072618599
   Volpi EV, 2000, J CELL SCI, V113, P1565
   Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103
   Wiblin AE, 2005, J CELL SCI, V118, P3861, DOI 10.1242/jcs.02500
   Xu N, 2006, SCIENCE, V311, P1149, DOI 10.1126/science.1122984
   Zink D, 2004, J CELL BIOL, V166, P815, DOI 10.1083/jcb.200404107
NR 72
TC 54
Z9 63
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2009
VL 221
IS 1
BP 130
EP 138
DI 10.1002/jcp.21836
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 491IZ
UT WOS:000269573400016
PM 19496171
DA 2025-01-12
ER

PT J
AU Martínez-Romero, C
   Rooman, I
   Skoudy, A
   Guerra, C
   Molero, X
   González, A
   Iglesias, M
   Lobato, T
   Bosch, A
   Barbacid, M
   Real, FX
   Hemández-Muñoz, I
AF Martinez-Romero, Carles
   Rooman, Ilse
   Skoudy, Anouchka
   Guerra, Carmen
   Molero, Xavier
   Gonzalez, Ana
   Iglesias, Mar
   Lobato, Tania
   Bosch, Almudena
   Barbacid, Mariano
   Real, Francisco X.
   Hemandez-Munoz, Inmaculada
TI The epigenetic regulators Bmi1 and Ring1B are differentially regulated
   in pancreatitis and pancreatic ductal adenocarcinoma
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE Polycomb; pancreas; pancreatitis; PDAC; acinoductal metaplasia;
   immunohistochemistry
ID CONTROL CELL FATE; DEVELOPMENTAL REGULATORS; POLYCOMB COMPLEXES; CANCER
   DEVELOPMENT; PROLIFERATION; TRANSDIFFERENTIATION; INACTIVATION;
   PROGRESSION; SENESCENCE; EXPRESSION
AB Chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC) are associated with major changes in cell differentiation. These changes may be at the basis of the increased risk for PDAC among patients with chronic pancreatitis. Polycomb proteins are epigenetic silencers expressed in adult stem cells; up-regulation of Polycomb proteins has been reported to occur in a variety of solid tumours such as colon and breast cancer. We hypothesized that Polycomb might play a role in preneoplastic states in the pancreas and in tumour development/progression. To test these ideas, we determined the expression of PRC1 complex proteins (Bmi1 and Ring1b) during pancreatic development and in pancreatic tissue from mouse models of disease: acute and chronic pancreatic injury, duct ligation, and in K-Ras(G12V) conditional knock-in and caerulein-treated K-Ras(G12V) mice. The study was extended to human pancreatic tissue samples. To obtain mechanistic insights, Bmi1 expression in cells undergoing in vitro exocrine cell metaplasia and the effects of Bmi1 depletion in an acinar cancer cell line were studied. We found that Bmi1 and Ring1B are expressed in pancreatic exocrine precursor cells during early development and in ductal and islet cells - but not acinar cells - in the adult pancreas. Bmi1 expression was induced in acinar cells during acute injury, in acinar-ductal metaplastic lesions, as well as in pancreatic intraepithelial neoplasia (PanIN) and PDAC. In contrast, Ring1B expression was only significantly and persistently up-regulated in high-grade PanINs and in PDAC. Bmi1 knockdown in cultured acinar tumour cells led to changes in the expression of various digestive enzymes. Our results suggest that Bmi1 and Ring1B are modulated in pancreatic diseases and could contribute differently to tumour development. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Martinez-Romero, Carles; Rooman, Ilse; Skoudy, Anouchka; Lobato, Tania; Bosch, Almudena; Real, Francisco X.; Hemandez-Munoz, Inmaculada] Hosp del Mar, IMIM, Programa Recerca Canc, Barcelona 08003, Spain.
   [Guerra, Carmen; Barbacid, Mariano] Ctr Nacl Invest Oncol, Programa Oncol Mol, Madrid 28029, Spain.
   [Molero, Xavier; Gonzalez, Ana] Univ Autonoma Barcelona, Inst Recerca, Hosp Univ Vall Hebron, Grp Recerca Fisiol & Fisiopatol Digest, E-08193 Barcelona, Spain.
   [Iglesias, Mar] Univ Autonoma Barcelona, Hosp Univ Mar, Dept Patol, E-08193 Barcelona, Spain.
   [Real, Francisco X.] Ctr Nacl Invest Oncol, Programa Patol Mol, Madrid 28029, Spain.
   [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain.
C3 Hospital del Mar Research Institute; Hospital del Mar; Autonomous
   University of Barcelona; Hospital Universitari Vall d'Hebron; Vall
   d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona;
   Pompeu Fabra University
RP Hemández-Muñoz, I (通讯作者)，Hosp del Mar, IMIM, Programa Recerca Canc, Parc Recerca Biomed Barcelona,Doctor Aiguader 88, Barcelona 08003, Spain.
EM mhemandez@imim.es
RI Guerra, Carmen/K-5852-2014; Iglesias, Mar/JMC-1014-2023; Real, Francisco
   X/H-5275-2015
OI Real, Francisco X/0000-0001-9501-498X; Rooman, Ilse/0000-0001-7264-2246;
   Martinez-Romero, Carles/0000-0001-8888-7715; Guerra,
   Carmen/0000-0002-3891-046X; Gonzalez Castro, Ana
   Maria/0000-0003-3955-3318
FU Instituto de Salud Carlos III [02/3053, PI05/2738, CP04/00292,
   PI05/1912]; Plan Nacional de I+D; Ministerio de Educacion y Ciencia
   [SAF2007-60860]; Biomed Programme [LSHB-CT-2006-018771 MOLDIAG-PaCa];
   Ministry of Education and Science; Marie Curie Intra-European Fellowship
   [MEIF-CT-023281]; Marie Curie Reintegration Grant [MERG-CT-2007-204582];
   Fund of Scientific Research - Flanders
FX This work should be attributed to Programa de Recerca en Cancer,
   Institut Municipal d'Investigacio Medica (IMIM-Hospital del Mar), Parc
   de Recerca Biomedica de Barcelona, Doctor Aiguader 88, 08003-Barcelona,
   Spain. We thank Xavier Sanjuan for microscopy technical support and
   Sergi Mojal for statistical analysis of the data. IH-M is supported by
   Instituto de Salud Carlos III. Work in Our laboratories is supported by
   grants from Plan Nacional de I+D, Ministerio de Educacion y Ciencia
   (SAF2007-60860 to FXR); Biomed Programme (LSHB-CT-2006-018771
   MOLDIAG-PaCa) to FXR, and Instituto de Salud Carlos III (02/3053 and
   PI05/2738 to AS; CP04/00292 and PI05/1912 to IH-M). CMR is a recipient
   of a graduate fellowship from the Ministry of Education and Science. IR
   is supported for this work by a Marie Curie Intra-European Fellowship
   (MEIF-CT-023281) and a Marie Curie Reintegration Grant
   (MERG-CT-2007-204582), as well as a post-doctoral fellowship from the
   Fund of Scientific Research - Flanders.
CR Boutsma E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002322
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144
   Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a
   Dimri GP, 2002, CANCER RES, V62, P4736
   Gesina E, 2006, DIABETOLOGIA, V49, P2939, DOI 10.1007/s00125-006-0449-3
   Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987
   Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012
   HALL PA, 1992, J PATHOL, V166, P97, DOI 10.1002/path.1711660203
   HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A
   Hernádez-Muñoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102
   Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X
   Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003
   Hruban RH, 2000, CLIN CANCER RES, V6, P2969
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jamal AM, 2003, CELL DEATH DIFFER, V10, P987, DOI 10.1038/sj.cdd.4401266
   Kanno R, 2008, CANCER SCI, V99, P1077, DOI 10.1111/j.1349-7006.2008.00797.x
   Lardon J, 2005, DIFFERENTIATION, V73, P278, DOI 10.1111/j.1432-0436.2005.00030.x
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442
   Magee CJ, 2002, BEST PRACT RES CL GA, V16, P435, DOI 10.1053/bega.2002.0317
   Malfertheiner P, 2006, AM J GASTROENTEROL, V101, P160, DOI 10.1111/j.1572-0241.2006.00402.x
   Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5
   Murtaugh LC, 2003, ANNU REV CELL DEV BI, V19, P71, DOI 10.1146/annurev.cellbio.19.111301.144752
   Nègre N, 2006, PLOS BIOL, V4, P917, DOI 10.1371/journal.pbio.0040170
   NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2
   ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050
   Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070
   Real FX, 2008, GASTROENTEROLOGY, V135, P724, DOI 10.1053/j.gastro.2008.07.033
   Rodolosse A, 2004, GASTROENTEROLOGY, V127, P937, DOI 10.1053/j.gastro.2004.06.058
   Rooman I, 2006, AM J PATHOL, V169, P1206, DOI 10.2353/ajpath.2006.050926
   Rosty C, 2003, AM J SURG PATHOL, V27, P1495, DOI 10.1097/00000478-200312000-00001
   Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165
   Schwartz YB, 2008, CURR OPIN CELL BIOL, V20, P266, DOI 10.1016/j.ceb.2008.03.002
   Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522
   Sipos B, 2009, PANCREATOLOGY, V9, P45, DOI 10.1159/000178874
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687
   Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792
   VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9
   VILA MR, 1994, LAB INVEST, V71, P423
   WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600
   Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200
   Weiderpass E, 1998, SCAND J WORK ENV HEA, V24, P165, DOI 10.5271/sjweh.295
   Zhou Q, 2007, DEV CELL, V13, P103, DOI 10.1016/j.devcel.2007.06.001
NR 45
TC 44
Z9 50
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD OCT
PY 2009
VL 219
IS 2
BP 205
EP 213
DI 10.1002/path.2585
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 501YZ
UT WOS:000270421900007
PM 19585519
DA 2025-01-12
ER

PT J
AU Kim, G
   Kim, JY
   An, HJ
   Kang, H
   Kim, TH
   Shim, JY
   Heo, JH
   Park, HL
   Choi, YK
AF Kim, Gwangil
   Kim, Ji Young
   An, Hee Jung
   Kang, Haeyoun
   Kim, Tae Heon
   Shim, Jung Yon
   Heo, Jin Hyung
   Park, Hai Lin
   Choi, Young Kil
TI The Loss of E-cadherin is Associated with the Epigenetic Alteration of
   <i>CDH1</i> in Breast Cancer and it is also Associated with an Abnormal
   β-catenin Expression in Lobular Carcinoma
SO KOREAN JOURNAL OF PATHOLOGY
LA English
DT Article
DE Breast neoplasms; Wnt1 protein; Beta catenin; DNA methylation;
   E-cadherin
ID PROMOTER HYPERMETHYLATION; APC GENE; IN-SITU; PROTEIN; TUMORS;
   INACTIVATION; MUTATIONS; PROGNOSIS; MOLECULES; RECEPTOR
AB Background: APC and E-cadherin are the key molecules in the Wnt/beta-catenin pathway. We attempted to define the epigenetic alteration of APC and CDH1 (the E-cadherin gene) and the expression of Wnt-related molecules in human mammary carcinomas. Methods : Sixty-four mammary carcinomas, including 52 invasive ductal carcinomas (IDCs) and 12 invasive lobular carcinomas (ILCs), were evaluated using methylation-specific PCR and immunohistochemistry. We performed immunohistochemistry for E-cadherin, beta-catenin, APC, Wnt1 cyclin D1 ER, PR and C-erb B2. Results : Hypermethylation of APC and CDH1 was observed in 38 (59%) and 28 (44%) Gases, respectively. CDH1 hypermethylation in ILCs was increased compared to that in IDCs (p=0.002) and it was associated with the loss of E-cadherin (p=0.02) and beta-catenin (p=0.042). APC methylation was positively correlated with the ER expression (p=0.021). Abnormal cytoplasmic localization of beta-catenin was found in 10 cases and any expression was not detected in six Gases. In ILCs, the E-cacherin or beta-catenin expression was markedly decreased compared to that in IDCs (p<0.001 in both). Conclusions : Methylation of APC or CDH1 was relatively frequent in mammary carcinomas. The loss of E-cadherin in mammary carcinoma was associated with CDH1 methylation, and abnormal beta-catenin expression was related to the loss of E-cadherin in ILC.
C1 [Kim, Gwangil; An, Hee Jung; Kang, Haeyoun; Kim, Tae Heon; Heo, Jin Hyung] CHA Univ, Dept Pathol, Bundang CHA Med Ctr, Sch Med, Songnam 463712, South Korea.
   [Kim, Ji Young; Shim, Jung Yon] CHA Univ, Sch Med, Gangnam CHA Med Ctr, Dept Pathol, Seoul, South Korea.
   [Park, Hai Lin] CHA Univ, Sch Med, Gangnam CHA Med Ctr, Dept Surg, Seoul, South Korea.
   [Choi, Young Kil] CHA Univ, Sch Med, Gangnam CHA Med Ctr, Dept Internal Med, Seoul, South Korea.
C3 Pochon Cha University; Pochon Cha University; Pochon Cha University;
   Pochon Cha University
RP Kim, G (通讯作者)，CHA Univ, Dept Pathol, Bundang CHA Med Ctr, Sch Med, 351 Yatap Dong, Songnam 463712, South Korea.
EM blacknw@hanmail.net
RI Kim, Tae/C-5935-2015
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D
   Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   *CTR CCR, 2003, ANN REP CENTR CANC R
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9
   DICOSTANZO D, 1990, AM J SURG PATHOL, V14, P12, DOI 10.1097/00000478-199001000-00002
   Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100
   Esteller M, 2000, CANCER RES, V60, P4366
   Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271
   Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253
   LESSER ML, 1982, SURGERY, V91, P234
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Meniel V, 2003, J MAMMARY GLAND BIOL, V8, P435, DOI 10.1023/B:JOMG.0000017430.12210.37
   MOLL R, 1993, AM J PATHOL, V143, P1731
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   OKA H, 1993, CANCER RES, V53, P1696
   Qiao QL, 2001, INT J CANCER, V95, P194, DOI 10.1002/1097-0215(20010520)95:3<194::AID-IJC1033>3.3.CO;2-D
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x
   Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035
NR 30
TC 1
Z9 1
U1 0
U2 9
PU KOREAN SOCIETY PATHOLOGISTS
PI SEOUL
PA ROOM 702 KOREAN MED ASSOC BLDG, 302-75 ICHON, 1 DONG, YOUNGSAN-GU,
   SEOUL, 140-721, SOUTH KOREA
SN 1738-1843
J9 KOREAN J PATHOL
JI Korean J. Pathol.
PD OCT
PY 2009
VL 43
IS 5
BP 400
EP 407
DI 10.4132/KoreanJPathol.2009.43.5.400
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 515VC
UT WOS:000271500000003
OA Bronze
DA 2025-01-12
ER

PT J
AU Valeri, N
   Vannini, I
   Fanini, F
   Calore, F
   Adair, B
   Fabbri, M
AF Valeri, Nicola
   Vannini, Ivan
   Fanini, Francesca
   Calore, Federica
   Adair, Brett
   Fabbri, Muller
TI Epigenetics, miRNAs, and human cancer: a new chapter in human gene
   regulation
SO MAMMALIAN GENOME
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA METHYLATION;
   BREAST-CANCER; COLORECTAL-CANCER; LUNG-CANCER; MICRORNA TARGETS;
   POOR-PROGNOSIS; EXPRESSION; CELLS
AB Cancer is a genetic and epigenetic disease. MicroRNAs (miRNAs), a class of small noncoding RNAs, have been shown to be deregulated in many diseases including cancer. An intertwined connection between epigenetics and miRNAs has been supported by the recent identification of a specific subgroup of miRNAs called "epi-miRNAs" that can directly and indirectly modulate the activity of the epigenetic machinery. The complexity of this connection is enhanced by the epigenetic regulation of miRNA expression that generates a fine regulatory feedback loop. This review focuses on how epigenetics affects the miRNome and how the recently identified epi-miRNAs regulate the epigenome in human cancers, ultimately contributing to human carcinogenesis.
C1 [Valeri, Nicola; Calore, Federica; Adair, Brett; Fabbri, Muller] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Valeri, Nicola; Calore, Federica; Adair, Brett; Fabbri, Muller] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Vannini, Ivan; Fanini, Francesca; Fabbri, Muller] Ist Sci Romagnolo Studio & Cura Tumori, I-47014 Meldola, Italy.
C3 James Cancer Hospital & Solove Research Institute; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University; IRCCS Meldola (IRST)
RP Fabbri, M (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Biomed Res Tower,460 W 12th Ave,Room 1092, Columbus, OH 43210 USA.
EM muller.fabbri@osumc.edu
RI Fanini, Francesca/H-6973-2019; Vannini, Ivan/T-7226-2019
OI Vannini, Ivan/0000-0002-9279-1801; valeri, nicola/0000-0002-5426-5683
FU American-Italian Cancer Foundation Post-Doctoral Research Fellowship;
   Kimmel Scholar Award
FX Nicola Valeri is supported by an American-Italian Cancer Foundation
   Post-Doctoral Research Fellowship. Muller Fabbri is supported by a 2009
   Kimmel Scholar Award.
CR Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025
   Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Boehm M, 2006, CELL CYCLE, V5, P837, DOI 10.4161/cc.5.8.2688
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Fabbri M, 2008, LEUKEMIA, V22, P1095, DOI 10.1038/leu.2008.30
   Fabbri M, 2008, CANCER J, V14, P1, DOI 10.1097/PPO.0b013e318164145e
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fabbri M, 2009, LEUKEMIA LYMPHOMA, V50, P160, DOI 10.1080/10428190802535114
   Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   Harfe BD, 2005, CURR OPIN GENET DEV, V15, P410, DOI 10.1016/j.gde.2005.06.012
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Nelson KM, 2008, MOL CANCER THER, V7, P3655, DOI 10.1158/1535-7163.MCT-08-0586
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pasquinelli AE, 2005, CURR OPIN GENET DEV, V15, P200, DOI 10.1016/j.gde.2005.01.002
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Vatolin S, 2006, J MOL BIOL, V358, P983, DOI 10.1016/j.jmb.2006.02.063
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
NR 73
TC 78
Z9 109
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-8990
EI 1432-1777
J9 MAMM GENOME
JI Mamm. Genome
PD OCT
PY 2009
VL 20
IS 9-10
BP 573
EP 580
DI 10.1007/s00335-009-9206-5
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 524XE
UT WOS:000272176900006
PM 19697081
DA 2025-01-12
ER

PT J
AU Sweeney, L
   Voelkel, NF
AF Sweeney, Lori
   Voelkel, Norbert F.
TI ESTROGEN EXPOSURE, OBESITY AND THYROID DISEASE IN WOMEN WITH SEVERE
   PULMONARY HYPERTENSION
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Severe pulmonary hypertension; Estrogen; Menopause; Thyroid Disease;
   Autoimmunity; Obesity
ID ARTERIAL-HYPERTENSION; BREAST-CANCER; POSTMENOPAUSAL WOMEN;
   ORAL-CONTRACEPTIVES; METABOLIC SYNDROME; NATIONAL-HEALTH; UNITED-STATES;
   RISK; PREVALENCE; HYPOTHYROIDISM
AB Severe pulmonary hypertension is a lethal group of disorders which preferentially afflicts women. It appears that in recent years the patient profile has shifted towards older, obese, and postmenopausal women, suggesting that endocrine factors may be important. Several studies have revealed an increased prevalence of thyroid disease in these patients, but no studies have evaluated for a coexistence of endocrine factors. In particular, no studies have attempted to evaluate for concurrent thyroid disease, obesity and long-term estrogen exposure in patients.
   88 patients attending the Pulmonary Hypertension Association 8th International meeting completed a questionnaire and were interviewed. Information was collected regarding reproductive history, height, weight, and previous diagnosis of thyroid disease.
   46% met criteria for obesity. 41% reported a diagnosis of thyroid disease. 81% of women reported prior use of hormone therapy 70% reported greater than 10 years of exogenous hormone use. 74% of female patients reported two or more of potentially disease modifying endocrine factors (obesity, thyroid disease or estrogen therapy).
   The coexistent high prevalence in our cohort of exogenous estrogen exposure, thyroid disease and obesity suggests that an interaction of multiple endocrine factors might contribute to the pathogenesis of pulmonary hypertension and may represent epigenetic modifiers in genetically-susceptible individuals.
C1 [Voelkel, Norbert F.] Virginia Commonwealth Univ, Dept Internal Med, Div Pulm & Crit Care Med, Richmond, VA 23298 USA.
   [Sweeney, Lori] Virginia Commonwealth Univ, Dept Internal Med, Div Endocrinol & Metab, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University
RP Voelkel, NF (通讯作者)，Virginia Commonwealth Univ, Dept Internal Med, Div Pulm & Crit Care Med, 1220 E Broad St,MMRB 2 Room 6052, Richmond, VA 23298 USA.
EM nvoelkel@mcvh-vcu.edu
FU Thomas F. Jeffress and Kate Miller Jeffress Memorial Trust; VCU Health
   System BIRCWH
FX This work has been supported by the following research grants to L.B.S.:
   Thomas F. Jeffress and Kate Miller Jeffress Memorial Trust research
   grant and VCU Health System BIRCWH award.
CR Aoki Y, 2007, THYROID, V17, P1211, DOI 10.1089/thy.2006.0235
   Applanat MP, 2008, ADV EXP MED BIOL, V617, P437, DOI 10.1007/978-0-387-69080-3_42
   Arroliga AC, 2000, CHEST, V118, P1224, DOI 10.1378/chest.118.4.1224
   Badesch DB, 2007, CHEST, V132, p473S
   BADESCH DB, 1993, ANN INTERN MED, V119, P44, DOI 10.7326/0003-4819-119-1-199307010-00008
   BAKHAI A, 2008, QJM             0610
   Bays Harold E, 2008, Expert Rev Cardiovasc Ther, V6, P343, DOI 10.1586/14779072.6.3.343
   Bosetti C, 2001, J CLIN EPIDEMIOL, V54, P902, DOI 10.1016/S0895-4356(01)00362-6
   Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798
   Casey PM, 2008, MAYO CLIN PROC, V83, P86, DOI 10.4065/83.1.86
   Crespo CJ, 2002, DIABETES CARE, V25, P1675, DOI 10.2337/diacare.25.10.1675
   Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059
   Després JP, 2001, ANN MED, V33, P534, DOI 10.3109/07853890108995963
   Eliassen AH, 2008, ADV EXP MED BIOL, V630, P148
   Ferris A, 2001, CHEST, V119, P1980, DOI 10.1378/chest.119.6.1980
   Ferris AM, 2000, CIRCULATION, V102, P426
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Galie N, 2008, DRUGS, V68, P1049, DOI 10.2165/00003495-200868080-00004
   Harrison RE, 2003, J MED GENET, V40, P865, DOI 10.1136/jmg.40.12.865
   Hausman GJ, 2004, J ANIM SCI, V82, P925
   Heilbronn LK, 2008, CURR PHARM DESIGN, V14, P1225, DOI 10.2174/138161208784246153
   Hill Nicholas S, 2008, Proc Am Thorac Soc, V5, P603, DOI 10.1513/pats.200803-032SK
   Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jacc.2004.02.029
   Hyduk Alexandra, 2005, Morbidity and Mortality Weekly Report, V54, P1
   Karagiannides I, 2007, CURR OPIN GASTROEN, V23, P661, DOI 10.1097/MOG.0b013e3282c8c8d3
   Kasahara T, 2006, ATHEROSCLEROSIS, V186, P207, DOI 10.1016/j.atherosclerosis.2005.07.018
   Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051
   Ko Kwang Pil, 2008, J Prev Med Public Health, V41, P181
   LA VC, 1993, INT J CANCER, V53, P215
   LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3
   Lee MY, 2008, CELL RES, V18, P491, DOI 10.1038/cr.2008.42
   Li JH, 2007, CHEST, V132, P793, DOI 10.1378/chest.07-0366
   Ma RC, 2005, AM J MED, V118, P927, DOI 10.1016/j.amjmed.2005.03.038
   MARADITKREMERS H, 2008, TREATMENT PATTERNS P
   Maskarinec G, 1998, CANCER EPIDEM BIOMAR, V7, P613
   Messina MJ, 2001, J NUTR, V131, p3095S, DOI 10.1093/jn/131.11.3095S
   MITSUMA T, 1986, ENDOCRINOL EXP, V20, P371
   Newman JH, 2004, J AM COLL CARDIOL, V43, p33S, DOI 10.1016/j.jacc.2004.02.028
   Nicolls MR, 2005, EUR RESPIR J, V26, P1110, DOI 10.1183/09031936.05.00045705
   Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2
   NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907
   Park JT, 2001, MEASUREMENT, V30, P95, DOI 10.1016/S0263-2241(00)00047-6
   Rai PR, 2008, AM J RESP CRIT CARE, V178, P558, DOI 10.1164/rccm.200709-1369PP
   Resta O, 2004, NUTR METAB CARDIOVAS, V14, P248, DOI 10.1016/S0939-4753(04)80051-6
   Rich S, 2000, CHEST, V117, P870, DOI 10.1378/chest.117.3.870
   RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216
   Rinaldi S, 2006, INT J CANCER, V118, P2832, DOI 10.1002/ijc.21730
   Shields Margot, 2008, Health Rep, V19, P61
   Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037
   Sitbon O, 2008, AM J RESP CRIT CARE, V177, P108, DOI 10.1164/rccm.200704-541OC
   Siu CW, 2007, J CLIN ENDOCR METAB, V92, P1736, DOI 10.1210/jc.2006-1877
   Taichman LS, 2005, J PERIODONTOL, V76, P1374, DOI 10.1902/jop.2005.76.8.1374
   Taraseviciute A, 2006, EUR J MED RES, V11, P198
   THOMAS DB, 1990, BRIT J CANCER, V61, P110
   Vinzio S, 2005, PRESSE MED, V34, P1147, DOI 10.1016/S0755-4982(05)84141-7
   VIRGOLINI S, 1987, PROG CLIN BIOL RES, V242, P35
   VOELKEL NF, 1979, LUNG BIOL HLTH DIS, P573
   Vona-Davis L, 2007, OBES REV, V8, P395, DOI 10.1111/j.1467-789X.2007.00396.x
   Wassink AMJ, 2007, EUR J CLIN INVEST, V37, P8, DOI 10.1111/j.1365-2362.2007.01755.x
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   You YJ, 2008, CELL METAB, V7, P249, DOI 10.1016/j.cmet.2008.01.005
   Zhang CH, 2008, BASIC RES CARDIOL, V103, P398, DOI 10.1007/s00395-008-0733-0
NR 62
TC 46
Z9 51
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD SEP 28
PY 2009
VL 14
IS 10
BP 433
EP 442
DI 10.1186/2047-783X-14-10-433
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 507ZN
UT WOS:000270895800003
PM 19748850
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Hu, GH
   Wei, Y
   Kang, YB
AF Hu, Guohong
   Wei, Yong
   Kang, Yibin
TI The Multifaceted Role of MTDH/AEG-1 in Cancer Progression
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ASTROCYTE-ELEVATED GENE-1; COMPARATIVE GENOMIC HYBRIDIZATION;
   FACTOR-KAPPA-B; BREAST-CANCER; TUMOR PROGRESSION; METASTASIS;
   ACTIVATION; PROTEIN; IDENTIFICATION; CELLS
AB Cancer is the result of the progressive acquisition of multiple malignant traits through the accumulation of genetic or epigenetic alterations. Recent studies have established a functional role of MTDH (Metadherin)/AEG-1 (Astrocyte Elevated Gene 1) in several crucial aspects of tumor progression, including transformation, evasion of apoptosis, invasion, metastasis, and chemoresistance. Overexpression of MTDH/AEG-1 is frequently observed in melanoma, glioma, neuroblastoma, and carcinomas of breast, prostate, liver, and esophagus and is correlated with poor clinical outcomes. MTDH/AEG-1 functions as a downstream mediator of the transforming activity of oncogenic Ha-Ras and c-Myc. Furthermore, MTDH/AEG-1 overexpression activates the PI3K/Akt, nuclear factor kappa B (NF kappa B), and Wnt/beta-catenin signaling pathways to stimulate proliferation, invasion, cell survival, and chemoresistance. The lung-homing domain of MTDH/AEG-1 also mediates the adhesion of tumor cells to the vasculature of distant organs and promotes metastasis. These findings suggest that therapeutic targeting of MTDH/AEG-1 may simultaneously suppress tumor growth, block metastasis, and enhance the efficacy of chemotherapeutic treatments. (Clin Cancer Res 2009;15(18):5615-20)
C1 [Hu, Guohong; Wei, Yong; Kang, Yibin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
   [Kang, Yibin] Canc Inst New Jersey, Breast Canc Program, New Brunswick, NJ USA.
C3 Princeton University; Rutgers University System; Rutgers University New
   Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers
   Cancer Institute of New Jersey
RP Kang, YB (通讯作者)，Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
EM ykang@princeton.edu
RI 胡, 国宏/HOH-6469-2023
OI Kang, Yibin/0000-0002-1626-6730; Hu, Guohong/0000-0002-2980-5166
FU NCI NIH HHS [R01 CA134519-02, R01 CA134519, R01 CA134519-01] Funding
   Source: Medline
CR Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296
   Britt DE, 2004, EXP CELL RES, V300, P134, DOI 10.1016/j.yexcr.2004.06.026
   Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0
   Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029
   Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013
   Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8
   Kang DC, 2005, GENE, V353, P8, DOI 10.1016/j.gene.2005.04.005
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572
   KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615
   Kwong LN, 2009, CANCER CELL, V15, P1, DOI 10.1016/j.ccr.2008.12.007
   Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713
   Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103
   Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054
   Liu HY, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-19
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200
   RIED T, 1995, CANCER RES, V55, P5415
   Rottmann S, 2005, P NATL ACAD SCI USA, V102, P15195, DOI 10.1073/pnas.0505114102
   Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164
   Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445
   Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020
   Thirkettle HJ, 2009, CLIN CANCER RES, V15, P3003, DOI 10.1158/1078-0432.CCR-08-2046
   Warr T, 2001, GENE CHROMOSOME CANC, V31, P15, DOI 10.1002/gcc.1113
   Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460
   Yu CP, 2009, CARCINOGENESIS, V30, P894, DOI 10.1093/carcin/bgp064
NR 37
TC 235
Z9 266
U1 0
U2 41
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2009
VL 15
IS 18
BP 5615
EP 5620
DI 10.1158/1078-0432.CCR-09-0049
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 496OA
UT WOS:000269982800004
PM 19723648
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Docquier, F
   Kita, GX
   Farrar, D
   Jat, P
   O'Hare, M
   Chernukhin, I
   Gretton, S
   Mandal, A
   Alldridge, L
   Klenova, E
AF Docquier, France
   Kita, Georgia-Xanthi
   Farrar, Dawn
   Jat, Parmjit
   O'Hare, Michael
   Chernukhin, Igor
   Gretton, Svetlana
   Mandal, Adhip
   Alldridge, Louise
   Klenova, Elena
TI Decreased Poly(ADP-Ribosyl)ation of CTCF, a Transcription Factor, Is
   Associated with Breast Cancer Phenotype and Cell Proliferation
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MYOEPITHELIAL CELLS; PROTEIN; EXPRESSION; CYCLE; GENE; EPIGENETICS;
   GLYCOHYDROLASE; PURIFICATION; METHYLATION; SPECIFICITY
AB Purpose: There is compelling evidence of a relationship between poly(ADP-ribosyl) ation and tumorigenesis; however, much less is known about the role of specific targets of poly(ADP-ribosyl)ation in tumor development. Two forms of the multifunctional transcription factor, CTCF, were previously identified: a 130-kDa protein (CTCF-130), characteristic for cell lines, and a 180-kDa protein (CTCF-180), modified by poly(ADP-ribosyl) ation. This study was aimed to investigate differential poly(ADP-ribosyl)ation of CTCF in normal and tumor breast tissues.
   Experimental Design: Western blot analysis, mass spectrometry, and immunohistochemical and immunofluorescent stainings were used to characterize CTCF-130 and CTCF-180 in breast cell lines, primary cultures, and normal and tumor breast tissues. The immunoreactivity score was used for CTCF-130 quantification in tissues.
   Results: We discovered that only CTCF-180 is detected in the normal breast tissues, whereas both CTCF-130 and CTCF-180 are present in breast tumors. Using an antibody specific for CTCF-130, we observed that 87.7% of breast tumors were positive for CTCF-130. A negative correlation existed between the levels of CTCF-130, tumor stage, and tumor size. Significantly, a transition from CTCF-180 to CTCF-130 was discovered in primary cultures generated from normal breast tissues, indicating a link between CTCF-130 and proliferation. Conversely, the appearance of CTCF-180 was observed following growth arrest in breast cell lines.
   Conclusions: Collectively, our data suggest that the loss of CTCF poly(ADP-ribosyl)ation is associated with cell proliferation and breast tumor development. We propose the use of CTCF-130 as a marker for tumor breast cells and lower levels of CTCF-130 as an indicator of unfavorable prognosis. (Clin Cancer Res 2009;15(18):5762-71)
C1 [Docquier, France; Kita, Georgia-Xanthi; Farrar, Dawn; Chernukhin, Igor; Gretton, Svetlana; Mandal, Adhip; Klenova, Elena] Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England.
   [Alldridge, Louise] Anglia Ruskin Univ, Helen Rollason Res Lab, Chelmsford, Essex, England.
   [Jat, Parmjit; O'Hare, Michael] UCL, Inst Neurol, Dept Neurodegenerat Dis, London, England.
C3 University of Essex; Anglia Ruskin University; University of London;
   University College London
RP Klenova, E (通讯作者)，Univ Essex, Dept Biol Sci, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.
EM klenovae@essex.ac.uk
RI Alldridge, louise/U-1641-2019
OI Jat, Parmjit/0000-0002-3354-0594
FU University of Essex; MRC [G0401088] Funding Source: UKRI
FX Breast Cancer Campaign IF. Docquier and E. Klenova), Breast Cancer
   Research Trust (G-X Kita and E. Klenova), Medical Research Council (D.
   Farrar and E. Klenova), Helen Rollason Cancer Charity (F. Docquier), the
   Wellcome Trust (P. Jat), and Research Promotion Fund from the University
   of Essex (F. Docquier, 1. Chernukhin, and E. Klenova). A. Mandal is a
   clinical research fellow supported by Colchester Hospital University NHS
   Foundation Trust.
CR Amé JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085
   BECK T, 1994, GYNECOL ONCOL, V53, P220, DOI 10.1006/gyno.1994.1119
   Bundred NJ, 2001, CANCER TREAT REV, V27, P137, DOI 10.1053/ctrv.2000.0207
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   Carbone M, 2008, ONCOGENE, V27, P6083, DOI 10.1038/onc.2008.221
   CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38
   Coradini D, 1997, CELL PROLIFERAT, V30, P149, DOI 10.1046/j.1365-2184.1997.00083.x
   Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100
   Cuzzocrea S, 2005, PHARMACOL RES, V52, P100, DOI 10.1016/j.phrs.2005.02.009
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263
   Denley H, 2001, J CLIN PATHOL, V54, P20, DOI 10.1136/jcp.54.1.20
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Duffy MJ, 2001, CLIN BIOCHEM, V34, P347, DOI 10.1016/S0009-9120(00)00201-0
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9
   Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172
   Guastafierro T, 2008, J BIOL CHEM, V283, P21873, DOI 10.1074/jbc.M801170200
   Habermann JK, 2004, CANCER GENET CYTOGEN, V148, P7, DOI 10.1016/S0165-4608(03)00245-0
   Hamilton A, 2000, Clin Breast Cancer, V1, P233, DOI 10.3816/CBC.2000.n.020
   Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428
   Hassa PO, 2008, FRONT BIOSCI-LANDMRK, V13, P3046, DOI 10.2741/2909
   Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610
   Jelinic P, 2007, J PATHOL, V211, P261, DOI 10.1002/path.2116
   JOSHI K, 1986, AM J PATHOL, V124, P199
   Klenova E, 2005, CELL CYCLE, V4, P96, DOI 10.4161/cc.4.1.1398
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553
   Miller WR, 1997, J STEROID BIOCHEM, V61, P193
   Miwa M, 2007, CANCER SCI, V98, P1528, DOI 10.1111/j.1349-7006.2007.00567.x
   OHISSON R, 2001, TRENDS GENET, V17, P520
   OKA J, 1984, J BIOL CHEM, V259, P986
   Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589
   POCSIK E, 1995, J CELL BIOCHEM, V59, P303, DOI 10.1002/jcb.240590303
   Rasko JEJ, 2001, CANCER RES, V61, P6002
   Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P7372, DOI 10.1093/nar/gkm896
   ROBERTS JH, 1973, BIOCHEM BIOPH RES CO, V52, P43, DOI 10.1016/0006-291X(73)90951-0
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Su L, 1996, HUM PATHOL, V27, P800, DOI 10.1016/S0046-8177(96)90452-9
   Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129
   Yousef GM, 2002, BRIT J CANCER, V87, P1287, DOI 10.1038/sj.bjc.6600623
   Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426
   Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2
NR 49
TC 36
Z9 44
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2009
VL 15
IS 18
BP 5762
EP 5771
DI 10.1158/1078-0432.CCR-09-0329
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 496OA
UT WOS:000269982800020
PM 19737964
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Shackleton, M
   Quintana, E
   Fearon, ER
   Morrison, SJ
AF Shackleton, Mark
   Quintana, Elsa
   Fearon, Eric R.
   Morrison, Sean J.
TI Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution
SO CELL
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; TUMOR-INITIATING CELLS; BREAST-CANCER; MOUSE
   MODEL; IDENTIFICATION; PROGENITOR; RESISTANCE; MICE; DIFFERENTIATION;
   TRANSPLANTATION
AB The identification and characterization of cancer stem cells might lead to more effective treatments for some cancers by focusing therapy on the most malignant cells. To achieve this goal it will be necessary to determine which cancers follow a cancer stem cell model and which do not, to address technical issues related to tumorigenesis assays, and to test the extent to which cancer cell heterogeneity arises from genetic versus epigenetic differences.
C1 [Shackleton, Mark; Quintana, Elsa; Morrison, Sean J.] Univ Michigan, Howard Hughes Med Inst, Inst Life Sci, Ctr Stem Cell Biol, Ann Arbor, MI 48109 USA.
   [Fearon, Eric R.; Morrison, Sean J.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
C3 Howard Hughes Medical Institute; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Morrison, SJ (通讯作者)，Univ Michigan, Howard Hughes Med Inst, Inst Life Sci, Ctr Stem Cell Biol, Ann Arbor, MI 48109 USA.
EM seanjm@umich.edu
RI Morrison, Sean/ABD-5326-2021
OI Morrison, Sean/0000-0003-1587-8329; Shackleton, Mark/0000-0002-7673-4655
FU Howard Hughes Medical Institute Funding Source: Medline
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barabé F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023
   Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103
   Feuring-Buske M, 2003, LEUKEMIA, V17, P760, DOI 10.1038/sj.leu.2402882
   ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549
   Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57
   Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596
   Kennedy James A, 2007, Science, V318, P1722
   KLEINSMITH LJ, 1964, CANCER RES, V24, P1544
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835
   Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120
   McKenzie JL, 2005, BLOOD, V106, P1259, DOI 10.1182/blood-2005-03-1081
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002
   Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95
   Oravecz-Wilson KI, 2009, CANCER CELL, V16, P137, DOI 10.1016/j.ccr.2009.06.007
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Shah NP, 2007, J CLIN INVEST, V117, P2562, DOI 10.1172/JCI30890
   Sikic B I., 2008, The Molecular Basis of Cancer, P583, DOI DOI 10.1016/B978-141603703-3.10049-4
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Williams RT, 2007, GENE DEV, V21, P2283, DOI 10.1101/gad.1588607
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353
NR 39
TC 871
Z9 1035
U1 3
U2 121
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD SEP 4
PY 2009
VL 138
IS 5
BP 822
EP 829
DI 10.1016/j.cell.2009.08.017
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 491FW
UT WOS:000269564600007
PM 19737509
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhao, L
   Wang, L
   Jin, F
   Ma, WF
   Ren, J
   Wen, XY
   He, M
   Sun, ML
   Tang, HT
   Wei, MJ
AF Zhao, Lin
   Wang, Lin
   Jin, Feng
   Ma, Wenfeng
   Ren, Jie
   Wen, Xiaoyan
   He, Miao
   Sun, Mingli
   Tang, Hongtao
   Wei, Minjie
TI Silencing of estrogen receptor α (ERα) gene by promoter hypermethylation
   is a frequent event in Chinese women with sporadic breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; ER alpha; Methylation; Chinese women
ID CPG-ISLAND METHYLATION; DNA METHYLATION; EXPRESSION; CARCINOMA;
   PATTERNS; TUMORS; BRCA1; BETA
AB Usually, the function of estrogen receptor alpha (ER alpha) could be silenced by ER alpha gene promoter hypermethylation. However, frequency of ER alpha promoter methylation and the clinicopathological characteristics of ER alpha methylation in Chinese women with sporadic breast cancer are unknown. The aim of this study was to determine the methylation status of ER alpha promoter and its possible correlation with clinicopathological features in a series of 138 sporadic breast cancers in Chinese women. ER1, ER3, ER4, and ER5 primers were used for methylation-specific polymerase chain reaction (MSP) to analyze the CpG methylation of promoter region of ER alpha gene. In general, we found that ER alpha was methylated in 60.1% (83/138) tumors, including 57 of 69 ER alpha negative tumors (82.6%, P < 0.00001). Specifically within each region the methylation percentage of ER1, ER3, ER4 and ER5 were 34.8%, 35.5%, 39.1%, and 36.9% respectively. The degree of methylation at four CpG sites was higher in breast cancer compared with benign breast hyperplasia (P < 0.00001). In addition, the levels of ER alpha protein expression diminished with the frequency of ER alpha methylation (P < 0.0001, r = -0.469), the probability of methylation was increased for cases with ER alpha and PgR negativity (P < 0.00001). Our preliminary findings demonstrate, for what we believe to be the first time, that ER alpha methylation occurs in high frequency and is one of the mechanisms of ER alpha expression silence in a subset of sporadic breast cancers from Chinese women. Epigenetic alteration of the ER alpha gene may play an important role in the pathogenesis of breast cancer.
C1 [Zhao, Lin; Wang, Lin; Ren, Jie; Wen, Xiaoyan; He, Miao; Sun, Mingli; Tang, Hongtao; Wei, Minjie] China Med Univ, Dept Pharmacol, Shenyang 110001, Liaoning, Peoples R China.
   [Wang, Lin] Hrbin Med Univ, Daqing Branch, Dept Physiol, Daqing 163319, Heilongjiang, Peoples R China.
   [Jin, Feng] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol, Shenyang 110001, Liaoning, Peoples R China.
   [Ma, Wenfeng] China Med Univ, Affiliated Hosp 1, Dept Gen Surg, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Wei, MJ (通讯作者)，China Med Univ, Dept Pharmacol, Shenyang 110001, Liaoning, Peoples R China.
EM mjwei@mail.cmu.edu.cn
FU Ministry of Education of China [20050159020]
FX M. Wei is supported by Fund of Ministry of Education of China (No.
   20050159020).
CR Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126
   Kiani J, 2006, PATHOL ONCOL RES, V12, P223, DOI 10.1007/BF02893416
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Nass SJ, 2000, CANCER RES, V60, P4346
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088
   Speirs V, 2002, J CLIN PATHOL, V55, P371, DOI 10.1136/jcp.55.5.371
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Walker RA, 1999, J PATHOL, V188, P229, DOI 10.1002/(SICI)1096-9896(199907)188:3<229::AID-PATH341>3.0.CO;2-F
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2002, CLIN CANCER RES, V8, P17
NR 24
TC 25
Z9 32
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2009
VL 117
IS 2
BP 253
EP 259
DI 10.1007/s10549-008-0192-1
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 483XD
UT WOS:000269005500004
PM 18814026
DA 2025-01-12
ER

PT J
AU Zhou, Q
   Shaw, PG
   Davidson, NE
AF Zhou, Qun
   Shaw, Patrick G.
   Davidson, Nancy E.
TI Inhibition of histone deacetylase suppresses EGF signaling pathways by
   destabilizing EGFR mRNA in ER-negative human breast cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE HDAC inhibitor; SAHA; ER; EGFR
ID GROWTH-FACTOR-RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; TAMOXIFEN
   SENSITIVITY; MCF-7 CELLS; ALPHA; P21-ACTIVATED-KINASE-1; ACTIVATION;
   PAK1; RESISTANCE
AB Estrogen receptor alpha (ER)-negative human breast cancer cells frequently overexpress epidermal growth factor receptor (EGFR) and respond poorly to endocrine therapies. Our previous studies demonstrate that histone deacetylation plays a key role in ER gene silencing, and ER expression can be restored with histone deacetylase (HDAC) inhibitors in ER-negative human breast cancer cells. Whether inhibition of HDAC also alters epidermal growth factor (EGF) signaling pathways is not defined. Here we present evidence that reexpression of ER protein by a clinically available HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA or vorinostat), is coupled with loss of EGFR in ER-negative human breast cancer cells. Consistent with this observation, MDA-MB-231 cells, which are ER-negative and overexpress EGFR, that are engineered to express ER show a decrease in EGFR protein expression. Down-regulation of EGFR by SAHA results from attenuation of its mRNA stability. We also confirm that new protein synthesis is required for maintaining EGFR mRNA stability. Further experiments indicate that a decrease in EGFR abolished EGF-initiated signaling pathways including phosphorylated PAK1, p38MAPK and AKT. Thus, SAHA may not only reactivate silenced ER, but also simultaneously deplete EGFR expression. These data suggest that inhibition of HDAC is a promising epigenetic therapy for ER-negative human breast cancer.
C1 [Zhou, Qun; Shaw, Patrick G.; Davidson, Nancy E.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Davidson, NE (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRBI Room 144, Baltimore, MD 21231 USA.
EM davidna@jhmi.edu
FU National Institutes of Health [CA88843]; Department of Defense [DAMD
   17-03-1-0376]; Avon Foundation; FAMRI [YCSA072084]
FX This work was supported by grants from the National Institutes of Health
   (CA88843), Department of Defense ( DAMD 17-03-1-0376), the Avon
   Foundation and FAMRI (YCSA072084).
CR Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041
   Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200
   Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9
   Boerner JL, 2005, MOL ENDOCRINOL, V19, P2660, DOI 10.1210/me.2004-0439
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736
   CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V31, P227, DOI 10.1007/BF00666156
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Garcia R, 2006, CELL CYCLE, V5, P1840
   Hirokawa Y, 2005, CANCER BIOL THER, V4, P956, DOI 10.4161/cbt.4.9.1911
   Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185
   Jordan NJ, 2004, BREAST CANCER RES TR, V87, P167, DOI 10.1023/B:BREA.0000041623.21338.47
   Keen JC, 2005, J BIOL CHEM, V280, P29519, DOI 10.1074/jbc.M505317200
   Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620
   Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368
   Massarweh S, 2006, CANCER RES, V66, P8266, DOI 10.1158/0008-5472.CAN-05-4045
   McInerney JM, 2001, J CELL BIOCHEM, V80, P538, DOI 10.1002/1097-4644(20010315)80:4<538::AID-JCB1008>3.0.CO;2-2
   NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187
   NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200
   Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922
   Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   SHEIKH MS, 1994, J CELL BIOCHEM, V54, P289, DOI 10.1002/jcb.240540305
   Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200
   Wilson MA, 2002, J CELL BIOCHEM, V85, P601, DOI 10.1002/jcb.10168
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 37
TC 55
Z9 58
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2009
VL 117
IS 2
BP 443
EP 451
DI 10.1007/s10549-008-0148-5
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 483XD
UT WOS:000269005500026
PM 18683042
DA 2025-01-12
ER

PT J
AU Valente, S
   Conte, M
   Tardugno, M
   Massa, S
   Nebbioso, A
   Altucci, L
   Mai, A
AF Valente, Sergio
   Conte, Mariarosaria
   Tardugno, Maria
   Massa, Silvio
   Nebbioso, Angela
   Altucci, Lucia
   Mai, Antonello
TI Pyrrole-Based Hydroxamates and 2-Aminoanilides: Histone Deacetylase
   Inhibition and Cellular Activities
SO CHEMMEDCHEM
LA English
DT Article
DE apoptosis; epigenetics; histone deacetylases; inhibitors; aminoanilides;
   hydroxamates
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; HUMAN BREAST-CANCER; CLASS-II;
   ANTITUMOR-ACTIVITY; PROSTATE-CANCER; GENE-EXPRESSION; LEUKEMIC-CELLS;
   GASTRIC-CANCER; LUNG-CANCER; IN-VITRO
C1 [Valente, Sergio; Tardugno, Maria; Mai, Antonello] Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   [Conte, Mariarosaria; Nebbioso, Angela; Altucci, Lucia] Univ Naples 2, Dipartimento Patol Gen, I-80138 Naples, Italy.
   [Massa, Silvio] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
C3 Sapienza University Rome; Fondazione Cenci Bolognetti; Universita della
   Campania Vanvitelli; University of Siena
RP Valente, S (通讯作者)，Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Ist Pasteur, Fdn Cenci Bolognetti, Ple A Moro 5, I-00185 Rome, Italy.
EM lucia.altucci@unina2.it; antonello.mai@uniroma1.it
RI Mai, Antonello/AAC-2144-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Altucci,
   Lucia/S-8031-2019; Conte, Mariarosaria/K-7352-2016; VALENTE,
   Sergio/K-2198-2016; NEBBIOSO, Angela/C-3566-2016
OI Conte, Mariarosaria/0000-0002-3622-1476; Mai,
   Antonello/0000-0001-9176-2382; VALENTE, Sergio/0000-0002-2241-607X;
   altucci, lucia/0000-0002-7312-5387; NEBBIOSO, Angela/0000-0001-5374-3527
FU AIRC; PRIN; RETI FIRB; Fondazione Roma; European Union [227952]
FX This work was supported by grants from AIRC, PRIN, RETI FIRB, Fondazione
   Roma, and European Union (ATLAS project number 227952).
CR Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532
   Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026
   Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511
   Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043
   Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007
   Haggarty SJ, 2003, CHEM BIOL, V10, P383, DOI 10.1016/S1074-5521(03)00095-4
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Illi B, 2008, CIRC RES, V102, P51, DOI 10.1161/CIRCRESAHA.107.157305
   Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563
   Itoh Y, 2007, J MED CHEM, V50, P5425, DOI 10.1021/jm7009217
   Keshelava N, 2007, JNCI-J NATL CANCER I, V99, P1107, DOI 10.1093/jnci/djm044
   Konstantinopoulos PA, 2006, CANCER CHEMOTH PHARM, V58, P711, DOI 10.1007/s00280-005-0182-5
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075
   Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a
   Mai A, 2007, MOL PHARMACOL, V72, P1111, DOI 10.1124/mol.107.036772
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a
   MORI K, 1988, TETRAHEDRON, V44, P6013, DOI 10.1016/S0040-4020(01)89789-1
   Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Park JH, 2008, BIOCHEM BIOPH RES CO, V368, P318, DOI 10.1016/j.bbrc.2008.01.056
   Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598
   Ragno R, 2008, EUR J MED CHEM, V43, P621, DOI 10.1016/j.ejmech.2007.05.004
   Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Sakuma T, 2006, INT J ONCOL, V29, P117
   Sasaki H, 2004, LUNG CANCER, V46, P171, DOI 10.1016/j.lungcan.2004.03.021
   Scognamiglio A, 2008, BBA-MOL CELL RES, V1783, P2030, DOI 10.1016/j.bbamcr.2008.07.007
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
NR 44
TC 10
Z9 12
U1 0
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1860-7179
J9 CHEMMEDCHEM
JI ChemMedChem
PD SEP
PY 2009
VL 4
IS 9
BP 1411
EP 1415
DI 10.1002/cmdc.200900082
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 497BD
UT WOS:000270027800002
PM 19504533
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, NH
   Yang, L
   Zhuo, ML
   Wang, J
   Wang, SH
   Zhao, J
   Bai, H
AF Liu, Ning-hong
   Yang, Lu
   Zhuo, Ming-lei
   Wang, Jie
   Wang, Shu-hang
   Zhao, Jun
   Bai, Hua
TI Expression of ΔDNMT3B variants and its association with
   estrogen/progestogen receptor status in breast cancer
SO CHINESE JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Delta DNMT3B variants; RT-PCR; Breast cancer; Estrogen receptor;
   Progestogen receptor
ID CELL LUNG-CANCER; MESSENGER-RNA EXPRESSION; DNA METHYLTRANSFERASES;
   METHYLATION STATUS; RASSF1A; EPIGENETICS; P16(INK4A); CARCINOMAS;
   DNMT3B; 3B
AB Our previous study has showed that Delta DNMT3B is the predominant form of DNMT3B in non-small cell lung cancer (NSCLC). In this study, we aimed to explore the expression patterns of the Delta DNMT3B variants in breast cancer and to identify whether the pattern was similar to that in NSCLC or not and its clinical significance.
   Expression of seven Delta DNMT3B variants in 59 breast cancer and the corresponding normal tissue was measured using RT-PCR. The correlations between the expressions of Delta DNMT3B variants and the clinical parameters including ER/PR status, clincopathologic feature and survivals were analyzed.
   There were significant differences in the expression ratios of Delta DNMT3B1-7 variants between breast cancer tissues and normal tissues (P < 0.001). The positive ratio of Delta DNMT3B1-7 variants were 66%, 71%, 17%, 51%, 76.2%, 50% and 61% in tumor tissue, respectively; while 16%, 8.4%, 3.38%, 3.38%, 11.8%, 13.5% and 5.08% in the corresponding normal tissue, which was different from the pattern of Delta DNMT3B1-7 expression in NSCLC (62%, 76%, 2.5%, 46%, 18%, 27% and 16% in tumor tissue, respectively; while 18%, 11%, 0%, 3.3%, 0%, 0% and 0% in normal lung tissue, respectively; P < 0.0001). Expressions of Delta DNMT3B2, 3B4 and 3B7 were higher in the patients with negative estrogen receptor (ER) than those with positive estrogen receptor (P=0.035, P=0.0141 and P=0.0219, respectively). Delta DNMT3B7 expression was higher for the patients with negative progestogen receptor (PR) compared to those with positive progestogen receptor (P=0.0379). Expression ratio of Delta DNMT3B5 in stage III tumors is lower than that in stage I/II ones (P= 0.041). But we did not find any relation between the Delta DNMT3B variants and the patients' survival.
   The pattern of Delta DNMT3B variants in breast cancer is different from that in NSCLC. Expressions of Delta DNMT3B2, 3B4 and 3B7 are associated with estrogen receptors status. While Delta DNMT3B7 is associated with progestogen receptor. No relation between the Delta DNMT3B variants and the patients' survival were found.
C1 [Liu, Ning-hong; Yang, Lu; Zhuo, Ming-lei; Wang, Jie; Wang, Shu-hang; Zhao, Jun; Bai, Hua] Peking Univ, Sch Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Thorac Med Oncol,Beijing Canc Ho, Beijing 100142, Peoples R China.
C3 Peking University
RP Wang, SH (通讯作者)，Peking Univ, Sch Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Thorac Med Oncol,Beijing Canc Ho, Beijing 100142, Peoples R China.
EM lnh197466@sina.com; wangjie_cc@yahoo.com
RI Wang, Shuhang/AAJ-7930-2020; Li, Mingzhou/H-1402-2011; Yang,
   Ya-Li/GYU-4320-2022
OI zhuo, minglei/0000-0003-2489-7791; Wang, Shuhang/0009-0003-2431-4944
FU National Natural Science Foundation of China [30572104, 30772472]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (No. 30572104, 30772472).
CR Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Herman JG, 2004, CHEST, V125, p119S, DOI 10.1378/chest.125.5_suppl.119S
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Oue N, 2001, ONCOL REP, V8, P1085
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581
   Wang J, 2006, CANCER RES, V66, P8361, DOI 10.1158/0008-5472.CAN-06-2031
   Wang L, 2006, INT J ONCOL, V29, P201
   Wang SH, 2008, CHINESE MED J-PEKING, V121, P1712, DOI 10.1097/00029330-200809010-00024
   Yakushiji T, 2003, INT J ONCOL, V22, P1201
NR 14
TC 1
Z9 1
U1 0
U2 8
PU CHINESE JOURNAL CANCER RESEARCH CO
PI BEIJING
PA LTD PEKING U CANCER HOSP & INST, NO 52, FUCHENG RD, HAIDIAN, BEIJING,
   100142, PEOPLES R CHINA
SN 1000-9604
EI 1993-0631
J9 CHINESE J CANCER RES
JI Chin. J. Cancer Res.
PD SEP
PY 2009
VL 21
IS 3
BP 229
EP 234
DI 10.1007/s11670-009-0229-y
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 482FI
UT WOS:000268869500010
DA 2025-01-12
ER

PT J
AU Mirisola, V
   Zuccarino, A
   Bachmeier, BE
   Sormani, MP
   Falter, J
   Nerlich, A
   Pfeffer, U
AF Mirisola, Valentina
   Zuccarino, Ambra
   Bachmeier, Beatrice E.
   Sormani, Maria Pia
   Falter, Judith
   Nerlich, Andreas
   Pfeffer, Ulrich
TI CXCL12/SDF1 expression by breast cancers is an independent prognostic
   marker of disease-free and overall survival
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Breast cancer; Chemokine; Metastasis; Prognostic marker
ID CELL LUNG-CANCER; CHEMOKINE RECEPTOR; FACTOR-I; METASTASIS; CXCR4; GENE;
   SDF-1/CXCL12; SENSITIVITY; SECRETION; SIGNATURE
AB The cytokine C-X-C motif chemokine 12 (CXCL12) is synthesised by metastasis target tissues and has been shown to attract tumour cells that express the receptor, C-X-C chemokine receptor type 4 (CXCR4). However, epigenetic silencing of CXCL12 has recently been reported to increase the metastatic potential of breast cancer cells and the reintroduction of the cytokine gene into MDA-MB-231 breast carcinoma cells decreases the number of metastases formed in vivo. We therefore wished to know whether CXCL12 expression correlates with relapse-free and overall survival in human breast cancer patients.
   The expression of C-X-C motif chemokine 12 (CXCL12) and C-X-C chemokine receptor type 4 (CXCR4) was analysed in 100 archival breast cancer samples by immunohistochemistry and in two breast cancer microarray datasets of 408 cases. Data were analysed by univariate and multivariate COX regression analyses.
   CXCL12 and CXCR4 are expressed by epithelial tumour cells and by stromal and endothelial cells. Microarray gene expression analysis and immunohistochemistry revealed that expression of CXCL12 but not of CXCR4 significantly correlates with disease-free and overall survival in oestrogen receptor-positive and -negative cancers. The expression of the oestrogen receptor a and that of CXCL12 do not correlate.
   CXCL12 is a strong, independent prognostic marker. We propose that saturation of the receptor through autocrine CXCL12 production reduces chemotaxis towards CXCL12-releasing metastasis target tissues. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Mirisola, Valentina; Zuccarino, Ambra; Pfeffer, Ulrich] Natl Inst Canc Res, I-16132 Genoa, Italy.
   [Bachmeier, Beatrice E.] Univ Munich, Dept Clin Chem & Clin Biochem, Munich, Germany.
   [Sormani, Maria Pia] Univ Genoa, DISSAL, I-16126 Genoa, Italy.
   [Falter, Judith; Nerlich, Andreas] Acad Hosp Munich Bogenhausen, Dept Pathol, Munich, Germany.
C3 University of Genoa; IRCCS AOU San Martino IST; University of Munich;
   University of Genoa; Munchen Klinik
RP Pfeffer, U (通讯作者)，Natl Inst Canc Res, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
EM ulrich.pfeffer@istge.it
RI Sormani, Maria/ABH-8756-2020; Pfeffer, Ulrich/J-7064-2016
OI Nerlich, Andreas/0000-0001-6562-1017; Pfeffer,
   Ulrich/0000-0003-0872-4671; Bachmeier, Beatrice/0000-0002-3592-7354
CR Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200
   Barbero S, 2003, CANCER RES, V63, P1969
   Berquin IM, 2005, J BIOL CHEM, V280, P36442, DOI 10.1074/jbc.M504945200
   Burger JA, 2009, LEUKEMIA, V23, P43, DOI 10.1038/leu.2008.299
   Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438
   Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769
   Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621
   Hassan S, 2008, CLIN CANCER RES, V14, P446, DOI 10.1158/1078-0432.CCR-07-1189
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Imai K, 1999, BRIT J HAEMATOL, V106, P905, DOI 10.1046/j.1365-2141.1999.01644.x
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400
   Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022
   Klier CM, 2001, BIOL CHEM, V382, P1405, DOI 10.1515/BC.2001.173
   Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006
   Liang ZX, 2007, BIOCHEM BIOPH RES CO, V363, P542, DOI 10.1016/j.bbrc.2007.09.007
   Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Liang ZX, 2005, CANCER RES, V65, P967
   Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC
   REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023
   Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751
NR 31
TC 86
Z9 100
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2009
VL 45
IS 14
BP 2579
EP 2587
DI 10.1016/j.ejca.2009.06.026
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 504VE
UT WOS:000270645100028
PM 19646861
DA 2025-01-12
ER

PT J
AU Xia, WH
   Zhao, T
   Lv, JH
   Xu, S
   Shi, JF
   Wang, S
   Han, X
   Sun, YJ
AF Xia, Wenhong
   Zhao, Tao
   Lv, Jinghuan
   Xu, Shan
   Shi, Junfeng
   Wang, Shui
   Han, Xiao
   Sun, Yujie
TI Celecoxib Enhanced the Sensitivity of Cancer Cells to Anticancer Drugs
   by Inhibition of the Expression of P-Glycoprotein Through a
   COX-2-Independent Manner
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE P-GLYCOPROTEIN; CELECOXIB; CYCLOOXYGANES-2; DRUG RESISTANCE; DNA
   METHYLATION
ID FAMILIAL ADENOMATOUS POLYPOSIS; NF-KAPPA-B; MULTIDRUG-RESISTANCE;
   IN-VITRO; PROSTATE-CANCER; BREAST-CANCER; LUNG-CANCER; CYCLOOXYGENASE-2
   INHIBITOR; DOWN-REGULATION; POTENTIAL ROLE
AB The P-glycoprotein (p 170, P-gp) encoded by human MDR1 gene functions as a Pump to extrude anticancer drugs from cancer cells. Overexpression of p 170 is closely related to primary and induced drug resistance phenotype of tumor cells. Recent studies have demonstrated that expression of cyclooxygenase-2 (COX-2) is positively correlated with the p 170 level, suggesting a potential of COX-2 specific inhibitors in regulation of cytotoxicity of anticancer agents. Celecoxib is one of the specific inhibitors of COX-2 and has been widely used in clinic. However, its function in the response of cancer cells to anticancer drugs and the related mechanism are still waiting to be investigated. To explore the correlation of celecoxib and the p170-mediated drug resistance, the role of celecoxib in drug response of cancer cells was analyzed with flow cytometry, high performance liquid chromatography (HPLC), and colony formation experiments. Celecoxib (50 mu M) was found to significantly enhance the sensitivity of MCF-7 and JAR/VP16 cells to tamoxifen and etoposide, respectively, by inhibition of p 170 expression and increase in intracellular accumulation of the drugs. However, celecoxib did not affect pump function of p170. Enzyme activity and methylation analyses demonstrated that the inhibitory effect of celecoxib on p170 was independent on COX-2 but closely related to hypermethylation of MDR1 gene promoter. Our study suggested that celecoxib was a potential agent for enhancement of the sensitivity of cancer cells to anticancer drugs. It also provided a links between epigenetic change of MDR1 and drug response of cancer cells. J. Cell. Biochem. 108: 181-194, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Xia, Wenhong; Zhao, Tao; Lv, Jinghuan; Shi, Junfeng; Han, Xiao; Sun, Yujie] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 210029, Peoples R China.
   [Zhao, Tao; Xu, Shan; Shi, Junfeng; Sun, Yujie] Nanjing Med Univ, Dept Cell Biol & Med Genet, Nanjing 210029, Peoples R China.
   [Wang, Shui] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, Ctr Canc, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Han, X (通讯作者)，Hanzhong Rd 140, Nanjing 210029, Peoples R China.
EM hanxiao@njmu.edu.cn; yujiesun@njmu.edu.cn
RI Sun, Yujie/HHZ-7619-2022
FU National Natural Science Foundation of China [30772490, 30870978];
   Special Funds for Major State Basic Research Program of China (973
   Program) [2006CB503908]; College Natural Science Foundation from Jiang
   Su Province [06KJB310068]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   numbers: 30772490, 30870978; Grant sponsor: Special Funds for Major
   State Basic Research Program of China (973 Program); Grant number:
   2006CB503908; Grant sponsor: Basic Research Programme of College Natural
   Science Foundation from Jiang Su Province; Grant number: 06KJB310068.
CR Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Awara WM, 2004, PHARMACOL RES, V50, P487, DOI 10.1016/j.phrs.2004.04.002
   Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100
   Chuang HC, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-38
   CORNWELL MM, 1993, J BIOL CHEM, V268, P19505
   Csiki I, 2005, CLIN CANCER RES, V11, P6634, DOI 10.1158/1078-0432.CCR-05-0436
   Dang CT, 2004, CLIN CANCER RES, V10, P4062, DOI 10.1158/1078-0432.CCR-03-0463
   Davies N M, 2001, Expert Opin Pharmacother, V2, P139, DOI 10.1517/14656566.2.1.139
   De Vries EFJ, 2008, NUCL MED BIOL, V35, P459, DOI 10.1016/j.nucmedbio.2008.01.005
   Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056
   Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081
   Fantappiè O, 2002, HEPATOLOGY, V35, P843, DOI 10.1053/jhep.2002.32469
   Fantappiè O, 2007, CANCER RES, V67, P4915, DOI 10.1158/0008-5472.CAN-06-3952
   Grösch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje
   Harris RE, 2000, CANCER RES, V60, P2101
   He Q, 2008, ONCOGENE, V27, P2656, DOI 10.1038/sj.onc.1210894
   Huet S, 1998, CYTOMETRY, V34, P248, DOI 10.1002/(SICI)1097-0320(19981215)34:6<248::AID-CYTO2>3.0.CO;2-X
   Hull MA, 2004, MOL CANCER THER, V3, P1031
   Kang HK, 2005, MOL CANCER THER, V4, P1358, DOI 10.1158/1535-7163.MCT-05-0139
   Kawamori T, 1998, CANCER RES, V58, P409
   Kimmel SE, 2005, ANN INTERN MED, V142, P157, DOI 10.7326/0003-4819-142-3-200502010-00005
   Lai GH, 2003, MOL CANCER THER, V2, P265
   Leahy KM, 2002, CANCER RES, V62, P625
   Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1
   Ludwig JA, 2006, CANCER RES, V66, P4808, DOI 10.1158/0008-5472.CAN-05-3322
   Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014
   MARIE JP, 1991, BLOOD, V78, P586
   Miller B, 2006, J AM SOC NEPHROL, V17, P977, DOI 10.1681/ASN.2005101076
   Müller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799
   Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P514
   Pereira MA, 2004, CARCINOGENESIS, V25, P1917, DOI 10.1093/carcin/bgh209
   Pyrko P, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-19
   Qiu YY, 2007, MOL CELL BIOCHEM, V301, P131, DOI 10.1007/s11010-006-9404-3
   Ratnasinghe D, 2001, ANTICANCER RES, V21, P2141
   Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078-0432.CCR-06-0112
   RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0
   Rohlff C, 1998, INT J ONCOL, V12, P383
   Sinicrope FA, 2004, CANCER EPIDEM BIOMAR, V13, P920
   Smith MR, 2006, J CLIN ONCOL, V24, P2723, DOI 10.1200/JCO.2005.03.7804
   Sorokin A, 2004, CURR PHARM DESIGN, V10, P647, DOI 10.2174/1381612043453117
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev
   UEDA K, 1987, J BIOL CHEM, V262, P17432
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   van Wijngaarden J, 2007, EUR J CANCER, V43, P433, DOI 10.1016/j.ejca.2006.09.010
   Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008-5472.CAN-03-1945
   Williams CS, 2000, CANCER RES, V60, P6045
NR 49
TC 31
Z9 32
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP 1
PY 2009
VL 108
IS 1
BP 181
EP 194
DI 10.1002/jcb.22239
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 491JC
UT WOS:000269573700020
PM 19562670
DA 2025-01-12
ER

PT J
AU Yuasa-Kawada, J
   Kinoshita-Kawada, M
   Rao, Y
   Wu, JY
AF Yuasa-Kawada, Junichi
   Kinoshita-Kawada, Mariko
   Rao, Yi
   Wu, Jane Y.
TI Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in
   inhibiting breast cancer cell migration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cell migration and motility; metastasis; Slit-Robo signaling
ID NF-KAPPA-B; LINDAU TUMOR-SUPPRESSOR; NEURONAL MIGRATION; AXON GUIDANCE;
   EPIGENETIC INACTIVATION; DIRECTIONAL GUIDANCE; LEUKOCYTE CHEMOTAXIS;
   PROTEIN; RECEPTORS; MECHANISMS
AB Slit regulates migration of not only neurons, but also nonneuronal cells, such as leukocytes and cancer cells. Slit effect on cancer cell migration has not been well-characterized. In this study, we used several different assays to examine Slit effect on breast cancer cell migration in vitro. We show that ubiquitin-specific protease 33 (USP33)/VDU1, originally identified as a von Hippel-Lindau tumor suppressor (VHL) protein-interacting deubiquitinating enzyme, binds to the Robo1 receptor, and that USP33 is required for Slit responsiveness in breast cancer cells. Slit induces redistribution of Robo1 from intracellular compartments to the plasma membrane in a USP33-dependent manner. Slit impairs directional migration of breast cancer cells without affecting their migration speed. This inhibitory effect is Robo-mediated and USP33-dependent. These data uncover a previously unknown function of USP33 and reveal a new player in Slit-Robo signaling in cancer cell migration.
C1 [Yuasa-Kawada, Junichi; Kinoshita-Kawada, Mariko; Rao, Yi; Wu, Jane Y.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Lurie Canc Ctr,Ctr Genet Med, Chicago, IL 60611 USA.
   [Yuasa-Kawada, Junichi; Kinoshita-Kawada, Mariko; Wu, Jane Y.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   [Rao, Yi] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China.
C3 Northwestern University; Feinberg School of Medicine; Robert H. Lurie
   Comprehensive Cancer Center; Vanderbilt University; Peking University
RP Wu, JY (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Neurol, Lurie Canc Ctr,Ctr Genet Med, Chicago, IL 60611 USA.
EM jane-wu@northwestern.edu
OI Yuasa-Kawada, Junichi/0000-0002-1382-3159
FU National Institutes of Health [CA114197, CA107193, DA0176404]; James S.
   McDonnell Foundation [JSMF220o20180]
FX We thank Dr. Fujio Murakami (Osaka University, Japan) for generously
   providing anti-Robo1 antibody. We are grateful to Drs. John Wikswo and
   Yuxin Liu for the early stages of chemotaxis analyses, Dr. James
   Monypenny for advice on the Dunn chamber assay, and Xiaoping Chen and Bo
   Zheng for excellent technical assistance. We thank Masanori Katakura and
   Dr. Shigeru Yanagi for their support, Yasutomo Kubota for instructions
   on Metamorph software and deconvolution analyses, Kazunori Hakozaki
   (Leica Microsystems) for providing Leica Deblur software and anonymous
   reviewers for helpful suggestions to improve this paper. This work was
   supported by National Institutes of Health Grants CA114197, CA107193 (to
   J. Y. W.), and DA0176404 (to Y. R.), and James S. McDonnell Foundation
   Grant JSMF220o20180 (to J. Y. W.).
CR Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003
   Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002
   Cummins J.M., 2004, Nature, V428, P1, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]
   Curcio-Morelli C, 2003, J CLIN INVEST, V112, P189, DOI 10.1172/JCI200318348
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8
   Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577
   GOTLIEB AI, 1981, J CELL BIOL, V91, P589, DOI 10.1083/jcb.91.2.589
   Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617
   Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139
   Ito H, 2006, CLIN CANCER RES, V12, P3257, DOI 10.1158/1078-0432.CCR-05-2787
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0
   Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802
   Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821
   Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7
   Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737
   Li ZB, 2005, EMBO REP, V6, P373, DOI 10.1038/sj.embor.7400377
   Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X
   Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200
   McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141
   MCCUTCHEON M, 1946, PHYSIOL REV, V26, P319, DOI 10.1152/physrev.1946.26.3.319
   Michaut MA, 2005, DEV BIOL, V280, P26, DOI 10.1016/j.ydbio.2005.01.006
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444
   Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200
   Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200
   Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678
   Rao Y, 2002, GENE DEV, V16, P2973, DOI 10.1101/gad.1005802
   ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8
   Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803
   Ward M, 2003, J NEUROSCI, V23, P5170
   Wells Claire M, 2005, Methods Mol Biol, V294, P31
   Werbowetski-Ogilvie TE, 2006, ONCOGENE, V25, P5103, DOI 10.1038/sj.onc.1209524
   Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X
   Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477
   ZICHA D, 1991, J CELL SCI, V99, P769
   ZIGMOND SH, 1974, NATURE, V249, P450, DOI 10.1038/249450a0
NR 56
TC 82
Z9 101
U1 0
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 25
PY 2009
VL 106
IS 34
BP 14530
EP 14535
DI 10.1073/pnas.0801262106
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 487SF
UT WOS:000269295100066
PM 19706539
OA Green Published
DA 2025-01-12
ER

PT J
AU Radpour, R
   Kohler, C
   Haghighi, MM
   Fan, AXC
   Holzgreve, W
   Zhong, XY
AF Radpour, R.
   Kohler, C.
   Haghighi, M. M.
   Fan, A. X. C.
   Holzgreve, W.
   Zhong, X. Y.
TI Methylation profiles of 22 candidate genes in breast cancer using
   high-throughput MALDI-TOF mass array
SO ONCOGENE
LA English
DT Article
DE breast cancer; DNA methylation; MALDI-TOF; mass spectrometry
ID DNA METHYLATION; PROMOTER METHYLATION; COLORECTAL CANCERS; SERUM;
   LANDSCAPES; PATTERNS; CLEAVAGE
AB Alterations of DNA methylation patterns have been suggested as biomarkers for diagnostics and therapy of cancers. Every novel discovery in the epigenetic landscape and every development of an improved approach for accurate analysis of the events may offer new opportunity for the management of patients. Using a novel high-throughput mass spectrometry on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) silico-chips, we determined semiquantitative methylation changes of 22 candidate genes in breast cancer tissues. For the first time we analysed the methylation status of a total of 42 528 CpG dinucleotides on 22 genes in 96 different paraffin-embedded tissues (48 breast cancerous tissues and 48 paired normal tissues). A two-way hierarchical cluster analysis was used to classify methylation profiles. In this study, 10 hypermethylated genes (APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3) were identified to distinguish between cancerous and normal tissues according to the extent of methylation. Individual assessment of the methylation status for each CpG dinucleotide indicated that cytosine hypermethylation in the cancerous tissue samples was mostly located near the consensus sequences of the transcription factor binding sites. These hypermethylated genes may serve as biomarkers for clinical molecular diagnosis and targeted treatments of patients with breast cancer. Oncogene (2009) 28, 2969-2978; doi:10.1038/onc.2009.149; published online 8 June 2009
C1 [Zhong, X. Y.] Univ Basel, Univ Basel Hosp, Womens Hosp, Lab Prenatal Med & Gynecol Oncol,Dept Biomed, CH-4031 Basel, Switzerland.
   [Haghighi, M. M.] E Tehran Branch, IAU, Fac Sci, Dept Biol, Tehran, Iran.
   [Holzgreve, W.] Univ Med Ctr Freiburg, Freiburg, Germany.
C3 University of Basel; University of Freiburg
RP Zhong, XY (通讯作者)，Univ Basel, Univ Basel Hosp, Womens Hosp, Lab Prenatal Med & Gynecol Oncol,Dept Biomed, Hebelstr 20,Room 416, CH-4031 Basel, Switzerland.
EM zhongx@uhbs.ch
RI Kohler, Corina/KTH-9502-2024; Fan, Alex/I-8247-2014; Radpour, PD Dr.
   Ramin/J-4949-2014
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833
FU Swiss National Science Foundation [320000-119722/1]; Swiss Cancer
   League; Krebsliga Beider Basel; Dr Hans Altschueler Stiftung
FX We thank Professor Charles Cantor (SEQUENOM) for reading the manuscript
   and making critical comments, Vivian Kiefer for her excellent assistance
   and Regan Geissmann for proofreading the text. We are indebted to the
   patients for their cooperation. This work was supported in part by Swiss
   National Science Foundation (320000-119722/1) and Swiss Cancer League,
   Krebsliga Beider Basel and Dr Hans Altschueler Stiftung.
CR Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0
   Stanssens P, 2004, GENOME RES, V14, P126
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Trent JM, 2007, SCIENCE, V318, P1079, DOI 10.1126/science.1151428
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900
   Zou HZ, 2002, CLIN CANCER RES, V8, P188
NR 20
TC 78
Z9 86
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 20
PY 2009
VL 28
IS 33
BP 2969
EP 2978
DI 10.1038/onc.2009.149
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 485SA
UT WOS:000269142800005
PM 19503099
DA 2025-01-12
ER

PT J
AU Hegi, ME
   Sciuscio, D
   Murat, A
   Levivier, M
   Stupp, R
AF Hegi, Monika E.
   Sciuscio, Davide
   Murat, Anastasia
   Levivier, Marc
   Stupp, Roger
TI Epigenetic Deregulation of DNA Repair and Its Potential for Therapy
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ANEMIA-BRCA PATHWAY; PROMOTER HYPERMETHYLATION; HUMAN CANCER; MGMT GENE;
   POLY(ADP-RIBOSE) POLYMERASE; HMLH1 PROMOTER; OVARIAN-CANCER;
   GLIOBLASTOMA; METHYLATION; INACTIVATION
AB Epigenetic silencing of essential components of DNA repair pathways is a common event in many tumor types, and comprise O6-methylguanine-DNA methyltransferase (MGMT), human mut L homolog 1 (hMLH1), Werner syndrome gene (WRN), breast cancer susceptibility gene 1 (BRCA1), and genes of the Fanconi anemia pathway. Most interestingly, some of these alterations become the Achilles heel of the affected tumors upon treatment with certain classes of anticancer agents. That is, patients whose tumors carry such defects can be stratified for respective therapy rendering some classic DNA damaging agents, such as alkylators or DNA crosslinking agents, into "targeted therapies." Here we review some of the affected repair pathways that, when inactivated, sensitize the tumors to specific drugs and are thus exploitable for individualized therapy. (Clin Cancer Res 2009;15(16):5026-31)
C1 [Hegi, Monika E.; Sciuscio, Davide; Murat, Anastasia] Univ Lausanne Hosp, CHUV, Lab Brain Tumor Biol & Genet, Lausanne, Switzerland.
   [Hegi, Monika E.; Sciuscio, Davide; Murat, Anastasia; Levivier, Marc; Stupp, Roger] Univ Lausanne Hosp, CHUV, Dept Neurosurg, Lausanne, Switzerland.
   [Hegi, Monika E.] ISREC SV EPFL, Natl Ctr Competence Res Mol Oncol, Lausanne, Switzerland.
C3 University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne; Swiss Institute Experimental Cancer Research
RP Hegi, ME (通讯作者)，CHUV BH19 110, Lab Brain Tumor Biol & Genet, Dept Neurosurg, 46 Rue Bugnon, CH-1011 Lausanne, Switzerland.
EM Monika.Hegi@chuv.ch
RI Stupp, Roger/L-3303-2019; Hegi, Monika/O-4796-2015
OI Hegi, Monika/0000-0003-0855-6495
CR Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Christmann M, 2008, DNA REPAIR, V7, P1999, DOI 10.1016/j.dnarep.2008.08.008
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Crinière E, 2007, J NEURO-ONCOL, V83, P173, DOI 10.1007/s11060-006-9320-0
   D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970
   Ernst RJ, 2009, J AM CHEM SOC, V131, P2359, DOI 10.1021/ja8081044
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2002, J NATL CANCER I, V94, P26
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Glas M, 2009, J CLIN ONCOL, V27, P1257, DOI 10.1200/JCO.2008.19.2195
   Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hess CJ, 2008, CELL ONCOL, V30, P299, DOI 10.3233/CLO-2008-0426
   Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016
   Möllemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575
   Ochs K, 2000, CANCER RES, V60, P5815
   Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X
   Peltomäki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060
   Plummer ER, 2007, CLIN CANCER RES, V13, P6252, DOI 10.1158/1078-0432.CCR-07-0617
   Quinn JA, 2009, J CLIN ONCOL, V27, P1262, DOI 10.1200/JCO.2008.18.8417
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Shen L, 2007, CLIN CANCER RES, V13, P6093, DOI 10.1158/1078-0432.CCR-07-1011
   Sidorova JM, 2008, DNA REPAIR, V7, P1776, DOI 10.1016/j.dnarep.2008.07.017
   Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048
   Zawlik I, 2009, NEUROEPIDEMIOLOGY, V32, P21, DOI 10.1159/000170088
NR 45
TC 46
Z9 50
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2009
VL 15
IS 16
BP 5026
EP 5031
DI 10.1158/1078-0432.CCR-08-1169
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 484DX
UT WOS:000269024900003
PM 19671858
OA Bronze
DA 2025-01-12
ER

PT J
AU Hinshelwood, RA
   Melki, JR
   Huschtscha, LI
   Paul, C
   Song, JZ
   Stirzaker, C
   Reddel, RR
   Clark, SJ
AF Hinshelwood, Rebecca A.
   Melki, John R.
   Huschtscha, Lily I.
   Paul, Cheryl
   Song, Jenny Z.
   Stirzaker, Clare
   Reddel, Roger R.
   Clark, Susan J.
TI Aberrant <i>de novo</i> methylation of the <i>p16<SUP>INK4A</SUP></i>
   CpG island is initiated post gene silencing in association with
   chromatin remodelling and mimics nucleosome positioning
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; CANCER EPIGENETICS; EARLY
   EVENT; IN-VIVO; EXPRESSION; SENESCENCE; GROWTH; P16; HYPERMETHYLATION
AB Changes in the epigenetic landscape are widespread in neoplasia, with de novo methylation and histone repressive marks commonly enriched in CpG island associated promoter regions. DNA hypermethylation and histone repression correlate with gene silencing, however, the dynamics of this process are still largely unclear. The tumour suppressor gene p16(INK4A) is inactivated in association with CpG island methylation during neoplastic progression in a variety of cancers, including breast cancer. Here, we investigated the temporal progression of DNA methylation and histone remodelling in the p16(INK4A) CpG island in primary human mammary epithelial cell (HMEC) strains during selection, as a model for early breast cancer. Silencing of p16(INK4A) has been previously shown to be necessary before HMECs can escape from selection. Here, we demonstrate that gene silencing occurs prior to de novo methylation and histone remodelling. An increase in DNA methylation was associated with a rapid loss of both histone H3K27 trimethylation and H3K9 acetylation and a gradual gain of H3K9 dimethylation. Interestingly, we found that regional-specific 'seeding' methylation occurs early after post-selection and that the de novo methylation pattern observed in HMECs correlates with the apparent footprint of nucleosomes across the p16(INK4A) CpG island. Our results demonstrate for the first time that p16(INK4A) gene silencing is a precursor to epigenetic suppression and that subsequent de novo methylation initially occurs in nucleosome-free regions across the p16(INK4A) CpG island and this is associated with a dynamic change in histone modifications.
C1 [Hinshelwood, Rebecca A.; Paul, Cheryl; Song, Jenny Z.; Stirzaker, Clare; Clark, Susan J.] Garvan Inst Med Res, Canc Program, Darlinghurst, NSW 2010, Australia.
   [Melki, John R.] Human Genet Signatures, N Ryde, NSW 1670, Australia.
   [Huschtscha, Lily I.; Reddel, Roger R.] Childrens Med Res Inst, Westmead, NSW 2145, Australia.
   [Reddel, Roger R.] Univ Sydney, Sydney, NSW 2006, Australia.
C3 Garvan Institute of Medical Research; Genetic Signatures Limited;
   Children's Medical Research Institute - Australia; University of Sydney
RP Clark, SJ (通讯作者)，Garvan Inst Med Res, Canc Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Reddel, Roger/A-6635-2014; Clark, Susan/B-2272-2008
OI Reddel, Roger/0000-0002-6302-6107; Stirzaker, Clare/0000-0001-5601-3140;
   Clark, Susan/0000-0001-5925-5030
FU Cancer Institute NSW; National Breast Cancer Foundation (NBCF); National
   Health and Medical Research Council; Dora Lush Biomedical Postgraduate
   Scholarship from the NHMRC; CI NSW Research Scholar Award; NBCF
   Excellence Award; NHMRC
FX This work is supported by Cancer Institute NSW (CI NSW), National Breast
   Cancer Foundation (NBCF) and National Health and Medical Research
   Council (NH&MRC) project grants; Dora Lush Biomedical Postgraduate
   Scholarship from the NH&MRC, CI NSW Research Scholar Award and NBCF
   Excellence Award (R. A. H.); and NH&MRC fellowships (S. J. C. and R. R.
   R.).
CR Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   Gal-Yam EN, 2006, PLOS GENET, V2, P1451, DOI 10.1371/journal.pgen.0020160
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Herman JG, 1999, GASTROENTEROLOGY, V116, P483, DOI 10.1016/S0016-5085(99)70146-0
   HINSHELWOOD RA, 2008, J MOL MED
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Holst CR, 2003, CANCER RES, V63, P1596
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Huschtscha LI, 2001, EXP CELL RES, V265, P125, DOI 10.1006/excr.2001.5178
   Jones PA, 2005, SEMIN HEMATOL, V42, pS3, DOI 10.1053/j.seminhematol.2005.05.001
   Kladde MP, 1996, METHOD ENZYMOL, V274, P214
   KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Micke Patrick, 2005, Methods Mol Biol, V293, P151
   Millar DS, 2002, METHODS, V27, P108, DOI 10.1016/S1046-2023(02)00061-0
   Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637
   Noble JR, 1996, ONCOGENE, V13, P1259
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sandhu C, 2000, ONCOGENE, V19, P5314, DOI 10.1038/sj.onc.1203908
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061
   STAMPFER MR, 1992, TRANSFORMATION HUMAN
   STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638
NR 50
TC 52
Z9 61
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2009
VL 18
IS 16
BP 3098
EP 3109
DI 10.1093/hmg/ddp251
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 475BN
UT WOS:000268330900015
PM 19477956
OA Bronze
DA 2025-01-12
ER

PT J
AU Gordian, E
   Ramachandran, K
   Singal, R
AF Gordian, Edna
   Ramachandran, Kavitha
   Singal, Rakesh
TI Methylation Mediated Silencing of TMS1 in Breast Cancer and its
   Potential Contribution to Docetaxel Cytotoxicity
SO ANTICANCER RESEARCH
LA English
DT Article
DE Epigenetics; breast cancer; DNA methylation; chemotherapy
ID RECRUITMENT DOMAIN PROTEIN; DNA METHYLATION; GENE; EXPRESSION;
   RESISTANCE
AB Background: The tumor suppressor gene TMS1 (target of methylation-induced silencing) has been described in the literature as a pro-apoptotic gene. This study examined the methylation status of TMSI in breast cancer cells and its potential role in sensitivity to docetaxel chemotherapy. Materials and Methods: Methylation of the TMS1 promoter was examined by methylation-specific PCR (MS-PCR) and gene expression was analyzed by reverse transcriptase PCR (RTPCR). Apoptosis was evaluated by annexin V/propidium iodide staining followed by flow cytometric analysis. Results and Conclusion: The TMSI promoter was unmethylated in ZR75-1, MB-231 and MCF7 cells which expressed the gene and partially methylated in SKBR3 and Hs578t cells in which TMS1 expression was down-regulated. Treatment of SKBR3 and Hs578t cells with demethylating agents resulted in reactivation of the TMS1 gene. Pretreatment with 5-azacytidine increased sensitivity to docetaxel treatment in SKBR3 and Hs578t cells, indicating that TMS1 reactivation in these cells may contribute to docetaxel sensitivity.
C1 [Gordian, Edna; Ramachandran, Kavitha; Singal, Rakesh] Univ Miami, Sylvester Canc Ctr, Miami, FL 33136 USA.
C3 University of Miami
RP Singal, R (通讯作者)，1550 NW 10th Ave PAP 219 M877, Miami, FL 33136 USA.
EM rsingal@med.miami.edu
FU University of Miami and Florida's Breast Cancer Coalition Research
   Foundation
FX This work was supported by grants from the Women's Cancer Association of
   the University of Miami and Florida's Breast Cancer Coalition Research
   Foundation (R.S.).
CR Akahira J, 2004, CANCER SCI, V95, P40, DOI 10.1111/j.1349-7006.2004.tb03168.x
   Arai T, 2008, EJSO-EUR J SURG ONC, V34, P734, DOI 10.1016/j.ejso.2007.07.008
   Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918
   Conway KE, 2000, CANCER RES, V60, P6236
   Das PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-28
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Gopisetty G, 2006, MOL IMMUNOL, V43, P1729, DOI 10.1016/j.molimm.2005.11.010
   Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   McConnell BB, 2000, CANCER RES, V60, P6243
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Ramachandran K, 2007, ANTICANCER RES, V27, P921
   Ramachandran K, 2009, CANCER RES, V69, P1527, DOI 10.1158/0008-5472.CAN-08-3609
   Sakin V., 2008, Experimental Oncology, V30, P202
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
NR 17
TC 19
Z9 22
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD AUG
PY 2009
VL 29
IS 8
BP 3207
EP 3210
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 481XQ
UT WOS:000268846800047
PM 19661336
DA 2025-01-12
ER

PT J
AU Finkova, A
   Vazna, A
   Hrachovina, O
   Bendova, S
   Prochazkova, K
   Sedlacek, Z
AF Finkova, Alena
   Vazna, Alzbeta
   Hrachovina, Ondrej
   Bendova, Sarka
   Prochazkova, Kamila
   Sedlacek, Zdenek
TI The <i>TP53</i> gene promoter is not methylated in families suggestive
   of Li-Fraumeni syndrome with no germline <i>TP53</i> mutations
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID P53 GENE; BREAST-CANCER; CPG METHYLATION; TELOMERE LENGTH; HCHK2
   MUTATIONS; BLOOD-CELLS; INDIVIDUALS; EPIMUTATION; CARCINOGENESIS;
   EXPRESSION
AB Germline TP53 mutations are found in only 70% of families with the Li-Fraumeni syndrome (LFS), and with an even lower frequency in families suggestive of LFS but not meeting clinical criteria of the syndrome. Despite intense efforts, to date, no other genes have been associated with the disorder in a significant number of TP53 mutation-negative families. A search for defects in TP53 other than heterozygous missense mutations showed that neither intron variants nor sequence variants in the TP53 promoter are frequent in LFS, and multiexon deletions have been found to be responsible for US only in several cases. Another cancer predisposition syndrome, hereditary non-polyposis colon cancer, has been associated with epigenetic silencing of one allele of the MLH1 or MSH2 genes. This prompted us to test the methylation of the TP53 gene promoter in a set of 14 families suggestive of LFS using bisulphite sequencing of three DNA fragments from the 5' region of the gene. We found no detectable methylation at any of the CG dinucleotides tested. Thus, epigenetic silencing of the TP53 promoter is not a frequent cause of the disorder in families suggestive of LFS but with no germline mutations in the coding part of the gene. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic.
   Univ Hosp Motol, Prague 15006 5, Czech Republic.
C3 Charles University Prague; Motol University Hospital
RP Sedlacek, Z (通讯作者)，Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Vuvalu 84, Prague 15006 5, Czech Republic.
EM zdenek.sedlacek@lfmotol.cuni.cz
OI Prochazkova, Kamila/0009-0008-5947-8021
FU  [MSM0021620813];  [MZO00064203]
FX This work was supported by grants MSM0021620813 and MZO00064203.
CR Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236
   Amatya VJ, 2005, ACTA NEUROPATHOL, V110, P178, DOI 10.1007/s00401-005-1041-5
   Attwooll CL, 2002, CANCER GENET CYTOGEN, V135, P165, DOI 10.1016/S0165-4608(01)00649-5
   Bachinski LL, 2005, CANCER RES, V65, P427
   Barlow JW, 2004, CANCER EPIDEM BIOMAR, V13, P1403
   Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528
   BIRCH JM, 1994, CANCER RES, V54, P1298
   Bougeard G, 2003, ONCOGENE, V22, P840, DOI 10.1038/sj.onc.1206155
   Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253
   Burt EC, 1999, BRIT J CANCER, V80, P9, DOI 10.1038/sj.bjc.6690313
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   Chompret A, 2001, J MED GENET, V38, P43, DOI 10.1136/jmg.38.1.43
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Kontorovich T, 2009, BREAST CANCER RES TR, V116, P195, DOI 10.1007/s10549-008-0121-3
   LI FP, 1988, CANCER RES, V48, P5358
   LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747
   Lima EM, 2008, BRAZ J MED BIOL RES, V41, P539, DOI 10.1590/S0100-879X2008000600017
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Morak M, 2008, EUR J HUM GENET, V16, P804, DOI 10.1038/ejhg.2008.25
   Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0
   Portwine C, 2000, J Med Genet, V37, pE13, DOI 10.1136/jmg.37.8.e13
   Romero-Giménez J, 2008, INT J CANCER, V122, P1422, DOI 10.1002/ijc.23247
   Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796
   Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172
   Shlien A, 2008, P NATL ACAD SCI USA, V105, P11264, DOI 10.1073/pnas.0802970105
   Sidhu S, 2005, EJSO, V31, P549, DOI 10.1016/j.ejso.2005.01.013
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Sodha N, 2002, HUM MUTAT, V20, P460, DOI 10.1002/humu.10136
   SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0
   Stone JG, 1999, CANCER LETT, V147, P181, DOI 10.1016/S0304-3835(99)00291-8
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Tabori U, 2007, CANCER RES, V67, P1415, DOI 10.1158/0008-5472.CAN-06-3682
   Trkova M, 2007, CANCER, V110, P694, DOI 10.1002/cncr.22834
   TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163
   Varley JM, 1997, CANCER RES, V57, P3245
   Varley JM, 2001, CANCER GENET CYTOGEN, V129, P85, DOI 10.1016/S0165-4608(01)00428-9
NR 37
TC 3
Z9 7
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD AUG
PY 2009
VL 193
IS 1
BP 63
EP 66
DI 10.1016/j.cancergencyto.2009.04.014
PG 4
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 482XC
UT WOS:000268922900008
PM 19602465
DA 2025-01-12
ER

PT J
AU Galván-Portillo, MV
   Cantoral, A
   Oñate-Ocaña, LF
   Chen, J
   Herrera-Goepfert, R
   Torres-Sanchez, L
   Hernandez-Ramirez, RU
   Palma-Coca, O
   López-Carrillo, L
AF Galvan-Portillo, Marcia V.
   Cantoral, Alejandra
   Onate-Ocana, Luis F.
   Chen, Jia
   Herrera-Goepfert, Roberto
   Torres-Sanchez, Luisa
   Hernandez-Ramirez, Raul U.
   Palma-Coca, Oswaldo
   Lopez-Carrillo, Lizbeth
TI Gastric cancer in relation to the intake of nutrients involved in
   one-carbon metabolism among <i>MTHFR 677 TT</i> carriers
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Gastric cancer; Diffuse; MTHFR; Folate; Choline; Vitamin B6; Mexico
ID HELICOBACTER-PYLORI INFECTION; METHYLENETETRAHYDROFOLATE-REDUCTASE;
   MTHFR POLYMORPHISMS; COLORECTAL-CANCER; BREAST-CANCER; MEXICAN WOMEN;
   FOLATE INTAKE; RISK; CARCINOGENESIS; SUSCEPTIBILITY
AB Background DNA methylation is an important epigenetic process for transcriptional control of human genome including those genes involved in cancer initiation and progression. Clinical studies have suggested that biological explanation to the protective effect of some nutrients could be linked with the DNA methylation. Folate is a primary methyl donor nutrient; it has been shown to play a key role in DNA methylation, repair and synthesis, by acting as co-factors and/or substrates in this metabolic pathway. Likewise, activity of a key enzyme, the methylenetetrahydrofolate reductase (MTHFR) has also been shown to influence DNA methylation. Overall, these findings support the notion that dietary intake as well as genetic factors play a role in one-carbon metabolism.
   Aim of the study This study is to evaluate the dietary intake of nutrients involved in one-carbon metabolism and the genotype of MTHFR 677 C>T with respect to GC risk.
   Methods We carried out in January 2004 a populationbased case-control study in the metropolitan area of Mexico City. A total of 248 histological confirmed GC patients were recruited from nine tertiary hospitals, along with 478 age and sex-matched controls. Nutrient intake was estimated from food frequency questionnaire; the MTHFR 677C > T genotype was determined by PCR-RFLP analysis.
   Results A significant reduction in diffuse GC risk was observed for MTHFR 677 TT genotype among individuals with high consumption of folate (OR = 0.23; 95% CI 0.06-0.84), choline (OR = 0.55; 95% CI 0.33-0.9) and Vitamin B-6 (OR = 0.59; 95% CI 0.36-0.96) compared to MTHFR 677 CC + CT carriers. Among subjects with low consumption of methionine, a reduced risk of diffuse GC was also detected (OR = 0.40; 95% CI 0.16-0.97). In contrast, carriers of the MTHFR 677 TT genotype with a low consumption of folate had a significant increased risk of intestinal GC (OR = 1.88 95% CI 1.02-3.47). A folate MTHFR 677 C>T interaction in the borderline of significance (P = 0.055) was detected.
   Conclusions It is probable that GC prevention requires dietary recommendations according to the individual genotype; nevertheless, the available information to this respect is still very limited.
C1 [Galvan-Portillo, Marcia V.; Cantoral, Alejandra; Torres-Sanchez, Luisa; Hernandez-Ramirez, Raul U.; Palma-Coca, Oswaldo; Lopez-Carrillo, Lizbeth] Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca 62508, Morelos, Mexico.
   [Onate-Ocana, Luis F.] Gastr Neoplasia Clin, Dept Gastroenterol, Natl Canc Inst, Mexico City 14080, DF, Mexico.
   [Chen, Jia] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA.
   [Herrera-Goepfert, Roberto] Natl Canc Inst, Dept Pathol, Mexico City 14080, DF, Mexico.
C3 Instituto Nacional de Salud Publica; Icahn School of Medicine at Mount
   Sinai
RP López-Carrillo, L (通讯作者)，Natl Inst Publ Hlth, Ctr Populat Hlth Res, Av Univ 655,Col Sta Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.
EM lizbeth@insp.mx
RI Cantoral, Alejandra/AAA-3615-2021; Onate Ocana, Luis F./A-2067-2008
OI Herrera-Goepfert, Roberto/0000-0001-7901-2378; Onate Ocana, Luis
   F./0000-0002-2020-0283
FU CONACYT [Salud-2002-001-7107]
FX The authors thanks Ms. Veronica Lopez for the logistic field
   coordination as well as Dr. Guillermo I Perez-Perez and Dr. Lilia Chihu
   for their laboratory support. This grant was supported by CONACYT
   (Salud-2002-001-7107).
CR [Anonymous], 2007, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective, P265
   BLASER MJ, 1995, CANCER RES, V55, P2111
   Boccia S, 2008, AM J EPIDEMIOL, V167, P505, DOI 10.1093/aje/kwm344
   BOURGES H, 2005, RECOMENDACIONES INGE, V1, P163
   Chen J, 1996, CANCER RES, V56, P4862
   Cho E, 2007, JNCI-J NATL CANCER I, V99, P1224, DOI 10.1093/jnci/djm082
   Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129
   CORREA P, 1975, LANCET, V2, P58
   Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   DOMMARCO JR, 2001, ENCUESTA NACL NUTRIC
   FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302
   Galvan-Portillo MV, 2007, SALUD PUBLICA MEXICO, V49, P126, DOI 10.1590/S0036-36342007000200008
   GALVANPORTILLO M, NUTRIENT IN PRESS
   GUTIERREZVALENZ.V, 2005, RECOMENDACIONES INGE, V1, P163
   Hernandez-Avila M, 1998, SALUD PUBLICA MEXICO, V40, P133, DOI 10.1590/S0036-36341998000200005
   Howe JC., 2004, USDA database for the choline content of common foods
   *I MED NAT AC SCI, 1998, DIET REF INT FOL THI
   Kim YI, 2004, AM J CLIN NUTR, V80, P1123, DOI 10.1093/ajcn/80.5.1123
   Kim YI, 1999, J NUTR BIOCHEM, V10, P66, DOI 10.1016/S0955-2863(98)00074-6
   Larsson SC, 2007, JNCI-J NATL CANCER I, V99, P64, DOI 10.1093/jnci/djk006
   Larsson SC, 2006, GASTROENTEROLOGY, V131, P1271, DOI 10.1053/j.gastro.2006.08.010
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   López-Carrillo L, 1997, INT J EPIDEMIOL, V26, P1166, DOI 10.1093/ije/26.6.1166
   López-Carrillo L, 1999, INT J CANCER, V83, P601, DOI 10.1002/(SICI)1097-0215(19991126)83:5<601::AID-IJC5>3.0.CO;2-6
   Mason JB, 2000, ADV ENZYME REGUL, V40, P127, DOI 10.1016/S0065-2571(99)00037-0
   Miao XP, 2002, CANCER EPIDEM BIOMAR, V11, P1454
   MUNOZ M, 2002, LOA ALIMENTOS SUS NU, P174
   PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603
   *REG HIST NEOPL MA, 2002, COMP CANC 2002
   Rizo P, 2007, CANCEROLOGIA, V2, P203
   Sanjoaquin MA, 2005, INT J CANCER, V113, P825, DOI 10.1002/ijc.20648
   Torres J, 2005, CANCER EPIDEM BIOMAR, V14, P1874, DOI 10.1158/1055-9965.EPI-05-0113
   Torres-Sánchez L, 2006, EUR J CLIN NUTR, V60, P691, DOI 10.1038/sj.ejcn.1602370
   Ulrich CM, 2007, JAMA-J AM MED ASSOC, V297, P2408, DOI 10.1001/jama.297.21.2408
   USDA ARS, 2003, USDA TABL NUTR RET F
   Vollset SE, 2007, CANCER EPIDEM BIOMAR, V16, P2416, DOI 10.1158/1055-9965.EPI-07-0256
   WCRF, 2007, WCRF AICR EXP REP FO
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Ziegler RG, 2007, JNCI-J NATL CANCER I, V99, P1214, DOI 10.1093/jnci/djm105
   Zintzaras E, 2006, J HUM GENET, V51, P618, DOI 10.1007/s10038-006-0405-6
NR 41
TC 41
Z9 43
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD AUG
PY 2009
VL 48
IS 5
BP 269
EP 276
DI 10.1007/s00394-009-0010-5
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 474UJ
UT WOS:000268309400002
PM 19288150
DA 2025-01-12
ER

PT J
AU Fillmore, RA
   Mitra, A
   Xi, YG
   Ju, JF
   Scammell, J
   Shevde, LA
   Samant, RS
AF Fillmore, Rebecca A.
   Mitra, Aparna
   Xi, Yaguang
   Ju, Jingfang
   Scammell, Jonathan
   Shevde, Lalita A.
   Samant, Rajeev S.
TI Nmi (N-Myc interactor) inhibits Wnt/β-catenin signaling and retards
   tumor growth
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE Nmi; Wnt; Dkk1; tumorigenesis
ID BREAST-CANCER; BETA-CATENIN; WNT ANTAGONIST; IFN-GAMMA; PROTEIN NMI;
   EPIGENETIC INACTIVATION; MDA-MB-435 CELLS; DUCTAL-CARCINOMA;
   LUNG-CANCER; EXPRESSION
AB We found that the expression levels of N-Myc interactor (Nmi) were low in aggressive breast cancer cell lines when compared with less aggressive cell lines. However, the lower levels in the aggressive lines were inducible by interferon-gamma (IFN-gamma). Because Nmi has been reported to be a transcription cofactor that augments IFN-gamma induced transcription activity, we decided to test whether Nmi regulates expression of Dkk1, which is also inducible by IFN-gamma. We established stable clones constitutively expressing Nmi in MDA-MB-231 (breast) and MDA-MB-435 (melanoma) cell lines. Dkk1 was significantly up-regulated in the Nmi expressing clones concurrent with reduced levels of the critical transcription cofactor of Writ pathway, beta-catenin. Treatment of the Nmi expressors with blocking antibody to Dkk1 restored P-catenin protein levels. c-Myc is a known downstream target of activated beta-catenin signaling. treatment of Nmi expressors with the proteosome inhibitor MG132, resulted in elevated beta-catenin levels with concomitant elevation of c-Myc levels. Our functional studies showed that constitutive expression of Nmi reduced the ability of tumor cells for the invasion, anchorage independent growth and tumor growth in vivo. Collectively, the data suggest that overexpression of Nmi inhibits the Wnt/beta-catenin signaling via up-regulation of Dkk1 and retards tumor growth. (C) 2009 UICC
C1 [Samant, Rajeev S.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA.
   [Scammell, Jonathan] Univ S Alabama, Dept Comparat Med, Mobile, AL 36604 USA.
   [Scammell, Jonathan] Univ S Alabama, Dept Pharmacol, Mobile, AL 36604 USA.
C3 University of South Alabama; University of South Alabama; University of
   South Alabama
RP Samant, RS (通讯作者)，Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, 1660 Spring Hill Ave, Mobile, AL 36604 USA.
EM rsamant@usouthal.edu
RI Xi, Yaguang/C-3328-2011
OI Samant, Rajeev/0000-0001-5681-4976; Ju, Jingfang/0000-0002-4821-7458;
   Xi, Yaguang/0000-0003-3681-9352
FU Susan G. Komen Breast Cancer Foundation [BCTR0503488]; Department of
   Defense [BCRP-W81XWH-07-1-0400]
FX Grant sponsor: The Susan G. Komen Breast Cancer Foundation: Grant
   number: BCTR0503488. Grant sponsor: The Department of
   Defense-BCRP-W81XWH-07-1-0400.
CR Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090
   Bao JX, 1996, ONCOGENE, V12, P2171
   Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Chen HP, 1999, ONCOL REP, V6, P117
   Chen J, 2000, J BIOL CHEM, V275, P36278, DOI 10.1074/jbc.M006975200
   Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cowling VH, 2007, CELL CYCLE, V6, P2625, DOI 10.4161/cc.6.21.4880
   Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505
   Gollob JA, 2005, CANCER RES, V65, P8869, DOI 10.1158/0008-5472.CAN-05-1387
   Gonzálex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047
   Hunter LA, 2003, POPUL ENVIRON, V25, P23, DOI 10.1023/A:1025595505532
   Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Korswagen HC, 1999, COLD SPRING HARB SYM, V64, P141, DOI 10.1101/sqb.1999.64.141
   Kuphal S, 2006, ONCOGENE, V25, P5027, DOI 10.1038/sj.onc.1209508
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902
   Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200
   Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0
   Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2
   Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A
   Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874
   Nakamura T, 2008, J CELL MOL MED, V12, P391, DOI 10.1111/j.1582-4934.2007.00201.x
   Nichols LM, 2006, HEALTH AFFAIR, V25, P81, DOI 10.1377/hlthaff.25.1.81
   Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039
   Piao Z, 2001, GENE CHROMOSOME CANC, V30, P113, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.3.CO;2-Y
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8
   Rae JM, 2004, CLIN EXP METASTAS, V21, P543, DOI 10.1007/s10585-004-3759-1
   Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263
   Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Schlierf B, 2005, J MOL BIOL, V353, P1033, DOI 10.1016/j.jmb.2005.09.013
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138
   Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218
   Sun GJ, 2002, ACTA BIOCH BIOPH SIN, V34, P369
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572
   Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899
   Tian F, 2003, CANCER RES, V63, P8284
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Voorzanger-Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   XIE X, 1992, CLIN EXP METASTAS, V10, P201, DOI 10.1007/BF00132752
   Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4
   Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8
NR 55
TC 64
Z9 76
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 1
PY 2009
VL 125
IS 3
BP 556
EP 564
DI 10.1002/ijc.24276
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 466CG
UT WOS:000267637600006
PM 19358268
OA Bronze
DA 2025-01-12
ER

PT J
AU Vallian, S
   Sedaghat, M
   Nassiri, I
   Frazmand, A
AF Vallian, Sadeq
   Sedaghat, Mandana
   Nassiri, Isar
   Frazmand, Ali
TI Methylation status of p16 <SUP>INK4A</SUP> tumor suppressor gene in
   Iranian patients with sporadic breast cancer
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Breast cancer; Hypermethylation; Iranian population; MSP; p16(INK4A)
   tumor suppressor gene; REP
ID MAMMARY EPITHELIAL-CELLS; DNA HYPERMETHYLATION; INACTIVATION;
   ASSOCIATION; EPIGENETICS; EXPRESSION; MUTATION; GROWTH; ISLAND
AB p16 (INK4A) is a tumor suppressor encoding the Cdk inhibitor protein, which acts to repress Cdk4/6 and pRb phosphorylation. p16 (INK4A) gene can be inactivated by a variety of events, including promoter hypermethylation.
   To investigate the methylation status of the p16 (INK4A) gene in Iranian patients with breast carcinoma, promoter methylation was studied by methylation-specific PCR (MSP) and restriction enzyme-related PCR (REP). In addition, p16 (INK4A) promoter was analyzed by PCR-SSCP in order to detection of mutation and single nucleotide polymorphisms.
   Analysis of 70 patients by MPS and REP showed hypermethylation of p16 (INK4A) promoter in 35.7% (25/70) and 40% (28/70) of samples, respectively. Comparison of the molecular data and pathological information of the samples suggested that p16 (INK4A) gene might be inactivated at the early stages in breast cancer.
   Therefore, it could be suggested that hypermethylation of p16 (INK4A) promoter is one of the epigenetic factors affecting the progress of sporadic breast carcinogenesis in Iranian patients.
C1 [Vallian, Sadeq; Nassiri, Isar] Univ Isfahan, Fac Sci, Dept Biol, Div Genet, Esfahan, Iran.
   [Sedaghat, Mandana; Frazmand, Ali] Univ Tehran, Fac Sci, Div Cell & Mol Biol, Tehran, Iran.
C3 University of Isfahan; University of Tehran
RP Vallian, S (通讯作者)，Univ Isfahan, Fac Sci, Dept Biol, Div Genet, Hezarjerib St, Esfahan, Iran.
EM svallian@medinews.com
RI Vallian, Sadeq/AAA-7085-2020
OI vallian, sadeq/0000-0002-5151-5923
CR Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bender CM, 1998, CANCER RES, V58, P95
   BO Z, 2007, J HUAZHONG U, V27, P543, DOI DOI 10.1007/S11596-007-0517-Z
   Brenner AJ, 1996, CLIN CANCER RES, V2, P1993
   Calvano JE, 1997, ANN SURG ONCOL, V4, P416, DOI 10.1007/BF02305555
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Dominguez G, 2003, MUTAT RES-FUND MOL M, V530, P9, DOI 10.1016/S0027-5107(03)00133-7
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   GONZALEZZULUETA M, 2000, CANCER RES, V55, P4531
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100
   Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901
   Larsen LA, 2007, NAT PROTOC, V2, P1458, DOI 10.1038/nprot.2007.200
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000
   MAO L, 1995, CANCER RES, V55, P2995
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   Myöhänen SK, 1998, CANCER RES, V58, P591
   Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X
   ZEE KJV, 1998, ONCOGENE, V16, P2723, DOI DOI 10.1038/SJ.ONC.1201794
NR 36
TC 21
Z9 26
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD AUG
PY 2009
VL 135
IS 8
BP 991
EP 996
DI 10.1007/s00432-008-0534-8
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 464DW
UT WOS:000267486400003
PM 19125298
DA 2025-01-12
ER

PT J
AU Zhai, RL
   Bin Wang, G
   Cai, KL
   Tao, KX
   Xu, F
   Zhang, WL
   Wang, ZY
AF Zhai, Rong Lin
   Bin Wang, Guo
   Cai, Kai Lin
   Tao, Kai Xiong
   Xu, Fei
   Zhang, Wan Li
   Wang, Zhi Yong
TI Transcriptional Inactivation of ERβ Gene Is Mediated by the Induction of
   Promoter Hypermethylation in a Rat Colonic Epithelial Cell Model
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE ER beta; methylation; promoter; colonic epithelium; model
ID ESTROGEN-RECEPTOR-BETA; DNA METHYLATION; PROSTATE-CANCER; BREAST-CANCER;
   EXPRESSION; CARCINOMA
AB Background. To construct a primary rat colonic epithelial cell model for treatment with specific methylated oligonucleotides (MOs) and to determine whether the transcriptional inactivation of ER beta mRNA is mediated by the induction of hypermethylation of the ER beta gene promoter.
   Methods. Suckling rat colonic epithelial cells were cultured in DMEM. Two methylated oligonucleotides complementary to the promoter regions of ER beta were synthesized and applied to the cultured cells to induce promoter hypermethylation of the ER beta gene. Methylation-specific PCR (MSP) was used to determine the methylation status of the ER beta promoter in the cultured cells. Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression of ER beta mRNA after treatment with MOs.
   Results. Suckling rat colonic epithelial cells were successfully cultured in vitro. The MOs and unmethylated oligonucleotides (LTMOs) we designed, synthesized, successfully transfected into the colonic epithelial cells, and assembled in the nuclei of the cells, which had extremely elevated proliferative activity. RT-PCR demonstrated that the expression of ER beta mRNA was significantly suppressed in the cells treated with MOs, whereas its expression in the control cells treated with UMOs was not. MSP analysis showed that the promoter of ER beta in the cells treated with MOs was hypermethylated compared with that of the control cells.
   Conclusion. The transcriptional inactivation of ER beta mRNA in rat colonic epithelial cells may be mediated by the hypermethylation of the ER beta gene promoter. Our model markedly simulates the epigenetic modification of the ER beta gene in colonic cancer cells. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.
C1 [Zhai, Rong Lin; Bin Wang, Guo; Cai, Kai Lin; Tao, Kai Xiong; Xu, Fei; Zhang, Wan Li; Wang, Zhi Yong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gen Surg, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Zhai, RL (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gen Surg, Wuhan 430022, Peoples R China.
EM zhaironglin@yahoo.com.cn
RI XU, FEI/KVY-3201-2024; Wanli, Zhang/AAO-4066-2020; cai,
   kailin/KIA-9950-2024
FU National Natural Science Foundation of China [30500488]
FX This study was supported by the National Natural Science Foundation of
   China, No. 30500488.
CR Altundag O, 2004, MED HYPOTHESES, V63, P684, DOI 10.1016/j.mehy.2004.03.017
   Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258
   EVANS GS, 1992, J CELL SCI, V101, P219
   Foley EF, 2000, CANCER RES, V60, P245
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   JARK SJ, 2002, METHODS, V27, P99
   Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9
   Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A
   Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5
   Wada-Hiraike O, 2006, P NATL ACAD SCI USA, V103, P2959, DOI 10.1073/pnas.0511271103
   Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
   Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869
NR 18
TC 2
Z9 2
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 2009
VL 155
IS 2
BP 306
EP 310
DI 10.1016/j.jss.2008.09.028
PG 5
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 488EP
UT WOS:000269332300019
PM 19520385
DA 2025-01-12
ER

PT J
AU Willers, H
   Taghian, AG
   Luo, CM
   Treszezamsky, A
   Sgroi, DC
   Powell, SN
AF Willers, Henning
   Taghian, Alphonse G.
   Luo, Chen-Mei
   Treszezamsky, Alejandro
   Sgroi, Dennis C.
   Powell, Simon N.
TI Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1
   Pathway Defects in Breast Cancer Biopsies
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID FANCONI-ANEMIA; HOMOLOGOUS RECOMBINATION; SPORADIC BREAST; DAMAGE
   RESPONSE; NUCLEAR FOCI; PHENOTYPE; PHOSPHORYLATION; MUTATIONS; PROMOTER;
   SUBTYPE
AB The DNA damage response pathway controlled by the breast cancer and Fanconi anemia (FA) genes can be disrupted by genetic or epigenetic mechanisms in breast cancer. Defects in this pathway may render the affected tumors hypersensitive to DNA-damaging agents. The identification of these defects poses a challenge because of the large number of genes involved in the FA/BRCA pathway. Many pathway components form subnuclear repair protein foci upon exposure to ionizing radiation in vitro, but it was unknown whether foci can be detected in live cancer tissues. Thus, the goal of this pilot study was to identify pathway defects by using a novel ex vivo foci biomarker assay on tumor biopsies. Fresh pretreatment biopsy specimens from patients with locally advanced sporadic breast cancer were irradiated or mock-treated in the laboratory (ex vivo). Foci formation of DNA repair proteins BRCA1, FANCD2, and RAD51 was detected by immunofluorescence microscopy. Three out of seven tumors showed intact radiation-induced foci formation, whereas the other four tumors exhibited a defective foci response. Notably, three of the foci-defective tumors were estrogen receptor/progesterone receptor/HER2-negative (triple-negative), a phenotype that has been associated with BRCA1 deficiency. In conclusion, in this pilot study, we report the successful detection of BRCA1, FANCD2, and RAD51 foci in breast cancer biopsies irradiated ex vivo. Our approach represents a potentially powerful biomarker assay for the detection of pre-existing and functionally important defects within the complex FA/BRCA pathway, which may ultimately allow us to tailor cancer treatment to the DNA repair profile of individual tumors. (Mol Cancer Res 2009;7(8):1304-9)
C1 [Powell, Simon N.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA.
   [Willers, Henning; Taghian, Alphonse G.; Luo, Chen-Mei; Treszezamsky, Alejandro; Powell, Simon N.] Harvard Univ, Massachusetts Gen Hosp, Lab Cellular & Mol Radiat Oncol, Dept Radiat Oncol,Canc Ctr,Med Sch, Charlestown, MA USA.
   [Sgroi, Dennis C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc,Dept Pathol, Charlestown, MA USA.
C3 Memorial Sloan Kettering Cancer Center; Harvard University;
   Massachusetts General Hospital; Harvard University; Massachusetts
   General Hospital
RP Powell, SN (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10065 USA.
EM powells@mskcc.org
RI Sgroi, Dennis/AAV-2487-2021
FU Avon-NCI Progress for Patients Award [CA089393]
FX Grant support: Avon-NCI Progress for Patients Award on the
   Dana-Farber/Harvard Cancer Center Specialized Programs of Research
   Excellence in Breast Cancer CA089393 (A.G. Taghian).
CR Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200
   Elkahloun AG, 2002, CANCER BIOL THER, V1, P354
   Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3
   Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874
   Kennedy RD, 2006, J CLIN ONCOL, V24, P3799, DOI 10.1200/JCO.2005.05.4171
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625
   Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2
   Powell SN, 2008, ANTI-CANCER AGENT ME, V8, P448, DOI 10.2174/187152008784220267
   Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678
   Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Shi W, 2008, J BIOL CHEM, V283, P31608, DOI 10.1074/jbc.M801082200
   Staff S, 2003, CANCER RES, V63, P4978
   Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263
   Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004
   Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004
NR 29
TC 99
Z9 103
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD AUG
PY 2009
VL 7
IS 8
BP 1304
EP 1309
DI 10.1158/1541-7786.MCR-09-0149
PG 6
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 486BK
UT WOS:000269170200011
PM 19671671
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Bendinelli, P
   Matteucci, E
   Maroni, P
   Desiderio, MA
AF Bendinelli, Paola
   Matteucci, Emanuela
   Maroni, Paola
   Desiderio, Maria Alfonsina
TI NF-κB Activation, Dependent on Acetylation/Deacetylation, Contributes to
   HIF-1 Activity and Migration of Bone Metastatic Breast Carcinoma Cells
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION;
   HYPOXIA-INDUCIBLE FACTOR-1; CANCER METASTASIS; FACTOR-I; CXCR4
   EXPRESSION; GENE-EXPRESSION; TUMOR-CELLS; C-SRC; TRANSCRIPTION
AB Here, we show that NF-kappa B-HIF-1 interaction contributed to breast cancer metastatic capacity by means of an incomplete epithelial/mesenchymal transition and influencing migration, as shown in 1833 (human) and 4T1 (mouse) metastatic cells after different stimuli. The 1833 and the transforming growth factor-beta 1-exposed 4T1 cells showed both epithelial (E-cadherins) and mesenchymal (N-cadherins and vimentin) markers, and common mechanisms contributed to the retention of certain epithelial characteristics and the control of migration. The complex NF-kappa B-HIF-1 reciprocal regulation and the enhanced c-Jun expression played a functional role in exacerbating the invasiveness of 1833 cells after p50/p65 transfection and of 4T1 cells exposed to transforming growth factor-beta 1. Twist expression seemed to exert a permissive role also regulating epithelial/mesenchymal transition markers. After c-Src wild-type (Srcwt) transfection, c-Src-signal transducer overexpression in 1833 cells increased HIF-1 transactivating activity and invasiveness, and changed E-cadherin/N-cadherin ratio versus mesenchymal phenotype. The transcription factor pattern and the motile phenotype of metastatic 1833 cells were influenced by p65-lysine acetylation and HDAC-dependent epigenetic mechanisms, which positively regulated basal NF-kappa B and HIF-1 activities. However, HDAC3 acted as a corepressor of NF-kappa B activity in parental MDA-MB231 cells, thus explaining many differences from the derived 1833 clone, including reduced HIF-1 alpha and c-Jun expression. Invasiveness was differently affected by HDAC knockdown in 1833 and MDA-MB231 cells. We suggest that acetylation/deacetylation are critical in establishing the bone-metastatic gene signature of 1833 cells by regulating the activity of NF-kappa B and HIF-1, and further clarity the epigenetic control of transcription factor network in the motile phenotype of 1833 cells. (Mol Cancer Res 2009;7(8):1328-41)
C1 [Desiderio, Maria Alfonsina] Univ Milan, Dipartimento Morfol Umana & Sci Biomed Citta Stud, Mol Pathol Lab, Sch Med, I-20133 Milan, Italy.
   [Maroni, Paola] Ist Ricovero & Cura Carattere Sci, Ist Ortoped Galeazzi, Milan, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   IRCCS Istituto Ortopedico Galeazzi
RP Desiderio, MA (通讯作者)，Univ Milan, Dipartimento Morfol Umana & Sci Biomed Citta Stud, Mol Pathol Lab, Sch Med, Via Luigi Mangiagalli 31, I-20133 Milan, Italy.
EM a.desiderio@unimi.it
RI Bendinelli, Paola/M-7324-2016; Desiderio, Maria/M-8870-2016; Maroni,
   Paola/B-1366-2017
OI Maroni, Paola/0000-0002-3444-9338
FU Ministero Istruzione [12-25201001-14]; Universita e Ricerca, Ricerca
   Corrente [2.30]; Ministero della Salute, Italy [RF 06-81]
FX Grant support: PRIN 2007 (grant no. 12-25201001-14) from Ministero
   Istruzione, Universita e Ricerca, Ricerca Corrente (grant no. 2.30), and
   Finalizzato (grant no. RF 06-81) from Ministero della Salute, Italy.
CR Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749
   Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002
   ANGUILERA C, 2006, J CELL SCI, V119, P3695
   Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9
   DEJARDIN E, 1995, ONCOGENE, V11, P1835
   Desiderio MA, 2007, CELL MOL LIFE SCI, V64, P1341, DOI 10.1007/s00018-007-7050-x
   Dittmer J, 2003, MOL CANCER, V2, P1
   DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Farhat N, 2008, BRIT J PHARMACOL, V153, P1420, DOI 10.1038/bjp.2008.25
   Firulli AB, 2008, CURR MED CHEM, V15, P2641, DOI 10.2174/092986708785908987
   Gao CF, 2005, P NATL ACAD SCI USA, V102, P10528, DOI 10.1073/pnas.0504367102
   Gao ZG, 2006, J BIOL CHEM, V281, P4540, DOI 10.1074/jbc.M507784200
   Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200
   Garcia T, 2008, CLIN EXP METASTAS, V25, P33, DOI 10.1007/s10585-007-9099-1
   Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Haddad JJ, 2005, INT IMMUNOPHARMACOL, V5, P461, DOI 10.1016/j.intimp.2004.11.009
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355
   Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070
   Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Jiao XM, 2008, MOL BIOL CELL, V19, P1378, DOI 10.1091/mbc.E07-08-0753
   Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kasper LH, 2006, CELL CYCLE, V5, P142, DOI 10.4161/cc.5.2.2353
   Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234
   Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787
   KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542
   Lee YH, 2008, CARCINOGENESIS, V29, P2243, DOI 10.1093/carcin/bgn199
   Liang ZX, 2005, CANCER RES, V65, P967
   Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658
   Manna PR, 2007, J MOL ENDOCRINOL, V39, P261, DOI 10.1677/JME-07-0065
   Maroni P, 2007, CARCINOGENESIS, V28, P267, DOI 10.1093/carcin/bgl129
   Matteucci E, 2006, CELL MOL LIFE SCI, V63, P2016, DOI 10.1007/s00018-006-6137-0
   Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008
   Matteucci E, 2007, MOL CANCER RES, V5, P833, DOI 10.1158/1541-7786.MCR-07-0054
   Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235
   Milani M, 2008, EUR J CANCER, V44, P2766, DOI 10.1016/j.ejca.2008.09.025
   Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695
   Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Ridolfi E, 2008, BRIT J CANCER, V99, P1623, DOI 10.1038/sj.bjc.6604726
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Shim H, 2006, BIOCHEM BIOPH RES CO, V346, P252, DOI 10.1016/j.bbrc.2006.05.110
   Sun HL, 2007, ONCOGENE, V26, P3941, DOI 10.1038/sj.onc.1210169
   Tacchini L, 2004, CARCINOGENESIS, V25, P2089, DOI 10.1093/carcin/bgh227
   Tacchini L, 2003, EXP CELL RES, V290, P391, DOI 10.1016/S0014-4827(03)00348-3
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wilson CL, 1997, ARCH BIOCHEM BIOPHYS, V346, P65, DOI 10.1006/abbi.1997.0289
   Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
NR 63
TC 56
Z9 60
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD AUG
PY 2009
VL 7
IS 8
BP 1328
EP 1341
DI 10.1158/1541-7786.MCR-08-0548
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 486BK
UT WOS:000269170200013
PM 19671685
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Tseng, RC
   Lee, CC
   Hsu, HS
   Tzao, C
   Wang, YC
AF Tseng, Ruo-Chia
   Lee, Chin-Chu
   Hsu, Han-Shui
   Tzao, Ching
   Wang, Yi-Ching
TI Distinct HIC1-SIRT1-p53 Loop Deregulation in Lung Squamous Carcinoma and
   Adenocarcinoma Patients
SO NEOPLASIA
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; HIC1 HYPERMETHYLATED-IN-CANCER-1; ALLELIC LOSS;
   P53; SIRT1; IDENTIFICATION; METHYLATION; FAMILY
AB A HIC1-SIRT1-p53 circular loop in which hypermethylation in cancer 1 (HIC1) represses the transcription of SIRT1 that deacetylates and inactivates p53 thus leading to HIC1 inactivation has been identified in cell and animal models. However, the alteration and prognostic effects of HIC1-SIRT1-p53 circular loop have never been demonstrated in human cancer patients. We examine the HIC1-SIRT1-p53 alterations in 118 lung cancer patients to define their etiological roles in tumorigenesis. We found that patients with lung squamous cell carcinoma with low p53 acetylation and SIRT1 expression mostly showed low HIC1 expression, confirming deregulation of HIC1-SIRT1-p53 circular loop in the clinical model. Interestingly, the expression of deleted in breast cancer 1 (DBC1), which blocks the interaction between SIRT1 deacetylase and p53, led to acetylated p53 in patients with lung adenocarcinoma. However, epigenetic alteration of HIC1 promoter by posttranslational modifications of histones and promoter hypermethylation favoring the compacted chromatin production attenuated the transcriptional induction by acetylated p53. Importantly, lung cancer patients with altered HIC1-SIRT1-p53 circular regulation showed poor prognosis. Our data show the first valid clinical evidence of the deregulation of HIC1-SIRT1-p53 loop in lung tumorigenesis and prognosis. Distinct status of p53 acetylation/deacetylation and HIC1 alteration mechanism result from different SIRT1-DBC1 control and epigenetic alteration in lung squamous cell carcinoma and lung adenocarcinoma.
C1 [Wang, Yi-Ching] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.
C3 National Cheng Kung University
RP Wang, YC (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.
EM ycw5798@mail.ncku.edu.tw
RI Wang, Yi-Ching/J-8702-2019
OI Wang, Yi-Ching/0000-0002-7694-2067
FU National Science Council [NSC96-2628-B-006-048-MY3]; Department of
   Health (The Executive Yuan, Republic of China) [DOH97-TD-G-111-035]
FX This work was supported in part by grant NSC96-2628-B-006-048-MY3 from
   the National Science Council and grant DOH97-TD-G-111-035 from the
   Department of Health (The Executive Yuan, Republic of China).
CR Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1
   Fleuriel C, 2009, INT J BIOCHEM CELL B, V41, P26, DOI 10.1016/j.biocel.2008.05.028
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500
   Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003
   Niklinski J, 2001, EUR J CANCER PREV, V10, P213, DOI 10.1097/00008469-200106000-00004
   Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rood BR, 2002, CANCER RES, V62, P3794
   Stöcklein H, 2008, ONCOGENE, V27, P2613, DOI 10.1038/sj.onc.1210901
   Sun YN, 2007, LUNG CANCER, V58, P21, DOI 10.1016/j.lungcan.2007.05.013
   Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178
   Tseng RC, 2008, LUNG CANCER, V59, P332, DOI 10.1016/j.lungcan.2007.08.038
   Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wang YC, 2005, J CLIN ONCOL, V23, P154, DOI 10.1200/JCO.2005.03.139
   Wang YC, 1998, CANCER RES, V58, P328
   Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515
NR 30
TC 81
Z9 91
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD AUG
PY 2009
VL 11
IS 8
BP 763
EP U65
DI 10.1593/neo.09470
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 470OI
UT WOS:000267984600005
PM 19649206
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pulukuri, SM
   Gorantla, B
   Knost, JA
   Rao, JS
AF Pulukuri, S. M.
   Gorantla, B.
   Knost, J. A.
   Rao, J. S.
TI Frequent loss of cystatin E/M expression implicated in the progression
   of prostate cancer
SO ONCOGENE
LA English
DT Article
DE cystatins; cathepsins; invasion; histone modification; chromatin;
   prostate cancer
ID UROKINASE PLASMINOGEN-ACTIVATOR; HISTONE DEACETYLASE INHIBITION;
   CYSTEINE PROTEINASE-INHIBITOR; ABERRANT DNA METHYLATION; HUMAN
   GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CATHEPSIN-B;
   EPIGENETIC INACTIVATION; INVASION
AB Cystatin E/M (CST6) is a natural inhibitor of lysosomal cysteine proteases. Recent studies have shown that experimental manipulation of CST6 expression alters the metastatic behavior of human breast cancer cells. However, the association of CST6 with prostate cancer invasion and progression remains unclear. Here, we show that CST6 is robustly expressed in normal human prostate epithelium, whereas its expression is downregulated in metastatic prostate cell lines and prostate tumor tissues. Treatment of metastatic prostate cell lines with the histone deacetylase inhibitor trichostatin A resulted in significant induction of CST6 mRNA levels and increased CST6 protein expression, indicating that epigenetic silencing may play a role in the loss of CST6 expression observed in prostate cancer. CST6 overexpression in human prostate cancer cells significantly reduced in vitro cell proliferation and matrigel invasion. Furthermore, the results from a bioluminescence tumor/metastasis model showed that the overexpression of CST6 significantly inhibits tumor growth and the incidence of lung metastasis. These results suggest that the downregulation of the CST6 gene is associated with promoter histone modi. cations and that this association plays an important role in prostate cancer progression during the invasive and metastatic stages of the disease. Oncogene (2009) 28, 2829-2838; doi:10.1038/onc.2009.134; published online 8 June 2009
C1 [Pulukuri, S. M.; Gorantla, B.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA.
   [Knost, J. A.] Illinois Canc Care, Peoria, IL USA.
   [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61605 USA.
C3 University of Illinois System; University of Illinois Peoria; University
   of Illinois System; University of Illinois Peoria
RP Rao, JS (通讯作者)，Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.
EM jsrao@uic.edu
FU National Cancer Institute [CA75557, CA92393, CA95058, CA116708,
   CA138409, NS47699, NS57529, NS61835]; Caterpillar Inc.,
FX We are grateful to Dr Hnilica of the Department of Pathology at the
   University of Illinois College of Medicine ( Peoria) for kindly
   providing normal and tumor human prostate tissues. We thank Shellee
   Abraham for preparing the paper and Diana Meister and Sushma Jasti for
   paper review. We also thank Noorjehan Ali and Lavanya Talluri, for
   technical assistance. This research was supported by National Cancer
   Institute Grant CA75557, CA92393, CA95058, CA116708, CA138409, N. I. N.
   D. S. NS47699, NS57529 and NS61835 and Caterpillar Inc., OSF St Francis
   Inc. Peoria, IL ( to JSR). The contents are solely the responsibility of
   the authors and do not necessarily represent the official views of NIH.
CR ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195
   Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757
   Brunner N, 1994, Cancer Treat Res, V71, P299
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M
   Esteller M, 2001, CANCER RES, V61, P3225
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949
   Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341
   Marks PA, 2001, CLIN CANCER RES, V7, P759
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Ni J, 1997, J BIOL CHEM, V272, P10853
   Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329
   Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200
   Pulukuri SMK, 2007, CANCER RES, V67, P6637, DOI 10.1158/0008-5472.CAN-07-0751
   Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757
   Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940
   Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   Veena MS, 2008, GENE CHROMOSOME CANC, V47, P740, DOI 10.1002/gcc.20576
   Yanamandra N, 2004, ONCOGENE, V23, P2224, DOI 10.1038/sj.onc.1207338
   Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
NR 34
TC 35
Z9 40
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG
PY 2009
VL 28
IS 31
BP 2829
EP 2838
DI 10.1038/onc.2009.134
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 479TS
UT WOS:000268684400006
PM 19503093
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Patani, N
   Jiang, W
   Mansel, R
   Newbold, R
   Mokbel, K
AF Patani, Neill
   Jiang, Wen
   Mansel, Robert
   Newbold, Robert
   Mokbel, Kefah
TI The mRNA expression of SATB1 and SATB2 in human breast cancer
SO CANCER CELL INTERNATIONAL
LA English
DT Article
ID POLYMERASE-III TRANSCRIPTION; MAR-BINDING PROTEIN; GENE-EXPRESSION;
   NUCLEAR-MATRIX; SPATIAL-ORGANIZATION; NEGATIVE REGULATOR; CHROMATIN
   DOMAINS; DNA ELEMENTS; CLEFT-PALATE; IN-VIVO
AB Background: SATB1 is a nuclear protein that has been recently reported to be a 'genome organizer' which delineates specific epigenetic modifications at target gene loci, directly up-regulating metastasis-associated genes while down-regulating tumor-suppressor genes. In this study, the level of mRNA expression of SATB1 and SATB2 were assessed in normal and malignant breast tissue in a cohort of women with breast cancer and correlated to conventional clinico-pathological parameters.
   Materials and methods: Breast cancer tissues (n = 115) and normal background tissues (n = 31) were collected immediately after excision during surgery. Following RNA extraction, reverse transcription was carried out and transcript levels were determined using real-time quantitative PCR and normalized against beta-actin expression. Transcript levels within the breast cancer specimens were compared to the normal background tissues and analyzed against TNM stage, nodal involvement, tumour grade and clinical outcome over a 10 year follow-up period.
   Results: The levels of SATB1 were higher in malignant compared with normal breast tissue (p = 0.0167). SATB1 expression increased with increasing TNM stage (TNM1 vs. TNM2 p = 0.0264), increasing tumour grade (grade1 vs. grade 3 p = 0.017; grade 2 vs. grade 3 p = 0.0437; grade 1 vs. grade 2&3 p = 0.021) and Nottingham Prognostic Index (NPI) (NPI-1 vs. NPI-3 p = 0.0614; NPI-2 vs. NPI-3 p = 0.0495). Transcript levels were associated with oestrogen receptor (ER) positivity (ER(-) vs. ER(+) p = 0.046). SABT1 expression was also significantly correlated with downstream regulated genes IL-4 and MAF-1 (Pearson's correlation coefficient r = 0.21 and r = 0.162) and SATB2 (r = 0.506). After a median follow up of 10 years, there was a trend for higher SATB1 expression to be associated with shorter overall survival (OS). Higher levels of SATB2 were also found in malignant compared to background tissue (p = 0.049). SATB2 expression increased with increasing tumour grade (grade 1 vs. grade 3 p = 0.035). SATB2 was associated with ER positivity (ER(-) vs. ER(+) p = 0.0283) within ductal carcinomas. Higher transcript levels showed a significant association with poorer OS (p = 0.0433).
   Conclusion: SATB1 mRNA expression is significantly associated with poor prognostic parameters in breast cancer, including increasing tumour grade, TNM stage and NPI. SATB2 mRNA expression is significantly associated with increasing tumour grade and poorer OS. These results are consistent with the notion that SATB1 acts as a 'master genome organizer' in human breast carcinogenesis.
C1 [Patani, Neill; Mokbel, Kefah] St Georges Univ London, Dept Breast Surg, London, England.
   [Patani, Neill; Mokbel, Kefah] Princess Grace Hosp, London Breast Inst, London, England.
   [Jiang, Wen; Mansel, Robert] Cardiff Univ, Univ Dept Surg, Metastasis & Angiogenesis Res Grp, Cardiff, S Glam, Wales.
   [Newbold, Robert; Mokbel, Kefah] Brunel Inst Canc Genet & Pharmacogenom, London, England.
C3 City St Georges, University of London; St Georges University London;
   Cardiff University; Brunel University
RP Mokbel, K (通讯作者)，St Georges Univ London, Dept Breast Surg, London, England.
EM neillpatani@hotmail.com; jiangw@cf.ac.uk; manselre@cf.ac.uk;
   robert.newbold@brunel.ac.uk; kefahmokbel@hotmail.com
RI Jiang, Wen/AAF-1876-2020; Newbold, Robert/JDN-0280-2023; Jiang, Wen
   G./B-1293-2010
OI Mokbel, Kefah/0000-0001-7255-7850; Jiang, Wen G./0000-0002-3283-1111;
   Patani, Neill/0000-0002-9591-8636
FU Breast Cancer Campaign
FX We are grateful to Breast Cancer Campaign for supporting our research
   programme.
CR Alvarez JD, 2000, GENE DEV, V14, P521
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   BEST JL, 2001, NAT REV MOL CELL BIO, V2, P202
   Bode J, 2000, CRIT REV EUKAR GENE, V10, P73
   BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545
   BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104
   Boulikas T, 1995, INT REV CYTOL, V162A, P279
   Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x
   Britanova O, 2006, AM J HUM GENET, V79, P668, DOI 10.1086/508214
   Brown KE, 2003, CHROMOSOME RES, V11, P423, DOI 10.1023/A:1024966424909
   CAI S, 2006, MOL CELL, V22, P231
   Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146
   Case SS, 1999, DNA CELL BIOL, V18, P805, DOI 10.1089/104454999314809
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075
   de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335
   de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726
   Dickinson LA, 1997, J BIOL CHEM, V272, P11463
   DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C
   Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003
   Drobic B, 2006, EXP SUPPL, V96, P25
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248
   Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916
   Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3
   Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   Galande S, 2001, MOL CELL BIOL, V21, P5591, DOI 10.1128/MCB.21.16.5591-5604.2001
   Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003
   Goodfellow SJ, 2008, J MOL BIOL, V378, P481, DOI 10.1016/j.jmb.2008.02.060
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Heng HHQ, 2004, J CELL SCI, V117, P999, DOI 10.1242/jcs.00976
   Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825
   Jiang WG, 2003, CLIN CANCER RES, V9, P6432
   Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302
   Johnson SS, 2007, MOL CELL, V26, P367, DOI 10.1016/j.molcel.2007.03.021
   Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323
   KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009
   KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j
   Kumar PP, 2007, J VIROL, V81, P5617, DOI 10.1128/JVI.01405-06
   Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516
   Kumar PP, 2005, MOL CELL BIOL, V25, P1620, DOI 10.1128/MCB.25.5.1620-1633.2005
   Laemmli UK, 1996, CURR OPIN CELL BIOL, V8, P299, DOI 10.1016/S0955-0674(96)80001-9
   Leoyklang P, 2007, HUM MUTAT, V28, P732, DOI 10.1002/humu.20515
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Nakayama Y, 2005, CELL CYCLE, V4, P1099
   Nie H, 2008, MOL IMMUNOL, V46, P207, DOI 10.1016/j.molimm.2008.07.007
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Recillas-Targa F, 2001, CRIT REV EUKAR GENE, V11, P227
   Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310
   Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273
   Scheuermann RH, 1999, CRIT REV EUKAR GENE, V9, P295, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.140
   Schubeler D, 2000, GENE DEV, V14, P940
   Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N
   Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200
   Seo S, 2005, DEVELOPMENT, V132, P105, DOI 10.1242/dev.01548
   Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724
   Spector DL, 2001, J CELL SCI, V114, P2891
   Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X
   Strick T, 2000, PROG BIOPHYS MOL BIO, V74, P115, DOI 10.1016/S0079-6107(00)00018-3
   Szemes M, 2006, NEUROCHEM RES, V31, P237, DOI 10.1007/s11064-005-9012-8
   Todaro M, 2008, CELL DEATH DIFFER, V15, P762, DOI 10.1038/sj.cdd.4402305
   Towpik J, 2008, J BIOL CHEM, V283, P17168, DOI 10.1074/jbc.M709157200
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wen J, 2005, BLOOD, V105, P3330, DOI 10.1182/blood-2004-08-2988
   Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95
   Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   Zheng J, 2008, WOMENS HEALTH, V4, P329, DOI 10.2217/17455057.4.4.329
NR 71
TC 93
Z9 113
U1 3
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD JUL 30
PY 2009
VL 9
AR 18
DI 10.1186/1475-2867-9-18
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 541CI
UT WOS:000273390000001
PM 19642980
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Schultz, J
   Ibrahim, SM
   Vera, J
   Kunz, M
AF Schultz, Julia
   Ibrahim, Saleh M.
   Vera, Julio
   Kunz, Manfred
TI 14-3-3σ gene silencing during melanoma progression and its role in cell
   cycle control and cellular senescence
SO MOLECULAR CANCER
LA English
DT Article
ID DOWN-REGULATION; MALIGNANT-MELANOMA; BRAF MUTATIONS; HIGH-FREQUENCY;
   BREAST-CANCER; HYPERMETHYLATION; ARREST; GROWTH; NEVI; P53
AB Background: The family of 14-3-3 proteins plays an important role in cancer biology by interfering with intracellular signalling pathways and cell cycle checkpoints. The 14-3-3 sigma isoform acts as a tumor suppressor and is often inactivated during tumor development.
   Results: Here, we demonstrate enhanced CpG methylation of the 14-3-3 sigma gene in lymph node and cutaneous melanoma metastases compared with primary tumors, associated with dramatically reduced mRNA expression. In line with this, treatment of different metastatic melanoma cell lines with 5-aza-2'-deoxycytidine (5-Aza-CdR), a potent inhibitor of cytosine methylation, significantly induces 14-3-3 sigma protein expression. Additional treatment with histone deacetylase inhibitor 4-phenylbutyric acid (Pba) further enhances 14-3-3 sigma expression. Induction of 14-3-3 sigma expression by 5-Aza-CdR/Pba treatment leads to almost complete inhibition of cell proliferation, with cells predominantly arrested in G2-M. The antiproliferative effect of 5-Aza-CdR/Pba was reversed in 14-3-3 sigma knockdown cells. Similarly, melanoma cell lines stably overexpressing 14-3-3 sigma show dramatically reduced cell proliferation rates. Moreover, synchronous 14-3-3 sigma stably overexpressing cells do not progress through cell cycle, but display a permanent increase in the population of 4n DNA containing cells. Interestingly, overexpression of 14-3-3 sigma induces senescence of melanoma cells and is involved in melanoma cell senescence under genotoxic stress. Finally, 14-3-3 sigma knockdown supports migratory capacity of melanoma cells in vitro, while 14-3-3 sigma overexpression has opposing effects.
   Conclusion: Taken together, the present report indicates that epigenetic silencing of 14-3-3 sigma might contribute to tumor progression in malignant melanoma via loss of cell cycle control, impaired cellular senescence program and support of migratory capacity.
C1 [Kunz, Manfred] Med Univ Lubeck, Comprehens Ctr Inflammat Med, D-23538 Lubeck, Germany.
   [Schultz, Julia] Univ Rostock, Dept Cardiac Surg, D-18055 Rostock, Germany.
   [Ibrahim, Saleh M.] Med Univ Lubeck, Dept Dermatol Allergol & Venerol, D-23538 Lubeck, Germany.
   [Vera, Julio] Univ Rostock, Dept Comp Sci, D-18051 Rostock, Germany.
C3 University of Lubeck; University of Rostock; University of Lubeck;
   University of Rostock
RP Kunz, M (通讯作者)，Med Univ Lubeck, Comprehens Ctr Inflammat Med, D-23538 Lubeck, Germany.
EM schultzj@gmx.de; saleh.ibrahim@uk-sh.de;
   jv030@informatik.uni-rostock.de; manfred.kunz@uk-sh.de
RI Ibrahim, Saleh/AAO-9541-2020; Vera, Julio/O-4134-2015
OI Vera, Julio/0000-0002-3076-5122; Ibrahim, Saleh/0000-0001-7827-2290
FU Erich and Gertrud Roggenbuck-Stiftung, Hamburg, Germany
FX We thank R. Water stradt for excellent technical assistance. This work
   was in part supported by the Erich and Gertrud Roggenbuck-Stiftung,
   Hamburg, Germany.
CR Bandyopadhyay D, 2002, CANCER RES, V62, P6231
   Bandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x
   Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145
   Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808
   Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092
   Dalal SN, 2004, CELL CYCLE, V3, P672
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117
   Dhillon AS, 2004, CANCER CELL, V5, P303, DOI 10.1016/S1535-6108(04)00087-X
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004
   Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123
   Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166
   Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3
   Nguyen A, 2004, NAT BIOTECHNOL, V22, P993, DOI 10.1038/nbt997
   Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444
   Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045
   Wilker EW, 2007, NATURE, V446, P329, DOI 10.1038/nature05584
   Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540
   Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003
NR 42
TC 42
Z9 45
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 30
PY 2009
VL 8
AR 53
DI 10.1186/1476-4598-8-53
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 486GG
UT WOS:000269183600002
PM 19642975
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hsu, PY
   Deatherage, DE
   Rodriguez, BAT
   Liyanarachchi, S
   Weng, YI
   Zuo, T
   Liu, J
   Cheng, ASL
   Huang, THM
AF Hsu, Pei-Yin
   Deatherage, Daniel E.
   Rodriguez, Benjamin A. T.
   Liyanarachchi, Sandya
   Weng, Yu-I
   Zuo, Tao
   Liu, Joseph
   Cheng, Alfred S. L.
   Huang, Tim H-M
TI Xenoestrogen-Induced Epigenetic Repression of
   <i>microRNA</i>-<i>9</i>-<i>3</i> in Breast Epithelial Cells
SO CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE-DISRUPTING COMPOUNDS; DNA
   METHYLATION; PROGENITOR CELLS; CANCER CELLS; GENE; DIETHYLSTILBESTROL;
   EXPRESSION; LYSINE-27; EXPOSURE
AB Early exposure to xenoestrogens may predispose to breast cancer risk later in adult life. It is likely that long-lived, self-regenerating epithelial progenitor cells are more susceptible to these exposure injuries over time and transmit the injured memory through epigenetic mechanisms to their differentiated progeny. Here, we used progenitor-containing mammospheres as an in vitro exposure model to study this epigenetic effect. Expression profiling identified that, relative to control cells, 9.1% of microRNAs (82 of 898 loci) were altered in epithelial progeny derived from mammospheres exposed to a synthetic estrogen, diethylstilbestrol. Repressive chromatin marks, trimethyl Lys27 of histone H3 (H3K27me3) and dimethyl Lys9 of historic H3 (113K9me2), were found at a down-regulated locus, miR-9-3, in epithelial cells preexposed to diethylstilbestrol. This was accompanied by recruitment of DNA methyltransferase I that caused an aberrant increase in DNA methylation of its promoter CpG island in mammosphere-derived epithelial cells on diethylstilbestrol preexposure. Functional analyses suggest that miR-9-3 plays a role in the p53-related apoptotic pathway. Epigenetic silencing of this gene, therefore, reduces this cellular function and promotes the proliferation of breast cancer cells. Promoter hypermethylation of this microRNA may be a hallmark for early breast cancer development, and restoration of its expression by epigenetic and microRNA-based therapies is another viable option for future treatment of this disease. [Cancer Res 2009;69(14):5936-45]
C1 [Hsu, Pei-Yin; Deatherage, Daniel E.; Rodriguez, Benjamin A. T.; Liyanarachchi, Sandya; Weng, Yu-I; Zuo, Tao; Liu, Joseph; Huang, Tim H-M] Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Fac Med, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; Chinese University of Hong Kong
RP Huang, THM (通讯作者)，Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Ctr Comprehens Canc, Room 814,460 12th W St, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Cheng, Alfred/C-3327-2014
OI Cheng, Alfred/0000-0003-2345-6951; Zuo, Tao/0000-0002-2125-7548; Zuo,
   Tao/0000-0001-8450-5281
FU NIH [U01 ES015986, U54 CA113001, R01 CA069065]; Ohio State University
   Comprehensive Cancer Center
FX NIH grants U01 ES015986, U54 CA113001, and R01 CA069065 and Ohio State
   University Comprehensive Cancer Center.
CR Bolstad BM, 2005, STAT BIOL HEALTH, P33
   Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Damdimopoulos AE, 2008, ENDOCRINOLOGY, V149, P339, DOI 10.1210/en.2007-0198
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Hemmati PG, 2008, ONCOGENE, V27, P6707, DOI 10.1038/onc.2008.193
   HO SM, 2006, CANCER RES, V147, pS11
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jensen EV, 2003, CLIN CANCER RES, V9, P1980
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125
   Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164
   NOLLER KL, 1974, MED CLIN N AM, V58, P793, DOI 10.1016/S0025-7125(16)32122-8
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Peekhaus NT, 2004, J MOL ENDOCRINOL, V32, P987, DOI 10.1677/jme.0.0320987
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596
   Rudel RA, 2001, J AIR WASTE MANAGE, V51, P499, DOI 10.1080/10473289.2001.10464292
   Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X
   Schaffer BS, 2006, CANCER RES, V66, P7793, DOI 10.1158/0008-5472.CAN-06-0143
   Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515
   Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753
NR 38
TC 101
Z9 112
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2009
VL 69
IS 14
BP 5936
EP 5945
DI 10.1158/0008-5472.CAN-08-4914
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 475LJ
UT WOS:000268360300042
PM 19549897
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Liu, Y
   Wang, Y
   Li, WQ
   Zheng, P
   Liu, Y
AF Liu, Yan
   Wang, Yin
   Li, Weiquan
   Zheng, Pan
   Liu, Yang
TI Activating Transcription Factor 2 and c-Jun-Mediated Induction of FoxP3
   for Experimental Therapy of Mammary Tumor in the Mouse
SO CANCER RESEARCH
LA English
DT Article
ID CANCER; EXPRESSION; GENE; REPRESSOR; APOPTOSIS; ONCOGENE; MUTATION;
   CELLS; MICE; P53
AB FOXP93 is inactivated in breast cancer cells by a number of mechanisms, including somatic mutations, deletion, and epigenetic silencing. Because the mutation and deletion are usually heterozygous in the cancer samples, it is of interest to determine whether the gene can be induced for the purpose of cancer therapy. Here, we report that anisomycin, a potent activator of activating transcription factor (ATF) 2, and c-Jun-NH2-kinase, induces expression of FoxP3 in both normal and malignant mammary epithelial cells. T e induction is mediated by ATF2 and c-Jun. Targeted mutation of ATF2 abrogates both constitutive and inducible expression of FoxP3 in normal epithelial cells. Both ATF2 and c-Jun interact with a novel enhancer in the intron 1 of the FoxP3 locus. Moreover, shRNA silencing of ATF2 and FoxP3 reveals an important role of ATF2-FoxP3 pathway in the anisomycin-induced apoptosis of breast cancer cells. A low dose of anisomycin was also remarkably effective in treating established mammary tumor in the mice. Our data showed that FoxP3 can be reactivated for cancer therapy. [Cancer Res 2009;69(14):5954-60]
C1 [Liu, Yan; Wang, Yin; Li, Weiquan; Zheng, Pan; Liu, Yang] Univ Michigan, Sect Gen Surg, Dept Surg, Div Immunol, Ann Arbor, MI 48109 USA.
   [Liu, Yan; Wang, Yin; Li, Weiquan; Zheng, Pan; Liu, Yang] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Zheng, Pan] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Liu, Yang] Univ Michigan, Div Mol Med & Genet, Dept Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Liu, Y (通讯作者)，Univ Michigan, Sect Gen Surg, Dept Surg, Div Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM yangl@umich.edu; panz@umich.edu
RI Liu, Yang/HNJ-6693-2023; Li, Weiquan/B-4897-2011; Zheng, Pan/E-8691-2011
OI Zheng, Pan/0000-0003-2598-3544; Liu, Yang/0000-0002-9442-700X
FU National Cancer Institute, Department of Defense; American Cancer
   Society
FX National Cancer Institute, Department of Defense, and American Cancer
   Society.
CR Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282
   Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Im Hogune, 2004, Methods Mol Biol, V284, P129
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06
   Rahman Irfan, 2002, Current Drug Targets - Inflammation and Allergy, V1, P291, DOI 10.2174/1568010023344607
   Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0
   Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509
   Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413
   SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6
   Tommasini A, 2002, CLIN EXP IMMUNOL, V130, P127, DOI 10.1046/j.1365-2249.2002.01940.x
   Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549
   Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194
   Venuprasad K, 2008, NAT IMMUNOL, V9, P245, DOI 10.1038/ni1564
   Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410
   Wang Y, 2008, CANCER RES, V68, P4039, DOI 10.1158/0008-5472.CAN-07-6314
   Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 25
TC 27
Z9 32
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2009
VL 69
IS 14
BP 5954
EP 5960
DI 10.1158/0008-5472.CAN-09-0778
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 475LJ
UT WOS:000268360300044
PM 19584270
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Hoffman, AE
   Zheng, TZ
   Yi, CH
   Leaderer, D
   Weidhaas, J
   Slack, F
   Zhang, YW
   Paranjape, T
   Zhu, Y
AF Hoffman, Aaron E.
   Zheng, Tongzhang
   Yi, Chunhui
   Leaderer, Derek
   Weidhaas, Joanne
   Slack, Frank
   Zhang, Yawei
   Paranjape, Trupti
   Zhu, Yong
TI microRNA miR-196a-2 and Breast Cancer: A Genetic and Epigenetic
   Association Study and Functional Analysis
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR; DOWN-REGULATION; EXPRESSION; INFLAMMATION; INHIBIN;
   S100A8
AB Increasing evidence has suggested that microRNAs (miRNA) play an important role in tumorigenesis. As transcription regulators, altered miRNA expression may affect many cancer-related biological pathways, indicating that miRNAs can function as tumor suppressors and/or oncogenes. We first performed a genetic association analysis by screening genetic variants in 15 miRNA genes and detected that a common sequence variant in hsa-miR-196a-2 (rs11614913, C -> T) was significantly associated with decreased breast cancer risk (for homozygous variant: odds ratio, 0.44; 95% confidence interval, 0.28-0.70). Hypermethylation of a CpG island upstream (-700 hp) of the miR-196a-2 precursor was also associated with reduced breast cancer risk (odds ratio, 0.35; 95% confidence interval, 0.15-0.81). By delivering expression vectors containing either wild-type or mutant precursors of miR-196a-2 into breast cancer cells, we showed that this variant led to less efficient processing of the miRNA precursor to its mature form as well as diminished capacity to regulate target genes. A whole-genome expression microarray was done and a pathway-based analysis identified a cancer-relevant network formed by genes significantly altered following enforced expression of miR-196a-2. Mutagenesis analysis further showed that cell cycle response to mutagen challenge was significantly enhanced in cells treated with variant miR-196a-2 compared with cells treated with the wild-type. Taken together, our findings suggest that miR-196a-2 might have a potentially oncogenic role in breast tumorigenesis, and the functional genetic variant in its mature region could serve as a novel biomarker for breast cancer susceptibility. [Cancer Res 2009;69(14):5970-7]
C1 [Hoffman, Aaron E.; Zheng, Tongzhang; Yi, Chunhui; Leaderer, Derek; Zhang, Yawei; Zhu, Yong] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Weidhaas, Joanne; Paranjape, Trupti] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA.
   [Slack, Frank] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.
C3 Yale University; Yale University; Yale University
RP Zhu, Y (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
RI Paranjape, Trupti/E-4338-2012
OI Weidhaas, Joanne/0000-0002-5096-3281; Slack, Frank/0000-0001-8263-0409
FU NIH [CA122676, CA110937, CA108369]
FX NIH grants CA122676, CA110937, and CA108369.
CR Arai K, 2008, CURR CANCER DRUG TAR, V8, P243, DOI 10.2174/156800908784533445
   BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934
   Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Pasquinelli AE, 2006, DEV CELL, V10, P419, DOI 10.1016/j.devcel.2006.03.005
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Reis FM, 2004, MOL CELL ENDOCRINOL, V225, P77, DOI 10.1016/j.mce.2004.02.016
   Sharifi N, 2007, J MOL ENDOCRINOL, V39, P329, DOI 10.1677/JME-07-0084
   Song Lin, 2006, Birth Defects Research, V78, P140, DOI 10.1002/bdrc.20070
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   VIAU CM, 2009, ARCH TOXICOL
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148
   Wijnhoven BPL, 2007, BRIT J SURG, V94, P23, DOI 10.1002/bjs.5673
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167
   Zhu Y, 2005, CANCER EPIDEM BIOMAR, V14, P268
NR 33
TC 311
Z9 336
U1 0
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2009
VL 69
IS 14
BP 5970
EP 5977
DI 10.1158/0008-5472.CAN-09-0236
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 475LJ
UT WOS:000268360300046
PM 19567675
OA Bronze, Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Thiel, A
   Ganesan, A
   Mrena, J
   Junnila, S
   Nykänen, A
   Hemmes, A
   Tai, HH
   Monni, O
   Kokkola, A
   Haglund, C
   Petrova, TV
   Ristimäki, A
AF Thiel, Alexandra
   Ganesan, Aparna
   Mrena, Johanna
   Junnila, Siina
   Nykanen, Antti
   Hemmes, Annabrita
   Tai, Hsin-Hsiung
   Monni, Outi
   Kokkola, Arto
   Haglund, Caj
   Petrova, Tatiana V.
   Ristimaki, Ari
TI 15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric
   Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID LUNG ADENOCARCINOMA CELLS; EPIDERMAL-GROWTH-FACTOR; TUMOR-SUPPRESSOR;
   COLORECTAL-CANCER; BREAST-CANCER; EXPRESSION; CYCLOOXYGENASE-2; COX-2;
   CARCINOMA; INHIBITION
AB Purpose: We have investigated the expression and regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in gastric cancer.
   Experimental Design: Clinical gastric adenocarcinoma samples were analyzed by immunohistochemistry and quantitative real-time PCR for protein and mRNA expression of 15-PGDH and for methylation status of 15-PGDH promoter. The effects of interleukin-1 beta (IL-1 beta) and epigenetic mechanisms on 15-PGDH regulation were assessed in gastric cancer cell lines.
   Results: In a gastric cancer cell line with a very low 15-PGDH expression (TMK-1), the 15-PGDH promoter was methylated and treatment with a demethylating agent 5-aza-2'-deoxycytidine restored 15-PGDH expression. In a cell line with a relatively high basal level of 15-PGDH (MKN-28), IL-1 beta repressed expression of 15-PGDH mRNA and protein. This effect of IL-1 beta was at least in part attributed to inhibition of 15-PGDH promoter activity. SiRNA-mediated knockdown of 15-PGDH resulted in strong increase of prostaglandin E-2 production in MKN-28 cells and increased cell growth of these cells by 31% in anchorage-independent conditions. In clinical gastric adenocarcinoma specimens, 15-PGDH mRNA levels were 5-fold lower in gastric cancer samples when compared with paired nonneoplastic tissues (n = 26) and 15-PGDH protein was lost in 65% of gastric adenocarcinomas (n = 210).
   Conclusions: 15-PGDH is down-regulated in gastric cancer, which could potentially lead to accelerated tumor progression. Importantly, our data indicate that a proinflammatory cytokine linked to gastric carcinogenesis, IL-1 beta suppresses 15-PGDH expression at least partially by inhibiting promoter activity of the 15-PGDH gene.
C1 [Ristimaki, Ari] Univ Helsinki, Genome Scale Biol Res Program, Biomedicum Helsinki, FIN-00014 Helsinki, Finland.
   [Nykanen, Antti; Petrova, Tatiana V.] Univ Helsinki, Mol Canc Biol Res Program, FIN-00014 Helsinki, Finland.
   [Junnila, Siina; Monni, Outi; Petrova, Tatiana V.] Univ Helsinki, Inst Biomed Med Biochem & Dev Biol, FIN-00014 Helsinki, Finland.
   [Thiel, Alexandra; Ganesan, Aparna; Hemmes, Annabrita; Ristimaki, Ari] Univ Helsinki, Cent Hosp, Dept Pathol, HUSLAB, FIN-00014 Helsinki, Finland.
   [Thiel, Alexandra; Ganesan, Aparna; Hemmes, Annabrita; Ristimaki, Ari] Univ Helsinki, Cent Hosp, Haartman Inst, FIN-00014 Helsinki, Finland.
   [Mrena, Johanna; Kokkola, Arto; Haglund, Caj] Univ Helsinki, Cent Hosp, Dept Surg, FIN-00014 Helsinki, Finland.
   [Tai, Hsin-Hsiung] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA.
   [Petrova, Tatiana V.] Univ Lausanne, CePO, Div Expt Oncol, Lausanne, Switzerland.
   [Ristimaki, Ari] Univ Oulu, Dept Pathol, Oulu, Finland.
   [Ristimaki, Ari] Oulu Univ Hosp, Oulu, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Helsinki University Central Hospital; University of
   Helsinki; Helsinki University Central Hospital; University of Kentucky;
   University of Lausanne; University of Oulu; University of Oulu
RP Ristimäki, A (通讯作者)，Univ Helsinki, Genome Scale Biol Res Program, Biomedicum Helsinki, Room B529b,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.
EM Ari.Ristimaki@helsinki.fi
RI Haglund, Caj/N-1240-2019
OI Hemmes, Annabrita/0009-0005-5051-9331
FU Academy of Finland [114899]; Helsinki University Central Hospital
   Research Funds; Sigrid Juselius Foundation; Finnish Cancer Society;
   University of Helsinki Funds
FX Academy of Finland (project 114899; A. Ristimaki), Helsinki University
   Central Hospital Research Funds (A. Ristimaki and C. Haglund), Sigrid
   Juselius Foundation (A. Ristimaki and T V Petrova), the Finnish Cancer
   Society (A. Ristimaki and TV Petrova), and the University of Helsinki
   Funds (A. Ristimaki). A. Thiel is a student in the Helsinki Biomedical
   Graduate School.
CR Backlund MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M411221200
   Backlund MG, 2008, CANCER RES, V68, P9331, DOI 10.1158/0008-5472.CAN-08-2893
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   Chong JM, 2002, J VIROL, V76, P6825, DOI 10.1128/JVI.76.13.6825-6831.2002
   Ding YF, 2005, CARCINOGENESIS, V26, P65, DOI 10.1093/carcin/bgh277
   El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081
   Gee JR, 2003, UROL ONCOL-SEMIN O I, V21, P266, DOI 10.1016/S1078-1439(02)00271-5
   Greenland KJ, 2000, ENDOCRINOLOGY, V141, P581, DOI 10.1210/en.141.2.581
   Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017
   Huang GS, 2008, CANCER RES, V68, P5040, DOI 10.1158/0008-5472.CAN-07-6575
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   Liu ZX, 2008, CARCINOGENESIS, V29, P1219, DOI 10.1093/carcin/bgm297
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mann JR, 2006, CANCER RES, V66, P6649, DOI 10.1158/0008-5472.CAN-06-1787
   Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764
   Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103
   Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pham H, 2008, MOL CARCINOGEN, V47, P466, DOI 10.1002/mc.20404
   Ristimaki A, 1997, CANCER RES, V57, P1276
   Ristimäki A, 2002, CANCER RES, V62, P632
   Saukkonen K, 2003, APMIS, V111, P915, DOI 10.1034/j.1600-0463.2003.1111001.x
   Saukkonen K, 2001, CLIN CANCER RES, V7, P1923
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Tahara Eiichi, 2004, IARC Sci Publ, P327
   TAI CL, 1990, BIOCHEM J, V267, P75, DOI 10.1042/bj2670075
   Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3
   Thiel A, 2006, J BIOL CHEM, V281, P4564, DOI 10.1074/jbc.M512722200
   Tong M, 2006, CARCINOGENESIS, V27, P2170, DOI 10.1093/carcin/bgl053
   Tong M, 2006, BIOCHEM PHARMACOL, V72, P701, DOI 10.1016/j.bcp.2006.06.004
   Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011
   van Rees BP, 2003, INT J CANCER, V107, P551, DOI 10.1002/ijc.11422
   Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101
   Yang L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287
   Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x
   Yoo NJ, 2007, PATHOLOGY, V39, P174, DOI 10.1080/00313020601123946
NR 40
TC 60
Z9 70
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2009
VL 15
IS 14
BP 4572
EP 4580
DI 10.1158/1078-0432.CCR-08-2518
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 482SG
UT WOS:000268908400010
PM 19584167
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, YY
   Liu, L
   Andrews, LG
   Tollefsbol, TO
AF Li, Yuanyuan
   Liu, Liang
   Andrews, Lucy G.
   Tollefsbol, Trygve O.
TI Genistein depletes telomerase activity through cross-talk between
   genetic and epigenetic mechanisms
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE genistein; hTERT; telomerase; epigenetic; E2F-1; breast cancer
ID REVERSE-TRANSCRIPTASE PROMOTER; CATALYTIC SUBUNIT HTERT; BREAST-CANCER;
   DNA METHYLATION; CELL-CYCLE; IN-VITRO; INHIBITION; HYPERMETHYLATION;
   CONTRIBUTE; CHROMATIN
AB Genistein, a natural isoflavone found in soybean products, has been reported to down-regulate telomerase activity and that this prevents cancer and contributes to the apoptosis of cancer cells. However, the precise molecular mechanism by which genistein represses telomerase is not clear. Here, we show that genistein inhibits the transcription of hTERT (human telomerase reverse transcriptase), the catalytic subunit of the human telomerase enzyme, in breast MCF10AT benign cells and MCF-7 cancer cells in a time- and dose-dependent manner. Three major DNA methyl-transferases (DNMT1, 3a and 3b) were also decreased in genistein-treated breast cancer cells suggesting that genistein may repress hTFRT by impacting epigenetic pathways. Sequential depletion of the hTERT promoter revealed that the hTFRT core promoter region is responsible for the genistein-induced repression of hTERT transcription. Using a newly developed technique of chromatin immunoprecipitation (ChIP)-related bifulfite sequencing analysis, we found an increased binding of E2F-1. to the hTERT promoter is due to the site-specific hypomethylation of the E2F-1 recognition site. In addition, we found that genistein can remodel chromatin structures of the hTERT promoter by increasing trimethyl-H3K9 but decreasing dimethyl-H3K4 in the hTERT promoter. The repression of hTERT was enhanced by combination with genistein and the DNMT inhibitor, 5-aza-2'-deoxycytidine (5-aza-dCyd). These findings collectively show that genistem is working, at least in part, through epigenetic mechanisms of telomerase inhibition in breast benign and cancer cells and may facilitate approaches to breast cancer prevention and treatment using an epigenetic modulator combined with genistein. (C) 2009 UICC
C1 [Li, Yuanyuan; Andrews, Lucy G.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Liu, Liang; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   [Liu, Liang; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Clin Nutr Res Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，CH 175,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
FU National Cancer Institute [RO1 CA129415]; Glenn Foundation for Medical
   Research
FX Grant sponsor: National Cancer Institute; Grant number: RO1 CA129415;
   Grant sponsors: Susan G. Komen for the Cure, and the Glenn Foundation
   for Medical Research.
CR Ahmed A, 2003, J AM GERIATR SOC, V51, P116, DOI 10.1034/j.1601-5215.2002.51019.x
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Cabanes A, 2004, CARCINOGENESIS, V25, P741, DOI 10.1093/carcin/bgh065
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Cassidy A, 2000, P NUTR SOC, V59, P489, DOI 10.1017/S0029665100000719
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137
   Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200
   Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Devereux TR, 1999, CANCER RES, V59, P6087
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fang CY, 2005, J AM DIET ASSOC, V105, P1552, DOI 10.1016/j.jada.2005.07.001
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690
   GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Gustafsson JA, 1998, CURR OPIN CHEM BIOL, V2, P508, DOI 10.1016/S1367-5931(98)80127-0
   Heppner Gloria H., 1999, Breast J, V5, P122, DOI 10.1046/j.1524-4741.1999.00136.x
   Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687
   Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085
   Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462
   Jagadeesh S, 2006, CANCER RES, V66, P2107, DOI 10.1158/0008-5472.CAN-05-2494
   Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.3.CO;2-9
   Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2
   Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011
   Liu L, 2004, MOL CANCER THER, V3, P1003
   Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Mentor-Marcel R, 2001, CANCER RES, V61, P6777
   Messina M, 2006, JNCI-J NATL CANCER I, V98, P1275, DOI 10.1093/jnci/djj356
   Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3
   OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5
   PAGLIACCI MC, 1994, EUR J CANCER, V30A, P1675, DOI 10.1016/0959-8049(94)00262-4
   Shon YH, 2006, J BIOCHEM MOL BIOL, V39, P448
   Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273
   WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265
   Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198
   Zafonte BT, 2000, FRONT BIOSCI-LANDMRK, V5, pD938, DOI 10.2741/zafonte
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
   1983, LANCET, V43, P3018
NR 45
TC 150
Z9 167
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 15
PY 2009
VL 125
IS 2
BP 286
EP 296
DI 10.1002/ijc.24398
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 460ZJ
UT WOS:000267231600005
PM 19358274
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Hollosi, P
   Yakushij, JK
   Fong, KSK
   Csiszar, K
   Fong, SFT
AF Hollosi, Peter
   Yakushij, Jana K.
   Fong, Keith S. K.
   Csiszar, Katalin
   Fong, Sheri F. T.
TI Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer
   cells but not in normal breast epithelial cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE LOXL2; epigenctic regulation; breast cancer
ID HUMAN GROWTH-HORMONE; TUMOR PROGRESSION; EXTRACELLULAR-MATRIX; FIBROTIC
   FOCUS; MOLECULAR ROLE; PROTEIN; EXPRESSION; CARCINOMA; DNA;
   PROLIFERATION
AB A growing number of studies indicate the importance of the lysyl oxidase family in the promotion of epithelial neoplasms towards their more aggressive forms. However, the role of individual family members in carcinoma progression has yet to be ascertained. In this study, we analyzed LOXL2 expression in malignantly transformed MCF-7 and normal MCF-10A mammary epithelial cell line clones stably transduced with LOXL2 in vitro, and in normal and cancerous breast tissue samples in vivo. We found LOXL2 to be catalytically active in both MCF-7 and MCF-10 clones. LOXL2 overexpression promoted a more mesenchymal morphology in both cell types, but LOXL2-induced increase in migratory ability could only be established in MCF-7 clones. We demonstrated altered localization of the LOXL2 protein in breast cancer tissue compared to normal mammary tissue, and altered localization and processing of LOXL2 protein in breast cancer cell lines compared to normal cell lines, which may allow LOXL2 to interact with different intra and extracellular components during tumor progression. Results support the role of LOXL2 in selectively promoting a metastatic phenotype in breast tumor cells. Additional data suggest epigenetic molecular mechanisms in tumor specific regulation of LOXL2 expression that could be explored as a molecular target in the prevention of breast cancer progression. (C) 2009 UICC
C1 [Yakushij, Jana K.; Fong, Keith S. K.; Fong, Sheri F. T.] Univ Hawaii Manoa, Dept Anat Biochem & Physiol, John A Burns Sch Med, Honolulu, HI 96813 USA.
   [Hollosi, Peter; Csiszar, Katalin] Univ Hawaii Manoa, Cardiovasc Res Ctr, John A Burns Sch Med, Honolulu, HI 96813 USA.
C3 University of Hawaii System; University of Hawaii Manoa; University of
   Hawaii System; University of Hawaii Manoa
RP Fong, SFT (通讯作者)，Univ Hawaii Manoa, Dept Anat Biochem & Physiol, John A Burns Sch Med, 651 Ilalo St, Honolulu, HI 96813 USA.
EM sherif@hawaii.edu
FU National Cancer Institute through Cancer Research Center of Hawaii
   [CA71789]; National Center for Research Resources [G12-RR-003061];
   Ingeborg V.F. McKee Fund of the Hawaii Community Foundation
FX Grant sponsor: National Cancer Institute through Cancer Research Center
   of Hawaii; Grant number: CA71789; Grant sponsor: National Center for
   Research Resources; Grant number: G12-RR-003061; Grant sponsor: Ingeborg
   V.F. McKee Fund of the Hawaii Community Foundation.
CR Akiri G, 2003, CANCER RES, V63, P1657
   BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934
   Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200
   Chakravarti P, 2005, INT J ONCOL, V26, P509
   Chrenek MA, 2001, BREAST CANCER RES, V3, P224, DOI 10.1186/bcr300
   CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1
   Colpaert C, 2001, AM J SURG PATHOL, V25, P1557, DOI 10.1097/00000478-200112000-00016
   Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200
   FONG KSK, 2006, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A002989.01
   Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Hasebe T, 2000, PATHOL INT, V50, P263, DOI 10.1046/j.1440-1827.2000.01035.x
   HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6
   Ito H, 2001, J BIOL CHEM, V276, P24023, DOI 10.1074/jbc.M100861200
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaku M, 2007, BIOCHEM BIOPH RES CO, V359, P463, DOI 10.1016/j.bbrc.2007.05.109
   Kanazawa T, 2002, INT J CANCER, V102, P225, DOI 10.1002/ijc.10690
   Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492
   Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872
   Kim MS, 2003, J BIOL CHEM, V278, P52071, DOI 10.1074/jbc.M308856200
   Kirschmann DA, 2002, CANCER RES, V62, P4478
   Kresse SH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-48
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Macartney-Coxson DP, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-187
   Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101
   Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274
   Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371
   Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781
   Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345
   Polgar N, 2007, J BIOL CHEM, V282, P3262, DOI 10.1074/jbc.M609407200
   Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157
   Salnikow K, 2008, CARCINOGENESIS, V29, P1493, DOI 10.1093/carcin/bgn088
   Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1
   Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606
   Schor SL, 2001, BREAST CANCER RES, V3, P373, DOI 10.1186/bcr325
   Sebban S, 2009, VIRCHOWS ARCH, V454, P71, DOI 10.1007/s00428-008-0694-6
   Skonier JE, 1997, PROTEIN SCI, V6, P1768, DOI 10.1002/pro.5560060818
   Takito J, 1999, AM J PHYSIOL-RENAL, V277, pF277, DOI 10.1152/ajprenal.1999.277.2.F277
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Vadasz Z, 2005, J HEPATOL, V43, P499, DOI 10.1016/j.jhep.2005.02.052
   Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078
   Zhu T, 2005, CANCER RES, V65, P317
NR 50
TC 69
Z9 85
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 15
PY 2009
VL 125
IS 2
BP 318
EP 327
DI 10.1002/ijc.24308
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 460ZJ
UT WOS:000267231600008
PM 19330836
OA Bronze
DA 2025-01-12
ER

PT J
AU Yang, XF
   Pursell, B
   Lu, SL
   Chang, TK
   Mercurio, AM
AF Yang, Xiaofang
   Pursell, Bryan
   Lu, Shaolei
   Chang, Tsun-Kai
   Mercurio, Arthur M.
TI Regulation of β4-integrin expression by epigenetic modifications in the
   mammary gland and during the epithelial-to-mesenchymal transition
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Epigenetic; Epithelial mesenchymal transition; Integrin
ID ALPHA-6-BETA-4 INTEGRIN; CARCINOMA-CELLS; DNA METHYLATION; CHEMOTACTIC
   MIGRATION; BREAST-CANCER; SURVIVAL; GENES; DEMETHYLATION; ASSOCIATION;
   GROWTH
AB The beta 4 integrin is expressed in epithelial cells, a few other cell types and in some carcinomas. Despite this restricted expression pattern and the functional importance of beta 4 integrin in epithelial and carcinoma biology, little is known about how its expression is regulated. Here, we assessed the epigenetic regulation of beta 4 integrin based on the presence of a large CpG island in the beta 4-integrin gene promoter. We separated basal (beta 4(+)) and luminal (beta 4(-)) epithelial cells from the mammary glands of K14-eGFP mice and demonstrated that the beta 4-integrin promoter is unmethylated in basal cells and methylated in luminal cells. We also observed that expression of beta 4 integrin and E-cadherin is lost during the epithelial-to-mesenchymal transition (EMT) of mammary gland cells induced by transforming growth factor beta (TGF beta), which is coincident with de novo DNA methylation, a decrease in active histone modifications (H3K9Ac and H3K4me3) and an increase in the repressive histone modification H3K27me3. Furthermore, TGF beta withdrawal promotes a mesenchymal-to-epithelial transition ( MET) and triggers the re-expression of beta 4 integrin and E-cadherin. Intriguingly, demethylation at either promoter is not obligatory for transcriptional reactivation after TGF beta withdrawal. However, both H3K9Ac and H3K4me3 modifications are restored during the MET, and H3K27me3 is reduced, strongly suggesting that reversible histone modifications rather than DNA demethylation are the predominant factors in reactivating expression of these genes. Our data indicate that complex epigenetic modifications contribute to the regulation of the beta 4 integrin and E-cadherin.
C1 [Mercurio, Arthur M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA.
   Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester
RP Mercurio, AM (通讯作者)，Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA.
EM arthur.mercurio@umassmed.edu
RI Yang, Xiaofang/K-4388-2012
OI Lu, Shaolei/0000-0003-2870-5793
FU NIH [CA1107548, CA80789, T32130807]; ACS Postdoctoral Fellowship; Susan
   G. Komen Breast Cancer Foundation [PDF0600265]
FX This work was supported by NIH Grants CA1107548 and CA80789 (A. M. M.)
   and T32130807 (X. Y.), an ACS Postdoctoral Fellowship Grant (X. Y.) and
   a Susan G. Komen Breast Cancer Foundation Grant PDF0600265 (S. L.).
   Deposited in PMC for release after 12 months.
CR Abecassis I, 2008, LEUKEMIA, V22, P511, DOI 10.1038/sj.leu.2405071
   Agius F, 2006, P NATL ACAD SCI USA, V103, P11796, DOI 10.1073/pnas.0603563103
   Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012
   Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420
   DAVID G, 1981, JNCI-J NATL CANCER I, V67, P719
   Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   FALCIONI R, 1986, CANCER RES, V46, P5772
   Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339
   Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741
   HEMLER ME, 1989, J BIOL CHEM, V264, P6529
   Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327
   Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116
   Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0
   MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X
   Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739
   Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7
   Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029
   O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Penterman J, 2007, P NATL ACAD SCI USA, V104, P6752, DOI 10.1073/pnas.0701861104
   Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147
   Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873
   Raymond K, 2007, MOL BIOL CELL, V18, P4210, DOI 10.1091/mbc.E06-08-0720
   Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076
   Sehgal BU, 2006, J BIOL CHEM, V281, P35487, DOI 10.1074/jbc.M606317200
   Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9
   Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371
   Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848
   Takkunen M, 2008, HISTOCHEM CELL BIOL, V130, P509, DOI 10.1007/s00418-008-0443-6
   Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0
   vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006
   Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023
NR 47
TC 71
Z9 86
U1 1
U2 13
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD JUL 15
PY 2009
VL 122
IS 14
BP 2473
EP 2480
DI 10.1242/jcs.049148
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 474BQ
UT WOS:000268257600017
PM 19549682
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Swisher, EM
   Gonzalez, RM
   Taniguchi, T
   Garcia, RL
   Walsh, T
   Goff, BA
   Welcsh, P
AF Swisher, Elizabeth M.
   Gonzalez, Rachel M.
   Taniguchi, Toshiyasu
   Garcia, Rochelle L.
   Walsh, Tom
   Goff, Barbara A.
   Welcsh, Piri
TI Methylation and protein expression of DNA repair genes: association with
   chemotherapy exposure and survival in sporadic ovarian and peritoneal
   carcinomas
SO MOLECULAR CANCER
LA English
DT Article
ID BRCA1 PROMOTER REGION; BREAST-CANCER CELLS; FANCONI-ANEMIA; HMLH1
   EXPRESSION; TP53 MUTATIONS; RESISTANCE; HYPERMETHYLATION; LOCALIZATION;
   CISPLATIN; TUMORS
AB Background: DNA repair genes critically regulate the cellular response to chemotherapy and epigenetic regulation of these genes may be influenced by chemotherapy exposure. Restoration of BRCA1 and BRCA2 mediates resistance to platinum chemotherapy in recurrent BRCA1 and BRCA2 mutated hereditary ovarian carcinomas. We evaluated BRCA1, BRCA2, and MLH1 protein expression in 115 sporadic primary ovarian carcinomas, of which 31 had paired recurrent neoplasms collected after chemotherapy. Additionally, we assessed whether promoter methylation of BRCA1, MLH1 or FANCF influenced response to chemotherapy or explained alterations in protein expression after chemotherapy exposure.
   Results: Of 115 primary sporadic ovarian carcinomas, 39 (34%) had low BRCA1 protein and 49 (42%) had low BRCA2 expression. BRCA1 and BRCA2 protein expression were highly concordant (p < 0.0001). MLH1 protein loss occurred in 28/115 (24%) primary neoplasms. BRCA1 protein loss in primary neoplasms was associated with better survival (p = 0.02 Log Rank test) and remained significant after accounting for either stage or age in a multivariate model (p = 0.04, Cox proportional hazards). In paired specimens, BRCA1 protein expression increased in 13/21 (62%) and BRCA2 protein expression increased in 15/21 (71%) of recurrent carcinomas with low or intermediate protein in the paired primary. In contrast MLH1 expression was rarely decreased in recurrent carcinomas (1/33, 3%). Similar frequencies of MLH1, BRCA1, and FANCF promoter methylation occurred in primary carcinomas without previous chemotherapy, after neoadjuvant chemotherapy, or in recurrent neoplasms.
   Conclusion: Low BRCA1 expression in primary sporadic ovarian carcinoma is associated with prolonged survival. Recurrent ovarian carcinomas commonly have increased BRCA1 and/or BRCA2 protein expression post chemotherapy exposure which could mediate resistance to platinum based therapies. However, alterations in expression of these proteins after chemotherapy are not commonly mediated by promoter methylation, and other regulatory mechanisms are likely to contribute to these alterations.
C1 [Swisher, Elizabeth M.; Goff, Barbara A.] Univ Washington, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
   [Swisher, Elizabeth M.; Gonzalez, Rachel M.; Walsh, Tom; Welcsh, Piri] Univ Washington, Sch Med, Div Med Genet, Dept Med, Seattle, WA 98195 USA.
   [Taniguchi, Toshiyasu] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.
   [Taniguchi, Toshiyasu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
   [Garcia, Rochelle L.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; Fred Hutchinson Cancer
   Center; Fred Hutchinson Cancer Center; University of Washington;
   University of Washington Seattle
RP Swisher, EM (通讯作者)，Univ Washington, Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
EM swishere@u.washington.edu; rmgher@myuw.net; ttaniguc@fhcrc.org;
   rochelle@u.washington.edu; twalsh@u.washington.edu;
   bgoff@u.washington.edu; piri@u.washington.edu
RI Taniguchi, Toshiyasu/ADD-8489-2022; Lin, Kevin/JFS-1634-2023
OI Taniguchi, Toshiyasu/0000-0002-7746-3658; Walsh,
   Tom/0000-0002-8875-0310; Goff, Barbara/0000-0003-0153-5544; Lin,
   Kevin/0000-0002-1236-9847
FU Florence and Marshall Schwid Award [KO8 CA96610-01]; Gynecologic Cancer
   Foundation (EMS)
FX This work was supported by KO8 CA96610-01 (EMS) and the Florence and
   Marshall Schwid Award from the Gynecologic Cancer Foundation (EMS). We
   thank Mary-Claire King, PhD for guidance and input.
CR Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Berchuck A, 1998, CLIN CANCER RES, V4, P2433
   Bernard-Gallon DJ, 2001, ANTICANCER RES, V21, P2011
   Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200
   Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506
   Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260
   Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167
   Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905
   Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034
   Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8
   Fink D, 1998, INT J CANCER, V77, P741, DOI 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4
   Foster KA, 1996, CANCER RES, V56, P3622
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4
   Greenblatt MS, 2001, CANCER RES, V61, P4092
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396
   Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834
   Husain A, 1998, CANCER RES, V58, P1120
   Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812
   Quinn JE, 2003, CANCER RES, V63, P6221
   Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526
   Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078
   Ramus SJ, 1999, GENE CHROMOSOME CANC, V25, P91, DOI 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5
   Rhei E, 1998, CANCER RES, V58, P3193
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Samimi G, 2000, CLIN CANCER RES, V6, P1415
   Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920
   Spillman MA, 1996, ONCOGENE, V13, P1639
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088
   Takahashi H, 1996, CANCER RES, V56, P2738
   TAKAHASHI H, 1995, CANCER RES, V55, P2998
   Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444
   Thrall M, 2006, INT J GYNECOL CANCER, V16, P166, DOI 10.1111/j.1525-1438.2006.00504.x
   Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Willner J, 2007, HUM PATHOL, V38, P607, DOI 10.1016/j.humpath.2006.10.007
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924
   Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319
NR 50
TC 89
Z9 98
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 14
PY 2009
VL 8
AR 48
DI 10.1186/1476-4598-8-48
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 486FZ
UT WOS:000269182900002
PM 19602291
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Veeck, J
   Wild, PJ
   Fuchs, T
   Schüffler, PJ
   Hartmann, A
   Knüchel, R
   Dahl, E
AF Veeck, Juergen
   Wild, Peter J.
   Fuchs, Thomas
   Schueffler, Peter J.
   Hartmann, Arndt
   Knuechel, Ruth
   Dahl, Edgar
TI Prognostic relevance of Wnt-inhibitory factor-1 (<i>WIF1</i>) and
   Dickkopf-3 (<i>DKK3</i>) promoter methylation in human breast cancer
SO BMC CANCER
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; ABERRANT METHYLATION;
   COLORECTAL-CANCER; FECAL DNA; APC GENE; TUMOR; HYPERMETHYLATION; LUNG;
   EXPRESSION; PROSTATE
AB Background: Secreted Wnt signaling antagonists have recently been described as frequent targets of epigenetic inactivation in human tumor entities. Since gene silencing of certain Wnt antagonists was found to be correlated with adverse patient survival in cancer, we aimed at investigating a potential prognostic impact of the two Wnt antagonizing molecules WIF1 and DKK3 in breast cancer, which are frequently silenced by promoter methylation in this disease.
   Methods: WIF1 and DKK3 promoter methylation were assessed by methylation-specific PCR with bisulfite-converted DNA from 19 normal breast tissues and 150 primary breast carcinomas. Promoter methylation was interpreted in a qualitative, binary fashion. Statistical evaluations included two-sided Fisher's exact tests, univariate log-rank tests of Kaplan-Meier curves as well as multivariate Cox regression analyses.
   Results: WIF1 and DKK3 promoter methylation were detected in 63.3% (95/150) and 61.3% (92/150) of breast carcinoma samples, respectively. In normal breast tissues, WIF1 methylation was present in 0% (0/19) and DKK3 methylation in 5.3% (1/19) of samples. In breast carcinomas, WIF1 methylation was significantly associated with methylation of DKK3 (p = 0.009). Methylation of either gene was not associated with clinicopathological parameters, except for DKK3 methylation being associated with patient age (p = 0.007). In univariate analysis, WIF1 methylation was not associated with clinical patient outcome. In contrast, DKK3 methylation was a prognostic factor in patient overall survival (OS) and disease-free survival (DFS). Estimated OS rates after 10 years were 54% for patients with DKK3-methylated tumors, in contrast to patients without DKK3 methylation in the tumor, who had a favorable 97% OS after 10 years (p < 0.001). Likewise, DFS at 10 years for patients harboring DKK3 methylation in the tumor was 58%, compared with 78% for patients with unmethylated DKK3 (p = 0.037). Multivariate analyses revealed that DKK3 methylation was an independent prognostic factor predicting poor OS ( hazard ratio (HR): 14.4; 95% confidence interval (CI): 1.9-111.6; p = 0.011), and short DFS ( HR: 2.5; 95% CI: 1.0-6.0; p = 0.047) in breast cancer.
   Conclusion: Although the Wnt antagonist genes WIF1 and DKK3 show a very similar frequency of promoter methylation in human breast cancer, only DKK3 methylation proves as a novel prognostic marker potentially useful in the clinical management of this disease.
C1 [Veeck, Juergen; Knuechel, Ruth; Dahl, Edgar] Univ Hosp RWTH Aachen, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany.
   [Wild, Peter J.] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland.
   [Fuchs, Thomas; Schueffler, Peter J.] ETH, Inst Computat Sci, CH-8092 Zurich, Switzerland.
   [Fuchs, Thomas; Schueffler, Peter J.] ETH, Dept Comp Sci, CH-8092 Zurich, Switzerland.
   [Hartmann, Arndt] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Zurich; University Zurich Hospital; Swiss Federal Institutes of
   Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology
   Domain; ETH Zurich; University of Erlangen Nuremberg
RP Dahl, E (通讯作者)，Univ Hosp RWTH Aachen, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM juergen.veeck@rwth-aachen.de; peter.wild@cell.biol.ethz.ch;
   thomas.fuchs@inf.ethz.ch; peter.schueffler@inf.ethz.ch;
   arndt.hartmann@uk-erlangen.de; rknuechel-larke@ukaachen.de;
   edahl@ukaachen.de
RI Veeck, Jurgen/B-9256-2008; Schuffler, Peter/C-1821-2018
OI Veeck, Jurgen/0000-0002-2952-6159; Schuffler, Peter/0000-0002-1353-8921;
   Wild, Peter Johannes/0000-0002-1017-3744
FU BMBF [01KW0401]
FX The expert technical assistance of Sevim Alkaya, Sonja von Serenyi and
   Inge Losen is greatly appreciated. We thank Dr. Dieter Niederacher (
   Heinrich-Heine University, Dusseldorf, Germany) and Prof. Matthias Durst
   (Friedrich-Schiller University, Jena, Germany) for kindly providing
   patient samples as well as Dr. Monika Klinkhammer-Schalke and Dr.
   Felicitas Horn ( Tumour Registry, Regensburg, Germany) for continuous
   help in obtaining clinical follow-up data. This work is a research
   project within the German Human Genome Project and has been supported by
   the BMBF grant 01KW0401 to ED.
CR Aguilera Oscar, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P13
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   ELSTON CW, 1993, J CLIN PATHOL, V46, P189
   ensembl, Ensemble Genome Browser
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferrero-Poüs M, 2000, CLIN CANCER RES, V6, P4745
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   Galm Oliver, 2005, V113, P279, DOI 10.1385/1-59259-916-8:279
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Huang ZH, 2007, WORLD J GASTROENTERO, V13, P950, DOI 10.3748/wjg.v13.i6.950
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kato T, 2001, BREAST CANCER RES TR, V70, P65, DOI 10.1023/A:1012534724488
   Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1
   Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526
   Li LC, 2004, BIOCHEM BIOPH RES CO, V321, P455, DOI 10.1016/j.bbrc.2004.06.164
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Mizobuchi Y, 2008, NEURO-ONCOLOGY, V10, P244, DOI 10.1215/15228517-2008-016
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Silva JM, 1999, CANCER RES, V59, P3251
   SOBIN L., 1997, TNM CLASSIFICATION M
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Wang XY, 2008, MOL CELL BIOL, V28, P3589, DOI 10.1128/MCB.00040-08
   Warwick J, 2004, CANCER-AM CANCER SOC, V100, P1331, DOI 10.1002/cncr.20140
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989
   Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267
NR 49
TC 77
Z9 91
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 1
PY 2009
VL 9
AR 217
DI 10.1186/1471-2407-9-217
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 477DI
UT WOS:000268497600001
PM 19570204
OA Green Published, gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Kontorovich, T
   Cohen, Y
   Nir, U
   Friedman, E
AF Kontorovich, Tair
   Cohen, Yoram
   Nir, Uri
   Friedman, Eitan
TI Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as
   putative cancer risk modifiers in Jewish <i>BRCA1</i>/<i>BRCA2</i>
   mutation carriers
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Methylation; BRCA1 BRCA2; Modifier genes; Cancer susceptibility;
   Epigenetic mechanisms
ID BREAST-CANCER; GERMLINE EPIMUTATION; DNA METHYLATION; GENE; PROGRESSION;
   EXPRESSION; CARCINOMA; ISLANDS
AB BRCA1/BRCA2 germline mutations substantially increase breast and ovarian cancer risk, yet penetrance is incomplete. We hypothesized that germline epigenetic gene silencing may affect mutant BRCA1/2 penetrance. To test this notion, we determined the methylation status, using methylation-specific quantitative PCR of the promoter in putative modifier genes: BRCA1, BRCA2, ATM, ATR and P53 in Jewish BRCA1/BRCA2 mutation carriers with (n = 41) or without (n = 48) breast cancer, in sporadic breast cancer (n = 52), and healthy controls (n = 89). Promoter hypermethylation was detected only in the BRCA1 promotor in 5.6-7.3% in each of the four subsets of participants, regardless of health and BRCA1/2 status.Germline promoter hypermethylation in the BRCA1 gene can be detected in about 5% of the female Israeli Jewish population, regardless of the BRCA1/2 status. The significance of this observation is yet to be determined.
C1 [Kontorovich, Tair; Friedman, Eitan] Chaim Sheba Med Ctr, Danek Gertner Inst Human Genet, Susanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer, Israel.
   [Friedman, Eitan] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel.
   [Cohen, Yoram] Chaim Sheba Med Ctr, Gynecooncol Dept, IL-52621 Tel Hashomer, Israel.
   [Kontorovich, Tair; Nir, Uri] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel.
C3 Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine; Chaim Sheba Medical Center; Bar Ilan University
RP Friedman, E (通讯作者)，Chaim Sheba Med Ctr, Danek Gertner Inst Human Genet, Susanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer, Israel.
EM eitan.friedman@sheba.health.gov.il
RI Cohen, Yoram/M-8802-2014
FU Israel cancer association
FX This study was done in part as fulfillment for the degree of Master of
   Sciences by Tair Knntorovich at the Department of life science, Bar Ilan
   University. This study was in part funded by a grant from the Israel
   cancer association to Eitan Friedman.
CR Antoniou AC, 2007, AM J HUM GENET, V81, P1186, DOI 10.1086/522611
   Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z
   Bastian PJ, 2004, EUR UROL, V46, P698, DOI 10.1016/j.eururo.2004.07.022
   Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Begg CB, 2002, J NATL CANCER I, V94, P1221
   BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5
   Chan KYK, 2002, CANCER RES, V62, P4151
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   Dobrovic A, 1997, CANCER RES, V57, P3347
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   KENNETH O, 2006, J NATL CANCER I, V98, P1675
   Levy-Lahad E, 2007, BRIT J CANCER, V96, P11, DOI 10.1038/sj.bjc.6603535
   Narod SA, 2006, ONCOGENE, V25, P5832, DOI 10.1038/sj.onc.1209870
   Narod SA, 1995, INT J CANCER, V64, P394, DOI 10.1002/ijc.2910640608
   Robles-Diaz Luis, 2004, Fam Cancer, V3, P259, DOI 10.1007/s10689-004-9552-0
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Treilleux I, 2007, HISTOPATHOLOGY, V51, P63, DOI 10.1111/j.1365-2559.2007.02726.x
   Wacholder S, 2004, SCIENCE, V306, P2188
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   WYLIE B, 2002, J NATL CANCER I, V94, P1185
NR 30
TC 34
Z9 35
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2009
VL 116
IS 1
BP 195
EP 200
DI 10.1007/s10549-008-0121-3
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 457QH
UT WOS:000266946700021
PM 18642075
DA 2025-01-12
ER

PT J
AU Kioulafa, M
   Kaklamanis, L
   Mavroudis, D
   Georgoulias, V
   Lianidou, ES
AF Kioulafa, Magdalini
   Kaklamanis, Loukas
   Mavroudis, Dimitris
   Georgoulias, Vassilis
   Lianidou, Evi S.
TI Prognostic significance of <i>RASSF1A</i> promoter methylation in
   operable breast cancer
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE RASSF1A; DNA methylation; Operable breast cancer; Epigenetic markers;
   Prognostic biomarker; Methylation Specific PCR
ID PUTATIVE TUMOR-SUPPRESSOR; DNA METHYLATION; EPIGENETIC INACTIVATION;
   IN-SITU; HYPERMETHYLATION; GENES; LUNG; ASSOCIATION; 3P21.3;
   IDENTIFICATION
AB Objectives: The aim of our study was to evaluate the prognostic significance of RASSF1A promoter methylation status in operable breast cancer.
   Design and methods: By using Methylation Specific PCR, we evaluated the specificity of RASSF1A promoter methylation in 10 breast tumors and matching normal tissues, 10 breast fibroadenomas and 11 normal breast tissues. The prognostic significance of RASSF1A methylation was validated in 93 formalin fixed paraffin-embedded (FFPE) tissues obtained from patients with operable breast cancer.
   Results: Methylation of RASSF1A promoter was observed in 1/31 (3.2%) non-cancerous breast tissues and 53/93 (57.0%) early stage breast tumors. The only positive sample in the non-cancerous breast tissues group was found in a histological normal tissue surrounding the tumor. During the follow-up period, 24/93 (25.8%) patients relapsed and 19/93 (20.4%) died. Disease-Free-Interval (DFI) was significantly associated with RASSF1A methylation (p=0.028).
   Conclusions: RASSF1A promoter methylation provides important prognostic information in early stage breast cancer patients. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Kioulafa, Magdalini; Lianidou, Evi S.] Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
   [Kaklamanis, Loukas] Onassis Cardiac Surg Ctr, Dept Pathol, Athens 17674, Greece.
   [Mavroudis, Dimitris; Georgoulias, Vassilis] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Greece.
C3 National & Kapodistrian University of Athens; Onassis Cardiac Surgery
   Center; University Hospital of Heraklion
RP Lianidou, ES (通讯作者)，Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
EM lianidou@chem.uoa.gr
OI Lianidou, Evi/0000-0002-7796-5914
FU National and Kapodistrian University of Athens; Greek Ministry of
   Health; Hellenic Oncology Research Group (HORG)
FX This work was supported by the Special Account for Research Grants
   (SARG) of the National and Kapodistrian University of Athens, as well as
   a Research Grant on Oncology from the Greek Ministry of Health. M.
   Kioulafa is as recipient of a PhD studentship from the Hellenic Oncology
   Research Group (HORG). We would like to thank Alexandros Xyrafas, MSc,
   for the assistance in the statistical evaluation of our data.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Eccleston A, 2007, NATURE, V447, P395, DOI 10.1038/447395a
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fiegl H, 2008, CLIN CANCER RES, V14, P3494, DOI 10.1158/1078-0432.CCR-07-4557
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Jarmalaite S, 2008, ONCOLOGY-BASEL, V75, P145, DOI 10.1159/000158665
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2
   Kroupis C, 2008, CLIN CHIM ACTA, V390, P141, DOI 10.1016/j.cca.2007.12.024
   Lerman MI, 2000, CANCER RES, V60, P6116
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Macheiner D, 2009, CANCER RES, V69, P235, DOI 10.1158/0008-5472.CAN-08-2144
   Máthé E, 2004, NAT GENET, V36, P117, DOI 10.1038/ng0204-117
   Müller HM, 2003, CANCER RES, V63, P7641
   Pfeifer GP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P576, DOI 10.1007/s10541-005-0151-y
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
NR 27
TC 28
Z9 34
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD JUL
PY 2009
VL 42
IS 10-11
BP 970
EP 975
DI 10.1016/j.clinbiochem.2009.04.003
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 461NN
UT WOS:000267274300006
PM 19374895
DA 2025-01-12
ER

PT J
AU Mostafaie, N
   Kállay, E
   Sauerzapf, E
   Bonner, E
   Kriwanek, S
   Cross, HS
   Huber, KR
   Krugluger, W
AF Mostafaie, Nazanin
   Kallay, Enikoe
   Sauerzapf, Elisabeth
   Bonner, Elisabeth
   Kriwanek, Stefan
   Cross, Heide S.
   Huber, Klaus Roland
   Krugluger, Walter
TI Correlated Downregulation of Estrogen Receptor Beta and the Circadian
   Clock Gene Per1 in Human Colorectal Cancer
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE circadian rhythm; colon carcinoma; tumor progression; estrogen receptor
   alpha and beta
ID ER-BETA; TUMOR SUPPRESSION; BREAST-CANCER; EXPRESSION; COLON;
   METHYLATION; MECHANISMS; ISOFORMS; TISSUES; MUCOSA
AB There is a growing body of evidence that disturbed circadian clock gene expression is associated with tumor development and tumor progression. Based on our initial experiments demonstrating decreased period 1 (Peri) expression in colon cancer, we evaluated clock gene and estrogen receptor (ER) alpha/beta expression in colon cancer cells of primary colorectal tumors and adjacent normal colon mucosa (NM) by real-time RT-PCR. Analysis of gene expression in G(2) and G(3) colorectal tumors revealed a decrease of Per1 mRNA compared with paired NM (G(2): 0.52-fold; P=n.s. and G(3): 0.48-fold; P=0.03). A significant gender specific difference of Per1 expression was observed in G(2) tumors as compared with NM (female: 0.38-fold; P=0.004 vs. male: 0.73-fold; P=n.s.). Expression of CLOCK was significantly elevated in G2 tumors of male patients (1.63-fold, P=0.01). The expression of ER-beta was significantly decreased in G(2) and G(3) tumors (G(2): 0.32-fold; P=0.003 and 0.27; P=0.001). No significant gender specific differences of ER-beta reduction in tumors were observed. A significant correlation between the decrease of Per1 and ER-beta in colorectal tumors (r=0.61; P<0.001) was found. No changes in gene expression were detected for ER-alpha and Per2. Our data demonstrate a correlated decrease of Per1 and ER-beta in colorectal tumors, mediated probably by epigenetic mechanisms. The observed gender differences in the expression of CLOCK and Per1 in G(2) tumors might suggest a gender-specific, distinctive role of the cellular clock in colorectal tumorigenesis. (C) 2009 Wiley-Liss, Inc.
C1 [Mostafaie, Nazanin; Huber, Klaus Roland; Krugluger, Walter] Donauspital, Dept Clin Chem, A-1220 Vienna, Austria.
   [Kallay, Enikoe; Cross, Heide S.] Med Univ Vienna, Inst Pathophysiol, Vienna, Austria.
   [Sauerzapf, Elisabeth] Hosp Rudolfstiftung, Fachhsch Wiener Neustadt, Vienna, Austria.
   [Bonner, Elisabeth] Hosp Rudolfstiftung, Dept Pathol, Vienna, Austria.
   [Kriwanek, Stefan] Hosp Rudolfstiftung, Dept Surg, Vienna, Austria.
C3 Donauspital; Medical University of Vienna; Rudolfstiftung Hospital;
   Rudolfstiftung Hospital; Rudolfstiftung Hospital
RP Krugluger, W (通讯作者)，Donauspital, Dept Clin Chem, Langobardenstr 122, A-1220 Vienna, Austria.
RI Cross, Heide/H-3812-2011
OI Kallay, Eniko/0000-0002-4996-0104
CR *ABI, 2001, B ABI, V2, P1
   Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001
   Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800
   Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1
   Cai W, 2008, MOL CELL BIOL, V28, P784, DOI 10.1128/MCB.00233-07
   Caiazza F, 2007, BIOCHEM BIOPH RES CO, V359, P102, DOI 10.1016/j.bbrc.2007.05.059
   Campbell-Thompson M, 2001, CANCER RES, V61, P632
   Chen GG, 2008, MED RES REV, V28, P954, DOI 10.1002/med.20131
   Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075
   Chen-Goodspeed M, 2007, J BIOL RHYTHM, V22, P291, DOI 10.1177/0748730407303387
   Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500
   Davidson AJ, 2003, GENES BRAIN BEHAV, V2, P32, DOI 10.1034/j.1601-183X.2003.00005.x
   Gery S, 2007, COLD SPRING HARB SYM, V72, P459, DOI 10.1101/sqb.2007.72.004
   Giacchetti S, 2006, J CLIN ONCOL, V24, P3562, DOI 10.1200/JCO.2006.06.1440
   Giroux V, 2008, INT J CANCER, V123, P303, DOI 10.1002/ijc.23532
   He PJ, 2007, J ENDOCRINOL, V194, P511, DOI 10.1677/JOE-07-0172
   HENDERSON BE, 1988, CANCER RES, V48, P246
   Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166
   Kennelly R, 2008, LANCET ONCOL, V9, P385, DOI 10.1016/S1470-2045(08)70100-1
   Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004-0027
   Konstantinopoulos PA, 2003, EUR J CANCER, V39, P1251, DOI 10.1016/S0959-8049(03)00239-9
   Krugluger W, 2007, CANCER RES, V67, P7917, DOI 10.1158/0008-5472.CAN-07-0133
   Lee CC, 2006, CANCER CAUSE CONTROL, V17, P525, DOI 10.1007/s10552-005-9003-8
   Levi F, 2007, ANNU REV PHARMACOL, V47, P593, DOI 10.1146/annurev.pharmtox.47.120505.105208
   Nakahata Y, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-1
   Nakamura TJ, 2005, J NEUROSCI RES, V82, P622, DOI 10.1002/jnr.20677
   Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A
   Pardini L, 2005, CHRONOBIOL INT, V22, P951, DOI 10.1080/07420520500395011
   Ripperger JA, 2001, CURR OPIN CELL BIOL, V13, P357, DOI 10.1016/S0955-0674(00)00220-9
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4
   Shih MC, 2006, MOL CARCINOGEN, V45, P732, DOI 10.1002/mc.20198
   Ström A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100
   WADAHIRAIKE O, 2006, P NATL ACAD SCI USA, P29959
   Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595
   Xie LQ, 2004, WORLD J GASTROENTERO, V10, P214
   Zhang Jing, 2004, Kobe Journal of Medical Sciences, V50, P101
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
NR 39
TC 80
Z9 88
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JUL
PY 2009
VL 48
IS 7
BP 642
EP 647
DI 10.1002/mc.20510
PG 6
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 462LJ
UT WOS:000267353800010
PM 19148895
DA 2025-01-12
ER

PT J
AU Kamalakaran, S
   Kendall, J
   Zhao, XY
   Tang, CL
   Khan, S
   Ravi, K
   Auletta, T
   Riggs, M
   Wang, Y
   Helland, Å
   Naume, B
   Dimitrova, N
   Boresen-Dale, AL
   Hicks, J
   Lucito, R
AF Kamalakaran, Sitharthan
   Kendall, Jude
   Zhao, Xiaoyue
   Tang, Chunlao
   Khan, Sohail
   Ravi, Kandasamy
   Auletta, Theresa
   Riggs, Michael
   Wang, Yun
   Helland, Aslaug
   Naume, Bjorn
   Dimitrova, Nevenka
   Boresen-Dale, Anne-Lise
   Hicks, Jim
   Lucito, Robert
TI Methylation detection oligonucleotide microarray analysis: a
   high-resolution method for detection of CpG island methylation
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID DNA METHYLATION; BREAST-CANCER; EPIGENETIC INACTIVATION; COMPREHENSIVE
   ANALYSIS; PROMOTER METHYLATION; WIDE; GENE; EXPRESSION;
   HYPERMETHYLATION; FREQUENT
AB Methylation of CpG islands associated with genes can affect the expression of the proximal gene, and methylation of non-associated CpG islands correlates to genomic instability. This epigenetic modification has been shown to be important in many pathologies, from development and disease to cancer. We report the development of a novel high-resolution microarray that detects the methylation status of over 25 000 CpG islands in the human genome. Experiments were performed to demonstrate low system noise in the methodology and that the array probes have a high signal to noise ratio. Methylation measurements between different cell lines were validated demonstrating the accuracy of measurement. We then identified alterations in CpG islands, both those associated with gene promoters, as well as non-promoter-associated islands in a set of breast and ovarian tumors. We demonstrate that this methodology accurately identifies methylation profiles in cancer and in principle it can differentiate any CpG methylation alterations and can be adapted to analyze other species.
C1 [Kendall, Jude; Zhao, Xiaoyue; Tang, Chunlao; Khan, Sohail; Ravi, Kandasamy; Auletta, Theresa; Riggs, Michael; Hicks, Jim; Lucito, Robert] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Kamalakaran, Sitharthan; Dimitrova, Nevenka] Philips Res N Amer, Briarcliff Manor, NY 10510 USA.
   [Wang, Yun; Helland, Aslaug; Boresen-Dale, Anne-Lise] Univ Oslo, Rikshosp, Univ Hosp, Dept Genet,Inst Canc Res,Norwegian Radium Hosp, N-0027 Oslo, Norway.
   [Helland, Aslaug; Naume, Bjorn] Univ Oslo, Rikshosp, Univ Hosp, Dept Oncol,Norwegian Radium Hosp, N-0027 Oslo, Norway.
   [Boresen-Dale, Anne-Lise] Univ Oslo, Fac Med, Norwegian Radium Hosp, Fac Div, N-0027 Oslo, Norway.
C3 Cold Spring Harbor Laboratory; Philips; Philips Research; University of
   Oslo; National Hospital Norway; University of Oslo; National Hospital
   Norway; University of Oslo
RP Lucito, R (通讯作者)，Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.
EM lucito@cshl.edu
RI Lucito, Robert/AID-7159-2022; Tang, Chunlao/F-9203-2010; Helland,
   Aslaug/H-3910-2015
OI Wang, Yun/0000-0002-9941-2130; Helland, Aslaug/0000-0002-5520-0275
FU National Institutes of Health and National Cancer Institute
   [K01CA93634-01]; Department of Defense [W81XWH-05-1-0068]
FX National Institutes of Health and National Cancer Institute
   [K01CA93634-01 to R. L.]; Department of Defense [W81XWH-05-1-0068 to R.
   L.] as well as by grants awarded to Michael Wigler from the Simons
   Foundation and the Breast Cancer Research Foundation. Funding for open
   access charge: awarded to to RL and Michael Wigler from Philips Research
   North America.
CR Adrien LR, 2006, CYTOGENET GENOME RES, V114, P16, DOI 10.1159/000091923
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   [Anonymous], 2003, PYTHON LANGUAGE REFE
   [Anonymous], 2007, R: A Language and Environment for Statistical Computing
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Balog RP, 2002, ANAL BIOCHEM, V309, P301, DOI 10.1016/S0003-2697(02)00294-4
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bird AP, 1996, CANCER SURV, V28, P87
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Brenner AJ, 1996, CLIN CANCER RES, V2, P1993
   Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106
   Chotai KA, 1998, J MED GENET, V35, P472, DOI 10.1136/jmg.35.6.472
   Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Estécio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fujino T, 2001, EXP HEMATOL, V29, P856, DOI 10.1016/S0301-472X(01)00655-5
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376
   Hatada I, 2006, ONCOGENE, V25, P3059, DOI 10.1038/sj.onc.1209331
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Ibrahim AEK, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl551
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437
   Khulan B, 2006, GENOME RES, V16, P1046, DOI 10.1101/gr.5273806
   Knoepfler PS, 2001, ONCOGENE, V20, P5440, DOI 10.1038/sj.onc.1204710
   Lavie L, 2005, J VIROL, V79, P876, DOI 10.1128/JVI.79.2.876-883.2005
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003
   Maeta Y, 2005, TUMOR BIOL, V26, P300, DOI 10.1159/000089288
   Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Naume B, 2007, MOL ONCOL, V1, P160, DOI 10.1016/j.molonc.2007.03.004
   Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208
   POLLARD K, 2004, BERKELEY DIV BIOSTAT, P164
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866
   Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008
   Shames DS, 2007, CURR MOL MED, V7, P85, DOI 10.2174/156652407779940413
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Smith IM, 2007, INT J CANCER, V121, P1724, DOI 10.1002/ijc.22889
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016
   Tryndyak V, 2006, ANAL BIOCHEM, V356, P202, DOI 10.1016/j.ab.2006.05.019
   Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106
   Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490
   Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yamada Y, 2004, GENOME RES, V14, P247, DOI 10.1101/gr.1351604
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Ying JM, 2007, BRIT J HAEMATOL, V136, P829, DOI 10.1111/j.1365-2141.2007.06512.x
   Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 62
TC 15
Z9 17
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL
PY 2009
VL 37
IS 12
AR e89
DI 10.1093/nar/gkp413
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 472FL
UT WOS:000268115200036
PM 19474344
OA Green Published, Green Submitted, gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Vicent, GP
   Zaurin, R
   Nacht, AS
   Li, A
   Font-Mateu, J
   Le Dily, F
   Vermeulen, M
   Mann, M
   Beato, M
AF Pablo Vicent, Guillermo
   Zaurin, Roser
   Silvina Nacht, A.
   Li, Ang
   Font-Mateu, Jofre
   Le Dily, Francois
   Vermeulen, Michiel
   Mann, Matthias
   Beato, Miguel
TI Two Chromatin Remodeling Activities Cooperate during Activation of
   Hormone Responsive Promoters
SO PLOS GENETICS
LA English
DT Article
ID TUMOR VIRUS PROMOTER; HISTONE ACETYLTRANSFERASE COMPLEXES; MMTV
   PROMOTER; PROGESTERONE-RECEPTOR; IN-VIVO; TRANSCRIPTIONAL ACTIVATION;
   GLUCOCORTICOID-RECEPTOR; H1 PHOSPHORYLATION; ESTROGEN-RECEPTOR; DIVERSE
   FUNCTIONS
AB Steroid hormones regulate gene expression by interaction of their receptors with hormone responsive elements (HREs) and recruitment of kinases, chromatin remodeling complexes, and coregulators to their target promoters. Here we show that in breast cancer cells the BAF, but not the closely related PBAF complex, is required for progesterone induction of several target genes including MMTV, where it catalyzes localized displacement of histones H2A and H2B and subsequent NF1 binding. PCAF is also needed for induction of progesterone target genes and acetylates histone H3 at K14, an epigenetic mark that interacts with the BAF subunits by anchoring the complex to chromatin. In the absence of PCAF, full loading of target promoters with hormone receptors and BAF is precluded, and induction is compromised. Thus, activation of hormone-responsive promoters requires cooperation of at least two chromatin remodeling activities, BAF and PCAF.
C1 [Pablo Vicent, Guillermo; Zaurin, Roser; Silvina Nacht, A.; Li, Ang; Font-Mateu, Jofre; Le Dily, Francois; Beato, Miguel] Univ Pompeu Fabra, CRG, Barcelona, Spain.
   [Vermeulen, Michiel; Mann, Matthias] Max Planck Inst Biochem, Dept Prote & Signal Transduct, D-82152 Martinsried, Germany.
   [Vermeulen, Michiel] Univ Med Ctr Utrecht, Dept Physiol Chem, Utrecht, Netherlands.
   [Vermeulen, Michiel] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands.
C3 Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG); Max Planck Society; Utrecht
   University; Utrecht University Medical Center; Utrecht University;
   Utrecht University Medical Center
RP Vicent, GP (通讯作者)，Univ Pompeu Fabra, CRG, Parc Recerca Biomed PRBB, Barcelona, Spain.
EM miguel.beato@crg.es
RI Mann, Matthias/A-3454-2013; Le Dily, François/J-9448-2015; Li,
   Ang/AAV-5427-2021; Font-Mateu, Jofre/AAE-9801-2019; Vermeulen,
   Michiel/C-8883-2013; Vicent, Guillermo Pablo/K-5432-2015; Beato,
   Miguel/B-5564-2015; Font-Mateu, Jofre/K-5492-2015
OI Vermeulen, Michiel/0000-0003-0836-6894; Vicent, Guillermo
   Pablo/0000-0002-0554-2226; Beato, Miguel/0000-0002-2878-2222; Li,
   Ang/0000-0002-8455-2309; Font-Mateu, Jofre/0000-0001-9983-9647
FU Departament d'Innovacio Universitat i Empresa (DIUiE); Ministerio de
   Educacion y Ciencia (MEC) [BMC 2003-02902]; Consolider [CSD2006-00049];
   Fondo de Investigacion Sanitaria (FIS) [PI0411605, CP04/00087]; EU IP
   HEROIC; Ramon y Cajal Programme; Dutch Cancer Society (KWF/NKB)
FX The experimental work was supported by grants from the Departament
   d'Innovacio Universitat i Empresa (DIUiE), Ministerio de Educacion y
   Ciencia (MEC) BMC 2003-02902, Consolider (CSD2006-00049) and Fondo de
   Investigacion Sanitaria (FIS) PI0411605 and CP04/00087, and EU IP
   HEROIC. GPV was a recipient of a fellowship of the Ramon y Cajal
   Programme. MV was supported by the Dutch Cancer Society (KWF/NKB). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3
   Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2
   Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741
   BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5
   Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   Bhattacharjee RN, 2006, VIROLOGY, V346, P1, DOI 10.1016/j.virol.2005.12.034
   Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001
   Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638
   BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273
   Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4
   Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2
   Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032
   García-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200
   Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2
   Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Hebbar PB, 2003, MOL CELL BIOL, V23, P887, DOI 10.1128/MCB.23.3.887-898.2003
   Hebbar PB, 2007, J BIOL CHEM, V282, P8284, DOI 10.1074/jbc.M610554200
   Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219
   Kane R, 2000, ADV EXP MED BIOL, V480, P117
   Kasten M, 2004, EMBO J, V23, P1348, DOI 10.1038/sj.emboj.7600143
   Koop R, 2003, EMBO J, V22, P588, DOI 10.1093/emboj/cdg052
   Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703
   Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516
   Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200
   Métivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200
   Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005
   MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x
   Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722
   Narayanan R, 2005, MOL CELL BIOL, V25, P264, DOI 10.1128/MCB.25.1.264-277.2005
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Nesvizhskii AI, 2007, NAT METHODS, V4, P787, DOI 10.1038/NMETH1088
   Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000
   Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200
   PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F
   PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U
   Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i
   Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979
   RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x
   Roberts SM, 1997, GENETICS, V147, P451
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189
   Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200
   Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9
   Shen WQ, 2007, BIOCHEMISTRY-US, V46, P2100, DOI 10.1021/bi0611208
   Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005
   Singh M, 2007, CHEMBIOCHEM, V8, P1308, DOI 10.1002/cbic.200600562
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strutt H, 1999, METH MOL B, V119, P455
   TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x
   Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025
   Vicent GP, 2006, ANN NY ACAD SCI, V1089, P59, DOI 10.1196/annals.1386.025
   Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011
   Wang F, 2004, J BIOL CHEM, V279, P46733, DOI 10.1074/jbc.M409002200
   Wang W, 2003, CURR TOP MICROBIOL, V274, P143
   Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117
   Whitehouse I, 2007, NATURE, V450, P1031, DOI 10.1038/nature06391
   Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597
   Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805
   Yang XF, 2007, NAT STRUCT MOL BIOL, V14, P540, DOI 10.1038/nsmb1238
   Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0
NR 72
TC 41
Z9 47
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JUL
PY 2009
VL 5
IS 7
AR e1000567
DI 10.1371/journal.pgen.1000567
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 486SZ
UT WOS:000269219500025
PM 19609353
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Novak, P
   Jensen, TJ
   Garbe, JC
   Stampfer, MR
   Futscher, BW
AF Novak, Petr
   Jensen, Taylor J.
   Garbe, James C.
   Stampfer, Martha R.
   Futscher, Bernard W.
TI Stepwise DNA Methylation Changes Are Linked to Escape from Defined
   Proliferation Barriers and Mammary Epithelial Cell Immortalization
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN BREAST-CANCER; EARLY EVENT; EPIGENETIC INACTIVATION;
   COLORECTAL-CANCER; P53 FUNCTION; GENE; TRANSFORMATION; SENESCENCE;
   HYPERMETHYLATION; P16(INK4A)
AB The timing and progression of DNA methylation changes during carcinogenesis are not completely understood. To develop a timeline of aberrant DNA methylation events during malignant transformation, we analyzed genome-wide DNA methylation patterns in an isogenic human mammary epithelial cell (HMEC) culture model of transformation. To acquire immortality and malignancy, the cultured finite lifespan HMEC must overcome two distinct proliferation barriers. The first barrier, stasis, is mediated by the retinoblastoma protein and can be overcome by loss of p16(INK4A) expression. HMEC that escape stasis and continue to proliferate become genomically unstable before encountering a second more stringent proliferation barrier, telomere dysfunction due to telomere attrition. re cells that acquire telomerase expression may escape this barrier, become immortal, and develop further malignant properties. Our analysis of HMEC transitioning from finite lifespan to malignantly transformed showed that aberrant DNA methylation changes occur in a stepwise fashion early in the transformation process. The first aberrant DNA methylation step coincides with overcoming stasis, and results in few to hundreds of changes, depending on how stasis was overcome. A second step coincides with immortalization and results in hundreds of additional DNA methylation changes regardless of the immortalization pathway. A majority of these DNA methylation changes are also found in malignant breast cancer cells. These results show that large-scale epigenetic remodeling occurs in the earliest steps of mammary carcinogenesis, temporally links DNA methylation changes and overcoming cellular proliferation barriers, and provides a bank of potential epigenetic biomarkers that may prove useful in breast cancer risk assessment. [Cancer Res 2009;69(12):5251-8]
C1 [Novak, Petr; Jensen, Taylor J.; Stampfer, Martha R.; Futscher, Bernard W.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
   [Jensen, Taylor J.; Futscher, Bernard W.] Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85724 USA.
   [Garbe, James C.; Stampfer, Martha R.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Novak, Petr] Biol Ctr ASCR, Inst Plant Mol Biol, Ceske Budejovice, Czech Republic.
C3 Arizona Center Cancer Care; University of Arizona; University of
   Arizona; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; University of California System; University of
   California Berkeley; Czech Academy of Sciences; Biology Centre of the
   Czech Academy of Sciences
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM bfutscher@azcc.arizona.edu
RI Novak, Petr/A-3059-2013
OI Novak, Petr/0000-0002-5068-9681
FU BIO5 Interdisciplinary Biotechnology Center at the University of
   Arizona; NIH [U54 CA112970]; Department of Defense [BCRP BC060444];
   Office of Energy Research, Office of Health and Biological Research,
   U.S. Department of Energy [DE-AC03-76SF00098];  [R01CA65662]; 
   [R33CA091351];  [P30ES06694];  [P30CA023074];  [ES007091];  [CA09213]
FX Grants R01CA65662 and R33CA091351 (B.W. Futscher); center grants
   P30ES06694 and P30CA023074 and the BIO5 Interdisciplinary Biotechnology
   Center at the University of Arizona (Genomics Shared Service); training
   grants ES007091 and CA09213 (T.J. Jensen); and NIH grant U54 CA112970,
   Department of Defense grant BCRP BC060444. and Office of Energy
   Research, Office of Health and Biological Research, U.S. Department of
   Energy contract DE-AC03-76SF00098 (J.C. Garbe and M.R. Stampfer).
CR [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bean GR, 2007, CLIN CANCER RES, V13, P6834, DOI 10.1158/1078-0432.CCR-07-0407
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   CLARK R, 1988, CANCER RES, V48, P4689
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Fury Wen, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5531
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519
   Geradts J, 1996, AM J PATHOL, V149, P15
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Holst CR, 2003, CANCER RES, V63, P1596
   Jensen TJ, 2008, CARCINOGENESIS, V29, P1500, DOI 10.1093/carcin/bgn102
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kuukasjarvi T, 1997, CANCER RES, V57, P1597
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7
   Liu TJ, 2008, HUM PATHOL, V39, P1637, DOI 10.1016/j.humpath.2008.04.001
   Melnikov AA, 2008, J MOL DIAGN, V10, P93, DOI 10.2353/jmoldx.2008.070077
   Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780
   Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Stampfer M., 1985, Journal of Tissue Culture Methods, V9, P107
   Stampfer M R, 1988, Cancer Treat Res, V40, P1
   Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391
   Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667
   Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3
   STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 45
TC 93
Z9 103
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2009
VL 69
IS 12
BP 5251
EP 5258
DI 10.1158/0008-5472.CAN-08-4977
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 464LM
UT WOS:000267506400042
PM 19509227
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Bots, M
   Johnstone, RW
AF Bots, Michael
   Johnstone, Ricky W.
TI Rational Combinations Using HDAC Inhibitors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HISTONE-DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER
   CELLS; VALPROIC ACID; CLINICAL-IMPLICATIONS; PROTEASOME INHIBITOR; DNA
   METHYLATION; RETINOIC ACID; BCR-ABL; THERAPEUTIC ACTIVITIES
AB In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs. In numerous in vitro and preclinical settings, these compounds have shown their vast potential as single agent anticancer therapies, but unfortunately equivalent responses have not always been observed in patients. Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs. In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong molecular rationale.
C1 [Bots, Michael; Johnstone, Ricky W.] Peter MacCallum Canc Ctr, CancerTherapeut Program, Melbourne, Vic 3002, Australia.
   [Johnstone, Ricky W.] Univ Melbourne, Melbourne, Vic 3010, Australia.
C3 Peter Maccallum Cancer Center; University of Melbourne
RP Johnstone, RW (通讯作者)，Peter MacCallum Canc Ctr, CancerTherapeut Program, St Andrews Pl, Melbourne, Vic 3002, Australia.
EM ricky.johnstone@petermac.org
RI Johnstone, Ricky/H-3748-2014
OI Johnstone, Ricky/0000-0001-7053-9237
FU NHMRC [251608]; Cancer Council Victoria; Leukaemia Foundation of
   Australia; Australian Rotary Health Research Fund; Netherlands
   Organisation for Scientific Research (NWO)
FX Grant support: R.W. Johnstone is a Pfizer Australia Research Fellow and
   is supported by NHMRC Program Grant 251608, the Cancer Council Victoria,
   the Leukaemia Foundation of Australia, and the Australian Rotary Health
   Research Fund. M. Bots is supported by a Rubicon research grant from
   Netherlands Organisation for Scientific Research (NWO).
CR Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004
   Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794
   BADROS AZ, 2008, J CLIN ONCOL S15, V26, P8548
   Bali P, 2005, CLIN CANCER RES, V11, P6382, DOI 10.1158/1078-0432.CCR-05-0344
   Banerji L, 2004, EXPERT OPIN THER TAR, V8, P221, DOI 10.1517/14728222.8.3.221
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Coffey DC, 2000, MED PEDIATR ONCOL, V35, P577, DOI 10.1002/1096-911X(20001201)35:6<577::AID-MPO18>3.0.CO;2-3
   Coffey DC, 2001, CANCER RES, V61, P3591
   Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050
   Copland JA, 2006, THYROID, V16, P1293, DOI 10.1089/thy.2006.16.1293
   Côté S, 2002, BLOOD, V100, P2586, DOI 10.1182/blood-2002-02-0614
   Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934
   Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fantin VR, 2008, CANCER RES, V68, P3785, DOI 10.1158/0008-5472.CAN-07-6091
   Ferrara FF, 2001, CANCER RES, V61, P2
   Frew AJ, 2008, P NATL ACAD SCI USA, V105, P11317, DOI 10.1073/pnas.0801868105
   Fuino L, 2003, MOL CANCER THER, V2, P971
   Furumai R, 2002, CANCER RES, V62, P4916
   Garcia-Manero G, 2007, J CLIN ONCOL, V25
   Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142
   George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413
   Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041
   Hahn CK, 2008, P NATL ACAD SCI USA, V105, P9751, DOI 10.1073/pnas.0710413105
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537
   Henderson C, 2003, DRUG RESIST UPDATE, V6, P247, DOI 10.1016/S1368-7646(03)00067-0
   Herranz Michel, 2007, Methods Mol Biol, V361, P25
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Juergens RA, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.19036
   Karpenko MJ, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3502
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095
   Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128
   Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961
   Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161
   Newbold A, 2008, MOL CANCER THER, V7, P1066, DOI 10.1158/1535-7163.MCT-07-2256
   Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675
   Odenike O, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.7057
   Park CM, 2008, J MED CHEM, V51, P6902, DOI 10.1021/jm800669s
   Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561
   Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785
   Rahmani M, 2005, MOL PHARMACOL, V67, P1166, DOI 10.1124/mol.104.007831
   Rao R, 2008, BLOOD, V112, P1886, DOI 10.1182/blood-2008-03-143644
   Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659
   Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2
   ROBERTS A, 2008, J CLIN ONCOL S, V26, P3542, DOI DOI 10.1200/jco.2008.26.15_suppl.3542
   Rodriguez-Gonzalez A, 2008, CANCER RES, V68, P2557, DOI 10.1158/0008-5472.CAN-07-5989
   Santos MDL, 2007, MOL ENDOCRINOL, V21, P2416, DOI 10.1210/me.2007-0151
   Schelman WR, 2007, J CLIN ONCOL, V25
   Schrump DS, 2009, CLIN CANCER RES, V15, P3947, DOI 10.1158/1078-0432.CCR-08-2787
   Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010
   Silverman LR, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.7000
   Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836
   Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   Whitecross KF, 2009, BLOOD, V113, P1982, DOI 10.1182/blood-2008-05-156851
   Wilson WH, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8511
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737
   Yu CR, 2003, CANCER RES, V63, P2118
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 77
TC 196
Z9 225
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2009
VL 15
IS 12
BP 3970
EP 3977
DI 10.1158/1078-0432.CCR-08-2786
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 459DP
UT WOS:000267080800011
PM 19509171
OA hybrid
DA 2025-01-12
ER

PT J
AU Lesma, E
   Sirchia, SM
   Ancona, S
   Carelli, S
   Bosari, S
   Ghelma, F
   Montanari, E
   Di Giulio, AM
   Gorio, A
AF Lesma, Elena
   Sirchia, Silvia Maria
   Ancona, Silvia
   Carelli, Stephana
   Bosari, Silvano
   Ghelma, Filippo
   Montanari, Emanuele
   Di Giulio, Anna Maria
   Gorio, Alfredo
TI The Methylation of the <i>TSC2</i> Promoter Underlies the Abnormal
   Growth of TSC2 Angiomyolipoma-Derived Smooth Muscle Cells
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID TUBEROUS SCLEROSIS COMPLEX; BREAST-CANCER CELLS; RENAL ANGIOMYOLIPOMA;
   PULMONARY LYMPHANGIOLEIOMYOMATOSIS; DNA METHYLATION; GENE; EXPRESSION;
   PATHOGENESIS; MODEL; IDENTIFICATION
AB Tuberous sclerosis complex (TSC) is an autosomal-dominant disease that is caused by mutations in either the TSC1 or TSC2 gene. Smooth muscle-like cells (ASMs) were isolated from an angiomyolipoma of a patient with TSC. These cells lacked tuberin, were labeled by both HMB45 and CD44v6 antibodies, and had constitutive S6 phosphorylation. The cells bear a germline TSC2 intron 8-exon 9 junction mutation, but DNA analysis and polymerase chain reaction amplification failed to demonstrate loss of heterozygosity. Testing for an epigenetic alteration, we detected methylation of the TSC2 promoter. Its biological relevance was confirmed by tuberin expression and a reduction in HMB45 labeling and S6 constitutive phosphorylation after exposure to the chromatin-remodeling agents, trichostatin A and 5-azacytidine. These cells were named TSC2(-/meth) ASMs. Their proliferation required epidermal growth factor in the medium as previously described for TSC2(-/-) ASMs. Blockade of epidermal growth factor with monoclonal antibodies caused the death of TSC2(-/meth) ASMs. in addition, rapamycin effectively blocked the proliferation of these cells. Our data show for the first time that methylation of the TSC2 promoter might cause a complete loss of tuberin in TSC2 cells, and that the pathogenesis of angiomyolipomas might also originate from epigenetic defects in smooth muscle cells. Additionally, the effect of chromatin-remodeling agents in these cells suggests a further avenue for the treatment of TSC as well as lymphangioleiomyomatosis. (Am J Pathol 2009, 174:2150-2159; DOI: 10.2353/ajpath.2009.080799)
C1 [Lesma, Elena; Ancona, Silvia; Carelli, Stephana; Di Giulio, Anna Maria; Gorio, Alfredo] Univ Milan, Fac Med, Polo H San Paolo, Dept Med Surg & Dent,Lab Pharmacol, I-20142 Milan, Italy.
   [Sirchia, Silvia Maria] Univ Milan, Fac Med, Polo H San Paolo, Dept Med Surg & Dent,Med Genet Unit, I-20142 Milan, Italy.
   [Bosari, Silvano] Univ Milan, Fac Med, Polo H San Paolo, Dept Med Surg & Dent,Div Pathol, I-20142 Milan, Italy.
   [Ghelma, Filippo] Univ Milan, Fac Med, Polo H San Paolo, Dept Med Surg & Dent,Disabled Adv Med Assistance, I-20142 Milan, Italy.
   [Montanari, Emanuele] Univ Milan, Fac Med, Polo H San Paolo, Dept Med Surg & Dent,Uorl Unit, I-20142 Milan, Italy.
   [Gorio, Alfredo] Ist Ricovero & Cura Carattere Sci Humanitas, Milan, Italy.
   [Bosari, Silvano] Osped Maggiore Policlin, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy.
C3 University of Milan; University of Milan; University of Milan;
   University of Milan; University of Milan; IRCCS Ca Granda Ospedale
   Maggiore Policlinico
RP Lesma, E (通讯作者)，Univ Milan, Fac Med, Polo H San Paolo, Dept Med Surg & Dent,Lab Pharmacol, Via A Rudini 8, I-20142 Milan, Italy.
EM elena.lesma@unimi.it
RI Carelli, Stephana/AAB-2365-2021; Sirchia, Silvia/AAB-2620-2019;
   MONTANARI, EMANUELE/I-8034-2015; Bosari, Silvano/K-7744-2016
OI MONTANARI, EMANUELE/0000-0002-3586-666X; Sirchia,
   Silvia/0000-0002-6106-3721; Di Giulio, Anna Maria/0000-0002-5702-4623;
   ancona, silvia/0000-0003-1999-129X; Lesma, Elena/0000-0002-9096-713X;
   Bosari, Silvano/0000-0002-9744-6951
FU Ministero Superiore delta Sanita; Italian Tuberous Sclerosis
   Association; Italian Lymphangioleiomyomatosis Association
FX Supported by the Ministero Superiore delta Sanita (IRCCS grant of rare
   diseases), the Italian Tuberous Sclerosis Association, and the Italian
   Lymphangioleiomyomatosis Association.
CR Arbiser JL, 2001, AM J PATHOL, V159, P483, DOI 10.1016/S0002-9440(10)61720-8
   Au KS, 1999, AM J HUM GENET, V65, P1790, DOI 10.1086/302648
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009
   Bi GF, 2006, CELL MOL IMMUNOL, V3, P285
   Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564
   Carelli S, 2007, MOL MED, V13, P166, DOI 10.2119/2006-00091.Carelli
   Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085
   Chakraborty S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-163
   Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236
   Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348
   El-Hashemite N, 2005, CANCER RES, V65, P2474, DOI 10.1158/0008-5472.CAN-04-3840
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X
   Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825
   Hengstschläger M, 2001, MUTAT RES-REV MUTAT, V488, P233, DOI 10.1016/S1383-5742(01)00058-8
   Henske EP, 1996, AM J HUM GENET, V59, P400
   Henske EP, 1997, AM J PATHOL, V151, P1639
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023
   Jones AC, 2000, HUM GENET, V106, P663, DOI 10.1007/s004390050040
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Koptides M, 2000, HUM MOL GENET, V9, P447, DOI 10.1093/hmg/9.3.447
   Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118
   Lesma E, 2005, AM J PATHOL, V167, P1093, DOI 10.1016/S0002-9440(10)61198-4
   Lesma E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003558
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   NELLIST M, 1993, CELL, V75, P1305
   Neumann H P, 1998, Semin Pediatr Neurol, V5, P269, DOI 10.1016/S1071-9091(98)80005-3
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972
   Pacheco-Rodriguez G, 2007, CANCER RES, V67, P10573, DOI 10.1158/0008-5472.CAN-07-1356
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805
   Vokes Everett E, 2006, Oncology (Williston Park), V20, P15
   Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3
NR 44
TC 30
Z9 31
U1 0
U2 8
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUN
PY 2009
VL 174
IS 6
BP 2150
EP 2159
DI 10.2353/ajpath.2009.080799
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 449ZT
UT WOS:000266370600019
PM 19443708
OA Green Submitted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Kioulafa, M
   Kaklamanis, L
   Stathopoulos, E
   Mavroudis, D
   Georgoulias, V
   Lianidou, ES
AF Kioulafa, M.
   Kaklamanis, L.
   Stathopoulos, E.
   Mavroudis, D.
   Georgoulias, V.
   Lianidou, E. S.
TI Kallikrein 10 (<i>KLK10</i>) methylation as a novel prognostic biomarker
   in early breast cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE DNA methylation; early breast cancer; epigenetic markers; KLK10;
   methylation-specific PCR; prognostic biomarker
ID CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; DOWN-REGULATION;
   SERINE-PROTEASE; IN-SITU; EXPRESSION; RASSF1A; OVARIAN; 3P21.3
AB Background: We evaluated the prognostic significance of KLK10 exon 3 methylation in patients with early-stage breast cancer since it has been shown to have a significant impact on biological characteristics of breast tumors.
   Materials and methods: Using methylation-specific PCR, we evaluated the specificity of KLK10 methylation in 10 breast tumors and matching normal tissues, 10 breast fibroadenomas, 11 normal breast tissues and in a testing group of 35 patients. The prognostic significance of KLK10 methylation was validated in an independent cohort of 93 patients.
   Results: KLK10 was not methylated in normal breast tissues and fibroadenomas while it was in 5 of 10 breast tumors and in 1 of 10 matching normal tissues. In the testing group of 35 patients, KLK10 methylation was detected in 70.0% of patients who relapsed (P = 0.001) and in 77.8% of patients who died (P = 0.025). In the independent cohort, 53 of 93 (57.0%) patients were found positive for KLK10 methylation. During the follow-up period, 24 of 93 (25.8%) patients relapsed and 19 of 93 (20.4%) died. Disease-free interval (DFI) and overall survival (OS) were significantly associated with KLK10 methylation (P = 0.0025 and P = 0.003). Multivariate analysis revealed that KLK10 methylation was an independent prognostic factor for DFI and OS.
   Conclusion: KLK10 exon 3 methylation provides important prognostic information in early breast cancer patients.
C1 [Kioulafa, M.; Lianidou, E. S.] Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
   [Kaklamanis, L.] Onassis Cardiac Surg Ctr, Dept Pathol, Athens, Greece.
   [Stathopoulos, E.] Univ Gen Hosp Herakl, Dept Pathol & Med Oncol, Iraklion, Greece.
   [Mavroudis, D.; Georgoulias, V.] Univ Gen Hosp Herakl, Dept Med Oncol, Iraklion, Greece.
C3 National & Kapodistrian University of Athens; Onassis Cardiac Surgery
   Center; University Hospital of Heraklion; University Hospital of
   Heraklion
RP Lianidou, ES (通讯作者)，Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece.
EM lianidou@chem.uoa.gr
OI Lianidou, Evi/0000-0002-7796-5914
FU National and Kapodistrian University of Athens; Greek Ministry of Health
FX Special Account for Research Grants of the National and Kapodistrian
   University of Athens; Research Grant on Oncology from the Greek Ministry
   of Health.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Borgoño CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474
   Dammann R, 2001, CANCER RES, V61, P3105
   Dhar S, 2001, CLIN CANCER RES, V7, P3393
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Goyal J, 1998, CANCER RES, V58, P4782
   Gralow J, 2008, J CLIN ONCOL, V26, P313, DOI 10.1200/JCO.2007.15.4088
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang W, 2007, CANCER LETT, V251, P78, DOI 10.1016/j.canlet.2006.11.006
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Li B, 2001, CANCER RES, V61, P8014
   Liu XL, 1996, CANCER RES, V56, P3371
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223
   Sidiropoulos M, 2005, TUMOR BIOL, V26, P324, DOI 10.1159/000089290
   Yousef GM, 2004, BRIT J CANCER, V90, P167, DOI 10.1038/sj.bjc.6601451
NR 19
TC 40
Z9 46
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2009
VL 20
IS 6
BP 1020
EP 1025
DI 10.1093/annonc/mdn733
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 449QA
UT WOS:000266343900008
PM 19150938
OA Bronze
DA 2025-01-12
ER

PT J
AU Courtwright, A
   Siamakpour-Reihani, S
   Arbiser, JL
   Banet, N
   Hilliard, E
   Fried, L
   Livasy, C
   Ketelsen, D
   Nepal, DB
   Perou, CM
   Patterson, C
   Klauber-DeMore, N
AF Courtwright, Andrew
   Siamakpour-Reihani, Sharareh
   Arbiser, Jack L.
   Banet, Natalie
   Hilliard, Eleanor
   Fried, Levi
   Livasy, Chad
   Ketelsen, David
   Nepal, Desh Bandhu
   Perou, Charles M.
   Patterson, Cam
   Klauber-DeMore, Nancy
TI Secreted Frizzle-Related Protein 2 Stimulates Angiogenesis via a
   Calcineurin/NFAT Signaling Pathway
SO CANCER RESEARCH
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; MAMMARY-GLAND TUMORS; CELL
   PROLIFERATION; NFAT ACTIVATION; BREAST-CANCER; SFRP GENES; BEVACIZUMAB;
   CARCINOMA; GROWTH; WNT
AB Secreted frizzle-related protein 2 (SFRP2), a modulator of Wnt signaling, has recently been found to be overexpressed in the vasculature of 85% of human breast tumors; however, its role in angiogenesis is unknown. We found that SFRP2 induced angiogenesis in the mouse Matrigel plug assay and the chick chorioallantoic membrane assay. SFRP2 inhibited hypoxia induced endothelial cell apoptosis, increased endothelial cell migration, and induced endothelial tube formation. The canonical Writ pathway was not affected by SFRP2 in endothelial cells; however, a component of the noncanonical Wnt/Ca2+ pathway was affected by SFRP2 as shown by an increase in NFATc3 in the nuclear fraction of SFRP2-treated endothelial cells. Tacrolimus, a calcineurin inhibitor that inhibits dephosphorylation of NFAT, inhibited SFRP2-induced endothelial tube formation. Tacrolimus 3 mg/kg/d inhibited the growth of SVR angiosarcoma xenografts in mice by 46% (P = 0.04). In conclusion, SFRP2 is a novel stimulator of angiogenesis that stimulates angiogenesis via a calcineurin/NFAT pathway and may be a favorable target for the inhibition of angiogenesis in solid tumors. [Cancer Res 2009;69(11):4621-8]
C1 [Courtwright, Andrew; Klauber-DeMore, Nancy] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA.
   [Banet, Natalie; Livasy, Chad; Perou, Charles M.] Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA.
   [Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
   [Siamakpour-Reihani, Sharareh; Livasy, Chad; Ketelsen, David; Nepal, Desh Bandhu; Perou, Charles M.; Patterson, Cam; Klauber-DeMore, Nancy] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Hilliard, Eleanor; Patterson, Cam; Klauber-DeMore, Nancy] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA.
   [Arbiser, Jack L.; Fried, Levi] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA.
   [Arbiser, Jack L.; Fried, Levi] Atlanta VA Med Ctr, Atlanta, GA USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Medical Center; Atlanta VA Health Care
   System
RP Klauber-DeMore, N (通讯作者)，Univ N Carolina, Dept Surg, 170 Manning Dr,Phys Off Bldg,CB 7213, Chapel Hill, NC 27599 USA.
EM nancy_demore@med.unc.edu
RI Perou, Charles/H-9934-2014
OI Perou, Charles/0000-0001-9827-2247; Siamakpour-Reihani,
   Sharareh/0000-0002-2837-443X
FU Department of Defense Physician Scientist Training Award for Breast
   Cancer Research [W23RYX-3340-N609]; National Cancer Institute [1 K08
   CA098034-01A2, P50-CA58223]; University Cancer Research Fund; NIH [R01
   AR02030]; Jamie Rabinowitch-Davis Foundation; Minsk Foundation
FX Department of Defense Physician Scientist Training Award for Breast
   Cancer Research W23RYX-3340-N609; National Cancer Institute grant 1 K08
   CA098034-01A2; University Cancer Research Fund (N. Klauber-DeMore); NIH,
   National Cancer Institute Breast Cancer Specialized Program of Research
   Excellence grant P50-CA58223 (N. Klauber-DeMore and C.M. Perou); and
   Veterans Administration Merit Award, NIH grant R01 AR02030, Jamie
   Rabinowitch-Davis Foundation, and Minsk Foundation (J.L. Arbiser).
CR Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861
   Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32
   Bhati R, 2008, AM J PATHOL, V172, P1381, DOI 10.2353/ajpath.2008.070988
   Espat N J, 2000, Sarcoma, V4, P173, DOI 10.1080/13577140020025896
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gehmert S, 2008, BIOCHEM BIOPH RES CO, V371, P752, DOI 10.1016/j.bbrc.2008.04.151
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kane RC, 2006, CLIN CANCER RES, V12, P7271, DOI 10.1158/1078-0432.CCR-06-1249
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kühl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701
   Lee JL, 2006, BREAST CANCER RES TR, V100, P49, DOI 10.1007/s10549-006-9233-9
   Lee JL, 2004, BREAST CANCER RES TR, V84, P139, DOI 10.1023/B:BREA.0000018412.83348.ff
   Martínez-Martínez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576
   Medyouf H, 2007, NAT MED, V13, P736, DOI 10.1038/nm1588
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Nilsson LM, 2007, AM J PHYSIOL-CELL PH, V292, pC1167, DOI 10.1152/ajpcell.00590.2005
   Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644
   Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P108, DOI 10.1161/hq0102.101843
   Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474
NR 29
TC 97
Z9 102
U1 1
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2009
VL 69
IS 11
BP 4621
EP 4628
DI 10.1158/0008-5472.CAN-08-3402
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 455JL
UT WOS:000266755000012
PM 19458075
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Woodfield, GW
   Hitchler, MJ
   Chen, Y
   Domann, FE
   Weigel, RJ
AF Woodfield, George W.
   Hitchler, Michael J.
   Chen, Yizhen
   Domann, Frederick E.
   Weigel, Ronald J.
TI Interaction of TFAP2C with the Estrogen Receptor-α Promoter Is
   Controlled by Chromatin Structure
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; DEACETYLASE INHIBITOR TRICHOSTATIN;
   GENE-EXPRESSION; DRUG-THERAPY; CPG ISLAND; METHYLATION; TRANSCRIPTION;
   CARCINOMA; DNA; PATHWAY
AB Purpose: Transcriptional regulation of estrogen receptor-alpha (ER alpha) involves both epigenetic mechanisms and trans-active factors, such as TFAP2C, which induces ER alpha transcription through an AP-2 regulatory region in the ER alpha promoter. Attempts to induce endogenous ER alpha expression in ER alpha-negative breast carcinomas by forced overexpression of TFAP2C have not been successful. We hypothesize that epigenetic chromatin structure alters the activity of TFAP2C at the ER alpha promoter.
   Experimental Design: DNA methylation, histone acetylation, and chromatin accessibility were examined at the ER alpha promoter in a panel of breast carcinoma cell lines. TFAP2C and polymerase II binding were analyzed by chromatin immunoprecipitation. Epigenetic chromatin structure was altered using drug treatment with 5-aza-2'-deoxycytidine (AZA) and trichostatin A (TSA).
   Results: The ER alpha promoter in the ER alpha-negative lines MDA-MB-231, MCF10A, and MCF75C show CpG island methylation, histone 3 lysine 9 deacetylation, and decreased chromatin accessibility compared with ER alpha-positive cell lines MCF7 and T47-D. Treatment with AZA/TSA increased chromatin accessibility at the ER alpha promoter and allowed TFAP2C to induce ER alpha expression in ER alpha-negative cells. Chromatin immunoprecipitation analysis showed that binding of TFAP2C to the ER alpha promoter is blocked in ER alpha- negative cells but that treatment with AZA/TSA enabled TFAP2C and polymerase 11 binding.
   Conclusion: We conclude that the activity of TFAP2C at specific target genes depends upon epigenetic chromatin structure. Furthermore, the combination of increasing chromatin accessibility and inducing TFAP2C provides a more robust activation of the ER alpha gene in ER alpha-negative breast cancer cells.
C1 [Woodfield, George W.; Chen, Yizhen; Weigel, Ronald J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA.
   [Hitchler, Michael J.; Domann, Frederick E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA.
   [Weigel, Ronald J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Weigel, RJ (通讯作者)，Univ Iowa, Dept Surg, 200 Hawkins Dr,1509 JCP, Iowa City, IA 52242 USA.
EM Ronald-Weigel@uiowa.edu
OI Weigel, Ronald/0000-0002-9249-0793; Domann,
   Frederick/0000-0002-0489-2179
FU NIH [R01CA109294, R01CA73612]; Kristen Olewine Milke Breast Cancer
   Research Fund;  [T32CA078586]
FX NIH grants R01CA109294 (R.J. Weigel) and R01CA73612 (F.E. Domann) and
   the Kristen Olewine Milke Breast Cancer Research Fund. M.J. Hitchler
   received partial salary support from T32CA078586. The costs of
   publication of this article were defrayed in part by the payment of page
   charges. This article must therefore be hereby marked advertisement in
   accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
CR Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Carmeci C, 1997, AM J PATHOL, V150, P1563
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   FISHER ER, 1980, CANCER-AM CANCER SOC, V45, P349, DOI 10.1002/1097-0142(19800115)45:2<349::AID-CNCR2820450226>3.0.CO;2-P
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430
   Ghosh MG, 2000, CANCER RES, V60, P6367
   Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004
   HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F
   Hitchler MJ, 2006, EPIGENETICS-US, V1, P163, DOI 10.4161/epi.1.4.3401
   Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   JIANG SY, 1992, MOL CELL ENDOCRINOL, V90, P77, DOI 10.1016/0303-7207(92)90104-E
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   JORDAN C, 1988, CRC CRITICAL REV CLI, P97
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200
   McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342
   McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200
   Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015
   Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Schuur ER, 2001, J BIOL CHEM, V276, P15519, DOI 10.1074/jbc.M009001200
   Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293
   Yang XW, 2001, CANCER RES, V61, P7025
NR 34
TC 27
Z9 33
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2009
VL 15
IS 11
BP 3672
EP 3679
DI 10.1158/1078-0432.CCR-08-2343
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 454CJ
UT WOS:000266659000005
PM 19458056
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Hauswald, S
   Duque-Afonso, J
   Wagner, MM
   Schertl, FM
   Lübbert, M
   Peschel, C
   Keller, U
   Licht, T
AF Hauswald, Stefanie
   Duque-Afonso, Jesus
   Wagner, Michaela M.
   Schertl, Florian M.
   Luebbert, Michael
   Peschel, Christian
   Keller, Ulrich
   Licht, Thomas
TI Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic
   Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by
   Modulation of Multiple ABC Transporter Genes
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SUBEROYLANILIDE HYDROXAMIC ACID; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN;
   MDR1 GENE; SODIUM PHENYLBUTYRATE; DEPSIPEPTIDE FK228; RENAL-CARCINOMA;
   VALPROIC ACID; CANCER CELLS; EXPRESSION
AB Purpose: Histone deacetylase inhibitors (HDACi) are being studied in clinical trials with the aim to induce cellular differentiation, growth arrest, and apoptosis of tumor cells. Recent reports suggest that the multidrug resistance-1 (MDR1) gene is regulated by epigenetic mechanisms. To investigate whether additional drug transporters are regulated by HDACi and how this affects cytotoxicity, acute myeloid leukemia (AML) cells were examined.
   Experimental Design: AML cells were cultured in the presence of phenylbutyrate, valproate, suberoylanilide hydroxamic acid, or trichostatin A and analyzed for drug transporter expression and function as well as sensitivity to anticancer drugs.
   Results: MDR1, breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins (MRP) 7 and 8 were induced in a dose- and time-dependent manner as shown by semiquantitative PCR. The pattern of gene induction was cell line specific. Phenylbutyrate induced P-glycoprotein and BCRP expression and the efflux of drugs as determined with labeled substrates. KG-1a cells treated with phenylbutyrate developed resistance to daunorubicin, mitoxantrone, etoposide, vinblastine, paclitaxel, topotecan, gemcitabine, and 5-fluorouracil; as a result drug-induced apoptosis was impaired. Chromatin immunoprecipitation revealed the hyperacetylation of histone proteins in the promoter regions of MDR1, BCRP, and MRP8 on valproate treatment. Furthermore, an alternative MRP8 promoter was induced by HDACi treatment.
   Conclusions: Exposure of AML cells to HDACi induces a drug resistance phenotype broader than the "classic multidrug resistance," which might negatively affect treatment effectiveness.
C1 [Hauswald, Stefanie; Wagner, Michaela M.; Schertl, Florian M.; Peschel, Christian; Keller, Ulrich; Licht, Thomas] Tech Univ Munich, Dept Med 3, D-81675 Munich, Germany.
   [Duque-Afonso, Jesus; Luebbert, Michael] Univ Klin Freiburg, Freiburg, Germany.
   [Licht, Thomas] HELIOS Schlossbergklin, Oberstaufen, Germany.
C3 Technical University of Munich; University of Freiburg
RP Keller, U (通讯作者)，Tech Univ Munich, Dept Med 3, Ismaninger Str 15, D-81675 Munich, Germany.
EM ulrich.keller@lrz.tum.de
RI Keller, Ulrich/L-1763-2016
FU German Jose Carreras Leukemia Foundation [R04/17, R06/40f]; LaCaixa-DAAD
   [314, A/05/29785]
FX German Jose Carreras Leukemia Foundation Project R04/17 IT. Licht and U.
   Keller), R06/40f (M. Lubbert) and LaCaixa-DAAD grant 314, A/05/29785 (J.
   Duque-Afonso),
CR Benderra Z, 2004, CLIN CANCER RES, V10, P7896, DOI 10.1158/1078-0432.CCR-04-0795
   Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856
   Carducci MA, 2001, CLIN CANCER RES, V7, P3047
   Chen ZS, 2003, MOL PHARMACOL, V63, P351, DOI 10.1124/mol.63.2.351
   CHIN KV, 1990, J BIOL CHEM, V265, P221
   Claus R, 2006, J LEUKOCYTE BIOL, V80, P1462, DOI 10.1189/jlb.0106005
   de Wolf C, 2008, MOL CANCER THER, V7, P3092, DOI 10.1158/1535-7163.MCT-08-0427
   DeVane C Lindsay, 2003, Psychopharmacol Bull, V37 Suppl 2, P25
   Drexler HG, 2003, ANN MED, V35, P404, DOI 10.1080/07853890310012094
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Eyal S, 2006, BRIT J PHARMACOL, V149, P250, DOI 10.1038/sj.bjp.0706830
   Gilbert J, 2001, CLIN CANCER RES, V7, P2292
   GOLDSTEIN LJ, 1989, JNCI-J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116
   Gómez-Martínez A, 2007, MOL CANCER RES, V5, P641, DOI 10.1158/1541-7786.MCR-06-0177
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Guo YP, 2003, J BIOL CHEM, V278, P29509, DOI 10.1074/jbc.M304059200
   Hopper-Borge E, 2004, CANCER RES, V64, P4927, DOI 10.1158/0008-5472.CAN-03-3111
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Kao HH, 2003, J BIOMED SCI, V10, P98, DOI 10.1159/000068078
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   Kim MS, 2003, CANCER RES, V63, P7291
   Kim YK, 2008, BIOCHEM BIOPH RES CO, V368, P959, DOI 10.1016/j.bbrc.2008.02.013
   Kruh GD, 2007, PFLUG ARCH EUR J PHY, V453, P675, DOI 10.1007/s00424-006-0114-1
   Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953
   Kuendgen A, 2007, CANCER-AM CANCER SOC, V110, P943, DOI 10.1002/cncr.22891
   LICHT T, 1991, INT J CANCER, V49, P630, DOI 10.1002/ijc.2910490427
   Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912
   Luong QT, 2006, CLIN CANCER RES, V12, P5570, DOI 10.1158/1078-0432.CCR-06-0367
   MORROW CS, 1994, J BIOL CHEM, V269, P10739
   Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Qadir M, 2005, CLIN CANCER RES, V11, P2320, DOI 10.1158/1078-0432.CCR-04-1725
   Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539
   Robey RW, 2006, CLIN CANCER RES, V12, P1547, DOI 10.1158/1078-0432.CCR-05-1423
   Sanchez-Gonzalez B, 2006, BLOOD, V108, P1174, DOI 10.1182/blood-2005-09-008086
   Schaich M, 2005, BRIT J HAEMATOL, V128, P324, DOI 10.1111/j.1365-2141.2004.05319.x
   SCHEINBERG DAM, 2005, CANC PRINCIPLES PRAC
   Schniewind Bodo, 2006, J Carcinog, V5, P25, DOI 10.1186/1477-3163-5-25
   Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126
   Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   To KKW, 2008, MOL CANCER RES, V6, P151, DOI 10.1158/1541-7786.MCR-07-0175
   To KKW, 2006, MOL CELL BIOL, V26, P8572, DOI 10.1128/MCB.00650-06
   UEDA K, 1987, J BIOL CHEM, V262, P17432
   Venditti A, 2000, BLOOD, V96, P3948, DOI 10.1182/blood.V96.12.3948.h8003948_3948_3952
   Xiao JJ, 2005, J PHARMACOL EXP THER, V314, P467, DOI 10.1124/jpet.105.083956
   Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865
   Yatouji S, 2007, INT J ONCOL, V30, P1003
NR 50
TC 96
Z9 109
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2009
VL 15
IS 11
BP 3705
EP 3715
DI 10.1158/1078-0432.CCR-08-2048
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 454CJ
UT WOS:000266659000009
PM 19458058
OA Green Submitted
DA 2025-01-12
ER

PT J
AU De Koning, L
   Savignoni, A
   Boumendil, C
   Rehman, H
   Asselain, B
   Sastre-Garau, X
   Almouzni, G
AF De Koning, Leanne
   Savignoni, Alexia
   Boumendil, Charlene
   Rehman, Haniya
   Asselain, Bernard
   Sastre-Garau, Xavier
   Almouzni, Genevieve
TI Heterochromatin protein 1α: a hallmark of cell proliferation relevant to
   clinical oncology
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE cancer; cell cycle; heterochromatin; HP1; proliferation
ID HISTONE DEACETYLASE INHIBITORS; CHROMATIN ASSEMBLY FACTOR-1; NUCLEAR
   COREPRESSOR KAP1; HP1 PROTEINS; MAMMALIAN-CELLS; BREAST-CANCER;
   PERICENTRIC HETEROCHROMATIN; DROSOPHILA-MELANOGASTER; CENTROMERE
   FUNCTION; GENE-EXPRESSION
AB Mammalian cells contain three closely related heterochromatin protein 1 (HP1) isoforms, HP1 alpha, beta and gamma, which, by analogy to their unique counterpart in Schizosaccharomyces pombe, have been implicated in gene silencing, genome stability and chromosome segregation. However, the individual importance of each isoform during normal cell cycle and disease has remained an unresolved issue. Here, we reveal that HP1 alpha shows a proliferation-dependent regulation, which neither HP1 beta nor gamma display. During transient cell cycle exit, the HP1 alpha mRNA and protein levels diminish. Transient depletion of HP1 alpha, but not HP1 beta or gamma, in tumoural and primary human cells leads to defects in chromosome segregation. Notably, analysis of an annotated collection of samples derived from carcinomas reveals an overexpression of HP1 alpha mRNA and protein, which correlates with clinical data and disease outcome. Our results unveil a specific expression pattern for the HP1 alpha isoform, suggesting a unique function related to cell division and tumour growth. The overexpression of HP1 alpha constitutes a new example of a potential epigenetic contribution to tumourigenesis that is of clinical interest for cancer prognosis.
C1 [De Koning, Leanne; Boumendil, Charlene; Rehman, Haniya; Almouzni, Genevieve] UPMC, CNRS, Inst Curie, Lab Nucl Dynam & Genome Plast,UMR218, F-75248 Paris 05, France.
   [Savignoni, Alexia; Asselain, Bernard] Inst Curie, Dept Biostat, F-75248 Paris 05, France.
   [Sastre-Garau, Xavier] Inst Curie, Dept Pathol, F-75248 Paris 05, France.
C3 Universite PSL; UNICANCER; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); Sorbonne Universite; UNICANCER;
   Universite PSL; Institut Curie; UNICANCER; Universite PSL; Institut
   Curie
RP Almouzni, G (通讯作者)，UPMC, CNRS, Inst Curie, Lab Nucl Dynam & Genome Plast,UMR218, 26 Rue Ulm, F-75248 Paris 05, France.
EM Genevieve.Almouzni@curie.fr
RI Almouzni, Genevieve/ABG-1029-2021; Boumendil, Charlene/GPS-4811-2022
OI Sastre-Garau, Xavier/0000-0001-5992-2083; Boumendil,
   Charlene/0000-0002-1953-3902
FU la Ligue Nationale contre le Cancer (Equipe labellisee la Ligue); PIC;
   European Commission [LSHG-CT-2004-503433]; ACI-2007-Canceropole IdF
   'Breast cancer and Epigenetics'; ANR [NT05-4_42267, PCV06_142302];
   Canceropole Ile-de-France; Association pour la recherche sur le cancer
   (ARC)
FX We thank all members of the UMR218 and Sophie Polo for help and
   discussions, Edith Heard for the KL1 marker; Martial Caly, Anne Vincent
   Salomon and Carine Ganem for help with patient samples, Patricia
   Decremoux for helpful discussions concerning Q-RT-PCR and Jennifer
   Nelson for Q-RT-PCR duplicates. The pCherry-N1 plasmid was kindly
   provided by Lise Andrieux and Wim Vermeulen (Rotterdam, The Netherlands)
   and we thank Isabelle Loiodice for cloning of the H2B-cherry. This work
   was supported by la Ligue Nationale contre le Cancer (Equipe labellisee
   la Ligue), PIC Programs ('Retinoblastome' and 'Replication, Instabilite
   chromosomique et cancer'), the European Commission Network of Excellence
   Epigenome (LSHG-CT-2004-503433), ACI-2007-Canceropole IdF 'Breast cancer
   and Epigenetics', ANR 'CenRNA' NT05-4_42267 and ANR 'FaRC' PCV06_142302.
   LDK was funded by Canceropole Ile-de-France and by Association pour la
   recherche sur le cancer (ARC).
CR Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763
   Andersson A, 2007, LEUKEMIA, V21, P1198, DOI 10.1038/sj.leu.2404688
   AUTH T, 2006, EXP CELL RES, V28, P28
   Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bártová E, 2005, J CELL SCI, V118, P5035, DOI 10.1242/jcs.02621
   Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228
   Baxter J, 2004, EMBO J, V23, P4462, DOI 10.1038/sj.emboj.7600414
   Berglund P, 2006, CELL CYCLE, V5, P606, DOI 10.4161/cc.5.6.2569
   Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200
   Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572
   de Cremoux P, 2004, ENDOCR-RELAT CANCER, V11, P489, DOI 10.1677/erc.1.00808
   De Lucia F, 2005, NUCLEIC ACIDS RES, V33, P2852, DOI 10.1093/nar/gki584
   Dialynas GK, 2007, J CELL SCI, V120, P3415, DOI 10.1242/jcs.012914
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126
   Ekwall K, 1996, J CELL SCI, V109, P2637
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694
   Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219
   Folco HD, 2008, SCIENCE, V319, P94, DOI 10.1126/science.1150944
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gilbert N, 2003, EMBO J, V22, P5540, DOI 10.1093/emboj/cdg520
   Grigoryev SA, 2004, J CELL SCI, V117, P6153, DOI 10.1242/cs.01537
   Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109
   HACKETT AJ, 1977, JNCI-J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635
   Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254
   Istomina NE, 2003, MOL CELL BIOL, V23, P6455, DOI 10.1128/MCB.23.18.6455-6468.2003
   JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862
   JONES PL, 1995, J CELL SCI, V108, P519
   Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Kirschner-Schwabe R, 2006, CLIN CANCER RES, V12, P4553, DOI 10.1158/1078-0432.CCR-06-0235
   Koch B, 2008, CHROMOSOMA, V117, P199, DOI 10.1007/s00412-007-0139-z
   Kwon SH, 2008, MOL CELLS, V26, P217
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100
   Lin CH, 2008, MOL CELL, V32, P696, DOI 10.1016/j.molcel.2008.11.008
   Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383
   Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563
   Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372
   Minc E., 2001, Methods in Cell Science, V23, P171, DOI 10.1023/A:1013168323754
   Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Muller M J, 2001, Obes Rev, V2, P15
   Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X
   Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   NORWOOD LE, 2006, J BIOL CHEM, V28, P28
   O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089
   Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200
   Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187
   Polo SE, 2004, CANCER RES, V64, P2371, DOI 10.1158/0008-5472.CAN-03-2893
   Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619
   Quade BJ, 2004, GENE CHROMOSOME CANC, V40, P97, DOI 10.1002/gcc.20018
   Quivy JP, 2008, NAT STRUCT MOL BIOL, V15, P972, DOI 10.1038/nsmb.1470
   Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Régnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Ritou E, 2007, J CELL SCI, V120, P3425, DOI 10.1242/jcs.012955
   Ryan RF, 1999, MOL CELL BIOL, V19, P4366
   Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010
   Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441
   Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005
   Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791
   Wang CG, 2007, J BIOL CHEM, V282, P29902, DOI 10.1074/jbc.M704757200
   Watrin E, 2006, CURR BIOL, V16, P863, DOI 10.1016/j.cub.2006.03.049
   Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X
   Williams L, 2000, TRENDS PLANT SCI, V5, P239, DOI 10.1016/S1360-1385(00)01653-8
   Yamagishi Y, 2008, NATURE, V455, P251, DOI 10.1038/nature07217
   Yamamoto K, 2004, J BIOL CHEM, V279, P401, DOI 10.1074/jbc.M307344200
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
NR 86
TC 65
Z9 72
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD JUN
PY 2009
VL 1
IS 3
BP 178
EP 191
DI 10.1002/emmm.200900022
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 543GX
UT WOS:000273563100005
PM 20049717
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU van der Kaay, DCM
   Hendriks, AEJ
   Ester, WA
   Leunissen, RWJ
   Willemsen, RH
   de Kort, SWK
   Paquette, JR
   Hokken-Koelega, ACS
   Deal, CL
AF van der Kaay, D. C. M.
   Hendriks, A. E. J.
   Ester, W. A.
   Leunissen, R. W. J.
   Willemsen, R. H.
   de Kort, S. W. K.
   Paquette, J. R.
   Hokken-Koelega, A. C. S.
   Deal, C. L.
TI Genetic and epigenetic variability in the gene for IGFBP-3
   (<i>IGFBP3</i>): Correlation with serum IGFBP-3 levels and growth in
   short children born small for gestational age
SO GROWTH HORMONE & IGF RESEARCH
LA English
DT Article
DE Small for gestational age; IGFBP3; Growth; GH treatment
ID FACTOR-BINDING PROTEIN-3; BREAST-CANCER RISK; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; HORMONE GH TREATMENT; FACTOR-I; ADULT HEIGHT;
   DEVELOPMENTAL ORIGINS; CIRCULATING LEVELS; PREDICTION MODEL;
   PLASMA-LEVELS
AB Context: IGF-1 and IGFBP-3 play a central role in fetal and postnatal growth and levels are low in short SGA children. The -202 A/C and -185 C/T SNPs are located near elements involved in directing IGFBP3 promoter activity and expression. Changes in promoter CpG methylation status affect transcription factor binding and transcriptional activation of IGFBP3 in vitro.
   Objective: To assess the relationship between IGFBP3 promoter SNPs, IGFBP-3 levels, spontaneous growth and growth response to CH treatment in short prepubertal SGA children. To assess promoter methylation status in a subgroup of short SGA subjects and controls.
   Patients: 292 Short prepubertal SGA children, 39 short young SGA adults and 85 young adults with normal Stature.
   Intervention: Short prepubertal SGA children received GH 1 mg/m(2)/day.
   Outcome measures: Fasting levels of IGF-1 and IGFBP-3, baseline and delta height SDS.
   Results: At baseline, IGFBP-3 levels were highest in SGA children with -202 AA genotype and lower in children with I or 2 copies of the C-allele (P < 0.001). Children with C-202/C-185 haplotype, compared to children with A(-202)/C-185 haplotype, had lower IGFBP-3 levels (P = 0.003) and were shorter (P = 0.03). During GH treatment, children with C-202/C-185 haplotype showed a significantly greater increase in IGFBP-3 SDS and in height SDS than children with A(-202)/C-185 haplotype, resulting in similar IGFBP-3 levels and similar height SDS after 12 months of GH treatment. CpG methylation patterns showed a trend towards more methylation of CpGs involved in transcription factor binding in short young SGA adults compared to controls.
   Conclusion: Polymorphic variation in the IGFBP3 promoter region is correlated with IGFBP-3 levels, spontaneous growth and response to GH treatment in short SGA children. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [van der Kaay, D. C. M.; Hendriks, A. E. J.; Paquette, J. R.; Deal, C. L.] Univ Montreal, Hop St Justine, Res Ctr, Endocrine Serv, Montreal, PQ H3T 1C5, Canada.
   [van der Kaay, D. C. M.; Hendriks, A. E. J.; Ester, W. A.; Leunissen, R. W. J.; Willemsen, R. H.; de Kort, S. W. K.; Hokken-Koelega, A. C. S.] Erasmus MC, Div Endocrinol, Dept Pediat, NL-3015 GJ Rotterdam, Netherlands.
   [van der Kaay, D. C. M.; Hokken-Koelega, A. C. S.] Dutch Growth Res Fdn, NL-3016 AH Rotterdam, Netherlands.
C3 Universite de Montreal; Erasmus University Rotterdam; Erasmus MC
RP Deal, CL (通讯作者)，Univ Montreal, Hop St Justine, Res Ctr, Endocrine Serv, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM cheri.l.deal@umontreal.ca
RI Willemsen, Ruben/JEP-3720-2023; Ester, Wietske/JZE-1102-2024
OI Willemsen, Ruben/0000-0002-4891-2506; /0000-0002-0795-1832; Ester,
   Wietske A./0000-0002-9666-4156
CR Al-Zahrani A, 2006, HUM MOL GENET, V15, P1, DOI 10.1093/hmg/ddi398
   Arends NJT, 2003, CLIN ENDOCRINOL, V59, P779, DOI 10.1046/j.1365-2265.2003.01905.x
   Bernig T, 2006, EXPERT REV MOL DIAGN, V6, P319, DOI 10.1586/14737159.6.3.319
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   BOGUSZEWSKI M, 1995, J CLIN ENDOCR METAB, V80, P2599, DOI 10.1210/jc.80.9.2599
   Brown CM, 2006, J MOL MED, V84, P561, DOI 10.1007/s00109-005-0037-x
   Chang YS, 2004, ONCOGENE, V23, P6569, DOI 10.1038/sj.onc.1207882
   Cutfield WS, 2007, PEDIATR RES, V61, p68R, DOI 10.1203/pdr.0b013e318045764c
   de Ridder MAJ, 2008, J CLIN ENDOCR METAB, V93, P477, DOI 10.1210/jc.2007-1381
   de Ridder MAJ, 2007, J CLIN ENDOCR METAB, V92, P925, DOI 10.1210/jc.2006-1259
   Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274
   Deng X, 2007, J BIOL CHEM, V282, P17517, DOI 10.1074/jbc.M702228200
   DEWAAL WJ, 1994, CLIN ENDOCRINOL, V41, P621
   Ferry RJ, 1999, HORM RES, V51, P53
   Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033
   Fredriks AM, 2000, PEDIATR RES, V47, P316, DOI 10.1203/00006450-200003000-00006
   Fredriks AM, 2000, ARCH DIS CHILD, V82, P107, DOI 10.1136/adc.82.2.107
   Gaunt TR, 2001, HUM MOL GENET, V10, P1491, DOI 10.1093/hmg/10.14.1491
   Haiman CA, 2007, CANCER RES, V67, P1893, DOI 10.1158/0008-5472.CAN-06-4123
   Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4
   Hanafusa T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-9
   Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081
   Jernström H, 2001, CANCER EPIDEM BIOMAR, V10, P377
   Juul A, 2003, GROWTH HORM IGF RES, V13, P113, DOI 10.1016/S1096-6374(03)00038-8
   Kaaks R, 2002, CANCER CAUSE CONTROL, V13, P307, DOI 10.1023/A:1015270324325
   Koo SH, 2006, CLIN EXP PHARMACOL P, V33, P525, DOI 10.1111/j.1440-1681.2006.04402.x
   Krajcik RA, 2002, CANCER EPIDEM BIOMAR, V11, P1566
   Kristrom B, 1997, J CLIN ENDOCR METAB, V82, P2889, DOI 10.1210/jc.82.9.2889
   Leunissen RWJ, 2008, J CLIN ENDOCR METAB, V93, P445, DOI 10.1210/jc.2007-1543
   Moon JW, 2006, INT J CANCER, V118, P353, DOI 10.1002/ijc.21339
   Murphy VE, 2006, ENDOCR REV, V27, P141, DOI 10.1210/er.2005-0011
   Ong K, 2005, EARLY HUM DEV, V81, P973, DOI 10.1016/j.earlhumdev.2005.10.010
   Paquette J, 2007, ENDOCRINOLOGY, V148, P6007, DOI 10.1210/en.2006-1729
   Ranke MB, 2003, J CLIN ENDOCR METAB, V88, P125, DOI 10.1210/jc.2002-020867
   Ren ZF, 2004, CANCER EPIDEM BIOMAR, V13, P1290
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Rikken B, 1998, HORM RES, V50, P166, DOI 10.1159/000023268
   Sas T, 1999, J CLIN ENDOCR METAB, V84, P3064, DOI 10.1210/jc.84.9.3064
   Schernhammer ES, 2003, INT J CANCER, V107, P60, DOI 10.1002/ijc.11358
   Schönau E, 2001, EUR J ENDOCRINOL, V144, P13, DOI 10.1530/eje.0.1440013
   Sing CF, 2003, ARTERIOSCL THROM VAS, V23, P1190, DOI 10.1161/01.ATV.0000075081.51227.86
   Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910
   van Dijk M, 2006, J CLIN ENDOCR METAB, V91, P1390, DOI 10.1210/jc.2005-1663
   van Pareren Y, 2003, J CLIN ENDOCR METAB, V88, P3584, DOI 10.1210/jc.2002-021172
   Verkauskiene R, 2005, J CLIN ENDOCR METAB, V90, P5672, DOI 10.1210/jc.2005-0423
   Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622
   Visscher PM, 2008, NAT GENET, V40, P489, DOI 10.1038/ng0508-489
   Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
NR 49
TC 30
Z9 32
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1096-6374
EI 1532-2238
J9 GROWTH HORM IGF RES
JI Growth Horm. IGF Res.
PD JUN
PY 2009
VL 19
IS 3
BP 198
EP 205
DI 10.1016/j.ghir.2008.08.010
PG 8
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 464UN
UT WOS:000267533400002
PM 18929499
DA 2025-01-12
ER

PT J
AU Maida, Y
   Kyo, S
   Sakaguchi, J
   Mizumoto, Y
   Hashimoto, M
   Mori, N
   Ikoma, T
   Nakamura, M
   Takakura, M
   Urata, Y
   Fujiwara, T
   Inoue, M
AF Maida, Yoshiko
   Kyo, Satoru
   Sakaguchi, Junko
   Mizumoto, Yasunari
   Hashimoto, Manabu
   Mori, Noriko
   Ikoma, Tomomi
   Nakamura, Mitsuhiro
   Takakura, Masahiro
   Urata, Yasuo
   Fujiwara, Toshiyoshi
   Inoue, Masaki
TI Diagnostic potential and limitation of imaging cancer cells in
   cytological samples using telomerase-specific replicative adenovirus
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE gynecologic cancers; cytological screening; molecular diagnosis;
   telomerase; adenovirus
ID CIRCULATING TUMOR-CELLS; MLH1 PROMOTER; MICROSATELLITE INSTABILITY;
   ENDOMETRIAL CANCERS; BREAST-CANCER; GENE; HYPERMETHYLATION; SURVIVAL
AB Cytological cancer screening that targets genetic or epigenetic abnormalities may be a viable alternative to morphological screening. Detecting cancer cells by specific genetic markers helps their easy detection in cytological samples. We recently established the telomerase-specific replication-selective adenovirus OBP-401, in which the human telomerase reverse transcriptase (hTERT) gene promoter has been inserted upstream of the El genes, and in which the green fluorescent protein (GFP) gene is driven by the CMV promoter. This virus selectively replicates only in telomerase-positive cells, expressing GFP, and therefore may be a toot for cancer screening. In the present study, we first confirmed that cytological samples can easily be infected with OBP-401, allowing visualization of GFP-positive cells under fluorescent microscopy 24 h after infection. After 32 cytological samples from patients with cervical, endometrial or ovarian cancers were infected with OBP-401, GFP signals were detected in 31 (96%) of the samples. However, some normal endometrial scrapings exhibited GFP-signals, possibly due to endometrial glandular cells with constitutive telomerase activity. The ability of OBP-401 to enrich cancer cells was then tested. Cytological samples containing cervical or endometrial cancer cells were infected with OBP-401, and GFP-positive cells were sorted by flow cytometry; DNA was extracted from the GFP-positive cells. Direct DNA sequencing or methylation-specific PCR identified cancer-derived mutations or hypermethylations of tumor suppressor genes more efficiently than analyses using crude cytological samples. Thus, OBP-401-Z, based sorting of GFP-positive cells successfully enriched cancer cells, allowing efficient detection of genetic or epigenetic abnormalities in cytological samples.
C1 [Maida, Yoshiko; Kyo, Satoru; Sakaguchi, Junko; Mizumoto, Yasunari; Hashimoto, Manabu; Mori, Noriko; Ikoma, Tomomi; Nakamura, Mitsuhiro; Takakura, Masahiro; Inoue, Masaki] Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan.
   [Urata, Yasuo] Oncolys BioPharma Inc, Minato Ku, Tokyo 1060032, Japan.
   [Fujiwara, Toshiyoshi] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan.
C3 Kanazawa University; Oncolys BioPharma; Okayama University
RP Kyo, S (通讯作者)，Kanazawa Univ, Sch Med Sci, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.
EM satoruky@med.kanazawa-u.ac.jp
RI Takakura, Masahiro/E-1080-2011
FU Japan Society for the Promotion of Science (JSPS); Megumi Medical
   Foundation of Kanazawa University
FX We wish to thank Mr. H. Kawamura, Oncolys BioPharma, Inc., for his
   helpful information on OBP-401. This study was supported by a
   Grant-in-Aid for Scientific Research from the Japan Society for the
   Promotion of Science (JSPS) and the Megumi Medical Foundation of
   Kanazawa University.
CR Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   CROOK T, 1991, ONCOGENE, V6, P873
   Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178
   Franco Eduardo L, 2003, J Natl Cancer Inst Monogr, P89
   Gruszka-Westwood AM, 2001, BLOOD, V97, P3552, DOI 10.1182/blood.V97.11.3552
   Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x
   Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365
   Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404
   Kyo S, 1997, CANCER RES, V57, P610
   Maida Y, 2002, INT J CANCER, V100, P714, DOI 10.1002/ijc.10543
   Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3
   Mocellin S, 2006, TRENDS MOL MED, V12, P130, DOI 10.1016/j.molmed.2006.01.006
   Moreno JG, 2005, UROLOGY, V65, P713, DOI 10.1016/j.urology.2004.11.006
   Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955
   Ring A, 2004, LANCET ONCOL, V5, P79, DOI 10.1016/S1470-2045(04)01381-6
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661
   Solomon Diane, 2003, J Natl Cancer Inst Monogr, P97
   Takakura M, 1999, CANCER RES, V59, P551
   Ulmer A, 2004, CLIN CANCER RES, V10, P531, DOI 10.1158/1078-0432.CCR-0424-03
   Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335
NR 23
TC 15
Z9 17
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUN
PY 2009
VL 34
IS 6
BP 1549
EP 1556
DI 10.3892/ijo_00000284
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 447FB
UT WOS:000266175900009
PM 19424572
OA Bronze
DA 2025-01-12
ER

PT J
AU Gu, BN
   Sun, P
   Yuan, YY
   Moraes, RC
   Li, AH
   Teng, AD
   Agrawal, A
   Rhéaume, C
   Bilanchone, V
   Veltmaat, JM
   Takemaru, KI
   Millar, S
   Lee, EYHP
   Lewis, MT
   Li, BA
   Dai, X
AF Gu, Bingnan
   Sun, Peng
   Yuan, Yuanyang
   Moraes, Ricardo C.
   Li, Aihua
   Teng, Andy
   Agrawal, Anshu
   Rheaume, Catherine
   Bilanchone, Virginia
   Veltmaat, Jacqueline M.
   Takemaru, Ken-Ichi
   Millar, Sarah
   Lee, Eva Y. -H. P.
   Lewis, Michael T.
   Li, Boan
   Dai, Xing
TI Pygo2 expands mammary progenitor cells by facilitating histone H3 K4
   methylation
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID WNT SIGNALING PATHWAY; STEM-CELL; BETA-CATENIN; BREAST-CANCER;
   PHD-FINGER; GLAND DEVELOPMENT; NUCLEAR-PROTEIN; GENE-EXPRESSION;
   DNA-DAMAGE; P21 LOSS
AB Recent studies have unequivocally identified multipotent stem/progenitor cells in mammary glands, offering a tractable model system to unravel genetic and epigenetic regulation of epithelial stem/progenitor cell development and homeostasis. In this study, we show that Pygo2, a member of an evolutionarily conserved family of plant homeo domain-containing proteins, is expressed in embryonic and postnatal mammary progenitor cells. Pygo2 deficiency, which is achieved by complete or epithelia-specific gene ablation in mice, results in defective mammary morphogenesis and regeneration accompanied by severely compromised expansive self-renewal of epithelial progenitor cells. Pygo2 converges with Wnt/beta-catenin signaling on progenitor cell regulation and cell cycle gene expression, and loss of epithelial Pygo2 completely rescues. beta-catenin-induced mammary outgrowth. We further describe a novel molecular function of Pygo2 that is required for mammary progenitor cell expansion, which is to facilitate K4 trimethylation of histone H3, both globally and at Wnt/beta-catenin target loci, via direct binding to K4-methyl histone H3 and recruiting histone H3 K4 methyltransferase complexes.
C1 [Gu, Bingnan; Sun, Peng; Yuan, Yuanyang; Li, Aihua; Teng, Andy; Rheaume, Catherine; Bilanchone, Virginia; Lee, Eva Y. -H. P.; Li, Boan; Dai, Xing] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
   [Agrawal, Anshu] Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA.
   [Dai, Xing] Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA.
   [Takemaru, Ken-Ichi] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.
   [Moraes, Ricardo C.; Lewis, Michael T.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Moraes, Ricardo C.; Lewis, Michael T.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
   [Millar, Sarah] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
   [Millar, Sarah] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA.
   [Yuan, Yuanyang; Li, Boan] Xiamen Univ, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Peoples R China.
   [Yuan, Yuanyang; Li, Boan] Xiamen Univ, Dept Biomed Sci, Xiamen 361005, Peoples R China.
   [Veltmaat, Jacqueline M.] ASTAR, Inst Mol & Cell Biol, Proteos 138673, Singapore.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine; State
   University of New York (SUNY) System; Stony Brook University; Baylor
   College of Medicine; Baylor College of Medicine; University of
   Pennsylvania; University of Pennsylvania; Xiamen University; Xiamen
   University; Agency for Science Technology & Research (A*STAR); A*STAR -
   Institute of Molecular & Cell Biology (IMCB)
RP Li, BA (通讯作者)，Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
EM bali@xmu.edu.cn; xdai@uci.edu
RI Gu, Bingnan/B-3880-2010; Sun, Peng/P-6099-2014; Veltmaat,
   Jacqueline/G-9648-2011; Lewis, Michael/A-9572-2009; Agrawal,
   Anshu/AAU-6341-2021
OI Dai, Xing/0000-0001-8134-1365; Millar, Sarah/0000-0001-8792-6890;
   Moraes, Ricardo/0000-0001-5455-092X; Rheaume,
   Catherine/0000-0002-9310-6044
FU Department of Defense [W81XWH04-1-0516]; National Institutes of Health
   [R01-AR47320, K02-AR51482, R01 CA127857, P01 CA30195]; National Key
   Research Project of Basic Sciences of China [973 project 2006CB708507];
   National Natural Science Foundation of China [30671173]; California
   Breast Cancer Research Program (CBCRP) postdoctoral fellowship
   [14FB-0129]; CBCRP award [10-FB-0116]; Children's Hospital Los Angeles
   fellowship; National Cancer Institute [P30CA062203] Funding Source: NIH
   RePORTER
FX This work was supported by Department of Defense grant W81XWH04-1-0516,
   National Institutes of Health grants R01-AR47320 and K02-AR51482 (to X.
   Dai), National Key Research Project of Basic Sciences of China (973
   project 2006CB708507), National Natural Science Foundation of China
   grant 30671173 (to B. Li), and National Institutes of Health grants R01
   CA127857 and P01 CA30195 (to M. T. Lewis). B. Gu is a recipient of a
   California Breast Cancer Research Program (CBCRP) postdoctoral
   fellowship (14FB-0129). J. M. Veltmaat acknowledges support from CBCRP
   award 10-FB-0116 and a Children's Hospital Los Angeles fellowship.
CR Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105
   Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956
   Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125
   Andrews PGP, 2007, INT J ONCOL, V30, P357
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Ball SM, 1998, ANAT REC, V250, P459, DOI 10.1002/(SICI)1097-0185(199804)250:4<459::AID-AR9>3.0.CO;2-S
   Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9
   Belenkaya TY, 2002, DEVELOPMENT, V129, P4089
   Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001
   Boras-Granic K, 2006, DEV BIOL, V295, P219, DOI 10.1016/j.ydbio.2006.03.030
   Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931
   Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804
   Chepko G, 1997, TISSUE CELL, V29, P239, DOI 10.1016/S0040-8166(97)80024-9
   Clarke RB, 2005, CELL PROLIFERAT, V38, P375, DOI 10.1111/j.1365-2184.2005.00357.x
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011
   Dai X, 1998, GENE DEV, V12, P3452, DOI 10.1101/gad.12.21.3452
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Fiedler M, 2008, MOL CELL, V30, P507, DOI 10.1016/j.molcel.2008.03.011
   Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022
   Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1
   Ginestier C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1741
   Grimm SL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1504
   Gu BN, 2009, CELL CYCLE, V8, P1409, DOI 10.4161/cc.8.9.8322
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8
   Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264
   Jessen S, 2008, BIOESSAYS, V30, P448, DOI 10.1002/bies.20757
   Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304
   Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305
   KITANO Y, 1983, BRIT J DERMATOL, V108, P555, DOI 10.1111/j.1365-2133.1983.tb01056.x
   Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048
   Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7
   Li BA, 2005, DEVELOPMENT, V132, P1463, DOI 10.1242/dev.01658
   Li B, 2007, GENESIS, V45, P318, DOI 10.1002/dvg.20299
   Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100
   Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200
   Mackay DR, 2006, DEV BIOL, V291, P38, DOI 10.1016/j.ydbio.2005.12.003
   Mailleux AA, 2002, DEVELOPMENT, V129, P53
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671
   Méndez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000
   Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065
   Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6
   Moraes RC, 2007, DEVELOPMENT, V134, P1231, DOI 10.1242/dev.02797
   Nair M, 2008, DEV BIOL, V320, P446, DOI 10.1016/j.ydbio.2008.05.553
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Niwa H, 2007, GENE DEV, V21, P2071, DOI 10.1101/gad.1615707
   Parker DS, 2002, DEVELOPMENT, V129, P2565
   Peña PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814
   Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schwab KR, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-15
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065
   SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161
   Smith GH, 2005, STEM CELL REV, V1, P215, DOI 10.1385/SCR:1:3:215
   Song N, 2007, DEVELOPMENT, V134, P1873, DOI 10.1242/dev.001495
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681
   Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570
   Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786
   Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089
   Townsley FM, 2004, J BIOL CHEM, V279, P5177, DOI 10.1074/jbc.M309722200
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691
   Veltmaat JM, 2006, DEVELOPMENT, V133, P2325, DOI 10.1242/dev.02394
   Veltmaat JM, 2004, DEV DYNAM, V229, P349, DOI 10.1002/dvdy.10441
   Veltmaat JM, 2003, DIFFERENTIATION, V71, P1, DOI 10.1046/j.1432-0436.2003.700601.x
   Voronina VA, 2009, J CELL BIOL, V185, P225, DOI 10.1083/jcb.200809144
   Wang XR, 2007, BIOCHEMISTRY-US, V46, P3553, DOI 10.1021/bi061994u
   Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789
   Zhu ED, 2008, J BIOL CHEM, V283, P7361, DOI 10.1074/jbc.M703304200
NR 86
TC 106
Z9 116
U1 0
U2 15
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD JUN 1
PY 2009
VL 185
IS 5
BP 811
EP 826
DI 10.1083/jcb.200810133
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 457EU
UT WOS:000266912100008
PM 19487454
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Gu, W
   Pan, F
   Singer, RH
AF Gu, Wei
   Pan, Feng
   Singer, Robert H.
TI Blocking β-catenin binding to the <i>ZBP1</i> promoter represses
   <i>ZBP1</i> expression, leading to increased proliferation and migration
   of metastatic breast-cancer cells
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE ZBP1 repression; Promoter methylation; Wnt-beta-catenin signaling; Cell
   proliferation; Metastasis
ID ACTIN MESSENGER-RNA; PRIMARY MAMMARY-TUMORS; PROTEIN CRD-BP; C-MYC; DNA
   METHYLATION; STABILIZING PROTEIN; CONFERS RESISTANCE; IN-VITRO; GROWTH;
   LOCALIZATION
AB ZBP1 (zipcode-binding protein 1, also known as IMP-1) is an mRNA regulator, functioning in mRNA localization, stability and translational control. ZBP1 is actively expressed during embryogenesis and tumorigenesis, but its expression is repressed in metastatic breast-cancer cell lines and tumors. In this article, we show that downregulation of ZBP1 expression results from its promoter methylation, an epigenetic process that remodels the chromatin structure and frequently represses gene activity. Demethylation of the ZBP1 promoter in metastatic cells reactivated ZBP1 expression, owing to restoration of the interaction of the ZBP1 promoter with beta-catenin. Loss of ZBP1 function not only increased growth ability of metastatic cells, but also promoted cell migration. We identified a number of mRNAs that were selectively associated with ZBP1 in breast-cancer cells. Many of these are involved in cell motility and in cell-cycle regulation, and displayed altered expression patterns in the absence of ZBP1. These data suggest that repression of ZBP1 deregulates its associated mRNAs, leading to the phenotypic changes of breast cancers.
C1 [Gu, Wei; Singer, Robert H.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.
   [Gu, Wei; Singer, Robert H.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA.
   [Pan, Feng] NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program, New York, NY 10012 USA.
C3 Yeshiva University; Montefiore Medical Center; Albert Einstein College
   of Medicine; Yeshiva University; Montefiore Medical Center; Albert
   Einstein College of Medicine; New York University
RP Gu, W (通讯作者)，Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM wgu@aecom.yu.edu; rhsinger@aecom.yu.edu
FU NIH [CA83208, AR41480]
FX We thank Jeffrey Segall and John Condeelis for providing the metastatic
   breast-cancer cell lines and Kyle Lapidus for providing the MTLn3-ZBP1
   stable cell line. We also thank Daniel Medrano for help in methylation
   assays and members of the Singer Lab for valuable discussions. This work
   was supported by NIH grants CA83208 and AR41480 to R.H.S. Deposited in
   PMC for release after 12 months.
CR Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1
   Bender CM, 1998, CANCER RES, V58, P95
   BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642
   Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419
   Capodieci P, 2005, NAT METHODS, V2, P663, DOI 10.1038/NMETH786
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Condeelis J, 2005, BIOL CELL, V97, P97
   Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07
   CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191
   El-Osta A, 2004, LEUKEMIA, V18, P233, DOI 10.1038/sj.leu.2403218
   Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003
   Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505
   Gu W, 2008, MOL CELL BIOL, V28, P4963, DOI 10.1128/MCB.00266-08
   Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399
   Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002
   Hüttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115
   Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200
   Ioannidis P, 2003, ANTICANCER RES, V23, P2179
   Ioannidis P, 2003, INT J CANCER, V104, P54, DOI 10.1002/ijc.10794
   Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512
   Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y
   Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263
   Köbel M, 2007, ONCOGENE, V26, P7584, DOI 10.1038/sj.onc.1210563
   Lapidus K, 2007, J CELL SCI, V120, P3173, DOI 10.1242/jcs.000638
   Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002
   Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200
   Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134
   Mingle LA, 2005, J CELL SCI, V118, P2425, DOI 10.1242/jcs.02371
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Moreau P, 2002, CELL MOL LIFE SCI, V59, P1460, DOI 10.1007/s00018-002-8521-8
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nielsen FC, 2001, SCAND J CLIN LAB INV, V61, P93
   Nielsen J, 1999, MOL CELL BIOL, V19, P1262
   Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839
   Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507
   Pan F, 2007, MOL CELL BIOL, V27, P8340, DOI 10.1128/MCB.00972-07
   Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158
   Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838
   Shestakova EA, 2001, P NATL ACAD SCI USA, V98, P7045, DOI 10.1073/pnas.121146098
   Stöhr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071
   Stove V, 2005, J VIROL, V79, P11422, DOI 10.1128/JVI.79.17.11422-11433.2005
   Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104
   Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039
   Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136
   Wang WG, 2002, CANCER RES, V62, P6278
   Yisraeli JK, 2005, BIOL CELL, V97, P87
   Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500
   Zajchowski DA, 2001, CANCER RES, V61, P5168
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
NR 57
TC 60
Z9 75
U1 0
U2 15
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD JUN 1
PY 2009
VL 122
IS 11
BP 1895
EP 1905
DI 10.1242/jcs.045278
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 448HS
UT WOS:000266254300019
PM 19461076
OA Green Published
DA 2025-01-12
ER

PT J
AU Zou, DH
   Yoon, HS
   Perez, D
   Weeks, RJ
   Guilford, P
   Humar, B
AF Zou, Donghui
   Yoon, Han-Seung
   Perez, David
   Weeks, Robert J.
   Guilford, Parry
   Humar, Bostjan
TI Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin
   (<i>CDH1</i>) as a target for chemoprevention of lobular neoplasia
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE lobular breast cancer; in situ; non-neoplastic epithelium; E-cadherin;
   epigenetic silencing; promoter methylation
ID DIFFUSE GASTRIC-CANCER; CARCINOMA IN-SITU; BENIGN BREAST EPITHELIUM;
   PROMOTER HYPERMETHYLATION; METHYLATION; EXPRESSION; RISK; GENES;
   INACTIVATION; LESIONS
AB Invasive lobular carcinoma (ILC) of the breast is believed to develop from in situ lesions, atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS). Down-regulation of the cell-cell adhesion protein E-cadherin is a defining feature of lobular breast cancer (LBC) and already occurs in ALH and LCIS. Apart from mutational mechanisms, epigenetic silencing of the E-cadherin gene (CDH1) is thought to be involved in E-cadherin down-regulation and has been observed at a high frequency in ILC. Whether CDH1 promoter methylation is already present in in situ lesions and thus contributes to the initiation of LBC is not established. We thus examined microdissected archived tissue from 20 LBCs by methylation-specific PCR to determine the CDH1 methylation status of lobular lesions. Nineteen of the 20 LBCs had a hypermethylated CDH1 promoter, including 13/14 ILCs and 13/13 ALHs or LCIS. Bisulphite sequencing indicated that methylation was complete within the investigated promoter fragment. Intriguingly, CDH1 methylation was likewise present in 8/8 adjacent non-neoplastic epithelia, but not in 6/6 mammary epithelia from healthy subjects. E-cadherin protein and mRNA were down-regulated in in situ lesions relative to adjacent epithelia. Together, these results indicate that CDH1 promoter methylation occurs in LBC prior to E-cadherin down-regulation and neoplastic formation. We thus propose that epigenetic silencing represents the first of the two hits required to silence both CDH1 alleles for LBC to develop. Because promoter methylation is in principle reversible, our findings suggest that chemoprevention of LBC by epigenetic drugs should be feasible. Furthermore, the presence of CDH1 methylation in pre-neoplastic epithelia suggests the existence of mammary regions with increased disease susceptibility, providing an explanation for the often multifocal presentation of LBC. Copyright (c) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Zou, Donghui; Weeks, Robert J.; Guilford, Parry; Humar, Bostjan] Univ Otago, Canc Genet Lab, Dept Biochem, Dunedin 9054, Aotearoa, New Zealand.
   [Yoon, Han-Seung] Univ Otago, Dept Pathol, Dunedin 9054, Aotearoa, New Zealand.
   [Perez, David] Univ Otago, Dept Oncol, Dunedin 9054, Aotearoa, New Zealand.
C3 University of Otago; University of Otago; University of Otago
RP Humar, B (通讯作者)，Univ Otago, Canc Genet Lab, Dept Biochem, POB 56, Dunedin 9054, Aotearoa, New Zealand.
EM bostjan.humar@otago.ac.nz
RI Perez, David/HMV-6566-2023; Weeks, Rob/A-6876-2012
OI Guilford, Parry/0000-0002-7256-9576; Weeks, Rob/0000-0003-0474-9089
CR Bean GR, 2007, CLIN CANCER RES, V13, P6834, DOI 10.1158/1078-0432.CCR-07-0407
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Frolik D, 2001, HISTOPATHOLOGY, V39, P503, DOI 10.1046/j.1365-2559.2001.01252.x
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Graziano F, 2004, CLIN CANCER RES, V10, P2784, DOI 10.1158/1078-0432.CCR-03-0320
   Guilford P, 2007, HERED CANCER CLIN PR, V5, P183, DOI 10.1186/1897-4287-5-4-183
   Hanby AM, 2008, HISTOPATHOLOGY, V52, P58, DOI 10.1111/j.1365-2559.2007.02891.x
   Humar B, 2001, INT J ONCOL, V19, P1179
   Humar B, 2007, CANCER RES, V67, P2480, DOI 10.1158/0008-5472.CAN-06-3021
   Humar B, 2009, CANCER RES, V69, P2050, DOI 10.1158/0008-5472.CAN-08-2457
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421
   Lombaerts M, 2004, BIOCHEM BIOPH RES CO, V319, P697, DOI 10.1016/j.bbrc.2004.05.041
   Masciari S, 2007, J MED GENET, V44, P726, DOI 10.1136/jmg.2007.051268
   Mastracci TL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1785
   Mastracci TL, 2005, MODERN PATHOL, V18, P741, DOI 10.1038/modpathol.3800362
   Mohsin SK, 2005, BREAST CANCER RES TR, V90, P249, DOI 10.1007/s10549-004-4493-8
   Sapino A, 2000, VIRCHOWS ARCH, V436, P421, DOI 10.1007/s004280050469
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Sarrío D, 2004, ONCOGENE, V23, P3272, DOI 10.1038/sj.onc.1207439
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523
   Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
NR 28
TC 39
Z9 40
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUN
PY 2009
VL 218
IS 2
BP 265
EP 272
DI 10.1002/path.2541
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 449NT
UT WOS:000266338000014
PM 19294736
OA Bronze
DA 2025-01-12
ER

PT J
AU Kataoka, H
   Nakano, S
   Kunimoto, Y
   Sugie, N
   Osaki, M
   Uzawa, N
   Yoshida, MA
   Oshimura, M
   Kitano, H
AF Kataoka, Hideyuki
   Nakano, Seiji
   Kunimoto, Yasuomi
   Sugie, Naoko
   Osaki, Mitsuhiko
   Uzawa, Narikazu
   Yoshida, Mitsuaki A.
   Oshimura, Mitsuo
   Kitano, Hiroya
TI Allele-Specific Expression Analysis of <i>PEG1</i>/<i>MEST</i> in Head
   and Neck Squamous Cell Carcinomas
SO YONAGO ACTA MEDICA
LA English
DT Article
DE head and neck squamous cell carcinoma; loss of imprinting; PEG1/MEST
ID INVASIVE BREAST-CANCER; IMPRINTED GENE; COLORECTAL CANCERS; FREQUENT
   LOSS; IGF2; TUMORIGENESIS; EPIGENETICS; LINES; MICE
AB Genomic imprinting is an epigenetic feature that plays a significant role in carcinogenesis. In this study, we examined the expression status of an imprinted gene, paternally expressed gene 1/mesoderm-specific transcript (PEG1/MEST), in 38 cases of head and neck squamous cell carcinomas (HNSCCs) and in 17 oral squamous cancer cell lines. Loss of imprinting (LOI) of PEG1/MEST was found in 8 of 10 (80%) in tumor specimens, and 6 of 10 (60%) informative cases even in the extracted normal tissue specimens. As for the oral squamous cancer cell lines, LOI was detected in 5 of 8 (62.5%) informative cases in PEG1/MEST. Thus, these data showed that abnormal expression of PEG1/MEST was found at a high frequency in the tumor, the extracted normal tissue specimens and the oral squamous cancer cell lines. PEG1/MEST LOI in extracted normal tissue specimens may have a potential individual cancer risk for HNSCC.
C1 [Kataoka, Hideyuki; Kunimoto, Yasuomi; Kitano, Hiroya] Tottori Univ, Fac Med, Div Otolaryngol Head & Neck Surg, Sch Med,Dept Med Sensory & Motor Organs, Yonago, Tottori 6838503, Japan.
   [Nakano, Seiji; Sugie, Naoko; Osaki, Mitsuhiko; Oshimura, Mitsuo] Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct,Div Mol Genet & Bio, Yonago, Tottori 6838503, Japan.
   [Uzawa, Narikazu] Tokyo Med & Dent Univ, Grad Sch, Div Maxillofacial & Neck Reconstruct, Bunkyo Ku, Tokyo 1138510, Japan.
   [Yoshida, Mitsuaki A.] Natl Inst Radiol Sci, Biodosimetry Sect, Dept Radiat Dosimetry, Res Ctr Radiat Emergency Med, Chiba 2638555, Japan.
C3 Tottori University; Tottori University; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU); National Institutes for
   Quantum Science & Technology
RP Kataoka, H (通讯作者)，Tottori Univ, Fac Med, Div Otolaryngol Head & Neck Surg, Sch Med,Dept Med Sensory & Motor Organs, Yonago, Tottori 6838503, Japan.
CR Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Delaval K, 2004, CURR OPIN GENET DEV, V14, P188, DOI 10.1016/j.gde.2004.01.005
   El-Naggar AK, 1999, ONCOGENE, V18, P7063, DOI 10.1038/sj.onc.1203192
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Goymer P, 2005, NAT REV GENET, V6, P878, DOI 10.1038/nrg1759
   Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007
   Kobayashi S, 1997, HUM MOL GENET, V6, P781, DOI 10.1093/hmg/6.5.781
   Lai SL, 2000, CLIN CANCER RES, V6, P3172
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008
   Nakanishi H, 2004, ONCOL REP, V12, P1273
   Nakano S, 2006, CANCER SCI, V97, P1147, DOI 10.1111/j.1349-7006.2006.00305.x
   Nishihara S, 2000, INT J ONCOL, V17, P317
   Pedersen IS, 2002, HUM MOL GENET, V11, P1449, DOI 10.1093/hmg/11.12.1449
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Rainho CA, 2001, HEAD NECK-J SCI SPEC, V23, P851, DOI 10.1002/hed.1124
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Sakatani T, 2001, BIOCHEM BIOPH RES CO, V283, P1124, DOI 10.1006/bbrc.2001.4916
   Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6
   Suda T, 2003, INT J MOL MED, V12, P243
   UZAWA N, 1995, ONCOGENE, V11, P1997
   Walter J, 2003, SEMIN CELL DEV BIOL, V14, P101, DOI 10.1016/S1084-9521(02)00142-8
NR 22
TC 1
Z9 1
U1 1
U2 2
PU TOTTORI UNIV, FACULTY MEDICINE
PI YONAGO
PA 86 NISHI-CHO, YONAGO, TOTTORI-KEN 683-8503, JAPAN
SN 0513-5710
J9 YONAGO ACTA MED
JI Yonago Acta Med.
PD JUN
PY 2009
VL 52
IS 2
BP 85
EP 90
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 482PY
UT WOS:000268902400002
DA 2025-01-12
ER

PT J
AU Lucas, ME
   Crider, KS
   Powell, DR
   Kapoor-Vazirani, P
   Vertino, PM
AF Lucas, Mary E.
   Crider, Krista S.
   Powell, Doris R.
   Kapoor-Vazirani, Priya
   Vertino, Paula M.
TI Methylation-sensitive Regulation of <i>TMS1</i>/<i>ASC</i> by the Ets
   Factor, GA-binding Protein-α
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRANSCRIPTION FACTOR GABP; LYSOZYME DOWNSTREAM ENHANCER; CASPASE
   RECRUITMENT DOMAIN; ABERRANT METHYLATION; DNA METHYLATION; ACTIVATING
   ADAPTER; PROSTATE-CANCER; GENE-EXPRESSION; BREAST-CANCER; RECEPTOR GENE
AB Epigenetic silencing involving the aberrant DNA methylation of promoter-associated CpG islands is one mechanism leading to the inactivation of tumor suppressor genes in human cancers. However, the molecular mechanisms underlying this event remains poorly understood. TMS1/ASC is a novel proapoptotic signaling factor that is subject to epigenetic silencing in human breast and other cancers. The TMS1 promoter is embedded within a CpG island that is unmethylated in normal cells and is spanned by three DNase I-hypersensitive sites (HS). Silencing of TMS1 in cancer cells is accompanied by local alterations in histone modification, remodeling of the HS, and hypermethylation of DNA. In this study, we probed the functional significance of the CpG island-specific HS. We identified a methylation-sensitive complex that bound a 55-bp intronic element corresponding to HS2. Affinity chromatography and mass spectrometry identified a component of this complex to be the GA-binding protein (GABP)alpha. Supershift analysis indicated that the GABP alpha binding partner, GABP beta 1, was also present in the complex. The HS2 element conferred a 3-fold enhancement in TMS1 promoter activity, which was dependent on both intact tandem ets binding sites and the presence of GABP alpha/beta 1 in trans. GABP alpha was selectively enriched at HS2 in human cells, and its occupancy was inversely correlated with CpG island methylation. Down-regulation of GABP alpha led to a concomitant decrease in TMS1 expression. These data indicate that the intronic HS2 element acts in cis to maintain transcriptional competency at the TMS1 locus and that this activity is mediated by the ets transcription factor, GABP alpha.
C1 Emory Univ, Winship Canc Inst, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA.
   [Lucas, Mary E.; Powell, Doris R.; Kapoor-Vazirani, Priya; Vertino, Paula M.] Emory Univ, Winship Canc Inst, Dept Radiat Oncol & Hematol, Atlanta, GA 30322 USA.
   [Lucas, Mary E.; Powell, Doris R.; Kapoor-Vazirani, Priya; Vertino, Paula M.] Emory Univ, Winship Canc Inst, Dept Med Oncol, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University
RP Vertino, PM (通讯作者)，1365-C Clifton Rd NE,Rm 4086, Atlanta, GA 30322 USA.
EM pvertin@emory.edu
OI Crider, Krista/0000-0001-6997-5955
FU National Institutes of Health NCI [2RO1 CA077337]
FX This work was supported, in whole or in part, by National Institutes of
   Health NCI Grant 2RO1 CA077337.
CR Ammerpohl O, 1997, GENE, V200, P75, DOI 10.1016/S0378-1119(97)00377-6
   Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890
   Aurrekoetxea-Hernández K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000
   BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502
   CARDOT P, 1994, BIOCHEMISTRY-US, V33, P12139, DOI 10.1021/bi00206a017
   Collard RL, 2006, PROSTATE, V66, P687, DOI 10.1002/pros.20371
   Conway KE, 2000, CANCER RES, V60, P6236
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996
   Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376
   Hasegawa M, 2007, ONCOGENE, V26, P1748, DOI 10.1038/sj.onc.1209965
   Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoare S, 1999, ENDOCRINOLOGY, V140, P2268, DOI 10.1210/endo.140.5.6710
   Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707
   Imaki H, 2003, CANCER RES, V63, P4607
   Kang HS, 2008, J MOL BIOL, V377, P636, DOI 10.1016/j.jmb.2008.01.054
   Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785
   Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351
   Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479
   Resendes KK, 2006, MOL CELL BIOL, V26, P3060, DOI 10.1128/MCB.26.8.3060-3070.2006
   Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004
   Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005
   Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954
   Schmitz A, 1997, J BIOL CHEM, V272, P20850, DOI 10.1074/jbc.272.33.20850
   Schweppe RE, 2003, J BIOL CHEM, V278, P16863, DOI 10.1074/jbc.M213063200
   Shiohara M, 2002, BIOCHEM BIOPH RES CO, V293, P1314, DOI 10.1016/S0006-291X(02)00384-4
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154
   Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200
   Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Valouev A, 2008, NAT METHODS, V5, P829, DOI [10.1038/nmeth.1246, 10.1038/NMETH.1246]
   VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Yang ZF, 2007, NAT CELL BIOL, V9, P339, DOI 10.1038/ncb1548
   Yokomori N, 1998, MOL ENDOCRINOL, V12, P1241, DOI 10.1210/me.12.8.1241
   YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355
   Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027
   Zhao H, 2006, J BIOL CHEM, V281, P30573, DOI 10.1074/jbc.M606803200
NR 49
TC 14
Z9 20
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 29
PY 2009
VL 284
IS 22
BP 14698
EP 14709
DI 10.1074/jbc.M901104200
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 448UT
UT WOS:000266288200006
PM 19324871
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Witcher, M
   Emerson, BM
AF Witcher, Michael
   Emerson, Beverly M.
TI Epigenetic Silencing of the <i>p16<SUP>INK4a</SUP></i> Tumor Suppressor
   Is Associated with Loss of CTCF Binding and a Chromatin Boundary
SO MOLECULAR CELL
LA English
DT Article
ID ENHANCER-BLOCKING ACTIVITY; MAMMARY EPITHELIAL-CELLS; DNA METHYLATION;
   PROMOTER METHYLATION; BREAST-CANCER; PROTEIN CTCF; LUNG-CANCER;
   HYPERMETHYLATION; EXPRESSION; GENE
AB The p16(INK4a) tumor suppressor gene is a frequent target of epigenetic inactivation in human cancers, which is an early event in breast carcinogenesis. We describe the existence of a chromatin boundary upstream of the p16 gene that is lost when this gene is aberrantly silenced. We show that the multifunctional protein CTCF associates in the vicinity of this boundary and absence of binding strongly coincides with p16 silencing in multiple types of cancer cells. CTCF binding also correlates with RASSF1A and CDH1 gene activation, and CTCF interaction is absent when these genes are methylated and silenced. Interestingly, defective poly(ADP-ribosyl)ation of CTCF and dissociation from the molecular chaperone Nucleolin occur in p 16-silenced cells, abrogating its proper function. Thus, destabilization of specific chromosomal boundaries through aberrant crosstalk between CTCF, poly(ADP-ribosyl)ation, and DNA methylation may be a general mechanism to inactivate tumor suppressor genes and initiate tumorigenesis in numerous forms of human cancers.
C1 [Witcher, Michael; Emerson, Beverly M.] Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA.
C3 Salk Institute
RP Emerson, BM (通讯作者)，Salk Inst Biol Studies, Regulatory Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM emerson@salk.edu
FU The Samuel Waxman Cancer Research Foundation; The Canadian Institute of
   Health Research
FX This work was supported by grants to B.M.E. from The Samuel Waxman
   Cancer Research Foundation and to M.W. from The Canadian Institute of
   Health Research. We thank Dr. S.V. del Rincon for technical assistance
   with retroviral packaging, Dr. Michal Krawczyk for help with CTCF
   constructs, and Dr. Fernando Lopez-Diaz for assistance with Lentiviral
   packaging.
CR Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   De la Rosa-Velázquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345
   Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Galande S, 2002, CURR CANCER DRUG TAR, V2, P157, DOI 10.2174/1568009023333917
   Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guastafierro T, 2008, J BIOL CHEM, V283, P21873, DOI 10.1074/jbc.M801170200
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Holst CR, 2003, CANCER RES, V63, P1596
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006
   Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191
   McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010
   Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500
   Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131
   OTTERSON GA, 1995, ONCOGENE, V11, P1211
   Paz MF, 2003, CANCER RES, V63, P1114
   Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100
   Raisner RM, 2006, CURR OPIN GENET DEV, V16, P119, DOI 10.1016/j.gde.2006.02.005
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Silva J, 2006, CLIN CANCER RES, V12, P6929, DOI 10.1158/1078-0432.CCR-06-0788
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Szabó PE, 2004, MOL CELL BIOL, V24, P4791, DOI 10.1128/MCB.24.11.4791-4800.2004
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wu JF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000164
   Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426
   Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2
   Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096
NR 45
TC 178
Z9 218
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAY 15
PY 2009
VL 34
IS 3
BP 271
EP 284
DI 10.1016/j.molcel.2009.04.001
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 446TP
UT WOS:000266144400003
PM 19450526
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Li, J
   Gao, F
   Li, N
   Li, ST
   Yin, GL
   Tian, G
   Jia, SG
   Wang, K
   Zhang, XQ
   Yang, HM
   Nielsen, AL
   Bolund, L
AF Li, Jian
   Gao, Fei
   Li, Ning
   Li, Shengting
   Yin, Guangliang
   Tian, Geng
   Jia, Shangang
   Wang, Kai
   Zhang, Xiuqing
   Yang, Huanming
   Nielsen, Anders Lade
   Bolund, Lars
TI An improved method for genome wide DNA methylation profiling correlated
   to transcription and genomic instability in two breast cancer cell lines
SO BMC GENOMICS
LA English
DT Article
ID GENE-EXPRESSION; HYPOMETHYLATION; CARCINOMAS; SUBCLASSES; TUMORS; SITES
AB Background: DNA methylation is a widely studied epigenetic mechanism known to correlate with gene repression and genomic stability. Development of sensitive methods for global detection of DNA methylation events is of particular importance.
   Results: We here describe a technique, called modified methylation-specific digital karyotyping (MMSDK) based on methylation-specific digital karyotyping (MSDK) with a novel sequencing approach. Briefly, after a tandem digestion of genomic DNA with a methylation-sensitive mapping enzyme and a fragmenting enzyme, short sequence tags are obtained. These tags are amplified, followed by direct, massively parallel sequencing (Solexa 1G Genome Analyzer). This method allows high-throughput and low-cost genome-wide DNA methylation mapping. We applied this method to investigate global DNA methylation profiles for widely used breast cancer cell lines, MCF-7 and MDA-MB-231, which are representatives for luminal-like and mesenchymal-like cancer types, respectively. By comparison, a highly similar overall DNA methylation pattern was revealed for the two cell lines. However a cohort of individual genomic loci with significantly different DNA methylation status between two cell lines was identified. Furthermore, we revealed a genome-wide significant correlation between gene expression and the methylation status of gene promoters with CpG islands (CGIs) in the two cancer cell lines, and a correlation of gene expression and the methylation status of promoters without CGIs in MCF-7 cells.
   Conclusion: The MMSDK method will be a valuable tool to increase the current knowledge of genome wide DNA methylation profiles.
C1 [Li, Jian; Gao, Fei; Li, Shengting; Wang, Kai; Nielsen, Anders Lade; Bolund, Lars] Univ Aarhus, Inst Human Genet, DK-8000 Aarhus C, Denmark.
   [Gao, Fei; Li, Ning; Tian, Geng; Jia, Shangang; Zhang, Xiuqing] Chinese Acad Sci, Beijing Inst Genom, Beijing 101300, Peoples R China.
   [Gao, Fei; Li, Ning; Yin, Guangliang; Tian, Geng; Jia, Shangang; Zhang, Xiuqing; Bolund, Lars] Beijing Genom Inst, Shenzhen 518083, Guangdong, Peoples R China.
   [Gao, Fei] Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China.
   [Wang, Kai] Univ Aarhus, BiRC, DK-8000 Aarhus, Denmark.
   [Yang, Huanming] Beijing Genom Inst, Beijing 101300, Peoples R China.
   [Li, Jian; Wang, Kai; Bolund, Lars] Danish Ctr Translat Breast Canc Res DCTB, DK-2100 Copenhagen, Denmark.
C3 Aarhus University; Chinese Academy of Sciences; Beijing Institute of
   Genomics, CAS; Beijing Genomics Institute (BGI); Chinese Academy of
   Sciences; University of Chinese Academy of Sciences, CAS; Aarhus
   University; Beijing Genomics Institute (BGI)
RP Li, J (通讯作者)，Univ Aarhus, Inst Human Genet, Bartholin Bldg, DK-8000 Aarhus C, Denmark.
EM jianl@humgen.au.dk; flys828@gmail.com; lining@genomics.org.cn;
   lishengting@genomics.org.cn; yinguangliang@genomics.org.cn;
   tiang@genomics.org.cn; jiashanggang@genomics.org.cn; wangk@humgen.au.dk;
   zhangxq@genomics.org.cn; yanghm@genomics.org.cn; aln@humgen.au.dk;
   bolund@humgen.au.dk
RI Xiuqing, Zhang/GNW-6730-2022; Nielsen, Anders Lade/Q-9604-2016; Yang,
   Huanming/C-6513-2013
OI Nielsen, Anders Lade/0000-0003-4372-9961; Yang,
   Huanming/0000-0002-0858-3410
FU Danish Cancer Society; Danish Medical Research Council; Sino-Danish
   Breast Cancer Research Centre; National Natural Science Foundation of
   China; Danish Centre for Translational Breast Cancer Research (DCTB);
   Hallas-Moller Fellowship; NovoNordisk Foundation
FX We would like to thank Bodil Schmidt and Eigil Kjeldsen for technical
   assistance. The project was supported by grants from the will of Edith
   Stern, the Danish Cancer Society and The Danish Medical Research
   Council. Our breast cancer research is performed under the auspices of
   the Sino-Danish Breast Cancer Research Centre financed by the Danish
   "Grundforskningsfond" and the National Natural Science Foundation of
   China. JL is a recipient of a fellowship from "A race against breast
   cancer" in the Danish Centre for Translational Breast Cancer Research
   (DCTB). ALN is supported by a Hallas-Moller Fellowship from the
   NovoNordisk Foundation.
CR Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004
   Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Beck S, 2008, TRENDS GENET, V24, P231, DOI 10.1016/j.tig.2008.01.006
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   Carr IM, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm330
   Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Forozan F, 2000, CANCER RES, V60, P4519
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fukasawa M, 2006, J HUM GENET, V51, P368, DOI 10.1007/s10038-005-0355-4
   Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Hu M, 2006, NAT PROTOC, V1, P1621, DOI 10.1038/nprot.2006.278
   Jacquemier J, 2005, CANCER RES, V65, P767
   Jurgens B, 1996, CANCER RES, V56, P5698
   Kisseljova NP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P743, DOI 10.1007/s10541-005-0179-z
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068
   Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Szyf Moshe, 2000, Current Drug Targets, V1, P101, DOI 10.2174/1389450003349362
   Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590
   Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899
   Zhang XX, 2005, AM J HUM GENET, V76, P312, DOI 10.1086/427762
NR 39
TC 23
Z9 29
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAY 13
PY 2009
VL 10
AR 223
DI 10.1186/1471-2164-10-223
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 467JP
UT WOS:000267735100001
PM 19439076
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Shah, R
   Smith, P
   Purdie, C
   Quinlan, P
   Baker, L
   Aman, P
   Thompson, AM
   Crook, T
AF Shah, R.
   Smith, P.
   Purdie, C.
   Quinlan, P.
   Baker, L.
   Aman, P.
   Thompson, A. M.
   Crook, T.
TI The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic
   silencing in breast cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; epigenetics; prolyl hydroxylase
ID MEMBRANE-ASSOCIATED PROTEOGLYCAN; GENE-EXPRESSION; CELL-LINES; COLLAGEN;
   SIGNATURE; FAMILY; HYPERMETHYLATION; 3-HYDROXYPROLINE; IDENTIFICATION;
   METASTASIS
AB Expression of P3H2 (Leprel1) and P3H3 (Leprel2) but not P3H1 (Leprecan) is down-regulated in breast cancer by aberrant CpG methylation in the 50 regulatory sequences of each gene. Methylation of P3H2 appears specific to breast cancer as no methylation was detected in a range of cell lines from other epithelial cancers or from primary brain tumours or malignant melanoma. Methylation in P3H2, but not P3H3, was strongly associated with oestrogen-receptor-positive breast cancers, whereas methylation in P3H3 was associated with higher tumour grade and Nottingham Prognostic Index. Ectopic expression of P3H2 and P3H3 in cell lines with silencing of the endogenous gene results in suppression of colony growth. This is the first demonstration of epigenetic inactivation of prolyl hydroxylases in human cancer, implying that this gene family represents a novel class of tumour suppressors. The restriction of silencing in P3H2 to breast carcinomas, and its association with oestrogen-receptor-positive cases, suggests that P3H2 may be a breast-cancer-specific tumour suppressor. British Journal of Cancer (2009) 100, 1687-1696. doi: 10.1038/sj.bjc.6605042 www.bjcancer.com (C) 2009 Cancer Research UK
C1 [Shah, R.; Smith, P.; Crook, T.] Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England.
   [Purdie, C.; Quinlan, P.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Pathol, Dundee DD1 9SY, Scotland.
   [Baker, L.; Thompson, A. M.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.
   [Aman, P.] Gothenburg Univ, Lundberg Lab Canc Res, Dept Pathol, S-41345 Gothenburg, Sweden.
C3 Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK; University of Dundee; University of Dundee;
   University of Gothenburg
RP Crook, T (通讯作者)，Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, Mary Jean Mitchell Green Bldg,237 Fulham Rd, London SW3 6JB, England.
EM tr.crook@gmail.com
OI Quinlan, Philip/0000-0002-3012-6646; Aman, Pierre/0000-0002-1482-8875;
   Purdie, Colin/0000-0002-1258-4010; Baker, Lee/0000-0003-4505-3678
FU Breakthrough Breast Cancer and Breast Cancer Research Scotland; CRUK
FX The work was funded by Breakthrough Breast Cancer and Breast Cancer
   Research Scotland. TC is a recipient of a CRUK Clinician Scientist
   award.
CR Baldridge D, 2008, HUM MUTAT, V29, P1435, DOI 10.1002/humu.20799
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Cabral WA, 2007, NAT GENET, V39, P359, DOI 10.1038/ng1968
   CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Fähling M, 2006, J BIOL CHEM, V281, P26089, DOI 10.1074/jbc.M604939200
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   GRYDER RM, 1975, J BIOL CHEM, V250, P2470
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x
   Ikeda K, 2006, AM J PATHOL, V168, P856, DOI 10.2353/ajpath.2006.050384
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   IVSHINA AV, 2004, CANCER RES, V66, P10292
   Järnum S, 2004, BIOCHEM BIOPH RES CO, V317, P342, DOI 10.1016/j.bbrc.2004.03.060
   Jenkins CL, 2003, J AM CHEM SOC, V125, P6422, DOI 10.1021/ja034015j
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaul SC, 2000, ONCOGENE, V19, P3576, DOI 10.1038/sj.onc.1203696
   KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773
   Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200
   Myllyharju J, 2005, TOP CURR CHEM, V247, P115, DOI 10.1007/b103821
   Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Sengupta PK, 2003, CANCER RES, V63, P1789
   Tiainen P, 2008, J BIOL CHEM, V283, P19432, DOI 10.1074/jbc.M802973200
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
NR 41
TC 50
Z9 54
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 12
PY 2009
VL 100
IS 10
BP 1687
EP 1696
DI 10.1038/sj.bjc.6605042
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 445BR
UT WOS:000266025100022
PM 19436308
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Xu, XR
   Gammon, MD
   Zhang, YJ
   Bestor, TH
   Zeisel, SH
   Wetmur, JG
   Wallenstein, S
   Bradshaw, PT
   Garbowski, G
   Teitelbaum, SL
   Neugut, AI
   Santella, RM
   Chen, J
AF Xu, Xinran
   Gammon, Marilie D.
   Zhang, Yujing
   Bestor, Timothy H.
   Zeisel, Steven H.
   Wetmur, James G.
   Wallenstein, Sylvan
   Bradshaw, Patrick T.
   Garbowski, Gail
   Teitelbaum, Susan L.
   Neugut, Alfred I.
   Santella, Regina M.
   Chen, Jia
TI <i>BRCA1</i> promoter methylation is associated with increased mortality
   among women with breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE BRCA1; Methylation; Epigenetics; One-carbon; Survival; Breast cancer
ID MODERATE FOLATE-DEPLETION; GENOMIC DNA METHYLATION; GENE-EXPRESSION;
   REDUCTASE GENE; LONG-ISLAND; MUTATIONS; PROTEIN; RISK; HYPOMETHYLATION;
   SUSCEPTIBILITY
AB Promoter-CpG island hypermethylation has been proposed as an alternative mechanism to inactivate BRCA1 in the breast where somatic mutations of BRCA1 are rare. To better understand breast cancer etiology and progression, we explored the association between BRCA1 promoter methylation status and prognostic factors as well as survival among women with breast cancer. Promoter methylation of BRCA1 was assessed in 851 archived tumor tissues collected from a population-based study of women diagnosed with invasive or in situ breast cancer in 1996-1997, and who were followed for vital status through the end of 2002. About 59% of the tumors were methylated at the promoter of BRCA1. The BRCA1 promoter methylation was more frequent in invasive cancers (P = 0.02) and among premenopausal cases (P = 0.05). BRCA1 promoter methylation was associated with increased risk of breast cancer-specific mortality (age-adjusted HR 1.71; 95% CI: 1.05-2.78) and all-cause mortality (age-adjusted HR 1.49; 95% CI: 1.02-2.18). Neither dietary methyl intakes in the year prior to the baseline interview nor the functional polymorphisms in one-carbon metabolism were associated with BRCA1 methylation status. Our study is the first epidemiological investigation on the prognostic value of BRCA1 promoter methylation in a large population-based cohort of breast cancer patients. Our results indicate that BRCA1 promoter methylation is an important factor to consider in predicting breast cancer survival.
C1 [Xu, Xinran; Wallenstein, Sylvan; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA.
   [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Zhang, Yujing; Garbowski, Gail; Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Bestor, Timothy H.] Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.
   [Zeisel, Steven H.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA.
   [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY 10032 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; University of North Carolina;
   University of North Carolina Chapel Hill; Columbia University; Columbia
   University; University of North Carolina; University of North Carolina
   Chapel Hill; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; Columbia University; Columbia University; Icahn
   School of Medicine at Mount Sinai; Icahn School of Medicine at Mount
   Sinai
RP Chen, J (通讯作者)，Mt Sinai Sch Med, Dept Community & Prevent Med, POB 1043,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM jia.chen@mssm.edu
RI Bradshaw, Patrick/AAJ-7529-2021; Zhang, Yujing/ABB-3590-2021
OI Xu, Xinran/0000-0001-6435-8181
FU NCI NIH HHS [U01 CA066572, R01 CA109753, P30 CA013696] Funding Source:
   Medline; NIDDK NIH HHS [R01 DK055865, P30 DK056350, R01 DK055865-07]
   Funding Source: Medline; NIEHS NIH HHS [P30 ES009089, P30 ES010126]
   Funding Source: Medline
CR Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005
   [Anonymous], 1998, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045
   Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630
   CHRISTMAN JK, 1993, CARCINOGENESIS, V14, P551, DOI 10.1093/carcin/14.4.551
   Cleveland RJ, 2007, CANCER EPIDEM BIOMAR, V16, P1803, DOI 10.1158/1055-9965.EPI-06-0889
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354
   Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073
   Fowler BM, 1998, CANCER EPIDEM BIOMAR, V7, P901
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677
   Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485
   Goffin JR, 2003, CANCER-AM CANCER SOC, V97, P527, DOI 10.1002/cncr.11080
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993
   Hopper JL, 2001, SEMIN CANCER BIOL, V11, P367, DOI 10.1006/scbi.2001.0392
   Hosmer DW., 1999, Applied survival analysis: regression modeling of time to event data
   Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Liebens FP, 2007, EUR J CANCER, V43, P238, DOI 10.1016/j.ejca.2006.07.019
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Moller P, 2007, INT J CANCER, V121, P1017, DOI 10.1002/ijc.22789
   Paz MF, 2002, CANCER RES, V62, P4519
   Pérez-Vallés A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476
   Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004
   Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998
   Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   Russo Jose, 1998, Frontiers in Bioscience, V3, pD944
   Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849
   Stoppa-Lyonnet D, 2000, J CLIN ONCOL, V18, P4053, DOI 10.1200/JCO.2000.18.24.4053
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   XU X, 2008, FASEB J
   Xu XR, 2007, CARCINOGENESIS, V28, P1504, DOI 10.1093/carcin/bgm061
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249
   Zeisel SH, 2003, J NUTR, V133, P1302
   1997, LANCET, V349, P1505, DOI DOI 10.1016/S0140-6736(96)10109-4
NR 46
TC 65
Z9 74
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2009
VL 115
IS 2
BP 397
EP 404
DI 10.1007/s10549-008-0075-5
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 450AD
UT WOS:000266372300020
PM 18521744
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Pampalakis, G
   Prosnikli, E
   Agalioti, T
   Vlahou, A
   Zoumpourlis, V
   Sotiropoulou, G
AF Pampalakis, Georgios
   Prosnikli, Evangelia
   Agalioti, Theodora
   Vlahou, Antonia
   Zoumpourlis, Vassilis
   Sotiropoulou, Georgia
TI A Tumor-Protective Role for Human Kallikrein-Related Peptidase 6 in
   Breast Cancer Mediated by Inhibition of Epithelial-to-Mesenchymal
   Transition
SO CANCER RESEARCH
LA English
DT Article
ID BINDING PROTEIN MECP2; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   HISTONE DEACETYLASE; SERINE-PROTEASE; SUPPRESSOR GENE; EMERGING ROLES;
   EXPRESSION; MECHANISM; REVEALS
AB Human kallikrein-related peptidase 6 (KLK6) was cloned as a putative class II tumor suppressor based on its inactivated expression in metastatic breast cancer. Here, we investigated the mechanism(s) underlying the silencing of KLK6 gene in metastatic breast cancer and its putative implications for tumor progression. We present evidence that tumor-specific loss of KLK6 expression is due to hypermethylation of specific CpGs located in the KLK6 proximal promoter. Methylation-dependent binding of methyl CpG-binding protein 2 and the formation of repressive chromatin mediated by localized histone deacetylation are critical components of KLK6 silencing in breast tumors. Re-expression of KLK6 in nonexpressing MDA-MB-231 breast tumor cells by stable cDNA transfection resulted in marked reversal of their malignant phenotype, manifested by lower proliferation rates and saturation density, marked inhibition of anchorage-independent growth, reduced cell motility, and their dramatically reduced ability to form tumors when implanted in severe combined immunodeficiency mice. Interestingly, inhibition of tumor growth was observed at physiologic concentrations of KLK6, but not when KLK6 was highly overexpressed, as observed in a subset of breast tumors. Differential proteomic profiling revealed that KLK6 re-expression results in significant down-regulation of vimentin which represents an established marker of epithelial-to-mesenchymal transition of tumor cells and in concomitant up-regulation of calreticutin and epithelial markers cytokeratin 8 and 19, indicating that KLK6 may play a protective role against tumor progression that is likely mediated by inhibition of epithelial-to-mesenchymal transition. We suggest that KLK6 is an epigenetically regulated tumor suppressor in human breast cancer and provide ways of pharmacologic modulation. [Cancer Res 2009;69(9):3779-87]
C1 [Pampalakis, Georgios; Prosnikli, Evangelia; Sotiropoulou, Georgia] Univ Patras, Dept Pharm, Rion 26500, Greece.
   [Agalioti, Theodora] Biomed Sci Res Ctr Alexander Fleming, Athens, Greece.
   [Vlahou, Antonia] Acad Athens, Fdn Biomed Res, Athens, Greece.
   [Zoumpourlis, Vassilis] Natl Hellen Res Fdn, Athens, Greece.
C3 University of Patras; Alexander Fleming Biomedical Sciences Research
   Center; Academy of Athens; National Hellenic Research Foundation
RP Sotiropoulou, G (通讯作者)，Univ Patras, Dept Pharm, Rion 26500, Greece.
EM gdsotiro@upatras.gr
RI Pampalakis, George/AFM-6440-2022
OI Agalioti, Theodora/0000-0002-5898-2751; Pampalakis,
   Georgios/0000-0002-2119-4292; Vlahou, Antonia/0000-0003-3284-5713
FU Research Committee of the University of Patras and PENED2003
   [03EDelta430]; E.U. European Social Fund; Greek Ministry of
   Development-GSRT
FX K Karatheodoris (C.186) provided by the Research Committee of the
   University of Patras and PENED2003 (03E Delta 430) cofunded by the E.U.
   European Social Fund (75%) and the Greek Ministry of Development-GSRT
   (25%).
CR Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2
   Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646
   Bayés A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061
   Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200
   Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje
   Borgoño CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474
   Bühler H, 2005, MOL CANCER RES, V3, P365, DOI 10.1158/1541-7786.MCR-04-0117
   Cheng WF, 2005, VACCINE, V23, P3864, DOI 10.1016/j.vaccine.2004.10.032
   Christophi GP, 2004, J NEUROCHEM, V91, P1439, DOI 10.1111/j.1471-4159.2004.02826.x
   Diamandis EP, 2000, CLIN BIOCHEM, V33, P369, DOI 10.1016/S0009-9120(00)00145-4
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200
   Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200
   Gomis-Rüth FX, 2002, J BIOL CHEM, V277, P27273, DOI 10.1074/jbc.M201534200
   GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
   Goyal J, 1998, CANCER RES, V58, P4782
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Li B, 2001, CANCER RES, V61, P8014
   Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243
   López-Otín C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ni X, 2004, BRIT J CANCER, V91, P725, DOI 10.1038/sj.bjc.6602041
   Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200
   Pálmer HG, 2003, CANCER RES, V63, P7799
   Pampalakis G, 2004, BIOCHEM BIOPH RES CO, V320, P54, DOI 10.1016/j.bbrc.2004.04.205
   Pampalakis G, 2008, COMPUT BIOL CHEM, V32, P111, DOI 10.1016/j.compbiolchem.2007.11.002
   Pampalakis G, 2007, BBA-REV CANCER, V1776, P22, DOI 10.1016/j.bbcan.2007.06.001
   Pampalakis G, 2006, BIOL CHEM, V387, P773, DOI 10.1515/BC.2006.097
   Rodriguez Luis G., 2004, V294, P23
   Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142
   Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
NR 43
TC 78
Z9 88
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2009
VL 69
IS 9
BP 3779
EP 3787
DI 10.1158/0008-5472.CAN-08-1976
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 441IG
UT WOS:000265761900009
PM 19383923
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Suzuki, J
   Chen, YY
   Scott, GK
   DeVries, S
   Chin, K
   Benz, CC
   Waldman, FM
   Hwang, ES
AF Suzuki, Junko
   Chen, Yunn-Yi
   Scott, Gary K.
   DeVries, Sandy
   Chin, Koei
   Benz, Christopher C.
   Waldman, Frederic M.
   Hwang, E. Shelley
TI Protein Acetylation and Histone Deacetylase Expression Associated with
   Malignant Breast Cancer Progression
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; PROSTATE-CANCER; MASS-SPECTROMETRY; EPIGENETIC
   EVENTS; COACTIVATOR AIB1; GASTRIC-CANCER; LUNG-CANCER; OVEREXPRESSION;
   INHIBITION; CARCINOMAS
AB Purpose: Excess histone deacetylase (HDAC) activity can induce hypoacetylation of histone and nonhistone protein substrates, altering gene expression patterns and cell behavior potentially associated with malignant transformation. However, HDAC expression and protein acetylation have not been studied in the context of breast cancer progression.
   Experimental Design: We assessed expression levels of acetylated histone H4 (ac-H4), ac-H4K12, ac-tubulin, HDAC1, HDAC2, and HDAC6 in 22 reduction mammoplasties and in 58 specimens with synchronous normal epithelium, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) components. Differences among groups were tested for significance using nonparametric tests.
   Results: From normal epithelium to DCIS, there was a marked reduction in histone acetylation (P < 0.0001). Most cases showed similar levels of acetylation in DCIS and IDC, although some showed further reduction of ac-H4 and ac-H4K12 from DCIS to IDC. Expression of HDAC1, HDAC2, and HDAC6 was also significantly reduced but by a smaller magnitude. Greater reductions of H4 acetylation and HDAC1 levels were observed from normal to DCIS in estrogen receptor - negative compared with estrogen receptor - positive, and in high-grade compared with non - high-grade tumors.
   Conclusion: Overall, there was a global pattern of hypoacetylation associated with progression from normal to DCIS to IDC. These findings suggest that the reversal of this hypoacetylation in DCIS and IDC could be an early measure of HDAC inhibitor activity.
C1 [Hwang, E. Shelley] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
   [Waldman, Frederic M.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
   [Waldman, Frederic M.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
   [Chen, Yunn-Yi] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
   [Suzuki, Junko; DeVries, Sandy; Chin, Koei; Waldman, Frederic M.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Scott, Gary K.; Benz, Christopher C.] Buck Inst Age Res, Novato, CA USA.
   [Suzuki, Junko] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   Buck Institute for Research on Aging; Juntendo University
RP Hwang, ES (通讯作者)，Univ Calif San Francisco, Dept Surg, Box 1710,1600 Divisadero St B611 UCSF, San Francisco, CA 94143 USA.
EM shelley.hwang@ucsfmedctr.org
FU Komen Foundation [CA367763]; NIH [K23 CA0977181-01A10]; BayArea Breast
   Cancer [P50 CA58207]; Merck Co., Inc.
FX Komen Foundation, CA367763, NIH K23 CA0977181-01A10, the BayArea Breast
   Cancer SPORE P50 CA58207, and Merck & Co., Inc.
CR Allred DC, 1998, MODERN PATHOL, V11, P155
   Bai X, 2008, J CANCER RES CLIN, V134, P83, DOI 10.1007/s00432-007-0252-7
   Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Fan SJ, 2002, CANCER RES, V62, P141
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561
   Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Isharwal S, 2008, PROSTATE, V68, P1097, DOI 10.1002/pros.20772
   Ishihama K, 2007, J CLIN PATHOL, V60, P1205, DOI 10.1136/jcp.2005.029165
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390
   Liu MZ, 2008, AM J CLIN PATHOL, V129, P728, DOI 10.1309/QMDTL82JKEX6E7H2
   Luo JH, 2008, INT J CANCER, V122, P2554, DOI 10.1002/ijc.23399
   Matthias P, 2008, CELL CYCLE, V7, P7, DOI 10.4161/cc.7.1.5186
   Mohamed MA, 2007, BJU INT, V99, P908, DOI 10.1111/j.1464-410X.2006.06704.x
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Muraoka M, 1996, ONCOGENE, V12, P1565
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Ren C, 2005, J AM SOC MASS SPECTR, V16, P1641, DOI 10.1016/j.jasms.2005.06.001
   Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646
   Sasaki H, 2004, LUNG CANCER, V46, P171, DOI 10.1016/j.lungcan.2004.03.021
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003
   Su XD, 2007, ANAL BIOCHEM, V363, P22, DOI 10.1016/j.ab.2006.12.031
   Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408
   Toh Y, 2004, INT J CANCER, V110, P362, DOI 10.1002/ijc.20154
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhang LW, 2007, J PROTEOME RES, V6, P81, DOI 10.1021/pr060139u
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 40
TC 93
Z9 116
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2009
VL 15
IS 9
BP 3163
EP 3171
DI 10.1158/1078-0432.CCR-08-2319
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 440PL
UT WOS:000265712100027
PM 19383825
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Dietrich, D
   Lesche, R
   Tetzner, R
   Krispin, M
   Dietrich, J
   Haedicke, W
   Schuster, M
   Kristiansen, G
AF Dietrich, Dimo
   Lesche, Ralf
   Tetzner, Reimo
   Krispin, Manuel
   Dietrich, Joern
   Haedicke, Wolfgang
   Schuster, Matthias
   Kristiansen, Glen
TI Analysis of DNA Methylation of Multiple Genes in Microdissected Cells
   From Formalin-fixed and Paraffin-embedded Tissues
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE DNA methylation; laser microdissection; multiplexed analysis;
   quantitative bisulfite sequencing; formalin-fixed and paraffin-embedded
   tissues; breast cancer
ID WHOLE-GENOME AMPLIFICATION; BREAST-CANCER PATIENTS; PROMOTER
   METHYLATION; TUMOR-MICROENVIRONMENT; PROTEIN EXPRESSION;
   PROSTATE-CANCER; PCR ASSAY; HYPERMETHYLATION; MARKER; PITX2
AB A procedure for simultaneous quantification of DNA methylation of several genes in minute amounts of sample material was developed and applied to microdissected formalin-fixed and paraffin-embedded breast tissues. The procedure is comprised of an optimized bisulfite treatment protocol suitable for samples containing only few cells, a multiplex preamplification and subsequent locus specific reamplification, and a novel quantitative bisulfite sequencing method based on the incorporation of a normalization domain into the PCR product. A real-time PCR assay amplifying repetitive elements was established to quantify low amounts of bisulfite-treated DNA. Ten prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast. The microdissected samples were obtained from several areas within the tumor tissue, including intraductal and invasive carcinoma, adenosis, and normal ductal epithelia of adjacent normal tissue, as well as stroma, tumor infiltrating lymphocytes, and adipose tissue. Overall, reliable quantification was possible for all genes. For most genes, increased DNA methylation in invasive and intraductal carcinoma cells compared with other tissue components was observed. For TFF1, decreased methylation levels were observed in tumor cells. (J Histochem Cytochem 57:477-489, 2009)
C1 [Dietrich, Dimo; Lesche, Ralf; Tetzner, Reimo; Krispin, Manuel; Dietrich, Joern; Schuster, Matthias] Epigen AG, D-10178 Berlin, Germany.
   [Haedicke, Wolfgang] MVZ Vorpommern GmbH, Pasewalk, Germany.
   [Kristiansen, Glen] Univ Zurich Hosp, Inst Clin Pathol, Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital
RP Dietrich, D (通讯作者)，Epigen AG, Kleine Prasidentenstr 1, D-10178 Berlin, Germany.
EM dimo.dietrich@epigenomics.com
CR Aitchison A, 2007, PROSTATE, V67, P638, DOI 10.1002/pros.20475
   Arriola E, 2007, LAB INVEST, V87, P75, DOI 10.1038/labinvest.3700495
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Charles MA, 2005, MOL ENDOCRINOL, V19, P1893, DOI 10.1210/me.2005-0052
   Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#
   Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Esposito G, 2007, ADV EXP MED BIOL, V593, P54
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   FOEKENS JA, 1990, CANCER RES, V50, P3832
   Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Greenspan EJ, 2006, CARCINOGENESIS, V27, P1316, DOI 10.1093/carcin/bgi373
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Han WG, 2006, ANAL BIOCHEM, V355, P50, DOI 10.1016/j.ab.2006.05.010
   Hanson JA, 2006, JNCI-J NATL CANCER I, V98, P255, DOI 10.1093/jnci/djj051
   Henrique R, 2006, MOL CANCER RES, V4, P1, DOI 10.1158/1541-7786.MCR-05-0113
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hui R, 2000, CLIN CANCER RES, V6, P2777
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   L'Honoré A, 2007, DEV BIOL, V307, P421, DOI 10.1016/j.ydbio.2007.04.034
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lehmann Ulrich, 2004, Methods Mol Biol, V287, P207
   LESCHE R, 2006, Patent No. 2006008128
   Lewin J, 2004, BIOINFORMATICS, V20, P3005, DOI 10.1093/bioinformatics/bth346
   Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159
   Liu Liang, 2004, Methods Mol Biol, V287, P169
   Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   MARTIN V, 1995, GENE, V157, P261, DOI 10.1016/0378-1119(95)00096-O
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Nakayama M, 2003, AM J PATHOL, V163, P923, DOI 10.1016/S0002-9440(10)63452-9
   Nimmrich I, 2008, BREAST CANCER RES TR, V111, P429, DOI 10.1007/s10549-007-9800-8
   Paez JG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh069
   Pakneshan P, 2005, CURR CANCER DRUG TAR, V5, P471, DOI 10.2174/156800905774574011
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rodriguez-Canales J, 2007, J PATHOL, V211, P410, DOI 10.1002/path.2133
   Ruibal A, 1999, INT J BIOL MARKER, V14, P186, DOI 10.1177/172460089901400311
   SCHWARTZ LH, 1991, CANCER RES, V51, P624
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078-0432.CCR-08-0935
   Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0
   Tanaka K, 2007, BIOORG MED CHEM LETT, V17, P1912, DOI 10.1016/j.bmcl.2007.01.040
   Tetzner R, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl955
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Witz IP, 2008, ADV CANCER RES, V100, P203, DOI 10.1016/S0065-230X(08)00007-9
   Woodson K, 2004, PROSTATE, V60, P25, DOI 10.1002/pros.20013
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yang WH, 2007, ANAL BIOCHEM, V369, P120, DOI 10.1016/j.ab.2007.06.017
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
NR 55
TC 63
Z9 74
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD MAY
PY 2009
VL 57
IS 5
BP 477
EP 489
DI 10.1369/jhc.2009.953026
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 434GL
UT WOS:000265263100007
PM 19153192
OA Green Published
DA 2025-01-12
ER

PT J
AU Cho, HJ
   Park, SC
   Kim, KW
   Kang, WK
   Cho, HM
   Kim, JS
   Kim, YA
   An, CH
AF Cho, Hang Joo
   Park, Sun Cheol
   Kim, Kee Whan
   Kang, Won Kyung
   Cho, Hyun Min
   Kim, Jeong Soo
   Kim, Young Ae
   An, Chang Hyeok
TI The Combination Effect of Sodium Butyrate, 5-aza-2′-deoxycytidine on the
   Tumor Suppressive Activity in RKO Colorectal Cancer and MCF-7 Breast
   Cancer Cell Lines
SO JOURNAL OF THE KOREAN SURGICAL SOCIETY
LA Korean
DT Article
DE Epigenetics; Histone deacetylase inhibitor; Demethylating agent
ID HISTONE-DEACETYLASE INHIBITORS; DEMETHYLATION; APOPTOSIS;
   P53/P21(WAF1/CIP1); PROLIFERATION; TRANSCRIPTION; REEXPRESSION; PATHWAY;
   GENE
AB Purpose: It is known that DNA methylation is associated with historic acetylation status in regulation of gene expression. In this study, we investigate the effect of demethylating agents and histone deacetylase (HDAC) inhibitor on the tumor suppression and the combined effect of two agents according to methylation status in human colon and breast cancer cell lines.
   Methods: In this Study, the RKO colorectal cancer cell line, MCF-7 breast cancer cell lines were considered. For each cell line, we used HDAC inhibitor sodium butyrate (SB), demethylating agent 5-aza-2'-deoxycytidine (5-aza-DC) and a combination of both agents. We estimated the percentage of cell survival using the XTT method and experimented with the augmentative effects of both agents.
   Results: In RKO cell line in which most of the genes are methylated, 74% of cell survival was shown for 5-aza-DC treatment and 83% of cell survival for SB treatment. In MCF-7 cell line that approximately half of the genes are methylated, 82% cell Survival was shown for 5-aza-DC treatment and 63% cell survival for SB treatment. We observed that the survival fraction is lower after the combined treatment of 5-aza-DC and SB than that of 5-aza-DC or SB alone in both RKO (53%) and MCF-7 (49%) cell lines (P<0.001).
   Conclusion: For highly methylated genes, 5-aza-DC is more effective on the tumor suppression than SB. On the other hand, if the methylation of the promoter region is at low density, SB is noted to be more effective than 5-aza-DC. Furthermore, the combined treatment of 5-aza-DC and SB is more effective than using each agent alone. (J Korean Surg Soc 2009;76:279-284)
C1 [Cho, Hang Joo; Park, Sun Cheol; Kim, Kee Whan; Kang, Won Kyung; Cho, Hyun Min; Kim, Jeong Soo; Kim, Young Ae; An, Chang Hyeok] Catholic Univ Korea, Coll Med, Dept Surg, Uijongbu, South Korea.
C3 Catholic University of Korea
RP Cho, HJ (通讯作者)，Catholic Univ Korea, Coll Med, Dept Surg, Uijongbu, South Korea.
EM achcolo@catholic.ac.kr
RI Kim, Sun-Ouck/HKE-9385-2023; Kim, Byung-Hak/AAY-9891-2020
CR Bar-Sela G, 2007, CANCER J, V13, P65, DOI 10.1097/PPO.0b013e31803c7565
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chai GL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002445
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   Murakami J, 2004, ORAL ONCOL, V40, P597, DOI 10.1016/j.oraloncology.2003.12.008
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Shen WJ, 2008, WORLD J GASTROENTERO, V14, P595, DOI 10.3748/wjg.14.595
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673
   Wang H, 2008, J BIOL CHEM, V283, P2564, DOI 10.1074/jbc.M702454200
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 21
TC 0
Z9 0
U1 0
U2 0
PU KOREAN SURGICAL SOCIETY
PI SEOUL
PA 3304HO, 101 DONG, BROWNSTONE SEOUL, 335, JUNGMIN-DONG, JUNG-GU, SEOUL,
   100-859, SOUTH KOREA
SN 2233-7903
EI 2093-0488
J9 J KOREAN SURG SOC
JI J. Korean Surg. Soc.
PD MAY
PY 2009
VL 76
IS 5
BP 279
EP 284
DI 10.4174/jkss.2009.76.5.279
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 492OO
UT WOS:000269668400002
OA gold
DA 2025-01-12
ER

PT J
AU Tung, EKK
   Wong, CM
   Yau, TO
   Lee, JMF
   Ching, YP
   Ng, IOL
AF Tung, Edmund Kwok-Kwan
   Wong, Chun-Ming
   Yau, Tai-On
   Lee, Joyce Man-Fong
   Ching, Yick-Pang
   Ng, Irene Oi-Lin
TI <i>HAI</i>-<i>2</i> is epigenetically downregulated in human
   hepatocellular carcinoma, and its Kunitz domain type 1 is critical for
   anti-invasive functions
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE HAI-2; epigenetics; HCC; serine protease inhibitor; Kunitz domain
ID HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR; SERINE-PROTEASE
   INHIBITOR; RENAL-CELL CARCINOMA; C-MET PROTOONCOGENE; BREAST-CANCER
   CELLS; PLACENTAL BIKUNIN; EXPRESSION; MATRIPTASE; GENE
AB Pharmacological de methylation-based gene expression profile analysis is a useful tool to identify epigenetically silenced tumour suppressor genes. HGF activator inhibitor 2 (HAI-2), a serine pro. tease inhibitor, has been identified as one of the candidate tumour suppressor genes in human hepatocellular carcinoma (HCC) with this technique. In this study, we aimed to characterise the epigenetic status and tumour suppressive function of HAI-2 in HCC. We validated that HAI-2 expression was either absent or low in most of the HCC cell lines tested, and 5-Aza-2'-deoxycytidine treatment significantly restored its expression in 9 (75%) of these 12 cell lines. HAI-2 wits found to be frequently underexpressed in human HCCs (p < 0.001). With bisulphite DNA sequencing and methylation-specific PCR, we round that the promoter of the HAI-2 gene was frequently hypermethylated in both HCC cell lines and human HCCs. Ectopic expression of HAI-2 significantly inhibited cell migration and invasiveness of HCC cells in vitro and suppressed tumourigenicity in vivo. In addition, we also provided the first evidence that HAI-2 mediated its tumour suppressor function via the Kunitz domain 1 (KD-1), as KD-1 but not KD-2 inactivating mutant abolished its anti-tumour invasiveness in vitro. Our findings suggest that HAI-2 is a candidate tumour suppressor gene that is frequently hypermethylated and underexpressed in human WAN, and the KD-1 domain of HAI-2 is the key region responsifile for its anti-invasive function. (C) Wiley-Liss, Inc.
C1 Univ Hong Kong, Dept Pathol, Fac Med, SH Ho Fdn Res Labs, Pokfulam, Hong Kong, Peoples R China.
   Univ Hong Kong, Liver Canc & Hepatitis Res Lab, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Ng, IOL (通讯作者)，Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Room 127B,Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.
EM iolng@hkucc.hku.hk
RI Ching, Yick/C-4244-2009; WONG, Chun-Ming/A-6739-2009
OI WONG, Chun-Ming/0000-0002-2497-7858; Ng, Irene
   Oi-lin/0000-0001-7532-2029; CHING, Yick Pang/0000-0002-6461-8358
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Benaud CM, 2002, CLIN EXP METASTAS, V19, P639, DOI 10.1023/A:1020985632550
   Betsunoh H, 2007, CANCER SCI, V98, P491, DOI 10.1111/j.1349-7006.2007.00412.x
   Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556
   Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209
   Förbs D, 2005, INT J ONCOL, V27, P1061
   Fukai K, 2003, CANCER RES, V63, P8674
   Hamasuna R, 2001, INT J CANCER, V93, P339, DOI 10.1002/ijc.1349.abs
   Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483
   Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x
   Johnson MD, 2003, EXPERT REV MOL DIAGN, V3, P331, DOI 10.1586/14737159.3.3.331
   Kapadia C, 2004, BIOCHEM BIOPH RES CO, V323, P1084, DOI 10.1016/j.bbrc.2004.08.206
   Kataoka H, 2003, CANCER METAST REV, V22, P223, DOI 10.1023/A:1023051500010
   Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558
   Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085
   Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200
   LI W, 2007, AACR ANN M LOS ANG C
   Luo YQ, 1999, WORLD J GASTROENTERO, V5, P119, DOI 10.3748/wjg.v5.i2.119
   Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202
   Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371
   Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3
   Parr C, 2006, INT J CANCER, V119, P1176, DOI 10.1002/ijc.21881
   Qin L, 1998, FEBS LETT, V436, P111, DOI 10.1016/S0014-5793(98)01105-3
   Rajapakse S, 2005, FEBS LETT, V579, P6879, DOI 10.1016/j.febslet.2005.11.039
   Schuster JM, 2003, J NEURO-ONCOL, V64, P219, DOI 10.1023/A:1025674227750
   Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   SUZUKI K, 1994, HEPATOLOGY, V20, P1231
   Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200
   Tavian D, 2000, INT J CANCER, V87, P644, DOI 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.3.CO;2-N
   Tsai WC, 2006, HISTOPATHOLOGY, V49, P388, DOI 10.1111/j.1365-2559.2006.02516.x
   Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413
   Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x
   Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023
   Wong CM, 2007, HEPATOLOGY, V45, P1129, DOI 10.1002/hep.21578
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Yamauchi M, 2004, J UROLOGY, V171, P890, DOI 10.1097/01.ju.0000092861.21122.d2
NR 40
TC 24
Z9 26
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2009
VL 124
IS 8
BP 1811
EP 1819
DI 10.1002/ijc.24115
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 422UH
UT WOS:000264452700009
PM 19107935
OA Bronze
DA 2025-01-12
ER

PT J
AU Yang, XJ
   Karuturi, RKM
   Sun, F
   Aau, MY
   Yu, K
   Shao, RG
   Miller, LD
   Tan, PBO
   Yu, Q
AF Yang, Xiaojing
   Karuturi, R. K. Murthy
   Sun, Feng
   Aau, Meiyee
   Yu, Kun
   Shao, Rongguang
   Miller, Lance D.
   Tan, Patrick Boon Ooi
   Yu, Qiang
TI <i>CDKN1C</i> (p57<SUP>KIP2</SUP>) Is a Direct Target of EZH2 and
   Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; PROMOTER DNA METHYLATION; GROUP PROTEIN EZH2;
   PROSTATE-CANCER; HISTONE H3; LYSINE-27 METHYLATION; CHROMATIN PATTERN;
   COLORECTAL-CANCER; GENE-EXPRESSION; HUMAN GENOME
AB CDKN1C (encoding tumor suppressor p57(KIP2)) is a cyclin-dependent kinase (CDK) inhibitor whose family members are often transcriptionally downregulated in human cancer via promoter DNA methylation. In this study, we show that CDKN1C is repressed in breast cancer cells mainly through histone modifications. In particular, we show that CDKN1C is targeted by histone methyltransferase EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3), and can be strongly activated by inhibition of EZH2 in synergy with histone deacetylase inhibitor. Consistent with the overexpression of EZH2 in a variety of human cancers including breast cancer, CDKN1C in these cancers is downregulated, and breast tumors expressing low levels of CDKN1C are associated with a poor prognosis. We further show that assessing both EZH2 and CDKN1C expression levels as a measurement of EZH2 pathway activity provides a more predictive power of disease outcome than that achieved with EZH2 or CDKN1C alone. Taken together, our study reveals a novel epigenetic mechanism governing CDKN1C repression in breast cancer. Importantly, as a newly identified EZH2 target with prognostic value, it has implications in patient stratification for cancer therapeutic targeting EZH2-mediated gene repression.
C1 [Yang, Xiaojing; Karuturi, R. K. Murthy; Sun, Feng; Aau, Meiyee; Miller, Lance D.; Tan, Patrick Boon Ooi; Yu, Qiang] ASTAR, Genome Inst Singapore, Singapore, Singapore.
   [Yang, Xiaojing; Shao, Rongguang] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing, Peoples R China.
   [Sun, Feng] Natl Univ Singapore, Dept Pharm, Singapore, Singapore.
   [Yu, Kun; Tan, Patrick Boon Ooi] Duke NUS, Grad Med Sch, Singapore, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); Chinese Academy of Medical Sciences -
   Peking Union Medical College; Institute of Medicinal Biotechnology -
   CAMS; National University of Singapore; National University of Singapore
RP Yang, XJ (通讯作者)，ASTAR, Genome Inst Singapore, Singapore, Singapore.
EM yuq@gis.a-star.edu.sg
RI Yang, Xiaojing/G-9201-2012; Miller, Lance/A-5633-2009
OI Miller, Lance/0000-0003-3799-2528; Yu, Qiang/0000-0003-2132-8278
FU Agency for Science, Technology & Research (A* Star) of Singapore
FX This work was supported by Agency for Science, Technology & Research (A*
   Star) of Singapore.(http://www.a-star.edu.sg). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Hall P, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-16
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Soejima H, 2004, ONCOGENE, V23, P4380, DOI 10.1038/sj.onc.1207576
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
NR 43
TC 147
Z9 176
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2009
VL 4
IS 4
AR e5011
DI 10.1371/journal.pone.0005011
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 437PZ
UT WOS:000265500700006
PM 19340297
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Bailet, O
   Fenouille, N
   Abbe, P
   Robert, G
   Rocchi, S
   Gonthier, N
   Denoyelle, C
   Ticchioni, M
   Ortonne, JP
   Ballotti, R
   Deckert, M
   Tartare-Deckert, S
AF Bailet, Olivier
   Fenouille, Nina
   Abbe, Patricia
   Robert, Guillaume
   Rocchi, Stephane
   Gonthier, Nadege
   Denoyelle, Christophe
   Ticchioni, Michel
   Ortonne, Jean-Paul
   Ballotti, Robert
   Deckert, Marcel
   Tartare-Deckert, Sophie
TI Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells
   by Inducing Senescence-like Growth Arrest
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN BREAST-CANCER; MALIGNANT-MELANOMA; SIGNALING PATHWAY; SYK GENE;
   P53; EXPRESSION; PROGRESSION; INDUCTION; PROLIFERATION; FIBRONECTIN
AB Loss of tumor-suppressive pathways that control cellular senescence is a crucial step in malignant transformation. Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase that has been recently implicated in tumor suppression of melanoma, a deadly skin cancer derived from pigment-producing melanocytes. However, the mechanism by which Syk suppresses melanoma growth remains unclear. Here, we report that reexpression of Syk in melanoma cells induces a p53-dependent expression of the cyclin-dependent kinase (cdk) inhibitor p21. and a senescence program. We first observed that Syk expression is lost in a subset of melanoma cell lines, primarily by DNA methylation-mediated gene silencing and restored after treatment with the demethylating agent 5-aza-2-deoxycytidine. We analyzed the significance of epigenetic inactivation of Syk and found that reintroduction of Syk in melanoma cells dramatically reduces clonogenic survival and three-dimensional tumor spheroid growth and invasion. Remarkably, melanoma cells reexpressing Syk display hallmarks of senescent cells, including reduction of proliferative activity and DNA synthesis, large and flattened morphology, senescence-associated beta-galactosidase activity, and heterochromatic foci. This phenotype is accompanied by hypophosphorylated retinoblastoma protein (Rb) and accumulation of p21, which depends on functional p53. Our results highlight a new role for Syk tyrosine kinase in regulating cellular senescence and identify Syk-mediated senescence as a novel tumor suppressor pathway the inactivation of which may contribute to melanoma tumorigenicity. [Cancer Res 2009;69(7):2748-56]
C1 [Tartare-Deckert, Sophie] Inst Natl Sante & Rech Med, U895, Fac Med, Team 1, F-06107 Nice 2, France.
   [Gonthier, Nadege; Ticchioni, Michel; Deckert, Marcel] Inst Natl Sante & Rech Med, U576, F-06107 Nice 2, France.
   [Deckert, Marcel] CHU Nice, Dept Clin Hematol, Nice, France.
   [Ortonne, Jean-Paul; Ballotti, Robert; Tartare-Deckert, Sophie] CHU Nice, Dept Dermatol, Nice, France.
   [Bailet, Olivier; Fenouille, Nina; Abbe, Patricia; Robert, Guillaume; Rocchi, Stephane; Denoyelle, Christophe; Ticchioni, Michel; Ballotti, Robert; Deckert, Marcel; Tartare-Deckert, Sophie] Univ Nice, Nice, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm); CHU
   Nice; CHU Nice; Universite Cote d'Azur
RP Tartare-Deckert, S (通讯作者)，Inst Natl Sante & Rech Med, U895, Fac Med, Team 1, 28 Ave Valombrose, F-06107 Nice 2, France.
EM tartare@unice.fr
RI Fenouille, Nina/AAI-1027-2021; BALLOTTI, Robert/F-8825-2013; Rocchi,
   Stephane/O-4152-2016; Ticchioni, Michel/P-8095-2016; DENOYELLE,
   Christophe/K-6205-2015; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert,
   Marcel/T-3566-2019; ROBERT, Guillaume/O-1935-2017
OI TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert,
   Marcel/0000-0003-2094-559X; ROBERT, Guillaume/0000-0002-6350-2222;
   BALLOTTI, Robert/0000-0002-7322-4908
FU INSERM ARC [3111]; INCa [PL 2007]
FX Grant support: INSERM ARC grant 3111 and INCa grant PL 2007. O. Bailet
   is a recipient of an INSERM-region Provence Alpes Cote d'Azur PhD
   fellowship in partnership with Galderma R&D (Sophia-Antipolis, France).
   S. Tartare-Deckert is a recipient of a Contrat d'Interface Clinique (CHU
   Nice).
CR Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805
   Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291
   Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206
   Collado M, 2005, CELL CYCLE, V4, P1722, DOI 10.4161/cc.4.12.2260
   Coopman PJ, 2006, CANCER LETT, V241, P159, DOI 10.1016/j.canlet.2005.11.004
   Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086
   Cozzi SJ, 2006, CANCER RES, V66, P10083, DOI 10.1158/0008-5472.CAN-06-0348
   Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984
   Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3
   Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Estève PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102
   Fogarty MP, 2003, BIOCHEM J, V371, P789, DOI 10.1042/BJ20021660
   Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318
   Gaggioli C, 2007, J INVEST DERMATOL, V127, P400, DOI 10.1038/sj.jid.5700524
   Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283
   Hoeller C, 2005, J INVEST DERMATOL, V124, P1293, DOI 10.1111/j.0022-202X.2005.23685.x
   Inatome R, 2001, BIOCHEM BIOPH RES CO, V286, P195, DOI 10.1006/bbrc.2001.5355
   Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733
   Law CL, 1996, MOL CELL BIOL, V16, P1305
   Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890
   Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166
   Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285
   Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520
   Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274
   Nakashima H, 2006, CANCER LETT, V236, P89, DOI 10.1016/j.canlet.2005.05.022
   NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063
   Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084
   Takano T, 2002, ANTIOXID REDOX SIGN, V4, P533, DOI 10.1089/15230860260196335
   Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9
   Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231
   Wang L, 2003, CANCER RES, V63, P4724
   Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788
   Yuan YF, 2001, CANCER RES, V61, P5558
   Zhou F, 2006, MOL CELL BIOL, V26, P3478, DOI 10.1128/MCB.26.9.3478-3491.2006
   Zyss D, 2005, CANCER RES, V65, P10872, DOI 10.1158/0008-5472.CAN-05-1270
NR 45
TC 64
Z9 75
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2009
VL 69
IS 7
BP 2748
EP 2756
DI 10.1158/0008-5472.CAN-08-2690
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 429GE
UT WOS:000264908100011
PM 19293188
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Gomez, A
   Ingelman-Sundberg, M
AF Gomez, A.
   Ingelman-Sundberg, M.
TI Pharmacoepigenetics: Its Role in Interindividual Differences in Drug
   Response
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID BREAST-CANCER CELLS; DNA METHYLATION; EPIGENETIC REGULATION;
   CHROMATIN-STRUCTURE; GENE-EXPRESSION; UP-REGULATION; RECEPTOR; PROMOTER;
   MICRORNA; REGION
AB Pharmacoepigenetics potentially offers another level of explanation for interindividual variations in drug response that cannot be accounted for on the basis of genetic polymorphism. Many genes encoding enzymes, drug transporters, transcription factors, drug targets, and nuclear receptors are under epigenetic control. In addition, microRNAs (miRNAs) that govern the expression of these genes have recently been identified. This finding has implications, for example, in the context of drug resistance during cancer treatment. In this overview, we summarize the field, which is still in its infancy.
C1 [Gomez, A.; Ingelman-Sundberg, M.] Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, Stockholm, Sweden.
C3 Karolinska Institutet
RP Ingelman-Sundberg, M (通讯作者)，Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, Stockholm, Sweden.
EM magnus.ingelman-sundberg@ki.se
RI Ingelman-Sundberg, Magnus/ABD-9302-2021
OI Ingelman-Sundberg, Magnus/0000-0002-7255-9079
FU Torsten and Ragnar Soderbergs Stiftelse; Swedish Cancer Foundation;
   Swedish Research Council
FX We are indebted to Inger Johansson and Isa Cavaco for reading the
   manuscript. The research in the authors' laboratory is supported by
   grants from Torsten and Ragnar Soderbergs Stiftelse, the Swedish Cancer
   Foundation, and the Swedish Research Council.
CR [Anonymous], 2007, SCI SINGAL, DOI DOI 10.1126/STKE.3672007RE1
   Anttila S, 2003, CANCER RES, V63, P8623
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   EDLER SK, 2008, EUR J CANC
   GHOTBI R, PHARMACOGEN IN PRESS
   Gomez A, 2007, PHARMACOGENOMICS, V8, P1315, DOI 10.2217/14622416.8.10.1315
   Hammons GJ, 2001, LIFE SCI, V69, P839, DOI 10.1016/S0024-3205(01)01175-4
   Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004
   JONES SM, 1992, BIOCHEM PHARMACOL, V43, P1876, DOI 10.1016/0006-2952(92)90726-Y
   Karlgren M, 2006, BIOCHEM BIOPH RES CO, V341, P451, DOI 10.1016/j.bbrc.2005.12.200
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Kubarek L, 2007, FEBS LETT, V581, P1441, DOI 10.1016/j.febslet.2007.02.070
   Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x
   Michelotti GA, 2007, FASEB J, V21, P1979, DOI 10.1096/fj.06-7118com
   Nakajima M, 2003, TOXICOL LETT, V144, P247, DOI 10.1016/S0378-4274(03)00216-9
   Onica T, 2008, MOL PHARMACOL, V73, P451, DOI 10.1124/mol.107.039354
   Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828
   Sato N, 2005, CANCER BIOL THER, V4, P70, DOI 10.4161/cbt.4.1.1378
   Takagi S, 2008, J BIOL CHEM, V283, P9674, DOI 10.1074/jbc.M709382200
   To KKW, 2008, MOL CELL BIOL, V28, P5147, DOI 10.1128/MCB.00331-08
   Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   Westberry JM, 2008, NEUROSCIENCE, V152, P982, DOI 10.1016/j.neuroscience.2008.01.048
   Woodson K, 2008, J UROLOGY, V179, P508, DOI 10.1016/j.juro.2007.09.073
   Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3
   Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908
   Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007
NR 31
TC 78
Z9 90
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD APR
PY 2009
VL 85
IS 4
BP 426
EP 430
DI 10.1038/clpt.2009.2
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 422VH
UT WOS:000264455300020
PM 19242404
DA 2025-01-12
ER

PT J
AU Kovacheva, VP
   Davison, JM
   Mellott, TJ
   Rogers, AE
   Yang, S
   O'Brien, MJ
   Blusztajn, JK
AF Kovacheva, Vesela P.
   Davison, Jessica M.
   Mellott, Tiffany J.
   Rogers, Adrianne E.
   Yang, Shi
   O'Brien, Michael J.
   Blusztajn, Jan Krzysztof
TI Raising gestational choline intake alters gene expression in DMBA-evoked
   mammary tumors and prolongs survival
SO FASEB JOURNAL
LA English
DT Article
DE DNA methylation; epigenetic; diet; breast cancer; nutrition; pregnancy
ID BREAST-CANCER RISK; ANTIESTROGEN RESISTANCE; EPIGENETIC REGULATION;
   GLAND CARCINOMAS; DNA METHYLATION; MESSENGER-RNA; CELL-GROWTH;
   IDENTIFICATION; RATS; HYPERMETHYLATION
AB Choline is an essential nutrient that serves as a donor of metabolic methyl groups used during gestation to establish the epigenetic DNA methylation patterns that modulate tissue-specific gene expression. Because the mammary gland begins its development prenatally, we hypothesized that choline availability in utero may affect the gland's susceptibility to cancer. During gestational days 11-17, pregnant rats were fed a control, choline-supplemented, or choline-deficient diet (8, 36, and 0 mmol/kg of choline, respectively). On postnatal day 65, the female offspring received 25 mg/kg of a carcinogen 7,12-dimethylbenz[alpha]anthracene. Approximately 70% of the rats developed mammary adenocarcinomas; prenatal diet did not affect tumor latency, incidence, size, and multiplicity. Tumor growth rate was inversely related to choline content in the prenatal diet, resulting in 50% longer survival until euthanasia, determined by tumor size, of the prenatally choline-supplemented rats compared with the prenatally choline-deficient rats. This was accompanied by distinct expression patterns of similar to 70 genes in tumors derived from the three dietary groups. Tumors from the prenatally choline-supplemented rats overexpressed genes that confer favorable prognosis in human cancers (Klf6, Klf9, Nid2, Ntn4, Per1, and Txnip) and underexpressed those associated with aggressive disease (Bcar3, Cldn12, Csf1, Jag1, Lgals3, Lypd3, Nme1, Ptges2, Ptgs1, and Smarcb1). DNA methylation within the tumor suppressor gene, stratifin (Sfn, 14-3-3 sigma), was proportional to the prenatal choline supply and correlated inversely with the expression of its mRNA and protein in tumors, suggesting that an epigenetic mechanism may underlie the altered molecular phenotype and tumor growth. Our results suggest a role for adequate maternal choline nutrition during pregnancy in prevention/alleviation of breast cancer in daughters.-Kovacheva, V. P., Davison, J. M., Mellott, T. J., Rogers, A. E., Yang, S., O'Brien, M. J., Blusztajn, J. K. Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival. (2009) FASEB J. 23, 1054-1063 (2009)
C1 [Kovacheva, Vesela P.; Davison, Jessica M.; Mellott, Tiffany J.; Rogers, Adrianne E.; Yang, Shi; O'Brien, Michael J.; Blusztajn, Jan Krzysztof] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
C3 Boston University
RP Blusztajn, JK (通讯作者)，Boston Univ, Sch Med, Dept Pathol & Lab Med, 72 E Concord St,L804, Boston, MA 02118 USA.
EM jbluszta@bu.edu
RI O'Brien, Michael/R-7179-2019
OI Yang, Shi/0000-0001-8316-6484; Mellott, Tiffany/0000-0003-3287-9374;
   O'Brien, Michael J/0000-0003-1124-3537; /0000-0001-8438-3122
FU National Institute of Health [CA120488, AG009525]
FX We thank Adam Lerner for the anti-BCAR3 antibody and Patrick Hogan and
   Bethany Shade for assistance. The Molecular Genetics Core Facility at
   Children's Hospital Boston performed the microarray analysis. These
   studies were supported by National Institute of Health grants CA120488
   and AG009525.
CR Alshafie GA, 2000, ONCOL REP, V7, P1377
   [Anonymous], 1998, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline, DOI DOI 10.17226/6015
   Bertagnolo V, 2006, INT J ONCOL, V28, P863
   Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794
   Buendia MA, 2007, J HEPATOL, V46, P546, DOI 10.1016/j.jhep.2007.01.005
   Cai DP, 2003, CANCER RES, V63, P6802
   Crawford NPS, 2008, CLIN EXP METASTAS, V25, P357, DOI 10.1007/s10585-008-9146-6
   Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399
   Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785
   Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Esseghir S, 2007, CLIN CANCER RES, V13, P3164, DOI 10.1158/1078-0432.CCR-07-0224
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5
   Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038
   Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807
   Gröne J, 2007, INT J COLORECTAL DIS, V22, P651, DOI 10.1007/s00384-006-0197-3
   Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9
   Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002
   HilakiviClarke L, 1996, JNCI-J NATL CANCER I, V88, P1821, DOI 10.1093/jnci/88.24.1821
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeronimo C, 2008, BREAST CANCER RES TR, V109, P27, DOI 10.1007/s10549-007-9620-x
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim SY, 2007, CELL MOL IMMUNOL, V4, P345
   Korkola JE, 2003, CANCER RES, V63, P7167
   Kovacheva VP, 2007, J BIOL CHEM, V282, P31777, DOI 10.1074/jbc.M705539200
   Kuramoto T, 2002, CANCER RES, V62, P3592
   LEONE A, 1993, ONCOGENE, V8, P855
   Lewis EM, 2002, DRUG CHEM TOXICOL, V25, P437, DOI 10.1081/DCT-120014794
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin JF, 2007, INT J CANCER, V121, P2596, DOI 10.1002/ijc.23016
   Liu PCC, 2001, MOL BIOL CELL, V12, P3644, DOI 10.1091/mbc.12.11.3644
   MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105
   Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000
   Mayoral MA, 2008, CANCER INVEST, V26, P615, DOI 10.1080/07357900701837051
   McCann JC, 2006, NEUROSCI BIOBEHAV R, V30, P696, DOI 10.1016/j.neubiorev.2005.12.003
   Meck WH, 2008, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.007.2007
   Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009
   Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4
   Medina D, 2005, J CELL SCI, V118, P123, DOI 10.1242/jcs.01597
   Mellott TJ, 2007, FASEB J, V21, P1311, DOI 10.1096/fj.06-6597com
   Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Oshiro MM, 2005, NEOPLASIA, V7, P799, DOI 10.1593/neo.05274
   Ouatas T, 2003, J BIOENERG BIOMEMBR, V35, P73, DOI 10.1023/A:1023497924277
   Papaconstantinou AD, 2006, INT J CANCER, V118, P17, DOI 10.1002/ijc.21247
   Paret C, 2007, BRIT J CANCER, V97, P1146, DOI 10.1038/sj.bjc.6604012
   Resseguie M, 2007, FASEB J, V21, P2622, DOI 10.1096/fj.07-8227com
   Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273
   Russo J., 1987, The mammary gland. Development, regulation, and function., P67
   RUSSO J, 1990, LAB INVEST, V62, P244
   Sapi E, 2004, EXP BIOL MED, V229, P1
   Shan L, 2005, TOXICOL PATHOL, V33, P768, DOI 10.1080/01926230500437027
   Shan L, 2005, CARCINOGENESIS, V26, P503, DOI 10.1093/carcin/bgh330
   Shan L, 2004, AM J PATHOL, V165, P191, DOI 10.1016/S0002-9440(10)63288-9
   Shan L, 2002, CARCINOGENESIS, V23, P1561, DOI 10.1093/carcin/23.10.1561
   Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187
   Smalley MJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1834
   Stark AH, 2003, NUTR CANCER, V46, P59, DOI 10.1207/S15327914NC4601_08
   STEEG PS, 1988, JNCI-J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200
   Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054
   Thompson H., 2000, Methods in Mammary Gland Biology and Breast Cancer Research, P19
   Thorat MA, 2008, MODERN PATHOL, V21, P15, DOI 10.1038/modpathol.3800970
   Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Ulazzi L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-17
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799
   Velarde MC, 2007, MOL ENDOCRINOL, V21, P2988, DOI 10.1210/me.2007-0242
   Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230
   Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595
   Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7
   Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961
   ZEISEL SH, 1995, J NUTR, V125, P3049
   Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156
NR 83
TC 38
Z9 50
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2009
VL 23
IS 4
BP 1054
EP 1063
DI 10.1096/fj.08-122168
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 453ZO
UT WOS:000266651600009
PM 19047067
OA Green Published
DA 2025-01-12
ER

PT J
AU Flanagan, JM
   Munoz-Alegre, M
   Henderson, S
   Tang, T
   Sun, P
   Johnson, N
   Fletcher, O
   Silva, ID
   Peto, J
   Boshoff, C
   Narod, S
   Petronis, A
AF Flanagan, James M.
   Munoz-Alegre, Marta
   Henderson, Stephen
   Tang, Thomas
   Sun, Ping
   Johnson, Nichola
   Fletcher, Olivia
   Silva, Isabel dos Santos
   Peto, Julian
   Boshoff, Chris
   Narod, Steven
   Petronis, Arturas
TI Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral
   breast cancer patients
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID EPIGENETIC VARIATION; METHYLATION; SUSCEPTIBILITY; PATTERNS;
   IDENTIFICATION; ASSOCIATION; EXPRESSION; VARIANTS; TARGET; WOMEN
AB Bilaterality of breast cancer is an indicator of constitutional cancer susceptibility; however, the molecular causes underlying this predisposition in the majority of cases is not known. We hypothesize that epigenetic misregulation of cancer-related genes could partially account for this predisposition. We have performed methylation microarray analysis of peripheral blood DNA from 14 women with bilateral breast cancer compared with 14 unaffected matched controls throughout 17 candidate breast cancer susceptibility genes including BRCA1, BRCA2, CHEK2, ATM, ESR1, SFN, CDKN2A, TP53, GSTP1, CDH1, CDH13, HIC1, PGR, SFRP1, MLH1, RARB and HSD17B4. We show that the majority of methylation variability is associated with intragenic repetitive elements. Detailed validation of the tiled region around ATM was performed by bisulphite modification and pyrosequencing of the same samples and in a second set of peripheral blood DNA from 190 bilateral breast cancer patients compared with 190 controls. We show significant hypermethylation of one intragenic repetitive element in breast cancer cases compared with controls (P = 0.0017), with the highest quartile of methylation associated with a 3-fold increased risk of breast cancer (OR 3.20, 95% CI 1.78-5.86, P = 0.000083). Increased methylation of this locus is associated with lower steady-state ATM mRNA level and correlates with age of cancer patients but not controls, suggesting a combined age-phenotype-related association. This research demonstrates the potential for gene-body epigenetic misregulation of ATM and other cancer-related genes in peripheral blood DNA that may be useful as a novel marker to estimate breast cancer risk.
   Accession numbers: The microarray data and associated .BED and .WIG files can be accessed through Gene Expression Omnibus accession number: GSE14603.
C1 [Flanagan, James M.; Munoz-Alegre, Marta; Henderson, Stephen; Boshoff, Chris] UCL, Inst Canc, CR UK Viral Oncol Grp, London WC1E 6BT, England.
   [Tang, Thomas; Petronis, Arturas] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada.
   [Sun, Ping; Narod, Steven] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON, Canada.
   [Johnson, Nichola; Fletcher, Olivia] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London, England.
   [Silva, Isabel dos Santos; Peto, Julian] London Sch Hyg & Trop Med, Canc Res UK Epidemiol & Genet Grp, London WC1, England.
   [Peto, Julian] Inst Canc Res, Surrey, England.
C3 University of London; University College London; University of Toronto;
   Centre for Addiction & Mental Health - Canada; University of Toronto;
   Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK; University of London; London School of Hygiene &
   Tropical Medicine; University of London; Institute of Cancer Research -
   UK
RP Flanagan, JM (通讯作者)，UCL, Inst Canc, CR UK Viral Oncol Grp, Paul OGorman Bldg,74 Huntley St, London WC1E 6BT, England.
EM j.flanagan@ucl.ac.uk
RI Narod, Steven/AAA-6112-2022; Petronis, Art/AAD-4491-2019
OI Petronis, Art/0000-0002-4538-1594; Flanagan, James/0000-0003-4955-1383;
   Henderson, Stephen/0000-0002-9032-3828; Munoz-Alegre,
   Marta/0000-0003-4775-286X; dos Santos Silva, Isabel/0000-0002-6596-8798;
   Fletcher, Olivia/0000-0001-9387-7116
FU Cancer Research UK Funding Source: Medline
CR Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   CHAUDARY MA, 1983, BRIT J RADIOL, V56, P703, DOI 10.1259/0007-1285-56-670-703
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Flanagan JM, 2006, AM J HUM GENET, V79, P67, DOI 10.1086/504729
   Flanagan James M, 2007, Genome Biol, V8, P307, DOI 10.1186/gb-2007-8-6-307
   Fletcher O, 2008, CANCER EPIDEM BIOMAR, V17, P702, DOI 10.1158/1055-9965.EPI-07-2564
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Henderson SR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r76
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Johnson N, 2005, LANCET, V366, P1554, DOI 10.1016/S0140-6736(05)67627-1
   KONTOROVICH T, 2008, BREAST CANC RES 0719
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Li SF, 2003, ANN NY ACAD SCI, V983, P161, DOI 10.1111/j.1749-6632.2003.tb05971.x
   Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Morgan DK, 2008, MAMM GENOME, V19, P394, DOI 10.1007/s00335-008-9124-y
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244
   Sakorafas GH, 2003, CANCER TREAT REV, V29, P79, DOI 10.1016/S0305-7372(02)00107-X
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330
   Song JS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r178
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602
   Tommiska J, 2008, ONCOGENE, V27, P2501, DOI 10.1038/sj.onc.1210885
   Treilleux I, 2007, HISTOPATHOLOGY, V51, P63, DOI 10.1111/j.1365-2559.2007.02726.x
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Weitzel JN, 2005, CANCER EPIDEM BIOMAR, V14, P1534, DOI 10.1158/1055-9965.EPI-05-0070
   Ye CZ, 2007, CANCER-AM CANCER SOC, V109, P1729, DOI 10.1002/cncr.22592
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 44
TC 110
Z9 123
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2009
VL 18
IS 7
BP 1332
EP 1342
DI 10.1093/hmg/ddp033
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 421XI
UT WOS:000264391200015
PM 19153073
OA Green Published, Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Fu, L
   Gao, ZF
   Zhang, XH
   Tsang, YH
   Goh, HK
   Geng, H
   Shimizu, N
   Tsuchiyama, J
   Srivastava, G
   Tao, Q
AF Fu, Li
   Gao, Zifen
   Zhang, Xiaohua
   Tsang, Ying Hung
   Goh, Hwee Koon
   Geng, Hua
   Shimizu, Norio
   Tsuchiyama, Junjiro
   Srivastava, Gopesh
   Tao, Qian
TI Frequent concomitant epigenetic silencing of the stress-responsive tumor
   suppressor gene <i>CADM1</i>, and its interacting partner
   <i>DAL</i>-<i>1</i> in nasal NK/T-cell lymphoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE nasal lymphoma; CADM1; DAL-1; methylation; tumor suppressor gene
ID EPSTEIN-BARR-VIRUS; NATURAL-KILLER; T-CELL; NASOPHARYNGEAL CARCINOMA;
   BREAST-CANCER; B-CELL; CONSISTENT PATTERNS; METHYLATION STATUS;
   CHROMOSOME 11Q; PPP2R1B GENE
AB Nasal NK/T-cell lymphoma (NL) is a rare but clinically important entity of lymphoma. Its preferential incidence in Orientals but not Caucasians suggests possible genetic predisposition. 11q deletion is common in NL, indicating certain tumor suppressor genes (TSGs) at this locus involved in its pathogenesis. We investigated the expression and methylation of an 11q23.2 TSG, CADM1 (or TSLC1), and its partner DAL-1 (or EPB41L3) in NL. Methylation and silencing of CADM1 were detected in 2 NL and 4 of 8 (50%) of non-Hodgkin lymphoma (NHL) cell lines, but not in normal NK cells and normal PBMC. Absence of CADM1 protein was also detected in NL cell lines. 5-aza-2'-deoxycytidine (Aza) demethylation or genetic knockout of both DNMT1 and 3B genes restored CADM1 and DAL-1 expression. CADM1 methylation was Further detected in 36 of 45 (80%) of NL tumors. Concomitantly, DAL-1 was epigenetically inactivated in NL cell lines and virtually all the tumors with methylated CADM1. A significant correlation between the methylation of both genes was found (p < 0.0001). Homozygous deletion of CADM1 was detected in only 3 of 18 (17%) of tumors. The stress-response of CADM1 was abolished when its promoter becomes methylated. Our results demonstrate a frequent, predominant epigenetic silencing of CADM1 and DAL-1 in NIL, which likely play a synergic role in NL pathogenesis. (C) 2008 Wiley-Liss, Inc.
C1 [Tao, Qian] Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc,Sir YK Pao Ctr Canc,Hong Kong Canc Inst, PWH,Canc Epigenet Lab,State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China.
   [Geng, Hua; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Fu, Li; Tsang, Ying Hung; Goh, Hwee Koon; Tao, Qian] Johns Hopkins Singapore, Singapore, Singapore.
   [Gao, Zifen; Zhang, Xiaohua] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100871, Peoples R China.
   [Shimizu, Norio] Tokyo Med & Dent Univ, Dept Virol, Tokyo, Japan.
   [Tsuchiyama, Junjiro] Kawasaki Med Sch, Dept Pathol, Okayama, Japan.
   [Srivastava, Gopesh] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Tao, Qian] Johns Hopkins Sch Med, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Johns Hopkins University; Johns Hopkins
   Medicine; Peking University; Institute of Science Tokyo; Tokyo Medical &
   Dental University (TMDU); Kawasaki Medical School; University of Hong
   Kong; Johns Hopkins University; Johns Hopkins Medicine
RP Tao, Q (通讯作者)，Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc,Sir YK Pao Ctr Canc,Hong Kong Canc Inst, PWH,Canc Epigenet Lab,State Key Lab Oncol S China, Rm 315, Hong Kong, Hong Kong, Peoples R China.
EM gopesh@pathology.hku.hk
RI Tao, Qian/T-4743-2018; Fu, Li/F-7182-2010
OI Tao, Qian/0000-0001-5383-4808; Fu, Li/0000-0003-2643-6278
FU Johns Hopkins Singapore; Chinese University of Hong Kong; University of
   Hong Kong [10207480]
FX Grant sponsors: Johns Hopkins Singapore (A*STAR grant), Chinese
   University of Hong Kong. Grant sponsor: University of Hong Kong; Grant
   number: 10207480.
CR AOZASA K, 1995, CANCER, V75, P894, DOI 10.1002/1097-0142(19950201)75:3<894::AID-CNCR2820750322>3.0.CO;2-I
   ARBER DA, 1993, AM J SURG PATHOL, V17, P392, DOI 10.1097/00000478-199304000-00010
   Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5
   Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470
   Chiang AKS, 1996, INT J CANCER, V68, P285, DOI 10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y
   Chiang AKS, 1996, HUM PATHOL, V27, P701, DOI 10.1016/S0046-8177(96)90401-3
   Connolly KC, 1999, CANCER RES, V59, P2806
   Davis M, 1996, CANCER RES, V56, P741
   Elenitoba-Johnson KSJ, 1998, MODERN PATHOL, V11, P754
   Feng P, 2000, J GEN VIROL, V81, P2417, DOI 10.1099/0022-1317-81-10-2417
   Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x
   Gaal K, 2000, AM J SURG PATHOL, V24, P1511, DOI 10.1097/00000478-200011000-00006
   Gao Z, 1998, Zhonghua Bing Li Xue Za Zhi, V27, P251
   Harn HJ, 2002, ORAL ONCOL, V38, P23, DOI 10.1016/S1368-8375(01)00008-2
   Heller G, 2006, ONCOGENE, V25, P959, DOI 10.1038/sj.onc.1209115
   HO FCS, 1990, HEMATOL ONCOL, V8, P271, DOI 10.1002/hon.2900080505
   HO FCS, 1984, INT J CANCER, V34, P143, DOI 10.1002/ijc.2910340202
   Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x
   Jaffe ES, 1996, AM J SURG PATHOL, V20, P103, DOI 10.1097/00000478-199601000-00012
   Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84
   Jiang W, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-4
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kawamata N, 2005, EUR J HAEMATOL, V74, P424, DOI 10.1111/j.1600-0609.2005.00417.x
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   Kwong YL, 2005, LEUKEMIA, V19, P2186, DOI 10.1038/sj.leu.2403955
   Lee KY, 2008, ONCOGENE, V27, P5267, DOI 10.1038/onc.2008.147
   Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590
   Martin ES, 2003, P NATL ACAD SCI USA, V100, P11517, DOI 10.1073/pnas.1934602100
   Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200
   MINAROVITS J, 1994, J GEN VIROL, V75, P77, DOI 10.1099/0022-1317-75-1-77
   Mugica-Van Herckenrode C, 1999, DIAGN MOL PATHOL, V8, P92
   Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x
   Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313
   NEGRINI M, 1995, CANCER RES, V55, P3003
   NG CS, 1986, CANCER-AM CANCER SOC, V58, P67, DOI 10.1002/1097-0142(19860701)58:1<67::AID-CNCR2820580113>3.0.CO;2-F
   Pulido HA, 2000, CANCER RES, V60, P6677
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025
   Siu LLP, 2000, AM J PATHOL, V157, P1803, DOI 10.1016/S0002-9440(10)64818-3
   Siu LLP, 1999, AM J PATHOL, V155, P1419, DOI 10.1016/S0002-9440(10)65454-5
   Siu LLP, 2002, AM J PATHOL, V160, P59
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   TAO Q, 1995, INT J CANCER, V60, P315, DOI 10.1002/ijc.2910600306
   Tao Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2672, DOI 10.2741/2000
   Tran YK, 1999, CANCER RES, V59, P35
   Uzawa K, 1996, INT J CANCER, V67, P510, DOI 10.1002/(SICI)1097-0215(19960807)67:4<510::AID-IJC8>3.3.CO;2-R
   Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284
   Wang SSQ, 1999, GENE CHROMOSOME CANC, V25, P154, DOI 10.1002/(SICI)1098-2264(199906)25:2<154::AID-GCC11>3.3.CO;2-N
   Wong SY, 2007, P NATL ACAD SCI USA, V104, P12784, DOI 10.1073/pnas.0705499104
   Yageta M, 2002, CANCER RES, V62, P5129
   Ying JM, 2007, EPIGENETICS-US, V2, P15, DOI 10.4161/epi.2.1.3883
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
NR 54
TC 19
Z9 26
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 1
PY 2009
VL 124
IS 7
BP 1572
EP 1578
DI 10.1002/ijc.24123
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 413PL
UT WOS:000263804900009
PM 19115211
OA Bronze
DA 2025-01-12
ER

PT J
AU Sadr-Nabavi, A
   Ramser, J
   Volkmann, J
   Naehrig, J
   Wiesmann, F
   Betz, B
   Hellebrand, H
   Engert, S
   Seitz, S
   Kreutzfeld, R
   Sasaki, T
   Arnold, N
   Schmutzler, R
   Kiechle, M
   Niederacher, D
   Harbeck, N
   Dahl, E
   Meindl, A
AF Sadr-Nabavi, Ariane
   Ramser, Juliane
   Volkmann, Juliane
   Naehrig, Joerg
   Wiesmann, Frank
   Betz, Beate
   Hellebrand, Heide
   Engert, Stefanie
   Seitz, Susanne
   Kreutzfeld, Rene
   Sasaki, Takako
   Arnold, Norbert
   Schmutzler, Rita
   Kiechle, Marion
   Niederacher, Dieter
   Harbeck, Nadia
   Dahl, Edgar
   Meindl, Alfons
TI Decreased expression of angiogenesis antagonist EFEMP1 in sporadic
   breast cancer is caused by aberrant promoter methylation and points to
   an impact of EFEMP1 as molecular biomarker
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; EFEMP1; angiogenesis; promoter methylation; molecular
   marker
ID EXTRACELLULAR-MATRIX PROTEINS; TISSUE LOCALIZATION; OVARIAN-CANCER;
   FIBULIN-1; IDENTIFICATION; CHEMOTHERAPY; CARCINOMAS; PROGNOSIS; DISEASE;
   FAMILY
AB EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) was recently described as an antagonist of angiogenesis. Motivated by a strong dependence of tumor growth and metastasis on angiogenesis, we investigated the role of EFEMP1 in human breast cancer. We applied RNA microarray expression analysis and quantitative real-time PCR (QRT) in a total of 45 sporadic breast cancer tissues and found EFEMP1 down-regulation in 59% and 61% of the analyzed tissues, respectively. This down-regulation was confirmed on protein level. Immunohistochemistry in 211 breast cancer tissues resulted in reduced or even abolished EFEMP1 expression in 57-62.5% of the tumors. Bisulphite genomic sequencing in breast cancer cell lines and primary breast cancer tissues revealed promoter methylation as the major cause of this down-regulation. Furthermore, analysis of 203 clinically well characterized primary breast cancers displayed a significant correlation of reduced EFEMP1 protein expression with poor disease-free (p = 0.037) and overall survival (p = 0.032), particularly in those node-positive patients who received adjuvant anthracycline-based chemotherapy, but not in those treated by either cyclophosphamide-methotrexate-5-fluorouracil (CMF) or Tamoxifen. In summary, the presented data demonstrate for the first time the reduced EFEMP1 expression on RNA and protein level in a substantial number of sporadic breast carcinomas and its correlation with epigenetic alterations. Furthermore, these data point towards a possible predictive impact of EFEMP1 expression in primary breast cancer. (C) 2008 Wiley-Liss, Inc.
C1 [Sadr-Nabavi, Ariane; Ramser, Juliane; Volkmann, Juliane; Hellebrand, Heide; Engert, Stefanie; Kiechle, Marion; Harbeck, Nadia; Meindl, Alfons] Tech Univ Munich, Dept Obstet & Gynecol, D-81675 Munich, Germany.
   [Sadr-Nabavi, Ariane] Univ Munich, Dept Med Genet, Munich, Germany.
   [Naehrig, Joerg] Tech Univ Munich, Dept Pathol, D-81675 Munich, Germany.
   [Wiesmann, Frank; Dahl, Edgar] Rhein Westfal TH Aachen, Inst Pathol, Univ Hosp, D-5100 Aachen, Germany.
   [Betz, Beate; Niederacher, Dieter] Univ Dusseldorf, Dept Gynecol & Obstet, D-4000 Dusseldorf, Germany.
   [Seitz, Susanne] Max Delbruck Ctr Mol Med MDC, Berlin, Germany.
   [Kreutzfeld, Rene; Schmutzler, Rita] Univ Cologne, Div Mol Gynecooncol, Dept Gynecol & Obstet, Cologne, Germany.
   [Sasaki, Takako] Max Planck Inst Biochem, Prot Chem Lab, D-82152 Martinsried, Germany.
   [Arnold, Norbert] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany.
C3 Technical University of Munich; University of Munich; Technical
   University of Munich; RWTH Aachen University; RWTH Aachen University
   Hospital; Heinrich Heine University Dusseldorf; Helmholtz Association;
   Max Delbruck Center for Molecular Medicine; University of Cologne; Max
   Planck Society; University of Kiel; Schleswig Holstein University
   Hospital
RP Meindl, A (通讯作者)，Tech Univ Munich, Dept Obstet & Gynecol, Ismaningerstr 22, D-81675 Munich, Germany.
EM alfons.meindl@lrz.tum.de
RI Harbeck, Nadia/JOZ-6178-2023; Arnold, Norbert/E-3012-2010
OI Arnold, Norbert/0000-0003-4523-8808
FU Deutsche Krebshilfe [70-2701]; German Ministry for Education and
   Research (BMBF)
FX Grant sponsor: Deutsche Krebshilfe; Grant number: 70-2701; Grant
   sponsor: German Ministry for Education and Research (BMBF).
CR Albig AR, 2006, CANCER RES, V66, P2621, DOI 10.1158/0008-5472.CAN-04-4096
   Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033
   Banerjee S, 2007, NAT CLIN PRACT ONCOL, V4, P536, DOI 10.1038/ncponc0905
   Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316
   Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Forti S, 2002, BREAST CANCER RES TR, V73, P245, DOI 10.1023/A:1015854415746
   Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001
   Gallagher WM, 2001, FEBS LETT, V489, P59, DOI 10.1016/S0014-5793(00)02389-9
   Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4
   Greene LM, 2003, BRIT J CANCER, V88, P871, DOI 10.1038/sj.bjc.6600802
   Harbeck N, 2001, CLIN CANCER RES, V7, P2757
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200
   Lennernäs B, 2003, ACTA ONCOL, V42, P294, DOI 10.1080/02841860310001835
   Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y
   Rhiem K, 2003, INT J CANCER, V106, P74, DOI 10.1002/ijc.11169
   Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X
   Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Viens P, 1999, BREAST CANCER RES TR, V54, P205, DOI 10.1023/A:1006112927565
   Wang DY, 2005, BRAIN PATHOL, V15, P318
   Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478
   Yue W, 2007, CLIN CANCER RES, V13, P4336, DOI 10.1158/1078-0432.CCR-07-0015
NR 25
TC 82
Z9 91
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 1
PY 2009
VL 124
IS 7
BP 1727
EP 1735
DI 10.1002/ijc.24108
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 413PL
UT WOS:000263804900030
PM 19115204
OA Bronze
DA 2025-01-12
ER

PT J
AU Yi, B
   Tan, SX
   Tang, CE
   Huang, WG
   Cheng, AL
   Li, C
   Zhang, PF
   Li, MY
   Li, JL
   Yi, H
   Peng, F
   Chen, ZC
   Xiao, ZQ
AF Yi, Bin
   Tan, Shuang-Xiang
   Tang, Can-E
   Huang, Wei-Guo
   Cheng, Ai-Lan
   Li, Cui
   Zhang, Peng-Fei
   Li, Mao-Yu
   Li, Jian-Ling
   Yi, Hong
   Peng, Fang
   Chen, Zhu-Chu
   Xiao, Zhi-Qiang
TI Inactivation of 14-3-3 σ by Promoter Methylation Correlates With
   Metastasis in Nasopharyngeal Carcinoma
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE NASOPHARYNGEAL CARCINOMA; HYPERMETHYLATION; 14-3-3 sigma; METASTASIS
ID SUPPRESSES TUMOR-GROWTH; PROTEOMIC ANALYSIS; DOWN-REGULATION;
   BREAST-CANCER; HYPERMETHYLATION; GENE; IDENTIFICATION; EXPRESSION;
   FREQUENT; CELLS
AB 14-3-3 sigma, the downstream target of p53, is a negative regulator of cell cycle G2-M phase checkpoint in response to DNA damage. Our previous comparative proteomics study showed that 14-3-3 sigma was downregulated or lost in nasopharyngeal carcinoma (NPC) tissue compared with non-cancerous nasopharyngeal epithelial tissue (NNET). In this study, we further investigated for the epigenetic mechanism of 14-3-3 sigma inactivation. Methylation-specific PCR showed 14-3-3 sigma promoter methylation in 100% of analyzed NPC cell lines (4/4) but not in immortalized human nasopharyngeal epithelial cell line NP69. Treatment of the four NPC cell lines with the methyltransferase inhibitor 5-aza-2'-dC resulted in the demethylation and upregulation of 14-3-3 sigma. In tissues, 14-3-3 sigma promoter methylation occurred at a higher frequency in NPC, 63/75 (84%), compared to adjacent NNET, 7/25 (28%), and fully methylated 14-3-3 sigma promoter was detected in NPC but not in any of adjacent NNET. RT-PCR, Western blotting, and immunohistochemistry showed that 14-3-3 sigma expression was downregulated or lost in NPC with methylation, and there was a negative correlation between the expression levels and methylation statuses of 14-3-3 sigma gene. In addition, the patients with methylated 14-3-3 sigma presented a higher frequency of lymph node and distant metastasis, and an advanced clinical stage, and overexpression of 14-3-3 sigma in NPC cell line 5-BF with high metastatic potential was able to inhibit its in vitro invasive ability. Our data are the first to show that 14-3-3 sigma is frequently inactivated by promoter methylation in NPC and this aberrant methylation correlates with lymph node and distant metastasis. J. Cell. Biochem. 106: 858-866, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Yi, Bin; Tan, Shuang-Xiang; Tang, Can-E; Huang, Wei-Guo; Cheng, Ai-Lan; Li, Cui; Zhang, Peng-Fei; Li, Mao-Yu; Li, Jian-Ling; Yi, Hong; Peng, Fang; Chen, Zhu-Chu; Xiao, Zhi-Qiang] Cent S Univ, Xiangya Hosp, Chinese Minist Hlth, Key Lab Canc Prote, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Xiao, ZQ (通讯作者)，Cent S Univ, Xiangya Hosp, Chinese Minist Hlth, Key Lab Canc Prote, Changsha 410008, Hunan, Peoples R China.
EM zqxiao2001@hotmail.com
RI Huang, Weiguo/D-9357-2016; li, yifan/GSD-1563-2022; Liu,
   Zhihong/AAP-1792-2021; Yi, Bin/E-8506-2017
FU Ministry of Education of China; Lotus Scholars Program of Hunan
   Province, China; Science and Technology Committee of Hunan Province,
   China [2001CB510207, 2002-48, 2007-362, 06SK2004]
FX National Key Basic Research Program of China; Grant sponsor: Outstanding
   Scholars of New Era of Ministry of Education of China; Grant sponsor:
   Lotus Scholars Program of Hunan Province, China; Grant sponsor: Science
   and Technology Committee of Hunan Province, China; Grant numbers:
   2001CB510207, 2002-48, 2007-362, 06SK2004.
CR Akahira J, 2004, CLIN CANCER RES, V10, P2687, DOI 10.1158/1078-0432.CCR-03-0510
   Cheng AL, 2008, CLIN CANCER RES, V14, P435, DOI 10.1158/1078-0432.CCR-07-1215
   Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130
   HO JHC, 1978, INT J RADIAT ONCOL, V4, P182
   Huang Chih-Jen, 1996, Kaohsiung Journal of Medical Sciences, V12, P229
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   King AD, 2000, HEAD NECK-J SCI SPEC, V22, P275
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   LEUNG SF, 1991, J OTOLARYNGOL, V20, P27
   Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801
   Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516
   Suzuki H, 2000, CANCER RES, V60, P4353
   Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2
   Uchida D, 2004, BRIT J CANCER, V91, P1131, DOI 10.1038/sj.bjc.6602004
   Yang HL, 2006, MOL CANCER THER, V5, P253, DOI 10.1158/1535-7163.MCT-05-0395
   Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003
   Yang XY, 2005, CELL ONCOL, V27, P215
   Yu M C, 1990, Prog Clin Biol Res, V346, P93
   Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858
NR 27
TC 38
Z9 46
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR 1
PY 2009
VL 106
IS 5
BP 858
EP 866
DI 10.1002/jcb.22051
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 425VE
UT WOS:000264664800013
PM 19160382
DA 2025-01-12
ER

PT J
AU Hostetter, CL
   Licata, LA
   Keen, JC
AF Hostetter, Christine L.
   Licata, Lauren A.
   Keen, Judith Clancy
TI Timing is everything: Order of administration of 5-aza 2′ deoxycytidine,
   trichostatin A and tamoxifen changes estrogen receptor mRNA expression
   and cell sensitivity
SO CANCER LETTERS
LA English
DT Article
DE Estrogen receptor; Tamoxifen; 5-aza-2 ' deoxycytidine; Trichostatin A;
   Epigenetic; MDA-MB-231; HuR
ID HUMAN-BREAST-CANCER; HISTONE DEACETYLASE INHIBITION; GENE-EXPRESSION;
   PROGESTERONE-RECEPTOR; CPG ISLAND; ALPHA ER; ACTIVATION; HUR;
   DEMETHYLATION; REEXPRESSION
AB Restoration of estrogen receptor (ER) expression using epigenetic inhibitors re-establishes expression of the estrogen receptor (ER) and restores tamoxifen sensitivity in ER negative breast cancer cells. We tested if order of administration of the DNMT (5-aza 2' deoxycytidine/AZA) or HDAC (trichostatin A/TSA) inhibitors and tamoxifen affected ER re-expression and tamoxifen sensitivity. Treatment with AZA followed by co-administration of TSA plus tamoxifen resulted in the greatest ER re-expression and tamoxifen sensitivity, although sensitivity was not increased as robustly as expected. This could be due to increased cytoplasmic levels of HuR, suggesting that cytoplasmic HuR levels are central to tamoxifen responsiveness. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Hostetter, Christine L.; Keen, Judith Clancy] Univ Med & Dent New Jersey, Cooper Canc Inst, Dept Med, Camden, NJ 08106 USA.
   [Licata, Lauren A.] Cooper Univ Hosp, Dept Surg, Camden, NJ USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers Cancer Institute of New
   Jersey; Cooper University Hospital
RP Keen, JC (通讯作者)，Univ Med & Dent New Jersey, Cooper Canc Inst, Dept Med, 401 Haddon Ave,Room 170,E&R Bldg, Camden, NJ 08106 USA.
EM keenjc@umndj.edu
OI Keen, Judith/0000-0002-2894-130X
CR Abukhdeir AM, 2006, BREAST CANCER RES TR, V99, P23, DOI 10.1007/s10549-006-9177-0
   Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102
   CLARKE R, 1992, CRIT REV ONCOL HEMAT, V12, P1, DOI 10.1016/1040-8428(92)90062-U
   Clarke R., 2000, disease fo the breast, P489
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   HOSTETTER C, 2008, CANC BIOL THER, V7
   Issa JPJ, 1996, CANCER RES, V56, P973
   Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Keen JC, 2001, AM J RESP CELL MOL, V24, P58, DOI 10.1165/ajrcmb.24.1.3870
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   PRYZBYLKOWSKI P, 2007, BREAST CANC RES TREA
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yango A Jr, 2002, Transpl Infect Dis, V4, P163
NR 23
TC 17
Z9 22
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 18
PY 2009
VL 275
IS 2
BP 178
EP 184
DI 10.1016/j.canlet.2008.10.005
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 416XA
UT WOS:000264037600003
PM 19013015
DA 2025-01-12
ER

PT J
AU Davies, GF
   Juurlink, BHJ
   Harkness, TAA
AF Davies, Gerald F.
   Juurlink, Bernhard H. J.
   Harkness, Troy A. A.
TI Troglitazone reverses the multiple drug resistance phenotype in cancer
   cells
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE chemotherapy; doxorubicin; breast cancer resistance protein-1; multiple
   drug resistance; multiple drug resistance protein 1
AB A major problem in treating cancer is the development of drug resistance. We previously demonstrated doxorubicin (DOX) resistance in K562 human leukemia cells that was associated with upregulation of glyoxalase 1 (GLO-1) and histone H3 expression. The thiazolidinedione troglitazone (TRG) downregulated GLO-1 expression and further upregulated histone H3 expression and post-translational modifications in these cells, leading to a regained sensitivity to DOX. Given the pleiotropic effects of epigenetic changes in cancer development, we hypothesized that TRG may downregulate the multiple drug resistance (MDR) phenotype in a variety of cancer cells. To test this, MCF7 human breast cancer cells and K562 cells were cultured in the presence of low-dose DOX to establish DOX-resistant cell lines (K562/DOX and MCF7/DOX). The MDR phenotype was confirmed by Western blot analysis of the 170 kDa P-glycoprotein (Pgp) drug efflux pump multiple drug resistance protein 1 (MDR-1), and the breast cancer resistance protein (BCRP). TRG markedly decreased expression of both MDR-1 and BCRP in these cells, resulting in sensitivity to DOX. Silencing of MDR-1 expression also sensitized MCF7/DOX cells to DOX. Use of the specific and irreversible peroxisome proliferator-activated receptor gamma (PPAR gamma) inhibitor GW9662 in the nanomolar range not only demonstrated that the action of TRG on MCF/DOX was PPAR gamma-independent, but indicated that PPAR gamma may play a role in the MDR phenotype, which is antagonized by TRG. We conclude that TRG is potentially a useful adjunct therapy in chemoresistant cancers.
C1 [Davies, Gerald F.; Harkness, Troy A. A.] Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada.
   [Juurlink, Bernhard H. J.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
C3 University of Saskatchewan; Alfaisal University
RP Harkness, TAA (通讯作者)，Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
EM troy.harkness@usask.ca
OI Harkness, Troy/0000-0002-8271-7229
FU Canadian Breast Cancer Foundation (Prairies, NWT)
FX This research was supported by the Canadian Breast Cancer Foundation
   (Prairies, NWT) grant to Troy AA Harkness and Bernhard HJ Juurlink. We
   thank Dr T Arnason for a careful reading of the manuscript.
CR Ando T, 2000, LEUKEMIA, V14, P1915, DOI 10.1038/sj.leu.2401914
   Anuchapreeda S, 2002, BIOCHEM PHARMACOL, V64, P573, DOI 10.1016/S0006-2952(02)01224-8
   Asakura K, 2004, MOL CANCER RES, V2, P339
   Atalay C, 2006, TUMOR BIOL, V27, P309, DOI 10.1159/000096086
   Borowski E, 2005, ACTA BIOCHIM POL, V52, P609
   Bostelman LJ, 2007, DNA REPAIR, V6, P383, DOI 10.1016/j.dnarep.2006.12.010
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brodbeck J, 2008, P NATL ACAD SCI USA, V105, P1343, DOI 10.1073/pnas.0709906104
   Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156
   Burton JD, 2007, ANTI-CANCER DRUG, V18, P525, DOI 10.1097/CAD.0b013e3280200414
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   Cheon CW, 2009, WORLD J GASTROENTERO, V15, P310, DOI 10.3748/wjg.15.310
   Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Davies GF, 2005, LEUKEMIA LYMPHOMA, V46, P1199, DOI 10.1080/10428190500102555
   Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X
   Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938
   El-Khoury V, 2007, BRIT J CANCER, V97, P562, DOI 10.1038/sj.bjc.6603914
   Fediuc S, 2008, J CELL PHYSIOL, V215, P392, DOI 10.1002/jcp.21321
   Giannini S, 2004, J ENDOCRINOL INVEST, V27, P982, DOI 10.1007/BF03347546
   Jiang YJ, 2008, J INVEST DERMATOL, V128, P104, DOI 10.1038/sj.jid.5700944
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Kaszubiak A, 2007, INT J ONCOL, V31, P419
   Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001
   Kim YK, 2007, BIOCHEM BIOPH RES CO, V358, P553, DOI 10.1016/j.bbrc.2007.04.165
   Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010
   Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581
   Levine MN, 2006, NEW ENGL J MED, V355, P1920, DOI 10.1056/NEJMe068204
   Liu M, 2008, J PATHOL, V214, P508, DOI 10.1002/path.2312
   Mayer EL, 2007, HEMATOL ONCOL CLIN N, V21, P257, DOI 10.1016/j.hoc.2007.03.001
   McDevitt CA, 2007, PHARMACOL THERAPEUT, V113, P429, DOI 10.1016/j.pharmthera.2006.10.003
   MCHALE AP, 1988, CANCER LETT, V41, P315, DOI 10.1016/0304-3835(88)90293-5
   Mechetner E, 1998, CLIN CANCER RES, V4, P389
   Miao ZH, 2003, CANCER RES, V63, P4527
   Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452
   Nobili S, 2006, CURR DRUG TARGETS, V7, P861, DOI 10.2174/138945006777709593
   O'Driscoll L, 2006, CURR CANCER DRUG TAR, V6, P365, DOI 10.2174/156800906777723958
   Pérez-Tomás R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077
   Planavila A, 2005, BIOCHEM PHARMACOL, V69, P1195, DOI 10.1016/j.bcp.2005.01.015
   Rios-Vazquez Ramon, 2006, Am J Cardiovasc Drugs, V6, P231
   Rulli A, 2001, BREAST CANCER RES TR, V66, P67, DOI 10.1023/A:1010632919129
   Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214
   Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661
   Scheen AJ, 2001, DIABETES METAB, V27, P305
   Seufert S, 2008, PPAR RES, V2008, DOI 10.1155/2008/513943
   Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097
   Wang LH, 2007, BLOOD, V110, P4373, DOI 10.1182/blood-2006-07-038026
   Wang PS, 2008, J SURG RES      0627
   Wu L, 2001, DIABETOLOGIA, V44, P2004, DOI 10.1007/s001250100004
   Xu D, 2006, CANCER LETT, V243, P274, DOI 10.1016/j.canlet.2005.11.031
   Yamashita M, 2008, PPAR RES, V29, P35
   Yang YC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-216
   Young PW, 1998, J PHARMACOL EXP THER, V284, P751
   Yu J, 2006, HEPATOLOGY, V43, P134, DOI 10.1002/hep.20994
   Zand H, 2008, MOL CELL BIOCHEM, V317, P113, DOI 10.1007/s11010-008-9838-x
   Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083
NR 56
TC 29
Z9 31
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PD MAR 17
PY 2009
VL 3
BP 79
EP 88
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V20WU
UT WOS:000208170900001
PM 19920924
DA 2025-01-12
ER

PT J
AU Friedman, JM
   Liang, GN
   Liu, CC
   Wolff, EM
   Tsai, YC
   Ye, W
   Zhou, XH
   Jones, PA
AF Friedman, Jeffrey M.
   Liang, Gangning
   Liu, Chun-Chi
   Wolff, Erika M.
   Tsai, Yvonne C.
   Ye, Wei
   Zhou, Xianghong
   Jones, Peter A.
TI The Putative Tumor Suppressor microRNA-101 Modulates the Cancer
   Epigenome by Repressing the Polycomb Group Protein EZH2
SO CANCER RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; DNA METHYLATION; PROSTATE-CANCER; NEOPLASTIC
   TRANSFORMATION; BREAST-CANCER; LUNG-CANCER; GENE; EXPRESSION;
   PROGRESSION; METHYLTRANSFERASES
AB The Polycomb Repressive Complex 2 (PRC2) mediates epigenetic gene silencing by trimethylating histone H3 lysine 27 (H3K27me3) and is known to aberrantly silence tumor suppressor genes in cancer. EZH2, the catalytic subunit of PRC2, enhances tumorigenesis and is commonly overexpressed in several types of cancer. Our microRNA profiling of bladder transitional cell carcinoma (TCC) patient samples revealed that microRNA-101 (miR-101) is down-regulated in TCC, and we showed that miR-101 inhibits cell proliferation and colony formation in TCC cell lines. Furthermore, our results confirm that miR-101 directly represses EZH2 and stable EZH2 knockdowns in TCC cell lines create a similar growth suppressive phenotype. This suggests that abnormal down-regulation of miR-101 could lead to the overexpression of EZH2 frequently seen in cancer. We conclude that miR-101 may be a potent tumor suppressor by altering global chromatin structure through repression of EZH2. [Cancer Res 2009;69(6):2623-9]
C1 [Friedman, Jeffrey M.; Liang, Gangning; Wolff, Erika M.; Tsai, Yvonne C.; Ye, Wei; Jones, Peter A.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Urol Biochem & Mol Biol, Los Angeles, CA 90033 USA.
   [Liu, Chun-Chi; Zhou, Xianghong] Univ So Calif, Dept Mol & Computat Biol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California
RP Jones, PA (通讯作者)，Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Urol Biochem & Mol Biol, 1441 Easdake Ave, Los Angeles, CA 90033 USA.
EM gliang@usc.edu; jones_p@ccnt.usc.edu
OI Liang, Gangning/0000-0001-8664-922X
FU NIH [RO1 CA 83867]
FX Grant support: NIH grant RO1 CA 83867 and the NIH/National Institute of
   General Medical Sciences-supported training program in Cellular,
   Biochemical and Molecular Sciences at the University of Southern
   California.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bar M, 2008, STEM CELLS, V26, P2496, DOI 10.1634/stemcells.2008-0356
   Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lakshmipathy U, 2007, STEM CELLS DEV, V16, P1003, DOI 10.1089/scd.2007.0026
   Lee ER, 2007, STEM CELLS, V25, P2191, DOI 10.1634/stemcells.2007-0203
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Pasini D, 2004, CELL CYCLE, V3, P396
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110
   Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
NR 34
TC 325
Z9 366
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2009
VL 69
IS 6
BP 2623
EP 2629
DI 10.1158/0008-5472.CAN-08-3114
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 424BU
UT WOS:000264541300058
PM 19258506
OA Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Bloushtain-Qimron, N
   Yao, J
   Shipitsin, M
   Maruyama, R
   Polyak, K
AF Bloushtain-Qimron, Noga
   Yao, Jun
   Shipitsin, Michail
   Maruyama, Reo
   Polyak, Kornelia
TI Epigenetic patterns of embryonic and adult stem cells
SO CELL CYCLE
LA English
DT Article
DE stem cells; epigenetics; DNA methylation; chromatin
ID HUMAN MAMMARY-GLAND; HISTONE DEACETYLASE ACTIVITY; BREAST-CANCER CELLS;
   DNA METHYLATION; PROGENITOR CELLS; SELF-RENEWAL; DEVELOPMENTAL
   REGULATORS; CELLULAR-DIFFERENTIATION; POLYCOMB COMPLEXES; IN-VITRO
AB Embryonic stem (ES) cells are pluripotent cells that differentiate into all cell types of the organism. In adult, multipotent tissue-specific stem cells undergo multi-lineage differentiation to preserve normal tissue homeostasis and repair potential injuries. The maintenance of stem cells and their differentiation follows defined epigenetic programs, including DNA methylation, histone modifications and small non-coding RNAs that result in gene expression, morphologic and functional changes. Recently, we reported for the first time the comprehensive characterization of the in vivo gene expression and DNA methylation profiles of four distinct populations of normal human mammary epithelial cells and the identification of cell type-specific DNA methylation patterns with clinical relevance. Our results together with other studies suggest an important role for epigenetic regulation in stem cell self-renewal, pluripotency and differentiation, and imply that abnormalities in these processes may play a role in tumor initiation and progression.
C1 [Bloushtain-Qimron, Noga; Yao, Jun; Shipitsin, Michail; Maruyama, Reo; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Yao, Jun; Shipitsin, Michail; Maruyama, Reo; Polyak, Kornelia] Harvard Univ, Sch Med, Boston, MA USA.
   [Bloushtain-Qimron, Noga] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, Beer Sheva, Israel.
   [Bloushtain-Qimron, Noga] Ben Gurion Univ Negev, Canc Res Ctr, IL-84105 Beer Sheva, Israel.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard Medical School; Ben Gurion University; Ben Gurion University
RP Polyak, K (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM kornelia_polyak@dfci.harvard.edu
RI Polyak, Kornelia/ACJ-5837-2022
FU NIH [CA89393, CA116235, 5PO1CA080111]; DOD [W81XWH-07-1-0294]; ACS
   [RSG-05-154-01-MGO]
FX This work was supported in part by NIH (CA89393, CA116235 and
   5PO1CA080111), DOD (W81XWH-07-1-0294) and ACS (RSG-05-154-01-MGO) grants
   awarded to K. P.
CR ADEI OM, 2008, CURR TOP MED CHEM, V8, P841
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903
   Alvi AJ, 2002, BREAST CANCER RES, V5, DOI [10.1186/bcr547, 10.1186/bcr563]
   Attema JL, 2007, P NATL ACAD SCI USA, V104, P12371, DOI 10.1073/pnas.0704468104
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906
   Billard LM, 2002, ONCOGENE, V21, P2704, DOI 10.1038/sj/onc/1205357
   BLOUSHTAINQIMRO.N, 2008, P NATL ACAD SCI US
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Carlone DL, 2005, MOL CELL BIOL, V25, P4881, DOI 10.1128/MCB.25.12.4881-4891.2005
   Cheng LC, 2005, NEURON, V46, P363, DOI 10.1016/j.neuron.2005.04.027
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Clayton H, 2004, EXP CELL RES, V297, P444, DOI 10.1016/j.yexcr.2004.03.029
   Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010
   Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602
   Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899
   Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006
   Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Ivascu C, 2007, INT J BIOCHEM CELL B, V39, P1523, DOI 10.1016/j.biocel.2007.02.006
   Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004
   Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101
   Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177
   Lunyak VV, 2008, HUM MOL GENET, V17, pR28, DOI 10.1093/hmg/ddn149
   Marin-Husstege M, 2002, J NEUROSCI, V22, P10333
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017
   Miao F, 2008, J IMMUNOL, V180, P2264, DOI 10.4049/jimmunol.180.4.2264
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Oki Y, 2006, REV RECENT CLIN TRIA, V1, P169, DOI 10.2174/157488706776876490
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037
   Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Reiner SL, 2005, HUM MOL GENET, V14, pR41, DOI 10.1093/hmg/ddi115
   Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306
   Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Ruau D, 2008, STEM CELLS, V26, P920, DOI 10.1634/stemcells.2007-0649
   Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schmid CD, 2007, CELL, V131, P831, DOI 10.1016/j.cell.2007.11.017
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Shukla V, 2008, MUTAT RES-FUND MOL M, V637, P1, DOI 10.1016/j.mrfmmm.2007.07.012
   Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301
   Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1046/j.1432-0436.1998.6340201.x
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7
   Stingl J, 2006, CELL CYCLE, V5, P1519, DOI 10.4161/cc.5.14.2983
   Tadokoro Y, 2007, J EXP MED, V204, P715, DOI 10.1084/jem.20060750
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wong DJ, 2008, CELL CYCLE, V7, P3622, DOI 10.4161/cc.7.23.7104
   Wu H, 2006, PEDIATR RES, V59, p21R, DOI 10.1203/01.pdr.0000203565.76028.2a
   Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761
   Yuan E, 2006, CANCER RES, V66, P3443, DOI 10.1158/0008-5472.CAN-05-3739
   Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100
NR 87
TC 43
Z9 49
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD MAR 15
PY 2009
VL 8
IS 6
BP 809
EP 817
DI 10.4161/cc.8.6.7938
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 426KG
UT WOS:000264706600007
PM 19229128
OA Bronze
DA 2025-01-12
ER

PT J
AU Frank, MJ
   Dawson, DW
   Bensinger, SJ
   Hong, JS
   Knosp, WM
   Xu, LZ
   Balatoni, CE
   Allen, EL
   Shen, RR
   Bar-Sagi, D
   Martin, GR
   Teitell, MA
AF Frank, Matthew J.
   Dawson, David W.
   Bensinger, Steven J.
   Hong, Jason S.
   Knosp, Wendy M.
   Xu, Lizhong
   Balatoni, Cynthia E.
   Allen, Eric L.
   Shen, Rhine R.
   Bar-Sagi, Dafna
   Martin, Gail R.
   Teitell, Michael A.
TI Expression of sprouty2 inhibits B-cell proliferation and is
   epigenetically silenced in mouse and human B-cell lymphomas
SO BLOOD
LA English
DT Article
ID TCL1 ONCOGENE EXPRESSION; DNA METHYLATION; GERMINAL CENTER; T-CELL;
   DOWN-REGULATION; BREAST-CANCER; RAS ONCOGENES; ERK PATHWAY; H-RAS;
   TRANSFORMATION
AB B-cell lymphoma is the most common immune system malignancy. TCL1 transgenic mice (TCL1-tg), in which TCL1 is ectopically expressed in mature lymphocytes, develop multiple B- and T-cell leukemia and lymphoma subtypes, supporting an oncogenic role for TCL1 that probably involves AKT and MAPK-ERK signaling pathway augmentation. Additional, largely unknown genetic and epigenetic alterations cooperate with TCL1 during lymphoma progression. We examined DNA methylation patterns in TCL1-tg B-cell tumors to discover tumor-associated epigenetic changes, and identified hypermethylation of sprouty2 (Spry2). Sprouty proteins are context-dependent negative or positive regulators of MAPK-ERK pathway signaling, but their role(s) in B-cell physiology or pathology are unknown. Here we show that repression of Spry2 expression in TCL1-tg mouse and human B- cell lymphomas and cell lines is associated with dense DNA hypermethylation and was reversed by inhibition of DNA methylation. Spry2 expression was induced in normal splenic B cells by CD40/B-cell receptor costimulation and regulated a negative feedback loop that repressed MAPK-ERK signaling and decreased B- cell viability. Conversely, loss of Spry2 function hyperactivated MAPK-ERK signaling and caused increased B- cell proliferation. Combined, these results implicate epigenetic silencing of Spry2 expression in B lymphoma progression and suggest it as a companion lesion to ectopic TCL1 expression in enhancing MAPK-ERK pathway signaling. (Blood. 2009;113:2478-2487)
C1 [Frank, Matthew J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Dawson, David W.; Teitell, Michael A.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Bensinger, Steven J.] Univ Calif Los Angeles, Inst Mol Med, Los Angeles, CA 90095 USA.
   [Knosp, Wendy M.; Martin, Gail R.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
   [Knosp, Wendy M.; Martin, Gail R.] Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA.
   [Xu, Lizhong; Bar-Sagi, Dafna] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA.
   [Teitell, Michael A.] Univ Calif Los Angeles, Inst Mol Biol, NDC Ctr Cell Control, Broad Inst Regenerat Med & Stem Cell Res, Los Angeles, CA 90095 USA.
   [Teitell, Michael A.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco; New York University; University of California
   System; University of California Los Angeles; University of California
   System; University of California Los Angeles
RP Teitell, MA (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 10833 Conte Ave, Los Angeles, CA 90095 USA.
EM mteitell@ucla.edu
RI Dawson, David/I-5917-2014
OI Knosp, Wendy/0000-0002-6863-2026; Bar-Sagi, Dafna/0000-0003-2597-8948
FU National Institutes of Health [T32-AI052031, T32-GM08042, CA78711,
   CA90571, CA107300, PN2EY018228]; Leukemia & Lymphoma Society (White
   Plains, NY); National Institute of General Medical Sciences
   [T32GM008042] Funding Source: NIH RePORTER
FX The authors thank members of the University of California-Los Angeles
   Flow Cytometry Core Facility and Joshua Troke for technical assistance
   and David Warburton (Childrens Hospital Los Angeles) for providing human
   SPRY2 promoter-reporter constructs.This work was supported by National
   Institutes of Health (Bethesda, MD; grants T32-AI052031 and T32-GM08042,
   M.J.F.; grant CA78711, G. R. M.; and CA90571, CA107300, and PN2EY018228,
   M. A. T.). M. A. T. is a Scholar of the Leukemia & Lymphoma Society
   (White Plains, NY).
CR ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   BOS JL, 1989, CANCER RES, V49, P4682
   BRUNET A, 1994, ONCOGENE, V9, P3379
   Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1
   Choi H, 2006, J IMMUNOL, V176, P6034, DOI 10.4049/jimmunol.176.10.6034
   Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1
   Coughlin JJ, 2005, J IMMUNOL, V175, P7179, DOI 10.4049/jimmunol.175.11.7179
   Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003
   Craxton A, 2005, J EXP MED, V202, P1363, DOI 10.1084/jem.20051283
   Daniel J, 2007, BIOCHEM PHARMACOL, V73, P831, DOI 10.1016/j.bcp.2006.11.024
   Dawson DW, 2007, ONCOGENE, V26, P4243, DOI 10.1038/sj.onc.1210211
   Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072
   French SW, 2002, CLIN IMMUNOL, V103, P217, DOI 10.1006/clim.2002.5186
   Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190
   Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8
   Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoyer KK, 2005, J IMMUNOL, V175, P864, DOI 10.4049/jimmunol.175.2.864
   Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199
   Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087
   Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400
   Kuraishy AI, 2007, P NATL ACAD SCI USA, V104, P10175, DOI 10.1073/pnas.0704170104
   LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917
   Lee JW, 2003, BRIT J CANCER, V89, P1958, DOI 10.1038/sj.bjc.6601371
   Lito P, 2008, J BIOL CHEM, V283, P2002, DOI 10.1074/jbc.M709046200
   Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032
   Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207
   Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004
   McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371
   Miin Wong Esther Sook, 2006, V327, P61
   Mizuno T, 2005, J IMMUNOL, V174, P3369, DOI 10.4049/jimmunol.174.6.3369
   Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246
   NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268
   OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723
   Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295
   Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8
   Rui LX, 2006, J IMMUNOL, V177, P5337, DOI 10.4049/jimmunol.177.8.5337
   Rush LJ, 2004, CANCER RES, V64, P2424, DOI 10.1158/0008-5472.CAN-03-2870
   Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264
   Sánchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129
   Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207
   Shen RR, 2006, BLOOD, V108, P1991, DOI 10.1182/blood-2006-02-001354
   Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009
   Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26
   STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431
   Sutterlüty H, 2007, MOL CANCER RES, V5, P509, DOI 10.1158/1541-7786.MCR-06-0273
   Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101
   Takahashi Y, 2005, IMMUNITY, V23, P127, DOI 10.1016/j.immuni.2005.06.010
   Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809
   Teitell MA, 2005, AM J CLIN PATHOL, V124, P569, DOI 10.1309/77V7U4E03V69QHRR
   Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672
   Wheeler K, 1996, INT IMMUNOL, V8, P815, DOI 10.1093/intimm/8.6.815
NR 59
TC 47
Z9 55
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 12
PY 2009
VL 113
IS 11
BP 2478
EP 2487
DI 10.1182/blood-2008-05-156943
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 417XA
UT WOS:000264110600016
PM 19147787
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Serafino, A
   Balestrieri, E
   Pierimarchi, P
   Matteucci, C
   Moroni, G
   Oricchio, E
   Rasi, G
   Mastino, A
   Spadafora, C
   Garaci, E
   Vallebona, PS
AF Serafino, A.
   Balestrieri, E.
   Pierimarchi, P.
   Matteucci, C.
   Moroni, G.
   Oricchio, E.
   Rasi, G.
   Mastino, A.
   Spadafora, C.
   Garaci, E.
   Vallebona, P. Sinibaldi
TI The activation of human endogenous retrovirus K (HERV-K) is implicated
   in melanoma cell malignant transformation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Human endogenous retrovirus; Human melanoma cells; Retroviral particle
   production; Malignant phenotype; Melanoma progression
ID ENV GENE-EXPRESSION; HUMAN-BREAST-CANCER; REVERSE-TRANSCRIPTASE;
   T-LYMPHOCYTES; HUMAN GENOME; DIFFERENTIATION; SEQUENCES; PARTICLES;
   ELEMENTS; ANTIGENS
AB Melanoma development is a multi-step process arising from a series of genetic and epigenetic events. Although the sequential stages involved in progression from melanocytes to malignant melanoma are clearly defined, our current understanding of the mechanisms leading to melanoma onset is still incomplete. Growing evidence show that the activation of endogenous retroviral sequences might be involved in transformation of melanocytes as well as in the increased ability of melanoma cells to escape immune Surveillance. Here we show that human melanoma cells in vitro undergo a transition from adherent to a more malignant, non-adherent phenotype when exposed to stress conditions. Melanoma-derived non-adherent cells are characterized by an increased proliferative potential and a decreased expression of both HLA class I molecules and Melan-A/ MART-1 antigen, similarly to highly malignant cells. These phenotypic and functional modifications are accompanied by the activation of human endogenous retrovirus K expression (HERV-K) and massive production of viral-like particles. Down-regulation of HERV-K expression by RNA interference prevents the transition from the adherent to the non-adherent growth phenotype in low serum. These results implicate HERV-K in at least some critical steps of melanoma progression. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Serafino, A.; Pierimarchi, P.; Rasi, G.] CNR, Inst Neurobiol & Mol Med ARTOV, I-00133 Rome, Italy.
   [Balestrieri, E.; Matteucci, C.; Moroni, G.; Oricchio, E.; Garaci, E.; Vallebona, P. Sinibaldi] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy.
   [Mastino, A.] Univ Messina, Dept Life Sci, I-98166 Messina, Italy.
   [Oricchio, E.; Spadafora, C.] Ist Super Sanita, I-00161 Rome, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor
   Vergata; University of Messina; Istituto Superiore di Sanita (ISS)
RP Serafino, A (通讯作者)，CNR, Inst Neurobiol & Mol Med ARTOV, Via Fosso Cavaliere 100, I-00133 Rome, Italy.
EM annalucia.serafino@artov.inmm.cnr.it
RI Pierimarchi, Pasquale/AAX-2833-2020; Matteucci, Claudia/AGH-6605-2022;
   Serafino, Annalucia/AAC-1719-2019; Mastino, Antonio/A-4686-2008; GARACI,
   ENRICO/AAB-3349-2021; RASI, GUIDO/AAC-8172-2021
OI MATTEUCCI, CLAUDIA/0000-0002-6058-1092; SINIBALDI VALLEBONA,
   PAOLA/0000-0002-8186-9861; SERAFINO, ANNALUCIA/0000-0002-1142-4752;
   Spadafora, Corrado/0000-0002-5743-3224; RASI, GUIDO/0000-0002-2191-1386;
   Oricchio, Elisa/0000-0002-1690-0447; Moroni,
   Gabriella/0000-0002-1215-423X; balestrieri, emanuela/0000-0001-5906-5907
FU Italian Ministry of Education; University and Research; National
   Interest
FX The authors would like to thank Dr. Patrizia Lavia for her critical
   reading of the manuscript, Federica Andreola, Manuela Zonfrillo and
   Fabio Falcione for their precious technical assistance, Martino Tony
   Miele for his excellent secretarial assistance and Dr. Paolo Daniele
   Siviero for advice on Intellectual Property Right.This work was
   supported by a grant from the Italian Ministry of Education, University
   and Research, Research Project of National Interest, to E. Garaci.
CR Bannert N, 2004, P NATL ACAD SCI USA, V101, P14572, DOI 10.1073/pnas.0404838101
   Belshaw R, 2005, J VIROL, V79, P12507, DOI 10.1128/JVI.79.19.12507-12514.2005
   Bieda K, 2001, J GEN VIROL, V82, P591, DOI 10.1099/0022-1317-82-3-591
   Boyd MT, 1997, BLOOD, V90, P4022, DOI 10.1182/blood.V90.10.4022
   Busam KJ, 1998, AM J SURG PATHOL, V22, P976, DOI 10.1097/00000478-199808000-00007
   Büscher K, 2005, CANCER RES, V65, P4172, DOI 10.1158/0008-5472.CAN-04-2983
   Depil S, 2002, LEUKEMIA, V16, P254, DOI 10.1038/sj.leu.2402355
   Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Flockerzi A, 2005, J VIROL, V79, P2941, DOI 10.1128/JVI.79.5.2941-2949.2005
   Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129
   Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290
   Geertsen RC, 1998, J INVEST DERMATOL, V111, P497, DOI 10.1046/j.1523-1747.1998.00305.x
   Gifford R, 2003, VIRUS GENES, V26, P291, DOI 10.1023/A:1024455415443
   Hagan Christy R, 2002, Am J Pharmacogenomics, V2, P25, DOI 10.2165/00129785-200202010-00003
   Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210
   Herbst H, 1996, AM J PATHOL, V149, P1727
   Hohenadl C, 1999, J INVEST DERMATOL, V113, P587, DOI 10.1046/j.1523-1747.1999.00728.x
   Hughes JR, 2005, GENETICS, V171, P1183, DOI 10.1534/genetics.105.043976
   Johnston JB, 2001, ANN NEUROL, V50, P434, DOI 10.1002/ana.1131
   KALTER SS, 1973, JNCI-J NATL CANCER I, V50, P1081, DOI 10.1093/jnci/50.4.1081
   Katsumata K, 1999, CLIN IMMUNOL, V93, P75, DOI 10.1006/clim.1999.4762
   Khan AS, 2001, VIRUS RES, V79, P39, DOI 10.1016/S0168-1702(01)00280-5
   Kirkin AF, 1998, APMIS, V106, P665, DOI 10.1111/j.1699-0463.1998.tb00210.x
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367
   Lee YN, 2007, PLOS PATHOG, V3, P119, DOI 10.1371/journal.ppat.0030010
   Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177
   LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480
   Maeurer MJ, 1996, J CLIN INVEST, V98, P1633, DOI 10.1172/JCI118958
   Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354
   Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766
   Melino G, 1993, CLIN CHEM ENZYM COMM, V6, P105
   Mills RE, 2007, TRENDS GENET, V23, P183, DOI 10.1016/j.tig.2007.02.006
   Moyes D, 2007, TRENDS GENET, V23, P326, DOI 10.1016/j.tig.2007.05.004
   Muster T, 2003, CANCER RES, V63, P8735
   Okahara G, 2004, GENOMICS, V84, P982, DOI 10.1016/j.ygeno.2004.09.004
   ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987
   ORGEL LE, 1980, NATURE, V288, P645, DOI 10.1038/288645a0
   Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214
   PRICE JE, 1986, JNCI-J NATL CANCER I, V77, P529
   Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562
   Seifarth W, 2005, J VIROL, V79, P341, DOI 10.1128/JVI.79.1.341-352.2005
   Seifarth W, 1998, J VIROL, V72, P8384, DOI 10.1128/JVI.72.10.8384-8391.1998
   Serafino A, 2004, FASEB J, V18, P1940, DOI 10.1096/fj.04-1925fje
   Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266
   Stauffer Yves, 2004, Cancer Immun, V4, P2
   URADE M, 1984, JNCI-J NATL CANCER I, V73, P1039
   VandenEynde BJ, 1997, INT J CLIN LAB RES, V27, P81, DOI 10.1007/BF02912440
   Wang-Johanning F, 2003, ONCOGENE, V22, P1528, DOI 10.1038/sj.onc.1206241
NR 50
TC 109
Z9 122
U1 2
U2 12
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD MAR 10
PY 2009
VL 315
IS 5
BP 849
EP 862
DI 10.1016/j.yexcr.2008.12.023
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 414JH
UT WOS:000263859200011
PM 19167380
DA 2025-01-12
ER

PT J
AU Carraway, HE
   Wang, S
   Blackford, A
   Guo, M
   Powers, P
   Jeter, S
   Davidson, NE
   Argani, P
   Terrell, K
   Herman, JG
   Lange, JR
AF Carraway, Hetty E.
   Wang, Shelun
   Blackford, Amanda
   Guo, Mingzho
   Powers, Penny
   Jeter, Stacie
   Davidson, Nancy E.
   Argani, Pedram
   Terrell, Kyle
   Herman, James G.
   Lange, Julie R.
TI Promoter hypermethylation in sentinel lymph nodes as a marker for breast
   cancer recurrence
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Bisulfite treatment; CpG Island; DNA methylation; Epigenetics;
   Methylation specific PCR; Nested MSP; Sentinel node
ID ROUTINE AXILLARY DISSECTION; GENE-EXPRESSION; DNA METHYLATION;
   EPITHELIAL-CELLS; COLORECTAL-CANCER; SURVIVAL; TRANSPORT; BIOPSY;
   CHROMATIN; LUNG
AB Purpose Promoter methylation of tumor suppressor genes in histologically negative sentinel lymph nodes (HNSN) of early stage breast cancer patients has not been extensively studied. This study evaluates the methylation frequency and pattern in HNSN to determine if detection of hypermethylation of one or more genes is associated with an increased recurrence risk in node negative breast cancer. Experimental design In 1998, a prospective study of patients with early stage breast cancer and HNSN was initiated in order to correlate sentinel node analysis with clinical outcome. Nodal tissue was selected from 120 HNSN patients for methylation analysis in at least one and up to six sentinel nodes using a panel of nine genes. Corresponding primary breast tumors from 79 patients were also evaluated for hypermethylation. Methylation analysis was performed using nested Methylation Sensitive PCR (n-MSP). Logistical regression was used to evaluate the relationship between clinical recurrence and methylation status. Results Over a median follow-up of 79 months, 13 of the 120 patients had clinical recurrence. Hypermethylation of genes was frequently observed in HNSN, but there was no correlation of methylation pattern and clinical recurrence. However, increased frequency of gene methylation of the primary tumor correlated with clinical recurrence. Conclusions Although hypermethylation of multiple genes occurs frequently in HNSN of breast cancer patients, it is not associated with breast cancer recurrence in the first 7 years of clinical follow-up.
C1 [Carraway, Hetty E.; Guo, Mingzho; Powers, Penny; Jeter, Stacie; Davidson, Nancy E.; Herman, James G.] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA.
   [Wang, Shelun] Dept Internal Med, Div Oncol, Beijing, Peoples R China.
   [Blackford, Amanda] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21205 USA.
   [Argani, Pedram] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21231 USA.
   [Terrell, Kyle; Lange, Julie R.] Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine
RP Carraway, HE (通讯作者)，Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,Canc Res Bldg I,Room 290, Baltimore, MD 21231 USA.
EM Hcarraw1@jhmi.edu
RI Carraway, Hetty/AAR-4977-2020
FU Flight Attendant Medical Research Institute (FAMRI); Department of
   Defense Breast Cancer Research Program (BCRP) of the Office of
   Congressionally Directed Medical Research Programs (CDMRP); NIH
   [CA88843]; Belfer and Avon Foundations
FX This work was funded by the Flight Attendant Medical Research Institute
   (FAMRI), the Department of Defense Breast Cancer Research Program (BCRP)
   of the Office of Congressionally Directed Medical Research Programs
   (CDMRP), the NIH CA88843, and the Belfer and Avon Foundations. We extend
   our gratitude to agencies like these that enable scientific pursuits for
   the benefit of all cancer patients.
CR Aoki Rika, 2007, J Med Invest, V54, P159, DOI 10.2152/jmi.54.159
   Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664
   Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051
   Bleiweiss IJ, 2006, J CLIN ONCOL, V24, P2013, DOI 10.1200/JCO.2005.04.7076
   Cady B, 1996, ARCH SURG-CHICAGO, V131, P301
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Carter BA, 2000, AM J CLIN PATHOL, V113, P259, DOI 10.1309/7EF8-F1W7-YVNT-H8H5
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Diaz NM, 2005, ADV ANAT PATHOL, V12, P7, DOI 10.1097/01.pap.0000151267.34438.a1
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0
   Gnerlich J, 2007, ANN SURG ONCOL, V14, P2187, DOI 10.1245/s10434-007-9438-0
   GRAFF JR, 1995, CANCER RES, V55, P5195
   GROEN RS, 2007, BREAST CANC RES TREA, V100, P229
   Herbert GS, 2007, AM J SURG, V193, P571, DOI 10.1016/j.amjsurg.2007.01.007
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jatoi I, 1999, J CLIN ONCOL, V17, P2334, DOI 10.1200/JCO.1999.17.8.2334
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3
   Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134
   Kahn HJ, 2006, BREAST J, V12, P294, DOI 10.1111/j.1075-122X.2006.00267.x
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Machida EO, 2006, CANCER RES, V66, P6210, DOI 10.1158/0008-5472.CAN-05-4447
   McMasters KM, 2000, J CLIN ONCOL, V18, P2560, DOI 10.1200/JCO.2000.18.13.2560
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   Pargaonkar AS, 2003, ARCH PATHOL LAB MED, V127, P701
   Pellikainen J, 2002, CLIN CANCER RES, V8, P3487
   ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355
   Sanchez-Cespedes M, 1999, CLIN CANCER RES, V5, P2450
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Engeland M, 2003, CANCER RES, V63, P3133
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782
   Veronesi U, 2001, EUR J CANCER, V37, P454, DOI 10.1016/S0959-8049(00)00410-X
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 47
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAR
PY 2009
VL 114
IS 2
BP 315
EP 325
DI 10.1007/s10549-008-0004-7
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 403GH
UT WOS:000263070600013
PM 18404369
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Vasilatos, SN
   Broadwater, G
   Barry, WT
   Baker, JC
   Lem, S
   Dietze, EC
   Bean, GR
   Bryson, AD
   Pilie, PG
   Goldenberg, V
   Skaar, D
   Paisie, C
   Torres-Hemandez, A
   Grant, TL
   Wilke, LG
   Ibarra-Drendall, C
   Ostrander, JH
   D'Amato, NC
   Zalles, C
   Jirtle, R
   Weaver, VM
   Seewaldt, VL
AF Vasilatos, Shauna N.
   Broadwater, Gloria
   Barry, William T.
   Baker, Joseph C., Jr.
   Lem, Siya
   dietze, Eric C.
   Bean, Gregory R.
   Bryson, Andrew D.
   Pilie, Patrick G.
   Goldenberg, Vanessa
   Skaar, David
   Paisie, Carolyn
   Torres-Hemandez, Alejandro
   Grant, Tracey L.
   Wilke, Lee G.
   Ibarra-Drendall, Catherine
   Ostrander, Julie H.
   D'Amato, Nicholas C.
   Zalles, Carola
   Jirtle, Randy
   Weaver, Valerie M.
   Seewaldt, Victoria L.
TI CpG Island Tumor Suppressor Promoter Methylation in Non-BRCA-Associated
   Early Mammary Carcinogenesis
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID ACID RECEPTOR-BETA; FINE-NEEDLE-ASPIRATION; BREAST-CANCER CELLS;
   COLORECTAL-CANCER; EPITHELIAL-CELLS; DNA METHYLATION; SPORADIC BREAST;
   PHENOTYPE CIMP; MICROSATELLITE INSTABILITY; EPIGENETIC CHANGES
AB Background: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known.
   Methods: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1.
   Results: Although the overall frequency of CpG island promoter methylation events increased with age (P < 0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P = 0.051), INK4a/ARF (P = 0.042), HIN-1 (P = 0.044), and PRA (P = 0.032), as well as the overall frequency of methylation events (P = 0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had :54 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P < 0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters.
   Conclusions: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2 familial breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(3):901-14)
C1 [Vasilatos, Shauna N.; Baker, Joseph C., Jr.; Lem, Siya; dietze, Eric C.; Bean, Gregory R.; Bryson, Andrew D.; Pilie, Patrick G.; Goldenberg, Vanessa; Skaar, David; Paisie, Carolyn; Torres-Hemandez, Alejandro; Grant, Tracey L.; Ibarra-Drendall, Catherine; Ostrander, Julie H.; Jirtle, Randy; Seewaldt, Victoria L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Wilke, Lee G.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   [D'Amato, Nicholas C.] Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA.
   [D'Amato, Nicholas C.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA.
   [Broadwater, Gloria; Barry, William T.] Duke Univ, Med Ctr, Canc Ctr Biostat, Durham, NC 27710 USA.
   [Zalles, Carola] Yale New Haven Med Ctr, Dept Pathol, New Haven, CT 06504 USA.
   [Weaver, Valerie M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
C3 Duke University; Duke University; Duke University; Duke University; Duke
   University; Yale University; University of California System; University
   of California San Francisco
RP Seewaldt, VL (通讯作者)，Duke Univ, Med Ctr, Dept Med, Box 2628, Durham, NC 27710 USA.
EM seewa001@mc.duke.edu
OI Weaver, Valerie marie/0000-0003-4786-6752
FU NIH/National Cancer Institute [CA68438-AV13]; Susan G. Komen Breast
   Cancer award [2P30CA14236-26, R01CA88799, R01CA98441, R01CA114068];
   V-Foundation award
FX NIH/National Cancer Institute grants CA68438-AV13 (AVON/National Cancer
   Institute Partners in Progress), 2P30CA14236-26, R01CA88799, R01CA98441,
   and R01CA114068, Susan G. Komen Breast Cancer award BCTR061314, and
   V-Foundation award (V.L. Seewaldt).
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baker JC, 2008, CANCER EPIDEM BIOMAR, V17, P1884, DOI 10.1158/1055-9965.EPI-07-2696
   Baldwin RL, 2000, CANCER RES, V60, P5329
   BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bean GR, 2005, CANCER EPIDEM BIOMAR, V14, P790, DOI 10.1158/1055-9965.EPI-04-0580
   Bean GR, 2007, CLIN CANCER RES, V13, P6834, DOI 10.1158/1078-0432.CCR-07-0407
   Bean GR, 2007, CANCER EPIDEM BIOMAR, V16, P50, DOI 10.1158/1055-9965.EPI-06-0598
   Bean GR, 2006, NEW ENGL J MED, V355, P1620, DOI 10.1056/NEJMc061954
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bistulfi G, 2006, CANCER RES, V66, P10308, DOI 10.1158/0008-5472.CAN-06-1052
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Campan M, 2006, CURR TOP MICROBIOL, V310, P141
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Curtin K, 2007, CARCINOGENESIS, V28, P1672, DOI 10.1093/carcin/bgm089
   Dammann R, 2001, CANCER RES, V61, P3105
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, CANCER RES, V62, P5902
   Euhus D M, 2001, Breast J, V7, P224, DOI 10.1046/j.1524-4741.2001.20012.x
   Fabian CJ, 2001, ANN NY ACAD SCI, V952, P44, DOI 10.1111/j.1749-6632.2001.tb02727.x
   Fabian CJ, 2000, JNCI-J NATL CANCER I, V92, P1217, DOI 10.1093/jnci/92.15.1217
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kawasaki T, 2007, NEOPLASIA, V9, P569, DOI 10.1593/neo.07334
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Krop I, 2003, CANCER RES, V63, P2024
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lee ES, 2008, CLIN CANCER RES, V14, P2664, DOI 10.1158/1078-0432.CCR-07-1232
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MASOOD S, 1990, CANCER-AM CANCER SOC, V66, P1480, DOI 10.1002/1097-0142(19901001)66:7<1480::AID-CNCR2820660708>3.0.CO;2-O
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738
   Mote PA, 2004, GENE CHROMOSOME CANC, V39, P236, DOI 10.1002/gcc.10321
   Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1
   Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x
   Ogino S, 2007, J MOL DIAGN, V9, P305, DOI 10.2353/jmoldx.2007.060170
   Ogino S, 2007, HUM PATHOL, V38, P614, DOI 10.1016/j.humpath.2006.10.005
   Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sasaki M, 2001, CANCER RES, V61, P97
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694
   Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Treuting PM, 2002, BREAST CANCER RES TR, V72, P79, DOI 10.1023/A:1014906529407
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Zalles C., 1995, The Breast Journal, V1, P343, DOI 10.1111/j.1524-4741.1995.tb00260.x
NR 68
TC 38
Z9 43
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAR
PY 2009
VL 18
IS 3
BP 901
EP 914
DI 10.1158/1055-9965.EPI-08-0875
PG 14
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 419NK
UT WOS:000264226100030
PM 19258476
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Parsons, MJ
   Patel, P
   Brat, DJ
   Colbert, L
   Vertino, PM
AF Parsons, Melissa J.
   Patel, Pritty
   Brat, Daniel J.
   Colbert, Laronna
   Vertino, Paula M.
TI Silencing of TMS1/ASC Promotes Resistance to Anoikis in Breast
   Epithelial Cells
SO CANCER RESEARCH
LA English
DT Article
ID RECRUITMENT DOMAIN PROTEIN; APOPTOSIS; CASPASE-8; METHYLATION; PATHWAY;
   CANCER; ASC; MOTILITY; ADHESION; ADAPTER
AB Ductal carcinoma in situ (DCIS) is characterized by ductal epithelial cells that have filled the luminal space of the breast duct and survive despite loss of extracellular matrix contact. In normal epithelial cells, the loss of such contact triggers a form of apoptosis known as detachment-induced apoptosis or "anoikis." TMS1/ASC is a bipartite adaptor molecule that participates in inflammatory and apoptotic signaling pathways. Epigenetic silencing of TMS1 has been observed in a significant proportion of human breast and other cancers, but the mechanism by which TMS-1 silencing contributes to carcinogenesis is unknown. Here, we examined the role of TMS1 in anoikis. We found that TMS1 expression is induced in response to loss of substratum interactions in breast epithelia] cells. siRNA-mediated knockdown of TMSI leads to anoikis resistance, due in part to the persistent activation of extracellular signal-regulated kinase and an impaired ability to up-regulate the BH3-only protein Bim. We further show that the detachment-induced cleavage of procaspase-8, a newly described mediator of cellular adhesion, is significantly inhibited in the absence of TMS1. These data show a novel upstream role for TMS1 in the promotion of anoikis, and suggest that silencing of TMS1 may contribute to the pathogenesis of breast cancer by allowing epithelial cells to bypass cell death in the early stages of breast cancer development. This conclusion is supported by in vivo data showing that TMS1 is selectively down-regulated in the aberrant epithelial cells filling the lumen of the breast duct in a subset of primary DCIS lesions. [Cancer Res 2009;69(5): 1706-11]
C1 [Parsons, Melissa J.; Patel, Pritty] Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA.
   [Vertino, Paula M.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Brat, Daniel J.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Brat, Daniel J.; Colbert, Laronna; Vertino, Paula M.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University; Emory University
RP Vertino, PM (通讯作者)，1365-C Clifton Rd NE, Atlanta, GA 30322 USA.
EM pvertin@emory.edu
FU National Cancer Institute [2RO1-CA077337]; American Cancer Society
   [RSG-02-144-01]; Department of Defense/Breast [Predoctoral Fellowship];
   Department of Homeland Security ORISE; Cancer Program
   [DAMD-17-03-1-0578, DAMD-W81XWH-08-1-0390]; Georgia Cancer Coalition
   [Distinguished Cancer Scholar]
FX National Cancer Institute (2RO1-CA077337) and the American Cancer
   Society (RSG-02-144-01; P.M. Vertino), a Predoctoral fellowship from the
   Department of Defense/Breast. Cancer Program fellowship
   (DAMD-17-03-1-0578; M.J. Parsons),and a Department of Homeland Security
   ORISE and Department of Defense/Breast. Cancer Program
   (DAMD-W81XWH-08-1-0390) fellowships (P. Patel). P.M. Vertino is a
   Georgia Cancer Coalition Distinguished Cancer Scholar.
CR Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Barbero S, 2008, J BIOL CHEM, V283, P13031, DOI 10.1074/jbc.M800549200
   Collard RL, 2006, PROSTATE, V66, P687, DOI 10.1002/pros.20371
   Conway KE, 2000, CANCER RES, V60, P6236
   Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Finlay D, 2007, CANCER RES, V67, P11704, DOI 10.1158/0008-5472.CAN-07-1906
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Hasegawa M, 2007, ONCOGENE, V26, P1748, DOI 10.1038/sj.onc.1209965
   Helfer B, 2006, CANCER RES, V66, P4273, DOI 10.1158/0008-5472.CAN-05-4183
   Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364
   Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7
   Mawji IA, 2007, CANCER RES, V67, P8307, DOI 10.1158/0008-5472.CAN-07-1687
   McConnell BB, 2000, CANCER RES, V60, P6243
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026
   Rytömaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0
   Senft J, 2007, CANCER RES, V67, P11505, DOI 10.1158/0008-5472.CAN-07-5755
   Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7
   Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200
   Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027
NR 23
TC 23
Z9 29
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2009
VL 69
IS 5
BP 1706
EP 1711
DI 10.1158/0008-5472.CAN-08-2351
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 415ML
UT WOS:000263937800003
PM 19223547
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Huang, CC
   Gadd, S
   Breslow, N
   Cutcliffe, C
   Sredni, ST
   Helenowski, IB
   Dome, JS
   Grundy, PE
   Green, DM
   Fritsch, MK
   Perlman, EJ
AF Huang, Chiang-Ching
   Gadd, Samantha
   Breslow, Norman
   Cutcliffe, Colleen
   Sredni, Simone T.
   Helenowski, Irene B.
   Dome, Jeffrey S.
   Grundy, Paul E.
   Green, Daniel M.
   Fritsch, Michael K.
   Perlman, Elizabeth J.
TI Predicting Relapse in Favorable Histology Wilms Tumor Using Gene
   Expression Analysis: A Report from the Renal Tumor Committee of the
   Children's Oncology Group
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CANCER-CELLS; PROGNOSTIC CLASSIFICATION; BREAST-CANCER; BETA-CATENIN;
   COLON-CANCER; STAGE-III; GROWTH; SUPPRESSOR; METHYLATION; PERIOSTIN
AB Purpose: The past two decades has seen significant improvement in the overall survival of patients with favorable histology Wilms tumor (FHWT); however, this progress has reached a plateau. Further improvements may rely on the ability to better stratify patients by risk of relapse. This study determines the feasibility and potential clinical utility of classifiers of relapse based on global gene expression analysis.
   Experimental Design: Two hundred fifty FHWT of all stages enriched for relapses treated on National Wilms Tumor Study-5 passed quality variables and were suitable for analysis using oligonucleoticle arrays. Relapse risk stratification used support vector machine; 2- and 10-fold cross-validations were applied.
   Results: The number of genes associated with relapse was less than that predicted by chance alone for 106 patients (32 relapses) with stages I and II FHWT treated with chemotherapy, and no further analyses were done. This number was greater than expected by chance for 76 local stage III patients. Cross-validation including an additional 68 local stage III patients (total 144 patients, 53 relapses) showed that classifiers for relapse composed of 50 genes were associated with a median sensitivity of 47% and specificity of 70%.
   Conclusions: This study shows the feasibility and modest accuracy of stratifying local stage III FHWT using a classifier of <50 genes. Validation using an independent patient population is needed. Analysis of genes differentially expressed in relapse patients revealed apoptosis, Writ signaling, insulin-like growth factor pathway, and epigenetic modification to be mechanisms important in relapse. Potential therapeutic targets include FRAP/MTOR and CD40.
C1 [Huang, Chiang-Ching; Helenowski, Irene B.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   [Gadd, Samantha; Cutcliffe, Colleen; Sredni, Simone T.; Perlman, Elizabeth J.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.
   [Gadd, Samantha; Cutcliffe, Colleen; Sredni, Simone T.; Perlman, Elizabeth J.] Robert H Lurie Canc Ctr, Chicago, IL USA.
   [Breslow, Norman] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Breslow, Norman] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Dome, Jeffrey S.] Childrens Natl Med Ctr, Div Oncol, Washington, DC 20010 USA.
   [Grundy, Paul E.] Cross Canc Inst, Dept Pediat & Oncol, Edmonton, AB T6G 1Z2, Canada.
   [Grundy, Paul E.] Univ Alberta, Edmonton, AB, Canada.
   [Green, Daniel M.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN USA.
   [Fritsch, Michael K.] Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine; Robert H. Lurie Comprehensive
   Cancer Center; University of Washington; University of Washington
   Seattle; Fred Hutchinson Cancer Center; Children's National Health
   System; University of Alberta; University of Alberta; St Jude Children's
   Research Hospital; University of Wisconsin System; University of
   Wisconsin Madison
RP Perlman, EJ (通讯作者)，Childrens Mem Hosp, 2300 Childrens Plaza,Box 17, Chicago, IL 60614 USA.
EM EPerlman@childrensmemorial.org
OI Sredni, Simone/0000-0002-1715-3885; Gadd, Samantha/0000-0001-5033-8585;
   Perlman, Elizabeth/0000-0001-6853-6221
FU NIH grants [U10CA42326, U10CA98543, U01CA88131]
FX NIH grants U10CA42326 (N. Breslow, D.M. Green, and E.J. Perlman),
   U10CA98543 (J.S. Dome, P.E. Grundy, and E.J. Perlman), and U01CA88131
   (E.J. Perlman).
CR [Anonymous], 1998, STAT LEARNING THEORY
   Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9
   BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U
   Bellone G, 2001, EUR J CANCER, V37, P224, DOI 10.1016/S0959-8049(00)00391-9
   Bentov I, 2003, ENDOCRINOLOGY, V144, P4276, DOI 10.1210/en.2003-0400
   Bonavida B, 2005, BIOMARKERS, V10, pS69, DOI 10.1080/13547500500216827
   Breslow NE, 2004, CANCER-AM CANCER SOC, V101, P1072, DOI 10.1002/cncr.20433
   Cho CY, 2007, J CELL PHYSIOL, V213, P65, DOI 10.1002/jcp.21089
   Dallman C, 2003, APOPTOSIS, V8, P45, DOI 10.1023/A:1021696902187
   Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050
   Dowdy SC, 2005, GYNECOL ONCOL, V99, P126, DOI 10.1016/j.ygyno.2005.05.036
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Granérus M, 2001, J CLIN PATHOL-MOL PA, V54, P30, DOI 10.1136/mp.54.1.30
   Green DM, 2004, J CLIN ONCOL, V22, P1366, DOI 10.1200/JCO.2004.08.008
   Green DM, 2001, J CLIN ONCOL, V19, P3719, DOI 10.1200/JCO.2001.19.17.3719
   Grundy PE, 2005, J CLIN ONCOL, V23, P7312, DOI 10.1200/JCO.2005.01.2799
   Grundy RG, 2004, PEDIATR BLOOD CANCER, V42, P311, DOI 10.1002/pbc.10477
   Hanavadi S, 2006, ANN SURG ONCOL, V13, P802, DOI 10.1245/ASO.2006.05.028
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Huang CC, 2006, PEDIATR BLOOD CANCER, V46, P728, DOI 10.1002/pbc.20773
   Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287
   Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151
   Kim CJ, 2005, INT J CANCER, V117, P51, DOI 10.1002/ijc.21120
   Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947
   Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008-5472.CAN-05-4540
   Kuefer R, 2006, NEOPLASIA, V8, P319, DOI 10.1593/neo.05682
   Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831
   Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532
   Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467
   Lu YJ, 2002, LANCET, V360, P385, DOI 10.1016/S0140-6736(02)09596-X
   Maiti S, 2000, CANCER RES, V60, P6288
   Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515
   Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0
   Natrajan R, 2006, J PATHOL, V210, P49, DOI 10.1002/path.2021
   Natrajan R, 2006, CANCER RES, V66, P11148, DOI 10.1158/0008-5472.CAN-06-1931
   Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031
   Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538
   Reichling T, 2005, CANCER RES, V65, P166
   Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509
   Shimokawa T, 2003, CANCER RES, V63, P6116
   Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Takino T, 2005, J BIOL CHEM, V280, P37772, DOI 10.1074/jbc.M505241200
   Tirrò E, 2006, CANCER RES, V66, P4263, DOI 10.1158/0008-5472.CAN-05-3248
   Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230
   Williams RD, 2004, GENE CHROMOSOME CANC, V41, P65, DOI 10.1002/gcc.20060
   Wright KO, 2002, J UROLOGY, V168, P2645, DOI 10.1016/S0022-5347(05)64236-X
   Zhang L, 2003, NAT BIOTECHNOL, V21, P818, DOI 10.1038/nbt836
   Zirn B, 2006, INT J CANCER, V118, P1954, DOI 10.1002/ijc.21564
NR 49
TC 40
Z9 45
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 1
PY 2009
VL 15
IS 5
BP 1770
EP 1778
DI 10.1158/1078-0432.CCR-08-1030
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 414GM
UT WOS:000263851900031
PM 19208794
OA Bronze, Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Eeckhoute, J
   Lupien, M
   Meyer, CA
   Verzi, MP
   Shivdasani, RA
   Liu, XS
   Brown, M
AF Eeckhoute, Jerrome
   Lupien, Mathieu
   Meyer, Clifford A.
   Verzi, Michael P.
   Shivdasani, Ramesh A.
   Liu, X. Shirley
   Brown, Myles
TI Cell-type selective chromatin remodeling defines the active subset of
   FOXA1-bound enhancers
SO GENOME RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; GENOME-WIDE ANALYSIS; TISSUE-SPECIFIC ENHANCERS;
   ALPHA-BINDING-SITES; ESTROGEN-RECEPTOR; BREAST-CANCER; TRANSCRIPTION
   FACTORS; ANDROGEN RECEPTOR; GENE-EXPRESSION; CHIP-CHIP
AB Selective activity of a specific set of enhancers defines tissue-specific gene transcription. The pioneer factor FOXA1 has been shown to induce functional enhancer competency through chromatin openings. We have previously found that FOXA1 is recruited to thousands of regions across the genome of a given cell type. Here, we monitored the chromatin structure at FOXA1 binding sites on a chromosome-wide scale using formaldehyde assisted isolation of regulatory elements (FAIRE). Surprisingly, we find that a significant fraction of FOXA1-bound sites have a relatively closed chromatin conformation linked to a shift of the epigenetic signature toward repressive histone marks. Importantly, these sites are not correlated with gene expression in a given cell type suggesting that FOXA1 is required, but not sufficient, for the functional activity of bound enhancers. Interestingly, we find that a significant proportion of the inactive FOXA1-bound regulatory sites in one cell type are actually functional in another cellular context. We found that at least half of the FOXA1 binding sites from a given cell type are shared with another cell lineage. Mechanisms that restrict the activity of shared FOXA1-bound enhancers likely play a significant role in defining the cell-type-specific functions of FOXA1.
C1 [Lupien, Mathieu; Verzi, Michael P.; Shivdasani, Ramesh A.; Brown, Myles] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, Boston, MA 02115 USA.
   [Eeckhoute, Jerrome] Univ Rennes 1, CNRS, UMR 6026, F-35042 Rennes, France.
   [Lupien, Mathieu; Verzi, Michael P.; Shivdasani, Ramesh A.; Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Lupien, Mathieu; Verzi, Michael P.; Shivdasani, Ramesh A.; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Meyer, Clifford A.; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Meyer, Clifford A.; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Universite de Rennes;
   Centre National de la Recherche Scientifique (CNRS); Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard Medical School;
   Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard T.H. Chan School of Public Health
RP Brown, M (通讯作者)，Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, Boston, MA 02115 USA.
EM myles_brown@dfci.harvard.edu
RI Brown, Myles/B-6906-2008; Liu, X Shirley/JQI-9418-2023; Eeckhoute,
   Jerome/AAN-8219-2021; Lupien, Mathieu/KFB-6691-2024
OI Eeckhoute, Jerome/0000-0002-7222-9264; Lupien,
   Mathieu/0000-0003-0929-9478; Brown, Myles/0000-0002-8213-1658
FU Centre National de la Recherche Scientifique (CNRS); University of
   Rennes 1; NIDDK [R01DK074967]; NCI [P01 CA8011105]; DF/HCC Breast Cancer
   SPORE Grant
FX The authors thank members of the SPARTE team for helpful discussions
   during the preparation of this manuscript. This work was supported by
   funds from the Centre National de la Recherche Scientifique (CNRS) and
   the University of Rennes 1 and by grants from the NIDDK (R01DK074967 to
   M. B.), the NCI (P01 CA8011105 and the DF/HCC Breast Cancer SPORE Grant
   to M. B.), and the DFCI Women's Cancers Program.
CR Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207
   Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014
   Bresnick EH, 2005, J CELL PHYSIOL, V205, P1, DOI 10.1002/jcp.20393
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Chan CS, 2008, CANCER RES, V68, P9041, DOI 10.1158/0008-5472.CAN-08-2632
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244
   Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Escamilla-Del-Arenal M, 2008, MOL CELL BIOL, V28, P575, DOI 10.1128/MCB.00943-07
   Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6
   Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983
   Gao H, 2008, MOL ENDOCRINOL, V22, P10, DOI 10.1210/me.2007-0121
   Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hogan GJ, 2006, PLOS GENET, V2, P1433, DOI 10.1371/journal.pgen.0020158
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   John S, 2008, MOL CELL, V29, P611, DOI 10.1016/j.molcel.2008.02.010
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Komashko VM, 2008, GENOME RES, V18, P521, DOI 10.1101/gr.074609.107
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Naeem H, 2007, MOL CELL BIOL, V27, P120, DOI 10.1128/MCB.00815-06
   Nagashima T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001803
   Nagy PL, 2003, P NATL ACAD SCI USA, V100, P6364, DOI 10.1073/pnas.1131966100
   Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769
   Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279
   Pennacchio LA, 2007, GENOME RES, V17, P201, DOI 10.1101/gr.5972507
   Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295
   Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Steinfeld I, 2007, NAT GENET, V39, P303, DOI 10.1038/ng1965
   Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Xi HL, 2007, PLOS GENET, V3, P1377, DOI 10.1371/journal.pgen.0030136
   Xu J, 2007, P NATL ACAD SCI USA, V104, P12377, DOI 10.1073/pnas.0704579104
   Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507
   Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018
   Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228
   Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563
NR 63
TC 87
Z9 105
U1 0
U2 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD MAR
PY 2009
VL 19
IS 3
BP 372
EP 380
DI 10.1101/gr.084582.108
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 414EU
UT WOS:000263847500003
PM 19129543
OA Green Accepted, Green Submitted, Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Wu, CY
   Tseng, RC
   Hsu, HS
   Wang, YC
   Hsu, MT
AF Wu, Chu-Yi
   Tseng, Ruo-Chia
   Hsu, Han-Shui
   Wang, Yi-Ching
   Hsu, Ming-Ta
TI Frequent down-regulation of hRAB37 in metastatic tumor by genetic and
   epigenetic mechanisms in lung cancer
SO LUNG CANCER
LA English
DT Article
DE hRAB37 gene; 5 ' and 3 ' RACE; mRNA expression; Promoter/exon1
   hypermethylation; LOH; NSCLC
ID SECRETORY GRANULES; BREAST-TUMORS; ALLELIC LOSS; REGION; METHYLATION;
   PROMOTER; HETEROZYGOSITY; 17Q25
AB We looked for the involvement tumor suppressor gene (TSG) in lung cancer in 17q25 region by loss of heterozygosity analysis and 5'/3' RACE and identified a candidate gene named human RAB37 (hRAB37), which encodes a small GTPase. The Ras-GTPase superfamily functions as important regulators including membrane trafficking and cytoskeletal organization. Therefore, we further examined the mRNA expression and promoter/exon1 hypermethylation of hRAB37 gene in paired normal and tumor lung tissue from 71 non-small cell lung cancer (NSCLC) patients. Low hRAB37 mRNA expression occurred in 47.9% (34/71) of patient and promoter/exon1 hypermethylation of hRAB37 was found in 57.7% (41/71) of patients. Low mRNA expression of hRAB37 was significantly associated with their promoter/exon1 hypermethylation. Importantly, a reduction in hRAB37 mRNA expression and promoter/exon1 hypermethylation was found to be significantly associated with lung metastatic patients as compared to non-metastatic patients. 5-Aza-2-deoxycytidine treatment of a highly metastatic cell line showed demethylation and re-expression of the hRAB37 gene and coincided with reduced migration. Knockdown of hRAB37 in low metastasis cell line led to a significant increase in cell migration. Our findings demonstrated that hRAB37 small GTPase and acts as a metastasis-related TSG in lung cancer. Promoter/exon1 methylation is the predominant mechanism in down-regulation of the hRAB37, and can serve as a potential prediction biomarker of NSCLC progression. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Tseng, Ruo-Chia; Wang, Yi-Ching] Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan 70101, Taiwan.
   [Wu, Chu-Yi; Hsu, Ming-Ta] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan.
   [Hsu, Han-Shui] Taipei Vet Gen Hosp, Div Thorac Surg, Dept Surg, Taipei, Taiwan.
C3 National Cheng Kung University; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital
RP Wang, YC (通讯作者)，Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, 1 Univ Rd, Tainan 70101, Taiwan.
EM ycw5798@mail.ncku.edu.tw; mth@ym.edu.tw
RI Wang, Yi-Ching/J-8702-2019; Wu, Chuyi/IXN-4115-2023
OI Wang, Yi-Ching/0000-0002-7694-2067
FU National Science Council [95-2752-B-010-003-PAE, 95-2320-B-087-MY3];
   Department of Health (The Executive Yuan, Republic of China)
   [96-TD-G-111-004]; National Yang-Ming University Aim for the top
   University Plan
FX This research was funded in part by National Science Council (The
   Executive Yuan, Republic of China) grant number 95-2752-B-010-003-PAE
   and 95-2320-B-087-MY3, and from Department of Health (The Executive
   Yuan, Republic of China) grant number 96-TD-G-111-004 and from National
   Yang-Ming University Aim for the top University Plan.
CR ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935
   Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606
   Brunner Y, 2007, MOL CELL PROTEOMICS, V6, P1007, DOI 10.1074/mcp.M600443-MCP200
   Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007
   Bucci C, 2006, CELL SIGNAL, V18, P1, DOI 10.1016/j.cellsig.2005.07.001
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   Chang KW, 2002, J PATHOL, V196, P300, DOI 10.1002/path.1047
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Hoon DSB, 2006, CANCER METAST REV, V25, P203, DOI 10.1007/s10555-006-8500-x
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013
   Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1
   Masuda ES, 2000, FEBS LETT, V470, P61, DOI 10.1016/S0014-5793(00)01288-6
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Pellinen T, 2006, J CELL SCI, V119, P3723, DOI 10.1242/jcs.03216
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P2665
   Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178
   von Brevern M, 1998, ONCOGENE, V17, P2101, DOI 10.1038/sj.onc.1202139
   Xinarianos G, 2006, HUM MOL GENET, V15, P2038, DOI 10.1093/hmg/ddl128
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 21
TC 46
Z9 52
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD MAR
PY 2009
VL 63
IS 3
BP 360
EP 367
DI 10.1016/j.lungcan.2008.06.014
PG 8
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 417PO
UT WOS:000264088700009
PM 18687502
DA 2025-01-12
ER

PT J
AU Mishra, PJ
   Bertino, JR
AF Mishra, Prasun J.
   Bertino, Joseph R.
TI MicroRNA polymorphisms: the future of pharmacogenomics, molecular
   epidemiology and individualized medicine
SO PHARMACOGENOMICS
LA English
DT Article
DE classification; diagnosis; disease; drug resistance; epidemiology;
   epigenetics; microRNA; miRSNP; mutations; pharmacogenomics;
   polymorphism; prognosis; SNP
ID SINGLE-NUCLEOTIDE POLYMORPHISM; DIHYDROFOLATE-REDUCTASE GENE;
   BINDING-SITE POLYMORPHISM; MESSENGER-RNA; BREAST-CANCER; TARGET SITE;
   UNTRANSLATED REGION; EXPRESSION; RISK; CELL
AB Referred to as the micromanagers of gene expression, microRNAs (miRNAs) are evolutionarily conserved small noncoding RNAs. Polymorphisms in the miRNA pathway (miR-polymorphisms) are emerging as powerful tools to study the biology of a disease and have the potential to be used in disease prognosis and diagnosis. Detection of miR-polymorphisms holds promise in the field of miRNA pharmacogenomics, molecular epidemiology and for individualized medicine. MiRNA pharmacogenomics can be defined as the study of miRNAs and polymorphisms affecting miRNA function in order to predict drug behavior and to improve drug efficacy. Advancements in the miRNA field indicate the clear involvement of miRNAs and genetic variations within the miRNA pathway in the progression and prognosis of diseases such as cancer, neurological disorders, muscular hypertrophy, gastric mucosal atrophy, cardiovascular disease and Type 11 diabetes. Various algorithms are available to predict miRNA-target mRNA sites; however, it is advisable to use multiple algorithms to confirm the predictions. Polymorphisms that may potentially affect miRNA-mediated regulation of the cell can be present not only in the 3'-UTR of a miRNA target gene, but also in the genes involved in miRNA biogenesis and in pri-, pre- and mature-miRNA sequences. A polymorphism in processed miRNAs may affect expression of several genes and have serious consequences, whereas a polymorphism in miRNA target site, in the 3'-UTR of the target mRNA, may be more target and/or pathway specific. In this review, we for the first time suggest a classification of miRNA polymorphisms/mutations. We also describe the importance and implications of miR-polymorphisms in gene regulation, disease progression, pharmacogenomics and molecular epidemiology.
C1 [Mishra, Prasun J.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA.
   [Bertino, Joseph R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Rutgers University System; Rutgers University New Brunswick;
   Rutgers University Biomedical & Health Sciences
RP Mishra, PJ (通讯作者)，NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA.
EM mishrapj@mail.nih.gov
FU Intramural NIH HHS [Z99 CA999999] Funding Source: Medline
CR Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502
   Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Arisawa T, 2007, DIGEST DIS SCI, V52, P1691, DOI 10.1007/s10620-006-9648-5
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Bao L, 2007, NUCLEIC ACIDS RES, V35, pD51, DOI 10.1093/nar/gkl797
   Barnes MR, 2007, EXPERT OPIN BIOL TH, V7, P1387, DOI 10.1517/14712598.7.9.1387
   Beetz C, 2008, BRAIN, V131, P1078, DOI 10.1093/brain/awn026
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bertino JR, 2007, PHARMACOGENOMICS, V8, P1625, DOI 10.2217/14622416.8.12.1625
   Brendle A, 2008, CARCINOGENESIS, V29, P1394, DOI 10.1093/carcin/bgn126
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Calin GA, 2006, LEUKEMIA RES, V30, P653, DOI 10.1016/j.leukres.2005.10.017
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190
   CHEN K, 2008, CARCINOGENESIS
   Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910
   Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810
   Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211
   Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002
   Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138
   Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062
   Evans SC, 2007, EURASIP J BIOINFORM, DOI 10.1155/2007/43670
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Glinsky GV, 2008, CELL CYCLE, V7, P2570, DOI 10.4161/cc.7.16.6524
   Goto Y, 2001, CLIN CANCER RES, V7, P1952
   Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   Hon LS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r166
   Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934
   Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105
   JENSEN KP, MOL PSYCHIATR, DOI DOI 10.1038/MP.2008.15
   Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038
   John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264
   Kapeller J, 2008, HUM MOL GENET, V17, P2967, DOI 10.1093/hmg/ddn195
   Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kuhn DE, 2008, METHODS, V44, P47, DOI 10.1016/j.ymeth.2007.09.005
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Landi D, 2008, CARCINOGENESIS, V29, P579, DOI 10.1093/carcin/bgm304
   Landi D, 2008, DNA CELL BIOL, V27, P35, DOI 10.1089/dna.2007.0650
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102
   Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772
   Marcucci G, 2008, J CLIN ONCOL, V26, P5078, DOI 10.1200/JCO.2008.17.5554
   Martin MM, 2007, J BIOL CHEM, V282, P24262, DOI 10.1074/jbc.M701050200
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Mishra PJ, 2008, CELL CYCLE, V7, P853, DOI 10.4161/cc.7.7.5666
   Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104
   Mishra Prasun J., 2007, Proceedings of the American Association for Cancer Research Annual Meeting, V48, P1070
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Raveche ES, 2007, BLOOD, V109, P5079, DOI 10.1182/blood-2007-02-071225
   Rigoutsos I, 2006, P NATL ACAD SCI USA, V103, P6605, DOI 10.1073/pnas.0601688103
   Rusinov V, 2005, NUCLEIC ACIDS RES, V33, pW696, DOI 10.1093/nar/gki364
   Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390
   Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Sethupathy P, 2008, TRENDS GENET, V24, P489, DOI 10.1016/j.tig.2008.07.004
   Sethupathy P, 2007, AM J HUM GENET, V81, P405, DOI 10.1086/519979
   Standart N, 2007, GENE DEV, V21, P1975, DOI 10.1101/gad.1591507
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200
   Wang G, 2008, AM J HUM GENET, V82, P283, DOI 10.1016/j.ajhg.2007.09.021
   WARTHMANN N, 2008, BRASSICACEAE MOL BIO, V25, P892
   Wexler Y, 2007, J COMPUT BIOL, V14, P856, DOI 10.1089/cmb.2007.R020
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang HS, 2008, CANCER RES, V68, P2530, DOI 10.1158/0008-5472.CAN-07-5991
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang R, 2008, NUCLEIC ACIDS RES, V36, P4621, DOI 10.1093/nar/gkn431
   Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
   Zuchner S, 2006, AM J HUM GENET, V79, P365, DOI 10.1086/505361
NR 96
TC 227
Z9 252
U1 1
U2 46
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD MAR
PY 2009
VL 10
IS 3
BP 399
EP 416
DI 10.2217/14622416.10.3.399
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 426EM
UT WOS:000264690800011
PM 19290790
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ramachandran, K
   Gopisetty, G
   Gordian, E
   Navarro, L
   Hader, C
   Reis, IM
   Schulz, WA
   Singal, R
AF Ramachandran, Kavitha
   Gopisetty, Gopal
   Gordian, Edna
   Navarro, Loida
   Hader, Christiane
   Reis, Isildinha M.
   Schulz, Wolfgang A.
   Singal, Rakesh
TI Methylation-Mediated Repression of <i>GADD45</i>α in Prostate Cancer and
   Its Role as a Potential Therapeutic Target
SO CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION; BREAST-CANCER; CELL-SURVIVAL; PROTEINS; GENES;
   DOCETAXEL; APOPTOSIS; GADD45A; GROWTH; MITOXANTRONE
AB Defects in apoptotic pathway contribute to uncontrolled proliferation of cancer cells and confer resistance to chemotherapy. Growth arrest and DNA damage inducible, alpha (GADD45 alpha) is up-regulated on docetaxel treatment and may contribute to docetaxel-mediated cytotoxicity. We examined the mechanism of regulation of GADD45 alpha in prostate cancer cells and the effect of its up-regulation on sensitivity to docetaxel chemotherapy. Expression of GADD45 alpha in PC3 cells was higher than that in Du145 and LCaP cells (17- and 12-fold, respectively; P < 0.05). Although the proximal promoter region was unmethylated in all three cell lines, methylation of a 4 CpG region upstream of the proximal promoter correlated inversely with gene expression levels. Methylation was reversed by treatment of Du145 and LNCaP cells with DNA methyltransferase inhibitors, leading to reactivation of GADD45 alpha expression in these cells. The 5' 4 CpG region was also frequently methylated in prostate cancer tissues. Methylation of this region correlated inversely with gene expression in prostate cancer and benign prostate tissues. The methyl binding protein MeCP2 was associated with the methylated 4 CpGs in Du145 cells, and knockdown of MeCP2 in these cells (Du145 MeCP2(-)) led to a significantly increased expression of GADD45 alpha (3-fold; P = 0.035) without affecting the methylation status of the gene. Enhanced sensitivity to docetaxel was observed by up-regulation of GADD45 alpha in Du145 cells by recombinant expression of GADD45 alpha or pretreatment with 5-azacytidine. Our results show that GADD45 alpha is epigenetically repressed and is a potential target for treatment of prostate cancer. [Cancer Res 2009;69(4):1527-35]
C1 [Ramachandran, Kavitha; Gopisetty, Gopal; Gordian, Edna; Navarro, Loida; Reis, Isildinha M.; Singal, Rakesh] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Hader, Christiane; Schulz, Wolfgang A.] Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
C3 University of Miami; Heinrich Heine University Dusseldorf
RP Singal, R (通讯作者)，Univ Miami, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.
EM rsingal@med.miami.edu
RI Schulz, Wolfgang/A-6523-2008; Gopisetty, Gopal/ABB-6470-2020
OI Schulz, Wolfgang/0000-0002-2196-463X; Gopisetty,
   Gopal/0000-0002-7869-4343
FU Department of Veterans Affairs and Pharmion Corporation; Deutsche
   Forschungsgerneinschaft
FX Department of Veterans Affairs and Pharmion Corporation (R. Singal) and
   by the Deutsche Forschungsgerneinschaft (W.A. Schulz).
CR Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x
   BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x
   Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004
   Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185
   Das PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-28
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Das PM, 2004, BIOTECHNIQUES, V37, P961, DOI 10.2144/04376RV01
   Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099
   Fulton B, 1996, DRUGS, V51, P1075, DOI 10.2165/00003495-199651060-00011
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Gopisetty G, 2006, MOL IMMUNOL, V43, P1729, DOI 10.1016/j.molimm.2005.11.010
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Li YW, 2004, NEOPLASIA, V6, P158, DOI 10.1593/neo.03391
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mann J, 2007, CELL DEATH DIFFER, V14, P275, DOI 10.1038/sj.cdd.4401979
   NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Ramachandran K, 2007, BIOCHEMISTRY-US, V46, P3416, DOI 10.1021/bi0620813
   ROSS DD, 1989, CANCER RES, V49, P3776
   Schulz WA, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-14
   Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9
   Singal R, 2004, ONCOL REP, V12, P631
   Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tong T, 2005, MOL CELL BIOL, V25, P4488, DOI 10.1128/MCB.25.11.4488-4500.2005
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008
   Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464
   Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706
   Zerbini LF, 2005, CLIN CANCER RES, V11, P6409, DOI 10.1158/1078-0432.CCR-05-1475
   Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101
   Zhan QM, 2005, MUTAT RES-FUND MOL M, V569, P133, DOI 10.1016/j.mrfmmm.2004.06.055
   ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361
NR 40
TC 64
Z9 75
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 2009
VL 69
IS 4
BP 1527
EP 1535
DI 10.1158/0008-5472.CAN-08-3609
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 407YB
UT WOS:000263399100037
PM 19190346
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Ostrow, KL
   Park, HL
   Hoque, MO
   Kim, MS
   Liu, JW
   Argani, P
   Westra, W
   Van Criekinge, W
   Sidransky, D
AF Ostrow, Kimberly Laskie
   Park, Hannah Lui
   Hoque, Mohammad Obaidul
   Kim, Myoung Sook
   Liu, Junwei
   Argani, Pedram
   Westra, William
   Van Criekinge, Wim
   Sidransky, David
TI Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast
   Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; WD-REPEAT PROTEINS; DNA METHYLATION; PROMOTER
   HYPERMETHYLATION; PROSTATE-CANCER; LUNG-CANCER; ABERRANT METHYLATION;
   BLADDER-CANCER; MULTIPLE GENES; EARLY EVENT
AB Purpose: Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of various cancers including breast cancer. Many epigenetically inactivated genes involved in breast cancer development remain to be identified. Therefore, in this study we used a pharmacologic unmasking approach in breast cancer cell lines with 5-aza-2'-deoxycytidine (5-aza-dC) followed by microarray expression analysis to identify epigenetically inactivated genes in breast cancer.
   Experimental Design: Breast cancer cell lines were treated with 5-aza-dC followed by microarray analysis to identify epigenetically inactivated genes in breast cancer. We then used bisulfite DNA sequencing, conventional methylation-specific PCR, and quantitative fluorogenic real-time methylation-specific PCR to confirm cancer-specific methylation in novel genes.
   Results: Forty-nine genes were up-regulated in breast cancer cells lines after 5-aza-dC treatment, as determined by microarray analysis. Five genes (MAL, FKBP4, VGF OGDHL, and KIF1A) showed cancer-specific methylation in breast tissues. Methylation of at least two was found at high frequency only in breast cancers (40 of 40) as compared with normal breast tissue (0 of 10; P < 0.0001, Fisher's exact test).
   Conclusions: This study identified new cancer-specific methylated genes to help elucidate the biology of breast cancer and as candidate diagnostic markers for the disease.
C1 [Sidransky, David] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21231 USA.
   [Argani, Pedram] Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
   [Van Criekinge, Wim] CHU Niveau 4, OncoMethylome Sci SA, Liege, Belgium.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Sidransky, D (通讯作者)，Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, 1550 Orleans St,5N03, Baltimore, MD 21231 USA.
EM dsidrans@jhmi.edu
RI KIM, JUSANG/AAB-3748-2019; Liu, Junwei/LXA-1062-2024
OI Van Criekinge, Wim/0000-0003-2971-5539; Hoque, Mohammad
   Obaidul/0000-0001-6701-9978
FU National Cancer Institute [U01-CA84986]; Oncomethylome Sciences, SA;
   Hopkins University Breast Specialized Program [CA88843]; Specialized
   Programs of Research Excellence in Cervical Cancer [P50 CA098252]
FX Grant support: National Cancer Institute grant U01-CA84986 and
   Oncomethylome Sciences, SA. The funding agency had no role in the design
   of the study, data collection, or analysis, in the interpretation of the
   results; in the preparation of the manuscript; or in the decision to
   submit the manuscript for publication. Dr. Argani is supported by The
   Johns Hopkins University Breast Specialized Program of Research
   Excellence grant CA88843. Dr. Hoclue is supported by FAMRI Young
   Clinical Scientist Award, International Association for the Study of
   Lung Cancer and Career development award from Specialized Programs of
   Research Excellence in Cervical Cancer grants P50 CA098252. The costs of
   publication of this article were defrayed in part by the payment of page
   charges. This article must therefore be hereby marked advertisement in
   accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   Note: Supplementary data for this article are available at Clinical
   Cancer Research Online (http://clincancerres.aacrjournals.org/).
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071
   Dammann R, 2001, CANCER RES, V61, P3105
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Elmore JG, 1998, J WOMENS HEALTH, V7, P443, DOI 10.1089/jwh.1998.7.443
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Hamill J, 2002, ACTA CYTOL, V46, P19, DOI 10.1159/000326710
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hernández-Vargas H, 2007, BREAST CANCER RES TR, V102, P157, DOI 10.1007/s10549-006-9322-9
   Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009
   Hoque MO, 2003, CANCER RES, V63, P2216
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Hsu HS, 2007, CANCER-AM CANCER SOC, V110, P2019, DOI 10.1002/cncr.23001
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Kazemi-Noureini S, 2004, WORLD J GASTROENTERO, V10, P1716
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Kumar P, 2001, BIOCHEM BIOPH RES CO, V284, P219, DOI 10.1006/bbrc.2001.4952
   Leonhardt H, 2000, J CELL BIOCHEM, P78
   Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838
   Lin JF, 2007, INT J CANCER, V121, P2596, DOI 10.1002/ijc.23016
   Lind GE, 2007, GASTROENTEROLOGY, V132, P1631, DOI 10.1053/j.gastro.2007.03.003
   Liu JW, 2008, PROSTATE, V68, P418, DOI 10.1002/pros.20709
   Lo YMD, 2001, ANN NY ACAD SCI, V945, P1
   Mimori K, 2003, ONCOGENE, V22, P3463, DOI 10.1038/sj.onc.1206378
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0
   Taback B, 2006, ANN NY ACAD SCI, V1075, P211, DOI 10.1196/annals.1368.029
   Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993
   Tokumaru Y, 2004, CLIN CANCER RES, V10, P5518, DOI 10.1158/1078-0432.CCR-04-0108
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Ward BK, 1999, BREAST CANCER RES TR, V58, P267
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
NR 45
TC 58
Z9 64
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2009
VL 15
IS 4
BP 1184
EP 1191
DI 10.1158/1078-0432.CCR-08-1304
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 410QI
UT WOS:000263592600010
PM 19228724
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Cheng, Y
   Kim, JW
   Liu, WN
   Dunn, TA
   Luo, J
   Loza, MJ
   Kim, ST
   Zheng, SL
   Xu, JF
   Isaacs, WB
   Chang, BL
AF Cheng, Yu
   Kim, Jin Woo
   Liu, Wennuan
   Dunn, Thomas A.
   Luo, Jun
   Loza, Matthew J.
   Kim, Seong-Tae
   Zheng, Siqun Lilly
   Xu, Jianfeng
   Isaacs, William B.
   Chang, Bao-Li
TI Genetic and Epigenetic Inactivation of <i>TNFRSF10C</i> in Human
   Prostate Cancer
SO PROSTATE
LA English
DT Article
DE promoter methylation; CpG islands; somatic copy number alterations
ID FADD-DEPENDENT APOPTOSIS; COPY NUMBER ALTERATIONS; NF-KAPPA-B; ALLELIC
   LOSS; NASOPHARYNGEAL CARCINOMA; BREAST-CANCER; METHYLATION; DELETION;
   FREQUENT; TUMOR
AB BACKGROUND. TNFRSF10C, is located on 8p21.3, one of the most frequently deleted loci in the genome of prostate cancer (PCa). Hypermethylation of TNFRSF10C promoter CpG island (CGI) had been reported in many tumors including PCa. However, the interplay between somatic deletion and promoter hypermethylation of TNFRSF10C on PCa development has not been investigated.
   METHODS. Methylation status of promoter CGI and deletion status of the TNFRSF10C locus was investigated by bisulfite sequencing and Affymetrix SNP array, respectively, in 59 pairs of PCa tumor and matched normal samples with three PCa cell lines. TNFRSF10C gene expression changes in relation to cancer-associated genetic/epigenetic changes in clinical specimens, and change of TNFRSF10C expression before and after 5-aza-2'-deoxycytidine treatment in the PC3 PCa cell line was assessed by real-time RT-PCR.
   RESULTS. We found that TNFRSF10C promoter CGI was differentially methylated in 46 of 59 primary cancers (78.0%). Hemizygous deletion at TNFRSF10C was found in 44 of the 59 prostate tumors (74.5%). Interestingly, in 94.9% of the tumors (56 out of 59), TNFRSF10C was either hemizygously deleted or its promoter CGI hypermethylated. Deletion and/or methylation of the TNFRSF10C gene were correlated with decreased mRNA expression of the gene in clinical specimens. Demethylation of the TNFRSF10C promoter CGI was accompanied by transcriptional re-activation of TNFRSF10C in the PCa cell line PC3.
   CONCLUSION. We found a notably high frequency of promoter CGI methylation and deletion of TNFRSF10C in PCa tissues. Our results indicated that inactivation of TNFRSF10C by chromosomal deletion and promoter methylation may play an important role in PCa development. Prostate 69:327-335,2009. (C) 2008 Wiley-Liss. Inc.
C1 [Dunn, Thomas A.; Luo, Jun; Isaacs, William B.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA.
   [Cheng, Yu; Kim, Jin Woo; Liu, Wennuan; Kim, Seong-Tae; Zheng, Siqun Lilly; Xu, Jianfeng; Chang, Bao-Li] Wake Forest Univ, Bowman Gray Sch Med, Ctr Canc Genom, Winston Salem, NC USA.
   [Cheng, Yu; Kim, Jin Woo; Liu, Wennuan; Loza, Matthew J.; Kim, Seong-Tae; Zheng, Siqun Lilly; Xu, Jianfeng; Chang, Bao-Li] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC USA.
   [Kim, Jin Woo] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA.
C3 Johns Hopkins University; Wake Forest University; Wake Forest Baptist
   Medical Center; Wake Forest University; Wake Forest Baptist Medical
   Center; Wake Forest University; Wake Forest Baptist Medical Center
RP Isaacs, WB (通讯作者)，Johns Hopkins Univ Hosp, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.
EM wisaacs@jhmi.edu; bchang@wfubmc.edu
RI cheng, yu/D-4673-2012; Kim, Seong-Tae/E-4474-2017
OI Kim, Seong-Tae/0000-0001-7436-1405; Loza, Matthew/0000-0002-8609-118X
FU National Cancer Institute [CA95052, CA119069]
FX The authors thank all the study subjects who participated in this study.
   and also thank A.R. Turner and T.S. Adams for their editorial
   assistance. This study is supported by National Cancer Institute CA95052
   to J.X. and CA119069 to B.C.
CR Adams J, 2005, CANCER RES, V65, P66
   Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074
   BOVA GS, 1993, CANCER RES, V53, P3869
   Chaib H, 2003, GENE CHROMOSOME CANC, V37, P306, DOI 10.1002/gcc.10226
   Chang BL, 2007, CANCER RES, V67, P4098, DOI 10.1158/0008-5472.CAN-06-4570
   Charafe-Jauffret E, 2002, INT J ONCOL, V21, P989
   Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8
   Chughtai SA, 1999, ONCOGENE, V18, P657, DOI 10.1038/sj.onc.1202340
   Dunn TA, 2006, AM J PATHOL, V169, P1843, DOI 10.2353/ajpath.2006.060316
   Gilmore TD, 1996, ONCOGENE, V13, P1367
   HORNSTEIN M, CANC GENOMICS PROTEO, V5, P123
   Liu W, 2007, CLIN CANCER RES, V13, P5028, DOI 10.1158/1078-0432.CCR-07-0300
   Liu WN, 2006, GENE CHROMOSOME CANC, V45, P1018, DOI 10.1002/gcc.20369
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Michalowski MB, 2006, CANCER GENET CYTOGEN, V166, P74, DOI 10.1016/j.cancergencyto.2005.09.004
   Murphy TM, 2008, ENDOCR-RELAT CANCER, V15, P11, DOI 10.1677/ERC-07-0208
   Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562
   Ono K, 1999, ONCOL REP, V6, P785
   Peng D, 2006, ACTA BIOCH BIOPH SIN, V38, P349, DOI 10.1111/j.1745-7270.2006.00164.x
   Sanlioglu AD, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-54
   Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Sun JS, 2007, PROSTATE, V67, P692, DOI 10.1002/pros.20543
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Takada H, 2006, ONCOGENE, V25, P6554, DOI 10.1038/sj.onc.1209657
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
   van Noesel MM, 2002, CANCER RES, V62, P2157
   Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wistuba II, 1999, CANCER RES, V59, P1973
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yi HM, 2006, ONCOL RES, V16, P261, DOI 10.3727/000000006783981008
NR 32
TC 26
Z9 29
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
EI 1097-0045
J9 PROSTATE
JI Prostate
PD FEB 15
PY 2009
VL 69
IS 3
BP 327
EP 335
DI 10.1002/pros.20882
PG 9
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 403YL
UT WOS:000263117800011
PM 19035483
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhou, W
   Jiang, Z
   Li, XG
   Xu, FH
   Liu, YB
   Wen, P
   Kong, L
   Hou, M
   Yu, JM
AF Zhou, Wei
   Jiang, Zheng
   Li, Xingang
   Xu, Fenghua
   Liu, Yanbing
   Wen, Peie
   Kong, Li
   Hou, Ming
   Yu, Jinming
TI EMP3 Overexpression in Primary Breast Carcinomas is not Associated with
   Epigenetic Aberrations
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE PMP22/EMP/MP20 Gene Family; Metastasis; Breast Neoplasms; DNA
   Methylation; Epigenetics; Genetic
ID PROMOTER HYPERMETHYLATION; GENE-EXPRESSION; DNA METHYLATION; CELL-LINES;
   FAMILY; CANCER; IDENTIFICATION; 19Q13.3; GLIOMA; MEMBER
AB Epithelial membrane protein 3 (EMP3) is a trans-membrane signaling molecule with important roles in the regulation of apoptosis, differentiation and invasion of cancer cells, but the detailed is largely still unknown. We analyzed the mRNA levels and methylation statuses of EMP3 in 63 primary breast carcinomas and assessed their correlations with clinicopathologic variables. The expression of EMP3 mRNA in primary breast carcinomas was significantly higher than the expression of 20 normal breast tissues (p<10(-7)). EMP3 overexpression in breast carcinomas was significantly related to histological grade III (p=3.9 x 10(-7)), lymph node metastasis (p=0.003), and strong Her-2 expression (p=3.3 x 10(-6)). Hypermethylation frequencies of EMP3 were detected in 36.5% of breast carcinomas by methylation-specific polymerase chain reaction. However, no significant correlations were found between methylation status of EMP3 and mRNA expression levels as well as other clinical parameters. In conclusion, EMP3 may be a novel marker of tumor aggressiveness. Overexpression of EMP3 in primary breast carcinoma is not associated with DNA methylation.
C1 [Zhou, Wei; Jiang, Zheng; Kong, Li; Yu, Jinming] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China.
   [Zhou, Wei; Xu, Fenghua] Shandong Univ, Shandong Tumor Hosp, Dept Radiat Oncol, Jinan, Shandong, Peoples R China.
   [Zhou, Wei; Jiang, Zheng; Li, Xingang] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
   [Hou, Ming] Shandong Univ, Qilu Hosp, Ctr Canc, Jinan, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong First Medical University & Shandong Academy of
   Medical Sciences; Shandong University; Shandong University; Shandong
   University
RP Yu, JM (通讯作者)，Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China.
EM dryujinming@hotmail.com
RI Zhou, Wei/AHB-6135-2022
FU Natural Science Foundation of Shandong [2006ZRC03115, Y2005C39];
   National High Technology Research and Development Program of China (863
   Program) [2007AA02Z437]
FX This study was supported partly by the Natural Science Foundation of
   Shandong, 2006ZRC03115 and Y2005C39 and partly by the National High
   Technology Research and Development Program of China (863 Program),
   2007AA02Z437.
CR Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Ben-Porath I, 1998, GENOMICS, V49, P443, DOI 10.1006/geno.1998.5238
   BenPorath I, 1996, GENE, V183, P69, DOI 10.1016/S0378-1119(96)00475-1
   Burns M, 2004, ARCHAEOLOGY, V57, P8
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Evtimova V, 2003, TUMOR BIOL, V24, P189, DOI 10.1159/000074429
   GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hühne K, 1999, J NEUROSCI RES, V58, P624
   Hwang KT, 2007, J KOREAN MED SCI, V22, pS24, DOI 10.3346/jkms.2007.22.S.S24
   Kunitz A, 2007, BRAIN PATHOL, V17, P363, DOI 10.1111/j.1750-3639.2007.00083.x
   Li KKW, 2007, INT J CANCER, V120, P947, DOI 10.1002/ijc.22415
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Schiemann S, 1997, ANTICANCER RES, V17, P13
   Taylor V, 1996, GENE, V175, P115, DOI 10.1016/0378-1119(96)00134-5
   *WHO, 1981, INT HIST CLASS TUM, V2
   Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200
NR 20
TC 20
Z9 21
U1 0
U2 4
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD FEB
PY 2009
VL 24
IS 1
BP 97
EP 103
DI 10.3346/jkms.2009.24.1.97
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 420TS
UT WOS:000264312700016
PM 19270820
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Irizarry, RA
   Ladd-Acosta, C
   Wen, B
   Wu, ZJ
   Montano, C
   Onyango, P
   Cui, HM
   Gabo, K
   Rongione, M
   Webster, M
   Ji, H
   Potash, JB
   Sabunciyan, S
   Feinberg, AP
AF Irizarry, Rafael A.
   Ladd-Acosta, Christine
   Wen, Bo
   Wu, Zhijin
   Montano, Carolina
   Onyango, Patrick
   Cui, Hengmi
   Gabo, Kevin
   Rongione, Michael
   Webster, Maree
   Ji, Hong
   Potash, James B.
   Sabunciyan, Sarven
   Feinberg, Andrew P.
TI The human colon cancer methylome shows similar hypo- and
   hypermethylation at conserved tissue-specific CpG island shores
SO NATURE GENETICS
LA English
DT Article
ID FALSE DISCOVERY RATE; GENE-EXPRESSION; DNA METHYLATION; BREAST-CANCER;
   GENOME; NORMALIZATION; PROMOTERS; FREQUENT
AB For the past 25 years, it has been known that alterations in DNA methylation (DNAm) occur in cancer, including hypomethylation of oncogenes and hypermethylation of tumor suppressor genes. However, most studies of cancer methylation have assumed that functionally important DNAm will occur in promoters, and that most DNAm changes in cancer occur in CpG islands. Here we show that most methylation alterations in colon cancer occur not in promoters, and also not in CpG islands, but in sequences up to 2 kb distant, which we term 'CpG island shores'. CpG island shore methylation was strongly related to gene expression, and it was highly conserved in mouse, discriminating tissue types regardless of species of origin. There was a notable overlap (45-65%) of the locations of colon cancer-related methylation changes with those that distinguished normal tissues, with hypermethylation enriched closer to the associated CpG islands, and hypomethylation enriched further from the associated CpG island and resembling that of noncolon normal tissues. Thus, methylation changes in cancer are at sites that vary normally in tissue differentiation, consistent with the epigenetic progenitor model of cancer, which proposes that epigenetic alterations affecting tissue-specific differentiation are the predominant mechanism by which epigenetic changes cause cancer.
C1 [Irizarry, Rafael A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.
   [Irizarry, Rafael A.; Ladd-Acosta, Christine; Wen, Bo; Montano, Carolina; Onyango, Patrick; Cui, Hengmi; Gabo, Kevin; Rongione, Michael; Ji, Hong; Potash, James B.; Sabunciyan, Sarven; Feinberg, Andrew P.] Johns Hopkins Univ, Sch Med, Ctr Epigenet, Inst Basic Biomed Sci, Baltimore, MD 21205 USA.
   [Ladd-Acosta, Christine; Wen, Bo; Montano, Carolina; Onyango, Patrick; Cui, Hengmi; Gabo, Kevin; Rongione, Michael; Ji, Hong; Feinberg, Andrew P.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Wu, Zhijin] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA.
   [Webster, Maree] Uniformed Serv Univ Hlth Sci, Stanley Lab Brain Res, Bethesda, MD 20892 USA.
   [Potash, James B.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.
   [Sabunciyan, Sarven] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins University; Brown
   University; Uniformed Services University of the Health Sciences - USA;
   Johns Hopkins University; Johns Hopkins University
RP Irizarry, RA (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA.
EM rafa@jhu.edu; afeinberg@jhu.edu
RI Feinberg, Andrew/AAY-7666-2020; Irizarry, Rafael/HTN-2745-2023; Wen,
   Bo/P-5332-2019; wu, zhijin/J-4995-2016
OI Feinberg, Andrew/0000-0002-8364-1991; Ji, Hong/0000-0002-9558-0620;
   Montano, Carolina/0000-0002-2772-2025; Sabunciyan,
   Sarven/0000-0002-7231-0820; wu, zhijin/0000-0002-9596-9134; Wen,
   Bo/0000-0003-0394-7366
FU US National Institutes of Health [P50HG003233, R37CA54358, 5R01RR021967]
FX We thank B. Volgelstein (Johns Hopkins University School of Medicine)
   for providing colon tumors and matched normal mucosa samples. Postmortem
   brain, liver and spleen tissue was donated by The Stanley Medical
   Research Institute collection courtesy of M. B. Knable, E. F. Torrey and
   R. H. Yolken, whom we also thank for making available gene expression
   data for the brain and the liver tissue. We thank B. Carvalho for help
   with statistical software and C. Crainiceanu for advice with statistical
   methods. This work was supported by US National Institutes of Health
   grants P50HG003233 (A. P. F.), R37CA54358 (A. P. F.) and 5R01RR021967
   (R. A. I.).
CR Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjornsson HT, 2008, GENOME RES, V18, P771, DOI 10.1101/gr.073254.107
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253
   Cantor AB, 2008, J EXP MED, V205, P611, DOI 10.1084/jem.20070544
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Efron B, 2001, J AM STAT ASSOC, V96, P1151, DOI 10.1198/016214501753382129
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029
   Glass JL, 2007, NUCLEIC ACIDS RES, V35, P6798, DOI 10.1093/nar/gkm489
   Higgs BW, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-70
   Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902
   Segditsas S, 2008, HUM MOL GENET, V17, P3864, DOI 10.1093/hmg/ddn286
   Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181
   Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100
   Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Wakaguri H, 2008, NUCLEIC ACIDS RES, V36, pD97, DOI 10.1093/nar/gkm901
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
NR 34
TC 1672
Z9 1940
U1 10
U2 141
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD FEB
PY 2009
VL 41
IS 2
BP 178
EP 186
DI 10.1038/ng.298
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 403OG
UT WOS:000263091300017
PM 19151715
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Riley, LB
   Desai, DC
AF Riley, Lee B.
   Desai, Darius C.
TI The Molecular Basis of Cancer and the Development of Targeted Therapy
SO SURGICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Targeted; Molecular; Genomic oncogenes; Epigenetic; Breast tumor
   suppressor
ID METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL;
   MONOCLONAL-ANTIBODY; PLUS IRINOTECAN; SOLID TUMORS; STEM-CELLS;
   EXPRESSION; CHEMOTHERAPY; BEVACIZUMAB
AB The sequencing of the human genome and the ability to rapidly identify genes and proteins, both normal and mutant, that are involved in tumorigenesis and malignant phenotypes, have changed the ability to understand malignant cells. Understanding and applying this information to the diagnosis and treatment of cancer are facilitated best with a multidisciplinary team. The cancer surgeon plays a pivotal role in this team. This article briefly summarizes: (1) the clinically relevant applications of molecular biology to the cancer surgeon, (2) the current understanding of the molecular basis for cancer, and (3) the current targeted agents and their clinical applications.
C1 [Riley, Lee B.; Desai, Darius C.] St Lukes Hosp & Hlth Network, Div Surg Oncol, Bethlehem, PA 18015 USA.
RP Riley, LB (通讯作者)，St Lukes Hosp & Hlth Network, Div Surg Oncol, 801 Ostrum St, Bethlehem, PA 18015 USA.
EM rileyl@slhn.org
CR Abdel-Rahman WM, 2006, CRIT REV ONCOL HEMAT, V58, P208, DOI 10.1016/j.critrevonc.2005.11.001
   ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Baselga J, 2002, ONCOLOGIST, V7, P2
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505
   Buchstaller J, 2008, MOL BASIS CANC, P141
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Charames GS, 2003, CURR MOL MED, V3, P589, DOI 10.2174/1566524033479456
   Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   D'Andrea AD., 2008, The Molecular Basis of Cancer, P39
   De Lange T, 2005, COLD SH Q B, V70, P197, DOI 10.1101/sqb.2005.70.032
   Dehdashti F, 2005, EUR J NUCL MED MOL I, V32, P344, DOI 10.1007/s00259-005-1764-5
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   Diaz-Rubio E, 2004, ONCOLOGIST, V9, P282, DOI 10.1634/theoncologist.9-3-282
   Dionigi G, 2007, EXPERT REV ANTICANC, V7, P877, DOI 10.1586/14737140.7.6.877
   Fernando NH, 2004, ONCOLOGIST, V9, P11, DOI 10.1634/theoncologist.9-suppl_1-11
   Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Galiatsatos P, 2006, AM J GASTROENTEROL, V101, P385, DOI 10.1111/j.1572-0241.2006.00375.x
   Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462
   Goldenberg David M, 2007, Update Cancer Ther, V2, P19, DOI 10.1016/j.uct.2007.04.003
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002
   Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067
   HARRIS H, 1987, P ROY SOC LOND B BIO, V179, P1
   Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364
   Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160
   Henshall SM, 2003, CANCER RES, V63, P4196
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Huang SM, 1999, CANCER RES, V59, P1935
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   *I NC, ACOSOGZ9001
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0
   Llovet J, 2007, J CLIN ONCOL, V25
   MacKenzie MJ, 2004, LANCET ONCOL, V5, P541, DOI 10.1016/S1470-2045(04)01565-7
   McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157
   Michaud D S, 2004, Minerva Chir, V59, P99
   Mimeault M, 2007, J CELL MOL MED, V11, P981, DOI 10.1111/j.1582-4934.2007.00088.x
   Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525
   NAIT W, 2008, MOL BASIS CANC, P571
   Olafsen T, 2004, PROTEIN ENG DES SEL, V17, P315, DOI 10.1093/protein/gzh040
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Palacios J, 2008, PATHOBIOLOGY, V75, P85, DOI 10.1159/000123846
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Peterson LM, 2008, J NUCL MED, V49, P367, DOI 10.2967/jnumed.107.047506
   Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467
   Presta LG, 1997, CANCER RES, V57, P4593
   Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
   Rubin BP, 2001, CANCER RES, V61, P8118
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sundaresan G, 2003, J NUCL MED, V44, P1962
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Virtanen Carl, 2008, V141, P87
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159
   Weinberg R.A., 2008, The Molecular Basis of Cancer, P3
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9
   Zureikat AH, 2008, SURG ONCOL CLIN N AM, V17, P279, DOI 10.1016/j.soc.2008.01.004
NR 74
TC 13
Z9 25
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0039-6109
EI 1558-3171
J9 SURG CLIN N AM
JI Surg. Clin.-North Am.
PD FEB
PY 2009
VL 89
IS 1
BP 1
EP +
DI 10.1016/j.suc.2008.09.016
PG 16
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 415NB
UT WOS:000263939400003
PM 19186227
DA 2025-01-12
ER

PT J
AU Slattery, ML
   Wolff, RK
   Curtin, K
   Fitzpatrick, F
   Herrick, J
   Potter, JD
   Caan, BJ
   Samowitz, WS
AF Slattery, Martha L.
   Wolff, Roger K.
   Curtin, Karen
   Fitzpatrick, Frank
   Herrick, Jennifer
   Potter, John D.
   Caan, Bette J.
   Samowitz, Wade S.
TI Colon tumor mutations and epigenetic changes associated with genetic
   polymorphism: Insight into disease pathways
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Insulin; Polymorphisms; Colon cancer; Aspirin; Non-steroidal
   anti-inflammatory; CIMP; p53; MSI; Ki-ras
ID ISLAND METHYLATOR PHENOTYPE; BREAST-CANCER RISK; FACTOR-I RECEPTOR;
   KI-RAS MUTATIONS; GROWTH-FACTOR-I; COLORECTAL-CANCER; LIFE-STYLE;
   MICROSATELLITE INSTABILITY; RECTAL-CANCER; UNITED-STATES
AB Variation in genes associated with serum levels of proteins may be useful for examining specific disease pathways. Using data from a large study of colon cancer, we examine genetic variants in insulin, inflammation, estrogen, metabolizing enzymes, and energy homeostasis genes to explore associations with microsatellite instability (MSI), CpG Island methylator phenotype (CIMP), mutations of p53 in exons 5 through 8, and mutations in codons 12 and 13 of Ki-ras. Insulin-related genes were associated with CIMP-positive and MSI tumors, with the strongest associations among aspirin users. The Fokl vitamin D receptor (VDR) polymorphism was associated with CIMP-positive/Ki-ras-mutated tumors; the Poly A and CDX2 VOR polymorphisms were associated only with Ki-ros-mutated tumors. NAT2 was associated with CIMP-positive/Ki-ras-mutated tumors but not with MSI tumors. The TCF7L2 rs7903146 polymorphism was associated with p53 mutated tumors. Most associations varied by recent aspirin/NSAID use: IL6 rs 1800796 and rs1800795 polymorphisms were associated inversely with tumor mutations in the presence of aspirin/NSAIDs; POMC significantly reduced risk of Ki-ras-mutated tumors when aspirin/NSAIDs were not used: the TCF712 rs7903146 was associated with reduced risk of Ki-ras-mutated tumors in the presence of aspirin and increased risk in the absence of aspirin. These data, although exploratory. identify specific tumor subsets that may be associated with specific exposures/polymorphism combinations. The important modifying effects of aspirin/NSAIDs oil associations with genetic polymorphisms reinforce the underlying role of inflammation in the etiology of colon cancer. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Slattery, Martha L.; Wolff, Roger K.; Curtin, Karen; Herrick, Jennifer] Univ Utah, Dept Med, Salt Lake City, UT 84108 USA.
   [Fitzpatrick, Frank] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84108 USA.
   [Potter, John D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Caan, Bette J.] Kaiser Permanente Med Ctr, Walnut Creek, CA 94596 USA.
   [Samowitz, Wade S.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Huntsman Cancer Institute; Fred
   Hutchinson Cancer Center; Kaiser Permanente; Utah System of Higher
   Education; University of Utah
RP Slattery, ML (通讯作者)，Univ Utah, Dept Med, 375 Chipeta Way,Suite A, Salt Lake City, UT 84108 USA.
EM marty.slattery@hsc.utah.edu
RI Potter, John/JEO-4316-2023
OI Herrick, Jennifer/0000-0001-9257-8843; Potter, John/0000-0001-5439-1500;
   Caan, Bette/0000-0002-5803-310X
FU National Cancer Institute , with additional support from the State of
   Utah Department of Health and the University of Utah [N01-PC-67000];
   Northern California Cancer Registry; Sacramento Tumor Registry; 
   [CA48998];  [CA85846];  [CA61757]
FX Grant support: This Study was funded by CA48998, CA85846, and CA61757 to
   Dr. Slattery. This research Was Supported by the Utah Cancer Registry,
   which is funded by Contract #N01-PC-67000 from the National Cancer
   Institute, with additional support from the State of Utah Department of
   Health and the University of Utah, the Northern California Cancer
   Registry, and the Sacramento Tumor Registry. The contents of this
   manuscript are solely the responsibility of the authors and do not
   necessarily represent the official view of the National Cancer
   Institute.
CR Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173
   Bennermo M, 2004, CLIN CHEM, V50, P2136, DOI 10.1373/clinchem.2004.037531
   Brockton N, 2000, AM J EPIDEMIOL, V151, P846
   Camp NJ, 2002, CANCER CAUSE CONTROL, V13, P813, DOI 10.1023/A:1020611416907
   Curtin K, 2004, CANCER EPIDEM BIOMAR, V13, P285, DOI 10.1158/1055-9965.EPI-03-0083
   Curtin K, 2007, INT J CANCER, V120, P2226, DOI 10.1002/ijc.22603
   Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274
   DeLellis K, 2003, BRIT J CANCER, V88, P277, DOI 10.1038/sj.bjc.6600728
   Ferrari SL, 2003, J CLIN ENDOCR METAB, V88, P255, DOI 10.1210/jc.2002-020092
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Freidlin B, 2002, HUM HERED, V53, P146, DOI 10.1159/000064976
   Friedman GD, 1998, PHARMACOEPIDEM DR S, V7, P99, DOI 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0
   Georges JL, 2003, AM J CARDIOL, V92, P515, DOI 10.1016/S0002-9149(03)00717-3
   Halle M, 2003, AM J PHYSIOL-REG I, V284, pR760, DOI 10.1152/ajpregu.00712.2002
   Landi S, 2003, CANCER RES, V63, P3560
   Liu GS, 2006, MOL PHARMACOL, V69, P440, DOI 10.1124/mol.105.015404
   Yang LY, 2006, WORLD J GASTROENTERO, V12, P6741, DOI 10.3748/wjg.v12.i42.6741
   Lyssenko V, 2007, J CLIN INVEST, V117, P2155, DOI 10.1172/JCI30706
   Martínez ME, 1999, CANCER RES, V59, P5181
   Möhlig M, 2004, J CLIN ENDOCR METAB, V89, P1885, DOI 10.1210/jc.2003-031101
   Morimoto LM, 2002, CANCER EPIDEM BIOMAR, V11, P1012
   Newcomb PA, 2007, CANCER RES, V67, P7534, DOI 10.1158/0008-5472.CAN-06-4275
   Nosho K, 2004, CLIN CANCER RES, V10, P7950, DOI 10.1158/1078-0432.CCR-04-0875
   Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860
   Salonen JT, 2007, AM J HUM GENET, V81, P338, DOI 10.1086/520599
   Samowitz WS, 2006, J NATL CANCER I, V98, P1731, DOI 10.1093/jnci/djj468
   Samowitz WS, 2007, MOL CANCER RES, V5, P165, DOI 10.1158/1541-7786.MCR-06-0398
   Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193
   Samowitz WS, 2006, MUTAT RES-FUND MOL M, V595, P117, DOI 10.1016/j.mrfmmm.2005.10.014
   Schernhammer ES, 2003, INT J CANCER, V107, P60, DOI 10.1002/ijc.11358
   Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104
   Slattery Martha L., 1995, Annals of Epidemiology, V5, P292, DOI 10.1016/1047-2797(94)00095-B
   Slattery ML, 2007, INT J CANCER, V120, P656, DOI 10.1002/ijc.22342
   Slattery ML, 2008, CANCER EPIDEM BIOMAR, V17, P978, DOI 10.1158/1055-9965.EPI-07-2687
   Slattery ML, 2008, INT J CANCER, V122, P1611, DOI 10.1002/ijc.23135
   Slattery ML, 2007, CANCER EPIDEM BIOMAR, V16, P2752, DOI 10.1158/1055-9965.EPI-07-2611
   Slattery ML, 2007, NUTR REV, V65, pS102, DOI 10.1111/j.1753-4887.2007.tb00332.x
   Slattery ML, 2007, CANCER CAUSE CONTROL, V18, P1095, DOI 10.1007/s10552-007-9049-x
   Slattery ML, 2007, CANCER EPIDEM BIOMAR, V16, P747, DOI 10.1158/1055-9965.EPI-06-0667
   Slattery ML, 2002, CANCER CAUSE CONTROL, V13, P527, DOI 10.1023/A:1016376016716
   Slattery ML, 2001, CANCER RES, V61, P1000
   Slattery ML, 2001, INT J CANCER, V93, P601, DOI 10.1002/ijc.1370
   Slattery ML, 2000, J NATL CANCER I, V92, P1831, DOI 10.1093/jnci/92.22.1831
   Slattery ML, 1997, CANCER RES, V57, P75
   Slattery ML, 2006, CANCER CAUSE CONTROL, V17, P239, DOI 10.1007/s10552-005-0411-6
   Slattery ML, 2005, CANCER EPIDEM BIOMAR, V14, P2936, DOI 10.1158/1055-9965.EPI-05-0514
   Slattery ML, 2005, CARCINOGENESIS, V26, P1422, DOI 10.1093/carcin/bgi088
   Slattery ML, 2004, CANCER EPIDEM BIOMAR, V13, P1206
   Slattery ML, 2002, CANCER EPIDEM BIOMAR, V11, P541
   Slattery ML, 2000, CANCER RES, V60, P6935
   Stoeltzing O, 2007, CANCER LETT, V258, P291, DOI 10.1016/j.canlet.2007.09.009
   Theodoropoulos G, 2006, WORLD J GASTROENTERO, V12, P5037, DOI 10.3748/wjg.v12.i31.5037
   Ulrich CM, 2005, CANCER EPIDEM BIOMAR, V14, P2509, DOI 10.1158/1055-9965.EPI-05-0261
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0
NR 59
TC 46
Z9 48
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD JAN 15
PY 2009
VL 660
IS 1-2
BP 12
EP 21
DI 10.1016/j.mrfmmm.2008.10.001
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 406SI
UT WOS:000263314800002
PM 18992263
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhao, HF
   Du, WT
   Gu, DS
   Wang, DH
   Xue, F
   Ge, J
   Sui, T
   Yang, RC
AF Zhao, Haifeng
   Du, Weiting
   Gu, Dongsheng
   Wang, Donghai
   Xue, Feng
   Ge, Jing
   Sui, Tao
   Yang, Renchi
TI DNMT3B 579G&gt;T Promoter Polymorphism and the Risk for Idiopathic
   Thrombocytopenic Purpura in a Chinese Population
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE DNA methyltransferase 3B; Polymorphism; Idiopathic thrombocytopenic
   purpura
ID MAMMALIAN DNA METHYLTRANSFERASES; SQUAMOUS-CELL CARCINOMA; LUNG-CANCER;
   HEPATOCELLULAR CARCINOMAS; PERIPHERAL-BLOOD; IMMUNE-SYSTEM;
   BREAST-CANCER; MESSENGER-RNA; EXPRESSION; METHYLATION
AB Epigenetics may influence the expression of numerous genes, which might contribute to autoimmune diseases. DNA methylation is mediated by DNA methyltransferases, especially DNA methyltransferase 3B (DNMT3B). Polymorphisms of the DNMT3B gene may influence DNMT3B activity on DNA methylation and increase the susceptibility to several diseases. The current study investigated the association between DNMT3B 579G > T and the risk for idiopathic thrombocytopenic purpura (ITP). The DNMT3B 579G > T polymorphisms were analyzed by PCR-RFLP. There was no significant difference in genotype and allele distribution between the ITP patient and the controls (p = 0.722 and 0.667, respectively). Similar results were observed between the 2 groups when stratified by age and disease course, including acute in childhood, chronic in childhood, acute in adult and chronic in adult. Importantly, this study showed a statistical difference in the distribution of SNP of DNMT3B between Chinese and Koreans or Americans. It is shown that the SNP of DNMT3B 579G > T may not be used on its own as a marker to predict the susceptibility to ITP in a Chinese population and that DNMT3B 579G > T promoter SNP varies from one ethnic population to another. Copyright (C) 2009 S. Karger AG, Basel
C1 [Zhao, Haifeng; Du, Weiting; Gu, Dongsheng; Xue, Feng; Ge, Jing; Sui, Tao; Yang, Renchi] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China.
   [Zhao, Haifeng; Du, Weiting; Gu, Dongsheng; Xue, Feng; Ge, Jing; Sui, Tao; Yang, Renchi] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China.
   [Zhao, Haifeng; Du, Weiting; Gu, Dongsheng; Xue, Feng; Ge, Jing; Sui, Tao; Yang, Renchi] Peking Union Med Coll, Tianjin 300020, Peoples R China.
   [Wang, Donghai] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Montefiore Med Ctr, Bronx, NY USA.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Institute of
   Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College;
   Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva
   University
RP Yang, RC (通讯作者)，Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
EM rcyang65@yahoo.com
RI zhao, haifeng/JNX-7170-2023; wang, zhe/JNE-3510-2023; Du,
   Weiting/C-9971-2014
FU National Natural Science Foundation of China [30670900]; Ministry of
   Education of China [20060023038]; Ministry of Health [200802031]
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (30670900), the Ministry of Education of
   China (20060023038) and the Ministry of Health (200802031).
CR Balada E, 2008, IMMUNOLOGY, V124, P339, DOI 10.1111/j.1365-2567.2007.02771.x
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Chang KP, 2007, ORAL ONCOL, V43, P345, DOI 10.1016/j.oraloncology.2006.04.006
   Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501
   Clarke LE, 2003, INT J ONCOL, V22, P425
   Cooper N, 2006, BRIT J HAEMATOL, V133, P364, DOI 10.1111/j.1365-2141.2006.06024.x
   Deng C, 2001, ARTHRITIS RHEUM, V44, P397, DOI 10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.0.CO;2-N
   Fitzpatrick DR, 2003, CLIN IMMUNOL, V109, P37, DOI 10.1016/S1521-6616(03)00205-5
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hong YS, 2007, BIOCHEM GENET, V45, P155, DOI 10.1007/s10528-006-9047-9
   Jung AY, 2008, CANCER EPIDEM BIOMAR, V17, P330, DOI 10.1158/1055-9965.EPI-07-2608
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Nagai M, 2003, HEPATOL RES, V26, P186, DOI 10.1016/S1386-6346(03)00091-3
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Shen HB, 2002, CANCER RES, V62, P4992
   Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739
   Tao J, 2008, J CLIN IMMUNOL, V28, P432, DOI 10.1007/s10875-008-9223-2
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Wang J, 2006, CANCER RES, V66, P8361, DOI 10.1158/0008-5472.CAN-06-2031
   Wilson CB, 2005, SEMIN IMMUNOL, V17, P105, DOI 10.1016/j.smim.2005.01.005
   Yakushiji T, 2003, INT J ONCOL, V22, P1201
   Yang RC, 2000, INT J HEMATOL, V71, P18
NR 27
TC 12
Z9 13
U1 2
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
EI 1421-9662
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PY 2009
VL 122
IS 1
BP 31
EP 35
DI 10.1159/000235616
PG 5
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 503SS
UT WOS:000270560600008
PM 19696477
DA 2025-01-12
ER

PT J
AU Dumont, N
   Crawford, YG
   Sigaroudinia, M
   Nagrani, SS
   Wilson, MB
   Buehring, GC
   Turashvili, G
   Aparicio, S
   Gauthier, ML
   Fordyce, CA
   McDermott, KM
   Tlsty, TD
AF Dumont, Nancy
   Crawford, Yongping G.
   Sigaroudinia, Mahvash
   Nagrani, Shefali S.
   Wilson, Matthew B.
   Buehring, Gertrude C.
   Turashvili, Gulisa
   Aparicio, Samuel
   Gauthier, Mona L.
   Fordyce, Colleen A.
   McDermott, Kimberly M.
   Tlsty, Thea D.
TI Human mammary cancer progression model recapitulates methylation events
   associated with breast premalignancy
SO BREAST CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-CELL LINE; EPIGENETIC INACTIVATION; UNFAVORABLE PROGNOSIS;
   ABERRANT METHYLATION; DNA METHYLATION; HIGH-FREQUENCY; RAS ONCOGENE;
   P16(INK4A); EXPRESSION; GENE
AB Introduction We have previously identified a rare subpopulation of variant human mammary epithelial cells (vHMEC) with repressed p16(INK4A) that exist in disease-free women yet display premalignant properties, suggesting that they have engaged the process of malignant transformation. In order to gain insight into the molecular alterations required for vHMEC to progress to malignancy, and to characterize the epigenetic events associated with early progression, we examined the effect of oncogenic stress on the behavior of these cells.
   Methods HMEC that express p16(INK4A) and vHMEC that do not, were transduced with constitutively active Ha-rasV12 and subsequently exposed to serum to determine whether signals from the cellular microenvironment could cooperate with ras to promote the malignant transformation of vHMEC. Epigenetic alterations were assessed using methylation-specific polymerase chain reaction (PCR).
   Results vHMEC expressing Ha-rasV12 (vHMEC-ras) bypassed the classic proliferative arrest that has been previously documented in normal fibroblasts following oncogenic stress, and that we also observe here in normal HMEC. Moreover, vHMEC-ras cells exhibited many additional alterations that are observed during progression to malignancy such as the generation of chromosomal abnormalities, upregulation of telomerase activity, immortalization following exposure to serum, and anchorage-independent growth, but they did not form tumors following orthotopic injection in vivo. Associated with their early progression to malignancy was an increase in the number of genes methylated, two of which (RASSF1A and SFRP1) were also methylated in other immortalized mammary cell lines as well as in breast cancer cells and tissues.
   Conclusions We have characterized a mammary progression model that recapitulates molecular and methylation alterations observed in many breast cancers. Our data suggest that concomitant methylation of RASSF1A and SFRP1 marks an early event in mammary transformation and may thus have prognostic potential.
C1 [Dumont, Nancy; Crawford, Yongping G.; Sigaroudinia, Mahvash; Nagrani, Shefali S.; Wilson, Matthew B.; Gauthier, Mona L.; Fordyce, Colleen A.; McDermott, Kimberly M.; Tlsty, Thea D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
   [Dumont, Nancy; Crawford, Yongping G.; Sigaroudinia, Mahvash; Nagrani, Shefali S.; Wilson, Matthew B.; Gauthier, Mona L.; Fordyce, Colleen A.; McDermott, Kimberly M.; Tlsty, Thea D.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   [Buehring, Gertrude C.] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Turashvili, Gulisa; Aparicio, Samuel] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada.
   [Wilson, Matthew B.] Natl Sci Fdn, Arlington, VA 22230 USA.
   [Gauthier, Mona L.] Univ Toronto, Dept Med Biophys, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada.
   [McDermott, Kimberly M.] Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; University of California System; University of California
   Berkeley; British Columbia Cancer Agency; National Science Foundation
   (NSF); University of Toronto; University of Arizona
RP Tlsty, TD (通讯作者)，Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave, San Francisco, CA 94143 USA.
EM thea.tlsty@ucsf.edu
RI Gill, Anthony/D-4215-2015; Turashvili, Gulisa/A-2431-2008
OI Aparicio, Samuel/0000-0002-0487-9599; Turashvili,
   Gulisa/0000-0001-6125-5865
FU Susan G. Komen Foundation [PDF124906]; NCI [T32 CA009043]; Department of
   Defense [BC023982, 14OB-0165]; NIH/NCI [CA097214, CA122024]
FX We would like to thank Krystyna Kozakiewicz for performing the
   chromosomal analysis, Chira Chen-Tanyolac for assistance with tumor DNA
   isolation, Dr. Sanjiv Sam Gambhir (Stanford University, Palo Alto, CA)
   for providing us with the GFP-luciferase lentiviral construct, and Dr.
   Philippe Gascard for critical discussions, review of the manuscript, and
   assistance with MSP primer mapping. This research was supported by the
   Susan G. Komen Foundation, postdoctoral award PDF124906 (ND), the NCI
   Institutional Training Grant T32 CA009043 (MBW), the Department of
   Defense Breast Cancer Research Program Concept Award BC023982 and
   14OB-0165 (TDT), the NIH/NCI CA097214 and CA122024 grants (TDT).
CR Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007
   Cheng XD, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.113pe14
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   DEBIASI F, 1989, INT J CANCER, V43, P431, DOI 10.1002/ijc.2910430315
   Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006
   Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Guerrero D, 2008, BJU INT, V102, P747, DOI 10.1111/j.1464-410X.2008.07603.x
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   HAND PH, 1987, JNCI-J NATL CANCER I, V79, P59
   Hayward SW, 2001, CANCER RES, V61, P8135
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Kobatake T, 2004, ONCOL REP, V12, P1087
   Liu LM, 2005, INT J ONCOL, V26, P275
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   OHUCHI N, 1986, CANCER RES, V46, P2511
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   PAGE DL, 1985, CANCER-AM CANCER SOC, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A
   Petko Z, 2005, CLIN CANCER RES, V11, P1203
   Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   SOULE HD, 1990, CANCER RES, V50, P6075
   SPANDIDOS DA, 1984, ANTICANCER RES, V4, P269
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   THALER S, 2009, CANC RES
   THEILLET C, 1986, CANCER RES, V46, P4776
   Tommasi S, 2005, CANCER RES, V65, P92
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
NR 45
TC 24
Z9 26
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
IS 6
AR R87
DI 10.1186/bcr2457
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 556DG
UT WOS:000274568000015
PM 19995452
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Eiseler, T
   Döppler, H
   Yan, IK
   Goodison, S
   Storz, P
AF Eiseler, Tim
   Doeppler, Heike
   Yan, Irene K.
   Goodison, Steve
   Storz, Peter
TI Protein kinase D1 regulates matrix metalloproteinase expression and
   inhibits breast cancer cell invasion
SO BREAST CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; C-MU; ACTIVATION; PATHWAY; DETOXIFICATION;
   IDENTIFICATION; SURVIVAL; GROWTH; SITES; DEATH
AB Introduction The biological and molecular events that regulate the invasiveness of breast tumour cells need to be further revealed to develop effective therapies that stop breast cancer from expanding and metastasising.
   Methods Human tissue samples of invasive breast cancer and normal breast, as well as breast cancer cell lines, were evaluated for protein kinase D (PKD) expression, to test if altered expression could serve as a marker for invasive breast cancer. We further utilised specific PKD1-shRNA and a system to inducibly-express PKD1 to analyse the role of PKD1 in the invasive behaviour of breast cancer cell lines in two-dimensional (2D) and three-dimensional (3D) culture. Invasive behaviour in breast cancer cell lines has been linked to matrix metalloproteinases (MMPs), so we also determined if PKD1 regulates the expression and activity of these enzymes.
   Results We found that the serine/threonine kinase, PKD1, is highly expressed in ductal epithelial cells of normal human breast tissue, but is reduced in its expression in more than 95% of all analysed samples of human invasive breast tumours. Additionally, PKD1 is not expressed in highly invasive breast cancer cell lines, whereas non-invasive or very low-invasive breast cancer cell lines express PKD1. Our results further implicate that in MDA-MB-231 cells PKD1 expression is blocked by epigenetic silencing via DNA methylation. The re-expression of constitutively-active PKD1 in MDA-MB-231 cells drastically reduced their ability to invade in 2D and 3D cell culture. Moreover, MCF-7 cells acquired the ability to invade in 2D and 3D cell culture when PKD1 expression was knocked-down by shRNA. PKD1 also regulated the expression of breast cancer cell MMPs, MMP-2, MMP-7, MMP-9, MMP-10, MMP-11, MMP-13, MMP-14 and MMP-15, providing a potential mechanism for PKD1 mediation of the invasive phenotype.
   Conclusions Our results identify decreased expression of the PKD1 as a marker for invasive breast cancer. They further suggest that the loss of PKD1 expression increases the malignant potential of breast cancer cells. This may be due to the function of PKD1 as a negative regulator of MMP expression. Our data suggest re-expression of PKD1 as a potential therapeutic strategy.
C1 [Eiseler, Tim; Doeppler, Heike; Yan, Irene K.; Storz, Peter] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA.
   [Goodison, Steve] Univ Florida, Dept Surg, Jacksonville, FL 32209 USA.
C3 Mayo Clinic; State University System of Florida; University of Florida
RP Storz, P (通讯作者)，Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Griffin Bldg,4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM storz.peter@mayo.edu
FU Mayo Foundation and the Mayo Clinic Comprehensive Cancer Center; Mayo
   Clinic Breast Cancer SPORE [CA116201-03DR4]; NCI/NIH [R01CA108597]; 
   [1-HMT-3522-S1];  [T4/2]
FX The authors would like to thank James N. Ingle and other members of the
   Mayo Clinic Breast Cancer SPORE, and Dr. Edith Perez, as well as members
   of the Storz laboratory for insightful discussions. We thank Derek C.
   Radisky for the 1-HMT-3522-S1 and T4/2 cell lines and Brandy H.
   Edenfield and Pamela Kreinest of the Mayo Clinic Jacksonville
   Histopathology Facility for immunohistochemistry. This work was
   sponsored in part by funds from the Mayo Foundation and the Mayo Clinic
   Comprehensive Cancer Center, the Mayo Clinic Breast Cancer SPORE
   (CA116201-03DR4), a "Friends for an Earlier Breast Cancer Test" Grant
   (all to PS) and NCI/NIH R01CA108597 (SG).
CR Bartsch JE, 2003, J SURG RES, V110, P383, DOI 10.1016/S0022-4804(03)00007-6
   Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827
   CHABOTTAUX V, 2007, CLIN LAB INT, P8
   Chen J, 2008, CANCER RES, V68, P3844, DOI 10.1158/0008-5472.CAN-07-5156
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Eiseler T, 2007, FEBS LETT, V581, P4279, DOI 10.1016/j.febslet.2007.07.079
   Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200
   Farina AR, 2002, EUR J BIOCHEM, V269, P4476, DOI 10.1046/j.1432-1033.2002.03142.x
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760
   Ha CH, 2008, J BIOL CHEM, V283, P14590, DOI 10.1074/jbc.M800264200
   Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289
   Hegedüs L, 2008, J CELL PHYSIOL, V216, P480, DOI 10.1002/jcp.21417
   Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806
   Jaggi M, 2003, BIOCHEM BIOPH RES CO, V307, P254, DOI 10.1016/S0006-291X(03)01161-6
   Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816
   Kim M, 2008, CARCINOGENESIS, V29, P629, DOI 10.1093/carcin/bgm291
   Klampfer L, 2007, CANCER RES, V67, P8477, DOI 10.1158/0008-5472.CAN-07-0210
   Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170
   Liu LT, 2003, CANCER RES, V63, P3069
   MARTIN M, 2004, CLIN LAB INT, P16
   MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Nelson KK, 2004, FREE RADICAL BIO MED, V37, P768, DOI 10.1016/j.freeradbiomed.2004.06.008
   Palmantier R, 1996, CANCER RES, V56, P2206
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243
   Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066
   Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200
   Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3
   Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247
   Song J, 2006, AM J PHYSIOL-CELL PH, V290, pC1469, DOI 10.1152/ajpcell.00486.2005
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667
   Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009
   Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005
   Storz P, 2007, TRENDS CELL BIOL, V17, P13, DOI 10.1016/j.tcb.2006.11.003
   Thomas P, 2000, J PATHOL, V190, P150
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494
   Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148
   Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781
   Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033
   Zhang B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-83
NR 49
TC 116
Z9 128
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
IS 1
AR R13
DI 10.1186/bcr2232
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 448LY
UT WOS:000266265300017
PM 19243594
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lieberthal, JG
   Kaminsky, M
   Parkhurst, CN
   Tanese, N
AF Lieberthal, Jason G.
   Kaminsky, Marissa
   Parkhurst, Christopher N.
   Tanese, Naoko
TI The role of YY1 in reduced HP1α gene expression in invasive human breast
   cancer cells
SO BREAST CANCER RESEARCH
LA English
DT Article
ID HETEROCHROMATIN PROTEIN-1 HP1; TRANSCRIPTION FACTOR YY1; NONHISTONE
   CHROMOSOMAL-PROTEIN; HISTONE H3; METASTATIC PHENOTYPE; FACTOR
   YIN-YANG-1; LYSINE 9; DROSOPHILA; BINDING; PHOSPHORYLATION
AB Introduction Heterochromatin protein 1 (HP1) associates with chromatin by binding to histone H3 and contributes to gene silencing. There are three isoforms of HP1 in mammals: HP1 alpha, beta, and gamma. Studies have shown that the level of HP1 alpha is reduced in invasive human breast cancer cell lines such as MDA-MB-231 and HS578T compared with non-invasive cell lines such as MCF7 and T47D. It is hypothesized that reduced HP1 alpha expression may lead to impaired epigenetic silencing of genes that are important in the acquisition of an invasive phenotype. We set out to determine whether reduced expression of HP1 alpha in invasive breast cancer cell lines occurs at the level of transcription.
   Methods We used transient transfection assays to investigate the mechanism of differential transcriptional activity of the human HP1 alpha gene promoter in different cell lines. Mutational analysis of putative transcription factor binding sites in an HP1 alpha gene reporter construct was performed to identify transcription factors responsible for the differential activity. SiRNA-mediated knockdown and chromatin immunoprecipitation experiments were performed to determine the role of a specific transcription factor in regulating the HP1 alpha gene.
   Results The transcription factor yin yang 1 (YY1) was found to play a role in differential transcriptional activity of the HP1 alpha gene. Examination of the YY1 protein and mRNA levels revealed that both were reduced in the invasive cell line HS578T compared with MCF7 cells. YY1 knockdown in MCF7 cells resulted in a decreased level of HP1 alpha mRNA, indicating that YY1 positively regulates HP1 alpha expression. Chromatin immunoprecipitation experiments verified YY1 occupancy at the HP1 alpha gene promoter in MCF7 cells but not HS578T cells. Overexpression of YY1 in HS578T cells decreased cell migration in a manner independent of HP1 alpha overexpression.
   Conclusions Our data suggests that a reduction of YY1 expression in breast cancer cells could contribute to the acquisition of an invasive phenotype through increased cell migration as well as by reduced expression of HP1 alpha.
C1 [Tanese, Naoko] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
   NYU, Sch Med, Inst Canc, New York, NY 10016 USA.
C3 New York University; New York University
RP Tanese, N (通讯作者)，NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.
EM tanesn01@med.nyu.edu
OI Tanese, Naoko/0000-0002-1946-3211
FU U. S. Army Medical Research and Materiel Command [DAMD17-03-1-0660];
   National Institutes of Health Training [5T32 AI07180]
FX We thank Brian Dynlacht, Susan Logan, and Angus Wilson for their help
   and guidance throughout the course of this study, and David Lam for
   performing the initial experiments. We thank Richard Scarpulla for the
   antibody to NRF-1, Steve Braunstein for reagents, and members of the
   Tanese lab for help with the project. This work was supported in part by
   the U. S. Army Medical Research and Materiel Command under
   DAMD17-03-1-0660. JGL was supported in part by the National Institutes
   of Health Training Grant 5T32 AI07180.
CR Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923
   Affar E, 2006, MOL CELL BIOL, V26, P3565, DOI 10.1128/MCB.26.9.3565-3581.2006
   Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1
   Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037
   Daujat S, 2005, J BIOL CHEM, V280, P38090, DOI 10.1074/jbc.C500229200
   De Lange R, 2001, ANTICANCER RES, V21, P2329
   de Nigris F, 2006, EUR J CANCER, V42, P2420, DOI 10.1016/j.ejca.2006.06.008
   Dialynas GK, 2006, J BIOL CHEM, V281, P14350, DOI 10.1074/jbc.M600558200
   Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007
   Donohoe ME, 1999, MOL CELL BIOL, V19, P7237
   EISSENBERG JC, 1992, GENETICS, V131, P345
   Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7
   EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923
   Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207
   Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023
   Fanti L, 2003, GENETICA, V117, P135, DOI 10.1023/A:1022971407290
   Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080
   Grönroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101
   Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732
   Hale TK, 2006, MOL CELL, V22, P693, DOI 10.1016/j.molcel.2006.04.016
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hiragami K, 2005, CELL MOL LIFE SCI, V62, P2711, DOI 10.1007/s00018-005-5287-9
   JAMES TC, 1989, EUR J CELL BIOL, V50, P170
   JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   KELLUM R, 1995, J CELL SCI, V108, P1419
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372
   Moriuchi M, 1999, J IMMUNOL, V162, P5986
   Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194
   Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385
   Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0
   Nindl I, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-30
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Norwood LE, 2004, GENE, V336, P37, DOI 10.1016/j.gene.2004.04.003
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802
   Ryan RF, 1999, MOL CELL BIOL, V19, P4366
   SAUNDERS WS, 1993, J CELL SCI, V104, P573
   Schug Jonathan, 2008, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0206s21
   Seligson D, 2005, INT J ONCOL, V27, P131
   Shapiro E, 2008, J UROLOGY, V179, P2435, DOI 10.1016/j.juro.2008.01.091
   Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5
   Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3
   SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6
   SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789
   SMALLWOOD A, 2009, NAT STRUCT IN PRESS
   Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004
   Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9
   Vassallo MF, 2002, P NATL ACAD SCI USA, V99, P5919, DOI 10.1073/pnas.092025499
   Wang CC, 2006, EXPERT OPIN THER TAR, V10, P253, DOI 10.1517/14728222.10.2.253
   Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573
   Wasenius VM, 2003, CLIN CANCER RES, V9, P68
NR 60
TC 29
Z9 35
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
IS 3
AR R42
DI 10.1186/bcr2329
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 487WS
UT WOS:000269309200023
PM 19566924
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Matsuda, Y
   Schlange, T
   Oakeley, EJ
   Boulay, A
   Hynes, NE
AF Matsuda, Yutaka
   Schlange, Thomas
   Oakeley, Edward J.
   Boulay, Anne
   Hynes, Nancy E.
TI WNT signaling enhances breast cancer cell motility and blockade of the
   WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ANTAGONIST SFRP1; DIFFERENTIAL EXPRESSION; EPIGENETIC INACTIVATION;
   PROSTATE-CANCER; BETA-CATENIN; CYCLIN D1; IN-VIVO; GENES; PROLIFERATION;
   ACTIVATION
AB Introduction In breast cancer, deregulation of the WNT signaling pathway occurs by autocrine mechanisms. WNT ligands and Frizzled receptors are coexpressed in primary breast tumors and cancer cell lines. Moreover, many breast tumors show hypermethylation of the secreted Frizzled-related protein 1 (sFRP1) promoter region, causing low expression of this WNT antagonist. We have previously shown that the WNT pathway influences proliferation of breast cancer cell lines via activation of canonical signaling and epidermal growth factor receptor transactivation, and that interference with WNT signaling reduces proliferation. Here we examine the role of WNT signaling in breast tumor cell migration and on xenograft outgrowth.
   Methods The breast cancer cell line MDA-MB-231 was used to study WNT signaling. We examined the effects of activating or blocking the WNT pathway on cell motility by treatment with WNT ligands or by ectopic sFPR1 expression, respectively. The ability of sFRP1-expressing MDA-MB-231 cells to grow as xenografts was also tested. Microarray analyses were carried out to identify targets with roles in MDA-MB-231/sFRP1 tumor growth inhibition.
   Results We show that WNT stimulates the migratory ability of MDA-MB-231 cells. Furthermore, ectopic expression of sFRP1 in MDA-MB-231 cells blocks canonical WNT signaling and decreases their migratory potential. Moreover, the ability of MDA-MB-231/sFRP1-expressing cells to grow as xenografts in mammary glands and to form lung metastases is dramatically impaired. Microarray analyses led to the identification of two genes, CCND1 and CDKN1A, whose expression level is selectively altered in vivo in sFRP1-expressing tumors. The encoded proteins cyclin D1 and p21Cip1 were downregulated and upregulated, respectively, in sFRP1-expressing tumors, suggesting that they are downstream mediators of WNT signaling.
   Conclusions Our results show that the WNT pathway influences multiple biological properties of MDA-MB-231 breast cancer cells. WNT stimulates tumor cell motility; conversely sFRP1-mediated WNT pathway blockade reduces motility. Moreover, ectopic sFRP1 expression in MDA-MB-231 cells has a strong negative impact on tumor outgrowth and blocked lung metastases. These results suggest that interference with WNT signaling using sFRP1 to block the ligand-receptor interaction may be a valid therapeutic approach in breast cancer.
C1 [Matsuda, Yutaka; Schlange, Thomas; Oakeley, Edward J.; Boulay, Anne; Hynes, Nancy E.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland.
C3 Friedrich Miescher Institute for Biomedical Research
RP Hynes, NE (通讯作者)，Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.
EM nancy.hynes@fmi.ch
FU Swiss Cancer League [OCS-01445-12-2003]; Friedrich Miescher Institute
   for Biomedical Research (Basel, Switzerland); Novartis Research
   Foundation
FX The authors acknowledge the contribution of Herbert Angliker in
   processing the Affymetrix microarrays. YM and TS were supported by a
   grant from the Swiss Cancer League (OCS-01445-12-2003). The laboratory
   of NEH is supported by the Friedrich Miescher Institute for Biomedical
   Research ( Basel, Switzerland), part of the Novartis Research
   Foundation.
CR Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266
   Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200
   Ezan J, 2004, CARDIOVASC RES, V63, P731, DOI 10.1016/j.cardiores.2004.05.006
   González-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6
   Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040
   Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Jones C, 2007, BIOESSAYS, V29, P120, DOI 10.1002/bies.20526
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464
   Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Milovanovic T, 2004, INT J ONCOL, V25, P1337
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Shulewitz M, 2006, ONCOGENE, V25, P4361, DOI 10.1038/sj.onc.1209470
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200
   Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250
   Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145
   Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103
NR 44
TC 128
Z9 156
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
IS 3
AR R32
DI 10.1186/bcr2317
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 487WS
UT WOS:000269309200013
PM 19473496
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Reis-Filho, JS
AF Reis-Filho, Jorge S.
TI Next-generation sequencing
SO BREAST CANCER RESEARCH
LA English
DT Article
ID COPY-NUMBER-VARIATION; CANCER CELL-LINE; BREAST-CANCER; DUCTAL
   CARCINOMAS; HUMAN GENOME; TRANSCRIPTOME; RESISTANCE; MUTATION; LEUKEMIA;
   IDENTIFICATION
AB Next-generation sequencing (also known as massively parallel sequencing) technologies are revolutionising our ability to characterise cancers at the genomic, transcriptomic and epigenetic levels. Cataloguing all mutations, copy number aberrations and somatic rearrangements in an entire cancer genome at base pair resolution can now be performed in a matter of weeks. Furthermore, massively parallel sequencing can be used as a means for unbiased transcriptomic analysis of mRNAs, small RNAs and noncoding RNAs, genome-wide methylation assays and high-throughput chromatin immunoprecipitation assays. Here, I discuss the potential impact of this technology on breast cancer research and the challenges that come with this technological breakthrough.
C1 Inst Canc Res, Breakthrough Breast Canc Res Ctr, Mol Pathol Team, London SW3 6JB, England.
C3 University of London; Institute of Cancer Research - UK; Royal Marsden
   NHS Foundation Trust
RP Reis-Filho, JS (通讯作者)，Inst Canc Res, Breakthrough Breast Canc Res Ctr, Mol Pathol Team, 237 Fulham Rd, London SW3 6JB, England.
EM Jorge.Reis-Filho@icr.ac.uk
FU Breakthrough Breast Cancer; NHS
FX The author is grateful to the Molecular Pathology Team and Dr Britta
   Weigelt for critically reading this manuscript. JSR-F is funded in part
   by Breakthrough Breast Cancer. NHS funding to the NIHR Biomedical
   Research Centre is also acknowledged.
CR Alkan C, 2009, NAT GENET, V41, P1061, DOI 10.1038/ng.437
   Ashworth A, 2008, CANCER RES, V68, P10021, DOI 10.1158/0008-5472.CAN-08-2287
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Bruder CEG, 2008, AM J HUM GENET, V82, P763, DOI 10.1016/j.ajhg.2007.12.011
   Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Fullwood MJ, 2009, GENOME RES, V19, P521, DOI 10.1101/gr.074906.107
   Geyer FC, 2009, J CELL MOL MED, V13, P4090, DOI 10.1111/j.1582-4934.2009.00906.x
   Geyer FC, 2009, INT J SURG PATHOL, V17, P285, DOI 10.1177/1066896908328577
   Godin-Heymann N, 2008, MOL CANCER THER, V7, P874, DOI 10.1158/1535-7163.MCT-07-2387
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461
   Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lister R, 2009, GENOME RES, V19, P959, DOI 10.1101/gr.083451.108
   Maher CA, 2009, P NATL ACAD SCI USA, V106, P12353, DOI 10.1073/pnas.0904720106
   Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638
   Marchiò C, 2009, J PATHOL, V218, P301, DOI 10.1002/path.2572
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Morozova O, 2008, GENOMICS, V92, P255, DOI 10.1016/j.ygeno.2008.07.001
   Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266
   Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250
   Pettersson E, 2009, GENOMICS, V93, P105, DOI 10.1016/j.ygeno.2008.10.003
   Piotrowski A, 2008, HUM MUTAT, V29, P1118, DOI 10.1002/humu.20815
   Pusztai L, 2008, ONCOLOGIST, V13, P350, DOI 10.1634/theoncologist.2007-0216
   Reis JS, 2008, J PATHOL, V216, P394, DOI 10.1002/path.2419
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342
   Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088
   Tan DSP, 2007, LAB INVEST, V87, P737, DOI 10.1038/labinvest.3700593
   ten Bosch JR, 2008, J MOL DIAGN, V10, P484, DOI 10.2353/jmoldx.2008.080027
   Tucker T, 2009, AM J HUM GENET, V85, P142, DOI 10.1016/j.ajhg.2009.06.022
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Voelkerding KV, 2009, CLIN CHEM, V55, P641, DOI 10.1373/clinchem.2008.112789
   Walter MJ, 2009, P NATL ACAD SCI USA, V106, P12950, DOI 10.1073/pnas.0903091106
   Wang J, 2008, NATURE, V456, P60, DOI 10.1038/nature07484
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407
   WEIGELT B, 2009, NAT REV CLIN ONCOL
   Weigelt B, 2009, MODERN PATHOL, V22, P1401, DOI 10.1038/modpathol.2009.112
   Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Zhao Q, 2009, P NATL ACAD SCI USA, V106, P1886, DOI 10.1073/pnas.0812945106
NR 50
TC 116
Z9 176
U1 0
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
SU 3
AR S12
DI 10.1186/bcr2431
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 587IK
UT WOS:000276984100012
PM 20030863
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Tommasi, S
   Karm, DL
   Wu, XW
   Yen, Y
   Pfeifer, GP
AF Tommasi, Stella
   Karm, Deborah L.
   Wu, Xiwei
   Yen, Yun
   Pfeifer, Gerd P.
TI Methylation of homeobox genes is a frequent and early epigenetic event
   in breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID MAMMARY-GLAND DEVELOPMENT; POLYCOMB TARGET GENES; DNA METHYLATION;
   PROMOTER HYPERMETHYLATION; DEVELOPMENTAL REGULATORS; CPG ISLANDS;
   IN-SITU; EXPRESSION; PATTERNS; IDENTIFICATION
AB Introduction Aberrant methylation of CpG islands is a hallmark of cancer and occurs at an early stage in breast tumorigenesis. However, its impact on tumor development is not fully determined, and its potential as a diagnostic biomarker remains to be validated. Methylation profiling of invasive breast carcinoma has been largely explored. Conversely, very little and sparse information is available on early-stage breast cancer. To gain insight into the epigenetic switches that may promote and/or contribute to the initial neoplastic events during breast carcinogenesis, we have analyzed the DNA methylation profile of ductal carcinoma in situ, a premalignant breast lesion with a great potential to progress toward invasive carcinoma.
   Methods We have utilized a comprehensive and sensitive array-based DNA mapping technique, the methylated-CpG island recovery assay, to profile the DNA methylation pattern in ductal carcinoma in situ. Differential methylation of CpG islands was compared genome-wide in tumor DNA versus normal DNA utilizing a statistical linear model in the LIMMA software package.
   Results Using this approach, we have identified 108 significant CpG islands that undergo aberrant DNA methylation in ductal carcinoma in situ and stage I breast tumors, with methylation frequencies greater than or comparable with those of more advanced invasive carcinoma (50% to 93%). A substantial fraction of these hypermethylated CpG islands (32% of the annotated CpG islands) is associated with several homeobox genes, such as the TLX1, HOXB13, and HNF1B genes. Fifty-three percent of the genes hypermethylated in early-stage breast cancer overlap with known Polycomb targets and include homeobox genes and other developmental transcription factors.
   Conclusions We have identified a series of new potential methylation biomarkers that may help elucidate the underlying mechanisms of breast tumorigenesis. More specifically, our results are suggestive of a critical role of homeobox gene methylation in the insurgence and/or progression of breast cancer.
C1 [Tommasi, Stella; Karm, Deborah L.; Pfeifer, Gerd P.] Beckman Res Inst City Hope, Dept Canc Biol, Duarte, CA 91010 USA.
   [Wu, Xiwei] Beckman Res Inst City Hope, Div Informat Sci, Duarte, CA 91010 USA.
   [Yen, Yun] Beckman Res Inst City Hope, Dept Clin & Mol Pharmacol, Duarte, CA 91010 USA.
C3 City of Hope; Beckman Research Institute of City of Hope; City of Hope;
   Beckman Research Institute of City of Hope; City of Hope; Beckman
   Research Institute of City of Hope
RP Tommasi, S (通讯作者)，Beckman Res Inst City Hope, Dept Canc Biol, Duarte, CA 91010 USA.
EM stommasi@coh.org
RI Tommasi, Stefania/J-6732-2012
OI Tommasi, Stella/0000-0001-6897-4985
FU NIH [CA084469, CA128495]
FX The authors would like to thank Dr Tibor Rauch and Maricela Covarrubias
   for help with MIRA and microarray processing, and thank Dr Therese
   Ibrahim for help with tumor retrieval. They are also grateful to Dr
   Ahmad Besaratinia for critical reading of the manuscript and to Dr Ben
   Paz for helpful discussion. This work was supported by NIH grants to GPP
   (CA084469 and CA128495).
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525
   Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Coletta RD, 2004, J MAMMARY GLAND BIOL, V9, P39, DOI 10.1023/B:JOMG.0000023587.40966.f6
   Ding L, 2006, CANCER RES, V66, P9352, DOI 10.1158/0008-5472.CAN-06-2384
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th
   Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holland PWH, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-47
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Melnikov AA, 2008, J MOL DIAGN, V10, P93, DOI 10.2353/jmoldx.2008.070077
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Piotrowski A, 2006, GENE CHROMOSOME CANC, V45, P656, DOI 10.1002/gcc.20331
   Raaphorst FM, 2005, HUM MOL GENET, V14, pR93, DOI 10.1093/hmg/ddi111
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Rauch T, 2005, LAB INVEST, V85, P1172, DOI 10.1038/labinvest.3700311
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Ringrose L, 2007, CURR OPIN CELL BIOL, V19, P290, DOI 10.1016/j.ceb.2007.04.010
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yan PS, 2001, CANCER RES, V61, P8375
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 57
TC 119
Z9 136
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
IS 1
AR R14
DI 10.1186/bcr2233
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 448LY
UT WOS:000266265300018
PM 19250546
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wiesmann, F
   Veeck, J
   Galm, O
   Hartmann, A
   Esteller, M
   Knüchel, R
   Dahl, E
AF Wiesmann, Frank
   Veeck, Juergen
   Galm, Oliver
   Hartmann, Arndt
   Esteller, Manel
   Knuechel, Ruth
   Dahl, Edgar
TI Frequent loss of endothelin-3 (EDN3) expression due to epigenetic
   inactivation in human breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; TUMOR CELL INVASION; PROSTATE-CANCER; B
   RECEPTOR; PROGNOSTIC MARKER; CARCINOMA-CELLS; OVARIAN-CANCER;
   GROWTH-FACTOR; EMERGING ROLE; CPG ISLANDS
AB Introduction Endothelin (EDN) signalling plays a crucial role in cell differentiation, proliferation and migration processes. There is compelling evidence that altered EDN signalling is involved in carcinogenesis by modulating cell survival and promoting invasiveness. To date, most reports have focused on the oncogenic potential of EDN1 and EDN2, both of which are overexpressed in various tumour entities. Here, we aimed at a first comprehensive analysis on EDN3 expression and its implication in human breast cancer.
   Methods EDN3 mRNA expression was assessed by Northern blotting in normal human tissues (n = 9) as well as in matched pairs of normal and tumourous tissues from breast specimens (n = 50). EDN3 mRNA expression in breast cancer was further validated by real-time polymerase chain reaction (PCR) (n = 77). A tissue microarray was used to study EDN3 protein expression in breast carcinoma (n = 150) and normal breast epithelium (n = 44). EDN3 promoter methylation was analysed by methylation-specific PCR in breast cell lines (n = 6) before and after demethylating treatment, normal breast tissues (n = 17) and primary breast carcinomas (n = 128). EDN3 expression and methylation data were statistically correlated with clinical patient characteristics and patient outcome.
   Results Loss of EDN3 mRNA expression in breast cancer, as initially detected by array-based expression profiling, could be confirmed by Northern blot analysis (> 2-fold loss in 96%) and real-time PCR (> 2-fold loss in 78%). Attenuated EDN3 expression in breast carcinoma was also evident at the protein level (45%) in association with adverse patient outcome in univariate (P = 0.022) and multivariate (hazard ratio 2.0; P = 0.025) analyses. Hypermethylation of the EDN3 promoter could be identified as the predominant mechanism leading to gene silencing. Reversion of the epigenetic lock by 5-aza-2'-deoxycytidine and trichostatin A resulted in EDN3 mRNA reexpression in vitro. Furthermore, EDN3 promoter hypermethylation was detected in 70% of primary breast carcinomas with significant association to loss of EDN3 mRNA expression (P = 0.005), whilst normal matched breast tissues revealed no EDN3 promoter methylation.
   Conclusions EDN3 is a frequent target of epigenetic inactivation in human breast cancer, potentially contributing to imbalanced EDN signalling commonly found in this disease. The clinical implication supports the view that EDN3, in contrast to EDN1 and EDN2, may act as natural tumour suppressor in the human mammary gland.
C1 [Wiesmann, Frank; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Univ Hosp, Mol Oncol Grp, Inst Pathol, D-52074 Aachen, Germany.
   [Veeck, Juergen; Esteller, Manel] Bellvitge Inst Biomed Res ICO IDIBELL, Canc Epigenet & Biol Program PEBC, Canc Epigenet Grp, E-08907 Barcelona, Spain.
   [Galm, Oliver] Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med Haematol Oncol 4, D-52074 Aachen, Germany.
   [Hartmann, Arndt] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); RWTH Aachen University;
   RWTH Aachen University Hospital; University of Erlangen Nuremberg
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Univ Hosp, Mol Oncol Grp, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Veeck, Jurgen/B-9256-2008; Esteller, Manel/L-5956-2014
OI Veeck, Jurgen/0000-0002-2952-6159; Esteller, Manel/0000-0003-4490-6093
FU Bundesministerium fur Bildung und Forschung (BMBF) [01KW040-1]
FX The excellent technical assistance from Sonja von Serenyi, Sevim Alkaya
   and Inge Losen is greatly appreciated. We thank Dieter Niederacher
   (Heinrich-Heine University, Dusseldorf, Germany) and Matthias Durst
   (Friedrich-Schiller University, Jena, Germany) for kindly providing
   patient samples. We thank Monika Klinkhammer-Schalke and Felicitas Horn
   (Tumour Registry, Regensburg, Germany) for continuous help in obtaining
   clinical patient information and follow-up data. Immunohistochemical
   scoring was kindly performed by Nuran Bektas (Institute of Pathology,
   University Hospital of the RWTH, Aachen, Germany). HMEC DNA was a
   generous gift by Bernhard Luscher (Institute of Biochemistry, University
   Hospital of the RWTH, Aachen, Germany). This work is a research project
   within the German Human Genome Project and was supported by a grant from
   the Bundesministerium fur Bildung und Forschung (BMBF) to ED
   (01KW040-1).
CR Akhavan A, 2006, NEOPLASIA, V8, P725, DOI 10.1593/neo.06388
   Alanen K, 2000, HISTOPATHOLOGY, V36, P161
   Bagnato A, 1998, TRENDS ENDOCRIN MET, V9, P378, DOI 10.1016/S1043-2760(98)00094-0
   Bagnato A, 2005, ENDOCR-RELAT CANCER, V12, P761, DOI 10.1677/erc.1.01077
   Bagnato A, 2002, CANCER RES, V62, P6381
   Bagnato Anna, 2004, J Transl Med, V2, P16, DOI 10.1186/1479-5876-2-16
   Berry P, 2002, CLIN SCI, V103, p322S, DOI 10.1042/CS103S322S
   Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893
   Chen SC, 2006, ONCOL REP, V15, P167
   Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687
   Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090
   Donninger H, 2004, ONCOGENE, V23, P8065, DOI 10.1038/sj.onc.1207959
   Dréau D, 2006, CLIN EXP METASTAS, V23, P41, DOI 10.1007/s10585-006-9016-z
   ELSTON CW, 1993, J CLIN PATHOL, V46, P189
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Grimshaw MJ, 2007, ENDOCR-RELAT CANCER, V14, P233, DOI 10.1677/ERC-07-0057
   Grimshaw MJ, 2005, CANCER LETT, V222, P129, DOI 10.1016/j.canlet.2004.08.029
   Grimshaw MJ, 2004, CANCER RES, V64, P2461, DOI 10.1158/0008-5472.CAN-03-1069
   Hagemann T, 2005, DNA CELL BIOL, V24, P766, DOI 10.1089/dna.2005.24.766
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hsiao PC, 2008, CHINESE J PHYSIOL, V51, P27
   Hsu LS, 2006, ONCOL REP, V15, P507
   Jazaeri AA, 2005, CLIN CANCER RES, V11, P6300, DOI 10.1158/1078-0432.CCR-04-2682
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Kopetz ES, 2002, INVEST NEW DRUG, V20, P173, DOI 10.1023/A:1015630513908
   LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lo KW, 2002, INT J CANCER, V98, P651, DOI 10.1002/ijc.10271
   Masaki T, 2000, J CARDIOVASC PHARM, V35, pS3, DOI 10.1097/00005344-200000002-00002
   Mateo AO, 1997, PHARMACOL RES, V36, P339, DOI 10.1006/phrs.1997.0246
   MITAKA C, 1994, AM J PHYSIOL-HEART C, V267, pH1530, DOI 10.1152/ajpheart.1994.267.4.H1530
   Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
   Nelson JB, 1996, CANCER RES, V56, P663
   Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903
   Pflug BR, 2007, CANCER LETT, V246, P139, DOI 10.1016/j.canlet.2006.02.007
   Pla P, 2003, INT J DEV BIOL, V47, P315
   POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rosano L, 2007, MOL CANCER THER, V6, P2003, DOI 10.1158/1535-7163.MCT-07-0151
   Smollich M, 2007, CURR VASC PHARMACOL, V5, P239
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200
   Sun DJ, 2007, HUM PATHOL, V38, P1047, DOI 10.1016/j.humpath.2006.12.015
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Thomson E, 2006, EXP BIOL MED, V231, P979
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   WALLACE BA, 1995, PROTEIN SCI, V4, P75
   Wülfing P, 2003, CLIN CANCER RES, V9, P4125
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Zhao BJ, 2009, DIS ESOPHAGUS, V22, P55, DOI 10.1111/j.1442-2050.2008.00848.x
NR 53
TC 42
Z9 46
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2009
VL 11
IS 3
AR R34
DI 10.1186/bcr2319
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 487WS
UT WOS:000269309200015
PM 19527488
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Thomassen, M
   Tan, QH
   Kruse, TA
AF Thomassen, Mads
   Tan, Qihua
   Kruse, Torben A.
TI Gene expression meta-analysis identifies chromosomal regions and
   candidate genes involved in breast cancer metastasis
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Metastasis; Distant metastasis; Metastasis genes; Causal genes; Breast
   cancer; Somatic mutations; Copy number; Microarray; Gene expression
   profiling
ID PROTEIN EXPRESSION; POOR-PROGNOSIS; ALLELIC LOSS; SURVIVAL; ASSOCIATION;
   PROFILES; HETEROZYGOSITY; SIGNATURE; RECEPTOR; OVARIAN
AB Breast cancer cells exhibit complex karyotypic alterations causing deregulation of numerous genes. Some of these genes are probably causal for cancer formation and local growth whereas others are causal for the various steps of metastasis. In a fraction of tumors deregulation of the same genes might be caused by epigenetic modulations, point mutations or the influence of other genes. We have investigated the relation of gene expression and chromosomal position, using eight datasets including more than 1200 breast tumors, to identify chromosomal regions and candidate genes possibly causal for breast cancer metastasis. By use of "Gene Set Enrichment Analysis" we have ranked chromosomal regions according to their relation to metastasis. Overrepresentation analysis identified regions with increased expression for chromosome 1q41-42, 8q24, 12q14, 16q22, 16q24, 17q12-21.2, 17q21-23, 17q25, 20q11, and 20q13 among metastasizing tumors and reduced gene expression at 1p31-21, 8p22-21, and 14q24. By analysis of genes with extremely imbalanced expression in these regions we identified DIRAS3 at 1p31, PSD3, LPL, EPHX2 at 8p21-22, and FOS at 14q24 as candidate metastasis suppressor genes. Potential metastasis promoting genes includes RECQL4 at 8q24, PRMT7 at 16q22, GINS2 at 16q24, and AURKA at 20q13.
C1 [Thomassen, Mads; Tan, Qihua; Kruse, Torben A.] Odense Univ, Dept Biochem Pharmacol & Genet, Odense, Denmark.
   [Thomassen, Mads; Tan, Qihua; Kruse, Torben A.] Univ So Denmark, Human Microarray Ctr, Odense, Denmark.
C3 University of Southern Denmark; University of Southern Denmark
RP Thomassen, M (通讯作者)，Odense Univ, Dept Biochem Pharmacol & Genet, Odense, Denmark.
EM mads.thomassen@ouh.regionsyddanmark.dk;
   qihua.tan@ouh.regionsyddanmark.dk; torben.kruse@ouh.regionsyddanmark.dk
RI Tan, Qihua/F-1349-2015
OI Tan, Qihua/0000-0003-3194-0030
CR Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945
   BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406
   Buffart TE, 2005, CELL ONCOL, V27, P57
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517
   Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985
   Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293
   Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   Hansen LL, 1998, CANCER RES, V58, P2166
   Heintel D, 2005, LEUKEMIA, V19, P1216, DOI 10.1038/sj.leu.2403748
   Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   ISOLA JJ, 1995, AM J PATHOL, V147, P905
   Janssen EAM, 2003, J PATHOL, V201, P555, DOI 10.1002/path.1475
   Karlsson E, 2007, CANCER GENET CYTOGEN, V172, P139, DOI 10.1016/j.cancergencyto.2006.09.019
   Kauraniemi P, 2003, AM J PATHOL, V163, P1979, DOI 10.1016/S0002-9440(10)63556-0
   Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095
   Landen CN, 2007, CLIN CANCER RES, V13, P4098, DOI 10.1158/1078-0432.CCR-07-0431
   Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245
   Martin MD, 2001, CANCER RES, V61, P3578
   Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Morikawa A, 2005, BREAST CANCER RES, V7, pR1051, DOI 10.1186/bcr1349
   Narayan G, 2007, GENE CHROMOSOME CANC, V46, P373, DOI 10.1002/gcc.20418
   PARSSINEN J, 2007, BR J CANC
   Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538
   Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234
   Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636
   Royce ME, 2004, CANCER, V100, P12, DOI 10.1002/cncr.11879
   Seki T, 2006, J BIOL CHEM, V281, P21422, DOI 10.1074/jbc.M603482200
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   TAN Q, 2007, CANC INFORM, V2, P133
   Thomassen M, 2007, CLIN CANCER RES, V13, P5355, DOI 10.1158/1078-0432.CCR-07-0249
   Thomassen M, 2007, INT J CANCER, V120, P1070, DOI 10.1002/ijc.22449
   Turbin DA, 2006, MODERN PATHOL, V19, P69, DOI 10.1038/modpathol.3800484
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570
   Wennmalm K, 2007, GENE CHROMOSOME CANC, V46, P87, DOI 10.1002/gcc.20392
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
NR 46
TC 92
Z9 105
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2009
VL 113
IS 2
BP 239
EP 249
DI 10.1007/s10549-008-9927-2
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 391KV
UT WOS:000262233100006
PM 18293085
DA 2025-01-12
ER

PT J
AU Bhavani, V
   Srinivasulu, M
   Ahuja, YR
   Hasan, Q
AF Bhavani, V.
   Srinivasulu, M.
   Ahuja, Y. R.
   Hasan, Q.
TI Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue
SO CANCER BIOMARKERS
LA English
DT Article
DE Breast cancer; BRCA1; estrogen; HSD17Bs; Methylation
ID TUMOR-RELATED GENES; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-1;
   PROMOTER HYPERMETHYLATION; SPORADIC BREAST; DNA METHYLATION; CPG ISLAND;
   REGION; EXPRESSION; CARCINOMA; DISEASE
AB The pattern of altered gene expression due to epigenetic change is of major importance in malignancies. Aberrant DNA methylation is one of the many potential causes for this and is considered to be an early event in the etiology of breast carcinogenesis.
   The present study assessed the methylation status of three genes relevant in breast cancer (BC): The breast cancer susceptibility gene 1 (BRCA1), 17 beta hydroxy steroid dehydrogenase type 1 (HSD17B1) and type 2 (HSD17B2). Restriction enzyme based Methylation specific PCR (REMS PCR) was carried out in 104 tumor samples from sporadic BC patients and 48 samples of adjacent normal breast tissue.
   The percentage of tumor samples showing BRCA1, HSD17B1 and HSD17B2 methylation was 20.4%, 83.3% and 31.3%, respectively. Methylation was higher in tumors when compared to adjacent normal breast tissue samples. This suggests that methylation of these three genes plays an important role in BC etiology. Methylation is responsible for gene silencing and since BRCA1 and HSD17B2 were not found to be methylated in the same tissue samples, this suggests that the etiology of > 50% of the tumors could be accounted for by the independent epigenetic silencing of these two genes. BRCA1 and HSD17B2 genes may increase the risk of developing BC via enhanced estradiol activity. It is for the first time that the role of HSD17B gene methylation in BC pathophysiology is being proposed.
C1 [Hasan, Q.] Kamineni Hosp, Dept Genet & Mol Med, Hyderabad 500068, Andhra Pradesh, India.
   [Bhavani, V.; Ahuja, Y. R.; Hasan, Q.] Vasavi Hosp & Res Ctr, Dept Genet, Hyderabad, Andhra Pradesh, India.
   [Bhavani, V.] Bhagwan Mahavir Med Res Ctr, Dept Genet, Hyderabad, Andhra Pradesh, India.
   [Srinivasulu, M.] MNJ Canc Hosp, Dept Oncol, Hyderabad, Andhra Pradesh, India.
RP Hasan, Q (通讯作者)，Kamineni Hosp, Dept Genet & Mol Med, Hyderabad 500068, Andhra Pradesh, India.
EM qhasan2000@yahoo.com
FU Department of Science and Technology, Govt. of India [SR/SO/HS-89/2004]
FX This work was supported by a grant (SR/SO/HS-89/2004) from the
   Department of Science and Technology, Govt. of India.
CR Baker ME, 2001, MOL CELL ENDOCRINOL, V171, P211, DOI 10.1016/S0303-7207(00)00414-7
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Chopra R, 2001, J CLIN ONCOL, V19, p106S
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Gunnarsson C, 2003, ONCOGENE, V22, P34, DOI 10.1038/sj.onc.1206078
   Hasan Qurratulain, 2004, Indian Journal of Experimental Biology, V42, P937
   HINSHELWOOD RA, 2008, J MOL MED        AUG, P21
   *IARC, 2002, GLOB
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   KONTOROVICH T, 2008, BREAST CANC RES  JUL, P19
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Oduwole OO, 2004, CANCER RES, V64, P7604, DOI 10.1158/0008-5472.CAN-04-0446
   Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361
   Piao YS, 1997, ENDOCRINOLOGY, V138, P898, DOI 10.1210/en.138.3.898
   Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207
   Rajkumar Thangarajan, 2003, Asian Pac J Cancer Prev, V4, P203
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   Sasano Hironobu, 2006, Breast Cancer, V13, P129, DOI 10.2325/jbcs.13.129
   Saxena S, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-75
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   SUIJKERBUIJK KP, 2008, ANN ONCOL        JUL, P22
   Suzuki T, 2000, BRIT J CANCER, V82, P518
   Valarmathi Mani T, 2004, Hum Mutat, V23, P205, DOI 10.1002/humu.9213
   Vasavi M, 2006, TUMORI J, V92, P155, DOI 10.1177/030089160609200212
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   WIDSCHWENDTER M, 2008, EPIGENOTYPING PERIPH, V3, pE2656
NR 34
TC 11
Z9 12
U1 0
U2 9
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2009
VL 5
IS 4-5
BP 207
EP 213
DI 10.3233/CBM-2009-0105
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 492BO
UT WOS:000269629300006
PM 19729830
DA 2025-01-12
ER

PT J
AU Buyru, N
   Altinisik, J
   Ozdemir, F
   Demokan, S
   Dalay, N
AF Buyru, Nur
   Altinisik, Julide
   Ozdemir, Filiz
   Demokan, Semra
   Dalay, Nejat
TI Methylation Profiles in Breast Cancer
SO CANCER INVESTIGATION
LA English
DT Article
DE Breast cancer; DNA methylation; MS-MLPA
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; CPG ISLAND; PROMOTER
   HYPERMETHYLATION; MULTIPLE GENES; RAR-BETA; RASSF1A; INACTIVATION;
   SERUM; LUNG
AB In this study, we sought to assess the aberrant methylation of multiple tumor-suppressor genes in a single reaction by using methylation-specific multiplex ligation-dependent probe amplification. Breast tumors and corresponding normal tissues of 77 patients were analyzed. In this study, 17 of 24 genes displayed promoter methylation in one or more of the tumor samples. The most frequently methylated genes were RASSF1 and GSTP1, followed by DAPK1 and CDKN2B. Our data indicate that the methylation of specific genes is a frequent event in breast cancer and show that MS-MLPA is a powerful tool to analyze epigenetic alterations for diagnostic, as well as therapeutic, purposes.
C1 [Demokan, Semra; Dalay, Nejat] Istanbul Univ, Inst Oncol, TR-34093 Istanbul, Turkey.
   [Buyru, Nur; Altinisik, Julide; Ozdemir, Filiz] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, TR-34093 Istanbul, Turkey.
C3 Istanbul University; Istanbul University; Istanbul University -
   Cerrahpasa
RP Dalay, N (通讯作者)，Istanbul Univ, Inst Oncol, TR-34093 Istanbul, Turkey.
EM ndalay@yahoo.com
RI Demokan, Semra/AAC-5943-2020; Altinisik, Julide/AAD-9481-2021; Ozdemir,
   Filiz/AAC-5744-2020; Buyru, Nur/D-1810-2019
OI ALTINISIK, NUR JULIDE/0000-0002-9913-4388; Buyru,
   Nur/0000-0002-6920-1455
CR Aggerholm A, 1999, CANCER RES, V59, P436
   ARAI T, 2006, BREAST CANC RES TREA, V100, P659
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Calmon MF, 2007, CANCER GENET CYTOGEN, V173, P31, DOI 10.1016/j.cancergencyto.2006.09.008
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R
   Dodge JE, 2001, LEUKEMIA RES, V25, P917, DOI 10.1016/S0145-2126(01)00053-4
   Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 1998, CANCER RES, V58, P4515
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lindberg D, 2008, CLIN ENDOCRINOL, V68, P271, DOI 10.1111/j.1365-2265.2007.03034.x
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Müller HM, 2003, CANCER RES, V63, P7641
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   Wang Y, 2008, CANCER-AM CANCER SOC, V112, P1325, DOI 10.1002/cncr.23312
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zhang Y, 1999, Zhonghua Xue Ye Xue Za Zhi, V20, P628
NR 40
TC 24
Z9 25
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0735-7907
EI 1532-4192
J9 CANCER INVEST
JI Cancer Invest.
PY 2009
VL 27
IS 3
BP 307
EP 312
DI 10.1080/07357900802350814
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 436CH
UT WOS:000265389700010
PM 19194828
DA 2025-01-12
ER

PT J
AU Lambertini, L
   Diplas, AI
   Wetmur, J
   Lee, MJ
   Chen, J
AF Lambertini, Luca
   Diplas, Andreas I.
   Wetmur, James
   Lee, Men-Jean
   Chen, Jia
TI Evaluation of genomic imprinting employing the analysis of Loss Of
   Imprinting (LOI) at the RNA level: preliminary results
SO EUROPEAN JOURNAL OF ONCOLOGY
LA English
DT Article
DE Loss Of Imprinting (LOI); Intra-Uterine Growth Restriction (IUGR); human
   placenta; gene expression; quantitative Allele-Specific PCR (qASPCR)
ID INTRAUTERINE GROWTH RESTRICTION; EXTENSION MS-SNUPE; BIRTH-WEIGHT;
   MAMMALIAN DEVELOPMENT; GESTATIONAL-AGE; PERINATAL-MORTALITY;
   GENE-EXPRESSION; HUMAN PLACENTA; METHYLATION; DNA
AB Aim. This manuscript summarizes the first results obtained on the investigation of the relationship between genomic imprinting dysregulation and intra-uterine growth restriction ( IUGR). Genomic imprinting refers to the silencing of one parental allele in the zygotes depending upon the parent of origin; this silencing occurs via epigenetic processes such as DNA methylation and histone modification resulting in monoallelic expression of the affected genes in the offspring. Genomic imprinting plays a critical role in placental and fetal development. Emerging evidence implicates Loss Of Imprinting (LOI) in reproductive and developmental diseases, neurological disorders and cancer. IUGR accounts for similar to 10% of all pregnancies in the US, it is associated with major postnatal morbidity and mortality in the newborn period and it has been associated with abnormalities in fetal growth that have been linked with developmental origins of many adult disorders, such as obesity and breast cancer. Some developmental syndromes have been moreover associated with known imprinted genes often seen in IUGR pregnancies that may therefore themself be associated with genomic imprinting dysregulation. Materials and Methods. We developed a functional and highly sensitive assay at the RNA level for measuring LOI. We also analyzed imprinted gene expression in normal and IUGR placentas by real-time PCR. Results. We showed that LOI is a common phenomenon in placenta that preferentially affects specific imprinted genes in IUGR compared to control placentas; however, this does not correlate with changes in expression of genes with a perturbed imprinting profile. Conclusions. Genomic imprinting dysregulation plays a role in the etiology of IUGR. Eur. J. Oncol., 14 (3), 161-169, 2009
C1 [Lambertini, Luca; Diplas, Andreas I.; Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA.
   [Wetmur, James] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   [Wetmur, James] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Lee, Men-Jean] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn
   School of Medicine at Mount Sinai
RP Lambertini, L (通讯作者)，Mt Sinai Sch Med, Dept Prevent Med, 17 E 102nd St,Box 1057, New York, NY 10029 USA.
EM luca.lambertini@mssm.edu
RI Chen, Jia/HQZ-3908-2023
OI Lambertini, Luca/0000-0003-3326-219X
FU National Institutes of Health [NO1 AI50028, U19 AI06231, P50 ES09584];
   Mount Sinai Children's Environmental Health Center [R827039]; Mount
   Sinai Child Health and Development Institute
FX Questo studio e stato supportato dai finanziamenti NO1 AI50028, U19
   AI06231 e P50 ES09584 dei National Institutes of Health, R827039 del
   U.S. Environmental Protection Administration e dal Venture Capital
   Research Funding Program del Mount Sinai Children's Environmental Health
   Center e Mount Sinai Child Health and Development Institute
CR Alexander GR, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e61
   [Anonymous], CONTRIBUTIONS CANADI
   [Anonymous], NCEH PUB
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Basso O, 2006, AM J EPIDEMIOL, V164, P303, DOI 10.1093/aje/kwj237
   Byun HM, 2007, CANCER RES, V67, P10753, DOI 10.1158/0008-5472.CAN-07-0329
   Chaddha Vandana, 2004, Semin Fetal Neonatal Med, V9, P357, DOI 10.1016/j.siny.2004.03.006
   Charalambous Marika, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P3, DOI 10.1097/MED.0b013e328013daa2
   Chen J, 2002, CANCER EPIDEM BIOMAR, V11, P131
   Chotalia M, 2009, GENE DEV, V23, P105, DOI 10.1101/gad.495809
   Coan PM, 2005, PLACENTA, V26, pS10, DOI 10.1016/j.placenta.2004.12.009
   Dindot SV, 2009, GENOME RES, V19, P1374, DOI 10.1101/gr.089185.108
   Diplas AI, 2009, EPIGENETICS-US, V4, P235, DOI 10.4161/epi.9019
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6
   Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s
   Gonzalgo ML, 2002, METHODS, V27, P128, DOI 10.1016/S1046-2023(02)00064-6
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Guo L, 2008, DEV BIOL, V320, P79, DOI 10.1016/j.ydbio.2008.04.025
   HAIG D, 1991, CELL, V64, P1045
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491
   Latini G, 2003, ENVIRON HEALTH PERSP, V111, P1783, DOI 10.1289/ehp.6202
   Lewis A, 2006, CYTOGENET GENOME RES, V113, P81, DOI 10.1159/000090818
   Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468
   Luedi PP, 2007, GENOME RES, V17, P1723, DOI 10.1101/gr.6584707
   Maynard ND, 2008, NAT METHODS, V5, P307, DOI [10.1038/NMETH.1194, 10.1038/nmeth.1194]
   MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1
   McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603
   McMinn J, 2006, PLACENTA, V27, P540, DOI 10.1016/j.placenta.2005.07.004
   Monk D, 2006, P NATL ACAD SCI USA, V103, P6623, DOI 10.1073/pnas.0511031103
   MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N
   Rakyan V, 2003, CURR BIOL, V13, pR6, DOI 10.1016/S0960-9822(02)01377-5
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Resnik R, 2002, OBSTET GYNECOL, V99, P490, DOI 10.1016/S0029-7844(01)01780-X
   Royo H, 2008, BIOL CELL, V100, P149, DOI 10.1042/BC20070126
   Santos F, 2004, REPRODUCTION, V127, P643, DOI 10.1530/rep.1.00221
   SASAKY H, 2006, CYTOGENETIC GENOME R
   Savitz DA, 2004, ETHNIC DIS, V14, P322
   Schabus M, 2006, J SLEEP RES, V15, P50
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Silva MJ, 2004, B ENVIRON CONTAM TOX, V72, P1226, DOI 10.1007/s00128-004-0374-4
   Smith GCS, 2004, SEMIN PERINATOL, V28, P41, DOI 10.1053/j.semperi.2003.10.012
   Svensson AC, 2006, AM J OBSTET GYNECOL, V194, P475, DOI 10.1016/j.ajog.2005.08.019
   Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0
   Tycko B, 2002, J CELL PHYSIOL, V192, P245, DOI 10.1002/jcp.10129
   Wagschal A, 2006, CYTOGENET GENOME RES, V113, P90, DOI 10.1159/000090819
   Walter J, 2003, SEMIN CELL DEV BIOL, V14, P101, DOI 10.1016/S1084-9521(02)00142-8
   WILCOX AJ, 1992, AM J PUBLIC HEALTH, V82, P378, DOI 10.2105/AJPH.82.3.378
   WILCOX AJ, 1993, AM J EPIDEMIOL, V137, P1098, DOI 10.1093/oxfordjournals.aje.a116613
   Wyatt SM, 2005, PLACENTA, V26, P372, DOI 10.1016/j.placenta.2004.07.003
NR 51
TC 3
Z9 3
U1 0
U2 2
PU MATTIOLI 1885
PI FIDENZA
PA VIA DELLA LODESANA 649-SX, FIDENZA, 43046 PR, ITALY
SN 1128-6598
J9 EUR J ONCOL
JI Eur. J. Oncol.
PY 2009
VL 14
IS 3
BP 161
EP 169
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 613UC
UT WOS:000279005900004
DA 2025-01-12
ER

PT J
AU Rivenbark, AG
   Coleman, WB
AF Rivenbark, Ashley G.
   Coleman, William B.
TI Epigenetic regulation of cystatins in cancer
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Cancer; Cystatins; Epigenetic; DNA Methylation; Cysteine Protease
   Inhibitor; Review
ID CYSTEINE PROTEINASE-INHIBITOR; ABERRANT PROMOTER METHYLATION; HUMAN
   COLON-CARCINOMA; CATHEPSIN-B; DNA METHYLATION; BREAST-CANCER;
   LAMININ-5-ENCODING GENES; CELL-LINES; STEFIN-A; ENDOGENOUS INHIBITORS
AB Cystatins function as cysteine protease inhibitors, are expressed in numerous cell types, and regulate a number of physiological processes. The cystatin superfamily consists of 12 members that divide into three types based on protein structure, location in the body, and physiological role. Four cystatin family members have been extensively studied: cystatin A, cystatin B, cystatin C, and cystatin M. Aberrant regulation of cystatin family members has been noted in a number of diseases, including cancer and certain neurodegenerative disorders. Recent advances in the understanding of cystatin function suggest that these proteins may regulate promotion or suppression of tumor growth, invasion, and metastasis. Cancer is a disease of abnormal gene expression characterized by inappropriate expression of positive mediators of cell proliferation in conjunction with diminished expression of negative mediators of cell growth. Cancer cells of many different human neoplasms exhibit aberrant epigenetic events (such as DNA methylation), which lead to gene silencing. Members of the cystatin family are epigenetically silenced through DNA methylation-dependent mechanisms in several forms of cancer, including breast, pancreatic, brain, and lung. These findings suggest that DNA methylation-dependent epigenetic mechanisms may play an important role in the loss of cystatin gene expression and protein function during neoplastic transformation and/or tumor progression. This review summarizes the biological processes in which cystatins function, focuses on the neoplastic events that involve aberrant regulation of cystatins, and discusses the possible epigenetic regulation of cystatins in cancer.
C1 [Rivenbark, Ashley G.; Coleman, William B.] Univ N Carolina, Dept Pathol & Lab Med, UNC Lineberger Comprehens Canc Ctr, Curriculum Toxicol,Sch Med, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP Coleman, WB (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, UNC Lineberger Comprehens Canc Ctr, Curriculum Toxicol,Sch Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM william.coleman@pathology.unc.edu
FU Susan G. Komen Breast Cancer Foundation [BCTR0100575]; National Cancer
   Institute (NIH) [CA78343]
FX This work was supported by grants from the Susan G. Komen Breast Cancer
   Foundation (BCTR0100575) and the National Cancer Institute (NIH grant
   CA78343).
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x
   Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004
   CORTICCHIATO O, 1992, INT J CANCER, V52, P645
   Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.0.CO;2-M
   Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345
   Deng GR, 2004, CANCER RES, V64, P2692, DOI 10.1158/0008-5472.CAN-03-3000
   Domej W, 2002, CLIN SCI, V102, P373, DOI 10.1042/CS20010168
   Dubin G, 2005, CELL MOL LIFE SCI, V62, P653, DOI 10.1007/s00018-004-4445-9
   Elzagheid A, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-41
   ERDEL M, 1992, ANTICANCER RES, V12, P349
   Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harmoinen A, 2000, PEDIATR NEPHROL, V15, P105, DOI 10.1007/s004670000421
   HAYASHI H, 1960, J EXP MED, V112, P237, DOI 10.1084/jem.112.2.237
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1
   JACOBSSON B, 1995, HISTOPATHOLOGY, V26, P559, DOI 10.1111/j.1365-2559.1995.tb00275.x
   Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   KATUNUMA N, 1981, ACTA BIOL MED GER, V40, P1419
   KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3
   Keppler D, 2006, CANCER LETT, V235, P159, DOI 10.1016/j.canlet.2005.04.001
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Koenig W, 2005, CLIN CHEM, V51, P321, DOI 10.1373/clinchem.2004.041889
   Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949
   Kopitar-Jerala N, 2006, FEBS LETT, V580, P6295, DOI 10.1016/j.febslet.2006.10.055
   Kos J, 1997, CLIN CANCER RES, V3, P1815
   Kos J, 1998, ONCOL REP, V5, P1349
   Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116
   Kos J, 2000, CLIN CANCER RES, V6, P505
   Kuopio T, 1998, CANCER RES, V58, P432
   Lah TT, 1998, BIOL CHEM, V379, P125
   LAH TT, 1992, INT J CANCER, V50, P36, DOI 10.1002/ijc.2910500109
   LAH TT, 1997, PATHOLOGY ONCOLOGY R, V3, P221
   Lehesjoki AE, 2003, EMBO J, V22, P3473, DOI 10.1093/emboj/cdg338
   Levicar N, 2002, J NEURO-ONCOL, V58, P21, DOI 10.1023/A:1015892911420
   Levicar N, 2002, CANCER DETECT PREV, V26, P42, DOI 10.1016/S0361-090X(02)00015-6
   Liang G, 2002, CANCER RES, V62, P961
   Lignelid H, 1997, ACTA NEUROPATHOL, V93, P494, DOI 10.1007/s004010050644
   LIGNELID H, 1992, VIRCHOWS ARCH A, V421, P491, DOI 10.1007/BF01606878
   Lux W, 2005, J THROMB HAEMOST, V3, P1009, DOI 10.1111/j.1538-7836.2005.01276.x
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Ni J, 1997, J BIOL CHEM, V272, P10853
   OBrien C, 1996, SCIENCE, V271, P1672, DOI 10.1126/science.271.5256.1672
   Ohgaki K, 1998, GENE CHROMOSOME CANC, V23, P244, DOI 10.1002/(SICI)1098-2264(199811)23:3<244::AID-GCC6>3.0.CO;2-1
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825
   RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453
   Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089
   RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5
   RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Sathyanarayana UG, 2004, CANCER RES, V64, P1425, DOI 10.1158/0008-5472.CAN-03-0701
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6395
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6389
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P2665
   Sato N, 2003, CANCER RES, V63, P3735
   SCHAGDARSURENGI.U, 2006, ONCOGENE
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Sinha AA, 2002, CANCER-AM CANCER SOC, V94, P3141, DOI 10.1002/cncr.10604
   Sokol JP, 2004, MOL CANCER RES, V2, P183
   SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H
   Song J, 2006, BIOCHEM BIOPH RES CO, V340, P175, DOI 10.1016/j.bbrc.2005.11.171
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698
   Strojan P, 2000, CLIN CANCER RES, V6, P1052
   Strojnik T, 2000, PFLUG ARCH EUR J PHY, V439, pR122, DOI 10.1007/s004240000114
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666
   Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487
   Vigneswaran N, 2006, LIFE SCI, V78, P898, DOI 10.1016/j.lfs.2005.05.096
   Vigneswaran N, 2005, PATHOL RES PRACT, V200, P753, DOI 10.1016/j.prp.2004.09.005
   Werle B, 2003, BIOL CHEM, V384, P281, DOI 10.1515/BC.2003.031
   Werle B, 2006, ONCOL REP, V16, P647
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zajc I, 2002, CANCER LETT, V187, P185, DOI 10.1016/S0304-3835(02)00452-4
   Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388
   Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
   ZHONG S, 2006, ONCOGENE
   Zore I, 2001, BIOL CHEM, V382, P805, DOI 10.1515/BC.2001.097
NR 92
TC 26
Z9 29
U1 0
U2 5
PU BIOSCIENCE RESEARCH INST-BRI
PI SINGAPORE
PA 7 TEMZASEK BLVD, SUNTEC TOWER ONE, SINGAPORE, SINGAPORE
SN 2768-6701
EI 2768-6698
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2009
VL 14
BP 453
EP 462
DI 10.2741/3254
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 393DZ
UT WOS:000262352400027
PM 19273077
OA Bronze
DA 2025-01-12
ER

PT J
AU Demircan, B
   Dyer, LM
   Gerace, M
   Lobenhofer, EK
   Robertson, KD
   Brown, KD
AF Demircan, Berna
   Dyer, Lisa M.
   Gerace, Mallory
   Lobenhofer, Edward K.
   Robertson, Keith D.
   Brown, Kevin D.
TI Comparative Epigenomics of Human and Mouse Mammary Tumors
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID NF-KAPPA-B; BREAST-CANCER; CPG ISLANDS; NEUTRAL-SPHINGOMYELINASE; DNA
   METHYLATION; ABERRANT METHYLATION; ADHESION MOLECULE; SPORADIC BREAST;
   IN-VIVO; GENE
AB Gene silencing by aberrant epigenetic chromatin alteration is a well-recognized event contributing to tumorigenesis. Although genetically engineered tumor-prone mouse models have proven a powerful tool in understanding many aspects of carcinogenesis, to date few studies have focused on epigenetic alterations in mouse tumors. To uncover epigenetically silenced tumor suppressor genes (TSGs) in mouse mammary tumor cells, we conducted initial genome-wide screening by combining the treatment of cultured cells with the DNA demethylating drug 5-aza-2'-deoxycytidine (5-azadC) and the histone deacetylase inhibitor trichostatin A (TSA) with expression microarray. By conducting this initial screen on EMT6 cells and applying protein function and genomic structure criteria to genes identified as upregulated in response to 5-azadC/ TSA, we were able to identify two characterized breast cancer TSGs (Timp3 and Rprm) and four putative TSGs (Atp/B2, Dusp2, FoxJ1 and Smpd3) silenced in this line. By testing a panel of 10 mouse mammary tumor lines, we determined that each of these genes is commonly hypermethylated, albeit with varying frequency. Furthermore, by examining a panel of human breast tumor lines and primary tumors we observed that the human orthologs of ATP1B2, FOXJ1 and SMPD3 are aberrantly hypermethylated in the human disease whereas DUSP2 was not hypermethylated in primary breast tumors. Finally, we examined hypermethylation of several genes targeted for epigenetic silencing in human breast tumors in our panel of 10 mouse mammary tumor lines. We observed that the orthologs of Cdhl, RarB, Gstp 1, RassF 1 genes were hypermethylated, whereas neither Dapk 1 nor Wif1 were aberrantly methylated in this panel of mouse tumor lines. From this study, we conclude that there is significant, but not absolute, overlap in the epigenome of human and mouse mammary tumors. (C) 2008 Wiley-Liss, Inc.
C1 [Demircan, Berna; Dyer, Lisa M.; Gerace, Mallory; Robertson, Keith D.; Brown, Kevin D.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Demircan, Berna; Dyer, Lisa M.; Gerace, Mallory; Robertson, Keith D.; Brown, Kevin D.] Univ Florida, Coll Med, UF Shands Canc Ctr Program Canc Genet Epigent & T, Gainesville, FL 32610 USA.
   [Lobenhofer, Edward K.] Cogenics, Div Clin Data, Morrisville, NC 27560 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Brown, KD (通讯作者)，Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.
EM kdbrown1@ufl.edu
OI Robertson, Keith/0000-0002-7508-3328
FU NIH [R21 CA102220]
FX NIH, Grant number: R21 CA102220.
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358
   ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587
   Bachman KE, 1999, CANCER RES, V59, P798
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bishop DT, 1999, ANN ONCOL, V10, P113, DOI 10.1023/A:1008358419310
   Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9
   Chen F, 2004, CANCER RES, V64, P8135, DOI 10.1158/0008-5472.CAN-04-2096
   Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Dobretsov M, 2005, FRONT BIOSCI-LANDMRK, V10, P2373, DOI 10.2741/1704
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones R, 2002, NAT REV NEUROSCI, V3, P4, DOI 10.1038/nrn719
   Katoh M, 2004, INT J ONCOL, V25, P1495
   Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341
   Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889
   Lu T, 2004, CELL CYCLE, V3, P1114
   Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200
   Nass SJ, 2000, CANCER RES, V60, P4346
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Senner V, 2003, NEUROPATH APPL NEURO, V29, P370, DOI 10.1046/j.1365-2990.2003.00473.x
   Stoffel W, 2007, AM J PATHOL, V171, P153, DOI 10.2353/ajpath.2007.061285
   STUEWING JP, 1997, NEW ENGL J MED, V336, P1401
   Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   van den Boom J, 2006, INT J CANCER, V119, P2330, DOI 10.1002/ijc.22108
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322
   Wu P, 2007, CANCER LETT, V256, P64, DOI 10.1016/j.canlet.2007.05.007
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Yu YP, 2005, CARCINOGENESIS, V26, P471, DOI 10.1093/carcin/bgh310
NR 46
TC 51
Z9 58
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD JAN
PY 2009
VL 48
IS 1
BP 83
EP 97
DI 10.1002/gcc.20620
PG 15
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 380IU
UT WOS:000261460200007
PM 18836996
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Almeida, LO
   Custódio, C
   Pinto, GR
   Santos, MJ
   Almeida, JRW
   Clara, CA
   Rey, JA
   Casartelli, C
AF Almeida, L. O.
   Custodio, C.
   Pinto, G. R.
   Santos, M. J.
   Almeida, J. R. W.
   Clara, C. A.
   Rey, J. A.
   Casartelli, C.
TI Polymorphisms and DNA methylation of gene TP53 associated with
   extra-axial brain tumors
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Polymorphism; Methylation; TP53; Metastases; Meningiomas; Schwannomas
ID GERM-LINE POLYMORPHISM; CODON-72 POLYMORPHISM; P53 GENE;
   HYPERMETHYLATION PROFILE; BREAST-CANCER; SUSCEPTIBILITY; PROMOTER;
   MENINGIOMAS; EXPRESSION; MUTATION
AB The p53 tumor suppressor gene is the most frequently mutated gene in human cancer; this gene is mutated in up to 50% of human tumors. It has a critical role in the cell cycle, apoptosis and cell senescence, and it participates in many crucial physiological and pathological processes. Polymorphisms of p53 have been suggested to be associated with genetically determined susceptibility in various types of cancer. Another process involved with the development and progression of tumors is DNA hypermethylation. Aberrant methylation of the promoter is an alternative epigenetic change in genetic mechanisms, leading to tumor suppressor gene inactivation. In the present study, we examined the TP53 Arg72Pro and Pro47Ser polymorphisms using PCR-RFLP and the pattern of methylation of the p53 gene by methylation-specific PCR in 90 extra-axial brain tumor samples. Patients who had the allele Pro of the TP53 Arg72Pro polymorphism had an increased risk of tumor development ( odds ratio, OR = 3.23; confidence interval at 95%, 95% CI = 1.71-6.08; P = 0.003), as did the allele Ser of TP53 Pro47Ser polymorphism (OR = 1.28; 95% CI = 0.03-2.10; P = 0.01). Comparison of overall survival of patients did not show significant differences. In the analysis of DNA methylation, we observed that 37.5% of meningiomas, 30% of schwannomas and 52.6% of metastases were hypermethylated, suggesting that methylation is important for tumor progression. We suggest that TP53 Pro47Ser and Arg72Pro polymorphisms and DNA hypermethylation are involved in susceptibility for developing extra-axial brain tumors.
C1 [Almeida, L. O.; Custodio, C.; Pinto, G. R.; Casartelli, C.] Univ Sao Paulo, Lab Oncogenet, Fac Med Ribeirao Preto, Dept Genet, BR-14049 Ribeirao Preto, SP, Brazil.
   [Santos, M. J.; Almeida, J. R. W.; Clara, C. A.] Hosp Canc Barretos, Fdn Pio 12, Barretos, SP, Brazil.
   [Pinto, G. R.] Univ Fed Piaui, Lab Genet Humana & Biol Mol, Parnaiba, PI, Brazil.
   [Rey, J. A.] Hosp Univ La Paz, Lab Oncogenet Mol, Dept Cirugia Expt, Madrid, Spain.
C3 Universidade de Sao Paulo; Hospital de Cancer de Barretos; Universidade
   Federal do Piaui; Hospital Universitario La Paz
RP Almeida, LO (通讯作者)，Univ Sao Paulo, Lab Oncogenet, Fac Med Ribeirao Preto, Dept Genet, BR-14049 Ribeirao Preto, SP, Brazil.
EM lu_olive@yahoo.com
RI Rey, Juan/H-5026-2013; Almeida, José/D-1472-2016; Pinto,
   Giovanny/G-9852-2012; de Almeida, Luciana/AAF-1662-2020; Oliveira de
   Almeida, Luciana/O-1013-2014
OI Oliveira de Almeida, Luciana/0000-0002-5342-0434; Pinto,
   Giovanny/0000-0001-9110-1840
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao
   de Apoio ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da
   Faculdade de Medicina de Ribeirao Preto (FAEPA)
FX We are grateful to the patients who took part in this investigation. We
   thank Vanderci Massaro de Oliveira and Marcio Rogerio Penha for the
   technical support provided in this study. Reseach supported by Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and Fundacao de Apoio
   ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da Faculdade
   de Medicina de Ribeirao Preto (FAEPA).
CR Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236
   Amatya VJ, 2004, MODERN PATHOL, V17, P705, DOI 10.1038/modpathol.3800111
   Bello MJ, 2004, ACTA NEUROPATHOL, V108, P413, DOI 10.1007/s00401-004-0911-6
   Biros E, 2002, PHYSIOL RES, V51, P59, DOI 10.33549/physiolres.930134
   Costa S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-32
   Drevelegas A, 2005, EUR RADIOL, V15, P453, DOI 10.1007/s00330-004-2557-0
   Esteller M, 2001, CANCER RES, V61, P3225
   FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752
   Hadhri-Guiga B, 2007, CANCER GENET CYTOGEN, V178, P89, DOI 10.1016/j.cancergencyto.2007.05.013
   Hurt EM, 2006, CANCER BIOL THER, V5, P1154, DOI 10.4161/cbt.5.9.3001
   Idbaih A, 2007, CANCER GENET CYTOGEN, V177, P103, DOI 10.1016/j.cancergencyto.2007.06.010
   Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266
   Kashima T, 2007, J HUM GENET, V52, P694, DOI 10.1007/s10038-007-0168-8
   Kuroda Y, 2003, CANCER LETT, V189, P77, DOI 10.1016/S0304-3835(02)00518-9
   Kuroda Y, 2007, ORAL ONCOL, V43, P1043, DOI 10.1016/j.oraloncology.2006.12.001
   Leite JL, 2006, TRANSPLANT INT, V19, P732, DOI 10.1111/j.1432-2277.2006.00346.x
   Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200
   Lima EM, 2008, BRAZ J MED BIOL RES, V41, P539, DOI 10.1590/S0100-879X2008000600017
   Liu YH, 2005, HUM PATHOL, V36, P416, DOI 10.1016/j.humpath.2005.02.006
   Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261
   Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367
   Pinto GR, 2008, GENET MOL RES, V7, P207, DOI 10.4238/vol7-1gmr415
   Sidhu S, 2005, EJSO, V31, P549, DOI 10.1016/j.ejso.2005.01.013
   Sprague BL, 2007, CARCINOGENESIS, V28, P1680, DOI 10.1093/carcin/bgm097
   Zhu ZZ, 2007, JPN J CLIN ONCOL, V37, P385, DOI 10.1093/jjco/hym034
NR 27
TC 24
Z9 29
U1 0
U2 4
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2009
VL 8
IS 1
BP 8
EP 18
DI 10.4238/vol8-1gmr518
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 438TP
UT WOS:000265578600002
PM 19224462
OA Bronze
DA 2025-01-12
ER

PT J
AU Smith, KT
   Workman, JL
AF Smith, Karen T.
   Workman, Jerry L.
TI Histone deacetylase inhibitors: Anticancer compounds
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE HDAC; Acetylation; Chromatin; Cancer; Cell cycle
ID SUBEROYLANILIDE HYDROXAMIC ACID; ESTROGEN-RECEPTOR-ALPHA;
   CARCINOMA-CELL-LINES; BREAST-CANCER CELLS; PML-RAR-ALPHA; VALPROIC ACID;
   PROTEASOMAL DEGRADATION; DNA METHYLTRANSFERASE-1; SODIUM-BUTYRATE; HDAC
   INHIBITORS
AB The reversible acetylation of proteins is mediated by histone acetytransferases which acetylate proteins and historic deacetylases that remove the acetyl groups. High levels of histone acetylation are correlated with active genes, while hypoacetylation of histones corresponds with gone repression. Importantly, acetylation also occurs on non-histone proteins all this call affect the activity and stability of these proteins. Aberrant epigenetic changes ate a common hallmark Of tumors and Imbalances in the activities of deacetylases have been associated with cancers. Accordingly, inhibitors to the historic deacetylases are in clinical trials for the treatment of several cancer types. These drugs mediate a number Of molecular changes and ill turn Call induce cell cycle arrest, apoptosis or differentiation of cancer cells while displaying limited toxicity in normal cells. (C) 2003 Elsevier Ltd. All rights reserved.
C1 [Smith, Karen T.; Workman, Jerry L.] Stowers Inst Med Res, Kansas City, MO 64110 USA.
C3 Stowers Institute for Medical Research
RP Workman, JL (通讯作者)，Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.
EM jlw@stowers-institute.org
FU NIGMS; National Cancer Institute
FX The Workman Laboratory is funded in part by a grant from NIGMS. K.T.S.
   is supported by a postdoctoral fellowship front the National Cancer
   Institute.
CR Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023
   Bokelmann I, 2008, MOL MED, V14, P20, DOI 10.2119/2007-00084.Bokelmann
   Dokmanovic M, 2007, MOL CANCER THER, V6, P2525, DOI 10.1158/1535-7163.MCT-07-0251
   Fenrick R, 1998, J CELL BIOCHEM, P194
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hahn CK, 2008, P NATL ACAD SCI USA, V105, P9751, DOI 10.1073/pnas.0710413105
   Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619
   Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070
   Im JY, 2008, CHEM-BIOL INTERACT, V172, P235, DOI 10.1016/j.cbi.2008.01.007
   Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kim SH, 2007, ONCOL REP, V17, P647
   Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564
   Komatsu N, 2006, ONCOL REP, V15, P187
   Krämer OH, 2008, FASEB J, V22, P1369, DOI 10.1096/fj.06-8050com
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558
   Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774
   Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807
   Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Martínez-Balbás MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Petrella A, 2008, EUR J CANCER, V44, P740, DOI 10.1016/j.ejca.2008.01.023
   Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598
   Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773
   Schuetz A, 2008, J BIOL CHEM, V283, P11355, DOI 10.1074/jbc.M707362200
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Sekhavat A, 2007, BIOCHEM CELL BIOL, V85, P751, DOI 10.1139/O07-145
   Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101
   Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103
   Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176
   Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   WU IP, 2008, MOL CELL BIOL
   Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843
   You JS, 2008, ONCOGENE, V27, P1376, DOI 10.1038/sj.onc.1210776
   Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006
   Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 49
TC 71
Z9 85
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JAN
PY 2009
VL 41
IS 1
BP 21
EP 25
DI 10.1016/j.biocel.2008.09.008
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 396VX
UT WOS:000262620400006
PM 18845268
DA 2025-01-12
ER

PT J
AU Dobrovic, A
   Kristensen, LS
AF Dobrovic, Alexander
   Kristensen, Lasse S.
TI DNA methylation, epimutations and cancer predisposition
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE DNA methylation; Cancer predisposition; Epimutations; Inheritance;
   Single nucleotide polymorphisms
ID TUMOR-SUPPRESSOR GENE; NONPOLYPOSIS COLORECTAL-CANCER; HERITABLE
   GERMLINE EPIMUTATION; BRCA1 PROMOTER METHYLATION; SPORADIC
   BREAST-CANCER; MICROSATELLITE INSTABILITY; EPIGENETIC INHERITANCE;
   ESTROGEN-RECEPTOR; OVARIAN-TUMORS; E-CADHERIN
AB Hereditary cancer syndromes caused by germline mutations give rise to distinct spectra of cancel's with characteristic clinico-pathological features. Many of these hereditary cancer genes are silenced by methylation in a similar spectrum of sporadic cancers. It is likely that the initiating event in some of those cases of sporadic cancer is the somatic epigenetic inactivation (epimutation) of the same hereditary cancer gene. Recently, it has been shown that epimutations of certain hereditary cancer genes can be constitutional i.e. Present till throughout the soma. These epimutations may be inherited or arise very early in the germline. The heritability of these epimutations is very low as in most cases they are erased by passage through the germline. In other cases, predisposition to epimutations rather than the epimutations themselves call be inherited. These cases are characterised by Mendelian inheritance and are likely to be associated with sequence variants. Other sequence variants and environmental influences may also affect methylation propensity at a global level. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
C1 [Dobrovic, Alexander; Kristensen, Lasse S.] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic 8006, Australia.
   [Dobrovic, Alexander] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.
   [Kristensen, Lasse S.] Univ Aarhus, Inst Human Genet, DK-8000 Aarhus C, Denmark.
C3 Peter Maccallum Cancer Center; University of Melbourne; Aarhus
   University
RP Dobrovic, A (通讯作者)，Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.
EM alexander.dobrovic@petermac.org
RI ; Kristensen, Lasse Sommer/G-6042-2016
OI Dobrovic, Alexander/0000-0003-3414-112X; Kristensen, Lasse
   Sommer/0000-0002-5980-7939
FU National Health and Medical Research Council of Australia; Cancer
   Council of Victoria; Susan Komen Foundation; US Department of Defense
   Breast Cancer Research Program [W81XWH-05-1-0500, W81XWH-06-1-0670]
FX The term Constitutional methylation was to Our best knowledge first used
   by Suet Yi Leung. Ida Candiloro critically read this MS. Alexander
   Dobrovic was Supported by grants from the National Health and Medical
   Research Council of Australia, the Cancer Council of Victoria, the Susan
   Komen Foundation and the US Department of Defense Breast Cancer Research
   Program under award numbers W81XWH-05-1-0500 and W81XWH-06-1-0670. Views
   and opinions of, and endorsements by the author(s) do not reflect those
   of the US Army or the Department of Defense.
CR Aggerholm A, 1999, CANCER RES, V59, P436
   Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N
   BEHNKRAPPA A, 1991, GENOMICS, V11, P1, DOI 10.1016/0888-7543(91)90095-V
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Boumber YA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000162
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Chang J, 2001, BREAST CANCER RES TR, V69, P101, DOI 10.1023/A:1012203917104
   Chen HP, 2007, INT J CANCER, V120, P1684, DOI 10.1002/ijc.22406
   Chong S, 2007, NAT GENET, V39, P574, DOI 10.1038/ng0507-574
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Gazzoli I, 2002, CANCER RES, V62, P3925
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Hitchins MP, 2007, NAT GENET, V39, P1289, DOI 10.1038/ng1107-1289
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230
   Horsthemke B, 2006, CURR TOP MICROBIOL, V310, P45
   Horsthemke B, 2007, NAT GENET, V39, P573, DOI 10.1038/ng0507-573b
   HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jass JR, 2007, SURG ONCOL, V16, pS7, DOI 10.1016/j.suronc.2007.10.039
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kane MF, 1997, CANCER RES, V57, P808
   Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174
   Kristensen LS, 2008, CANCER EPIDEM BIOMAR, V17, P1240, DOI 10.1158/1055-9965.EPI-07-2531
   Kristensen LS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn113
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138
   Leung SY, 2007, NAT GENET, V39, P576, DOI 10.1038/ng0507-576
   Lombaerts M, 2004, BIOCHEM BIOPH RES CO, V319, P697, DOI 10.1016/j.bbrc.2004.05.041
   Melki JR, 2000, BLOOD, V95, P3208
   MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439
   Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859
   MORAK M, 2008, EUR J HUM GENET
   Nakagawa H, 2001, CANCER RES, V61, P6991
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Ogino S, 2007, CARCINOGENESIS, V28, P1985, DOI 10.1093/carcin/bgm160
   Pappas JJ, 2008, GENE CHROMOSOME CANC, V47, P978, DOI 10.1002/gcc.20603
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Reddy AN, 2003, CANCER RES, V63, P7694
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791
   Suter CM, 2007, NAT GENET, V39, P573, DOI 10.1038/ng0507-573a
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   SUTER CM, 2007, NAT GENET, V39, P576
   Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Valle L, 2007, CLIN GENET, V71, P232, DOI 10.1111/j.1399-0004.2007.00751.x
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Young J, 2006, CANCER EPIDEM BIOMAR, V15, P1778, DOI 10.1158/1055-9965.EPI-06-0164
NR 71
TC 54
Z9 60
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JAN
PY 2009
VL 41
IS 1
BP 34
EP 39
DI 10.1016/j.biocel.2008.09.006
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 396VX
UT WOS:000262620400008
PM 18835361
DA 2025-01-12
ER

PT J
AU Travaglini, L
   Vian, L
   Billi, M
   Grignani, F
   Nervi, C
AF Travaglini, Lorena
   Vian, Laura
   Billi, Monia
   Grignani, Francesco
   Nervi, Clara
TI Epigenetic reprogramming of breast cancer cells by valproic acid occurs
   regardless of estrogen receptor status
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Breast cancer; Estrogen receptor; Valproic acid; Histone deacetylases;
   Chromatin remodeling
ID HISTONE DEACETYLASE INHIBITORS; WAF1/CIP1 GENE PROMOTER; ACUTE
   MYELOID-LEUKEMIA; SP1 SITES; TRANSCRIPTIONAL RESPONSES; HDAC INHIBITORS;
   IN-VIVO; DIFFERENTIATION; ACETYLATION; EXPRESSION
AB Estrogen receptors (ERs) are a recognized prognostic factor and therapeutic target in breast cancer. The loss of ER expression relates to poor prognosis, poor clinical outcomes and impairs the use of anti-estrogenic treatment. Historic deacetylase inhibitors are candidate drugs for cancer therapy. Among them, valproic acid (VPA) is a long used and safe anti-epileptic drug. We studied the biological consequences of the chromatin remodeling action of VPA in a normal human mammary epithelial cell line and in ER alpha-positive and ER alpha-negative breast cancel, cell lines. In these cells and regardless of their ER Status, VPA-induced cell differentiation. as shown by increased milk lipids product ion, decreased expression of the CD44 antigen and growth arrest in the G(0)-G(1) phase of the cell cycle. These effects were accompanied by decreased Rb phosphorylation, hyperacetylation of the p21(WAFI/CIPI) gene promoter and increased p21 protein expression. Only in breast cancer cells, cyclin B1 expression was decreased and the cells accumulated also in G(2.) ER alpha expression decreased in ER alpha-positive, increased in ER alpha-negative and Was unchanged in normal mammary epithelial cells, as did the expression of progesterone receptor, a physiological ER alpha target. VPA decreased the expression of the invasiveness marker pS2 in ER alpha-positive breast cancer cells, but did not cause its re-expression in ER alpha-negative cells. Overall, these data suggest that in both ER alpha-positive and -negative malignant mammary epithelial cells VPA reprograms the cells to a more differentiated and physiologic" phenotype that may improve the sensitivity to endocrine therapy and/or chemotherapy in breast cancer patients. (C) 2008 Elsever Ltd. All rights reserved.
C1 [Billi, Monia; Grignani, Francesco] Univ Perugia, Dept Clin & Expt Med, Gen Pathol Sect, Monteluce Policlin, I-06123 Perugia, Italy.
   [Travaglini, Lorena; Vian, Laura; Nervi, Clara] Univ Roma La Sapienza, Dept Histol & Med Embryol, Rome, Italy.
   [Travaglini, Lorena; Vian, Laura; Nervi, Clara] San Raffaele Biomed Pk Fdn, Rome, Italy.
C3 University of Perugia; Sapienza University Rome
RP Grignani, F (通讯作者)，Univ Perugia, Dept Clin & Expt Med, Gen Pathol Sect, Monteluce Policlin, Via Brunamonti, I-06123 Perugia, Italy.
EM fragrig@unipg.it; clara.nervi@uniroma1.it
RI Grignani, Francesco/AAC-2565-2022; Travaglini, Lorena/AAA-6245-2020
OI Grignani, Francesco/0000-0003-0563-5673; Travaglini,
   Lorena/0000-0003-0142-6516; Billi, Monia/0000-0002-5284-7380; NERVI,
   Clara/0000-0001-9341-0188
FU AIRC; Ministero dell'Istruzione dell'Universita e della Ricerca;
   University of Roma La Sapienza"; Ministero della Salute
FX We thank Drs. Fabrizio Padula and Silvia Di Cesare for FACS analysis.
   Drs. Margherita Retrosi, Daria Brambilla and Giuseppe Sciume for
   experimental help. This work was supported by grants from, AIRC,
   Ministero dell'Istruzione dell'Universita e della Ricerca, University of
   Roma La Sapienza" and Ministero della Salute.
CR BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218
   Blaheta RA, 2002, CURR MED CHEM, V9, P1417, DOI 10.2174/0929867023369763
   Chavez-Blanco A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-2
   Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9
   Cimino G, 2006, CANCER RES, V66, P8903, DOI 10.1158/0008-5472.CAN-05-2726
   Davidson NE, 2000, J NATL CANCER I, V92, P859, DOI 10.1093/jnci/92.11.859
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286
   Foijer F, 2006, CELL CYCLE, V5, P831, DOI 10.4161/cc.5.8.2687
   Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319
   Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108
   Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799
   Huang HJ, 1999, CANCER RES, V59, P2981
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X
   Karat D, 1999, BRIT J CANCER, V80, P1271, DOI 10.1038/sj.bjc.6690497
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Lallemand F, 1999, EXP CELL RES, V247, P432, DOI 10.1006/excr.1998.4370
   Lostumbo A, 2006, EXP MOL PATHOL, V80, P46, DOI 10.1016/j.yexmp.2005.09.007
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Munster PN, 2001, CANCER RES, V61, P8492
   Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199
   NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935
   Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161
   Olsen CM, 2004, MOL CELL ENDOCRINOL, V213, P173, DOI 10.1016/j.mce.2003.10.032
   Ouhtit A, 2007, AM J PATHOL, V171, P2033, DOI 10.2353/ajpath.2007.070535
   Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7
   Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446
   Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003
   Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016
   RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593
   Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940
   Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786
   Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140-6736(05)66546-4
   Yi P, 2002, MOL ENDOCRINOL, V16, P674, DOI 10.1210/me.16.4.674
   Yi P, 2002, MOL ENDOCRINOL, V16, P1810, DOI 10.1210/me.2001-0323
NR 48
TC 40
Z9 41
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JAN
PY 2009
VL 41
IS 1
BP 225
EP 234
DI 10.1016/j.biocel.2008.08.019
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 396VX
UT WOS:000262620400027
PM 18789398
DA 2025-01-12
ER

PT J
AU Stephen, JK
   Chen, KM
   Raitanen, M
   Grénman, S
   Worsham, MJ
AF Stephen, Josena K.
   Chen, Kang Mei
   Raitanen, Misa
   Grenman, Seija
   Worsham, Maria J.
TI DNA Hypermethylation Profiles in Squamous Cell Carcinoma of the Vulva
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
LA English
DT Article
DE Squamous cell carcinoma of vulva (SCV); Epigenetics; Promoter
   hypermethylation; Methylation-specific multiplex ligation-dependent
   probe amplification (MS-MLPA) assay
ID TUMOR-SUPPRESSOR GENES; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND
   HYPERMETHYLATION; PROMOTER HYPERMETHYLATION; BREAST-CANCER; FHIT GENE;
   PROTEIN-KINASE; LUNG-CANCER; TRANSCRIPTIONAL INACTIVATION; DISEASE
   PROGRESSION
AB Gene silencing through promoter hypermethylation is a growing concept in the development of human cancers. In this Study, we examined the contribution of aberrant methylation of promoter regions ill methylation-prone tumor Suppressors to the pathogenesis of vulvar cancer. Thirteen cell lilies from 12 patients with squamous Cell carcinoma Of the Vulva were evaluated for aberrant methylation status and gene copy number alterations, concomitantly, using the methylation-specific multiplex ligation-dependent probe amplification assay. Of the 22 tumor suppressor genes examined, aberrant methylation was observed for 9 genes: tumor protein p73 (TP73), fragile histidine triad (FHIT), von Hippel-Lindau (VHL), adenomatosis polyposis coli (APC), estrogen receptor 1 (ESR1), cyclin-dependent kinase inhibitor 2B (CDKN2B), death-associated protein kinase 1 (DAPK1), glutathione S-transferase pi (GSTP1), and immunoglobin superfamily, member 4 (IGSF4). The most frequently methylated genes included TP73 in 9 of 13 cell lilies, and IGSF4, DAPK1, and FHIT in 3 of 13 cell lilies. Methylation-specific polymerase chain reaction was performed for TP73 and FHIT to confirm aberrant methylation by methylation-specific multiplex ligation-dependent probe amplification. In the context of gene copy number and methylation status, both copies of the TP73 gene were hypermethylated. Loss or decreased mRNA expression of TP73 and IGSF4 by reverse transcription polymerase chain reaction confirmed aberrant methylation. Frequent, genetic alterations of loss and gain of gene copy number included gain of GSTP1 and multiple endocrine neoplasia type I (MEN1), and loss of malignant fibrous histiocytoma amplified sequence 1 (MFHAS1) and IGSF4 in over 50% of the squamous Cell carcinoma of the vulva cell lilies. These findings underscore the contribution or both genetic and epigenetic events to the underlying pathogenesis of squamous cell carcinoma of the vulva.
C1 [Worsham, Maria J.] Henry Ford Hosp, Wayne State Sch Med, Dept Pathol, Dept Otolaryngol Head & Neck Res, Detroit, MI 48202 USA.
   [Grenman, Seija] Turku Univ, Cent Hosp, Dept Obstet & Gynecol, Turku, Finland.
   [Raitanen, Misa] Turku Univ, Cent Hosp, Dept Otolaryngol Head & Neck Surg, Turku, Finland.
   [Worsham, Maria J.] Satakunta Cent Hosp, Pori, Finland.
C3 Wayne State University; Henry Ford Health System; Henry Ford Hospital;
   University of Turku; University of Turku; Satakunta Central Hospital
RP Worsham, MJ (通讯作者)，Henry Ford Hosp, Wayne State Sch Med, Dept Pathol, Dept Otolaryngol Head & Neck Res, 1 Ford Pl,1D, Detroit, MI 48202 USA.
EM mworsha1@hfhs.org
RI Zhou, yin/HGE-2329-2022
FU  [R01 NIH DE 15990];  [DAMD17-02-1-0406];  [DAMD17-00-1-0288]
FX This work was Supported by R01 NIH DE 15990 (Maria J. Worsharn),
   DAMD17-02-1-0406 (Maria J. Worsham), and DAMD17-00-1-0288 (Maria J..
   Worsham).
CR Agarwal SK, 2005, HORM METAB RES, V37, P369, DOI 10.1055/s-2005-870139
   Bai T, 2004, ONCOL REP, V11, P661
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Beers MarkH., 1999, MERCK MANUAL DIAGNOS, V17th
   CAREY TE, 1985, HEAD NECK CANCER, P287
   Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x
   Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404
   Chen KM, 2007, ARCH OTOLARYNGOL, V133, P1131, DOI 10.1001/archotol.133.11.1131
   Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998
   Dong SM, 2001, CLIN CANCER RES, V7, P1982
   Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204
   Eads CA, 2000, CANCER RES, V60, P5021
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 1998, CANCER RES, V58, P4515
   GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538
   Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256
   GRENMAN R, 1988, ARCH OTOLARYNGOL, V114, P427
   GRENMAN SE, 1990, INT J CANCER, V45, P920, DOI 10.1002/ijc.2910450524
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Ito T, 2003, CANCER RES, V63, P6320
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1
   Kunjoonju JR, 2005, GENE CHROMOSOME CANC, V44, P185, DOI 10.1002/gcc.20230
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   Kuroki T, 2003, CANCER RES, V63, P3724
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177
   Martinez-Delgado B, 2002, INT J CANCER, V102, P15, DOI 10.1002/ijc.10618
   MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095
   MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518
   Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153
   NAGAI H, 1995, CANCER RES, V55, P1752
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x
   RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753
   Raitanen M, 2004, GYNECOL ONCOL, V93, P155, DOI 10.1016/j.ygyno.2003.12.033
   Rantanen V, 2002, EUR J CANCER, V38, P1783, DOI 10.1016/S0959-8049(02)00119-3
   Saglam O, 2007, DIAGN MOL PATHOL, V16, P218, DOI 10.1097/PDM.0b013e3180d0aab5
   Sakabe T, 1999, CANCER RES, V59, P511
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031
   Stephen JK, 2007, MODERN PATHOL, V20, P1019, DOI 10.1038/modpathol.3800944
   Stephen JK, 2007, ARCH OTOLARYNGOL, V133, P684, DOI 10.1001/archotol.133.7.684
   Tada Y, 2002, CANCER RES, V62, P4048
   Tagawa H, 2004, ONCOGENE, V23, P2576, DOI 10.1038/sj.onc.1207352
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tanaka H, 1998, CANCER RES, V58, P3429
   Uesugi H, 2005, INT J MOL MED, V15, P597
   Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770
   WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209
   WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520
   Wong TS, 2003, INT J ONCOL, V22, P869
   Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   WORSHAM MJ, 1991, GENE CHROMOSOME CANC, V3, P420, DOI 10.1002/gcc.2870030604
   Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P409, DOI 10.1001/archotol.132.4.409
   Worsham MJ, 2003, ARCH OTOLARYNGOL, V129, P702, DOI 10.1001/archotol.129.7.702
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 67
TC 19
Z9 26
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-1691
EI 1538-7151
J9 INT J GYNECOL PATHOL
JI Int. J. Gynecol. Pathol.
PD JAN
PY 2009
VL 28
IS 1
BP 63
EP 75
DI 10.1097/PGP.0b013e31817d9c61
PG 13
WC Obstetrics & Gynecology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Pathology
GA 389MA
UT WOS:000262095600011
PM 19047905
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Karray-Chouayekh, S
   Trifa, F
   Khabir, A
   Boujelbane, N
   Sellami-Boudawara, T
   Daoud, J
   Frikha, M
   Gargouri, A
   Mokdad-Gargouri, R
AF Karray-Chouayekh, Sondes
   Trifa, Fatma
   Khabir, Abdelmajid
   Boujelbane, Nouredine
   Sellami-Boudawara, Tahia
   Daoud, Jamel
   Frikha, Mounir
   Gargouri, Ali
   Mokdad-Gargouri, Raja
TI Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in
   Tunisian Patients with Invasive Breast Carcinoma
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
ID DNA METHYLATION PROFILES; MISMATCH-REPAIR SYSTEM; SPORADIC BREAST;
   MICROSATELLITE INSTABILITY; PROMOTER METHYLATION; RECEPTOR STATUS;
   OVARIAN-CANCER; HYPERMETHYLATION; GENES; WOMEN
AB Aberrant hypermethylation of gene promoter regions is one of the mechanisms for inactivation of tumour suppressor genes in many human cancers including breast carcinoma. In the current study, we aimed to assess by MSP, the methylation pattern of two cancer-related genes involved in DNA repair: hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) and BRCA1 (breast cancer 1, early onset) in 78 primary breast cancers from Tunisian patients. The methylation frequencies were 24.36% for hMLH1 and 46% for BRCA1. BRCA1 methylation correlated with age at diagnosis (P = .015) and 5-years disease free survival (P = .016) while hMLH1 methylation was more frequent in larger tumors (P = .002) and in presence of distant metastasis (P = .004). Furthermore, methylation of hMLH1 significantly correlated with high level of P53 expression (P = .006) and with overall survival (P = .015) suggesting that silencing of hMLH1 through aberrant promoter methylation could be used as a poor prognosis indicator in breast cancer. Copyright (C) 2009 Sondes Karray-Chouayekh et al.
C1 [Karray-Chouayekh, Sondes; Trifa, Fatma; Gargouri, Ali; Mokdad-Gargouri, Raja] Ctr Biotechnol, Unitede Genet Canc & Prod Prot Therapeut, Sfax 3018, Tunisia.
   [Khabir, Abdelmajid; Boujelbane, Nouredine; Sellami-Boudawara, Tahia; Daoud, Jamel; Frikha, Mounir] Univ Habib Bourguiba, Ctr Hosp, Sfax 3000, Tunisia.
C3 Centre de Biotechnologie de Sfax; Centre de Biotechnologie de Borj
   Cedria; Universite de Sfax; Universite de Sfax; Hopital Habib Bourguiba
RP Mokdad-Gargouri, R (通讯作者)，Ctr Biotechnol, Unitede Genet Canc & Prod Prot Therapeut, Route Sidi Mansour,BP 1177, Sfax 3018, Tunisia.
EM raja.gargouri@cbs.rnrt.tn
OI ABDELMAJID, KHABIR/0000-0003-0031-2242
FU Ministere de l'Enseignement Superieur et de la Recherche Scientifique
   Tunisien
FX This work was supported by a Grant of the "Ministere de l'Enseignement
   Superieur et de la Recherche Scientifique Tunisien". The authors would
   like to thank all clinicians and pathologists at CHU Habib Bourguiba at
   Sfax-Tunisia, and Dr. Khemais Ben-Hadj for critical suggestions.
CR Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   BIRGISDOTTIR V, 2006, BREAST CANCER RES, V8, P1
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Campan M, 2006, CURR TOP MICROBIOL, V310, P141
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Duffy MJ, 2006, CRIT REV CL LAB SCI, V43, P325, DOI 10.1080/10408360600739218
   ELSTON CW, 1998, BREAST SYSTEMIC PATH, V13, P385
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034
   Jascur T, 2006, INT J CANCER, V119, P2030, DOI 10.1002/ijc.22023
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   MOURALI N, 1980, CANCER-AM CANCER SOC, V46, P2741, DOI 10.1002/1097-0142(19801215)46:12<2741::AID-CNCR2820461234>3.0.CO;2-W
   Murata H, 2005, CANCER LETT, V223, P143, DOI 10.1016/j.canlet.2004.09.039
   Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683
   Naqvi RA, 2008, HUM PATHOL, V39, P672, DOI 10.1016/j.humpath.2007.09.011
   PARKIN DM, 2003, CANC AFRICA EPIDEMIO, V153, P262
   Rhee J., 2008, BMC CANCER, V8, P1
   Rusiecki JA, 2005, CANCER DETECT PREV, V29, P419, DOI 10.1016/j.cdp.2005.07.004
   Russo Jose, 1998, Frontiers in Bioscience, V3, pD944
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Sobin LH., 2010, TNM CLASSIFICATION M
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Thomas DC, 1996, MUTAT RES-FUND MOL M, V350, P201, DOI 10.1016/0027-5107(95)00112-3
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
NR 39
TC 24
Z9 25
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110-7243
EI 1110-7251
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PY 2009
AR 369129
DI 10.1155/2009/369129
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 485HL
UT WOS:000269111700001
PM 19644562
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Degner, SC
   Papoutsis, AJ
   Selmin, O
   Romagnolo, DF
AF Degner, Stephanie C.
   Papoutsis, Andreas J.
   Selmin, Ornella
   Romagnolo, Donato F.
TI Targeting of Aryl Hydrocarbon Receptor-Mediated Activation of
   Cyclooxygenase-2 Expression by the Indole-3-Carbinol Metabolite
   3,3′-Diindolylmethane in Breast Cancer Cells
SO JOURNAL OF NUTRITION
LA English
DT Article
ID IN-VIVO; TRANSCRIPTION; RESVERATROL; DIOXIN; TUMORIGENESIS; PROMOTER;
   LIGANDS; CYP1A1; MCF-7; TRANSFORMATION
AB Ligands of the aryl hydrocarbon receptor (AhR) include the environmental xenobiotic 2,3,7,8 tetrachlorodibenzo(p)dioxin (TCDD), polycyclic aryl hydrocarbons, and the dietary compounds 3, 3'-diindolylmethane (DIM), a condensation product of indol-3-carbinol found in Brassica vegetables, and the phytoalexin resveratrol (RES). The AhR and its cofactors regulate the expression of target genes at pentameric (GCGTG) xenobiotic responsive elements (XRE). Because the activation of cyclooxygenase-2 (COX-2) expression by AhR ligands may contribute to inflammation and tumorigenesis, we investigated the epigenetic regulation of the COX-2 gene by TCDD and the reversal effects of DIM in MCF-7 breast cancer cells. Results of DNA binding and chromatin immunoprecipitation (ChIP) studies documented that the treatment with TCDD induced the association of the AhR to XRE harbored in the COX-2 promoter and control CYP1A1 promoter oligonucleotides. The TCDD-induced binding of the AhR was reduced by small-interfering RNA for the AhR or the cotreatment with synthetic (3-methoxy-4-naphthoflavone) or dietary AhR antagonists (DIM, RES). In time course ChIP studies, TCDD induced the rapid (15 min) occupancy by the AhR, the histone acetyl transferase p300, and acetylated histone H4 (AcH4) at the COX-2 promoter. Conversely, the cotreatment of MCF-7 cells with DIM (10 mu mol/L) abrogated the TCDD-induced recruitment of the AhR and AcH4 to the COX-2 promoter and the induction of COX-2 mRNA and protein levels. Taken together, these data suggest that naturally occurring modulators of the AhR such as DIM may be effective agents for dietary strategies against epigenetic activation of COX-2 expression by AhR agonists. J. Nutr. 139: 26-32, 2009.
C1 [Degner, Stephanie C.; Papoutsis, Andreas J.; Romagnolo, Donato F.] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
   [Selmin, Ornella] Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ 85721 USA.
C3 University of Arizona; University of Arizona
RP Romagnolo, DF (通讯作者)，Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
EM donato@u.arizona.edu
RI Selmin, Ornella/ABC-8971-2020
FU Graduate Training Program in Toxicology and Toxicogenomics [T32
   ES-07091-24]; NIEHS-NIH; Kraft American Society for Nutrition
   Predoctoral Fellowship; Arizona Biomedical Research Commission [100116,
   0819]; Susan G. Komen Breast Cancer Foundation [BCTR0707643]
FX Supported in part by the Graduate Training Program in Toxicology and
   Toxicogenomics T32 ES-07091-24, NIEHS-NIH, Kraft American Society for
   Nutrition Predoctoral Fellowship (S. C. D.), and grants from the Arizona
   Biomedical Research Commission (100116, 0819, D, F. R), and Susan G.
   Komen Breast Cancer Foundation (BCTR0707643, D. F. R.).
CR Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373
   Amakura Y, 2003, BIOL PHARM BULL, V26, P532, DOI 10.1248/bpb.26.532
   Ashida H, 2000, FEBS LETT, V476, P213, DOI 10.1016/S0014-5793(00)01730-0
   Banerjee S, 2002, CANCER RES, V62, P4945
   BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185
   Burchiel SW, 2001, CLIN IMMUNOL, V98, P2, DOI 10.1006/clim.2000.4934
   Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC
   Casper RF, 1999, MOL PHARMACOL, V56, P784
   Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631
   Chen ZH, 2004, CARCINOGENESIS, V25, P2005, DOI 10.1093/carcin/bgh183
   Ciolino HP, 1999, BIOCHEM J, V340, P715, DOI 10.1042/0264-6021:3400715
   Ciolino HP, 1998, BIOCHEM PHARMACOL, V56, P197, DOI 10.1016/S0006-2952(98)00143-9
   Davies G, 2003, CLIN CANCER RES, V9, P2651
   Degner SC, 2007, NUTR CANCER, V59, P248, DOI 10.1080/01635580701485585
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   Fattore E, 2006, MOL NUTR FOOD RES, V50, P915, DOI 10.1002/mnfr.200500212
   Gouédard C, 2004, MOL CELL BIOL, V24, P5209, DOI 10.1128/MCB.24.12.5209-5222.2004
   Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   Howells LM, 2007, ACTA PHARMACOL SIN, V28, P1274, DOI 10.1111/j.1745-7254.2007.00690.x
   JELLINCK PH, 1993, BIOCHEM PHARMACOL, V45, P1129, DOI 10.1016/0006-2952(93)90258-X
   Ko HSP, 1996, MOL CELL BIOL, V16, P430
   Li ZG, 2002, CARCINOGENESIS, V23, P1531, DOI 10.1093/carcin/23.9.1531
   Liem AKD, 2000, FOOD ADDIT CONTAM, V17, P241, DOI 10.1080/026520300283324
   Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200
   Martey CA, 2005, AM J PHYSIOL-LUNG C, V289, pL391, DOI 10.1152/ajplung.00062.2005
   Medjakovic S, 2008, J STEROID BIOCHEM, V108, P171, DOI 10.1016/j.jsbmb.2007.10.001
   Miao F, 2004, J BIOL CHEM, V279, P18091, DOI 10.1074/jbc.M311786200
   Miller ME, 2005, CLIN EXP METASTAS, V22, P149, DOI 10.1007/s10585-005-6536-x
   Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X
   Oliveira VM, 2006, BREAST CANCER RES TR, V95, P235, DOI 10.1007/s10549-005-9010-1
   Puppala D, 2007, CARCINOGENESIS, V28, P639, DOI 10.1093/carcin/bgl169
   Reed GA, 2006, CANCER EPIDEM BIOMAR, V15, P2477, DOI 10.1158/1055-9965.EPI-06-0396
   Ristimäki A, 2002, CANCER RES, V62, P632
   Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145
   Whitsett Timothy, 2006, J Carcinog, V5, P15, DOI 10.1186/1477-3163-5-15
NR 37
TC 81
Z9 93
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD JAN
PY 2009
VL 139
IS 1
BP 26
EP 32
DI 10.3945/jn.108.099259
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 384XI
UT WOS:000261777100006
PM 19056653
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Vinothini, G
   Balachandran, C
   Nagini, S
AF Vinothini, G.
   Balachandran, C.
   Nagini, S.
TI Evaluation of Molecular Markers in Canine Mammary Tumors: Correlation
   With Histological Grading
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Apoptosis; Breast cancer; Canine mammary tumors; Estradiol
ID ENDOTHELIAL GROWTH-FACTOR; KAPPA-B ACTIVATION; BREAST-CANCER;
   ESTROGEN-RECEPTOR; GLAND TUMORS; IMMUNOHISTOCHEMICAL ANALYSIS;
   MATRIX-METALLOPROTEINASE; PROGNOSTIC-SIGNIFICANCE; METABOLIZING ENZYMES;
   EXPRESSION
AB The objective of this study was to evaluate molecular markers involved in mammary tumorigenesis in a canine model that mimics many essential elements of human breast cancer. Thirty mammary gland tumors and control tissues obtained from female dogs were included in the study. We analyzed changes in the expression of markers of hormone and receptor status (estradiol, estrogen receptor; ER and HER-2/neu), hormone metabolism (CYP1A1 and CYP1B1), cell proliferation and survival [proliferating cell nuclear antigen (PCNA), glutathione S-transferase-P (GST-P), nuclear factor-kappa B (NF-kappa B-p50, NF-kappa B-p65), phosphorylated-inhibitor of kappa B-alpha (p-I kappa B-alpha) and [kappa B], apoptosis (Bcl-2, Bax, caspases, Apaf-1, cytochrome-C, and PARP), invasion [matrix metalloproteinases-2 and -9 (MMP-2, MMP-9), tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), and reversion-inducing cysteine-rich protein with Kazal motifs (RECK)], angiogenesis [vascular endothelial growth factor (VEGF)], and epigenetics [DNA methyltransferase (Dnmt-1), histone deacetylase (HDAC-1)] by immunohistochemical localization and Western blot analysis and correlated these with histological grade. The present study provides evidence that increased expression of ER, HER-2/neu, estradiol, and its metabolizing enzymes, as well as proteins involved in cell proliferation, apoptosis evasion, invasion, and angiogenesis may confer a selective growth advantage to canine mammary tumors. To our knowledge this is the first report on the hallmark capabilities of canine mammary tumors, which lends credence to the view that the dog is a valuable model for human breast cancer studies.
C1 [Vinothini, G.; Nagini, S.] Annamalai Univ, Fac Sci, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India.
   [Balachandran, C.] Madras Vet Coll, Dept Vet Pathol, Madras, Tamil Nadu, India.
C3 Annamalai University; Tamil Nadu Veterinary & Animal Sciences University
RP Nagini, S (通讯作者)，Annamalai Univ, Fac Sci, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India.
EM s_nagini@yahoo.com
CR Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen JQ, 2008, ADV EXP MED BIOL, V630, P1
   Clark JCM, 2007, CANCER METAST REV, V26, P675, DOI 10.1007/s10555-007-9093-8
   de las Mulas JM, 2003, BREAST CANCER RES TR, V80, P363, DOI 10.1023/A:1024929730165
   Fox EM, 2009, STEROIDS, V74, P622, DOI 10.1016/j.steroids.2008.10.014
   Funakoshi Y, 2000, VET PATHOL, V37, P177, DOI 10.1354/vp.37-2-177
   Giancotti V, 2006, CANCER LETT, V243, P145, DOI 10.1016/j.canlet.2006.01.035
   HAMPE JF, 1974, B WORLD HEALTH ORGAN, V50, P111
   Hellmén E, 2005, J DAIRY RES, V72, P90, DOI 10.1017/S002202990500124X
   Hirayama K, 2002, J COMP PATHOL, V127, P249, DOI 10.1053/jcpa.2002.0590
   Huang JX, 2004, ONCOL REP, V12, P921
   ILLERA JC, 2006, J STEROID BIOCHEM, V94, P181
   ISCHIOKA C, 2008, GAN TO KAGAKU RYOHO, V35, P1261
   Kato Y, 2007, J VET MED SCI, V69, P77, DOI 10.1292/jvms.69.77
   Kumaraguruparan R, 2006, VET J, V172, P364, DOI 10.1016/j.tvjl.2005.05.013
   Kumaraguruparan R, 2006, RES VET SCI, V81, P218, DOI 10.1016/j.rvsc.2005.08.002
   Kumaraguruparan R, 2006, CLIN CHIM ACTA, V365, P168, DOI 10.1016/j.cca.2005.08.018
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338
   MACEWEN EG, 1990, CANCER METAST REV, V9, P125, DOI 10.1007/BF00046339
   Malkas LH, 2006, P NATL ACAD SCI USA, V103, P19472, DOI 10.1073/pnas.0604614103
   Marinelli L, 2004, J STEROID BIOCHEM, V92, P167, DOI 10.1016/j.jsbmb.2004.08.001
   Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239
   OWEN LN, 1979, INVEST CELL PATHOL, V2, P257
   Peña L, 2003, J STEROID BIOCHEM, V84, P211, DOI 10.1016/S0960-0760(03)00030-X
   Rossmeisl JH, 2007, AM J VET RES, V68, P1239, DOI 10.2460/ajvr.68.11.1239
   RUSSO J, 1990, LAB INVEST, V62, P244
   Takagi S, 2005, J VET MED SCI, V67, P761, DOI 10.1292/jvms.67.761
   Takagi S, 2005, J VET MED SCI, V67, P385, DOI 10.1292/jvms.67.385
   Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531
   Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007
   Vinothini G, 2009, ONCOL RES, V17, P483, DOI 10.3727/096504009789735459
   Vinothini G, 2008, ARCH MED SCI, V4, P129
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yang WY, 2006, J COMP PATHOL, V134, P70, DOI 10.1016/j.jcpa.2005.07.002
NR 37
TC 27
Z9 28
U1 0
U2 23
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2009
VL 18
IS 5-6
BP 193
EP 201
DI 10.3727/096504009X12596189659042
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 554UG
UT WOS:000274459900001
PM 20225757
OA hybrid
DA 2025-01-12
ER

PT J
AU Sun, P
   Xia, SL
   Lal, B
   Eberhart, CG
   Quinones-Hinojosa, A
   Maciaczyk, J
   Matsui, W
   DiMeco, F
   Piccirillo, SM
   Vescovi, AL
   Laterra, J
AF Sun, Peng
   Xia, Shuli
   Lal, Bachchu
   Eberhart, Charles G.
   Quinones-Hinojosa, Alfredo
   Maciaczyk, Jarek
   Matsui, William
   DiMeco, Francesco
   Piccirillo, Sara M.
   Vescovi, Angelo L.
   Laterra, John
TI <i>DNER</i>, an Epigenetically Modulated Gene, Regulates
   Glioblastoma-Derived Neurosphere Cell Differentiation and Tumor
   Propagation
SO STEM CELLS
LA English
DT Article
DE Histone acetylation; Glioma; Stem cell; Oncosphere
ID HISTONE-DEACETYLASE INHIBITORS; CANCER STEM-CELLS; VIVO
   ANTITUMOR-ACTIVITY; ACUTE MYELOID-LEUKEMIA; IN-VIVO; GROWTH-FACTOR;
   NEURONAL DIFFERENTIATION; NEURAL PROGENITORS; INITIATING CELLS;
   BREAST-CANCER
AB Neurospheres derived from glioblastoma (GBM) and other solid malignancies contain neoplastic stem-like cells that efficiently propagate tumor growth and resist cytotoxic therapeutics. The primary objective of this study was to use histone-modifying agents to elucidate mechanisms by which the phenotype and tumor-promoting capacity of GBM-derived neoplastic stem-like cells are regulated. Using established GBM-derived neurosphere lines and low passage primary GBM-derived neurospheres, we show that histone deacetylase (HDAC) inhibitors inhibit growth, induce differentiation, and induce apoptosis of neoplastic neurosphere cells. A specific gene product induced by HDAC inhibition, Delta/Notch-like epidermal growth factor-related receptor (DNER), inhibited the growth of GBM-derived neurospheres, induced their differentiation in vivo and in vitro, and inhibited their engraftment and growth as tumor xenografts. The differentiating and tumor suppressive effects of DNER, a noncanonical Notch ligand, contrast with the previously established tumor-promoting effects of canonical Notch signaling in brain cancer stem-like cells. Our findings are the first to implicate noncanonical Notch signaling in the regulation of neoplastic stem-like cells and suggest novel neoplastic stem cell targeting treatment strategies for GBM and potentially other solid malignancies. STEM CELLS 2009; 27: 1473-1486
C1 [Sun, Peng; Xia, Shuli; Lal, Bachchu; Laterra, John] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.
   [Sun, Peng; Xia, Shuli; Lal, Bachchu; Laterra, John] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Eberhart, Charles G.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA.
   [Quinones-Hinojosa, Alfredo] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA.
   [Matsui, William] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA.
   [Maciaczyk, Jarek] Univ Freiburg, Dept Gen Neurosurg, Freiburg, Germany.
   [Maciaczyk, Jarek] Univ Freiburg, Lab Mol Neurosurg, Freiburg, Germany.
   [DiMeco, Francesco] Inst Nazl Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
   [Piccirillo, Sara M.; Vescovi, Angelo L.] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns
   Hopkins University; Johns Hopkins Medicine; University of Freiburg;
   University of Freiburg; Fondazione IRCCS Istituto Neurologico Carlo
   Besta; University of Milano-Bicocca
RP Laterra, J (通讯作者)，Hugo W Moser Res Inst Kennedy Krieger, 707 N Broadway, Baltimore, MD 21205 USA.
EM laterra@kennedykrieger.org
RI Sun, Peng/KDO-4243-2024; Matsui, William/C-3383-2009; vescovi,
   angelo/A-4919-2015; Maciaczyk, Jaroslaw/ABB-2663-2021; DiMeco,
   Francesco/Z-5431-2019; DiMeco, Francesco/Q-3785-2016
OI Matsui, William/0000-0002-3088-0964; Vescovi, Angelo
   Luigi/0000-0002-1742-4112; DiMeco, Francesco/0000-0001-6213-5793;
   Piccirillo, Sara Grazia Maria/0000-0003-4109-1992; Maciaczyk,
   Jaroslaw/0000-0003-3565-543X
FU NIH [NS43987, NS055089]; The Maryland Stem Cell Research Fund; The Brain
   Tumor Funders Collaborative
FX This work was funded by NIH grants NS43987 (J.L.) and NS055089 (C.G.E.),
   The Maryland Stem Cell Research Fund (J.L.), and The Brain Tumor Funders
   Collaborative.
CR Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Balasubramaniyan V, 2006, NEUROSCIENCE, V143, P939, DOI 10.1016/j.neuroscience.2006.08.082
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008-5472.CAN-03-2630
   Canes D, 2005, INT J CANCER, V113, P841, DOI 10.1002/ijc.20634
   Cui XY, 2004, J BIOL CHEM, V279, P25858, DOI 10.1074/jbc.M313505200
   Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001
   Dalgard CL, 2008, CLIN CANCER RES, V14, P3113, DOI 10.1158/1078-0432.CCR-07-4836
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Eiraku M, 2005, NAT NEUROSCI, V8, P873, DOI 10.1038/nn1492
   Eiraku M, 2002, J BIOL CHEM, V277, P25400, DOI 10.1074/jbc.M110793200
   Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246
   Hahn CK, 2008, P NATL ACAD SCI USA, V105, P9751, DOI 10.1073/pnas.0710413105
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675
   Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101
   Hulleman E, 2009, J CELL MOL MED, V13, P136, DOI 10.1111/j.1582-4934.2008.00307.x
   Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kanamori M, 2007, J NEUROSURG, V106, P417, DOI 10.3171/jns.2007.106.3.417
   KASTAN MB, 1990, BLOOD, V75, P1947
   Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404
   Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lee J, 2003, CANCER RES, V63, P8877
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3
   Lyssiotis CA, 2007, P NATL ACAD SCI USA, V104, P14982, DOI 10.1073/pnas.0707044104
   Marin-Husstege M, 2002, J NEUROSCI, V22, P10333
   Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308
   Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096
   PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411
   Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Piccirillo SGM, 2007, EXPERT OPIN BIOL TH, V7, P1129, DOI 10.1517/14712598.7.8.1129
   Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236
   Romanski A, 2004, HAEMATOLOGICA, V89, P419
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Simonini MV, 2006, P NATL ACAD SCI USA, V103, P1587, DOI 10.1073/pnas.0510341103
   Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998
   Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002
   Xia SL, 2005, CANCER RES, V65, P5248, DOI 10.1158/0008-5472.CAN-04-4332
   Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200
NR 57
TC 84
Z9 92
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PY 2009
VL 27
IS 7
BP 1473
EP 1486
DI 10.1002/stem.89
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 474BL
UT WOS:000268257100003
PM 19544453
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Tse, KY
   Liu, VWS
   Chan, DW
   Chiu, PM
   Tam, KF
   Chan, KKL
   Liao, XY
   Cheung, ANY
   Ngan, HYS
AF Tse, Ka Yu
   Liu, Vincent Wing Sun
   Chan, David Wai
   Chiu, Pui Man
   Tam, Kar Fai
   Chan, Karen Kar Loen
   Liao, Xiao Yun
   Cheung, Annie Nga Yin
   Ngan, Hextan Yuen Sheung
TI Epigenetic Alteration of the Metallothionein 1E Gene in Human
   Endometrial Carcinomas
SO TUMOR BIOLOGY
LA English
DT Article
DE Endometrial carcinoma; Metallothionein 1E gene; Promoter
   hypermethylation
ID BREAST-CANCER; EXPRESSION; CARCINOGENESIS; ESTROGEN; CELLS
AB Aberrant expression of metallothioneins (AMTs) has been observed in several human tumors. In our microarray analysis, MT-1E was found to have much lower expression in endometrial cancer cells as compared with other types of cancer cells generated from the cervix, ovary or prostate. The result was confirmed by quantitative RT-PCR analysis of the MT-1E levels in individual cancer cells. Treatment of endometrial cancer cells with 5-azacytidine could reactivate MT-1E expression. We further analyzed the DNA methylation status of the promoter region of MT-1E using methylation-sensitive restriction enzymes HhaI and HpaII, followed by PCR. Promoter hypermethylation was detected in 42.4% (53/125) of the endometrial carcinoma samples, whilst none of the 38 normal tissues or hyperplasia samples were methylated. The mRNA levels of MT-1E were significantly lower in the methylation-positive than in the methylation-negative samples. Endometrial carcinoma samples with low MT-1E expression coincidently had low levels of estrogen receptor-alpha expression and vice versa. This phenomenon was not observed in the expression pattern between estrogen receptor-beta and MT-1E. There was no significant correlation between MT-1E methylation and any clinical parameters. In conclusion, a high frequency of cancer-specific hypermethylation of MT-1E was found in endometrial carcinomas. Its functional consequence in the development of endometrial cancer warrants further investigation. Copyright (C) 2009 S. Karger AG, Basel
C1 [Tse, Ka Yu; Liu, Vincent Wing Sun; Chan, David Wai; Chiu, Pui Man; Tam, Kar Fai; Chan, Karen Kar Loen; Ngan, Hextan Yuen Sheung] Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynecol, Pokfulam, Hong Kong, Peoples R China.
   [Liao, Xiao Yun; Cheung, Annie Nga Yin] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Ngan, HYS (通讯作者)，Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynecol, Pokfulam, Hong Kong, Peoples R China.
EM hysngan@hkucc.hku.hk
RI Cheung, Annie/C-4230-2009; liu, V/KIA-9904-2024; Luo,
   Xiaodong/G-5953-2011; Chan, Karen/E-4041-2015; Cheung, Annie Nga
   Yin/C-4231-2009; Chan, David/O-9896-2018
OI Chan, Karen/0000-0001-9947-4713; Cheung, Annie Nga
   Yin/0000-0002-1584-7568; Chan, David/0000-0002-6951-3467; Tse, Ka
   Yu/0000-0001-8330-0970; Ngan, Hextan Y S/0000-0003-3945-159X
FU Wong Check She Charitable Foundation; Hospital Authority, Hong Kong
FX This study was supported by the Wong Check She Charitable Foundation and
   in part by the Training and Research Assistance Scheme of the Hospital
   Authority, Hong Kong.
CR Bay BH, 2006, EXP BIOL MED, V231, P1516, DOI 10.1177/153537020623100910
   Cherian MG, 2003, MUTAT RES-FUND MOL M, V533, P201, DOI 10.1016/j.mrfmmm.2003.07.013
   Datta J, 2007, CANCER RES, V67, P2736, DOI 10.1158/0008-5472.CAN-06-4433
   Ferrario C, 2008, LAB INVEST, V88, P474, DOI 10.1038/labinvest.2008.17
   Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173
   Ioachim EE, 2000, J PATHOL, V191, P269, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH616>3.0.CO;2-Q
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jin R, 2000, BRIT J CANCER, V83, P319, DOI 10.1054/bjoc.2000.1276
   Kvasha S, 2008, CANCER LETT, V265, P250, DOI 10.1016/j.canlet.2008.02.036
   Liu Y, 2008, FERTIL STERIL, V90, P2152, DOI 10.1016/j.fertnstert.2007.10.020
   McCluggage WG, 1999, HISTOPATHOLOGY, V34, P51
   Morahan JM, 2007, TOXICOL LETT, V168, P83, DOI 10.1016/j.toxlet.2006.11.003
   Nagasaka T, 2008, INT J CANCER, V122, P2429, DOI 10.1002/ijc.23398
   Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6
   PECORELLI S, 2006, INT J GYNECOL OBSTET, V95, P105
   Poulsen CB, 2006, BLOOD, V108, P3514, DOI 10.1182/blood-2006-04-015305
   Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879
   Shukla VK, 1998, HISTOPATHOLOGY, V33, P154, DOI 10.1046/j.1365-2559.1998.00474.x
   Surowiak P, 2005, VIRCHOWS ARCH, V447, P626, DOI 10.1007/s00428-005-1228-0
   Surowiak P, 2007, VIRCHOWS ARCH, V450, P279, DOI 10.1007/s00428-006-0362-7
   Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x
   Wei H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-7
   Weinlich G, 2007, HISTOPATHOLOGY, V51, P280, DOI 10.1111/j.1365-2559.2007.02744.x
   Zhou XC, 2007, GYNECOL ONCOL, V107, P143, DOI 10.1016/j.ygyno.2007.06.019
NR 24
TC 15
Z9 17
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PY 2009
VL 30
IS 2
BP 93
EP 99
DI 10.1159/000218032
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 446CM
UT WOS:000266098000006
PM 19420986
DA 2025-01-12
ER

PT J
AU Liu, X
   Lam, EKY
   Wang, X
   Zhang, JB
   Cheng, YY
   Lam, YW
   Ng, EKO
   Yu, J
   Chan, FKL
   Jin, HC
   Sung, JJY
AF Liu, Xin
   Lam, Emily K. Y.
   Wang, Xian
   Zhang, Jianbin
   Cheng, Yuen Yee
   Lam, Yun W.
   Ng, Enders K. O.
   Yu, Jun
   Chan, Francis K. L.
   Jin, HongChuan
   Sung, Joseph J. Y.
TI Promoter Hypermethylation Mediates Downregulation of Thiamine Receptor
   SLC19A3 in Gastric Cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Gastric cancer; Methylation; SLC19A3
ID TUMOR-SUPPRESSOR; EPIGENETIC IDENTIFICATION; TRANSPORTER THTR2;
   GENE-EXPRESSION; BREAST-CANCER; METHYLATION; ESOPHAGEAL; FAMILY
AB As an important way to inactivate tumor suppressor genes (TSGs) during cancer development, promoter hypermethylation can be used to define novel TSGs and identify biomarkers for cancer diagnosis. SLC19A3 (solute carrier family 19, member 3) was found to be such a biomarker. SLC19A3 expression was downregulated in gastric cancer cell lines (71%, 5/7) and restored after pharmacological demethylation. Notably, hypermethylation of SLC19A3 promoter was detected in gastric cancer cell lines (57%, 4/7), primary gastric carcinoma tissues (51%, 52/101) and precancerous lesion (intestinal metaplasia) tissues (32%, 8/25). Exogenous SLC19A3 expression caused growth inhibition of gastric cancer cells. In summary, SLC19A3 was epigenetically downregulated in gastric cancer. Methylation of SLC19A3 promoter could be a novel biomarker for early gastric cancer development. Copyright (C) 2009 S. Karger AG, Basel
C1 [Liu, Xin; Lam, Emily K. Y.; Zhang, Jianbin; Cheng, Yuen Yee; Ng, Enders K. O.; Yu, Jun; Chan, Francis K. L.; Jin, HongChuan; Sung, Joseph J. Y.] Chinese Univ Hong Kong, Fac Med, Dept Med & Therapeut, Inst Digest Dis,Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Xian; Lam, Yun W.] City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; City
   University of Hong Kong
RP Jin, HC (通讯作者)，Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
EM jinhc@srrsh.com
RI Jin, Hongchuan/C-3686-2009; Yu, Shi-Tong/H-3747-2018; NG,
   Enders/T-3881-2019; Cheng, Yuen/AAU-2402-2020; Chan, Francis
   K.L./F-4851-2010; Cheng, Yuen Yee/G-4406-2016; Jun, Yu/D-8569-2015;
   SUNG, Joseph J Y/R-3203-2018
OI Liu, Michelle Xin/0000-0002-5795-2948; Wang, Xian/0000-0003-0041-7589;
   Chan, Francis K.L./0000-0001-7388-2436; Cheng, Yuen
   Yee/0000-0001-7060-0624; Ng, Enders Kai-on/0000-0002-5293-3529; Jun,
   Yu/0000-0001-5008-2153; Ng, Enders Kai-on/0000-0002-6955-0030; Jin,
   Hongchuan/0000-0002-6697-3097; SUNG, Joseph J Y/0000-0003-3125-5199;
   Lam, Yun Wah/0000-0001-8929-5965
FU Institute of Digestive Disease; Chinese University of Hong Kong
   [2007.1.034]
FX The project was supported by Research Funding from the Institute of
   Digestive Disease, the Chinese University of Hong Kong and CUHK direct
   grant (2007.1.034).
CR Chan MWY, 2004, BIOTECHNOL LETT, V26, P1289, DOI 10.1023/B:BILE.0000044922.43572.2d
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   CHENG YY, 2008, BR J CANC
   Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112
   Ganapathy V, 2004, PFLUG ARCH EUR J PHY, V447, P641, DOI 10.1007/s00424-003-1068-1
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Lee BY, 2005, ONCOL REP, V14, P1589
   Liu SQ, 2004, MOL CANCER RES, V2, P477
   Liu SQ, 2003, MOL CANCER RES, V1, P665
   Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207
   Rajgopal A, 2001, BBA-MOL BASIS DIS, V1537, P175, DOI 10.1016/S0925-4439(01)00073-4
   Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657
   To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783
   Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9
   Wang LJ, 2009, BIOCHEM BIOPH RES CO, V379, P959, DOI 10.1016/j.bbrc.2008.12.180
   Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343
NR 22
TC 23
Z9 25
U1 0
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PY 2009
VL 30
IS 5-6
BP 242
EP 248
DI 10.1159/000243767
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 523WY
UT WOS:000272106800002
PM 19816091
DA 2025-01-12
ER

PT J
AU Serrano, A
   Redondo, M
   Tellez, T
   Castro-Vega, I
   Roldan, MJ
   Mendez, R
   Rueda, A
   Jimenez, E
AF Serrano, Alfonso
   Redondo, Maximino
   Tellez, Teresa
   Castro-Vega, Isabel
   Jose Roldan, M.
   Mendez, Rosa
   Rueda, Antonio
   Jimenez, Eugenio
TI Regulation of Clusterin Expression in Human Cancer via DNA Methylation
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; Clusterin; Methylation
ID GENE; CELLS; HYPOMETHYLATION; HYPERMETHYLATION; OVEREXPRESSION;
   APOPTOSIS; PROSTATE; PROMOTER
AB Background/Aims: Clusterin has attracted much recent attention because of its association with tumorigenesis and the progression of human carcinomas. The present study was designed to examine the role of clusterin methylation as an indicator of clusterin expression in tumor cell lines and breast tissue samples. Methods: For this purpose, we used methylation-sensitive restriction analysis followed by PCR. Results: None of the non-tumoral breast samples showed expression of clusterin by immunohistochemistry, and a methylated state was found in the promoter region of the gene. However, a demethylated state was found in 5 of 6 analyzed carcinoma cell lines. Four of 5 demethylated cell lines presented moderate to strong expression of clusterin, while no expression was detected in the unmethylated cell line. The inverse correlation found in most cell lines between clusterin expression and promoter methylation was also found in most human tumors analyzed (p < 0.001). Thus, a methylated state was present in 14 carcinomas, 12 of them with a null expression of clusterin, while a demethylated state was detected in 7 breast tumor samples, with 5 of them presenting strong expression. Conclusions: We conclude that clusterin expression is under epigenetic control via methylation of its promoter. Copyright (C) 2009 S. Karger AG, Basel
C1 [Redondo, Maximino; Tellez, Teresa; Jose Roldan, M.] Hosp Costa Sol, Dept Biochem, ES-29600 Marbella, Spain.
   [Rueda, Antonio] Hosp Costa Sol, Dept Oncol, ES-29600 Marbella, Spain.
   [Redondo, Maximino] CIBER Epidemiol & Salud Publ, Barcelona, Spain.
   [Mendez, Rosa] Hosp Univ Virgen Nieves, Dept Immunol, Granada, Spain.
   [Redondo, Maximino; Jimenez, Eugenio] Univ Malaga, Dept Biochem & Mol Biol, E-29071 Malaga, Spain.
   [Serrano, Alfonso; Castro-Vega, Isabel] Univ Malaga, Hosp Clin Univ, Dept Immunol, E-29071 Malaga, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Hospital
   Universitario Virgen de las Nieves; Universidad de Malaga; Universidad
   de Malaga
RP Redondo, M (通讯作者)，Hosp Costa Sol, Dept Biochem, Carretera Cadiz Km 187, ES-29600 Marbella, Spain.
EM mredondo@hcs.es
RI Redondo, Maximino/AAA-6213-2020; Tellez Santana, Teresa/AFT-1553-2022
OI Tellez Santana, Teresa/0000-0002-9935-5586
FU Fondo de Investigaciones Sanitarias; Junta de Andalucia, Spain
FX We thank Yolanda de la Torre and Irene Gonzalez-Robles for their
   excellent technical assistance. M. Redondo is a member of the programme
   'Intensification of Research' at the Instituto de Salud Carlos III. This
   work was supported by grants from Fondo de Investigaciones Sanitarias
   and Junta de Andalucia, Spain.
CR BEDFORD MT, 1987, CANCER RES, V47, P5274
   Biroccio A, 2005, J CELL PHYSIOL, V204, P463, DOI 10.1002/jcp.20295
   Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Gutacker C, 1999, BIOCHEM J, V339, P759, DOI 10.1042/0264-6021:3390759
   HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377
   JOHSON CA, 1999, SEMIN CELL DEV BIOL, V10, P179
   Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103
   Lund P, 2006, ONCOGENE, V25, P4890, DOI 10.1038/sj.onc.1209502
   Rauhala HE, 2008, INT J CANCER, V123, P1601, DOI 10.1002/ijc.23658
   Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X
   Redondo M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1835
   ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069
   ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M
   SENSIBAR JA, 1995, CANCER RES, V55, P2431
   Serrano A, 1996, INT J CANCER, V68, P464, DOI 10.1002/(SICI)1097-0215(19961115)68:4<464::AID-IJC11>3.3.CO;2-H
   Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779
   SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6
   So A, 2005, MOL CANCER THER, V4, P1837, DOI 10.1158/1535-7163.MCT-05-0178
   Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009
   Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9
   WONG P, 1993, J BIOL CHEM, V268, P5021
   ZWAIN IH, 1994, MOL CELL NEUROSCI, V5, P229, DOI 10.1006/mcne.1994.1027
NR 25
TC 16
Z9 16
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PY 2009
VL 30
IS 5-6
BP 286
EP 291
DI 10.1159/000259912
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 523WY
UT WOS:000272106800007
PM 19940549
DA 2025-01-12
ER

PT J
AU Avci, ME
   Konu, O
   Yagci, T
AF Avci, Mehmet Ender
   Konu, Ozlen
   Yagci, Tamer
TI Quantification of <i>SLIT</i>-<i>ROBO</i> transcripts in hepatocellular
   carcinoma reveals two groups of genes with coordinate expression
SO BMC CANCER
LA English
DT Article
ID REPULSIVE AXON GUIDANCE; BREAST-CANCER CELLS; EPIGENETIC INACTIVATION;
   ROUNDABOUT RECEPTOR; MAGIC ROUNDABOUT; LIVER-CANCER; MIGRATION;
   PROTEINS; ANGIOGENESIS; REPELLENT
AB Background: SLIT-ROBO families of proteins mediate axon pathfinding and their expression is not solely confined to nervous system. Aberrant expression of SLIT-ROBO genes was repeatedly shown in a wide variety of cancers, yet data about their collective behavior in hepatocellular carcinoma (HCC) is missing. Hence, we quantified SLIT-ROBO transcripts in HCC cell lines, and in normal and tumor tissues from liver.
   Methods: Expression of SLIT-ROBO family members was quantified by real-time qRT-PCR in 14 HCC cell lines, 8 normal and 35 tumor tissues from the liver. ANOVA and Pearson's correlation analyses were performed in R environment, and different clinicopathological subgroups were pairwise compared in Minitab. Gene expression matrices of cell lines and tissues were analyzed by Mantel's association test.
   Results: Genewise hierarchical clustering revealed two subgroups with coordinate expression pattern in both the HCC cell lines and tissues: ROBO1, ROBO2, SLIT1 in one cluster, and ROBO4, SLIT2, SLIT3 in the other, respectively. Moreover, SLIT-ROBO expression predicted AFP-dependent subgrouping of HCC cell lines, but not that of liver tissues. ROBO1 and ROBO2 were significantly up-regulated, whereas SLIT3 was significantly down-regulated in cell lines with high-AFP background. When compared to normal liver tissue, ROBO1 was found to be significantly overexpressed, while ROBO4 was down-regulated in HCC. We also observed that ROBO1 and SLIT2 differentiated histopathological subgroups of liver tissues depending on both tumor staging and differentiation status. However, ROBO4 could discriminate poorly differentiated HCC from other subgroups.
   Conclusion: The present study is the first in comprehensive and quantitative evaluation of SLIT-ROBO family gene expression in HCC, and suggests that the expression of SLIT-ROBO genes is regulated in hepatocarcinogenesis. Our results implicate that SLIT-ROBO transcription profile is bimodular in nature, and that each module shows intrinsic variability. We also provide quantitative evidence for potential use of ROBO1, ROBO4 and SLIT2 for prediction of tumor stage and differentiation status.
C1 [Avci, Mehmet Ender; Konu, Ozlen; Yagci, Tamer] Bilkent Univ, Dept Mol Biol, Ankara, Turkey.
C3 Ihsan Dogramaci Bilkent University
RP Yagci, T (通讯作者)，Bilkent Univ, Dept Mol Biol, Ankara, Turkey.
EM aender@bilkent.edu.tr; konu@fen.bilkent.edu.tr;
   tyagci@fen.bilkent.edu.tr
RI AVCI, Mehmet/P-7458-2019
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [104S243]; Bilkent University
FX The authors are grateful to Dr. E. Oztas for his help in image
   processing. This work was supported by grant 104S243 from the Scientific
   and Technological Research Council of Turkey (TUBITAK), and funds from
   Bilkent University.
CR Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1
   Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5
   Celikkaya H, 2007, HYBRIDOMA, V26, P55, DOI 10.1089/hyb.2006.047
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Dickson BJ, 2006, ANNU REV CELL DEV BI, V22, P651, DOI 10.1146/annurev.cellbio.21.090704.151234
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Grieshammer U, 2004, DEV CELL, V6, P709, DOI 10.1016/S1534-5807(04)00108-X
   Guan HB, 2003, J IMMUNOL, V171, P6519, DOI 10.4049/jimmunol.171.12.6519
   Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745
   Ito H, 2006, CLIN CANCER RES, V12, P3257, DOI 10.1158/1078-0432.CCR-05-2787
   Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821
   Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165
   Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025
   Midorikawa Y, 2006, ONCOGENE, V25, P5581, DOI 10.1038/sj.onc.1209537
   Midorikawa Y, 2007, WORLD J GASTROENTERO, V13, P1487, DOI 10.3748/wjg.v13.i10.1487
   Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pournelle G. H., 1953, Journal of Mammalogy, V34, P133
   Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200
   Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669
   Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0
   Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250
   Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8
   Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Xian J, 2004, CANCER RES, V64, P6432, DOI 10.1158/0008-5472.CAN-04-2561
   Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098
NR 36
TC 41
Z9 45
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 29
PY 2008
VL 8
AR 392
DI 10.1186/1471-2407-8-392
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 402GD
UT WOS:000263001300001
PM 19114000
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Campbell, CT
   Aich, U
   Weier, CA
   Wang, JJ
   Choi, SS
   Wen, MM
   Maisel, K
   Sampathkumar, SG
   Yarema, KJ
AF Campbell, Christopher T.
   Aich, Udayanath
   Weier, Christopher A.
   Wang, Jean J.
   Choi, Sean S.
   Wen, Mary M.
   Maisel, Katharina
   Sampathkumar, Srinivasa-Gopalan
   Yarema, Kevin J.
TI Targeting Pro-Invasive Oncogenes with Short Chain Fatty Acid-Hexosamine
   Analogues Inhibits the Mobility of Metastatic MDA-MB-231 Breast Cancer
   Cells
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; SIALIC-ACID; METABOLIC FLUX; EXPRESSION;
   TUMOR; BUTYRATE; BIOSYNTHESIS; PATHWAYS; GM3
AB Per-butanoylated N-acetyl-D-mannosamine (Bu(4)ManNAc), a SCFA-hexosamine cancer drug candidate with activity manifest through intact n-butyrate-carbohydrate linkages, reduced the invasion of metastatic MDA-MB-231 breast cancer cells unlike per-butanoylated-D-mannose (Bu(5)Man), a clinically tested compound that did not alter cell mobility. To gain molecular-level insight, therapeutic targets implicated in metastasis were investigated. The active compound Bu(4)ManNAc reduced both MUC1 expression and MMP-9 activity (via down-regulation of CXCR4 transcription), whereas "inactive" Bu(5)Man had counterbalancing effects on these oncogenes. This divergent impact on transcription was linked to interplay between HDACi activity (held by both Bu(4)ManNAc and Bu(5)Man) and NF-kappa B activity, which was selectively down-regulated by Bu(4)ManNAc. Overall, these results establish a new therapeutic end point (control of invasion) for SCFA-hexosamine hybrid molecules, define relative contributions of molecular players involved in cell mobility and demonstrate that Bu(4)ManNAc breaks the confounding link between beneficial HDACi activity and the simultaneous deleterious activation of NF-kappa B often found in epigenetic drug candidates.
C1 [Campbell, Christopher T.; Aich, Udayanath; Weier, Christopher A.; Wang, Jean J.; Choi, Sean S.; Wen, Mary M.; Maisel, Katharina; Sampathkumar, Srinivasa-Gopalan; Yarema, Kevin J.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.
C3 Johns Hopkins University
RP Yarema, KJ (通讯作者)，Clark Hall 106A,3400 N Charles St, Baltimore, MD 21218 USA.
EM kyarema1@jhu.edu
RI Maisel, Katharina/JWP-2583-2024; Yarema, Kevin/A-3329-2010;
   Sampathkumar, Srinivasa-Gopalan/C-9951-2017
OI Sampathkumar, Srinivasa-Gopalan/0000-0002-0616-8977; Maisel,
   Katharina/0000-0002-3560-9751
FU National Institutes of Health [CA112314-01A1, AR054005-01]; Susan G.
   Komen Foundation [BCTR0503768]
FX Funding was provided by the National Institutes of Health (CA112314-01A1
   for ManNAc analogue synthesis and analysis of pro-invasive oncogenes and
   AR054005-01 for GlcNAc analogue synthesis) and by the Susan G. Komen
   Foundation (BCTR0503768) for the invasion assays.
CR Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661
   Aich U, 2008, ACS CHEM BIOL, V3, P230, DOI 10.1021/cb7002708
   Albini A, 2004, INT J DEV BIOL, V48, P563, DOI 10.1387/ijdb.041822aa
   Basson MD, 2000, J GASTROINTEST SURG, V4, P501, DOI 10.1016/S1091-255X(00)80093-1
   Campbell CT, 2007, MOL BIOSYST, V3, P187, DOI 10.1039/b614939c
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   Crazzolara R, 2002, BRIT J HAEMATOL, V119, P965, DOI 10.1046/j.1365-2141.2002.03955.x
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   FINNIE IA, 1995, GUT, V36, P93, DOI 10.1136/gut.36.1.93
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Hatayama H, 2007, BIOCHEM BIOPH RES CO, V356, P599, DOI 10.1016/j.bbrc.2007.03.025
   Jacobs CL, 2000, METHOD ENZYMOL, V327, P260, DOI 10.1016/S0076-6879(00)27282-0
   Jones MB, 2004, BIOTECHNOL BIOENG, V85, P394, DOI 10.1002/bit.10901
   JOURDIAN GW, 1971, J BIOL CHEM, V246, P430
   KAYSER H, 1992, J BIOL CHEM, V267, P16934
   Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R
   Khan A, 2007, CURR MED CHEM, V14, P2257, DOI 10.2174/092986707781696618
   Kim EJ, 2004, BIOTECHNOL PROGR, V20, P1674, DOI 10.1021/bp049841q
   Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200
   Lavis LD, 2008, ACS CHEM BIOL, V3, P203, DOI 10.1021/cb800065s
   Lemieux GA, 1999, J AM CHEM SOC, V121, P4278, DOI 10.1021/ja984228m
   Liu TM, 2000, J BIOL CHEM, V275, P32832, DOI 10.1074/jbc.C000573200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Meutermans W, 2006, CHEMMEDCHEM, V1, P1164, DOI 10.1002/cmdc.200600150
   Miki K, 2007, BIOORG MED CHEM LETT, V17, P772, DOI 10.1016/j.bmcl.2006.10.075
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Monks NR, 2006, J CELL BIOCHEM, V98, P221, DOI 10.1002/jcb.20789
   Pouillart P, 1999, EUR J PHARM SCI, V7, P93, DOI 10.1016/S0928-0987(98)00011-6
   Redondo-Muñoz J, 2006, BLOOD, V108, P3143, DOI 10.1182/blood-2006-03-007294
   Sampathkumar SG, 2006, CHEM BIOL, V13, P1265, DOI 10.1016/j.chembiol.2006.09.016
   Sampathkumar SG, 2006, DRUG FUTURE, V31, P1099, DOI 10.1358/dof.2006.031.12.1049173
   SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323
   TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x
   Thathiah A, 2004, ENDOCRINOLOGY, V145, P4192, DOI 10.1210/en.2004-0399
   Wang QL, 2007, BIOORGAN MED CHEM, V15, P7561, DOI 10.1016/j.bmc.2007.09.005
   Wang ZY, 2006, J BIOL CHEM, V281, P27016, DOI 10.1074/jbc.M604903200
   Williams EA, 2003, P NUTR SOC, V62, P107, DOI 10.1079/PNS2002230
   Yarema KJ, 2001, NAT BIOTECHNOL, V19, P553, DOI 10.1038/89305
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 41
TC 45
Z9 50
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 25
PY 2008
VL 51
IS 24
BP 8135
EP 8147
DI 10.1021/jm800873k
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 386IH
UT WOS:000261876400050
PM 19053749
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Lin, HJL
   Zuo, T
   Lin, CH
   Kuo, CT
   Liyanarachchi, S
   Sun, SY
   Shen, RL
   Deatherage, DE
   Potter, D
   Asamoto, L
   Lin, SL
   Yan, PS
   Cheng, AL
   Ostrowski, MC
   Huang, THM
AF Lin, Huey-Jen L.
   Zuo, Tao
   Lin, Ching-Hung
   Kuo, Chieh Ti
   Liyanarachchi, Sandya
   Sun, Shuying
   Shen, Rulong
   Deatherage, Daniel E.
   Potter, Dustin
   Asamoto, Lisa
   Lin, Shili
   Yan, Pearlly S.
   Cheng, Ann-Lii
   Ostrowski, Mchael C.
   Huang, Tim H. -M.
TI Breast Cancer-Associated Fibroblasts Confer AKT1-Mediated Epigenetic
   Silencing of <i>Cystatin M</i> in Epithelial Cells
SO CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION; STROMAL FIBROBLASTS; GROWTH; CONTRIBUTES; INHIBITION;
   SENESCENCE; PROTEIN; ARREST; GENES; CST6
AB The interplay between histone modifications and promoter hypermethylation provides a causative explanation for epigenetic gene silencing in cancer. Less is known about the upstream initiators that direct this process. Here, we report that the Cystatin M (CST6) tumor suppressor gene is concurrently down-regulated with other loci in breast epithelial cells cocultured with cancer-associated fibroblasts (CAF). Promoter hypermethylation of CST6 is associated with aberrant AKT1 activation in epithelial cells, as well as the disabled INNP4B regulator resulting from the suppression by CAFs. Repressive chromatin, marked by trimethyl-H3K27 and dimethyl-H3K9, and de novo DNA methylation is established at the promoter. The findings suggest that microenvironmental stimuli are triggers in this epigenetic cascade, leading to the long-term silencing of CST6 in breast tumors. Our present findings implicate a causal mechanism defining how tumor stromal fibroblasts support neoplastic progression by manipulating the epigenome of mammary epithelial cells. The result also highlights the importance of direct cell-cell contact between epithelial cells and the surrounding fibroblasts that confer this epigenetic perturbation. Because this two-way interaction is anticipated, the described coculture system can be used to determine the effect of epithelial factors on fibroblasts in future studies. [Cancer Res 2008;68(24):10257-66]
C1 [Lin, Huey-Jen L.; Zuo, Tao; Kuo, Chieh Ti; Liyanarachchi, Sandya; Deatherage, Daniel E.; Potter, Dustin; Yan, Pearlly S.; Huang, Tim H. -M.] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA.
   [Lin, Huey-Jen L.; Zuo, Tao; Asamoto, Lisa] Ohio State Univ, Div Med Technol, Sch Allied Med Profess, Columbus, OH 43210 USA.
   [Sun, Shuying] Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA.
   [Shen, Rulong] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
   [Ostrowski, Mchael C.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   [Lin, Shili] Ohio State Univ, Dept Stat, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Lin, Ching-Hung; Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; James Cancer Hospital & Solove
   Research Institute; University System of Ohio; Ohio State University;
   National Taiwan University; National Taiwan University Hospital
RP Huang, THM (通讯作者)，Ohio State Univ, Human Canc Genet Program, 814 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.
EM huey-jen.lin@osumc.edu; tim.huang@osumc.edu
RI Lin, Huey-Jen/E-3514-2011; Lin, Chih-Cheng/IQT-4912-2023; Yan,
   Pearlly/E-4339-2011; Cheng, Ann-Lii/ACM-0936-2022; Shen,
   Rulong/E-4079-2011; Ostrowski, Michael/H-3108-2011
OI Zuo, Tao/0000-0001-8450-5281; Ostrowski, Michael/0000-0003-2948-6297;
   Cheng, Ann-Lii/0000-0002-9152-6512; Zuo, Tao/0000-0002-2125-7548; LIN,
   CHING-HUNG/0000-0003-2403-4056
FU American Cancer Society [U54CA113001, RO1CA069065]; Department of
   Defense [BC073892]; Susan G. Komen Breast Cancer Foundation [KG081123];
   Ohio State University Comprehensive Cancer Center; National Science
   Foundation [0112050];  [NIH T32 CA106196-03]
FX NIH grants U54CA113001 and RO1CA069065, (T. Huang) funds from American
   Cancer Society, Department of Defense grant BC073892, Susan G. Komen
   Breast Cancer Foundation grant KG081123, (H. Lin) Ohio State University
   Comprehensive Cancer Center, and NIH T32 CA106196-03 (D. Potter) and
   National Science Foundation 0112050 (S. Sun) postdoctoral fellowships.
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7
   Barnache S, 2006, ONCOGENE, V25, P1420, DOI 10.1038/sj.onc.1209187
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Chung I, 2007, J BIOL CHEM, V282, P8704, DOI 10.1074/jbc.M608894200
   Ehrich M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1134
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106
   HARRELL JF, 2001, REGRESSION MODELING, P90
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kim JB, 2005, TUMOR BIOL, V26, P173, DOI 10.1159/000086950
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Plimack ER, 2007, J CLIN ONCOL, V25, P4519, DOI 10.1200/JCO.2007.12.6029
   Priore R, 2006, J CELL PHYSIOL, V207, P800, DOI 10.1002/jcp.20620
   Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Shekhar MPV, 2001, CANCER RES, V61, P1320
   SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435
   SOULE HD, 1990, CANCER RES, V50, P6075
   Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1046/j.1432-0436.1998.6340201.x
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
NR 42
TC 55
Z9 62
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2008
VL 68
IS 24
BP 10257
EP 10266
DI 10.1158/0008-5472.CAN-08-0288
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 386FD
UT WOS:000261866800032
PM 19074894
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Aleman, A
   Cebrian, V
   Alvarez, M
   Lopez, V
   Orenes, E
   Lopez-Serra, L
   Algaba, F
   Bellmunt, J
   López-Beltrán, A
   Gonzalez-Peramato, P
   Cordon-Cardo, C
   García, J
   del Muro, JG
   Esteller, M
   Sánchez-Carbayo, M
AF Aleman, Ainel
   Cebrian, Virginia
   Alvarez, Miguel
   Lopez, Virginia
   Orenes, Esteban
   Lopez-Serra, Lidia
   Algaba, Ferran
   Bellmunt, Joaquin
   Lopez-Beltran, Antonio
   Gonzalez-Peramato, Pilar
   Cordon-Cardo, Carlos
   Garcia, Javier
   Garcia del Muro, Javier
   Esteller, Mane
   Sanchez-Carbayo, Marta
TI Identification of PMF1 Methylation in Association with Bladder Cancer
   Progression
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID COLON CARCINOMA-CELLS; GENE-EXPRESSION; BREAST-CANCER; MICROARRAYS;
   HYPERMETHYLATION; MECHANISMS; DIAGNOSIS; TRANSCRIPTION; DISEASE; NRF-2
AB Purpose: Polyamines are important regulators of cell growth and death. The polyamine modulated factor-1 (PMF-1) is involved in polyamine homeostasis. After identifying an enriched CpG island encompassing the PMF1 promoter, we aimed at evaluating the clinical relevance of PMF1 methylation in bladder cancer.
   Experimental Design: The epigenetic silencing of PMF1 by hypermethylation was tested in bladder cancer cells (n = 11) after azacytidine treatment. PMF1 methylation status was evaluated in 507 bladder tumors and 118 urinary specimens of bladder cancer patients and controls. PMF1 protein expression was analyzed by immunohistochemistry on tissue arrays containing bladder tumors for which PMF1 methylation was assessed (n = 218).
   Results: PMF1 hypermethylation was associated with gene expression loss, being restored in vitro by a demethylating agent. An initial set of 101 primary frozen bladder tumors served to identify PMF1 hypermethylation in 88.1% of the cases. An independent set of 406 paraffin-embedded tumors also revealed a high PMF1 methylation rate (77.6%). PMF1 methylation was significantly associated with increasing stage (P = 0.025). Immunohistochemical analyses revealed that PMF1 methylation was associated with cytoplasmic PMF1 expression loss (P = 0.032). PMF1 protein expression patterns were significantly associated with stage (P < 0.001), grade (P < 0.001), and poor overall survival using univariate (P < 0.001) and multivariate (P = 0.011) analyses. Moreover, PMF1 methylation in urinary specimens distinguished bladder cancer patients from controls (area under the curve = 0.800).
   Conclusion: PMF1 was identified to be epigenetically modified in bladder cancer. The association of PMF1 methylation with tumor progression and its diagnostic ability using urinary specimens support including PMF1 assessment for the clinical management of bladder cancer patients.
C1 [Aleman, Ainel; Cebrian, Virginia; Lopez, Virginia; Orenes, Esteban; Sanchez-Carbayo, Marta] Spanish Natl Canc Ctr, Mol Pathol Program, Tumor Markers Grp, E-28029 Madrid, Spain.
   [Lopez-Serra, Lidia; Esteller, Mane] Spanish Natl Canc Ctr, Mol Pathol Program, Epigenet Grp, E-28029 Madrid, Spain.
   [Alvarez, Miguel] Univ Oviedo, Hosp Cent Asturias, Dept Urol, E-33080 Oviedo, Spain.
   [Garcia del Muro, Javier] Inst Catala Oncol, Dept Oncol, Barcelona, Spain.
   [Lopez-Beltran, Antonio] Hosp Reina Sofia, Dept Pathol, Cordoba, Spain.
   [Gonzalez-Peramato, Pilar] Hosp Guadalajara, Dept Pathol, Guadalajara, Spain.
   [Cordon-Cardo, Carlos] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Garcia, Javier] Hosp Univ Salamanca, Dept Urol, Salamanca, Spain.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional
   de Investigaciones Oncologicas (CNIO); Central University Hospital
   Asturias; University of Oviedo; Institut Catala d'Oncologia; Hospital
   Universitario Reina Sofia - Cordoba; Memorial Sloan Kettering Cancer
   Center; University of Salamanca
RP Sánchez-Carbayo, M (通讯作者)，Spanish Natl Canc Ctr, Mol Pathol Program, Tumor Markers Grp, 310A,Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.
EM mscarbayo@cnio.es
RI Orenes-Piñero, Esteban/AAG-8752-2019; López-Beltrán,
   António/AAK-7326-2020; Bellmunt, Joaquim/B-8151-2019; Gonzalez-Peramato,
   Pilar/E-1997-2014; Lopez, Virginia/AAC-1321-2021; Esteller,
   Manel/L-5956-2014
OI Gonzalez-Peramato Gutierrez, Maria Del Pilar/0000-0001-6912-3293;
   Orenes-Pinero, Esteban/0000-0003-3979-6678; Cebrian,
   Virginia/0000-0002-3414-4796; Lopez-Beltran,
   Antonio/0000-0002-0724-1267; Lopez, Virginia/0000-0002-0065-7999;
   Esteller, Manel/0000-0003-4490-6093
FU Spanish Ministry of Education and Culture [SAF2006-08519]
FX Spanish Ministry of Education and Culture grant SAF2006-08519 (M.
   Sanchez-Carbayo) and predoctoral award (V. Lopez).
CR Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143
   Baffa R, 2006, J EXP CLIN CANC RES, V25, P145
   CELANO P, 1988, J BIOL CHEM, V263, P5491
   CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6
   Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563
   Cordon-Cardo C, 2000, SCAND J UROL NEPHROL, V34, P82, DOI 10.1080/003655900750169338
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dawson-Saunders B., 1994, Basic and clinical biostatistics, V2
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Gonzalgo ML, 2007, UROL ONCOL-SEMIN ORI, V25, P228, DOI 10.1016/j.urolonc.2006.07.020
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hu YC, 2002, ONCOGENE, V21, P7289, DOI 10.1038/sj.onc.1205805
   Huang Y, 2005, ANTI-CANCER DRUG, V16, P229, DOI 10.1097/00001813-200503000-00002
   Husbeck B, 2003, BIOCHEM BIOPH RES CO, V306, P469, DOI 10.1016/S0006-291X(03)00993-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim WJ, 2005, J CELL BIOCHEM, V95, P24, DOI 10.1002/jcb.20412
   Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062
   Paz MF, 2003, CANCER RES, V63, P1114
   Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375
   Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973
   Stephenson AH, 2006, LIFE SCI, V79, P1221, DOI 10.1016/j.lfs.2006.03.042
   WANG JY, 1993, AM J PHYSIOL, V265, pG331, DOI 10.1152/ajpgi.1993.265.2.G331
   WANG JY, 1994, AM J PHYSIOL, V266, pG878, DOI 10.1152/ajpgi.1994.266.5.G878
   Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095
   Wang YL, 2002, BIOCHEM J, V366, P79, DOI 10.1042/bj20020211
   Wang YL, 2001, BIOCHEM J, V355, P45, DOI 10.1042/0264-6021:3550045
   Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Zhang ZW, 2006, UROL ONCOL-SEMIN ORI, V24, P152, DOI 10.1016/j.urolonc.2005.11.004
NR 30
TC 34
Z9 38
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2008
VL 14
IS 24
BP 8236
EP 8243
DI 10.1158/1078-0432.CCR-08-0778
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 384ZL
UT WOS:000261782600033
PM 19088041
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Bigl, M
   Jandrig, B
   Horn, LC
   Eschrich, K
AF Bigl, Marina
   Jandrig, Burkhard
   Horn, Lars-Christian
   Eschrich, Klaus
TI Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes
   in cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Breast cancer; Cell line; DNA methylation; Fructose 1,6-bisphosphatase;
   Gene expression; Gluconeogenesis; Promoter; Tissue-specific expression
ID CARBOHYDRATE-METABOLIZING ENZYMES; MUSCLE FRUCTOSE-1,6-BISPHOSPHATASE;
   BREAST-CANCER; EXPRESSION; PROMOTER; TUMOR; IDENTIFICATION;
   LOCALIZATION; GROWTH; CELLS
AB A possible epigenetic regulation of the two isoenzymes of fructose 1,6-bisphosphatase (FBPase) was studied in liver, muscle, mamma, breast cancer and in different cancer cell lines. Results obtained after bisulfite sequencing revealed a different CpG methylation of both promoters in liver, muscle and breast tissue which is putatively involved in the cell-type specific gene expression of the two enzymes. In tumor cell lines, demethylation with 5-aza-deoxycytidine activated the expression of both isoenzymes. Additional inhibition of histone deacetylase with trichostatin A further increased FBPase mRNA concentrations. Since cancers typically have an abnormal energy metabolism and exhibit a low gluconeogenic phenotype, it was studied whether promoter methylation contributes to the decreased expression of FBPase in breast cancer. When non-malignant and malignant tissue samples from the same patient were compared a correlation between an increase of FBPase promoter methylation and a decrease of FBPase mRNA levels was observed. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Bigl, Marina; Eschrich, Klaus] Univ Leipzig, Fac Med, Inst Biochem, D-04103 Leipzig, Germany.
   [Jandrig, Burkhard] Max Delbruck Ctr Mol Med, Berlin, Germany.
   [Horn, Lars-Christian] Univ Leipzig, Inst Pathol, Div Gynecol & Perinatal Pathol, D-04103 Leipzig, Germany.
C3 Leipzig University; Helmholtz Association; Max Delbruck Center for
   Molecular Medicine; Leipzig University
RP Eschrich, K (通讯作者)，Univ Leipzig, Fac Med, Inst Biochem, Johannisallee 30, D-04103 Leipzig, Germany.
EM eschrich@uni-leipzig.de
CR Al-Robaiy S, 1999, BIOL CHEM, V380, P1079, DOI 10.1515/BC.1999.134
   DEVILLIERS N, 1993, CANCER BIOCHEM BIOPH, V13, P255
   ELMAGHRABI MR, 1995, GENOMICS, V27, P520, DOI 10.1006/geno.1995.1085
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fella K, 2005, PROTEOMICS, V5, P1914, DOI 10.1002/pmic.200401067
   Gleeson TT, 1996, ANNU REV PHYSIOL, V58, P565, DOI 10.1146/annurev.ph.58.030196.003025
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Hannemann A, 2005, GENE, V345, P237, DOI 10.1016/j.gene.2004.11.018
   Herzog B, 2000, BIOCHEM J, V351, P385, DOI 10.1042/0264-6021:3510385
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jandrig B, 2004, ONCOGENE, V23, P9295, DOI 10.1038/sj.onc.1208131
   Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675
   Jin B, 2005, BIOL PHARM BULL, V28, P2054, DOI 10.1248/bpb.28.2054
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Muindi JR, 2007, CANCER CHEMOTH PHARM, V59, P97, DOI 10.1007/s00280-006-0247-0
   PARIMALA R, 1993, MOL CELL BIOCHEM, V125, P59, DOI 10.1007/BF00926835
   Perumal SS, 2005, CANCER CHEMOTH PHARM, V56, P105, DOI 10.1007/s00280-004-0943-6
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sujatha V, 2002, PHYTOTHER RES, V16, pS14, DOI 10.1002/ptr.777
   Tillmann H, 1998, GENE, V212, P295, DOI 10.1016/S0378-1119(98)00181-4
   Tillmann H, 2000, GENE, V247, P241, DOI 10.1016/S0378-1119(00)00079-2
   Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680
   Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215
   Zeitschel U, 2002, J NEUROCHEM, V83, P371, DOI 10.1046/j.1471-4159.2002.01127.x
NR 26
TC 22
Z9 26
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 12
PY 2008
VL 377
IS 2
BP 720
EP 724
DI 10.1016/j.bbrc.2008.10.045
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 378DO
UT WOS:000261301600075
PM 18938139
DA 2025-01-12
ER

PT J
AU Cheng, YY
   Jin, H
   Liu, X
   Siu, JMT
   Wong, YP
   Ng, EKO
   Yu, J
   Leung, WK
   Sung, JJY
   Chan, FKL
AF Cheng, Y. Y.
   Jin, H.
   Liu, X.
   Siu, J. M. T.
   Wong, Y. P.
   Ng, E. K. O.
   Yu, J.
   Leung, W-K
   Sung, J. J. Y.
   Chan, F. K. L.
TI Fibulin 1 is downregulated through promoter hypermethylation in gastric
   cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE FBLN1; methylation; tumour suppressor gene; gastric cancer
ID TUMOR-RELATED GENES; BREAST-CANCER; METHYLATION; CARCINOGENESIS;
   PROGRESSION; CARCINOMA; EVENTS
AB Tumour suppressor genes (TSGs) were frequently inactivated through promoter hypermethylation in gastric carcinoma as well as pre-malignant gastric lesions, suggesting that promoter hypermethylation can be used as a marker to define novel TSGs and also biomarkers for early detection of gastric cancer. In an effort to search for such genes aberrantly methylated in gastric cancer development, fibulin 1 (FBLN1) was found as a candidate TSG epigenetically downregulated in gastric cancer. FBLN1 expression was downregulated in all of gastric cancer cell lines used (100%, 7 out of 7) and the primary gastric carcinoma tissues (84%, 86 out of 102) and significantly restored after pharmacological demethylation. Hypermethylation of the FBLN1 promoter was frequently (71%, 5 out of 7) detected in gastric cancer cell lines and primary gastric carcinoma tissues. Ectopic expression of FBLN1 led to the growth inhibition of gastric cancer cells through the induction of apoptosis. In summary, FBLN1 was identified as a novel candidate TSG epigenetically downregulated in gastric cancer.
C1 [Cheng, Y. Y.; Jin, H.; Liu, X.; Siu, J. M. T.; Wong, Y. P.; Ng, E. K. O.; Yu, J.; Leung, W-K; Sung, J. J. Y.; Chan, F. K. L.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Fac Med, Dept Med & Therapeut,Inst Digest Dis, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Chan, FKL (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
EM fklchan@cuhk.edu.hk
RI NG, Enders/T-3881-2019; Jin, Hongchuan/C-3686-2009; Chan, Francis
   K.L./F-4851-2010; SUNG, Joseph J Y/R-3203-2018; Leung, Wai
   Keung/B-8140-2011; Jun, Yu/D-8569-2015; Cheng, Yuen Yee/G-4406-2016
OI Chan, Francis K.L./0000-0001-7388-2436; Liu, Michelle
   Xin/0000-0002-5795-2948; Ng, Enders Kai-on/0000-0002-5293-3529; Jin,
   Hongchuan/0000-0002-6697-3097; SUNG, Joseph J Y/0000-0003-3125-5199;
   Leung, Wai Keung/0000-0002-5993-1059; Jun, Yu/0000-0001-5008-2153;
   Cheng, Yuen Yee/0000-0001-7060-0624; Ng, Enders
   Kai-on/0000-0002-6955-0030
FU Research Funding from the Institute of Digestive Disease, the Chinese
   University of Hong Kong
FX The project was supported by Research Funding from the Institute of
   Digestive Disease, the Chinese University of Hong Kong.
CR Chan AOO, 2006, CURR MOL MED, V6, P401, DOI 10.2174/156652406777435417
   Chan MWY, 2004, BIOTECHNOL LETT, V26, P1289, DOI 10.1023/B:BILE.0000044922.43572.2d
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293
   Du MJ, 2002, BIOCHEM BIOPH RES CO, V296, P962, DOI 10.1016/S0006-291X(02)02041-7
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294
   Pan TC, 1999, FEBS LETT, V444, P38, DOI 10.1016/S0014-5793(99)00024-1
   Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207
   Pupa SM, 2004, ONCOGENE, V23, P2153, DOI 10.1038/sj.onc.1207323
   Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657
   To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783
   Twal WO, 2001, J CELL SCI, V114, P4587
   Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Vogiatzi P, 2007, J CELL PHYSIOL, V211, P287, DOI 10.1002/jcp.20982
   Wlazlinski A, 2007, PROSTATE, V67, P1770, DOI 10.1002/pros.20667
   Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478
NR 26
TC 67
Z9 76
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD DEC 9
PY 2008
VL 99
IS 12
BP 2083
EP 2087
DI 10.1038/sj.bjc.6604760
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 382QI
UT WOS:000261620100016
PM 18985039
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Kozlowska, A
   Jagodzinski, PP
AF Kozlowska, A.
   Jagodzinski, P. P.
TI Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine
   kinase expression in Hut-78 T-lymphoma cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE T-lymphoma; Fyn tyrosine kinase; Epigenetics
ID SRC FAMILY KINASES; NEGATIVE REGULATION; GENE-EXPRESSION; BREAST-CANCER;
   METHYLATION; DECITABINE; DELETION; PHASE; HETEROZYGOSITY; CHROMOSOME-6
AB Tyrosine kinase Fyn, the expression of which is epigenetically regulated, has been proposed to be a tumour suppressor gene. A frequent deletion at the 6q chromosomal region encoding the Fyn gene in lymphomas has been reported. Therefore, we assessed the impact of 5-Aza-2'-deoxycytidine (5-dAzaC), a DNA methyltransferase (DNMTs) inhibitor on Fyn expression in Hut-78 T-lymphoma cells. Using reverse transcription, real-time quantitative PCR (RQ-PCR), and western blot analyses, we found that 5-dAzaC significantly increased transcript and protein levels of Fyn in Hut-78 T-lymphoma cells. However, bisulfite sequencing revealed that Hut-78 T-lymphoma cells cultured in the absence of 5-dAzaC contained unmethylated cytosine in the cytosine-guanosine dinucleotide island of the Fyn promoter. Our results suggest that the DNMTs activity may have an indirect influence on the expression of Fyn without altering the methylation level of its promoter in Hut-78 T-lymphoma cells. (c) 2008 Elsevier Masson SAS. All rights reserved.
C1 [Kozlowska, A.; Jagodzinski, P. P.] Karol Marcinkowski Univ Med Sci, Dept Biochem & Mol Biol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences
RP Jagodzinski, PP (通讯作者)，Karol Marcinkowski Univ Med Sci, Dept Biochem & Mol Biol, 6 Swiecickiego St, PL-60781 Poznan, Poland.
EM pjagodzi@am.poznan.pl
RI Kozlowska, Anna/P-1620-2015; Jagodzinski, Pawel/KWV-0637-2024
OI Jagodzinski, Pawel/0000-0002-9046-6802; Kozlowska, Anna
   Karolina/0000-0003-2465-217X
FU Polish Ministry of Scientific Research and Information Technology [N
   N402 2424 33]
FX Supported by grant No. N N402 2424 33 from Polish Ministry of Scientific
   Research and Information Technology. We would like to acknowledge
   Margarita Lianeri for her assistance.
CR Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275
   Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4
   Carvalho B, 2001, CANCER GENET CYTOGEN, V131, P54, DOI 10.1016/S0165-4608(01)00514-3
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0
   DAVIDSON D, 1960, MOL CELL BIOL, V2007, P27
   Filby A, 2007, J IMMUNOL, V179, P4635, DOI 10.4049/jimmunol.179.7.4635
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121
   Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Noviello C, 1996, CLIN CANCER RES, V2, P1601
   OKADA M, 1991, J BIOL CHEM, V266, P24249
   Oki Y, 2007, CANCER, V109, P899, DOI 10.1002/cncr.22470
   Piotrowska H, 2007, BIOMED PHARMACOTHER, V61, P451, DOI 10.1016/j.biopha.2007.03.007
   POPESCU NC, 1987, ONCOGENE, V1, P449
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Richardson B, 1999, J LAB CLIN MED, V134, P333, DOI 10.1016/S0022-2143(99)90147-6
   Schrump DS, 2006, CLIN CANCER RES, V12, P5777, DOI 10.1158/1078-0432.CCR-06-0669
   Sorensen KD, 2008, INT J CANCER, V122, P509, DOI 10.1002/ijc.23136
   Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949
   Szabo A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r59
   Taborelli M, 2006, CANCER GENET CYTOGEN, V165, P106, DOI 10.1016/j.cancergencyto.2005.06.025
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813
   Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205
NR 35
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2008
VL 62
IS 10
BP 672
EP 676
DI 10.1016/j.biopha.2008.01.011
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 385PE
UT WOS:000261825300002
PM 18337055
DA 2025-01-12
ER

PT J
AU Jiang, L
   Gonda, TA
   Gamble, MV
   Salas, M
   Seshan, V
   Tu, S
   Twaddell, WS
   Hegyi, P
   Lazar, G
   Steele, I
   Varro, A
   Wang, TC
   Tycko, B
AF Jiang, Le
   Gonda, Tamas A.
   Gamble, Mary V.
   Salas, Martha
   Seshan, Venkatraman
   Tu, Shuiping
   Twaddell, William S.
   Hegyi, Peter
   Lazar, Gyorgy
   Steele, Islay
   Varro, Andrea
   Wang, Timothy C.
   Tycko, Benjamin
TI Global Hypomethylation of Genomic DNA in Cancer-Associated
   Myofibroblasts
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; STROMAL CELLS; TUMOR-STROMA; MATRIX METALLOPROTEINASE-7;
   METHYLATION PATTERNS; GENETIC ALTERATIONS; EPITHELIAL-CELLS; IN-VITRO;
   HETEROZYGOSITY; EXPRESSION
AB Global hypomethylation has long been recognized as a feature of the malignant epithelial component in human carcinomas. Here we show evidence for this same type of epigenetic alteration in cancer-associated stromal myofibroblasts. We used methylation-sensitive SNP array analysis (MSNP) to profile DNA methylation in early-passage cultures of stromal myofibroblasts isolated from human gastric cancers. The MSNP data indicated widespread hypomethylation in these cells, with rare focal gains of methylation, conclusions that were independently validated by bisulfate sequencing and by a methylation-sensitive cytosine incorporation assay. Immunohistochemistry with anti-5-methylcytosine (anti-5-methyl-C) in a series of gastrectomy specimens showed frequent loss of methylation in nuclei of both the malignant epithelial cells and a-smooth muscle actin (ASMA)-positive stromal myofibroblasts of both intestinal-type and diffuse carcinomas. We confirmed this phenomenon and established its onset at the stage of noninvasive dysplastic lesions by immunohistochemistry for anti-5-methyl-C in a transgenic mouse model of multistage gastric carcinogenesis. These findings indicate similar general classes of epigenetic alterations in carcinoma cells and their accompanying reactive stromal cells and add to accumulating evidence for biological differences between normal and cancer-associated myofibroblasts. [Cancer Res 2008;68(23):9900-8]
C1 [Jiang, Le; Salas, Martha; Tycko, Benjamin] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.
   [Gonda, Tamas A.; Tu, Shuiping; Wang, Timothy C.] Columbia Univ, Dept Med, New York, NY 10032 USA.
   [Gamble, Mary V.] Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Seshan, Venkatraman] Columbia Univ, Dept Biostat, New York, NY 10032 USA.
   [Twaddell, William S.; Tycko, Benjamin] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   [Hegyi, Peter; Lazar, Gyorgy] Univ Szeged, Dept Med, Szeged, Hungary.
   [Hegyi, Peter; Lazar, Gyorgy] Univ Szeged, Dept Surg, Szeged, Hungary.
   [Steele, Islay; Varro, Andrea] Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Columbia University; Szeged University; Szeged University;
   University of Liverpool
RP Tycko, B (通讯作者)，Columbia Univ, Inst Canc Genet, 1130 St Nicholas Ave, New York, NY 10032 USA.
EM bt12@columbia.edu
RI Varro, Andras/M-2647-2016; wang, tim/JXM-8048-2024; Hegyi,
   Péter/B-3163-2016
OI Wang, Timothy/0000-0001-5730-3019
FU Medical Research Council and North West Cancer Research Fund
   [U54-CA126513]
FX Medical Research Council and North West Cancer Research Fund (A. Varro)
   and grant U54-CA126513 (T.C. Wang and B. Tycko).
CR Campbell IG, 2008, NEW ENGL J MED, V358, P1634, DOI 10.1056/NEJMc086024
   Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10
   Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434
   Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X
   Desmoulière A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Hanson JA, 2006, JNCI-J NATL CANCER I, V98, P255, DOI 10.1093/jnci/djj051
   Hernandez-Blazquez FJ, 2000, GUT, V47, P689, DOI 10.1136/gut.47.5.689
   Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x
   Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174
   Kim YI, 1998, AM J CLIN NUTR, V68, P866, DOI 10.1093/ajcn/68.4.866
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686
   Mann J, 2007, CELL DEATH DIFFER, V14, P275, DOI 10.1038/sj.cdd.4401979
   McCaig C, 2006, GASTROENTEROLOGY, V130, P1754, DOI 10.1053/j.gastro.2006.02.031
   MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617
   Moinfar F, 2000, CANCER RES, V60, P2562
   MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440
   Nakayama H, 2002, J CLIN PATHOL, V55, P741, DOI 10.1136/jcp.55.10.741
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Paterson RF, 2003, CANCER, V98, P1830, DOI 10.1002/cncr.11747
   Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825
   Piyathilake CJ, 2001, HUM PATHOL, V32, P856, DOI 10.1053/hupa.2001.26471
   Piyathilake CJ, 2000, BIOTECH HISTOCHEM, V75, P251, DOI 10.3109/10520290009085128
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005
   Roukos DH, 2008, NEW ENGL J MED, V358, P1636
   Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191
   TU SCG, 2007, GASTROENTEROLOGY, V132, pA25
   Walter K, 2008, CANCER BIOL THER, V7, P882, DOI 10.4161/cbt.7.6.5869
   WILSON VL, 1983, SCIENCE, V220, P1054
   Yuan E, 2006, CANCER RES, V66, P3443, DOI 10.1158/0008-5472.CAN-05-3739
   Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082
NR 47
TC 122
Z9 133
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2008
VL 68
IS 23
BP 9900
EP 9908
DI 10.1158/0008-5472.CAN-08-1319
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 380TU
UT WOS:000261488900043
PM 19047171
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Misawa, K
   Ueda, Y
   Kanazawa, T
   Misawa, Y
   Jang, I
   Brenner, JC
   Ogawa, T
   Takebayashi, S
   Grenman, R
   Herman, JG
   Mineta, H
   Carey, TE
AF Misawa, Kiyoshi
   Ueda, Yo
   Kanazawa, Takeharu
   Misawa, Yuki
   Jang, Ilwhan
   Brenner, John Chadwick
   Ogawa, Tetsuya
   Takebayashi, Satoru
   Grenman, ReidarA.
   Herman, James G.
   Mineta, Hiroyuki
   Carey, Thomas E.
TI Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; PROTEIN-COUPLED RECEPTORS; TRANSCRIPTION FACTOR
   AP-2; DNA METHYLATION; GENE-EXPRESSION; SIGNALING PATHWAYS; PROMOTER
   REGION; BREAST-CANCER; PROLIFERATION; ACTIVATION
AB Purpose: One copy of the galanin receptor 1 (GALR1) locus on 18q is often deleted and expression is absent in some head and neck squamous cell carcinoma (HNSCC) cell lines. To determine if loss of heterozygosity and hypermethylation might silence the GALR1 gene, promoter methylation status and gene expression were assessed in a large panel of HNSCC cell lines and tumors.
   Experimental Design: Promoter methylation of GALR1 in 72 cell lines and 100 primary tumor samples was analyzed using methylation-specific PCR. GALR1 expression and methylation status were analyzed further by real-time PCR and bisulfite sequencing analysis.
   Results: The GALR1 promoter was fully or partially methylated in 38 of 72 (52.7 %) HNSCC cell lines but not in the majority 18 of 20 (90.0%) of nonmalignant lines. GALR1 methylation was also found in 38 of 100 (38%) primary tumor specimens. Methylation correlated with decreased GALR1 expression. In tumors, methylation was significantly correlated with increased tumor size (P = 0.0036), lymph node status (P = 0.0414), tumor stage (P = 0.0037), cyclin D1 expression (P = 0.0420), and p16 methylation (P = 0.0494) and survival (P = 0.045). Bisulfite sequencing of 36 CpG sites upstream of the transcription start site revealed that CpG methylation within transcription factor binding sites correlated with complete suppression of GALR1 mRNA. Treatment with trichostatin A and 5-azacyticline restored GALR1 expression. In UM-SCC-23 cells that have total silencing of GALR1, exogenous GALR1 expression and stimulation with galanin suppressed cell proliferation.
   Conclusions: Frequent promoter hypermethylation, gene silencing, association with prognosis, and growth suppression after reexpression support the hypothesis that GALR1 is a tumor suppressor gene in HNSCC.
C1 [Misawa, Kiyoshi; Ueda, Yo; Kanazawa, Takeharu; Misawa, Yuki; Jang, Ilwhan; Brenner, John Chadwick; Ogawa, Tetsuya; Takebayashi, Satoru; Carey, Thomas E.] Univ Michigan, Lab Head & Neck Canc Biol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Misawa, Kiyoshi; Ueda, Yo; Misawa, Yuki; Takebayashi, Satoru; Mineta, Hiroyuki] Hamamatsu Univ Sch Med, Shizuoka, Japan.
   [Kanazawa, Takeharu] Jichi Univ, Sch Med, Saitama, Japan.
   [Jang, Ilwhan] Ghil Hosp, Inchon, South Korea.
   [Ogawa, Tetsuya] Aichi Canc Ctr, Nagoya, Aichi 464, Japan.
   [Grenman, ReidarA.] Turku Univ, Cent Hosp, Turku, Finland.
   [Herman, James G.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
C3 University of Michigan System; University of Michigan; Hamamatsu
   University School of Medicine; Jichi Medical University; Aichi Cancer
   Center; University of Turku; Johns Hopkins University; Johns Hopkins
   Medicine
RP Carey, TE (通讯作者)，Univ Michigan, Lab Head & Neck Canc Biol, Ctr Comprehens Canc, 1150 W Med Ctr Dr,Room 5311, Ann Arbor, MI 48109 USA.
EM careyte@umich.edu
RI Kanazawa, Takeharu/H-2789-2014
OI Carey, Thomas/0000-0002-5202-7518
FU NCI NIH HHS [P30 CA046592, P50 CA097248, 1 P50 CA97248, 5 P30 CA46592]
   Funding Source: Medline; NIDCD NIH HHS [P30 DC005188, P30 DC05188]
   Funding Source: Medline; NIDCR NIH HHS [R01 DE012477, 5R01 DE12477]
   Funding Source: Medline; National Cancer Institute [P30CA046592] Funding
   Source: NIH RePORTER
CR BARTFAI T, 1992, TRENDS PHARMACOL SCI, V13, P312, DOI 10.1016/0165-6147(92)90098-Q
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Berger A, 2004, ENDOCRINOLOGY, V145, P500, DOI 10.1210/en.2003-0649
   Berger A, 2002, NEUROENDOCRINOLOGY, V75, P130, DOI 10.1159/000048229
   Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2
   Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008
   Cheung JOP, 2003, J PATHOL, V201, P496, DOI 10.1002/path.1462
   Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236
   Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003
   Gschwind A, 2002, CANCER RES, V62, P6329
   Gundlach AL, 2002, EUR J PHARMACOL, V440, P255, DOI 10.1016/S0014-2999(02)01433-4
   Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186
   Henson BS, 2005, J BIOL CHEM, V280, P22564, DOI 10.1074/jbc.M414589200
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6
   Kanazawa T, 2007, ONCOGENE, V26, P5762, DOI 10.1038/sj.onc.1210384
   Kuroki T, 2003, CANCER RES, V63, P3724
   Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243
   LISMAA TP, 1998, ANN NY ACAD SCI, V863, P56
   Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764
   Mineta H, 2000, ORAL ONCOL, V36, P194, DOI 10.1016/S1368-8375(99)00078-0
   Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1
   OGAWA T, 2001, P AACR, P621
   PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627
   Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#
   Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920
   Spiegelberg BD, 2007, CURR OPIN GENET DEV, V17, P40, DOI 10.1016/j.gde.2006.12.002
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Taborga M, 2007, MINI-REV MED CHEM, V7, P245, DOI 10.2174/138955707780059826
   Takebayashi S, 2000, CANCER RES, V60, P3397
   Takebayashi S, 2004, GENE CHROMOSOME CANC, V41, P145, DOI 10.1002/gcc.20066
   Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453
   Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876
   Touge H, 2007, INT J ONCOL, V30, P709
   Toyooka S, 2002, CANCER RES, V62, P3382
   VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395
   Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405
   WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670
   Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777
   Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401
   Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504
   Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103
   Zhang X, 2004, CLIN CANCER RES, V10, P8451, DOI 10.1158/1078-0432.CCR-04-0546
   Zou MX, 2004, ONCOGENE, V23, P330, DOI 10.1038/sj.onc.1207053
NR 48
TC 54
Z9 57
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 1
PY 2008
VL 14
IS 23
BP 7604
EP 7613
DI 10.1158/1078-0432.CCR-07-4673
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 379JK
UT WOS:000261392300005
PM 19047085
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Tang, WY
   Newbold, R
   Mardilovich, K
   Jefferson, W
   Cheng, RYS
   Medvedovic, M
   Ho, SM
AF Tang, Wan-Yee
   Newbold, Retha
   Mardilovich, Katerina
   Jefferson, Wendy
   Cheng, Robert Y. S.
   Medvedovic, Mario
   Ho, Shuk-Mei
TI Persistent Hypomethylation in the Promoter of <i>Nucleosomal Binding
   Protein</i> 1 (<i>Nsbp</i>1) Correlates with Overexpression of
   <i>Nsbp</i>1 in Mouse Uteri Neonatally Exposed to Diethylstilbestrol or
   Genistein
SO ENDOCRINOLOGY
LA English
DT Article
ID DNA METHYLATION; BREAST-CANCER; DEVELOPMENTAL EXPOSURE; IN-UTERO;
   EXPRESSION; CHROMATIN; ADENOCARCINOMA; ABNORMALITIES; ESTROGENS; GENE
AB Neonatal exposure of CD-1 mice to diethylstilbestrol (DES) or genistein (GEN) induces uterine adenocarcinoma in aging animals. Uterine carcinogenesis in this model is ovarian dependent because its evolution is blocked by prepubertal ovariectomy. This study seeks to discover novel uterine genes whose expression is altered by such early endocrine disruption via an epigenetic mechanism. Neonatal mice were treated with 1 or 1000 mu g/kg DES, 50 mg/kg GEN, or oil (control) on d 1-5. One group of treated mice was killed before puberty on d 19. Others were ovariectomized or left intact, and killed at 6 and 18 months of age. Methylation-sensitive restriction fingerprinting was performed to identify differentially methylated sequences associated with neonatal exposure to DES/GEN. Among 14 candidates, nucleosomal binding protein 1 (Nsbp1), the gene for a nucleosome-core-particle binding protein, was selected for further study because of its central role in chromatin remodeling. In uteri of immature control mice, Nsbp1 promoter CpG island (CGI) was minimally methylated. Once control mice reached puberty, the Nsbp1 CGI became hypermethylated, and gene expression declined further. In contrast, in neonatal DES/GEN-treated mice, the Nsbp1 CGI stayed anomalously hypomethylated, and the gene exhibited persistent overexpression throughout life. However, if neonatal DES/GEN-treated mice were ovariectomized before puberty, the CGI remained minimally to moderately methylated, and gene expression was subdued except in the group treated with 1000 mu g/kg DES. Thus, the life reprogramming of uterine Nsbp1 expression by neonatal DES/GEN exposure appears to be mediated by an epigenetic mechanism that interacts with ovarian hormones in adulthood. (Endocrinology 149: 5922-5931, 2008)
C1 [Ho, Shuk-Mei] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Sch Med, Cincinnati, OH 45267 USA.
   [Medvedovic, Mario; Ho, Shuk-Mei] Univ Cincinnati, Sch Med, Ctr Environm Genet, Cincinnati, OH 45267 USA.
   [Ho, Shuk-Mei] Univ Cincinnati, Sch Med, Ctr Canc, Cincinnati, OH 45267 USA.
   [Tang, Wan-Yee; Mardilovich, Katerina; Cheng, Robert Y. S.; Ho, Shuk-Mei] Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01605 USA.
   [Newbold, Retha; Jefferson, Wendy] NIEHS, Mol Toxicol Lab, US Dept HHS, NIH, Res Triangle Pk, NC 27709 USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati; University System of Ohio; University
   of Cincinnati; University of Massachusetts System; University of
   Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH
   National Institute of Environmental Health Sciences (NIEHS)
RP Ho, SM (通讯作者)，Univ Cincinnati, Med Ctr, Dept Environm Hlth, Sch Med, Kettering Complex,Room 128,3223 Eden Ave,POB 6700, Cincinnati, OH 45267 USA.
EM shuk-mei.ho@uc.edu
RI Cheng, Robert/E-9799-2013
OI Cheng, Robert/0000-0003-0287-6439; Tang, Wan-Yee/0000-0002-0663-9820
FU National Institutes of Health (NIH) [ES013071, ES006096, ES015584,
   ES015905, CA015776, CA112532, HG003749]; National Institute of
   Environmental Health Sciences; Department of Defense Prostate Cancer
   [W81XWH-06-1-0373]
FX We thank Ping Zhou, Jennifer Barker, Monica Summe, and Carol Szeto for
   sample preparation. Received May 9, 2008. Accepted July 24, 2008.
   Address all correspondence and requests for reprints to: Shuk-Mei Ho,
   Department of Environmental Health, Kettering Complex, Room 128, 3223
   Eden Avenue, University of Cincinnati Medical Center, P.O. Box 670056,
   Cincinnati, Ohio 45267-0056. E-mail: shuk-mei.ho@uc.edu. This research
   was supported by the Intramural Research Program of the National
   Institutes of Health (NIH)-National Institute of Environmental Health
   Sciences (to R.N. and W.J.), NIH Grants ES013071, ES006096, ES015584,
   ES015905, CA015776, and CA112532 (to S.-M. H.), and HG003749 (to M. M.),
   and the Department of Defense Prostate Cancer Program Grant
   W81XWH-06-1-0373 (to W.-Y.T.). Present address for K. M.: Department of
   Cancer Biology, University of Massachusetts Medical School, 364
   Plantation Street, LRB Room 426, Worcester, Massachusetts 01605. Present
   address for R.Y.S.C.: National Cancer Institute at Frederick, National
   Institutes of Health, Building 528, Room 141, P.O. Box B, Frederick,
   Maryland 21702. Disclosure Statement: The authors have nothing to
   disclose.
CR Badger TM, 2002, J NUTR, V132, p559S, DOI 10.1093/jn/132.3.559S
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Brouwers MM, 2007, EUR J PEDIATR, V166, P671, DOI 10.1007/s00431-006-0304-z
   BURROUGHS CD, 1990, J TOXICOL ENV HEALTH, V30, P105, DOI 10.1080/15287399009531415
   Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8
   Catez F, 2003, BIOCHEM CELL BIOL, V81, P113, DOI 10.1139/o03-040
   Daniel W. W., 1999, Biostatistics: A foundation for analysis in the health sciences, V7th ed.
   DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237
   Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843
   DRASH AL, 1994, PEDIATRICS, V94, P752
   Elmore LW, 2001, ARCH PATHOL LAB MED, V125, P146
   Erdogan G, 2007, APMIS, V115, P204, DOI 10.1111/j.1600-0463.2007.apm_419.x
   Everitt B.S., 1993, CLUSTER ANAL
   Fujii S, 2008, DIGESTION, V77, P2, DOI 10.1159/000111482
   Geller MA, 2004, GYNECOL ONCOL, V95, P632, DOI 10.1016/j.ygyno.2004.07.049
   GIUSTI RM, 1995, ANN INTERN MED, V122, P778, DOI 10.7326/0003-4819-122-10-199505150-00008
   Hammes B, 2003, J MIDWIFERY WOM HEAL, V48, P19, DOI 10.1016/S1526-9523(02)00370-7
   HENDERSON BE, 1976, PEDIATRICS, V58, P505
   HERBST AL, 1972, OBSTET GYNECOL, V40, P287
   HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604
   Herbst AL, 1981, DEV EFFECTS DIETHYLS
   Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089
   Hilakivi-Clarke L, 2007, CURR CANCER DRUG TAR, V7, P465
   Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Huang THM, 1997, CANCER RES, V57, P1030
   Janatpour MJ, 2000, DEVELOPMENT, V127, P549
   Jefferson WN, 2007, REPROD TOXICOL, V23, P308, DOI 10.1016/j.reprotox.2006.11.012
   Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008
   King LM, 2001, GENOMICS, V71, P163, DOI 10.1006/geno.2000.6443
   Klip H, 2002, LANCET, V359, P1102, DOI 10.1016/S0140-6736(02)08152-7
   Klish WJ, 1998, PEDIATRICS, V101, P148, DOI 10.1542/peds.101.1.148
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S
   Leath CA, 2004, J REPROD MED, V49, P71
   Li SF, 1997, CANCER RES, V57, P4356
   Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147
   Li SF, 2001, MOL CARCINOGEN, V32, P213, DOI 10.1002/mc.10015
   McLachlan JA, 2006, BEST PRACT RES CL EN, V20, P63, DOI 10.1016/j.beem.2005.09.009
   Menczer J, 2005, GYNECOL ONCOL, V97, P166, DOI 10.1016/j.ygyno.2004.12.006
   Messina M, 1997, LANCET, V350, P971, DOI 10.1016/S0140-6736(05)64062-7
   Newbold RR, 2001, CANCER RES, V61, P4325
   NEWBOLD RR, 1990, CANCER RES, V50, P7677
   *NIH, 1999, 004722 DES NIH
   Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222
   Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009
   Salvatierra A, 2006, GYNECOL ONCOL, V101, P545, DOI 10.1016/j.ygyno.2006.01.024
   Shirakawa H, 2000, J BIOL CHEM, V275, P37937, DOI 10.1074/jbc.M000989200
   Sinclair K D, 2007, Soc Reprod Fertil Suppl, V64, P425
   Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4
   Thigpen JE, 1999, LAB ANIM SCI, V49, P530
   Turck D, 2007, CURR OPIN CLIN NUTR, V10, P360, DOI 10.1097/MCO.0b013e3280fa821b
   Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321
   WHITTEN PL, 1995, J NUTR, V125, pS771, DOI 10.1093/jn/125.3_Suppl.771S
   Woodruff Teresa K, 2008, Fertil Steril, V89, pe47, DOI 10.1016/j.fertnstert.2007.12.029
   Wu MC, 2004, ONCOGENE, V23, P250, DOI 10.1038/sj.onc.1207076
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
NR 57
TC 125
Z9 141
U1 0
U2 13
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2008
VL 149
IS 12
BP 5922
EP 5931
DI 10.1210/en.2008-0682
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 376AX
UT WOS:000261156300004
PM 18669593
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hu, M
   Polyak, K
AF Hu, Min
   Polyak, Kornelia
TI Molecular characterisation of the tumour microenvironment in breast
   cancer
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Tumour microenvironment; Epithelial-stromal cell interaction; Paracrine
   signalling
ID MAMMARY EPITHELIAL-CELLS; HUMAN COLON-CARCINOMA; GROWTH IN-VIVO; STROMAL
   INTERACTIONS; GENETIC ALTERATIONS; EPIGENETIC CHANGES; PROTEOGLYCAN
   GENE; METASTASIS; FIBROBLASTS; EXPRESSION
AB The tumour microenvironment plays important roles in cancer initiation, growth, progression, invasion and metastasis, yet the molecular basis underlying these tumour-promoting effects is not fully delineated. Recent advances in gene expression, genetic and epigenetic profiling of stromal cells have improved our understanding of how mesenchymal-epithelial cell interactions may create a permissive microenvironment for malignancy and identified potential targets for cancer prevention and treatment including chemokine and cytokine networks. However, translating these findings into clinical practice may be difficult due to the complexity and redundancy of the interactions and the inherent ability of tumour epithelial cells to evolve and thrive in diverse environmental conditions. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard Medical School; Harvard University; Brigham & Women's Hospital
RP Polyak, K (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,D740C, Boston, MA 02115 USA.
EM kornelia-polyak@dfci.harvard.edu
RI Polyak, Kornelia/ACJ-5837-2022
FU Novartis; NIH [CA89393, CA94074, CA116235]; DOD [W81XWH-07-1-029]; ACS
   [RSG-05-154-01-MGO]; Avon Foundation; Susan G. Komen Foundation
   fellowship [PDF042234]
FX Studies in this laboratory are supported by Novartis, NIH (CA89393,
   CA94074 and CA116235), DOD (W81XWH-07-1-029), ACS (RSG-05-154-01-MGO)
   and Avon Foundation grants to K.P., and Susan G. Komen Foundation
   fellowship (PDF042234) to M.H.
CR Aboseif S, 1999, DIFFERENTIATION, V65, P113, DOI 10.1046/j.1432-0436.1999.6520113.x
   ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301
   ADANY R, 1990, BIOCHEM BIOPH RES CO, V171, P1402, DOI 10.1016/0006-291X(90)90841-A
   ADANY R, 1990, J BIOL CHEM, V265, P11389
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Brown LF, 1999, CLIN CANCER RES, V5, P1041
   CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75
   Chen Hubert, 2005, Health Qual Life Outcomes, V3, P68, DOI 10.1186/1477-7525-3-68
   Chen W, 2003, J SURG RES, V113, P208, DOI 10.1016/S0022-4804(03)00188-4
   Cheng N, 2007, CANCER RES, V67, P4869, DOI 10.1158/0008-5472.CAN-06-3381
   Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Creighton CJ, 2005, MOL CANCER RES, V3, P119, DOI 10.1158/1541-7786.MCR-04-0189
   DUSTAN HP, 1995, HYPERTENSION, V26, P858, DOI 10.1161/01.HYP.26.6.858
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866
   Fukino K, 2007, JAMA-J AM MED ASSOC, V297, P2103, DOI 10.1001/jama.297.19.2103
   Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507
   Hanson JA, 2006, JNCI-J NATL CANCER I, V98, P255, DOI 10.1093/jnci/djj051
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Hunter KW, 2004, BRIT J CANCER, V90, P752, DOI 10.1038/sj.bjc.6601590
   Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kirsh VA, 2007, AM J EPIDEMIOL, V166, P709, DOI 10.1093/aje/kwm216
   Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907
   Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013
   Luo X, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-35
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Moinfar F, 2000, CANCER RES, V60, P2562
   Montel V, 2006, INT J CANCER, V119, P251, DOI 10.1002/ijc.21757
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677
   Shim V, 2003, CANCER RES, V63, P2347
   SINGER CF, 2007, BREAST CANC RES TREA
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Vaccariello M, 1999, J INVEST DERMATOL, V113, P384, DOI 10.1046/j.1523-1747.1999.00701.x
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089
   Weber F, 2005, BRIT J CANCER, V92, P1922, DOI 10.1038/sj.bjc.6602557
   Weber F, 2006, AM J HUM GENET, V78, P961, DOI 10.1086/504090
   Winter JM, 2006, CANCER BIOL THER, V5, P360, DOI 10.4161/cbt.5.4.2552
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   YANG L, 2008, CANC CELL
NR 53
TC 91
Z9 122
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD DEC
PY 2008
VL 44
IS 18
SI SI
BP 2760
EP 2765
DI 10.1016/j.ejca.2008.09.038
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 387HC
UT WOS:000261941300009
PM 19026532
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Hitchiler, MJ
   Oberley, LW
   Domann, FE
AF Hitchiler, Michael J.
   Oberley, Larry W.
   Domann, Frederick E.
TI Epigenetic silencing of <i>SOD2</i> by histone modifications in human
   breast cancer cells
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Methylation; Chromatin; Mammary; Carcinoma; Antioxidant
ID MANGANESE SUPEROXIDE-DISMUTASE; MULTIPLE-MYELOMA CELLS; MNSOD
   EXPRESSION; PANCREATIC-CARCINOMA; MALIGNANT PHENOTYPE;
   TRANSFORMED-CELLS; GENE-EXPRESSION; DNA METHYLATION; OVEREXPRESSION;
   GROWTH
AB Many breast cancer cells typically exhibit lower expression of manganese superoxide dismutase (MnSOD) compared to the normal cells from which they arise. This decrease can often be attributed to a defect in the transcription of SOD2, the gene encoding MnSOD; however, the mechanism responsible for this change remains unclear. Here, we describe how altered histone modifications and a repressive chromatin structure constitute an epigenetic process to down regulate SOD2 in human breast carcinoma cell lines. Utilizing chromatin immunoprecipitation (ChIP) we observed decreased levels of dimethyl H3K4 and acetylated H3K9 at key regulatory elements of the SOD2 gene. Consistent with these results, we show that loss of these histone modifications creates a repressive chromatin structure at SOD2. Transcription factor Chip experiments revealed that this repressive chromatin structure influences the binding of SP-1, AP-1, and NF kappa B to SCD2 regulatory cis-elements in vivo. Lastly, we show that treatment with the histone deacetylase inhibitors trichostatin A and sodium butyrate can reactivate SOD2 expression in breast cancer cell lines. Taken together, these results indicate that epigenetic silencing of SOD2 could be facilitated by changes in histone modifications and represent one mechanism leading to the altered expression of MnSOD observed in many breast cancers. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Hitchiler, Michael J.; Oberley, Larry W.; Domann, Frederick E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Domann, FE (通讯作者)，Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA.
EM frederick-domann@uiowa.edu
OI Domann, Frederick/0000-0002-0489-2179
FU NIH [CA073612, CA115438]
FX This work was supported by NIH grants CA073612 to F.E.D. and CA115438 to
   L.W.O. MJ.H. received salary support from T32 CA078586.
CR BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8
   BORRELLO S, 1993, MOL ASPECTS MED, V14, P253, DOI 10.1016/0098-2997(93)90012-3
   BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200
   Hitchler MJ, 2006, EPIGENETICS-US, V1, P163, DOI 10.4161/epi.1.4.3401
   Hodge DR, 2005, CANCER BIOL THER, V4, P585, DOI 10.4161/cbt.4.5.1704
   Hodge DR, 2005, CANCER RES, V65, P6255, DOI 10.1158/0008-5472.CAN-04-4482
   Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6
   Huang YH, 1999, DNA CELL BIOL, V18, P643, DOI 10.1089/104454999315051
   Hurt EM, 2007, BRIT J CANCER, V97, P1116, DOI 10.1038/sj.bjc.6604000
   Hurt EM, 2007, BLOOD, V109, P3953, DOI 10.1182/blood-2006-07-035162
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Lewis A, 2005, CLIN EXP METASTAS, V22, P523, DOI 10.1007/s10585-005-4919-7
   LI JJ, 1995, ONCOGENE, V10, P1989
   Lomberk G, 2005, BIOCHEM J, V392, P1, DOI 10.1042/BJ20051234
   Maehara K, 2002, BIOCHEM BIOPH RES CO, V295, P187, DOI 10.1016/S0006-291X(02)00646-0
   Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773
   Musri MM, 2006, J BIOL CHEM, V281, P17180, DOI 10.1074/jbc.M601295200
   OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9
   Ough M, 2004, FREE RADICAL RES, V38, P1223, DOI 10.1080/10715760400017376
   Ranjan P, 2006, APOPTOSIS, V11, P1837, DOI 10.1007/s10495-006-9530-0
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   St Clair DK, 2002, METHOD ENZYMOL, V349, P306, DOI 10.1016/S0076-6879(02)49345-7
   STCLAIR DK, 1991, CANCER RES, V51, P939
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441
   Weydert C, 2003, MOL CANCER THER, V2, P361
   Weydert CJ, 2006, FREE RADICAL BIO MED, V41, P226, DOI 10.1016/j.freeradbiomed.2006.03.015
   Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265
   Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852
   Zhu CH, 2001, ANTIOXID REDOX SIGN, V3, P387, DOI 10.1089/15230860152409031
   Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200
NR 36
TC 68
Z9 74
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD DEC 1
PY 2008
VL 45
IS 11
BP 1573
EP 1580
DI 10.1016/j.freeradbiomed.2008.09.005
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 384CJ
UT WOS:000261721600009
PM 18845242
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Rhee, DK
   Park, SH
   Jang, YY
AF Rhee, Dong Keun
   Park, Su Hyung
   Jang, Yeun Yu
TI Molecular signatures associated with transformation and progression to
   breast cancer in the isogenic MCF10 model
SO GENOMICS
LA English
DT Article
DE Isogenic human breast cancer cell lines; Epigenetic inactivation; S100
   calcium-binding protein family; Progression; Transformation; Molecular
   signatures
ID RECEPTOR TYROSINE KINASE; CPG-BINDING-PROTEINS; GENE-EXPRESSION;
   TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; DNA METHYLATION; XENOGRAFT
   MODEL; S100 PROTEINS; CELL-LINES; IN-SITU
AB Comparative microarray analyses provided insight into understanding transcript changes during cancer progression; however, a reproducible signature underlying breast carcinogenesis has yet to be little available. We utilized gene expression profiling to define molecular signatures associated with transformation and cancer progression in a series of isogenic human breast cancer cell lines including a normal, benign, noninvasive and invasive carcinoma. Clustering analysis revealed four distinct expression patterns based on upregulation or downregulation patterns. These profiles proved quite useful for describing breast cancer tumorigenesis and invasiveness. Downregulation of TNFSF7, S100A4, S100A7, S100A8, and S100A9 (calcium-binding protein family), and upregulation of kallikrein-5 and thrombospondin-1 were associated with transformation and progression of breast cancer cells. Importantly, downregulation of the genes was reversed by treatment with silencing inhibitors, implying the potential roles of epigenetic inactivation in breast carcinogenesis. Exogenous expressions of S100A8 and S100A9 inhibit growth in benign and noninvasive carcinoma cells, suggesting their negative role in cell proliferation. The data presented here may facilitate the identification and functional analyses of prognostic biomarkers for breast cancer. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Rhee, Dong Keun; Park, Su Hyung; Jang, Yeun Yu] Yonsei Univ, Dept Biol, Coll Life Sci & Biotechnol, Seoul 120749, South Korea.
   [Rhee, Dong Keun; Park, Su Hyung; Jang, Yeun Yu] Yonsei Univ, Yonsei Biomol Res Initiat, Seoul 120749, South Korea.
C3 Yonsei University; Yonsei University
RP Jang, YY (通讯作者)，Yonsei Univ, Dept Biol, Coll Life Sci & Biotechnol, 134 Shinchon Dong, Seoul 120749, South Korea.
EM ykjang@yonsei.ac.kr
FU Ministry of Education, Science Technology [M10601000116-07N0100-11610];
   Korea Government (MOEST) [ROI-2007-000-20047-0(2007)]; National Cancer
   Center Research [0510050]; University Research Fund [2007-7-0178]; Brain
   Korea21 (BK21) Program
FX We thank Fred Miller and S.J. Santner for providing human breast cell
   lines kindly. This work was supported by Research Program for New Drug
   Target Discovery (No. M10601000116-07N0100-11610) grant from the
   Ministry of Education, Science & Technology, and in part by the Korea
   Science and Engineering Foundation (KOSEF) grant funded by the Korea
   Government (MOEST) [No. ROI-2007-000-20047-0(2007)]. In addition, this
   work was supported by the National Cancer Center Research Grants
   (0510050) to Y.K.J. and partly by University Research Fund of 2007 (No.
   2007-7-0178) and by the Brain Korea21 (BK21) Program. D.K.R is
   fellowship awardee by BK21 Program.
CR Abramovitz Mark, 2007, Cancer Genomics & Proteomics, V4, P135
   Alvarez-Medina R, 2008, DEVELOPMENT, V135, P237, DOI 10.1242/dev.012054
   Arpino G, 2005, ANN INTERN MED, V143, P446, DOI 10.7326/0003-4819-143-6-200509200-00009
   Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Baylin S.B., 2007, Epigenetics, P457
   Becker M, 2005, MOL CANCER THER, V4, P151
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Brennan Donal J., 2007, Cancer Genomics & Proteomics, V4, P121
   Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203
   Carlsson H, 2005, INT J ONCOL, V27, P1473
   Chen JP, 2007, CANCER EPIDEM BIOMAR, V16, P577, DOI 10.1158/1055-9965.EPI-06-0923
   CHEN L, 1990, ONCOGENE, V5, P1391
   Chénais B, 2005, MOL ENDOCRINOL, V19, P125, DOI 10.1210/me.2003-0379
   Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008
   CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0
   Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x
   Dawson PJ, 1996, AM J PATHOL, V148, P313
   El-Rifai W, 2002, CANCER RES, V62, P6823
   Ellsworth RE, 2005, ANN SURG ONCOL, V12, P1054, DOI 10.1245/ASO.2005.03.522
   Feng G, 2001, CANCER RES, V61, P7999
   Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190
   Ghavami S, 2004, J LEUKOCYTE BIOL, V76, P169, DOI 10.1189/jlb.0903435
   Grandér D, 1998, MED ONCOL, V15, P20, DOI 10.1007/BF02787340
   Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864
   Grusch M, 2006, J HEPATOL, V45, P673, DOI 10.1016/j.jhep.2006.06.014
   Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024
   Han WL, 2003, GENOMICS, V81, P609, DOI 10.1016/S0888-7543(03)00095-8
   Hartmann LC, 2007, INT J CANCER, V121, P938, DOI 10.1002/ijc.22811
   HINTZEN RQ, 1994, J IMMUNOL, V152, P1762
   Jachimczak P, 2005, INT J CANCER, V113, P88, DOI 10.1002/ijc.20549
   Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044
   Kodama J, 2007, ANN ONCOL, V18, P269, DOI 10.1093/annonc/mdl370
   Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P1033, DOI 10.1677/ERC-06-0001
   LINGBAO A, 2006, CANCER RES, V66, P7899
   Liu D, 2000, BRIT J CANCER, V83, P1473, DOI 10.1054/bjoc.2000.1488
   Lodish H., 1999, MOL CELL BIOL, V4th
   Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003
   Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200
   MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725
   Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A
   Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
   NEUBAUER A, 1994, BLOOD, V84, P1931
   OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ramankulov A, 2008, CANCER SCI, V99, P1188, DOI 10.1111/j.1349-7006.2008.00802.x
   Rath GM, 2006, BBA-MOL CELL RES, V1763, P1125, DOI 10.1016/j.bbamcr.2006.08.001
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Roberts DD, 2007, CLIN CANCER RES, V13, P795, DOI 10.1158/1078-0432.CCR-06-1758
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009
   Santamaría I, 1998, CANCER RES, V58, P1624
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107
   Scott DK, 2007, BRIT J DERMATOL, V156, P1156, DOI 10.1111/j.1365-2133.2007.07875.x
   SOULE HD, 1990, CANCER RES, V50, P6075
   Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218
   Tysnes BB, 2007, BBA-REV CANCER, V1775, P283, DOI 10.1016/j.bbcan.2007.01.001
   Uemura Y, 2007, ONCOL REP, V17, P955
   Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4
   Winkles JA, 2006, CANCER LETT, V235, P11, DOI 10.1016/j.canlet.2005.03.048
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   Wysoczynski M, 2007, CANCER RES, V67, P2131, DOI 10.1158/0008-5472.CAN-06-1021
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Yao RS, 2007, NEOPLASIA, V9, P207, DOI 10.1593/neo.06814
   Yui S, 2003, BIOL PHARM BULL, V26, P753
NR 67
TC 41
Z9 59
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD DEC
PY 2008
VL 92
IS 6
BP 419
EP 428
DI 10.1016/j.ygeno.2008.08.005
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 380IT
UT WOS:000261460100007
PM 18804527
OA Bronze
DA 2025-01-12
ER

PT J
AU Cao, Q
   Yu, J
   Dhanasekaran, SM
   Kim, JH
   Mani, RS
   Tomlins, SA
   Mehra, R
   Laxman, B
   Cao, X
   Yu, J
   Kleer, CG
   Varambally, S
   Chinnaiyan, AM
AF Cao, Q.
   Yu, J.
   Dhanasekaran, S. M.
   Kim, J. H.
   Mani, R-S
   Tomlins, S. A.
   Mehra, R.
   Laxman, B.
   Cao, X.
   Yu, J.
   Kleer, C. G.
   Varambally, S.
   Chinnaiyan, A. M.
TI Repression of E-cadherin by the polycomb group protein EZH2 in cancer
SO ONCOGENE
LA English
DT Article
DE polycomb group protein; histone; EZH2; E-cadherin; epigenetics
ID CELL-CELL-ADHESION; HUMAN BREAST-CANCER; H3 LYSINE-27 METHYLATION;
   EMBRYONIC STEM-CELLS; PROSTATE-CANCER; DOWN-REGULATION; TARGET GENES;
   DEVELOPMENTAL REGULATORS; CATENIN EXPRESSION; EPITHELIAL-CELLS
AB Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.
C1 [Cao, Q.; Yu, J.; Dhanasekaran, S. M.; Kim, J. H.; Mani, R-S; Tomlins, S. A.; Mehra, R.; Laxman, B.; Yu, J.; Kleer, C. G.; Varambally, S.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Cao, Q.; Yu, J.; Dhanasekaran, S. M.; Kim, J. H.; Mani, R-S; Tomlins, S. A.; Mehra, R.; Laxman, B.; Cao, X.; Yu, J.; Varambally, S.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
   [Mehra, R.; Kleer, C. G.; Varambally, S.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Cao, X.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.
   [Chinnaiyan, A. M.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; Howard Hughes Medical Institute; University of Michigan
   System; University of Michigan
RP Chinnaiyan, AM (通讯作者)，Univ Michigan, Sch Med, Dept Pathol, 1400 E Med Ctr Dr,5316 CCGC, Ann Arbor, MI 48109 USA.
EM arul@umich.edu
RI Chinnaiyan, Arul/LCE-5288-2024; Cao, Qi/A-5517-2010
OI Dhanasekaran, saravana mohan/0000-0002-0489-2224; Tomlins,
   Scott/0000-0001-8661-9821; Varambally,
   Sooryanarayana/0000-0002-2277-1127; Cao, Qi/0000-0002-5140-3681; kim,
   julie/0000-0001-8300-6448; Mani, Ram/0000-0003-3552-7905
FU National Institutes of Health [R01 CA97063, U01 CA111275, P50 CA69568];
   Department of Defense [PC040517, PC051081, PC060266, R01CA107469];
   National Cancer Institute [R01CA107469] Funding Source: NIH RePORTER
FX We thank Professor Eric Fearon for providing the E-cadherin
   promoter-reporter constructs. We thank Jill Granger for critically
   reading the paper and for her thoughtful suggestions. We thank R Kunkel
   for help in figure preparation and the staff of the Microscopy and Image
   Analyses laboratory at the University of Michigan for their assistance
   in the microscopic analyses employed in this study. We thank the
   University of Michigan Vector Core for virus generation. AMC is
   supported by a Burroughs Welcome Foundation Award in Clinical
   Translational Research. SAT is supported by the Medical Scientist
   Training Program and a Rackham Pre-doctoral Award. This research was
   supported in part by National Institutes of Health Grant R01 CA97063 (to
   AMC); U01 CA111275 (to AMC); P50 CA69568 (to AMC); Department of Defense
   Grants PC040517 (to RM), PC051081 (to AMC and SV), PC060266 (to JY) and
   R01CA107469 (to CGK).
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3
   Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656
   DORUDI S, 1995, BRIT J CANCER, V71, P614, DOI 10.1038/bjc.1995.119
   FRIXEN UH, 1993, CANCER RES, V53, P3618
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806
   HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62
   Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x
   Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5
   Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   MAYER B, 1993, CANCER RES, V53, P1690
   MOLL R, 1993, AM J PATHOL, V143, P1731
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   OKA H, 1993, CANCER RES, V53, P1696
   Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005
   PALACIOS J, 1995, VIRCHOWS ARCH, V427, P259
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   PIERCEALL WE, 1995, ONCOGENE, V11, P1319
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   ROSEN PP, 1990, SURG CLIN N AM, V70, P937
   Saito T, 2004, ONCOGENE, V23, P8629, DOI 10.1038/sj.onc.1207960
   Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Taghavi P, 2006, NATURE, V439, P794, DOI 10.1038/439794a
   Takeno S, 2004, AM J CLIN PATHOL, V122, P78, DOI 10.1309/WJL90JPEM17RBUHT
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792
   UMBAS R, 1994, CANCER RES, V54, P3929
   Umbas R, 1997, INT J CANCER, V74, P374, DOI 10.1002/(SICI)1097-0215(19970822)74:4<374::AID-IJC2>3.0.CO;2-S
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Weikert S, 2005, INT J MOL MED, V16, P349
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x
   Wu ZY, 2005, WORLD J GASTROENTERO, V11, P3139, DOI 10.3748/wjg.v11.i20.3139
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
NR 61
TC 467
Z9 536
U1 1
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD DEC
PY 2008
VL 27
IS 58
BP 7274
EP 7284
DI 10.1038/onc.2008.333
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 382FI
UT WOS:000261590300005
PM 18806826
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Guerrero-Preston, R
AF Guerrero-Preston, Rafael
TI Global Epigenetic Screening Technologies: a Novel Tool to Address Cancer
   Health Disparities in High-Risk Population Groups
SO PUERTO RICO HEALTH SCIENCES JOURNAL
LA English
DT Article
DE Epigenomics; Epigenetic screening technologies; Cancer health
   disparities; High risk population groups; Molecular cancer screening
   technologies
ID ABERRANT DNA METHYLATION; BREAST-CANCER; COLORECTAL-CANCER;
   CERVICAL-CANCER; UNITED-STATES; COLON-CANCER; ENVIRONMENTAL EXPOSURES;
   CLINICAL-TRIALS; GENE-EXPRESSION; AMERICAN WOMEN
AB Racial, ethnic and class disparities in cancer incidence and mortality have been well documented. Disparities in the utilization of preventive, curative and treatment services among ethnic minorities have been reported. Screening can be effective at detecting cancer at treatable stages, but a large proportion of people at risk have not been screened or are not regularly screened, as recommended by the American Cancer Society's national guidelines. Early detection technologies have the potential of both influencing mortality from cancer, as well as enhancing primary prevention through detection and removal of lesions that could potentially develop into cancer. Cancer is an epigenetic disease characterized by the breakdown of DNA methylation and histones modification patterns. Epigenetic approaches may contribute to a reduction in cancer health disparities impacting early detection and increasing cancer treatment options. Epigenetic events represent selectively activated or inactivated, through genetic and non-genetic manifestations. Emerging evidence indicates that various epigenetic alterations, such as global histones modifications and DNA hypomethylation, common to most types of cancer, are modified by environmental exposures throughout the life course. A simple, easily explained and easy to understand non-invasive test, such as the DNA methylation index, that may screen for several cancer sites at once, may remove some of the existing barriers to cancer screening utilization, and contribute to the reduction of cancer disparities. Epigenetic approaches may also prove to be useful in identifying environmental and lifestyle factors that contribute to the prevalence of other chronic conditions in high risk populations, such as Puerto Rican populations in the United States and Puerto Rico.
C1 [Guerrero-Preston, Rafael] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Canc Res, Baltimore, MD 21218 USA.
   [Guerrero-Preston, Rafael] Univ Puerto Rico, Sch Publ Hlth, Dept Environm Hlth Sci, San Juan, PR 00936 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Puerto
   Rico; University of Puerto Rico Medical Sciences Campus
RP Guerrero-Preston, R (通讯作者)，1550 Orleans St,Room 5N-03, Baltimore, MD 21231 USA.
EM rguerre3@jhmi.edu
OI Guerrero-Preston, Rafael/0000-0002-6639-6488
CR Adams EK, 2007, CANCER-AM CANCER SOC, V109, P348, DOI 10.1002/cncr.22353
   Agarwal G, 2007, WORLD J SURG, V31, P1031, DOI 10.1007/s00268-005-0585-9
   Ahmed FE, 2007, EXPERT REV MOL DIAGN, V7, P569, DOI 10.1586/14737159.7.5.569
   Bao YH, 2007, HEALTH SERV RES, V42, P950, DOI 10.1111/j.1475-6773.2006.00638.x
   Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030
   Battaglia TA, 2007, CANCER, V109, P359, DOI 10.1002/cncr.22354
   Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704
   Bressler B, 2004, GASTROINTEST ENDOSC, V60, P921, DOI 10.1016/S0016-5107(04)02231-X
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Canino G, 1997, P R Health Sci J, V16, P117
   Chu KC, 2007, J NATL MED ASSOC, V99, P1092
   Costa VL, 2007, DIS MARKERS, V23, P31, DOI 10.1155/2007/356742
   Cruz GD, 2007, J HEALTH CARE POOR U, V18, P833
   Dassow P, 2005, J WOMENS HEALTH, V14, P324, DOI 10.1089/jwh.2005.14.324
   de González AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357
   Duenas-Gonzalez A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-38
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P1, DOI 10.1111/j.1749-6632.2003.tb05957.x
   Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Esteller M, 2000, CANCER RES, V60, P4366
   Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029
   Feng QH, 2006, CRIT REV CL LAB SCI, V43, P497, DOI 10.1080/10408360600922632
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Freeman H P, 1995, Cancer Pract, V3, P19
   Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2
   Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb
   Gomez SL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-201
   Guerrero-Preston R, 2007, EPIGENETICS-US, V2, P223, DOI 10.4161/epi.2.4.5214
   Habermann JK, 2008, LANGENBECK ARCH SURG, V393, P93, DOI 10.1007/s00423-007-0230-1
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hiatt RA, 2001, PREV MED, V33, P190, DOI 10.1006/pmed.2001.0871
   Hlavaty T, 2004, Bratisl Lek Listy, V105, P215
   Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009
   Jagot Claire, 2004, Nurs Times, V100, P30
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Jones WD, 2005, IEEE SPECTRUM, V42, P8
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Katz ML, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-62
   Krieger N, 2005, AM J PUBLIC HEALTH, V95, P2155, DOI 10.2105/AJPH.2005.067108
   Lance P, 2008, CANCER EPIDEM BIOMAR, V17, P2205, DOI 10.1158/1055-9965.EPI-08-0688
   Leach Corinne R, 2007, Prev Chronic Dis, V4, pA95
   Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018
   Lund MJ, 2008, BREAST CANCER RES TR, V109, P545, DOI 10.1007/s10549-007-9675-8
   Makuc DM, 2007, J WOMENS HEALTH, V16, P349, DOI 10.1089/jwh.2006.0072
   Maly RC, 2006, CANCER-AM CANCER SOC, V106, P957, DOI 10.1002/cncr.21680
   Martin GM, 2005, P NATL ACAD SCI USA, V102, P10413, DOI 10.1073/pnas.0504743102
   McDougall JA, 2007, CANCER CAUSE CONTROL, V18, P1175, DOI 10.1007/s10552-007-9056-y
   Meissner HI, 2006, CANCER EPIDEM BIOMAR, V15, P389, DOI 10.1158/1055-9965.EPI-05-0678
   Menon U, 2007, CANCER NURS, V30, P178, DOI 10.1097/01.NCC.0000270706.80037.05
   Miller BA, 2006, CANCER, V106, P670, DOI 10.1002/cncr.21647
   Miyachi H, 2001, Rinsho Byori, V49, P139
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Ortega Alexander N, 2002, Ment Health Serv Res, V4, P131, DOI 10.1023/A:1019707012403
   Ortega AN, 2005, J BEHAV HEALTH SER R, V32, P320, DOI 10.1007/BF02291831
   Osada S, 2007, YAKUGAKU ZASSHI, V127, P469, DOI 10.1248/yakushi.127.469
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Puschel K, 2001, HEALTH EDUC BEHAV, V28, P573, DOI 10.1177/109019810102800505
   Read JG, 2006, SOC SCI MED, V62, P1045, DOI 10.1016/j.socscimed.2005.07.009
   Roux AVD, 2007, REV EPIDEMIOL SANTE, V55, P13, DOI 10.1016/j.respe.2006.12.003
   Roux AVD, 2007, ANN EPIDEMIOL, V17, P569, DOI 10.1016/j.annepidem.2007.03.001
   Sassi F, 2006, AM J PUBLIC HEALTH, V96, P2165, DOI 10.2105/AJPH.2005.071761
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Shokar NK, 2007, J COMMUN HEALTH, V32, P311, DOI 10.1007/s10900-007-9052-x
   Singh M, 2007, PANCREATOLOGY, V7, P9, DOI 10.1159/000101873
   Smith CAS, 2005, REV PANAM SALUD PUBL, V18, P381, DOI 10.1590/S1020-49892005001000001
   Steinberg ML, 2006, CANCER, V107, P2669, DOI 10.1002/cncr.22319
   Stewart JH, 2007, ANN SURG ONCOL, V14, P3328, DOI 10.1245/s10434-007-9500-y
   Taback B, 2006, ANN NY ACAD SCI, V1075, P211, DOI 10.1196/annals.1368.029
   Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Thorpe JM, 2006, MED CARE, V44, P187, DOI 10.1097/01.mlr.0000196965.54871.d5
   Vadaparampil ST, 2006, CANCER EPIDEM BIOMAR, V15, P618, DOI 10.1158/1055-9965.EPI-05-0378
   Verma M, 2006, MOL DIAGN THER, V10, P1
   Vernia M, 2003, ANN NY ACAD SCI, V983, P170, DOI 10.1111/j.1749-6632.2003.tb05972.x
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Vlahov David, 2005, Ethn Dis, V15, P76
   Wang JHY, 2006, ETHNIC DIS, V16, P404
   Weidman JR, 2007, CANCER J, V13, P9, DOI 10.1097/PPO.0b013e31803c71f2
   Weinhold B, 2006, ENVIRON HEALTH PERSP, V114, pA160, DOI 10.1289/ehp.114-a160
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wilson RT, 2007, J HEALTH CARE POOR U, V18, P648, DOI 10.1353/hpu.2007.0071
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
NR 89
TC 5
Z9 7
U1 0
U2 8
PU UNIV PUERTO RICO MEDICAL SCIENCES CAMPUS
PI SAN JUAN
PA OFFICE DEAN ACADEMIC AFFAIRS BOX 365067, SAN JUAN, PR 00936-5067 USA
SN 0738-0658
J9 P R HEALTH SCI J
JI P. R. Health Sci. J.
PD DEC
PY 2008
VL 27
IS 4
BP 350
EP 356
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 380RM
UT WOS:000261482900010
PM 19069364
DA 2025-01-12
ER

PT J
AU Jin, Z
   Cheng, YL
   Olaru, A
   Kan, T
   Yang, J
   Paun, B
   Ito, T
   Hamilton, JP
   David, S
   Agarwal, R
   Selaru, FM
   Sato, F
   Abraham, JM
   Beer, DG
   Mori, Y
   Shimada, Y
   Meltzer, SJ
AF Jin, Zhe
   Cheng, Yulan
   Olaru, Alexandru
   Kan, Takatsugu
   Yang, Jian
   Paun, Bogdan
   Ito, Tetsuo
   Hamilton, James P.
   David, Stefan
   Agarwal, Rachana
   Selaru, Florin M.
   Sato, Fumiaki
   Abraham, John M.
   Beer, David G.
   Mori, Yuriko
   Shimada, Yutaka
   Meltzer, Stephen J.
TI Promoter hypermethylation of CDH13 is a common, early event in human
   esophageal adenocarcinogenesis and correlates with clinical risk factors
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE CDH13; hypermethylation; EAC; ESCC
ID SEGMENT BARRETTS-ESOPHAGUS; H-CADHERIN CDH13; ABERRANT METHYLATION;
   NEOPLASTIC PROGRESSION; T-CADHERIN; BREAST-CANCER; CELL-ADHESION;
   LUNG-CANCER; FOLLOW-UP; GENE
AB Although the CDH13 gene has been shown to undergo epigenetic silencing by promoter methylation in many types of tumors, hypermethylation of this gene in Barrett's-associated esophageal adenocarcinogenesis has not been studied. Two hundred fifty-nine human esophageal tissues were therefore examined for CDH13 promoter hypermethylation by real-time methylation-specific PCR. CDH13 hypermethylation showed discriminative receiver-operator characteristic curve profiles, sharply demarcating esophageal adenocarcinoma (EAC) from esophageal squamous cell carcinoma (ESCC) and normal esophagus (NE) (p < 0.0001). CDH13 normalized methylation values (NMV) were significantly higher in Barrett's esophagus (BE), dysplastic BE (D) and EAC than in NE (p < 0.0000001). CDH13 hypermethylation frequency was 0% in NE but increased early during neoplastic progression, rising to 70% in BE, 77.5% in D and 76.1% in EAC. Both CDH13 hypermethylation frequency and its mean NMV were significantly higher in BE with than without accompanying EAC. In contrast, only 5 (19.2%) of 26 ESCCs exhibited CDH13 hypermethylation. Furthermore, both CDH13 hypermethylation frequency and its mean NMV were significantly higher in EAC than in ESCC, as well as in BE or D vs. ESCC. Interestingly, mean CDH13 NMV was significantly lower in short-segment than in long-segment BE, a known clinical risk factor for neoplastic progression. Similarly, BE segment length was significantly lower in specimens with unmethylated than with methylated CDH13 promoters. 5-aza-2'-deoxycytidine treatment of OE33 EAC and KYSE220 ESCC cells reduced CDH13 methylation and increased CDH13 mRNA expression. These findings suggest that hypermethylation of CDH13 is a common, tissue-specific event in human EAC, occurs early during BE-associated neoplastic progression, and correlates with known clinical neoplastic progression risk factors. (C) 2008 Wiley-Liss, Inc.
C1 [Jin, Zhe; Cheng, Yulan; Olaru, Alexandru; Kan, Takatsugu; Yang, Jian; Paun, Bogdan; Ito, Tetsuo; Hamilton, James P.; David, Stefan; Agarwal, Rachana; Selaru, Florin M.; Sato, Fumiaki; Abraham, John M.; Mori, Yuriko; Meltzer, Stephen J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21231 USA.
   [Beer, David G.] Univ Michigan, Sch Med, Dept Surg, Div Gen Thorac Surg, Ann Arbor, MI USA.
   [Shimada, Yutaka] Hyogo Med Univ, Dept Surg, Nishinomiya, Hyogo, Japan.
   [Meltzer, Stephen J.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; University of Michigan System; University of
   Michigan; Hyogo Medical University; Johns Hopkins University; Johns
   Hopkins Medicine
RP Meltzer, SJ (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Rm 112, Baltimore, MD 21231 USA.
EM smeltzer@jhmi.edu
OI Selaru, Florin/0000-0001-7990-8238
FU NIH [CA085069, CA 084986, CA001808, CA106763]
FX Grant sponsor: NIH; Grant numbers: CA085069, CA 084986, CA001808,
   CA106763.
CR Angst BD, 2001, J CELL SCI, V114, P629
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Eads CA, 2001, CANCER RES, V61, P3410
   Fang MZ, 2005, INT J ONCOL, V26, P615
   Fukuoka T, 2006, ANTICANCER RES, V26, P3333
   Hage M, 2004, SCAND J GASTROENTERO, V39, P1175, DOI 10.1080/00365520410003524
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647
   Hibi K, 2004, BRIT J CANCER, V91, P1139, DOI 10.1038/sj.bjc.6602095
   Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X
   Jin Z, 2007, ONCOGENE, V26, P6332, DOI 10.1038/sj.onc.1210461
   Jin Z, 2008, CANCER EPIDEM BIOMAR, V17, P111, DOI 10.1158/1055-9965.EPI-07-0407
   Jin Z, 2008, CANCER-AM CANCER SOC, V112, P43, DOI 10.1002/cncr.23135
   Jin Z, 2007, CLIN CANCER RES, V13, P6293, DOI 10.1158/1078-0432.CCR-07-0818
   Kawakami M, 1999, INT J ONCOL, V15, P715
   Lee SW, 1998, CARCINOGENESIS, V19, P1157, DOI 10.1093/carcin/19.6.1157
   Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Mori Y, 1999, BRIT J CANCER, V80, P556, DOI 10.1038/sj.bjc.6690391
   Mukoyama Y, 2005, J INVEST DERMATOL, V124, P833, DOI 10.1111/j.0022-202X.2005.23660.x
   RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7
   Riegman PHJ, 2001, CANCER RES, V61, P3164
   Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598
   Shibata DM, 2002, CANCER RES, V62, P5637
   Sun D, 2007, ORAL ONCOL, V43, P82, DOI 10.1016/j.oraloncology.2006.01.007
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Toyooka S, 2002, CANCER RES, V62, P3382
   Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625
   van Dekken H, 1999, CANCER RES, V59, P748
   VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451
   Weston AP, 1997, AM J GASTROENTEROL, V92, P407
   Zhong Y, 2001, CLIN CANCER RES, V7, P1683
NR 38
TC 52
Z9 59
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2008
VL 123
IS 10
BP 2331
EP 2336
DI 10.1002/ijc.23804
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 365XQ
UT WOS:000260443300014
PM 18729198
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Ridolfi, E
   Matteucci, E
   Maroni, P
   Desiderio, MA
AF Ridolfi, E.
   Matteucci, E.
   Maroni, P.
   Desiderio, M. A.
TI Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast
   carcinoma cells, and role of HDACs
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE hepatocyte growth factor; breast cancer; CXCR4; signalling pathways;
   HDAC inhibitors; trichostatin A
ID HEPATOCYTE GROWTH-FACTOR; NF-KAPPA-B; HISTONE DEACETYLASE INHIBITORS;
   CANCER-CELLS; INDUCE APOPTOSIS; TUMOR INVASION; TRICHOSTATIN-A; MET
   RECEPTOR; C-SRC; CXCR4
AB Hepatocyte growth factor (HGF), through Met receptor binding, fulfils numerous functions in invasive tumour growth (survival/ proliferation, motility, apoptosis), but epigenetic control of gene expression in this process is poorly understood. In HGF-treated breast cancer cells we studied ( a) the chemoinvasion towards CXCL12 ( ligand of the chemokine-receptor CXCR4) and (b) the mechanistic basis, that is, the transduction pathways that regulate CXCR4-mediated invasion, and the role played by histone deacetylases (HDACs) after blockade with trichostatin A (TSA). In highly invasive and metastatic MDA-MB231 cells HGF had a dual inhibitory effect, reducing spontaneous migration and specific chemoinvasion towards CXCL12, the latter by decreasing CXCR4 transactivation and protein level. After HGF the levels of phosphorylated ( therefore active) c-Src and Akt persistently increased, indicating a role of these signal transducers in the HGF-dependent cellular and molecular effects. c-Src wild-type expression vector (Srcwt) increased active c-Src and mimicked the HGF-dependent inhibition of CXCR4 transactivation. Our findings indicate that HDACs participated in the HGF-inhibitory effects. In fact, blockade of HDACs hindered the HGF- and Srcwt-dependent reductions of CXCR4 transactivation and invasiveness, while inhibition of endogenous c-Src was additive with HGF, further reducing specific chemoinvasion. In conclusion, in MDA-MB231 cells HDAC blockade with TSA partly counteracted the HGF- dependent effects through molecular events that included enhancement of the expression of the genes for invasiveness Met and CXCR4 ( depending on serum conditions), reduction of endogenous phospho-c-Src/c-Src and phosphoAkt/Akt ratios and triggering of apoptosis. The potential therapeutic use of TSA should take into account the variable aggressiveness of breast carcinoma cells and microenvironment signals such as HGF at the secondary growth site of the tumour. It was interesting that HGF reduced motility and CXCR4 functionality only of MDA-MB231 cells, and not of low-invasive MCF-7 cells, suggesting a mechanism implicated in metastatic cell homing.
C1 [Desiderio, M. A.] Univ Milan, Sch Med, Inst Gen Pathol, I-20133 Milan, Italy.
   [Maroni, P.] IRCCS, Ist Ortoped Galeazzi, Milan, Italy.
C3 University of Milan; IRCCS Istituto Ortopedico Galeazzi
RP Desiderio, MA (通讯作者)，Univ Milan, Sch Med, Inst Gen Pathol, Via Luigi Mangiagalli 31, I-20133 Milan, Italy.
EM a.desiderio@unimi.it
RI Desiderio, Maria/M-8870-2016; Maroni, Paola/B-1366-2017
OI Maroni, Paola/0000-0002-3444-9338
FU PRIN 2007; Universita e Ricerca and Finalizzato; Ministero della Salute,
   Italy
FX We thank Dr Maurizio D'Incalci for a critical reading of the manuscript.
   We are grateful to Eugenio Erba and Giada Dogliotti for fluorescent
   microscopy and cytofluorimetric analysis support. This paper was
   supported by Grants PRIN 2007 from Ministero Istruzione, Universita e
   Ricerca and Finalizzato (no. RF 06-81) from Ministero della Salute,
   Italy.
CR Arthur JSC, 2008, FRONT BIOSCI-LANDMRK, V13, P5866, DOI 10.2741/3122
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284
   Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183
   Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236
   Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433
   Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000
   Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Carey N, 2006, CURR OPIN PHARMACOL, V6, P369, DOI 10.1016/j.coph.2006.03.010
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088
   Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje
   deGraffenried LA, 2004, ANN ONCOL, V15, P885, DOI 10.1093/annonc/mdh232
   Dehm SM, 2004, MOL CELL BIOL, V24, P2296, DOI 10.1128/MCB.24.6.2296-2307.2004
   Desiderio MA, 2007, CELL MOL LIFE SCI, V64, P1341, DOI 10.1007/s00018-007-7050-x
   Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910
   Furlan A, 2008, J CELL PHYSIOL, V215, P782, DOI 10.1002/jcp.21360
   Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200
   Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
   Gort EH, 2006, ONCOGENE, V25, P6123, DOI 10.1038/sj.onc.1209643
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197
   Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070
   Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y
   Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767
   Huang Y, 2003, CLIN CANCER RES, V9, P2769
   Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Liang ZX, 2005, CANCER RES, V65, P967
   Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322
   Maroni P, 2007, CARCINOGENESIS, V28, P267, DOI 10.1093/carcin/bgl129
   Matheu A, 2005, J BIOL CHEM, V280, P42433, DOI 10.1074/jbc.M508270200
   Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808
   Matsumoto Y, 2008, BIOCHEM BIOPH RES CO, V366, P110, DOI 10.1016/j.bbrc.2007.11.089
   Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008
   MATTEUCCI E, 2007, MOL CANCER RES, V5, P1
   Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200
   Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786
   Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585
   Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Shim H, 2006, BIOCHEM BIOPH RES CO, V346, P252, DOI 10.1016/j.bbrc.2006.05.110
   Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9
   Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585
   Song KH, 2007, HEPATOLOGY, V46, P1993, DOI 10.1002/hep.21878
   Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330
   Tacchini L, 2000, EXP CELL RES, V256, P272, DOI 10.1006/excr.2000.4824
   Toillon RA, 2002, EXP CELL RES, V275, P31, DOI 10.1006/excr.2002.5490
   Uchida D, 2007, MOL CANCER RES, V5, P685, DOI 10.1158/1541-7786.MCR-06-0368
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Wang H, 2007, ONCOGENE, V26, P2058, DOI 10.1038/sj.onc.1210003
   Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006
   YANG S, 2007, BIOCHIM BIOPHYS ACTA, V1873, P903
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   Yilmaz M, 2007, TRENDS MOL MED, V13, P535, DOI 10.1016/j.molmed.2007.10.004
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113
NR 64
TC 22
Z9 23
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD NOV 11
PY 2008
VL 99
IS 10
BP 1623
EP 1634
DI 10.1038/sj.bjc.6604726
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 371LI
UT WOS:000260832400010
PM 18941460
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Van der Auwera, I
   Van Laere, SJ
   Van den Bosch, SM
   Van den Eynden, GG
   Trinh, BX
   van Dam, PA
   Colpaert, CG
   van Engeland, M
   Van Marck, EA
   Vermeulen, PB
   Dirix, LY
AF Van der Auwera, I.
   Van Laere, S. J.
   Van den Bosch, S. M.
   Van den Eynden, G. G.
   Trinh, B. X.
   van Dam, P. A.
   Colpaert, C. G.
   van Engeland, M.
   Van Marck, E. A.
   Vermeulen, P. B.
   Dirix, L. Y.
TI Aberrant methylation of the <i>Adenomatous Polyposis Coli</i>
   (<i>APC</i>) gene promoter is associated with the inflammatory breast
   cancer phenotype
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE APC; inflammatory breast cancer; laser microdissection; methylation;
   methylation-specific PCR
ID CPG-ISLAND METHYLATION; DNA METHYLATION; COLORECTAL TUMORIGENESIS;
   SOMATIC MUTATIONS; LUNG-CANCER; EXPRESSION; CARCINOMAS; SERUM;
   HYPERMETHYLATION; IDENTIFICATION
AB Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter occurs in about 40% of breast tumours and has been correlated with reduced APC protein levels. To what extent epigenetic alterations of the APC gene may differ according to specific breast cancer phenotypes, remains to be elucidated. Our aim was to explore the role of APC methylation in the inflammatory breast cancer (IBC) phenotype. The status of APC gene promoter hypermethylation was investigated in DNA from normal breast tissues, IBC and non-IBC by both conventional and real-time quantitative methylation-specific PCR (MSP). APC methylation levels were compared with APC mRNA and protein levels. Hypermethylation of the APC gene promoter was present in 71% of IBC samples (n=21) and 43% of non- IBC samples (n=30) by conventional MSP (P=0.047). The APC gene also showed an increased frequency of high methylation levels in IBC (in 74% of cases, n=19) vs non-IBC ( in 46% of cases, n=35) using a qMSP assay (P=0.048). We observed no significant association between APC methylation levels by qMSP and APC mRNA or protein expression levels. In conclusion, for the first time, we report the association of aberrant methylation of the APC gene promoter with the IBC phenotype, which might be of biological and clinical importance.
C1 [Vermeulen, P. B.] Gen Hosp St Augustinus, Ctr Oncol, Pathol Lab, B-2610 Antwerp, Belgium.
   Univ Antwerp, Univ Antwerp Hosp, Pathol Lab, Translat Canc Res Grp Antwerp, B-2650 Edegem, Belgium.
   [Van den Bosch, S. M.; van Engeland, M.] Univ Maastricht, Res Inst GROW, Dept Pathol, NL-6200 MD Maastricht, Netherlands.
C3 University of Antwerp; Maastricht University
RP Vermeulen, PB (通讯作者)，Gen Hosp St Augustinus, Ctr Oncol, Pathol Lab, Oosterveldlaan 24, B-2610 Antwerp, Belgium.
EM peter.vermeulen@gza.be
RI Dirix, Luc/AAI-8880-2020; Van Laere, Steven/GQA-8872-2022; van Engeland,
   Manon/A-7479-2009
OI Van Laere, Steven/0000-0002-2640-0040
FU Scientific Research Flanders; University of Antwerp; Scientific Research
   Flanders [0430.03]
FX Ilse Van der Auwera is a research assistant of the Fund for Scientific
   Research Flanders. Steven Van Laere is a predoctoral assistant of the
   University of Antwerp. This work was supported by the Fund for
   Scientific Research Flanders Grant No G. 0430.03. We thank Manon van
   Engeland for the collaboration and support in the DNA methylation
   experiments. Furthermore, we thank the technical staff of the
   Laboratories of Pathology from the General Hospital Sint-Augustinus and
   the University of Antwerp for technical assistance.
CR Aggerholm A, 2000, BLOOD, V95, P2997, DOI 10.1182/blood.V95.9.2997.009k40d_2997_2999
   Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0
   Brakensiek K, 2004, BLOOD, V104, P1586, DOI 10.1182/blood-2004-03-0898
   Chen Yang-lin, 2007, Zhonghua Yufang Yixue Zazhi, V41, P17
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Dirix LY, 2006, CURR OPIN ONCOL, V18, P563, DOI 10.1097/01.cco.0000245307.29026.0a
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   ELSTON CW, 1984, AUST NZ J SURG, V54, P11, DOI 10.1111/j.1445-2197.1984.tb06677.x
   Esteller M, 2000, CANCER RES, V60, P4366
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0
   Ho KYK, 1999, HISTOPATHOLOGY, V35, P249
   House MG, 2003, CARCINOGENESIS, V24, P193, DOI 10.1093/carcin/24.2.193
   Issa JP, 2000, CURR TOP MICROBIOL, V249, P101
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jönsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2
   JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Lee A, 2004, ARCH PATHOL LAB MED, V128, P1251
   Lerebours F, 2005, BREAST CANCER RES, V7, P52, DOI 10.1186/bcr997
   Liu Zhen, 2007, Ai Zheng, V26, P586
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MEDEIROS AC, 1994, CANCER EPIDEM BIOMAR, V3, P331
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Palmisano WA, 2000, CANCER RES, V60, P5954
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Roa JC, 2004, REV MED CHILE, V132, P1069
   Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453
   Singletary SE, 2002, J CLIN ONCOL, V20, P3628, DOI 10.1200/JCO.2002.02.026
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Sparks AB, 1998, CANCER RES, V58, P1130
   THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Usadel H, 2002, CANCER RES, V62, P371
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Van der Auwera I, 2004, CLIN CANCER RES, V10, P7965, DOI 10.1158/1078-0432.CCR-04-0063
   Van Laere S, 2007, BRIT J CANCER, V97, P1165, DOI 10.1038/sj.bjc.6603967
   Van Laere S, 2005, BREAST CANCER RES TR, V93, P237, DOI 10.1007/s10549-005-5157-z
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
NR 49
TC 54
Z9 61
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD NOV 11
PY 2008
VL 99
IS 10
BP 1735
EP 1742
DI 10.1038/sj.bjc.6604705
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 371LI
UT WOS:000260832400025
PM 18841156
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Tian, KG
   Wang, YZ
   Huang, Y
   Sun, BQ
   Li, YX
   Xu, HP
AF Tian, Kegui
   Wang, Yuezeng
   Huang, Yu
   Sun, Boqiao
   Li, Yuxin
   Xu, Haopeng
TI Methylation of <i>WTH3</i>, a possible drug resistant gene, inhibits
   <i>p53</i> regulated expression
SO BMC CANCER
LA English
DT Article
ID BACTERIAL TRANSPORT PROTEINS; BREAST-CANCER CELLS; MULTIDRUG-RESISTANT;
   DNA METHYLATION; P-GLYCOPROTEIN; APOPTOSIS; FAMILY; OVEREXPRESSION;
   TRANSCRIPTION; CHEMOTHERAPY
AB Background: Previous results showed that over-expression of the WTH3 gene in MDR cells reduced MDR1 gene expression and converted their resistance to sensitivity to various anticancer drugs. In addition, the WTH3 gene promoter was hypermethylated in the MCF7/AdrR cell line and primary drug resistant breast cancer epithelial cells. WTH3 was also found to be directly targeted and up regulated by the p53 gene. Furthermore, over expression of the WTH3 gene promoted the apoptotic phenotype in various host cells.
   Methods: To further confirm WTH3's drug resistant related characteristics, we recently employed the small hairpin RNA (shRNA) strategy to knockdown its expression in HEK293 cells. In addition, since the WTH3 promoter's p53-binding site was located in a CpG island that was targeted by methylation, we were interested in testing the possible effect this epigenetic modification had on the p53 transcription factor relative to WTH3 expression. To do so, the in vitro methylation method was utilized to examine the p53 transgene's influence on either the methylated or non-methylated WTH3 promoter.
   Results: The results generated from the gene knockdown strategy showed that reduction of WTH3 expression increased MDR1 expression and elevated resistance to Doxorubicin as compared to the original control cells. Data produced from the methylation studies demonstrated that DNA methylation adversely affected the positive impact of p53 on WTH3 promoter activity.
   Conclusion: Taken together, our studies provided further evidence that WTH3 played an important role in MDR development and revealed one of its transcription regulatory mechanisms, DNA methylation, which antagonized p53's positive impact on WTH3 expression.
C1 [Tian, Kegui; Wang, Yuezeng; Huang, Yu; Xu, Haopeng] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
   [Wang, Yuezeng] Jilin Univ, Lab Pathobiol, Changchun 130023, Peoples R China.
   [Wang, Yuezeng; Li, Yuxin] NE Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun, Peoples R China.
   [Sun, Boqiao] Tech Univ Munich, Ctr Life & Food Sci Weihenstephan, D-8000 Munich, Germany.
C3 State University of New York (SUNY) System; Stony Brook University;
   Jilin University; Northeast Normal University - China; Technical
   University of Munich
RP Tian, KG (通讯作者)，SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
EM ktian@ms.cc.sunysb.eu; yuezwang@ms.cc.sunysb.edu; huangyu69@sohu.com;
   boqiao.sun@mytum.de; liyx486@nenu.edu.cn; hduffy@notes.cc.sunysb.edu
RI Li, yuxin/GSD-1668-2022
FU National Cancer Institute [1R01CA090443-01A2]; American Cancer Society
   [RSG-03137-01-CDD]
FX We thank for Dr. U. M. Moll and Dr. J. Cao for the DNA constructs and
   cell lines. We thank J. C. Duffy for preparation of the manuscript. This
   work was supported in part by the National Cancer Institute (Grant#
   1R01CA090443-01A2) and American Cancer Society (Grant# RSG-03137-01-CDD)
   awards.
CR Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811
   Antequera F., 1993, Experientia Supplementum (Basel), V64, P169
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   BARBACID M, 1987, ANNU REV BIOCHEM, V779, P827
   BARTLETT KT, 2001, DUKE J GENDER LAW PO, V8, P1
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704
   DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521
   Doerfler W., 1983, COLD SPRING HARB SYM, V47, P593
   Echard A, 2000, MOL BIOL CELL, V11, P3819, DOI 10.1091/mbc.11.11.3819
   Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580
   GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5
   GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0
   Johnson RA, 2005, J BIOL CHEM, V280, P13213, DOI 10.1074/jbc.M414646200
   Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085
   Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1
   Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947
   Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855
   Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515
   Righetti SC, 1996, CANCER RES, V56, P689
   Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830
   Schmitt CA, 1999, J PATHOL, V187, P127
   Shan JD, 2000, GENE, V257, P67, DOI 10.1016/S0378-1119(00)00395-4
   Shan JD, 2002, BBA-MOL CELL RES, V1589, P112, DOI 10.1016/S0167-4889(02)00164-7
   Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8
   Smith ND, 2003, J UROLOGY, V169, P1219, DOI 10.1097/01.ju.0000056085.58221.80
   Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024
   Steele RJC, 2005, SURG-J R COLL SURG E, V3, P197, DOI 10.1016/S1479-666X(05)80041-1
   Tian K, 2007, BRIT J CANCER, V96, P1579, DOI 10.1038/sj.bjc.6603724
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   Tian KG, 2005, CANCER RES, V65, P7421, DOI 10.1158/0008-5472.CAN-05-0658
   Xu HP, 2007, CANCER RES, V67, P1239, DOI 10.1158/0008-5472.CAN-06-3688
   Yuan LM, 1999, CANCER RES, V59, P3215
   ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394
NR 39
TC 13
Z9 20
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 7
PY 2008
VL 8
AR 327
DI 10.1186/1471-2407-8-327
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 381SP
UT WOS:000261556500004
PM 18992151
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ko, CY
   Hsu, HC
   Shen, MR
   Chang, WC
   Wang, JM
AF Ko, Chiung-Yuan
   Hsu, Hey-Chi
   Shen, Meng-Ru
   Chang, Wen-Chang
   Wang, Ju-Ming
TI Epigenetic Silencing of CCAAT/Enhancer-binding Protein δ Activity by
   YY1/Polycomb Group/DNA Methyltransferase Complex
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DNA CYTOSINE-5 METHYLTRANSFERASES; ACUTE MYELOID-LEUKEMIA; EMBRYONIC
   STEM-CELLS; C/EBP-DELTA; ADIPOCYTE DIFFERENTIATION; BREAST-CANCER;
   IN-VIVO; HEPATOCELLULAR-CARCINOMA; PROMOTER ACTIVATION; MOLECULAR TARGET
AB Human CCAAT/enhancer-binding protein delta (CEBPD) has been reported as a tumor suppressor because it both induces growth arrest involved in differentiation and plays a crucial role as a regulator of pro-apoptotic gene expression. In this study, CEBPD gene expression is down-regulated, and " loss of function" alterations in CEBPD gene expression are observed in cervical cancer and hepatocellular carcinoma. Suppressor of zeste 12 (SUZ12), a component of the polycomb repressive complex 2 (PRC2), silences CEBPD promoter activity, enhancing the methylation of exogenous CEBPD promoter through the proximal CpG islands. Moreover, this molecular approach is consistent with the opposite mRNA expression pattern between SUZ12 and CEBPD in cervical cancer and hepatocellular carcinoma patients. We further demonstrated that Yin-Yang-1 (YY1) physically interacts with SUZ12 and can act as a mediator to recruit the polycomb group proteins and DNA methyltransferases to participate in the CEBPD gene silencing process. Taking these results into consideration, we not only demonstrate the advantage of SUZ12-silenced CEBPD expression in tumor formation but also clarify an in vivo evidence for YY1-mediated silencing paths of SUZ12 and DNA methyltransferases on the CEBPD promoter.
C1 [Shen, Meng-Ru; Chang, Wen-Chang] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.
   [Ko, Chiung-Yuan; Chang, Wen-Chang] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan.
   [Chang, Wen-Chang; Wang, Ju-Ming] Natl Cheng Kung Univ, Inst Biosignal Transduct, Tainan 70101, Taiwan.
   [Chang, Wen-Chang; Wang, Ju-Ming] Natl Cheng Kung Univ, Inst Bioinformat, Coll Biosci & Biotechnol, Tainan 70101, Taiwan.
   [Chang, Wen-Chang; Wang, Ju-Ming] Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan.
   [Hsu, Hey-Chi] Natl Taiwan Univ, Coll Med, Dept Pathol, Taipei 10002, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University; National Cheng Kung University; National Cheng
   Kung University; National Taiwan University
RP Chang, WC (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.
EM wcchang@mail.ncku.edu.tw; wwwjm4721@yahoo.com.tw
RI wang, ju-ming/A-1875-2011
FU Taiwan National Science Council [96-2320-B-006-044-MY2]
FX This work was supported by and the funding to pay the Open Access
   publication charges for this article were provided by Grant
   96-2320-B-006-044-MY2 from the Taiwan National Science Council. The
   costs of publication of this article were defrayed in part by the
   payment of page charges. This article must therefore be hereby marked "
   advertisement" in accordance with 18 U. S. C. Section 1734 solely to
   indicate this fact.
CR Agrawal S, 2007, BLOOD, V109, P3895, DOI 10.1182/blood-2006-08-040147
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124
   Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074
   Bell DR, 2004, ONCOGENE, V23, P7290, DOI 10.1038/sj.onc.1207949
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brenner S, 2003, J BIOL CHEM, V278, P5597, DOI 10.1074/jbc.M207448200
   Brücher BLDM, 2006, INT J CANCER, V119, P1298, DOI 10.1002/ijc.21990
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057
   Gery S, 2005, ONCOGENE, V24, P1589, DOI 10.1038/sj.onc.1208393
   Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306
   Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285
   Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619
   Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03
   Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401
   Kim J, 2008, HUM MOL GENET, V17, P391, DOI 10.1093/hmg/ddm316
   KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lei H, 1996, DEVELOPMENT, V122, P3195
   LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Liu YW, 2003, J IMMUNOL, V171, P821, DOI 10.4049/jimmunol.171.2.821
   Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0
   Peng SY, 2004, INT J CANCER, V112, P44, DOI 10.1002/ijc.20279
   Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   RUESGA MA, 2006, CANC LETT, V250, P140
   Sanford DC, 2005, PROSTATE, V63, P143, DOI 10.1002/pros.20159
   Scardocci A, 2006, BRIT J CANCER, V95, P1108, DOI 10.1038/sj.bjc.6603392
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Sivko GS, 2004, J CELL BIOCHEM, V93, P830, DOI 10.1002/jcb.20223
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093
   Takeji M, 2004, J AM SOC NEPHROL, V15, P2383, DOI 10.1097/01.ASN.0000136426.01160.2F
   Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432
   Tang D, 2006, BREAST CANCER RES TR, V95, P161, DOI 10.1007/s10549-005-9061-3
   Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711
   Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang JM, 2006, NUCLEIC ACIDS RES, V34, P217, DOI 10.1093/nar/gkj422
   Wang JM, 2005, MOL BIOL CELL, V16, P3365, DOI 10.1091/mbc.E05-02-0105
   Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001
   Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299
NR 60
TC 72
Z9 82
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 7
PY 2008
VL 283
IS 45
BP 30919
EP 30932
DI 10.1074/jbc.M804029200
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 367ID
UT WOS:000260544800047
PM 18753137
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Veeck, J
   Noetzel, E
   Bektas, N
   Jost, E
   Hartmann, A
   Knüchel, R
   Dahl, E
AF Veeck, Juergen
   Noetzel, Erik
   Bektas, Nuran
   Jost, Edgar
   Hartmann, Arndt
   Knuechel, Ruth
   Dahl, Edgar
TI Promoter hypermethylation of the <i>SFRP2</i> gene is a high-frequent
   alteration and tumor-specific epigenetic marker in human breast cancer
SO MOLECULAR CANCER
LA English
DT Article
ID ABERRANT DNA METHYLATION; ANTAGONIST FAMILY GENES; MAMMARY-GLAND TUMORS;
   RENAL-CELL CARCINOMA; COLORECTAL-CANCER; BETA-CATENIN; PROGNOSTIC
   MARKER; GASTRIC-CANCER; FECAL DNA; CYCLIN D1
AB Background: We have previously reported that expression of the Wnt antagonist genes SFRP1 and SFRP5 is frequently silenced by promoter hypermethylation in breast cancer. SFRP2 is a further Wnt inhibitor whose expression was recently found being downregulated in various malignancies. Here we investigated whether SFRP2 is also implicated in human breast cancer, and if so whether SFRP2 promoter methylation might serve as a potential tumor biomarker.
   Methods: We analyzed SFRP2 mRNA expression and SFRP2 promoter methylation in 10 breast cell lines, 199 primary breast carcinomas, 20 matched normal breast tissues and 17 cancer-unrelated normal breast tissues using RT-PCR, realtime PCR, methylation-specific PCR and Pyrosequencing, respectively. SFRP2 protein expression was assessed by immunohistochemistry on a tissue microarray. Proliferation assays after transfection with an SFRP2 expression vector were performed with mammary MCF10A cells. Statistical evaluations were accomplished with SPSS 14.0 software.
   Results: Of the cancerous breast cell lines, 7/8 (88%) lacked SFRP2 mRNA expression due to SFRP2 promoter methylation (P < 0.001). SFRP2 expression was substantially restored in most breast cell lines after treatment with 5-aza-2'-deoxycytidine and trichostatin A. In primary breast carcinomas SFRP2 protein expression was strongly reduced in 93 of 125 specimens (74%). SFRP2 promoter methylation was detected in 165/199 primary carcinomas (83%) whereas all cancer-related and unrelated normal breast tissues were not affected by SFRP2 methylation. SFRP2 methylation was not associated with clinicopathological factors or clinical patient outcome. However, loss of SFRP2 protein expression showed a weak association with unfavorable patient overall survival (P = 0.071). Forced expression of SFRP2 in mammary MCF10A cells substantially inhibited proliferation rates (P = 0.045).
   Conclusion: The SFRP2 gene is a high-frequent target of epigenetic inactivation in human breast cancer. Its methylation leads to abrogation of SFRP2 expression, conferring a growth advantage to epithelial mammary cells. This altogether supports a tumor suppressive function of SFRP2. Although clinical patient outcome was not associated with SFRP2 methylation, the high frequency of this epimutation and its putative specificity to neoplastic cells may qualify SFRP2 promoter methylation as a potential candidate screening marker helping to improve early breast cancer detection.
C1 [Veeck, Juergen; Noetzel, Erik; Bektas, Nuran; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany.
   [Jost, Edgar] Rhein Westfal TH Aachen, Univ Hosp, Dept Internal Med Hematol & Oncol 4, D-52074 Aachen, Germany.
   [Hartmann, Arndt] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen
   University; RWTH Aachen University Hospital; University of Erlangen
   Nuremberg
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM juergen.veeck@rwth-aachen.de; enoetzel@ukaachen.de; nbektas@ukaachen.de;
   ejost@ukaachen.de; arndt.hartmann@uk-erlangen.de;
   rknuechel-clarke@ukaachen.de; edahl@ukaachen.de
RI Noetzel-Reiss, Erik/GYV-0999-2022; Veeck, Jurgen/B-9256-2008
OI Veeck, Jurgen/0000-0002-2952-6159; Noetzel-Reiss,
   Erik/0000-0003-3163-6848
FU Bundesministerium fur Bildung und Forschung [01KW0401]
FX The expert technical help of Sevim Alkaya, Sonja von Serenyi and Inge
   Losen is greatly appreciated. We thank Dr. Dieter Niederacher
   (Department of Gynecology and Obstetrics, Heinrich-Heine-University,
   Dusseldorf, Germany) and Prof. Matthias Durst (Friedrich-Schiller
   University, Jena, Germany) for kindly providing patient samples. We are
   thankful to Dr. Monika Klinkhammer-Schalke and Monika Kerscher from the
   Tumor Registry Regensburg for continuous help in obtaining clinical
   follow-up data. The SFRP2/WNT1 vectors were a kind gift from Dr. Hiromu
   Suzuki (Sapporo Medical University, Sapporo, Japan). This work is a
   research project within the German Human Genome Project and has been
   supported by the grant from the Bundesministerium fur Bildung und
   Forschung to Edgar Dahl (01KW0401).
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Bukholm IK, 2000, J PATHOL, V190, P15
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   *CPG, CPG ISL SEARCH
   Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345
   Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   ELSTON CW, 1993, J CLIN PATHOL, V46, P189
   ensembl, Ensemble Genome Browser
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Galm Oliver, 2005, V113, P279, DOI 10.1385/1-59259-916-8:279
   GRAFF JR, 1995, CANCER RES, V55, P5195
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang ZH, 2007, WORLD J GASTROENTERO, V13, P950, DOI 10.3748/wjg.v13.i6.950
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lee JL, 2006, BREAST CANCER RES TR, V100, P49, DOI 10.1007/s10549-006-9233-9
   Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200
   Lee JL, 2004, BREAST CANCER RES TR, V84, P139, DOI 10.1023/B:BREA.0000018412.83348.ff
   Lehmann U, 2002, CANCER RES, V62, P6634
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712
   Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Nomoto S, 2007, BRIT J CANCER, V97, P1260, DOI 10.1038/sj.bjc.6604016
   Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2
   OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Polakis P, 2000, GENE DEV, V14, P1837
   Qi J, 2006, WORLD J GASTROENTERO, V12, P7113, DOI 10.3748/wjg.v12.i44.7113
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793
   SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Sobin LH., 1997, UICC-TNM classification of malignant tumours, V5th
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 65
TC 75
Z9 83
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD NOV 6
PY 2008
VL 7
AR 83
DI 10.1186/1476-4598-7-83
PG 19
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 393NC
UT WOS:000262379000001
PM 18990230
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Suijkerbuijk, KPM
   Fackler, MJ
   Sukumar, S
   van Gils, CH
   van Laar, T
   van der Wall, E
   Vooijs, M
   van Diest, PJ
AF Suijkerbuijk, K. P. M.
   Fackler, M. J.
   Sukumar, S.
   van Gils, C. H.
   van Laar, T.
   van der Wall, E.
   Vooijs, M.
   van Diest, P. J.
TI Methylation is less abundant in BRCA1-associated compared with sporadic
   breast cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE BRCA1; breast cancer; hereditary; methylation; QM-MSP
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; CARCINOGENESIS; EXPRESSION;
   PATTERNS; BRCA2; TUMOR; RISK; GENE; TUMORIGENESIS
AB Background: Promoter methylation is a common epigenetic mechanism to silence tumor suppressor genes during breast cancer development. We investigated whether BRCA1-associated breast tumors show cancer-predictive methylation patterns similar to those found in sporadic tumors.
   Patients and methods: Quantitative multiplex methylation-specific PCR of 11 genes involved in breast carcinogenesis (RARB, RASSF1, TWIST1, CCND2, ESR1, SCGB3A1, BRCA1, BRCA2, CDKN2A, APC, CDH1) was carried out on 32 BRCA1-associated and 46 sporadic breast carcinomas and on normal breast tissue from seven BRCA1 mutation carriers and 13 non-carriers.
   Results: The extent of cumulative methylation increased with age (P < 0.001). The median cumulative methylation index (CMI) of all studied genes was significantly higher in tumors (89) than in normal tissue (13, P < 0.001). The median CMI was significantly lower in BRCA1-associated (59) than in sporadic breast tumors (122, P = 0.001), in estrogen receptor (ER)-negative tumors (73) than in ER-positive tumors (122, P = 0.005) and in lymph node-negative (77) compared with lymph node-positive tumors (137, P = 0.007). In subgroup analysis, the effect of a BRCA1 germline mutation on methylation proved to be independent of ER status, lymph node status and age.
   Conclusions: These data indicate that BRCA1-associated breast cancers show less promoter methylation compared with sporadic breast carcinomas indicating a difference in disease etiology.
C1 [Suijkerbuijk, K. P. M.; van Laar, T.; Vooijs, M.; van Diest, P. J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands.
   [van der Wall, E.] Univ Med Ctr Utrecht, Div Internal Med & Dermatol, NL-3508 GA Utrecht, Netherlands.
   [Fackler, M. J.; Sukumar, S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
   [van Gils, C. H.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University; Utrecht University Medical Center; Johns Hopkins University;
   Johns Hopkins Medicine; Utrecht University; Utrecht University Medical
   Center
RP van Diest, PJ (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM p.j.vandiest@umcutrecht.nl
RI Vooijs, Marc/K-3522-2019
OI Suijkerbuijk, Karijn/0000-0003-3604-5430
FU Dutch Cancer Society [UU 2007-3977]; "Integraal Kankercentrum
   Midden-Nederland (IKMN)''; "Ate Visser Stichting''; American Women's
   Club of The Hague; NCI-SPORE [P50 CA88843]
FX This work was funded by the Dutch Cancer Society (research year for
   residents UU 2007-3977 to KS), the "Integraal Kankercentrum
   Midden-Nederland (IKMN)'', the "Ate Visser Stichting'' and the American
   Women's Club of The Hague. Grant support from the NCI-SPORE grant P50
   CA88843 to SS.
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Ahuja N, 1997, CANCER RES, V57, P3370
   Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932
   Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Deshmane VH, 2001, LANCET, V358, P507, DOI 10.1016/S0140-6736(01)05647-1
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jönsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Korsching E, 2002, LAB INVEST, V82, P1525, DOI 10.1097/01.LAB.0000038508.86221.B3
   Kriege M, 2006, BREAST CANCER RES TR, V100, P109, DOI 10.1007/s10549-006-9230-z
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001
   Tirkkonen M, 1997, CANCER RES, V57, P1222
   Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002
   Van Diest PJ, 1999, J PATHOL, V187, P383, DOI 10.1002/(SICI)1096-9896(199903)187:4<383::AID-PATH299>3.0.CO;2-H
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
NR 29
TC 66
Z9 68
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD NOV
PY 2008
VL 19
IS 11
BP 1870
EP 1874
DI 10.1093/annonc/mdn409
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 365BO
UT WOS:000260381100008
PM 18647968
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Hou, P
   Ji, MJ
   Xing, MZ
AF Hou, Peng
   Ji, Meiju
   Xing, Mingzhao
TI Association of <i>PTEN</i> Gene Methylation With Genetic Alterations in
   the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway in Thyroid
   Tumors
SO CANCER
LA English
DT Article
DE PTEN gene; methylation; PI3K/AKT pathway; genetic alterations; thyroid
   tumors
ID PHOSPHATASE-ACTIVITY; BREAST-CANCER; BRAF MUTATION; DNA METHYLATION;
   SUPPRESSOR GENE; PIK3CA GENE; EXPRESSION; CARCINOMAS; CELLS; KINASE
AB BACKGROUND. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway plays an important role in thyroid tumorigenesis and progression. Genetic alterations, particularly PIK3CA amplification and mutations and ras mutations, are the major cause of aberrant activation of this pathway in thyroid tumors. Epigenetic silencing of the PTEN gene, a negative regulator of the PI3K/AKT pathway, also occurs in thyroid tumors, hut its relationship with genetic alterations in this pathway is unclear.
   METHODS. By using quantitative methylation-specific polymerase chain reaction, the authors examined PTFN methylation and its relationship with genetic alterations in the PI3K/AKT pathway in various types of thyroid tumors.
   RESULTS. The authors found PTEN methylation to become progressively higher from benign thyroid adenoma to follicular thyroid cancer and to aggressive anaplastic thyroid cancer, which harbored activating genetic alterations in the PI3K/AKT pathway correspondingly with a progressively higher prevalence. The association of PTEN methylation was seen with both overall genetic alterations and individual genetic alterations, particularly PIK3CA alterations and ras mutations, in the PI3K/AKT pathway within each of the 3 types of thyroid tumors. In contrast, no such relationship was observed for the tumor suppressor gene RASSF1A.
   CONCLUSIONS. The authors found an interesting association of PTEN methylation with the activating genetic alterations in the PI3K/AKT pathway in thyroid tumors. This finding is consistent with a model in which aberrant methylation and hence silencing of the PTEN gene, which coexists with activating genetic alterations of the PI3K/AKf pathway, may enhance the signaling of this pathway aberrantly activated by genetic alterations and hence contribute to tire progression of thyroid tumors. Cancer 2008;113:2440-7. (C) 2008 American Cancer Society.
C1 [Hou, Peng; Ji, Meiju; Xing, Mingzhao] Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Baltimore, MD 21287 USA.
C3 Johns Hopkins University
RP Xing, MZ (通讯作者)，Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, 1830 E Monument St,Suite 333, Baltimore, MD 21287 USA.
EM mxing1@jhmi.edu
RI Hou, Peng/H-8073-2015
FU American Cancer Society [RSG-05-199-01-CCE]
FX This work was supported by the American Cancer Society grant
   RSG-05-199-01-CCE to Mingzhao Xing.
CR Ain KB, 1998, THYROID, V8, P715, DOI 10.1089/thy.1998.8.715
   Alvarez-Nuñez F, 2006, THYROID, V16, P17, DOI 10.1089/thy.2006.16.17
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633
   Cornett Wendy R, 2007, Curr Oncol Rep, V9, P152, DOI 10.1007/s11912-007-0014-3
   Dahia PLM, 1997, CANCER RES, V57, P4710
   Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371
   Furnari FB, 1998, CANCER RES, V58, P5002
   García-Rostán G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259
   Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7
   Gimm O, 2001, J CLIN ENDOCR METAB, V86, P1801, DOI 10.1210/jc.86.4.1801
   Gustafson S, 2007, SEMIN ONCOL, V34, P428, DOI 10.1053/j.seminoncol.2007.07.009
   Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2
   Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125
   Hu SY, 2006, INT J CANCER, V119, P2322, DOI 10.1002/ijc.22110
   Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
   Kada Faiza, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P181, DOI 10.2174/1568008043339857
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Liu DX, 2007, CLIN CANCER RES, V13, P1341, DOI 10.1158/1078-0432.CCR-06-1753
   Lu R, 2007, J BIOL CHEM, V282, P12249, DOI 10.1074/jbc.M608525200
   MACHAMA T, 1998, J BIOL CHEM, V273, P13375
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6
   Miyakawa M, 2003, ENDOCR J, V50, P77, DOI 10.1507/endocrj.50.77
   Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513
   Oelke K, 2004, INT REV IMMUNOL, V23, P315, DOI 10.1080/08830180490452567
   Porra V, 2005, J CLIN ENDOCR METAB, V90, P3028, DOI 10.1210/jc.2004-1394
   Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200
   Ries LA., 2007, SEER CANC STAT REV 1
   Ringel MD, 2001, CANCER RES, V61, P6105
   Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9
   Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141
   Santarpia L, 2008, J CLIN ENDOCR METAB, V93, P278, DOI 10.1210/jc.2007-1076
   Schagdarsurengin U, 2006, THYROID, V16, P633, DOI 10.1089/thy.2006.16.633
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339
   Wang YG, 2007, J CLIN ENDOCR METAB, V92, P2387, DOI 10.1210/jc.2006-2019
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weng LP, 1999, CANCER RES, V59, P5808
   Wu GJ, 2005, J CLIN ENDOCR METAB, V90, P4688, DOI 10.1210/jc.2004-2281
   Xing MZ, 2007, ENDOCRINOLOGY, V148, P948, DOI 10.1210/en.2006-0927
   Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242
   Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#
NR 44
TC 122
Z9 140
U1 1
U2 12
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008-543X
J9 CANCER
JI Cancer
PD NOV 1
PY 2008
VL 113
IS 9
BP 2440
EP 2447
DI 10.1002/cncr.23869
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 365KL
UT WOS:000260405100011
PM 18831514
OA Bronze
DA 2025-01-12
ER

PT J
AU Liu, J
   Lam, JBB
   Chow, KHM
   Xu, AM
   Lam, KSL
   Moon, RT
   Wang, Y
AF Liu, Jing
   Lam, Janice B. B.
   Chow, Kim H. M.
   Xu, Aimin
   Lam, Karen S. L.
   Moon, Randall T.
   Wang, Yu
TI Adiponectin stimulates Wnt inhibitory factor-1 expression through
   epigenetic regulations involving the transcription factor specificity
   protein 1
SO CARCINOGENESIS
LA English
DT Article
ID BREAST-CANCER CELLS; SIGNALING PATHWAY; MAMMARY TUMORIGENESIS;
   BLADDER-CANCER; OBESITY; GENE; SP1; INACTIVATION; RISK; PROSTATE
AB Adiponectin (ADN) is an adipokine possessing growth inhibitory activities against various types of cancer cells. Our previous results demonstrated that ADN could impede Wnt/beta-catenin-signaling pathways in MDA-MB-231 human breast carcinoma cells [Wang,Y. et al. (2006) Adiponectin modulates the glycogen synthase kinase-3 beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res., 66, 11462-11470]. Here, we extended our studies to elucidate the effects of ADN on regulating the expressions of Wnt inhibitory factor-1 (WIF1), a Wnt antagonist frequently silenced in human breast tumors. Our results showed that ADN time dependently stimulated WIF1 gene and protein expressions in MDA-MB-231 cells. Overexpression of WIF1 exerted similar inhibitory effects to those of ADN on cell proliferations, nuclear beta-catenin activities, cyclin D1 expressions and serum-induced phosphorylations of Akt and glycogen synthase kinase-3 beta. Blockage of WIF1 activities significantly attenuated the suppressive effects of ADN on MDA-MB-231 cell growth. Furthermore, our in vivo studies showed that both supplementation of recombinant ADN and adenovirus-mediated overexpression of this adipokine substantially enhanced WIF1 expressions in MDA-MB-231 tumors implanted in nude mice. More interestingly, we found that ADN could alleviate methylation of CpG islands located within the proximal promoter region of WIF1, possibly involving the specificity protein 1 (Sp1) transcription factor and its downstream target DNA methyltransferase 1 (DNMT1). Upon ADN treatment, the protein levels of both Sp1 and DNMT1 were significantly decreased. Using silencing RNA approaches, we confirmed that downregulation of Sp1 resulted in an increased expression of WIF1 and decreased methylation of WIF1 promoter. Taken together, these data suggest that ADN might elicit its antitumor activities at least partially through promoting WIF1 expressions.
C1 [Liu, Jing; Lam, Janice B. B.; Chow, Kim H. M.; Xu, Aimin; Wang, Yu] Univ Hong Kong, Dept Pharmacol, Pokfulam, Hong Kong, Peoples R China.
   [Moon, Randall T.] Univ Washington, Howard Hughes Med Inst, Sch Med, Seattle, WA 98195 USA.
   [Lam, Janice B. B.] Univ Auckland, Sch Biol Sci, Auckland 1003, New Zealand.
   [Liu, Jing; Lam, Janice B. B.; Chow, Kim H. M.; Xu, Aimin; Lam, Karen S. L.] Univ Hong Kong, Dept Med, Pokfulam, Hong Kong, Peoples R China.
   [Liu, Jing; Lam, Janice B. B.; Chow, Kim H. M.; Xu, Aimin; Lam, Karen S. L.; Wang, Yu] Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; Howard Hughes Medical Institute; University of
   Washington; University of Washington Seattle; University of Auckland;
   University of Hong Kong; University of Hong Kong
RP Wang, Y (通讯作者)，Univ Hong Kong, Dept Pharmacol, Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM yuwanghk@hku.hk
RI Chow, Hei-Man/LFR-9773-2024; Wang, Yu/B-4534-2009; Xu,
   Aimin/D-3291-2013; Moon, Randall/B-1743-2014
OI wang, yu/0000-0001-8697-2940; Moon, Randall/0000-0002-9352-1408; Chow,
   Hei-Man/0000-0003-1203-2096
FU University of Hong Kong [200511159013]; Hong Kong Research Grant Council
   [HKU 778007, HKU 7645/06M]
FX University of Hong Kong ( 200511159013 to Y.W.); Hong Kong Research
   Grant Council (HKU 778007 to Y.W., HKU 7645/06M to A. X.).
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Arditi JD, 2007, HORM METAB RES, V39, P9, DOI 10.1055/s-2007-956518
   Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535
   Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33
   Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276
   Carmichael AR, 2004, BREAST, V13, P85, DOI 10.1016/j.breast.2003.03.001
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Danielson KG, 1995, J BIOL CHEM, V270, P31225, DOI 10.1074/jbc.270.52.31225
   De Luca A, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-39
   Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076
   GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3
   Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166
   Harvie M, 2003, Obes Rev, V4, P157, DOI 10.1046/j.1467-789X.2003.00108.x
   Housa D, 2006, PHYSIOL RES, V55, P233, DOI 10.33549/physiolres.930848
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Kang JH, 2005, ARCH PHARM RES, V28, P1263, DOI 10.1007/BF02978210
   Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kirikoshi H, 2001, INT J ONCOL, V19, P1221
   Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x
   Körner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858
   KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0
   Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lorincz AM, 2006, ENDOCR-RELAT CANCER, V13, P279, DOI 10.1677/erc.1.00729
   Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804
   Maor S, 2007, HORM METAB RES, V39, P179, DOI 10.1055/s-2007-970415
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586
   Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699
   Ohigashi T, 2005, PROSTATE, V62, P61, DOI 10.1002/pros.20117
   Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761
   Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Stephenson GD, 2003, NUTR CANCER, V45, P1, DOI 10.1207/S15327914NC4501_1
   Stoll BA, 2002, INT J OBESITY, V26, P747, DOI 10.1038/sj.ijo.0801998
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tworoger SS, 2007, J CLIN ENDOCR METAB, V92, P1510, DOI 10.1210/jc.2006-1975
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Vona-Davis L, 2007, OBES REV, V8, P395, DOI 10.1111/j.1467-789X.2007.00396.x
   WANG XB, 2007, ZHENG, V26, P996
   Wang Y, 2008, BIOCHEM J, V409, P623, DOI 10.1042/BJ20071492
   Wang Y, 2007, CELL RES, V17, P280, DOI 10.1038/cr.2007.14
   Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Zannetti A, 2005, BIOCHEM PHARMACOL, V70, P1277, DOI 10.1016/j.bcp.2005.07.024
NR 49
TC 50
Z9 56
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD NOV
PY 2008
VL 29
IS 11
BP 2195
EP 2202
DI 10.1093/carcin/bgn194
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 373NE
UT WOS:000260977900021
PM 18701434
DA 2025-01-12
ER

PT J
AU Metge, BJ
   Frost, AR
   King, JA
   Dyess, DL
   Welch, DR
   Samant, RS
   Shevde, LA
AF Metge, Brandon J.
   Frost, Andra R.
   King, Judy A.
   Dyess, Donna Lynn
   Welch, Danny R.
   Samant, Rajeev S.
   Shevde, Lalita A.
TI Epigenetic silencing contributes to the loss of BRMS1 expression in
   breast cancer
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE BRMS1; methylation; epigenetic silencing; CpG island
ID METASTASIS-SUPPRESSOR GENE; PROMOTER METHYLATION; MDA-MB-435 CELLS; DNA
   METHYLATION; MESSENGER-RNA; BINDING PROTEINS; LUNG-CANCER;
   HYPERMETHYLATION; CARCINOMA; 14-3-3-SIGMA
AB Breast Cancer Metastasis Suppressor 1 (BRMS1) suppresses metastasis of human breast cancer, ovarian cancer and melanoma in athymic mice. Studies have also shown that BRMS1 is significantly downregulated in some breast tumors, especially in metastatic disease. However, the mechanisms which regulate BRMS1 expression are currently unknown. Upon examination of the BRMS1 promoter region by methylation specific PCR (MSP) analysis, we discovered a CpG island (-3477 to -2214), which was found to be hypermethylated across breast cancer cell lines. A panel of 20 patient samples analyzed showed that 45% of the primary tumors and 60% of the matched lymph node metastases, displayed hypermethylation of BRMS1 promoter. Furthermore, we found a direct correlation between the methylation status of the BRMS1 promoter in the DNA isolated from tissues, with the loss of BRMS1 expression assessed by immunohistochemistry. There are several studies investigating the mechanism by which BRMS1 suppresses metastasis; however thus far there is no study that reports the cause(s) of loss of BRMS1 expression in aggressive breast cancer. Here we report for the first time that BRMS1 is a novel target of epigenetic silencing; and aberrant methylation in the BRMS1 promoter may serve as a cause of loss of its expression.
C1 [Metge, Brandon J.; Samant, Rajeev S.; Shevde, Lalita A.] Univ S Alabama, Dept Oncol Sci, Mitchell Canc Inst, Mobile, AL 36688 USA.
   [Welch, Danny R.] Univ Alabama Birmingham, NFCR Ctr Metastasis Res, Birmingham, AL USA.
   [Frost, Andra R.; Welch, Danny R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [King, Judy A.] Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA.
   [King, Judy A.] Univ S Alabama, Dept Pathol, Mobile, AL 36688 USA.
   [Dyess, Donna Lynn] Univ S Alabama, Dept Surg, Mobile, AL 36688 USA.
C3 University of South Alabama; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of South Alabama; University of South Alabama;
   University of South Alabama
RP Shevde, LA (通讯作者)，Univ S Alabama, Dept Oncol Sci, Mitchell Canc Inst, 307 N Univ Blvd, Mobile, AL 36688 USA.
EM danwelch@uab.edu; lsamant@usouthal.edu
RI ; Welch, Danny/B-7310-2009
OI Samant, Rajeev/0000-0001-5681-4976; Welch, Danny/0000-0002-1951-4947
FU National Foundation for Cancer Research;  [BCTR0402317];  [BCTR0503488];
    [CA88728];  [CA89019]
FX This work was supported by grants BCTR0402317 (LAS) and BCTR0503488
   (RSS) from Susan G. Komen for the Cure and CA88728 (DRW) and CA89019
   (DRW, ARF, LRS, RSS), National Foundation for Cancer Research (DRW,
   ARF).
CR Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Campbell IG, 2006, CLIN CANCER RES, V12, P3713, DOI 10.1158/1078-0432.CCR-06-0800
   Champine PJ, 2007, CLIN EXP METASTAS, V24, P551, DOI 10.1007/s10585-007-9092-8
   Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652
   Christgen M, 2007, CANCER BIOL THER, V6, P1355
   Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139
   Cicek M, 2004, CLIN EXP METASTAS, V21, P149, DOI 10.1023/B:CLIN.0000024729.19084.f0
   DeWald DB, 2005, CANCER RES, V65, P713
   Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294
   Evron E, 2001, CANCER RES, V61, P2782
   Fang JY, 2004, WORLD J GASTROENTERO, V10, P3394
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006
   Gumy-Pause F, 2006, LEUKEMIA RES, V30, P335, DOI 10.1016/j.leukres.2005.07.012
   Hartsough MT, 2001, CANCER RES, V61, P2320
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Henrique R, 2005, DNA CELL BIOL, V24, P264, DOI 10.1089/dna.2005.24.264
   Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635
   Hurst DR, 2008, J BIOL CHEM, V283, P7438, DOI 10.1074/jbc.M709446200
   Hurst DR, 2006, BIOCHEM BIOPH RES CO, V348, P1429, DOI 10.1016/j.bbrc.2006.08.005
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009
   Jing F, 2007, ONKOLOGIE, V30, P14, DOI 10.1159/000096892
   Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171
   Kelly LM, 2005, TUMOR BIOL, V26, P213, DOI 10.1159/000086955
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06
   Loeb DM, 2001, CANCER RES, V61, P921
   Lombardi G, 2007, INT J CANCER, V120, P1169, DOI 10.1002/ijc.22379
   Lu Rong, 2004, Zhonghua Yi Xue Za Zhi, V84, P1014
   Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200
   Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8
   Rae JM, 2004, CLIN EXP METASTAS, V21, P543, DOI 10.1007/s10585-004-3759-1
   Rivera J, 2007, J PROTEOME RES, V6, P4006, DOI 10.1021/pr0703167
   Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6
   Samant RS, 2002, INT J CANCER, V97, P15, DOI 10.1002/ijc.1569
   Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581
   Saunders MM, 2001, CANCER RES, V61, P1765
   Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504
   Sellappan S, 2004, CANCER RES, V64, P3479, DOI 10.1158/0008-5472.CAN-3299-2
   Seraj MJ, 2000, CANCER RES, V60, P2764
   Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5
   Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452
   Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2
   Stark AM, 2005, J CANCER RES CLIN, V131, P191, DOI 10.1007/s00432-004-0629-9
   Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012
   Takai Daiya, 2003, In Silico Biology, V3, P235
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Wang L, 2006, INT J ONCOL, V29, P201
   Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347
NR 58
TC 52
Z9 57
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD NOV
PY 2008
VL 25
IS 7
BP 753
EP 763
DI 10.1007/s10585-008-9187-x
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 355PG
UT WOS:000259720200006
PM 18566899
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Gray, SG
   Al-Sarraf, N
   Baird, AM
   Gately, K
   McGovern, E
   O'Byrne, KJ
AF Gray, Steven G.
   Al-Sarraf, Nael
   Baird, Anne-Marie
   Gately, Kathy
   McGovern, Eilish
   O'Byrne, Kenneth J.
TI Transcriptional Regulation of <i>IRS5/DOK4</i> Expression in
   Non-Small-Cell Lung Cancer Cells
SO CLINICAL LUNG CANCER
LA English
DT Article
DE Acetylation; Chromatin; DNA methylation; Histone
ID INSULIN-RECEPTOR SUBSTRATE-1; ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE
   METASTASES; BREAST-CANCER; SIGNALING PATHWAYS; DOK-4; ACTIVATION;
   CARCINOMA; HYPOXIA; PROTEINS
AB The insulin-receptor substrate family plays important roles in cellular growth, signaling, and survival. Two new members of this family have recently been isolated: IRS5/Dok4 and IRS6/Dok5. This study examines the expression of IRS5/DOK4 in a panel of lung cancer cell lines and tumor specimens. The results demonstrate that expression of IRS5/DOK4 is frequently altered with both elevated and decreased expression in non-small-cell lung cancer (NSCLC) tumor specimens. The altered expression of IRS5/DOK4 observed in tumor samples is not due to aberrant methylation. In vitro cell culture studies demonstrate that treatment of NSCLC cell lines with the histone deacetylase inhibitor trichostatin A (TSA) upregulates IRS5/DOK4. This finding indicates that expression is regulated epigenetically at the level of chromatin remodeling. Chromatin immunoprecipitation experiments confirm that the IRS5/DOK4 promoter has enhanced histone hyperacetylation following treatments with TSA. Finally, hypoxia was demonstrated to downregulate IRS5/DOK4 expression. This expression was restored by TSA. The clinical relevance of altered IRS5/DOK4 expression in NSCLC requires further evaluation.
C1 [Gray, Steven G.; Al-Sarraf, Nael; Baird, Anne-Marie; Gately, Kathy; O'Byrne, Kenneth J.] St James Hosp, Trinity Ctr Hlth Sci, Inst Mol Med, Thorac Oncol Res Grp,Dept Clin Med, Dublin 8, Ireland.
   [Al-Sarraf, Nael; McGovern, Eilish] St James Hosp, Dept Surg, Dublin 8, Ireland.
C3 Trinity College Dublin; Trinity College Dublin
RP O'Byrne, KJ (通讯作者)，St James Hosp, Trinity Ctr Hlth Sci, Inst Mol Med, Thorac Oncol Res Grp,Dept Clin Med, Dublin 8, Ireland.
EM kobyrne@stjames.ie
RI Gately, Kathy/G-3834-2015; Gray, Steven/I-3081-2019
OI Gray, Steven/0000-0002-5850-6392; Gately, Kathy/0000-0002-9616-424X;
   O'Byrne, Kenneth/0000-0002-6754-5633; Baird,
   Anne-Marie/0000-0001-7501-1159
CR Al-Sarraf N, 2007, INT J CANCER, V121, P992, DOI 10.1002/ijc.22776
   Baldwin C, 2007, BIOCHEM BIOPH RES CO, V354, P783, DOI 10.1016/j.bbrc.2007.01.054
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bedirian A, 2004, J BIOL CHEM, V279, P19335, DOI 10.1074/jbc.M310689200
   Bermont L, 2001, J CLIN ENDOCR METAB, V86, P363, DOI 10.1210/jc.86.1.363
   Björnholm M, 2002, DIABETOLOGIA, V45, P1697, DOI 10.1007/s00125-002-0945-z
   Boissan M, 2005, AM J PATHOL, V167, P869, DOI 10.1016/S0002-9440(10)62058-5
   Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200
   Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X
   Chang Q, 2002, CANCER RES, V62, P6035
   Cui XJ, 2006, CANCER RES, V66, P5304, DOI 10.1158/0008-5472.CAN-05-2858
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   Favre C, 2003, GENES IMMUN, V4, P40, DOI 10.1038/sj.gene.6363891
   Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158
   GOLSHANI S, 1992, BIOCHEM MED METAB B, V47, P108, DOI 10.1016/0885-4505(92)90014-P
   Gray SG, 2003, HORM METAB RES, V35, P857
   Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080
   Gray ST, 2005, DIABETES-METAB RES, V21, P416, DOI 10.1002/dmrr.559
   Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032
   Han CH, 2006, ONCOL REP, V16, P1205
   Hartog H, 2007, EUR J CANCER, V43, P1895, DOI 10.1016/j.ejca.2007.05.021
   Hoang CD, 2004, CANCER RES, V64, P7479, DOI 10.1158/0008-5472.CAN-04-1898
   Itoh S, 2005, J BIOL CHEM, V280, P26383, DOI 10.1074/jbc.M410262200
   Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200
   Karamouzis MV, 2006, TRENDS MOL MED, V12, P595, DOI 10.1016/j.molmed.2006.10.003
   Koda M, 2005, NEOPLASMA, V52, P361
   Koda M, 2005, J CLIN PATHOL, V58, P645, DOI 10.1136/jcp.2004.022590
   Lee YH, 2004, ARCH PHARM RES, V27, P361, DOI 10.1007/BF02980074
   Leitlein J, 2001, J IMMUNOL, V166, P7238, DOI 10.4049/jimmunol.166.12.7238
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023
   Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200
   Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077
   Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684
   Nagle JA, 2004, MOL CELL BIOL, V24, P9726, DOI 10.1128/MCB.24.22.9726-9735.2004
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641
   Swinson DEB, 2004, INT J CANCER, V111, P43, DOI 10.1002/ijc.20052
   Swinson DEB, 2003, J CLIN ONCOL, V21, P473, DOI 10.1200/JCO.2003.11.132
   Takahash M, 2005, INT J ONCOL, V26, P923
   Uchida M, 2006, J CELL SCI, V119, P3067, DOI 10.1242/jcs.03043
   White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001
   Wu CD, 2005, EXP GERONTOL, V40, P894, DOI 10.1016/j.exger.2005.08.002
NR 45
TC 9
Z9 10
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1525-7304
EI 1938-0690
J9 CLIN LUNG CANCER
JI Clin. Lung Cancer
PD NOV
PY 2008
VL 9
IS 6
BP 367
EP 374
DI 10.3816/CLC.2008.n.053
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 378DT
UT WOS:000261302100008
PM 19073520
DA 2025-01-12
ER

PT J
AU Feng, QH
   Deftereos, G
   Hawes, SE
   Stern, JE
   Willner, JB
   Swisher, EM
   Xi, L
   Drescher, C
   Urban, N
   Kiviat, N
AF Feng, Qinghua
   Deftereos, Georgicis
   Hawes, Stephen E.
   Stern, Joshua E.
   Willner, Julia B.
   Swisher, Elizabeth M.
   Xi, Longfu
   Drescher, Charles
   Urban, Nicole
   Kiviat, Nancy
TI DNA hypermethylation, Her-2/neu overexpression and p53 mutations in
   ovarian carcinoma
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Hypermethylation; Her-2/neu overexpression; p53; Ovarian cancer
ID TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; METHYLATION PROFILES;
   CPG ISLAND; MULTIPLE GENES; BREAST-CANCER; STROMAL CELLS; EXPRESSION;
   INACTIVATION; PROGNOSIS
AB Objectives. To define patterns of aberrant DNA methylation, p53 Mutation and Her-2/neu overexpression in tissues front benign (n = 29), malignant (n = 100) and border line malignant ovaries (n = 10), as compared to normal (n = 68) ovarian tissues. Further, to explore the relationship between the presence of genetic and epigenetic abnormalities in ovarian cancers. and assess the association between epigenetic changes and clinical stage of malignancy at presentation and response to therapy.
   Methods. The methylation status of 23 genes that were previously reported associated with various epithelial malignancies was assessed in normal and abnormal ovarian tissues by methylation-specific PCR. The presence of p53 Mutation (n = 82 cases) and Her-2/neu overexpression (n = 51 cases) were assessed by DNA sequencing and immunohistochemistry, respectively.
   Results. Methylation of four genes (MINT31, RASSF1, and CABIN1) was significantly associated with ovarian cancer but not other ovarian pathology. Her-2/neu overexpression was associated with aberrant methylation of three genes (MINT31, RASSF1 and CDH13), although aberrant methylation was not associated with p53 Mutations. Methylation of RASSF1 and HIC1 was more frequent in early compared to late stage ovarian cancer, while methylation of CABIN1 and RASSF1 was associated with response to chemotherapy.
   Conclusion. DNA methylation of tumor suppressor genes is a frequent event in ovarian cancer, and in some cases is associated with Her-2/neu overexpression. Methylation of CABIN1 and RASSF1 may have the utility to predict response to therapy. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Feng, Qinghua; Deftereos, Georgicis; Stern, Joshua E.; Xi, Longfu; Kiviat, Nancy] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98109 USA.
   [Hawes, Stephen E.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98109 USA.
   [Swisher, Elizabeth M.] Univ Washington, Dept Obstet & Gynecol, Sch Med, Seattle, WA 98109 USA.
   [Drescher, Charles; Urban, Nicole] Fred Hutchinson Canc Res Ctr, Dept Publ Hlth, Seattle, WA 98104 USA.
   [Willner, Julia B.] Univ Calif Irvine, Dept Obstet & Gynecol, Orange, CA 92668 USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of
   Washington; University of Washington Seattle; Fred Hutchinson Cancer
   Center; University of California System; University of California Irvine
RP Feng, QH (通讯作者)，Univ Washington, Dept Pathol, Sch Med, 815 Mercer St,UW Med,Box 358050, Seattle, WA 98109 USA.
EM qf@u.washington.edu
RI Lin, Kevin/JFS-1634-2023
OI Lin, Kevin/0000-0002-1236-9847
FU NCI NIH HHS [P50CA83636, U01 CA085050-05, P50 CA083636-05, P50 CA083636,
   U01 CA085050, R01CA85050] Funding Source: Medline
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Boyd J, 1997, GYNECOL ONCOL, V64, P196, DOI 10.1006/gyno.1996.4572
   Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552
   Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034
   Dhillon VS, 2004, BRIT J CANCER, V90, P874, DOI 10.1038/sj.bjc.6601567
   Dong SM, 2001, CLIN CANCER RES, V7, P1982
   Du Y, 2001, CANCER RES, V61, P8094
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 1998, CANCER RES, V58, P4515
   Feng QH, 2005, JNCI-J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fraser Michael, 2003, Reprod Biol Endocrinol, V1, P66, DOI 10.1186/1477-7827-1-66
   Fu YX, 2003, MOL CANCER RES, V1, P569
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Jerónimo C, 2002, UROLOGY, V60, P1131
   KAMIKIHARA T, 2005, INT J CANC
   Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018
   Klimp AH, 2001, CANCER RES, V61, P7305
   Ludbrook J, 2000, CLIN EXP PHARMACOL P, V27, P212, DOI 10.1046/j.1440-1681.2000.03223.x
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   McCullach P., 1989, Generalized Linear Models, V2nd
   O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183
   SHAMES DS, 2006, METHODS DETECTING DN
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Strathdee G, 2005, GYNECOL ONCOL, V97, P898, DOI 10.1016/j.ygyno.2005.03.023
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
   Swisher EM, 2005, AM J OBSTET GYNECOL, V193, P662, DOI 10.1016/j.ajog.2005.01.054
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1
   TAM KF, 2006, J CANC RES CLIN ONCO
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433
   Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625
   Tuhkanen H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733
   Tuhkanen H, 2006, INT J CANCER, V119, P1345, DOI 10.1002/ijc.21785
   Wang ZH, 2006, CANCER BIOL THER, V5, P256, DOI 10.4161/cbt.5.3.2380
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   Yang HJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-212
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   Yuan YF, 2001, CANCER RES, V61, P5558
   YUEEHENG Y, 2006, CLIN EXP METASTAS, V23, P65
NR 54
TC 35
Z9 39
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD NOV
PY 2008
VL 111
IS 2
BP 320
EP 329
DI 10.1016/j.ygyno.2008.07.036
PG 10
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 373QS
UT WOS:000260987700027
PM 18757082
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Marmé, A
   Zimmermann, HP
   Moldenhauer, G
   Schorpp-Kistner, M
   Müller, C
   Keberlein, O
   Giersch, A
   Kretschmer, J
   Seib, B
   Spiess, E
   Hunziker, A
   Merchán, F
   Möller, P
   Hahn, U
   Kurek, R
   Marmé, F
   Bastert, G
   Wallwiener, D
   Ponstingl, H
AF Marme, Alexander
   Zimmermann, Hans-Peter
   Moldenhauer, Gerhard
   Schorpp-Kistner, Marina
   Mueller, Claudia
   Keberlein, Olga
   Giersch, Antje
   Kretschmer, Juergen
   Seib, Brigitte
   Spiess, Eberhard
   Hunziker, Andreas
   Merchan, Faustino
   Moeller, Peter
   Hahn, Uwe
   Kurek, Raffael
   Marme, Frederik
   Bastert, Gunther
   Wallwiener, Diethelm
   Ponstingl, Herwig
TI Loss of Drop1 expression already at early tumor stages in a wide range
   of human carcinomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE biomarker; epigenetic regulation; hMOF
ID RECESSIVE CEREBELLAR-ATAXIA; NUCLEAR-MEMBRANE; BREAST-CANCER; HISTONE
   ACETYLTRANSFERASE; GENE-EXPRESSION; PROTEIN; METHYLATION; SYNE-1;
   HETEROZYGOSITY; TISSUES
AB In a study on gene deregulation in ovarian carcinoma we found a mRNA ceding for a 350 kDa protein, Drop1, to be downregulated 20- to 180-fold in the majority of ovarian and mammary carcinomas. The mRNA is encoded by a set of exons in the 5' region of the SYNE1 gene. Immunohistochemical staining for Drop1 protein by a specific monoclonal antibody corresponds to the pattern seen for the mRNA. cDNA arrays of matched pairs of tumor and normal tissue and in situ hybridizations confirmed the drastic loss of Drop1 mRNA as a common feature in uterus, cervix, kidney, lung, thyroid and pancreas carcinomas, already at early tumor stages and in all metastases. Two-hybrid studies suggest a role of this deficiency in the malignant progression of epithelial tumors. (c) 2008 Wiley-Liss, Inc.
C1 [Zimmermann, Hans-Peter; Mueller, Claudia; Keberlein, Olga; Giersch, Antje; Kretschmer, Juergen; Seib, Brigitte; Ponstingl, Herwig] German Canc Res Ctr, Div Mol Biol Mitosis, D-69120 Heidelberg, Germany.
   [Marme, Alexander; Hahn, Uwe; Marme, Frederik; Bastert, Gunther] Univ Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany.
   [Marme, Alexander; Kurek, Raffael; Wallwiener, Diethelm] Univ Tubingen, Dept Obstet & Gynecol, D-7400 Tubingen, Germany.
   [Moldenhauer, Gerhard] Deutsch Krebsforschungszentrum, Div Mol Immunol, D-6900 Heidelberg, Germany.
   [Schorpp-Kistner, Marina] Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-6900 Heidelberg, Germany.
   [Spiess, Eberhard] Deutsch Krebsforschungszentrum, Biomed Struct Anal Grp, D-6900 Heidelberg, Germany.
   [Hunziker, Andreas] Deutsch Krebsforschungszentrum, DNA Sequencing Unit, D-6900 Heidelberg, Germany.
   [Merchan, Faustino] Univ Extremadura, Fac Vet Med, Dept Biochem & Mol Biol, Caceres, Spain.
   [Moeller, Peter] Univ Ulm, Dept Pathol, Ulm, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ); Helmholtz Association; German Cancer Research Center
   (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ);
   Universidad de Extremadura; Ulm University
RP Ponstingl, H (通讯作者)，German Canc Res Ctr, Div Mol Biol Mitosis, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM ponstingl@dkfz.de
RI Merchan, Faustino/K-8667-2014
OI Merchan, Faustino/0000-0003-4540-5725
FU Strategiefords; Helmholtz-Gemeinschaft Deutscher Forschungszentren
FX Strategiefords Grant, Helmholtz-Gemeinschaft Deutscher
   Forschungszentren.
CR Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275
   Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200
   Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200
   Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857
   Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224
   Cottrell JR, 2004, NEURON, V44, P677, DOI 10.1016/j.neuron.2004.10.025
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Dupré N, 2007, ANN NEUROL, V62, P93, DOI 10.1002/ana.21143
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Fan J, 2004, J CELL SCI, V117, P619, DOI 10.1242/jcs.00892
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4
   Gao Hui, 2002, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V19, P14
   Gough LL, 2003, MOL BIOL CELL, V14, P2410, DOI 10.1091/mbc.E02-07-0446
   Gros-Louis F, 2007, NAT GENET, V39, P80, DOI 10.1038/ng1927
   Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550
   Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kayser S, 2003, J CANCER RES CLIN, V129, P397, DOI 10.1007/s00432-003-0445-7
   Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625
   Liang P, 2003, NAT REV CANCER, V3, P869, DOI 10.1038/nrc1214
   MECHTERSHEIMER G, 1990, INT J CANCER, V46, P813, DOI 10.1002/ijc.2910460512
   Meléndez B, 2004, GENE CHROMOSOME CANC, V41, P353, DOI 10.1002/gcc.20105
   Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007
   Mislow JMK, 2002, FEBS LETT, V525, P135, DOI 10.1016/S0014-5793(02)03105-8
   Mislow JMK, 2002, J CELL SCI, V115, P61
   MOMBURG F, 1987, CANCER RES, V47, P2883
   Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4
   Nedivi E, 1996, P NATL ACAD SCI USA, V93, P2048, DOI 10.1073/pnas.93.5.2048
   Noviello C, 1996, CLIN CANCER RES, V2, P1601
   O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028
   Padmakumar VC, 2004, EXP CELL RES, V295, P330, DOI 10.1016/j.yexcr.2004.01.014
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Wan JS, 1996, NAT BIOTECHNOL, V14, P1685, DOI 10.1038/nbt1296-1685
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wilhelmsen K, 2006, J CELL SCI, V119, P5021, DOI 10.1242/jcs.03295
   Wisman GBA, 2006, INT J CANCER, V119, P1908, DOI 10.1002/ijc.22060
   Zhang QP, 2007, HUM MOL GENET, V16, P2816, DOI 10.1093/hmg/ddm238
   Zhang QP, 2005, J CELL SCI, V118, P673, DOI 10.1242/jcs.01642
   Zhang QP, 2002, GENOMICS, V80, P473, DOI 10.1006/geno.2002.6859
   Zhang QP, 2001, J CELL SCI, V114, P4485
   Zhang XC, 2007, DEVELOPMENT, V134, P901, DOI 10.1242/dev.02783
NR 46
TC 30
Z9 35
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 1
PY 2008
VL 123
IS 9
BP 2048
EP 2056
DI 10.1002/ijc.23763
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 357HE
UT WOS:000259836100009
PM 18709643
OA Bronze
DA 2025-01-12
ER

PT J
AU Kinyamu, HK
   Collins, JB
   Grissom, SF
   Hebbar, PB
   Archer, TK
AF Kinyamu, H. Karimi
   Collins, Jennifer B.
   Grissom, Sherry F.
   Hebbar, Pratibha B.
   Archer, Trevor K.
TI Genome Wide Transcriptional Profiling in Breast Cancer Cells Reveals
   Distinct Changes in Hormone Receptor Target Genes and Chromatin
   Modifying Enzymes After Proteasome inhibition
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE proteasome inhibitor; receptors; glucocorticoid; estrogen; gene
   expression profiling; microarray analysis
ID GLUCOCORTICOID-RECEPTOR; ESTROGEN-RECEPTOR; REGULATED TRANSCRIPTION;
   PROSTATE-CANCER; PROTEIN-DEGRADATION; NUCLEAR RECEPTORS;
   CERVICAL-CANCER; HUMAN-DISEASES; EXPRESSION; UBIQUITIN
AB Steroid hormone receptors, like glucocorticoid (GR) and estrogen receptors (ER), are master regulators of genes that control many biological processes implicated in health and disease. Gene expression is dependent on receptor levels which are tightly regulated by the ubiquitin-proteasome system. Previous studies have shown that proteasome inhibition increases GR, but decreases ER-mediated gene expression. At the gene expression level this divergent role of the proteasome in receptor-dependent transcriptional regulation is not well understood. We have used a genomic approach to examine the impact of proteasome activity on GR- and ER-mediated gene expression in MCF-7 breast cancer cells treated with dexamethasone (DEX) or 17 beta-estradiol (E2), the proteasome inhibitor MG132 (MG) or MG132 and either hormone (MID or ME2) for 24 h. Transcript profiling reveals that inhibiting proteasome activity modulates gene expression by GR and ER in a similar manner in that several GR and ER target genes are upregulated and downregulated after proteasome inhibition. In addition, proteasome inhibition modulates receptor-dependent genes involved in the etiology of a number of human pathological states, including multiple myeloma, leukemia, breast/prostate cancer, HIV/AIDS, and neurodegenerative disorders. Importantly, our analysis reveals that a number of transcripts encoding histone and DNA modifying enzymes, prominently histone/DNA methyltransf erases and demethylases, are altered after proteasome inhibition. As proteasome inhibitors are currently in clinical trials as therapy for multiple myeloma, HIV/AIDS and leukemia, the possibility that some of the target molecules are hormone regulated and chromatin modifying enzymes is intriguing in this era of epigenetic therapy. Published 2008 Wiley-Liss, Inc.
C1 [Kinyamu, H. Karimi; Hebbar, Pratibha B.; Archer, Trevor K.] Natl Inst Environm Hlth Sci, Chromatin & Gene Express Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.
   [Collins, Jennifer B.; Grissom, Sherry F.] Natl Inst Environm Hlth Sci, Microarray Grp, NIH, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS)
RP Kinyamu, HK (通讯作者)，Natl Inst Environm Hlth Sci, Chromatin & Gene Express Sect, Mol Carcinogenesis Lab, NIH, 111 Alexander Dr,POB 12233,MD C4-06, Res Triangle Pk, NC 27709 USA.
RI kinyamu, Harriet/AAG-9069-2019
OI Archer, Trevor K/0000-0001-7651-3644; Kinyamu,
   Harriet/0000-0002-2377-7408
FU NIH; NIEHS
FX We are deeply grateful to Dr. Pierre Bushel (Biostatistics Branch,
   NIEHS) for providing help with the statistical analysis and rewriting
   the methods section to answer the reviewers concerns. We thank Wendy
   Jefferson and Sylvia Hewitt for helpful comments in organizing the
   paper. This research was supported by the Intramural Research Program of
   NIH and NIEHS.
CR Alami Y, 1999, BIOCHEM BIOPH RES CO, V257, P738, DOI 10.1006/bbrc.1999.0516
   Baker SP, 2005, CELL, V123, P361, DOI 10.1016/j.cell.2005.10.013
   Bandyopadhyay S, 2003, CANCER RES, V63, P1731
   Banks GC, 2001, J BIOL CHEM, V276, P36467, DOI 10.1074/jbc.M104641200
   Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200
   Carlsson H, 2005, INT J ONCOL, V27, P1473
   Ciechanover Aaron, 2006, Hematology Am Soc Hematol Educ Program, P1
   Cillo C, 1996, INT J CANCER, V66, P692, DOI 10.1002/(SICI)1097-0215(19960529)66:5<692::AID-IJC18>3.3.CO;2-1
   Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009
   De Smet C, 1999, MOL CELL BIOL, V19, P7327
   Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5
   Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459
   Hebbar PB, 2007, J BIOL CHEM, V282, P8284, DOI 10.1074/jbc.M610554200
   Hess JL, 2004, CRIT REV EUKAR GENE, V14, P235, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.10
   Hoang T, 2004, J BIOL CHEM, V279, P49120, DOI 10.1074/jbc.M409746200
   Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287
   Jagannath S, 2004, BRIT J HAEMATOL, V127, P165, DOI 10.1111/j.1365-2141.2004.05188.x
   Jiang HY, 2007, J BIOL CHEM, V282, P3755, DOI 10.1074/jbc.M606461200
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kinyamu HK, 2007, MOL CELL BIOL, V27, P4891, DOI 10.1128/MCB.02162-06
   Kinyamu HK, 2005, J MOL ENDOCRINOL, V34, P281, DOI 10.1677/jme.1.01680
   Kinyamu HK, 2004, BBA-GENE STRUCT EXPR, V1677, P30, DOI 10.1016/j.bbaexp.2003.09.015
   Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003
   Kishimoto M, 2006, ENDOCR J, V53, P157, DOI 10.1507/endocrj.53.157
   Koritschoner NP, 1997, J BIOL CHEM, V272, P9573
   Lachat P, 2002, HISTOCHEM CELL BIOL, V118, P399, DOI 10.1007/s00418-002-0460-9
   Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008
   LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0
   Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037
   Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66
   Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200
   Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098
   Lobenhofer EK, 2002, MOL ENDOCRINOL, V16, P1215, DOI 10.1210/me.16.6.1215
   Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102
   Musto P, 2007, CANCER-AM CANCER SOC, V109, P2285, DOI 10.1002/cncr.22700
   Nakamura N, 1998, CLIN EXP METASTAS, V16, P471
   Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6
   Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388
   Orlowski RZ, 2003, BREAST CANCER RES, V5, P1, DOI 10.1186/bcr460
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2
   Rasmussen T, 2002, BRIT J HAEMATOL, V117, P626, DOI 10.1046/j.1365-2141.2002.03429.x
   Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X
   Reinstein E, 2006, ANN INTERN MED, V145, P676, DOI 10.7326/0003-4819-145-9-200611070-00010
   Rhen T, 2003, FASEB J, V17, P1849, DOI 10.1096/fj.02-1099com
   Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51
   Richardson Paul G, 2005, Future Oncol, V1, P161, DOI 10.1517/14796694.1.2.161
   Roccaro AM, 2006, CURR PHARM BIOTECHNO, V7, P441, DOI 10.2174/138920106779116865
   Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100
   Rohr O, 2000, J BIOL CHEM, V275, P2654, DOI 10.1074/jbc.275.4.2654
   Schwartz AL, 1999, ANNU REV MED, V50, P57
   Shim C, 1998, CLIN CANCER RES, V4, P3045
   Stavreva DA, 2006, MOL CELL BIOL, V26, P5131, DOI 10.1128/MCB.02227-05
   Stojadinovic O, 2007, J BIOL CHEM, V282, P4021, DOI 10.1074/jbc.M606262200
   Vergote D, 2006, P NATL ACAD SCI USA, V103, P19182, DOI 10.1073/pnas.0604678103
   Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806
   Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200
   Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204
   Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101
   Wang Z, 2007, MED HYPOTHESES, V69, P816, DOI 10.1016/j.mehy.2007.01.069
   Weng L, 2006, BIOINFORMATICS, V22, P1111, DOI 10.1093/bioinformatics/btl045
   Wright KJ, 2006, P NATL ACAD SCI USA, V103, P12347, DOI 10.1073/pnas.0605499103
   Wu LG, 2005, MOL CELL BIOL, V25, P9198, DOI 10.1128/MCB.25.21.9198-9208.2005
   Xie B, 2007, J VIROL, V81, P4226, DOI 10.1128/JVI.01888-06
   YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209
   Yan F, 2003, MOL ENDOCRINOL, V17, P1315, DOI 10.1210/me.2002-0209
   Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306
   Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496
   Zhu YL, 2006, INT J ONCOL, V29, P1581
NR 83
TC 26
Z9 31
U1 0
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD NOV
PY 2008
VL 47
IS 11
BP 845
EP 885
DI 10.1002/mc.20440
PG 41
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 371BZ
UT WOS:000260808100004
PM 18381591
OA hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Krum, SA
   Miranda-Carboni, GA
   Lupien, M
   Eeckhoute, J
   Carroll, JS
   Brown, M
AF Krum, Susan A.
   Miranda-Carboni, Gustavo A.
   Lupien, Mathieu
   Eeckhoute, Jerome
   Carroll, Jason S.
   Brown, Myles
TI Unique ERα Cistromes Control Cell Type-Specific Gene Regulation
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; OSTEOBLAST DIFFERENTIATION;
   ALKALINE-PHOSPHATASE; ANTIGEN PROMOTER; BONE-FORMATION; BINDING-SITES;
   HIGH-AFFINITY; TARGET GENE; CYCLIN D1
AB Estrogens play an important role in normal physiology and in a variety of pathological states involving diverse tissues including breast and bone. The mechanism by which estrogens exert cell type- and disease-specific effects, however, remains to be explained. We have compared the gene expression profile of the MCF7 breast cancer cell line with that of the osteoblast-like cell line U2OS-ER alpha by expression microarrays. We find that fewer than 10% of the 17 beta-estradiol (E2)-regulated genes are common to both cell types. We have validated this in primary calvarial osteoblasts. To dissect the mechanism underlying the cell type- specific E2 regulation of gene expression in MCF7 and U2OS-ER alpha cells, we compared the ER alpha binding sites on DNA in the two cell types by performing chromatin immunoprecipitation (ChIP) on genomic tiling arrays (ChIP-on-chip). Consistent with the distinct patterns of E2-regulated gene expression in these two cell lines, we find that the vast majority of ER alpha binding sites are also cell type specific and correlate both in position and number with cell type-specific gene regulation. Interestingly, although the forkhead factor FoxA1 plays a critical role in defining the ER alpha cistrome in MCF7 cells, it is not expressed in U2OS-ER alpha cells, and forkhead motifs are not enriched in the ER alpha cistrome in these cells. Finally, the ER alpha cistromes are correlated with cell type- specific epigenetic histone modifications. These results support a model for the cell type-specific action of E2 being driven primarily through specific ER alpha occupancy of epigenetically marked cis-regulatory regions of target genes. (Molecular Endocrinology 22: 2393-2406, 2008)
C1 [Krum, Susan A.; Lupien, Mathieu; Eeckhoute, Jerome; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA.
   [Miranda-Carboni, Gustavo A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   [Miranda-Carboni, Gustavo A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Carroll, Jason S.] Cambridge Res Inst, Canc Res UK, Cambridge CB2 0RE, England.
C3 Harvard University; Dana-Farber Cancer Institute; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; University of Cambridge; CRUK
   Cambridge Institute; Cancer Research UK
RP Brown, M (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, 44 Binney St,D730, Boston, MA 02115 USA.
EM myles_brown@dfci.harvard.edu
RI Krum, Susan/D-7282-2013; Eeckhoute, Jerome/AAN-8219-2021; Brown,
   Myles/B-6906-2008; Lupien, Mathieu/KFB-6691-2024
OI Eeckhoute, Jerome/0000-0002-7222-9264; Krum, Susan/0000-0002-6414-6397;
   Brown, Myles/0000-0002-8213-1658; Lupien, Mathieu/0000-0003-0929-9478;
   Carroll, Jason/0000-0003-3643-0080
FU NCI NIH HHS [P01 CA8011105] Funding Source: Medline; NIDDK NIH HHS
   [R01DK074967, R01 DK074967] Funding Source: Medline
CR Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bodine PVN, 1998, ENDOCRINOLOGY, V139, P2048, DOI 10.1210/en.139.4.2048
   Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441
   Carlberg C, 2007, J STEROID BIOCHEM, V103, P338, DOI 10.1016/j.jsbmb.2006.12.044
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200
   Chagin AS, 2007, J CLIN ENDOCR METAB, V92, P4873, DOI 10.1210/jc.2007-0814
   Chen XW, 2002, BIOCHEM BIOPH RES CO, V295, P417, DOI 10.1016/S0006-291X(02)00667-8
   Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148
   Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kassem M, 1996, J BONE MINER RES, V11, P193
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550-06
   Krum SA, 2008, CELL CYCLE, V7, P1348, DOI 10.4161/cc.7.10.5892
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Mansouri A, 1996, DEVELOPMENT, V122, P831
   MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x
   Monroe DG, 2005, MOL ENDOCRINOL, V19, P1555, DOI 10.1210/me.2004-0381
   Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633
   Plant A, 2001, J CELL BIOCHEM, V82, P683, DOI 10.1002/jcb.1201
   Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756-3282(97)00276-7
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Rickard DJ, 1998, J CLIN INVEST, V101, P413, DOI 10.1172/JCI119880
   RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602
   Romm E, 2005, J NEUROCHEM, V93, P1444, DOI 10.1111/j.1471-4159.2005.03131.x
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   SCHEVEN BAA, 1992, BIOCHEM BIOPH RES CO, V186, P54, DOI 10.1016/S0006-291X(05)80774-0
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Simoncini T, 2004, STEROIDS, V69, P537, DOI 10.1016/j.steroids.2004.05.009
   Simpson ER, 2001, ANN NY ACAD SCI, V949, P58
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   van Leeuwen JPTM, 2001, CRIT REV EUKAR GENE, V11, P199
   Vanyushin BF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P488, DOI 10.1007/s10541-005-0143-y
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
NR 51
TC 108
Z9 129
U1 0
U2 8
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD NOV
PY 2008
VL 22
IS 11
BP 2393
EP 2406
DI 10.1210/me.2008-0100
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 365SZ
UT WOS:000260429400003
PM 18818283
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Cecener, G
   Tunca, B
   Egeli, U
   Karadag, M
   Vatan, O
   Uzaslan, E
   Tolunay, S
AF Cecener, Gulsah
   Tunca, Berrin
   Egeli, Unal
   Karadag, Mehmet
   Vatan, Ozgur
   Uzaslan, Esra
   Tolunay, Sahsine
TI Mutation analysis of the <i>FHIT</i> gene in bronchoscopic specimens
   from patients with suspected lung cancer
SO TUMORI
LA English
DT Article
DE lung cancer; bronchoscopy specimen; FHIT gene; sequence variant;
   single-strand conformation polymorphism; DNA sequencing
ID BREAST-CANCER; 3P14.2; CARCINOMA; LESIONS
AB Aims and background. Lung cancer is a leading cause of cancer death worldwide. However, despite recent advances in molecular biology that have revealed various genetic changes in lung cancer, the prognostic Outcome of lung cancer patients has improved only minimally. This Situation has changed fundamentally With the identification of molecular abnormalities that are characteristic of premalignant changes, Such as changes ill tumor suppressor genes, loss of heterozygosity at crucial sites, and activation of oncogenes. Inactivation of the tumor suppressor gene Fragile Histidine Triad (FHIT) is a frequent genetic change in lung cancer. The aim of this study was to identify FHIT-gene alterations in bronchoscopy specimens of patients with suspected lung cancer and to determine the molecular relevance, if any, of FHIT alterations in the development of cancer.
   Patients and methods. Sixty-two patients with suspected lung tumors were screened for variations within exons 5-9 of the FHIT gene using intronic primer pairs and single-strand conformation polymorphism and sequencing analysis.
   Results. FHIT gene alterations were detected in 27 out of 62 bronchoscopic specimens (43.54%). All of these alterations were identified as T to A alteration at position IVS8-17. This intronic variant also was identified in approximately half of control cases (45%).
   Conclusions. Our findings showed that the FHIT IVS8-17 T to A alteration identified in bronchoscopy specimens from patients with clinically suspected lung cancer is a polymorphism found in the Turkish population. We think that this polymorphism does not affect gene function because it is located in the intron portion of the gene and is present in many cancer patients as well as healthy Subjects. We Suggest that the FHIT gene may be turned off in lung carcinogenesis via other genetic or epigenetic mechanisms rather than mutations.
C1 [Cecener, Gulsah; Tunca, Berrin; Egeli, Unal] Uludag Univ, Fac Med, Dept Med Biol, TR-16059 Bursa, Turkey.
   [Karadag, Mehmet; Uzaslan, Esra] Uludag Univ, Fac Med, Dept Chest Dis, TR-16059 Bursa, Turkey.
   [Vatan, Ozgur] Uludag Univ, Fac Sci & Arts, Dept Biol, TR-16059 Bursa, Turkey.
   [Tolunay, Sahsine] Uludag Univ, Fac Med, Dept Pathol, TR-16059 Bursa, Turkey.
C3 Uludag University; Uludag University; Uludag University; Uludag
   University
RP Egeli, U (通讯作者)，Uludag Univ, Fac Med, Dept Med Biol, TR-16059 Bursa, Turkey.
EM egeli@uludag.edu.tr
RI Tunca, Berrin/ABI-6078-2020; Tolunay, Sahsine/AAI-1612-2021; Cecener,
   Gulsah/AAP-9988-2020; Karadağ, Mehmet/AAG-8744-2021; Egeli,
   Unal/AAH-1420-2021; VATAN, Ozgur/ISV-0209-2023; VATAN, Ozgur/O-7508-2015
OI Karadag, Mehmet/0000-0002-9027-1132; Egeli, Unal/0000-0001-7904-883X;
   Cecener, Gulsah/0000-0002-3820-424X; VATAN, Ozgur/0000-0002-7687-3284
FU Society of Investigation and Prevention of Genetic Diseases
FX We thank Prizma and Elips Ltd for their support in supplying the
   experimental equipment. This research was supported by the Society of
   Investigation and Prevention of Genetic Diseases.
CR Ahmadian M, 1997, CANCER RES, V57, P3664
   Bekar A, 2007, TUMORI J, V93, P604
   Çeçener G, 2007, TUMORI J, V93, P597
   Fong KM, 1997, CANCER RES, V57, P2256
   Gemma A, 1997, CANCER RES, V57, P1435
   Kannan K, 2000, INT J ONCOL, V17, P1031
   Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857
   Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Thiagalingam S, 1996, CANCER RES, V56, P2936
   Travis W.D., 1999, WHO HISTOLOGICAL TYP
   *TURK MIN HLTH, 2000, REP TURK HLTH STAT
   Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349
   Yanagisawa K, 1996, CANCER RES, V56, P5579
   Yoshino K, 1998, INT J CANCER, V76, P176, DOI 10.1002/(SICI)1097-0215(19980413)76:2<176::AID-IJC2>3.0.CO;2-U
   Zhao Xi-Rong, 2003, Ai Zheng, V22, P50
NR 16
TC 6
Z9 9
U1 0
U2 4
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 0300-8916
EI 2038-2529
J9 TUMORI
JI Tumori
PD NOV-DEC
PY 2008
VL 94
IS 6
BP 845
EP 848
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 412UY
UT WOS:000263750900012
PM 19267103
DA 2025-01-12
ER

PT J
AU Wang, C
   Yu, J
   Kallen, CB
AF Wang, Cheng
   Yu, Jie
   Kallen, Caleb B.
TI Two Estrogen Response Element Sequences Near the <i>PCNA</i> Gene Are
   Not Responsible for Its Estrogen-Enhanced Expression in MCF7 Cells
SO PLOS ONE
LA English
DT Article
AB Background: The proliferating cell nuclear antigen (PCNA) is an essential component of DNA replication, cell cycle regulation, and epigenetic inheritance. High expression of PCNA is associated with poor prognosis in patients with breast cancer. The 5'-region of the PCNA gene contains two computationally-detected estrogen response element (ERE) sequences, one of which is evolutionarily conserved. Both of these sequences are of undocumented cis-regulatory function. We recently demonstrated that estradiol (E2) enhances PCNA mRNA expression in MCF7 breast cancer cells. MCF7 cells proliferate in response to E2.
   Methodology/Principal Findings: Here, we demonstrate that E2 rapidly enhanced PCNA mRNA and protein expression in a process that requires ER alpha as well as de novo protein synthesis. One of the two upstream ERE sequences was specifically bound by ER alpha-containing protein complexes, in vitro, in gel shift analysis. Yet, each ERE sequence, when cloned as a single copy, or when engineered as two tandem copies of the ERE-containing sequence, was not capable of activating a luciferase reporter construct in response to E2. In MCF7 cells, neither ERE-containing genomic region demonstrated E2-dependent recruitment of ER alpha by sensitive ChIP-PCR assays.
   Conclusion/Significance: We conclude that E2 enhances PCNA gene expression by an indirect process and that computational detection of EREs, even when evolutionarily conserved and when near E2-responsive genes, requires biochemical validation.
C1 [Wang, Cheng; Yu, Jie; Kallen, Caleb B.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30322 USA.
C3 Emory University
RP Wang, C (通讯作者)，Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30322 USA.
EM caleb.kallen@emory.edu
OI Kallen, Caleb/0000-0002-4156-6719
FU Research Scientist Development Program; NIH [5K12HD00849]; Society for
   Gynecologic Investigation
FX CBK is supported by a grant from the Research Scientist Development
   Program (NIH-5K12HD00849) and by the Society for Gynecologic
   Investigation. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR AALTOMAA S, 1993, ANTICANCER RES, V13, P533
   ALDER H, 1992, NUCLEIC ACIDS RES, V20, P1769, DOI 10.1093/nar/20.7.1769
   ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575
   BASERGA R, 1991, J CELL SCI, V98, P433
   Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0
   Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663
   Bouras T, 2002, CANCER RES, V62, P1289
   Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441
   Bourdeau V, 2008, NUCLEIC ACIDS RES, V36, P76, DOI 10.1093/nar/gkm945
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Deschênes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200
   DUBIK D, 1992, ONCOGENE, V7, P1587
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269
   Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008
   Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200
   Horita K, 2001, EUR J HISTOCHEM, V45, P73
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Huang DY, 1996, J BIOL CHEM, V271, P1218, DOI 10.1074/jbc.271.2.1218
   Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x
   JASKULSKI D, 1988, J BIOL CHEM, V263, P10175
   Jin VX, 2004, NUCLEIC ACIDS RES, V32, P6627, DOI 10.1093/nar/gkh1005
   Kamalakaran S, 2005, J BIOL CHEM, V280, P21491, DOI 10.1074/jbc.M409176200
   Kannabiran C, 1999, ONCOGENE, V18, P7825, DOI 10.1038/sj.onc.1203294
   KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993
   Kato T, 2000, BRIT J CANCER, V82, P404, DOI 10.1054/bjoc.1999.0934
   Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   KONIECKI J, 1991, CANCER RES, V51, P1465
   Krieg AJ, 2006, MOL CELL BIOL, V26, P7030, DOI 10.1128/MCB.00322-06
   Krikun G, 2004, ENDOCRINOLOGY, V145, P2291, DOI 10.1210/en.2003-1606
   Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104
   LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697
   LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481
   Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998
   Li YY, 2003, FEBS LETT, V544, P112, DOI 10.1016/S0014-5793(03)00485-X
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433
   Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653
   Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808
   Martin PJ, 2005, NUCLEIC ACIDS RES, V33, P4311, DOI 10.1093/nar/gki745
   MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895
   MORRIS GF, 1989, J BIOL CHEM, V264, P13856
   Nair HB, 2005, CANCER RES, V65, P11164, DOI 10.1158/0008-5472.CAN-05-1087
   Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694
   NARITA T, 1993, JPN J CLIN ONCOL, V23, P20
   NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777
   Nunez E, 2008, CELL, V132, P996, DOI 10.1016/j.cell.2008.01.051
   O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044
   Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802
   Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4
   Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066
   SCHIMMELPENNING H, 1993, VIRCHOWS ARCH A, V423, P273, DOI 10.1007/BF01606890
   SCHONBORN I, 1995, J CANCER RES CLIN, V121, P115, DOI 10.1007/BF01202223
   Schultz-Norton JR, 2007, NUCLEIC ACIDS RES, V35, P5028, DOI 10.1093/nar/gkm533
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   SheenChen SM, 1997, ARCH SURG-CHICAGO, V132, P264
   Shimomura Y, 1998, J CLIN ENDOCR METAB, V83, P2192, DOI 10.1210/jc.83.6.2192
   SHIPMANAPPASAMY P, 1990, J BIOL CHEM, V265, P19180
   Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115
   Stender JD, 2007, MOL ENDOCRINOL, V21, P2112, DOI 10.1210/me.2006-0474
   Tang SS, 2004, NUCLEIC ACIDS RES, V32, P6212, DOI 10.1093/nar/gkh943
   Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829
   Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9
   Vavouri T, 2006, TRENDS GENET, V22, P5, DOI 10.1016/j.tig.2005.10.005
   WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0
   WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0
   Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.0.CO;2-#
   Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672
   WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097
   WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816
   Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927
   Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114
   Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
NR 87
TC 22
Z9 23
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2008
VL 3
IS 10
AR e3523
DI 10.1371/journal.pone.0003523
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 432IJ
UT WOS:000265126400008
PM 18949048
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Seo, SY
   Kim, EO
   Jang, KL
AF Seo, So Young
   Kim, Eun-Ok
   Jang, Kyung Lib
TI Epstein-Barr virus latent membrane protein 1 suppresses the
   growth-inhibitory effect of retinoic acid by inhibiting retinoic acid
   receptor-β2 expression via DNA methylation
SO CANCER LETTERS
LA English
DT Article
DE DNA methylation; EBV; LMP1; NPC; RAR-beta(2)
ID BREAST-CANCER CELLS; RECEPTOR-BETA; LATENT MEMBRANE-PROTEIN-1;
   NASOPHARYNGEAL CARCINOMA; LUNG-CANCER; MULTIPLE GENES; CPG ISLANDS;
   DIFFERENTIATION; ACTIVATION; ARREST
AB Epigenetic alteration through DNA methylation in retinoic acid receptor-beta(2) (RAR-beta(2)) is common in human tumors including nasopharyngeal carcinoma (NPC); however, the mechanism and its biological significance are unknown. Here, we report that the Epstein-Barr virus (EBV) oncogene product, latent membrane protein 1 (LMP1), induces promoter hypermethylation of RAR-beta(2) via up-regulation of DNA methyltransferases 1, 3a, and 3b, leading to decrease in RAR-beta(2) expression in NPC cells. In addition, LMP1 abolished the potentials of retinoic acid (RA) to down-regulate Cdk2 and Cdk4 and to up-regulate p16, p21, and p27, resulting in activation of E2F1 in the presence of RA. As a consequence, LMP1 could abrogate the growth-inhibitory effect of RA by releasing cell cycle arrest at G, phase. Considering that RAR-beta(2) is a major executor of the anti-tumor potentials of retinoids, its down-regulation by LMP1 might play an important role during EBV-mediated tumorigenesis. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Seo, So Young; Kim, Eun-Ok; Jang, Kyung Lib] Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea.
C3 Pusan National University
RP Jang, KL (通讯作者)，Pusan Natl Univ, Coll Nat Sci, Div Biol Sci, Pusan 609735, South Korea.
EM kljang@pusan.ac.kr
RI Kim, Jwa/AAH-9915-2021
CR Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011
   Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005
   BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   DE LUCA LM, 1991, FASEB J, V5, P2924
   Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   GEBERT JF, 1991, ONCOGENE, V6, P1859
   Grote HJ, 2005, INT J CANCER, V116, P720, DOI 10.1002/ijc.21090
   Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271
   Herbig U, 2006, MECH AGEING DEV, V127, P16, DOI 10.1016/j.mad.2005.09.002
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoffman AD, 1996, CLIN CANCER RES, V2, P1077
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   HSU MM, 1983, CANCER-AM CANCER SOC, V52, P362, DOI 10.1002/1097-0142(19830715)52:2<362::AID-CNCR2820520230>3.0.CO;2-V
   HU L, 1991, CANCER RES, V51, P3972
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jung JK, 2007, CANCER RES, V67, P5771, DOI 10.1158/0008-5472.CAN-07-0529
   Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2
   Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818
   Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372
   Rickinson A.B., 2001, FIELDS VIROLOGY, V2, P2575
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062
   Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200
   TAKIMOTO T, 1986, CANCER RES, V46, P2085
   Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365
   Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194
   Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399
   Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698
   Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004
   XU XC, 1994, CANCER RES, V54, P3580
   Xu XC, 2007, CANCER LETT, V253, P14, DOI 10.1016/j.canlet.2006.11.019
   Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089
   Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001
   Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217
NR 44
TC 51
Z9 57
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 18
PY 2008
VL 270
IS 1
BP 66
EP 76
DI 10.1016/j.canlet.2008.04.043
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 357LL
UT WOS:000259847200007
PM 18539384
DA 2025-01-12
ER

PT J
AU Novak, P
   Jensen, T
   Oshiro, MM
   Watts, GS
   Kim, CJ
   Futscher, BW
AF Novak, Petr
   Jensen, Taylor
   Oshiro, Marc M.
   Watts, George S.
   Kim, Christina J.
   Futscher, Bernard W.
TI Agglomerative Epigenetic Aberrations Are a Common Event in Human Breast
   Cancer
SO CANCER RESEARCH
LA English
DT Article
ID CPG-ISLAND METHYLATION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION;
   TRANSCRIPTION FACTOR; COLORECTAL-CANCER; MASS-SPECTROMETRY;
   EPITHELIAL-CELLS; BINDING SITES; HUMAN GENOME; CTCF
AB Changes in DNA methylation patterns are a common characteristic of cancer cells. Recent studies suggest that DNA methylation affects not only discrete genes, but it can also affect large chromosomal regions, potentially leading to LRES. It is unclear whether such long-range epigenetic events are relatively rare or frequent occurrences in cancer. Here, we use a high-resolution promoter tiling array approach to analyze DNA methylation in breast cancer specimens and normal breast tissue to address this question. We identified 3,506 cancer-specific differentially methylated regions (DMR) in human breast cancer with 2,033 being hypermethylation events and 1,473 hypomethylation events. Most of these DMRs are recurrent in breast cancer; 90% of the identified DMRs occurred in at least 33% of the samples. Interestingly, we found a nottrandom spatial distribution of aberrantly methylated regions across the genome that showed a tendency to concentrate in relatively small genomic regions. Such agglomerates of hypermethylated and hypomethylated DMRs spanned up to several hundred kilobases and were frequently found at gene family clusters. The hypermethylation events usually occurred in the proximity of the transcription start site in CpG island promoters, whereas hypomethylation events were frequently found in regions of segmental duplication. One example of a newly discovered agglomerate of hypermethylated DMRs associated with gene silencing in breast cancer that we examined in greater detail involved the protocadherin gene family clusters on chromosome 5 (PCDHA, PCDHB, and PCDHG). Taken together, our results suggest that agglomerative epigenetic aberrations are frequent events in human breast cancer. [Cancer Res 2008;68(20):8616-25]
C1 [Novak, Petr; Jensen, Taylor; Oshiro, Marc M.; Watts, George S.; Kim, Christina J.; Futscher, Bernard W.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
   [Jensen, Taylor; Futscher, Bernard W.] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA.
   [Kim, Christina J.] Univ Arizona, Dept Surg, Tucson, AZ 85724 USA.
   [Novak, Petr] Inst Plant Mol Biol As CR, Ceske Budejovice, Czech Republic.
C3 University of Arizona; Arizona Center Cancer Care; University of
   Arizona; University of Arizona; Czech Academy of Sciences
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM bfutscher@azcc.arizona.edu
RI Novak, Petr/A-3059-2013
OI Novak, Petr/0000-0002-5068-9681
FU interdisciplinary biotechnology center [BI05];  [R01CA65662]; 
   [R33CA0951];  [P30ES06694];  [P30CA023074];  [ES007091];  [CA09213]
FX Grant support: R01CA65662 and R33CA0951 (B.W. Futscher); Center Grants
   P30ES06694 and P30CA023074, and the BI05 interdisciplinary biotechnology
   center at the CA supported the Genomics Shared Service; and training
   grants ES007091 and CA09213 (T. Jensen).
CR BAYLIN SB, 1992, AIDS RES HUM RETROV, V8, P811
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   Chen ZX, 2007, BIOINFORMATICS, V23, P321, DOI 10.1093/bioinformatics/btl609
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   COLES C, 1992, CANCER RES, V52, P5291
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dammann R, 2001, CANCER RES, V61, P3105
   De Backer O, 1999, CANCER RES, V59, P3157
   De la Rosa-Velázquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024
   Decensi A, 2003, J MAMMARY GLAND BIOL, V8, P19, DOI 10.1023/A:1025779120649
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 2005, DEV CELL, V8, P31, DOI 10.1016/j.devcel.2004.10.018
   Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Huang THM, 1997, CANCER RES, V57, P1030
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jensen TJ, 2008, CARCINOGENESIS, V29, P1500, DOI 10.1093/carcin/bgn102
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202. Article published online before March 2002
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A
   Li J, 1996, CLIN CANCER RES, V2, P1619
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   VERTINO PM, 1993, CANCER RES, V53, P1684
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Whitman SP, 2005, BLOOD, V106, P345, DOI 10.1182/blood-2005-01-0204
   Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8
   Xie XH, 2007, P NATL ACAD SCI USA, V104, P7145, DOI 10.1073/pnas.0701811104
   YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0
NR 50
TC 121
Z9 134
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2008
VL 68
IS 20
BP 8616
EP 8625
DI 10.1158/0008-5472.CAN-08-1419
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 364GE
UT WOS:000260323400050
PM 18922938
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Müerköster, SS
   Werbing, V
   Koch, D
   Sipos, B
   Ammerpohl, O
   Kalthoff, H
   Tsao, MS
   Fölsch, UR
   Schäfer, H
AF Mueerkoester, Susanne Sebens
   Werbing, Veronika
   Koch, Dorothee
   Sipos, Bence
   Ammerpohl, Ole
   Kalthoff, Holger
   Tsao, Ming-Sound
   Foelsch, Ulrich R.
   Schaefer, Heiner
TI Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma
   -: Epigenetic downregulation of caspases
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE chemoresistance; pancreatic cancer; epigenetic gene silencing;
   myofibroblasts
ID NITRIC-OXIDE; CELL-LINES; DNA METHYLATION; S-NITROSYLATION; DEATH
   RECEPTOR; BREAST-CANCER; APOPTOSIS; EXPRESSION; STAT1; HYPERMETHYLATION
AB We recently reported on continuous tumor-stroma interactions essentially contributing to chemoresistance of pancreatic ductal adenocarinoma (PDAC) cells. As demonstrated here, long-term coculture with pancreatic myofibroblasts representing the main stromal compartment of PDAC resulted in a chemoresistant phenotype in the pancreatic ductal epithelial cell line H6c7 as well as in the chemosensitive PDAC cell line T3M4. This involved a reduced expression of caspases and the caspase inducing transcription factor STAT1, both caused by diminished gene transcription. The DNA-methylation inhibitor 5-azadeoxycytidine enhanced caspase and STAT1 expression in cocultured H6c7 and T3M4 cells along with an increased chemosensitivity, indicating a role for CpG DNA-hypermethylation in the downregulation of these crucial apoptosis mediators. Cocultured H6c7 and T3M4 cells exhibited elevated nuclear levels of DNA-methyltransferase-1 (DNMT1). Silencing of DNMT1 expression by siRNA increased expression of caspases and STAT1 and restored chemosensitivity. In SCID mice, tumors arising from coinoculated T3M4 cells and myofibroblasts (co-tumors) responded less towards chemotherapy than mono-tumors, exhibiting decreased apoptosis, no remission and reduced expression of caspases and STAT1. These data underscore the role of myofibroblasts in chemoresistance of PDAC and point to the importance of caspases as central target structures of epigenetic regulation in this scenario. Furthermore, an activated microenvironment might apparently promote the manifestation of chemoresistance already in premalignant precursor cells at early stages of PDAC tumorigenesis. (C) 2008 Wiley-Liss, Inc.
C1 [Mueerkoester, Susanne Sebens; Werbing, Veronika; Koch, Dorothee; Foelsch, Ulrich R.; Schaefer, Heiner] UKSH Campus Kiel, Lab Mol Gastroenterol & Hepatol, Clin Gen Internal Med, D-24105 Kiel, Germany.
   [Sipos, Bence] UKSH Campus Kiel, Dept Pathol, D-24105 Kiel, Germany.
   [Ammerpohl, Ole; Kalthoff, Holger] UKSH Campus Kiel, Mol Oncol Unit, Clin Gen Surg, D-24105 Kiel, Germany.
   [Tsao, Ming-Sound] Univ Hlth Network, Princess Margaret Hosp, Toronto, ON, Canada.
   [Tsao, Ming-Sound] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; Schleswig Holstein University Hospital; University of Kiel;
   Schleswig Holstein University Hospital; University of Toronto;
   University Health Network Toronto; Princess Margaret Cancer Centre;
   University of Toronto; University Health Network Toronto
RP Schäfer, H (通讯作者)，UKSH Campus Kiel, Lab Mol Gastroenterol & Hepatol, Clin Gen Internal Med, Schittenhelmstr 12, D-24105 Kiel, Germany.
EM hschaef@1med.uni-kiel.de
RI Schäfer, Heiner/C-1055-2011; Ammerpohl, Ole/G-2691-2010; Tsao,
   Ming/M-3503-2017; Sebens, Susanne/C-1222-2010; Kalthoff,
   Holger/B-1618-2010
OI Schafer, Heiner/0000-0001-6936-9090; Tsao, Ming/0000-0002-9160-5405
FU German Research Society DFG Scha 677/7-3; Hensel-Stiftung of the
   University Kiel
FX Grant sponsors: German Research Society DFG Scha 677/7-3,
   Hensel-Stiftung of the University Kiel.
CR Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673
   Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719
   Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044
   Friesen C, 1999, CELL DEATH DIFFER, V6, P471, DOI 10.1038/sj.cdd.4400512
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Grützmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696
   Harada K, 2002, CANCER RES, V62, P5897
   Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6
   Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jin F, 2005, GYNECOL ONCOL, V96, P531, DOI 10.1016/j.ygyno.2004.10.039
   KALTHOFF H, 1993, ONCOGENE, V8, P289
   Laimer K, 2007, CANCER, V110, P326, DOI 10.1002/cncr.22813
   Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672
   Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055
   Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8
   Lockhart AC, 2005, GASTROENTEROLOGY, V128, P1642, DOI 10.1053/j.gastro.2005.03.039
   Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122
   Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012
   Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018
   Müerköster SS, 2006, ONCOGENE, V25, P3973, DOI 10.1038/sj.onc.1209423
   Müerköster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860
   Müerköster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963
   Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890
   Peng DF, 2005, CANCER SCI, V96, P403, DOI 10.1111/j.1349-7006.2005.00071.x
   Schäfer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131
   Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001
   Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200
   Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956
   Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462
   Ueki T, 2000, CANCER RES, V60, P1835
   Widschwendter A, 2002, CLIN CANCER RES, V8, P3065
   Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
NR 37
TC 58
Z9 64
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 15
PY 2008
VL 123
IS 8
BP 1751
EP 1760
DI 10.1002/ijc.23703
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 352TA
UT WOS:000259519100003
PM 18649362
DA 2025-01-12
ER

PT J
AU Wang, RH
   Zheng, Y
   Kim, HS
   Xu, XL
   Cao, L
   Luhasen, T
   Lee, MH
   Xiao, CY
   Vassilopoulos, A
   Chen, WP
   Gardner, K
   Man, YG
   Hung, MC
   Finkel, T
   Deng, CX
AF Wang, Rui-Hong
   Zheng, Yin
   Kim, Hyun-Seok
   Xu, Xiaoling
   Cao, Liu
   Luhasen, Tyler
   Lee, Mi-Hye
   Xiao, Cuiying
   Vassilopoulos, Athanassios
   Chen, Weiping
   Gardner, Kevin
   Man, Yan-Gao
   Hung, Mien-Chie
   Finkel, Toren
   Deng, Chu-Xia
TI Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated
   Tumorigenesis
SO MOLECULAR CELL
LA English
DT Article
ID NF-KAPPA-B; BREAST-CANCER; CELL-CYCLE; CHEMOPREVENTIVE AGENT;
   TRANSCRIPTION FACTORS; CALORIE RESTRICTION; SPINDLE CHECKPOINT;
   REGULATES SIRT1; RESVERATROL; ACTIVATION
AB Germline mutations of BRCA1 predispose women to breast and ovarian cancers. However, the downstream mediators of BRCA1 function in tumor suppression remain elusive. We found that human BRCA1-associated breast cancers have lower levels of SIRT1 than their normal controls. We further demonstrated that mammary tumors from Brca1 mutant mice have low levels of Sirt1 and high levels of Survivin, which is reversed by induced expression of Brca1. BRCA1 binds to the SIRT1 promoter and increases SIRT1 expression, which in turn inhibits Survivin by changing the epigenetic modification of histone H3. Absence of SIRT1 blocks the regulation of Survivin by BRCA1. Furthermore, we demonstrated that activation of Sirt1 and inhibition of Survivin expression by resveratrol elicit a more profound inhibitory effect on Brca1 mutant cancer cells than on Brca1-wild-type cancer cells both in vitro and in vivo. These findings suggest that resveratrol treatment serves as an excellent strategy for targeted therapy for BRCA1-associated breast cancer.
C1 [Wang, Rui-Hong; Zheng, Yin; Kim, Hyun-Seok; Xu, Xiaoling; Cao, Liu; Luhasen, Tyler; Lee, Mi-Hye; Xiao, Cuiying; Vassilopoulos, Athanassios; Deng, Chu-Xia] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
   [Chen, Weiping] NIDDK, Microarray Core Facil, NIH, Bethesda, MD 20892 USA.
   [Gardner, Kevin] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA.
   [Finkel, Toren] NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA.
   [Man, Yan-Gao] Armed Forces Inst Pathol, Dept Gynecol & Breast Pathol, Washington, DC 20306 USA.
   [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of
   Health (NIH) - USA; NIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); National Institutes of Health (NIH) -
   USA; NIH National Heart Lung & Blood Institute (NHLBI); United States
   Department of Defense; University of Texas System; UTMD Anderson Cancer
   Center
RP Deng, CX (通讯作者)，NIDDK, Genet Dev & Dis Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
EM chuxiad@bdg10.niddk.nih.gov
RI Hung, Mien-Chie/ABD-5911-2021; Chen, Weiping/C-9550-2011; deng,
   chuxia/N-6713-2016; Xu, Xiaoling/JTT-9808-2023
OI Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mi-Hye/0000-0002-5484-3383
FU National Institute of Diabetes, Digestive and Kidney Diseases, National
   Institutes of Health, USA.
FX We thank Dr. Zhi-Ming Zheng for critical reading of the manuscript, Dr.
   Stina Oredsson for the L56Br-C1 cell line, and Dr. Junjie Chen for the
   HCC1937 and HCC1937-BRCA1-WT cell lines. This work was supported by the
   Intramural Research Program of the National Institute of Diabetes,
   Digestive and Kidney Diseases, National Institutes of Health, USA.
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003
   Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293
   Aziz MH, 2005, PHOTOCHEM PHOTOBIOL, V81, P25, DOI 10.1562/2004-08-13-RA-274.1
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651
   Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115
   CAP L, 2003, GENE DEV, V17, P201
   CAP L, 2007, CARCINOGENESIS, V28, P1401
   Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357
   Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Coumoul X, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh083
   Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331
   Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010
   Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713
   Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Eccles DM, 2005, LANCET ONCOL, V6, P705, DOI 10.1016/S1470-2045(05)70318-1
   Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7
   Guarente L, 2000, GENE DEV, V14, P1021
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hsieh TC, 2000, ANTICANCER RES, V20, P225
   Johannsson OT, 2003, LAB INVEST, V83, P387, DOI 10.1097/01.LAB.0000060030.10652.8C
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   Kennedy SM, 2003, BRIT J CANCER, V88, P1077, DOI 10.1038/sj.bjc.6600776
   Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307
   Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731
   Sato A, 2006, INT J ONCOL, V28, P841
   Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5
   Shukla V, 2006, CANCER RES, V66, P7151, DOI 10.1158/0008-5472.CAN-05-4570
   Simeone AM, 2005, CARCINOGENESIS, V26, P1000, DOI 10.1093/carcin/bgi038
   Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001
   Tominaga Y, 2007, CELL DEATH DIFFER, V14, P472, DOI 10.1038/sj.cdd.4402037
   Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101
   WANG RH, 2008, CANC CELL IN PRESS
   Whitsett Timothy, 2006, J Carcinog, V5, P15, DOI 10.1186/1477-3163-5-15
   Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753
   Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x
   Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192
NR 55
TC 280
Z9 323
U1 0
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD OCT 10
PY 2008
VL 32
IS 1
BP 11
EP 20
DI 10.1016/j.molcel.2008.09.011
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 363BF
UT WOS:000260240200002
PM 18851829
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Bhawal, UK
   Sugiyama, M
   Nomura, Y
   Kuniyasu, H
   Tsukinoki, K
AF Bhawal, Ujjal K.
   Sugiyama, Masaru
   Nomura, Yuji
   Kuniyasu, Hiroki
   Tsukinoki, Keiichi
TI Loss of 14-3-3 Sigma Protein Expression and Presence of Human
   Papillomavirus Type 16 E6 in Oral Squamous Cell Carcinoma
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID PRIMARY HUMAN KERATINOCYTES; EPIGENETIC INACTIVATION; 14-3-3-PROTEIN
   FAMILY; BREAST-CANCER; DNA; ASSOCIATION; EVOLUTION; SURVIVAL; CLONING;
   HEAD
AB Objective: To confirm the expression of 14-3-3 sigma in oral malignant lesions and in adjacent nonmalignant oral epithelium to provide a clue to the involvement in the cell cycle progression and note any association with human papillomavirus (HPV) status. 14-3-3 Sigma plays important roles in a wide range of vital regulatory processes, including signal transduction, apoptosis, cell cycle progression, and DNA replication. 14-3-3 Sigma is an exclusive epithelial marker, and data on its expression in different malignancies are very scarce.
   Design: Western blotting, immunohistochemical analysis, and polymerase chain reaction were performed.
   Setting: An academic university laboratory.
   Patients: Adults with known oral squamous cell carcinomas (SCCs) that were surgically resected.
   Main Outcome Measures: The DNA of HPV-16 E6 was detected by polymerase chain reaction, and protein expression of 14-3-3 sigma was evaluated by Western blot and inummohistochemical analysis.
   Results: The inummoreactive 14-3-3 sigma protein was detected mainly in the cytoplasm of differentiated squamous cells of oral SCC lesions as well as adjacent nonmalignant squamous mucosa. Immunoreactivity for 14-3-3 sigma was observed in 93% of SCC lesions (27 of 29), including HPV-negative cases. No significant association was observed between 14-3-3 sigma expression and clinicopathologic parameters. A statistically significant correlation was found between 14-3-3 sigma protein expression and the Ki-67 labeling index. 14-3-3 Sigma expression was correlated inversely with HPV-16 E6.
   Conclusion: These findings suggest that 14-3-3 sigma may act as a negative regulator of the cell cycle progression in oral SCC.
C1 [Bhawal, Ujjal K.; Tsukinoki, Keiichi] Kanagawa Dent Coll, Dept Diagnost Sci, Div Pathol, Yokosuka, Kanagawa 2388580, Japan.
   [Bhawal, Ujjal K.; Tsukinoki, Keiichi] Kanagawa Dent Coll, High Tech Res Ctr, Yokosuka, Kanagawa 2388580, Japan.
   [Bhawal, Ujjal K.; Kuniyasu, Hiroki] Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan.
   [Sugiyama, Masaru] Hiroshima Univ, Sch Oral Hlth Sci, Dept Oral Hlth Res, Fac Dent, Hiroshima, Japan.
   [Nomura, Yuji] Hiroshima Univ, Grad Sch Biomed Sci, Dept Biomat Sci, Hiroshima, Japan.
C3 Kanagawa Dental College; Kanagawa Dental College; Nara Medical
   University; Hiroshima University; Hiroshima University
RP Bhawal, UK (通讯作者)，Kanagawa Dent Coll, Dept Diagnost Sci, Div Pathol, Yokosuka, Kanagawa 2388580, Japan.
EM bhawal2002@yahoo.co.in
RI Sugiyama, Masaru/IZE-3770-2023
FU Ministry of Education, Sports, and Science of Japan [16390590];
   Grants-in-Aid for Scientific Research [16390590] Funding Source: KAKEN
FX This work was supported by grant 16390590 from the Ministry of
   Education, Sports, and Science of Japan (Dr Sugiyama).
CR Akahira J, 2004, CLIN CANCER RES, V10, P2687, DOI 10.1158/1078-0432.CCR-03-0510
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Gasco M, 2002, CANCER RES, V62, P2072
   Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709
   Haraf DJ, 1996, CLIN CANCER RES, V2, P755
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   Nakanishi Kozo, 1997, Human Antibodies, V8, P189
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107
   Sano T, 2004, PATHOL INT, V54, P743, DOI 10.1111/j.1440-1827.2004.01747.x
   Schwartz SR, 2001, OTOLARYNG HEAD NECK, V125, P1, DOI 10.1067/mhn.2001.116979
   Shoji Masahiro, 1994, Human Antibodies and Hybridomas, V5, P123
   Sugiyama M, 2003, ORAL SURG ORAL MED O, V95, P594, DOI 10.1067/moe.2003.36
   Sugiyama M, 2007, BRIT J ORAL MAX SURG, V45, P116, DOI 10.1016/j.bjoms.2006.04.012
   Suzuki H, 2000, CANCER RES, V60, P4353
   Tanaka K, 2004, INT J ONCOL, V25, P1591
   Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9
   Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76
   Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008
   Wang WF, 1996, J MOL EVOL, V43, P384
   WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286
NR 27
TC 9
Z9 10
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0886-4470
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD OCT
PY 2008
VL 134
IS 10
BP 1055
EP 1059
DI 10.1001/archotol.134.10.1055
PG 5
WC Otorhinolaryngology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Otorhinolaryngology; Surgery
GA 359KP
UT WOS:000259985900005
PM 18936350
DA 2025-01-12
ER

PT J
AU Nimmrich, I
   Sieuwerts, AM
   Gelder, MEM
   Schwope, I
   Vries, JB
   Harbeck, N
   Koenig, T
   Hartmann, O
   Kluth, A
   Dietrich, D
   Magdolen, V
   Portengen, H
   Look, MP
   Klijn, JGM
   Lesche, R
   Schmitt, M
   Maier, S
   Foekens, JA
   Martens, JWM
AF Nimmrich, Inko
   Sieuwerts, Anieta M.
   Gelder, Marion E. Meijer-van
   Schwope, Ina
   Vries, Joan Bolt-de
   Harbeck, Nadia
   Koenig, Thomas
   Hartmann, Oliver
   Kluth, Antje
   Dietrich, Dimo
   Magdolen, Viktor
   Portengen, Henk
   Look, Maxime P.
   Klijn, Jan G. M.
   Lesche, Ralf
   Schmitt, Manfred
   Maier, Sabine
   Foekens, John A.
   Martens, John W. M.
TI DNA hypermethylation of <i>PITX2</i> is a marker of poor prognosis in
   untreated lymph node-negative hormone receptor-positive breast cancer
   patients
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; DNA-methylation; estrogen receptor; PITX2; prognosis
ID METHYLATION ANALYSIS; GENE; ESTROGEN; IDENTIFICATION; ASSOCIATION;
   EPIGENETICS; EXPRESSION; PROMOTER; DISEASE; ALPHA
AB Background In this study, we evaluated if PITX2 DNA methylation is a marker for disease recurrence in lymph node-negative (LNN), steroid hormone receptor-positive (HR+) breast cancer patients. In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression. Patients and methods PITX2 DNA-methylation was measured in tumor tissue from 412 LNN/HR+ breast cancer patients who had not received any adjuvant systemic treatment. In addition, PITX2 DNA-methylation and mRNA expression was evaluated in 32 breast cancer cell lines. Results In univariate Cox regression analysis, DNA-methylation of PITX2 as a continuous variable was associated with early distant metastasis (HR = 1.71; P < 0.01) and poor overall survival (HR = 1.71; P < 0.01). In multivariate analysis together with the established prognostic factors age, tumor size and tumor grade, and steroid hormone receptor levels, both associations retained their significance (for MFS, HR = 1.74; P < 0.01; for OS, HR = 1.46; P = 0.02). In the breast cancer cell lines, PITX2 DNA methylation was inversely association with PITX2A and PITX2B mRNA expression (P < 0.01). Conclusions Hypermethylation of PITX2 is, in cell lines, negatively associated with PITX2 mRNA expression and, in clinical specimens, positively associated with breast cancer disease progression.
C1 [Sieuwerts, Anieta M.; Gelder, Marion E. Meijer-van; Vries, Joan Bolt-de; Portengen, Henk; Look, Maxime P.; Klijn, Jan G. M.; Foekens, John A.; Martens, John W. M.] Erasmus MC, Josephine Nefkens Inst, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands.
   [Nimmrich, Inko; Schwope, Ina; Koenig, Thomas; Hartmann, Oliver; Kluth, Antje; Dietrich, Dimo; Lesche, Ralf; Maier, Sabine] Epigen AG, Dept Biomed Res & Dev & Technol Dev, Berlin, Germany.
   [Harbeck, Nadia; Magdolen, Viktor; Schmitt, Manfred] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany.
C3 Erasmus University Rotterdam; Erasmus MC; Technical University of Munich
RP Martens, JWM (通讯作者)，Erasmus MC, Josephine Nefkens Inst, Dept Med Oncol, Room Be 400,POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM j.martens@erasmusmc.nl
RI Koenig, Thomas/F-6454-2010; Harbeck, Nadia/JOZ-6178-2023
FU European Union Sixth Framework Program [LSHC-CT-2003-504586]
FX We would like to thank Dr. M. Schutte ( Dept. Medical Oncology. Erasmus
   MC, Rotterdam, The Netherlands) for providing genomic DNA from all the
   cell lines included in the study. The European Union Sixth Framework
   Program ( LSHC-CT-2003-504586) supported this project.
CR Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Esteller M, 2001, CANCER RES, V61, P3225
   FOEKENS JA, 1989, CANCER RES, V49, P5823
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   GASPARINI G, 1993, J NATL CANCER I, V85, P1206, DOI 10.1093/jnci/85.15.1206
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X
   Kitamura K, 1999, DEVELOPMENT, V126, P5749
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lewin J, 2004, BIOINFORMATICS, V20, P3005, DOI 10.1093/bioinformatics/bth346
   Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064
   Martens JWM, 2003, THROMB HAEMOSTASIS, V89, P393
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   PERSYN JP, 1980, EUR J CANCER, V16, P1513
   Resnick EM, 2000, J BIOL CHEM, V275, P7158, DOI 10.1074/jbc.275.10.7158
   Schausi D, 2003, ENDOCRINOLOGY, V144, P2845, DOI 10.1210/en.2003-0024
   Schweickert A, 2000, MECH DEVELOP, V90, P41, DOI 10.1016/S0925-4773(99)00227-0
   Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392
   Shiratori H, 2001, MOL CELL, V7, P137, DOI 10.1016/S1097-2765(01)00162-9
   Sieuwerts AM, 2005, CLIN CANCER RES, V11, P7311, DOI 10.1158/1078-0432.CCR-05-0560
   van Dijk JP, 2002, AM J PATHOL, V161, P807, DOI 10.1016/S0002-9440(10)64240-X
   WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 30
TC 82
Z9 93
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2008
VL 111
IS 3
BP 429
EP 437
DI 10.1007/s10549-007-9800-8
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 347FP
UT WOS:000259126300005
PM 17965955
DA 2025-01-12
ER

PT J
AU Xu, J
   Souter, LH
   Chambers, AF
   Rodenhiser, DI
   Tuck, AB
AF Xu, Jie
   Souter, Lesley H.
   Chambers, Ann F.
   Rodenhiser, David I.
   Tuck, Alan B.
TI Distinct karyotypes in three breast cancer cell lines-21PTCi, 21NTCi,
   and 21MT-1-derived from the same patient and representing different
   stages of tumor progression
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID OSTEOPONTIN; EXPRESSION; LINES
AB Three breast carcinoma cell lines - 21PTCi, 21NTCi, and 21MT-1 - all originating from a 36-year-old woman with metastatic breast cancer, have been characterized previously as stably representing different stages of progression: (nontumorigenic [21PTCi]; tumorigenic, nonmetastatic [21NTCi]; and tumorigenic, weakly metastatic [21MT-1]). These cell lines were investigated for cytogenetic characteristics using G-banding and spectral karyotyping. All three cell lines have multiple chromosome aberrations, but they differ in the types of rearrangements and breakpoints. 21PTCi cells have a modal number (mn) of 56, with 55 types of aberrations, including 16 numeric and 39 structural. 21NTCi cells have a mn of 56, with 70 types of aberrations, including 19 numerical and 51 structural. Finally, 21MT-1 cells have a mn of 54, with 43 types of aberrations, including 14 numerical and 29 structural. The most common rearrangements differ in each cell line [i.e., der(X)t(X;3), der(4)t(1;4), del(6q) and der(19)t(17;19)(q11.2;q13.4) in 21PTCi; der(4)t(1;4), der(12)t(12;15) and -16 in 21NTCi; and der(1)t(1;10), +5, der(6)t(6;7), der(11)t(11;13), -20, and der(20)t(20;21) in 21MT-1]. This cytogenetic result is consistent with previous findings in that the three cell lines represent different stages of tumor progression. We hypothesize that the cytogenetic changes in these cell lines may be related to their distinct biologic characteristics. These three cell lines, with their different karyotypes and biologic characteristics, provide a vital tool for further study of the genetic and epigenetic events involved in transitions between premalignant and malignant phenotypes. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Xu, Jie] Univ Western Ontario, London Hlth Sci Ctr, Cytogenet Lab, London, ON N6A 4G5, Canada.
   [Souter, Lesley H.; Chambers, Ann F.; Rodenhiser, David I.; Tuck, Alan B.] Univ Western Ontario, London Reg Canc Program, London, ON N6A 4G5, Canada.
   [Souter, Lesley H.; Tuck, Alan B.] Univ Western Ontario, Dept Pathol, London Hlth Sci Ctr, London, ON N6A 4G5, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Childrens Hlth Res Inst, Schulich Sch Med & Dent, London, ON N6A 4G5, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON N6A 4G5, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Dept Oncol, Schulich Sch Med & Dent, London, ON N6A 4G5, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Dept Paediat, Schulich Sch Med & Dent, London, ON N6A 4G5, Canada.
C3 London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); London
   Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Xu, J (通讯作者)，Univ Western Ontario, London Hlth Sci Ctr, Cytogenet Lab, 375 S St,Room N258, London, ON N6A 4G5, Canada.
EM Jie.Xu@lhsc.on.ca
RI Chambers, Ann/L-6285-2015
OI Chambers, Ann/0000-0002-9509-5123
FU Canadian Breast Cancer Foundation [016506]; Cancer Research Society;
   Canada Research Chairs Program; Canadian Foundation of Innovation
FX We thank Carol Richmond, Brenda Hamilton, and Shirley Nan (Cytogenetics,
   London Health Science Centre) for excellent technical assistance. This
   research was funded by grant no. 016506 from the Canadian Breast Cancer
   Research Alliance "Special Competition in New Approaches to Metastatic
   Disease" with special funding support from the Canadian Breast Cancer
   Foundation,and The Cancer Research Society. A.F.C. is Canada Research
   Chair in Oncology and is supported by the Canada Research Chairs
   Program. The molecular cytogenetics infrastructure used in this study
   was funded by the Canadian Foundation of Innovation via the Canadian
   Molecular Cytogenetics Platform.
CR BAND V, 1990, CANCER RES, V50, P7351
   BAND V, 1989, GENE CHROMOSOME CANC, V1, P48, DOI 10.1002/gcc.2870010109
   Furger KA, 2003, MOL CANCER RES, V1, P810
   HEIM S, 1995, CANC CYTOGENETICS CH
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Kerangueven F, 1997, CANCER RES, V57, P5469
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799
   WAZER DE, 1993, INT J RADIAT ONCOL, V26, P81, DOI 10.1016/0360-3016(93)90176-V
   Xu J, 2008, CANCER GENET CYTOGEN, V181, P1, DOI 10.1016/j.cancergencyto.2007.05.030
NR 10
TC 0
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD OCT 1
PY 2008
VL 186
IS 1
BP 33
EP 40
DI 10.1016/j.cancergencyto.2008.05.012
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 360EC
UT WOS:000260039000006
PM 18786440
DA 2025-01-12
ER

PT J
AU Guerra, E
   Trerotola, M
   Dell'Arciprete, R
   Bonasera, V
   Palombo, B
   El-Sewedy, T
   Ciccimarra, T
   Crescenzi, C
   Lorenzini, F
   Rossi, C
   Vacca, G
   Lattanzio, R
   Piantelli, M
   Alberti, S
AF Guerra, Emanuela
   Trerotola, Marco
   Dell'Arciprete, Roberta
   Bonasera, Veronica
   Palombo, Barbara
   El-Sewedy, Tarek
   Ciccimarra, Tommaso
   Crescenzi, Carlo
   Lorenzini, Franco
   Rossi, Cosmo
   Vacca, Giovanna
   Lattanzio, Rossano
   Piantelli, Mauro
   Alberti, Saverio
TI A bicistronic <i>CYCLIN D1-TROP2</i> mRNA chimera demonstrates a novel
   oncogenic mechanism in human cancer
SO CANCER RESEARCH
LA English
DT Article
ID CELL-SURFACE GLYCOPROTEIN; CYCLIN D1; HUMAN CARCINOMAS; HUMAN BREAST;
   GENE; EXPRESSION; TROP-2; IDENTIFICATION; PROTOONCOGENE; SEQUENCE
AB A chimeric CYCLIN D1-TROP2 mRNA was isolated from human ovarian and mammary cancer cells. The CYCLIN D1-TROP2 mRNA was shown to be a potent oncogene as it transforms naive, primary cells in vitro and induces aggressive tumor growth in vivo in cooperation with activated RAS. Silencing of the chimeric mRNA inhibits the growth of breast cancer cells. The CYCLIN D1-TROP2 mRNA was expressed by a large fraction of the human gastrointestinal, ovarian, and endometrial tumors analyzed. It is most frequently detected in intestinal cell aneuploid cancers and it is coexpressed with activated RAS oncogenes, consistent with a cooperative transforming activity in human cancers. The chimeric mRNA is a bicistronic transcript of posttranscriptional origin that independently translates the Cyclin D1 and Trop-2 proteins. This is a novel mechanism of CYCLIN D1 activation that achieves the truncation of the CYCLIN D1 mRNA in the absence of chromosomal rearrangements. This leads to a higher CYCLIN D1 mRNA stability, with inappropriate expression during the cell cycle. The stabilized CYCLIN D1 mRNA cooperates with TROP2 in stimulating the growth of the expressing cells. These findings show a novel epigenetic, oncogenic mechanism, which seems to be widespread in human cancers.
C1 [Guerra, Emanuela; Trerotola, Marco; Bonasera, Veronica; Palombo, Barbara; Rossi, Cosmo; Vacca, Giovanna; Lattanzio, Rossano; Piantelli, Mauro; Alberti, Saverio] Univ G Annunzio Fdn, Ctr Excellence Res Aging, Dept Oncol & Neurosci, Unit Canc Pathol, I-66100 Chieti, Italy.
   [Guerra, Emanuela; Trerotola, Marco; Bonasera, Veronica; Palombo, Barbara; Rossi, Cosmo; Vacca, Giovanna; Lattanzio, Rossano; Piantelli, Mauro; Alberti, Saverio] Univ G Annunzio Fdn, CeSI, I-66100 Chieti, Italy.
   [Guerra, Emanuela; Trerotola, Marco; Dell'Arciprete, Roberta; Palombo, Barbara; El-Sewedy, Tarek; Ciccimarra, Tommaso; Crescenzi, Carlo; Lorenzini, Franco; Vacca, Giovanna; Alberti, Saverio] Inst Mario Negri Sud, Dept Cell Biol & Oncol, Expt Oncol Lab, Chieti, Italy.
   [Rossi, Cosmo] Inst Mario Negri Sud, Anim Care Unit & Expt Models, Chieti, Italy.
RP Alberti, S (通讯作者)，Univ G Annunzio Fdn, Ctr Excellence Res Aging, Dept Oncol & Neurosci, Unit Canc Pathol, Via Colle dell Ara, I-66100 Chieti, Italy.
EM s.alberti@unich.it
RI Guerra, Emanuela/HOF-2772-2023; Sewedy, Tarek/N-3945-2018; Trerotola,
   Marco/J-9015-2016; Lattanzio, Rossano/K-1927-2018; Alberti,
   Saverio/M-4511-2014
OI elsewedy, tarek/0000-0003-2937-0657; Guerra,
   Emanuela/0000-0002-7091-8621; Piantelli, Mauro/0000-0003-0154-482X;
   Trerotola, Marco/0000-0003-1855-7002; Lattanzio,
   Rossano/0000-0001-9803-4476; Alberti, Saverio/0000-0002-4647-6042
FU Italian Association for Cancer Research (Italy); Fondazione of the Cassa
   di Risparmio della Provincia di Chieti; Association for the Application
   of Biotechnology in Oncology [VE01D0019]; Marie Curie Transfer of
   Knowledge Fellowship-European Community's Sixth Framework Programme
   [014541]
FX Italian Association for Cancer Research (Italy), Fondazione of the Cassa
   di Risparmio della Provincia di Chieti, Association for the Application
   of Biotechnology in Oncology (ABO and ABO Project S.p.A., grant no.
   VE01D0019), and Marie Curie Transfer of Knowledge Fellowship-European
   Community's Sixth Framework Programme, contract number 014541.
CR ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539
   Back SH, 2006, J BIOL CHEM, V281, P18691, DOI 10.1074/jbc.M602030200
   BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419
   BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010
   Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001
   Bringuier PP, 1996, ONCOGENE, V12, P1747
   Buratti E, 2006, NUCLEIC ACIDS RES, V34, P3494, DOI 10.1093/nar/gkl498
   Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891
   El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5
   FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520
   Giavazzi R, 1988, Adv Exp Med Biol, V233, P39
   GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547
   HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709
   Horiuchi T, 2006, BIOL CELL, V98, P135, DOI 10.1042/BC20050002
   JIANG W, 1992, CANCER RES, V52, P2980
   Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100
   KLEIN CE, 1990, J INVEST DERMATOL, V95, P74, DOI 10.1111/1523-1747.ep12873988
   LEBWOHL DE, 1994, ONCOGENE, V9, P1925
   Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007
   LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27
   Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5
   MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205
   MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0
   MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1
   Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733
   Novo FJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-33
   Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961
   Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2
   Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3
   Paushkin SV, 2004, CELL, V117, P311, DOI 10.1016/S0092-8674(04)00342-3
   Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9
   RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204
   Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640
   Ripani E, 1998, INT J CANCER, V76, P671
   Romani A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng017
   SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927
   Terrinoni A, 2001, GENE CHROMOSOME CANC, V31, P209, DOI 10.1002/gcc.1137
   vanErp PEJ, 1996, ANAL CELL PATHOL, V11, P43
   VELLARD M, 1991, ONCOGENE, V6, P505
   WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D
   Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785
   Zhang C, 2003, DNA CELL BIOL, V22, P303, DOI 10.1089/104454903322216653
   Zhang H, 2007, P NATL ACAD SCI USA, V104, P4618, DOI 10.1073/pnas.0700258104
NR 45
TC 78
Z9 92
U1 3
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2008
VL 68
IS 19
BP 8113
EP 8121
DI 10.1158/0008-5472.CAN-07-6135
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 360AR
UT WOS:000260029900050
PM 18829570
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Gao, W
   Kondo, Y
   Shen, L
   Shimizu, Y
   Sano, T
   Yamao, K
   Natsume, A
   Goto, Y
   Ito, M
   Murakami, H
   Osada, H
   Zhang, JX
   Issa, JPJ
   Sekido, Y
AF Gao, Wentao
   Kondo, Yutaka
   Shen, Lanlan
   Shimizu, Yasuhiro
   Sano, Tsuyoshi
   Yamao, Kenji
   Natsume, Atsushi
   Goto, Yasuhiro
   Ito, Motokazu
   Murakami, Hideki
   Osada, Hirotaka
   Zhang, Jiexin
   Issa, Jean-Pierre J.
   Sekido, Yoshitaka
TI Variable DNA methylation patterns associated with progression of disease
   in hepatocellular carcinomas
SO CARCINOGENESIS
LA English
DT Article
ID CPG ISLAND HYPERMETHYLATION; CHRONIC HEPATITIS; LIVER-CIRRHOSIS;
   BISULFITE PCR; BREAST-CANCER; GENE; CHROMATIN; GENOME; CELLS; WIDE
AB Hepatocellular carcinoma (HCC) most commonly arises from chronic inflammation due to viral infection, as a result of genetic and epigenetic abnormalities. A global picture of epigenetic changes in HCC is lacking. We used methylated CpG island amplification microarrays (MCAMs) to study 6458 CpG islands in HCC and adjacent preneoplastic tissues [chronic hepatitis (CH) or liver cirrhosis (LC)] in comparison with normal liver tissues where neither viral infection nor hepatitis has existed. MCAM identified 719 (11%) prominent genes of hypermethylation in HCCs. HCCs arising from LC had significantly more methylation than those arising from CH (1249 genes or 19% versus 444 genes or 7%, P < 0.05). There were four patterns of aberrant methylation: Type I (4%, e. g. matrix metalloproteinase 14) shows a substantially high methylation level in adjacent tissue and does not increase further in cancer. Type II (55%, e. g. RASSF1A) shows progressively increasing methylation from adjacent tissue to HCC. Type III (4%, e. g. GNA14) shows decreased methylation in adjacent tissue but either similar or increased methylation in HCC. Type IV (37%, e. g. CDKN2A) shows low levels of methylation in normal tissue and adjacent tissue but high levels in HCC. These DNA methylation changes were confirmed by quantitative pyrosequencing methylation analysis in representative 24 genes and were analyzed for correlation with clinicopathological parameters in 38 patients. Intriguingly, methylation in the Type IV genes is characteristic of moderately/ poorly differentiated cancer. Our global epigenome analysis reveals distinct patterns of methylation that are probably to represent different pathophysiologic processes in HCCs.
C1 [Gao, Wentao; Kondo, Yutaka; Goto, Yasuhiro; Ito, Motokazu; Murakami, Hideki; Osada, Hirotaka; Sekido, Yoshitaka] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Gao, Wentao] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing 210029, Peoples R China.
   [Shen, Lanlan; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Shimizu, Yasuhiro; Sano, Tsuyoshi] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Yamao, Kenji] Aichi Canc Ctr Hosp, Dept Gastroenterol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.
   [Natsume, Atsushi] Nagoya Univ, Sch Med, Dept Neurosurg, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Zhang, Jiexin] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
C3 Aichi Cancer Center; Nanjing Medical University; University of Texas
   System; UTMD Anderson Cancer Center; Aichi Cancer Center; Aichi Cancer
   Center; Nagoya University; University of Texas System; UTMD Anderson
   Cancer Center
RP Kondo, Y (通讯作者)，Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.
EM ykondo@aichi-cc.jp
RI Sekido, Yoshitaka/P-9756-2015; Osada, Hirotaka/G-4553-2011; Natsume,
   Atsushi/I-7364-2014
OI Shen, Lanlan/0000-0002-1532-5807; Sekido, Yoshitaka/0000-0002-2428-3848;
   Issa, Jean-Pierre/0000-0003-2258-5030; Natsume,
   Atsushi/0000-0002-9113-0470
FU Ministry of Health, Labor and Welfare of Japan; Japan Society for
   Promotion of Science; Japan-China Sasakawa Medical Fellowship
FX Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and
   Welfare of Japan; Grant-in-Aid for Scientific Research from Japan
   Society for Promotion of Science; Japan-China Sasakawa Medical
   Fellowship to W. G.
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Du J, 2008, J CELL BIOCHEM, V103, P1584, DOI 10.1002/jcb.21547
   Eads CA, 1999, CANCER RES, V59, P2302
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ekins S, 2007, METH MOL B, V356, P319
   Estécio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   He LS, 1998, CANCER RES, V58, P4238
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X
   Kaneto H, 2001, GUT, V48, P372, DOI 10.1136/gut.48.3.372
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x
   Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   LENCIONI R, 1994, ITAL J GASTROENTEROL, V26, P163
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lin CH, 2001, CANCER RES, V61, P4238
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009
   MURAKAMI Y, 1991, CANCER RES, V51, P5520
   Myöhänen SK, 1998, CANCER RES, V58, P591
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181
   Shen LL, 2007, BIOTECHNIQUES, V42, P48, DOI 10.2144/000112312
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   Toyota M, 1999, CANCER RES, V59, P2307
   Toyota M, 1999, CANCER RES, V59, P4535
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
NR 47
TC 104
Z9 112
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2008
VL 29
IS 10
BP 1901
EP 1910
DI 10.1093/carcin/bgn170
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 356HD
UT WOS:000259768400007
PM 18632756
OA Bronze
DA 2025-01-12
ER

PT J
AU Cheng, YW
   Pincas, H
   Bacolod, MD
   Schemmann, G
   Giardina, SF
   Huang, J
   Barral, S
   Idrees, K
   Khan, SA
   Zeng, Z
   Rosenberg, S
   Notterman, DA
   Ott, J
   Paty, P
   Barany, F
AF Cheng, Yu-Wei
   Pincas, Hanna
   Bacolod, Manny D.
   Schemmann, Gunter
   Giardina, Sarah F.
   Huang, Jianmin
   Barral, Sandra
   Idrees, Kamran
   Khan, Sajid A.
   Zeng, Zhaoshi
   Rosenberg, Shoshana
   Notterman, Daniel A.
   Ott, Jurg
   Paty, Philip
   Barany, Francis
TI CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal
   Abnormalities in Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MICROSATELLITE INSTABILITY; BIALLELIC INACTIVATION; DNA METHYLATION;
   COLON-CANCER; BREAST-CANCER; BRAF MUTATION; GENE; TUMORS;
   HYPERMETHYLATION; EPIGENETICS
AB Purpose: Aberrant promoter methylation and genomic instability occur frequently during colorectal cancer development. CpG island methylator phenotype (CIMP) has been shown to associate with microsatellite instability, and BRAF mutation and is often found in the right-side colon. Nevertheless, the relative importance of CIMP and chromosomal instability (CIN) for tumorigenesis has yet to be thoroughly investigated in sporadic colorectal cancers.
   Experimental Design: We determined CIMP in 161 primary colorectal cancers and 66 matched normal mucosae using a quantitative bisulfite/PCR/ligase detection reaction (LDR)/Universal Array assay. The validity of CIMP was confirmed in a subset of 60 primary tumors using MethyLight assay and five independent markers. In parallel, CIN was analyzed in the same study cohort using Affymetrix 50K Human Mapping arrays.
   Results: The identified CIMP-positive cancers correlate with microsatellite instability (P = 0.075) and the BRAF mutation V600E (P = 0.00005). The array-based high-resolution analysis of chromosomal aberrations indicated that the degree of aneuploidy is spread over a wide spectrum among analyzed colorectal cancers. Whether CIN was defined by copy number variations in selected microsatellite loci (criterion 1) or considered as a continuous variable (criterion 2), CIMP-positive samples showed a strong correlation with low-degree chromosomal aberrations (P = 0.075 and P = 0.012, respectively). Similar correlations were observed when CIMP was determined by MethyLight assay (P = 0.001 and P = 0.013, respectively).
   Conclusion: CIMP-positive tumors generally possess lower chromosomal aberrations, which may only be revealed using a genome-wide approach. The significant difference in the degree of chromosomal aberrations between CIMP-positive and the remainder of samples suggests that epigenetic (CIMP) and genetic (CIN) abnormalities may arise from independent molecular mechanisms of tumor progression.
C1 [Cheng, Yu-Wei; Pincas, Hanna; Bacolod, Manny D.; Giardina, Sarah F.; Huang, Jianmin; Barany, Francis] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
   [Barral, Sandra] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA.
   [Idrees, Kamran; Khan, Sajid A.; Zeng, Zhaoshi; Rosenberg, Shoshana; Paty, Philip] Mem Sloan Kettering Canc Ctr, Colorectal Surg Serv, Dept Surg, New York, NY 10021 USA.
   [Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Schemmann, Gunter; Notterman, Daniel A.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
   [Ott, Jurg] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
C3 Cornell University; Weill Cornell Medicine; Columbia University;
   Memorial Sloan Kettering Cancer Center; Rockefeller University;
   Princeton University; Chinese Academy of Sciences; Beijing Institute of
   Genomics, CAS
RP Barany, F (通讯作者)，Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.
EM barany@med.cornell.edu
RI Huang, Jianmin/JMC-6122-2023; khan, sajid/HGE-2406-2022
OI Bacolod, Manny/0000-0002-2085-4877; Giardina, Sarah/0000-0002-8879-9384
FU National Cancer Institute [P01-CA65930, R01-CA81467]; Natural Science
   Foundation of China [30730057]; Gilbert Family Foundation; Ludwig
   Institute for Cancer Research; Conrad N. Hilton Foundation joint
   Hilton-Ludwig Cancer Metastasis Initiative
FX National Cancer Institute grants P01-CA65930 and R01-CA81467, Natural
   Science Foundation of China grant 30730057 (J. Ott), and the Gilbert
   Family Foundation and the Ludwig Institute for Cancer Research/Conrad N.
   Hilton Foundation joint Hilton-Ludwig Cancer Metastasis Initiative.
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Cheng YW, 2006, GENOME RES, V16, P282, DOI 10.1101/gr.4181406
   Eads CA, 1999, CANCER RES, V59, P2302
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018
   Hawkins N, 2002, GASTROENTEROLOGY, V122, P1376, DOI 10.1053/gast.2002.32997
   Huang Jing, 2004, Human Genomics, V1, P287
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Li Z, 2002, CANCER RES, V62, P1939
   Lips EH, 2005, CANCER RES, V65, P10188, DOI 10.1158/0008-5472.CAN-05-2486
   Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154
   Nash GM, 2003, J CLIN ONCOL, V21, P3105, DOI 10.1200/JCO.2003.11.133
   Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933
   Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099
   Rodriguez J, 2006, CANCER RES, V66, P8462, DOI 10.1158/0008-5472.CAN-06-0293
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Trautmann K, 2006, CLIN CANCER RES, V12, P6379, DOI 10.1158/1078-0432.CCR-06-1248
   Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569
   Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
NR 32
TC 82
Z9 98
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 1
PY 2008
VL 14
IS 19
BP 6005
EP 6013
DI 10.1158/1078-0432.CCR-08-0216
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 361QP
UT WOS:000260142500011
PM 18829479
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Zhou, W
   Jiang, Z
   Song, X
   Liu, YL
   Wen, P
   Guo, Y
   Xu, FH
   Kong, L
   Zhang, PL
   Han, AQ
   Yu, JM
AF Zhou, Wei
   Jiang, Zheng
   Song, Xianrang
   Liu, Yonglei
   Wen, Peie
   Guo, Yuan
   Xu, Fenghua
   Kong, Li
   Zhang, Pinliang
   Han, Anqin
   Yu, Jinming
TI Promoter hypermethylation-mediated down-regulation of CXCL12 in human
   astrocytoma
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE gene regulation; neuropathology; methyl-CpG-binding protein; epigenetic
ID CHEMOKINE RECEPTOR CXCR4; DNA METHYLTRANSFERASES; CELL-CARCINOMA;
   BREAST-CANCER; EXPRESSION; GLIOMA; METHYLATION; INVASION; DNMT1;
   PROLIFERATION
AB It has recently been demonstrated that CXCL12 is absent in colonic carcinoma, and hypermethylation of CXCL12 contributes to CXCL12/CXCR4 signaling in carcinoma metastasis. However, the role of CXCL12/CXCR4 axis, especially CXCL12, in the regulation of tumor invasiveness is largely still unknown. Using real-time quantitative RT-PCR assays, we observed that CXCR4 expression increased with increasing WHO grade in astrocytoma, suggesting that CXCR4 may be a marker of aggressive biological behavior of astrocytoma. Methylation of CXCL12 was detected in 34.2% (26/76) of astrocytomas by methylation-specific PCR. Epigenetic inactivation of CXCL12 was implicated mainly in low-grade astrocytomas, via DNA hypermethylation by DNMT1, -3A, and -3B; 21.1% (16/76) of the astrocytomas showed reduced or lack of CXCL12 expression, in line with epigenetic silencing of gene transcripts. However, it is interesting to note that 61.8% (47/76) of tumors, mainly high-grade astrocytomas, displayed elevated transcription of CXCL12. The expression levels of CXCL12 mRNA in glioblastomas (WHO grade IV) were significantly higher than in normal brain tissues. In summary, our data show that CXCL12 promoter hypermethylation is an early event in astrocytoma development. However, the high expressions of CXCR4 and CXCL12 in glioblastomas, the more invasive astrocytomas, suggest a different role of CXCL12/CXCR4 signaling axis in astrocytoma progression. (C) 2008 Wiley-Liss, Inc.
C1 [Yu, Jinming] Shandong Canc Hosp & Inst, Radiat Dept, Jinan 250117, Shandong Prov, Peoples R China.
   [Zhou, Wei] Shandong Univ, Shandong Tumor Hosp, Jinan 250100, Shandong, Peoples R China.
   [Jiang, Zheng; Guo, Yuan] Shandong Univ, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
   [Wen, Peie] Shandong Acad Med Sci, Inst Basic Med, Jinan, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong First Medical University & Shandong Academy of
   Medical Sciences; Shandong University; Shandong University; Shandong
   First Medical University & Shandong Academy of Medical Sciences;
   University of Jinan
RP Yu, JM (通讯作者)，Shandong Canc Hosp & Inst, Radiat Dept, Jiyan Rd 440, Jinan 250117, Shandong Prov, Peoples R China.
EM dryujinming@hotmail.com
RI Zhou, Wei/AHB-6135-2022; Guo, Yuan-Lin/K-4887-2019
FU Natural Science Foundation of Shandong [2006ZRC03115, Y2005C39];
   National High Technology, Research and Development Program of China
   [2007AA02Z437]
FX Contract grant sponsor Natural Science Foundation of Shandong Contract
   grant number 2006ZRC03115: Contract grant number: Y2005C39: Contract
   grant sponsor National High Technology, Research and Development Program
   of China (863 Program); Contract grant number: 2007AA02Z437
CR Bajetto A, 2006, NEUROCHEM INT, V49, P423, DOI 10.1016/j.neuint.2006.03.003
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Chu CY, 2007, ONCOGENE, V26, P2491, DOI 10.1038/sj.onc.1210040
   Costello JF, 2003, FRONT BIOSCI, V8, pS175, DOI 10.2741/1027
   Ehtesham M, 2006, ONCOGENE, V25, P2801, DOI 10.1038/sj.onc.1209302
   Esteller M, 2001, CANCER RES, V61, P3225
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hong X, 2006, CANCER LETT, V236, P39, DOI 10.1016/j.canlet.2005.05.011
   Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006
   Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c
   Kleihues P, 2000, PATHOLOGY GENETICS T, P9
   Kwon YM, 2007, J CANCER RES CLIN, V133, P219, DOI 10.1007/s00432-006-0160-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maroni P, 2007, CARCINOGENESIS, V28, P267, DOI 10.1093/carcin/bgl129
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Ottaiano A, 2005, CANCER IMMUNOL IMMUN, V54, P781, DOI 10.1007/s00262-004-0636-3
   Rempel SA, 2000, CLIN CANCER RES, V6, P102
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Salmaggi A, 2005, J NEURO-ONCOL, V74, P287, DOI 10.1007/s11060-004-7327-y
   Salmaggi A, 2004, J NEURO-ONCOL, V67, P305, DOI 10.1023/B:NEON.0000024241.05346.24
   Scala S, 2006, CLIN CANCER RES, V12, P2427, DOI 10.1158/1078-0432.CCR-05-1940
   Schimanski CC, 2006, BRIT J CANCER, V95, P210, DOI 10.1038/sj.bjc.6603251
   Sehgal A, 1998, J SURG ONCOL, V69, P99, DOI 10.1002/(SICI)1096-9098(199810)69:2<99::AID-JSO10>3.3.CO;2-D
   Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245
   Sowinska A, 2007, CANCER LETT, V255, P153, DOI 10.1016/j.canlet.2007.04.004
   Tabatabai G, 2006, BRAIN, V129, P2426, DOI 10.1093/brain/awl173
   Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490
   WANG J, 2007, ROLE CXCR7 RDC1 CHEM
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406
NR 36
TC 18
Z9 20
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD OCT
PY 2008
VL 86
IS 13
BP 3002
EP 3010
DI 10.1002/jnr.21746
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 356PU
UT WOS:000259790900021
PM 18512766
DA 2025-01-12
ER

PT J
AU Lin, J
   Yao, DM
   Qian, J
   Wang, YL
   Han, LX
   Jiang, YW
   Fei, X
   Cen, JN
   Chen, ZX
AF Lin, Jiang
   Yao, Dong-ming
   Qian, Jun
   Wang, Ya-li
   Han, Lan-xiu
   Jiang, Yun-wei
   Fei, Xia
   Cen, Jian-nong
   Chen, Zi-xing
TI Methylation status of fragile histidine triad (<i>FHIT</i>) gene and its
   clinical impact on prognosis of patients with myelodysplastic syndrome
SO LEUKEMIA RESEARCH
LA English
DT Article
DE FHIT gene; myelodysplastic syndrome; methylation; prognosis
ID ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; HYPERMETHYLATION; HEMATOPOIESIS;
   EXPRESSION; APOPTOSIS; LUNG; MDS
AB The fragile histidine triad (FHIT) gene plays an important role in anti-cancer and the abnormal methylation of FHIT gene is found in many carcinomas. The epigenetic changes of tumor suppressor genes (TSG) are now recognized as an abnormal mechanism contributing to the development of myelodysplastic syndrome (MDS). To clarify the role of FHIT in MDS, we examined the methylation status of FHIT in patients with MDS. Methylation-specific polymerase (MSP) chain reaction was performed to detect the aberrant promoter methylation of FHIT gene in 55 patients with MDS. The abnormal methylation of the FHIT gene was found in 26 of 55 (47.2%) MDS cases, but it was not in normal control. No relationship was found between FHIT gene methylation and sex, hematologic parameters, chromosomal abnormalities of MDS patients. However, the significant difference was observed in the frequencies of FHIT gene hypermethylation among patients with RA/RARS (7/25, 28.0%), RAEB (11/18, 6 1.1 %) and RAEBt (8/11, 72.7%) (chi(2) value=7.938, P=0.019). Furthermore, there was a positive correlation between the frequency of FHIT gene hypermethylation and different IPSS groups (chi(2) value = 10.110, P=0.018). The MDS patients with FHIT gene methylation had significantly shorter survival time than those without FHIT methylation (20.0 months vs. 40.0 months, P=0.025). These results suggested that aberrant methylation of the FHIT gene might be one of molecular events involved in the disease progression of MDS and be an adverse prognostic factor in MDS. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Lin, Jiang; Yao, Dong-ming; Qian, Jun; Wang, Ya-li; Han, Lan-xiu; Jiang, Yun-wei; Fei, Xia] Univ Jiangsu, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang 212002, Peoples R China.
   [Cen, Jian-nong; Chen, Zi-xing] Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
C3 Jiangsu University; Soochow University - China
RP Qian, J (通讯作者)，Univ Jiangsu, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang 212002, Peoples R China.
EM qianjun0007@hotmail.com
RI Liu, XiaoYan/GQA-7216-2022
CR Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x
   Boultwood J, 2007, BRIT J HAEMATOL, V138, P3, DOI 10.1111/j.1365-2141.2007.06604.x
   Cilloni D, 2006, ANN NY ACAD SCI, V1089, P411, DOI 10.1196/annals.1386.030
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492
   Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079
   Hirai H, 2002, INT J HEMATOL, V76, P213, DOI 10.1007/BF03165120
   Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Iwai M, 2005, LEUKEMIA, V19, P1367, DOI 10.1038/sj.leu.2403805
   Kantarjian HM, 2007, CANCER-AM CANCER SOC, V109, P1133, DOI 10.1002/cncr.22508
   Kerbauy DB, 2007, EXP HEMATOL, V35, P1739, DOI 10.1016/j.exphem.2007.09.007
   Luan X, 1998, CYTOGENET CELL GENET, V81, P183, DOI 10.1159/000015025
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Parker JE, 2000, BLOOD, V96, P3932, DOI 10.1182/blood.V96.12.3932.h8003932_3932_3938
   Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2
   Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256
   Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6
   Valent P, 2007, LEUKEMIA RES, V31, P727, DOI 10.1016/j.leukres.2006.11.009
   Voso MT, 2004, BLOOD, V103, P698, DOI 10.1182/blood-2003-07-2249
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 22
TC 26
Z9 34
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
J9 LEUKEMIA RES
JI Leuk. Res.
PD OCT
PY 2008
VL 32
IS 10
BP 1541
EP 1545
DI 10.1016/j.leukres.2008.02.008
PG 5
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA 325DR
UT WOS:000257569100009
PM 18367246
DA 2025-01-12
ER

PT J
AU Liu, SH
   Ren, SP
   Howell, P
   Fodstad, O
   Riker, AI
AF Liu, Suhu
   Ren, Suping
   Howell, Paul
   Fodstad, Oystein
   Riker, Adam I.
TI Identification of novel epigenetically modified genes in human melanoma
   via promoter methylation gene profiling
SO PIGMENT CELL & MELANOMA RESEARCH
LA English
DT Article
DE melanoma; promoter hypermethylation; methylation profiling; epigenetics;
   quantitative methylationspecific PCR
ID HUMAN-MALIGNANT MELANOMA; TUMOR-SUPPRESSOR ACTIVITY; LYSYL-OXIDASE;
   CUTANEOUS MELANOMA; BREAST-CANCER; CELL-LINES; ABERRANT METHYLATION; DNA
   METHYLATION; PROSTATE-CANCER; DECOY RECEPTORS
AB The inactivation of tumor-related genes through the aberrant methylation of promoter CpG islands is thought to contribute to tumor initiation and progression. We therefore investigated promoter methylation events involved in cutaneous melanoma by screening 30 genes of interest for evidence of promoter hypermethylation, examining 20 melanoma cell lines and 40 freshly procured melanoma samples. Utilizing quantitative methylation-specific PCR, we identified five genes (SOCS1, SOCS2, RAR-beta 2, TNFSF10C, and TNFSF10D) with hypermethylation frequencies ranging from 50% to 80% in melanoma cell lines as well as freshly procured tissue samples. Eighteen genes (LOX, RASSF1A, WFDC1, TM, APC, TFPI2, TNFSF10A, CDKN2A, MGMT, TIMP3, ASC, TPM1, IRF8, CIITA-PIV, CDH1, SYK, HOXB13, and DAPK1) were methylated at lower frequencies (2-30%). Two genes (CDKN1B and PTEN), previously reported as methylated in melanoma, and five other genes (RECK, IRF7, PAWR, TNFSF10B, and Rb) were not methylated in the samples screened here. Daughter melanoma cell lines showed identical methylation patterns when compared with original samples from which they were derived, as did synchronous metastatic lesions from the same patient. We identified four genes (TNFSF10C, TNFSF10D, LOX, and TPM1) that have never before been identified as hypermethylated in melanoma, with an overall methylation frequency of 60, 80, 50, and 10%, respectively, hypothesizing that these genes may play an important role in melanoma progression.
C1 [Liu, Suhu; Ren, Suping; Howell, Paul; Fodstad, Oystein; Riker, Adam I.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.
C3 University of South Alabama
RP Riker, AI (通讯作者)，Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.
EM ariker@usouthal.edu
RI Riker, Adam/A-6065-2011; Ren, Suping/V-4489-2017
FU Abraham A. Mitchell Clinical Research Scholarship
FX This research was supported by the Abraham A. Mitchell Clinical Research
   Scholarship (A. I. R.).
CR Appleton K, 2007, J CLIN ONCOL, V25, P4603, DOI 10.1200/JCO.2007.10.8688
   Bae SI, 2008, ONCOGENE, V27, P490, DOI 10.1038/sj.onc.1210655
   Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D
   Chang HC, 2007, CANCER SCI, V98, P169, DOI 10.1111/j.1349-7006.2006.00367.x
   Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   FODSTAD O, 1988, INT J CANCER, V41, P442, DOI 10.1002/ijc.2910410322
   Furuta J, 2005, MELANOMA RES, V15, P15, DOI 10.1097/00008390-200502000-00004
   Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gonzalgo ML, 1997, CANCER RES, V57, P5336
   Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543
   Kirschmann DA, 2002, CANCER RES, V62, P4478
   KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7
   Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x
   Liu XG, 2005, CANCER RES, V65, P9169, DOI 10.1158/0008-5472.CAN-05-0939
   Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200
   Marini A, 2006, J INVEST DERMATOL, V126, P422, DOI 10.1038/sj.jid.5700073
   Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867
   Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384
   Moreno-Bueno G, 2007, CANCER RES, V67, P1927, DOI 10.1158/0008-5472.CAN-06-2687
   Mori T, 2005, J CLIN ONCOL, V23, P9351, DOI 10.1200/JCO.2005.02.9876
   Moulin AP, 2008, BRIT J OPHTHALMOL, V92, P281, DOI 10.1136/bjo.2007.127035
   Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274
   Nobeyama Y, 2007, INT J CANCER, V121, P301, DOI 10.1002/ijc.22637
   Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371
   Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074
   Riker AI, 2004, METH MOLEC MED, V88, P93
   Riker AI, 1999, CANCER DETECT PREV, V23, P387, DOI 10.1046/j.1525-1500.1999.99045.x
   Rothhammer T, 2007, PIGM CELL RES, V20, P92, DOI 10.1111/j.1600-0749.2007.00367.x
   Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Tsutsumida A, 2004, INT J ONCOL, V25, P1415
   van Noesel MM, 2002, CANCER RES, V62, P2157
   Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688
   WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211
   WELCH DR, 1994, ONCOGENE, V9, P255
   Worm J, 2000, ONCOGENE, V19, P5111, DOI 10.1038/sj.onc.1203891
   Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647
   Wu M, 2007, CANCER RES, V67, P6278, DOI 10.1158/0008-5472.CAN-07-0776
   Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
NR 53
TC 100
Z9 115
U1 0
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-1471
J9 PIGM CELL MELANOMA R
JI Pigment Cell Melanoma Res.
PD OCT
PY 2008
VL 21
IS 5
BP 545
EP 558
DI 10.1111/j.1755-148X.2008.00484.x
PG 14
WC Oncology; Cell Biology; Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Dermatology
GA 350KW
UT WOS:000259352300011
PM 18627528
DA 2025-01-12
ER

PT J
AU Prasad, A
   Paruchuri, V
   Preet, A
   Latif, F
   Ganju, RK
AF Prasad, Anil
   Paruchuri, Vikram
   Preet, Anju
   Latif, Farida
   Ganju, Ramesh K.
TI Slit-2 induces a tumor-suppressive effect by regulating β-catenin in
   breast cancer cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID OLFACTORY-BULB AXONS; COLORECTAL-CANCER; ROBO RECEPTORS; EPIGENETIC
   INACTIVATION; EXPRESSION PATTERNS; SIGNALING PATHWAYS; LUNG DEVELOPMENT;
   VERTEBRATE SLIT; CARCINOMA CELLS; WNT PATHWAY
AB SLIT-2 is considered as a candidate tumor suppressor gene, because it is frequently inactivated in various cancers due to hypermethylation of its promoter region and allelic loss. However, the exact mechanism of its tumor-suppressive effect has not been elucidated. Here, we observed that Slit-2-overexpressing breast cancer cells exhibited decreased proliferation and migration capabilities compared with control cells under in vitro conditions. These results were confirmed in vivo in mouse model systems. Mice injected with MCF-7/Slit-2 cells showed a 60-70% reduction in tumor size compared with mice injected with MCF-7/VC cells both in the absence and presence of estrogen. Upon further elucidation, we observed that Slit-2 mediates the tumor-suppressive effect via a coordinated regulation of the beta-catenin and PI3K signaling pathways and by enhancing beta-catenin/E-cadherin-mediated cell-cell adhesion. Our study for the first time reveals that Slit-2-overexpressing breast cancer cells exhibit tumor suppressor capabilities through the novel mechanism of beta-catenin modulation.
C1 [Prasad, Anil; Paruchuri, Vikram; Preet, Anju; Ganju, Ramesh K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA.
   [Latif, Farida] Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School; University of Birmingham
RP Prasad, A (通讯作者)，Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Expt Med, HIM 342, Boston, MA 02115 USA.
EM abailugu@bidmc.harvard.edu
FU National Institutes of Health [CA109527]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant CA109527. This work was also supported by the Susan G.
   Komen Breast Cancer Foundation (to R. K. G.). The costs of publication
   of this article were defrayed in part by the payment of page charges.
   This article must therefore be hereby marked "advertisement" in
   accordance with 18 U. S. C. Section 1734 solely to indicate this fact.
CR Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Anselmo MA, 2003, GENE EXPR PATTERNS, V3, P13, DOI 10.1016/S1567-133X(02)00095-9
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X
   Battye R, 2001, J NEUROSCI, V21, P4290, DOI 10.1523/JNEUROSCI.21-12-04290.2001
   Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y
   Chen JH, 2001, J NEUROSCI, V21, P1548, DOI 10.1523/JNEUROSCI.21-05-01548.2001
   Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597
   Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515
   Fujiwara M, 2006, VASC MED, V11, P115, DOI 10.1191/1358863x06vm658ra
   Georgas K, 1999, CYTOGENET CELL GENET, V86, P246, DOI 10.1159/000015351
   Gilles C, 2003, CANCER RES, V63, P2658
   Grieshammer U, 2004, DEV CELL, V6, P709, DOI 10.1016/S1534-5807(04)00108-X
   Gröne J, 2006, ONCOL REP, V15, P1437
   Guan HB, 2003, J IMMUNOL, V171, P6519, DOI 10.4049/jimmunol.171.12.6519
   Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446
   Katoh Y, 2005, ONCOL REP, V14, P1351
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Kramer SG, 2001, SCIENCE, V292, P737, DOI 10.1126/science.1058766
   Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7
   Mestdagt M, 2006, INT J CANCER, V118, P35, DOI 10.1002/ijc.21291
   Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9
   Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X
   Papkoff J, 1996, MOL CELL BIOL, V16, P2128
   Piper M, 2000, MECH DEVELOP, V94, P213, DOI 10.1016/S0925-4773(00)00313-0
   Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200
   Rajagopalan S, 2000, NEURON, V28, P767, DOI 10.1016/S0896-6273(00)00152-5
   Ray G, 2005, ONCOL REP, V13, P445
   Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858
   Rhee J, 2007, NAT CELL BIOL, V9, P883, DOI 10.1038/ncb1614
   Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023
   Santiago-Martínez E, 2006, P NATL ACAD SCI USA, V103, P12441, DOI 10.1073/pnas.0605284103
   Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250
   Simpson JH, 2000, NEURON, V28, P753, DOI 10.1016/S0896-6273(00)00151-3
   Stuart RO, 2003, KIDNEY INT, V64, P1997, DOI 10.1046/j.1523-1755.2003.00383.x
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516
   Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0
   Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7
   Watson PH, 1996, CURR TOP MICROBIOL, V213, P267
   Werbowetski-Ogilvie TE, 2006, ONCOGENE, V25, P5103, DOI 10.1038/sj.onc.1209524
   Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2
   Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X
   Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098
   Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371
   Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024
NR 63
TC 91
Z9 111
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 26
PY 2008
VL 283
IS 39
BP 26624
EP 26633
DI 10.1074/jbc.M800679200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 350GV
UT WOS:000259341600038
PM 18611862
OA Green Published
DA 2025-01-12
ER

PT J
AU Ng, W
   Loh, AXW
   Teixeira, AS
   Pereira, SP
   Swallow, DM
AF Ng, W.
   Loh, A. X. W.
   Teixeira, A. S.
   Pereira, S. P.
   Swallow, D. M.
TI Genetic regulation of <i>MUC1</i> alternative splicing in human tissues
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE MUC1; splicing; polymorphism; transcript; gene regulation
ID BREAST-CANCER TISSUE; TANDEM REPEATS; TUMOR-ANTIGEN; PREFERENTIAL
   EXPRESSION; VARIANTS; POLYMORPHISM; CARCINOMA; GASTRITIS; CLONING;
   PROTEIN
AB The membrane mucin MUC1 is aberrantly expressed in a variety of cancers, and in stomach, it is a ligand for Helicobacter pylori where it plays a role in gastric carcinogenesis. Splicing variation, leading to a 9-amino acid insertion in the signal peptide region, was proposed to be because of a single-nucleotide polymorphism (rs4072037) at the 5' end of exon 2, but is also reported to be cancer-associated. However, the effect of rs4072037 on this splicing event in healthy non-cancer tissues and on the additional spliceoforms of MUC1, including those lacking the polymorphic tandem repeat (TR) domain, has never been investigated. Here we show that in both foetal and adult tissues of known genotype, there is clear evidence for the role of rs4072037 in controlling alternative splicing of the 5' exon 2 region of both full-length transcripts and those lacking the TR domain. Although there is some evidence for additional genetic and epigenetic influences, there is no indication of an effect of the TR domain on the proportions of the spliceoforms. In conclusion, over-representation of certain transcripts in tumour material cannot be evaluated without information on the SNP genotype as well.
C1 [Ng, W.; Loh, A. X. W.; Teixeira, A. S.; Swallow, D. M.] UCL, Res Dept Genet Evolut & Environm, London NW1 2HE, England.
   [Pereira, S. P.] Royal Free & Univ Coll Med Sch, Sch Med, Inst Hepatol, Div Med, London, England.
   [Ng, W.] John Radcliffe Hosp, Univ Dept Pediat, Oxford OX3 9DU, England.
C3 University of London; University College London; University of London;
   University College London; UCL Medical School; University of Oxford
RP Swallow, DM (通讯作者)，UCL, Res Dept Genet Evolut & Environm, Wolfson House,4 Stephenson Way, London NW1 2HE, England.
EM d.swallow@ucl.ac.uk
RI Pereira, Stephen/C-5639-2009
OI Pereira, Stephen/0000-0003-0821-1809
FU Annals of Human Genetics; Oxford University Department of Paediatrics;
   Fundacao para a Ciencia e a Tecnologia, Portugal,; The Wellcome Trust
   [070395/Z/03/Z]; Department of Health's National Institute for Health
   Research (NIHR) Biomedical Research Centres
FX We acknowledge an MRC PhD Studentship and grants from the Annals of
   Human Genetics and the Oxford University Department of Paediatrics for W
   Ng, UCL ORS scholarship for AL, GABBA PhD program studentship and
   Fundacao para a Ciencia e a Tecnologia, Portugal, for AT, The Wellcome
   Trust grant ref 070395/Z/03/Z, for supporting the preliminary work, and
   Adil Elamin for help with sample collection and Jeremy Hull who provided
   the tumour cell lines. The work was undertaken at UCLH/UCL, which
   received a proportion of funding from the Department of Health's
   National Institute for Health Research (NIHR) Biomedical Research
   Centres funding scheme. We thank Sue Povey for helpful discussions.
CR Baruch A, 1999, CANCER RES, V59, P1552
   Baruch A, 1997, INT J CANCER, V71, P741
   Carvalho F, 1997, GLYCOCONJUGATE J, V14, P107, DOI 10.1023/A:1018573201347
   Fowler JC, 2003, HUM GENET, V113, P473, DOI 10.1007/s00439-003-1011-8
   GENDLER S, 1988, J BIOL CHEM, V263, P12820
   GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309
   GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060
   HAREUVENI M, 1990, EUR J BIOCHEM, V189, P475, DOI 10.1111/j.1432-1033.1990.tb15512.x
   Hartman ML, 1999, INT J CANCER, V82, P256, DOI 10.1002/(SICI)1097-0215(19990719)82:2<256::AID-IJC17>3.0.CO;2-C
   Imbert Y, 2006, EXP EYE RES, V83, P493, DOI 10.1016/j.exer.2006.01.031
   Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200
   LAN MS, 1985, CANCER RES, V45, P305
   Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200
   LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297
   LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573
   Lindén S, 2004, BIOCHEM J, V384, P263, DOI 10.1042/BJ20040402
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700
   Mcguckin MA, 2007, GASTROENTEROLOGY, V133, P1210, DOI 10.1053/j.gastro.2007.07.003
   Obermair A, 2002, INT J CANCER, V100, P166, DOI 10.1002/ijc.10456
   Obermair A, 2001, GYNECOL ONCOL, V83, P343, DOI 10.1006/gyno.2001.6396
   Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775
   Pratt WS, 1996, ANN HUM GENET, V60, P21, DOI 10.1111/j.1469-1809.1996.tb01168.x
   Schmid BC, 2003, ONCOL REP, V10, P1981
   Schmid BC, 2002, BREAST CANCER RES TR, V76, P211, DOI 10.1023/A:1020853900765
   SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155
   Silva F, 2003, EUR J HUM GENET, V11, P380, DOI 10.1038/sj.ejhg.5200978
   Silva F, 2001, EUR J HUM GENET, V9, P548, DOI 10.1038/sj.ejhg.5200677
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0
   Taylor-Papadimitriou J, 2002, J MAMMARY GLAND BIOL, V7, P209, DOI 10.1023/A:1020360121451
   TEIXEIRA AS, 2005, THESIS U LONDON LOND
   Vinall LE, 2002, GASTROENTEROLOGY, V123, P41, DOI 10.1053/gast.2002.34157
   Weiss M, 1996, INT J CANCER, V66, P55, DOI 10.1002/(SICI)1097-0215(19960328)66:1<55::AID-IJC10>3.0.CO;2-A
   ZRIHANLICHT S, 1994, EUR J BIOCHEM, V224, P787, DOI 10.1111/j.1432-1033.1994.00787.x
   ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 36
TC 45
Z9 45
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD SEP 9
PY 2008
VL 99
IS 6
BP 978
EP 985
DI 10.1038/sj.bjc.6604617
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 346IK
UT WOS:000259061800019
PM 19238635
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Lujambio, A
   Calin, GA
   Villanueva, A
   Ropero, S
   Sánchez-Céspedes, M
   Blanco, D
   Montuenga, LM
   Rossi, S
   Nicoloso, MS
   Faller, WJ
   Gallagher, WM
   Eccles, SA
   Croce, CM
   Esteller, M
AF Lujambio, Amaia
   Calin, George A.
   Villanueva, Alberto
   Ropero, Santiago
   Sanchez-Cespedes, Montserrat
   Blanco, David
   Montuenga, Luis M.
   Rossi, Simona
   Nicoloso, Milena S.
   Faller, William J.
   Gallagher, William M.
   Eccles, Suzanne A.
   Croce, Carlo M.
   Esteller, Manel
TI A microRNA DNA methylation signature for human cancer metastasis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID TUMOR-SUPPRESSOR MICRORNAS; BREAST-CANCER; P53; EXPRESSION; CELLS; GENE;
   HYPERMETHYLATION; TRANSCRIPTS; ACTIVATION; CARCINOMA
AB MicroRNAs (miRNAs) are small, noncoding RNAs that can contribute to cancer development and progression by acting as oncogenes or tumor suppressor genes. Recent studies have also linked different sets of miRNAs to metastasis through either the promotion or suppression of this malignant process. Interestingly, epigenetic silencing of miRNAs with tumor suppressor features by CpG island hypermethylation is also emerging as a common hallmark of human tumors. Thus, we wondered whether there was a miRNA hypermethylation profile characteristic of human metastasis. We used a pharmacological and genomic approach to reveal this aberrant epigenetic silencing program by treating lymph node metastatic cancer cells with a DNA demethylating agent followed by hybridization to an expression microarray. Among the miRNAs that were reactivated upon drug treatment, miR-148a, miR-34b/c, and miR-9 were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues. The reintroduction of miR-148a and miR-34b/c in cancer cells with epigenetic inactivation inhibited their motility, reduced tumor growth, and inhibited metastasis formation in xenograft models' with an associated down-regulation of the miRNA oncogenic target genes, such as C-MYC, E2F3, CDK6, and TGIF2. Most important, the involvement of miR-148a, miR-34b/c, and miR-9 hypermethylation in metastasis formation was also suggested in human primary malignancies (n = 207) because it was significantly associated with the appearance of lymph node metastasis. Our findings indicate that DNA methylation-associated silencing of tumor suppressor miRNAs contributes to the development of human cancer metastasis.
C1 [Lujambio, Amaia; Ropero, Santiago; Esteller, Manel] Spanish Natl Canc Res Ctr, Canc Epigenet Lab, Madrid 28029, Spain.
   [Lujambio, Amaia; Esteller, Manel] Catalan Inst Oncol, Canc Epigenet & Biol Program, Barcelona 08907, Catalonia, Spain.
   [Calin, George A.; Rossi, Simona; Nicoloso, Milena S.] Texas State Univ, MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Villanueva, Alberto] Inst Invest Biomed Bellvitge, Catalan Inst Oncol, Lab Translat Res, Barcelona 08907, Spain.
   [Sanchez-Cespedes, Montserrat] Spanish Natl Canc Res Ctr, Lung Canc Lab, Madrid 28029, Spain.
   [Blanco, David; Montuenga, Luis M.] Ctr Appl Med Res, Div Oncol, Pamplona 31008, Spain.
   [Faller, William J.; Gallagher, William M.] Univ Coll Dublin, Conway Inst, Sch Biomol & Biomed Sci, Dublin 4, Ireland.
   [Eccles, Suzanne A.] Canc Res UK Ctr Canc Therapeut, Inst Canc Res, Tumour Biol & Metastasis Team, McElwain Labs, Sutton SM2 5NG, Surrey, England.
   [Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Institut Catala
   d'Oncologia; University of Texas System; UTMD Anderson Cancer Center;
   Texas State University System; Texas State University San Marcos;
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut
   Catala d'Oncologia; Centro Nacional de Investigaciones Oncologicas
   (CNIO); University of Navarra; University College Dublin; University of
   London; Institute of Cancer Research - UK; Cancer Research UK;
   University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute
RP Esteller, M (通讯作者)，Spanish Natl Canc Res Ctr, Canc Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.
EM mesteller@cnio.es
RI Calin, George/E-9390-2011; Rossi, Simona/ABD-3688-2020; Nicoloso,
   Milena/K-6411-2012; Montuenga, Luis M/AAF-7783-2020; Esteller,
   Manel/L-5956-2014; /P-5869-2014; Sanchez-Cespedes, Montse/H-8485-2012
OI Nicoloso, Milena/0000-0003-4231-9303; Montuenga, Luis
   M/0000-0002-8739-1387; Gallagher, William/0000-0002-4307-5999; Faller,
   William James/0000-0002-0738-2254; Esteller, Manel/0000-0003-4490-6093;
   /0000-0001-7867-0010; Lujambio, Amaia/0000-0002-2798-1481; Calin,
   George/0000-0001-6704-5615; Sanchez-Cespedes,
   Montse/0000-0002-6045-5627; Ropero, Santiago/0000-0003-3522-8104
FU Health Research Board of Ireland [SAF2007-00027-65134, CSD2006-49];
   Spanish Association Against Cancer; Formacion de Profesorado
   Universitario; Francisco Cobos Foundation
FX We thank Cristian Taccioli, Chang-gong Liu, Shauna Hegarty, and Mairin
   Rafferty for technical support. This work was supported by the Grants
   SAF2007-00027-65134, Consolider CSD2006-49, the Health Research Board of
   Ireland, and the Spanish Association Against Cancer. A.L. is supported
   by a Formacion de Profesorado Universitario Fellowship and the Francisco
   Cobos Foundation.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Grossel MJ, 2006, CELL CYCLE, V5, P266, DOI 10.4161/cc.5.3.2385
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hammond SM, 2007, NAT GENET, V39, P582, DOI 10.1038/ng0507-582
   Han L, 2007, CANCER BIOL THER, V6, P1284
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Imoto I, 2000, BIOCHEM BIOPH RES CO, V276, P264, DOI 10.1006/bbrc.2000.3449
   Jackson DG, 2007, CANCER TREAT RES, P39
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705
   Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102
   Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037
NR 38
TC 857
Z9 1021
U1 1
U2 84
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 9
PY 2008
VL 105
IS 36
BP 13556
EP 13561
DI 10.1073/pnas.0803055105
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 349AR
UT WOS:000259251700068
PM 18768788
OA Green Published
DA 2025-01-12
ER

PT J
AU Pryzbylkowski, P
   Obajimi, O
   Keen, JC
AF Pryzbylkowski, Peter
   Obajimi, Oluwakemi
   Keen, Judith Clancy
TI Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor
   mRNA stability in ER positive MCF7 cells through modulation of HuR
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE 5-Aza-2'deoxycytidine; Actinomycin D; breast cancer; estrogen receptor
   alpha; HuR; MCF7; mRNA stability; trichostatin A
ID BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITOR; BINDING-PROTEINS;
   ALPHA ER; 3'-UNTRANSLATED REGION; DNA METHYLTRANSFERASE; TAMOXIFEN
   SENSITIVITY; EXPRESSION; GENE; DEMETHYLATION
AB Trichostatin A (TSA) and 5-Aza 2'deoxycytidine (AZA), two well characterized pharmacologic inhibitors of histone deacetylation and DNA methylation, affect estrogen receptor alpha (ER) levels differently in ER-positive versus ER-negative breast cancer cell lines. Whereas pharmacologic inhibition of these epigenetic mechanisms results in re-expression and increased estrogen receptor alpha (ER) levels in ER-negative cells, treatment in ER-positive MCF7 cells results in decreased ER mRNA and protein levels. This decrease is dependent upon protein interaction with the ER 3'UTR. Actinomycin D studies showed a 37.5% reduction in ER mRNA stability from 4 to 1.5 h in AZA/TSA treated MCF7 cell lines; an effect not seen in 231ER + cells transfected with the ER coding region but lacking incorporation of the 3'UTR. AZA/TSA do not appear to directly interact with the 3'UTR but rather decrease stability through altered subcellular localization of the RNA binding protein, HuR. siRNA inhibition of HuR expression reduces both the steady-state and stability of ER mRNA, suggesting that HuR plays a critical role in the control of ER mRNA stability. Our data suggest that epigenetic modulators can alter stability through modulation of HuR subcellular distribution. Taken together, these data provide a novel anti-estrogenic mechanism for AZA and TSA in ER positive human breast cancer cells.
C1 [Pryzbylkowski, Peter; Obajimi, Oluwakemi; Keen, Judith Clancy] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Mol Med, Dept Med, Camden, NJ 08103 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences
RP Keen, JC (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Mol Med, Dept Med, Rm 170 E&R Bldg,401 Haddon Ave, Camden, NJ 08103 USA.
EM keenjc@umdnj.edu
OI Keen, Judith/0000-0002-2894-130X
CR Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023
   Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854
   Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070
   ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801
   Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200
   Guo X, 2006, CANCER RES, V66, P7948, DOI 10.1158/0008-5472.CAN-05-4362
   Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765
   Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jordan VC, 2007, STEROIDS, V72, P7, DOI 10.1016/j.steroids.2006.10.009
   Keen JC, 2005, J BIOL CHEM, V280, P29519, DOI 10.1074/jbc.M505317200
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   KEEN JC, 2004, P AM ASSOC CANC RES, V45, P2399
   Kenealy MR, 1996, BIOCHEM SOC T, V24, pS107, DOI 10.1042/bst024107s
   Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805
   Locker GY, 1998, CANCER TREAT REV, V24, P221, DOI 10.1016/S0305-7372(98)90051-2
   Margueron R, 2004, J MOL ENDOCRINOL, V32, P583, DOI 10.1677/jme.0.0320583
   Nass SJ, 2000, CANCER RES, V60, P4346
   Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Sommer S, 2005, J STEROID BIOCHEM, V97, P219, DOI 10.1016/j.jsbmb.2005.09.002
   Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1
   Wang LH, 2006, CANCER CELL, V10, P487, DOI 10.1016/j.ccr.2006.09.015
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 31
TC 62
Z9 75
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2008
VL 111
IS 1
BP 15
EP 25
DI 10.1007/s10549-007-9751-0
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 327FI
UT WOS:000257714600003
PM 17891453
DA 2025-01-12
ER

PT J
AU Mc Cormack, O
   Chung, WY
   Fitzpatrick, P
   Cooke, F
   Flynn, B
   Harrison, M
   Fox, E
   Gallagher, E
   McGoldrick, A
   Dervan, PA
   McCann, A
   Kerin, MJ
AF Mc Cormack, Orla
   Chung, Wen Y.
   Fitzpatrick, Patricia
   Cooke, Fiachra
   Flynn, Barbara
   Harrison, Michele
   Fox, Edward
   Gallagher, Emma
   McGoldrick, Aloysius
   Dervan, Peter A.
   McCann, Amanda
   Kerin, Michael J.
TI Progesterone receptor B (PRB) promoter hypermethylation in sporadic
   breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; immunohistochemistry; epigenetics; oestrogen receptor
   alpha; progesterone receptor B; promoter hypermethylation
ID ESTROGEN-RECEPTOR; DNA METHYLATION; ENDOCRINE THERAPY; INACTIVATION;
   EXPRESSION; TAMOXIFEN; ISOFORM; TUMORS; CELLS
AB Introduction Oestrogen receptor alpha (ER alpha) is traditionally measured on all breast tumour specimens to identify those patients more likely to respond to anti-oestrogens. Progesterone receptor (PR) status has contributed useful information in defining more responsive subgroups. PR negativity may be a marker for increased signalling through growth factor receptor tyrosine kinase pathways. Progesterone acts through two PRs, PRA and PRB. PRB, the functionally active PR, can be silenced by promoter hypermethylation. Methods Following DNA and RNA extraction from 94 breast carcinomas, the methylation status of the PRB promoter was assessed by sodium bisulphite modification and methylation sensitive PCR (MSP). A quantitative realtime PCR analysis (QRTPCR) was used to determine the levels of PRB mRNA expression. Protein expression was evaluated immunohistochemically with a commercially available PRB antibody. Results 76% of the primary breast carcinoma samples demonstrated a methylated band for PRB. PRB methylation significantly compromised total PR immunohistochemistry (IHC) expression (P = 0.03). PRB mRNA correlated positively with total PR IHC (r = 0.58, P = 0.04), ER alpha IHC (P = 0.02), and tumour grade (P = 0.01). PRB protein expression was significantly associated with a number of favourable prognostic variables including smaller (P = 0.004) lower grade (P = 0.007), ER alpha IHC positive tumours (P < 0.001), and tumours with a low Nottingham Prognostic Index (NPI) (P = 0.0008). PRB mRNA levels were significantly associated with better overall survival (P = 0.04) in a univariate analysis. Conclusion The majority of tumours were methylated for PRB. This did not directly compromise PRB expression suggesting that other factors may down regulate the PR gene. When PRB was expressed, it correlated with good prognostic markers and better overall survival.
C1 [Mc Cormack, Orla] Dublin Incorporating Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin 24, Ireland.
   [Chung, Wen Y.; Cooke, Fiachra; Flynn, Barbara; Fox, Edward; Gallagher, Emma; McGoldrick, Aloysius; McCann, Amanda] UCD Conway Inst, UCD Sch Med & Med Sci SMMS, Dublin 4, Ireland.
   [Fitzpatrick, Patricia] UCD Sch Publ Hlth & Populat Sci, Dublin 4, Ireland.
   [Harrison, Michele; Dervan, Peter A.] Mater Misericordiae Univ Hosp, Dept Pathol, Dublin 7, Ireland.
   [Kerin, Michael J.] Univ Coll Hosp, Inst Clin Sci, Galway, Ireland.
C3 Trinity College Dublin; University College Dublin; University College
   Dublin; Mater Misericordiae University Hospital; University College
   Dublin; Ollscoil na Gaillimhe-University of Galway
RP Mc Cormack, O (通讯作者)，Dublin Incorporating Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin 24, Ireland.
EM omccormack@rcsi.ie; paddywen@yahoo.co.uk; patriciafitzpatrick@ucd.ie;
   fiachracooke@hotmail.com; barbara.flynn@ucd.ie; mharrison@mater.ie;
   eddiejfox@gmail.com; emma.m.gallagher@ucd.ie;
   aloysius.mcgoldrick@ucd.ie; pdervan@mater.ie; amanda.mccann@ucd.ie;
   michael.kerin@mailn.hse.ie
RI Kerin, Michael/D-6748-2013; Fitzpatrick, Patricia/Y-6017-2019; Cormack,
   Orla/F-6664-2014; Fox, Edward/A-4675-2011
OI Fitzpatrick, Patricia/0000-0003-2524-3677; McCann,
   Amanda/0000-0003-1911-3307; Fox, Edward/0000-0002-3740-651X; Kerin,
   Michael/0000-0003-4164-5561; Chung, Wen Yuan/0000-0003-0970-0639
CR Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249
   Blamey RW., 1996, Breast, V5, P156
   Dowsett M, 2003, BREAST CANCER RES TR, V82, pS7
   Edwards DP, 2002, J STEROID BIOCHEM, V83, P173, DOI 10.1016/S0960-0760(02)00265-0
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Hopp TA, 2004, CLIN CANCER RES, V10, P2751, DOI 10.1158/1078-0432.CCR-03-0141
   Kiani J, 2006, PATHOL ONCOL RES, V12, P223, DOI 10.1007/BF02893416
   Lakhani S R, 1999, Breast Cancer Res, V1, P31, DOI 10.1186/bcr10
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488
   Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100
   Osborne CK, 2005, BREAST, V14, P458, DOI 10.1016/j.breast.2005.08.024
   Punglia RS, 2006, CANCER-AM CANCER SOC, V106, P2576, DOI 10.1002/cncr.21919
   Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200
   SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244
   Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140-6736(05)66546-4
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Widschwendter M, 2002, CLIN CANCER RES, V8, P17
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 22
TC 17
Z9 20
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2008
VL 111
IS 1
BP 45
EP 53
DI 10.1007/s10549-007-9757-7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 327FI
UT WOS:000257714600005
PM 17896177
DA 2025-01-12
ER

PT J
AU Latimer, JJ
   Johnson, JM
   Miles, TD
   Dimsdale, JM
   Edwards, RP
   Kelley, JL
   Grant, SG
AF Latimer, Jean J.
   Johnson, Jennifer M.
   Miles, Tiffany D.
   Dimsdale, Jason M.
   Edwards, Robert P.
   Kelley, Joseph L.
   Grant, Stephen G.
TI Cell-type-specific level of DNA nucleotide excision repair in primary
   human mammary and ovarian epithelial cell cultures
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE primary ovarian epithelial culture; nucleotide excision repair;
   unscheduled DNA synthesis; xeroderma pigmentosum; BRCA1; human
ID XERODERMA-PIGMENTOSUM; BREAST-CANCER; BRCA1; LYMPHOCYTES; MUTATIONS;
   CARCINOMA; CAPACITY; TISSUE; DAMAGE; WOMEN
AB DNA repair, a fundamental function of cellular metabolism, has long been presumed to be constitutive and equivalent in all cells. However, we have previously shown that normal levels of nucleotide excision repair (NER) can vary by 20-fold in a tissue-specific pattern. We have now successfully established primary cultures of normal ovarian tissue from seven women by using a novel culture system originally developed for breast epithelial cells. Epithelial cells in these cultures aggregated to form three-dimensional structures called "attached ovarian epispheres". The availability of these actively proliferating cell cultures allowed us to measure NER functionally and quantitatively by the unscheduled DNA synthesis (UDS) assay, a clinical test used to diagnose constitutive deficiencies in NER capacity. We determined that ovarian epithelial cells manifested an intermediate level of NER capacity in humans, viz., only 25% of that of foreskin fibroblasts, but still 2.5-fold higher than that of peripheral blood lymphocytes. This level of DNA repair capacity was indistinguishable from that of normal breast epithelial cells, suggesting that it might be characteristic of the epithelial cell type. Similar levels of NER activity were observed in cultures established from a disease-free known carrier of a BRCA1 truncation mutation, consistent with previous normal results shown in breast epithelium and blood lymphocytes. These results establish that at least three "normal" levels of such DNA repair occur in human tissues, and that NER capacity is epigenetically regulated during cell differentiation and development.
C1 [Latimer, Jean J.; Miles, Tiffany D.; Grant, Stephen G.] Univ Pittsburgh, Inst Canc, Ctr Environm Oncol, Pittsburgh, PA 15232 USA.
   [Johnson, Jennifer M.] Univ Pittsburgh, Sch Med, Program Biochem & Mol Genet, Pittsburgh, PA 15261 USA.
   [Latimer, Jean J.; Dimsdale, Jason M.; Edwards, Robert P.; Kelley, Joseph L.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, Pittsburgh, PA 15213 USA.
   [Latimer, Jean J.; Dimsdale, Jason M.; Edwards, Robert P.; Kelley, Joseph L.] Magee Womens Hosp, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Latimer, JJ (通讯作者)，Univ Pittsburgh, Inst Canc, Ctr Environm Oncol, Pittsburgh, PA 15232 USA.
EM latimerjj@upmc.edu
RI Grant, Stephen/D-6984-2014
OI Grant, Stephen/0000-0002-9236-0913; Latimer, Jean/0000-0002-4882-5170
FU NCI NIH HHS [R29 CA7189, R29 CA071894] Funding Source: Medline
CR Auersperg N, 1997, J CELL PHYSIOL, V173, P261, DOI 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G
   Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652
   ENGEL LW, 1978, CANCER RES, V38, P4327
   Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X
   Forlenza MJ, 2000, PSYCHOL HEALTH, V15, P881, DOI 10.1080/08870440008405589
   Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002
   Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953
   Kelly CM, 2005, METH MOL B, V291, P303
   Kennedy DO, 2005, JNCI-J NATL CANCER I, V97, P127, DOI 10.1093/jnci/dji013
   Kleijer WJ, 2007, PRENATAL DIAG, V27, P1133, DOI 10.1002/pd.1849
   KOVACS E, 1986, EUR J CANCER CLIN ON, V22, P863, DOI 10.1016/0277-5379(86)90375-5
   KOVACS E, 1987, EUR J CANCER CLIN ON, V23, P1051, DOI 10.1016/0277-5379(87)90358-0
   KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511
   Latimer JJ, 1996, EXP CELL RES, V228, P19, DOI 10.1006/excr.1996.0294
   Latimer JJ, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-26
   Latimer JJ, 2003, EXP CELL RES, V291, P111, DOI 10.1016/S0014-4827(03)00368-9
   LATIMER JJ, 2000, Patent No. 6074874
   Li QD, 2000, ANTICANCER RES, V20, P645
   Martin GM, 1996, HUM MOL GENET, V5, P215, DOI 10.1093/hmg/5.2.215
   MILO Y, 1994, POSTGRAD MED J, V70, P240, DOI 10.1136/pgmj.70.821.240-a
   NAROD SA, 1994, BRIT MED BULL, V50, P656, DOI 10.1093/oxfordjournals.bmb.a072915
   Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1
   Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257
   States JC, 1996, CANCER LETT, V108, P233, DOI 10.1016/S0304-3835(96)04428-X
   Tada T, 2001, CELL STRUCT FUNCT, V26, P149, DOI 10.1247/csf.26.149
   Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   van Hoffen A, 2003, TOXICOLOGY, V193, P79, DOI 10.1016/j.tox.2003.06.001
   Xiong P, 2001, CANCER RES, V61, P8465
   Yu JJ, 2000, CANCER LETT, V151, P127, DOI 10.1016/S0304-3835(99)00390-0
NR 30
TC 6
Z9 9
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD SEP
PY 2008
VL 333
IS 3
BP 461
EP 467
DI 10.1007/s00441-008-0645-1
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 338SE
UT WOS:000258528200010
PM 18575893
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Reed, K
   Hembruff, SL
   Laberge, ML
   Villeneuve, DJ
   Cêté, GB
   Parissenti, AM
AF Reed, Kerry
   Hembruff, Stacey L.
   Laberge, Monique L.
   Villeneuve, David J.
   Cote, Gilbert B.
   Parissenti, Amadeo M.
TI Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1
   gene amplification and increased expression in docetaxel-resistant MCF-7
   breast tumor cells
SO EPIGENETICS
LA English
DT Article
DE epigenetics; DNA methylation; hypermethylation; drug resistance;
   docetaxel; MCF-7 cells; breast cancer; ABCB1; MDR1; upstream promoter
ID P-GLYCOPROTEIN EXPRESSION; MDR1 UPSTREAM PROMOTER; MULTIDRUG-RESISTANCE;
   DNA METHYLATION; CANCER-CELLS; CHROMATIN-STRUCTURE; RNA EXPRESSION;
   ACTIVATION; REGION; DOXORUBICIN
AB Drug transporters have been implicated in resistance of solid and non-solid tumors to a variety of chemotherapeutic agents. Higher expression of the ABCB1 drug transporter is often observed in drug-resistant tumor cells, although the precise mechanism remains unclear. During selection of MCF-7 cells for survival in increasing concentrations of docetaxel (MCF-7(TXT) cells), we observed in this study a temporal correlation between the acquisition of docetaxel resistance at selection dose 9 and the increased expression of ABCB1. Both the magnitude of docetaxel resistance and the level of ABCB1 expression then rose as the selection dose was further elevated. We also observed through bisulfite sequencing experiments that the ABCB1 downstream promoter became increasingly methylated following the acquisition of drug resistance (selection doses 10-12). Transcription was solely attributed to the upstream ABCB1 promoter within MCF-7(TXT) cells at the highest selection dose suggesting that hypermethylation caused a shift in promoter usage. The hypermethylation was also accompanied by regional amplification of chromosome 7 containing the ABCB1 gene and its neighbor ABCB4 but not DBF-4. The amplification of the ABCB1 gene correlated positively both with the hypermethylation of the ABCB1 downstream promoter (r = 0.90) and the increased expression of ABCB1 (r = 0.78). Moreover demethylation of the ABCB1 downstream promoter induced by 5-aza-2' deoxycytidine treatment decreased the expression of ABCB1 mRNA in MCF-7(TXT) cells. Taken together, our findings suggest that the increased expression of ABCB1 upon acquisition of docetaxel resistance in breast tumor cells can be multifactorial, involving both epigenetic changes in promoter usage and regional chromosome amplification.
C1 [Reed, Kerry; Parissenti, Amadeo M.] Laurentian Univ, Dept Biomol Sci, Sudbury, ON P3E 2C6, Canada.
   [Reed, Kerry; Hembruff, Stacey L.; Laberge, Monique L.; Villeneuve, David J.; Parissenti, Amadeo M.] Sudbury Reg Hosp, Tumour Biol Res Program, Sudbury, ON P3E 5J1, Canada.
   [Cote, Gilbert B.] Sudbury Reg Hosp, Genet Lab Div, Sudbury, ON P3E 5J1, Canada.
   [Parissenti, Amadeo M.] No Ontario Sch Med, Div Med Sci, Sudbury, ON, Canada.
C3 Laurentian University; Health Sciences North; Health Sciences North;
   NOSM University
RP Parissenti, AM (通讯作者)，Sudbury Reg Hosp, Reg Canc Program, 41 Ramsey Lake Rd, Sudbury, ON P3E 5J1, Canada.
EM aparissenti@hrsrh.on.ca
CR Ando T, 2000, LEUKEMIA, V14, P1915, DOI 10.1038/sj.leu.2401914
   Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Ballestar E, 2005, PROG MOLEC, V38, P169
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Burger H, 2003, CLIN CANCER RES, V9, P827
   Buys TPH, 2007, GENE CHROMOSOME CANC, V46, P1069, DOI 10.1002/gcc.20492
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   CORNWELL MM, 1993, J BIOL CHEM, V268, P19505
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   de Silva MG, 1999, CANCER GENET CYTOGEN, V110, P28, DOI 10.1016/S0165-4608(98)00195-2
   Desiderato L, 1997, SOMAT CELL MOLEC GEN, V23, P391, DOI 10.1007/BF02673749
   ERCOLANI L, 1988, J BIOL CHEM, V263, P15335
   Gómez-Martínez A, 2007, MOL CANCER RES, V5, P641, DOI 10.1158/1541-7786.MCR-06-0177
   Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188
   Guo BQ, 2004, BREAST CANCER RES TR, V85, P31, DOI 10.1023/B:BREA.0000021046.29834.12
   Hembruff SL, 2005, ANAL BIOCHEM, V345, P237, DOI 10.1016/j.ab.2005.07.014
   Hembruff SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-318
   Ho MM, 2008, EXP HEMATOL, V36, P433, DOI 10.1016/j.exphem.2007.11.014
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Kitada K, 2007, CANCER GENET CYTOGEN, V178, P120, DOI 10.1016/j.cancergencyto.2007.06.014
   Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x
   Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X
   LISCOVITCH M, 2006, CANC LETT
   Masanek U, 1997, ANTI-CANCER DRUG, V8, P189, DOI 10.1097/00001813-199702000-00010
   Mechetner E, 1998, CLIN CANCER RES, V4, P389
   Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362
   Raguz S, 2004, CLIN CANCER RES, V10, P2776, DOI 10.1158/1078-0432.CCR-03-0517
   Raguz S, 2008, INT J CANCER, V122, P1058, DOI 10.1002/ijc.23149
   SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471
   Tada Y, 2000, CLIN CANCER RES, V6, P4618
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Takai Daiya, 2003, In Silico Biology, V3, P235
   UEDA K, 1987, J BIOL CHEM, V262, P17432
   UEDA K, 1987, J BIOL CHEM, V262, P505
   UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X
   Wang YC, 2006, GENE CHROMOSOME CANC, V45, P365, DOI 10.1002/gcc.20300
   Wu X, 2002, ONCOGENE, V21, P7786, DOI 10.1038/sj.onc.1205914
   Yabuki N, 2007, CANCER GENET CYTOGEN, V173, P1, DOI 10.1016/j.cancergencyto.2006.07.020
   Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003
NR 40
TC 39
Z9 46
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD SEP-OCT
PY 2008
VL 3
IS 5
BP 270
EP 280
DI 10.4161/epi.3.5.6868
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 369VF
UT WOS:000260721300008
PM 19001875
OA Bronze
DA 2025-01-12
ER

PT J
AU Chan, DW
   Lee, JMF
   Chan, PCY
   Ng, IOL
AF Chan, David W.
   Lee, Joyce M. F.
   Chan, Patrick C. Y.
   Ng, Irene O. L.
TI Genetic and epigenetic inactivation of <i>T</i>-<i>cadherin</i> in human
   hepatocellular carcinoma cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE T-cadherin; hepatocellular carcinoma cells; endothelial cells;
   underexpression; LOH; hypermethylation; c-Jun; HCC
ID H-CADHERIN; ABERRANT METHYLATION; PROMOTER REGION; BREAST-CANCER;
   TUMOR-CELLS; EXPRESSION; CDH13; APOPTOSIS; MOLECULE; PATHWAYS
AB T-cadherin is an atypical cadherin and growing evidence has indicated that T-cadherin exerts tumor-suppressive effects on cancers of epithelial cell type and also causes positive effects on tumor angiogenesis. Human hepatocellular carcinoma (HCC) is a hyper-vascular tumor and T-cadherin has been shown to be overexpressed in intratumoral endothelial cells of HCCs. However, the expression status and functions of T-cadherin in hepatocytes or HCC cells remain unclear. Here, we demonstrated that T-cadherin was underexpressed in HCC cells (26.5%, 13/49 cases), but was frequently (77.6%, 38/49) overexpressed in intratumoral endothelial cells immunohistochemically. Semiquantitative RT-PCR analysis also showed that the T-cadherin gene was underexpressed in 7 of 11 HCC cell lines. Loss of heterozygosity analysis revealed that 32-38% of the 42 human HCC samples had allelic losses at this locus. Upon pharmacological treatment with demethylating agent 5-aza-2'-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines. Functionally, enforced expression of T-cadherin induced G(2)/M cell cycle arrest, reduced cell proliferation in low serum medium, suppressed anchorage-independent growth in soft agar and increased sensitivity to TNF alpha-mediated apoptosis in HCC cells. Intriguingly, we found that T-cadherin significantly suppressed the activity of c-Jun, a crucial oncoprotein constitutively activated in HCC cells. To conclude, T-cadherin was differentially expressed in human HCCs. The underexpression of T-cadherin in HCC cells suggests it may be another critical event in addition to T-cadherin-mediated angiogenesis during HCC development. (C) 2008 Wiley-Liss, Inc.
C1 Univ Hong Kong, Dept Pathol, SH Ho Fdn Res Labs, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong
RP Ng, IOL (通讯作者)，Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Liver Canc & Hepatitis Res Lab, Room 127B,Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.
EM iolng@hkucc.hku.hk
RI Chan, David/O-9896-2018
OI Chan, David/0000-0002-6951-3467; Ng, Irene Oi-lin/0000-0001-7532-2029
CR Adachi Y, 2006, VIRCHOWS ARCH, V448, P311, DOI 10.1007/s00428-005-0098-9
   Angst BD, 2001, J CELL SCI, V114, P629
   Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019
   Chan DW, 2006, J PATHOL, V208, P372, DOI 10.1002/path.1901
   CHEN PJ, 1989, GASTROENTEROLOGY, V96, P527, DOI 10.1016/0016-5085(89)91581-3
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200
   Fukuoka T, 2006, ANTICANCER RES, V26, P3333
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110
   Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647
   Huang ZY, 2003, MOL CELL BIOL, V23, P566, DOI 10.1128/MCB.23.2.566-578.2003
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030
   Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6
   Kuntzen C, 2005, CANCER RES, V65, P6780, DOI 10.1158/0008-5472.CAN-04-2618
   Lee SW, 1998, CARCINOGENESIS, V19, P1157, DOI 10.1093/carcin/19.6.1157
   Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776
   Mukoyama Y, 2005, J INVEST DERMATOL, V124, P833, DOI 10.1111/j.0022-202X.2005.23660.x
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   NOWELL PC, 1986, CANCER RES, V46, P2203
   Piao Z, 1999, BRIT J CANCER, V80, P850, DOI 10.1038/sj.bjc.6690431
   Riou P, 2002, CLIN CANCER RES, V8, P3178
   Riou P, 2006, FASEB J, V20, P2291, DOI 10.1096/fj.06-6085com
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Sun HC, 2004, J CANCER RES CLIN, V130, P307, DOI 10.1007/s00432-003-0530-y
   Takeuchi T, 2000, HISTOPATHOLOGY, V37, P193, DOI 10.1046/j.1365-2559.2000.00985-5.x
   Takeuchi T, 1999, HISTOPATHOLOGY, V35, P87
   Takeuchi T, 2002, MOL CARCINOGEN, V35, P173, DOI 10.1002/mc.10088
   Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1
   Takeuchi T, 2001, HISTOL HISTOPATHOL, V16, P1287, DOI 10.14670/HH-16.1287
   Toyooka S, 2002, CANCER RES, V62, P3382
   Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792
   Wyder L, 2000, CANCER RES, V60, P4682
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zöchbauer-Müller S, 2003, INT J CANCER, V107, P612, DOI 10.1002/ijc.11458
NR 38
TC 38
Z9 53
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2008
VL 123
IS 5
BP 1043
EP 1052
DI 10.1002/ijc.23634
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 334TE
UT WOS:000258243300008
PM 18553387
DA 2025-01-12
ER

PT J
AU Wei, YK
   Xia, WY
   Zhang, ZH
   Liu, JS
   Wang, HM
   Adsay, NV
   Albarracin, C
   Yu, DH
   Abbruzzese, JL
   Mills, GB
   Bast, RC
   Hortobagyi, GN
   Hung, MC
AF Wei, Yongkun
   Xia, Weiya
   Zhang, Zhihong
   Liu, Jinsong
   Wang, Huamin
   Adsay, Nazmi V.
   Albarracin, Constance
   Yu, Dihua
   Abbruzzese, James L.
   Mills, Gordon B.
   Bast, Robert C., Jr.
   Hortobagyi, Gabriel N.
   Hung, Mien-Chie
TI Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor
   outcome in breast, ovarian, and pancreatic cancers
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE histone modification; cancer; prognosis
ID METHYLTRANSFERASE ACTIVITY; PROSTATE-CANCER; METHYLATION; EZH2;
   COMPLEXES; EXPRESSION; ENHANCER; PROTEIN; CELLS; GENE
AB Methylation of lysine 27 on histone H3 (H3K27) by the EZH2 complex is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis in both breast and prostate cancers. However, the status of H3K27 methylation and its clinical implication in cancer patients have not been reported. We thus examined trimethylation of H3K27 (H3K27me3) by irnmunohistochemistry and its association with clinical variables and prognosis in breast, ovarian, and pancreatic cancers. We found that H3K27me3 expression was significantly lower in breast, ovarian and pancreatic cancers than in normal tissues (62% in breast cancer vs. 88% in normal breast tissue, P = 0.001; 38.4% in ovarian cancer vs. 83.3% in normal ovarian tissue, P < 0.05; and 26% in pancreatic cancer vs. 89% in normal pancreatic tissue, P < 0.001). H3K27me3 expression showed significant prognostic impact in breast, ovarian and pancreatic cancers in univanate survival analyses. In all three cancer types, patients with low expression of H3K27me3 had significantly shorter overall survival time when compared with those with high H3K27me3 expression. In a multivariate model, H3K27me3 expression was an independent prognostic value for overall survival in all three cancer types. These results suggest that H3K27me3 expression is a prognostic indicator for clinical outcome in patients with breast, ovarian, and pancreatic cancers. (C) 2008 Wiley-Liss, Inc.
C1 [Wei, Yongkun; Xia, Weiya; Yu, Dihua; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Zhang, Zhihong; Liu, Jinsong; Wang, Huamin; Albarracin, Constance] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Adsay, Nazmi V.] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48202 USA.
   [Adsay, Nazmi V.] Wayne State Univ, Harpei Univ Hosp, Detroit, MI 48202 USA.
   [Abbruzzese, James L.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol & Med Oncol, Houston, TX 77030 USA.
   [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Bast, Robert C., Jr.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Barbara Ann Karmanos Cancer
   Institute; Wayne State University; Wayne State University; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Hung, MC (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.
RI Huang, Youju/A-9477-2011; Hung, Mien-Chie/ABD-5911-2021; Mills,
   Gordon/L-5416-2014; Li, Tingting/HKE-0812-2023; Bast,
   Robert/E-6585-2011; Adsay, Volkan/N-7130-2017
OI Yu, Dihua/0000-0001-6231-9381; Adsay, Volkan/0000-0002-1308-3701; Hung,
   Mien-Chie/0000-0003-4317-4740
FU NIH [R01 CA109311, P01 CA099031, CA116199]; NIH SPORE [11,50 CA83639];
   NIH SPORE grant in in Pancreatic Cancer [P20CA1101936]; National Breast
   Cancer Foundation, Inc.; Breast Cancer Research Foundation; Anderson
   Cancer Center Support Grant [CA16672]
FX This work Was supported by NIH grants R01 CA109311, P01 CA099031, NIH
   SPOIZL grant ill Breast Cancer CA116199, NIH SPORE grant in Ovarian
   Cancer 11,50 CA83639, NIH SPORE grant in in Pancreatic Cancer
   P20CA1101936, National Breast Cancer Foundation, Inc., Breast Cancer
   Research Foundation, and M.D. Anderson Cancer Center Support Grant
   CA16672. We Would like to thank Drs. Jeng C. Cheng and Stephanie A.
   Miller for editing the manuscript.
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
NR 20
TC 216
Z9 254
U1 0
U2 18
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD SEP
PY 2008
VL 47
IS 9
BP 701
EP 706
DI 10.1002/mc.20413
PG 6
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 340JW
UT WOS:000258642900006
PM 18176935
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Mujtaba, S
   Manzur, KL
   Gurnon, JR
   Kang, M
   Van Etten, JL
   Zhou, MM
AF Mujtaba, Shiraz
   Manzur, Karishma L.
   Gurnon, James R.
   Kang, Ming
   Van Etten, James L.
   Zhou, Ming-Ming
TI Epigenetic transcriptional repression of cellular genes by a viral SET
   protein
SO NATURE CELL BIOLOGY
LA English
DT Article
ID HISTONE METHYLTRANSFERASE ACTIVITY; H3 LYSINE-27 METHYLATION; POLYCOMB
   GROUP PROTEINS; EMBRYONIC STEM-CELLS; CHROMATIN-STRUCTURE; H3K27
   DEMETHYLASES; CHLORELLA VIRUSES; PCAF BROMODOMAIN; STRUCTURAL BASIS;
   BREAST-CANCER
AB Viruses recruit host proteins to secure viral genome maintenance and replication. However, whether they modify host histones directly to interfere with chromatin-based transcription is unknown. Here we report that Paramecium bursaria chlorella virus 1 (PBCV-1) encodes a functional SET domain histone Lys methyltransferase (HKMTase) termed vSET, which is linked to rapid inhibition of host transcription after viral infection. We show that vSET is packaged in the PBCV-1 virion, and that it contains a nuclear localization signal and probably represses host transcription by methylating histone H3 at Lys 27 (H3K27), a modification known to trigger gene silencing in eukaryotes. We also show that vSET induces cell accumulation at the G2/M phase by recruiting the Polycomb repressive complex CBX8 to the methylated H3K27 site in a heterologous system. vSET-like proteins that have H3K27 methylation activity are conserved in chlorella viruses. Our findings suggest a viral mechanism to repress gene transcription by direct modification of chromatin by PBCV-1 vSET.
C1 [Gurnon, James R.; Kang, Ming; Van Etten, James L.] Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA.
   [Gurnon, James R.; Kang, Ming; Van Etten, James L.] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA.
   [Mujtaba, Shiraz; Manzur, Karishma L.; Zhou, Ming-Ming] NYU, Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA.
C3 University of Nebraska System; University of Nebraska Lincoln;
   University of Nebraska System; University of Nebraska Lincoln; New York
   University; Icahn School of Medicine at Mount Sinai
RP Van Etten, JL (通讯作者)，Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA.
EM jvanetten@unlnotes.unl.edu; ming-ming.zhou@mssm.edu
FU NIH-NCI; National Institutes of Health
FX We thank L. W. Enquist for the Us9-GFP construct, M. Ptashne for the
   Gal4-DBD construct, P. Traber for the firefly luciferase construct, R.
   Slany for the HOX7A luciferase construct, I. V. Agarkova for the results
   used in Fig. 1a, and M. Walsh for helpful discussions. Fluorescence
   microscopy imaging was performed at the Mount Sinai Microscopy Shared
   Resource Facility supported in part with funding from NIH-NCI shared
   resources grant. This work was supported by grants from the National
   Institutes of Health (M.-M.Z. and J.L.V.E.).
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Alvarez-Venegas R, 2007, MOL BIOL EVOL, V24, P482, DOI 10.1093/molbev/msl184
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715
   Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9
   Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117
   Kang M, 2004, VIROLOGY, V326, P150, DOI 10.1016/j.virol.2004.05.023
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Manzur KL, 2005, FEBS LETT, V579, P3859, DOI 10.1016/j.febslet.2005.05.026
   Manzur KL, 2003, NAT STRUCT BIOL, V10, P187, DOI 10.1038/nsb898
   Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603
   Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Qian C, 2006, CELL MOL LIFE SCI, V63, P2755, DOI 10.1007/s00018-006-6274-5
   Qian CM, 2006, J MOL BIOL, V359, P86, DOI 10.1016/j.jmb.2006.03.006
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   SCHUSTER AM, 1986, VIROLOGY, V150, P170, DOI 10.1016/0042-6822(86)90276-X
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Svingen T, 2003, CANCER BIOL THER, V2, P518, DOI 10.4161/cbt.2.5.441
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915
   Whitcomb SJ, 2007, TRENDS GENET, V23, P494, DOI 10.1016/j.tig.2007.08.006
   Yap KL, 2006, RES PRO CEL, V41, P1, DOI 10.1007/010
   You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7
NR 35
TC 50
Z9 66
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD SEP
PY 2008
VL 10
IS 9
BP 1114
EP 1122
DI 10.1038/ncb1772
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 344EW
UT WOS:000258910400018
PM 19160493
OA Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Shi, Y
   Chen, JY
   Yang, J
   Li, B
   Chen, ZH
   Xiao, CG
AF Shi, Ying
   Chen, Jian-Ying
   Yang, Jun
   Li, Bin
   Chen, Zhao-Hui
   Xiao, Chuan-Guo
TI DBC2 gene is silenced by promoter methylation in bladder cancer
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE bladder cancer; DBC2; methylation; epigenetics
ID TUMOR-SUPPRESSOR GENES; CHROMOSOME 8P; CPG ISLANDS; CARCINOMA;
   CANDIDATE; DELETIONS; RHOBTB2
AB Deletions at 8p are frequent in many human cancers and represent a genetic marker associated with a more aggressive tumor phenotype. Previous mutational analysis of DBC2 (deleted in breast cancer 2), a tumor suppressor gene located in the region of loss of heterozygosity (LOH) on 8p21. failed to show a high frequency of mutation linked to low expression in bladder cancer. promoter hypermethylation may be an alternative mechanism of inactivation of the second allele. We detected the methylation Status and expression of the DBC2 gene in 75 bladder cancer samples and 57 corresponding normal tissues. Aberrant methylation and down-regulation of DBC2 were observed preferentially in tumor samples (P < 0.05). and the expression changes were associated with methylation (P < 0.05). These findings. together with the previously Mutation reports. suggest that aberrant methylation in DBC2 promoter may be responsible for the expression loss of DBC2 expression in bladder cancer and this hypermethylation event could play a crucial role in the early stage of bladder tumorigenesis. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Shi, Ying; Yang, Jun; Li, Bin; Chen, Zhao-Hui; Xiao, Chuan-Guo] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Urol, Wuhan 430074, Peoples R China.
   [Chen, Jian-Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gen Surg, Wuhan 430074, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Xiao, CG (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Urol, Wuhan 430074, Peoples R China.
EM xiaocg@mails.tjmu.edu.cn
OI shi, ying/0000-0003-4439-0592
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   BENNETT WP, 1993, CANCER RES, V53, P4817
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   FUJIWARA Y, 1993, CANCER RES, V53, P1172
   Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   KAGAN J, 1995, ONCOGENE, V11, P2121
   Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047
   MACOSKA JA, 1995, CANCER RES, V55, P5390
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Takle LA, 1996, ONCOGENE, V12, P1083
   Wagner U, 1997, AM J PATHOL, V151, P753
   Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905
   Westra WH, 1996, CANCER RES, V56, P2224
   Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904
   Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447
NR 18
TC 17
Z9 19
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD SEP-OCT
PY 2008
VL 26
IS 5
BP 465
EP 469
DI 10.1016/j.urolonc.2007.08.009
PG 5
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Urology & Nephrology
GA 351IC
UT WOS:000259416900002
PM 18640857
DA 2025-01-12
ER

PT J
AU Lal, G
   Padmanabha, L
   Provenzano, M
   Fitzgerald, M
   Weydert, J
   Domann, FE
AF Lal, Geeta
   Padmanabha, Lakshm
   Provenzano, Matthew
   Fitzgerald, Matthew
   Weydert, Jamie
   Domann, Frederick E.
TI Regulation of <i>14</i>-<i>3</i>-<i>3</i>σ expression in human thyroid
   carcinoma is epigenetically regulated by aberrant cytosine methylation
SO CANCER LETTERS
LA English
DT Article
DE 14-3-3 sigma; thyroid; cancer; hypermethylation
ID BREAST-CANCER; PAPILLARY-CARCINOMA; GENE-EXPRESSION; SIGMA GENE;
   HYPERMETHYLATION; INACTIVATION; PROGRESSION; FREQUENT; TUMOR;
   ADENOCARCINOMA
AB Increased 14-3-3 sigma expression has been observed by immunohistochemistry in papillary and anaplastic tumors, but not follicular thyroid cancers. 14-3-3 sigma mRNA expression and methylation status was examined in tumor Cell lines and primary thyroid tissues using real-time RT-PCR, bisulfite sequencing and methylation-specific PCR. Most of the 27 CpG's in the gene's CpG island were methylated in normal thyroid, TPC-1, NPA, FTC-238 and 2-7, which did not express 14-3-3 sigma. In contrast, they were unmethylated in KAK-1 and anaplastic lines KAT4 and DRO-90. 14-3-3 sigma expression was not increased in thyroid carcinomas, the majority of which had a methylated CpG island. In addition, 5-aza-dC treatment increased 14-3-3 sigma expression in the FTC-238 and NPA cell lines, which had low baseline expression. We conclude 14-3-3 sigma expression in thyroid carcinomas is regulated by CpG island hypermethylation. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Lal, Geeta; Padmanabha, Lakshm] Univ Iowa Hosp & Clin, Div Surg Oncol, Dept Surg, Iowa City, IA 52242 USA.
   [Provenzano, Matthew] Univ Iowa, Dept Otolaryngol, Iowa City, IA 52242 USA.
   [Fitzgerald, Matthew; Domann, Frederick E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA.
   [Fitzgerald, Matthew; Domann, Frederick E.] Univ Iowa, Free Rad & Radiat Oncol Program, Iowa City, IA 52242 USA.
   [Weydert, Jamie] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
   [Domann, Frederick E.] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; University of Iowa; University of Iowa
RP Lal, G (通讯作者)，Univ Iowa Hosp & Clin, Div Surg Oncol, Dept Surg, 200 Hawkins Drive,4641 JCP, Iowa City, IA 52242 USA.
EM Geeta-lal@uiowa.edu
OI Lal, Geeta/0000-0001-6471-6479; Domann, Frederick/0000-0002-0489-2179
FU NCI NIH HHS [R01 CA073612-07, R01 CA073612-08, R01 CA73612, R01
   CA073612] Funding Source: Medline
CR *ABI PRISM, 1997, US B ABI PRISM, V2
   Ain KB, 1997, J CLIN ENDOCR METAB, V82, P1857, DOI 10.1210/jcem.82.6.4013
   Akahira J, 2004, CLIN CANCER RES, V10, P2687, DOI 10.1158/1078-0432.CCR-03-0510
   Boltze C, 2003, PATHOL RES PRACT, V199, P399, DOI 10.1078/0344-0338-00436
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8
   Green LD, 2006, J SURG ONCOL, V94, P725, DOI 10.1002/jso.20691
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Ide M, 2004, CANCER LETT, V207, P241, DOI 10.1016/j.canlet.2003.11.009
   Ito K, 2005, CLIN CANCER RES, V11, P7384, DOI 10.1158/1078-0432.CCR-05-0187
   Ito Y, 2005, PATHOL RES PRACT, V201, P545, DOI 10.1016/j.prp.2005.08.002
   Ito Y, 2003, CANCER LETT, V200, P161, DOI 10.1016/S0304-3835(03)00282-9
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Lal G, 2006, CANCER, V107, P2752, DOI 10.1002/cncr.22325
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801
   Logsdon CD, 2003, CANCER RES, V63, P2649
   Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291
   Mocellin S, 2003, TRENDS MOL MED, V9, P189, DOI 10.1016/S1471-4914(03)00047-9
   Nacht M, 1999, CANCER RES, V59, P5464
   Nakanishi Kozo, 1997, Human Antibodies, V8, P189
   Nakayama H, 2005, PATHOL INT, V55, P707, DOI 10.1111/j.1440-1827.2005.01900.x
   Nuciforo PG, 2003, HUM PATHOL, V34, P639, DOI 10.1016/S0046-8177(03)00238-7
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Oshiro MM, 2005, NEOPLASIA, V7, P799, DOI 10.1593/neo.05274
   Perathoner A, 2005, CLIN CANCER RES, V11, P3274, DOI 10.1158/1078-0432.CCR-04-2207
   Rocha AS, 2004, THYROID, V14, P902
   Sato N, 2003, CANCER RES, V63, P4158
   Suzuki H, 2000, CANCER RES, V60, P4353
   Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056
   Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826
   Venkataraman GM, 1999, J CLIN ENDOCR METAB, V84, P2449, DOI 10.1210/jc.84.7.2449
   Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008
   Xing MZ, 2003, CANCER RES, V63, P2312
   Xing MZ, 2003, CANCER RES, V63, P2316
   Xu XL, 2003, CLIN CANCER RES, V9, P5968
NR 37
TC 11
Z9 14
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD AUG 18
PY 2008
VL 267
IS 1
BP 165
EP 174
DI 10.1016/j.canlet.2008.03.017
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 332BQ
UT WOS:000258057100016
PM 18440129
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Crabb, SJ
   Howell, M
   Rogers, H
   Ishfaq, M
   Yurek-George, A
   Carey, K
   Pickering, BM
   East, P
   Mitter, R
   Maeda, S
   Johnson, PWM
   Townsend, P
   Shin-Ya, K
   Yoshida, M
   Ganesan, A
   Packham, G
AF Crabb, Simon J.
   Howell, Melanie
   Rogers, Helen
   Ishfaq, Muhammad
   Yurek-George, Alexander
   Carey, Krystle
   Pickering, Becky M.
   East, Phil
   Mitter, Richard
   Maeda, Satoko
   Johnson, Peter W. M.
   Townsend, Paul
   Shin-ya, Kazuo
   Yoshida, Minoru
   Ganesan, A.
   Packham, Graham
TI Characterisation of the <i>in vitro</i> activity of the depsipeptide
   histone deacetylase inhibitor spiruchostatin A
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE spiruchostatin A; depsipeptide; FK228; histone deacetylase inhibitor;
   cancer; epigenetic
ID SUBEROYLANILIDE HYDROXAMIC ACID; BREAST-CANCER CELLS; SLUG REPRESSOR
   PROTEIN; GENE-EXPRESSION; PHASE-I; CARCINOMA-CELLS; CDNA MICROARRAY;
   TRICHOSTATIN-A; E-CADHERIN; FK228
AB We recently completed the total synthesis of spiruchostatin A, a depsipeptide natural product with close structural similarities to FK228, a histone deacetylase (HDAC) inhibitor (HDI) currently being evaluated in clinical trials for cancer. Here we report a detailed characterisation of the in vitro activity of spiruchostatin A. Spiruchostatin A was a potent (sub-nM) inhibitor of class I HDAC activity in vitro and acted as a prodrug, requiring reduction for activity. Spiruchostatin A was a potent (low nM) inhibitor of the growth of various cancer cell lines. Spiruchostatin A-induced acetylation of specific lysine residues within histones H3 and H4, and increased the expression of p21(cip/waf1), but did not induce acetylation of alpha-tubulin. Spiruchostatin A also induced cell cycle arrest, differentiation and cell death in MCF7 breast cancer cells. Like FK228, spiruchostatin A was both an inducer and substrate of the ABCB1 drug efflux pump. Whereas spiruchostatin A and FK228-induced protracted histone acetylation, hydroxamate HDI-induced short-lived histone acetylation. Using a subset of HDI-target genes identified by microarray analysis, we demonstrated that these differences in kinetics of histone acetylation between HDI correlated with differences in the kinetics of induction or repression of specific target genes. Our results demonstrate that spiruchostatin A is a potent inhibitor of class I HDACs and anti-cancer agent. Differences in the kinetics of action of HDI may be important for the clinical application of these compounds. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Crabb, Simon J.; Howell, Melanie; Carey, Krystle; Pickering, Becky M.; Johnson, Peter W. M.; Packham, Graham] Univ Southampton, Sch Med, Southampton Gen Hosp MP824, Canc Sci Div,Canc Res UK Clin Ctr, Southampton SO16 6YD, Hants, England.
   [Rogers, Helen; Ishfaq, Muhammad; Townsend, Paul; Ganesan, A.; Packham, Graham] Univ Southampton, John Fairclough Ctr, Karus Therapeut Ltd, Southampton SO17 1BJ, Hants, England.
   [Yurek-George, Alexander; Ganesan, A.] Univ Southampton, Sch Chem, Southampton SO17 1BJ, Hants, England.
   [East, Phil; Mitter, Richard] Canc Res UK Bioinformat Unit, London WC2A 3PX, England.
   [Maeda, Satoko; Yoshida, Minoru] RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan.
   [Townsend, Paul] Univ Southampton, Sch Med, Southampton Gen Hosp, Div Human Genet, Southampton SO16 6YD, Hants, England.
   [Shin-ya, Kazuo] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
C3 University of Southampton; Cancer Research UK; University of
   Southampton; University of Southampton; Cancer Research UK; RIKEN;
   University of Southampton; University of Tokyo
RP Crabb, SJ (通讯作者)，Univ Southampton, Sch Med, Southampton Gen Hosp MP824, Canc Sci Div,Canc Res UK Clin Ctr, Southampton SO16 6YD, Hants, England.
EM S.J.Crabb@southampton.ac.uk
RI Ishfaq, Muhammad/D-2217-2012; Johnson, Peter/O-3529-2019; Ganesan,
   A/F-6698-2011; Townsend, Paul/AAF-8234-2020; Shin-ya, Kazuo/L-9613-2018;
   Yoshida, Minoru/C-8049-2014; Johnson, Peter/L-2403-2018
OI Yoshida, Minoru/0000-0002-4376-5674; Mitter,
   Richard/0000-0002-1279-3760; East, Philip/0000-0001-5801-5713; Johnson,
   Peter/0000-0003-2306-4974; Townsend, Paul A./0000-0001-8956-9508; Crabb,
   Simon/0000-0003-3521-9064; Packham, Graham/0000-0002-9232-5691; Ganesan,
   A/0000-0003-4862-7999
FU Cancer Research UK, Karus Therapeutics Ltd; Health Science of the
   National Institute of Biomedical Innovation, Japan
FX We thank Dr. Jeremy Blaydes for the kind gift of BT474 cells and Michael
   Shipton and Charlotte Hinds for per-forming some of the growth
   inhibition assays. This work was funded by Cancer Research UK, Karus
   Therapeutics Ltd. and the Program for the Promotion of Fundamental
   Studies in Health Science of the National Institute of Biomedical
   Innovation, Japan.
CR Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043
   Bates SE, 2007, CANCER J, V13, P80, DOI 10.1097/PPO.0b013e318063bd9f
   Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893
   Bevins RL, 2005, CANCER RES, V65, P6957, DOI 10.1158/0008-5472.CAN-05-0836
   Cesarone G, 2006, J CELL BIOCHEM, V98, P440, DOI 10.1002/jcb.20817
   Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004
   Cheng YQ, 2007, APPL ENVIRON MICROB, V73, P3460, DOI 10.1128/AEM.01751-06
   Chiba T, 2004, J HEPATOL, V41, P436, DOI 10.1016/j.jhep.2004.05.018
   Crabb SJ, 2008, ONCOL REP, V19, P689
   de Ruijter AJM, 2005, EXP CELL RES, V309, P451, DOI 10.1016/j.yexcr.2005.06.024
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897
   Furumai R, 2002, CANCER RES, V62, P4916
   Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Gray SG, 2004, INT J ONCOL, V24, P773
   GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965
   Hajra KM, 2002, CANCER RES, V62, P1613
   HARKER WG, 1985, CANCER RES, V45, P4091
   Hildmann C, 2006, J BIOTECHNOL, V124, P258, DOI 10.1016/j.jbiotec.2006.01.030
   Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z
   Lee HS, 2004, BIOL PHARM BULL, V27, P1497, DOI 10.1248/bpb.27.1497
   Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045
   Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5
   Masuoka Y, 2001, TETRAHEDRON LETT, V42, P41, DOI 10.1016/S0040-4039(00)01874-8
   Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   MOORE PS, 2004, BIOCHIM BIOPHYS ACTA, P167
   Munster PN, 2001, CANCER RES, V61, P8492
   Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807
   Rampalli S, 2005, MOL CELL BIOL, V25, P8415, DOI 10.1128/MCB.25.19.8415-8429.2005
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Sato T, 2006, INT J ONCOL, V28, P1233
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Sood R, 2000, BBA-GENE STRUCT EXPR, V1491, P285, DOI 10.1016/S0167-4781(00)00031-2
   Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126
   Townsend P.A., 2007, CHEM BIOL, P693
   Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200
   Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V329, P508, DOI 10.1016/j.bbrc.2005.02.006
   Uchikado Y, 2005, CLIN CANCER RES, V11, P1174
   UEDA H, 1994, J ANTIBIOT, V47, P301
   Xiao JJ, 2005, J PHARMACOL EXP THER, V314, P467, DOI 10.1124/jpet.105.083956
   Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676
   Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805
   Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Yurek-George A, 2004, J AM CHEM SOC, V126, P1030, DOI 10.1021/ja039258q
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
NR 58
TC 57
Z9 60
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD AUG 15
PY 2008
VL 76
IS 4
BP 463
EP 475
DI 10.1016/j.bcp.2008.06.004
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 338XM
UT WOS:000258542700003
PM 18611394
DA 2025-01-12
ER

PT J
AU Kapoor-Vazirani, P
   Kagey, JD
   Powell, DR
   Vertino, PM
AF Kapoor-Vazirani, Priya
   Kagey, Jacob D.
   Powell, Doris R.
   Vertino, Paula M.
TI Role of hMOF-dependent histone H4 lysine 16 acetylation in the
   maintenance of <i>TMS1</i>/<i>ASC</i> gene activity
SO CANCER RESEARCH
LA English
DT Article
ID DE-NOVO METHYLATION; RECRUITMENT DOMAIN PROTEIN; HISTONE H4 ACETYLATION;
   BREAST-CANCER CELLS; CPG ISLAND; ABERRANT METHYLATION;
   COLORECTAL-CANCER; DNA METHYLATION; X-INACTIVATION; HUMAN GENOME
AB Epigenetic silencing of tumor suppressor genes in human cancers is associated with aberrant methylation of promoter region CpG islands and local alterations in histone modifications. However, the mechanisms that drive these events remain unclear. Here, we establish an important role for histone H4 lysine 16 acetylation (H4K16Ac) and the histone acetyltransferase hMOF in the regulation of TMS1/ASC, a proapoptotic gene that undergoes epigenetic silencing in human cancers. In the unmethylated and active state, the TMS1 CpG island is spanned by positioned nucleosomes and marked by histone H3K4 methylation. H4K16Ac was uniquely localized to two sharp peaks that flanked the unmethylated CpG island and corresponded to strongly positioned nucleosomes. Aberrant methylation and silencing of TMS1 was accompanied by loss of the H4K16Ac peaks, loss of nucleosome positioning, hypomethylation of H3K4, and hypermethylation of H3K9. In addition, a single peak of histone H4 lysine 20 trimethylation was observed near the transcription start site. Down-regulation of hMOF or another component of the MSL complex resulted in a gene-specific decrease in H4K16Ac, loss of nucleosome positioning, and silencing of TMS1. Gene silencing induced by H4K16 deacetylation occurred independently of changes in histone methylation and DNA methylation and was reversed on hMOF reexpression. These results indicate that the selective marking of nucleosomes flanking the CpG island by hMOF is required to maintain TMS1 gene activity and suggest that the loss of H4K16Ac, mobilization of nucleosomes, and transcriptional down-regulation may be important events in the epigenetic silencing of certain tumor suppressor genes in cancer.
C1 [Vertino, Paula M.] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA.
   Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
C3 Emory University; Emory University
RP Vertino, PM (通讯作者)，Emory Univ, Winship Canc Ctr, 1365-C Clifton Rd NE, Atlanta, GA 30322 USA.
EM pvertin@emory.edu
OI Kagey, Jacob/0000-0002-6994-1795
FU NIH [2R01-CA077337]; Canadian Institute of Health Research Postdoctoral
   Fellowship; National Science Foundation Problems and Research
   [DGE0536941, DGE0231900]
FX Grant support: NIH grant 2R01-CA077337 (P.M. Vertino). Canadian
   Institute of Health Research Postdoctoral Fellowship (P.
   Kapoor-Vazirani). and National Science Foundation Problems and Research
   to Integrate Science and Mathematics Fellowship. nos. DGE0536941 and
   DGE0231900 (J.D. Kagey). P.M. Vertino is a Georgia Cancer Coalition
   Distinguished Cancer Scholar. The costs of publication of this article
   were defrayed in part by the payment of page charges. This article must
   therefore be hereby marked advertisement in accordance with 18 U.S.C.
   Section 1734 sole)V to indicate this fact. We thank Dr. Edwin Smith for
   the hMOF and hMSL1 antibodies. and Dr. John Lucchesi for critical
   reading of the manuscript.
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Chen C, 2001, MOL CELL BIOL, V21, P7682, DOI 10.1128/MCB.21.22.7682-7695.2001
   Conway KE, 2000, CANCER RES, V60, P6236
   Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056
   Davey C, 2003, J MOL BIOL, V325, P873, DOI 10.1016/S0022-2836(02)01340-2
   Davie JR, 1999, J CELL BIOCHEM, P141
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gal-Yam EN, 2006, PLOS GENET, V2, P1451, DOI 10.1371/journal.pgen.0020160
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5
   Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005
   Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282
   Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835
   Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9
   MCCONNELL BB, 2000, CANCER RES, V62, P13
   Moriai R, 2002, ANTICANCER RES, V22, P4163
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684
   Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813
   Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979
   Shogren-Knaak M, 2006, CELL CYCLE, V5, P1361, DOI 10.4161/cc.5.13.2891
   Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005
   Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200
   Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7
   Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027
   Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178
NR 50
TC 63
Z9 78
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2008
VL 68
IS 16
BP 6810
EP 6821
DI 10.1158/0008-5472.CAN-08-0141
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 338ZP
UT WOS:000258548200040
PM 18701507
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Negraes, PD
   Favaro, FP
   Camargo, JLV
   Oliveira, MLCS
   Goldberg, J
   Rainho, CA
   Salvadori, DMF
AF Negraes, Priscilla D.
   Favaro, Francine P.
   Camargo, Joao Lauro V.
   Oliveira, Maria Luiza C. S.
   Goldberg, Jose
   Rainho, Claudia A.
   Salvadori, Daisy M. F.
TI DNA methylation patterns in bladder cancer and washing cell sediments: a
   perspective for tumor recurrence detection
SO BMC CANCER
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; CPG ISLAND METHYLATION; E-CADHERIN GENE;
   BREAST-CANCER; URINARY-BLADDER; UROTHELIAL CARCINOMA;
   ULCERATIVE-COLITIS; MULTIPLE GENES; FREQUENT HYPERMETHYLATION;
   SUPPRESSOR GENES
AB Background: Epigenetic alterations are a hallmark of human cancer. In this study, we aimed to investigate whether aberrant DNA methylation of cancer-associated genes is related to urinary bladder cancer recurrence.
   Methods: A set of 4 genes, including CDH1 (E-cadherin), SFN (stratifin), RARB (retinoic acid receptor, beta) and RASSF1A (Ras association (RalGDS/AF-6) domain family 1), had their methylation patterns evaluated by MSP (Methylation-Specific Polymerase Chain Reaction) analysis in 49 fresh urinary bladder carcinoma tissues (including 14 cases paired with adjacent normal bladder epithelium, 3 squamous cell carcinomas and 2 adenocarcinomas) and 24 cell sediment samples from bladder washings of patients classified as cancer-free by cytological analysis (control group). A third set of samples included 39 archived tumor fragments and 23 matched washouts from 20 urinary bladder cancer patients in post-surgical monitoring. After genomic DNA isolation and sodium bisulfite modification, methylation patterns were determined and correlated with standard clinic-histopathological parameters.
   Results: CDH1 and SFN genes were methylated at high frequencies in bladder cancer as well as in paired normal adjacent tissue and exfoliated cells from cancer-free patients. Although no statistically significant differences were found between RARB and RASSF1A methylation and the clinical and histopathological parameters in bladder cancer, a sensitivity of 95% and a specificity of 71% were observed for RARB methylation (Fisher's Exact test (p < 0.0001; OR = 48.89) and, 58% and 17% (p < 0.05; OR = 0.29) for RASSF1A gene, respectively, in relation to the control group.
   Conclusion: Indistinct DNA hypermethylation of CDH1 and SFN genes between tumoral and normal urinary bladder samples suggests that these epigenetic features are not suitable biomarkers for urinary bladder cancer. However, RARB and RASSF1A gene methylation appears to be an initial event in urinary bladder carcinogenesis and should be considered as defining a panel of differentially methylated genes in this neoplasia in order to maximize the diagnostic coverage of epigenetic markers, especially in studies aiming at early recurrence detection.
C1 [Negraes, Priscilla D.; Favaro, Francine P.; Rainho, Claudia A.] Sao Paulo State Univ, UNESP, Biosci Inst, Dept Genet, BR-18618000 Botucatu, SP, Brazil.
   [Negraes, Priscilla D.; Camargo, Joao Lauro V.; Oliveira, Maria Luiza C. S.; Salvadori, Daisy M. F.] Sao Paulo State Univ, UNESP, Botucatu Med Sch, Dept Pathol, BR-18618000 Botucatu, SP, Brazil.
   [Goldberg, Jose] Sao Paulo State Univ, UNESP, Botucatu Med Sch, Dept Urol, BR-18618000 Botucatu, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista;
   Universidade Estadual Paulista
RP Rainho, CA (通讯作者)，Sao Paulo State Univ, UNESP, Biosci Inst, Dept Genet, BR-18618000 Botucatu, SP, Brazil.
EM prinegraes@yahoo.com.br; franfavaro@yahoo.com.br; decam@fmb.unesp.br;
   mdeolive@fmb.unesp.br; goldberg@fmb.unesp.br; rainho@ibb.unesp.br;
   dfavero@fmb.unesp.br
RI Rainho, Claudia Aparecida/B-7567-2012; Camargo, Joao Lauro Viana
   de/G-3735-2012; FAVERO SALVADORI, DAISY MARIA/E-7744-2012
OI Rainho, Claudia Aparecida/0000-0002-0285-1162; Camargo, Joao Lauro Viana
   de/0000-0003-3833-4172; FAVERO SALVADORI, DAISY
   MARIA/0000-0001-9323-3134; Cotrim Sartor de Oliveira, Maria
   Luiza/0000-0002-8830-1267
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [03/11730-8, 04/00108-7]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)
FX To the staff at Amaral Carvalho Hospital, Jau, SP, Brazil for the
   agreement to contribute to this study, especially to Dr. Renato Costa
   Prado from the Department of Urology; Dr. Adauto Jose Ferreira Nunes and
   Dr. Francisco Carlos Quevedo from the Department of Pathology. To Joao
   Paulo de Castro Marcondes, Merielen Garcia Nascimento and Bruna Liboni
   for other contributions. PDN was supported by grants from Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 03/11730-8). This study
   was financially supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP 04/00108-7) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq).
CR Azarschab P, 2002, GENE CHROMOSOME CANC, V35, P121, DOI 10.1002/gcc.10101
   Bartoletti R, 2007, J SURG RES, V143, P422, DOI 10.1016/j.jss.2007.01.012
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0
   Brtko Julius, 2007, Central European Journal of Public Health, V15, P3
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cairns P, 2007, NAT REV CANCER, V7, P531, DOI 10.1038/nrc2170
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Chan EC, 2005, CANCER GENET CYTOGEN, V162, P10, DOI 10.1016/j.cancergencyto.2005.03.008
   Chan MWY, 2002, CLIN CANCER RES, V8, P464
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Cho HY, 2007, J INT MED RES, V35, P224, DOI 10.1177/147323000703500206
   Christoph F, 2006, INT J CANCER, V119, P1396, DOI 10.1002/ijc.21971
   Cianciulli AM, 2003, HUM PATHOL, V34, P214, DOI 10.1053/hupa.2003.30
   Corn PG, 2001, CLIN CANCER RES, V7, P2765
   Costa VL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-133
   Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645
   Dhawan D, 2006, J PATHOL, V209, P336, DOI 10.1002/path.1991
   Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Friedrich MG, 2005, EUR J CANCER, V41, P2769, DOI 10.1016/j.ejca.2005.07.019
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Gutiérrez MI, 2004, MODERN PATHOL, V17, P1268, DOI 10.1038/modpathol.3800177
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x
   Hoque MO, 2003, CANCER RES, V63, P2216
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Horikawa Y, 2003, J UROLOGY, V169, P1541, DOI 10.1097/01.ju.0000046242.55722.1c
   Hsieh CJ, 1998, CANCER RES, V58, P3942
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Jass JR, 2002, J GASTROEN HEPATOL, V17, P17, DOI 10.1046/j.1440-1746.2002.02635.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062
   Knowles MA, 2007, FRONT BIOSCI-LANDMRK, V12, P2233, DOI 10.2741/2226
   Kunze E, 2006, INT J MOL MED, V18, P547
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Leonardo C, 2005, J EXP CLIN CANC RES, V24, P633
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Lombaerts M, 2004, BIOCHEM BIOPH RES CO, V319, P697, DOI 10.1016/j.bbrc.2004.05.041
   Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172
   Maruyama R, 2001, CANCER RES, V61, P8659
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Nass SJ, 2000, CANCER RES, V60, P4346
   Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009
   Qian ZR, 2007, MODERN PATHOL, V20, P1269, DOI 10.1038/modpathol.3800965
   Reuter VE, 2006, UROLOGY, V67, P11, DOI 10.1016/j.urology.2006.01.037
   Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Sathyanarayana UG, 2007, CANCER LETT, V245, P112, DOI 10.1016/j.canlet.2005.12.042
   Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63
   Smith LT, 2007, TRENDS GENET, V23, P449, DOI 10.1016/j.tig.2007.07.005
   Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407
   Trkova M, 2006, CANCER LETT, V242, P68, DOI 10.1016/j.canlet.2005.10.036
   Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8
   Turyn J, 2006, ONCOL REP, V15, P259
   Tzai TS, 2003, UROLOGY, V62, P378, DOI 10.1016/S0090-4295(03)00344-3
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Waterland RA, 2006, J NUTR, V136, p1706S, DOI 10.1093/jn/136.6.1706S
   WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
   Zhang JJ, 2004, CARCINOGENESIS, V25, P343, DOI 10.1093/carcin/bgh015
NR 76
TC 39
Z9 44
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 14
PY 2008
VL 8
AR 238
DI 10.1186/1471-2407-8-238
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 346MN
UT WOS:000259072700002
PM 18702824
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Smiraglia, DJ
   Kulawiec, M
   Bistulfi, GL
   Gupta, SG
   Singh, KK
AF Smiraglia, Dominic J.
   Kulawiec, Mariola
   Bistulfi, Gaia L.
   Gupta, Sampa Ghoshal
   Singh, Keshav K.
TI A novel role for mitochondria in regulating epigenetic modification in
   the nucleus
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE mitochondria; epigenetic; retrograde; mitochondrial DNA; mtDNA
   depletion; RLGS; OXPHOS; rho(0)
ID CPG ISLAND HYPERMETHYLATION; BREAST-CANCER PATIENTS; RENAL-CELL
   CARCINOMA; GENOME INSTABILITY; DNA METHYLATION; 5-METHYLCYTOSINE
   CONTENT; RETROGRADE RESPONSE; HUMAN MALIGNANCIES; COPY NUMBER;
   CROSS-TALK
AB Epigenetic modification in the nuclear genome plays a key role in human tumorigenesis. In this paper, we investigated whether changes in the mtDNA copy number frequently reported to vary in a number of human tumors induce methylation changes in the nucleus. We utilized the Restriction Landmark Genomic Scanning (RLGS) to identify genes that undergo changes in their methylation status in response to the depletion and repletion of mtDNA. Our study demonstrates that depletion of mtDNA results in significant changes in methylation pattern of a number of genes. Furthermore, our study suggests that methylation changes are reversed by the restoration of mtDNA in cells otherwise lacking the entire mitochondrial genome. These studies provide the first direct evidence that mitochondria regulate epigenetic modification in the nucleus that may contribute to tumorigenesis.
C1 [Smiraglia, Dominic J.; Kulawiec, Mariola; Bistulfi, Gaia L.; Gupta, Sampa Ghoshal; Singh, Keshav K.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center
RP Singh, KK (通讯作者)，Roswell Pk Canc Inst, Dept Canc Genet, BLSC Bldg,Room 3316,Elm & Carlton St, Buffalo, NY 14263 USA.
EM keshav.singh@roswellpark.org
RI Smiraglia, Dominic/R-2069-2019
OI Smiraglia, Dominic/0000-0001-8852-1510
FU NIH [RO1 121904, RO1CA116430]; NY State Department of Health-Breast
   Cancer Program [CO21336]; National Cancer Institute [CA 16056]
FX We thank Ms. Paula Jones for editing this manuscript. The research in
   our laboratory was supported by NIH grant RO1 121904 and RO1CA116430 (to
   KKS) and NY State Department of Health-Breast Cancer Program Contract #
   CO21336 (MK and KKS). It was also supported, in part, by the National
   Cancer Institute Support Grant to Roswell Park Cancer Institute, CA
   16056.
CR Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072
   Bianchi NO, 2001, MUTAT RES-REV MUTAT, V488, P9, DOI 10.1016/S1383-5742(00)00063-6
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Chomyn A, 1996, Methods Enzymol, V264, P334, DOI 10.1016/S0076-6879(96)64031-2
   Clayton D A, 2000, Hum Reprod, V15 Suppl 2, P11
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083
   Damiani S, 1998, AM J SURG PATHOL, V22, P221, DOI 10.1097/00000478-199802000-00011
   Damiani S, 1999, SEMIN DIAGN PATHOL, V16, P117
   Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6
   Desler C, 2007, MUTAT RES-FUND MOL M, V625, P112, DOI 10.1016/j.mrfmmm.2007.06.002
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087
   Grossman LI, 1996, BIOESSAYS, V18, P983, DOI 10.1002/bies.950181208
   HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523
   Hawes SM, 2002, HUM REPROD, V17, P850, DOI 10.1093/humrep/17.4.850
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HIROTSUNE S, 1992, CANCER RES, V52, P3642
   Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   Kulawiec M, 2006, CANCER BIOL THER, V5, P967, DOI 10.4161/cbt.5.8.2880
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Larosche I, 2007, J PHARMACOL EXP THER, V321, P526, DOI 10.1124/jpet.106.114546
   Lee HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011
   Modica-Napolitano Josephine S, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004453
   Modica-Napolitano JS, 2007, CURR MOL MED, V7, P121, DOI 10.2174/156652407779940495
   Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027
   OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134
   Park SY, 2004, J BIOL CHEM, V279, P7512, DOI 10.1074/jbc.M307677200
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Rasmussen AK, 2003, NUCLEIC ACIDS RES, V31, P3909, DOI 10.1093/nar/gkg446
   Rempel A, 1996, CANCER RES, V56, P2468
   Richard SM, 2000, CANCER RES, V60, P4231
   Saffran HA, 2007, EMBO REP, V8, P188, DOI 10.1038/sj.embor.7400878
   Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763
   Selvanayagam P, 1996, LAB INVEST, V74, P592
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   Singh K., 1998, Mitochondrial DNA Mutations in Aging, Disease and Cancer
   Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056
   Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027
   Smiraglia DJ, 2003, J MED GENET, V40, P25, DOI 10.1136/jmg.40.1.25
   Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488
   Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608
   Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Smiraglia DJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-446
   Tallini G, 1998, VIRCHOWS ARCH, V433, P5, DOI 10.1007/s004280050209
   Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   WARBURG O, 1956, SCIENCE, V124, P269
   Wu CW, 2005, GENE CHROMOSOME CANC, V44, P19, DOI 10.1002/gcc.20213
   Yin PH, 2004, BRIT J CANCER, V90, P2390, DOI 10.1038/sj.bjc.6601838
   Yu L, 2004, GENOMICS, V84, P647, DOI 10.1016/j.ygeno.2004.06.010
   Yu M, 2007, IUBMB LIFE, V59, P450, DOI 10.1080/15216540701509955
   Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007
NR 65
TC 161
Z9 182
U1 0
U2 24
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD AUG
PY 2008
VL 7
IS 8
BP 1182
EP 1190
DI 10.4161/cbt.7.8.6215
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 342HI
UT WOS:000258774800005
PM 18458531
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Barkan, D
   Kleinman, H
   Simmons, JL
   Asmussen, H
   Kamaraju, AK
   Hoenorhoff, MJ
   Liu, ZY
   Costes, SV
   Cho, EH
   Lockett, S
   Khanna, C
   Chambers, AF
   Green, JE
AF Barkan, Dalit
   Kleinman, Hynda
   Simmons, Justin L.
   Asmussen, Holly
   Kamaraju, Anil K.
   Hoenorhoff, Mark J.
   Liu, Zi-yao
   Costes, Sylvain V.
   Cho, Edward H.
   Lockett, Stephen
   Khanna, Chand
   Chambers, Ann F.
   Green, Jeffrey E.
TI Inhibition of metastatic outgrowth from single dormant tumor cells by
   targeting the cytoskeleton
SO CANCER RESEARCH
LA English
DT Article
ID LIGHT-CHAIN KINASE; BASEMENT-MEMBRANE CULTURES; MAMMARY-CARCINOMA CELLS;
   BREAST-CANCER CELLS; IN-VIVO; 3-DIMENSIONAL CULTURE; MALIGNANT
   PHENOTYPE; SMOOTH-MUSCLE; BONE-MARROW; GROWTH
AB Metastatic breast cancer may emerge from latent tumor cells that remain dormant at disseminated sites for many years. Identifying mechanisms regulating the switch from dormancy to proliferative metastatic growth has been elusive due to the lack of experimental models of tumor cell dormancy. We characterized the in vitro growth characteristics of cells that exhibit either dormant (D2.0R, MCF-7, and K7M2AS1.46) or proliferative (D2A1, MDA-MB-231, and K7M2) metastatic behavior in vivo. Although these cells proliferate readily in two-dimensional culture, we show that when grown in three-dimensional matrix, distinct growth properties of the cells were revealed that correlate to their dormant or proliferative behavior at metastatic sites in vivo. In three-dimensional culture, cells with dormant behavior in vivo remained cell cycle arrested with elevated nuclear expression of p16 and p27. The transition from quiescence to proliferation of D2A1 cells was dependent on fibronectin production and signaling through integrin beta 1, leading to cytoskeletal reorganization with filamentous actin (F-actin) stress fiber formation. We show that phosphorylation of myosin light chain (MLC) by MLC kinase (MLCK) through integrin beta 1 is required for actin stress fiber formation and proliferative growth. Inhibition of integrin beta 1 or MLCK prevents transition from a quiescent to proliferative state in vitro. Inhibition of MLCK significantly reduces metastatic outgrowth in vivo. These studies show that the switch from dormancy to metastatic growth may be regulated, in part, through epigenetic signaling from the microenvironment, leading to changes in the cytoskeletal architecture of dormant cells. Targeting this process may provide therapeutic strategies for inhibition of the dormant-to-proliferative metastatic switch.
C1 [Barkan, Dalit; Simmons, Justin L.; Asmussen, Holly; Kamaraju, Anil K.; Hoenorhoff, Mark J.; Liu, Zi-yao; Green, Jeffrey E.] NCI, Cell Biol & Genet Lab, NIH, Bethesda, MD 20892 USA.
   [Kleinman, Hynda] Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, Bethesda, MD USA.
   [Khanna, Chand] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.
   [Costes, Sylvain V.] Lawrence Livermore Natl Lab, Dept Canc Biol, Berkeley, CA USA.
   [Cho, Edward H.; Lockett, Stephen] Sci Applicat Int Corp Frederick, Natl Canc Inst Fredrick, Image Anal Lab, Frederick, MD USA.
   [Chambers, Ann F.] London Reg Canc Program, London, ON, Canada.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Institute
   of Dental & Craniofacial Research (NIDCR); National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); United States
   Department of Energy (DOE); Lawrence Livermore National Laboratory;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Science Applications International Corporation (SAIC); Western
   University (University of Western Ontario)
RP Green, JE (通讯作者)，NCI, Cell Biol & Genet Lab, NIH, Bldg 37,Room 4054,37 Convent Dr, Bethesda, MD 20892 USA.
EM jegreen@nih.gov
RI ; Costes, Sylvain/D-2522-2013; Cho, Edward/B-3727-2012; Chambers,
   Ann/L-6285-2015
OI Barkan, Dalit/0000-0003-4714-0580; Costes, Sylvain/0000-0002-8542-2389;
   Cho, Edward/0000-0002-0278-334X; Chambers, Ann/0000-0002-9509-5123
FU Intramural NIH HHS [Z01 BC005740-15] Funding Source: Medline
CR Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G
   Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385
   Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005
   Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7
   Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   Gassmann P, 2004, ONKOLOGIE, V27, P577, DOI 10.1159/000081343
   Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89
   Goldberg SF, 1999, CLIN EXP METASTAS, V17, P601, DOI 10.1023/A:1006718800891
   Harms JF, 2002, BIOTECHNIQUES, V33, P1197, DOI 10.2144/02336bm02
   Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997
   Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044
   Kaneko K, 2002, PANCREAS, V24, P34, DOI 10.1097/00006676-200201000-00005
   Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481
   Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853
   Larsen M, 2006, CURR OPIN CELL BIOL, V18, P463, DOI 10.1016/j.ceb.2006.08.009
   Minamiya Y, 2005, TUMOR BIOL, V26, P153, DOI 10.1159/000086487
   MORRIS VL, 1994, CLIN EXP METASTAS, V12, P357, DOI 10.1007/BF01755879
   MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071
   NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295
   Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068
   Naumov GN, 2003, BREAST CANCER RES TR, V82, P199, DOI 10.1023/B:BREA.0000004377.12288.3c
   Naumov GN, 2002, CANCER RES, V62, P2162
   Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001
   PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Roth JM, 2005, AM J PATHOL, V166, P901, DOI 10.1016/S0002-9440(10)62310-3
   SAITOH M, 1987, J BIOL CHEM, V262, P7796
   Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z
   SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0
   Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718
   THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062
   Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101
   Walker JL, 2005, CYTOKINE GROWTH F R, V16, P395, DOI 10.1016/j.cytogfr.2005.03.003
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025
NR 45
TC 323
Z9 393
U1 0
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2008
VL 68
IS 15
BP 6241
EP 6250
DI 10.1158/0008-5472.CAN-07-6849
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 333UI
UT WOS:000258177600028
PM 18676848
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Ji, M
   Zhang, Q
   Ye, JW
   Wang, XY
   Yang, W
   Zhu, DH
AF Ji, Ming
   Zhang, Qiang
   Ye, Jianwei
   Wang, Xueyan
   Yang, Wei
   Zhu, Dahai
TI Myostatin induces p300 degradation to silence <i>cyclin</i> <i>D1</i>
   expression through the PI3K/PTEN/Akt pathway
SO CELLULAR SIGNALLING
LA English
DT Article
DE myostatin; Akt; p300; histone acetylation
ID ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; HISTONE
   ACETYLTRANSFERASES; SIGNALING PATHWAY; TRANSCRIPTION; AKT; GROWTH;
   PHOSPHORYLATION; ARREST; PTEN
AB Myostatin is a negative regulator of skeletal muscle growth and affects numerous genes expression involved in cell proliferation, differentiation and metabolism. However, the molecular mechanisms underlying myostatin-regulated genes expression remain to be elucidated. In this study, we showed that myostatin blocked the recruitment of p300 to the cyclin D1 promoter, resulting in the silence of cyclin D1 expression. Our data further demonstrated that myostatin decreased the protein level of p300 by inducing p300 degradation via the ubiquitin-proteasome system. In addition, we provided experimental evidence to show that myostatin-induced p300 degradation was mediated by the phosphatidylinositol 3-kinase/PTEN/Akt signaling pathway and this could be antagonized by IGF-1 or insulin. Results presented in this study uncovered an epigenetic control of genes expression in response to myostatin. (c) 2008 Elsevier Inc. All rights reserved.
C1 Tsinghua Univ, Chinese Acad Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.
   Tsinghua Univ, Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100005, Peoples R China.
   Tsinghua Univ, Peking Union Med Coll, Beijing 100005, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Tsinghua University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Tsinghua University; Institute of Basic Medical
   Sciences - CAMS; Tsinghua University; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
RP Zhu, DH (通讯作者)，Tsinghua Univ, Chinese Acad Med Sci, Natl Lab Med Mol Biol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.
EM dhzhu@pumc.edu.cn
RI Zhu, Dahai/ABA-5315-2021; Zhang, Qiang/K-8476-2017; Ye,
   Jian-Wei/JVN-1230-2024
OI Ye, Jianwei/0009-0000-3519-9150
CR Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200
   Chen J, 2004, CELL MOL LIFE SCI, V61, P1675, DOI 10.1007/s00018-004-4103-9
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Duclos M J, 2005, J Physiol Pharmacol, V56 Suppl 3, P25
   Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033
   Iwao K, 1999, Nucleic Acids Symp Ser, P207
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   Morissette MR, 2006, CIRC RES, V99, P15, DOI 10.1161/01.RES.0000231290.45676.d4
   Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Partanen M, 1999, INT J DEV BIOL, V43, P487
   Philip B, 2005, CELL SIGNAL, V17, P365, DOI 10.1016/j.cellsig.2004.08.003
   Poizat C, 2005, MOL CELL BIOL, V25, P2673, DOI 10.1128/MCB.25.7.2673-2687.2005
   Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003
   Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003
   Sánchez-Molina S, 2006, BIOCHEM J, V398, P215, DOI 10.1042/BJ20060052
   Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200
   Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200
   von Wichert T, 2005, ONCOGENE, V24, P1284, DOI 10.1038/sj.onc.1208264
   Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599
   Yang W, 2006, CANCER RES, V66, P1320, DOI 10.1158/0008-5472.CAN-05-3060
   Yang W, 2005, BIOCHEM BIOPH RES CO, V326, P660, DOI 10.1016/j.bbrc.2004.11.096
   Yang W, 2007, J BIOL CHEM, V282, P3799, DOI 10.1074/jbc.M610185200
   Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4
   Yu CT, 2002, MOL CELL BIOL, V22, P4556, DOI 10.1128/MCB.22.13.4556-4566.2002
   Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057
NR 35
TC 42
Z9 58
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD AUG
PY 2008
VL 20
IS 8
BP 1452
EP 1458
DI 10.1016/j.cellsig.2008.03.013
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 329DX
UT WOS:000257848200006
PM 18472397
DA 2025-01-12
ER

PT J
AU Itadani, H
   Mizuarai, S
   Kotani, H
AF Itadani, Hiraku
   Mizuarai, Shinji
   Kotani, Hidehito
TI Can systems biology understand pathway activation? Gene expression
   signatures as surrogate markers for understanding the complexity of
   pathway activation
SO CURRENT GENOMICS
LA English
DT Article
DE expression signature; signaling pathway; drug discovery; cancer therapy;
   systems biology
ID INTESTINAL STEM-CELLS; HUMAN BREAST-CANCER; COLORECTAL-CANCER;
   LUNG-CANCER; MICROARRAY ANALYSIS; KINASE INHIBITORS; DNA-REPLICATION;
   PROSTATE-CANCER; MUTATION STATUS; P53 STATUS
AB Cancer is thought to be caused by a sequence of multiple genetic and epigenetic alterations which occur in one or more of the genes controlling cell cycle progression and signaling transduction. The complexity of carcinogenic mechanisms leads to heterogeneity in molecular phenotype, pathology, and prognosis of cancers.
   Genome-wide mutational analysis of cancer genes in individual tumors is the most direct way to elucidate the complex process of disease progression, although such high-throughput sequencing technologies are not yet fully developed. As a surrogate marker for pathway activation analysis, expression profiling using microarrays has been successfully applied for the classification of tumor types, stages of tumor progression, or in some cases, prediction of clinical outcomes. However, the biological implication of those gene expression signatures is often unclear.
   Systems biological approaches leverage the signature genes as a representation of changes in signaling pathways, instead of interpreting the relevance between each gene and phenotype. This approach, which can be achieved by comparing the gene set or the expression profile with those of reference experiments in which a defined pathway is modulated, will improve our understanding of cancer classification, clinical outcome, and carcinogenesis. In this review, we will discuss recent studies on the development of expression signatures to monitor signaling pathway activities and how these signatures can be used to improve the identification of responders to anticancer drugs.
C1 [Itadani, Hiraku; Mizuarai, Shinji; Kotani, Hidehito] Merck Res Lab, Dept Canc Res, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan.
C3 Merck & Company
RP Kotani, H (通讯作者)，Merck Res Lab, Dept Canc Res, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan.
EM hidehito_kotani@merck.com
CR Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987
   Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100
   Baker M, 2005, NAT BIOTECHNOL, V23, P297, DOI 10.1038/nbt0305-297
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Black EP, 2003, CANCER RES, V63, P3716
   Blum R, 2007, CANCER RES, V67, P3320, DOI 10.1158/0008-5472.CAN-06-4287
   BOS JL, 1989, CANCER RES, V49, P4682
   Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200
   Choi K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001226
   Creighton CJ, 2007, ONCOGENE, V26, P4648, DOI 10.1038/sj.onc.1210245
   Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363
   Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027
   Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003
   Elkon R, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-r43
   Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07
   Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928
   Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192
   Gazel A, 2006, J BIOL CHEM, V281, P20530, DOI 10.1074/jbc.M602712200
   Goss VL, 2006, BLOOD, V107, P4888, DOI 10.1182/blood-2005-08-3399
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Hall DA, 2004, SCIENCE, V306, P482, DOI 10.1126/science.1096773
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928
   Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258
   Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001
   Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Kim IJ, 2006, CARCINOGENESIS, V27, P392, DOI 10.1093/carcin/bgi237
   Kim MJ, 2006, EMBO J, V25, P3056, DOI 10.1038/sj.emboj.7601180
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   MacBeath G, 2000, SCIENCE, V289, P1760
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043
   Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741
   May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285
   Mayburd AL, 2006, CLIN CANCER RES, V12, P1820, DOI 10.1158/1078-0432.CCR-05-2149
   Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025
   Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104
   Mellinghoff IK, 2007, CLIN CANCER RES, V13, P378, DOI 10.1158/1078-0432.CCR-06-1992
   Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229
   Müller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
   Nikolsky Y, 2005, TOXICOL LETT, V158, P20, DOI 10.1016/j.toxlet.2005.02.004
   O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103
   Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a
   Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563
   Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Ranganathan P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-98
   Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295
   Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7
   Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104
   Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233
   Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490
   Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975
   Troester MA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-276
   Türeci Ö, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com
   Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006
   Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433
   Werner T, 2008, CURR OPIN BIOTECH, V19, P50, DOI 10.1016/j.copbio.2007.11.005
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Wu KM, 2003, J BIOL CHEM, V278, P51673, DOI 10.1074/jbc.M310021200
   Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28
NR 82
TC 32
Z9 42
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
J9 CURR GENOMICS
JI Curr. Genomics
PD AUG
PY 2008
VL 9
IS 5
BP 349
EP 360
DI 10.2174/138920208785133235
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 341WA
UT WOS:000258744900006
PM 19517027
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Wendt, MK
   Drury, LJ
   Vongsa, RA
   Dwinell, MB
AF Wendt, Michael K.
   Drury, Luke J.
   Vongsa, Rebecca A.
   Dwinell, Michael B.
TI Constitutive CXCL12 expression induces anoikis in colorectal carcinoma
   cells
SO GASTROENTEROLOGY
LA English
DT Article
ID INTESTINAL EPITHELIAL-CELLS; CHEMOKINE RECEPTOR CXCR4;
   GASTROINTESTINAL-TRACT; BREAST-CANCER; FACTOR-I; APOPTOSIS; ACTIVATION;
   METASTASIS; GROWTH; SDF-1-ALPHA
AB Background & Aims: CXCL12 and CXCR4 signaling plays critical roles in development, homeostasis, and tumor metastasis. Previously, we have shown that epigenetic silencing of CXCL12 in colorectal. and mammary carcinomas promotes metastasis. Anoikis is an essential process of colonic epithelial turnover and limits the metastatic progression of carcinoma. We sought to determine the role for anoikis in limiting tumor metastasis following reexpression of CXCL12 in human colorectal carcinoma cells. Methods: Tumor formation and metastasis of colonic carcinoma cells was monitored using in vivo bioluminescence imaging. Anoikis was defined by using caspase-3/7, focal adhesion kinase (FAK) and p130Cas cleavage, DNA fragmentation, and cell survival assays. Phosphorylation of extracellular-regulated kinase-1/2 (ERK1/2) was monitored by immunoblot and immunohistochemistry, and activity was inhibited by using U0126. Results: Constitutive expression of CXCL12 in human colorectal carcinoma cells reduced orthotopic tumor formation and inhibited metastasis in severe combined immunodeficient mice. Further, CXCL12 expression induced apoptosis specifically in nonadherent colorectal carcinoma cells. Apoptotic cell death was preceded by hypophosphorylation and cleavage of FAK and p130Cas, leading to increased cellular detachment in culture, and depended on alterations in the extracellular matrix. Similar to in vivo colonic epithelium, CXCL12-induced anoikis of carcinoma cells depended on basal ERK1/2 activation. Conclusions: These data significantly expand the current paradigm of chemokine signaling in carcinogenesis by showing that endogenous CXCL12, in marked contrast to exogenous ligand, inhibits tumor metastasis through increased anoikis. Altered ERK1/2 signaling provides a mechanism for the dichotomy between the physiologic and pathophysiologic roles of CXCL12-CXCR4 signaling in the intestinal epithelium.
C1 [Wendt, Michael K.; Drury, Luke J.; Vongsa, Rebecca A.; Dwinell, Michael B.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Ctr Canc, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Dwinell, MB (通讯作者)，Med Coll Wisconsin, Dept Microbiol & Mol Genet, Ctr Canc, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM mdwinell@mcw.edu
OI Wendt, Mike/0000-0002-3665-7413
FU NIDDK NIH HHS [R01 DK062066, R01 DK062066-04, R56 DK062066, DK062066]
   Funding Source: Medline
CR Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8
   BEAULIEU JF, 1991, ANAT EMBRYOL, V183, P363
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Brand S, 2005, EXP CELL RES, V310, P117, DOI 10.1016/j.yexcr.2005.07.006
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Cagnol S, 2006, APOPTOSIS, V11, P337, DOI 10.1007/s10495-006-4065-y
   Colamussi ML, 2001, J LEUKOCYTE BIOL, V69, P263
   Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379
   Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004
   FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Grossmann J, 2002, AM J GASTROENTEROL, V97, P1421, DOI 10.1016/S0002-9270(02)04143-6
   Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693
   Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879
   HALL PA, 1994, J CELL SCI, V107, P3569
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1
   Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095
   Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815
   RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587
   Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   SMITH JM, 1965, AM J PHYSIOL-GASTR L, V288, pG316
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579
   Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546
   Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760
   Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 35
TC 43
Z9 52
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD AUG
PY 2008
VL 135
IS 2
BP 508
EP 517
DI 10.1053/j.gastro.2008.05.033
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 337MJ
UT WOS:000258439900028
PM 18558091
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Fiegl, H
   Windbichler, G
   Mueller-Holzner, E
   Goebel, G
   Lechner, M
   Jacobs, IJ
   Widschwendter, M
AF Fiegl, Heidi
   Windbichler, Gudrun
   Mueller-Holzner, Elisabeth
   Goebel, Georg
   Lechner, Matthias
   Jacobs, Ian J.
   Widschwendter, Martin
TI <i>HOXA11</i> DNA methylation -: A novel prognostic biomarker in ovarian
   cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; epigenetics; HOX genes; ovarian cancer; biomarker;
   prognosis
ID BREAST-CANCER; GENES; CELLS; TOOL
AB Epigenetic alterations play a major role in cancers Recently we reported that stem cell Polycomb group targets (PcGTs) are up to 12-fold more likely to have cancer-specific promoter DNA hyper-methylation than nontargets. To identify potential, prognostic DNA methylation markers in ovarian cancer we analyzed the DNA methylation at 71 different loci in 22 ovarian cancers and 18 non-neoplastic ovarian specimens by means of a quantitative, real-time PCR-based technique (MethyLight). We identified DNA methylation of HOXA10 and HOXA11, both of them PcGTs, to be the best discriminators between cancer and non-neoplastic tissue. In an independent set consisting of 92 ovarian cancer specimens further analysis demonstrated that HOXA11 DNA methylation is (i) strongly associated with the residual tumor after cytoreductive surgery and (h) is a marker indicating poor prognosis. HOXA11 DNA methylation was independently associated with poor outcome [relative risk for death 3.4 (95% CI 1.2-9.9; p = 0.03)]. These findings support the view that the technical inability to optimally cytoreduce ovarian cancer is associated with particular molecular alterations in the tumor which per se define a subgroup of patients with poor outcome. (c) 2008 Wiley-Liss, Inc.
C1 [Fiegl, Heidi] Tyrolean Canc Res Inst, Innsbruck, Austria.
   [Windbichler, Gudrun; Mueller-Holzner, Elisabeth] Innsbruck Med Univ, Dept Obstet & Gynecol, Innsbruck, Austria.
   [Goebel, Georg] Innsbruck Med Univ, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
   [Lechner, Matthias] Innsbruck Med Univ, Christian Doppler Res Lab Gut Inflammat, Dept Med, Innsbruck, Austria.
C3 Medical University of Innsbruck; Medical University of Innsbruck;
   Medical University of Innsbruck
RP Widschwendter, M (通讯作者)，UCL, UCL EGA Inst Womens Hlth, Dept Gynecol Oncol, EGA Hosp, 2nd Floor Huntley St, London WC1E 6DH, England.
EM m.widschwendter@ucl.ac.uk
RI Goebel, Georg/P-6909-2015; Zeimet, Alain/AFK-2441-2022; Jacobs,
   Ian/F-1743-2013; Fiegl, Heidi/K-4445-2017
OI Fiegl, Heidi/0000-0002-1236-6806; Jacobs, Ian/0000-0002-5005-2672;
   Widschwendter, Martin/0000-0002-7778-8380
CR Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230
   Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052
   Du HL, 2004, ANN NY ACAD SCI, V1034, P152, DOI 10.1196/annals.1335.018
   Dübel S, 1999, TUMOR TARGET, V4, P37
   Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882
   HOISCHNEIDER C, 2000, SEMIN SURG ONCOL, V19, P3
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Markman M, 2007, J CLIN ONCOL, V25, P4168, DOI 10.1200/JCO.2007.11.8992
   Müller HM, 2004, CLIN CHEM, V50, P2171, DOI 10.1373/clinchem.2004.034090
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Spizzo G, 2007, CANCER LETT, V246, P253, DOI 10.1016/j.canlet.2006.03.002
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828
NR 20
TC 90
Z9 94
U1 0
U2 11
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 1
PY 2008
VL 123
IS 3
BP 725
EP 729
DI 10.1002/ijc.23563
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 319NY
UT WOS:000257171900032
PM 18478570
DA 2025-01-12
ER

PT J
AU Shibui, T
   Higo, Y
   Tsutsui, TW
   Uchida, M
   Oshimura, M
   Barrett, JC
   Tsutsui, T
AF Shibui, Takeo
   Higo, Yukari
   Tsutsui, Takeo W.
   Uchida, Minoru
   Oshimura, Mitsuo
   Barrett, J. Carl
   Tsutsui, Takeki
TI Changes in expression of imprinted genes following treatment of human
   cancer cell lines with non-mutagenic or mutagenic carcinogens
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE epigenetic modification; imprinted genes; chemical carcinogens; human
   cells
ID PRADER-WILLI-SYNDROME; HISTONE H3 LYSINE-9; DNA METHYLATION; EPIGENETIC
   MECHANISMS; ASSOCIATION; IMMORTALIZATION; ACETYLATION; FIBROBLASTS;
   CHROMATIN; HYPOMETHYLATION
AB It remains possible that chemicals that act by mutagenic mechanisms as well as chemicals that do not induce gene mutations may affect epigenetic gene expression. To test the possibility, we investigated the ability of both types of chemicals to alter the expression of five imprinted genes, PEG3, SNRPN, NDN, ZAC and H19, using two human colon cancer cell lines and a human breast cancer cell line. The expression of imprinted genes was changed by some non-mutagenic and mutagenic carcinogens independent of their mutagenic activity. The genes most commonly exhibiting the changes in expression were SNRPN and PEG3. Alterations of the expression of NDN and ZAC were also observed in some conditions. Methylation-specific PCR and chromatin immunoprecipitation assays suggest the possibility that changes in the expression of SNRPN may be associated with DNA hypomethylation and historic acetylation of the promoters and euchromatinization of the heterochromatic domains of the promoters. Changes in expression of the imprinted genes, PEG3 and NDN, were also observed in cells immortalized by treatment of normal human fibroblasts with 4-nitroquinoline 1-oxide or aflatoxin B-1 We previously demonstrated that expression of the cancer-related gene, INK4a, in these immortal cells was lost via epigenetic mechanisms. The results prove that, in cancer cells, some mutagenic or non-mutagenic carcinogens can epigenetically influence the transcription levels of imprinted genes and also suggest the possibility that some chemical carcinogens may have epigenetic carcinogenic effects in human cells.
C1 [Tsutsui, Takeki] Nippon Dent Univ Tokyo, Sch Life Dent, Dept Pharmacol, Chiyoda Ku, Tokyo 1028159, Japan.
   [Shibui, Takeo; Uchida, Minoru] Nippon Dent Univ Hosp Tokyo, Tokyo 1028158, Japan.
   [Oshimura, Mitsuo] Tottori Univ, Sch Life Sci, Dept Mol & Cellular Genet, Tottori 6800022, Japan.
   [Barrett, J. Carl] NCI, Lab Biosyst & Cancer, NIH, Bethesda, MD 20892 USA.
C3 Nippon Dental University; Nippon Dental University; Tottori University;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Tsutsui, T (通讯作者)，Nippon Dent Univ Tokyo, Sch Life Dent, Dept Pharmacol, Chiyoda Ku, 1-9-20 Fujimi, Tokyo 1028159, Japan.
EM takeki@tokyo.ndu.ac.jp
RI Tsutsui, Takeo/ABB-4046-2020
CR ASHBY J, 1985, PROGR MUTATION RES, V5
   BAI L, 1993, INT J CANCER, V53, P451, DOI 10.1002/ijc.2910530317
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787
   Broday L, 2000, CANCER RES, V60, P238
   Chen HB, 2006, MOL CELL BIOL, V26, P3728, DOI 10.1128/MCB.26.10.3728-3737.2006
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Costa M, 2001, MOL CELL BIOCHEM, V222, P205, DOI 10.1023/A:1017978500031
   Cui X, 2006, HUM PATHOL, V37, P298, DOI 10.1016/j.humpath.2005.10.013
   Dean W, 1998, DEVELOPMENT, V125, P2273
   El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200
   Feinberg AP, 2002, CANCER RES, V62, P6784
   Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253
   Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402
   Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757
   Jirtle Randy L., 2000, Environmental Health Perspectives, V108, P271, DOI 10.2307/3454445
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kumakura S, 2005, CANCER RES, V65, P2778, DOI 10.1158/0008-5472.CAN-04-1819
   Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147
   Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034
   Malik K, 2000, BRIT J CANCER, V83, P1583, DOI 10.1054/bjoc.2000.1549
   Murphy SK, 2000, ENVIRON HEALTH PERSP, V108, P5, DOI 10.2307/3454628
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768
   POLL EHA, 1984, HUM GENET, V68, P228, DOI 10.1007/BF00418393
   Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206
   Riesewijk AM, 1997, GENOMICS, V42, P236, DOI 10.1006/geno.1997.4731
   Saitoh S, 2000, AM J HUM GENET, V66, P1958, DOI 10.1086/302917
   Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6
   Takahashi M, 2002, INT J CANCER, V99, P629, DOI 10.1002/ijc.10407
   TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25
   Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111
   Tsutsui TW, 2006, ODONTOLOGY, V94, P44, DOI 10.1007/s10266-006-0065-1
   Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.3.CO;2-O
   Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462
   Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
   Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907
NR 43
TC 5
Z9 8
U1 0
U2 4
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2008
VL 33
IS 2
BP 351
EP 360
DI 10.3892/ijo_00000015
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 338CB
UT WOS:000258481400015
PM 18636156
OA Bronze
DA 2025-01-12
ER

PT J
AU Nackerdien, ZE
AF Nackerdien, Zeena E.
TI Perspectives on microbes as oncogenic infectious agents and implications
   for breast cancer
SO MEDICAL HYPOTHESES
LA English
DT Article
ID ESCHERICHIA-COLI; PEPTIDOGLYCAN SYNTHESIS; IMMUNE-RESPONSE; SOIL
   BACTERIA; L-FORM; ETIOLOGY; DISEASES; THERAPY; MAMMARY; TUMORS
AB Cancer management is partly based on weighing risk factors attributed to noninfectious agents, human genes and epigenetic factors. Infectious disease causation has largely been restricted to genes directly responsible for causing cancer after sustaining damage i.e. oncogenes. Lately, evidence has emerged linking infectious agents to a number of chronic diseases. These studies have recognized the influence that acute, atypical, latent and chronic infections may play in tricking the immune system and affecting disease etiology. Similar evidence is emerging in model systems with respect to the rote of infectious agents in gastrointestinal, liver and lung cancers. Although viruses have been found in association with breast cancer, skepticism remains about a role for other infectious agents, notably microbes in the disease etiology. Improved experimental designs employed in different cancer studies and a less rigid definition of infectious causation may aid in confirming or refuting a microbe-breast cancer connection. Cancer recurrence could potentially be minimized and treatment options further tailored on a case by case basis if microbes/microbial components/strain variants associated with breast cancer are identified; probiotics are employed to reduce treatment side-effects and if microbes could effectively be harnessed in immunotherapy. (c) 2008 Elsevier Ltd. All rights reserved.
C1 Rockefeller Univ, Raymond & Beverly Sackler Lab Mol Genet & Informa, New York, NY 10021 USA.
C3 Rockefeller University
RP Nackerdien, ZE (通讯作者)，Rockefeller Univ, Raymond & Beverly Sackler Lab Mol Genet & Informa, 1230 York Ave, New York, NY 10021 USA.
EM nackerz@mail.rockefeller.edu
CR Agrawal N, 2004, P NATL ACAD SCI USA, V101, P15172, DOI 10.1073/pnas.0406242101
   Astrauskiene D, 2007, CLIN EXP RHEUMATOL, V25, P470
   Cairns J., 1997, MATTERS LIFE DEATH P
   Canney PA, 2006, EUR J CANCER, V42, P2751, DOI 10.1016/j.ejca.2006.08.014
   CANTWELL AR, 1981, J DERMATOL SURG ONC, V7, P483, DOI 10.1111/j.1524-4725.1981.tb00682.x
   CANTWELL AR, 1990, CANC MICROBE
   Casadesús J, 2007, BIOESSAYS, V29, P1189, DOI 10.1002/bies.20680
   Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651
   Chlebowski RT, 2007, JAMA-J AM MED ASSOC, V298, P2135, DOI 10.1001/jama.298.18.2135-a
   DAVID H, 1988, PATHOL RES PRACT, V183, P356, DOI 10.1016/S0344-0338(88)80138-9
   De Assis S, 2006, ANN NY ACAD SCI, V1089, P14, DOI 10.1196/annals.1386.039
   DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746
   Ewald PaulW., 2000, PLAGUE TIME STEALTH
   Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824
   Fredricks DN, 1998, CURR CLIN TOPICS INF, V18, P180
   Fujimori M, 2002, CURR OPIN DRUG DI DE, V5, P200
   Ghafoor A, 2003, CA-CANCER J CLIN, V53, P342, DOI 10.3322/canjclin.53.6.342
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234
   Ivanova EH, 1997, FEMS IMMUNOL MED MIC, V17, P27, DOI 10.1111/j.1574-695X.1997.tb00993.x
   Janssen PH, 2002, APPL ENVIRON MICROB, V68, P2391, DOI 10.1128/AEM.68.5.2391-2396.2002
   Joseleau-Petit D, 2007, J BACTERIOL, V189, P6512, DOI 10.1128/JB.00273-07
   LEDERBERG J, 1958, J BACTERIOL, V75, P143, DOI 10.1128/JB.75.2.143-160.1958
   Lewis CE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1679
   MADIGAN MP, 2005, J NAT CANC, V87, P1681
   Marx J, 2004, SCIENCE, V306, P966, DOI 10.1126/science.306.5698.966
   Mazhar D, 2006, BRIT J CANCER, V94, P346, DOI 10.1038/sj.bjc.6602942
   McCarthy Edward F, 2006, Iowa Orthop J, V26, P154
   McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107
   Melana SM, 2007, CANCER RES, V67, P8960, DOI 10.1158/0008-5472.CAN-06-3892
   Michailova L, 2007, FEMS MICROBIOL LETT, V268, P88, DOI 10.1111/j.1574-6968.2006.00567.x
   Morino G, 2007, TROP DOCT, V37, P177, DOI 10.1258/004947507781524872
   Nuzum J., 1925, SURG GYNECOL OBSTET, V11, P343
   NUZUM JW, 1921, SURG GYNECOL OBSTET, V33, P167
   O'Keefe SJD, 2008, CURR OPIN GASTROEN, V24, P51, DOI 10.1097/MOG.0b013e3282f323f3
   Österlund P, 2007, BRIT J CANCER, V97, P1028, DOI 10.1038/sj.bjc.6603990
   Plomp M, 2007, J BACTERIOL, V189, P6457, DOI 10.1128/JB.00757-07
   Pogo BGT, 1997, BIOL TRACE ELEM RES, V56, P131, DOI 10.1007/BF02778989
   Proctor RA, 2006, NAT REV MICROBIOL, V4, P295, DOI 10.1038/nrmicro1384
   Ran VP, 2007, CANCER RES, V67, P847, DOI 10.1158/0008-5472.CAN-06-3468
   Rao VP, 2006, CANCER RES, V66, P7395, DOI 10.1158/0008-5472.CAN-06-0558
   Rao VP, 2006, CANCER RES, V66, P57, DOI 10.1158/0008-5472.CAN-05-3445
   Sait M, 2002, ENVIRON MICROBIOL, V4, P654, DOI 10.1046/j.1462-2920.2002.00352.x
   Sasaki T, 2006, CANCER SCI, V97, P649, DOI 10.1111/j.1349-7006.2006.00221.x
   Satia JA, 2007, J HEALTH CARE POOR U, V18, P146, DOI 10.1353/hpu.2007.0114
   Sfanos KS, 2008, PROSTATE, V68, P306, DOI 10.1002/pros.20680
   STARNES CO, 1992, NATURE, V357, P11, DOI 10.1038/357011a0
   Tamaki K, 2008, J RHEUMATOL, V35, P114
   Thomas W, 2008, FRONT BIOSCI-LANDMRK, V13, P2604, DOI 10.2741/2869
   Wang KX, 2004, WORLD J GASTROENTERO, V10, P1306
   Wang Y, 2001, ARCH VIROL, V146, P171, DOI 10.1007/s007050170201
NR 50
TC 4
Z9 4
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD AUG
PY 2008
VL 71
IS 2
BP 302
EP 306
DI 10.1016/j.mehy.2008.02.016
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 331LN
UT WOS:000258013800028
PM 18445513
DA 2025-01-12
ER

PT J
AU Yu, JS
   Koujak, S
   Nagase, S
   Li, CM
   Su, T
   Wang, X
   Keniry, M
   Memeo, L
   Rojtman, A
   Mansukhani, M
   Hibshoosh, H
   Tycko, B
   Parsons, R
AF Yu, J. S.
   Koujak, S.
   Nagase, S.
   Li, C-M
   Su, T.
   Wang, X.
   Keniry, M.
   Memeo, L.
   Rojtman, A.
   Mansukhani, M.
   Hibshoosh, H.
   Tycko, B.
   Parsons, R.
TI <i>PCDH8</i>, the human homolog of <i>PAPC</i>, is a candidate tumor
   suppressor of breast cancer
SO ONCOGENE
LA English
DT Article
DE PCDH8; protocadherin; breast cancer; tumor suppressor
ID TRANSCRIPTION FACTOR SNAIL; PARAXIAL PROTOCADHERIN; STRUCTURAL BASIS;
   CELL MOVEMENTS; CHROMOSOME 13Q; CADHERIN; MORPHOGENESIS; ADHESION; GENE;
   PROLIFERATION
AB Carcinoma is an altered state of tissue differentiation in which epithelial cells no longer respond to cues that keep them in their proper position. A break down in these cues has disastrous consequences not only in cancer but also in embryonic development when cells of various lineages must organize into discrete entities to form a body plan. Paraxial protocadherin (PAPC) is an adhesion protein with six cadherin repeats that organizes the formation and polarity of developing cellular structures in frog, fish and mouse embryos. Here we show that protocadherin-8 (PCDH8), the human ortholog of PAPC, is inactivated through either mutation or epigenetic silencing in a high fraction of breast carcinomas. Loss of PCDH8 expression is associated with loss of heterozygosity, partial promoter methylation, and increased proliferation. Complementation of mutant tumor cell line HCC2218 with wild-type PCDH8 inhibited its growth. Two tumor mutants, E146K and R343H, were defective for inhibition of cell growth and migration. Sur prisingly, the E146K mutant transformed the human mammary epithelial cell line MCF10A and sustained the expression of cyclin D1 and MYC without epidermal growth factor. We propose that loss of PCDH8 promotes oncogenesis in epithelial human cancers by disrupting cell-cell communication dedicated to tissue organization and repression of mitogenic signaling.
C1 [Parsons, R.] Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Parsons, R.] Columbia Univ, Dept Med, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Parsons, R (通讯作者)，Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, 1130 St Nicholas Ave, New York, NY 10032 USA.
EM rep15@columbia.edu
RI Parsons, Ramon/KFT-2922-2024
OI Nagase, Satoru/0000-0001-5212-1128; Parsons, Ramon/0000-0002-6656-3514;
   Memeo, Lorenzo/0000-0003-4251-7203
FU NCI NIH HHS [R01 CA082783-04, R01 CA082783-07, R01 CA082783-05, R01
   CA082783, R01 CA082783-06] Funding Source: Medline
CR Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D
   Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089
   Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102
   Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699
   Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437
   Kim SH, 1998, DEVELOPMENT, V125, P4681
   Kim SH, 2000, CURR BIOL, V10, P821, DOI 10.1016/S0960-9822(00)00580-7
   LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152
   Medina A, 2004, EMBO J, V23, P3249, DOI 10.1038/sj.emboj.7600329
   Melamed J, 1997, CLIN CANCER RES, V3, P1867
   Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785
   Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0
   Rhee J, 2003, DEV BIOL, V254, P248, DOI 10.1016/S0012-1606(02)00085-4
   SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2
   Unterseher F, 2004, EMBO J, V23, P3259, DOI 10.1038/sj.emboj.7600332
   WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351
NR 30
TC 126
Z9 145
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG
PY 2008
VL 27
IS 34
BP 4657
EP 4665
DI 10.1038/onc.2008.101
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 334QM
UT WOS:000258236300004
PM 18408767
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ho, CC
   Ling, YC
   Chang, LW
   Tsai, HT
   Tsai, MH
   Lin, P
AF Ho, Chia-Chi
   Ling, Yong-Chien
   Chang, Louis W.
   Tsai, Hui-Ti
   Tsai, Ming-Hsien
   Lin, Pinpin
TI 17-beta estradiol and hydroxyestradiols interact via the NF-Kappa B
   pathway to elevate cyclooxygenase 2 expression and prostaglandin E2
   secretion in human bronchial epithelial cells
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE nongenotoxic; endocrine; estrogens
ID ARYL-HYDROCARBON RECEPTOR; BREAST-CANCER CELLS; HUMAN LUNG;
   4-HYDROXYESTRADIOL; ESTROGEN; 17-BETA-ESTRADIOL; MCF-7;
   2-HYDROXYESTRADIOL; OVEREXPRESSION; REQUIREMENT
AB Some epidemiological studies suggest women may be at greater risk for lung cancer than men. Hydroxyestradiols (OHE(2)) are genotoxic and considered as carcinogenic metabolites of estrogens. In this study, we demonstrate that treatment with 0.1 or 1nM 2/4OHE(2) significantly increased intracellular oxidative stress, nuclear factor kappa B (NF-kappa B) activity, and cyclooxygenase-2 (COX-2) expression within 24 h in human bronchial epithelial cells BEAS-2B. Cotreatment with the NF-kappa B inhibitor, Bay 117085, prevented OHE(2)-induced COX-2 mRNA accumulation, suggesting that OHE(2) induced COX-2 expression via the NF-kappa B dependent pathway. Furthermore, cotreatment with 10nM 17-beta estradiol (E(2)) significantly enhanced OHE(2)-increased intracellular oxidative stress and significantly increased not only NF-kappa B activity but also COX-2 levels. As COX-2 participates in biosynthesis of prostaglandin E2 (PGE2), PGE2 secretion was enhanced by the cotreatment of 1nM OHE(2) and 10nM E(2). To understand the enhancement mechanism between OHE(2) and E(2), cells were cotreated with an antioxidant, N-acetylcysteine (NAC), or NF-kappa B inhibitor, Bay 117085. Both NAC and Bay 117085 prevented the enhancement in COX-2 expression and PGE2 secretion by the cotreatment of E(2) and OHE(2) in BEAS-2B cells. Similarly, Bay 117085 prevented PGE2 secretion induced by the cotreatment of E(2) and OHE(2) in rat lung slice cultures. These results suggest that E(2) enhanced OHE(2)-increased intracellular oxidative stress which increased NF-kappa B activity, COX-2 expression, and PGE2 secretion. Elevated COX-2 expression and PGE2 secretion has been shown to increase the risk of cancer development. Our present data suggest a pathway that contributes an epigenetic mechanism to the overall mechanism of carcinogenesis.
C1 [Chang, Louis W.; Tsai, Hui-Ti; Tsai, Ming-Hsien; Lin, Pinpin] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan 350, Miaoli County, Taiwan.
   [Ho, Chia-Chi; Ling, Yong-Chien] Natl Tsing Hua Univ, Inst Nanoengn & Microsyst, Zhunan, Taiwan.
   [Ling, Yong-Chien] Natl Tsing Hua Univ, Dept Chem, Zhunan, Taiwan.
C3 National Health Research Institutes - Taiwan; National Tsing Hua
   University; National Tsing Hua University
RP Lin, P (通讯作者)，Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, 35 Keyan Rd, Zhunan 350, Miaoli County, Taiwan.
EM pplin@nhri.org.tw
RI Tsai, Ming-Hsien/AAT-8218-2021; 凌Ling, 永健Yong-Chien/L-5829-2013; Lin,
   Pinpin/B-2668-2010; Lin, Pinpin/A-2006-2019
OI Lin, Pinpin/0000-0001-5459-907X
CR Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561
   Boerner JL, 2005, MOL ENDOCRINOL, V19, P2660, DOI 10.1210/me.2004-0439
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   Chang H, 2006, TOXICOL SCI, V89, P205, DOI 10.1093/toxsci/kfj025
   Chang JHT, 2007, CLIN CANCER RES, V13, P38, DOI 10.1158/1078-0432.CCR-06-1166
   Chang LW, 2007, CARCINOGENESIS, V28, P1606, DOI 10.1093/carcin/bgm013
   Chen ZH, 2005, TOXICOL APPL PHARM, V208, P46, DOI 10.1016/j.taap.2005.01.010
   Chen ZT, 2003, J CELL BIOCHEM, V89, P1206, DOI 10.1002/jcb.10590
   Dawling S, 2003, CANCER RES, V63, P3127
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Fernandez SV, 2006, INT J CANCER, V118, P1862, DOI 10.1002/ijc.21590
   FRENKEL K, 1991, FREE RADICAL RES COM, V12-3, P783, DOI 10.3109/10715769109145860
   Fujita H, 2002, PROSTATE, V53, P232, DOI 10.1002/pros.10152
   FUNAHASHI A, 1994, CHEST, V106, P166, DOI 10.1378/chest.106.1.166
   Gasperino James, 2004, Clin Lung Cancer, V5, P353, DOI 10.3816/CLC.2004.n.013
   Gupta M, 1998, J STEROID BIOCHEM, V67, P413, DOI 10.1016/S0960-0760(98)00135-6
   Hastürk S, 2002, CANCER, V94, P1023, DOI 10.1002/cncr.10262.abs
   Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776
   Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8
   Hukkanen J, 2002, CRIT REV TOXICOL, V32, P391, DOI 10.1080/20024091064273
   Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452
   Kasai A, 2006, CANCER RES, V66, P7143, DOI 10.1158/0008-5472.CAN-05-4541
   Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070
   Keith RL, 2006, ANTICANCER RES, V26, P2857
   Kreutzer M, 2007, ONCOL REP, V18, P497
   Lareef MH, 2005, INT J ONCOL, V26, P423
   Liao QJ, 2005, WORLD J GASTROENTERO, V11, P6433, DOI 10.3748/wjg.v11.i41.6433
   LIEHR JG, 1986, J STEROID BIOCHEM, V24, P353, DOI 10.1016/0022-4731(86)90080-4
   Lin P, 2003, LUNG CANCER-J IASLC, V42, P255, DOI 10.1016/S0169-5002(03)00359-3
   Lin PP, 2004, TOXICOL APPL PHARM, V195, P83, DOI 10.1016/j.taap.2003.11.001
   Martey CA, 2004, AM J PHYSIOL-LUNG C, V287, pL981, DOI 10.1152/ajplung.00239.2003
   Mueck AO, 2002, MATURITAS, V43, P1, DOI 10.1016/S0378-5122(02)00141-X
   Ndengele MM, 2005, SHOCK, V23, P186, DOI 10.1097/01.shk.0000144130.36771.d6
   Ochiai M, 1999, JPN J CANCER RES, V90, P1338, DOI 10.1111/j.1349-7006.1999.tb00717.x
   Paquette B, 2005, INT J CANCER, V113, P706, DOI 10.1002/ijc.20647
   Prosperi JR, 2004, PROSTAG OTH LIPID M, V73, P249, DOI 10.1016/j.prostaglandis.2004.03.004
   Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X
   Singer CA, 2003, AM J PHYSIOL-LUNG C, V285, pL1087, DOI 10.1152/ajplung.00409.2002
   Smith GBJ, 2001, CANCER EPIDEM BIOMAR, V10, P839
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K
   Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315
   VANASWEGEN CH, 1989, J STEROID BIOCHEM, V32, P485, DOI 10.1016/0022-4731(89)90380-4
   Wistuba II, 2007, CURR MOL MED, V7, P3, DOI 10.2174/156652407779940468
   Yamaki T, 2004, CANCER LETT, V214, P115, DOI 10.1016/j.canlet.2004.04.013
NR 46
TC 12
Z9 18
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD AUG
PY 2008
VL 104
IS 2
BP 294
EP 302
DI 10.1093/toxsci/kfn096
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 328HR
UT WOS:000257789500006
PM 18480072
OA Bronze
DA 2025-01-12
ER

PT J
AU Pietersen, AM
   Evers, B
   Prasad, AA
   Tanger, E
   Cornelissen-Steijger, P
   Jonkers, J
   van Lohuizen, M
AF Pietersen, Alexandra M.
   Evers, Bastiaan
   Prasad, Asheeta A.
   Tanger, Ellen
   Cornelissen-Steijger, Paulien
   Jonkers, Jos
   van Lohuizen, Maarten
TI Bmi1 regulates stem cells and proliferation and differentiation of
   committed cells in mammary epithelium
SO CURRENT BIOLOGY
LA English
DT Article
ID SELF-RENEWAL; CYCLIN D1; DEVELOPMENTAL REGULATORS; GLAND DEVELOPMENT;
   BREAST-CANCER; POLYCOMB; GROWTH; MICE; SUPPRESSION; P16(INK4A)
AB PolycombGroup (PcG) proteins are epigenetic silencers involved in maintaining cellular identity, and their deregulation can result in cancer [1]. Mice without the PcG gene Bmi1 are runted and suffer from progressive loss of hematopoietic and neural stem cells [2-4]. Here, we assess the effects of Bmi1 on stem cells and differentiation of an epithelial tissue in vivo. We chose the mammary gland because it allows limiting dilution transplantations [5, 6] and because Bmi1 is overexpressed in breast cancer [7, 8]. Our analyses show that Bmi1 is expressed in all cells of the mouse mammary gland and is especially high in luminal cells. Loss of Bmi1 results in a severe mammary-epithelium growth defect, which can be rescued by codeletion of the Ink4a/Arf locus or pregnancy. Even though mammary stem cells are present in the absence of Bmi1, their activity is reduced, and this is only partially due to Ink4a/Arf expression. Interestingly, loss of Bmi1 causes premature lobuloalveolar differentiation, whereas overexpression of Bmi1 inhibits lobuloalveolar differentiation induced by pregnancy hormones. Because Bmi1 affects not only mammary stem cells but also, more committed cells, our data warrant a more detailed analysis of the different roles of Bmi1 in breast-cancer etiology.
C1 [Pietersen, Alexandra M.; Prasad, Asheeta A.; Tanger, Ellen; Cornelissen-Steijger, Paulien; van Lohuizen, Maarten] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands.
   [Evers, Bastiaan; Jonkers, Jos] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands.
C3 Netherlands Cancer Institute; Netherlands Cancer Institute
RP van Lohuizen, M (通讯作者)，Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM m.v.lohuizen@nki.ni
RI Jonkers, Jos/AAG-3246-2019
OI prasad, asheeta/0000-0001-9752-8175; Jonkers, Jos/0000-0002-9264-9792
CR Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8
   Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271
   Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305
   Dimri GP, 2002, CANCER RES, V62, P4736
   Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001
   Gadd M, 2001, CANCER RES, V61, P8811
   Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6
   HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027
   Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691
   Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060
   Moraes RC, 2007, DEVELOPMENT, V134, P1231, DOI 10.1242/dev.02797
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004
   Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8
   Shillingford JM, 2003, J HISTOCHEM CYTOCHEM, V51, P555, DOI 10.1177/002215540305100501
   SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9
   Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212
   Smith GH, 2003, CELL PROLIFERAT, V36, P3, DOI 10.1046/j.1365-2184.36.s.1.2.x
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757
   Yi YJ, 2004, MOL BIOL CELL, V15, P2302, DOI 10.1091/mbc.E03-11-0785
NR 34
TC 105
Z9 123
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD JUL 22
PY 2008
VL 18
IS 14
BP 1094
EP 1099
DI 10.1016/j.cub.2008.06.070
PG 6
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 336PW
UT WOS:000258378100035
PM 18635350
OA Bronze
DA 2025-01-12
ER

PT J
AU Widschwendter, M
   Apostolidou, S
   Raum, E
   Rothenbacher, D
   Fiegl, H
   Menon, U
   Stegmaier, C
   Jacobs, IJ
   Brenner, H
AF Widschwendter, Martin
   Apostolidou, Sophia
   Raum, Elke
   Rothenbacher, Dietrich
   Fiegl, Heidi
   Menon, Usha
   Stegmaier, Christa
   Jacobs, Ian J.
   Brenner, Hermann
TI Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A
   Proof of Principle Study
SO PLOS ONE
LA English
DT Article
AB Background: Epigenetic changes are emerging as one of the most important events in carcinogenesis. Two alterations in the pattern of DNA methylation in breast cancer (BC) have been previously reported; active estrogen receptor-a (ER-a) is associated with decreased methylation of ER-a target (ERT) genes, and polycomb group target (PCGT) genes are more likely than other genes to have promoter DNA hypermethylation in cancer. However, whether DNA methylation in normal unrelated cells is associated with BC risk and whether these imprints can be related to factors which can be modified by the environment, is unclear.
   Methodology/Principal Findings: Using quantitative methylation analysis in a case-control study (n = 1,083) we found that DNA methylation of peripheral blood cell DNA provides good prediction of BC risk. We also report that invasive ductal and invasive lobular BC is characterized by two different sets of genes, the latter particular by genes involved in the differentiation of the mesenchyme (PITX2, TITF1, GDNF and MYOD1). Finally we demonstrate that only ERT genes predict ER positive BC; lack of peripheral blood cell DNA methylation of ZNF217 predicted BC independent of age and family history (odds ratio 1.49; 95% confidence interval 1.12-1.97; P = 0.006) and was associated with ER-a bioactivity in the corresponding serum.
   Conclusion/Significance: This first large-scale epigenotyping study demonstrates that DNA methylation may serve as a link between the environment and the genome. Factors that can be modulated by the environment (like estrogens) leave an imprint in the DNA of cells that are unrelated to the target organ and indicate the predisposition to develop a cancer. Further research will need to demonstrate whether DNA methylation profiles will be able to serve as a new tool to predict the risk of developing chronic diseases with sufficient accuracy to guide preventive measures.
C1 [Widschwendter, Martin; Apostolidou, Sophia; Fiegl, Heidi; Menon, Usha; Jacobs, Ian J.] UCL, Dept Gynecol Oncol, Inst Womens Hlth, London, England.
   [Raum, Elke; Rothenbacher, Dietrich; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Ageing Res, Heidelberg, Germany.
   [Stegmaier, Christa] Saarland Canc Registry, Saarbrucken, Germany.
C3 University of London; University College London; Helmholtz Association;
   German Cancer Research Center (DKFZ)
RP Widschwendter, M (通讯作者)，UCL, Dept Gynecol Oncol, Inst Womens Hlth, London, England.
EM M.Widschwendter@ucl.ac.uk
RI Menon, Usha/C-4716-2008; Zeimet, Alain/AFK-2441-2022; Jacobs,
   Ian/F-1743-2013; Brenner, Hermann/ABE-6383-2020; Fiegl,
   Heidi/K-4445-2017
OI Jacobs, Ian/0000-0002-5005-2672; Brenner, Hermann/0000-0002-6129-1572;
   Apostolidou, Sophia/0000-0003-2659-0451; Widschwendter,
   Martin/0000-0002-7778-8380; Fiegl, Heidi/0000-0002-1236-6806;
   Rothenbacher, Dietrich/0000-0002-3563-2791; Menon,
   Usha/0000-0003-3708-1732
FU The Eve Appeal; The Oak Foundation; European Union; FWF Austrian Science
   Fund; Baden-Wurttemberg Ministry of Research, Science and Arts
FX The work described in this manuscript was supported by The Eve Appeal
   and The Oak Foundation and grants from the European Union and the FWF
   Austrian Science Fund (awarded to M. Widschwendter) and by a grant from
   the Baden-Wurttemberg Ministry of Research, Science and Arts (awarded to
   H. Brenner). The funders did not play any role in the design or conduct
   of the study.
CR Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   De Langhe SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001516
   Decarli A, 2006, J NATL CANCER I, V98, P1686, DOI 10.1093/jnci/djj463
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Gail MH, 2005, BIOSTATISTICS, V6, P227, DOI 10.1093/biostatistics/kxi005
   Garcia-Barceló MM, 2007, ANN HUM GENET, V71, P746, DOI 10.1111/j.1469-1809.2007.00384.x
   Gosden RG, 2007, NEW ENGL J MED, V356, P731, DOI 10.1056/NEJMe068284
   Hasenbrink G, 2006, FASEB J, V20, P1552, DOI 10.1096/fj.05-5413fje
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336
   Nonet GH, 2001, CANCER RES, V61, P1250
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shakya R, 2005, DEV BIOL, V283, P70, DOI 10.1016/j.ydbio.2005.04.008
   Sievernich A, 2004, J STEROID BIOCHEM, V92, P455, DOI 10.1016/j.jsbmb.2004.09.004
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Terry P, 2002, INT J CANCER, V97, P864, DOI 10.1002/ijc.10138
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
NR 36
TC 126
Z9 150
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2008
VL 3
IS 7
AR e2656
DI 10.1371/journal.pone.0002656
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 417DX
UT WOS:000264057200002
PM 18628976
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ronneberg, JA
   Tost, J
   Solvang, HK
   Alnaes, GIG
   Johansen, FE
   Brendeford, EM
   Yakhini, Z
   Gut, IG
   Lonning, PE
   Borresen-Dale, AL
   Gabrielsen, OS
   Kristensen, VN
AF Ronneberg, Jo Anders
   Tost, Jorg
   Solvang, Hiroko K.
   Alnaes, Grethe I. G.
   Johansen, Fredrik E.
   Brendeford, Elen M.
   Yakhini, Zohar
   Gut, Ivo G.
   Lonning, Per Eystein
   Borresen-Dale, Anne-Lise
   Gabrielsen, Odd S.
   Kristensen, Vessela N.
TI <i>GSTP1</i> promoter haplotypes affect DNA methylation levels and
   promoter activity in breast carcinomas
SO CANCER RESEARCH
LA English
DT Article
ID GLUTATHIONE-S-TRANSFERASE; ESTROGEN-RECEPTOR EXPRESSION; CPG ISLAND
   METHYLATION; C-MYB; CANCER-CELLS; GENE-EXPRESSION; P1 GENE;
   HYPERMETHYLATION; PI; CHROMATIN
AB The CpG island spanning the transcription start of the glutathione S-transferase P1 becomes methylated in a variety of human cancers including breast cancer. To study the effect of sequence variation on hypermethylation of the GSTP1 promoter, we analyzed the genetic and epigenetic variability in 90 tumors from patients with locally advanced breast cancer. High-resolution quantitative analysis revealed large variability in the DNA methylation levels. Lack of methylation was more often observed in the basal and normal-like estrogen receptor (ER)-negative tumors, and methylated GSTP1 was associated with better overall survival (P = 0.00063). Studies of the genetic variation identified 14 different haplotypes. The distribution of methylation levels of tumors homozygous for the most frequent haplotype was significantly different from other haplotype combinations (P = 0.011), the difference being more pronounced in ER-positive (P = 0.005) and progesterone receptor-positive (P = 0.008) tumors. Regression modeling identified the ER status and haplotype as the main determinants of DNA methylation variability. We identified a putative c-Myb response element (MRE) that was present in one of two minimal promoter haplotypes. In vitro analysis showed that c-Myb binds to the MRE, but binding was weakened by the two polymorphisms. Transient cotransfections in luminal-type and basal-like breast cancer cell lines confirmed cell-specific differential binding of c-Myb to the polymorphic sites, leading to a change in the expression from the GSTP1 promoter in vivo. GSTP1 expression was moderately but significantly (P = 0.01) reduced after siRNA-mediated knockdown of c-Myb. Our results indicate that haplotype structure of a promoter is important for the extent of DNA methylation.
C1 [Ronneberg, Jo Anders; Solvang, Hiroko K.; Alnaes, Grethe I. G.; Johansen, Fredrik E.; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] Univ Hosp, Rikshosp, Norwegian Radium Hosp, Dept Genet, Montebello, Norway.
   [Ronneberg, Jo Anders; Borresen-Dale, Anne-Lise] Univ Oslo, Fac Div Norwegian Radium Hosp, Oslo, Norway.
   [Tost, Jorg; Brendeford, Elen M.; Gabrielsen, Odd S.] Univ Oslo, Dept Mol Biosci, Oslo, Norway.
   [Gut, Ivo G.] CEA Inst Genom, Ctr Natl Genotypage, Lab Epigenet, Evry, France.
   [Lonning, Per Eystein] Univ Bergen, Sect Oncol, Inst Med, Bergen, Norway.
   [Lonning, Per Eystein] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway.
   [Yakhini, Zohar] Technion Israel Inst Technol, Dept Comp Sci, Technion, Haifa, Israel.
   [Johansen, Fredrik E.; Kristensen, Vessela N.] Univ Oslo, Fac Div Ahus Univ Hosp, Oslo, Norway.
C3 University of Oslo; National Hospital Norway; University of Oslo;
   University of Oslo; Universite Paris Saclay; CEA; University of Bergen;
   University of Bergen; Haukeland University Hospital; Technion Israel
   Institute of Technology; University of Oslo
RP Kristensen, VN (通讯作者)，Univ Hosp, Rikshosp, Norwegian Radium Hosp, N-0310 Oslo, Norway.
EM Vessela.N.Kristensen@rr-research.no
RI Gut, Ivo/ABF-3188-2020; Tost, Jorg/H-7129-2019
OI Lonning, Per Eystein/0000-0002-8890-6303; Yakhini,
   Zohar/0000-0002-0420-5412; Tost, Jorg/0000-0002-2683-0817
CR Aas T, 2003, EUR J CANCER, V39, P438, DOI 10.1016/S0959-8049(02)00732-3
   Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Ban N, 1996, CANCER RES, V56, P3577
   Berge T, 2007, BLOOD CELL MOL DIS, V39, P278, DOI 10.1016/j.bcmd.2007.05.007
   Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546
   Bi X, 2004, MOL CELL BIOL, V24, P2118, DOI 10.1128/MCB.24.5.2118-2131.2004
   Cauchi S, 2006, CANCER RES, V66, P6439, DOI 10.1158/0008-5472.CAN-05-4457
   CHOW NWI, 1988, J BIOL CHEM, V263, P12797
   COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2001, CANCER RES, V61, P3225
   Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016
   Gaszner M, 2006, NAT REV GENET, V7, P703, DOI 10.1038/nrg1925
   GILBERT L, 1993, J CLIN ONCOL, V11, P49, DOI 10.1200/JCO.1993.11.1.49
   GUDAS JM, 1995, CLIN CANCER RES, V1, P235
   GUERIN M, 1990, ONCOGENE, V5, P131
   Huang JX, 2003, MODERN PATHOL, V16, P558, DOI 10.1097/01.MP.0000071842.83169.5A
   Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kristensen V N, 2001, Hum Mutat, V17, P238, DOI 10.1002/humu.17
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lee WP, 1996, CANCER CHEMOTH PHARM, V38, P45, DOI 10.1007/s002800050446
   Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199
   Moureau-Zabotto L, 2006, BRIT J CANCER, V94, P473, DOI 10.1038/sj.bjc.6602958
   MULDER TPJ, 1995, CANCER RES, V55, P2696
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050
NR 36
TC 42
Z9 48
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2008
VL 68
IS 14
BP 5562
EP 5571
DI 10.1158/0008-5472.CAN-07-5828
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 327ZZ
UT WOS:000257768300012
PM 18632608
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Kvasha, S
   Gordiyuk, V
   Kondratov, A
   Ugryn, D
   Zgonnyk, YM
   Rynditch, AV
   Vozianov, AF
AF Kvasha, Sergiy
   Gordiyuk, Vasily
   Kondratov, Alexandr
   Ugryn, Dmytro
   Zgonnyk, Yury M.
   Rynditch, Alla V.
   Vozianov, Alexandr F.
TI Hypermethylation of the 5′CpG island of the <i>FHIT</i> gene in clear
   cell renal carcinomas
SO CANCER LETTERS
LA English
DT Article
DE FHIT gene; CpG island hypermethylation; clear cell renal carcinoma
ID HISTIDINE TRIAD GENE; LUNG-CANCER; ABERRANT METHYLATION; PROTEIN
   EXPRESSION; TUMOR-DEVELOPMENT; WORSE PROGNOSIS; BREAST-CANCER; FRA3B
   REGION; CPG ISLANDS; APOPTOSIS
AB FHIT is a tumour suppressor gene which is frequently inactivated in different types of cancer. Both genetic (mutations, deletions, chromosomal rearrangements) and epigenetic (aberrant methylation of the 5'CpG island) alterations of the FHIT gene have been reported in various malignancies. Yet little is known about the mechanism of FHIT inactivation in clear cell renal carcinomas. Since genetic alterations were not frequently observed in DNA corresponding to the FHIT gene in renal tumours, to elucidate the mechanism of FHIT gene silencing we examined 22 paired samples of clear cell renal carcinoma and non-malignant renal tissue for the methylation of the FHIT 5'CpG island by methylation-specific PCR. Hypermethylation of the FHIT 5'CpG island was detected in 54.5% (12/22) of clear cell renal carcinomas. Bisulfite sequencing of the FHIT 5'CpG island confirmed the results obtained by methylation-specific PCR for selected samples. We showed here that expression of the FHIT gene is inversely correlated with hypermethylation of the FHIT 5'CpG island in the selected samples. Our results suggest that hypermethylation of the FHIT 5'CpG island may be responsible for inactivation of the FHIT gene in clear cell renal carcinomas. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Kvasha, Sergiy; Gordiyuk, Vasily; Kondratov, Alexandr; Ugryn, Dmytro; Rynditch, Alla V.] Natl Acad Sci, Inst Mol Biol & Genet, UA-03143 Kiev, Ukraine.
   [Zgonnyk, Yury M.; Vozianov, Alexandr F.] Ukraine Acad Med Sci, Inst Urol, UA-04053 Kiev, Ukraine.
C3 National Academy of Sciences Ukraine; Institute of Molecular Biology &
   Genetics of NASU; National Academy of Medical Sciences of Ukraine; O. F.
   Vozianov Institute of Urology of the National Academy of Medical
   Sciences of Ukraine
RP Kvasha, S (通讯作者)，Natl Acad Sci, Inst Mol Biol & Genet, 150 Zabolotnogo St, UA-03143 Kiev, Ukraine.
EM s.m.kvasha@imbg.org.ua; rynditch@imbg.org.ua
OI Rynditch, Alla/0000-0003-1590-7839
CR [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   [Anonymous], AJCC CANC STAG MAN
   Baffa R, 1998, CANCER RES, V58, P4708
   Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t
   Bugert P, 1997, GENE CHROMOSOME CANC, V20, P9, DOI 10.1002/(SICI)1098-2264(199709)20:1<9::AID-GCC2>3.0.CO;2-Z
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Druck T, 1997, CANCER RES, V57, P504
   Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098
   Dumon KR, 2001, CANCER RES, V61, P4827
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Greenspan DL, 1997, CANCER RES, V57, P4692
   Guerin LA, 2006, ARCH PATHOL LAB MED, V130, P158
   Hadaczek P, 1998, CANCER RES, V58, P2946
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HIBI K, 1992, ONCOGENE, V7, P445
   Hong Fan-zhen, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P257
   Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139
   HUEBNER K, 1997, BIOCHIM BIOPHYS ACTA, V1332, P65
   Lee EJ, 2006, EUR J CANCER, V42, P972, DOI 10.1016/j.ejca.2006.01.021
   NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101
   Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2
   Ramp U, 2002, J PATHOL, V196, P430, DOI 10.1002/path.1062
   Roa JC, 2004, REV MED CHILE, V132, P1069
   Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799
   Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323
   SHI HR, 2005, ZHENG, V24, P7
   Sozzi G, 1998, CANCER RES, V58, P5032
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Tanaka H, 1998, CANCER RES, V58, P3429
   Toledo G, 2004, MODERN PATHOL, V17, P440, DOI 10.1038/modpathol.3800081
   Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576
   Yang Y, 2006, LEUKEMIA RES, V30, P98, DOI 10.1016/j.leukres.2005.06.002
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 35
TC 25
Z9 32
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUL 8
PY 2008
VL 265
IS 2
BP 250
EP 257
DI 10.1016/j.canlet.2008.02.036
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 313HA
UT WOS:000256730500010
PM 18378390
DA 2025-01-12
ER

PT J
AU Fleury, L
   Gerus, M
   Lavigne, AC
   Richard-Foy, H
   Bystricky, K
AF Fleury, L.
   Gerus, M.
   Lavigne, A. C.
   Richard-Foy, H.
   Bystricky, K.
TI Eliminating epigenetic barriers induces transient hormone-regulated gene
   expression in estrogen receptor negative breast cancer cells
SO ONCOGENE
LA English
DT Article
DE breast cancer; chromatin; ER alpha; PR; methylation
ID BONE MORPHOGENETIC PROTEIN-6; HISTONE DEACETYLASE INHIBITION; DNA
   METHYLATION; PROGESTERONE-RECEPTOR; PROSTATE-CANCER; COPY NUMBER; ALPHA;
   BINDING; PROGRESSION; PROMOTER
AB In breast cancer, approximately one-third of tumors express neither the estrogen receptor ( ER alpha) nor estrogen-regulated genes such as the progesterone receptor gene ( PR). Our study provides new insights into the mechanism allowing hormone-activated expression of ER alpha target genes silenced in ER alpha-negative mammary tumor cells. In cell lines derived from ER alpha-negative MDA-MB231 cells, stable expression of different levels of ER alpha from a transgene did not result in transcription of PR. A quantitative comparative analysis demonstrates that inhibiting DNA methyltransferases using 5-aza-2 '-deoxycytidine or specific disruption of DNMT1 by small interfering RNAs and treatment with the histone-deacetylase inhibitor trichostatin A enabled ER alpha-mediated hormone-dependent expression of endogenous PR. We show that demethylation of a CpG island located in the first exon of PR was a prerequisite for ER alpha binding to these regulatorysequences. Although not a general requirement, DNA demethylation is also necessary for derepression of a subset of ER alpha target genes involved in tumorigenesis. PR transcription did not subsist 4 days after removal of the DNA methyltransferase blocking agents, suggesting that hormone-induced expression of ER alpha target genes in ER alpha-negative tumor cells is transient. Our observations support a model where an epigenetic mark confers stable silencing by precluding ER alpha access to promoters.
C1 [Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.] Univ Toulouse, Lab Biol Mol Eucaryote, IBCG, F-31062 Toulouse, Midi Pyrenees, France.
   [Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.] CNRS, UMR 5099, Toulouse, France.
C3 Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre
   National de la Recherche Scientifique (CNRS); Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier
RP Bystricky, K (通讯作者)，Univ Toulouse, Lab Biol Mol Eucaryote, IBCG, 118 Route Narbonne, F-31062 Toulouse, Midi Pyrenees, France.
EM kerstin@ibcg.biotoul.fr
RI Bystricky, Kerstin/AAA-3003-2020; Lavigne, Anne-Claire/O-8805-2015;
   Bystricky, Kerstin/B-8670-2009
OI Bystricky, Kerstin/0000-0001-6717-3721
CR Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O
   Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317
   GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515
   Hamdy FC, 1997, CANCER RES, V57, P4427
   Heikinheimo AK, 1999, CANCER RES, V59, P5815
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07
   Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104
   Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lande-Diner L, 2007, J BIOL CHEM, V282, P12194, DOI 10.1074/jbc.M607838200
   Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   Métivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002
   Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4
   RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1
   Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609
   ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A
   Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066
   Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhang M, 2007, J STEROID BIOCHEM, V105, P91, DOI 10.1016/j.jsbmb.2007.01.002
NR 46
TC 21
Z9 25
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL 3
PY 2008
VL 27
IS 29
BP 4075
EP 4085
DI 10.1038/onc.2008.41
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 321RV
UT WOS:000257325100007
PM 18317449
DA 2025-01-12
ER

PT J
AU Rodriguez, BAT
   Cheng, ASL
   Yan, PS
   Potter, D
   Agosto-Perez, FJ
   Shapiro, CL
   Huang, THM
AF Rodriguez, Benjamin A. T.
   Cheng, Alfred S. L.
   Yan, Pearlly S.
   Potter, Dustin
   Agosto-Perez, Francisco J.
   Shapiro, Charles L.
   Huang, Tim H. -M.
TI Epigenetic repression of the estrogen-regulated <i>Homeobox B13</i> gene
   in breast cancer
SO CARCINOGENESIS
LA English
DT Article
ID 2-GENE EXPRESSION RATIO; RECEPTOR; HOXB13; SURVIVAL
AB Several studies have reported that a high expression ratio of HOXB13 to IL17BR predicts tumor recurrence in node-negative, estrogen receptor (ER) alpha-positive breast cancer patients treated with tamoxifen. The molecular mechanisms underlying this dys-regulation of gene expression remain to be explored. Our epigenetic analysis has found that increased promoter methylation of one of these genes, HOXB13, correlate with the decreased expression of its transcript in breast cancer cell lines (P < 0.005). Transcriptional silencing of this gene can be reversed by a demethylation treatment. HOXB13 is suppressed by the activation of estrogen signaling in ER alpha-positive breast cancer cells. However, treatment with 4-hydroxytamoxifen (4-OHT), an antiestrogen, abrogates the ER alpha-mediated suppression in cancer cells. The notion that this transcriptional induction of HOXB13 occurs in vitro with simultaneous exposure to both estrogen and 4-OHT may provide a biological explanation for its aberrant expression in many node-negative patients undergoing tamoxifen therapy. Interestingly, promoter hypermethylation of HOXB13 is more frequently observed in ER alpha-positive patients with increased lymph node metastasis (P = 0.031) and large tumor sizes (> 5 cm) (P = 0.008). In addition, this aberrant epigenetic event is associated with shorter disease-free survival (P = 0.029) in cancer patients. These results suggest that hypermethylation of HOXB13 is a late event of breast tumorigenesis and a poor prognostic indicator of node-positive cancer patients.
C1 [Huang, Tim H. -M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.
   [Shapiro, Charles L.] Ohio State Univ, Ctr Comprehens Canc, Dept Hematol & Oncol, Columbus, OH 43210 USA.
   [Potter, Dustin] Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA.
   [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
   [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
C3 James Cancer Hospital & Solove Research Institute; University System of
   Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; Chinese University of Hong Kong;
   Chinese University of Hong Kong
RP Huang, THM (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Room 814,Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Yan, Pearlly/E-4339-2011; Cheng, Alfred/C-3327-2014
OI Cheng, Alfred/0000-0003-2345-6951
CR Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   BRITTA MJ, 2003, J MAMMARY GLAND BIOL, V8, P257
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9
   Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261
   FISHER B, 1968, ANN SURG, V168, P337, DOI 10.1097/00000658-196809000-00004
   Girault I, 2004, CANCER LETT, V215, P101, DOI 10.1016/j.canlet.2004.05.006
   Goetz MP, 2006, CLIN CANCER RES, V12, P2080, DOI 10.1158/1078-0432.CCR-05-1263
   Ihaka R., 1996, J Comput Graph Stat, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Jansen MPHM, 2007, J CLIN ONCOL, V25, P662, DOI 10.1200/JCO.2006.07.3676
   Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49
   López R, 2006, INT J GYNECOL CANCER, V16, P1289, DOI 10.1111/j.1525-1438.2006.00603.x
   Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944
   Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
   Miao J, 2007, P NATL ACAD SCI USA, V104, P17093, DOI 10.1073/pnas.0707938104
   Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274
   Nathwani PS, 2000, ENDOCRINOLOGY, V141, P1754, DOI 10.1210/en.141.5.1754
   NEMOTO T, 1980, CANCER-AM CANCER SOC, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nicolini A, 2006, FRONT BIOSCI-LANDMRK, V11, P1818, DOI 10.2741/1926
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Okuda H, 2006, ONCOGENE, V25, P1733, DOI 10.1038/sj.onc.1209200
   Osborne CK, 2001, CLIN CANCER RES, V7, p4338S
   ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090
   Sengupta K, 2003, INT J ONCOL, V22, P609
   Wang Z, 2007, CLIN CANCER RES, V13, P6327, DOI 10.1158/1078-0432.CCR-07-0310
   Yamashita T, 2006, INT J ONCOL, V28, P931
   Zhao YW, 2005, ONCOL REP, V13, P721
NR 29
TC 37
Z9 44
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2008
VL 29
IS 7
BP 1459
EP 1465
DI 10.1093/carcin/bgn115
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 335XX
UT WOS:000258330000023
PM 18499701
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Barbisan, F
   Mazzucchelli, R
   Santinelli, A
   Stramazzotti, D
   Scarpelli, M
   Lopez-Beltran, A
   Cheng, L
   Montironi, R
AF Barbisan, F.
   Mazzucchelli, R.
   Santinelli, A.
   Stramazzotti, D.
   Scarpelli, M.
   Lopez-Beltran, A.
   Cheng, L.
   Montironi, R.
TI IMMUNOHISTOCHEMICAL EVALUATION OF GLOBAL DNA METHYLATION AND H I STONE
   ACETYLATION IN PAPILLARY UROTHELIAL NEOPLASM OF LOW MALIGNANT POTENTIAL
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Article
DE urothelium; papillary urothelial neoplasm of low malignant potential;
   recurrence; global DNA methlylation; global histone acetylation
ID HISTONE ACETYLATION; BREAST-CANCER; PATTERNS; HYPOMETHYLATION; GENE;
   DEACETYLATION; SEQUENCES; DIAGNOSIS
AB A preceding study has shown that karyometry detected subvisual differences in chromatin organization status between non-recurrent and recurrent papillary urothelial neoplasm of low malignant potential (PUNLMP). The status of chromatin organization depends on epigenetic events, such as DNA methylation and histone acetylation. The aim of this study is to explore global DNA methylation and global histone acetylation in non-recurrent and recurrent PUNLMP. 5-methylcytosine (5MeC) and acetylated histone H3 lysine 9 (AcH3K9) were investigated by immunohistochemistry (IHC) in 20 PUNLMP cases (10 non-recurrent and 10 recurrent), in 5 cases of normal urothelium (NU) and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). For global DNA methylation, the mean percentage of positive nuclei in the cells adjacent to the stroma increased from NU (79%) through non-recurrent and recurrent PUNLMP (86% and 93%, respectively) to UC (97%). The percentages of positive nuclei in the intermediate cell layers and in the superficial cells in the four groups were similar to those adjacent to the stroma. The proportion of nuclei with weak-to-mode rate intensity was far greater than that of those strongly stained and increased steadily from NU to UC. For global histone acetylation, the mean percentage of positive nuclei was highest in non-recurrent PUNLMP (i.e. 90%) and lowest in recurrent PUNLMP (i.e. 81%). In NU and UC the mean percentages of positive nuclei were 84% and 861%, respectively. The percentage of positive nuclei decreased from the cell layer adjacent to the stroma to the superficial cell layer. The proportion of nuclei with weak-to-moderate intensity was slightly greater than that of those strongly stained. In comparison with global DNA methylation, the proportion of strongly stained nuclei was much higher. In conclusion, there are differences in global DNA methylation and histone acetylation patterns between non-recurrent and recurrent PUNLMP. Further studies are needed to elucidate the complex interplay between chromatin structure, its modifications and recurrence of PUNLMP.
C1 [Barbisan, F.; Mazzucchelli, R.; Santinelli, A.; Stramazzotti, D.; Scarpelli, M.; Montironi, R.] Polytech Univ Marche Reg, United Hosp, Sect Pathol Anat, Sch Med, I-60126 Ancona, Italy.
   [Lopez-Beltran, A.] Reina Sofia Univ Hosp, Dept Pathol, Cordoba, Spain.
   [Cheng, L.] Fac Med, Cordoba, Spain.
C3 Marche Polytechnic University; Hospital Universitario Reina Sofia -
   Cordoba
RP Montironi, R (通讯作者)，Polytech Univ Marche Reg, United Hosp, Sect Pathol Anat, Sch Med, Via Conca 71, I-60126 Ancona, Italy.
EM r.montironi@univpm.it
RI López-Beltrán, António/AAK-7326-2020
OI Lopez-Beltran, Antonio/0000-0002-0724-1267; Montironi,
   Rodolfo/0000-0003-3938-610X
FU Associazione Italiana per la Ricerca sul Cancro
FX This study was supported by a grant from the Associazione Italiana per
   la Ricerca sul Cancro (Marche Region section) (RM). We gratefully thank
   Miss Aurora Baldini for her excellent technical contribution.
CR Alsheikh A, 2001, MODERN PATHOL, V14, P267, DOI 10.1038/modpathol.3880300
   [Anonymous], 1973, INT CLASSIFICATION T
   BEDFORD MT, 1987, CANCER RES, V47, P5274
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Galusca B, 2005, VIRCHOWS ARCH, V447, P18, DOI 10.1007/s00428-005-1268-5
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hakkarainen M, 1996, INT J CANCER, V69, P471, DOI 10.1002/(SICI)1097-0215(19961220)69:6<471::AID-IJC9>3.3.CO;2-A
   Hernandez-Blazquez FJ, 2000, GUT, V47, P689, DOI 10.1136/gut.47.5.689
   Herranz Michel, 2007, Methods Mol Biol, V361, P25
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Mariño-Ramírez L, 2005, EXPERT REV PROTEOMIC, V2, P719, DOI 10.1586/14789450.2.5.719
   Marte B, 2005, NATURE, V435, P1172, DOI 10.1038/4351172b
   Mohamed MA, 2007, BJU INT, V99, P908, DOI 10.1111/j.1464-410X.2006.06704.x
   Montironi R, 2008, J CLIN PATHOL, V61, P3, DOI 10.1136/jcp.2007.049312
   Montironi R, 2007, CELL ONCOL, V29, P47
   Orr JA, 2007, ANAL QUANT CYTOL, V29, P17
   Piyathilake CJ, 2005, DIS MARKERS, V21, P147, DOI 10.1155/2005/285134
   Piyathilake CJ, 2003, CANCER CAUSE CONTROL, V14, P37, DOI 10.1023/A:1022573630082
   Piyathilake CJ, 2002, J NUTR, V132, p2340S, DOI 10.1093/jn/132.8.2340S
   Piyathilake CJ, 2001, HUM PATHOL, V32, P856, DOI 10.1053/hupa.2001.26471
   Piyathilake CJ, 2000, BIOTECH HISTOCHEM, V75, P251, DOI 10.3109/10520290009085128
   Qian DZ, 2007, PROSTATE, V67, P1182, DOI 10.1002/pros.20611
   Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108
   Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952
   Sasco AJ, 1996, CANCER LETT, V108, P157, DOI 10.1016/S0304-3835(96)04393-5
   Sauter G., 2004, Pathology and genetics of tumours of the urinary system and male genital organs (IARC/World Health Organization Classification of Tumours), P89
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127
NR 36
TC 26
Z9 27
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394-6320
EI 2058-7384
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD JUL-SEP
PY 2008
VL 21
IS 3
BP 615
EP 623
DI 10.1177/039463200802100315
PG 9
WC Immunology; Pathology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pathology; Pharmacology & Pharmacy
GA 359KR
UT WOS:000259986100015
PM 18831929
DA 2025-01-12
ER

PT J
AU Liu, HL
   Jin, GF
   Wang, HF
   Wu, WT
   Liu, YH
   Qian, J
   Fan, WW
   Ma, HX
   Miao, RF
   Hu, ZB
   Sun, WW
   Wang, Y
   Jin, L
   Wei, QY
   Shen, HB
   Huang, W
   Lu, D
AF Liu, Hongliang
   Jin, Guangfu
   Wang, Haifeng
   Wu, Wenting
   Liu, Yanhong
   Qian, Ji
   Fan, Weiwei
   Ma, Hongxia
   Miao, Ruifen
   Hu, Zhibin
   Sun, Weiwei
   Wang, Yi
   Jin, Li
   Wei, Qingyi
   Shen, Hongbing
   Huang, Wei
   Lu, Daru
TI Association of polymorphisms in one-carbon metabolizing genes and lung
   cancer risk: a case-control study in Chinese population
SO LUNG CANCER
LA English
DT Article
DE lung cancer; one-carbon metabolizing genes; polymorphism; haplotype;
   case-control study; Chinese population; MDR
ID METHYLENE-TETRAHYDROFOLATE REDUCTASE; BREAST-CANCER;
   METHYLENETETRAHYDROFOLATE REDUCTASE; XUAN-WEI; FOLATE; SUSCEPTIBILITY;
   EPIDEMIOLOGY; SMOKING
AB One-carbon metabolism facilitates the cross-talk between genetic and epigenetic processes, making it a good candidate for studying the risk of lung cancer. To investigate the role of common variants of one-carbon metabolizing genes on lung cancer risk, total 25 single nucleotide polymorphisms (SNPs) in 7 genes were genotyped among 500 incident lung cancer patients and 517 cancer-free controls. An increased risk was suggested for the variant allele carriers of MTHFR rs17037396 [odds ratio (OR)= 1.39, 95% confidence interval (Cl): 1.00-1.94] and rs3753584 (OR= 1.46, 95% CI: 1.03-2.08), compared with subjects with wild homozygote, respectively, and the risk was more pronounced among older individuals (> 60 years). In contrast, a decreased risk was observed for TYMS rs2853742 variant allele carriers (OR=0.44, 95% CI: 0.19-0.99) and MTHFD rs2236225 variant allele carriers (OR=0.76, 95% CI: 0.59-0.99). Haplotype analysis revealed that MTHFR "ACCACC" haplotype may contribute to the risk of lung cancer (OR=1.49, 95% CI: 1.03-2.14, local test p value 0.032). A data mining method, multifactor dimensionality reduction (MDR), predicted a four-factor interaction model (rs1801133, rs4659731, rs2273029 and rs699517) with the lowest average prediction error (45.08%, p < 0.001). These findings suggest that genetic variants in one-carbon metabolizing genes might modulate the risk of lung cancer. Validation of these findings in larger studies is needed. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
C1 [Wang, Haifeng; Sun, Weiwei; Wang, Yi; Jin, Li; Huang, Wei] Chinese Natl Human Genome Ctr Shanghai, Dept Genet, Shanghai 201203, Peoples R China.
   [Liu, Hongliang; Wu, Wenting; Liu, Yanhong; Qian, Ji; Fan, Weiwei; Jin, Li; Lu, Daru] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Jin, Guangfu; Ma, Hongxia; Miao, Ruifen; Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Canc Res Ctr, Dept Epidemiol & Biostat, Nanjing 210029, Peoples R China.
   [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
C3 Fudan University; Nanjing Medical University; University of Texas
   System; UTMD Anderson Cancer Center
RP Huang, W (通讯作者)，Chinese Natl Human Genome Ctr Shanghai, Dept Genet, Shanghai 201203, Peoples R China.
EM huangwei@chgc.sh.cn; drlu@fudan.edu.cn
RI wu, wenting/Q-4979-2016; Huang, Wei/L-7090-2019; LIU,
   YANHONG/A-1495-2010; Frank, Viki/GXZ-9902-2022; shen,
   hong/HTQ-6147-2023; Wei, Yingying/HLW-6638-2023; Jin, Li/M-5063-2019;
   Liu, Hongliang/P-3444-2014
OI Jin, Li/0000-0001-9201-2321; Liu, Hongliang/0000-0001-7639-0904
CR [Anonymous], 1999, Nutrition
   Chou YC, 2006, CARCINOGENESIS, V27, P2295, DOI 10.1093/carcin/bgl108
   Darby S, 2001, BRIT J CANCER, V84, P728, DOI 10.1054/bjoc.2000.1668
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gao X, 2003, J NUTR, V133, P3636, DOI 10.1093/jn/133.11.3636
   Goldbohm RA, 2000, NES NUTR WS, V4, P23
   González JR, 2007, BIOINFORMATICS, V23, P644, DOI 10.1093/bioinformatics/btm025
   Grieu F, 2004, ANTICANCER RES, V24, P3215
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   Hao L, 2003, J NUTR, V133, P3630, DOI 10.1093/jn/133.11.3630
   Honecker F, 2003, LAB INVEST, V83, P1489, DOI 10.1097/01.LAB.0000090221.95883.41
   HU Z, 2007, HUM MUTAT        FEB
   Hu ZB, 2006, CANCER EPIDEM BIOMAR, V15, P1336, DOI 10.1158/1055-9965.EPI-06-0194
   Hubner RA, 2006, CANCER EPIDEM BIOMAR, V15, P1607, DOI 10.1158/1055-9965.EPI-06-0274
   HUNG RJ, 2007, CARCINOGENESIS
   Koushik A, 2006, CANCER EPIDEM BIOMAR, V15, P2408, DOI 10.1158/1055-9965.EPI-06-0624
   Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027
   Männistö S, 2004, CANCER EPIDEM BIOMAR, V13, P40, DOI 10.1158/1055-9965.EPI-038-3
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Shen HB, 2003, CANCER EPIDEM BIOMAR, V12, P980
   Shen HB, 2001, CANCER EPIDEM BIOMAR, V10, P397
   Shen M, 2005, LUNG CANCER-J IASLC, V49, P299, DOI 10.1016/j.lungcan.2005.04.002
   Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117
   Shi QL, 2005, CANCER EPIDEM BIOMAR, V14, P1477, DOI 10.1158/1055-9965.EPI-04-0905
   Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832
   Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x
   Zhai XJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-138
NR 29
TC 43
Z9 47
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD JUL
PY 2008
VL 61
IS 1
BP 21
EP 29
DI 10.1016/j.lungcan.2007.12.001
PG 9
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 330IN
UT WOS:000257934400003
PM 18221821
DA 2025-01-12
ER

PT J
AU Kovalchuk, O
   Filkowski, J
   Meservy, J
   IInytskyy, Y
   Tryndyak, VP
   Chekhun, VF
   Pogribny, IP
AF Kovalchuk, Olga
   Filkowski, Jody
   Meservy, James
   IInytskyy, Yaroslav
   Tryndyak, Volodymyr P.
   Chekhun, Vasyl' F.
   Pogribny, Igor P.
TI Involvement of microRNA-451 in resistance of the MCF-7 breast cancer
   cells to chemotherapeutic drug doxorubicin
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID MULTIDRUG-RESISTANCE; TUMOR-SUPPRESSOR; DOWN-REGULATION; MESSENGER-RNA;
   EXPRESSION; GENE; TARGETS; OVEREXPRESSION; PHENOTYPE; MECHANISM
AB Many chemotherapy regiments are successfully used to treat breast cancer; however, often breast cancer cells develop drug resistance that usually leads to a relapse and worsening of prognosis. We have shown recently that epigenetic changes such as DNA methylation and histone modifications play an important role in breast cancer cell resistance to chemotherapeutic agents. Another mechanism of gene expression control is mediated via the function of small regulatory RNA, particularly microRNA (miRNA); its role in cancer cell drug resistance still remains unexplored. In the present study, we investigated the role of miRNA in the resistance of human MCF-7 breast adenocarcinoma cells to doxorubicin (DOX). Here, we for the first time show that DOX-resistant MCF-7 cells (MCF-7/DOX) exhibit a considerable dysregulation of the miRNAome profile and altered expression of miRNA processing enzymes Dicer and Argonaute 2. The mechanistic link of miRNAome deregulation and the multidrug-resistant phenotype of MCF-7/DOX cells was evidenced by a remarkable correlation between specific miRNA expression and corresponding changes in protein levels of their targets, specifically those ones that have a documented role in cancer drug resistance. Furthermore, we show that microRNA-451 regulates the expression of multidrug resistance 1 gene. More importantly, transfection of the MCF-7/DOX-resistant cells with microRNA-451 resulted in the increased sensitivity of cells to DOX, indicating that correction of altered expression of miRNA may have significant implications for therapeutic strategies aiming to overcome cancer cell resistance.
C1 [Kovalchuk, Olga; Filkowski, Jody; Meservy, James; IInytskyy, Yaroslav] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
   [Tryndyak, Volodymyr P.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   [Chekhun, Vasyl' F.] RE Kavetsky Inst Expt Pathol,Oncol & Radiobiol, Dept Mechanisms Anticanc Therapy, Kiev, Ukraine.
C3 University of Lethbridge; US Food & Drug Administration (FDA); National
   Academy of Sciences Ukraine; Kavetsky Institute of Experimental
   Pathology, Oncology & Radiobiology of NASU
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca; igor.pogribny@fda.hhs.gov
RI ; Chekhun, Vasyl/A-7124-2015
OI Tryndyak, Volodymyr/0000-0002-8319-2954; Chekhun,
   Vasyl/0000-0003-1024-3703
CR Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Baker EK, 2004, CANCER BIOL THER, V3, P819, DOI 10.4161/cbt.3.9.1101
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Blenkiron C, 2007, HUM MOL GENET, V16, pR106, DOI 10.1093/hmg/ddm056
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   Chiosea S, 2007, CANCER RES, V67, P2345, DOI 10.1158/0008-5472.CAN-06-3533
   Climent J, 2007, CANCER RES, V67, P818, DOI 10.1158/0008-5472.CAN-06-3307
   Cox Michael C, 2006, Expert Opin Emerg Drugs, V11, P489, DOI 10.1517/14728214.11.3.489
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Duesberg P, 2007, DRUG RESIST UPDATE, V10, P51, DOI 10.1016/j.drup.2007.02.003
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   FUKUDA Y, 2005, NUCL ACIDS S SER, V49, P341
   Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024
   Gottesman MM, 2006, FEBS LETT, V580, P998, DOI 10.1016/j.febslet.2005.12.060
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   ILAGE H, 2006, CURR DRUG TARGETS, V7, P813
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Iwasa Y, 2006, GENETICS, V172, P2557, DOI 10.1534/genetics.105.049791
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kaszubiak A, 2007, INT J ONCOL, V31, P419
   Klein ME, 2007, NAT NEUROSCI, V10, P1513, DOI 10.1038/nn2010
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Lehnert M, 1998, ANTICANCER RES, V18, P2225
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lowery AJ, 2008, CLIN CANCER RES, V14, P360, DOI 10.1158/1078-0432.CCR-07-0992
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Matarazzo MR, 2007, P NATL ACAD SCI USA, V104, P16546, DOI 10.1073/pnas.0702924104
   Megraw M, 2007, NUCLEIC ACIDS RES, V35, pD149, DOI 10.1093/nar/gkl904
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Roberti A, 2006, J CELL PHYSIOL, V207, P571, DOI 10.1002/jcp.20515
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Schmitter D, 2006, NUCLEIC ACIDS RES, V34, P4801, DOI 10.1093/nar/gkl646
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965
   Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859
   Tricoli James V, 2007, Cancer Res, V67, P4553, DOI 10.1158/0008-5472.CAN-07-0563
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   WEIDHAAS JB, CANC RES, V67, P11111
   Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 50
TC 536
Z9 631
U1 2
U2 51
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2008
VL 7
IS 7
BP 2152
EP 2159
DI 10.1158/1535-7163.MCT-08-0021
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 330SW
UT WOS:000257964100042
PM 18645025
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Privette, LM
   Weier, JF
   Nguyen, HN
   Yu, X
   Petty, EM
AF Privette, Lisa M.
   Weier, Jingly F.
   Nguyen, Ha Nam
   Yu, Xiaochun
   Petty, Elizabeth M.
TI Loss of CHFR in human mammary epithelial cells causes genomic
   instability by disrupting the mitotic spindle assembly checkpoint
SO NEOPLASIA
LA English
DT Article
ID AURORA-A KINASE; BREAST-CANCER; EPIGENETIC INACTIVATION; MICROTUBULE
   INHIBITORS; TUBULIN DEACETYLASE; ENDOMETRIAL CANCER; STRESS CHECKPOINT;
   TUMOR SUPPRESSION; CPG ISLAND; GENE
AB CHFR is an E3 ubiquitin ligase and an early mitotic checkpoint protein implicated in many cancers and in the maintenance of genomic stability. To analyze the role of CHFR in genomic stability, by siRNA, we decreased its expression in genomically stable MCF10A cells. Lowered CHFR expression quickly led to increased aneuploidy due to many mitotic defects. First, we confirmed that CHFR interacts with the mitotic kinase Aurora A to regulate its expression. Furthermore, we found that decreased CHFR led to disorganized multipolar mitotic spindles. This was supported by the finding that CHFR interacts with alpha-tubulin and can regulate its ubiquitination in response to nocodazole and the amount of acetylated alpha-tubulin, a component of the mitotic spindle. Finally, we found a novel CHFR interacting protein, the spindle checkpoint protein MAD2. Decreased CHFR expression resulted in the mis-localization of both MAD2 and BUBR1 during mitosis and impaired MAD2/CDC20 complex formation. Further evidence of a compromised spindle checkpoint was the presence of misaligned metaphase chromosomes, lagging anaphase chromosomes, and defective cytokinesis in CHFR knockdown cells. Importantly, our results suggest a novel role for CHFR regulating chromosome segregation where decreased expression, as seen in cancer cells, contributes to genomic instability by impairing the spindle assembly checkpoint.
RP Petty, EM (通讯作者)，5220A MSRBIII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM epetty@umich.edu
OI Privette Vinnedge, Lisa/0000-0003-2087-4920
FU National Institute of General Medical Sciences [T32GM007544] Funding
   Source: NIH RePORTER; NCI NIH HHS [R01 CA130899, R01 CA072877, R01
   CA132755-02, R01CA072877, R01 CA132755, R01 CA130899-01A2] Funding
   Source: Medline; NIGMS NIH HHS [T32 GM007544, 5-T32-GM07544] Funding
   Source: Medline
CR Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0
   Chaturvedi P, 2002, CANCER RES, V62, P1797
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Dowdy SC, 2006, MOL CANCER THER, V5, P2767, DOI 10.1158/1535-7163.MCT-06-0209
   Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161
   Fukuda T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001776
   Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2
   Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849
   Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104
   Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526
   McGhee EM, 2006, CANCER GENET CYTOGEN, V168, P36, DOI 10.1016/j.cancergencyto.2005.12.015
   Michael S, 2008, BIOINFORMATICS, V24, P453, DOI 10.1093/bioinformatics/btm624
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Murone M, 1996, EMBO J, V15, P6605, DOI 10.1002/j.1460-2075.1996.tb01051.x
   Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   Ogi K, 2005, CANCER BIOL THER, V4, P773, DOI 10.4161/cbt.4.7.1896
   Park JH, 2008, J MOL MED, V86, P117, DOI 10.1007/s00109-007-0260-8
   Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N
   Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019
   PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289
   Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109
   PRIVETTE LM, TRANSL ONCO IN PRESS
   Sakai M, 2005, HEPATO-GASTROENTEROL, V52, P1854
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958
   Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695
   Summers MK, 2005, ONCOGENE, V24, P2589, DOI 10.1038/sj.onc.1208428
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707
   WEBSTER DR, 1989, J CELL SCI, V92, P57
   Yanokura M, 2007, ONCOL REP, V17, P41
   Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005
   Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
   Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496
NR 40
TC 31
Z9 37
U1 0
U2 19
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
   USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD JUL
PY 2008
VL 10
IS 7
BP 643
EP 652
DI 10.1593/neo.08176
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 313VT
UT WOS:000256768800002
PM 18592005
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Shoulars, K
   Rodriguez, MA
   Thompson, T
   Turk, J
   Crowley, J
   Markaverich, BM
AF Shoulars, Kevin
   Rodriguez, Mary Ann
   Thompson, Trellis
   Turk, John
   Crowley, Jan
   Markaverich, Barry M.
TI Regulation of the nitric oxide pathway genes by tetrahydrofurandiols:
   Microarray analysis of MCF-7 human breast cancer cells
SO CANCER LETTERS
LA English
DT Article
DE tetrahydrofurandiol; nitric oxide; human breast cancer; growth
   regulation; microarray; reproduction; endocrine disruptor
ID ENDOCRINE-DISRUPTING AGENT; ACID METABOLISM; L-ARGININE; SYNTHASE;
   GROWTH; STIMULATION; INHIBITION; EXPRESSION; ACTIVATION; CAVEOLIN-1
AB THF-diols (9,12-oxy-10,13-dihydroxyoctadecanoic and 10,13-oxy-9,12-dihydroxyoctadecanoic acids) are endocrine disrupters in rats and mitogens in breast cancer cells. Microarray analyses and real-time PCR analyses oil RNA from THF-treated MCF-7 cells revealed a number of genes (caveolin 1, heat shock protein 90 alpha and 90 beta, vascular endothelial growth factor, ATPase, Ca++ transporting, ubiquitous) in the nitric oxide pathway (NOP) were targets for THF-diols. Chromatin immunoprecipitation studies suggest THF-diols modify of historic H4 acetylation at the caveolin I promoter via all epigenetic mechanism. These findings are consistent with the well-known involvement of NOP genes in cell proliferation and sexual behavior. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Shoulars, Kevin; Rodriguez, Mary Ann; Thompson, Trellis; Markaverich, Barry M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Markaverich, Barry M.] Baylor Coll Med, Ctr Comparat Med, Houston, TX 77030 USA.
   [Turk, John; Crowley, Jan] Washington Univ, Sch Med, Dept Med, Mass Spectrometry Facil, St Louis, MO 63110 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Washington
   University (WUSTL)
RP Markaverich, BM (通讯作者)，Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Room 405A, Houston, TX 77030 USA.
EM barrym@bcm.tmc.edu
FU NCI NIH HHS [R01 CA035480, CA 35480] Funding Source: Medline; NIEHS NIH
   HHS [R01 ES009964, ES-09964, R01 ES009964-08] Funding Source: Medline
CR Baldi C, 2003, J CELL BIOCHEM, V88, P1265, DOI 10.1002/jcb.10471
   Bonello N, 1996, BIOL REPROD, V54, P436, DOI 10.1095/biolreprod54.2.436
   Buhimschi I, 1996, HUM REPROD, V11, P1755
   Burnett AL, 1996, MOL MED, V2, P288, DOI 10.1007/BF03401627
   BUSCONI L, 1993, J BIOL CHEM, V268, P8410
   DAVIDOFF MS, 1995, ARCH HISTOL CYTOL, V58, P17, DOI 10.1679/aohc.58.17
   Dixit VD, 2001, ANIM REPROD SCI, V65, P1, DOI 10.1016/S0378-4320(00)00224-4
   GLASGOW WC, 1990, MOL PHARMACOL, V38, P503
   GLASGOW WC, 1994, ARCH BIOCHEM BIOPHYS, V311, P286, DOI 10.1006/abbi.1994.1239
   GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   HELLSTROM WJG, 1994, FERTIL STERIL, V61, P1117
   HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V143, P299, DOI 10.1111/j.1748-1716.1991.tb09236.x
   Jadeski LC, 2002, CAN J PHYSIOL PHARM, V80, P125, DOI 10.1139/Y02-007
   Karpuzoglu E, 2006, NITRIC OXIDE-BIOL CH, V15, P177, DOI 10.1016/j.niox.2006.03.009
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li C., 2001, Genome Biol, P2
   Mani SK, 2005, STEROIDS, V70, P750, DOI 10.1016/j.steroids.2005.04.004
   Markaverich B, 2002, ENVIRON HEALTH PERSP, V110, P169, DOI 10.1289/ehp.02110169
   Markaverich BM, 2007, ENVIRON HEALTH PERSP, V115, P1727, DOI 10.1289/ehp.10659
   Markaverich BM, 2007, ENVIRON HEALTH PERSP, V115, P702, DOI 10.1289/ehp.9311
   Markaverich BM, 2006, STEROIDS, V71, P865, DOI 10.1016/j.steroids.2006.05.017
   Markaverich BM, 1998, INT J ONCOL, V12, P1127
   Markaverich BM, 2005, ENVIRON HEALTH PERSP, V113, P1698, DOI 10.1289/ehp.8231
   MARKAVERICH BM, 1995, ENVIRON HEALTH PERSP, V103, P574, DOI 10.2307/3432433
   Markaverich BM, 2002, BIOCHEM BIOPH RES CO, V291, P692, DOI 10.1006/bbrc.2002.6499
   McCann SM, 1996, P SOC EXP BIOL MED, V211, P7
   Mount PF, 2007, J MOL CELL CARDIOL, V42, P271, DOI 10.1016/j.yjmcc.2006.05.023
   NOLAN RD, 1988, MOL PHARMACOL, V33, P650
   Orucevic A, 1996, CANCER IMMUNOL IMMUN, V42, P38, DOI 10.1007/s002620050249
   Pan YM, 2006, ACTA PHARMACOL SIN, V27, P1567, DOI 10.1111/j.1745-7254.2006.00462.x
   PORT CD, 1969, LAB ANIM CARE, V19, P46
   Rosselli M, 1997, MOL HUM REPROD, V3, P639, DOI 10.1093/molehr/3.8.639
   Rosselli M, 1998, HUM REPROD UPDATE, V4, P3, DOI 10.1093/humupd/4.1.3
   Rosselli M, 1996, MOL HUM REPROD, V2, P607, DOI 10.1093/molehr/2.8.607
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200
   Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200
   Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927
   Tsumori M, 1999, ENDOCR J, V46, P779, DOI 10.1507/endocrj.46.779
   VanVoorhis BJ, 1995, J CLIN INVEST, V96, P2719, DOI 10.1172/JCI118339
   Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133
NR 42
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 18
PY 2008
VL 264
IS 2
BP 265
EP 273
DI 10.1016/j.canlet.2008.01.048
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 313YW
UT WOS:000256776900012
PM 18346845
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhang, M
   Behbod, F
   Atkinson, RL
   Landis, MD
   Kittrell, F
   Edwards, D
   Medina, D
   Tsimelzon, A
   Hilsenbeck, S
   Green, JE
   Michalowska, AM
   Rosen, JM
AF Zhang, Mei
   Behbod, Fariba
   Atkinson, Rachel L.
   Landis, Melissa D.
   Kittrell, Frances
   Edwards, David
   Medina, Daniel
   Tsimelzon, Anna
   Hilsenbeck, Susan
   Green, Jeffrey E.
   Michalowska, Aleksandra M.
   Rosen, Jeffrey M.
TI Identification of tumor-initiating cells in a p53-null mouse model of
   breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION; MAMMARY-GLAND; SELF-RENEWAL;
   PROGNOSTIC MARKERS; STEM-CELLS; BIOLOGY; HIERARCHY; INDUCE; BMI-1
AB Using a syngeneic p53-null mouse mammary gland tumor model that closely mimics human breast cancer, we have identified, by limiting dilution transplantation and in vitro mammosphere assay, a Lin(-)CD29(H)CD24(H) subpopulation of tumor-initiating cells. Upon subsequent transplantation, this subpopulation generated heterogeneous tumors that displayed properties similar to the primary tumor. Analysis of biomarkers suggests the Lin-CD29(H)CD24(H) subpopulation may have arisen from a bipotent mammary progenitor. Differentially expressed genes in the Lin(-)CD29(H)CD24(H) mouse mammary gland tumor-initiating cell population include those involved in DNA damage response and repair, as well as genes involved in epigenetic regulation previously shown to be critical for stem cell self-renewal. These studies provide in vitro and in vivo data that support the cancer stem cell (CSC) hypothesis. Furthermore, this p53-null mouse mammary tumor model may allow us to identify new CSC markers and to test the functional importance of these markers.
C1 Baylor Coll Med, Dept Mol & Cellular Biol, Grad program Translat Biol & Mol Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
   [Green, Jeffrey E.; Michalowska, Aleksandra M.] NCI, Canc Biol Lab, Bethesda, MD 20892 USA.
C3 Baylor College of Medicine; National Institutes of Health (NIH) - USA;
   NIH National Cancer Institute (NCI)
RP Rosen, JM (通讯作者)，Baylor Coll Med, Dept Mol & Cellular Biol, Grad program Translat Biol & Mol Med, Lester & Sue Smith Breast Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.
EM jrosen@bcm.edu
RI Zhang, Mei/G-8690-2014
FU Intramural NIH HHS [Z01 BC005740-15] Funding Source: Medline; NCI NIH
   HHS [U01 CA084243-10, U01 CA084243, R01 CA016303, R37 CA016303,
   U01-CA84243, R37 CA016303-33, K99 CA127462-02, CA16303, K99 CA127462]
   Funding Source: Medline
CR Abba MC, 2007, CANCER RES, V67, P4104, DOI 10.1158/0008-5472.CAN-06-4672
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Aldaz CM, 2002, ONCOGENE, V21, P6366, DOI 10.1038/sj.onc.1205816
   Asselin-Labat ML, 2006, J NATL CANCER I, V98, P1011, DOI 10.1093/jnci/djj267
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277
   Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440
   Choi CH, 2006, EUR J OBSTET GYN R B, V128, P243, DOI 10.1016/j.ejogrb.2006.01.017
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080
   Huntly BJP, 2005, NATURE, V435, P1169, DOI 10.1038/4351169a
   Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028
   Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585
   Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596
   Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100
   Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101
   Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Medina D, 2005, CANCER RES, V65, P3493, DOI 10.1158/0008.5472.CAN-04-3869
   Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje
   Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   PARDO FS, 1994, RADIAT RES, V140, P180, DOI 10.2307/3578901
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065
   Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x
NR 45
TC 266
Z9 310
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2008
VL 68
IS 12
BP 4674
EP 4682
DI 10.1158/0008-5472.CAN-07-6353
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 315CO
UT WOS:000256855700025
PM 18559513
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Freedberg, DE
   Rigas, SH
   Russak, J
   Gai, WM
   Kaplow, M
   Osman, I
   Turner, F
   Randerson-Moor, JA
   Houghton, A
   Busam, K
   Bishop, DT
   Bastian, BC
   Newton-Bishop, JA
   Polsky, D
AF Freedberg, Daniel E.
   Rigas, Sushila H.
   Russak, Julie
   Gai, Weiming
   Kaplow, Margarita
   Osman, Iman
   Turner, Faye
   Randerson-Moor, Juliette A.
   Houghton, Alan
   Busam, Klaus
   Bishop, D. Timothy
   Bastian, Boris C.
   Newton-Bishop, Julia A.
   Polsky, David
TI Frequent p16-independent inactivation of p14<SUP>ARF</SUP> in human
   melanoma
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID HUMAN-MALIGNANT MELANOMA; PROMOTER HYPERMETHYLATION; CUTANEOUS MELANOMA;
   GERMLINE MUTATIONS; FAMILIAL MELANOMA; SPORADIC MELANOMA; TUMOR
   SUPPRESSION; BREAST-CANCER; CDKN2B GENES; P53
AB Background The tumor suppressors p14(ARF) (ARF) and p16(INK4A) (p16) are encoded by overlapping reading frames at the CDKN2A/INK4A locus on chromosome 9p21. In human melanoma, the accumulated evidence has suggested that the predominant tumor suppressor at 9p21 is p16, not ARF. However, recent observations from melanoma-prone families and murine melanoma models suggest a p16-independent tumor suppressor role for ARF. We analyzed a group of melanoma metastases and cell lines to investigate directly whether somatic alterations to the ARF gene support its role as a p16-independent tumor suppressor in human melanoma, assuming that two alterations (genetic and/or epigenetic) would be required to inactivate a gene.
   Methods We examined the p16/ARF locus in 60 melanoma metastases from 58 patients and in 9 human melanoma cell lines using multiplex ligation-dependent probe amplification and multiplex polymerase chain reaction (PCR) to detect deletions, methylation-specific PCR to detect promoter methylation, direct sequencing to detect mutations affecting ARF and p16, and, in a subset of 20 tumors, immunohistochemistry to determine the effect of these alterations on p16 protein expression. All statistical tests were two-sided.
   Results We observed two or more alterations to the ARF gene in 26/60 (43%) metastases. The p16 gene sustained two or more alterations in 13/60 (22%) metastases (P = .03). Inactivation of ARF in the presence of wild-type p16 was seen in 18/60 (30%) metastases.
   Conclusion Genetic and epigenetic analyses of the human 9p21 locus indicate that modifications of ARF occur independently of p16 inactivation in human melanoma and suggest that ARF is more frequently inactivated than p16.
C1 [Freedberg, Daniel E.; Russak, Julie; Gai, Weiming; Kaplow, Margarita; Osman, Iman; Polsky, David] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA.
   [Rigas, Sushila H.; Turner, Faye; Randerson-Moor, Juliette A.; Bishop, D. Timothy; Newton-Bishop, Julia A.] St James Univ Hosp, Epidemiol & Biostat Sect, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England.
   [Houghton, Alan; Busam, Klaus] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Bastian, Boris C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
   [Bastian, Boris C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA.
   [Bastian, Boris C.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
C3 New York University; Cancer Research UK; Saint James's University
   Hospital; University of Leeds; Memorial Sloan Kettering Cancer Center;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center
RP Polsky, D (通讯作者)，NYU, Sch Med, Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.
EM david.polsky@med.nyu.edu
RI Randerson, James/Y-2550-2019; Polsky, David/AAO-6254-2020; Houghton,
   Alan/KBR-1218-2024; FAN, LIU/JGD-8882-2023
OI Bishop, Tim/0000-0002-8752-8785; Bastian, Boris/0000-0003-1836-6062;
   Newton-Bishop, Julia/0000-0001-9147-6802; Rigas,
   Sushila/0000-0002-0401-7681
FU NCI NIH HHS [P01 CA025874, R33 CA095300, R21 CA109388, R33 CA95300, P01
   CA025874-25-A1] Funding Source: Medline; NIAMS NIH HHS [K08 AR02129]
   Funding Source: Medline
CR Aitken J, 1999, JNCI-J NATL CANCER I, V91, P446, DOI 10.1093/jnci/91.5.446
   ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006
   Baisse B, 2001, INT J CANCER, V93, P346, DOI 10.1002/ijc.1343
   Bastian BC, 1998, CANCER RES, V58, P2170
   CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167
   CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27
   CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407
   Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092
   Della Torre G, 2001, BRIT J CANCER, V85, P836
   Domínguez G, 2002, CLIN CANCER RES, V8, P980
   Esteller M, 2000, CANCER RES, V60, P129
   Esteve A, 1996, INT J CANCER, V66, P301
   FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541
   Flores JF, 1996, CANCER RES, V56, P5023
   Fujii H, 1996, CANCER RES, V56, P1493
   Gonzalgo ML, 1997, CANCER RES, V57, P5336
   Grafström E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731
   Gretarsdottir S, 1998, Hum Mutat, V12, P212
   GRUIS NA, 1995, AM J PATHOL, V146, P1199
   Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104
   Harland M, 2005, ONCOGENE, V24, P4604, DOI 10.1038/sj.onc.1208678
   Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273
   Hogervorst FBL, 2003, CANCER RES, V63, P1449
   Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002
   HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15
   KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584
   Laud K, 2006, J MED GENET, V43, P39, DOI 10.1136/jmg.2005.033498
   Li W, 2006, PATHOLOGY, V38, P287, DOI 10.1080/00313020600817951
   Mistry SH, 2005, GENE CHROMOSOME CANC, V44, P292, DOI 10.1002/gcc.20238
   Nakayama T, 2001, AM J PATHOL, V158, P1371, DOI 10.1016/S0002-9440(10)64088-6
   Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697
   Polsky D, 2001, CANCER RES, V61, P6008
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55
   Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728
   Rousseau E, 2003, NEUROPATH APPL NEURO, V29, P574, DOI 10.1046/j.0305-1846.2003.00505.x
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592
   Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461
   Sherr CJ, 2000, CANCER RES, V60, P3689
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Straume O, 2002, AM J PATHOL, V161, P229, DOI 10.1016/S0002-9440(10)64174-0
   van der Velden PA, 2001, CANCER RES, V61, P5303
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
NR 51
TC 82
Z9 95
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUN 4
PY 2008
VL 100
IS 11
BP 784
EP 795
DI 10.1093/jnci/djn157
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 310IU
UT WOS:000256522900009
PM 18505964
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Cui, Y
   Lu, CL
   Kang, AJ
   Liu, LY
   Tan, SN
   Sun, DG
   Hu, JG
   Ma, X
AF Cui, Yi
   Lu, Cailing
   Kang, Aijun
   Liu, Liyong
   Tan, Sainan
   Sun, Daguang
   Hu, Jianguo
   Ma, Xu
TI Nordihydroguaiaretic acid restores expression of silenced E-cadherin
   gene in human breast cancer cell lines and xenografts
SO ANTI-CANCER DRUGS
LA English
DT Article
DE E-cadherin; lignan; methylation; nordihydroguaiaretic acid
ID DNA METHYLTRANSFERASE; PROMOTER HYPERMETHYLATION; DIETARY LIGNANS;
   CARCINOMA-CELLS; CPG ISLAND; PHASE-I; METHYLATION; GROWTH; RISK;
   5-AZA-2'-DEOXYCYTIDINE
AB In our study we use nordihydroguaiaretic acid (NDGA), the naturally occurring lignan, to investigate whether it plays a role in the prevention and treatment of cancer by epigenetic modifications. The growth inhibitory effect of NDGA on human breast cancer cell lines was determined using the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay). It substantially inhibited the growth of human breast cancer cell lines SKBR3 and MDA-MB-435 with an estimated IC50 of 31.09 +/- 1.6 and 38.8 +/- 2.1 mu mol/l respectively, after 4 days incubation with different NDGA concentrations. The in-vivo anticancer activity of NDGA was evaluated by calculating the tumor growth inhibition value. NDGA substantially inhibited the growth of human breast carcinoma cells in both animal and cell-based models. We also found that a single treatment with NDGA reactivates methylation-silenced E-cadherin gene in vitro and in vivo, suggesting an intriguing concept that lignans may act as natural effective epigenetic modifiers in the prevention and treatment of cancer.
C1 [Cui, Yi; Lu, Cailing; Tan, Sainan; Sun, Daguang; Ma, Xu] Natl Res Inst Family Planning, Reprod & Genet Ctr, Beijing, Peoples R China.
   [Tan, Sainan; Sun, Daguang; Ma, Xu] Peking Union Med Coll, Dept Genet, Beijing, Peoples R China.
   [Cui, Yi; Lu, Cailing; Tan, Sainan; Sun, Daguang; Ma, Xu] WHO, Collaborat Ctr Res Human Reproduct, Beijing, Peoples R China.
   [Kang, Aijun; Hu, Jianguo] Peking Univ, Dept Lab Anim Sci, Beijing 100871, Peoples R China.
   [Liu, Liyong] N China Coal Med Coll, Tangshan, Peoples R China.
C3 National Research Institute for Family Planning - China; Chinese Academy
   of Medical Sciences - Peking Union Medical College; Peking Union Medical
   College; World Health Organization; Peking University; North China
   University of Science & Technology
RP Ma, X (通讯作者)，Natl Res Inst Family Planning, Reprod & Genet Ctr, Da Huisi St 12, Beijing, Peoples R China.
EM genetic@263.net.cn
RI LIU, QQ/KSM-8971-2024
CR Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Arteaga S, 2005, J ETHNOPHARMACOL, V98, P231, DOI 10.1016/j.jep.2005.02.002
   Bender CM, 1998, CANCER RES, V58, P95
   Boccardo F, 2006, CLIN CHIM ACTA, V365, P58, DOI 10.1016/j.cca.2005.07.026
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005
   Dai Q, 2003, CANCER EPIDEM BIOMAR, V12, P497
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Fujimoto N, 2004, LIFE SCI, V74, P1417, DOI 10.1016/j.lfs.2003.08.012
   Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hausott B, 2003, J CANCER RES CLIN, V129, P569, DOI 10.1007/s00432-003-0461-7
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015
   JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681
   JIAYOU L, 2003, ACTA ACAD MED MILITA, V25, P283
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kinniry P, 2006, J NUTR, V136, P1545, DOI 10.1093/jn/136.6.1545
   Lee MK, 2007, BIOL PHARM BULL, V30, P814, DOI 10.1248/bpb.30.814
   Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9
   Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486
   Meyer GE, 2007, J CELL BIOCHEM, V102, P1529, DOI 10.1002/jcb.21373
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Saarinen NM, 2007, MOL NUTR FOOD RES, V51, P857, DOI 10.1002/mnfr.200600240
   Sancéau J, 2002, ONCOGENE, V21, P7700, DOI 10.1038/sj.onc.1205881
   Strickley RG, 2004, PHARM RES-DORDR, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120
   Wang L, 2005, INT J CANCER, V116, P793, DOI 10.1002/ijc.21067
   Webb AL, 2005, NUTR CANCER, V51, P117, DOI 10.1207/s15327914nc5102_1
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yuan E, 2006, CANCER RES, V66, P3443, DOI 10.1158/0008-5472.CAN-05-3739
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
NR 37
TC 12
Z9 12
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4973
EI 1473-5741
J9 ANTI-CANCER DRUG
JI Anti-Cancer Drugs
PD JUN
PY 2008
VL 19
IS 5
BP 487
EP 494
DI 10.1097/CAD.0b013e3282fd5310
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 297JX
UT WOS:000255614100005
PM 18418215
DA 2025-01-12
ER

PT J
AU Yin, QY
   McBride, J
   Fewell, C
   Lacey, M
   Wang, X
   Lin, Z
   Cameron, J
   Flemington, EK
AF Yin, Qinyan
   McBride, Jane
   Fewell, Claire
   Lacey, Michelle
   Wang, Xia
   Lin, Zhen
   Cameron, Jennifer
   Flemington, Erik K.
TI MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates
   Epstein-Barr virus-regulated gene expression pathways
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN BREAST-CANCER; CELL-PROLIFERATION; BURKITTS-LYMPHOMA;
   MESSENGER-RNAS; TRANSCRIPTION; MIR-155; INFECTION; LATENT; INHIBITION;
   ONCOGENE
AB The cellular microRNA miR-155 has been shown to be involved in lymphocyte activation and is expressed in Epstein-Barr virus (EBV)-infected cells displaying type III latency gene expression but not type I latency gene expression. We show here that the elevated levels of miR-155 in type III latency cells is due to EBV gene expression and not epigenetic differences in cell lines tested, and we show that expression in EBV-infected cells requires a conserved AP-1 element in the miR-155 promoter. Gene expression analysis was carried out in a type I latency cell line transduced with an miR-155-expressing retrovirus. This analysis identified both miR-155-suppressed and -induced cellular mRNAs and suggested that in addition to direct targeting of 3' untranslated regions (UTRs), miR-155 alters gene expression in part through the alteration of signal transduction pathways. 3' UTR reporter analysis of predicted miR-155 target genes identified the transcriptional regulatory genes encoding BACH1, ZIC3, HIVEP2, CEBPB, ZNF652, ARID2, and SMAD5 as miR-155 targets. Western blot analysis of the most highly suppressed of these, BACH1, showed lower expression in cells transduced with a miR-155 retrovirus. Inspection of the promoters from genes regulated in EBV-infected cells and in cells infected with an miR-155 retrovirus identified potential binding sequences for BACH1 and ZIC3. Together, these experiments suggest that the induction of miR-155 by EBV contributes to EBV-mediated signaling in part through the modulation of transcriptional regulatory factors.
C1 [Yin, Qinyan; Lin, Zhen; Cameron, Jennifer; Flemington, Erik K.] Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70118 USA.
   [Yin, Qinyan; McBride, Jane; Fewell, Claire; Wang, Xia; Lin, Zhen; Flemington, Erik K.] Tulane Univ, Dept Pathol, New Orleans, LA 70118 USA.
   [Lacey, Michelle] Tulane Univ, Dept Math, New Orleans, LA 70118 USA.
C3 Tulane University; Tulane University; Tulane University
RP Flemington, EK (通讯作者)，Tulane Univ, Hlth Sci Ctr, 1430 Tulane Ave,SL79, New Orleans, LA 70112 USA.
EM eflemin@tulane.edu
OI Cameron, Jennifer/0000-0002-5785-2410
FU NCI NIH HHS [R01 CA124311] Funding Source: Medline; NCRR NIH HHS [P20
   RR020152] Funding Source: Medline; NIDCR NIH HHS [R21 DE017008,
   R21-DE17008] Funding Source: Medline; NIGMS NIH HHS [R01 GM048045,
   R01-GM48045] Funding Source: Medline
CR Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07
   CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657
   Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103
   Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Farrell CJ, 2004, P NATL ACAD SCI USA, V101, P4625, DOI 10.1073/pnas.0306482101
   Fingeroth JD, 1999, J VIROL, V73, P2115, DOI 10.1128/JVI.73.3.2115-2125.1999
   Fujii H, 2005, BREAST CANCER RES TR, V91, P103, DOI 10.1007/s10549-004-5779-6
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gottwein E, 2007, NATURE, V450, P1096, DOI 10.1038/nature05992
   Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Itkes A, 2000, FEBS LETT, V474, P23, DOI 10.1016/S0014-5793(00)01562-3
   Jiang JM, 2006, GENE CHROMOSOME CANC, V45, P103, DOI 10.1002/gcc.20264
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Joseph AM, 2000, J VIROL, V74, P9964, DOI 10.1128/JVI.74.21.9964-9971.2000
   Kanezaki R, 2001, J BIOL CHEM, V276, P7278, DOI 10.1074/jbc.M004227200
   Kluiver J, 2006, GENE CHROMOSOME CANC, V45, P147, DOI 10.1002/gcc.20273
   Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Liu JD, 2005, NAT CELL BIOL, V7, P1261, DOI 10.1038/ncb1333
   Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067
   Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Rao SP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-3
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Schaefer BC, 2001, ANAL BIOCHEM, V297, P86, DOI 10.1006/abio.2001.5327
   Skalsky RL, 2007, J VIROL, V81, P12836, DOI 10.1128/JVI.01804-07
   Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102
   Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490
   TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994
   van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   WAKAGURI H, 1997, NUCLEIC ACIDS RES, V36, pD97
   Ware SM, 2006, DEV DYNAM, V235, P776, DOI 10.1002/dvdy.20668
   Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549
   Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070
   Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
NR 49
TC 218
Z9 251
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2008
VL 82
IS 11
BP 5295
EP 5306
DI 10.1128/JVI.02380-07
PG 12
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA 301FN
UT WOS:000255881900018
PM 18367535
OA Green Published
DA 2025-01-12
ER

PT J
AU Wu, XD
   Gong, YH
   Yue, JP
   Qiang, BQ
   Yuan, JG
   Peng, XZ
AF Wu, Xudong
   Gong, Yanhua
   Yue, Jiping
   Qiang, Boqin
   Yuan, Jiangang
   Peng, Xiaozhong
TI Cooperation between EZH2, NSPc1-mediated histone H2A ubiquitination and
   Dnmt1 in HOX gene silencing
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; POLYCOMB GROUP PROTEINS; PROSTATE-CANCER CELLS;
   GENOME-WIDE ANALYSIS; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION;
   DEVELOPMENTAL REGULATORS; DROSOPHILA-MELANOGASTER; EPIGENETIC
   INACTIVATION; BREAST-CANCER
AB An intricate interplay between DNA methylation and polycomb-mediated gene silencing has been highlighted recently. Here we provided evidence that Nervous System Polycomb 1 (NSPc1), a BMI1 homologous polycomb protein, plays important roles in promoting H2A ubiquitination and cooperates with DNA methylation in HOX gene silencing. We showed that NSPc1 stimulates H2A ubiquitination in vivo and in vitro through direct interaction with both RING2 and H2A. RT-PCR analysis revealed that loss of NSPc1, EZH2 or DNA methyltransferase 1 (Dnmt1), or inhibition of DNA methylation in HeLa cells de-represses the expression of HOXA7. Chromatin immunoprecipitation (ChIP) assays demonstrated that NSPc1, EZH2 and Dnmt1 bind to the promoter of HOXA7, which is frequently hypermethylated in tumors. Knockdown of NSPc1 results in significant reduction of H2A ubiquitination and DNA demethylation as well as Dnmt1 dissociation in the HOXA7 promoter. Meanwhile Dnmt1 deficiency affects NSPc1 recruitment and H2A ubiquitination, whereas on both cases EZH2-mediated H3K27 trimethylation remains unaffected. When EZH2 was depleted, however, NSPc1 and Dnmt1 enrichment was abolished concomitant with local reduction of H3K27 trimethylation, H2A ubiquitination and DNA methylation. Taken together, our findings indicated that NSPc1-mediated H2A ubiquitination and DNA methylation, both being directed by EZH2, are interdependent in long-term target gene silencing within cancer cells.
C1 Peking Union Med Coll, Sch Basic Med, Beijing 100730, Peoples R China.
   Chinese Acad Med Sci, Inst Basic Med Sci, Natl Key Lab Med Mol Biol, Beijing 100005, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Institute of Basic Medical Sciences -
   CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College
RP Yuan, JG (通讯作者)，Peking Union Med Coll, Sch Basic Med, Beijing 100730, Peoples R China.
EM yuanjiangang@pumc.edu.cn; pengxiaozhong@pumc.edu.cn
RI Wu, Xudong/F-9666-2013
OI Peng, Xiaozhong/0000-0002-9592-9554; Gong, Yanhua/0000-0002-2693-0498;
   Wu, Xudong/0000-0001-9594-479X
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bruggeman SWM, 2006, CELL CYCLE, V5, P1281, DOI 10.4161/cc.5.12.2806
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354
   Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06
   Gieseg MA, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-35
   Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117
   Gong YH, 2006, NUCLEIC ACIDS RES, V34, P6158, DOI 10.1093/nar/gkl834
   Hernández-Muñoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005
   Jorgensen HF, 2006, CELL CYCLE, V5, P1411, DOI 10.4161/cc.5.13.2927
   Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330
   Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016
   Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274
   Negishi M, 2007, BIOCHEM BIOPH RES CO, V353, P992, DOI 10.1016/j.bbrc.2006.12.166
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Nunes M, 2001, MECH DEVELOP, V102, P219, DOI 10.1016/S0925-4773(01)00288-X
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Okuda H, 2006, ONCOGENE, V25, P1733, DOI 10.1038/sj.onc.1209200
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Pritsker M, 2006, P NATL ACAD SCI USA, V103, P6946, DOI 10.1073/pnas.0509861103
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Sakamoto Y, 2007, J BIOL CHEM, V282, P16391, DOI 10.1074/jbc.M700011200
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046
   Sridhar VV, 2007, NATURE, V447, P735, DOI 10.1038/nature05864
   Sültmann H, 2005, CLIN CANCER RES, V11, P646
   Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104
   Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Xi SC, 2007, P NATL ACAD SCI USA, V104, P14366, DOI 10.1073/pnas.0703669104
   Zhou W, 2008, MOL CELL, V29, P69, DOI 10.1016/j.molcel.2007.11.002
NR 54
TC 81
Z9 98
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN
PY 2008
VL 36
IS 11
BP 3590
EP 3599
DI 10.1093/nar/gkn243
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 319UC
UT WOS:000257188700008
PM 18460542
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Noetzel, E
   Veeck, J
   Niederacher, D
   Galm, O
   Horn, F
   Hartmann, A
   Knüchel, R
   Dahl, E
AF Noetzel, Erik
   Veeck, Juergen
   Niederacher, Dieter
   Galm, Oliver
   Horn, Felicitas
   Hartmann, Arndt
   Knuechel, Ruth
   Dahl, Edgar
TI Promoter methylation-associated loss of <i>ID4</i> expression is a
   marker of tumour recurrence in human breast cancer
SO BMC CANCER
LA English
DT Article
ID LOOP-HELIX PROTEINS; DNA METHYLATION; UNFAVORABLE PROGNOSIS;
   GENE-EXPRESSION; CELL-GROWTH; DIFFERENTIATION; HYPERMETHYLATION;
   CARCINOMAS; MAMMARY; BRCA1
AB Background: Inhibitor of DNA binding/Inhibitor of differentiation 4 (ID4) is a critical factor for cell proliferation and differentiation in normal vertebrate development. ID4 has regulative functions for differentiation and growth of the developing brain. The role of ID1, ID2 and ID3 are expected to be oncogenic due to their overexpression in pancreatic cancer and colorectal adenocarcinomas, respectively. Aside from these findings, loss of ID3 expression was demonstrated in ovarian cancer. The aim of the present study was to reveal the factual role of ID4 in carcinogenesis in more detail, since its role for the pathogenesis of human breast cancer has been discussed controversially, assigning both oncogenic and tumour suppressive functions.
   Methods: ID4 promoter methylation, ID4 mRNA expression and ID4 protein expression were analysed in primary human breast cancer specimens using methylation-specific PCR (MSP) (n=170), semiquantitative realtime RT-PCR (n=46) and immunhistochemistry (n=3), respectively. In order to demonstrate a functional association of ID4 promoter methylation with its gene silencing, we performed DNA demethylation analysis with four human breast cell lines using MSP and semiquantitative realtime RT-PCR. In addition, we performed correlations of ID4 promoter methylation with ID4 mRNA and ID4 protein expression in matched samples of breast tumour and corresponding normal tissue. We carried out statistical analyses in order to find correlations between ID4 promoter methylation and clinicopathological parameters.
   Results: Frequent ID4 promoter methylation was observed in primary breast cancer samples (69%, 117/170). We found a tight correlation (P<0.0001) between ID4 promoter methylation and loss of ID4 expression in primary breast cancer 3 specimens. Demethylating treatment with breast cancer cell lines was associated with clear ID4 mRNA re-expression. Tumours with ID4 promoter methylation showed distinct loss of ID4 expression on both transcription and protein level. Interestingly, ID4 promoter methylation was a factor for unfavourable recurrence-free survival (P=0.036) and increased risk for lymph node metastasis (P=0.030).
   Conclusion: ID4 is indeed a novel tumour suppressor gene in normal human breast tissue and is epigenetically silenced during cancer development, indicating increased risk for tumour relapse. Thus, ID4 methylation status could serve as a prognostic biomarker in human breast cancer.
C1 [Noetzel, Erik; Veeck, Juergen; Knuechel, Ruth; Dahl, Edgar] Univ Hosp RWTH Aachen, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
   [Niederacher, Dieter] Univ Dusseldorf, Dept Obstet & Gynaecol, Dusseldorf, Germany.
   [Galm, Oliver] Univ Hosp RWTH Aachen, Med Clin 4, Aachen, Germany.
   [Horn, Felicitas] Univ Regensburg, Dept Obstet & Gynaecol, Regensburg, Germany.
   [Hartmann, Arndt] Univ Erlangen Nurnberg, Inst Pathol, Erlangen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine
   University Dusseldorf; RWTH Aachen University; RWTH Aachen University
   Hospital; University of Regensburg; University of Erlangen Nuremberg
RP Noetzel, E (通讯作者)，Univ Hosp RWTH Aachen, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
EM enoetzel@ukaachen.de; juergen.veeck@rwth-aachen.de;
   niederac@uni-duesseldorf.de; oliver.galm@post.rwth-aachen.de;
   fhorn@caritasstjosef.de; arndt.hartmann@uk-erlangen.de;
   rknuechel-clarke@ukaachen.de; edahl@ukaachen.de
RI Noetzel-Reiss, Erik/GYV-0999-2022; Veeck, Jurgen/B-9256-2008
OI Veeck, Jurgen/0000-0002-2952-6159; Noetzel-Reiss,
   Erik/0000-0003-3163-6848
CR Arnold JM, 2001, BRIT J CANCER, V85, P1351, DOI 10.1054/bjoc.2001.2075
   Asirvatham AJ, 2006, PROSTATE, V66, P921, DOI 10.1002/pros.20366
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090
   de Candia P, 2006, HUM PATHOL, V37, P1032, DOI 10.1016/j.humpath.2006.03.004
   Deleu S, 2002, EXP CELL RES, V279, P62, DOI 10.1006/excr.2002.5589
   Desprez PY, 2003, J MAMMARY GLAND BIOL, V8, P225, DOI 10.1023/A:1025957025773
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Itahana Y, 2003, CANCER RES, V63, P7098
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kleeff J, 1998, CANCER RES, V58, P3769
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093
   Lin CQ, 2000, CANCER RES, V60, P1332
   Norton JD, 2000, J CELL SCI, V113, P3897
   Perk J, 2006, CANCER RES, V66, P10870, DOI 10.1158/0008-5472.CAN-06-2643
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Roldán G, 2006, CANCER BIOL THER, V5, P505, DOI 10.4161/cbt.5.5.2597
   Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8
   Sobin LH, 1997, TNM CLASSIFICATION M
   TURNER NC, 2006, ONCOGENE, P2126
   Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   Wilson JW, 2001, CANCER RES, V61, P8803
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092
NR 36
TC 59
Z9 74
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 30
PY 2008
VL 8
AR 154
DI 10.1186/1471-2407-8-154
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 320QU
UT WOS:000257250900001
PM 18513385
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kim, MS
   Lebron, C
   Nagpal, JK
   Chae, YK
   Chang, XF
   Huang, YP
   Chuang, T
   Yamashita, K
   Trink, B
   Ratovitski, EA
   Califano, JA
   Sidransky, D
AF Kim, Myoung Sook
   Lebron, Cinthia
   Nagpal, Jatin K.
   Chae, Young Kwang
   Chang, Xiaofei
   Huang, Yiping
   Chuang, Tony
   Yamashita, Keishi
   Trink, Barry
   Ratovitski, Edward A.
   Califano, Joseph A.
   Sidransky, David
TI Methylation of the <i>DFNA5</i> increases risk of lymph node metastasis
   in human breast cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE DFNA5; the human deafness; autosomal dominant 5 gene; promoter
   methylation; breast cancer
ID ESTROGEN-RECEPTOR BETA; GENE; CELLS; EXPRESSION; ICERE-1
AB The pathogenesis of breast cancer involves multiple genetic and epigenetic events. In this study, we report an epigenetic alteration of DFNA5 in human breast cancer. DFNA5 gene was silenced in breast cancer cell lines that were methylated in the DFNA5 promoter, and restored by treatment with the demethylating agent, 5 -aza-dC, and gene knock-down of DFNA5 increased cellular invasiveness in vitro. The mRNA expression of DFNA5 in breast cancer tissues was down-regulated as compared to normal tissues. Moreover, the DFNA5 promoter was found to be methylated in primary tumor tissues with high frequency (53%,18/34). Quantitative methylation-specific PCR of DFNA5 clearly discriminated primary breast cancer tissues from normal breast tissues (15.3%, 2/13). Moreover, methylation status of DFNA5 was correlated with lymph node metastasis in breast cancer patients. Our data implicate DFNA5 promoter methylation as a novel molecular biomarker in human breast cancer. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Kim, Myoung Sook; Lebron, Cinthia; Nagpal, Jatin K.; Chae, Young Kwang; Chang, Xiaofei; Huang, Yiping; Chuang, Tony; Yamashita, Keishi; Trink, Barry; Ratovitski, Edward A.; Califano, Joseph A.; Sidransky, David] Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Inst, Baltimore, MD 21231 USA.
C3 Johns Hopkins University
RP Sidransky, D (通讯作者)，Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Inst, 1550 Orleans St 5N03, Baltimore, MD 21231 USA.
EM dsidran1@jhmi.edu
RI KIM, JUSANG/AAB-3748-2019
FU NCI NIH HHS [U01 CA084986, U01 CA084986-07] Funding Source: Medline
CR Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x
   Arai N, 2000, BIOCHEM BIOPH RES CO, V270, P425, DOI 10.1006/bbrc.2000.2444
   Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Fiorelli G, 1999, BIOCHEM BIOPH RES CO, V261, P521, DOI 10.1006/bbrc.1999.1062
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608
   KIM MS, IN PRESS ONCOGENE
   Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3
   Rosenberg K, 1998, J Nurse Midwifery, V43, P394
   Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x
   Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0
   Van Laer L, 1998, NAT GENET, V20, P194
   VANCAMP G, 1995, HUM MOL GENET, V4, P2159
NR 16
TC 116
Z9 124
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 23
PY 2008
VL 370
IS 1
BP 38
EP 43
DI 10.1016/j.bbrc.2008.03.026
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 294ST
UT WOS:000255426700008
PM 18346456
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Dougherty, CJ
   Ichim, TE
   Liu, L
   Reznik, G
   Min, WP
   Ghochikyan, A
   Agadjanyan, MG
   Reznik, BN
AF Dougherty, Christopher J.
   Ichim, Thomas E.
   Liu, Liping
   Reznik, Gary
   Min, Wei-Ping
   Ghochikyan, Anahit
   Agadjanyan, Michael G.
   Reznik, Boris N.
TI Selective apoptosis of breast cancer cells by siRNA targeting of BORIS
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE BORIS breast cancer; siRNA; apoptosis; caspase; CTCF; zinc finger
ID TRANSCRIPTION FACTOR; CTCF; DNA; PROTEIN; GENE; DEREPRESSION;
   EXPRESSION; REGULATOR; SEQUENCE; RECEPTOR
AB Brother of the regulator of imprinted sites (BORIS) is an epigenetically acting transcription factor which represses the tumor inhibitor functions of the tumor suppressor protein CTCF. BORIS expression has not been documented in adult females, making it an exciting molecular target for drug development in breast cancer. Previously, we demonstrated that vaccination of mice with zing-finger (ZF)-deleted non-functional BORIS results in regression of breast cancer and generation of potent anti-tumor immune responses. RNAi induction can be used as an alternative approach for selective tumor cell killing. Short interfering RNA (siRNA) molecules targeting BORIS were generated and their efficacy was tested in MDA-MB-231 breast cancer and non-malignant epithelial cell lines. Treatment with BORIS-specific siRNA, but not control siRNA led to a concentration-dependent reduction in BORIS expression and proportional apoptotic death of the cancer but not control cells. To our knowledge this is first report demonstrating a critical role of BORIS in maintaining tumor cell viability. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Dougherty, Christopher J.; Ghochikyan, Anahit; Agadjanyan, Michael G.] Florida Atlantic Univ, Charles E Schmidt Coll Biomed Sci, Boca Raton, FL 33431 USA.
   [Ichim, Thomas E.; Liu, Liping; Reznik, Boris N.] OncoMune LLC, Hollywood, FL 33021 USA.
   [Min, Wei-Ping] Univ Western Ontario, Dept Surg, London, ON N6A 5A5, Canada.
   [Ghochikyan, Anahit; Agadjanyan, Michael G.] Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA 92647 USA.
   [Ichim, Thomas E.; Reznik, Boris N.] BioRASI LLC, Hollywood, FL 33021 USA.
   [Reznik, Gary] Vita Med Ctr, Los Angeles, CA 90048 USA.
C3 State University System of Florida; Florida Atlantic University; Western
   University (University of Western Ontario)
RP Dougherty, CJ (通讯作者)，Florida Atlantic Univ, Charles E Schmidt Coll Biomed Sci, 777 Glades Rd,BC-71,Room 202, Boca Raton, FL 33431 USA.
EM cdougher@fau.edu
OI Ghochikyan, Anahit/0000-0001-5436-0616; Min, Weiping/0000-0001-7389-3194
CR Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405
   DARCY V, 2008, BR J CANC
   Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9
   Ghochikyan A, 2007, J IMMUNOL, V178, P566, DOI 10.4049/jimmunol.178.1.566
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   Kunigal S, 2007, INT J CANCER, V121, P2307, DOI 10.1002/ijc.22962
   Li MJ, 2003, OLIGONUCLEOTIDES, V13, P401, DOI 10.1089/154545703322617087
   LOBANENKOV VV, 1990, ONCOGENE, V5, P1743
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   Loukinov D, 2006, J CELL BIOCHEM, V98, P1037, DOI 10.1002/jcb.20953
   Mkrtichyan M, 2008, GENE THER, V15, P61, DOI 10.1038/sj.gt.3303044
   MKRTICHYAN M, 2007, GENE THER
   OHRI SS, 2007, CANC BIOL THER, V6
   Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100
   Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989
   Risinger JI, 2007, CLIN CANCER RES, V13, P1713, DOI 10.1158/1078-0432.CCR-05-2569
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
NR 18
TC 42
Z9 50
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 23
PY 2008
VL 370
IS 1
BP 109
EP 112
DI 10.1016/j.bbrc.2008.03.040
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 294ST
UT WOS:000255426700022
PM 18355444
DA 2025-01-12
ER

PT J
AU De Bruyne, E
   Bos, TJ
   Asosingh, K
   Broek, IV
   Menu, E
   Van Valckenborgh, E
   Atadja, P
   Coiteux, V
   Leleu, X
   Thielemans, K
   Van Camp, B
   Vanderkerken, K
   Van Riet, I
AF De Bruyne, Elke
   Bos, Tomas Jan
   Asosingh, Kewal
   Broek, Isabelle Vande
   Menu, Eline
   Van Valckenborgh, Els
   Atadja, Peter
   Coiteux, Valerie
   Leleu, Xavier
   Thielemans, Kris
   Van Camp, Ben
   Vanderkerken, Karin
   Van Riet, Ivan
TI Epigenetic silencing of the tetraspanin CD9 during disease progression
   in multiple myeloma cells and correlation with survival
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PROTEASOME INHIBITOR BORTEZOMIB; DNA METHYLATION; GENE-EXPRESSION;
   HEMATOPOIETIC MALIGNANCIES; PROMOTER HYPERMETHYLATION; KAI1/CD82
   EXPRESSION; FUNDAMENTAL ROLE; DENDRITIC CELLS; PROTEIN-KINASE;
   BREAST-CANCER
AB Purpose: The purpose of this study was to investigate expression and epigenetic regulation of CD9 in multiple myeloma (MM) cells during disease progression.
   Experimental Design: CD9 expression was retrospectively analyzed on bone marrow myeloma samples from 81 patients by immunophenotyping. CD9 expression by murine 5TMM cells was detected by flow cytometric staining and quantitative PCR. The methylation status of the CD9 promoter was determined by bisulfite PCR sequencing.
   Results: Primary plasma cells in the majority of MM patients with nonactive disease (n = 28) showed CD9 expression, whereas most cases with active disease (n = 53) were CD9 negative. CD9 expression in diagnostic bone marrow samples (n = 74) correlated with survival. Moreover, CD9 expression on murine 5T33 and 5T2MM cells was significantly down-regulated during disease development. Treatment of CD9-nonexpressing 5T33MMvt cells with the clinically relevant histone deacetylase inhibitor LBH589 resulted in a significant increase in CD9 expression. In contrast, cells treated with the demethylation agent 5-aza-2'deoxycytidine barely showed any increase. A combination study with both compounds resulted in a strong synergistic reactivation of CD9. CD9-expressing 5T33MMvv cells and 5T33MMvt cells stably transduced with a mCD9 lentiviral transferplasmid were shown to be more susceptible to natural killer cell - mediated cytolysis than CD9-negative 5T33MMvt cells.
   Conclusions: CD9 expression correlates with disease status and survival of MM patients. In the murine 5T33MM model, we show that histone modifications, and to a lesser extent CpG methylation, are key epigenetic events in CD9 down-regulation. Furthermore, as CD9 expression becomes down-regulated, 5T33MM cells become less susceptible to natural killer cell - mediated cytolysis.
C1 [De Bruyne, Elke; Bos, Tomas Jan; Broek, Isabelle Vande; Menu, Eline; Van Valckenborgh, Els; Van Camp, Ben; Vanderkerken, Karin; Van Riet, Ivan] Vrije Univ Brussels, Dept Hematol & Immunol, B-1090 Brussels, Belgium.
   [Thielemans, Kris] Vrije Univ Brussels, Lab Mol & Cellular Therapy, Dept Physiol Immunol, B-1090 Brussels, Belgium.
   [Asosingh, Kewal] Cleveland Clin Fdn, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Atadja, Peter] Novartis Inst Biomed Res, Cambridge, MA USA.
   [Coiteux, Valerie; Leleu, Xavier] Ctr Hosp Reg & Univ Lille, Hop Huriez, Dept Hematol, F-59037 Lille, France.
C3 Vrije Universiteit Brussel; Vrije Universiteit Brussel; Cleveland Clinic
   Foundation; Novartis; Novartis USA; Universite de Lille; CHU Lille
RP Van Riet, I (通讯作者)，Vrije Univ Brussels, Dept Hematol & Immunol, Laarbeeklaan 101, B-1090 Brussels, Belgium.
EM ivan.vanriet@uzbrussel.be
RI De Bruyne, Elke/R-2145-2019; Van Valckenborgh, Els/GRO-7224-2022;
   Vanderkerken, Karin/I-3513-2013; LELEU, Xavier/ABP-5732-2022; Menu,
   Eline/K-2856-2015
OI Menu, Eline/0000-0002-0805-6581; Vanderkerken,
   Karin/0000-0002-2137-7179; De Bruyne, Elke/0000-0003-4012-4617
CR Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397
   Asosingh K, 2003, BLOOD, V101, P3136, DOI 10.1182/blood-2002-10-3000
   Barrena S, 2005, LEUKEMIA, V19, P1376, DOI 10.1038/sj.leu.2403822
   Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307
   Berditchevski F, 2001, J CELL SCI, V114, P4143
   Breckpot K, 2003, J GENE MED, V5, P654, DOI 10.1002/jgm.400
   Breckpot K, 2004, J IMMUNOL, V172, P2232, DOI 10.4049/jimmunol.172.4.2232
   Catley L, 2006, BLOOD, V108, P3441, DOI 10.1182/blood-2006-04-016055
   Chim CS, 2004, LEUKEMIA RES, V28, P379, DOI 10.1016/j.leukres.2003.08.008
   De Bruyne E, 2006, LEUKEMIA, V20, P1870, DOI 10.1038/sj.leu.2404343
   DEWAELE M, 1989, J HISTOCHEM CYTOCHEM, V37, P1855, DOI 10.1177/37.12.2584693
   Drucker L, 2006, CARCINOGENESIS, V27, P197, DOI 10.1093/carcin/bgi209
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006
   Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735
   Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061
   Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589
   HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127
   Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729
   Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaji K, 2002, DEV BIOL, V247, P327, DOI 10.1006/dbio.2002.0694
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   LOKHORST HM, 1994, BLOOD, V84, P2269
   Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523
   Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008-5472.CAN-05-4186
   Martin F, 2005, J VIROL, V79, P10839, DOI 10.1128/JVI.79.17.10839-10851.2005
   Mateos MV, 2002, BRIT J HAEMATOL, V118, P1034, DOI 10.1046/j.1365-2141.2002.03749.x
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   MIYAKE M, 1995, CANCER RES, V55, P4127
   Mori M, 1998, CLIN CANCER RES, V4, P1507
   Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500
   Ng MHL, 2002, APOPTOSIS, V7, P261, DOI 10.1023/A:1015364104672
   Ng MHL, 2001, CLIN CANCER RES, V7, P1724
   Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561
   Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970
   Sauer G, 2003, CLIN CANCER RES, V9, P6426
   Schulz WA, 2006, J CELL MOL MED, V10, P100, DOI 10.1111/j.1582-4934.2006.tb00293.x
   Shallal S, 2000, BLOOD, V96, P224, DOI 10.1182/blood.V96.1.224.013k25_224_233
   Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716
   Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4
   Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186
   Vanderkerken K, 2003, IMMUNOL REV, V194, P196, DOI 10.1034/j.1600-065X.2003.00035.x
   Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371
   Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365-2141.2005.05860.x
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 51
TC 37
Z9 40
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 15
PY 2008
VL 14
IS 10
BP 2918
EP 2926
DI 10.1158/1078-0432.CCR-07-4489
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 303AW
UT WOS:000256012700004
PM 18483358
OA Bronze
DA 2025-01-12
ER

PT J
AU Calcagno, AM
   Fostel, JM
   To, KK
   Salcido, CD
   Martin, SE
   Chewning, KJ
   Wu, CP
   Varticovski, L
   Bates, SE
   Caplen, NJ
   Ambudkar, SV
AF Calcagno, A. M.
   Fostel, J. M.
   To, K. K. W.
   Salcido, C. D.
   Martin, S. E.
   Chewning, K. J.
   Wu, C-P
   Varticovski, L.
   Bates, S. E.
   Caplen, N. J.
   Ambudkar, S. V.
TI Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug
   transporter through epigenetic changes
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE multidrug resistance (MDR); doxorubicin; ABCG2; epigenetics; single-step
   selection
ID MULTIDRUG-RESISTANCE PROTEINS; BREAST-CANCER; CARCINOMA-CELLS;
   SUBSTRATE-SPECIFICITY; FUMITREMORGIN C; P-GLYCOPROTEIN; MDR1 GENE;
   IDENTIFICATION; EXPRESSION; MUTATION
AB Understanding the mechanisms of multidrug resistance (MDR) could improve clinical drug efficacy. Multidrug resistance is associated with ATP binding cassette (ABC) transporters, but the factors that regulate their expression at clinically relevant drug concentrations are poorly understood. We report that a single-step selection with low doses of anti-cancer agents, similar to concentrations reported in vivo, induces MDR that is mediated exclusively by ABCG2. We selected breast, ovarian and colon cancer cells (MCF-7, IGROV-1 and S-1) after exposure to 14 or 21 nM doxorubicin for only 10 days. We found that these cells overexpress ABCG2 at the mRNA and protein levels. RNA interference analysis confirmed that ABCG2 confers drug resistance. Furthermore, ABCG2 upregulation was facilitated by histone hyperacetylation due to weaker histone deacetylase 1-promoter association, indicating that these epigenetic changes elicit changes in ABCG2 gene expression. These studies indicate that the MDR phenotype arises following low-dose, single-step exposure to doxorubicin, and further suggest that ABCG2 may mediate early stages of MDR development. This is the first report to our knowledge of single-step, low-dose selection leading to overexpression of ABCG2 by epigenetic changes in multiple cancer cell lines.
C1 [Calcagno, A. M.; Chewning, K. J.; Wu, C-P; Ambudkar, S. V.] NCI, Cell Biol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA.
   [Fostel, J. M.] Alpha Gamma Technol Inc, Raleigh, NC 27609 USA.
   [To, K. K. W.; Bates, S. E.] NCI, Med Oncol Branch, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA.
   [Salcido, C. D.; Varticovski, L.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA.
   [Martin, S. E.; Caplen, N. J.] NCI, Gene Silencing Sect, Genet Branch,DHHS, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI)
RP Ambudkar, SV (通讯作者)，NCI, Cell Biol Lab, Ctr Canc Res, NIH,DHHS, Bethesda, MD 20892 USA.
EM ambudkar@helix.nih.gov
RI Bates, Susan/AFP-9514-2022; Calcagno, Anna/A-5617-2012; Ambudkar,
   Suresh/L-1317-2016; To, Kenneth/M-4500-2013; Caplen, Natasha/H-2768-2016
OI To, Kenneth/0000-0003-2755-0283; Varticovski, Lyuba/0000-0002-5105-9008;
   Calcagno, Anna Maria/0000-0002-0804-2753; Caplen,
   Natasha/0000-0002-0001-9460
FU Intramural NIH HHS [Z01 BC010622-03, Z01 BC010609-02, Z01 BC010030-11]
   Funding Source: Medline; NCI NIH HHS [R01 CA053094-09] Funding Source:
   Medline
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Allen JD, 2002, CANCER RES, V62, P2294
   Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   BARRAND MA, 1994, J NATL CANCER I, V86, P110, DOI 10.1093/jnci/86.2.110
   BEKETICORESKOVIC L, 1995, J NATL CANCER I, V87, P1593, DOI 10.1093/jnci/87.21.1593
   Burger H, 2003, CLIN CANCER RES, V9, P827
   Calcagno AM, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-29
   CHEN G, 1994, CANCER RES, V54, P4980
   CHEN YN, 1990, J BIOL CHEM, V265, P10073
   Clayton H, 2004, EXP CELL RES, V297, P444, DOI 10.1016/j.yexcr.2004.03.029
   Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199
   Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7
   Honjo Y, 2001, CANCER RES, V61, P6635
   Huss WJ, 2005, CANCER RES, V65, P6640, DOI 10.1158/0008-5472.CAN-04-2548
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Kamalakaran S, 2005, J BIOL CHEM, V280, P21491, DOI 10.1074/jbc.M409176200
   KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0
   Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238
   Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879
   Kytölä S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
   Lage H., 2003, Cancer Therapy, V1, P81
   Leggas M, 2004, MOL CELL BIOL, V24, P7612, DOI 10.1128/MCB.24.17.7612-7621.2004
   Lorusso V, 2007, ANN ONCOL, V18, P70, DOI 10.1093/annonc/mdm229
   Maliepaard M, 2001, CANCER RES, V61, P3458
   Matsumoto Y, 1997, CANCER RES, V57, P5086
   MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316
   Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6
   Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126
   Pérez-Tomás R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077
   Rabindran SK, 1998, CANCER RES, V58, P5850
   Rabindran SK, 2000, CANCER RES, V60, P47
   Reid G, 2003, MOL PHARMACOL, V63, P1094, DOI 10.1124/mol.63.5.1094
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Robey RW, 2001, CLIN CANCER RES, V7, P145
   SHEN DW, 1986, J BIOL CHEM, V261, P7762
   Thigpen JT, 2005, GYNECOL ONCOL, V96, P10, DOI 10.1016/j.ygyno.2004.09.046
   To KKW, 2006, MOL CELL BIOL, V26, P8572, DOI 10.1128/MCB.00650-06
   Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321
   Wu CP, 2005, FEBS J, V272, P4725, DOI 10.1111/j.1742-4658.2005.04888.x
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 44
TC 107
Z9 123
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 5
PY 2008
VL 98
IS 9
BP 1515
EP 1524
DI 10.1038/sj.bjc.6604334
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 297AQ
UT WOS:000255588000005
PM 18382425
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Pezzolesi, MG
   Platzer, P
   Waite, KA
   Eng, C
AF Pezzolesi, Marcus G.
   Platzer, Petra
   Waite, Kristin A.
   Eng, Charis
TI Differential expression of PTEN-targeting microRNAs
   <i>miR</i>-<i>19</i>a and <i>miR</i>-<i>21</i> in Cowden Syndrome
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID RILEY-RUVALCABA-SYNDROME; BANNAYAN-ZONANA-SYNDROME; TUMOR-SUPPRESSOR;
   PHOSPHATASE-ACTIVITY; PROMOTER MUTATIONS; BREAST-CANCER; PROTEIN; GENE;
   DISEASE; RNA
AB Germline mutations in the gene encoding phosphatase and tensin homolog deleted on chromosome ten (PTEN [MIM 601728]) are associated with a number of clinically distinct heritable cancer syndromes, including both Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS). Seemingly identical pathogenic PTEN mutations have been observed in patients with CS and BRRS, as well as in patients with incomplete features of CS, referred to as CS-like (CSL) patients. These observations indicate that additional, unidentified, genetic and epigenetic factors act as phenotypic modifiers in these disorders. These genetic factors could also contribute to disease in patients with CS, CSL, or BRRS without identifiable PTEN mutations. Two potential modifiers are miR-19a and miR-21, which are previously identified PTEN-targeting miRNAs. We investigated the role of these miRNAs by characterizing their relative expression levels in PTEN-mutation-positive and PTEN-mutation-negative patients with CS, CSL, or BRRS. Interestingly, we observed differential expression of miR-19a and miR-21 in our PTEN-mutation-positive patients. Both were found to be significantly overexpressed within this group (p < 0.01) and were inversely correlated with germline PTEN protein levels. Similarly, the relative expression of miR-19a and miR-21 was differentially expressed in a series of PTEN-mutation-negative patients with CS or CSL with variable clinical phenotypes and decreased full-length PTEN protein expression. Among PTEN-mutation-positive patients with CS, both miRNAs were significantly overexpressed (p = 0.006-0.013). Taken together, our study results suggest that differential expression of PTEN-targeting miR-19a and miR-21 modulates the PTEN protein levels and the CS and CSL phenotypes, irrespective of the patient's mutation status, and support their roles as genetic modifiers in CS and CSL.
C1 [Pezzolesi, Marcus G.; Platzer, Petra; Waite, Kristin A.; Eng, Charis] Cleveland Clin Fdn, Lerner Res Inst, Inst Med Genet, Cleveland, OH 44195 USA.
   [Waite, Kristin A.; Eng, Charis] Cleveland Clin Fdn, Lerner Res Inst, Inst Med Genet, Taussig Canc Inst, Cleveland, OH 44195 USA.
   [Eng, Charis] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Eng, Charis] Case Western Reserve Univ, Dept Genet, CASE Comprehens Canc Ctr, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University
RP Eng, C (通讯作者)，Cleveland Clin Fdn, Lerner Res Inst, Inst Med Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM engc@ccf.org
RI Waite, Kristin/AAB-1031-2021
OI Eng, Charis/0000-0002-3693-5145
FU NCI NIH HHS [P01 CA124570, 1P01CA124570-01A1] Funding Source: Medline
CR Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   ECCLES DM, 1992, ONCOGENE, V7, P2069
   Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257
   Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6
   Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057
   Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240
   Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513
   Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114
   Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200
   Pezzolesi MG, 2007, HUM MOL GENET, V16, P1058, DOI 10.1093/hmg/ddm053
   Sarquis MS, 2006, AM J HUM GENET, V79, P23, DOI 10.1086/504392
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051
   Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026
   Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069
   Wang G, 2008, AM J HUM GENET, V82, P283, DOI 10.1016/j.ajhg.2007.09.021
   Weng LP, 1999, CANCER RES, V59, P5808
   Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037
   Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109
NR 32
TC 88
Z9 105
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAY
PY 2008
VL 82
IS 5
BP 1141
EP 1149
DI 10.1016/j.ajhg.2008.04.005
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 301VJ
UT WOS:000255923600013
PM 18460397
OA Green Accepted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Jeronimo, C
   Monteiro, P
   Henrique, R
   Dinis-Ribeiro, M
   Costa, I
   Costa, VL
   Filipe, L
   Carvalho, AL
   Hoque, MO
   Pais, I
   Leal, C
   Teixeira, MR
   Sidransky, D
AF Jeronimo, Carmen
   Monteiro, Paula
   Henrique, Rui
   Dinis-Ribeiro, Mario
   Costa, Isabel
   Costa, Vera L.
   Filipe, Luisa
   Carvalho, Andre L.
   Hoque, Mohammad O.
   Pais, Irene
   Leal, Conceicao
   Teixeira, Manuel R.
   Sidransky, David
TI Quantitative hypermethylation of a small panel of genes augments the
   diagnostic accuracy in fine-needle aspirate washings of breast lesions
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; fine needle aspiration biopsy; quantitative
   methylation-specific PCR; epigenetic profile; cancer biomarkers
ID METHYLATION-SPECIFIC PCR; PROMOTER HYPERMETHYLATION; PROSTATE-CANCER;
   DNA METHYLATION; CPG ISLAND; ABERRANT METHYLATION; ESTROGEN-RECEPTOR;
   TUMOR-SUPPRESSOR; HIGH-FREQUENCY; BENIGN
AB Purpose We hypothesized that comprehensive breast cancer methylation profiling might provide biomarkers for diagnostic assessment of suspicious breast lesions using fine needle aspiration biopsy (FNA).
   Experimental design Twenty-three gene promoters were surveyed by quantitative methylation-specific PCR in bisulfite-modified DNA from 66 breast carcinomas (BCa), 31 fibroadenomas (FB) and 12 normal breast (NT) samples to define a set of genes differentially methylated in malignant and non-malignant tissues. This set was tested in 78 FNA washings obtained pre-operatively (66 malignant, 12 benign), with histopathological diagnosis. Receiver operator characteristic (ROC) curve analysis identified a gene panel which might distinguish cancer from non-cancerous lesions. Finally, this panel was validated in an independent series of FNA washings (45 cases) in which cytomorphology did not reach definitive diagnosis.
   Results In tissue samples, 14-3-3-sigma, DAPK, CCND2, RASSF1A, CALCA, APC, HIN1, RAR beta 2, TIG1, and GSTP1 methylation levels differed significantly among BCa, FB, and NT. ROC curve analysis identified a panel of four gene loci (CCND2, RASSF1A, APC, and HIN1) that discriminated BCa from benign lesions in a set of 78 FNA washings from histologically characterized breast lesions. When this panel was tested in the validation dataset of 45 FNA washings, breast cancer was identified with perfect specificity (100%) when 3 of 4 gene loci tested positive, providing estimated added information of 91% over cytomorphologic evaluation alone.
   Conclusions Our data provide evidence that multigene methylation analysis augments diagnostic accuracy of cytological assessment of suspicious breast lesions, and might be a valuable ancillary tool for breast cancer diagnosis.
C1 [Jeronimo, Carmen; Costa, Vera L.; Filipe, Luisa; Pais, Irene; Teixeira, Manuel R.] Portuguese Oncol Inst, Dept Genet, Oporto, Portugal.
   [Monteiro, Paula; Henrique, Rui; Costa, Isabel; Pais, Irene; Leal, Conceicao] Portuguese Inst Oncol, Dept Pathol, Oporto, Portugal.
   [Dinis-Ribeiro, Mario] Portuguese Inst Oncol, Dept Gastroenterol, Oporto, Portugal.
   [Jeronimo, Carmen] Fernando Pessoa Univ Sch Hlth Sci, Oporto, Portugal.
   [Jeronimo, Carmen; Henrique, Rui; Teixeira, Manuel R.] Univ Porto, ICBAS, Dept Pathol & Mol Immunol, P-4100 Oporto, Portugal.
   [Dinis-Ribeiro, Mario] Univ Porto, Fac Med, Dept Biostat & Med Informat, P-4100 Oporto, Portugal.
   [Carvalho, Andre L.; Hoque, Mohammad O.; Sidransky, David] Johns Hopkins Univ, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Sch Med, Baltimore, MD USA.
C3 Portuguese Institute of Oncology; Universidade de Coimbra; Universidade
   de Coimbra; Universidade Fernando Pessoa; Universidade do Porto;
   Universidade do Porto; Johns Hopkins University
RP Jeronimo, C (通讯作者)，Portuguese Oncol Inst, Dept Genet, Rua Dr Antonio Bernardio Almeida, Oporto, Portugal.
EM cjeroni@ufp.pt
RI Filipe, Luísa/D-8836-2011; Henrique, Rui/I-2757-2013; Jeronimo,
   Carmen/H-3284-2013; Lopes Carvalho, Andre/S-7053-2016; Rodrigues
   Teixeira, Manuel Antonio/E-4885-2011; Dinis-Ribeiro, Mario/A-9248-2010
OI Henrique, Rui/0000-0003-3171-4666; Jeronimo, Carmen/0000-0003-4186-5345;
   Hoque, Mohammad Obaidul/0000-0001-6701-9978; Lopes Carvalho,
   Andre/0000-0001-7214-6402; Rodrigues Teixeira, Manuel
   Antonio/0000-0002-4896-5982; Filipe, Luisa/0000-0002-6405-9234;
   Monteiro, Paula/0000-0002-3482-2307; Dinis-Ribeiro,
   Mario/0000-0003-0121-6850
CR [Anonymous], 2002, AJCC CANC STAGING HD
   Cairns P, 2001, CLIN CANCER RES, V7, P2727
   Dammann R, 2001, CANCER RES, V61, P3105
   Eads CA, 2000, CANCER RES, V60, P5021
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Elston C W., 1998, Systemic pathology: the Breast, V13, P365
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hamill J, 2002, ACTA CYTOL, V46, P19, DOI 10.1159/000326710
   Henrique R, 2005, CANCER EPIDEM BIOMAR, V14, P1274, DOI 10.1158/1055-9965.EPI-04-0659
   Henrique R, 2005, DNA CELL BIOL, V24, P264, DOI 10.1089/dna.2005.24.264
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Müller HM, 2003, CANCER RES, V63, P7641
   Nass SJ, 2000, CANCER RES, V60, P4346
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Rosenbaum E, 2005, CLIN CANCER RES, V11, P8321, DOI 10.1158/1078-0432.CCR-05-1183
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   [No title captured]
NR 44
TC 41
Z9 49
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2008
VL 109
IS 1
BP 27
EP 34
DI 10.1007/s10549-007-9620-x
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 289BW
UT WOS:000255031000003
PM 17549626
DA 2025-01-12
ER

PT J
AU Euhus, DM
   Bu, DW
   Milchgrub, S
   Xie, XJ
   Bian, A
   Leitch, AM
   Lewis, CM
AF Euhus, David M.
   Bu, Dawei
   Milchgrub, Sara
   Xie, Xian-Jin
   Bian, Aihua
   Leitch, A. Marilyn
   Lewis, Cheryl M.
TI DNA methylation in benign breast epithelium in relation to age and
   breast cancer risk
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID PROMOTER METHYLATION; CPG ISLAND; MULTIPLE GENES; HYPERMETHYLATION;
   CELLS; LUNG; VALIDATION; PREDICTION; PHENOTYPE; APOPTOSIS
AB Background: Many established breast cancer risk factors are related to the timing and duration of exposure to reproductive hormones, which are known to drive breast epithelial cell proliferation. The epigenetic molecular clock hypothesis suggests that CpG island methylation records the cell division history of benign epithelium. In proliferative epithelium, such as breast, this may provide an individualized cell-based measure of cancer risk.
   Methods: Methylation of cyclin D2, APC, HIN1, RASSF1A, and RAR-beta 2 was measured by quantitative multiplex methylation-specific PCR in 290 benign and malignant breast epithelial cell samples obtained by palpation-directed fine-needle aspiration biopsy from 164 women. Univariate, multivariate, and unsupervised cluster analysis was used to establish the relationship between TSG methylation and a personal history of breast cancer, predicted breast cancer risk, and specific breast cancer risk factors.
   Results: RASSF1A methylation was highly correlated with breast cancer risk [odds ratio (OR), 5.28; 95% confidence interval (95% CI), 1.95-14.32; P = 0.001], atypical cytology (OR, 4.11; 95% CI, 1.30-12.98; P = 0.016), and benign breast disease requiring biopsy (OR, 6.12; 95% CI, 1.41-26.51; P = 0.016). RASSF1A methylation increased linearly between ages 32 and 55. Increasing parity was associated with decreased APC methylation.
   Conclusions: TSG methylation increases in benign breast epithelium with increasing age. Because it is independently related to a personal history of benign or malignant breast disease and to predicted breast cancer risk, it may have value for breast cancer risk stratification and as a surrogate endpoint marker in prevention trials.
C1 [Euhus, David M.; Bu, Dawei; Leitch, A. Marilyn; Lewis, Cheryl M.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.
   [Milchgrub, Sara] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Xie, Xian-Jin; Bian, Aihua] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
   [Euhus, David M.; Xie, Xian-Jin; Bian, Aihua] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas
RP Euhus, DM (通讯作者)，E6-222,5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM david.euhus@utsouthwestern.ediu
CR Bean GR, 2007, CANCER EPIDEM BIOMAR, V16, P50, DOI 10.1158/1055-9965.EPI-06-0598
   Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   CLAUS EB, 1994, CANCER, P643
   Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541
   denTonkelaar I, 1996, BREAST CANCER RES TR, V38, P253, DOI 10.1007/BF01806143
   Euhus DM, 2007, CANCER EPIDEM BIOMAR, V16, P1812, DOI 10.1158/1055-9965.EPI-06-1034
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fabian CJ, 2000, JNCI-J NATL CANCER I, V92, P1217, DOI 10.1093/jnci/92.15.1217
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   GAIL MH, 1989, JNCI-J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   Gompel A, 2001, MATURITAS, V38, P39, DOI 10.1016/S0378-5122(00)00190-0
   Goyal R, 2006, NUCLEIC ACIDS RES, V34, P1182, DOI 10.1093/nar/gkl002
   Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757
   Kim JY, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-10
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K
   LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355
   Lindsey JK, 1998, STAT MED, V17, P447, DOI 10.1002/(SICI)1097-0258(19980228)17:4<447::AID-SIM752>3.3.CO;2-7
   MASOOD S, 1990, CANCER-AM CANCER SOC, V66, P1480, DOI 10.1002/1097-0142(19901001)66:7<1480::AID-CNCR2820660708>3.0.CO;2-O
   Navarrete MAH, 2005, BREAST CANCER RES, V7, pR306, DOI 10.1186/bcr994
   Peters I, 2007, CANCER EPIDEM BIOMAR, V16, P2526, DOI 10.1158/1055-9965.EPI-07-0203
   Rockhill B, 2001, J NATL CANCER I, V93, P358, DOI 10.1093/jnci/93.5.358
   Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1
   So KJ, 2006, CANCER SCI, V97, P1155, DOI 10.1111/j.1349-7006.2006.00302.x
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Watanabe N, 2006, CURR TOP MICROBIOL, V310, P199
   Watson CJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1401
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wong DJ, 1999, MOL CELL BIOL, V19, P5642
   *WRIT GROUP WOM HL, 2002, WOMENS HLTH, V288, P321
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 41
TC 63
Z9 72
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAY
PY 2008
VL 17
IS 5
BP 1051
EP 1059
DI 10.1158/1055-9965.EPI-07-2582
PG 9
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 303AX
UT WOS:000256012800007
PM 18483325
DA 2025-01-12
ER

PT J
AU Veeck, J
   Geisler, C
   Noetzel, E
   Alkaya, S
   Hartmann, A
   Knüchel, R
   Dahl, E
AF Veeck, Juergen
   Geisler, Cordelia
   Noetzel, Erik
   Alkaya, Sevim
   Hartmann, Arndt
   Knuechel, Ruth
   Dahl, Edgar
TI Epigenetic inactivation of the secreted frizzled-related protein-5
   (<i>SFRP5</i>) gene in human breast cancer is associated with
   unfavorable prognosis
SO CARCINOGENESIS
LA English
DT Article
ID ABERRANT DNA METHYLATION; ANTAGONIST FAMILY GENES; RENAL-CELL CARCINOMA;
   BETA-CATENIN; BLADDER-CANCER; WNT PATHWAY; E-CADHERIN; C-MYC;
   DOWN-REGULATION; SOLID TUMORS
AB Disruption of the Wnt pathway is thought to be crucial in the development of human cancer. Pathway inhibitory members of the secreted frizzled-related protein (SFRP) family were found to be downregulated due to epigenetic inactivation in various malignancies. To date, only SFRP1 has been studied in human breast cancer and we questioned whether other SFRP genes may be implicated in the pathogenesis of this disease as well. An initial real-time polymerase chain reaction analysis of SFRP5 expression in normal human tissues (n=9) revealed weak expression in most tissues, including breast. Malignant mammary cell lines showed further SFRP5 expression loss in five of six cases. Consistently, in matched pairs of primary breast tumor/normal breast tissue, this downregulation (> 5-fold) could be confirmed (n=8/13; 62%). We identified promoter methylation as the predominant mechanism of SFRP5 gene silencing since SFRP5 promoter methylation correlated significantly with loss of SFRP5 expression in cell lines (P=0.040) and primary tumors (P =0.003). Moreover, cancerous cell lines re-expressed SFRP5 messenger RNA following treatment with DNA-demethylating drugs. Of 168 primary breast carcinomas, 73% harbored a methylated SFRP5 promoter, whereas 27% were unaffected by epigenetic alteration. Most interestingly, SFRP5 methylation was associated with reduced overall survival (OS) (P=0.045) and was an independent risk factor affecting OS in a multivariate Cox proportional hazard model (hazard ratio): 4.55; 95% confidence interval: 1.01-20.56; P= 0.049). In conclusion, SFRP5 is a target of epigenetic inactivation in human breast cancer, supporting the hypothesis of its role as tumor suppressor gene. SFRP5 methylation may be a novel DNA-based biomarker potentially useful in clinical breast cancer management.
C1 [Veeck, Juergen; Geisler, Cordelia; Noetzel, Erik; Alkaya, Sevim; Knuechel, Ruth; Dahl, Edgar] Univ Hosp RWTH Aachen, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany.
   [Hartmann, Arndt] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Erlangen Nuremberg
RP Dahl, E (通讯作者)，Univ Hosp RWTH Aachen, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Noetzel-Reiss, Erik/GYV-0999-2022; Veeck, Jurgen/B-9256-2008
OI Veeck, Jurgen/0000-0002-2952-6159; Noetzel-Reiss,
   Erik/0000-0003-3163-6848
CR Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703
   Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bukholm IK, 2000, J PATHOL, V190, P15
   Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575
   Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06
   Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0
   Marsit CJ, 2006, CANCER RES, V66, P10621, DOI 10.1158/0008-5472.CAN-06-1687
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Nomoto S, 2007, BRIT J CANCER, V97, P1260, DOI 10.1038/sj.bjc.6604016
   OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Polakis P, 2000, GENE DEV, V14, P1837
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Shulewitz M, 2006, ONCOGENE, V25, P4361, DOI 10.1038/sj.onc.1209470
   Sobin L., 2002, UICC: TNM Classification of malignant tumors, V6th
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 52
TC 79
Z9 89
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAY
PY 2008
VL 29
IS 5
BP 991
EP 998
DI 10.1093/carcin/bgn076
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 325GI
UT WOS:000257576600018
PM 18356147
OA Bronze
DA 2025-01-12
ER

PT J
AU Chen, XW
   Weaver, J
   Bove, BA
   Vanderveer, LA
   Weil, SC
   Miron, A
   Daly, MB
   Godwin, AK
AF Chen, Xiaowei
   Weaver, JoEllen
   Bove, Betsy A.
   Vanderveer, Lisa A.
   Weil, Susan C.
   Miron, Alexander
   Daly, Mary B.
   Godwin, Andrew K.
TI Allelic imbalance in <i>BRCA1</i> and <i>BRCA2</i> gene expression is
   associated with an increased breast cancer risk
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SPORADIC BREAST; MESSENGER-RNA; PROMOTER DELETIONS; OVARIAN CARCINOMAS;
   MUTATIONS; SEQUENCE; WOMEN; PCR; HYPERMETHYLATION; IDENTIFICATION
AB The contribution of BRCA1 and BRCA2 to familial and non-familial forms of breast cancer has been difficult to accurately estimate because of the myriad of potential genetic and epigenetic mechanisms that can ultimately influence their expression and involvement in cellular activities. As one of these potential mechanisms, we investigated whether allelic imbalance (AI) of BRCA1 or BRCA2 expression was associated with an increased risk of developing breast cancer. By developing a quantitative approach utilizing allele-specific real-time PCR, we first evaluated AI caused by nonsense-mediated mRNA decay in patients with frameshift mutations in BRCA1 and BRCA2. We next measured AI for BRCA1 and BRCA2 in lymphocytes from three groups: familial breast cancer patients, non-familial breast cancer patients and age-matched cancer-free females. The AI ratios of BRCA1, but not BRCA2, in the lymphocytes from familial breast cancer patients were found to be significantly increased as compared to cancer-free women (BRCA1: 0.424 versus 0.211, P = 0.00001; BRCA2: 0.206 versus 0.172, P = 0.38). Similarly, the AI ratios were greater for BRCA1 and BRCA2 in the lymphocytes of non-familial breast cancer cases versus controls (BRCA1: 0.353, P = 0.002; BRCA2: 0.267, P = 0.03). Furthermore, the distribution of under-expressed alleles between cancer-free controls and familial cases was significantly different for both BRCA1 and BRCA2 gene expression (P < 0.02 and P < 0.02, respectively). In conclusion, we have found that AI affecting BRCA1 and to a lesser extent BRCA2 may contribute to both familial and non-familial forms of breast cancer.
C1 [Chen, Xiaowei; Weaver, JoEllen; Bove, Betsy A.; Vanderveer, Lisa A.; Godwin, Andrew K.] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA.
   [Daly, Mary B.] Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA.
   [Weil, Susan C.] Morphotek Inc, Exton, PA 19341 USA.
   [Miron, Alexander] Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 Fox Chase Cancer Center; Fox Chase Cancer Center; Eisai Co Ltd; Harvard
   University; Harvard Medical School; Dana-Farber Cancer Institute
RP Godwin, AK (通讯作者)，Fox Chase Canc Ctr, Div Med Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM andrew.godwin@fccc.edu
FU NCI NIH HHS [R25 CA057708, P50 CA83638, U01 CA69631] Funding Source:
   Medline
CR Baldwin RL, 2000, CANCER RES, V60, P5329
   Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   Bièche I, 1999, ONCOGENE, V18, P5232, DOI 10.1038/sj.onc.1202903
   Bove BA, 2002, BREAST CANCER: PROGNOSIS, TREATMENT, AND PREVENTION, P555
   Brown MA, 2002, HUM MUTAT, V19, P435, DOI 10.1002/humu.10055
   Buckland PR, 2004, HUM MOL GENET, V13, pR255, DOI 10.1093/hmg/ddh227
   Chen XW, 2006, HUM MUTAT, V27, P427, DOI 10.1002/humu.20319
   Chiang PW, 1996, GENOME RES, V6, P1013, DOI 10.1101/gr.6.10.1013
   Dite GS, 2003, J NATL CANCER I, V95, P448, DOI 10.1093/jnci/95.6.448
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396
   Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865
   Lambie H, 2003, J PATHOL, V200, P207, DOI 10.1002/path.1348
   Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238
   LIVAK KJ, 1995, PCR METH APPL, V4, P357
   Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603
   Mátyás G, 2002, HUM MUTAT, V19, P58, DOI 10.1002/humu.10013
   McClain MR, 2005, GENET MED, V7, P28, DOI 10.1097/01.GIM.0000151155.36470.FF
   Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915
   Pezzolesi MG, 2007, HUM MOL GENET, V16, P1058, DOI 10.1093/hmg/ddm053
   Rudkin TM, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-15
   Rusinov V, 2005, NUCLEIC ACIDS RES, V33, pW696, DOI 10.1093/nar/gki364
   Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B
   Signori E, 2001, ONCOGENE, V20, P4596, DOI 10.1038/sj.onc.1204620
   Smith LD, 2007, EUR J CANCER, V43, P823, DOI 10.1016/j.ejca.2007.01.011
   Southey MC, 1999, BRIT J CANCER, V79, P34, DOI 10.1038/sj.bjc.6690008
   Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513
   Thrall M, 2006, INT J GYNECOL CANCER, V16, P166, DOI 10.1111/j.1525-1438.2006.00504.x
   Wang BL, 2004, MECH MATER, V36, P215, DOI 10.1016/S0167-6636(03)00008-5
   Weitzel JN, 2005, CANCER EPIDEM BIOMAR, V14, P1666, DOI 10.1158/1055-9965.EPI-05-0072
   Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103
   Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498
   Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108
   Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799
   Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545
   Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109
NR 44
TC 58
Z9 66
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2008
VL 17
IS 9
BP 1336
EP 1348
DI 10.1093/hmg/ddn022
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 290VR
UT WOS:000255151300014
PM 18204050
OA Bronze
DA 2025-01-12
ER

PT J
AU Naqvi, RA
   Hussain, A
   Deo, SSV
   Kukreti, H
   Chauhan, M
   Sarin, R
   Saxena, A
   Asim, M
   Shukla, NK
   Husain, SA
   Pasha, ST
   Basir, SF
AF Naqvi, Raza Ali
   Hussain, Arif
   Deo, Suryanarayan S. V.
   Kukreti, Himani
   Chauhan, Madhur
   Sarin, Ritu
   Saxena, Anubha
   Asim, Mohammad
   Shukla, Nootan Kumar
   Husain, Syed Akhtar
   Pasha, Syed Tazeen
   Basir, Seemi Farhat
TI Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in
   locally advanced breast cancers in Indian women
SO HUMAN PATHOLOGY
LA English
DT Article
DE hypermethylation; breast cancer; hmlh1; hmlh2
ID NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; DNA
   METHYLATION; PROMOTER HYPERMETHYLATION; CONSENSUS PANEL; HIGH-FREQUENCY;
   COLON-CANCER; MUTATIONS; TUMORS; EXPRESSION
AB Alterations in protooncogenes and tumor-suppressor genes at the DNA and/or protein level, which indicate the biological properties of individual breast cancers, led us to design a study encompassing the dilemma of "epigenetic silencing-driven genomic instabilities." In this study, we analyzed the promoter methylation of potent mismatch repair genes (hmlh1 and hmsh2) for the first time in 232 Indian patients with primary breast cancer (using methylation-specific polymerase chain reaction and expressional analysis). The study evaluates the gamut of epigenetic aberrations as well as genomic instabilities (microsatellite instabilities and loss of heterozygosity) and includes analysis of BAT-25, BAT-26, D2S123, D5S346, and D17S250. We observed hypermethylation of the hmlh1 gene in 43.5% of patients with primary breast cancer, of whom 66.9% had locally advanced breast cancer (stage IIIA, 11113, and IIIC) (P < .0001). Similarly, we also found hypermethylation of the hmsh 2 gene in 16% of primary breast cancer cases. Of these patients, 21.3% had locally advanced breast cancer (P = . 01). To determine the effect of methylation, we also performed expressional studies using reverse transcriptase polymerase chain reaction and Nor-them blotting, but we were unable to get any significant expression in the presence of hypermethylation of either gene (hmlh1 and hmsh2). Interestingly, statistical analysis revealed that hypermethylation of the hmlh1 gene is one of the peculiar attributes of locally advanced breast cancer. In addition, this study indicates that for more sensitive stage-specific diagnosis or prognosis, both methylation of promoter and expression studies must be considered in the analyses in a reproducible manner. Therefore, pinpointing the methylation fingerprints (5'CpG island methylation) of potent DNA repairing genes not only shows the specific attributes of locally advanced breast cancer but also provides important insight into the mode of therapy to be used by clinical oncologists. (C) 2008 Published by Elsevier Inc.
C1 [Naqvi, Raza Ali; Hussain, Arif; Chauhan, Madhur; Saxena, Anubha; Asim, Mohammad; Husain, Syed Akhtar; Basir, Seemi Farhat] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
   [Deo, Suryanarayan S. V.; Shukla, Nootan Kumar] All India Inst Med Sci, BR Ambedkar Inst Rotary Canc Hosp IRCH, Dept Surg Oncol, New Delhi 110029, India.
   [Kukreti, Himani; Pasha, Syed Tazeen] NICD, Div Biochem & Biotechnol, Delhi 110054, India.
   [Sarin, Ritu] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
C3 Jamia Millia Islamia; All India Institute of Medical Sciences (AIIMS)
   New Delhi; National Centre for Disease Control (NCDC); University of
   Chicago
RP Basir, SF (通讯作者)，Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
EM seemi_farbat@yahoo.co.in
RI Naqvi, Raza/AAE-5550-2022; Basir, Seemi Farhat/GOE-4171-2022; Shukla,
   Neeraj/ABD-4938-2020; Hussain, Arif/H-6286-2018
OI Hussain, Arif/0000-0002-0851-4845; husain, syed
   akhtar/0000-0002-6513-7759
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101
   Abe O, 1998, LANCET, V352, P930
   ALDAZ CM, 1995, CANCER RES, V55, P3976
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065
   Bubb VJ, 1996, ONCOGENE, V12, P2641
   Chialina SG, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-5
   CONTEGIACOMO A, 1995, INT J CANCER, V64, P264, DOI 10.1002/ijc.2910640409
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CUI J, 1998, CHUNG HUA I HSUEH I, V15, P348
   Cunningham JM, 1998, CANCER RES, V58, P3455
   DEVITA VT, 2005, CANC PRINCIPLES PRAC, P1435
   Eads CA, 2001, CANCER RES, V61, P3410
   *EARL BREAST CANC, 2002, NAT REV GENET, V3, P415
   Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178
   Esteller M, 2001, CANCER RES, V61, P3225
   Fujii Satoshi, 1998, Hiroshima Journal of Medical Sciences, V47, P89
   Goessl C, 2000, CANCER RES, V60, P5941
   Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817
   Harima Y, 2000, CLIN CANCER RES, V6, P1079
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 2000, CURR TOP MICROBIOL, V249, P35
   Ichikawa Y, 2002, JPN J CLIN ONCOL, V32, P110, DOI 10.1093/jjco/hyf026
   Jonsson M, 1995, EUR J CANCER, V31A, P2330, DOI 10.1016/0959-8049(95)00447-5
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48
   Mackay HJ, 2000, J CLIN ONCOL, V18, P87, DOI 10.1200/JCO.2000.18.1.87
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K
   Patel A, 2003, ANN NY ACAD SCI, V983, P286, DOI 10.1111/j.1749-6632.2003.tb05983.x
   Paulson TG, 1996, CANCER RES, V56, P4021
   Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4
   Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240
   Salvesen HB, 2000, CLIN CANCER RES, V6, P3607
   Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Thibodeau SN, 1996, CANCER RES, V56, P4836
   Wang YC, 2003, J CLIN INVEST, V111, P887, DOI 10.1172/JCI200315475
   Wang YC, 1998, CANCER RES, V58, P328
NR 43
TC 14
Z9 19
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD MAY
PY 2008
VL 39
IS 5
BP 672
EP 680
DI 10.1016/j.humpath.2007.09.011
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 299BN
UT WOS:000255730900006
PM 18329696
DA 2025-01-12
ER

PT J
AU Beltran, AS
   Sun, XG
   Lizard, PM
   Blancafort, P
AF Beltran, Adriana S.
   Sun, Xueguang
   Lizard, Paul M.
   Blancafort, Pilar
TI Reprogramming epigenetic silencing:: artificial transcription factors
   synergize with chromatin remodeling drugs to reactivate the tumor
   suppressor <i>mammary serine protease inhibitor</i>
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID DNA METHYLATION; MASPIN; EXPRESSION; GENOME; GENES
AB Mammary serine protease inhibitor (maspin) is an important tumor suppressor gene whose expression is associated not only with tumor growth inhibition but also with decreased angiogenesis and metastasis. Maspin expression is down-regulated in metastatic tumors by epigenetic mechanisms, including aberrant promoter hypermethylation. We have constructed artificial transcription factors (ATFs) as novel therapeutic effectors able to bind 18-bp sites in the maspin promoter and reactivate maspin expression in cell lines that harbor an epigenetically silenced promoter. In this article, we have investigated the influence of epigenetic modifications on ATF-mediated regulation of maspin by challenging MDA-MB-231 breast cancer cells, comprising a methylated maspin promoter, with different doses of ATFs and chromatin remodeling drugs: the methyltransferase inhibitor 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor suberoylanilide hydroxamic acid. We found that the ATFs synergized with both inhibitors in reactivating endogenous maspin expression. The strongest synergy was observed with the triple treatment ATF-126 + 5-aza-2'-deoxycytidine + suberoylanilide hydroxamic acid, in which the tumor suppressor was reactivated by 600-fold. Furthermore, this combination inhibited tumor cell proliferation by 95%. Our data suggest that ATFs enhance the efficiency of chromatin remodeling drugs in reactivating silenced tumor suppressors. Our results document the power of a novel therapeutic approach that combines both epigenetic and genetic (sequence-specific ATFs) strategies to reactivate specifically silenced regions of the genome and reprogram cellular phenotypes.
C1 [Beltran, Adriana S.; Blancafort, Pilar] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
   [Beltran, Adriana S.; Blancafort, Pilar] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Sun, Xueguang; Lizard, Paul M.] Yale Univ, Med Ctr, Dept Biochem & Biophys, New Haven, CT USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Yale University
RP Blancafort, P (通讯作者)，Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
EM pilar_blancafort@med.unc.edu
RI Blancafort, Pilar/K-9029-2012
OI Blancafort, Pilar/0000-0002-3881-7396
FU NCI NIH HHS [R01 CA125273-03, R01 CA125273-05, R21 CA116079-01, R01
   CA125273-01, R01 CA125273-03S1, R21 CA116079, R01 CA125273-04, R01
   CA125273-02, R01 CA125273, 1R01CA125273-01] Funding Source: Medline
CR Bastian PJ, 2004, EUR UROL, V46, P698, DOI 10.1016/j.eururo.2004.07.022
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   BAYLIN SB, 2007, NATURE, V7153, P553
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Becker Jurgen C, 2006, J Dtsch Dermatol Ges, V4, P108, DOI 10.1111/j.1610-0387.2006.05920.x
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
   Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794
   Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886
   Brock MV, 2007, CANCER J, V13, P3
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Chou T C, 1994, Contrib Gynecol Obstet, V19, P91
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255
   CREUSOT F, 1982, J BIOL CHEM, V257, P2041
   Desmond JC, 2007, LEUKEMIA, V21, P1026, DOI 10.1038/sj.leu.2404611
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003
   Hurtubise A, 2006, CANCER CHEMOTH PHARM, V58, P618, DOI 10.1007/s00280-006-0225-6
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Nuyt AM, 2007, CIRC RES, V100, P452, DOI 10.1161/01.RES.0000260292.95612.ac
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07
   Patnaik A, 2002, CLIN CANCER RES, V8, P2142
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   Reid T, 2004, LUNG CANCER, V45, P381, DOI 10.1016/j.lungcan.2004.03.002
   Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   SHAKER S, 2005, LEUKEMIA RES, V5, P437
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   TALLARIDA RJ, 2000, DRYG SYNERGISM DOSE, P15
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Winquist E, 2006, INVEST NEW DRUG, V24, P159, DOI 10.1007/s10637-006-5938-1
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
   Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 53
TC 51
Z9 59
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2008
VL 7
IS 5
BP 1080
EP 1090
DI 10.1158/1535-7163.MCT-07-0526
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 301RS
UT WOS:000255913900009
PM 18483297
OA Green Published, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Li, YM
   Wei, QJ
   Cao, F
   Cao, X
AF Li, Yongmei
   Wei, Qinjun
   Cao, Fang
   Cao, Xin
TI Expression and promoter methylation of the <i>RASSF1A</i> gene in
   sporadic breast cancers in Chinese women
SO ONCOLOGY REPORTS
LA English
DT Article
DE methylation; breast cancer; Ras association domain family 1A
ID TUMOR-SUPPRESSOR GENE; DOMAIN FAMILY 1A; CPG ISLAND; EPIGENETIC
   INACTIVATION; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION;
   HYPERMETHYLATION; ASSOCIATION; LUNG; 3P21.3
AB The novel tumor suppressor RASSF1A is frequently inactivated during human tumorigenesis by promoter methylation. In this study, we detected the RASSF1A promoter methylation by methylated-specific PCR and investigated RASSF1A gene expression by semi-quantitative RT-PCR and inummohistochemical staining in 36 cases of breast cancer and their adjacent normal tissues in Chinese women. The promoter methylation of the RASSF1A gene was found to be a frequent event in the breast cancers (61.1%). RASSF1A methylation was not found in the matched adjacent normal tissues. The loss frequency of RASSF1A mRNA was 33.3% and that of the RASSF1A protein was 44.4% in breast cancers. RASSF1A mRNA and protein were all expressed in adjacent normal tissues. The mRNA and protein expression level of RASSF1A was significantly lower in breast cancer than in adjacent normal tissue. However, the promoter methylation of the RASSF1A gene in breast cancers were not correlated with clinical parameters, such as ages, histological types, TNM stages and lymph node metastases. Thus, the promoter methylation of RASSF1A was one reason for the low level of RASSF1A mRNA and protein expression and was a frequent event in primary sporadic breast tumorigenesis in Chinese women.
C1 [Li, Yongmei; Wei, Qinjun; Cao, Fang; Cao, Xin] Nanjing Med Univ, Dept Biotechnol, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Cao, X (通讯作者)，Nanjing Med Univ, Dept Biotechnol, Nanjing 210029, Jiangsu, Peoples R China.
EM caoxin@njmu.edu.cn
RI cao, xin/GLS-7854-2022
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   BURBEE DG, 2001, J NATL CANCER I, V93, P664
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   GENG C, 2006, CHIN J CANC PREV T P, V13, P1631
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lehmann U, 2007, HUM MOL GENET, V16, P1335, DOI 10.1093/hmg/ddm082
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005
   Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Tommasi S, 2005, CANCER RES, V65, P92
   Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792
   Yan PS, 2003, CANCER RES, V63, P6178
   Zhong S, 2003, CLIN CANCER RES, V9, P3376
NR 23
TC 12
Z9 16
U1 0
U2 3
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2008
VL 19
IS 5
BP 1149
EP 1153
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 293CI
UT WOS:000255312000011
PM 18425370
DA 2025-01-12
ER

PT J
AU Chan, TA
   Glockner, S
   Yi, JM
   Chen, W
   Van Neste, L
   Cope, L
   Herman, JG
   Velculescu, V
   Schuebel, KE
   Ahuja, N
   Baylin, SB
AF Chan, Timothy A.
   Glockner, Sabine
   Yi, Joo Mi
   Chen, Wei
   Van Neste, Leander
   Cope, Leslie
   Herman, James G.
   Velculescu, Victor
   Schuebel, Kornel E.
   Ahuja, Nita
   Baylin, Stephen B.
TI Convergence of mutation and epigenetic alterations identifies common
   genes in cancer that predict for poor prognosis
SO PLOS MEDICINE
LA English
DT Article
ID TUMOR-SUPPRESSOR; METHYLATION STATUS; DNA METHYLATION; HUMAN BREAST;
   EXPRESSION; PROMOTER; INACTIVATION; HAPLOINSUFFICIENCY; SIGNATURE;
   HYPERMETHYLATION
AB Background
   The identification and characterization of tumor suppressor genes has enhanced our understanding of the biology of cancer and enabled the development of new diagnostic and therapeutic modalities. Whereas in past decades, a handful of tumor suppressors have been slowly identified using techniques such as linkage analysis, large-scale sequencing of the cancer genome has enabled the rapid identification of a large number of genes that are mutated in cancer. However, determining which of these many genes play key roles in cancer development has proven challenging. Specifically, recent sequencing of human breast and colon cancers has revealed a large number of somatic gene mutations, but virtually all are heterozygous, occur at low frequency, and are tumor-type specific. We hypothesize that key tumor suppressor genes in cancer may be subject to mutation or hypermethylation.
   Methods and Findings
   Here, we show that combined genetic and epigenetic analysis of these genes reveals many with a higher putative tumor suppressor status than would otherwise be appreciated. At least 36 of the 189 genes newly recognized to be mutated are targets of promoter CpG island hypermethylation, often in both colon and breast cancer cell lines. Analyses of primary tumors show that 18 of these genes are hypermethylated strictly in primary cancers and often with an incidence that is much higher than for the mutations and which is not restricted to a single tumor-type. In the identical breast cancer cell lines in which the mutations were identified, hypermethylation is usually, but not always, mutually exclusive from genetic changes for a given tumor, and there is a high incidence of concomitant loss of expression. Sixteen out of 18 (89%) of these genes map to loci deleted in human cancers. Lastly, and most importantly, the reduced expression of a subset of these genes strongly correlates with poor clinical outcome.
   Conclusions
   Using an unbiased genome-wide approach, our analysis has enabled the discovery of a number of clinically significant genes targeted by multiple modes of inactivation in breast and colon cancer. Importantly, we demonstrate that a subset of these genes predict strongly for poor clinical outcome. Our data define a set of genes that are targeted by both genetic and epigenetic events, predict for clinical prognosis, and are likely fundamentally important for cancer initiation or progression.
C1 [Chan, Timothy A.; Glockner, Sabine; Yi, Joo Mi; Chen, Wei; Herman, James G.; Schuebel, Kornel E.; Ahuja, Nita; Baylin, Stephen B.] Johns Hopkins Kimmel Canc Ctr, Canc Biol Program, Baltimore, MD USA.
   [Chan, Timothy A.] Johns Hopkins Kimmel Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA.
   [Glockner, Sabine; Ahuja, Nita] Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA.
   [Chen, Wei; Baylin, Stephen B.] Johns Hopkins Univ, Predoctoral Training Program Human Genet, Baltimore, MD USA.
   [Van Neste, Leander] Univ Ghent, Dept Mol Biotechnol, Ghent, Belgium.
   [Cope, Leslie] Johns Hopkins Kimmel Canc Ctr, Biometry & Clin Trials Div, Baltimore, MD USA.
   [Velculescu, Victor] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD USA.
   [Velculescu, Victor] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Ghent University; Johns
   Hopkins University; Johns Hopkins Medicine; Johns Hopkins University;
   Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins
   Medicine; Howard Hughes Medical Institute
RP Schuebel, KE (通讯作者)，Johns Hopkins Kimmel Canc Ctr, Canc Biol Program, Baltimore, MD USA.
EM kornels@jhmi.edu; nahuja@jhmi.ed; sbaylin@jhmi.edu
RI Ahuja, Nita/H-1064-2011; cope, leslie/LTE-4234-2024; Chan,
   Timothy/ABD-5850-2021; Velculescu, Victor/B-3247-2009
OI Velculescu, Victor/0000-0003-1195-438X
FU NCI NIH HHS [R01 CA043318, CA043318] Funding Source: Medline; NIEHS NIH
   HHS [ES11858, R01 ES011858] Funding Source: Medline
CR Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034
   Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226
   Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2
   Bouffler SD, 2000, BRIT J CANCER, V83, P1291, DOI 10.1054/bjoc.2000.1422
   Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433
   BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834
   Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Getz G, 2007, SCIENCE, V317, DOI 10.1126/science.1138764
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   GRADY WM, 2008, ONCOGENE IN PRESS
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Ihaka R., 1996, J Comput Graph Stat, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687
   Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742-4658.2006.05343.x
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kato K, 2008, INT J CANCER, V122, P603, DOI 10.1002/ijc.23143
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Lu Y, 2007, J CELL BIOCHEM, V101, P676, DOI 10.1002/jcb.21220
   Lund P, 2006, ONCOGENE, V25, P4890, DOI 10.1038/sj.onc.1209502
   Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D
   Myöhänen SK, 1998, CANCER RES, V58, P591
   Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207
   Ramirez JL, 2005, J CLIN ONCOL, V23, P9105, DOI 10.1200/JCO.2005.02.2905
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rubin AF, 2007, SCIENCE, V317, DOI 10.1126/science.1138956
   Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5
   Soerjomataram I, 2008, BREAST CANCER RES TR, V107, P309, DOI 10.1007/s10549-007-9556-1
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168
   Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799
   Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007
NR 64
TC 121
Z9 142
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2008
VL 5
IS 5
BP 823
EP 838
AR e114
DI 10.1371/journal.pmed.0050114
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 315AL
UT WOS:000256850200022
PM 18507500
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Chung, W
   Kwabi-Addo, B
   Ittmann, M
   Jelinek, J
   Shen, L
   Yu, YH
   Issa, JPJ
AF Chung, Woonbok
   Kwabi-Addo, Bernard
   Ittmann, Michael
   Jelinek, Jaroslav
   Shen, Lanlan
   Yu, Yinhua
   Issa, Jean-Pierre J.
TI Identification of Novel Tumor Markers in Prostate, Colon and Breast
   Cancer by Unbiased Methylation Profiling
SO PLOS ONE
LA English
DT Article
AB DNA hypermethylation is a common epigenetic abnormality in cancer and may serve as a useful marker to clone cancer-related genes as well as a marker of clinical disease activity. To identify CpG islands methylated in prostate cancer, we used methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) on prostate cancer cell lines. We isolated 34 clones that corresponded to promoter CpG islands, including 5 reported targets of hypermethylation in cancer. We confirmed the data for 17 CpG islands by COBRA and/or pyrosequencing. All 17 genes were methylated in at least 2 cell lines of a 21-cancer cell line panel containing prostate cancer, colon cancer, leukemia, and breast cancer. Based on methylation in primary tumors compared to normal adjacent tissues, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS and NSE1 are candidate biomarkers for prostate cancer (methylation range 50%-85%). The combination of NSE1 or SPOCK2 hypermethylation showed a sensitivity of 80% and specificity of 95% in differentiating cancer from normal. Similarly NKX2-5, SPOCK2, SLC16A12, DPYS and GALR2 are candidate biomarkers for colon cancer (methylation range 60%-95%) and GALR2 hypermethylation showed a sensitivity of 85% and specificity of 95%. Finally, SLC16A12, GALR2, TOX, SPOCK2, EGFR5 and DPYS are candidate biomarkers for breast cancer (methylation range 33%-79%) with the combination of EGFR5 or TOX hypermethylation showing a sensitivity of 92% and specificity of 92%. Expression analysis for eight genes that had the most hypermethylation confirmed the methylation associated silencing and reactivation with 5-aza-2'-deoxycytidine treatment. Our data identify new targets of transcriptional silencing in cancer, and provide new biomarkers that could be useful in screening for prostate cancer and other cancers.
C1 [Chung, Woonbok; Jelinek, Jaroslav; Shen, Lanlan; Issa, Jean-Pierre J.] Baylor Coll Med, Dept Leukemia, Houston, TX 77030 USA.
   [Kwabi-Addo, Bernard; Ittmann, Michael] Baylor Coll Med, Dept Pathol, Houston, TX USA.
   [Yu, Yinhua] Baylor Coll Med, Monroe Dunaway M. D. Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX USA.
C3 Baylor College of Medicine; Baylor College of Medicine; University of
   Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine
RP Chung, W (通讯作者)，Baylor Coll Med, Dept Leukemia, Houston, TX 77030 USA.
EM jpissa@mdanderson.org
RI Kwabi-Addo, Bernard/A-6993-2016; Jelinek, Jaroslav/D-2282-2012
OI Kwabi-Addo, Bernard/0000-0003-3692-6350; Jelinek,
   Jaroslav/0000-0002-2533-0220; CHUNG, WOONBOK/0000-0002-3663-8554; Shen,
   Lanlan/0000-0002-1532-5807; Issa, Jean-Pierre/0000-0003-2258-5030
FU National Institutes of Health [CA100632, CA098006]
FX This work was supported in part by National Institutes of Health Grants
   CA100632 and CA098006.
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHRISTIAN BJ, 1987, CANCER RES, V47, P6066
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Estécio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Schmutte C, 1998, BIOL CHEM, V379, P377
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Singal R, 2001, CANCER RES, V61, P4820
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200
   Toyota M, 1999, CANCER RES, V59, P2307
   Webber MM, 1996, CARCINOGENESIS, V17, P1641, DOI 10.1093/carcin/17.8.1641
   Wimmer K, 2002, GENE CHROMOSOME CANC, V33, P285, DOI 10.1002/gcc.10030
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamada Y, 2003, CANCER SCI, V94, P536, DOI 10.1111/j.1349-7006.2003.tb01479.x
   Yamanaka M, 2003, INT J CANCER, V106, P382, DOI 10.1002/ijc.11227
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78
NR 32
TC 105
Z9 131
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2008
VL 3
IS 4
AR e2079
DI 10.1371/journal.pone.0002079
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 381YR
UT WOS:000261572300047
PM 18446232
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Vydra, J
   Selicharová, I
   Smutná, K
   Sanda, M
   Matousková, E
   Bursíková, E
   Prchalová, M
   Velenská, Z
   Coufal, D
   Jirácek, J
AF Vydra, Jan
   Selicharova, Irena
   Smutna, Katerina
   Sanda, Miloslav
   Matouskova, Eva
   Bursikova, Eva
   Prchalova, Marketa
   Velenska, Zuzana
   Coufal, David
   Jiracek, Jiri
TI Two-dimensional electrophoretic comparison of metastatic and
   non-metastatic human breast tumors using <i>in vitro</i> cultured
   epithelial cells derived from the cancer tissues
SO BMC CANCER
LA English
DT Article
ID PROGENITOR CELLS; 2-DE ANALYSIS; PROTEOMICS; LINE; EVOLUTION; DISCOVERY;
   EXPANSION; GROWTH; EM-G3; GENE
AB Background: Breast carcinomas represent a heterogeneous group of tumors diverse in behavior, outcome, and response to therapy. Identification of proteins resembling the tumor biology can improve the diagnosis, prediction, treatment selection, and targeting of therapy. Since the beginning of the post-genomic era, the focus of molecular biology gradually moved from genomes to proteins and proteomes and to their functionality. Proteomics can potentially capture dynamic changes in protein expression integrating both genetic and epigenetic influences.
   Methods: We prepared primary cultures of epithelial cells from 23 breast cancer tissue samples and performed comparative proteomic analysis. Seven patients developed distant metastases within three-year follow-up. These samples were included into a metastase-positive group, the others formed a metastase-negative group. Two-dimensional electrophoretical (2-DE) gels in pH range 4-7 were prepared. Spot densities in 2-DE protein maps were subjected to statistical analyses (R/maanova package) and data-mining analysis (GUHA). For identification of proteins in selected spots, liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed.
   Results: Three protein spots were significantly altered between the metastatic and non-metastatic groups. The correlations were proven at the 0.05 significance level. Nucleophosmin was increased in the group with metastases. The levels of 2,3-trans-enoyl-CoA isomerase and glutathione peroxidase 1 were decreased.
   Conclusion: We have performed an extensive proteomic study of mammary epithelial cells from breast cancer patients. We have found differentially expressed proteins between the samples from metastase-positive and metastase-negative patient groups.
C1 [Selicharova, Irena; Smutna, Katerina; Sanda, Miloslav; Jiracek, Jiri] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Prague, Czech Republic.
   [Vydra, Jan] Charles Univ Prague, Fac Med 1, Dept Oncol, CR-11636 Prague 1, Czech Republic.
   [Matouskova, Eva; Bursikova, Eva] Charles Univ Prague, Fac Med 1, Inst Biochem & Expt Oncol, CR-11636 Prague 1, Czech Republic.
   [Matouskova, Eva; Bursikova, Eva; Prchalova, Marketa] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic.
   [Matouskova, Eva; Bursikova, Eva; Prchalova, Marketa] Charles Univ Prague, Fac Med 3, Prague Burn Ctr, CR-11636 Prague 1, Czech Republic.
   [Velenska, Zuzana] Charles Univ Prague, Fac Med 1, Inst Pathol, CR-11636 Prague 1, Czech Republic.
   [Coufal, David] Acad Sci Czech Republic, Inst Comp Sci, Prague, Czech Republic.
C3 Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry
   of the Czech Academy of Sciences; Charles University Prague; Charles
   University Prague; Czech Academy of Sciences; Institute of Molecular
   Genetics of the Czech Academy of Sciences; Charles University Prague;
   Charles University Prague; Czech Academy of Sciences; Institute of
   Computer Science of the Czech Academy of Sciences
RP Selicharová, I (通讯作者)，Acad Sci Czech Republic, Inst Organ Chem & Biochem, Prague, Czech Republic.
EM vydra@medico.cz; selicharova@uochb.cas.cz; smutna@lacomed.cz;
   sanda@uochb.cas.cz; matous@img.cas.cz; Eva.Bursikova@1lf.cuni.cz;
   mprch@seznam.cz; velenska.zuzana@vfn.cz; david.coufal@cs.cas.cz;
   jiracek@uochb.cas.cz
RI Coufal, David/A-3457-2013; Selicharova, Irena/G-5546-2014; Velenska,
   Zuzana/H-1062-2017; Jiracek, Jiri/A-7124-2008; Sanda,
   Miloslav/P-1631-2017
OI Velenska, Zuzana/0000-0002-6160-5930; Jiracek, Jiri/0000-0003-3848-2773;
   Sanda, Miloslav/0000-0002-7735-3635
CR [Anonymous], R Project for Statistical Computing (Version 3.0.2)
   Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519
   Biron DG, 2006, PROTEOMICS, V6, P5577, DOI 10.1002/pmic.200600223
   Breiman L, 1984, Classification and Regression Trees
   Brozova M, 2007, BREAST CANCER RES TR, V103, P247, DOI 10.1007/s10549-006-9358-x
   Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844
   Challapalli KK, 2004, ELECTROPHORESIS, V25, P3040, DOI 10.1002/elps.200405979
   Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307
   Coufal D, 2007, NEURAL NETW WORLD, V17, P447
   Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642
   Guo J, 2007, INT J CANCER, V121, P1296, DOI 10.1002/ijc.22763
   Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041
   He QH, 2007, MAGN RESON MED, V58, P1079, DOI 10.1002/mrm.21335
   Hondermarck H, 2003, MOL CELL PROTEOMICS, V2, P281, DOI 10.1074/mcp.R300003-MCP200
   Hondermarck H, 2001, PROTEOMICS, V1, P1216, DOI 10.1002/1615-9861(200110)1:10<1216::AID-PROT1216>3.3.CO;2-G
   JANSSEN U, 1994, GENOMICS, V23, P223, DOI 10.1006/geno.1994.1480
   Kapoor A, 2005, EXPERT REV ANTICANC, V5, P269, DOI 10.1586/14737140.5.2.269
   Krásná L, 2002, BREAST CANCER RES TR, V71, P219, DOI 10.1023/A:1014457731494
   Lei XG, 2007, ANNU REV NUTR, V27, P41, DOI 10.1146/annurev.nutr.27.061406.093716
   Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100
   Lim MJ, 2006, CANCER DETECT PREV, V30, P481, DOI 10.1016/j.cdp.2006.10.008
   Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5
   Marahatta SB, 2006, CANCER LETT, V236, P276, DOI 10.1016/j.canlet.2005.05.020
   Matousková E, 2000, BREAST CANCER RES TR, V60, P241, DOI 10.1023/A:1006409605067
   Mischak H, 2007, PROTEOM CLIN APPL, V1, P148, DOI 10.1002/prca.200600771
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.0.CO;2-H
   Selicharova I, 2008, ONCOL REP, V19, P1237
   Selicharová I, 2007, PROTEOMICS, V7, P1549, DOI 10.1002/pmic.200600907
   Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021
   Storey JD, 2004, J R STAT SOC B, V66, P187, DOI 10.1111/j.1467-9868.2004.00439.x
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343
   Torre GC, 1998, TUMOR BIOL, V19, P517, DOI 10.1159/000030045
   Villadsen R, 2005, APMIS, V113, P903, DOI 10.1111/j.1600-0463.2005.apm_344.x
   Zhang YP, 2004, CELL CYCLE, V3, P259
NR 35
TC 16
Z9 16
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 16
PY 2008
VL 8
AR 107
DI 10.1186/1471-2407-8-107
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 302AP
UT WOS:000255938700001
PM 18416831
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Deubzer, HE
   Ehemann, V
   Westermann, F
   Heinrich, R
   Mechtersheimer, G
   Kulozik, AE
   Schwab, M
   Witt, O
AF Deubzer, Hedwig E.
   Ehemann, Volker
   Westermann, Frank
   Heinrich, Ralf
   Mechtersheimer, Gunhild
   Kulozik, Andreas E.
   Schwab, Manfred
   Witt, Olaf
TI Histone deacetylase inhibitor <i>Helminthosporium carbonum</i>
   (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE epigenetic therapy; cell cycle arrest; differentiation; E2F-1 regulated
   genes; RB tumor suppressor network
ID HUMAN NEURO-BLASTOMA; BONE-MARROW-TRANSPLANTATION; BREAST-CANCER CELLS;
   HC-TOXIN; RETINOIC ACID; 13-CIS-RETINOIC ACID; ANTITUMOR-ACTIVITY;
   GENE-EXPRESSION; NERVOUS-SYSTEM; TUMOR-CELLS
AB The survival rate of children with advanced neuroblastoma (NB) is dismal despite intensive multimodal therapy. The limited efficacy and the frequent and serious side effects of currently used therapeutic regimens necessitate the development of new, less toxic treatment strategies. This study shows that the histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of both established NB cell lines and primary NB cells with and without amplified MYCN at dosages lower than 20 nM. HC-toxin induces cell cycle arrest and apoptosis as well as neuronal differentiation and diminishes both colony formation and invasive growth. These cellular changes are accompanied by the transcriptional repression of cell cycle regulators of the retinoblastoma (RB) tumor suppressor network found at high levels in NBs with poor prognosis, like E2F-1 and its targets Skp2, N-myc, Mad2 and survivin. The levels of the hypophosphorylated active form of RB, and of cyclin-dependent kinase inhibitors including P15(INK4b), p16(INK4a), p21(cip1/waf-1) and p27(kip1) are increased. In conclusion, nanomolar doses of the HDACI HC-toxin cause a shift to a differentiated and benign phenotype of NB cells that is associated with an activation of the RB tumor suppressor network. (c) 2007 Wiley-Liss, Inc.
C1 [Deubzer, Hedwig E.; Witt, Olaf] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol G340, D-69120 Heidelberg, Germany.
   [Deubzer, Hedwig E.; Kulozik, Andreas E.; Witt, Olaf] Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, D-6900 Heidelberg, Germany.
   [Ehemann, Volker] Univ Heidelberg, Inst Pathol, Dept Gen Pathol Cytometry Facil, D-6900 Heidelberg, Germany.
   [Schwab, Manfred] German Canc Res Ctr, Dept Tumor Genet, D-6900 Heidelberg, Germany.
   [Heinrich, Ralf] Univ Goettingen, Inst Zool, Dept Neurobiol, Gottingen, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; Ruprecht Karls University Heidelberg;
   Helmholtz Association; German Cancer Research Center (DKFZ); University
   of Gottingen
RP Deubzer, HE (通讯作者)，German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol G340, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM h.deubzer@dkfz-heidelberg.de
RI Kulozik, Andreas/AAO-2432-2020; Westermann, Frank/F-7509-2013; Deubzer,
   Hedwig/P-3258-2018
OI Deubzer, Hedwig/0000-0002-6115-4893
CR ALBINI A, 1987, CANCER RES, V47, P3239
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941
   Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560
   Cinatl J, 1996, ANTI-CANCER DRUG, V7, P766, DOI 10.1097/00001813-199609000-00008
   Coffey DC, 2001, CANCER RES, V61, P3591
   DAHLSTRAND J, 1992, CANCER RES, V52, P5334
   De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84
   DEVEAS RG, 1995, J CANCER RES CLIN, V121, P275, DOI 10.1007/BF01209593
   Escobar MA, 2006, J PEDIATR SURG, V41, P377, DOI 10.1016/j.jpedsurg.2005.11.032
   Fischer M, 2006, CLIN CANCER RES, V12, P5118, DOI 10.1158/1078-0432.CCR-06-0985
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820
   Hildmann C, 2006, J BIOTECHNOL, V124, P258, DOI 10.1016/j.jbiotec.2006.01.030
   HOCKFIELD S, 1985, J NEUROSCI, V5, P3310
   Ito R, 2005, BIOL PHARM BULL, V28, P565, DOI 10.1248/bpb.28.565
   Jaboin J, 2002, CANCER RES, V62, P6108
   Joung KE, 2004, ARCH PHARM RES, V27, P640, DOI 10.1007/BF02980164
   Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187
   Keshelava N, 2007, JNCI-J NATL CANCER I, V99, P1107, DOI 10.1093/jnci/djm044
   Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X
   Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601
   Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5
   Min KN, 2004, ARCH PHARM RES, V27, P554, DOI 10.1007/BF02980131
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Oberthuer A, 2007, CANCER LETT, V250, P250, DOI 10.1016/j.canlet.2006.10.016
   Ouwehand K, 2005, FEBS LETT, V579, P1523, DOI 10.1016/j.febslet.2005.01.058
   RAZA A, 1993, AM J HEMATOL, V42, P147, DOI 10.1002/ajh.2830420202
   SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0
   Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5
   SIDELL N, 1982, JNCI-J NATL CANCER I, V68, P589
   Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102
   TANNOCK IF, 1998, BASIC SCI ONCOLOGY, P350
   THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0
   VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894
   Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310
   Walton JD, 2006, PHYTOCHEMISTRY, V67, P1406, DOI 10.1016/j.phytochem.2006.05.033
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Westermann F, 2007, CLIN CANCER RES, V13, P4695, DOI 10.1158/1078-0432.CCR-06-2818
   Witt O, 2003, BLOOD, V101, P2001, DOI 10.1182/blood-2002-08-2617
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 43
TC 44
Z9 54
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2008
VL 122
IS 8
BP 1891
EP 1900
DI 10.1002/ijc.23295
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 275JS
UT WOS:000254068300031
PM 18074352
OA Bronze
DA 2025-01-12
ER

PT J
AU Westberry, JM
   Prewitt, AK
   Wilson, ME
AF Westberry, J. M.
   Prewitt, A. K.
   Wilson, M. E.
TI Epigenetic regulation of the estrogen receptor alpha promoter in the
   cerebral cortex following ischemia in male and female rats
SO NEUROSCIENCE
LA English
DT Article
DE stroke; methylation; methyl binding proteins; estrogen
ID ESTRADIOL-MEDIATED PROTECTION; HUMAN BREAST-CANCER; DNA METHYLATION;
   BRAIN-INJURY; MESSENGER-RNA; EXPERIMENTAL STROKE; GENE-EXPRESSION;
   RETT-SYNDROME; BETA-AGONIST; CELL-DEATH
AB Permanent middle cerebral artery occlusion (MCAO) causes neuronal cell death in the striatum and cortex. In rodents, estradiol treatment protects the cortex from cell death in an estrogen receptor alpha (ER alpha) dependent manner. ER alpha is only transiently expressed in the cortex during neonatal development and is very low in uninjured adult cortex. Following MCAO, ER alpha mRNA expression is upregulated in the cortex of female rats, but the mechanism of this increase is still unknown. It is also unknown whether a similar increase in ER alpha expression in seen in males. In the following studies, male and vehicle or estradiol-treated ovariectomized (OVX) female rats underwent MCAO to investigate the regulation of ER alpha expression after ischemia. Twenty-four hours after surgery, mRNA or genomic DNA was collected from 1 mm micropunches taken from 300 mu m brain sections for quantitative reverse transcription-polymerase chain reaction (RT-PCR) or methylation-specific (MSP) PCR, respectively. Additionally, adjacent 20 mu m sections were processed for ERa immunohistochemistry. In OVX females, ER alpha mRNA and protein were increased in the ischemic cortex, but unchanged in males. We hypothesized that this increase in ER alpha in females is due to a reversal of gene silencing by DNA methylation. Using MSP targeting of CpG islands within the 5' untranslated region (UTR) of the rat ER alpha gene, we found that ischemia decreased methylation in the ischemic cortex of both groups of females, but there was no change in methylation in males. Using chromatin immunoprecipitation, we found that MeCP2 associates with ER alpha 5'UTR corresponding with the methylation status of the promoter. These data are the first to demonstrate a difference in the regulation of ER alpha expression in response to MCAO between males and females and that methylation of the ER alpha gene corresponds with mRNA levels in the brain. (c) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Westberry, J. M.; Prewitt, A. K.; Wilson, M. E.] Univ Kentucky, Coll Med, Dept Psychol, Lexington, KY 40536 USA.
C3 University of Kentucky
RP Wilson, ME (通讯作者)，Univ Kentucky, Coll Med, Dept Psychol, 800 Rose St, Lexington, KY 40536 USA.
EM melinda.wilson@uky.edu
FU NCRR NIH HHS [P20 RR015592, P20 RR015592-09, P20 RR 15592] Funding
   Source: Medline; NHLBI NIH HHS [R01 HL073693, HL073693, R01 HL073693-05]
   Funding Source: Medline
CR Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159
   Bienvenu T, 2006, NAT REV GENET, V7, P415, DOI 10.1038/nrg1878
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004
   Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119
   Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446
   Dubal DB, 1999, J NEUROSCI, V19, P6385
   Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012
   Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43
   Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198
   Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177
   Farr TD, 2007, BRAIN RES, V1185, P275, DOI 10.1016/j.brainres.2007.09.009
   HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61
   Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001
   KELLEY MR, 1993, ALCOHOL, V10, P185, DOI 10.1016/0741-8329(93)90033-K
   Klose R, 2003, SCIENCE, V302, P793, DOI 10.1126/science.1091762
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   MIRANDA RC, 1992, CEREB CORTEX, V2, P1, DOI 10.1093/cercor/2.1.1
   Moretti P, 2006, CURR OPIN GENET DEV, V16, P276, DOI 10.1016/j.gde.2006.04.009
   Namura S, 1998, J NEUROSCI, V18, P3659
   Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200
   PREWITT AK, 2007, DEV REGULATION ESTRO
   Prewitt AK, 2007, BRAIN RES, V1134, P62, DOI 10.1016/j.brainres.2006.11.069
   Prokai L, 2007, PHARMACOL THERAPEUT, V114, P1, DOI 10.1016/j.pharmthera.2007.01.006
   Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665
   Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738
   Sawada M, 2000, J CEREBR BLOOD F MET, V20, P112, DOI 10.1097/00004647-200001000-00015
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Simpkins JW, 2005, CNS NEUROL DISORD-DR, V4, P69, DOI 10.2174/1568007053005073
   Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724
   Singer CA, 1999, J NEUROSCI, V19, P2455
   SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219
   Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666
   WELLMAN SE, 1987, GENE, V59, P29, DOI 10.1016/0378-1119(87)90263-0
   Wilson ME, 2000, BRAIN RES, V873, P235, DOI 10.1016/S0006-8993(00)02479-3
   Wilson ME, 2002, MOL BRAIN RES, V102, P48, DOI 10.1016/S0169-328X(02)00181-X
   Wise PM, 2005, ENDOCR REV, V26, P308, DOI 10.1210/er.2004-0014
   Yang XW, 2001, CANCER RES, V61, P7025
NR 43
TC 83
Z9 95
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD APR 9
PY 2008
VL 152
IS 4
BP 982
EP 989
DI 10.1016/j.neuroscience.2008.01.048
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 290WF
UT WOS:000255152800012
PM 18353557
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Wu, ZX
   Luo, JF
   Ge, QY
   Lu, ZH
AF Wu, Zhixiang
   Luo, Junfeng
   Ge, Qinyu
   Lu, Zuhong
TI Microarray-based Ms-SNuPE: Near-quantitative analysis for a
   high-throughput DNA methylation
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE methylation; single base extension; tag; microarray; CpG dinucleotides;
   methylation-specific PCR
ID GENE; EPIGENETICS; ISLANDS; CANCER
AB Aberrant DNA methylation of CpG site in the gene promoter region has been confirmed to be closely associated with carcinogenesis. In the present study, a microarray-based methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for parallel detecting changes of DNA methylation in cancer was developed. After modification by sodium sulfite, the unmethylated cytosine in the genomic DNA is converted to uracil while leaving the 5-methylcytosine unchanged, which can be detected by bifunctional primer carrying a unique sequence tag in addition to a locus-specific sequence. Because each locus has a distinct tag, the detecting reactions can be performed in a highly multiplexed fashion and the resulting product then be hybridized to the reverse complements of the sequence tags arrayed on a glass slide for methylation analysis. The calibration curves with the correlation coefficient >0.97 were established, which suggested that the method could be used in near-quantitative DNA methylation analysis. Two breast tumor-related genes (E-cad and p16) are successfully analyzed by two group primers (22 primers total), and the results are compatible with that of methylation-specific PCR (MSP). Our research proved that the method is simple and inexpensive, and could be applied as a high-throughput tool to quantitatively determine methylation status of the investigated genes. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Wu, Zhixiang; Luo, Junfeng; Lu, Zuhong] SE Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Peoples R China.
   [Ge, Qinyu; Lu, Zuhong] SE Univ, Minist Educ, Kye Lab Child Dev & Learning Sci, Nanjing 210096, Peoples R China.
C3 Southeast University - China; Southeast University - China
RP Lu, ZH (通讯作者)，SE Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Peoples R China.
EM zhlu@seu.edu.cn
RI Ge, Qinyu/B-5055-2012; Lu, Zuhong/A-5448-2013; Luo,
   Junfeng/GPP-7603-2022
OI Lu, Zuhong/0000-0003-3332-2615
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Brakensiek K, 2007, CLIN CHEM, V53, P17, DOI 10.1373/clinchem.2007.072629
   CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cottrell SE, 2004, CLIN BIOCHEM, V37, P595, DOI 10.1016/j.clinbiochem.2004.05.010
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Gonzalgo ML, 2007, NAT PROTOC, V2, P1931, DOI 10.1038/nprot.2007.271
   Gonzalgo ML, 2002, METHODS, V27, P128, DOI 10.1016/S1046-2023(02)00064-6
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469
   Hirschhorn JN, 2000, P NATL ACAD SCI USA, V97, P12164, DOI 10.1073/pnas.210394597
   Hou P, 2004, WORLD J GASTROENTERO, V10, P3553, DOI 10.3748/wjg.v10.i24.3553
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Schatz P, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl218
   Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3
   Valenzuela MT, 2002, EUR UROL, V42, P622, DOI 10.1016/S0302-2838(02)00468-2
   Zhou DR, 2006, J BIOCHEM BIOPH METH, V66, P33, DOI 10.1016/j.jbbm.2005.11.004
NR 24
TC 18
Z9 20
U1 0
U2 15
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR
PY 2008
VL 23
IS 9
BP 1333
EP 1339
DI 10.1016/j.bios.2007.11.018
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 291WD
UT WOS:000255226900003
PM 18215791
DA 2025-01-12
ER

PT J
AU Fujii, S
   Ochiai, A
AF Fujii, Satoshi
   Ochiai, Atsushi
TI Enhancer of zeste homolog 2 downregulates E-cadherin by mediating
   histone H3 methylation in gastric cancer cells
SO CANCER SCIENCE
LA English
DT Article
ID GROUP PROTEIN EZH2; AGGRESSIVE BREAST-CANCER; CONTROLS DNA METHYLATION;
   H3 LYSINE-9 METHYLATION; GENE-MUTATIONS PROVIDE; POLYCOMB-GROUP GENE;
   METHYLTRANSFERASE ACTIVITY; PROMOTER METHYLATION; ADHESION MOLECULES;
   EPITHELIAL-CELLS
AB Overexpression of enhancer of zeste homolog 2 (EZH2), an epigenetic repressor, occurs in various malignancies and is associated with poor prognosis; however, the functional role of EZH2 overexpression in cancer versus non-cancerous tissue remains unclear. In this study, we found an inverse correlation between EZH2 and E-cadherin gene expression in gastric cancer cells. Knockdown of EZH2 by short interfering RNA in gastric cancer cells resulted in a restoration of the E-cadherin gene. We showed that the EZH2 complex existed with histone H3 and Lys27, which were methylated on E-cadherin promoter regions in gastric cancer cells. The restoration of E-cadherin was not involved in the change of the DNA methylation status in the E-cadherin promoter region. Immunofluorescence staining confirmed the expression of E-cadherin protein present in the cell membrane was restored after knockdown of EZH2, resulting in changing the cancer phenotype, such as its invasive capacity. In vivo, the relationship of inverse expression between EZH2 protein and E-cadherin protein was observed at the individual cellular level in gastric cancer tissue. This study provides into the mechanisms underlying the functional role of EZH2 overexpression in gastric cancer cells and a new modality of regulation of E-cadherin expression in silencing mechanisms of tumor suppressor genes. Our present study paves the way for exploring the blockade of EZH2 overexpression as a novel approach to treating cancer.
C1 [Fujii, Satoshi; Ochiai, Atsushi] Natl Canc Ctr, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan.
C3 National Cancer Center - Japan
RP Ochiai, A (通讯作者)，Natl Canc Ctr, Div Pathol, Res Ctr Innovat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.
EM aochiai@east.ncc.go.jp
CR Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575
   Ascaño JJ, 2001, MODERN PATHOL, V14, P942, DOI 10.1038/modpathol.3880416
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   BECKER KF, 1994, CANCER RES, V54, P3845
   BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204
   Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O
   Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918
   HASHIMOTO M, 1989, JPN J CANCER RES, V80, P459, DOI 10.1111/j.1349-7006.1989.tb02336.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   House MG, 2003, CARCINOGENESIS, V24, P193, DOI 10.1093/carcin/24.2.193
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593
   KUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Li LC, 2000, CANCER RES, V60, P873
   Liu YC, 2006, WORLD J GASTROENTERO, V12, P2168, DOI 10.3748/wjg.v12.i14.2161
   Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234
   Machado JC, 1999, LAB INVEST, V79, P459
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   PIGNATELLI M, 1994, HUM PATHOL, V25, P849, DOI 10.1016/0046-8177(94)90002-7
   Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z
   TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200
   Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
NR 46
TC 83
Z9 101
U1 0
U2 9
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2008
VL 99
IS 4
BP 738
EP 746
DI 10.1111/j.1349-7006.2008.00743.x
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 281LK
UT WOS:000254498800017
PM 18377425
OA hybrid
DA 2025-01-12
ER

PT J
AU Wang, HJ
   Liu, Y
   Tan, W
   Zhang, Y
   Zhao, NQ
   Jiang, Y
   Lin, CZ
   Hao, BT
   Zhao, D
   Qian, J
   Lu, DR
   Jin, L
   Wei, QY
   Lin, DX
   He, FC
AF Wang, Haijian
   Liu, Yang
   Tan, Wen
   Zhang, Yang
   Zhao, Naiqing
   Jiang, Yan
   Lin, Chengzhao
   Hao, Bingtao
   Zhao, Dan
   Qian, Ji
   Lu, Daru
   Jin, Li
   Wei, Qingyi
   Lin, Dongxin
   He, Fuchu
TI Association of the variable number of tandem repeats polymorphism in the
   promoter region of the <i>SMYD3</i> gene with risk of esophageal
   squamous cell carcinoma in relation to tobacco smoking
SO CANCER SCIENCE
LA English
DT Article
ID LUNG-CANCER; HISTONE METHYLTRANSFERASE; PROSTATE-CANCER; BREAST-CANCER;
   SUSCEPTIBILITY; P16(INK4A); EXPOSURE; CHINA; POPULATION; EXPRESSION
AB The etiology of esophageal squamous cell carcinoma (ESCC) has been shown to be multifactorial, including genetic, epigenetic, and environmental factors, such as tobacco smoking. A variable number of tandem repeats (VNTR) polymorphism in the promoter region of SMYD3, a recently characterized histone lysine methyltransferase gene that is implicated in cell proliferation and carcinogenesis, has been shown to be functional, but its association with cancer risk has not been well established because of apparently discrepant results in different populations. In this case-control study, we genotyped 567 patients with newly diagnosed ESCC and 567 healthy controls and found an increased ESCC risk (odds ratio [OR] = 1.42, 95% confidence interval [CI] = 1.05-1.91) associated with the common SMYD3 VNTR genotype. Stratification analysis revealed that the increased risk was limited to smokers (OR = 1.99; 95% CI = 1.27-3.12). Furthermore, compared with the reference group of non-smokers carrying the homozygous or heterozygous genotype, ORs (95% CI) of the wild genotype for non-smokers, smokers who smoked <25, and >= 25 pack-years were 1.03 (0.70-1.53), 2.80 (1.66-4.70), and 4.76 (2.67-8.46), respectively (P < 0.001 for trend test), suggesting an interaction between this genetic polymorphism and smoking status. These findings provide additional evidence that the common VNTR polymorphism in the promoter region of SMYD3 gene may be a susceptibility factor for human cancers such as ESCC by interacting with tobacco carcinogens.
C1 [Tan, Wen; Zhao, Dan; Lin, Dongxin] Chinese Acad Med Sci, Inst Canc, Dept Etiol & Carcinogenesis, Beijing 100021, Peoples R China.
   [Tan, Wen; Zhao, Dan; Lin, Dongxin] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Zhao, Naiqing] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai 200032, Peoples R China.
   [Hao, Bingtao; He, Fuchu] Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Proteom, Beijing 102206, Peoples R China.
   [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Fudan University; Academy of Military
   Medical Sciences - China; University of Texas System; UTMD Anderson
   Cancer Center
RP Lin, DX (通讯作者)，Chinese Acad Med Sci, Inst Canc, Dept Etiol & Carcinogenesis, Beijing 100021, Peoples R China.
EM dLin@public.bta.net.cn; hefc@fudan.edu.cn
RI Chen, Chien-Jen/C-6976-2008; He, FC/KGL-6713-2024; Liu,
   Yang/HKV-2798-2023; Jin, Li/H-3383-2011; Zhao, Dan/D-1031-2013; Wei,
   Yingying/HLW-6638-2023; Li, Xingchuan/JFB-4764-2023; Hao,
   Bingtao/G-6648-2011; Zhao, Dan/KFT-3113-2024
OI Hao, Bingtao/0000-0003-1997-9338; Liu, Yang/0000-0003-3849-9049; Zhao,
   Dan/0000-0001-7066-9058; Jin, Li/0000-0001-9201-2321; Lin,
   Dongxin/0000-0002-8723-8868
CR Bachmann N, 2005, PROSTATE, V65, P252, DOI 10.1002/pros.20296
   Brennan P, 2002, CARCINOGENESIS, V23, P381, DOI 10.1093/carcin/23.3.381
   Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227
   Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047
   Frank B, 2006, INT J CANCER, V118, P2917, DOI 10.1002/ijc.21696
   GAO YT, 1994, INT J CANCER, V58, P192, DOI 10.1002/ijc.2910580208
   Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372
   Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101
   Kim DH, 2001, CANCER RES, V61, P3419
   Kraunz KS, 2006, INT J CANCER, V118, P1364, DOI 10.1002/ijc.21522
   Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126
   Lockett KL, 2004, CANCER RES, V64, P6344, DOI 10.1158/0008-5472.CAN-04-0338
   Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604
   Sims RJ, 2004, NAT CELL BIOL, V6, P685, DOI 10.1038/ncb0804-685
   Smeds J, 2002, CARCINOGENESIS, V23, P645, DOI 10.1093/carcin/23.4.645
   Spadaccini R, 2006, J MOL BIOL, V358, P498, DOI 10.1016/j.jmb.2006.01.087
   Sun T, 2004, JNCI-J NATL CANCER I, V96, P1030, DOI 10.1093/jnci/djh187
   Sun T, 2007, NAT GENET, V39, P605, DOI 10.1038/ng2030
   Tan W, 2000, CANCER EPIDEM BIOMAR, V9, P551
   Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638
   Wang X. Q., 2007, Experimental Oncology, V29, P71
   Yang L, 2003, INT J CANCER, V106, P771, DOI 10.1002/ijc.11300
   Yoon KA, 2006, CARCINOGENESIS, V27, P2217, DOI 10.1093/carcin/bgl084
   Zhang XM, 2005, CANCER RES, V65, P722
NR 29
TC 21
Z9 29
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2008
VL 99
IS 4
BP 787
EP 791
DI 10.1111/j.1349-7006.2008.00729.x
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 281LK
UT WOS:000254498800023
PM 18294291
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Kim, CJ
   Song, JH
   Cho, YG
   Cao, Z
   Lee, YS
   Nam, SW
   Lee, JY
   Park, WS
AF Kim, C. J.
   Song, J. H.
   Cho, Y. G.
   Cao, Z.
   Lee, Y. S.
   Nam, S. W.
   Lee, J. Y.
   Park, W. S.
TI Down-regulation of <i>ATBF1</i> is a major inactivating mechanism in
   hepatocellular carcinoma
SO HISTOPATHOLOGY
LA English
DT Article
DE alpha-fetoprotein; ATBF1; expression; genetic alteration; hepatocellular
   carcinoma
ID ALPHA-FETOPROTEIN GENE; TRANSCRIPTION FACTOR ATBF1;
   GASTROINTESTINAL-TRACT; PROSTATE-CANCER; BREAST-CANCER; YOLK-SAC;
   EXPRESSION; PROTEIN; ACTIVATION; MUTATIONS
AB Aims: alpha-Fetoprotein (AFP) is frequently detected in hepatocellular carcinomas (HCCs) and AT motif binding factor 1 (ATBF1) down-regulates AFP gene expression in hepatic cells. The ATBF1 gene also inhibits cell growth and differentiation, and altered gene expression is associated with malignant transformation. The aim was to investigate the potential role of the ATBF1 gene in HCCs.
   Methods and results: Somatic mutations, allelic loss and hypermethylation of the ATBF1 gene were analysed in 76 sporadic HCCs. The level of ATBF-1 mRNA expression was analysed using quantitative real-time reverse transcriptase-polymerase chain reaction. Genetic studies of the ATBF1 gene revealed absence of somatic mutation in the hotspot region and 15 (25%) of 60 informative cases showed allelic loss at the ATBF1 locus. Hypermethylation in the intron 1 region of the ATBF1 gene was detected in only one case. Interestingly, ATBF1 mRNA expression in HCCs was significantly reduced in 55 (72.4%) samples compared with the corresponding surrounding liver tissues. Reduced expression was not statistically associated with clinicopathological parameters including stage, histological grade, infective virus type, and serum alpha-fetoprotein level.
   Conclusion: The ATBF1 gene may contribute to the development of HCCs via transcriptional down-regulation of mRNA expression, but not by genetic or epigenetic alterations.
C1 [Kim, C. J.; Song, J. H.; Cho, Y. G.; Cao, Z.; Lee, Y. S.; Nam, S. W.; Lee, J. Y.; Park, W. S.] Catholic Univ, Coll Med, Dept Pathol, Seoul 137701, South Korea.
C3 Catholic University of Korea
RP Park, WS (通讯作者)，Catholic Univ, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.
EM wonsang@catholic.ac.kr
RI Cho, Yong-Gu/AAV-1904-2021; lee, yeo/AAG-4342-2020; Lee,
   Jinseok/ACF-1247-2022
CR *AM JOINT COMM CAN, 2002, AJCC CANC STAG HDB
   BOURREILLE J, 1970, PRESSE MED, V78, P1277
   Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   GITLIN D, 1972, CANCER RES, V32, P979
   Ido A, 1996, GENE, V168, P227, DOI 10.1016/0378-1119(95)00740-7
   ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6
   Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422
   Kataoka H, 2001, ONCOGENE, V20, P869, DOI 10.1038/sj.onc.1204160
   Lazarevich NL, 2000, BIOCHEMISTRY-MOSCOW+, V65, P117
   Miura Y, 2004, MICROBIOL IMMUNOL, V48, P137, DOI 10.1111/j.1348-0421.2004.tb03491.x
   MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840
   MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041
   Ninomiya T, 2002, HEPATOLOGY, V35, P82, DOI 10.1053/jhep.2002.30420
   Nishimura T, 2006, CANCER GENET CYTOGEN, V167, P57, DOI 10.1016/j.cancergencyto.2005.09.002
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   SAKAMOTO M, 1991, HUM PATHOL, V22, P172, DOI 10.1016/0046-8177(91)90039-R
   Shin Hai-Rim, 2004, Cancer Res Treat, V36, P103, DOI 10.4143/crt.2004.36.2.103
   Song J, 2006, J GASTROEN HEPATOL, V21, P1286, DOI 10.1111/j.1440-1746.2006.04445.x
   Sun XD, 2005, NAT GENET, V37, P407, DOI 10.1038/ng1528
   Sun XD, 2007, J CANCER RES CLIN, V133, P103, DOI 10.1007/s00432-006-0148-y
   TSUCHIDA Y, 1973, CANCER-AM CANCER SOC, V32, P917, DOI 10.1002/1097-0142(197310)32:4<917::AID-CNCR2820320425>3.0.CO;2-X
   TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915
   Walker DG, 2006, J LEUKOCYTE BIOL, V79, P596, DOI 10.1189/jlb.0705377
   WATANABE K, 1987, J BIOL CHEM, V262, P4812
   Xu JY, 2006, PROSTATE, V66, P1082, DOI 10.1002/pros.20430
   YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395
   Zhang ZH, 2005, CLIN CANCER RES, V11, P193
NR 28
TC 26
Z9 30
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD APR
PY 2008
VL 52
IS 5
BP 552
EP 559
DI 10.1111/j.1365-2559.2008.02980.x
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 280GU
UT WOS:000254414700002
PM 18312352
DA 2025-01-12
ER

PT J
AU Hua, S
   Kallen, CB
   Dhar, R
   Baquero, MT
   Mason, CE
   Russell, BA
   Shah, PK
   Liu, J
   Khramtsov, A
   Tretiakova, MS
   Krausz, TN
   Olopade, OI
   Rimm, DL
   White, KP
AF Hua, Sujun
   Kallen, Caleb B.
   Dhar, Ruby
   Baquero, Maria T.
   Mason, Christopher E.
   Russell, Beth A.
   Shah, Parantu K.
   Liu, Jiang
   Khramtsov, Andrey
   Tretiakova, Maria S.
   Krausz, Thomas N.
   Olopade, Olufunmilayo I.
   Rimm, David L.
   White, Kevin P.
TI Genomic analysis of estrogen cascade reveals histone variant H2A.Z
   associated with breast cancer progression
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; MITOTIC CHECKPOINT GENES; C-MYC; INTERACTION
   NETWORKS; EXPRESSION PATTERNS; CYCLE PROGRESSION; BINDING-SITES;
   RECEPTOR; TRANSCRIPTION; PROTEIN
AB We demonstrate an integrated approach to the study of a transcriptional regulatory cascade involved in the progression of breast cancer and we identify a protein associated with disease progression. Using chromatin immunoprecipitation and genome tiling arrays, whole genome mapping of transcription factor-binding sites was combined with gene expression profiling to identify genes involved in the proliferative response to estrogen (E2). Using RNA interference, selected ER alpha and c-MYC gene targets were knocked down to identify mediators of E2-stimulated cell proliferation. Tissue microarray screening revealed that high expression of an epigenetic factor, the E2-inducible histone variant H2A. Z, is significantly associated with lymph node metastasis and decreased breast cancer survival. Detection of H2A. Z levels independently increased the prognostic power of biomarkers currently in clinical use. This integrated approach has accelerated the identification of a molecule linked to breast cancer progression, has implications for diagnostic and therapeutic interventions, and can be applied to a wide range of cancers.
C1 [Hua, Sujun; Dhar, Ruby; Russell, Beth A.; Shah, Parantu K.; Liu, Jiang; White, Kevin P.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   [Hua, Sujun; Dhar, Ruby; Russell, Beth A.; Shah, Parantu K.; Liu, Jiang; White, Kevin P.] Univ Chicago, Joint Inst Genom & Syst Biol, Chicago, IL 60637 USA.
   [Hua, Sujun; Dhar, Ruby; Russell, Beth A.; Shah, Parantu K.; Liu, Jiang; White, Kevin P.] Argonne Natl Lab, Chicago, IL USA.
   [Hua, Sujun] Yale Univ, Interdepartmental Program Computat Biol & Bioinfo, New Haven, CT USA.
   [Kallen, Caleb B.] Emory Univ, Dept Gynecol & Obstet, Atlanta, GA 30322 USA.
   [Baquero, Maria T.; Rimm, David L.] Yale Univ, Dept Pathol, New Haven, CT USA.
   [Mason, Christopher E.; Russell, Beth A.] Yale Univ, Dept Genet, New Haven, CT USA.
   [Khramtsov, Andrey; Olopade, Olufunmilayo I.] Univ Chicago, Med Ctr, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
   [Tretiakova, Maria S.; Krausz, Thomas N.] Univ Chicago Hosp, Dept Pathol, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; United States Department
   of Energy (DOE); Argonne National Laboratory; Yale University; Emory
   University; Yale University; Yale University; University of Chicago;
   University of Chicago Medical Center; University of Illinois System;
   University of Chicago
RP White, KP (通讯作者)，Univ Chicago, Dept Human Genet, 1639 Pierce Dr,WMB 4211, Chicago, IL 60637 USA.
EM kpwhite@uchicago.edu
RI Rimm, David/HCH-4681-2022; Tretiakova, Maria/U-3320-2019; Mason,
   Christopher/HCH-3977-2022; Khramtsov, Andrey/H-8701-2018
OI Kallen, Caleb/0000-0002-4156-6719; Rimm, David/0000-0001-5820-4397;
   Khramtsov, Andrey/0000-0001-6301-4619
FU NICHD NIH HHS [5K12HD00849, K12 HD000849] Funding Source: Medline
CR Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Brickner DG, 2007, PLOS BIOL, V5, P704, DOI 10.1371/journal.pbio.0050081
   Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465
   Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690
   Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Cheung E, 2005, P NATL ACAD SCI USA, V102, P559, DOI 10.1073/pnas.0407113102
   Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021
   Clarke M, 1998, LANCET, V351, P1451
   Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7
   DUBIK D, 1992, ONCOGENE, V7, P1587
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Farris SD, 2005, J BIOL CHEM, V280, P25298, DOI 10.1074/jbc.M501784200
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Gao F, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-31
   Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800
   Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820
   Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164
   Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102
   Keightley PD, 2005, PLOS BIOL, V3, P282, DOI 10.1371/journal.pbio.0030042
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191
   Lucas JJ, 2004, MOL CANCER RES, V2, P105
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5
   Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
   Métivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377
   Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002
   Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755
   Olesen SH, 2001, CARCINOGENESIS, V22, P813, DOI 10.1093/carcin/22.5.813
   Pan KH, 2005, P NATL ACAD SCI USA, V102, P8961, DOI 10.1073/pnas.0502674102
   Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Polo SE, 2004, CANCER RES, V64, P2371, DOI 10.1158/0008-5472.CAN-03-2893
   Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017
   Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086
   Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005
   Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115
   Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083
   Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van der Hage JA, 2004, BRIT J CANCER, V90, P1543, DOI 10.1038/sj.bjc.6601741
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vavouri T, 2006, TRENDS GENET, V22, P5, DOI 10.1016/j.tig.2005.10.005
   Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903
   Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2
NR 73
TC 153
Z9 189
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD APR
PY 2008
VL 4
AR 188
DI 10.1038/msb.2008.25
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 296MU
UT WOS:000255551300008
PM 18414489
OA Green Published
DA 2025-01-12
ER

PT J
AU Lupien, M
   Eeckhoute, J
   Meyer, CA
   Wang, QB
   Zhang, Y
   Li, W
   Carroll, JS
   Liu, XS
   Brown, M
AF Lupien, Mathieu
   Eeckhoute, Jerome
   Meyer, Clifford A.
   Wang, Qianben
   Zhang, Yong
   Li, Wei
   Carroll, Jason S.
   Liu, X. Shirley
   Brown, Myles
TI FoxA1 translates epigenetic signatures into enhancer-driven
   lineage-specific transcription
SO CELL
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; CELL-CYCLE PROGRESSION; BREAST-CANCER;
   GENE-EXPRESSION; BINDING-SITES; HUMAN GENOME; CHROMATIN SIGNATURES;
   COMPACTED CHROMATIN; ANDROGEN RECEPTOR; LOCATION ANALYSIS
AB Complex organisms require tissue-specific transcriptional programs, yet little is known about how these are established. The transcription factor FoxA1 is thought to contribute to gene regulation through its ability to act as a pioneer factor binding to nucleosomal DNA. Through genome-wide positional analyses, we demonstrate that FoxA1 cell type-specific functions rely primarily on differential recruitment to chromatin predominantly at distant enhancers rather than proximal promoters. This differential recruitment leads to cell type-specific changes in chromatin structure and functional collaboration with lineage-specific transcription factors. Despite the ability of FoxA1 to bind nucleosomes, its differential binding to chromatin sites is dependent on the distribution of histone H3 lysine 4 dimethylation. Together, our results suggest that methylation of histone H3 lysine 4 is part of the epigenetic signature that defines lineage-specific FoxA1 recruitment sites in chromatin. FoxA1 translates this epigenetic signature into changes in chromatin structure thereby establishing lineage-specific transcriptional enhancers and programs.
C1 [Lupien, Mathieu; Eeckhoute, Jerome; Wang, Qianben; Carroll, Jason S.; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA.
   [Lupien, Mathieu; Eeckhoute, Jerome; Wang, Qianben; Carroll, Jason S.; Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Lupien, Mathieu; Eeckhoute, Jerome; Wang, Qianben; Carroll, Jason S.; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Meyer, Clifford A.; Zhang, Yong; Li, Wei; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Meyer, Clifford A.; Zhang, Yong; Li, Wei; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard Medical School;
   Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard T.H. Chan School of Public Health
RP Brown, M (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02115 USA.
EM myles_brown@dfci.harvard.edu
RI Brown, Myles/B-6906-2008; Eeckhoute, Jerome/AAN-8219-2021; Liu, X
   Shirley/JQI-9418-2023; Li, Wei/A-8544-2009; Wang, Qianben/E-4267-2011;
   Zhang, Yong/B-4838-2011; Lupien, Mathieu/KFB-6691-2024
OI Brown, Myles/0000-0002-8213-1658; Carroll, Jason/0000-0003-3643-0080;
   Eeckhoute, Jerome/0000-0002-7222-9264; Zhang, Yong/0000-0001-6316-2734;
   Lupien, Mathieu/0000-0003-0929-9478; Li, Wei/0000-0001-9931-5990
FU NCI NIH HHS [P01 CA080111, P50 CA089393-080012, P01 CA080111-090002, P01
   CA080111-080002, P01 CA080111-100002, P50 CA089393, P01 CA8011105, P01
   CA080111-070002, P50 CA089393-060012, P50 CA089393-070012, P01
   CA080111-060002, P01 CA080111-010002] Funding Source: Medline; NHGRI NIH
   HHS [R01 HG004069, 1R01 HG004069-02, R01 HG004069-02] Funding Source:
   Medline; NIDDK NIH HHS [R56 DK074967, R56 DK074967-01, R01
   DK074967-01A1, R01 DK074967, R01DK074967] Funding Source: Medline
CR Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606
   Bossard P, 2000, DEVELOPMENT, V127, P4915
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6
   Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020
   Geles KG, 2006, P NATL ACAD SCI USA, V103, P2594, DOI 10.1073/pnas.0510764103
   Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670
   Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322
   Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395
   Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Lin L, 2002, CANCER RES, V62, P5273
   Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717
   Lupien M, 2007, MOL ENDOCRINOL, V21, P797, DOI 10.1210/me.2006-0074
   Marr MT, 2006, GENE DEV, V20, P1458, DOI 10.1101/gad.1418806
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299
   Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292
   Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129
   Schwartz B, 2007, ONCOGENE, V26, P4049, DOI 10.1038/sj.onc.1210193
   Sekiya T, 2007, MOL CELL, V28, P291, DOI 10.1016/j.molcel.2007.10.002
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094
   Son CG, 2005, GENOME RES, V15, P443, DOI 10.1101/gr.3124505
   Spear BT, 2006, CELL MOL LIFE SCI, V63, P2922, DOI 10.1007/s00018-006-6258-5
   Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200
   Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Workman CT, 2005, NUCLEIC ACIDS RES, V33, pW389, DOI 10.1093/nar/gki439
NR 53
TC 759
Z9 947
U1 1
U2 50
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAR 21
PY 2008
VL 132
IS 6
BP 958
EP 970
DI 10.1016/j.cell.2008.01.018
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 278GR
UT WOS:000254273600015
PM 18358809
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Suzuki, H
   Toyota, M
   Caraway, H
   Gabrielson, E
   Ohmura, T
   Fujikane, T
   Nishikawa, N
   Sogabe, Y
   Nojima, M
   Sonoda, T
   Mori, M
   Hirata, K
   Imai, K
   Shinomura, Y
   Baylin, SB
   Tokino, T
AF Suzuki, H.
   Toyota, M.
   Caraway, H.
   Gabrielson, E.
   Ohmura, T.
   Fujikane, T.
   Nishikawa, N.
   Sogabe, Y.
   Nojima, M.
   Sonoda, T.
   Mori, M.
   Hirata, K.
   Imai, K.
   Shinomura, Y.
   Baylin, S. B.
   Tokino, T.
TI Frequent epigenetic inactivation of Wnt antagonist genes in breast
   cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE Wnt; SFRP; DKK1; methylation; breast cancer
ID HUMAN COLORECTAL-CANCER; CHROMOSOME ARM 8P; BETA-CATENIN; DIFFERENTIAL
   EXPRESSION; SFRP1 EXPRESSION; PROTEIN-1 SFRP1; PROGRESSION; PATHWAY;
   TUMORS; HYPERMETHYLATION
AB Although mutation of APC or CTNNB1 ( beta- catenin) is rare in breast cancer, activation of Wnt signalling is nonetheless thought to play an important role in breast tumorigenesis, and epigenetic silencing of Wnt antagonist genes, including the secreted frizzled- related protein ( SFRP) and Dickkopf ( DKK) families, has been observed in various tumours. In breast cancer, frequent methylation and silencing of SFRP1 was recently documented; however, altered expression of other Wnt antagonist genes is largely unknown. In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines ( SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours ( SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%). We also observed methylation of DKK1, although less frequently, in cell lines ( 3 out of 11, 27%) and primary tumours ( 15 out of 78, 19%). Breast cancer cell lines express various Wnt ligands, and overexpression of SFRPs inhibited cancer cell growth. In addition, overexpression of a beta- catenin mutant and depletion of SFRP1 using small interfering RNA synergistically upregulated transcriptional activity of T- cell factor/ lymphocyte enhancer factor. Our results confirm the frequent methylation and silencing of Wnt antagonist genes in breast cancer, and suggest that their loss of function contributes to activation of Wnt signalling in breast carcinogenesis.
C1 [Suzuki, H.; Toyota, M.; Shinomura, Y.] Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan.
   [Toyota, M.; Sogabe, Y.] Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido 0608543, Japan.
   [Toyota, M.] Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama, Japan.
   [Caraway, H.; Baylin, S. B.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD USA.
   [Gabrielson, E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Ohmura, T.; Fujikane, T.; Nishikawa, N.; Hirata, K.] Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido, Japan.
   [Nojima, M.; Sonoda, T.; Mori, M.] Sapporo Med Univ, Dept Publ Hlth, Sapporo, Hokkaido, Japan.
C3 Sapporo Medical University; Sapporo Medical University; Japan Science &
   Technology Agency (JST); Johns Hopkins University; Johns Hopkins
   Medicine; Johns Hopkins University; Sapporo Medical University; Sapporo
   Medical University
RP Toyota, M (通讯作者)，Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, S1,W16, Sapporo, Hokkaido 0608543, Japan.
EM mtoyota@sapmed.ac.jp
RI Tokino, Takashi/AAI-9887-2021; Nojima, Masanori/ABE-2237-2020
OI Nojima, Masanori/0000-0002-8788-2522
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232
   Dale TC, 1996, CANCER RES, V56, P4320
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   Polakis P, 2000, GENE DEV, V14, P1837
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
NR 28
TC 207
Z9 251
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAR 18
PY 2008
VL 98
IS 6
BP 1147
EP 1156
DI 10.1038/sj.bjc.6604259
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 281WI
UT WOS:000254529200019
PM 18283316
OA hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Cheng, ASL
   Culhane, AC
   Chan, MWY
   Venkataranm, CR
   Ehrich, M
   Nasir, A
   Rodriguez, BAT
   Liu, J
   Yan, PS
   Quackenbush, J
   Nephew, KP
   Yeatman, TJ
   Huang, THM
AF Cheng, Alfred S. L.
   Culhane, Aedin C.
   Chan, Michael W. Y.
   Venkataranm, Chinnambally R.
   Ehrich, Mathias
   Nasir, Aejaz
   Rodriguez, Benjamin A. T.
   Liu, Joseph
   Yan, Pearlly S.
   Quackenbush, John
   Nephew, Kenneth P.
   Yeatman, Timothy J.
   Huang, Tim H-M.
TI Epithelial progeny of estrogen-exposed breast progenitor cells display a
   cancer-like methylome
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR ACTIVITY; DNA METHYLATION; RECEPTOR-ALPHA; STEM;
   HYPERMETHYLATION; CARCINOGENESIS; MECHANISMS; REVEALS; RUNX3
AB Estrogen imprinting is used to describe a phenomenon in which early developmental exposure to endocrine disruptors increases breast cancer risk later in adult life. We propose that long-lived, self-regenerating stem and progenitor cells are more susceptible to the exposure injury than terminally differentiated epithelial cells in the breast duct. Mammospheres, containing enriched breast progenitors, were used as an exposure system to simulate this imprinting phenomenon in vitro. Using MeDIP-chip, a methylation microarray screening method, we found that 0.5% (120 loci) of human CpG islands were hypermethylated in epithelial cells derived from estrogen-exposed progenitors compared with the non-estrogen-exposed control cells. This epigenetic event may lead to progressive silencing of tumor suppressor genes, including RUNX3, in these epithelial cells, which also occurred in primary breast tumors. Furthermore, normal tissue in close proximity to the tumor site also displayed RUNX3 hypermethylation, suggesting that this aberrant event occurs in early breast carcinogenesis. The high prevalence of estrogen-induced epigenetic changes in primary tumors and the surrounding histologically normal tissues provides the first empirical link between estrogen injury of breast stem/progenitor cells and carcinogenesis. This finding also offers a mechanistic explanation as to why a tumor suppressor gene, such as RUNX3, can be heritably silenced by epigenetic mechanisms in breast cancer.
C1 [Cheng, Alfred S. L.; Chan, Michael W. Y.; Rodriguez, Benjamin A. T.; Liu, Joseph; Yan, Pearlly S.; Huang, Tim H-M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.
   [Culhane, Aedin C.; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Comp Biol, Boston, MA 02115 USA.
   [Venkataranm, Chinnambally R.; Yeatman, Timothy J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL USA.
   [Ehrich, Mathias] Sequenom Inc, San Diego, CA USA.
   [Cheng, Alfred S. L.] Indiana Univ, Sch Med, Bloomington, IN USA.
   [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China.
C3 James Cancer Hospital & Solove Research Institute; University System of
   Ohio; Ohio State University; Harvard University; Dana-Farber Cancer
   Institute; H Lee Moffitt Cancer Center & Research Institute; Sequenom;
   Indiana University System; Indiana University Bloomington; Chinese
   University of Hong Kong
RP Huang, THM (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Yeatman, Timothy/LJK-6730-2024; Quackenbush, John/JJD-1148-2023;
   Culhane, Aedin/AAG-8490-2019; Yan, Pearlly/E-4339-2011; Cheng,
   Alfred/C-3327-2014; Chan, Michael/F-9615-2018
OI Quackenbush, John/0000-0002-2702-5879; Cheng,
   Alfred/0000-0003-2345-6951; Chan, Michael/0000-0003-0314-2437; Chan,
   Michael/0000-0003-1431-322X; Culhane, Aedin/0000-0002-1395-9734
FU NCI NIH HHS [R01 CA098522, R01 CA069065, P30 CA016058, U54 CA11300, P30
   CA16058, U19 CA148065] Funding Source: Medline; NIEHS NIH HHS [U01
   ES015986] Funding Source: Medline
CR Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bolstad BM, 2005, STAT BIOL HEALTH, P33
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Feinberg AP, 2001, NAT GENET, V27, P9, DOI 10.1038/83825
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Fukamachi H, 2006, DEV GROWTH DIFFER, V48, P1, DOI 10.1111/j.1440-169x.2006.00832.x
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164
   O'Neill LP, 2006, NAT GENET, V38, P835, DOI 10.1038/ng1820
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com
   Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008
   Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515
   Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
NR 30
TC 111
Z9 126
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2008
VL 68
IS 6
BP 1786
EP 1796
DI 10.1158/0008-5472.CAN-07-5547
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 274TO
UT WOS:000254024400023
PM 18339859
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Pfister, S
   Rea, S
   Taipale, M
   Mendrzyk, F
   Straub, B
   Ittrich, C
   Thuerigen, O
   Sinn, HP
   Akhtar, A
   Lichter, P
AF Pfister, Stefan
   Rea, Stephen
   Taipale, Mikko
   Mendrzyk, Frank
   Straub, Beate
   Ittrich, Carina
   Thuerigen, Olaf
   Sinn, Hans Peter
   Akhtar, Asifa
   Lichter, Peter
TI The histone acetyltransferase hMOF is frequently downregulated in
   primary breast carcinoma and medulloblastoma and constitutes a biomarker
   for clinical outcome in medulloblastoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE medulloblastoma; hMOF; MYST1; epigenetic; histone acetylation
ID ACETYLATION; EXPRESSION; H4; GEMCITABINE; EPIRUBICIN; DROSOPHILA;
   DOCETAXEL; CHROMATIN; CANCER
AB Loss of H4 lysine 16 (H4K16) acetylation was shown to be a common feature in human cancer. However, it remained unclear which enzyme is responsible for the loss of this modification. Having recently identified the histone acetyltransferase human, MOF (hMOF) to be required for bulk H4K16 acetylation, here we examined the involvement of hMOF expression and H4K16 acetylation in breast cancer and medulloblastoma. Analysis of a recent mRNA expression profiling study in breast cancer (n = 100 cases) and an array-CGH screen in medulloblastomas (n = 102 cases), revealed downregulation in 40% and genomic loss in 11% of cases, respectively. We investigated hMOF protein expression as well as H4K16 acetylation in large series of primary breast carcinomas (n = 298) and primary medulloblastomas (n = 180) by immunohistochemistry. In contrast to nontransformed control tissues, significant fractions of both primary breast carcinomas and medulloblastomas showed markedly reduced hMOF mRNA and protein expression. In addition, hMOF protein expression tightly correlated with acetylation of H4K16 in all tested samples. For medulloblastoma, downregulation of hMOF protein expression was associated with lower survival rates identifying hMOF as an independent prognostic marker for clinical outcome in univariate as well as multivariate analyses. (C) 2007 Wiley-Liss, Inc.
C1 [Pfister, Stefan; Mendrzyk, Frank; Thuerigen, Olaf; Lichter, Peter] German Canc Res Ctr, Dept Mol Genet, D-69120 Heidelberg, Germany.
   [Pfister, Stefan] Heidelberg Univ, Dept Pediat Oncol, Heidelberg, Germany.
   [Rea, Stephen; Taipale, Mikko; Akhtar, Asifa] European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany.
   [Straub, Beate; Sinn, Hans Peter] Heidelberg Univ, Dept Pathol, D-6900 Heidelberg, Germany.
   [Ittrich, Carina] German Canc Res Ctr, Div Biostat, D-69120 Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; European Molecular Biology Laboratory
   (EMBL); Ruprecht Karls University Heidelberg; Helmholtz Association;
   German Cancer Research Center (DKFZ)
RP Lichter, P (通讯作者)，German Canc Res Ctr, Dept Mol Genet, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
EM asifa.akhtar@embl.de; m.macleod@dkfz.de
RI Lichter, Peter/I-3483-2013; Pfister, Stefan/F-6860-2013; Sinn,
   Hans-Peter/C-5661-2008
OI Pfister, Stefan/0000-0002-5447-5322; Straub, Beate/0000-0002-4857-1561;
   Rea, Stephen/0000-0001-5797-5157; Sinn, Hans-Peter/0000-0003-2836-6699;
   Taipale, Mikko/0000-0003-3811-1761
CR [Anonymous], R LANG ENV STAT COMP
   Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3
   Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Freier K, 2003, CANCER RES, V63, P1179
   Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536
   Giangaspero F, 2006, ACTA NEUROPATHOL, V112, P5, DOI 10.1007/s00401-006-0064-x
   Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005
   Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007
   Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589
   MUNKS RJL, 1991, FEBS LETT, V284, P245, DOI 10.1016/0014-5793(91)80695-Y
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Schneeweiss A, 2005, ANTI-CANCER DRUG, V16, P1023, DOI 10.1097/01.cad.0000176508.73090.fb
   Schneeweiss Andreas, 2004, Oncology (Williston Park), V18, P27
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005
   Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019
   Van Holde K. E., 1988, Chromatin
NR 26
TC 127
Z9 152
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2008
VL 122
IS 6
BP 1207
EP 1213
DI 10.1002/ijc.23283
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 264QE
UT WOS:000253302800002
PM 18058815
DA 2025-01-12
ER

PT J
AU Han, HJ
   Russo, J
   Kohwi, Y
   Kohwi-Shigematsu, T
AF Han, Hye-Jung
   Russo, Jose
   Kohwi, Yoshinori
   Kohwi-Shigematsu, Terumi
TI SATB1 reprogrammes gene expression to promote breast tumour growth and
   metastasis
SO NATURE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITIONS; CANCER METASTASIS;
   SIGNAL-TRANSDUCTION; BINDING PROTEIN; IN-VIVO; CHROMATIN; CELLS;
   PROGRESSION; ARCHITECTURE; APOPTOSIS
AB Mechanisms underlying global changes in gene expression during tumour progression are poorly understood. SATB1 is a genome organizer that tethers multiple genomic loci and recruits chromatin- remodelling enzymes to regulate chromatin structure and gene expression. Here we show that SATB1 is expressed by aggressive breast cancer cells and its expression level has high prognostic significance ( P < 0.0001), independent of lymph- node status. RNA- interference- mediated knockdown of SATB1 in highly aggressive ( MDA- MB- 231) cancer cells altered the expression of >1,000 genes, reversing tumorigenesis by restoring breast- like acinar polarity and inhibiting tumour growth and metastasis in vivo. Conversely, ectopic SATB1 expression in non- aggressive ( SKBR3) cells led to gene expression patterns consistent with aggressive- tumour phenotypes, acquiring metastatic activity in vivo. SATB1 delineates specific epigenetic modifications at target gene loci, directly upregulating metastasis- associated genes while downregulating tumour- suppressor genes. SATB1 reprogrammes chromatin organization and the transcription profiles of breast tumours to promote growth and metastasis; this is a new mechanism of tumour progression.
C1 [Han, Hye-Jung; Kohwi, Yoshinori; Kohwi-Shigematsu, Terumi] Univ Calif Berkeley, Div Life Sci, Lawrence Berkeley Lab, Berkeley, CA 94720 USA.
   [Russo, Jose] Fox Chase Canc Ctr, Breast Canc Res Lab, Philadelphia, PA 19111 USA.
C3 University of California System; University of California Berkeley;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; Fox Chase Cancer Center
RP Kohwi-Shigematsu, T (通讯作者)，Univ Calif Berkeley, Div Life Sci, Lawrence Berkeley Lab, Berkeley, CA 94720 USA.
EM YKohwi@lbl.gov; Terumiks@lbl.gov
CR Alvarez JD, 2000, GENE DEV, V14, P521
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545
   Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007
   Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913
   Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146
   Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C
   Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6
   Drobic B, 2006, EXP SUPPL, V96, P25
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Galande S, 2000, J CELL BIOCHEM, P36
   Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613
   Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006
   Ince TA, 2002, CANCER CELL, V1, P15, DOI 10.1016/S1535-6108(02)00023-5
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323
   KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005
   Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Parker BS, 2003, CANCER BIOL THER, V2, P14
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001
   Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273
   Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2
   Severgnini M, 2006, ANAL BIOCHEM, V353, P43, DOI 10.1016/j.ab.2006.03.023
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967
   Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tokés AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983
   Underwood JM, 2006, J CELL PHYSIOL, V208, P141, DOI 10.1002/jcp.20639
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084
NR 50
TC 436
Z9 519
U1 3
U2 39
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 13
PY 2008
VL 452
IS 7184
BP 187
EP 193
DI 10.1038/nature06781
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 273JG
UT WOS:000253925600034
PM 18337816
DA 2025-01-12
ER

PT J
AU Cooper, WN
   Dickinson, RE
   Dallol, A
   Grigorieva, EV
   Pavlova, T
   Hesson, LB
   Bieche, I
   Broggini, M
   Maher, ER
   Zabarovsky, ER
   Clark, GJ
   Latif, F
AF Cooper, W. N.
   Dickinson, R. E.
   Dallol, A.
   Grigorieva, E. V.
   Pavlova, T. V.
   Hesson, L. B.
   Bieche, I.
   Broggini, M.
   Maher, E. R.
   Zabarovsky, E. R.
   Clark, G. J.
   Latif, F.
TI Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in
   breast and lung cancer
SO ONCOGENE
LA English
DT Article
DE RASSF2; breast cancer; lung cancer; epigenetic inactivation; nuclear
   localization signal
ID ISLAND PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; CPG ISLAND; K-RAS;
   GENE; INACTIVATION; 3P21.3; REGION; IDENTIFICATION; OVARIAN
AB RASSF2 is a recently identified member of a class of novel tumour suppressor genes, all containing a ras-association domain. RASSF2 resides at 20p13, a region frequently lost in human cancers. In this report we investigated methylation status of the RASSF2 promoter CpG island in a series of breast, ovarian and non-small cell lung cancers (NSCLC). RASSF2 was frequently methylated in breast tumour cell lines (65%, 13/20) and in primary breast tumours (38%, 15/40). RASSF2 expression could be switched back on in methylated breast tumour cell lines after treatment with 5'-aza-2'deoxycytidine. RASSF2 was also frequently methylated in NSCLC tumours (44%, (22/50). The small number of corresponding normal breast and lung tissue DNA samples analysed were unmethylated. We also did not detect RASSF2 methylation in ovarian tumours (0/17). Furthermore no mutations were found in the coding region of RASSF2 in these ovarian tumours. We identified a highly conserved putative bipartite nuclear localization signal (NLS) and demonstrated that endogenous RASSF2 localized to the nucleus. Mutation of the putative NLS abolished the nuclear localization. RASSF2 suppressed breast tumour cell growth in vitro and in vivo, while the ability of NLS-mutant RASSF2 to suppress growth was much diminished. Hence we demonstrate that RASSF2 has a functional NLS that is important for its tumour suppressor gene function. Our data from this and a previous report indicate that RASSF2 is frequently methylated in colorectal, breast and NSCLC tumours. We have identified RASSF2 as a novel methylation marker for multiple malignancies and it has the potential to be developed into a valuable marker for screening several cancers in parallel using promoter hypermethylation profiles.
C1 [Cooper, W. N.; Dickinson, R. E.; Dallol, A.; Hesson, L. B.; Maher, E. R.; Latif, F.] Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
   [Grigorieva, E. V.; Pavlova, T. V.; Zabarovsky, E. R.] Karolinska Inst, MTC, Stockholm, Sweden.
   [Grigorieva, E. V.] Inst Mol Biol & Biophys SD RAMS, Novosibirsk, Russia.
   [Pavlova, T. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia.
   [Bieche, I.] Ctr Rene Huguenin, INSERM, Lab Oncogenet E0017, St Cloud, France.
   [Broggini, M.] Ist Ric Farmacol Mario Negri, Mol Pharmacol Lab, Milan, Italy.
   [Clark, G. J.] Univ Louisville, Dept Med, JG Brown Canc Ctr, Mol Targets Grp, Louisville, KY 40292 USA.
C3 University of Birmingham; Karolinska Institutet; Russian Academy of
   Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of
   Molecular Biology, RAS; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Rene Huguenin Hospital; Istituto di Ricerche
   Farmacologiche Mario Negri IRCCS; University of Louisville
RP Latif, F (通讯作者)，Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.
EM f.latif@bham.ac.uk
RI Hesson, Luke/HDM-0311-2022; broggini, massimo/AAA-6460-2020; Zabarovsky,
   Eugene/A-6645-2010; Cooper, Wendy/JZE-5930-2024; Dallol,
   Ashraf/H-8661-2012; Grigorieva, Elvira/A-4937-2010; Bieche,
   Ivan/O-7399-2017; MAHER, EAMONN/A-9507-2008
OI Dallol, Ashraf/0000-0002-8803-228X; Grigorieva,
   Elvira/0000-0003-2457-9179; Pavlova, Tatiana/0000-0002-2857-5696;
   Bieche, Ivan/0000-0002-2430-5429; BROGGINI, MASSIMO/0000-0002-8138-9358;
   MAHER, EAMONN/0000-0002-6226-6918
FU Cancer Research UK [A7205] Funding Source: Medline; Breast Cancer Now
   [2005NOV13] Funding Source: Medline
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051
   ALLEN NP, 2007, ONCOGENE
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111
   Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065
   Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055
   Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407
   Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191
   Hesson L.B., 2007, ONCOGENE
   Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566
   Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914
   Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101
   Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681
   Lerman MI, 2000, CANCER RES, V60, P6116
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Park HW, 2007, INT J CANCER, V120, P7, DOI 10.1002/ijc.22276
   Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283
   ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T
   Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1
   Schubbert S, 2007, CURR OPIN GENET DEV, V17, P15, DOI 10.1016/j.gde.2006.12.004
   Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2
   Tommasi S, 2005, CANCER RES, V65, P92
   Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365
   van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005
   Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185
NR 31
TC 38
Z9 45
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR 13
PY 2008
VL 27
IS 12
BP 1805
EP 1811
DI 10.1038/sj.onc.1210805
PG 7
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 273WF
UT WOS:000253962100017
PM 17891178
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ai, LB
   Kim, WJ
   Demircan, B
   Dyer, LM
   Bray, KJ
   Skehan, RR
   Massoll, NA
   Brown, KD
AF Ai, Lingbao
   Kim, Wan-Ju
   Demircan, Berna
   Dyer, Lisa M.
   Bray, Kevin J.
   Skehan, Ryan R.
   Massoll, Nicole A.
   Brown, Kevin D.
TI The transglutaminase 2 gene (<i>TGM2</i>), a potential molecular marker
   for chemotherapeutic drug sensitivity, is epigenetically silenced in
   breast cancer
SO CARCINOGENESIS
LA English
DT Article
ID GROWTH-FACTOR-BETA; FACTOR-KAPPA-B; TISSUE TRANSGLUTAMINASE;
   TUMOR-GROWTH; DNA METHYLATION; CROSS-LINKING; CPG ISLANDS; CELL-DEATH;
   EXPRESSION; APOPTOSIS
AB Tissue transglutaminase (TG2) is a ubiquitously expressed enzyme capable of catalyzing protein cross-links. TG2-dependent cross-links are important in extracellular matrix integrity and it has been proposed that this TG2 activity establishes a barrier to tumor spread. Furthermore, TG2 controls sensitivity to the chemotherapeutic drug doxorubicin. Both doxorubicin sensitivity and TG2 expression are highly variable in cultured human breast cancer cell lines and inspection of the human gene (termed TGM2) determined that a canonical CpG island exists within its 5' flank. These features, when combined with its potential tumor suppressor activity, make TG2 an attractive candidate for epigenetic silencing. Consistent with this, we observed that culturing breast tumor cells with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-azadC) resulted in a robust increase in TG2 expression. Analysis of DNA harvested from cultured lines and primary breast tumor samples indicated that TGM2 often displays aberrant hypermethylation and that there is a statistically significant correlation between gene methylation and reduced expression. Finally, we observed that doxorubicin-resistant MCF-7/ADR cells do not show TGM2 silencing but that doxorubicin-sensitive MCF-7 cells do and that culturing MCF-7 cells on 5-azadC and subsequently restoring TG2 expression reduced sensitivity to doxorubicin. This work indicates that the TGM2 gene is a target for epigenetic silencing in breast cancer and suggests that this aberrant molecular event is a potential marker for chemotherapeutic drug sensitivity.
C1 [Ai, Lingbao; Kim, Wan-Ju; Demircan, Berna; Dyer, Lisa M.; Bray, Kevin J.; Skehan, Ryan R.; Brown, Kevin D.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Ai, Lingbao; Kim, Wan-Ju; Demircan, Berna; Dyer, Lisa M.; Bray, Kevin J.; Skehan, Ryan R.; Brown, Kevin D.] Univ Florida, Coll Med, Shands Canc Ctr, Program Canc Genet Epigenet & Tumor Virol, Gainesville, FL 32610 USA.
   [Massoll, Nicole A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida
RP Brown, KD (通讯作者)，Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
EM kdbrown1@ufl.edu
OI Ai, Lingbao/0009-0004-8907-8564
FU NCI NIH HHS [R01 CA102289, R21 CA102220] Funding Source: Medline
CR Adamson AW, 2005, MOL BIOL CELL, V16, P1513, DOI 10.1091/mbc.e04-02-0089
   Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200
   Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Fésüs L, 2005, FEBS LETT, V579, P3297, DOI 10.1016/j.febslet.2005.03.063
   Fok JY, 2006, MOL CANCER THER, V5, P1493, DOI 10.1158/1535-7163.MCT-06-0083
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   GENTILE V, 1994, GENOMICS, V20, P295, DOI 10.1006/geno.1994.1170
   Haroon ZA, 1999, LAB INVEST, V79, P1679
   Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HORTOBAGYI GN, 1995, SEMIN ONCOL, V22, P101
   Huang S, 2005, CANCER CELL, V8, P175, DOI 10.1016/j.ccr.2005.08.009
   Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2
   JOHNSON TS, 1994, ONCOGENE, V9, P2935
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones RA, 2006, CELL DEATH DIFFER, V13, P1442, DOI 10.1038/sj.cdd.4401816
   Kim DS, 2006, CANCER RES, V66, P10936, DOI 10.1158/0008-5472.CAN-06-1521
   Kim WJ, 2005, TOXICOL APPL PHARM, V202, P84, DOI 10.1016/j.taap.2004.06.009
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602
   Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692
   Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457
   MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316
   Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200
   Perez EA, 2001, CANCER INVEST, V19, P155, DOI 10.1081/CNV-100000150
   Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200
   Telci D, 2006, FRONT BIOSCI-LANDMRK, V11, P867, DOI 10.2741/1843
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001
   Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322
   Xu L, 2006, P NATL ACAD SCI USA, V103, P9023, DOI 10.1073/pnas.0602681103
   Yamaguchi H, 2006, MOL CELL BIOL, V26, P569, DOI 10.1128/MCB.26.2.569-579.2006
   Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863
NR 45
TC 82
Z9 89
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2008
VL 29
IS 3
BP 510
EP 518
DI 10.1093/carcin/bgm280
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 274NP
UT WOS:000254008300007
PM 18174247
OA Bronze
DA 2025-01-12
ER

PT J
AU Herrera, LA
   Prada, D
   Andonegui, MA
   Dueñas-González, A
AF Herrera, Luis A.
   Prada, Diddier
   Andonegui, Marco A.
   Duenas-Gonzalez, Alfonso
TI The epigenetic origin of aneuploidy
SO CURRENT GENOMICS
LA English
DT Article
DE aneuploidy; cancer; epigenetics; chromosome instability
ID SPINDLE ASSEMBLY CHECKPOINT; SISTER-CHROMATID EXCHANGES; ICF SYNDROME
   CELLS; MALE GERM-CELLS; CHROMOSOMAL INSTABILITY; DNA METHYLATION;
   MAMMALIAN-CELLS; TELOMERE LENGTH; BREAST-CANCER; HISTONE
   METHYLTRANSFERASES
AB Theodore Boveri, eminent German pathologist, observed aneuploidy in cancer cells more than a century ago and suggested that cancer cells derived from a single progenitor cell that acquires the potential for uncontrolled continuous proliferation. Currently, it is well known that aneuploidy is observed in virtually all cancers. Gain and loss of chromosomal material in neoplastic cells is considered to be a process of diversification that leads to survival of the fittest clones. According to Darwin's theory of evolution, the environment determines the grounds upon which selection takes place and the genetic characteristics necessary for better adaptation. This concept can be applied to the carcinogenesis process, connecting the ability of cancer cells to adapt to different environments and to resist chemotherapy, genomic instability being the driving force of tumor development and progression. What causes this genome instability? Mutations have been recognized for a long time as the major source of genome instability in cancer cells. Nevertheless, an alternative hypothesis suggests that aneuploidy is a primary cause of genome instability rather than solely a simple consequence of the malignant transformation process. Whether genome instability results from mutations or from aneuploidy is not a matter of discussion in this review. It is most likely both phenomena are intimately related; however, we will focus on the mechanisms involved in aneuploidy formation and more specifically on the epigenetic origin of aneuploid cells. Epigenetic inheritance is defined as cellular information - other than the DNA sequence itself - that is heritable during cell division. DNA methylation and histone modifications comprise two of the main epigenetic modifications that are important for many physiological and pathological conditions, including cancer. Aberrant DNA methylation is the most common molecular cancer- cell lesion, even more frequent than gene mutations; tumor suppressor gene silencing by CpG island promoter hypermethylation is perhaps the most frequent epigenetic modification in cancer cells. Epigenetic characteristics of cells may be modified by several factors including environmental exposure, certain nutrient deficiencies, radiation, etc. Some of these alterations have been correlated with the formation of aneuploid cells in vivo. A growing body of evidence suggests that aneuploidy is produced and caused by chromosomal instability. We propose and support in this manuscript that not only genetics but also epigenetics, contribute in a major fashion to aneuploid cell formation.
C1 [Herrera, Luis A.; Prada, Diddier; Andonegui, Marco A.; Duenas-Gonzalez, Alfonso] Univ Nacl Autonoma Mexico, Inst Invest Biomed, UIBC, Inst Nacl Cancerol, Mexico City 04510, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Instituto Nacional de
   Cancerologia (INCAN)
RP Herrera, LA (通讯作者)，Univ Nacl Autonoma Mexico, Inst Invest Biomed, UIBC, Inst Nacl Cancerol, POB 70-228,Ciudad Univ, Mexico City 04510, DF, Mexico.
EM herreram@biomedicas.unam.mx
RI Herrera, Luis/GOV-3311-2022
CR Abramson-Zetterberg L, 2006, MUTAT RES-GEN TOX EN, V603, P33, DOI 10.1016/j.mrgentox.2005.11.009
   ADAMS RLP, 1995, BIOESSAYS, V17, P139, DOI 10.1002/bies.950170209
   Albanesi T, 1999, MUTAT RES-FUND MOL M, V429, P239, DOI 10.1016/S0027-5107(99)00112-8
   Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0
   Bailey SM, 2006, NUCLEIC ACIDS RES, V34, P2408, DOI 10.1093/nar/gkl303
   Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X
   Beetstra S, 2006, CARCINOGENESIS, V27, P517, DOI 10.1093/carcin/bgi226
   Bensaada M, 1998, CANCER GENET CYTOGEN, V103, P101, DOI 10.1016/S0165-4608(97)00409-3
   BIGGART NW, 1986, MUTAT RES, V175, P209, DOI 10.1016/0165-7992(86)90056-4
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   Bouilly K, 2006, AQUAT TOXICOL, V78, P149, DOI 10.1016/j.aquatox.2006.02.028
   Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886
   Brenner C, 2006, CURR TOP MICROBIOL, V301, P45
   Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030
   Chen H, 2001, TOXICOL APPL PHARM, V175, P260, DOI 10.1006/taap.2001.9253
   Chen HB, 2006, MOL CELL BIOL, V26, P3728, DOI 10.1128/MCB.26.10.3728-3737.2006
   Costa M, 2005, MUTAT RES-FUND MOL M, V592, P79, DOI 10.1016/j.mrfmmm.2005.06.008
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772
   DAS KC, 1986, ACTA HAEMATOL-BASEL, V76, P146, DOI 10.1159/000206040
   DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518
   der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152
   Doak SH, 2004, MUTAT RES-FUND MOL M, V547, P133, DOI 10.1016/j.mrfmmm.2003.12.009
   Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8
   Fauth E, 1998, MUTAGENESIS, V13, P235, DOI 10.1093/mutage/13.3.235
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Fenech M, 1998, CARCINOGENESIS, V19, P1163, DOI 10.1093/carcin/19.7.1163
   Fenech M, 2006, MUTAT RES-FUND MOL M, V600, P58, DOI 10.1016/j.mrfmmm.2006.05.028
   Fouladi B, 2000, NEOPLASIA, V2, P540, DOI 10.1038/sj.neo.7900107
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   García-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278
   García-Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011
   Gisselsson D, 2005, CHROMOSOMA, V114, P118, DOI 10.1007/s00412-005-0343-7
   Gollin SM, 2005, SEMIN CANCER BIOL, V15, P33, DOI 10.1016/j.semcancer.2004.09.004
   Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386
   Güerci A, 2000, MUTAT RES-GEN TOX EN, V469, P35, DOI 10.1016/S1383-5718(00)00057-7
   GUTTENBACH M, 1994, EXP CELL RES, V211, P127, DOI 10.1006/excr.1994.1068
   Habib M, 1999, EXP CELL RES, V249, P46, DOI 10.1006/excr.1999.4434
   Hassan KMA, 2001, HUM GENET, V109, P452
   Hata K, 2006, MOL REPROD DEV, V73, P116, DOI 10.1002/mrd.20387
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   KOKALJVOKAC N, 1993, CYTOGENET CELL GENET, V63, P11, DOI 10.1159/000133492
   Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597
   LAVIA P, 1985, MUTAT RES, V149, P463, DOI 10.1016/0027-5107(85)90164-2
   LEE YW, 1995, MOL CELL BIOL, V15, P2547
   Lee YW, 1998, MUTAT RES-GEN TOX EN, V415, P213, DOI 10.1016/S1383-5718(98)00078-3
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   LEVINE DS, 1991, GASTROENTEROLOGY, V101, P1198, DOI 10.1016/0016-5085(91)90068-V
   Loumbourdis NS, 2005, ARCH TOXICOL, V79, P434, DOI 10.1007/s00204-005-0652-x
   Ma YH, 2005, J CELL SCI, V118, P1607, DOI 10.1242/jcs.02291
   Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03
   Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000
   Minhas KM, 2003, INT J CANCER, V107, P46, DOI 10.1002/ijc.11341
   Miniou P, 1997, CYTOGENET CELL GENET, V77, P308, DOI 10.1159/000134605
   Nakagawa T, 2005, J UROLOGY, V173, P243, DOI 10.1097/01.ju.0000141577.98902.49
   Ohshima S, 2003, MUTAGENESIS, V18, P133, DOI 10.1093/mutage/18.2.133
   Pantic M, 2006, ONCOGENE, V25, P4413, DOI 10.1038/sj.onc.1209486
   PERTICONE P, 1990, MUTAT RES, V245, P211, DOI 10.1016/0165-7992(90)90052-L
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Pihan GA, 2003, CANCER RES, V63, P1398
   Poirier LA, 2002, ENVIRON HEALTH PERSP, V110, P793, DOI 10.1289/ehp.02110s5793
   Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2
   Reichard JF, 2007, BIOCHEM BIOPH RES CO, V352, P188, DOI 10.1016/j.bbrc.2006.11.001
   REID BJ, 1987, GASTROENTEROLOGY, V93, P1
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rodriguez MJ, 2001, MUTAGENESIS, V16, P109, DOI 10.1093/mutage/16.2.109
   Schübeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000
   Sciandrello G, 2004, CARCINOGENESIS, V25, P413, DOI 10.1093/carcin/bgh029
   Seoane AI, 2002, ENVIRON MOL MUTAGEN, V40, P200, DOI 10.1002/em.10110
   Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39
   Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276
   Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272
   Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4
   Titenko-Holland N, 1998, MUTAT RES-GEN TOX EN, V417, P101, DOI 10.1016/S1383-5718(98)00104-1
   Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395
   Von Hoff D D, 1976, Ann Intern Med, V85, P237
   Wang ZH, 2004, CANCER RES, V64, P2998, DOI 10.1158/0008-5472.CAN-04-0587
   Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1
   Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636
   Wu CW, 2004, WORLD J GASTROENTERO, V10, P3240, DOI 10.3748/wjg.v10.i22.3240
   Xie ZH, 2006, HUM MOL GENET, V15, P1375, DOI 10.1093/hmg/ddl059
   Yan Y, 2003, TOXICOL APPL PHARM, V190, P272, DOI 10.1016/S0041-008X(03)00169-8
   Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903
   Zhang RG, 2007, MOL CELL BIOL, V27, P949, DOI 10.1128/MCB.01639-06
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005
NR 95
TC 55
Z9 61
U1 1
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PD MAR
PY 2008
VL 9
IS 1
BP 43
EP 50
DI 10.2174/138920208783884883
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 283RS
UT WOS:000254654800006
PM 19424483
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Choi, AO
   Brown, SE
   Szyf, M
   Maysinger, D
AF Choi, Angela O.
   Brown, Shelley E.
   Szyf, Moshe
   Maysinger, Dusica
TI Quantum dot-induced epigenetic and genotoxic changes in human breast
   cancer cells
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE nanoepigenetics; nanoparticles; p53; cell death; trichostatin A;
   pifithrin-alpha
ID OXIDATIVE STRESS; APOPTOSIS; DEATH; P53; MITOCHONDRIA; CYTOTOXICITY;
   TOXICITY; MOLECULE; CADMIUM; DAMAGE
AB The staggering array of nanotechnological products, found in our environment and those applicable in medicine, has stimulated a growing interest in examining their long-term impact on genetic and epigenetic processes. We examined here the epigenomic and genotoxic response to cadmium telluride quantum dots (QDs) in human breast carcinoma cells. QD treatment induced global hypoacetylation implying a global epigenomic response. The ubiquitous responder to genotoxic stress, p53, was activated by QD challenge resulting in translocation of p53, with subsequent upregulation of downstream targets Puma and Noxa. Consequential decrease in cell viability was in part prevented by the p53 inhibitor pifithrin-alpha, suggesting that p53 translocation contributes to QD-induced cytotoxicity. These findings suggest three levels of nanoparticle-induced cellular changes: non-genomic, genomic and epigenetic. Epigenetic changes may have long-term effects on gene expression programming long after the initial signal has been removed, and if these changes remain undetected, it could lead to long-term untoward effects in biological systems. These studies suggest that aside from genotoxic effects, nanoparticles could cause more subtle epigenetic changes which merit thorough examination of environmental nanoparticles and novel candidate nanomaterials for medical applications.
C1 [Choi, Angela O.; Brown, Shelley E.; Szyf, Moshe; Maysinger, Dusica] McGill Univ, Dept Pharm & Therapeut, Montreal, PQ H3G 1Y6, Canada.
C3 McGill University
RP Maysinger, D (通讯作者)，McGill Univ, Dept Pharm & Therapeut, 3655 Promenade Sir William Osler,McIntyre Med Sci, Montreal, PQ H3G 1Y6, Canada.
EM dusica.maysinger@mcgill.ca
RI Maysinger, Dusica/GYU-6332-2022
CR Bakalova R, 2004, NAT BIOTECHNOL, V22, P1360, DOI 10.1038/nbt1104-1360
   Berthiaume M, 2006, DNA CELL BIOL, V25, P124, DOI 10.1089/dna.2006.25.124
   Boix-Chornet M, 2006, J BIOL CHEM, V281, P13540, DOI 10.1074/jbc.M601136200
   Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095
   Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596
   Cho SJ, 2007, LANGMUIR, V23, P1974, DOI 10.1021/la060093j
   Choi Angela O., 2007, Journal of Nanobiotechnology, V5, P1, DOI 10.1186/1477-3155-5-1
   Courty S, 2006, NANO LETT, V6, P1491, DOI 10.1021/nl060921t
   Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149
   Du W, 2006, ANAL BIOANAL CHEM, V386, P444, DOI 10.1007/s00216-006-0541-z
   Esteller M, 2006, CARCINOGENESIS, V27, P1121, DOI 10.1093/carcin/bgl033
   Fasanya-Odewumi C, 1998, INT J MOL MED, V1, P1001
   Fischer HC, 2006, ADV FUNCT MATER, V16, P1299, DOI 10.1002/adfm.200500529
   Funnell W Robert J, 2006, J Nanobiotechnology, V4, P10, DOI 10.1186/1477-3155-4-10
   Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737
   Green M, 2005, CHEM COMMUN, P121, DOI 10.1039/b413175d
   Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9
   Hardman R, 2006, ENVIRON HEALTH PERSP, V114, P165, DOI 10.1289/ehp.8284
   Lovric J, 2005, CHEM BIOL, V12, P1227, DOI 10.1016/j.chembiol.2005.09.008
   Lovric J, 2005, J MOL MED, V83, P377, DOI 10.1007/s00109-004-0629-x
   Maysinger D, 2007, EUR J PHARM BIOPHARM, V65, P270, DOI 10.1016/j.ejpb.2006.08.011
   McCord JM, 2005, BIOMED PHARMACOTHER, V59, P139, DOI 10.1016/j.biopha.2005.03.005
   Murphy ME, 2004, CELL CYCLE, V3, P836
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Pinaud F, 2006, BIOMATERIALS, V27, P1679, DOI 10.1016/j.biomaterials.2005.11.018
   Robertson RP, 2007, FEBS LETT, V581, P3743, DOI 10.1016/j.febslet.2007.03.087
   Ryman-Rasmussen JP, 2007, J INVEST DERMATOL, V127, P143, DOI 10.1038/sj.jid.5700508
   Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950
   Shi HL, 2004, FREE RADICAL BIO MED, V37, P582, DOI 10.1016/j.freeradbiomed.2004.03.012
   Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809
   Sundaram N, 2000, J NEURO-ONCOL, V46, P125, DOI 10.1023/A:1006436326003
   Taghiyev AF, 2006, CANCER BIOL THER, V5, P1199, DOI 10.4161/cbt.5.9.3168
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
NR 36
TC 169
Z9 189
U1 0
U2 49
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0946-2716
J9 J MOL MED-JMM
JI J. Mol. Med.
PD MAR
PY 2008
VL 86
IS 3
BP 291
EP 302
DI 10.1007/s00109-007-0274-2
PG 12
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 267RZ
UT WOS:000253528200006
PM 17965848
DA 2025-01-12
ER

PT J
AU Wendt, MK
   Cooper, AN
   Dwinell, MB
AF Wendt, M. K.
   Cooper, A. N.
   Dwinell, M. B.
TI Epigenetic silencing of CXCL12 increases the metastatic potential of
   mammary carcinoma cells
SO ONCOGENE
LA English
DT Article
DE chemokine; DNA hypermethylation; cancer; metastasis; CXCR4
ID CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER; FACTOR-I; DOWN-REGULATION;
   HOST-DEFENSE; TUMOR-GROWTH; EXPRESSION; GENE; HYPERMETHYLATION;
   ACTIVATION
AB Expression of the chemokine receptor CXCR4 has been linked with increased metastasis and decreased clinical prognosis in breast cancer. The current paradigm dictates that CXCR4 fosters carcinoma cell metastasis along a chemotactic gradient to organs expressing the ligand CXCL12. The present study asked if alterations in autocrine CXCR4 signaling via dysregulation of CXCL12 in mammary carcinoma cells modulated their metastatic potential. While CXCR4 was consistently detected, expression of CXCL12 characteristic of human mammary epithelium was silenced by promoter hypermethylation in breast cancer cell lines and primary mammary tumors. Stable re-expression of functional CXCL12 in ligand null cells increased orthotopic primary tumor growth in the mammary fat-pad model of tumorigenesis. Those data parallel increased carcinoma cell proliferation measured in vitro with little-to-no-impact on apoptosis. Moreover, re-expression of autocrine CXCL12 markedly reduced metastatic lung invasion assessed using in vivo bioluminescence imaging following tail vein injection. Consistent with those data, decreased metastasis reflected diminished intracellular calcium signaling and chemotactic migration in response to exogenous CXCL12 independent of changes in CXCR4 express ion. Together these data suggest that an elevated migratory signaling response to ectopic CXCL12 contributes to the metastatic potential of CXCR4-expressing mammary carcinoma cells, subsequent to epigenetic silencing of autocrine CXCL12.
C1 [Wendt, M. K.; Cooper, A. N.; Dwinell, M. B.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Dwinell, MB (通讯作者)，Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM mdwinell@mcw.edu
OI Wendt, Mike/0000-0002-3665-7413
CR Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8
   Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010
   Brauweiler A, 2007, J IMMUNOL, V178, P3353, DOI 10.4049/jimmunol.178.6.3353
   Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9
   Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004
   Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294
   García-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016
   Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hesselgesser J, 1998, J IMMUNOL, V160, P877
   Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026
   Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8
   Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004
   Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 34
TC 100
Z9 118
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 28
PY 2008
VL 27
IS 10
BP 1461
EP 1471
DI 10.1038/sj.onc.1210751
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 267ZR
UT WOS:000253548200013
PM 17724466
DA 2025-01-12
ER

PT J
AU Sadikovic, B
   Andrews, J
   Carter, D
   Robinson, J
   Rodenhiser, DI
AF Sadikovic, Bekim
   Andrews, Joseph
   Carter, David
   Robinson, John
   Rodenhiser, David I.
TI Genome-wide H3K9 histone acetylation profiles are altered in
   benzopyrene-treated MCF7 breast cancer cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DNA METHYLATION; GENE-EXPRESSION; DIOL EPOXIDE; EPIGENETICS; EXPOSURE;
   IMPACT; SITES; LUNG; HYPERMETHYLATION; HYPOMETHYLATION
AB Current toxicogenomic approaches generate transcriptional profiles that can identify functional gene expression signatures of environmental toxicants. However, the intricate processes governing transcription are overlaid with a complex set of molecular instructions involving epigenetic modifications. These commands regulate both gene expression and chromatin organization through coordinated sets of histone modifications and heritable DNA methylation patterns. Although the effects of specific environmental toxicants on gene expression are the subject of much study, the epigenetic effects of such compounds are poorly understood. Here we have used human promoter tiling arrays along with chromatin immunoprecipitation to identify changes in histone acetylation profiles because of chemical exposure. Chromatin from cells exposed to the polyaromatic hydrocarbon benzo(a) pyrene was immunoprecipitated with antibodies against acetylated histones. Affymetrix promoter tiling microarrays were probed to generate epigenomic profiles of hypo-and hyperacetylated chromatin localized to gene promoter regions. Statistical analyses, data mining, and expression studies revealed that treated cells possessed differentially acetylated gene promoter regions and gene-specific expression changes. This chromatin immunoprecipitation-on-chip approach permits genome-wide profiling of histone acetylation patterns that can identify chromatin-related signatures of environmental toxicants and potentially determine the molecular pathways these changes target. This approach also has potential applications for profiling histone modifications and DNA methylation changes during embryonic development, in cancer biology, and in the development and assessment of cancer therapeutics.
C1 [Sadikovic, Bekim; Andrews, Joseph; Rodenhiser, David I.] London Hlth Sci Ctr, London Reg Canc Program, London, ON N6A 4L6, Canada.
   [Carter, David; Robinson, John; Rodenhiser, David I.] Univ Western Ontario, Childrens Hlth Res Inst, EpiGenWestern Res Grp, London, ON N6A 4L6, Canada.
   [Carter, David; Robinson, John] Univ Western Ontario, Robarts Res Inst, London, ON N6A 4L6, Canada.
   [Sadikovic, Bekim; Rodenhiser, David I.] Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada.
   [Sadikovic, Bekim; Rodenhiser, David I.] Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada.
   [Sadikovic, Bekim; Rodenhiser, David I.] Univ Western Ontario, Dept Paediat, London, ON N6A 4L6, Canada.
C3 London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario)
RP Rodenhiser, DI (通讯作者)，London Hlth Sci Ctr, London Reg Canc Program, A4-134 Victroria Res Labs,790 Commiss Rd E, London, ON N6A 4L6, Canada.
EM drodenhi@uwo.ca
CR Baskunov VB, 2005, BIOCHEMISTRY-US, V44, P1054, DOI 10.1021/bi048130y
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   Chen H, 2004, CARCINOGENESIS, V25, P1779, DOI 10.1093/carcin/bgh161
   Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430
   DIPPLE A, 1991, MUTAT RES, V259, P263, DOI 10.1016/0165-1218(91)90122-3
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s
   Iguchi T, 2006, ENVIRON HEALTH PERSP, V114, P101, DOI 10.1289/ehp.8061
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Irwin Richard D, 2004, Toxicol Pathol, V32 Suppl 1, P72, DOI 10.1080/01926230490424752
   Jhaveri MS, 2001, MOL PHARMACOL, V60, P1288, DOI 10.1124/mol.60.6.1288
   Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200
   Kim YI, 2005, J NUTR, V135, P2703, DOI 10.1093/jn/135.11.2703
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lettieri T, 2006, ENVIRON HEALTH PERSP, V114, P4, DOI 10.1289/ehp.8194
   Mahadevan B, 2005, CANCER RES, V65, P1251, DOI 10.1158/0008-5472.CAN-04-2357
   Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215
   Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200
   Neumann NF, 2002, BIOTECHNOL ADV, V20, P391, DOI 10.1016/S0734-9750(02)00025-3
   Revel A, 2003, J APPL TOXICOL, V23, P255, DOI 10.1002/jat.916
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Roh TY, 2007, GENOME RES, V17, P74, DOI 10.1101/gr.5767907
   Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799
   Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012
   Scherer G, 2000, CANCER EPIDEM BIOMAR, V9, P373
   Schmidt CW, 2002, ENVIRON HEALTH PERSP, V110, pA750, DOI 10.1289/ehp.110-a750
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weisenberger DJ, 1999, J BIOL CHEM, V274, P23948, DOI 10.1074/jbc.274.34.23948
   WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7
   WILSON VL, 1984, CARCINOGENESIS, V5, P1027, DOI 10.1093/carcin/5.8.1027
   Yoon JH, 2001, CANCER RES, V61, P7110
   Zhang N, 2005, J MOL BIOL, V346, P951, DOI 10.1016/j.jmb.2004.12.027
NR 41
TC 66
Z9 73
U1 0
U2 19
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 15
PY 2008
VL 283
IS 7
BP 4051
EP 4060
DI 10.1074/jbc.M707506200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 261MO
UT WOS:000253083500040
PM 18065415
OA hybrid
DA 2025-01-12
ER

PT J
AU Weichert, W
   Röske, A
   Gekeler, V
   Beckers, T
   Stephan, C
   Jung, K
   Fritzsche, FR
   Niesporek, S
   Denkert, C
   Dietel, M
   Kristiansen, G
AF Weichert, W.
   Roeske, A.
   Gekeler, V.
   Beckers, T.
   Stephan, C.
   Jung, K.
   Fritzsche, F. R.
   Niesporek, S.
   Denkert, C.
   Dietel, M.
   Kristiansen, G.
TI Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer
   and HDAC2 expression is associated with shorter PSA relapse time after
   radical prostatectomy
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE HDAC; prostate cancer; prognostic marker; immunohistochemistry
ID SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN BREAST-CANCER; VALPROIC ACID;
   UP-REGULATION; IN-VITRO; INHIBITORS; CELLS; DIFFERENTIATION; APOPTOSIS;
   MIGRATION
AB High activity of histone deacetylases (HDACs) causes epigenetic alterations associated with malignant cell behaviour. Consequently, HDAC inhibitors have entered late-phase clinical trials as new antineoplastic drugs. However, little is known about expression and function of specific HDAC isoforms in human tumours including prostate cancer. We investigated the expression of class I HDACs in 192 prostate carcinomas by immunohistochemistry and correlated our findings to clinicopathological parameters including follow-up data. Class I HDAC isoforms were strongly expressed in the majority of the cases (HDAC1: 69.8%, HDAC2: 74%, HDAC3: 94.8%). High rates of HDAC1 and HDAC2 expression were significantly associated with tumour dedifferentiation. Strong expression of all HDACs was accompanied by enhanced tumour cell proliferation. In addition, HDAC2 was an independent prognostic marker in our prostate cancer cohort. In conclusion, we showed that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate cancer, which might be important for upcoming studies on HDAC inhibitors in this tumour entity. Also, the highly significant prognostic value of HDAC2 clearly deserves further study.
C1 [Fritzsche, F. R.; Kristiansen, G.] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital
RP Kristiansen, G (通讯作者)，Univ Zurich Hosp, Inst Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.
EM glen.kristiansen@usz.ch
RI Denkert, Carsten/AHE-2675-2022; Jung, Klaus/Z-2122-2018
OI Denkert, Carsten/0000-0002-2249-0982; Jung, Klaus/0000-0001-9797-5362;
   Stephan, Carsten/0000-0002-3270-258X
CR Andrén O, 2006, J UROLOGY, V175, P1337, DOI 10.1016/S0022-5347(05)00734-2
   Blaheta RA, 2005, MED RES REV, V25, P383, DOI 10.1002/med.20027
   Butler LM, 2000, CANCER RES, V60, P5165
   Carroll PR, 2005, J UROLOGY, V173, P1061, DOI 10.1097/01.ju.0000156838.67623.10
   Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Floryk D, 2005, CANCER RES, V65, P11588, DOI 10.1158/0008-5472.CAN-05-1831
   Fronsdal K, 2005, PROSTATE, V62, P299, DOI 10.1002/pros.20140
   Gediya LK, 2005, J MED CHEM, V48, P5047, DOI 10.1021/jm058214k
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kattan MW, 1999, J CLIN ONCOL, V17, P1499, DOI 10.1200/JCO.1999.17.5.1499
   Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932
   Kim SH, 2004, BIOCHEM BIOPH RES CO, V315, P964, DOI 10.1016/j.bbrc.2004.01.149
   Klisovic DD, 2005, MELANOMA RES, V15, P147, DOI 10.1097/00008390-200506000-00002
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510
   Kwon HJ, 2002, INT J CANCER, V97, P290, DOI 10.1002/ijc.1602
   Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Munster PN, 2001, CANCER RES, V61, P8492
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Noske A, 2005, EUR J CANCER, V41, P461, DOI 10.1016/j.ejca.2004.10.025
   Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132
   Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376
   Rombouts K, 2002, J HEPATOL, V37, P788, DOI 10.1016/S0168-8278(02)00275-1
   Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581
   Takai N, 2004, CANCER-AM CANCER SOC, V101, P2760, DOI 10.1002/cncr.20709
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Thelen P, 2004, INT J ONCOL, V24, P25
   Uchida H, 2005, ENDOCRINOLOGY, V146, P5365, DOI 10.1210/en.2005-0359
   Waltregny D, 2004, EUR J HISTOCHEM, V48, P273
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang ZW, 2006, UROL ONCOL-SEMIN ORI, V24, P152, DOI 10.1016/j.urolonc.2005.11.004
NR 37
TC 387
Z9 449
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD FEB 12
PY 2008
VL 98
IS 3
BP 604
EP 610
DI 10.1038/sj.bjc.6604199
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 259IR
UT WOS:000252933500013
PM 18212746
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Xu, J
   Chambers, AF
   Tuck, AB
   Rodenhiser, DI
AF Xu, Jie
   Chambers, Ann F.
   Tuck, Alan B.
   Rodenhiser, David I.
TI Molecular cytogenetic characterization of human breast cancer cell line
   MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic
   metastasis
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID HER-2
AB Two human breast carcinoma cell lines, MDA-MB-468 and its variant N4DA-MB-468LN, which displays aggressive lymphatic metastasis, were investigated for molecular cytogenetic characteristics using G-banding, spectral karyotyping, and fluorescence in situ hybridization (FISH). Both cell lines have multiple chromosome aberrations, but differ in the types of rearrangements and their breakpoints. The MDA-MB-468 karyotype identified in the present stud), differs from that previously reported, which suggests that this cell line is unstable. Neither cell line exhibited amplification of ERBB2 (alias HER-2) by FISH. MDA-MB-468 cells have a modal number of 60, with 42 types of aberrations: 11 numerical and 31 structural. 468LN cells have a modal number of 55, with 37 types of aberrations: 10 numerical and 27 structural. The most common aberrations in MDA-MB-468 cells were der(5)t(5;16), i(7)(p10) i(18)(p10) der(19)t(2;19), del(6)(q23), and der(10)t(1;10). The most common aberrations in 468LN cells were der(18)t(10;18), +5, der(1;7)(q10;q10), der(19)t(2;18;19), and der(20)t(20;21). This cytogenetic result is consistent with previous findings that showed differences in tumorigenicity and metastatic capability of these two cell lines and indicates that 468LN is a new cell line distinctive from MDA-MB-468. We hypothesize that the cytogenetic changes in 468LN may be related to its new biological characteristics. Knowledge of the chromosome aberrations and breakpoints identified could be useful for further genetic and epigenetic studies of breast cancer. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Xu, Jie] Univ Western Ontario, Hlth Sci Ctr, Cytogenet Lab, London, ON N6A 4G5, Canada.
   [Chambers, Ann F.; Tuck, Alan B.; Rodenhiser, David I.] Univ Western Ontario, Schulich Sch Med & Dent, London Reg Canc Program, London, ON, Canada.
   [Tuck, Alan B.] Univ Western Ontario, Hlth Sci Ctr, Dept Pathol, Schulich Sch Med & Dent, London, ON, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Schulich Sch Med & Dent, Child Hlth Res Inst, London, ON, Canada.
C3 Western University (University of Western Ontario); London Health
   Sciences Centre; Western University (University of Western Ontario);
   London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario)
RP Xu, J (通讯作者)，Univ Western Ontario, Hlth Sci Ctr, Cytogenet Lab, 375 S St,Rm N258, London, ON N6A 4G5, Canada.
EM Jie.Xu@lhsc.on.ca
RI Chambers, Ann/L-6285-2015
OI Chambers, Ann/0000-0002-9509-5123
CR CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251
   HEIM S, 1995, CANC CYTOGENETICS CH
   Kumaravel TS, 2005, BREAST CANCER RES TR, V91, P89, DOI 10.1007/s10549-004-5780-0
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   PATHAK S, 1979, JNCI-J NATL CANCER I, V62, P263
   Press MF, 2005, CLIN CANCER RES, V11, P6598, DOI 10.1158/1078-0432.CCR-05-0636
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
NR 10
TC 9
Z9 11
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD FEB
PY 2008
VL 181
IS 1
BP 1
EP 7
DI 10.1016/j.cancergencyto.2007.05.030
PG 7
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 265MY
UT WOS:000253364800001
PM 18262045
DA 2025-01-12
ER

PT J
AU Zhang, DD
   Wang, Y
   Bai, YF
   Ge, QY
   Qiao, YJ
   Luo, JF
   Jia, C
   Lu, ZH
AF Zhang, Dingdong
   Wang, Yan
   Bai, Yunfei
   Ge, Qinyu
   Qiao, Yingjuan
   Luo, Junfeng
   Jia, Chao
   Lu, Zuhong
TI A novel method to quantify local CpG methylation density by regional
   methylation elongation assay on microarray
SO BMC GENOMICS
LA English
DT Article
ID DNA METHYLATION; PROMOTER METHYLATION; ISLAND METHYLATION;
   BREAST-CANCER; BISULFITE; HYPERMETHYLATION; EPIGENETICS; GENES; PCR;
   TECHNOLOGY
AB Background: DNA methylation based techniques are important tools in both clinical diagnostics and therapeutics. But most of these methods only analyze a few CpG sites in a target region. Indeed, difference of site-specific methylation may also lead to a change of methylation density in many cases, and it has been found that the density of methylation is more important than methylation of single CpG site for gene silencing.
   Results: We have developed a novel approach for quantitative analysis of CpG methylation density on the basis of microarray-based hybridization and incorporation of Cy5-dCTP into the Cy3 labeled target DNA by using Taq DNA Polymerase on microarray. The quantification is achieved by measuring Cy5/Cy3 signal ratio which is proportional to methylation density. This methylation-sensitive technique, termed RMEAM (regional methylation elongation assay on microarray), provides several advantages over existing methods used for methylation analysis. It can determine an exact methylation density of the given region, and has potential of high throughput. We demonstrate a use of this method in determining the methylation density of the promoter region of the tumor-related gene MLH1, TERT and MGMT in colorectal carcinoma patients.
   Conclusion: This technique allows for quantitative analysis of regional methylation density, which is the representative of all allelic methylation patterns in the sample. The results show that this technique has the characteristics of simplicity, rapidness, specificity and high-throughput.
C1 [Zhang, Dingdong; Wang, Yan; Bai, Yunfei; Ge, Qinyu; Qiao, Yingjuan; Luo, Junfeng; Jia, Chao; Lu, Zuhong] Southeast Univ, State Key Lab Bioelect, Nanjing 210096, Peoples R China.
   [Zhang, Dingdong] Jinling Inst Technol, Coll Anim Sci & Technol, Nanjing 210038, Peoples R China.
C3 Southeast University - China; Jinling Institute of Technology
RP Lu, ZH (通讯作者)，Southeast Univ, State Key Lab Bioelect, Nanjing 210096, Peoples R China.
EM zdd_7597@seu.edu.cn; wfyee@163.com; whitecf@seu.edu.cn;
   qgge2004@163.com; gbbgbb@etang.com; lbee1978_down@163.com;
   jiachaonj@hotmail.com; zhlu@seu.edu.cn
RI Lu, Zuhong/A-5448-2013; Ge, Qinyu/B-5055-2012; Luo,
   Junfeng/GPP-7603-2022
OI Lu, Zuhong/0000-0003-3332-2615
FU NIAAA NIH HHS [F31 AA020702] Funding Source: Medline
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Cheng YW, 2006, GENOME RES, V16, P282, DOI 10.1101/gr.4181406
   Clément G, 2005, J CLIN PATHOL, V58, P155, DOI 10.1136/jcp.2004.021147
   Deng GR, 1999, CANCER RES, V59, P2029
   Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R
   Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Galm O, 2002, GENOME RES, V12, P153, DOI 10.1101/gr.202501
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Hatada I, 2006, ONCOGENE, V25, P3059, DOI 10.1038/sj.onc.1209331
   Hatada I, 2002, J HUM GENET, V47, P448, DOI 10.1007/s100380200063
   HAYATSU H, 1970, BIOCHEMISTRY-US, V9, P2858, DOI 10.1021/bi00816a016
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jorgensen HF, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl527
   Lippman Z, 2005, NAT METHODS, V2, P219, DOI 10.1038/nmeth0305-219
   Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230
   Müller HM, 2004, CANCER LETT, V209, P231, DOI 10.1016/j.canlet.2003.12.016
   Nagasaka T, 2003, CLIN CANCER RES, V9, P5306
   Palmisano WA, 2000, CANCER RES, V60, P5954
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   Roloff TC, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-1
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   Shames DS, 2007, CANCER LETT, V251, P187, DOI 10.1016/j.canlet.2006.10.014
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   WOGN DJ, 1999, MOL CELL BIOL, V19, P5642
   Yan PS, 2003, CANCER RES, V63, P6178
NR 38
TC 11
Z9 16
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD JAN 31
PY 2008
VL 9
AR 59
DI 10.1186/1471-2164-9-59
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 274FW
UT WOS:000253988200001
PM 18237388
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Press, JZ
   De Luca, A
   Boyd, N
   Young, S
   Troussard, A
   Ridge, Y
   Kaurah, P
   Kalloger, SE
   Blood, KA
   Smith, M
   Spellman, PT
   Wang, Y
   Miller, DM
   Horsman, D
   Faham, M
   Gilks, CB
   Gray, J
   Huntsman, DG
AF Press, Joshua Z.
   De Luca, Alessandro
   Boyd, Niki
   Young, Sean
   Troussard, Armelle
   Ridge, Yolanda
   Kaurah, Pardeep
   Kalloger, Steve E.
   Blood, Katherine A.
   Smith, Margaret
   Spellman, Paul T.
   Wang, Yuker
   Miller, Dianne M.
   Horsman, Doug
   Faham, Malek
   Gilks, C. Blake
   Gray, Joe
   Huntsman, David G.
TI Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct
   molecular abnormalities
SO BMC CANCER
LA English
DT Article
ID CANCER SUSCEPTIBILITY GENE; GYNECOLOGIC-ONCOLOGY-GROUP; FAMILIAL
   BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; SEROUS CARCINOMA; PROMOTER
   HYPERMETHYLATION; ENDOMETRIAL CARCINOMA; EXPRESSION PROFILES; SOMATIC
   MUTATIONS; GERMLINE BRCA1
AB Background: Subclassification of ovarian carcinomas can be used to guide treatment and determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. The mechanism of BRCA1/2 loss is a potential method of subclassifying high grade serous carcinomas.
   Methods: A consecutive series of 49 ovarian cancers was assessed for mutations status of BRCA1 and BRCA2, LOH at the BRCA1 and BRCA2 loci, methylation of the BRCA1 promoter, BRCA1, BRCA2, PTEN, and PIK3CA transcript levels, PIK3CA gene copy number, and BRCA1, p21, p53, and WT-1 immunohistochemistry.
   Results: Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1. All of these tumours were high-grade serous or undifferentiated type. None of the endometrioid (n = 5), clear cell (n = 4), or low grade serous (n = 2) carcinomas showed loss of BRCA1, whereas 47% of the 38 high-grade serous or undifferentiated carcinomas had loss of BRCA1. It was possible to distinguish high grade serous carcinomas with BRCA1 mutations from those with epigenetic BRCA1 loss: tumours with BRCA1 mutations typically had decreased PTEN mRNA levels while those with epigenetic loss of BRCA1 had copy number gain of PIK3CA. Overexpression of p53 with loss of p21 expression occurred significantly more frequently in high grade serous carcinomas with epigenetic loss of BRCA1, compared to high grade serous tumors without loss of BRCA1.
   Conclusion: High grade serous carcinomas can be subclassified into three groups: BRCA1 loss (genetic), BRCA1 loss (epigenetic), and no BRCA1 loss. Tumors in these groups show distinct molecular alterations involving the PI3K/AKT and p53 pathways.
C1 [De Luca, Alessandro; Boyd, Niki; Young, Sean; Troussard, Armelle; Blood, Katherine A.; Horsman, Doug; Gilks, C. Blake; Huntsman, David G.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
   [Press, Joshua Z.] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada.
   [Young, Sean; Ridge, Yolanda; Kaurah, Pardeep; Huntsman, David G.] Univ British Columbia, Hereditary Canc Program, Vancouver, BC V5Z 1M9, Canada.
   [Kalloger, Steve E.; Gilks, C. Blake; Huntsman, David G.] Vancouver Gen Hosp, Genet Pathol Evaluat Ctr Prostate Ctr, Vancouver, BC, Canada.
   [Smith, Margaret; Horsman, Doug] Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
   [Spellman, Paul T.; Gray, Joe] Univ Calif San Francisco, Lawrence Berkeley Natl Lab, Div Life Sci, San Francisco, CA 94143 USA.
   [Wang, Yuker; Faham, Malek] Affymetrix Inc, San Francisco, CA USA.
   [Miller, Dianne M.] Univ British Columbia, Dept Gynecol Oncol, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia; University of British Columbia;
   Melbourne Health; Royal Melbourne Hospital; University of California
   System; University of California San Francisco; United States Department
   of Energy (DOE); Lawrence Berkeley National Laboratory; Affymetrix;
   University of British Columbia
RP Gilks, CB (通讯作者)，Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
EM drjpress@telus.net; alessandro.deluca@vch.ca; nboyd@bccancer.bc.ca;
   syoung@bccancer.bc.ca; atroussa@bccrc.ca; yridge@bccancer.bc.ca;
   pkaurah@bccancer.bc.ca; skalloger@mac.com; kblood@bccrc.ca;
   margie.smith@mh.org.au; ptspellman@lbl.gov; Yuker_Wang@affymetrix.com;
   Dianne.Miller@vch.ca; DHorsman@bccancer.bc.ca;
   Malek_Faham@affymetrix.com; Blake.Gilks@vch.ca; JWGray@lbl.gov;
   dhuntsma@bccancer.bc.ca
RI Kalloger, Steve/B-3949-2010; Gray, Joe/AAX-9549-2020; Gilks,
   Blake/IAN-2684-2023; Huntsman, David/ABE-6082-2020; De Luca,
   Alessandro/B-2179-2017
OI De Luca, Alessandro/0000-0002-4408-8062
FU NCI NIH HHS [P50 CA058207, P01 CA 64602, P50 CA83639, P50 CA083639, P01
   CA064602, P50 CA 58207] Funding Source: Medline
CR Agarwal R, 2006, CURR OPIN PHARMACOL, V6, P345, DOI 10.1016/j.coph.2006.02.007
   Al-Hussaini M, 2004, HISTOPATHOLOGY, V44, P109, DOI 10.1111/j.1365-2559.2004.01787.x
   ALBERTSEN HM, 1994, NAT GENET, V7, P472, DOI 10.1038/ng0894-472
   Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113
   Aunoble B, 2000, INT J ONCOL, V16, P567
   Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306
   BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412
   Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633
   Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260
   Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248
   Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Burden D., 2004, STAT APPL GENET MOL, V3, P35, DOI [10.2202/1544-6115.1095, DOI 10.2202/1544-6115.1095]
   Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310
   Chan KYK, 2002, CANCER RES, V62, P4151
   CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148
   CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267
   Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, CANCER RES, V60, P5021
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   ENOMOTO T, 1991, AM J PATHOL, V139, P777
   ESRIG D, 1993, AM J PATHOL, V143, P1389
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Goffin JR, 2003, CANCER-AM CANCER SOC, V97, P527, DOI 10.1002/cncr.11080
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Hardenbol P, 2005, GENOME RES, V15, P269, DOI 10.1101/gr.3185605
   Hayes MP, 2006, CLIN CANCER RES, V12, P5932, DOI 10.1158/1078-0432.CCR-06-1375
   Hogervorst FBL, 2003, CANCER RES, V63, P1449
   Hu LM, 2002, CANCER RES, V62, P1087
   Hu LM, 2000, CLIN CANCER RES, V6, P880
   Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176
   Jass JR, 2002, EUR J CANCER, V38, P858, DOI 10.1016/S0959-8049(02)00041-2
   Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990
   Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077
   Koul A, 2000, INT J GYNECOL CANCER, V10, P289, DOI 10.1046/j.1525-1438.2000.010004289.x
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396
   Majdak EJ, 2005, CANCER, V104, P1004, DOI 10.1002/cncr.21276
   Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009
   Markman M, 2003, J CLIN ONCOL, V21, P2460, DOI 10.1200/JCO.2003.07.013
   McGivern A, 2004, Fam Cancer, V3, P101
   MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   MILNER BJ, 1993, CANCER RES, V53, P2128
   Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620
   Page C, 2000, ANTICANCER RES, V20, P407
   Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536
   Regitnig P, 2002, J PATHOL, V198, P190, DOI 10.1002/path.1193
   Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x
   Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913
   Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581
   SASANO H, 1992, AM J PATHOL, V141, P545
   Schöndorf T, 2003, EUR J CLIN INVEST, V33, P256, DOI 10.1046/j.1365-2362.2003.01116.x
   Seidman JD, 2004, INT J GYNECOL PATHOL, V23, P41, DOI 10.1097/01.pgp.0000101080.35393.16
   Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3
   Shaw PA, 2002, INT J GYNECOL PATHOL, V21, P407, DOI 10.1097/00004347-200210000-00011
   Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042
   Silverberg SG, 2000, INT J GYNECOL PATHOL, V19, P7, DOI 10.1097/00004347-200001000-00003
   Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484
   Soslow RA, 1998, INT J GYNECOL PATHOL, V17, P129, DOI 10.1097/00004347-199804000-00006
   Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2
   Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852
   Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333
   Thrall M, 2006, INT J GYNECOL CANCER, V16, P166, DOI 10.1111/j.1525-1438.2006.00504.x
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507
   Wang YK, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni177
   Werness BA, 2004, INT J GYNECOL PATHOL, V23, P29, DOI 10.1097/01.pgp.0000101083.35393.cd
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016
   Yokomizo A, 1998, INT J ONCOL, V13, P101
   Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200
NR 81
TC 224
Z9 249
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 22
PY 2008
VL 8
AR 17
DI 10.1186/1471-2407-8-17
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 268RJ
UT WOS:000253596800001
PM 18208621
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Aleman, A
   Adrien, L
   Lopez-Serra, L
   Cordon-Cardo, C
   Esteller, M
   Belbin, TJ
   Sanchez-Carbayo, M
AF Aleman, A.
   Adrien, L.
   Lopez-Serra, L.
   Cordon-Cardo, C.
   Esteller, M.
   Belbin, T. J.
   Sanchez-Carbayo, M.
TI Identification of DNA hypermethylation of <i>SOX9</i> in association
   with bladder cancer progression using CpG microarrays
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE bladder cancer; CpG arrays; methylation
ID EPIGENETIC INACTIVATION; PROMOTER HYPERMETHYLATION; ISLAND MICROARRAY;
   CELL-CARCINOMA; BREAST-CANCER; METHYLATION; GENE; EXPRESSION; PATTERNS;
   MARKERS
AB CpG island arrays represent a high-throughput epigenomic discovery platform to identify global disease-specific promoter hypermethylation candidates along bladder cancer progression. DNA obtained from 10 pairs of invasive bladder tumours were profiled vs their respective normal urothelium using differential methylation hybridisation on custom-made CpG arrays (n = 12288 clones). Promoter hypermethylation of 84 clones was simultaneously shown in at least 70% of the tumours. SOX9 was selected for further validation by bisulphite genomic sequencing and methylation-specific polymerase chain reaction in bladder cancer cells ( n = 11) and primary bladder tumours ( n = 101). Hypermethylation was observed in bladder cancer cells and associated with lack of gene expression, being restored in vitro by a demethylating agent. In primary bladder tumours, SOX9 hypermethylation was present in 56.4% of the cases. Moreover, SOX9 hypermethylation was significantly associated with tumour grade and overall survival. Thus, this high-throughput epigenomic strategy has served to identify novel hypermethylated candidates in bladder cancer. In vitro analyses supported the role of methylation in silencing SOX9 gene. The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer.
C1 [Aleman, A.; Sanchez-Carbayo, M.] Spanish Natl Canc Ctr, Mol Pathol Program, Tumor Markers Grp, Madrid, Spain.
   [Adrien, L.; Belbin, T. J.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA.
   [Lopez-Serra, L.; Esteller, M.] Spanish Natl Canc Ctr, Mol Pathol Program, Epigenet Grp, Madrid, Spain.
   [Cordon-Cardo, C.] Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA.
C3 Centro Nacional de Investigaciones Oncologicas (CNIO); Yeshiva
   University; Montefiore Medical Center; Albert Einstein College of
   Medicine; Centro Nacional de Investigaciones Oncologicas (CNIO);
   Memorial Sloan Kettering Cancer Center
RP Sanchez-Carbayo, M (通讯作者)，Ctr Nacl Invest Oncol, Tumor Markers Grp 208A, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.
EM mscarbayo@cnio.es
RI Belbin, Thomas/JFK-5670-2023; Esteller, Manel/L-5956-2014
OI Belbin, Thomas/0000-0001-6867-654X; Esteller, Manel/0000-0003-4490-6093
CR Adrien LR, 2006, CYTOGENET GENOME RES, V114, P16, DOI 10.1159/000091923
   Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985
   Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163
   Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411
   Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439
   Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563
   Cordon-Cardo C, 2000, SCAND J UROL NEPHROL, V34, P82, DOI 10.1080/003655900750169338
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Dawson-Saunders B., 1994, Basic and clinical biostatistics, V2
   Drivdahl R, 2004, ONCOGENE, V23, P4584, DOI 10.1038/sj.onc.1207603
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000
   Jay P, 2005, CANCER RES, V65, P2193, DOI 10.1158/0008-5472.CAN-04-1484
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647
   Lee MG, 2001, CANCER RES, V61, P6688
   Liang G, 2002, CANCER RES, V62, P961
   Markl IDC, 2001, CANCER RES, V61, P5875
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Muto S, 2000, CANCER RES, V60, P4021
   Paz MF, 2003, CANCER RES, V63, P1114
   Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375
   Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973
   Söderström M, 2002, INT J CANCER, V100, P144, DOI 10.1002/ijc.10457
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Wehrli BM, 2003, HUM PATHOL, V34, P263, DOI 10.1053/hupa.2003.41
   Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318
   Yan Pearlly S, 2002, Methods Mol Biol, V200, P87
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
NR 36
TC 79
Z9 87
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JAN 22
PY 2008
VL 98
IS 2
BP 466
EP 473
DI 10.1038/sj.bjc.6604143
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 259IQ
UT WOS:000252933400030
PM 18087279
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Moulis, S
   Sgroi, DC
AF Moulis, Sharon
   Sgroi, Dennis C.
TI Re-evaluating early breast neoplasia
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ATYPICAL DUCTAL HYPERPLASIA; CARCINOMA IN-SITU; COMPARATIVE GENOMIC
   HYBRIDIZATION; GENE-EXPRESSION PROFILES; HISTOLOGIC GRADE; CANCER;
   PROGRESSION; TAMOXIFEN; RATIO; HETEROZYGOSITY
AB Historically, histomorphological and epidemiological data suggested that atypical ductal hyperplasia and ductal carcinoma in situ are the earliest recognizable neoplastic stages of breast cancer progression. Over the past several years, detailed high-throughput molecular genetic, gene expression and epigenetic analyses have enhanced our understanding of these early neoplastic lesions and have re- shaped our view of human breast cancer progression to include multiple distinct pathways of evolution.
C1 [Moulis, Sharon; Sgroi, Dennis C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol,Mol Pathol Res Unit, Boston, MA 02129 USA.
   [Moulis, Sharon; Sgroi, Dennis C.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02129 USA.
C3 Harvard University; Harvard Medical School; Massachusetts General
   Hospital; Harvard University; Massachusetts General Hospital
RP Sgroi, DC (通讯作者)，Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol,Mol Pathol Res Unit, Boston, MA 02129 USA.
EM dsgroi@partners.org
RI Sgroi, Dennis/AAV-2487-2021
FU NCI NIH HHS [R01 CA112021, R01-1CA112021-01] Funding Source: Medline
CR Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L
   Chuaqui RF, 1997, AM J PATHOL, V150, P297
   Desmedt C, 2006, CELL CYCLE, V5, P2198, DOI 10.4161/cc.5.19.3254
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Goetz MP, 2006, CLIN CANCER RES, V12, P2080, DOI 10.1158/1078-0432.CCR-05-1263
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Jansen MPHM, 2007, J CLIN ONCOL, V25, P662, DOI 10.1200/JCO.2006.07.3676
   Lakhani SR, 1999, J PATHOL, V187, P272, DOI 10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2
   Larson PS, 2006, J PATHOL, V209, P307, DOI 10.1002/path.1973
   Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   Pinder SE, 2003, BREAST CANCER RES, V5, P254, DOI 10.1186/bcr623
   Porter D, 2003, MOL CANCER RES, V1, P362
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   TAVASSOLI FA, 1990, CANCER-AM CANCER SOC, V65, P518, DOI 10.1002/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O
   Yang CW, 2006, CANCER RES, V66, P11649, DOI 10.1158/0008-5472.CAN-06-1645
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
NR 20
TC 15
Z9 20
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2008
VL 10
IS 1
AR 302
DI 10.1186/bcr1853
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 285YF
UT WOS:000254811400007
PM 18279539
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Rodenhiser, DI
   Andrews, J
   Kennette, W
   Sadikovic, B
   Mendlowitz, A
   Tuck, AB
   Chambers, AF
AF Rodenhiser, David I.
   Andrews, Joseph
   Kennette, Wendy
   Sadikovic, Bekim
   Mendlowitz, Ariel
   Tuck, Alan B.
   Chambers, Ann F.
TI Epigenetic mapping and functional analysis in a breast cancer metastasis
   model using whole-genome promoter tiling microarrays
SO BREAST CANCER RESEARCH
LA English
DT Article
ID DEPENDENT NEUROPROTECTIVE PROTEIN; MESSENGER-RNA-EXPRESSION;
   SYNUCLEIN-GAMMA-GENE; CELL-LINE; HYPERMETHYLATION; METHYLATION;
   HYPOMETHYLATION; MDA-MB-468; SIGNATURE; CARCINOMA
AB Introduction Breast cancer metastasis is a complex, multi-step biological process. Genetic mutations along with epigenetic alterations in the form of DNA methylation patterns and histone modifications contribute to metastasis-related gene expression changes and genomic instability. So far, these epigenetic contributions to breast cancer metastasis have not been well characterized, and there is only a limited understanding of the functional mechanisms affected by such epigenetic alterations. Furthermore, no genome-wide assessments have been undertaken to identify altered DNA methylation patterns in the context of metastasis and their effects on specific functional pathways or gene networks.
   Methods We have used a human gene promoter tiling microarray platform to analyze a cell line model of metastasis to lymph nodes composed of a poorly metastatic MDA-MB-468GFP human breast adenocarcinoma cell line and its highly metastatic variant (468LN). Gene networks and pathways associated with metastasis were identified, and target genes associated with epithelial-mesenchymal transition were validated with respect to DNA methylation effects on gene expression.
   Results We integrated data from the tiling microarrays with targets identified by Ingenuity Pathways Analysis software and observed epigenetic variations in genes implicated in epithelial-mesenchymal transition and with tumor cell migration. We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the CDH1, CST6, EGFR, SNAI2 and ZEB2 genes by quantitative real-time PCR. Our data also suggest that the complex genomic reorganization present in cancer cells may be superimposed over promoter-specific methylation events that are responsible for gene-specific expression changes.
   Conclusion This is the first whole-genome approach to identify genome-wide and gene-specific epigenetic alterations, and the functional consequences of these changes, in the context of breast cancer metastasis to lymph nodes. This approach allows the development of epigenetic signatures of metastasis to be used concurrently with genomic signatures to improve mapping of the evolving molecular landscape of metastasis and to permit translational approaches to target epigenetically regulated molecular pathways related to metastatic progression.
C1 [Rodenhiser, David I.; Andrews, Joseph; Kennette, Wendy; Sadikovic, Bekim; Mendlowitz, Ariel; Tuck, Alan B.; Chambers, Ann F.] London Hlth Sci Ctr, Victoria Res Labs, London Reg Canc Program, London, ON N6A 4L6, Canada.
   [Rodenhiser, David I.; Sadikovic, Bekim; Mendlowitz, Ariel] Univ Western Ontario, Schulich Sch Med & Dent, Dept Biochem, London, ON N6A 3K7, Canada.
   [Rodenhiser, David I.; Tuck, Alan B.; Chambers, Ann F.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Oncol, London, ON N6A 3K7, Canada.
   [Rodenhiser, David I.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Paediat, London, ON N6A 3K7, Canada.
   [Rodenhiser, David I.] Victoria Res Labs, Childrens Hlth Res Inst, EpiGenWestern Res Grp, London, ON N6C 2V5, Canada.
   [Tuck, Alan B.; Chambers, Ann F.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Pathol, London, ON N6A 3K7, Canada.
C3 London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Rodenhiser, DI (通讯作者)，London Hlth Sci Ctr, Victoria Res Labs, London Reg Canc Program, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.
EM drodenhi@uwo.ca
RI Chambers, Ann/L-6285-2015
OI Chambers, Ann/0000-0002-9509-5123
FU Canadian Breast Cancer Research Alliance [016506]; Canadian Breast
   Cancer Foundation; The Cancer Research Society; Canada Research Chairs
   Program
FX We recognize our colleagues on the Metastasis Project research team [62]
   including Dr Catherine Ebbs; David Carter at the London Regional
   Genomics Centre; and our colleagues and trainees at the London Regional
   Cancer Program, who provided helpful discussions in the preparation of
   this manuscript. This research was funded by grant no. 016506 from the
   Canadian Breast Cancer Research Alliance 'Special Competition in New
   Approaches to Metastatic Disease' with special funding support from the
   Canadian Breast Cancer Foundation and The Cancer Research Society. AFC
   is Canada Research Chair in Oncology, supported by the Canada Research
   Chairs Program.
CR [Anonymous], UCSC Genome Browser LiftOver Utility
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cavalli LR, 2003, CANCER GENET CYTOGEN, V146, P33, DOI 10.1016/S0165-4608(03)00123-7
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Choi IS, 2007, MODERN PATHOL, V20, P802, DOI 10.1038/modpathol.3800825
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Downey T, 2006, METHOD ENZYMOL, V411, P256, DOI 10.1016/S0076-6879(06)11013-7
   Driouch K, 2007, CLIN EXP METASTAS, V24, P575, DOI 10.1007/s10585-007-9110-x
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fabianowska-Majewska K, 2006, NUCLEOS NUCLEOT NUCL, V25, P1025, DOI 10.1080/15257770600890640
   Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Guo HS, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-110
   Gupta A, 2003, CANCER RES, V63, P664
   Harms JF, 2003, CLIN EXP METASTAS, V20, P11, DOI 10.1023/A:1022530100931
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hu XC, 2003, ONCOL REP, V10, P1811
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jamerson MH, 2004, J MAMMARY GLAND BIOL, V9, P27, DOI 10.1023/B:JOMG.0000023586.69263.0b
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kluger HM, 2005, CANCER RES, V65, P5578, DOI 10.1158/0008-5472.CAN-05-0108
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   Mandel S, 2007, J BIOL CHEM, V282, P34448, DOI 10.1074/jbc.M704756200
   Mimori K, 2005, CLIN EXP METASTAS, V22, P59, DOI 10.1007/s10585-005-4417-y
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Montero AJ, 2006, CANCER BIOL THER, V5, P1494, DOI 10.4161/cbt.5.11.3299
   Murata H, 2005, CANCER LETT, V223, P143, DOI 10.1016/j.canlet.2004.09.039
   Nimmrich I, 2008, BREAST CANCER RES TR, V111, P429, DOI 10.1007/s10549-007-9800-8
   Opavsky R, 2007, PLOS GENET, V3, P1757, DOI 10.1371/journal.pgen.0030167
   Osanai T, 2005, JPN J CLIN ONCOL, V35, P121, DOI 10.1093/jjco/hyi036
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Quintana FJ, 2006, ANN NY ACAD SCI, V1070, P500, DOI 10.1196/annals.1317.069
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2
   Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200
   Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sigalotti L, 2007, J CELL PHYSIOL, V212, P330, DOI 10.1002/jcp.21066
   Stark AM, 2005, J CANCER RES CLIN, V131, P191, DOI 10.1007/s00432-004-0629-9
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751
   Woelfle U, 2003, CANCER RES, V63, P5679
   Xu J, 2008, CANCER GENET CYTOGEN, V181, P1, DOI 10.1016/j.cancergencyto.2007.05.030
NR 58
TC 54
Z9 65
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2008
VL 10
IS 4
AR R62
DI 10.1186/bcr2121
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 360FQ
UT WOS:000260043500013
PM 18638373
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sunami, E
   Shinozaki, M
   Sim, MS
   Nguyen, SL
   Vu, AT
   Giuliano, AE
   Hoon, DSB
AF Sunami, Eiji
   Shinozaki, Masaru
   Sim, Myung-Shin
   Nguyen, Sandy L.
   Vu, Anh-Thu
   Giuliano, Armando E.
   Hoon, Dave S. B.
TI Estrogen receptor and HER2/neu status affect epigenetic differences of
   tumor-related genes in primary breast tumors
SO BREAST CANCER RESEARCH
LA English
DT Article
ID TRIPLE-NEGATIVE PHENOTYPE; ABERRANT PROMOTER METHYLATION; LYMPH-NODE
   METASTASIS; DNA METHYLATION; RISK-FACTORS; E-CADHERIN; SERINE-PROTEASE;
   SUPPRESSOR GENE; BASAL-LIKE; IN-SITU
AB Introduction Estrogen receptor (ER)-positive breast cancers are considered prognostically more favorable than ER-negative tumors, whereas human epidermal growth factor receptor (HER) 2/neu-positive breast cancers are associated with worse prognosis. The objective of the present study was to determine whether ER-positive and ER-negative status relates to epigenetic changes in breast cancer-related genes. To evaluate epigenetic differences in tumor-related genes relating to ER and HER2/neu status of primary tumors, we examined the promoter methylation status of the promoter region CpG islands of eight major breast tumor-related genes (RASSF1A, CCND2, GSPT1, TWIST, APC, NES1, RAR beta 2, and CDH1).
   Methods Paired ER-positive (n = 65) and ER-negative (n = 65) primary breast tumors (n = 130) matched for prognostic factors were assessed. DNA was extracted from paraffin-embedded tumor tissue after microdissection, and methylation-specific PCR and capillary-array electrophoresis analysis were performed.
   Results In early stages of tumor progression (T1 and N0), RASSF1A and CCND2 were significantly (P < 0.05) more methylated in ER-positive than in ER-negative tumors. GSTP1 hypermethylation was more frequent in the lymph node metastasis positive group than in the negative group. Double negative (ER-negative, HER2/neu-negative) breast cancers had significantly lesser frequencies of RASSF1A, GSTP1, and APC methylation (P < 0.0001, P < 0.0001, and P = 0.0035, respectively). Both ER and HER2/neu status correlated independently with these epigenetic alterations.
   Conclusion We demonstrated significant differences in tumor-related gene methylation patterns relevant to ER and HER2/neu status of breast tumors. This may be of significance in the assessment of targeted therapy resistance related to ER and HER2/neu status in breast cancer patients.
C1 [Sunami, Eiji; Shinozaki, Masaru; Nguyen, Sandy L.; Vu, Anh-Thu; Hoon, Dave S. B.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Sim, Myung-Shin] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Biostat, Santa Monica, CA 90404 USA.
   [Giuliano, Armando E.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Surg Oncol, Santa Monica, CA 90404 USA.
C3 John Wayne Cancer Institute; John Wayne Cancer Institute; John Wayne
   Cancer Institute
RP Hoon, DSB (通讯作者)，St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Balsari A, 1999, AM J PATHOL, V155, P1543, DOI 10.1016/S0002-9440(10)65470-3
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chu KC, 2002, BREAST CANCER RES TR, V74, P199, DOI 10.1023/A:1016361932220
   Colditz GA, 2004, JNCI-J NATL CANCER I, V96, P218, DOI 10.1093/jnci/djh025
   D'Andrea MR, 2007, BREAST CANCER RES TR, V101, P279, DOI 10.1007/s10549-006-9300-2
   Duffy MJ, 2006, CRIT REV CL LAB SCI, V43, P325, DOI 10.1080/10408360600739218
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Francis G, 2006, PATHOLOGY, V38, P391, DOI 10.1080/00313020600922488
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Goyal J, 1998, CANCER RES, V58, P4782
   Greene F., 2002, Cancer Staging Manual, V6th
   Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110
   Huang HJ, 2005, ANN ONCOL, V16, P1755, DOI 10.1093/annonc/mdi364
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kepple J, 2006, AM J SURG, V192, P68, DOI 10.1016/j.amjsurg.2006.04.002
   Key TJ, 2003, BREAST, V12, P412, DOI 10.1016/S0960-9776(03)00145-0
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Lee MG, 2001, CANCER RES, V61, P6688
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Liu XL, 1996, CANCER RES, V56, P3371
   Ma HY, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1514
   Mahler-Araujo B, 2008, J CLIN PATHOL, V61, P615, DOI 10.1136/jcp.2007.053991
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Nass SJ, 2000, CANCER RES, V60, P4346
   Padar A, 2003, CLIN CANCER RES, V9, P4730
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   READ LD, 1990, CANCER RES, V50, P3947
   Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413
   Rusiecki JA, 2005, CANCER DETECT PREV, V29, P419, DOI 10.1016/j.cdp.2005.07.004
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339
   Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zanardi S, 2006, ENDOCR-RELAT CANCER, V13, P51, DOI 10.1677/erc.1.00938
NR 53
TC 80
Z9 93
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2008
VL 10
IS 3
AR R46
DI 10.1186/bcr2098
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 329LR
UT WOS:000257869600014
PM 18485221
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Veeck, J
   Bektas, N
   Hartmann, A
   Kristiansen, G
   Heindrichs, U
   Knüchel, R
   Dahl, E
AF Veeck, Juergen
   Bektas, Nuran
   Hartmann, Arndt
   Kristiansen, Glen
   Heindrichs, Uwe
   Knuechel, Ruth
   Dahl, Edgar
TI Wnt signalling in human breast cancer: expression of the putative Wnt
   inhibitor Dickkopf-3 (<i>DKK3</i>) is frequently suppressed by promoter
   hypermethylation in mammary tumours
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ANTAGONIST FAMILY GENES; EPIGENETIC INACTIVATION; DOWN-REGULATION;
   ABERRANT METHYLATION; REDUCED EXPRESSION; DNA METHYLATION; REIC/DKK-3
   GENE; CELLS; RECEPTOR; GROWTH
AB Introduction Expression of the putative Wnt signalling inhibitor Dickkopf-3 (DKK3) is frequently lost in human cancer tissues because of aberrant 5'-cytosine methylation within the DKK3 gene promoter. Since other Wnt signalling inhibitors have been reported to be targets of epigenetic inactivation in human breast cancer, we questioned if DKK3 expression is also epigenetically silenced during breast carcinogenesis and therefore might contribute to oncogenic Wnt signalling commonly found in this disease.
   Methods DKK3 mRNA expression and DKK3 promoter methylation were determined by RT-PCR, realtime PCR and methylation-specific PCR in breast cell lines (n = 9), normal breast tissues (n = 19) and primary breast carcinomas (n = 150), respectively. In vitro DNA demethylation was performed by incubating breast cell lines with 5-aza-2'-deoxycytidine and trichostatin A. DKK3 protein expression was analysed by immunohistochemistry in breast carcinomas (n = 16) and normal breast tissues (n = 8). Methylation data were statistically correlated with clinical patient characteristics. All statistical evaluations were performed with SPSS 14.0 software.
   Results DKK3 mRNA was downregulated in 71% (five of seven) of breast cancer cell lines and in 68% of primary breast carcinomas (27 of 40) compared with benign cell lines and normal breast tissues, respectively. A DNA demethylating treatment of breast cell lines resulted in strong induction of DKK3 mRNA expression. In tumourous breast tissues, DKK3 mRNA downregulation was significantly associated with DKK3 promoter methylation (p < 0.001). Of the breast carcinomas, 61% (92 of 150) revealed a methylated DKK3 promoter, whereas 39% (58 of 150) retained an unmethylated promoter. Loss of DKK3 expression in association with DKK3 promoter methylation (p = 0.001) was also confirmed at the protein level (p < 0.001). In bivariate analysis, DKK3 promoter methylation was not associated with investigated clinicopathological parameters except patient age (p = 0.007).
   Conclusions DKK3 mRNA expression and consequently DKK3 protein expression become frequently downregulated during human breast cancer development due to aberrant methylation of the DKK3 promoter. Since DKK3 is thought to negatively regulate oncogenic Wnt signalling, DKK3 may be a potential tumour suppressor gene in normal breast tissue.
C1 [Veeck, Juergen; Bektas, Nuran; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany.
   [Hartmann, Arndt] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
   [Kristiansen, Glen] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland.
   [Heindrichs, Uwe] Rhein Westfal TH Aachen, Univ Hosp, Dept Gynecol Breast Surg & Mastol, D-52074 Aachen, Germany.
   [Heindrichs, Uwe] Brustzentrum Aachen Stadt, D-52074 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Erlangen Nuremberg; University of Zurich; University Zurich Hospital;
   RWTH Aachen University; RWTH Aachen University Hospital
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Veeck, Jurgen/B-9256-2008
OI Veeck, Jurgen/0000-0002-2952-6159
FU Bundesministerium fur Bildung und Forschung [01KW0401]
FX The expert technical assistance of Sevim Alkaya, Sonja von Serenyi and
   Inge Losen is greatly appreciated. We thank Dr Dieter Niederacher
   (Heinrich-Heine University, Dusseldorf, Germany) and Professor Matthias
   Durst (Friedrich-Schiller University, Jena, Germany) for kindly
   providing patient samples. This work is a research project within the
   German Human Genome Project and has been supported by a
   Bundesministerium fur Bildung und Forschung grant 01KW0401 to Edgar
   Dahl.
CR Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Edamura K, 2007, CANCER GENE THER, V14, P765, DOI 10.1038/sj.cgt.7701071
   ELSTON CW, 1993, J CLIN PATHOL, V46, P189
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Henderson DJ, 2006, TRENDS CARDIOVAS MED, V16, P38, DOI 10.1016/j.tcm.2005.11.005
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952
   Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138
   Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661
   KAWASAKI K, 2008, CANCER GENE THER, DOI DOI 10.1038/CAT.2008.58
   Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0
   Kuphal S, 2006, ONCOGENE, V25, P5027, DOI 10.1038/sj.onc.1209508
   Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4
   Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X
   Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0
   Namba M, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P27
   Nozaki I, 2001, INT J ONCOL, V19, P117
   Polakis P, 2000, GENE DEV, V14, P1837
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Román-Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   SOBIN L., 1997, TNM CLASSIFICATION M
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki M, 2007, CLIN CANCER RES, V13, P6087, DOI 10.1158/1078-0432.CCR-07-0591
   Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6
   Tanimoto R, 2007, INT J MOL MED, V19, P363
   Tavassoli FA., 2003, WHO CLASSIFICATION T
   Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067
   Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972
   Untergasser G, 2002, CANCER RES, V62, P6255
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267
NR 46
TC 67
Z9 72
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2008
VL 10
IS 5
AR R82
DI 10.1186/bcr2151
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 381TO
UT WOS:000261559000019
PM 18826564
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Dejligbjerg, M
   Grauslund, M
   Christensen, IJ
   Tjornelund, J
   Jensen, PB
   Sehested, M
AF Dejligbjerg, Marielle
   Grauslund, Morten
   Christensen, Ib Jarle
   Tjornelund, Jette
   Jensen, Peter Buhl
   Sehested, Maxwell
TI Identification of predictive biomarkers for the histone deacetylase
   inhibitor belinostat in a panel of human cancer cell lines
SO CANCER BIOMARKERS
LA English
DT Article
DE HDACi; belinostat; predictive biomarker; sensitivity; cancer cell panel
ID GENE-EXPRESSION; HDAC INHIBITORS; BREAST-CANCER; CARCINOMA;
   TRANSCRIPTION; SENSITIVITY; TARGET; SKI; REPRESSION; RESISTANCE
AB Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics rapidly approaching clinical use. HDACi increases acetylation levels of histone and non-histone proteins and causes an alteration in gene-expression levels, ultimately resulting in proliferation arrest or apoptosis of especially cancer cells. However, the precise mechanism of action of this class of therapeutics and the genes implicated in sensitivity remain obscure. Hence, there is a need for identifying predictive biomarkers. In this study, we examined the gene-expression levels of selected possible HDACi biomarkers, as suggested in the literature. This was correlated with the inherent sensitivity towards the HDACi belinostat in a panel of 18 wild-type cancer cell lines with up to a 30-fold difference in chemosensitivity, which matched IC50 data from the NCI60 screen. Of 16 genes examined, 4 showed a correlation in their expression levels to belinostat sensitivity: Ornithine decarboxylase (ODC1), v-ski sarcoma viral oncogene homolog ( SKI), signal transducer and activator of transcription 1 (STAT1), and thymidylate synthetase (TYMS). Including ODC and SKI simultaneously further strengthened the model. Further, there was no correlation between sensitivity and intracellular belinostat uptake or with histone and tubulin acetylation. Therefore, the genes identified in this study may be potential biomarkers for predicting clinical HDACi sensitivity.
C1 [Dejligbjerg, Marielle; Grauslund, Morten; Tjornelund, Jette; Jensen, Peter Buhl; Sehested, Maxwell] Topo Target AS, DK-2100 Copenhagen, Denmark.
   [Dejligbjerg, Marielle; Grauslund, Morten; Sehested, Maxwell] Natl Univ Hosp, Expt Pathol Unit, Copenhagen, Denmark.
   [Christensen, Ib Jarle] Natl Univ Hosp, Finsen Lab, Copenhagen Bioctr, DK-2200 Copenhagen, Denmark.
   [Jensen, Peter Buhl] Natl Univ Hosp, Finsen Lab, Dept Oncol, DK-2200 Copenhagen, Denmark.
RP Dejligbjerg, M (通讯作者)，Topo Target AS, Symb Sci Pk,Fruebjergvej 3, DK-2100 Copenhagen, Denmark.
EM mdejligbjerg@gmail.com
RI Grauslund, Morten/I-1133-2019
OI Grauslund, Morten/0000-0001-6416-8660
CR Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200
   Benecke A, 2006, EUR PHYS J E, V19, P353, DOI 10.1140/epje/i2005-10068-8
   Brieger A, 2004, BIOCHEM PHARMACOL, V68, P85, DOI 10.1016/j.bcp.2004.02.028
   Carey N, 2006, CURR OPIN PHARMACOL, V6, P369, DOI 10.1016/j.coph.2006.03.010
   Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243
   de Ruijter AJM, 2005, EXP CELL RES, V309, P451, DOI 10.1016/j.yexcr.2005.06.024
   DELEIJ L, 1985, CANCER RES, V45, P6024
   Epping MT, 2007, P NATL ACAD SCI USA, V104, P17777, DOI 10.1073/pnas.0702518104
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007
   Gojo I, 2007, BLOOD, V109, P2781, DOI 10.1182/blood-2006-05-021873
   Gray SG, 2004, INT J ONCOL, V24, P773
   Gunawardena RW, 2007, J BIOL CHEM, V282, P20116, DOI 10.1074/jbc.M701406200
   Hobbs CA, 2002, CANCER RES, V62, P67
   Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003
   Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200
   Kobayashi N, 2007, GENES CELLS, V12, P375, DOI 10.1111/j.1365-2443.2007.01052.x
   Lai JP, 2006, GASTROENTEROLOGY, V130, P2130, DOI 10.1053/j.gastro.2006.02.056
   Marks PA, 2006, SEMIN CANCER BIOL, V16, P436, DOI 10.1016/j.semcancer.2006.09.005
   Moore PS, 2004, BBA-MOL CELL RES, V1693, P167, DOI 10.1016/j.bbamcr.2004.07.001
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Nicolini A, 2006, BIOMED PHARMACOTHER, V60, P548, DOI 10.1016/j.biopha.2006.07.086
   Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412
   Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100
   Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Ritter M, 2006, LEUKEMIA, V20, P437, DOI 10.1038/sj.leu.2404093
   Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773
   Sakuma T, 2006, INT J ONCOL, V29, P117
   Sasakawa Y, 2005, BIOCHEM PHARMACOL, V69, P603, DOI 10.1016/j.bcp.2004.11.008
   Saunders LR, 2006, MOL CANCER THER, V5, P2777, DOI 10.1158/1535-7163.MCT-06-0298
   Tumber A, 2007, CANCER CHEMOTH PHARM, V60, P275, DOI 10.1007/s00280-006-0374-7
   Xu JK, 2007, CURR MED CHEM, V14, P689, DOI 10.2174/092986707780059580
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
NR 37
TC 20
Z9 20
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2008
VL 4
IS 2
BP 101
EP 109
DI 10.3233/CBM-2008-4206
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 303UW
UT WOS:000256067400006
PM 18503161
DA 2025-01-12
ER

PT J
AU Liu, YQ
   Zhao, Y
   Wu, CY
   Ho, KS
   Koh, PK
   Chong, SF
   Eu, KW
AF Liu, Yanqun
   Zhao, Yi
   Wu, Chiyu
   Ho, Kok Sun
   Koh, Poh Koon
   Chong, Stephanie Fook
   Eu, Kong Weng
TI Modest promoter methylation of E-cadherin gene in sporadic colorectal
   cancers: A quantitative analysis
SO CANCER BIOMARKERS
LA English
DT Article
DE E-cadherin downregulation; epigenetic silencing; methyLight; colorectal
   cancer
ID COLON-CARCINOMA CELLS; 5' CPG ISLAND; DNA METHYLATION; REDUCED
   EXPRESSION; BREAST-CANCER; HYPERMETHYLATION; PROGRESSION; TRANSCRIPTION;
   MOLECULES; ADHESION
AB Although E-cadherin expression is frequently reduced in colorectal cancers (CRCs), this does not appear to be due to gene mutation or allele loss. We investigated the hypothesis that promoter methylation could be responsible for supression of E-cadherin expression in 142 pairs of sporadic CRCs and respective normal mucosae. E-cadherin expression was examined by Western blot. E-cadherin methylation at two promoter regions was quantitatively measured by methylation specific real time PCR (MethyLight). We found that E-cadherin protein levels were significantly lower in CRCs, even in Dukes' A tumors, compared to normal mucosae. Decreased E-cadherin protein expression in CRCs was an independent poor prognostic factor in multivariate disease-free survival analysis. However, the extent of DNA methylation was extremely modest at both regions of the E-cadherin promoter. There was no correlation between DNA methylation and E-cadherin protein levels in either tumors or matched normal tissues. These findings suggested that supression of E-cadherin expression in CRCs is a significant event and is possibly involved in both carcinoma development and progression. However, our data did not support a crucial role of promoter methylation of the E-cadherin gene in the remarkable downregulation of E-cadherin expression in CRCs. Methylated E-cadherin gene as a CRC biomarker therefore needs further validation.
C1 [Liu, Yanqun; Wu, Chiyu; Ho, Kok Sun; Koh, Poh Koon; Eu, Kong Weng] Singapore Gen Hosp, Dept Colorectal Surg, Singapore 169608, Singapore.
   [Zhao, Yi; Chong, Stephanie Fook] Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore.
C3 Singapore General Hospital; Singapore General Hospital
RP Liu, YQ (通讯作者)，Singapore Gen Hosp, Dept Colorectal Surg, Outram Rd, Singapore 169608, Singapore.
EM yan.qun@sgh.com.sg
RI Liu, Yanqun/F-2305-2010
CR Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495
   BREEN E, 1995, ANN SURG ONCOL, V2, P378, DOI 10.1007/BF02306369
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Darwanto A, 2003, CANCER SCI, V94, P442, DOI 10.1111/j.1349-7006.2003.tb01462.x
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316
   GAGLIARDI G, 1995, VIRCHOWS ARCH, V426, P149
   Garinis GA, 2002, J PATHOL, V198, P442, DOI 10.1002/path.1237
   Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hao XP, 1997, ANTICANCER RES, V17, P2241
   Harington KJ, 2000, ANN SURG ONCOL, V7, P783, DOI 10.1007/s10434-000-0783-5
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ikeguchi M, 2000, SCAND J GASTROENTERO, V35, P839
   Ilyas M, 1997, GUT, V40, P654, DOI 10.1136/gut.40.5.654
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   KINSELLA AR, 1994, CLIN EXP METASTAS, V12, P335, DOI 10.1007/BF01753841
   Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108
   Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8
   Lin SY, 2004, ONCOL REP, V11, P341
   LIU Y, 2008, IN PRESS CANC INVEST
   Mohri Y, 1997, SURG TODAY, V27, P606, DOI 10.1007/BF02388215
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ngan CY, 2007, J SURG ONCOL, V95, P652, DOI 10.1002/jso.20638
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200
   Peña C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   Reinhold WC, 2007, MOL CANCER THER, V6, P391, DOI 10.1158/1535-7163.MCT-06-0609
   Roca F, 2006, J SURG ONCOL, V93, P151, DOI 10.1002/jso.20413
   Saito Y, 1998, INT J ONCOL, V12, P293
   Schuhmacher C, 1999, VIRCHOWS ARCH, V434, P489, DOI 10.1007/s004280050373
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367
   Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441
NR 39
TC 5
Z9 7
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2008
VL 4
IS 2
BP 111
EP 120
DI 10.3233/CBM-2008-4207
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 303UW
UT WOS:000256067400007
PM 18503162
DA 2025-01-12
ER

PT J
AU Ye, F
   Zhang, SF
   Xie, X
   Lu, WG
AF Ye, Feng
   Zhang, Song-Fa
   Xie, Xing
   Lu, Wei-Guo
TI OPCML gene promoter methylation and gene expression in tumor and stroma
   cells of invasive cervical carcinoma
SO CANCER INVESTIGATION
LA English
DT Article
DE OPCML; promoter methylation; epigenetics; cervical carcinoma
ID BREAST-CANCER; SUPPRESSOR GENE; OPIOID-BINDING; HETEROZYGOSITY;
   PROFILES; LOCALIZATION; PROGRESSION; HISTORY; PROTEIN; OBCAM
AB To investigate the CpG island methylation and the mRNA expression of OPCML gene in patients with cervical carcinoma, we collected tumor and stroma cells from 36 invasive cervical carcinoma samples and 16 normal cervical tissues as well as Hela cells. Methylation specific PCR was used to detect promoter CpG island methylation status, and fluorescence quantitative RT-PCR was used to detection of OPCML gene expression. Our data showed that OPCML gene promoter methylation may play an important role in the carcinogenesis of cervical carcinoma and OPCML gene may be a cervical carcinoma-associated candidate TSG (tumor suppressor gene).
C1 [Ye, Feng; Lu, Wei-Guo] Zhejiang Univ, Zhejiang Prov Womens Hosp, Sch Med, Womens Reprod Hlth Lab, Hangzhou 310006, Peoples R China.
   [Zhang, Song-Fa] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Obstet & Gynecol, Shanghai 200030, Peoples R China.
   [Xie, Xing] Zhejiang Univ, Womens Hosp, Sch Med, Dept Gynecol Oncol, Hangzhou 310027, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University; Zhejiang University
RP Lu, WG (通讯作者)，Zhejiang Univ, Zhejiang Prov Womens Hosp, Sch Med, Womens Reprod Hlth Lab, Xueshi Rd 2, Hangzhou 310006, Peoples R China.
EM lvwg202@sina.com
CR Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107
   Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1
   Connolly KC, 1999, CANCER RES, V59, P2806
   Davis M, 1996, CANCER RES, V56, P741
   Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866
   Funatsu N, 1999, J BIOL CHEM, V274, P8224, DOI 10.1074/jbc.274.12.8224
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hachisuka A, 1999, BRAIN RES, V842, P482, DOI 10.1016/S0006-8993(99)01831-4
   HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Kersemaekers AMF, 1999, GENE CHROMOSOME CANC, V26, P346, DOI 10.1002/(SICI)1098-2264(199912)26:4<346::AID-GCC9>3.0.CO;2-D
   KNUDSON AG, 1993, MED PEDIATR ONCOL, V21, P193, DOI 10.1002/mpo.2950210308
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   LEVITT P, 1984, SCIENCE, V223, P299, DOI 10.1126/science.6199842
   Matrisian LM, 2001, CANCER RES, V61, P3844
   Matsumoto N, 2003, BRIT J CANCER, V89, P707, DOI 10.1038/sj.bjc.6601141
   Mei FC, 2005, FASEB J, V19, P497, DOI 10.1096/fj.05-4586fje
   Miyai K, 2004, GYNECOL ONCOL, V94, P115, DOI 10.1016/j.ygyno.2004.04.013
   Miyata S, 2000, J COMP NEUROL, V424, P74, DOI 10.1002/1096-9861(20000814)424:1<74::AID-CNE6>3.0.CO;2-5
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   MURTHY NS, 1990, BRIT J CANCER, V61, P732, DOI 10.1038/bjc.1990.164
   Ntougkos E, 2005, CLIN CANCER RES, V11, P5764, DOI 10.1158/1078-0432.CCR-04-2388
   OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186
   Phillips JL, 2001, CANCER RES, V61, P8143
   SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x
   Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183
   Shen CY, 2000, CANCER RES, V60, P3884
   STRUYK AF, 1995, J NEUROSCI, V15, P2141, DOI 10.1523/JNEUROSCI.15-03-02141.1995
   Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Zhang Z, 2006, ONCOGENE, V25, P5436, DOI 10.1038/sj.onc.1209530
   ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071
NR 35
TC 22
Z9 25
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0735-7907
EI 1532-4192
J9 CANCER INVEST
JI Cancer Invest.
PY 2008
VL 26
IS 6
BP 569
EP 574
DI 10.1080/07357900701837044
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 319CO
UT WOS:000257141900004
PM 18584347
DA 2025-01-12
ER

PT J
AU Liu, YQ
   Hong, Y
   Zhao, Y
   Ismail, TM
   Wong, YH
   Eu, KW
AF Liu, Yanqun
   Hong, Yi
   Zhao, Yi
   Ismail, Tuty M.
   Wong, YuHui
   Eu, Kong Weng
TI Histone H3 (lys-9) deacetylation is associated with transcriptional
   silencing of E-cadherin in colorectal cancer cell lines
SO CANCER INVESTIGATION
LA English
DT Article
DE E-cadherin; epigenetic silencing; histone H3; acetylation; methylation;
   colorectal cancer
ID COLON-CARCINOMA CELLS; HUMAN BREAST-CANCER; CPG ISLAND; DNA METHYLATION;
   ESTROGEN-RECEPTOR; H3 METHYLATION; EXPRESSION; GENE; COMPLEX; ACTIVATION
AB Epigenetic parameters linked to E-cadherin gene were investigated in 5 human colorectal cancer cell lines. Treatment with trichostatin A led to enhanced acetylation of histone H3-K9 with concurrent induction of E-cadherin mRNA in 3 E-cadherin low/negative cell lines that are not DNA methylated. Co-treatment with 5-aza-2'-deoxycytidine and trichostatin A resulted in additive/synergic induction of E-cadherin mRNA in all 5 cell lines with concomitant enhancement of histone H3-K9 acetylation in 4 E-cadherin low/negative cell lines. Our results suggest that histone H3-K9 deacetylation appears to play a crucial role in transcriptional repression of E-cadherin in colorectal cancers.
C1 [Liu, Yanqun; Hong, Yi; Ismail, Tuty M.; Wong, YuHui; Eu, Kong Weng] Singapore Gen Hosp, Dept Colorectal Surg, Singapore 169608, Singapore.
   [Zhao, Yi] Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore.
C3 Singapore General Hospital; Singapore General Hospital
RP Liu, YQ (通讯作者)，Singapore Gen Hosp, Dept Colorectal Surg, Outram Rd, Singapore 169608, Singapore.
EM liu.yan.qun@sgh.com.sg
RI Liu, Yanqun/F-2305-2010
CR BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495
   BREEN E, 1995, ANN SURG ONCOL, V2, P378, DOI 10.1007/BF02306369
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Fang JY, 2004, CELL RES, V14, P217, DOI 10.1038/sj.cr.7290222
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Garinis GA, 2002, J PATHOL, V198, P442, DOI 10.1002/path.1237
   Ghadimi BM, 1999, EUR J CANCER, V35, P60, DOI 10.1016/S0959-8049(98)00344-X
   Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831
   Harington KJ, 2000, ANN SURG ONCOL, V7, P783, DOI 10.1007/s10434-000-0783-5
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ikeguchi M, 2000, SCAND J GASTROENTERO, V35, P839
   Ilyas M, 1997, GUT, V40, P654, DOI 10.1136/gut.40.5.654
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   KINSELLA AR, 1994, CLIN EXP METASTAS, V12, P335, DOI 10.1007/BF01753841
   Koizume S, 2003, BIOL CHEM, V384, P787, DOI 10.1515/BC.2003.087
   Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593
   Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108
   Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8
   Mohri Y, 1997, SURG TODAY, V27, P606, DOI 10.1007/BF02388215
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204
   Reinhold WC, 2007, MOL CANCER THER, V6, P391, DOI 10.1158/1535-7163.MCT-06-0609
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Saito Y, 1998, INT J ONCOL, V12, P293
   Schuhmacher C, 1999, VIRCHOWS ARCH, V434, P489, DOI 10.1007/s004280050373
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2
   Yang XW, 2000, CANCER RES, V60, P6890
NR 39
TC 17
Z9 22
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0735-7907
EI 1532-4192
J9 CANCER INVEST
JI Cancer Invest.
PY 2008
VL 26
IS 6
BP 575
EP 582
DI 10.1080/07357900701837168
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 319CO
UT WOS:000257141900005
PM 18584348
DA 2025-01-12
ER

PT J
AU Gao, BN
   Xie, XJ
   Huang, CX
   Shames, DS
   Chen, TTL
   Lewis, CM
   Bian, AH
   Zhang, BF
   Olopade, OI
   Garber, JE
   Euhus, DM
   Tomlinson, GE
   Minna, JD
AF Gao, Boning
   Xie, Xian-Jin
   Huang, Chunxian
   Shames, David S.
   Chen, Tina T-L.
   Lewis, Cheryl M.
   Bian, Aihua
   Zhang, Bifeng
   Olopade, Olufunmilayo I.
   Garber, Judy E.
   Euhus, David M.
   Tomlinson, Gail E.
   Minna, John D.
TI <i>RASSF1A</i> polymorphism A133S is associated with early onset breast
   cancer in <i>BRCA1/2</i> mutation carriers
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR RASSF1A; EPIGENETIC INACTIVATION; LUNG; RAS; 3P21.3;
   GENES; RISK
AB The tumor suppressor gene RASSF1A regulates cell cycle progression, apoptosis, and microtubule stability and is inactivated by promoter methylation in similar to 50% of breast cancers. It has been shown previously that the polymorphism A133S in RASSF1A reduces its ability to regulate cell cycle progression and this polymorphism is associated with an increased risk of breast cancer. We analyzed the frequency of RASSF1A A133S in 190 Caucasian women without breast cancer and 653 patients with breast cancer including 138 BRCA1 and BRCA2 (BRCA1/2) mutation carriers, 395 non-BRCA1/2 mutations carriers, and 120 untested for BRCA1/2 mutations. Patients with breast cancer had a higher frequency of A133S than the controls [P = 0.017; odds ratios (OR), 1.71; 95% confidence intervals (95% CI), 1.10-2.66]. There is also a higher frequency of A133S in patients with higher familial breast cancer risk (P = 0.029; OR, 1.76; 95% CI, 1.06-2.92) and patients carrying BRCA1/2 mutations (P = 0.037, OR, 1.82; 95% CI, 1.04-3.18). Importantly, we found that the co-occurrence of a BRCA1 or BRCA2 mutation and A133S in RASSF1A was associated with earlier onset of breast cancer compared with those individuals with either a BRCA-1/2 mutation or the A133S polymorphism alone (36.0 versus 42.0 years old, P = 0.002). Our data suggest that the presence of the RASSF1A A133S polymorphism is associated with breast cancer pathogenesis in general and modifies breast cancer age of onset in BBCA1/2 mutations carriers. Our results warrant a large-scale study to examine the effect of the A133S polymorphism in the development of breast and other types of cancers.
C1 [Gao, Boning; Huang, Chunxian; Shames, David S.; Tomlinson, Gail E.; Minna, John D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   [Gao, Boning; Xie, Xian-Jin; Huang, Chunxian; Shames, David S.; Bian, Aihua; Euhus, David M.; Minna, John D.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.
   [Gao, Boning; Huang, Chunxian; Shames, David S.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
   [Xie, Xian-Jin; Bian, Aihua] Univ Texas SW Med Ctr Dallas, Div Biostat, Dallas, TX 75390 USA.
   [Chen, Tina T-L.; Tomlinson, Gail E.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
   [Lewis, Cheryl M.; Euhus, David M.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.
   [Zhang, Bifeng; Olopade, Olufunmilayo I.] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA.
   [Garber, Judy E.] Dana Farber Canc Inst, Dept Oncol, Ctr Populat Sci, Boston, MA 02115 USA.
   [Tomlinson, Gail E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78284 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Chicago; University of
   Chicago Medical Center; Harvard University; Dana-Farber Cancer
   Institute; University of Texas System; University of Texas Health
   Science Center at San Antonio
RP Gao, BN (通讯作者)，Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM boning.gao@utsouthwestern.edu
RI Tomlinson, Gail/AAR-9776-2020; Minna, John/AAB-1036-2022
OI Shames, David/0000-0002-5900-1177
FU NCI NIH HHS [P50 CA070907, P50 CA070907-11, R01 CA071618, P50
   CA070907-10, CA71618, R01 CA071618-07, P50 CA070907-12, R01 CA071618-06,
   P50 CA70907] Funding Source: Medline
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Berry DA, 1997, J NATL CANCER I, V89, P227, DOI 10.1093/jnci/89.3.227
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Euhus DM, 2002, J NATL CANCER I, V94, P844, DOI 10.1093/jnci/94.11.844
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Lerman MI, 2000, CANCER RES, V60, P6116
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896
   LYNCH HT, 1991, ANN MED, V23, P475, DOI 10.3109/07853899109150505
   Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025
   Rebbeck TR, 2002, ENVIRON MOL MUTAGEN, V39, P228, DOI 10.1002/em.10050
   Schagdarsurengin U, 2005, INT J ONCOL, V27, P185
   Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Tommasi S, 2005, CANCER RES, V65, P92
   Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010
NR 19
TC 36
Z9 39
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2008
VL 68
IS 1
BP 22
EP 25
DI 10.1158/0008-5472.CAN-07-5183
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 247IP
UT WOS:000252072100007
PM 18172292
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Ying, JM
   Li, HY
   Yu, J
   Ng, KM
   Poon, FF
   Wong, SCC
   Chan, ATC
   Sung, JJY
   Tao, Q
AF Ying, Jianming
   Li, Hongyu
   Yu, Jun
   Ng, Ka Man
   Poon, Fan Fong
   Wong, Sze Chuen Cesar
   Chan, Anthony T. C.
   Sung, Joseph J. Y.
   Tao, Qian
TI <i>WNT5A</i> exhibits tumor-suppressive activity through antagonizing
   the Wnt/β-catenin signaling, and is frequently methylated in colorectal
   cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BETA-CATENIN; EPIGENETIC INACTIVATION; ECTOPIC EXPRESSION;
   EPITHELIAL-CELLS; GASTRIC-CANCER; WNT-5A PROTEIN; MESSENGER-RNA;
   BREAST-CANCER; GROWTH-FACTOR; UP-REGULATION
AB Purpose: Aberrant activation of theWnt/beta-catenin signaling pathway is associated with multiple tumors including colorectal cancer (CRC). WNT5A is a member of the nontransforming Wnt protein family, whose role in tumorigenesis is still ambiguous. We investigated its epigenetic alteration in CRCs.
   Experimental Design: We examined its expression and methylation in normal colon, CRC cell lines, and tumors. We also evaluated its tumor-suppressive function and its modulation to Wnt signaling in CRC cells.
   Results: WNT5A is silenced in most CRC cell lines due to promoter methylation, but is expressed in most normal tissues including the colon, and is unmethylated in normal colon epithelial cells. WNT5A expression could be reactivated by pharmacologic or genetic demethylation, indicating that methylation directly mediates its silencing. WNT5A methylation was frequently detected in CRC tumors (14 of 29, 48%), but only occasionally in paired normal colon tissues (2 of 15,13%; P = 0.025). Ectopic expression of WNT5A, but not its nonfunctional short-isoform with the WNT domain deleted, in silenced CRC cells resulted in substantial inhibition of tumor cell clonogenicity, which is associated with down-regulated intracellular beta-catenin protein level and concomitant decrease in p-catenin activity.
   Conclusions: WNT5A is frequently inactivated in CRC by tumor-specific methylation, and thus, is a potential biomarker. WNT5A could act as a tumor suppressor for CRC by antagonizing theWnt/beta-catenin signaling.
C1 [Ying, Jianming; Li, Hongyu; Ng, Ka Man; Poon, Fan Fong; Wong, Sze Chuen Cesar; Chan, Anthony T. C.; Tao, Qian] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China.
   [Ying, Jianming; Li, Hongyu; Yu, Jun; Ng, Ka Man; Poon, Fan Fong; Chan, Anthony T. C.; Sung, Joseph J. Y.; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Yu, Jun; Sung, Joseph J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
   [Ying, Jianming] Chinese Acad Med Sci, Inst Canc, Dept Pathol, Beijing 100021, Peoples R China.
   [Ying, Jianming] Chinese Acad Med Sci, Canc Hosp, Peking Union Med Coll, Beijing 100037, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Peking Union Medical College; Cancer
   Institute & Hospital - CAMS
RP Tao, Q (通讯作者)，Chinese Univ Hong Kong, Ctr Canc, Dept Clin Oncol, Prince Wales Hosp, Room 315, Shatin, Hong Kong, Peoples R China.
EM qtao@clo.cuhk.edu.hk
RI SUNG, Joseph J Y/R-3203-2018; Tao, Qian/T-4743-2018; Jun,
   Yu/D-8569-2015; Chan, Anthony Tak Cheung/R-3940-2018
OI SUNG, Joseph J Y/0000-0003-3125-5199; WONG, Sze Chuen
   Cesar/0000-0003-0058-140X; Tao, Qian/0000-0001-5383-4808; Jun,
   Yu/0000-0001-5008-2153; Chan, Anthony Tak Cheung/0000-0002-6912-8091
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463
   Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710
   Esteller M, 2000, CANCER RES, V60, P4366
   He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652
   Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330
   IOZZO RV, 1995, CANCER RES, V55, P3495
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jönsson M, 2002, CANCER RES, V62, P409
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x
   Leandersson K, 2006, NUCLEIC ACIDS RES, V34, P3988, DOI 10.1093/nar/gkl571
   LEJEUNE S, 1995, CLIN CANCER RES, V1, P215
   Leris ACA, 2005, ANTICANCER RES, V25, P731
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014
   Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417
   Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Saitoh T, 2002, INT J MOL MED, V9, P515
   Sato N, 2003, CANCER RES, V63, P3735
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278
   Yang SH, 2005, CLIN CANCER RES, V11, P612
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
NR 48
TC 176
Z9 211
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 1
PY 2008
VL 14
IS 1
BP 55
EP 61
DI 10.1158/1078-0432.CCR-07-1644
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 248FV
UT WOS:000252138800010
PM 18172252
DA 2025-01-12
ER

PT J
AU Carvalho, AL
   Jeronimo, C
   Kim, MM
   Henrique, R
   Zhang, Z
   Hoque, MO
   Chang, S
   Brait, M
   Nayak, CS
   Jiang, WW
   Claybourne, Q
   Tokumaru, Y
   Lee, J
   Goldenberg, D
   Garrett-Mayer, E
   Goodman, S
   Moon, CS
   Koch, W
   Westra, WH
   Sidransky, D
   Califano, JA
AF Carvalho, Andre Lopes
   Jeronimo, Carmen
   Kim, Michael M.
   Henrique, Rui
   Zhang, Zhe
   Hoque, Mohammad O.
   Chang, Steve
   Brait, Mariana
   Nayak, Chetan S.
   Jiang, Wei-Wen
   Claybourne, Quia
   Tokumaru, Yutaka
   Lee, Juna
   Goldenberg, David
   Garrett-Mayer, Elizabeth
   Goodman, Steven
   Moon, Chul-so
   Koch, Wayne
   Westra, William H.
   Sidransky, David
   Califano, Joseph A.
TI Evaluation of promoter hypermethylation detection in body fluids as a
   Screening/Diagnosis tool for head and neck squamous cell carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; THROAT RINSING FLUID; HUMAN BREAST-CANCER;
   REAL-TIME PCR; LUNG-CANCER; DNA METHYLATION; MULTIPLE GENES; ABERRANT
   METHYLATION; NASOPHARYNGEAL SWAB; PERIPHERAL-BLOOD
AB Purpose: To evaluate aberrant promoter hypermethylation of candidate tumor suppressor genes as a means to detect epigenetic alterations specific to solid tumors, including head and neck squamous cell carcinoma (HNSCC).
   Experimental Design: Using promoter regions identified via a candidate gene and discovery approach, we evaluated the ability of an expanded panel of CpG-rich promoters known to be differentia lly hypermethylated in HNSCC in detection of promoter hypermethylation in serum and salivary rinses associated with HNSCC.We did preliminary evaluation via quantitative methylation-specific PCR (Q-MSP) using a panel of 21 genes in a limited cohort of patients with HNSCC and normal controls. Using sensitivity and specificity for individual markers as criteria, we selected panels of eight and six genes, respectively, for use in salivary rinse and serum detection and tested these in an expanded cohort including up to 211 patients with HNSCC and 527 normal controls.
   Results: Marker panels in salivary rinses showed improved detection when compared with single markers, including a panel with 35% sensitivity and 90% specificity and a panel with 85% sensitivity and 30% specificity. A similar pattern was noted in serum panels, including a panel with 84.5% specificity with 50.0% sensitivity and a panel with sensitivity of 81.0% with specificity of 43.5%.We also noted that serum and salivary rinse compartments showed a differential pattern of methylation in normal subjects that influenced the utility of individual markers.
   Conclusions: Q-MSP detection of HNSCC in serum and salivary rinses using multiple targets offers improved performance when compared with single markers. Compartment-specific methylation in normal subjects affects the utility of Q-MSP detection strategies.
C1 [Carvalho, Andre Lopes; Jeronimo, Carmen; Kim, Michael M.; Henrique, Rui; Hoque, Mohammad O.; Chang, Steve; Brait, Mariana; Nayak, Chetan S.; Jiang, Wei-Wen; Claybourne, Quia; Tokumaru, Yutaka; Lee, Juna; Goldenberg, David; Garrett-Mayer, Elizabeth; Moon, Chul-so; Koch, Wayne; Sidransky, David; Califano, Joseph A.] Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA.
   [Westra, William H.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   [Zhang, Zhe; Goodman, Steven] Johns Hopkins Med Inst, Div Oncol Biostat, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine
RP Califano, JA (通讯作者)，Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, 601 N Caroline St,6th Floor, Baltimore, MD 21287 USA.
EM jcalifa@jhmi.edu
RI Chang, Steve/HIR-3815-2022; Nayak, Chetan/AHB-3885-2022; YU,
   JINGWEN/KRQ-6490-2024; Lopes Carvalho, Andre/S-7053-2016; Henrique,
   Rui/I-2757-2013; Jeronimo, Carmen/H-3284-2013
OI Lopes Carvalho, Andre/0000-0001-7214-6402; Brait,
   Mariana/0000-0002-1652-8921; Hoque, Mohammad
   Obaidul/0000-0001-6701-9978; Claybourne, Quia/0000-0003-1056-235X;
   Henrique, Rui/0000-0003-3171-4666; Jeronimo, Carmen/0000-0003-4186-5345;
   Garrett-Mayer, Elizabeth/0000-0003-4709-0333
FU NCI NIH HHS [P50 CA96784] Funding Source: Medline; NIDCR NIH HHS [1R01
   DE015939-01] Funding Source: Medline
CR Adrien LR, 2006, CYTOGENET GENOME RES, V114, P16, DOI 10.1159/000091923
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Bernard PS, 2002, CLIN CHEM, V48, P1178
   Chang HSW, 2004, CANCER-AM CANCER SOC, V101, P125, DOI 10.1002/cncr.20323
   Chang HW, 2003, INT J CANCER, V105, P851, DOI 10.1002/ijc.11162
   Chang HW, 2003, CLIN CANCER RES, V9, P1033
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   El-Naggar AK, 2001, J MOL DIAGN, V3, P164, DOI 10.1016/S1525-1578(10)60668-X
   Esteller M, 2001, CANCER RES, V61, P3225
   Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4
   Harden SV, 2003, CLIN CANCER RES, V9, P1370
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Hu SY, 2006, J CLIN ENDOCR METAB, V91, P98, DOI 10.1210/jc.2005-1810
   Hu YC, 2002, ONCOGENE, V21, P7289, DOI 10.1038/sj.onc.1205805
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Lee A, 2004, ARCH PATHOL LAB MED, V128, P1251
   López M, 2003, EUR J CANCER, V39, P2306, DOI 10.1016/S0959-8049(03)00550-1
   Maruya SI, 2004, CLIN CANCER RES, V10, P3825, DOI 10.1158/1078-0432.CCR-03-0370
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Nakahara Y, 2006, INT J ORAL MAX SURG, V35, P362, DOI 10.1016/j.ijom.2005.08.005
   Nass SJ, 2000, CANCER RES, V60, P4346
   *NCI, 2006, OR CANC SCREEN
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Nunes DN, 2000, ORAL ONCOL, V36, P525, DOI 10.1016/S1368-8375(00)00045-2
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Ransohoff DF, 2005, J NATL CANCER I, V97, P315, DOI 10.1093/jnci/dji054
   Reddy AN, 2003, CANCER RES, V63, P7694
   Rosas SLB, 2001, CANCER RES, V61, P939
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Speight PM, 2006, HEALTH TECHNOL ASSES, V10, P1
   Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993
   Usadel H, 2002, CANCER RES, V62, P371
   Wadsworth JT, 2004, ARCH OTOLARYNGOL, V130, P98, DOI 10.1001/archotol.130.1.98
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Wong IHN, 2003, CLIN CANCER RES, V9, P1047
   Wong TS, 2003, EUR J CANCER, V39, P1881, DOI 10.1016/S0959-8049(03)00428-3
   Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3
NR 48
TC 148
Z9 159
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 1
PY 2008
VL 14
IS 1
BP 97
EP 107
DI 10.1158/1078-0432.CCR-07-0722
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 248FV
UT WOS:000252138800016
PM 18172258
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Malik, FA
   Kayani, MA
   Iqbal, H
   Jiang, WG
   Sadiq, R
AF Malik, Fraz Arshad
   Kayani, Mahmood Akhter
   Iqbal, Hina
   Jiang, Wen G.
   Sadiq, Rafshan
TI Screening of coding region of metastasis suppressor genes KISS1 and
   KAI-1 for germ line mutations in breast cancer patients
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Article
DE sporadic breast cancer; KISS1; KAI1; Single strand Conformational
   polymorphism; SSCP
ID FREQUENT DOWN-REGULATION; SQUAMOUS-CELL CARCINOMA; MESSENGER-RNA;
   BLADDER-CANCER; EXPRESSION; PROTEIN; P53; MELANOMA; DNA; LOCALIZATION
AB Breast cancer is one of the most common female cancers worldwide. Abnormalities of genetic or epigenetic factors are mainly responsible for the development and progression of mammary tumours. In patients with breast cancer, metastasis is the leading cause of death. In recent years, a group of genes has been identified as metastasis suppressor genes (MSGs), which are involved in the suppression of the growth of secondary tumours. Down regulations of MSG expression have been frequently observed in advanced tumours. The present study was designed to screen two of the most frequently down-regulated MSGs (KAI1 and KISS1) for germ line mutations in sporadic breast cancer cases of the Pakistani population. 170 cases of unilateral breast cancer patients, who had no prior history of breast cancer and no other disease in general in their families with age ranging from 35-75yrs, were included in this study. Mutational analysis for the entire coding region of KAI1 and KISS1 (including 10 exons and 3 exons, respectively) was carried out by using the Single Strand Conformational Polymorphism (SSCP) technique. No germ line mutation was observed on the entire coding region in the samples from patients with breast cancer in the Pakistani population. Splice site variants on these genes were also absent in breast cancer patients. Involvement of germ line mutations for these MSGs is thus considered to be an event that occurs less frequently in breast cancer patients of Pakistani population. Conserved coding regions of both MSGs indirectly enlighten the involvement of transacting factor on DNA sequence as major contributor in the progression and aggression of tumours rather than any high risk associated mutation itself. A detailed analysis of regulatory mechanism is required to explore the genetic basis of down regulation of these MSGs for a better understanding of breast cancer progression.
C1 [Malik, Fraz Arshad; Jiang, Wen G.] Cardiff Univ, Sch Med, Univ Dept Surg, Cardiff CF14 4XN, S Glam, Wales.
   [Sadiq, Rafshan] PINUM, Punjab Inst Nucl Med, Faisalabad, Pakistan.
   [Malik, Fraz Arshad; Kayani, Mahmood Akhter; Iqbal, Hina] COMSATS Inst Informat Technol, Dept Biosci, Canc Gene Lab, Islamabad, Pakistan.
C3 Cardiff University; COMSATS University Islamabad (CUI)
RP Malik, FA (通讯作者)，Cardiff Univ, Sch Med, Dept Surg, Cardiff CF14 4XN, S Glam, Wales.
EM Fraz_cemb@yahoo.com
RI Jiang, Wen/AAF-1876-2020; Kayani, Mahmood/I-7760-2015; Jiang, Wen
   G./B-1293-2010
OI Jiang, Wen G./0000-0002-3283-1111
CR Anderson D, 1997, TERATOGEN CARCIN MUT, V17, P115, DOI 10.1002/(SICI)1520-6866(1997)17:3<115::AID-TCM3>3.3.CO;2-F
   Briese J, 2008, VIRCHOWS ARCH, V453, P89, DOI 10.1007/s00428-008-0608-7
   Farhadieh RD, 2004, CANCER LETT, V213, P91, DOI 10.1016/j.canlet.2004.03.004
   Gasser RB, 1997, INT J PARASITOL, V27, P1449, DOI 10.1016/S0020-7519(97)00131-8
   Goldberg SF, 2003, CANCER RES, V63, P432
   Guénard F, 2007, FAM CANCER, V6, P483, DOI 10.1007/s10689-007-9151-y
   Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729
   Hsieh S M, 2006, Breast Dis, V26, P157
   Huang HY, 2005, CLIN CANCER RES, V11, P4357, DOI 10.1158/1078-0432.CCR-04-2107
   ICHIKAWA T, 1992, CANCER RES, V52, P3486
   Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02
   Jackson P, 2003, PROSTATE CANCER P D, V6, P174, DOI 10.1038/sj.pcan.4500634
   Jackson P, 2007, ONCOL REP, V18, P1357
   Karges B, 2005, ENDOCRIN DEV, V8, P67, DOI 10.1159/000084094
   Koechl Silvano, 2005, V297, P13
   Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.0.CO;2-3
   Lallas TA, 1998, MOL GENET METAB, V64, P173, DOI 10.1006/mgme.1998.2713
   Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275
   Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731
   Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801
   MALIK F, BRIT J CANC IN PRESS
   Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216
   Martin TA, 2005, CLIN EXP METASTAS, V22, P503, DOI 10.1007/s10585-005-4180-0
   Martins CMO, 2008, EYE, V22, P707, DOI 10.1038/sj.eye.6703090
   Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307
   Meyer A, 2007, RADIOTHER ONCOL, V82, P349, DOI 10.1016/j.radonc.2006.12.002
   Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z
   NAGIRA M, 1994, CELL IMMUNOL, V157, P144, DOI 10.1006/cimm.1994.1212
   Nash KT, 2006, FRONT BIOSCI-LANDMRK, V11, P647, DOI 10.2741/1824
   Nollau P, 1997, CLIN CHEM, V43, P1114
   Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7
   ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012
   Rubin H, 2001, CANCER RES, V61, P799
   Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0
   Schindl M, 2000, ANTICANCER RES, V20, P4551
   Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X
   Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016
   Stark AM, 2005, J CANCER RES CLIN, V131, P191, DOI 10.1007/s00432-004-0629-9
   STEEG PS, 1988, JNCI-J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200
   Terao Y, 2004, BBA-GENE STRUCT EXPR, V1678, P102, DOI 10.1016/j.bbaexp.2004.02.005
   Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002
   Tsutsumi S, 2005, HEPATO-GASTROENTEROL, V52, P281
   Wang Xin-Yun, 2005, Ai Zheng, V24, P1091
   White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852
   Yang JM, 2008, LIVER INT, V28, P132, DOI 10.1111/j.1478-3231.2007.01620.x
   Yu GZ, 2007, INT J EXP PATHOL, V88, P175, DOI 10.1111/j.1365-2613.2006.00510.x
NR 46
TC 3
Z9 4
U1 0
U2 2
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PY 2008
VL 12B
BP 239
EP 246
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 439JM
UT WOS:000265623400009
DA 2025-01-12
ER

PT J
AU Korshunova, Y
   Maloney, RK
   Lakey, N
   Citek, RW
   Bacher, B
   Budiman, A
   Ordway, JM
   McCombie, WR
   Leon, J
   Jeddeloh, JA
   McPherson, JD
AF Korshunova, Yalia
   Maloney, Rebecca K.
   Lakey, Nathan
   Citek, Robert W.
   Bacher, Blaire
   Budiman, Arief
   Ordway, Jared M.
   McCombie, W. Richard
   Leon, Jorge
   Jeddeloh, Jeffrey A.
   McPherson, John D.
TI Massively parallel bisulphite pyrosequencing reveals the molecular
   complexity of breast cancer-associated cytosine-methylation patterns
   obtained from tissue and serum DNA
SO GENOME RESEARCH
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; CIRCULATING NUCLEIC-ACIDS; CELL-FREE DNA;
   PROSTATE-CANCER; LUNG-CANCER; BODILY FLUIDS; HYPERMETHYLATION; GENOME;
   ORIGIN; PLASMA
AB Cytosine-methylation changes are stable and thought to be among the earliest events in tUrnorigenesis. Theoretically, DNA carrying tumor-specifying methylation patterns escape the tumors and may be found circulating in the sera from cancer patients, thus providing the basis for development of noninvasive clinical tests for early cancer detection. Indeed, using methylation-specific PCR-based techniques, several groups reported the detection of tumor-associated methylated DNA in the sera from cancer patients with varying clinical success. However, by design, such analytical approaches allow assessment of the presence of molecules with only one rnethylation pattern, leaving the bigger Picture unexplored. The limited knowledge about circulating DNA methylation patterns hinders the efficient development of clinical methylation tests and testing platforms. Here, we report the results of a comprehensive methylation pattern analysis from breast cancer clinical tissues and sera obtained using massively parallel bisulphite pyrosequencing. The four loci studied were recently discovered by Our group, and demonstrated to be powerful epigenetic biomarkers of breast cancer. The detailed analysis of more than 700,000 DNA fragments derived from more than 50 individuals (cancer and cancer-free) revealed all unappreciated complexity of genomic cytosine-methylation patterns in both tissue derived and Circulating DNAs. Both tumor and cancer-free tissues (as well as sera) contained molecules with nearly every conceivable cytosine-methylation pattern at each locus. Tumor samples displayed more variation in methylation level than normal samples. Importantly, by establishing the rnethylation landscape within circulating DNA, this Study has better defined the development challenges facing DNA methylation-based cancer-detection tests.
C1 [Korshunova, Yalia; Maloney, Rebecca K.; Lakey, Nathan; Citek, Robert W.; Bacher, Blaire; Budiman, Arief; Ordway, Jared M.; Leon, Jorge; Jeddeloh, Jeffrey A.] Orion Genom LLC, St Louis, MO 63108 USA.
   [McCombie, W. Richard] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11723 USA.
   [McPherson, John D.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Jeddeloh, Jeffrey A.] Roche NimbleGen, Madison, WI 53719 USA.
C3 Cold Spring Harbor Laboratory; Baylor College of Medicine; Roche Holding
RP Jeddeloh, JA (通讯作者)，Orion Genom LLC, St Louis, MO 63108 USA.
EM jjeddeloh@nimblegen.com
RI McCombie, William/ACF-2412-2022; McPherson, John/D-2633-2017
OI McPherson, John/0000-0001-8049-9347; McCombie, W.
   Richard/0000-0003-1899-0682
CR Bastian PJ, 2005, CLIN CANCER RES, V11, P4037, DOI 10.1158/1078-0432.CCR-04-2446
   BAYLIN SB, 2005, HUM MOL GENET S1, V2, pS4
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533
   Binladen J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000197
   Boddy JL, 2006, ONCOL RES, V16, P35, DOI 10.3727/000000006783981297
   Boddy JL, 2005, CLIN CANCER RES, V11, P1394, DOI 10.1158/1078-0432.CCR-04-1237
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   Dudoit S, 2002, J AM STAT ASSOC, V97, P77, DOI 10.1198/016214502753479248
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Goessl C, 2000, CANCER RES, V60, P5941
   Goldberg SMD, 2006, P NATL ACAD SCI USA, V103, P11240, DOI 10.1073/pnas.0604351103
   Herman JG, 1996, CANCER RES, V56, P722
   Jerónimo C, 2002, UROLOGY, V60, P1131
   JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734
   Jost JP, 2001, NUCLEIC ACIDS RES, V29, P4452, DOI 10.1093/nar/29.21.4452
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959
   Ordway JM, 2005, BIOTECHNIQUES, V39, P464, DOI 10.2144/000112035
   ORDWAY JM, 2007, IN PRESS PLOS ONE
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Penterman J, 2007, P NATL ACAD SCI USA, V104, P6752, DOI 10.1073/pnas.0701861104
   Reibenwein J, 2007, PROSTATE, V67, P427, DOI 10.1002/pros.20533
   Ruczinski I, 2003, J COMPUT GRAPH STAT, V12, P475, DOI 10.1198/1061860032238
   Sozzi G, 2003, J CLIN ONCOL, V21, P3902, DOI 10.1200/JCO.2003.02.006
   Stroun M, 2000, ANN NY ACAD SCI, V906, P161
   STROUN M, 1989, ONCOLOGY-BASEL, V46, P318
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090
   Tsang JCH, 2007, PATHOLOGY, V39, P197, DOI 10.1080/00313020701230831
   Wang YC, 2007, LUNG CANCER, V56, P289, DOI 10.1016/j.lungcan.2006.12.007
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   Wicker T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-275
   Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8
NR 39
TC 98
Z9 126
U1 1
U2 14
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD JAN
PY 2008
VL 18
IS 1
BP 19
EP 29
DI 10.1101/gr.6883307
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 245UW
UT WOS:000251965300003
PM 18032725
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU van Hattem, WA
   Carvalho, R
   Li, A
   Offerhaus, GJA
   Goggins, M
AF van Hattem, W. Arnout
   Carvalho, Ralph
   Li, Ang
   Offerhaus, G. Johan A.
   Goggins, Michael
TI Amplification of <i>EMSY</i> Gene in a Subset of Sporadic Pancreatic
   Adenocarcinomas
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Pancreatic cancer; EMSY; BRCA2; FISH; amplification
ID HOMOLOGOUS RECOMBINATION; EPIGENETIC ALTERATIONS; CRYSTAL-STRUCTURE;
   BRCA2 MUTATIONS; BREAST-CANCER; DNA-DAMAGE; PATHWAY; EXPRESSION; REPAIR;
   DEFICIENCY
AB Mutations in the breast cancer susceptibility gene 2 (BRCA2) are commonly found in familial pancreatic cancer. Recently, EMSY (11q13.5) has been described as a BRCA2 interacting protein capable of binding and inactivating the protein domain encoded by exon 3 of the BRCA2 gene. Amplification of EMSY occurs in 13% of sporadic breast cancers and is directly linked to increased expression. Here we investigate the amplification status of this new potential oncogene in 59 sporadic pancreatic cancers using fluorescence in situ hybridization (FISH) and tissue microarray (TMA). Real-time quantitative RT-PCR was performed on 20 pancreatic cancer cell lines and overexpression was calculated using the delta-delta-Ct-method. Amplification of EMSY was found in 8/59 cases (13.6%). 9/20 (45%) cell line samples showed overexpression of EMSY. In conclusion, sporadic pancreatic cancer shows amplification of EMSY at prevalence similar to that found in other cancers.
C1 [Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Res Ctr, Baltimore, MD 21205 USA.
   [Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Med, Sol Goldman Pancreat Res Ctr, Baltimore, MD 21205 USA.
   [van Hattem, W. Arnout; Carvalho, Ralph; Offerhaus, G. Johan A.] Johns Hopkins Univ, Sch Med, Ctr Oncol, Sol Goldman Pancreat Res Ctr, Baltimore, MD 21205 USA.
   [van Hattem, W. Arnout; Carvalho, Ralph; Li, Ang; Goggins, Michael] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands.
   [van Hattem, W. Arnout; Offerhaus, G. Johan A.] Univ Med Ctr, Utrecht, Netherlands.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins Medicine; Vrije Universiteit Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam; Utrecht
   University; Utrecht University Medical Center
RP Goggins, M (通讯作者)，Johns Hopkins Med Inst, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, 1550 Orleans St, Baltimore, MD 21205 USA.
EM mgoggins@jhmi.edu
RI Liu, JingMin/P-6729-2014
FU NCI [CA62924]; Michael Rolfe Foundation
FX This work was supported by the NCI grant (CA62924) and the Michael Rolfe
   Foundation.
CR Abaji C, 2005, CANCER RES, V65, P4117, DOI 10.1158/0008-5472.CAN-04-3071
   Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978
   Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586
   Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699
   Biankin AV, 2002, J CLIN ONCOL, V20, P4531, DOI 10.1200/JCO.2002.12.063
   Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Chavali GB, 2005, J MOL BIOL, V350, P964, DOI 10.1016/j.jmb.2005.05.047
   Couch FJ, 2007, CANCER EPIDEM BIOMAR, V16, P342, DOI 10.1158/1055-9965.EPI-06-0783
   Couch FJ, 2005, CANCER RES, V65, P383
   Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039
   Ekblad CMS, 2005, EMBO REP, V6, P675, DOI 10.1038/sj.embor.7400415
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Gallmeier E, 2005, CANCER BIOL THER, V4, P703, DOI 10.4161/cbt.4.7.1909
   Gallmeier E, 2007, CLIN CANCER RES, V13, P4, DOI 10.1158/1078-0432.CCR-06-1637
   Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X
   Goggins M, 1996, CANCER RES, V56, P5360
   Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214
   Hay T, 2005, CANCER RES, V65, P10145, DOI 10.1158/0008-5472.CAN-05-1186
   Huang Y, 2006, STRUCTURE, V14, P703, DOI 10.1016/j.str.2006.01.007
   Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9
   Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023
   Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824
   Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108
   Lakhani SR, 1997, LANCET, V349, P1505
   Martin ST, 2005, ONCOGENE, V24, P3652, DOI 10.1038/sj.onc.1208411
   McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   Murphy KM, 2002, CANCER RES, V62, P3789
   NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R
   Nordling M, 1998, CANCER RES, V58, P1372
   Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0
   Raouf A, 2005, JNCI-J NATL CANCER I, V97, P1302, DOI 10.1093/jnci/dji254
   Rodriguez C, 2004, CLIN CANCER RES, V10, P5785, DOI 10.1158/1078-0432.CCR-03-0410
   Rogers CD, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.024851
   Rogers CD, 2004, CANCER BIOL THER, V3, P167, DOI 10.4161/cbt.3.2.609
   Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008
   Sato N, 2005, ONCOGENE, V24, P850, DOI 10.1038/sj.onc.1208050
   Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807
   Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P286, DOI 10.1007/s00534-005-1057-1
   Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P280, DOI 10.1007/s00534-005-1056-2
   SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950
   Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0
   Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102
   Tascilar M, 2001, CLIN CANCER RES, V7, P4115
   Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704
   Ueki T, 2000, CANCER RES, V60, P1835
   van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048
   Van der Heijden MS, 2004, AM J PATHOL, V165, P651, DOI 10.1016/S0002-9440(10)63329-9
   van der Heijden MS, 2003, CANCER RES, V63, P2585
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Wang X, 2007, CELL DEATH DIFFER, V14, P924, DOI 10.1038/sj.cdd.4402105
   Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498
   Yeo CJ, 1998, ANN SURG, V227, P821, DOI 10.1097/00000658-199806000-00005
NR 56
TC 17
Z9 18
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2008
VL 1
IS 4
BP 343
EP 351
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA V18RH
UT WOS:000208021400006
PM 18787609
DA 2025-01-12
ER

PT J
AU Lehmann, U
   Hasemeier, B
   Christgen, M
   Müller, M
   Römermann, D
   Länger, F
   Kreipe, H
AF Lehmann, U.
   Hasemeier, B.
   Christgen, M.
   Mueller, M.
   Roemermann, D.
   Laenger, F.
   Kreipe, H.
TI Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast
   cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE microRNA genes; mir-9-1; DNA methylation; breast cancer; epigenetics
ID PROMOTER HYPERMETHYLATION; DNA METHYLATION; DOWN-REGULATION;
   CPG-ISLANDS; EXPRESSION
AB MicroRNAs (miRNAs) represent a new class of small non-coding RNAs regulating gene expression by inducing RNA degradation or interfering with translation. Aberrant miRNA expression has been described for several human malignancies and tumour suppressor functions have been ascribed to this new class of small regulatory RNAs. Accordingly, inactivation due to deletion or mutation has been found in human malignancies. Here, we describe the role of aberrant hypermethylation as an additional mechanism for miRNA gene inactivation in human breast cancer. Aberrant hypermethylation was shown for mir-9-1, mir-124a3, mir-148, mir-152, and mir-663 in 34-86% of cases in a series of 71 primary human breast cancer specimens. For comprehensive methylation analysis, combined bisulphite restriction analysis, bisulphite sequencing, and Pyrosequencing (TM) were employed. miRNA gene hypermethylation correlated strongly with methylation of known tumour suppressor genes (p=0.003). After treatment of various breast cancer cell lines with the demethylating agent 5-aza-2'-deoxycytidine, reduction of mir-9-1 gene methylation and concomitant reactivation of expression could be observed. For the mir-9-1 gene, which is already hypermethylated in pre-invasive intraductal lesions, a good correlation between quantitative methylation level and reduction of expression could be demonstrated in a subset of primary human breast cancer specimen (r=0.8). In conclusion, this study demonstrates that various microRNA genes are also affected by epigenetic inactivation due to aberrant hypermethylation and that this is an early and frequent event in breast cancer development. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons., Ltd.
C1 [Lehmann, U.; Hasemeier, B.; Christgen, M.; Mueller, M.; Roemermann, D.; Laenger, F.; Kreipe, H.] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany.
C3 Hannover Medical School
RP Lehmann, U (通讯作者)，Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM Lehmonn.Ulrich@MH-Honnover.de
OI Laenger, Florian/0000-0003-1191-4855
CR Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Brakensiek K, 2007, CLIN CHEM, V53, P17, DOI 10.1373/clinchem.2007.072629
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lehmann U, 2001, AM J PATHOL, V159, P2023, DOI 10.1016/S0002-9440(10)63054-4
   Lehmann U, 2001, LAB INVEST, V81, P635, DOI 10.1038/labinvest.3780272
   Lehmann U, 2000, AM J PATHOL, V156, P1855, DOI 10.1016/S0002-9440(10)65059-6
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Marsh S, 2005, METH MOL B, V311, P97
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046
   Nass SJ, 2000, CANCER RES, V60, P4346
   O'Rourke Jason R., 2006, Birth Defects Research, V78, P172, DOI 10.1002/bdrc.20071
   Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Sugito N, 2006, CLIN CANCER RES, V12, P7322, DOI 10.1158/1078-0432.CCR-06-0515
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
NR 34
TC 381
Z9 446
U1 1
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2008
VL 214
IS 1
BP 17
EP 24
DI 10.1002/path.2251
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 247TP
UT WOS:000252103900004
PM 17948228
DA 2025-01-12
ER

PT J
AU Jing, F
   Jun, L
   Yong, Z
   Wang, YP
   Fei, X
   Zhang, JC
   Hu, LH
AF Jing, Feng
   Jun, Lu
   Yong, Zhang
   Wang, Yuping
   Fei, Xie
   Zhang, Jicai
   Hu, Lihua
TI Multigene methylation in serum of sporadic Chinese female breast cancer
   patients as a prognostic biomarker
SO ONCOLOGY
LA English
DT Article
DE breast cancer; gene amplification; methylation; promoter
ID PLASMA DNA; PROMOTER HYPERMETHYLATION; TUMOR DNA; RANDOMIZED-TRIALS;
   GENE; MARKER; BRCA1; PHENOTYPE; CARCINOMA
AB Objective: DNA methylation is a common molecular alteration in human neoplasia and can be detected easily in the bloodstream of patients. Here, we investigated whether DNA methylation in sera is of prognostic significance in breast cancer patients. Methods: Methylation status of BRCA1, p16 and 14-3-3 sigma was examined by methylation-specific PCR assay in the sera of sporadic breast cancer patients and healthy serum controls. Results: The panel gene methylation frequencies were 29% of sporadic breast cancers for p16, 32% for BRCA1 and 82% for 14-3-3 sigma; all were significantly associated with grades and estrogen receptor status. Only p16 methylation was associated with histological type. p16 and BRCA1 methylation were associated with progesterone receptor status, while 14-3-3 sigma was significantly associated with lymph node metastases. Seventy percent of patients with p16 methylation showed elevated serum CEA levels; of the breast cancer patients with BRCA1 methylation, 75.8% showed elevated serum CEA levels and 69.7% showed elevated serum CA15.3 levels. When analyzing all investigated patients, multivariate analysis showed methylated BRCA1 and/or p16 serum DNA to be independently associated with poor outcome, with a relative risk of death of 6.0. Conclusions: Epigenetic markers in sera, especially BRCA1/p16, may be more promising targets for the diagnosis of sporadic breast cancer than previous prognostic markers. Copyright (C) 2008 S. Karger AG, Basel.
C1 [Jing, Feng; Jun, Lu; Yong, Zhang; Wang, Yuping; Fei, Xie; Zhang, Jicai] Taihe Hosp, Yunyang Med Coll, Ctr Lab Med, Shiyan 442000, Peoples R China.
   [Jing, Feng; Hu, Lihua] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Lab Med, Wuhan 430074, Peoples R China.
C3 Huazhong University of Science & Technology
RP Jing, F (通讯作者)，Taihe Hosp, Yunyang Med Coll, Ctr Lab Med, Renmin So 32, Shiyan 442000, Peoples R China.
EM fengjinggood@hotmail.com
RI Zhang, Jicai/G-1520-2013; Wang, Yuping/AAW-2930-2021; Hu,
   Lihua/AGG-8893-2022; jun, lu/ISS-3806-2023
OI Wang, Yuping/0000-0003-0087-4771
FU Natural Science Funds of Hubei Province [2007ABA371]; Hubei Provincial
   Department of Education [Q20082407]
FX This study was funded by the Natural Science Funds of Hubei Province
   (Grant No. 2007ABA371) and the Hubei Provincial Department of Education
   (No. Q20082407).
CR Abe O, 1998, LANCET, V352, P930
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   Chang HW, 2002, JNCI-J NATL CANCER I, V94, P1697
   Chen XQ, 1999, CLIN CANCER RES, V5, P2297
   Clarke M, 1998, LANCET, V351, P1451
   COUCH FJ, 2001, METABOLIC MOL BASIS, P999
   Deng CX, 2000, BIOESSAYS, V22, P728
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Guadagni F, 2001, CLIN CANCER RES, V7, P2357
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805
   Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0
   Leitch A M, 1999, Surg Oncol Clin N Am, V8, P657
   LEON SA, 1977, CANCER RES, V37, P646
   Lo YMD, 2001, BIOMED PHARMACOTHER, V55, P362, DOI 10.1016/S0753-3322(01)00083-X
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Müller HM, 2003, CANCER RES, V63, P7641
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Shao ZM, 2001, CLIN CANCER RES, V7, P2222
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 2002, ANN SURG ONCOL, V9, P71, DOI 10.1245/aso.2002.9.1.71
   Silva JM, 1999, CANCER RES, V59, P3251
   Wallner M, 2006, CLIN CANCER RES, V12, P7347, DOI 10.1158/1078-0432.CCR-06-1264
   Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Zhang CS, 2007, CLIN CANCER RES, V13, P944, DOI 10.1158/1078-0432.CCR-06-2268
NR 34
TC 24
Z9 27
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2008
VL 75
IS 1-2
BP 60
EP 66
DI 10.1159/000155145
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 358BY
UT WOS:000259892700008
PM 18784433
DA 2025-01-12
ER

PT S
AU Barton, CA
   Clark, SJ
   Hacker, NR
   O'Brien, PM
AF Barton, Caroline A.
   Clark, Susan J.
   Hacker, Neville F.
   O'Brien, Philippa M.
BE Coukos, G
   Berchuck, A
   Ozols, R
TI Epigenetic markers of ovarian cancer
SO OVARIAN CANCER: STATE OF THE ART AND FUTURE DIRECTIONS IN TRANSLATIONAL
   RESEARCH
SE Advances in Experimental Medicine and Biology
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; CPG-ISLAND METHYLATION; FACTOR-BINDING PROTEIN-3;
   PROGRESSION-FREE SURVIVAL; ABERRANT DNA METHYLATION; TIGHT JUNCTION
   PROTEINS; SQUAMOUS-CELL CARCINOMA; ACUTE MYELOID-LEUKEMIA; BRCA1
   PROMOTER REGION; BREAST-CANCER
C1 [Barton, Caroline A.] Ovarian Canc Ctr, Darlinghurst, NSW 2010, Australia.
RP Barton, CA (通讯作者)，Ovarian Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
EM c.barton@garvan.org.au
RI Clark, Susan/B-2272-2008
OI Clark, Susan/0000-0001-5925-5030; Hacker, Neville/0000-0002-1445-2302
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291
   Akahira J, 2004, CLIN CANCER RES, V10, P2687, DOI 10.1158/1078-0432.CCR-03-0510
   Akahira J, 2004, CANCER SCI, V95, P40, DOI 10.1111/j.1349-7006.2004.tb03168.x
   Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bird AP, 1996, CANCER SURV, V28, P87
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brown I, 2001, ONCOL REP, V8, P1359
   Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167
   Buller RE, 2002, CLIN CANCER RES, V8, P1196
   CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213
   Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chan KYK, 2002, CANCER RES, V62, P4151
   Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100
   Chang YS, 2002, CLIN CANCER RES, V8, P3669
   Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64
   Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   CZEKIERDOWSKI A, 2006, NEURO ENDOCRINOL LET, V27
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Esteller M, 2001, CANCER RES, V61, P3225
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Furonaka O, 2004, PATHOL INT, V54, P549, DOI 10.1111/j.1440-1827.2004.01663.x
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Grady WM, 2005, BIOCHEM SOC T, V33, P684, DOI 10.1042/BST0330684
   Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187
   Gupta A, 2003, CANCER RES, V63, P664
   Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4
   Hashiguchi Y, 2001, HUM PATHOL, V32, P988, DOI 10.1053/hupa.2001.27115
   Helleman J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-201
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8
   Hickey KP, 1999, BRIT J CANCER, V80, P1803, DOI 10.1038/sj.bjc.6690601
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136
   Hough CD, 2000, CANCER RES, V60, P6281
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaneuchi M, 2005, CANCER-AM CANCER SOC, V104, P1924, DOI 10.1002/cncr.21397
   Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171
   Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018
   Kwong J, 2006, NEOPLASIA, V8, P268, DOI 10.1593/neo.05502
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Leung WK, 2005, AM J GASTROENTEROL, V100, P2274, DOI 10.1111/j.1572-0241.2005.50412.x
   Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   Melki JR, 1999, CANCER RES, V59, P3730
   Melki JR, 2002, SEMIN CANCER BIOL, V12, P347, DOI 10.1016/S1044-579X(02)00055-X
   Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12
   Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Niederacher D, 1999, BRIT J CANCER, V80, P1920, DOI 10.1038/sj.bjc.6690621
   Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146
   Petrocca F, 2006, CANCER RES, V66, P10287, DOI 10.1158/0008-5472.CAN-06-2289
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Plumb JA, 2000, CANCER RES, V60, P6039
   Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2
   Rand KN, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni120
   Rangel LBA, 2003, CLIN CANCER RES, V9, P2567
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   SCHULTZ DC, 1995, CANCER RES, V55, P2150
   Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183
   Shen DH, 2005, CARCINOGENESIS, V26, P855, DOI 10.1093/carcin/bgi011
   Shridhar V, 2001, CANCER RES, V61, P4258
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Strathdee G, 2005, GYNECOL ONCOL, V97, P898, DOI 10.1016/j.ygyno.2005.03.023
   Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005
   Terasawa K, 2006, BRIT J CANCER, V94, P914, DOI 10.1038/sj.bjc.6602984
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Wang ZH, 2006, CANCER BIOL THER, V5, P256, DOI 10.4161/cbt.5.3.2380
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Wei SH, 2003, ANN NY ACAD SCI, V983, P243, DOI 10.1111/j.1749-6632.2003.tb05979.x
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wilcox CB, 2005, CANCER GENET CYTOGEN, V159, P114, DOI 10.1016/j.cancergencyto.2004.12.017
   Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Wong TS, 2003, EUR J CANCER, V39, P1881, DOI 10.1016/S0959-8049(03)00428-3
   Yanaihara N, 2004, INT J CANCER, V112, P150, DOI 10.1002/ijc.20339
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
   Yu YH, 2006, METHOD ENZYMOL, V407, P455, DOI 10.1016/S0076-6879(05)07037-0
   Yuan JH, 2003, CANCER RES, V63, P4174
   Zhang W, 2006, CLIN LAB HAEMATOL, V28, P177, DOI 10.1111/j.1365-2257.2006.00784.x
   Zhu YH, 2006, INT J CANCER, V118, P1884, DOI 10.1002/ijc.21506
NR 133
TC 13
Z9 14
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 2214-8019
BN 978-0-387-68966-1
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2008
VL 622
BP 35
EP 51
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA BHU19
UT WOS:000256388400004
PM 18546617
DA 2025-01-12
ER

PT J
AU Jiang, Y
   Tong, DD
   Lou, G
   Zhang, Y
   Geng, JS
AF Jiang, Ying
   Tong, Dandan
   Lou, Ge
   Zhang, Ying
   Geng, Jingshu
TI Expression of RUNX3 gene, methylation status and clinicopathological
   significance in breast cancer and breast cancer cell lines
SO PATHOBIOLOGY
LA English
DT Article
DE breast cancer; methylation; RUNX3 gene; prognosis
ID GASTRIC-CANCER; PROMOTER HYPERMETHYLATION; PROTEIN MISLOCALIZATION;
   EPIGENETICS; CARCINOMA; AML1
AB Background: Runt-related transcription factor 3 (RUNX3) is a novel tumor suppressor gene that is frequently silenced by promoter hypermethylation in gastric cancer. In this study, we aimed to analyze the methylation status of the RUNX3 promoter in breast cancer and to evaluate the relationship between RUNX3 expression and breast carcinogenesis and prognosis. Methods: RT-PCR and Western blot were applied on 5 breast cancer cell lines, the human normal breast cell line Hs578Bst and 30 pairs of breast cancer and their matching normal breast tissues to detect mRNA and protein expression of the RUNX3 gene. Methylation-specific PCR was employed to detect the methylation status of the RUNX3 promoter. Immunohistochemical study was performed to analyze RUNX3 protein expression in 88 breast cancer tissues and 40 breast fibroadenomas. Results: The expression of RUNX3 mRNA and protein were negative in 3 breast cancer cell lines (T47D, MCF7 and SKBR3) as analyzed by RT-PCR and Western blotting. Hypermethylation of the RUNX3 promotor was identified in the T47D and MCF7 cell lines, but was not detected in SKBR3. Western blot analysis showed that the RUNX3 protein of 44 kDa was detected in 15 of 30 (50%) breast cancers. However, RUNX3 protein was detected in all normal breast tissues. Methylation was detected in 13 of the 15 tissues (86.67%) that did not express RUNX3 protein, but was never detected in any surrounding normal tissues. Immunohistochemistry results revealed that the positive rate of RUNX3 protein expression in breast cancer (35.23%) was much lower than that in breast fibroadenoma (85%). RUNX3 expression was correlated with tumor infiltration, clinical stage, lymph node metastasis and the expression of estrogen and progesterone receptor (p < 0.05), but was not related to age, tumor types and pathological grade (p < 0.05). The survival rate of the patients with RUNX3-positive expression was higher than that with RUNX3-negative expression (p < 0.05). Conclusions: The expression of RUNX3 gene is decreased in breast cancer. The RUNX3 gene may play an important role in the carcinogenesis of breast cancer. The mechanism of its inactivation may be hypermethylation of the promoter. With the increased progression of breast cancer, the expression of RUNX3 protein tends to decrease. The expression of RUNX3 protein has a definite value in judging prognosis in breast cancer. Copyright (c) 2008 S. Karger AG, Basel.
C1 [Geng, Jingshu] Harbin Med Coll, Affiliated Hosp 3, Dept Pathol, Harbin 150086, Peoples R China.
   [Jiang, Ying; Lou, Ge; Zhang, Ying] Harbin Med Coll, Affiliated Hosp 2, Dept Pathol, Harbin 150086, Peoples R China.
   [Tong, Dandan] Harbin Med Coll, Basic Med Coll, Dept Pathol, Harbin 150086, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Geng, JS (通讯作者)，Harbin Med Coll, Affiliated Hosp 3, Dept Pathol, Haping Rd 150,Nangang Dist, Harbin 150086, Peoples R China.
EM jeangeng2004@yahoo.com.cn
OI Jiang, Ying/0000-0002-2896-3760
CR BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730
   Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiramatsu T, 2005, PATHOBIOLOGY, V72, P316, DOI 10.1159/000091329
   Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731
   Ku JL, 2002, BRIT J CANCER, V87, P187, DOI 10.1038/sj.bjc.6600440
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307
   Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1
   Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0
   Suzuki M, 2003, CLIN CANCER RES, V9, P5636
   Tada Y, 2002, CANCER RES, V62, P4048
   Wang LW, 2003, CLIN CANCER RES, V9, P6371
   Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3
   WEITH A, 1995, CYTOGENET CELL GENET, V72, P114
   Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376
   Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846
NR 26
TC 50
Z9 61
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-2008
J9 PATHOBIOLOGY
JI Pathobiology
PY 2008
VL 75
IS 4
BP 244
EP 251
DI 10.1159/000132385
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 320PL
UT WOS:000257247400004
PM 18580070
OA Bronze
DA 2025-01-12
ER

PT J
AU Ordway, JM
   Budiman, MA
   Korshunova, Y
   Maloney, RK
   Bedell, JA
   Citek, RW
   Bacher, B
   Peterson, S
   Rohlfing, T
   Hall, J
   Brown, R
   Lakey, N
   Doerge, RW
   Martienssen, RA
   Leon, J
   McPherson, JD
   Jeddeloh, JA
AF Ordway, Jared M.
   Budiman, Muhammad A.
   Korshunova, Yulia
   Maloney, Rebecca K.
   Bedell, Joseph A.
   Citek, Robert W.
   Bacher, Blaire
   Peterson, Seth
   Rohlfing, Tracy
   Hall, Jacqueline
   Brown, Robert
   Lakey, Nathan
   Doerge, Rebecca W.
   Martienssen, Robert A.
   Leon, Jorge
   McPherson, John D.
   Jeddeloh, Jeffrey A.
TI Identification of Novel High-Frequency DNA Methylation Changes in Breast
   Cancer
SO PLOS ONE
LA English
DT Article
AB Recent data have revealed that epigenetic alterations, including DNA methylation and chromatin structure changes, are among the earliest molecular abnormalities to occur during tumorigenesis. The inherent thermodynamic stability of cytosine methylation and the apparent high specificity of the alterations for disease may accelerate the development of powerful molecular diagnostics for cancer. We report a genome-wide analysis of DNA methylation alterations in breast cancer. The approach efficiently identified a large collection of novel differentially DNA methylated loci (, 200), a subset of which was independently validated across a panel of over 230 clinical samples. The differential cytosine methylation events were independent of patient age, tumor stage, estrogen receptor status or family history of breast cancer. The power of the global approach for discovery is underscored by the identification of a single differentially methylated locus, associated with the GHSR gene, capable of distinguishing infiltrating ductal breast carcinoma from normal and benign breast tissues with a sensitivity and specificity of 90% and 96%, respectively. Notably, the frequency of these molecular abnormalities in breast tumors substantially exceeds the frequency of any other single genetic or epigenetic change reported to date. The discovery of over 50 novel DNA methylation-based biomarkers of breast cancer may provide new routes for development of DNA methylation-based diagnostics and prognostics, as well as reveal epigenetically regulated mechanism involved in breast tumorigenesis.
C1 [Ordway, Jared M.; Budiman, Muhammad A.; Korshunova, Yulia; Maloney, Rebecca K.; Bedell, Joseph A.; Citek, Robert W.; Bacher, Blaire; Peterson, Seth; Rohlfing, Tracy; Lakey, Nathan; Leon, Jorge; Jeddeloh, Jeffrey A.] Orion Genom, St Louis, MO USA.
   [Hall, Jacqueline] McGill Univ, Ctr Bioinformat, Montreal, PQ, Canada.
   [Brown, Robert] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England.
   [Doerge, Rebecca W.] Purdue Univ, Dept Agron, Lafayette, IN USA.
   [Doerge, Rebecca W.] Purdue Univ, Dept Stat, Lafayette, IN USA.
   [Martienssen, Robert A.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [McPherson, John D.] Ontario Inst Canc Res, Toronto, ON, Canada.
C3 McGill University; Imperial College London; Purdue University System;
   Purdue University; Purdue University System; Purdue University; Cold
   Spring Harbor Laboratory; Ontario Institute for Cancer Research;
   University of Toronto
RP Ordway, JM (通讯作者)，Orion Genom, St Louis, MO USA.
EM jordway@oriongenomics.com
RI ; McPherson, John/D-2633-2017
OI Hall, Jacqueline/0000-0003-0708-1360; Brown, Robert/0000-0001-7960-5755;
   McPherson, John/0000-0001-8049-9347
CR Akashi M, 1998, CLIN OBSTET GYNECOL, V41, P172, DOI 10.1097/00003081-199803000-00024
   Barzon L, 2005, ONCOLOGY-BASEL, V68, P414, DOI 10.1159/000086983
   CHOI YC, 1991, J BIOL CHEM, V266, P20504
   Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0
   COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338
   COLES C, 1992, CANCER RES, V52, P5291
   Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974
   Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009
   Jeffery PL, 2005, ENDOCR-RELAT CANCER, V12, P839, DOI 10.1677/erc.1.00984
   Jeffery PL, 2003, CYTOKINE GROWTH F R, V14, P113, DOI 10.1016/S1359-6101(02)00089-8
   JOHNSON N, 1995, FAM PRACT, V12, P287, DOI 10.1093/fampra/12.3.287
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39
   KORSHUNOVA K, GENOME RES IN PRESS
   Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759
   Linke SP, 2006, CLIN CANCER RES, V12, P1175, DOI 10.1158/1078-0432.CCR-05-1562
   Lippman Z, 2005, NAT METHODS, V2, P219, DOI 10.1038/nmeth0305-219
   Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651
   McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miller AB, 2002, ANN INTERN MED, V137, P305, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00005
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Naidu R, 2002, INT J MOL MED, V9, P189
   Nyström L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161
   Ordway JM, 2005, BIOTECHNIQUES, V39, P464, DOI 10.2144/000112035
   Petersenn S, 2001, ENDOCRINOLOGY, V142, P2649, DOI 10.1210/en.142.6.2649
   Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837
   Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581
   Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404
   Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Weischer M, 2007, J CLIN ONCOL, V25, P57, DOI 10.1200/JCO.2005.05.5160
   Wolfinger RD, 2001, J COMPUT BIOL, V8, P625, DOI 10.1089/106652701753307520
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Zahl PH, 2004, BMJ-BRIT MED J, V328, P921, DOI 10.1136/bmj.38044.666157.63
NR 49
TC 86
Z9 99
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 19
PY 2007
VL 2
IS 12
AR e1314
DI 10.1371/journal.pone.0001314
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V10JF
UT WOS:000207459600002
PM 18091988
OA Green Accepted, Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Milstein, M
   Mooser, CK
   Hu, HL
   Fejzo, M
   Slamon, D
   Goodglick, L
   Dry, S
   Colicelli, J
AF Milstein, Marc
   Mooser, Chelsea K.
   Hu, Hailiang
   Fejzo, Marlena
   Slamon, Dennis
   Goodglick, Lee
   Dry, Sarah
   Colicelli, John
TI RIN1 is a breast tumor suppressor gene
SO CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; E-CADHERIN; METASTASIS SUPPRESSOR; MESENCHYMAL
   TRANSITION; PROSTATE-CANCER; SNAIL GENES; CARCINOMA; INVASION;
   EXPRESSION; INACTIVATION
AB Breast cancer progression is driven by altered gene expression. We show that the RIN1 gene, which encodes a RAS effector regulating epithelial cell properties, is silenced in breast tumor cell lines compared with cultured human mammary epithelial cells. We also report that RIN1 is often reduced in human breast tumor cells compared with morphologically normal breast glandular cells. At least two silencing mechanisms seem to be involved. Overexpression of the transcription repressor SNAI1 (Snail) was observed in ZR75-1 cells, and SNAI1 knockdown restored RIN1 expression. In addition, DNA methylation within the RIN1 promoter and the first exon in KPL-I cells suggested that epigenetic modifications may contribute to silencing, and demethylation was shown to restore RIN1 expression. Reexpression of RIN1 was shown to inhibit anchorage-independent growth in soft agar. In addition, RIN1 expression inhibited both the initiation and progression of tumorigenesis for two breast tumor cell lines in a mouse model, consistent with a tumor suppressor function. We also show that RIN1 acts as. a negative regulator of tumor cell invasive growth and that this requires the ABL kinase-signaling function of RIN1, suggesting a mechanism through which RIN1 silencing may contribute to breast cancer progression.
C1 [Milstein, Marc; Mooser, Chelsea K.; Hu, Hailiang; Colicelli, John] Univ Calif Los Angeles, Jonsson Canc Ctr, Dept Biol Chem, Ctr Hlth Sci 33 257,David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Fejzo, Marlena; Slamon, Dennis] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Goodglick, Lee; Dry, Sarah] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Slamon, Dennis; Goodglick, Lee; Dry, Sarah; Colicelli, John] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Slamon, Dennis; Colicelli, John] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA.
C3 UCLA Jonsson Comprehensive Cancer Center; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; UCLA Jonsson
   Comprehensive Cancer Center; University of California System; University
   of California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Colicelli, J (通讯作者)，Univ Calif Los Angeles, Jonsson Canc Ctr, Dept Biol Chem, Ctr Hlth Sci 33 257,David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM colicelli@mednet.ucla.edu
RI Hu, Hailiang/AAS-2390-2020
OI Hu, Hailiang/0000-0001-9205-1603; Fejzo, Marlena/0000-0001-6800-687X
FU NCI NIH HHS [CA-86366] Funding Source: Medline; NINDS NIH HHS [R01
   NS046787-04, NS046787, R01 NS046787, R01 NS046787-05] Funding Source:
   Medline
CR Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943
   Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410
   Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13
   Dale JK, 2006, DEV CELL, V10, P355, DOI 10.1016/j.devcel.2006.02.011
   Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635
   DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374
   Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065
   Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878
   Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232
   Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566
   Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Kang JY, 2003, CANCER RES, V63, P1101
   Kim HL, 2001, CANCER RES, V61, P2833
   Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013
   Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991
   Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812
   Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438
   RO J, 1988, CANCER RES, V48, P161
   Rodriguez-Viciana P, 2005, COLD SH Q B, V70, P461, DOI 10.1101/sqb.2005.70.044
   Seraj MJ, 2000, CANCER RES, V60, P2764
   Sharp JA, 2004, CLIN EXP METASTAS, V21, P19, DOI 10.1023/B:CLIN.0000017167.17065.61
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Srinivasan D., 2007, ONCOGENE
   Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734
   STEEG PS, 1988, JNCI-J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200
   Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9
   Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048
   Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200
   Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200
   Wadehra M, 2002, BIOTECHNIQUES, V32, P242, DOI 10.2144/02322bm02
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 46
TC 30
Z9 46
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2007
VL 67
IS 24
BP 11510
EP 11516
DI 10.1158/0008-5472.CAN-07-1147
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 244HV
UT WOS:000251857900009
PM 18089779
OA Green Accepted, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Hinshelwood, RA
   Huschtscha, LI
   Melki, J
   Stirzaker, C
   Abdipranoto, A
   Vissel, B
   Ravasi, T
   Wells, CA
   Hume, DA
   Reddel, RR
   Clark, SJ
AF Hinshelwood, Rebecca A.
   Huschtscha, Lily I.
   Melki, John
   Stirzaker, Clare
   Abdipranoto, Andrea
   Vissel, Bryce
   Ravasi, Timothy
   Wells, Christine A.
   Hume, David A.
   Reddel, Roger R.
   Clark, Susan J.
TI Concordant epigenetic silencing of transforming growth factor-β
   signaling pathway genes occurs early in breast carcinogenesis
SO CANCER RESEARCH
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION;
   DNA METHYLATION; CANCER-CELLS; DI-METHYLATION; EXPRESSION;
   HYPERMETHYLATION; PROMOTER; LINES
AB Human mammary epithelial cells (HMEC) grown under standard cell culture conditions enter a growth phase referred to as selection, but a subpopulation is able to escape from arrest and continue to proliferate. These cells, called post-selection or variant HMECs, may be derived from progenitor cells found in normal mammary epithelium that subsequently acquire premalignant lesions, including p16(INK4A) promoter hypermethylation. Epigenetic silencing of tumor suppressor genes through DNA methylation and histone modification is an early event in tumorigenesis. A major challenge is to find genes or gene pathways that are commonly silenced to provide 9 early epigenetic diagnostic and therapeutic cancer targets. To identify very early epigenetic events that occur in breast cancer, we used microarrays to screen for gene pathways that were suppressed in post-selection HMECs but reactivated after treatment with the demethylation agent 5-aza-2'-deoxycytidine. We found that several members of the transforming growth factor beta (TGF-beta) signaling pathway were consistently down-regulated in the post-selection HMEC populations, and this was associated with a marked decrease in Smad4 nuclear staining. Gene suppression was not associated with DNA methylation but with chromatin remodeling, involving a decrease in histone H3 lysine 27 trimethylation and an increase in histone H3 lysine 9 dimethylation and deacetylation. These results show for the first time that TGF-beta 2, its receptors TGF-beta R1 and TGF-beta R2, and activator thrombospondin-1 are concordantly suppressed early in breast carcinogenesis by histone modifications and indicate that the TGF-beta signaling pathway is a novel target for gene activation by epigenetic therapy.
C1 [Hinshelwood, Rebecca A.; Stirzaker, Clare; Abdipranoto, Andrea; Vissel, Bryce; Clark, Susan J.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia.
   [Huschtscha, Lily I.; Reddel, Roger R.] Childrens Med Res Inst, Westmead, NSW, Australia.
   [Melki, John] Human Genet Signatures, N Ryde, NSW, Australia.
   [Ravasi, Timothy; Hume, David A.] Univ Queensland, Inst Mol Biosci, ARC Special Res Ctr Funct & Appl Genom, St Lucia, Qld 4067, Australia.
   [Wells, Christine A.] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Brisbane, Qld 4111, Australia.
   [Hume, David A.] Univ Edinburgh, Roslin Inst, Roslin, Midlothian, Scotland.
C3 NSW Health; St Vincents Hospital Sydney; Garvan Institute of Medical
   Research; Children's Medical Research Institute - Australia; Genetic
   Signatures Limited; University of Queensland; Griffith University; UK
   Research & Innovation (UKRI); Biotechnology and Biological Sciences
   Research Council (BBSRC); Roslin Institute; University of Edinburgh
RP Clark, SJ (通讯作者)，St Vincents Hosp, Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Ravasi, Timothy/B-8777-2008; Hume, David/C-7695-2013; Wells,
   Christine/A-5071-2010; Reddel, Roger/A-6635-2014; Clark,
   Stewart/A-3462-2012; Clark, Susan/B-2272-2008
OI Wells, Christine/0000-0003-3133-3628; Hume, David/0000-0002-2615-1478;
   Ravasi, Timothy/0000-0002-9950-465X; Vissel, Bryce/0000-0001-8860-8050;
   Stirzaker, Clare/0000-0001-5601-3140; Reddel, Roger/0000-0002-6302-6107;
   Clark, Stewart/0000-0003-4792-7738; Clark, Susan/0000-0001-5925-5030
CR Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200
   Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3
   Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Chen TP, 1998, CANCER RES, V58, P4805
   Cheng KH, 2004, CANCER RES, V64, P1639, DOI 10.1158/0008-5472.CAN-03-2688
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43
   Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032
   Holst CR, 2003, CANCER RES, V63, P1596
   HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705
   Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42
   Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663
   Lynch MA, 1998, CANCER RES, V58, P4227
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Osada H, 2005, MOL CARCINOGEN, V44, P233, DOI 10.1002/mc.20135
   Osada H, 2001, CANCER RES, V61, P8331
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
   Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580
   Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048
NR 54
TC 70
Z9 89
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2007
VL 67
IS 24
BP 11517
EP 11527
DI 10.1158/0008-5472.CAN-07-1284
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 244HV
UT WOS:000251857900010
PM 18089780
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Sadikovic, B
   Andrews, J
   Rodenhiser, DI
AF Sadikovic, Bekim
   Andrews, Joseph
   Rodenhiser, David I.
TI DNA methylation analysis using CpG microarrays is impaired in
   benzopyrene exposed cells
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE DNA methylation; benzopyrene; microarrays; epigenetic; environmental
ID ADDUCT FORMATION; AROMATIC-HYDROCARBONS; ESTROGEN-RECEPTOR; DIETARY
   SELENIUM; DRUG-RESISTANCE; GENE-EXPRESSION; RAT-LIVER; IN-VITRO; CANCER;
   INHIBITION
AB Epigenetic alterations have emerged as a key mechanism involved in tumorigenesis. These disruptions are partly due to environmental factors that change normal DNA methylation patterns necessary for transcriptional regulation and chromatin compaction. Microarray technologies are allowing environmentally susceptible epigenetic patterns to be mapped and the precise targets of environmentally induced alterations to be identified. Previously, we observed BaP-induced epigenetic events and cell cycle disruptions in breast cancer cell lines that included time- and concentration-dependent loss of proliferation as well as sequence-specific hypo- and hypermethylation events. In this present report, we further characterized epigenetic changes in BaP-exposed MCF-7 cells. We analyzed DNA methylation on a CpG island microarray platform with over 5400 unique genomic regions. Depleted and enriched microarray targets, representative of putative DNA methylation changes, were identified across the genome; however, subsequent sodium bisulfite analyses revealed no changes in DNA methylation at a number of these loci. Instead, we found that the identification of DNA methylation changes using this restriction enzyme-based microarray approach corresponded with the regions of DNA bound by the BaP derived DNA adducts. This DNA adduct formation occurs at both methylated and unmethylated CpG dinucleotides and affects PCR amplification during sample preparation. Our data suggest that caution should be exercised when interpreting data from comparative microarray experiments that rely on enzymatic reactions. These results are relevant to genome screening approaches involving environmental exposures in which DNA adduct formation at specific nucleotide sites may bias target acquisition and compromise the correct identification of epigenetically responsive genes. (c) 2007 Elsevier Inc. All rights reserved.
C1 London Hlth Sci Ctr, London Reg Canc Program, Victoria Res Labs, London, ON N6A 4L6, Canada.
   Univ Western Ontario, Dept Biochem, London, ON N6A 3K7, Canada.
   Univ Western Ontario, Dept Oncol, London, ON N6A 3K7, Canada.
   Univ Western Ontario, Dept Paediat, London, ON N6A 3K7, Canada.
   Childrens Hlth Res Inst, London, ON, Canada.
   EpiGenWestern Res Grp London, London, ON, Canada.
C3 Western University (University of Western Ontario); London Health
   Sciences Centre; Western University (University of Western Ontario);
   Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Rodenhiser, DI (通讯作者)，London Hlth Sci Ctr, London Reg Canc Program, Victoria Res Labs, Room A4-134,790 Commiss Rd E, London, ON N6A 4L6, Canada.
EM drodenhi@uwo.ca
CR [Anonymous], 2003, Health risks of persistent organic pollutants from long-range transboundary air pollution
   Baskunov VB, 2005, BIOCHEMISTRY-US, V44, P1054, DOI 10.1021/bi048130y
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200
   Ciganek M, 2004, SCI TOTAL ENVIRON, V334, P141, DOI 10.1016/j.scitotenv.2004.04.034
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cooney CA, 2001, J NUTR, V131, P1871, DOI 10.1093/jn/131.6.1871
   Davis CD, 2000, J NUTR, V130, P2903, DOI 10.1093/jn/130.12.2903
   Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gorlewska-Roberts K, 2002, ENVIRON MOL MUTAGEN, V39, P184, DOI 10.1002/em.10060
   Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hsu GW, 2005, J BIOL CHEM, V280, P3764, DOI 10.1074/jbc.M411276200
   Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s
   Jeffy BD, 1999, MOL CARCINOGEN, V26, P100, DOI 10.1002/(SICI)1098-2744(199910)26:2<100::AID-MC5>3.0.CO;2-1
   Jeffy BD, 2002, CANCER RES, V62, P113
   Kang SC, 2005, J TOXICOL ENV HEAL A, V68, P1833, DOI 10.1080/15287390500182883
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   LEE YW, 1995, MOL CELL BIOL, V15, P2547
   Li DH, 1996, CANCER RES, V56, P287
   Li DH, 2002, ENVIRON MOL MUTAGEN, V39, P193, DOI 10.1002/em.10063
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liang ZD, 2003, CANCER RES, V63, P1470
   LIJINSKY W, 1991, MUTAT RES, V259, P251, DOI 10.1016/0165-1218(91)90121-2
   Mahadevan B, 2005, CANCER RES, V65, P1251, DOI 10.1158/0008-5472.CAN-04-2357
   Moore LE, 2003, ANN NY ACAD SCI, V983, P181, DOI 10.1111/j.1749-6632.2003.tb05973.x
   NYCE J, 1989, CANCER RES, V49, P5829
   Nyce JW, 1997, MUTAT RES-REV MUTAT, V386, P153, DOI 10.1016/S1383-5742(96)00051-8
   PFEIFER GP, 1984, CARCINOGENESIS, V5, P931, DOI 10.1093/carcin/5.7.931
   PRUESSSCHWARTZ D, 1986, CANCER RES, V46, P2697
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Rosenkranz HS, 1996, MUTAT RES-GENET TOX, V367, P65, DOI 10.1016/0165-1218(95)00066-6
   RUCHIRAWAT M, 1984, BIOCHEMISTRY-US, V23, P5426, DOI 10.1021/bi00318a008
   Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799
   Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012
   Safe S, 2002, INT J ONCOL, V20, P1123
   Scherer G, 2000, CANCER EPIDEM BIOMAR, V9, P373
   Sparfel L, 2006, CARCINOGENESIS, V27, P656, DOI 10.1093/carcin/bgi256
   STAMPFER MR, 1981, P NATL ACAD SCI-BIOL, V78, P6251, DOI 10.1073/pnas.78.10.6251
   Subach OM, 2007, FEBS J, V274, P2121, DOI 10.1111/j.1742-4658.2007.05754.x
   Subach OM, 2006, BIOCHEMISTRY-US, V45, P6142, DOI 10.1021/bi0511639
   Thompson PA, 2002, ENVIRON MOL MUTAGEN, V39, P134, DOI 10.1002/em.10067
   WANG X, 1993, MOL CELL ENDOCRINOL, V96, P159, DOI 10.1016/0303-7207(93)90106-T
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7
   WILSON VL, 1984, CARCINOGENESIS, V5, P1027, DOI 10.1093/carcin/5.8.1027
   WOJCIECHOWSKI MF, 1984, J BIOL CHEM, V259, P9711
   Yan PS, 2002, J NUTR, V132, p2430S, DOI 10.1093/jn/132.8.2430S
NR 52
TC 24
Z9 25
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD DEC 15
PY 2007
VL 225
IS 3
BP 300
EP 309
DI 10.1016/j.taap.2007.08.013
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 239RI
UT WOS:000251535000008
PM 17904174
DA 2025-01-12
ER

PT J
AU Guo, HS
   Lin, YF
   Zhang, HW
   Liu, J
   Zhang, N
   Li, YM
   Kong, DS
   Tang, QQ
   Ma, D
AF Guo, Hongshen
   Lin, Yifeng
   Zhang, Hongwei
   Liu, Juan
   Zhang, Nong
   Li, Yiming
   Kong, Desheng
   Tang, Qiqun
   Ma, Duan
TI Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation
   through inhibition of KLF6 binding in highly invasive breast cancer
   cells
SO BMC MOLECULAR BIOLOGY
LA English
DT Article
ID HUMAN GLIOMA-CELLS; DNA METHYLATION; TRANSCRIPTIONAL ACTIVATION;
   EPIGENETIC ALTERATIONS; PROTEASE INHIBITOR; MAMMALIAN-CELLS; PROMOTER
   REGION; GROWTH-FACTOR; TFPI-2 GENE; EXPRESSION
AB Background: Tissue factor pathway inhibitor-2 (TFPI-2) is a matrix-associated Kunitz inhibitor that inhibits plasmin and trypsin-mediated activation of zymogen matrix metalloproteinases involved in tumor progression, invasion and metastasis. Here, we have investigated the mechanism of DNA methylation on the repression of TFPI-2 in breast cancer cell lines.
   Results: We found that both protein and mRNA of TFPI-2 could not be detected in highly invasive breast cancer cell line MDA-MB-435. To further investigate the mechanism of TFPI-2 repression in breast cancer cells, 1.5 Kb TFPI-2 promoter was cloned, and several genetic variations were detected, but the promoter luciferase activities were not affected by the point mutation in the promoter region and the phenomena was further supported by deleted mutation. Scan mutation and informatics analysis identified a potential KLF6 binding site in TFPI-2 promoter. It was revealed, by bisulfite modified sequence, that the CpG island in TFPI-2 promoter region was hypermethylated in MDA-MB-435. Finally, using EMSA and ChIP assay, we demonstrated that the CpG methylation in the binding site of KLF-6 diminished the binding of KLF6 to TFPI-2 promoter.
   Conclusion: In this study, we found that the CpG islands in TFPI-2 promoter was hypermethylated in highly invasive breast cancer cell line, and DNA methylation in the entire promoter region caused TFPI-2 repression by inducing inactive chromatin structure and decreasing KLF6 binding to its DNA binding sequence.
C1 [Guo, Hongshen; Kong, Desheng; Tang, Qiqun; Ma, Duan] Fudan Univ, Shanghai Med Coll, Minist Educ, Key Lab Mol Med, Shanghai 200032, Peoples R China.
   [Lin, Yifeng; Zhang, Nong] Shanghai Med Coll, Dept Pathol, Minist Educ, Key Lab Mol Med, Shanghai 200032, Peoples R China.
   [Zhang, Hongwei; Liu, Juan] Fudan Univ, Zhongshan Hosp, Dept Surg, Shanghai 200032, Peoples R China.
   [Li, Yiming] Fudan Univ, Huashan Hosp, Dept Endocrinol, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Ma, D (通讯作者)，Fudan Univ, Shanghai Med Coll, Minist Educ, Key Lab Mol Med, Yixueyuan Rd 138, Shanghai 200032, Peoples R China.
EM eagooselj@yahoo.com.cn; linyifeng0510@yahoo.com.cn;
   hwzhang@zshospital.net; vickyliu@hotmail.com; nzhang@fudan.edu.cn;
   yimingli@fudan.edu.cn; dshkong@126.com; qqtang@shmu.edu.cn;
   duanma@shmu.edu.cn
RI Ma, Duan/I-8330-2014
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Blanchon L, 2006, BIOCHEM BIOPH RES CO, V343, P745, DOI 10.1016/j.bbrc.2006.03.032
   Blindt R, 2002, J VASC RES, V39, P340, DOI 10.1159/000065546
   Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Dykxhoorn DM, 1997, NUCLEIC ACIDS RES, V25, P4209, DOI 10.1093/nar/25.21.4209
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Hubé F, 2003, THROMB RES, V109, P207, DOI 10.1016/S0049-3848(03)00147-6
   Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0
   Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200
   Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695
   Konduri SD, 2003, INT J ONCOL, V22, P1277
   Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983
   Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847
   Kong DS, 2004, BIOCHEM BIOPH RES CO, V324, P1179, DOI 10.1016/j.bbrc.2004.09.179
   Koritschoner NP, 1997, J BIOL CHEM, V272, P9573
   Liu YY, 1999, ARCH BIOCHEM BIOPHYS, V370, P112, DOI 10.1006/abbi.1999.1371
   Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083
   Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955
   Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764
   Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326
   NIIMI T, 2006, BIOCH BIOPHYS ACTA
   NOBEYAMA Y, 2007, INT J CANC
   Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d
   Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484
   Rollin J, 2005, BRIT J CANCER, V92, P775, DOI 10.1038/sj.bjc.6602298
   Ruf W, 2003, CANCER RES, V63, P5381
   Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3
   Sato N, 2005, ONCOGENE, V24, P850, DOI 10.1038/sj.onc.1208050
   Siegling S, 2006, ANN HEMATOL, V85, P32, DOI 10.1007/s00277-005-0023-y
   Siegling S, 2004, THROMB RES, V113, P341, DOI 10.1016/j.thromres.2004.03.019
   SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200
   Xu ZH, 2006, ARTERIOSCL THROM VAS, V26, P2819, DOI 10.1161/01.ATV.0000248731.55781.87
   Yan PS, 2001, CANCER RES, V61, P8375
   Yanamandra N, 2005, INT J CANCER, V115, P998, DOI 10.1002/ijc.20965
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469
NR 44
TC 49
Z9 57
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2199
J9 BMC MOL BIOL
JI BMC Mol. Biol.
PD DEC 3
PY 2007
VL 8
AR 110
DI 10.1186/1471-2199-8-110
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 261WI
UT WOS:000253110300001
PM 18053161
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Kouidou, S
   Malousi, A
   Kyventidis, A
   Fragou, A
   Maglaveras, N
AF Kouidou, Sofia
   Malousi, Andigoni
   Kyventidis, Anastasios
   Fragou, Aikaterini
   Maglaveras, Nicos
TI G:C &gt; A:T mutations and potential epigenetic regulation of <i>p53</i>
   in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE p53; asymmetric methylation; breast cancer; Li-Fraumeni syndrome; p53
   isoforms; somatic germline mutations
ID METHYLATION; GENE; DNA; SPECTRA; MUTAGENESIS; SEQUENCES; PROMOTER;
   ORIGIN; POINT
AB Analysis of germline p53 mutations in breast cancer reveals that the Li-Fraumeni and Li-Fraumeni-like syndromes are mostly related to the loss of initiation codon 133 of regulatory TP53 isoforms (Delta 133p53). In eight codons of exons 5-8 (including 133), mutations are frequent in Li-Fraumeni-related, but scarce in sporadic breast cancer, while in six more codons they are frequent both in familial and sporadic breast cancers. At the proximity of these codons, we observed in somatic mutation databases, 16 codons (minihotspots mostly in exons 7, 8) which undergo frequent G:C > A:T transitions (non-CpG) in all sporadic cancers. In addition, in sporadic breast cancer we observed 35 adjacent codons in which the following types of mutation are observed: frequent G:C > A:T transitions at CCs/GGs, frequent silent mutations in exons 5,6 and suppressed nonsense mutations (5 codons, few records). Non-CpG G:C > A:T transitions in the 35 codons are rare in familial cancers (p53, BRCA1, or BRCA2-related), but frequent in sporadic cancers in organs where Li-Fraumeni-related carcinogenesis is common e.g. adrenal cortex, soft tissues. These data are in support of the following tissue-specific processes: in sporadic breast cancer (sarcomas etc.), loss of methylation sites (in 35 codons mostly next to codon 133), might lead to loss of silencing of TP53 isoforms which are suppressed in these tissues. On the contrary, "spreading" of cytosine methylation (asymmetric) in a G:C-rich region next to common hotspots (codons 238-252 in minihotspots) and mutagenesis probably destabilizes all tissues. Frequent C > T activation at non-CpG is also observed in prostate sporadic cancer, which similarly to breast, undergoes age-related crisis. The above data reveal that tissue-specific epigenetic regulatory mechanisms might be involved in p53 instability.
C1 Aristotle Univ Thessaloniki, Sch Med, Dept Biol Chem, Thessaloniki 54124, Greece.
   Aristotle Univ Thessaloniki, Sch Med, Lab Med Informat, Thessaloniki 54124, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki
RP Kouidou, S (通讯作者)，Aristotle Univ Thessaloniki, Sch Med, Dept Biol Chem, Thessaloniki 54124, Greece.
EM kouidou@auth.gr; andigoni@med.auth.gr; tasoskyventidis@yahoo.gr;
   katerinafragou@hotmail.com; nicmag@med.auth.gr
RI Malousi, Andigoni/K-3754-2019; Maglaveras, Nicos/ABI-2190-2020; Malousi,
   Andigoni/A-9460-2012
OI Malousi, Andigoni/0000-0002-1968-7020; Kouidou,
   Sofia/0000-0002-1934-3260
CR Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236
   Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905
   Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516
   Cao XF, 2002, P NATL ACAD SCI USA, V99, P16491, DOI 10.1073/pnas.162371599
   de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099
   Dollé MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403
   Glazko GV, 2004, BBA-GENE STRUCT EXPR, V1679, P95, DOI 10.1016/j.bbaexp.2004.05.004
   Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367
   HO PS, 1985, EMBO J, V4, P3617, DOI 10.1002/j.1460-2075.1985.tb04125.x
   JI CA, 1991, CHEM RES TOXICOL, V4, P77, DOI 10.1021/tx00019a010
   Kouidou S, 2005, LUNG CANCER-J IASLC, V50, P299, DOI 10.1016/j.lungcan.2005.06.012
   Kouidou S, 2006, MUTAT RES-FUND MOL M, V599, P167, DOI 10.1016/j.mrfmmm.2006.03.002
   Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1
   Rajesh M, 2005, BIOCHEMISTRY-US, V44, P2197, DOI 10.1021/bi0480032
   Rodin SN, 1998, P NATL ACAD SCI USA, V95, P11927, DOI 10.1073/pnas.95.20.11927
   Rodin SN, 2002, MUTAT RES-FUND MOL M, V510, P153, DOI 10.1016/S0027-5107(02)00260-9
   Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190
   Theisen J, 2005, ANN SURG, V241, P63, DOI 10.1097/01.sla.0000150072.55037.e3
   TORNALETTI S, 1995, ONCOGENE, V10, P1493
   You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322
NR 20
TC 7
Z9 7
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2007
VL 106
IS 3
BP 351
EP 360
DI 10.1007/s10549-007-9514-y
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 226HJ
UT WOS:000250579800007
PM 17505880
DA 2025-01-12
ER

PT J
AU Losi-Guembarovski, R
   Kuasne, H
   Guembarovski, AL
   Rainho, CA
   Cólus, IMS
AF Losi-Guembarovski, Roberta
   Kuasne, Hellen
   Guembarovski, Alda L.
   Rainho, Claudia A.
   Colus, Ilce M. S.
TI DNA methylation patterns of the CDHI, RARB, and SFN genes in choroid
   plexus tumors
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; RETINOIC ACID RECEPTORS; CPG ISLAND
   METHYLATION; E-CADHERIN GENE; BREAST-CANCER; ABERRANT METHYLATION;
   14-3-3 SIGMA; HYPERMETHYLATION; EXPRESSION; SYSTEM
AB Genetic and epigenetic alterations in choroid plexus tumors, a rare neuroepithelial neoplasm most frequently detected in children, are poorly characterized. Epigenetic silencing associated with aberrant CpG island methylation is one mechanism leading to the loss of tumor suppressor functions in cancer cells. Using methylation-specific polymerase chain reaction, the methylation patterns of the genes CDH1 (E-cadherin), RARB (retinoic acid receptor, beta), and SFN (stratifin; 14-3-3 sigma) were retrospectively investigated in eight choroid plexus tumors (five papillomas, two atypical papillomas, and one carcinoma), as well as in two normal cortexes obtained after autopsy from male individuals aged 6 months and 64 years. Among the six pediatric tumors, the mean age at diagnosis was 1.8 years old (range, 0.2-6) and the two adult tumors were detected in a 66-year-old man and a 45-year-old woman. A high frequency of hypermethylation was detected in CDH1 and SFN genes in tumoral and normal cortex tissues. Tumor-specific RARB hypermethylation was observed in four papillomas. Further studies are required to evaluate the role of aberrant methylation in choroid plexus tumor progression. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Estadual Londrina, Ctr Biol Sci, Dept Gen Biol, Londrina, PR, Brazil.
   Univ Fed Parana, Dept Genet, BR-80060000 Curitiba, Parana, Brazil.
   Univ Estadual Londrina, Dept Appl Pathol, Londrina, PR USA.
   Sao Paulo State Univ, UNESP, Biosci Inst, Dept Genet, BR-18618000 Botucatu, SP, Brazil.
C3 Universidade Estadual de Londrina; Universidade Federal do Parana;
   Universidade Estadual de Londrina; Universidade Estadual Paulista
RP Rainho, CA (通讯作者)，Univ Estadual Londrina, Ctr Biol Sci, Dept Gen Biol, Londrina, PR, Brazil.
EM rainho@ibb.unesp.br
RI Colus, Ilce/F-9423-2013; Rainho, Claudia Aparecida/B-7567-2012
OI Rainho, Claudia Aparecida/0000-0002-0285-1162
CR Azarschab P, 2002, GENE CHROMOSOME CANC, V35, P121, DOI 10.1002/gcc.10101
   Banelli B, 2005, ONCOGENE, V24, P5619, DOI 10.1038/sj.onc.1208722
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0
   BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x
   BRADA M, 1995, OXFORD TXB ONCOLOGY, P2085
   Cao WD, 2006, J NEURO-ONCOL, V77, P125, DOI 10.1007/s11060-005-9027-7
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Corn PG, 2001, CLIN CANCER RES, V7, P2765
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FIGARELLABRANGER D, 1995, ACTA NEUROPATHOL, V89, P248
   Grill J, 2002, CANCER GENET CYTOGEN, V136, P121, DOI 10.1016/S0165-4608(02)00516-2
   Herman JG, 2005, COLD SH Q B, V70, P329, DOI 10.1101/sqb.2005.70.036
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x
   ISOLA J, 1994, AM J PATHOL, V145, P1301
   Jass JR, 2002, J GASTROEN HEPATOL, V17, P17, DOI 10.1046/j.1440-1746.2002.02635.x
   Kleihues PCW., 2000, WORLD HLTH ORG CLASS
   Klein O, 2005, NEUROCHIRURGIE, V51, P147, DOI 10.1016/S0028-3770(05)83470-8
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lodygin D, 2006, SEMIN CANCER BIOL, V16, P214, DOI 10.1016/j.semcancer.2006.03.008
   Michalowski MB, 2006, CANCER GENET CYTOGEN, V166, P74, DOI 10.1016/j.cancergencyto.2005.09.004
   Nass SJ, 2000, CANCER RES, V60, P4346
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009
   Rickert CH, 2002, AM J PATHOL, V160, P1105, DOI 10.1016/S0002-9440(10)64931-0
   RUBERTE E, 1993, DEVELOPMENT, V118, P267
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407
   Toyooka S, 2002, CANCER RES, V62, P3382
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Van Dyke Terry A., 1993, P287
   Zakrzewska M, 2005, CANCER GENET CYTOGEN, V156, P179, DOI 10.1016/j.cancergencyto.2004.05.002
NR 35
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD DEC
PY 2007
VL 179
IS 2
BP 140
EP 145
DI 10.1016/j.cancergencyto.2007.05.029
PG 6
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 238WD
UT WOS:000251478000009
PM 18036402
DA 2025-01-12
ER

PT J
AU Stearns, V
   Zhou, Q
   Davidson, NE
AF Stearns, Vered
   Zhou, Qun
   Davidson, Nancy E.
TI Epigenetic regulation as a new target for breast cancer therapy
SO CANCER INVESTIGATION
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID;
   METHYLATION-SPECIFIC PCR; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   PHASE-I; CELLS; GENE; ER; METHYLTRANSFERASE
C1 [Stearns, Vered; Zhou, Qun; Davidson, Nancy E.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA.
C3 Johns Hopkins University
RP Stearns, V (通讯作者)，Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA.
FU NCI NIH HHS [CA88843] Funding Source: Medline
CR Bali P, 2005, CLIN CANCER RES, V11, P6382, DOI 10.1158/1078-0432.CCR-05-0344
   Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fuino L, 2003, MOL CANCER THER, V2, P971
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   KIM MS, 2003, P AM ASSOC CANC RES, V44, pA790
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Luo RX, 1999, JNCI-J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045
   Munster PN, 2001, CANCER RES, V61, P8492
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168
   Toulouse A, 1996, BBA-GENE STRUCT EXPR, V1309, P1, DOI 10.1016/S0167-4781(96)00126-1
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang XW, 2001, CANCER RES, V61, P7025
   ZHOU Q, 2006, 97 ANN M WASH DC APR
NR 30
TC 59
Z9 66
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0735-7907
EI 1532-4192
J9 CANCER INVEST
JI Cancer Invest.
PD DEC
PY 2007
VL 25
IS 8
BP 659
EP 665
DI 10.1080/07357900701719234
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 248KI
UT WOS:000252151800001
PM 18058459
DA 2025-01-12
ER

PT J
AU Vogiatzi, P
   Aimola, P
   Scarano, MI
   Claudio, PP
AF Vogiatzi, Paraskevi
   Aimola, Pierpaolo
   Scarano, Maria Irene
   Claudio, Pier Paolo
TI Epigenome-derived drugs: Recent advances and future perspectives
SO DRUG NEWS & PERSPECTIVES
LA English
DT Article
ID HISTONE-DEACETYLASE INHIBITORS; TEA POLYPHENOL
   (-)-EPIGALLOCATECHIN-3-GALLATE; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; DNA
   METHYLATION INHIBITORS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER CELLS;
   PHASE-I; CLINICAL DEVELOPMENT; RNA INTERFERENCE; OVARIAN-CANCER
AB This review highlights the current knowledge of epigenetic targets of anticancer therapy and outlines the current limitations of epigenetic approaches and the difficulties in defining preventive tools and strategies. Promising strategies towards achieving the goal of developing effective epigenetic treatments are discussed, including restoration or enhancement of sensitivity to other treatment modalities, and combinations with other agents and new therapeutic areas. (c) 2007 Prous Science. All rights reserved.
C1 [Scarano, Maria Irene; Claudio, Pier Paolo] Marshall Univ, Dept Biochem & Microbiol, Joan C Edwards Sch Med, Huntington, WV 25755 USA.
   [Claudio, Pier Paolo] Marshall Univ, Dept Surg, Joan C Edwards Sch Med, Huntington, WV 25755 USA.
   [Vogiatzi, Paraskevi] Univ Siena, Med Genet Unit, Dept Mol Biol, I-53100 Siena, Italy.
   [Aimola, Pierpaolo] Univ L Aquila, Dept Basic & Appl Biol, Laquila, Italy.
C3 Marshall University; Marshall University; University of Siena;
   University of L'Aquila
RP Claudio, PP (通讯作者)，Marshall Univ, Dept Biochem & Microbiol, Joan C Edwards Sch Med, 1 John Marshall Dr,Robert C Byrd Biotechnol Sci C, Huntington, WV 25755 USA.
EM claudiop@marshall.edu
RI Claudio, Pier Paolo/AAW-7282-2021; Vogiatzi, Paraskevi/AAH-4494-2021
OI Claudio, Pier Paolo/0000-0001-7790-1622
CR Balch C, 2005, MOL CANCER THER, V4, P1505, DOI 10.1158/1535-7163.MCT-05-0216
   Ben-Kasus T, 2005, BIOCHEM PHARMACOL, V70, P121, DOI 10.1016/j.bcp.2005.04.010
   Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848
   Byrd JC, 2005, BLOOD, V105, P959, DOI 10.1182/blood-2004-05-1693
   Castanotto D, 2005, MOL THER, V12, P179, DOI 10.1016/j.ymthe.2005.03.003
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Deng C, 2003, ARTHRITIS RHEUM, V48, P746, DOI 10.1002/art.10833
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Fang MZ, 2003, CANCER RES, V63, P7563
   Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725
   Fujiki H, 1999, J CANCER RES CLIN, V125, P589, DOI 10.1007/s004320050321
   Gilbert J, 2001, CLIN CANCER RES, V7, P2292
   Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Ishiguro M, 2007, ANN SURG ONCOL, V14, P1752, DOI 10.1245/s10434-006-9285-4
   Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636
   Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200
   Len YW, 2003, CANCER RES, V63, P6110
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Lu Q, 2006, AGEING RES REV, V5, P449, DOI 10.1016/j.arr.2006.07.001
   Lu QJ, 2005, J IMMUNOL, V174, P6212, DOI 10.4049/jimmunol.174.10.6212
   Lübbert M, 2000, CURR TOP MICROBIOL, V249, P135
   Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037
   Milhem M, 2004, BLOOD, V103, P4102, DOI 10.1182/blood-2003-07-2431
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Murgo AJ, 2005, SEMIN ONCOL, V32, P458, DOI 10.1053/j.seminoncol.2005.07.004
   Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536
   Parker BS, 2003, CANCER BIOL THER, V2, P259, DOI 10.4161/cbt.2.3.364
   Pilatrino C, 2005, CANCER-AM CANCER SOC, V104, P101, DOI 10.1002/cncr.21132
   Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501
   Saunthararajah Y, 2004, SEMIN HEMATOL, V41, P11, DOI 10.1053/j.seminhematol.2004.08.003
   Shi HD, 2003, CANCER RES, V63, P2164
   SORM F, 1964, NEOPLASMA, V11, P123
   Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
NR 48
TC 4
Z9 5
U1 0
U2 3
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0214-0934
J9 DRUG NEWS PERSPECT
JI Drug News Perspect.
PD DEC
PY 2007
VL 20
IS 10
BP 627
EP 633
DI 10.1358/dnp.2007.20.10.1181356
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 268GI
UT WOS:000253566900004
PM 18301797
DA 2025-01-12
ER

PT J
AU Roman-Gomez, J
   Jimenez-Velasco, A
   Cordeu, L
   Vilas-Zornoza, A
   Jose-Eneriz, ES
   Garate, L
   Castillejo, JA
   Martin, V
   Prosper, F
   Heiniger, A
   Torres, A
   Agirre, X
AF Roman-Gomez, Jose
   Jimenez-Velasco, Antonio
   Cordeu, Lucia
   Vilas-Zornoza, Amaia
   Jose-Eneriz, Edurne San
   Garate, Leire
   Castillejo, Juan A.
   Martin, Vanesa
   Prosper, Felipe
   Heiniger, Anabel
   Torres, Antonio
   Agirre, Xabier
TI WNT5A, a putative tumour suppressor of lymphoid malignancies, is
   inactivated by aberrant methylation in acute lymphoblastic leukaemia
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Wnt-signalling pathway; Wnt5a; methylation; ALL
ID BETA-CATENIN; GROWTH-FACTOR; SIGNALING PATHWAY; PETHEMA ALL-89;
   BREAST-CANCER; CELL-LINES; EXPRESSION; WNT-5A; MUTATIONS; CHILDREN
AB Wnt5a is a member of the Wnt family of proteins that signals through the non-canonical Wnt/Ca2+ pathway to suppress cyclin D1 expression and negatively regulate B cell proliferation suggesting that it acts as an tumour suppressor for lymphoid leukemogenesis. Although canonical Wnt pathway is a 'hot spot' for methylation in acute lymphoblastic leukaemia (ALL), the role of Wnt5a abnormalities has never been evaluated in this clinical setting. The methylation status of the WNT5A promoter was analysed by methylation-specific PCR (MSP) and sequencing in six ALL-derived cell lines (TOM-1, NALM-20, MY, LOUCY, JUR-KAT and TANOUE) and in 307 ALL patients. WNT5A and CYCLIN D1 expressions were assessed by quantitative RT-PCR. We observed WNT5A hypermethylation in all cell lines and in cells from 43% (132/307) of ALL patients. WNT5A methylation was associated with decreased WNT5A mRNA expression (P < 0.001) and this expression was restored after exposure to the demethylating agent 5-Aza-2'-deoxycytidine. Moreover, WNT5A hypermethylation correlated with upregulation of CYCLIN D1 expression (P = 0.002). Disease-free survival (DFS) and overall survival (OS) at 13 and 14 years, respectively, were 59% and 53% for unmethylated patients and 28% and 31% for hypermethylated patients (P = 0.0003 and P = 0.003). Multivariate analysis demonstrated that WNT5A methylation was an independent prognostic factor predicting DFS (P = 0.003) and OS (P = 0.04). We have demonstrated that WNT5A, a putative tumour suppressor gene in ALL, is silenced by methylation in this disease and that this epigenetic event is associated with upregulation of CYCLIN D1 expression and confers poor prognosis in this group of patients. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Roman-Gomez, Jose; Castillejo, Juan A.; Martin, Vanesa; Torres, Antonio] Reina Sofia Hosp, Dept Hematol, Cordoba 14004, Spain.
   [Jimenez-Velasco, Antonio; Heiniger, Anabel] Carlos Haya Hosp, Dept Hematol, Malaga, Spain.
   [Cordeu, Lucia; Vilas-Zornoza, Amaia; Jose-Eneriz, Edurne San; Garate, Leire; Prosper, Felipe; Agirre, Xabier] Univ Navarra, Fdn Appl Med Res, Clin Univ Sch Med, Cellular Therapy Area,Hematol Dept, E-31080 Pamplona, Spain.
C3 Hospital Universitario Reina Sofia - Cordoba; Hospital Carlos Haya;
   University of Navarra
RP Roman-Gomez, J (通讯作者)，Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.
EM peperosa@teleline.es
RI Agirre, Xabier/ABE-4110-2020; San Jose-Eneriz, Edurne/AAD-7288-2020;
   Vilas-Zornoza, Amaia/AAD-4004-2020; Prosper, Felipe/H-6859-2017
OI San Jose-Eneriz, Edurne/0000-0001-5786-5273; Vilas-Zornoza,
   Amaia/0000-0001-6693-0989; Prosper, Felipe/0000-0001-6115-8790
CR Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056
   Blanc E, 2005, CANCER LETT, V228, P117, DOI 10.1016/j.canlet.2004.11.061
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063
   HUGUET EL, 1995, J BIOL CHEM, V270, P12851, DOI 10.1074/jbc.270.21.12851
   IOZZO RV, 1995, CANCER RES, V55, P3495
   Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4
   Jönsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511
   Kitaeva MN, 1997, CANCER RES, V57, P4478
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x
   Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359
   LEJEUNE S, 1995, CLIN CANCER RES, V1, P215
   Leris ACA, 2005, ANTICANCER RES, V25, P731
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X
   Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346
   Ortega JJ, 1998, INT J PEDIAT HEM ONC, V5, P163
   Ortega JJ, 2001, HAEMATOLOGICA, V86, P586
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Ribera JM, 2002, HAEMATOLOGICA, V87, P154
   Ribera JM, 1998, HAEMATOLOGICA, V83, P222
   Roman-Gomez J, 2005, J CLIN ONCOL, V23, P7043, DOI 10.1200/JCO.2005.01.4944
   Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954
   Román-Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043
   Roman-Gomez J, 2006, CLIN CANCER RES, V12, P4845, DOI 10.1158/1078-0432.CCR-05-2592
   Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463
   Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18
   Wang Q, 2007, ONCOGENE, V26, P6560, DOI 10.1038/sj.onc.1210472
   Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.3.CO;2-R
NR 30
TC 64
Z9 80
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD DEC
PY 2007
VL 43
IS 18
BP 2736
EP 2746
DI 10.1016/j.ejca.2007.10.004
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 248HB
UT WOS:000252142300018
PM 18032022
DA 2025-01-12
ER

PT J
AU Belguise, K
   Sonenshein, GE
AF Belguise, Karine
   Sonenshein, Gail E.
TI PKCθ promotes c-Rel-driven mammary tumorigenesis in mice and humans by
   repressing estrogen receptor α synthesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PROTEIN-KINASE-C; NF-KAPPA-B; TRANSCRIPTION FACTOR FOXO3A; HUMAN
   BREAST-CANCER; GENE-EXPRESSION; SELECTIVE-INHIBITION; CARCINOMA CELLS;
   TRANSGENIC MICE; ACTIVATION; SURVIVAL
AB The vast majority of primary human breast cancer tissues display aberrant nuclear NF-kappa B c-Rel expression. A causal role for c-Rel in mammary tumorigenesis has been demonstrated using a c-Rel transgenic mouse model; however, tumors developed with a long latency, suggesting a second event is needed to trigger tumorigenesis. Here we show that c-Rel activity in the mammary gland is repressed by estrogen receptor alpha (ER alpha) signaling, and we identify an epigenetic mechanism in breast cancer mediated by activation of what we believe is a novel PKC theta-Akt pathway that leads to downregulation of ER alpha synthesis and derepression of c-Rel. ER alpha levels were lower in c-Rel-induced mammary tumors compared with normal mammary gland tissue. PKC theta induced c-Rel activity and target gene expression and promoted growth of c-Rel- and c-ReNCK2 alpha-driven mouse mammary tumor-derived cell lines. RNA expression levels of PKC theta and c-Rel target genes were inversely correlated with ERa levels in human breast cancer specimens. PKC theta activated Akt, thereby inactivating forkhead box O protein 3a (FOXO3a) and leading to decreased synthesis of its target genes, ERa and p27(KiP1). Thus we have shown that activation of PKC theta inhibits the FOXO3a/ER alpha/p27(Kip1) axis that normally maintains an epithelial cell phenotype and induces c-Rel target genes, thereby promoting proliferation, survival, and more invasive breast cancer.
C1 Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Womens Hlth Interdisciplinary Res Ctr, Boston, MA 02118 USA.
C3 Boston University; Boston University
RP Sonenshein, GE (通讯作者)，Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.
EM gsonensh@bu.edu
OI Belguise, Karine/0000-0003-3426-8040
CR BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842
   Belguise K, 2007, CANCER RES, V67, P5763, DOI 10.1158/0008-5472.CAN-06-4327
   BIRT DF, 1995, J NUTR, V125, pS1673
   BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310
   Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Clayton SJ, 1997, MOL CELL ENDOCRINOL, V128, P57, DOI 10.1016/S0303-7207(96)04016-6
   Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412
   Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097
   Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727
   Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9
   Grumont R, 2004, IMMUNITY, V21, P19, DOI 10.1016/j.immuni.2004.06.004
   Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004
   Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129
   Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2
   Hyder SM, 1997, CANCER RES, V57, P2547
   Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807
   Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kavok NS, 2003, EXP GERONTOL, V38, P441, DOI 10.1016/S0531-5565(02)00246-2
   Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001
   Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411
   LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169
   Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000
   Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Mineva ND, 2007, J BIOL CHEM, V282, P17475, DOI 10.1074/jbc.M607313200
   Moscat J, 2006, CELL DEATH DIFFER, V13, P702, DOI 10.1038/sj.cdd.4401823
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0
   OBRIAN CA, 1989, CANCER RES, V49, P3215
   Oliveira Cleida A, 2003, Reprod Biol Endocrinol, V1, P75, DOI 10.1186/1477-7827-1-75
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257
   Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221
   RISHI AK, 1995, CANCER RES, V55, P4999
   Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003
   Romieu-Mourez R, 2002, CANCER RES, V62, P6770
   Salvador GA, 2002, EXP GERONTOL, V37, P543, DOI 10.1016/S0531-5565(01)00214-5
   SETH A, 1992, J BIOL CHEM, V267, P24796
   Sivaraman L, 2002, J MAMMARY GLAND BIOL, V7, P77, DOI 10.1023/A:1015774524076
   Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848
   Srivastava KK, 2004, J BIOL CHEM, V279, P29911, DOI 10.1074/jbc.M401997200
   Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371
   Sun M, 2001, CANCER RES, V61, P5985
   Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326
   Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712
   Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003
   Wang Y, 2002, J UNIV SCI TECHNOL B, V9, P470
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
   Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245
NR 62
TC 65
Z9 75
U1 1
U2 4
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD DEC
PY 2007
VL 117
IS 12
BP 4009
EP 4021
DI 10.1172/JCI32424
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 237SL
UT WOS:000251396600048
PM 18037997
OA Green Accepted, Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Lee, WJ
AF Lee, Won Jun
TI Current status and future perspective for the mechanism of action of
   dietary polyphenols on epigenetic mechanisms
SO KOREAN JOURNAL OF GENETICS
LA English
DT Article
DE polyphenols; DNA methylation; histone methylation; cancer prevention
ID CATECHOL-O-METHYLTRANSFERASE; HISTONE LYSINE METHYLATION; HUMAN
   CANCER-CELLS; DNA METHYLATION; BREAST-CANCER; GREEN TEA; REPRESS
   TRANSCRIPTION; GENE-EXPRESSION; CHROMATIN; INHIBITION
AB DNA methylation and histone modifications are two major epigenetic mechanisms that can affect gene expression through chromatin structure. Although many dietary polyphenolic compounds have strong cancer-preventive effects in various cancers, the modulating effect of dietary polyphenols on DNA methylation and histone methylation status has still not been characterized very well. DNA methylation and histone methylation. can each modulate gene expression separately, there is growing evidence that an interplay exists between cytosine methylation and histone modification to from a transcriptionally inactive chromatin state. Therefore, the ability of dietary polyphenols to inhibit DNA methylation may also modulate the key parameters of histone methylation and reactivate the expression of tumor suppressor genes in cancer cells. However, it is hypothesized that all dietary polyphenols may not be the same in terms of reactivating silenced genes and modulating the methylation status of histone proteins due to the fact that each polyphenol has varying degrees of inhibition protencies and dfficacies. More studies are warranted to further test these unknown hypotheses.
C1 Ewha Womans Univ, Coll Hlth Sci, Seoul 120750, South Korea.
C3 Ewha Womans University
RP Lee, WJ (通讯作者)，Ewha Womans Univ, Coll Hlth Sci, Seoul 120750, South Korea.
EM jun@ewha.ac.kr
CR Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   GROSSMAN MH, 1992, GENOMICS, V12, P822, DOI 10.1016/0888-7543(92)90316-K
   GULDBERG HC, 1975, PHARMACOL REV, V27, P135
   Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v
   Inoue M, 2001, CANCER LETT, V167, P175, DOI 10.1016/S0304-3835(01)00486-4
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Karpf AR, 2007, CURR OPIN MOL THER, V9, P231
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   LEE WJ, 2005, MED HYPOT RES, V2, P325
   LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Milner JA, 2003, J NUTR, V133, p3820S, DOI 10.1093/jn/133.11.3820S
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Nan XS, 1996, MOL CELL BIOL, V16, P414
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nichols K E, 2000, Rev Immunogenet, V2, P256
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Potter JD, 2002, J NUTR, V132, p2410S, DOI 10.1093/jn/132.8.2410S
   Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   SOH KJ, 1999, CARCINOGENESIS, V20, P2345
   Song J, 2000, CANCER RES, V60, P3191
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8
   Umov FD, 2002, J NUTR, V132, p2450S, DOI 10.1093/jn/132.8.2450S
   Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711
   Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6
   Wu AH, 2003, CANCER RES, V63, P7526
   WU AH, 2005, INT J CANCER, V106, P574
   XU Y, 1992, CANCER RES, V52, P3875
   Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   Zhu BT, 2000, DRUG METAB DISPOS, V28, P1024
   Zhu BT, 1996, J BIOL CHEM, V271, P1357, DOI 10.1074/jbc.271.3.1357
   Zhu BT, 2001, XENOBIOTICA, V31, P879, DOI 10.1080/00498250110079798
   ZHU BT, 1994, J BIOL CHEM, V269, P292
NR 69
TC 0
Z9 0
U1 2
U2 2
PU GENETICS SOC KOREA
PI SEOUL
PA KOREA SCI & TECHNOL CENT, RM 1002, 635-4 YEOKSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 0254-5934
J9 KOREAN J GENETIC
JI Korean J. Genet.
PD DEC
PY 2007
VL 29
IS 4
BP 537
EP 546
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 253VV
UT WOS:000252546600015
DA 2025-01-12
ER

PT J
AU Dahl, C
   Guldberg, P
AF Dahl, Christina
   Guldberg, Per
TI A ligation assay for multiplex analysis of CpG methylation using
   bisulfite-treated DNA
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID PCR ASSAY; ISLAND METHYLATION; HYPERMETHYLATION; EPIGENETICS; SEQUENCES;
   RECOVERY; PROTOCOL; NUMBER; LIGASE
AB Aberrant methylation of promoter CpG islands is causally linked with a number of inherited syndromes and most sporadic cancers, and may provide valuable diagnostic and prognostic biomarkers. In this report, we describe an approach to simultaneous analysis of multiple CpG islands, where methylation-specific oligonucleotide probes are joined by ligation and subsequently amplified by polymerase chain reaction (PCR) when hybridized in juxtaposition on bisulfite-treated DNA. Specificity of the ligation reaction is achieved by (i) using probes containing CpGpCpG (for methylated sequences) or CpApCpA (for unmethylated sequences) at the 3 ends, (ii) including three or more probes for each target, and (iii) using a thermostable DNA ligase. The external probes carry universal tails to allow amplification of multiple ligation products using a common primer pair. As proof-of-principle applications, we established duplex assays to examine the FMR1 promoter in individuals with fragile-X syndrome and the SNRPN promoter in individuals with Prader-Willi syndrome or Angelman syndrome, and a multiplex assay to simultaneously detect hypermethylation of seven genes (ID4, APC, RASSF1A, CDH1, ESR1, HIN1 and TWIST1) in breast cancer cell lines and tissues. These data show that ligation of oligonucleotide probes hybridized to bisulfite-treated DNA is a simple and cost-effective approach to analysis of CpG methylation.
C1 [Dahl, Christina; Guldberg, Per] Danish Canc Soc, Inst Canc Biol, Dept Genom, Copenhagen, Denmark.
   [Dahl, Christina; Guldberg, Per] Danish Canc Soc, Inst Canc Biol, Danish Ctr Translat Breast Canc Res, Copenhagen, Denmark.
C3 Danish Cancer Society; Danish Cancer Society
RP Guldberg, P (通讯作者)，Danish Canc Soc, Inst Canc Biol, Dept Genom, Copenhagen, Denmark.
EM perg@cancer.dk
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   Bhagwat AS, 1999, NUCLEIC ACIDS RES, V27, P4028, DOI 10.1093/nar/27.20.4028
   Boyd VL, 2004, ANAL BIOCHEM, V326, P278, DOI 10.1016/j.ab.2003.11.020
   Brena RM, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj017
   Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479
   Cabezón T, 2007, INT J CANCER, V121, P1433, DOI 10.1002/ijc.22850
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   Dahl C, 2003, BIOGERONTOLOGY, V4, P233, DOI 10.1023/A:1025103319328
   Dahl C, 2007, CLIN CHEM, V53, P790, DOI 10.1373/clinchem.2006.080762
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Horsthemke B, 2006, CYTOGENET GENOME RES, V113, P292, DOI 10.1159/000090844
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lin ZW, 1996, P NATL ACAD SCI USA, V93, P2582, DOI 10.1073/pnas.93.6.2582
   Lu J, 2004, BBA-PROTEINS PROTEOM, V1701, P37, DOI 10.1016/j.bbapap.2004.06.008
   Munson K, 2007, NUCLEIC ACIDS RES, V35, P2893, DOI 10.1093/nar/gkm055
   Nilsson M, 2000, NAT BIOTECHNOL, V18, P791, DOI 10.1038/77367
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422
   Warren S. T., 2001, METABOLIC MOL BASES, P1257
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Worm J, 2001, CLIN CHEM, V47, P1183
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 43
TC 24
Z9 29
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2007
VL 35
IS 21
AR e144
DI 10.1093/nar/gkm984
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 244MA
UT WOS:000251868800006
PM 17998253
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Chen, LB
   Xu, JY
   Yang, Z
   Wang, GB
AF Chen, Li-Bo
   Xu, Jun-Yao
   Yang, Zhen
   Wang, Guo-Bin
TI Silencing SYMD3 in hepatoma demethylates RIZI promoter induces apoptosis
   and inhibits cell proliferation and migration
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE SMYD3; hepatocellular carcinoma; retinoblastoma protein-interacting zinc
   finger gene; histone methyltransferase; DNA methylation
ID HUMAN HEPATOCELLULAR-CARCINOMA; CANDIDATE TUMOR-SUPPRESSOR;
   BREAST-CANCER; EPIGENETIC THERAPY; DNA METHYLATION; EXPRESSION; GENES;
   CARCINOGENESIS; REGION; LIVER
AB AIM: To investigate the role of SMYD3 in hepatocellular carcinoma (HCC) development and progression and to verify whether its regulation activity was through RIZ1 inactivation.
   METHODS: Expression of SMYD3 in HCC cell lines and tissues were measured; silencing of SMYD3 by RNA interference (RNAi) was effectuated, hepatoma cell proliferation, migration and apoptosis were tested, with RIZ1 CpG promoter methylation, and corresponding mRNA expression were investigated.
   RESULTS: SMYD3 over-expression in HCC was associated with RIZ1 hypermethylation and mRNA down-expression. Suppression of SMYD3 expression demethylated RIZ1 CpG promoter (P < 0.01) and increased RIZ1 mRNA expression (P < 0.01). Consequently, SMYD3 down-expression with RIZ1 de-methylation strongly inhibited hepatoma cell growth (MTT inhibitory rates: Pgenesil-1-s1 60.95% +/- 7.97%, Pgenesil-1-s2 72.14% +/- 9.68% vs Pgenesil-1-hk 6.89% +/- 4.12%, P < 0.01) and migration (Pgenesil-1-s1 4.24% +/- 1.58%, Pgenesil-1-s1 4.87% +/- 0.73% vs Pgenesil-1 19.03% +/- 4.63%, Pgenesil-1-hk 19.95% +/- 5.21%, P < 0.01) and induced apoptosis (FCM subG1 phase Pgenesil-1-s1 19.07% +/- 1.78%, Pgenesil-1-s2 17.68% +/- 2.36% vs Pgenesil-1 0.47% +/- 0.12%, Pgenesil-1-hk 1.46% +/- 0.28%, P < 0.01. TUNEL-positive cells: Pgenesil-1-s1 40.24% +/- 5.18%, Pgenesil-1-s2 38.48% +/- 4.65% vs Pgenesil-1 2.18% +/- 1.34%, Pgenesil-1-hk 2.84% +/- 1.22%, P < 0.01) in HepG2 cells.
   CONCLUSION: These results demonstrate that SMYD3 plays a critical role in the carcinogenesis and progression of HCC. The proliferation, migration induction and apoptosis inhibition activities of SMYD3 may be mediated through RIZ1 CpG promoter hypermethylation. (C) 2007 WJG. All rights reserved.
C1 Huazhong Univ Sci & Technol, Union Hosp, Hepatobiliary Ctr, Wuhan 430022, Peoples R China.
   Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China.
   Huazhong Univ Sci & Technol, Tongji Hosp, Dept Integrated Surg, Wuhan 430030, Hubei Province, Peoples R China.
C3 Huazhong University of Science & Technology; Sun Yat Sen University;
   Huazhong University of Science & Technology
RP Chen, LB (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Hepatobiliary Ctr, Wuhan 430022, Peoples R China.
EM libo_chen@hotmail.com
OI Chen, Li-Bo/0000-0002-7755-6408
CR Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283
   Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917
   Benhaj K, 2006, ONCOL REP, V15, P701
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Deprez P, 2003, J BIOL CHEM, V278, P23233, DOI 10.1074/jbc.M301384200
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667
   Frachon S, 2001, J HEPATOL, V34, P850, DOI 10.1016/S0168-8278(01)00049-6
   Frank B, 2006, INT J CANCER, V118, P2917, DOI 10.1002/ijc.21696
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   He LS, 1998, CANCER RES, V58, P4238
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Jiang GL, 2001, CANCER RES, V61, P1796
   Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F
   Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553
   Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4
   Kajiyama Y, 2002, MOL CELL BIOL, V22, P6122, DOI 10.1128/MCB.22.17.6122-6130.2002
   Kirikoshi H, 2002, INT J ONCOL, V21, P895
   Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101
   Kondoh N, 1999, CANCER RES, V59, P4990
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Nishimura T, 2005, GENE CHROMOSOME CANC, V42, P34, DOI 10.1002/gcc.20117
   Piao Z, 2000, CANCER RES, V60, P4701
   Ricketts SL, 2003, MOL CARCINOGEN, V36, P90, DOI 10.1002/mc.10101
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu J, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-65
NR 29
TC 37
Z9 50
U1 0
U2 6
PU W J G PRESS
PI BEIJING
PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345,
   BEIJING 100023, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD NOV 21
PY 2007
VL 13
IS 43
BP 5718
EP 5724
DI 10.3748/wjg.v13.i43.5718
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 229JR
UT WOS:000250799600007
PM 17963297
OA Green Published
DA 2025-01-12
ER

PT J
AU Yu, J
   Yu, J
   Rhodes, DR
   Tomlins, SA
   Cao, X
   Chen, G
   Mehra, R
   Wang, X
   Ghosh, D
   Shah, RB
   Varambally, S
   Pienta, KJ
   Chinniaiyan, AM
AF Yu, Jindan
   Yu, Jianjun
   Rhodes, Daniel R.
   Tomlins, Scott A.
   Cao, Xuhong
   Chen, Guoan
   Mehra, Rohit
   Wang, Xiaoju
   Ghosh, Debashis
   Shah, Raja B.
   Varambally, Sooryanarayana
   Pienta, Kenneth J.
   Chinniaiyan, Arul M.
TI A polycomb repression signature in metastatic prostate cancer predicts
   cancer outcome
SO CANCER RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; BREAST-CANCER; DEVELOPMENTAL REGULATORS;
   EXPRESSION SIGNATURE; RECURRENCE; PATTERNS; SURVIVAL; RISK
AB The Polycomb Group (PcG) protein EZH2 is a critical component of a multiprotein complex that methylates Lys(27) of historic 3 (H3K27), which consequently leads to the repression of target gene expression. We have previously reported that EZH2 is overexpressed in metastatic prostate cancer and is a marker of aggressive diseases in clinically localized solid tumors. However, the global set of genes directly regulated by PcG in tumors is largely unknown, and thus how PcG mediates tumor progression remains unclear. Herein we mapped genome-wide H3K27 methylation in aggressive, disseminated human prostate cancer tissues. Integrative analysis revealed that a significant subset of these genes are also targets of PcG in embryonic stem cells, and their repression in tumors is associated with poor prognosis. By stepwise cross-validation, we developed a "Polycomb repression signature" composed of 14 direct targets of PcG in metastatic tumors. Notably, solid tumor subtypes in which this gene signature is repressed show poor clinical outcome in multiple microarray data sets of tumors including breast and prostate cancer. Taken together, our results show a fingerprint of PcG-mediated transcriptional repression in metastatic prostate cancer that is reminiscent of stem cells and associated with cancer progression. Therefore, PcG proteins play a central role in the epigenetic silencing of target genes and functionally link stem cells, metastasis, and cancer survival.
C1 Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Dept Pathol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Bioinformat Program, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Chinniaiyan, AM (通讯作者)，Univ Michigan, Sch Med, Ctr Comprehens Canc, 1400 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM arul@umich.edu
RI Chen, Guoan/J-9140-2018; Ghosh, Debashis/KZT-8916-2024; Pienta,
   Kenneth/E-7679-2015
OI Pienta, Kenneth/0000-0002-4138-2186; Tomlins, Scott/0000-0001-8661-9821;
   Ghosh, Debashis/0000-0001-6618-1316; Varambally,
   Sooryanarayana/0000-0002-2277-1127
FU NCI NIH HHS [R01 CA97063, R01 CA102872, U01 CA111275, P50 CA69568]
   Funding Source: Medline
CR Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833
   Freedland SJ, 2005, JAMA-J AM MED ASSOC, V294, P433, DOI 10.1001/jama.294.4.433
   Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
   Zhang Kai Qi, 2003, Clin Med Res, V1, P21
NR 20
TC 263
Z9 318
U1 1
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2007
VL 67
IS 22
BP 10657
EP 10663
DI 10.1158/0008-5472.CAN-07-2498
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 232UA
UT WOS:000251044000006
PM 18006806
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Zhang, X
   Leung, YK
   Ho, SM
AF Zhang, X.
   Leung, Y-K
   Ho, S-M
TI AP-2 regulates the transcription of estrogen receptor (<i>ER</i>)-β by
   acting through a methylation hotspot of the <i>0N</i> promoter in
   prostate cancer cells
SO ONCOGENE
LA English
DT Article
DE epigenetics; promoter analysis; non-canonical; cis-element; tumor
   suppressor; gene regulation
ID ER-BETA; ACTIVATOR PROTEIN-2-ALPHA; GENE-EXPRESSION; BREAST-CANCER;
   BINDING; CLONING; FAMILY; DNA; CARCINOGENESIS; CARCINOMA
AB We reported previously that the loss of expression of estrogen receptor (ER)-beta during the development of prostate cancer (PCa) is associated with methylation of a CpG island located in the 5'-flanking sequence of the 0N promoter. Three methylation hotspots, referred to as centers 1, 2 and 3, were identified in the CpG island. In this study, we demonstrated that a 581-bp region with these three centers within it is sufficient for the promoter activity in PCa cells. Deletion analyses indicated that center 1 ( 16 bp), with a putative activator protein-2 (AP-2) binding site, is essential for gene transactivation. Chromatin immunoprecipitation assays showed that AP-2 alpha occupies a short sequence containing center 1. Forced expression of AP-2 alpha or -2 gamma, but not -2 beta, increased activity of the ER beta 0N promoter and the accumulation of mRNA. Conversely, siRNA-mediated AP-2 alpha and -2 gamma knockdown reduced levels of ERb transcript and promoter activity. Quantitative reverse transcription - PCR showed that AP-2 alpha and -2 gamma are the predominant transcripts expressed in PCa cells, and levels of ERb transcript correlate with levels of these AP-2 transcripts among different PCa cell lines. These results provide the first evidence that ERb is an AP-2-regulated gene. They also support the hypothesis that certain cis-acting elements are methylation hotspots susceptible to epigenetic modi. cations during cancer progression.
C1 Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA.
C3 University System of Ohio; University of Cincinnati
RP Ho, SM (通讯作者)，Univ Cincinnati, Coll Med, Dept Environm Hlth, 130 Kettering,3223 Eden Ave,PO Box 670056, Cincinnati, OH 45267 USA.
EM shuk-mei.ho@uc.edu
RI Zhang, Xiang/D-3632-2009
OI Leung, Yuet-kin/0000-0003-2063-277X
FU NIDDK NIH HHS [DK061084] Funding Source: Medline
CR Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bosher JM, 1996, ONCOGENE, V13, P1701
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Comhaire F, 2004, Aging Male, V7, P155
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F
   Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6
   Hirata S, 2001, J STEROID BIOCHEM, V78, P33, DOI 10.1016/S0960-0760(01)00071-1
   Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Horvath LG, 2001, CANCER RES, V61, P5331
   Imamov O, 2005, BIOL REPROD, V73, P866, DOI 10.1095/biolreprod.105.043497
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036
   Lau KM, 2000, CANCER RES, V60, P3175
   Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216
   Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200
   Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760
   Nieto M, 2007, INT J BIOCHEM CELL B, V39, P1562, DOI 10.1016/j.biocel.2007.01.005
   Ockrim J, 2006, NAT CLIN PRACT ONCOL, V3, P552, DOI 10.1038/ncponc0602
   Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648
   Ruiz M, 2001, CLIN CANCER RES, V7, P4086
   Shoda T, 2002, J STEROID BIOCHEM, V82, P201, DOI 10.1016/S0960-0760(02)00186-3
   Signoretti S, 2001, AM J PATHOL, V159, P13, DOI 10.1016/S0002-9440(10)61666-5
   Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0
   Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200
   ZHU X, 2004, AM J PATHOL, V546, P17
NR 30
TC 40
Z9 49
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD NOV 15
PY 2007
VL 26
IS 52
BP 7346
EP 7354
DI 10.1038/sj.onc.1210537
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 231NP
UT WOS:000250955700006
PM 17525739
DA 2025-01-12
ER

PT J
AU Wu, ZX
   Luo, JF
   Ge, QY
   Zhang, DD
   Wang, Y
   Jia, C
   Lu, ZH
AF Wu, Zhixiang
   Luo, Junfeng
   Ge, Qinyu
   Zhang, Dingdong
   Wang, Yan
   Jia, Chao
   Lu, Zuhong
TI Allele-specific extension on microarray for DNA methylation analysis
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE methylation; microarray; allele-specific extension; methylation-specific
   PCR
ID PRIMER EXTENSION; EPIGENETICS; GENE; CANCER; ASSAY
AB Aberrant DNA methylation of CpG site in the gene promoter region has been confirmed to be closely associated with carcinogenesis. In this present study, a new method based on the allele-specific extension on microarray technique for detecting changes of DNA methylation in cancer was developed. The target gene regions were amplified from the bisulfite treated genomic DNA (gDNA) with modified primers and treated with exonuclease to generate single-strand targets. Allele-specific extension of the immobilized primers took place along a stretch of target sequence with the presence of DNA polymerase and CyS-labeled dGTP. To control the false positive signals, the hybridization condition, DNA polymerase, extension time and primers design were optimized. Two breast tumor-related genes (P16 and E-cadherin) were analyzed with this present method successfully and all the results were compatible with that of traditional methylation-specific PCR. The experiments results demonstrated that this DNA microarray-based method could be applied as a high throughput tool for methylation status analysis of the cancer-related genes, which could be widely used in cancer diagnosis or the detection of recurrence. (c) 2007 Elsevier B.V. All rights reserved.
C1 SE Univ, State Key Lab Bioelectron, Nanjing 210096, Peoples R China.
   SE Univ, Minist Educ, Key Lab Child Dev & Learning Sci, Nanjing 210096, Peoples R China.
C3 Southeast University - China; Southeast University - China
RP Lu, ZH (通讯作者)，SE Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelectron, Nanjing 210096, Peoples R China.
EM zhlu@seu.edu.cn
RI Ge, Qinyu/B-5055-2012; Luo, Junfeng/GPP-7603-2022; Lu,
   Zuhong/A-5448-2013
OI Lu, Zuhong/0000-0003-3332-2615
CR Ahmadian A, 2002, BIOTECHNIQUES, V32, P748, DOI 10.2144/02324bm06
   Ahmadian A, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.24.e121
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Brakensiek K, 2007, CLIN CHEM, V53, P17, DOI 10.1373/clinchem.2007.072629
   CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5
   Cottrell SE, 2004, CLIN BIOCHEM, V37, P595, DOI 10.1016/j.clinbiochem.2004.05.010
   Erdogan F, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e36
   Ericsson O, 2003, ELECTROPHORESIS, V24, P3330, DOI 10.1002/elps.200305583
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Goessl C, 2000, Prostate Cancer Prostatic Dis, V3, pS17, DOI 10.1038/sj.pcan.4500441
   Gonzalgo ML, 2002, METHODS, V27, P128, DOI 10.1016/S1046-2023(02)00064-6
   Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547
   Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hou P, 2004, WORLD J GASTROENTERO, V10, P3553, DOI 10.3748/wjg.v10.i24.3553
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X
   O'Meara D, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf074
   Ohashi Haruhiko, 2002, Methods Mol Biol, V192, P91
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Russom A, 2003, ELECTROPHORESIS, V24, P158, DOI 10.1002/elps.200390008
   Swift-Scanlan T, 2006, BIOTECHNIQUES, V40, P210, DOI 10.2144/000112097
   Valenzuela MT, 2002, EUR UROL, V42, P622, DOI 10.1016/S0302-2838(02)00468-2
NR 26
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD NOV 12
PY 2007
VL 603
IS 2
BP 199
EP 204
DI 10.1016/j.aca.2007.09.027
PG 6
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 232VA
UT WOS:000251047000010
PM 17963840
DA 2025-01-12
ER

PT J
AU Pasquali, L
   Bedeir, A
   Ringquist, S
   Styche, A
   Bhargava, R
   Trucco, G
AF Pasquali, Lorenzo
   Bedeir, Ahmed
   Ringquist, Steven
   Styche, Alexis
   Bhargava, Rohit
   Trucco, Giuliana
TI Quantification of CpG island methylation in progressive breast lesions
   from normal to invasive carcinoma
SO CANCER LETTERS
LA English
DT Article
DE CpG islands; pyrosequencing; breast cancer; RASSFA1; GSTP1; methylation
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; E-CADHERIN; RAR-BETA;
   IN-SITU; CANCER; RECEPTOR; RASSF1A; INACTIVATION; GENES
AB Epigenetic silencing of specific genes is associated with cancer progression. CpG islands are present at higher frequency in promoter regions, their methylation leading to gene underexpression. Pyrosequencing provides sequencing analysis of genetic markers, e.g., sin le nucleotide polymorphisms and DNA methylation. We investigated methylation levels of a spectrum of neoplastic breast lesions, ranging from hyperplasia to invasive carcinoma obtained from the same patient. Assays were designed to analyze promoter regions of RASSF1A, GSTP1, RAR beta, and E-cadherin. Methylation increased from normal to hyperplasia, the increase being significantly higher in invasive and in situ tumors for RASSF1A (p = 0.00006 and p = 0.009, respectively). (C) 2007 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat,Rangos Res Ctr,Div Immunogenet, Pittsburgh, PA 15213 USA.
   Univ Genoa, Dept Pediat, Inst G Gaslini, I-16174 Genoa, Italy.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Genoa; IRCCS Istituto
   Giannina Gaslini
RP Trucco, G (通讯作者)，Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA 15213 USA.
EM gtrucco@mail.magee.edu
RI Pasquali, Lorenzo/B-6239-2008; Bhargava, Rohit/B-6866-2008
OI Pasquali, Lorenzo/0000-0003-2423-1826
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herranz Michel, 2007, Methods Mol Biol, V361, P25
   HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   Marsh Sharon, 2007, V373, P15
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ringquist Steven, 2007, V373, P115
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   SHAMES DS, 2006, CANC LETT, P187
   Shaw RJ, 2007, ORAL ONCOL, V43, P878, DOI 10.1016/j.oraloncology.2006.10.006
   Shaw RJ, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl424
   Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Tost J, 2006, BIOTECHNIQUES, V40, P721, DOI 10.2144/000112190
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
NR 29
TC 34
Z9 41
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD NOV 8
PY 2007
VL 257
IS 1
BP 136
EP 144
DI 10.1016/j.canlet.2007.07.010
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 226OB
UT WOS:000250597300014
PM 17706863
DA 2025-01-12
ER

PT J
AU Paz, N
   Levanon, EY
   Amariglio, N
   Heimberger, AB
   Ram, Z
   Constantini, S
   Barbash, ZS
   Adamsky, K
   Safran, M
   Hirschberg, A
   Krupsky, M
   Ben-Dov, I
   Cazacu, S
   Mikkelsen, T
   Brodie, C
   Eisenberg, E
   Rechavi, G
AF Paz, Nurit
   Levanon, Erez Y.
   Amariglio, Ninette
   Heimberger, Amy B.
   Ram, Zvi
   Constantini, Shlomi
   Barbash, Zohar S.
   Adamsky, Konstantin
   Safran, Michal
   Hirschberg, Avi
   Krupsky, Meir
   Ben-Dov, Issachar
   Cazacu, Simona
   Mikkelsen, Tom
   Brodie, Chaya
   Eisenberg, Eli
   Rechavi, Gideon
TI Altered adenosine-to-inosine RNA, editing in human cancer
SO GENOME RESEARCH
LA English
DT Article
ID HUMAN BLADDER-CANCER; PRE-MESSENGER-RNA; HUMAN TRANSCRIPTOME; DNA
   METHYLATION; GENE-EXPRESSION; BREAST-CANCER; ALU ELEMENTS; C-MYC;
   DEAMINASE; RECEPTOR
AB Adenosine-to-inosine (A-to-I) RNA editing was recently shown to be abundant in the human transcriptome, affecting thousands of genes. Employing a bioinformatic approach, we identified significant global hypoediting of AN repetitive elements in brain, prostate, lung, kidney, and testis tumors. Experimental validation confirmed this finding, showing significantly reduced editing in Alu sequences within MED13 transcripts in brain tissues. Looking at editing of specific recoding and noncoding sites, including in cancer-related genes, a more complex picture emerged, with a gene-specific editing pattern in tumors vs. normal tissues. Additionally, we found reduced RNA levels of all three editing mediating enzymes, ADAP, ADARB1, and ADARB2, in brain tumors. The reduction of ADARB2 correlated with the grade of malignancy of glioblastoma multiforme, the most aggressive of brain tumors, displaying a 99% decrease in ADARB2 RNA levels. Consistently, overexpression of ADAR and ADARB1 in the U87 glioblastoma multiforme cell line resulted in decreased proliferation rate, suggesting that reduced A-to-l editing in brain tumors is involved in the pathogenesis of cancer. Altered epigenetic control was recently shown to play a central role in oncogenesis. We suggest that A-to-l RNA editing may serve as an additional epigenetic mechanism relevant to cancer development and progression.
C1 Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
   Compugen Ltd, IL-69512 Tel Aviv, Israel.
   Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Brain Tumor Ctr, Houston, TX 77030 USA.
   Sourasky Med Ctr, Dept Neurosurg, IL-64239 Tel Aviv, Israel.
   Sourasky Med Ctr, Dept Pediat Neurosurg, Dana Childrens Hosp, IL-64239 Tel Aviv, Israel.
   Chaim Sheba Med Ctr, Dept Internal Med, IL-52621 Tel Hashomer, Israel.
   Chaim Sheba Med Ctr, Pulm Inst, IL-52621 Tel Hashomer, Israel.
   Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
   NINDS, Neurooncol Branch, NCI, NIH, Bethesda, MD 20892 USA.
   Tel Aviv Univ, Sch Phys & Astron, Raymond & Beverly Sackler Fac Exact Sci, IL-69978 Tel Aviv, Israel.
C3 Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine; University of Texas System; UTMD Anderson Cancer Center; Tel
   Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical
   Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv
   Sourasky Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical
   Center; Henry Ford Health System; Henry Ford Hospital; National
   Institutes of Health (NIH) - USA; NIH National Institute of Neurological
   Disorders & Stroke (NINDS); NIH National Cancer Institute (NCI); Tel
   Aviv University
RP Rechavi, G (通讯作者)，Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel.
EM gidi.rechavi@sheba.health.gov.il
RI Eisenberg, Eli/D-2587-2009; Levanon, Erez/A-8128-2012
OI Levanon, Erez/0000-0002-3641-4198; Eisenberg, Eli/0000-0001-8681-3202
CR Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391
   Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Blow M, 2004, GENOME RES, V14, P2379, DOI 10.1101/gr.2951204
   Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27
   Boulton SJ, 2006, CELL CYCLE, V5, P1481, DOI 10.4161/cc.5.14.2930
   BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677
   Ceballos E, 2005, ONCOGENE, V24, P4559, DOI 10.1038/sj.onc.1208652
   Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170
   Cheng CK, 2005, CANCER RES, V65, P8646, DOI 10.1158/0008-5472.CAN-04-4243
   Clutterbuck DR, 2005, BIOINFORMATICS, V21, P2590, DOI 10.1093/bioinformatics/bti411
   Coons SW, 1997, CANCER, V79, P1381, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W
   Eisenberg E, 2005, TRENDS GENET, V21, P77, DOI 10.1016/j.tig.2004.12.005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fernandez HR, 2005, CURR BIOL, V15, pR132, DOI 10.1016/j.cub.2005.02.012
   Gourzi P, 2006, IMMUNITY, V24, P779, DOI 10.1016/j.immuni.2006.03.021
   Gromova I, 2002, INT J CANCER, V98, P539, DOI 10.1002/ijc.10244
   Gurevich I, 2002, NEURON, V34, P349, DOI 10.1016/S0896-6273(02)00660-8
   Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200
   Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558
   Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a
   Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504
   Levanon EY, 2005, NUCLEIC ACIDS RES, V33, P1162, DOI 10.1093/nar/gki239
   Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996
   Levanon K, 2005, EMBO REP, V6, P831, DOI 10.1038/sj.embor.7400507
   Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304
   Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398
   Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298
   Neeman Y, 2006, RNA, V12, P1802, DOI 10.1261/rna.165106
   Nie YZ, 2007, J VIROL, V81, P917, DOI 10.1128/JVI.01527-06
   Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0
   PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376
   Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033
   Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H
   Sardi I, 1997, EUR UROL, V31, P224
   Scadden ADJ, 2005, NUCLEIC ACIDS RES, V33, P5954, DOI 10.1093/nar/gki909
   Schenck A, 2003, NEURON, V38, P887, DOI 10.1016/S0896-6273(03)00354-4
   Smalheiser NR, 2006, TRENDS GENET, V22, P532, DOI 10.1016/j.tig.2006.08.007
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Su Hai-chuan, 2003, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V19, P465
   Tonkin LA, 2003, SCIENCE, V302, P1725, DOI 10.1126/science.1091340
   Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483
   Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041
   Yao J, 2007, MOL CELL BIOCHEM, V297, P81, DOI 10.1007/s11010-006-9332-2
NR 49
TC 279
Z9 325
U1 2
U2 20
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD NOV
PY 2007
VL 17
IS 11
BP 1586
EP 1595
DI 10.1101/gr.6493107
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 227FD
UT WOS:000250641700005
PM 17908822
OA hybrid, Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Zhang, Q
   Wang, HY
   Liu, XB
   Wasik, MA
AF Zhang, Qian
   Wang, Hong Y.
   Liu, Xiaobin
   Wasik, Mariusz A.
TI STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and
   acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK
   expression
SO NATURE MEDICINE
LA English
DT Article
ID MALIGNANT T-LYMPHOCYTES; NON-HODGKINS-LYMPHOMA; HUMAN BREAST-CANCER;
   SIGNAL TRANSDUCER; CELL LYMPHOMA; NPM-ALK; TRANSCRIPTION FACTORS;
   ACTIVATION; GENE; PROLIFERATION
AB Although STAT5A and STAT5B have some nonredundant functional properties, their distinct contributions to carcinogenesis are not clearly defined. Here we report that STAT5A expression is selectively inhibited by DNA methylation of the STAT5A gene promoter region in cells expressing the oncogenic tyrosine kinase NPM1-ALK ( also known as NPM-ALK). The DNA methylation is induced by NPM1-ALK itself via STAT3, and is associated with binding to the promoter of the gene encoding MeCP2 capping protein and with lack of binding of the STAT5A gene transcription activator SP1. Reversal of methylation by the DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine restores SP1 binding and STAT5A gene expression. Notably, the induced or exogenously expressed STAT5A protein binds to the enhancer and intron 14 of the NPM1-ALK gene and triggers selective suppression of NPM1-ALK expression. These results show that NPM1-ALK induces epigenetic silencing of STAT5A gene and that STAT5A protein can act as a key tumor suppressor by reciprocally inhibiting expression of NPM1-ALK.
C1 Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Zhang, Q (通讯作者)，Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM qian2@mail.med.upenn.edu
RI Zhang, Qian/IUO-9417-2023
FU NCI NIH HHS [R01-CA96856, R01-CA89194] Funding Source: Medline
CR Ambrosio R, 2002, GENE, V285, P311, DOI 10.1016/S0378-1119(02)00421-3
   Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312
   Bondarenko VA, 2003, BIOCHEM CELL BIOL, V81, P241, DOI 10.1139/o03-051
   Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008
   Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051
   Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343
   Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814
   Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7
   Crispi S, 2004, FEBS LETT, V562, P27, DOI 10.1016/S0014-5793(04)00166-8
   Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004
   Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331
   Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200
   Fujioka H, 2002, CHEM IMMUNOL, V80, P1
   Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103
   GouilleuxGruart V, 1996, BLOOD, V87, P1692
   Hehlmann R, 2005, ANN HEMATOL, V84, P487, DOI 10.1007/s00277-005-1039-z
   Hendry L, 2004, EUR J BIOCHEM, V271, P4613, DOI 10.1111/j.1432-1033.2004.04424.x
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067
   Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901
   Lai SY, 2005, ONCOGENE, V24, P4442, DOI 10.1038/sj.onc.1208635
   Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179
   Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348
   MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283
   Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010
   Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4
   MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112
   Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1
   Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046
   Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229
   Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517
   SHIOTA M, 1994, ONCOGENE, V9, P1567
   Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000
   Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203
   Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340
   Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254
   Wasik Mariusz A, 2002, Am J Clin Pathol, V118 Suppl, pS81
   Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180
   XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
   Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148
   Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466
   Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377
NR 44
TC 103
Z9 119
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2007
VL 13
IS 11
BP 1341
EP 1348
DI 10.1038/nm1659
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 228NP
UT WOS:000250736900027
PM 17922009
DA 2025-01-12
ER

PT J
AU Tan, SH
   Ida, H
   Lau, QC
   Goh, BC
   Chieng, WS
   Loh, M
   Ito, Y
AF Tan, Sing-Huang
   Ida, Hiroshi
   Lau, Quek-Choon
   Goh, Boon-Cher
   Chieng, Wei-Shieng
   Loh, Marie
   Ito, Yoshiaki
TI Detection of promoter hypermethylation in serum samples of cancer
   patients by methylation-specific polymerase chain reaction for tumour
   suppressor genes including <i>RUNX3</i>
SO ONCOLOGY REPORTS
LA English
DT Article
DE promoter hypermethylation; serum; RUNX3; methylation-specific polymerase
   chain reaction
ID CPG ISLAND HYPERMETHYLATION; ABERRANT P16 METHYLATION; CARCINOMA
   IN-SITU; CELL LUNG-CANCER; BREAST-CANCER; EPIGENETIC INACTIVATION;
   COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; E-CADHERIN; GASTRIC-CANCER
AB The purpose was to validate the use of RUNX3 as a potential biomarker for detection of cancer in serum samples and to determine its sensitivity alone and in combination with p16, RASSF1A and CDH1 using methylation-specific polymerase chain reaction (MSP). We examined the promoter methylation status of RUNX3, p16, RASSF1A and CDH1 by MSP using the serum of 70 metastatic breast, non-small cell lung, gastric, pancreatic, colorectal or hepatocellular carcinomas. The DNA from 10 healthy serum controls was used to determine the specificity of methylation. According to our results, promoter hyper-methylation of RUNX3 was detected in the serum of 44 patients comprising breast 9/19 (47%), non-small cell lung 11/20 (55%), gastric 4/4 (100%), pancreatic 2/2 (100%), colorectal 11/17 (65%) and liver 7/8 (88%) carcinomas. Comparative figures for the other genes were as follows: p16 - 39/70 (7/19, 10/20, 2/4, 0/2, 12/17, 8/8); RASSF1A - 24/70 (8/19, 6/20, 1/4, 1/2, 4/17, 4/8); CDH1 - 10/70 (0/19, 4/20, 1/4, 1/2, 3/17, 1/8). Using a panel of four genes, hypermethylation of one or more genes was found in 62/70 samples (15/19, 19/20, 4/4, 2/2, 14/17, 8/8). A panel of three genes omitting RUNX3 detected hypermethylation in only 50/70 samples. No methylation was detected in the 10 healthy serum controls. Thus, RUNX3 can be detected in the serum of a high proportion of advanced cancers. This suggests that serum hypermethylation of RUNX3 is at least as, or possibly more sensitive a marker, than other tumor suppressor genes currently under investigation. Inclusion of RUNX3 in gene panels can potentially increase the sensitivity of such panels for serum diagnosis of malignancies and warrants further study.
C1 Inst Mol & Cell Biol, Mol Oncol Lab, Singapore 138673, Singapore.
   Natl Univ Singapore Hosp, Dept Hematol Oncol, Singapore 119074, Singapore.
   Sch Life Sci & Chem Technol, Ngee Ann Polytech, Singapore 599489, Singapore.
   Bioinformat Inst, Singapore 138671, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Institute of
   Molecular & Cell Biology (IMCB); National University of Singapore;
   Agency for Science Technology & Research (A*STAR); A*STAR -
   Bioinformatics Institute (BII)
RP Ito, Y (通讯作者)，Inst Mol & Cell Biol, Mol Oncol Lab, 61 Biopolis Dr, Singapore 138673, Singapore.
EM itoy@imcb.a-star.edu.sg
OI Loh, Marie/0000-0003-3626-8466
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibi K, 1998, CANCER RES, V58, P1405
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Horikawa Y, 2003, J UROLOGY, V169, P1541, DOI 10.1097/01.ju.0000046242.55722.1c
   Hu XC, 2003, ONCOL REP, V10, P1811
   Imamura Y, 2005, ANTICANCER RES, V25, P2627
   Jarmalaite S, 2003, INT J CANCER, V106, P913, DOI 10.1002/ijc.11322
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kanyama Y, 2003, CANCER SCI, V94, P418, DOI 10.1111/j.1349-7006.2003.tb01457.x
   Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   LEE J, 1997, CARBOHYDR LETT, V2, P307
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   LEON SA, 1977, CANCER RES, V37, P646
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G
   Matsumura T, 2001, CLIN CANCER RES, V7, P594
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x
   Mulcahy HE, 1998, CLIN CANCER RES, V4, P271
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Sato K, 2006, ONCOL REP, V15, P129
   Silva JM, 1999, CANCER RES, V59, P3251
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Wong IHN, 1999, CANCER RES, V59, P71
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x
   Zou HZ, 2002, CLIN CANCER RES, V8, P188
NR 49
TC 117
Z9 132
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2007
VL 18
IS 5
BP 1225
EP 1230
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 226EN
UT WOS:000250570400024
PM 17914577
DA 2025-01-12
ER

PT J
AU Gurzov, EN
   Nabha, SM
   Yamamoto, H
   Meng, H
   Scharovsky, OG
   Bonfil, RD
AF Gurzov, Esteban N.
   Nabha, Sanaa M.
   Yamamoto, Hamilto
   Meng, Hong
   Scharovsky, O. Graciela
   Bonfil, R. Daniel
TI Paradoxical antiproliferative effect by a murine mammary tumor-derived
   epithelial cell line
SO BMC CANCER
LA English
DT Article
ID HUMAN BREAST-CANCER; HUMAN MYOEPITHELIAL CELL; MALIGNANT BREAST;
   MESSENGER-RNA; IN-VITRO; FIBROBLASTS; DIFFERENTIATION; MYOFIBROBLASTS;
   PROGRESSION; METASTASIS
AB Background: Despite significant advancement in breast cancer therapy, there is a great need for a better understanding of the mechanisms involved in breast carcinogenesis and progression, as well as of the role of epigenetic contributions from stromal cells in mammary tumorigenesis. In this study, we isolated and characterized murine mammary tumor-derived epithelial and myofibroblast cell lines, and investigated the in vitro and in vivo effect of cellular soluble factors produced by the epithelial cell line on tumor cells.
   Methods: Morphology, immunophenotype, cytogenetics, invasiveness, and tumorigenicity of epithelial (LM-234ep) and myofibroblast (LM-234mf) cell lines isolated from two murine mammary adenocarcinomas with common ancestor were studied. The in vitro effects of LM-234ep conditioned medium on proliferation, cell cycle distribution, and expression of cell cycle proteins, were investigated in LM-234mf cells, mouse melanoma cells (B16-F10), and human cervical adenocarcinoma cells (HeLa). The in vivo anti-tumor activity of LM-234ep conditioned media was evaluated in subcutaneous tumors formed in nude mice by B16-F10 and HeLa cells.
   Results: LM-234ep cells were found to be cytokeratin positive and hipertriploid, whereas LM-234mf cells were alpha-smooth muscle actin positive and hypohexaploid. Chromosome aberrations were found in both cases. Only LM-234mf revealed to be invasive in vitro and to secrete active MMP-2, though neither of the cell types were able to produce progressing tumors. LM-234ep-derived factors were able to inhibit the in vitro growth of LM-234mf, B16-F10, and HeLa cells, inducing cell cycle arrest in G(0)/G(1) phase. The administration of LM-234ep conditioned medium inhibited the growth of B16-F10 and HeLa tumors in nude mice.
   Conclusion: Our data suggest the existence of epithelial cell variants with tumor suppressive properties within mammary tumors. To our knowledge, this is the first report showing antiproliferative and antineoplastic activities induced by tumor-derived epithelial cells.
C1 [Gurzov, Esteban N.] Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochao, Dept Mol Biol, E-28049 Madrid, Spain.
   [Nabha, Sanaa M.; Yamamoto, Hamilto; Meng, Hong; Bonfil, R. Daniel] Wayne State Univ, Sch Med, Dept Urol, Detroit, MI USA.
   [Nabha, Sanaa M.; Yamamoto, Hamilto; Meng, Hong; Bonfil, R. Daniel] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
   [Nabha, Sanaa M.; Yamamoto, Hamilto; Meng, Hong; Bonfil, R. Daniel] Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
   [Scharovsky, O. Graciela] Univ Nacl Rosario, Sch Med Sci, Inst Genet Expt, RA-2000 Rosario, Argentina.
C3 Autonomous University of Madrid; Wayne State University; Wayne State
   University; Barbara Ann Karmanos Cancer Institute; National University
   of Rosario
RP Gurzov, EN (通讯作者)，Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochao, Dept Mol Biol, E-28049 Madrid, Spain.
EM egurzov@cbm.uam.es; snabha@med.wayne.edu; hamilto@fmb.unesp.br;
   hmeng@med.wayne.edu; ogs@citynet.net.ar; dbonfil@med.wayne.edu
RI ; Yamamoto, Hamilto/C-8294-2018
OI Bonfil, R. Daniel/0000-0002-1605-8317; Yamamoto,
   Hamilto/0000-0002-9688-137X; Gurzov, Esteban/0000-0003-4642-0273
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Atula S, 1997, EXP CELL RES, V235, P180, DOI 10.1006/excr.1997.3676
   BABA M, 1988, JPN J CANCER RES, V79, P734, DOI 10.1111/j.1349-7006.1988.tb02230.x
   Barsky SH, 2005, J MAMMARY GLAND BIOL, V10, P249, DOI 10.1007/s10911-005-9585-5
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Binda MM, 2002, INT J CANCER, V100, P14, DOI 10.1002/ijc.10425
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Boivin-Angele S, 2000, J HEPATOL, V33, P290, DOI 10.1016/S0168-8278(00)80370-0
   Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645
   BONFIL RD, 1994, INT J CANCER, V58, P233
   CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75
   De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398
   DECOSSE JJ, 1973, SCIENCE, V181, P1057, DOI 10.1126/science.181.4104.1057
   DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002-9440(10)62337-1
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   FIDLER IJ, 1975, CANCER RES, V35, P218
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jones C, 2001, BRIT J CANCER, V85, P422, DOI 10.1054/bjoc.2001.1869
   Kataoka Hiroaki, 2003, Hum Cell, V16, P1, DOI 10.1111/j.1749-0774.2003.tb00123.x
   KOVACSOVICSBANKOWSKI M, 1994, EUR J IMMUNOL, V24, P2421
   Micke P, 2005, EXPERT OPIN THER TAR, V9, P1217, DOI 10.1517/14728222.9.6.1217
   Nguyen M, 2000, ONCOGENE, V19, P3449, DOI 10.1038/sj.onc.1203677
   Nielsen BS, 1996, LAB INVEST, V74, P168
   OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730
   Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5
   RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736
   RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69
   Samoszuk M, 2005, BREAST CANCER RES, V7, pR274, DOI 10.1186/bcr995
   SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695
   Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580
   Shen Q., 2007, ONCOGENE
   Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201
   Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050
   Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949
   Thompson DL, 1998, J BONE MINER RES, V13, P195, DOI 10.1359/jbmr.1998.13.2.195
   Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x
   Unden AB, 1996, J INVEST DERMATOL, V107, P147, DOI 10.1111/1523-1747.ep12329541
   Walter-Yohrling J, 2003, CANCER CHEMOTH PHARM, V52, P263, DOI 10.1007/s00280-003-0664-2
NR 40
TC 2
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 1
PY 2007
VL 7
AR 184
DI 10.1186/1471-2407-7-184
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 240SR
UT WOS:000251608100001
PM 17908302
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wolf, I
   Bose, S
   Desmond, JC
   Lin, BT
   Williamson, EA
   Karlan, BY
   Koeffler, HP
AF Wolf, Ido
   Bose, Shikha
   Desmond, Julian C.
   Lin, Bryan T.
   Williamson, Elizabeth A.
   Karlan, Beth Y.
   Koeffler, H. Phillip
TI Unmasking of epigenetically silenced genes reveals DNA promoter
   methylation and reduced expression of PTCH in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE breast cancer; methylation; PTCH; GLI1; hedgehog pathway
ID HISTONE DEACETYLASE INHIBITION; TUMOR-SUPPRESSOR GENES; HEDGEHOG
   PATHWAY; ESTROGEN-RECEPTOR; PATCHED GENE; MUTATIONS;
   5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; ACTIVATION; CARCINOMA
AB A pharmacological-based global screen for epigenetically silenced tumor suppressor genes was performed in MCF-7 and MDA-MB-231 breast cancer cells. Eighty-one genes in MCF-7 cells and 131 in MDA-MB-231 cells were identified, that had low basal expression and were significantly upregulated following treatment. Eighteen genes were studied for methylation and/or expression in breast cancer; PTCH, the receptor for the hedgehog (Hh) pathway and a known tumor suppressor gene, was selected for further analysis. Methylation of the PTCH promoter was found in MCF-7 cells and in breast cancer samples, and correlated with low PTCH expression. Immunohistochemical analysis of breast tissue arrays revealed high expression of PTCH in normal breast compared to ductal carcinomas in situ (DCIS) and invasive ductal carcinomas; furthermore, association was found between PTCH expression and favorable prognostic factors. PTCH is an inhibitor of the Hh pathway, and its silencing activates the pathway and promotes growth. Indeed, high activity of the Hh pathway was identified in MCF-7 cells and overexpression of PTCH inhibited the pathway. Moreover, treatment with cyclopamine, an inhibitor of the pathway, reduced cell growth and slowed the cell cycle in these cells. Thus, unmasking of epigenetic silencing in breast cancer enabled us to discover a large number of candidate tumor suppressor genes. Further analysis suggested a role of one of these genes, PTCH, in breast cancer tumorigenesis.
C1 Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Israel.
   Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Anat Pathol, Los Angeles, CA 90048 USA.
   Tarzana Reg Med Ctr, Tarzana, CA USA.
   Univ Calif Los Angeles, Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA.
C3 Chaim Sheba Medical Center; University of California System; University
   of California Los Angeles; Cedars Sinai Medical Center; Cedars Sinai
   Medical Center; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; Cedars Sinai Medical Center
RP Wolf, I (通讯作者)，Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Israel.
EM wolf-i@inter.net.il
RI Lin, Bryan/JJF-9160-2023
CR Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733
   Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972
   Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chang-Claude J, 2003, INT J CANCER, V103, P779, DOI 10.1002/ijc.10889
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Cormier-Daire V, 2005, AM J MED GENET C, V137C, P1, DOI 10.1002/ajmg.c.30059
   Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002
   Grothey A, 2000, BRIT J CANCER, V83, P870, DOI 10.1054/bjoc.2000.1395
   Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4
   Hu ZL, 2003, CANCER RES, V63, P923
   Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962
   Katayama M, 2002, J NEURO-ONCOL, V59, P107, DOI 10.1023/A:1019660421216
   Kogerman P, 2002, ONCOGENE, V21, P6007, DOI 10.1038/sj.onc.1205865
   Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lewis MT, 2004, J MAMMARY GLAND BIOL, V9, P165, DOI 10.1023/B:JOMG.0000037160.24731.35
   Lewis MT, 1999, DEVELOPMENT, V126, P5181
   Lewis MT, 2001, DEV BIOL, V238, P133, DOI 10.1006/dbio.2001.0410
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H
   McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045
   Minobe K, 1998, JPN J CANCER RES, V89, P916, DOI 10.1111/j.1349-7006.1998.tb00649.x
   Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906
   Munster PN, 2001, CANCER RES, V61, P8492
   Nagao K, 2005, GENOMICS, V85, P462, DOI 10.1016/j.ygeno.2004.11.014
   Oniscu A, 2004, J PATHOL, V203, P909, DOI 10.1002/path.1591
   Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Raffel C, 1997, CANCER RES, V57, P842
   Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101
   Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29
   Spychala J, 2004, CLIN CANCER RES, V10, P708, DOI 10.1158/1078-0432.CCR-0811-03
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008
   Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989
   Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993
   Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823
   Uhmann A, 2005, INT J ONCOL, V27, P1567
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   Xie JW, 1997, CANCER RES, V57, P2369
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
NR 52
TC 85
Z9 101
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2007
VL 105
IS 2
BP 139
EP 155
DI 10.1007/s10549-006-9440-4
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 207NJ
UT WOS:000249257500003
PM 17295047
DA 2025-01-12
ER

PT J
AU Osanai, M
   Murata, M
   Chiba, H
   Kojima, T
   Sawada, N
AF Osanai, Makoto
   Murata, Masaki
   Chiba, Hideki
   Kojima, Takashi
   Sawada, Norimasa
TI Epigenetic silencing of claudin-6 promotes anchorage-independent growth
   of breast carcinoma cells
SO CANCER SCIENCE
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; TIGHT JUNCTIONS; EXPRESSION DECREASES; CANCER;
   OCCLUDIN; APOPTOSIS; GENES; EPHA2; PROLIFERATION; TUMORIGENESIS
AB Cancer cells often exhibit loss of functional tight junctions (TJ), and disruption of the TJ structure is associated with cancer development. However, whether loss of a certain type of claudin, an integral membrane protein of TJ, is involved in malignant phenotypes remains to be clarified. Based on a report that claudin-6 functions as a tumor suppressor for breast cancer, the authors show here that suppression of claudin-6 expression results in increased resistance to various apoptogens, and causally enhances anchorage-independent growth properties. Because claudin-6 expression is partially silenced by promoter CpG island hypermethylation in MCF7 breast carcinoma cells, a synergistic effect of a demethylator and histone deacetylase inhibitor up-regulates the expression of endogenous claudin-6, which is sufficient for apoptotic sensitization and abrogation of colony-forming efficacy. In addition, decreased expression of claudin-6 promotes cellular invasiveness and transendothelial migration, accompanied by an increase in matrix metalloproteinase activity. These data suggest that the methylator phenotype of claudin-6 may at least partially contribute to enhanced tumorigenic and invasive properties of breast carcinoma cells.
C1 Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 060, Japan.
C3 Sapporo Medical University
RP Osanai, M (通讯作者)，Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 060, Japan.
EM osanaim@sapmed.ac.jp
CR CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Hoevel T, 2004, INT J CANCER, V108, P374, DOI 10.1002/ijc.11571
   Hough CD, 2000, CANCER RES, V60, P6281
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Krämer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375
   Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791
   Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005
   Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055
   Michl P, 2003, CANCER RES, V63, P6265
   Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200
   Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782
   Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769
   Osanai M, 2002, JPN J CANCER RES, V93, P532, DOI 10.1111/j.1349-7006.2002.tb01288.x
   Osanai M, 2007, CANCER SCI, V98, P1027, DOI 10.1111/j.1349-7006.2007.00494.x
   Osanai M, 2006, CANCER RES, V66, P9125, DOI 10.1158/0008-5472.CAN-06-1864
   Quan CS, 2003, CARCINOGENESIS, V24, P1593, DOI 10.1093/carcin/bgg129
   Resnick MB, 2005, MODERN PATHOL, V18, P511, DOI 10.1038/modpathol.3800301
   Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131
   Tanaka M, 2005, J BIOL CHEM, V280, P42375, DOI 10.1074/jbc.M503786200
   Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013
   Tokés AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Zelinski DP, 2001, CANCER RES, V61, P2301
NR 28
TC 62
Z9 82
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1347-9032
J9 CANCER SCI
JI Cancer Sci.
PD OCT
PY 2007
VL 98
IS 10
BP 1557
EP 1562
DI 10.1111/j.1349-7006.2007.00569.x
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 204JN
UT WOS:000249039900008
PM 17645772
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Rivenbark, AG
   Livasy, CA
   Boyd, CE
   Keppler, D
   Coleman, WB
AF Rivenbark, Ashley G.
   Livasy, Chad A.
   Boyd, Courtney E.
   Keppler, Daniel
   Coleman, William B.
TI Methylation-dependent silencing of CST6 in primary human breast tumors
   and metastatic lesions
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE breast cancer; cystatin M; methylation; metastasis
ID CYSTEINE PROTEINASE-INHIBITOR; CYSTATIN-M; CATHEPSIN-B; GENE-EXPRESSION;
   CANCER; DEGRADATION; PROGRESSION; IDENTIFICATION; CARCINOMA; BINDING
AB CST6 is a breast tumor suppressor gene that is expressed in normal breast epithelium, but is epigenetically silenced as a consequence of promoter hypermethylation in metastatic breast cancer cell lines. In the current study, we investigated the expression and methylation status of CST6 in primary breast tumors and lymph node metastases. 25/45 (56%) primary tumors and 17/20 (85%) lymph node metastases expressed significantly lower levels of cystatin M compared to normal breast tissue. Bisulfite sequencing demonstrated CST6 promoter hypermethylation in 11/23 (48%) neoplastic lesions analyzed, including 3/11 (27%) primary tumors and 8/12 (67%) lymph node metastases. In most cases (12/23, 52%), the expression of cystatin M directly reflected CST6 promoter methylation status. In remaining lesions (8/23, 35%) loss of cystatin M was not associated with CST6 promoter hypermethylation, indicating that other mechanisms can account for loss of CST6 expression. These results show that methylation-dependent silencing of CST6 occurs in a subset of primary breast cancers, but more frequently in metastatic lesions, possibly reflecting progression-related genomic events. To examine this possibility, primary breast tumors and matched lymph node metastases were analyzed. In 2/3 (67%) patients, primary tumors were positive for cystatin M and negative for CST6 promoter methylation, and matched metastatic lesions lacked cystatin M expression and CST6 was hypermethylated. This observation suggests that progression-related epigenetic alterations in CST6 gene expression can accompany metastatic spread from a primary tumor site. Overall, the results of the current investigation suggest that methylation-dependent epigenetic silencing of CST6 represents an important mechanism for loss of CST6 during breast tumorigenesis and/or progression to metastasis. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Curriculam Toxicol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, Shreveport, LA 71130 USA.
   Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill; Louisiana State University System; Louisiana State
   University Health Sciences Center at Shreveport; Louisiana State
   University System; Louisiana State University Health Sciences Center at
   Shreveport
RP Coleman, WB (通讯作者)，Univ N Carolina, Sch Med, Dept Pathol & Lab Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM william.coleman@pathology.unc.edu
RI Keppler, Daniel/B-4309-2012
FU NCI NIH HHS [R01 CA078343, R01 CA078434-10, R56 CA078343, CA78343]
   Funding Source: Medline
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273
   Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345
   Deng GR, 2004, CANCER RES, V64, P2692, DOI 10.1158/0008-5472.CAN-03-3000
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x
   Kane S E, 1990, Semin Cancer Biol, V1, P127
   Keppler D, 2006, CANCER LETT, V235, P159, DOI 10.1016/j.canlet.2005.04.001
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116
   Lah TT, 1998, BIOL CHEM, V379, P125
   Lau R, 2001, INT J ONCOL, V18, P17
   MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D
   Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159
   Mirza AN, 2002, ANN SURG, V235, P10, DOI 10.1097/00000658-200201000-00003
   MULLER V, 2005, MOL ONCOLOGY BREAST, P117
   Ni J, 1997, J BIOL CHEM, V272, P10853
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   Reed W, 2000, CANCER, V88, P804, DOI 10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757
   Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209
   Song J, 2006, BIOCHEM BIOPH RES CO, V340, P175, DOI 10.1016/j.bbrc.2005.11.171
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698
   SYMMANS WF, 2005, MOL ONCOLOGY BREAST, P106
   Vigneswaran N, 2006, LIFE SCI, V78, P898, DOI 10.1016/j.lfs.2005.05.096
   Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388
   Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
NR 35
TC 37
Z9 42
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD OCT
PY 2007
VL 83
IS 2
BP 188
EP 197
DI 10.1016/j.yexmp.2007.03.008
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 216BX
UT WOS:000249853900005
PM 17540367
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Kunze, E
   Schlott, T
AF Kunze, Ekkehard
   Schlott, Thilo
TI High frequency of promoter methylation of the 14-3-3 σ and CAGE-1 genes,
   but lack of hypermethylation of the caveolin-1 gene, in primary
   adenocarcinomas and signet ring cell carcinomas of the urinary bladder
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
ID PROTEIN HDAB2IP GENE; BREAST-CANCER; NONUROTHELIAL CARCINOMAS; DNA
   METHYLATION; ANTIGEN EXPRESSION; PROSTATE-CANCER; EARLY EVENT; SIGMA
   GENE; CYCLIN B1; HYPOMETHYLATION
AB The molecular mechanisms underlying the histogenesis of nonurothelial carcinomas of the urinary bladder are not yet clearly understood. There is a growing body of evidence that, generally, epigenetic regulation mediated by methylation of normally unmethylated CpG islands at the 5' promoter regions of genes is involved in the modification of tumorigenesis. This prompted the current study to explore the methylation status of a broad panel of various genes implicated in cell differentiation and tumor suppression in 10 adenocarcinomas and 6 signet ring cell carcinomas of the bladder. Using methylation-specific PCR, we were able to detect a high frequency of promoter methylation of the 14-3-3 sigma (100%) and CAGE-1 (80%) genes in adenocarcinomas, and in nearly all signet ring cell carcinomas. The SYK and hDAB2IP genes proved to be hypermethylated in only single cases, whereas the caveolin-1 gene failed to be hypermethylated in all cases. The present data suggest that promoter methylation of the 14-3-3 sigma and CAGE-1 genes plays a crucial role during the phenotypical morphogenesis of vesical adenocarcinomas including signet ring cell carcinomas by an epigenetic mechanism.
C1 Univ Gottingen, Dept Osteopathol & Haematopathol, D-37099 Gottingen, Germany.
C3 University of Gottingen
RP Kunze, E (通讯作者)，Univ Gottingen, Dept Osteopathol & Haematopathol, Robert Koch Str 40, D-37099 Gottingen, Germany.
EM ekunze@med.uni-goettingen.de
CR Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BULLOCK PS, 1987, CANCER-AM CANCER SOC, V59, P2086, DOI 10.1002/1097-0142(19870615)59:12<2086::AID-CNCR2820591220>3.0.CO;2-J
   Campbell L, 2003, BRIT J CANCER, V89, P1909, DOI 10.1038/sj.bjc.6601359
   Chan TF, 2003, INT J ONCOL, V23, P599
   Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914
   Cheng KWE, 2002, COMPEL, V21, P573, DOI 10.1108/03321640210437824
   Cho B, 2002, BIOCHEM BIOPH RES CO, V292, P715, DOI 10.1006/bbrc.2002.6701
   Cho BS, 2003, BIOCHEM BIOPH RES CO, V307, P52, DOI 10.1016/S0006-291X(03)01121-5
   DELLAMBRA E, 1995, J CELL SCI, V108, P3569
   Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   EDWARDS PD, 1972, J UROLOGY, V108, P568, DOI 10.1016/S0022-5347(17)60804-8
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fine SW, 2001, AM J CLIN PATHOL, V115, P719
   Gasco M, 2002, CANCER RES, V62, P2072
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2
   Ito Y, 2002, BRIT J CANCER, V86, P912, DOI 10.1038/sj.bjc.6600172
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171
   Kunze E, 2006, INT J MOL MED, V17, P3
   Kunze E, 2002, UROL RES, V30, P66, DOI 10.1007/s00240-001-0232-3
   Kunze E, 1998, EXP TOXICOL PATHOL, V50, P341, DOI 10.1016/S0940-2993(98)80015-8
   Kunze E, 2001, VIRCHOWS ARCH, V439, P609, DOI 10.1007/s004280100429
   KUNZE E, IN PRESS HISTOL HIST
   KUNZE E, 1998, FORMALE PATHOGENESE, P14
   Kunze E, 2006, INT J MOL MED, V18, P547
   LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346
   MOSTOFI FK, 1954, J UROLOGY, V71, P705, DOI 10.1016/S0022-5347(17)67849-2
   Park S, 2003, BBA-GENE STRUCT EXPR, V1625, P173, DOI 10.1016/S0167-4781(02)00620-6
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431
   Resnick MB, 2002, INT J CANCER, V101, P190, DOI 10.1002/ijc.10585
   Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Suzuki H, 2000, CANCER RES, V60, P4353
   Suzuoki M, 2002, BRIT J CANCER, V87, P1140, DOI 10.1038/sj.bjc.6600619
   Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Wang S, 2004, WORLD J GASTROENTERO, V10, P1815
   Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200
   Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678
   Yang G, 1999, CANCER RES, V59, P5719
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Yuan YF, 2001, CANCER RES, V61, P5558
   Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200
NR 54
TC 14
Z9 15
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD OCT
PY 2007
VL 20
IS 4
BP 557
EP 563
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 215GT
UT WOS:000249797000019
PM 17786288
DA 2025-01-12
ER

PT J
AU Banno, K
   Yanokura, M
   Kawaguchi, M
   Kuwabara, Y
   Akiyoshi, J
   Kobayashi, Y
   Iwata, T
   Hirasawa, A
   Fujii, T
   Susumu, N
   Tsukazaki, K
   Aoki, D
AF Banno, Kouji
   Yanokura, Megumi
   Kawaguchi, Makiko
   Kuwabara, Yoshiko
   Akiyoshi, Jyunko
   Kobayashi, Yusuke
   Iwata, Takashi
   Hirasawa, Akira
   Fujii, Takuma
   Susumu, Nobuyuki
   Tsukazaki, Kastumi
   Aoki, Daisuke
TI Epigenetic inactivation of the <i>CHFR</i> gene in cervical cancer
   contributes to sensitivity to taxanes
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE CHFR; cervical cancer; DNA hypermethyltion; taxane; chemosensitivity
ID MITOTIC STRESS CHECKPOINT; SQUAMOUS-CELL-CARCINOMA; 5' CPG ISLAND;
   CHROMOSOMAL INSTABILITY; ABERRANT HYPERMETHYLATION; INCIDENCE TRENDS;
   UTERINE CERVIX; OVARIAN-CANCER; BREAST-CANCER; ADENOCARCINOMA
AB A relationship between inactivation of mitotic checkpoint genes and sensitivity of cancer cells to anticancer agents has been reported. We investigated the effect of epigenetic inactivation by aberrant hypermethylation of the mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger) on the sensitivity of cervical cancer cells to taxanes. Methylation-specific PCR (MSP) of cervical smears showed aberrant methylation of CHFR in 12.3% (2/14) of adenocarcinoma specimens. In contrast, aberrant DNA methylation was not detected in normal cervical cells or squamous cell carcinoma cells. Aberrant methylation of CHFR was also analyzed in 6 human cervical carcinoma-derived cell lines and was observed in SKG-IIIb and HeLa cells. These cell lines showed high sensitivity to taxanes, but became taxane-resistant upon treatment with 5-azacytidine. Furthermore, suppression of CHFR expression in siRNA-transfected SKG-IIIa cells caused increased sensitivity to taxanes. In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. To our knowledge, this study is the first to examine epigenetic inactivation by aberrant hypermethylation of CHFR in cervical cancer.
C1 Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University
RP Banno, K (通讯作者)，Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.
EM kbanno@sc.itc.keio.ac.jp
RI Kobayashi, Yusuke/M-5174-2019; Yanokura, Megumi/W-2667-2017; Banno,
   Kouji/C-9638-2014; Iwata, Takashi/G-2619-2015; Aoki, Daisuke/E-6650-2014
OI Kobayashi, Yusuke/0000-0002-4503-2845
CR BERAL V, 1994, CANCER SURV, V20, P265
   BEREK JS, 1985, OBSTET GYNECOL, V65, P46
   Bray F, 2005, CANCER EPIDEM BIOMAR, V14, P2191, DOI 10.1158/1055-9965.EPI-05-0231
   Bulk S, 2003, BRIT J CANCER, V89, P834, DOI 10.1038/sj.bjc.6601157
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   CURTIN JP, 1999, J CLIN ONCOL, V17, P761
   DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532
   Fraizer GC, 2004, INT J ONCOL, V25, P1631
   Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101
   Irie T, 2000, EUR J SURG ONCOL, V26, P464, DOI 10.1053/ejso.1999.0923
   Kawaguchi M, 2005, ANTICANCER RES, V25, P3547
   Kuzmin I, 2003, CANCER RES, V63, P1888
   Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Nakashima R, 1999, BRIT J CANCER, V80, P458, DOI 10.1038/sj.bjc.6690379
   Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5
   Sasieni P, 2001, LANCET, V357, P1490, DOI 10.1016/S0140-6736(00)04646-8
   Satoh A, 2003, CANCER RES, V63, P8606
   SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Susumu- N, 2005, INT J GYNECOL CANCER, V15, P70, DOI 10.1111/j.1048-891x.2005.14424.x
   Suzuki H, 2000, CANCER RES, V60, P4353
   THIGPEN JT, 1986, CANCER TREAT REP, V70, P1097
   Tokunaga E, 2006, BREAST CANCER RES TR, V97, P199, DOI 10.1007/s10549-005-9112-9
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Wang SS, 2004, CANCER-AM CANCER SOC, V100, P1035, DOI 10.1002/cncr.20064
   Yanokura M, 2007, ONCOL REP, V17, P41
   Yu MY, 2003, INT J CANCER, V105, P204, DOI 10.1002/ijc.11051
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
NR 29
TC 33
Z9 40
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD OCT
PY 2007
VL 31
IS 4
BP 713
EP 720
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 215GC
UT WOS:000249795300004
PM 17786301
DA 2025-01-12
ER

PT J
AU Stephen, JK
   Vaught, LE
   Chen, KM
   Sethi, S
   Shah, V
   Benninger, MS
   Gardner, GM
   Schweitzer, VG
   Khan, M
   Worsham, MJ
AF Stephen, Josena K.
   Vaught, Lori E.
   Chen, Kang M.
   Sethi, Seema
   Shah, Veena
   Benninger, Michael S.
   Gardner, Glendon M.
   Schweitzer, Vanessa G.
   Khan, Mumtaz
   Worsham, Maria J.
TI Epigenetic events underlie the pathogenesis of sinonasal papillomas
SO MODERN PATHOLOGY
LA English
DT Article
DE sinonasal papillomas; inverted papillomas; promoter hypermethylation;
   methylation-specific multiplex-ligation-specific polymerase assay;
   methylation specific PCR; epigenetics
ID SQUAMOUS-CELL CARCINOMA; INVERTED PAPILLOMA; BREAST-CANCER; DISEASE
   PROGRESSION; P16(INK4A) GENES; DNA METHYLATION; NECK-CANCER; IN-SITU;
   P53; EXPRESSION
AB Benign inverted papillomas have been reported as monoclonal but lacking common genetic alterations identified in squamous cell carcinoma of the head and neck. Epigenetic changes alter the heritable state of gene expression and chromatin organization without change in DNA sequence. We investigated whether epigenetic events of aberrant promoter hypermethylation in genes known to be involved in squamous head and neck cancer underlie the pathogenesis of sinonasal papillomas. Ten formalin-fixed paraffin DNA samples from three inverted papilloma cases, two exophytic ( everted) papilloma cases, and two cases with inverted and exophytic components were studied. DNA was obtained from microdissected areas of normal and papilloma areas and examined using a panel of 41 gene probes, designed to interrogate 35 unique genes for aberrant methylation status ( 22 genes) using the methylation-specific multiplex-ligation-specific polymerase assay. Methylation-specific PCR was employed to confirm aberrant methylation detected by the methylation-specific multiplexligation-specific polymerase assay. All seven cases indicated at least one epigenetic event of aberrant promoter hypermethylation. The CDKN2B gene was a consistent target of aberrant methylation in six of seven cases. Methylation-specific PCR confirmed hypermethylation of CDKN2B. Recurrent biopsies from two inverted papilloma cases had common epigenetic events. Promoter hypermethylation of CDKN2B was a consistent epigenetic event. Common epigenetic alterations in recurrent biopsies underscore a monoclonal origin for these lesions. Epigenetic events contribute to the underlying pathogenesis of benign inverted and exophytic papillomas. As a consistent target of aberrant promoter hypermethylation, CDKN2B may serve as an important epigenetic biomarker for gene reactivation studies.
C1 Henry Ford Hosp, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA.
   Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA.
C3 Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System;
   Henry Ford Hospital
RP Worsham, MJ (通讯作者)，Wayne State Univ, Sch Med, Henry Ford Hosp, Dept Otolaryngol Head & Neck Res, 1 Ford Pl,1D, Detroit, MI 48202 USA.
EM mworsha1@hfhs.org
RI cao, yutong/JJF-4531-2023
FU NIDCR NIH HHS [R01 DE015990, R01 DE15990] Funding Source: Medline
CR Batsakis JG, 2001, ADV ANAT PATHOL, V8, P53, DOI 10.1097/00125480-200103000-00001
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BRANDWEIN M, 1989, CANCER-AM CANCER SOC, V63, P1708
   BUCHWALD C, 1995, LARYNGOSCOPE, V105, P66, DOI 10.1288/00005537-199501000-00015
   Buchwald C, 2001, LARYNGOSCOPE, V111, P1104, DOI 10.1097/00005537-200106000-00032
   Califano J, 2000, AM J PATHOL, V156, P333, DOI 10.1016/S0002-9440(10)64734-7
   Danahey DG, 1999, ACTA OTO-LARYNGOL, V119, P285
   Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204
   Eads CA, 2000, CANCER RES, V60, P5021
   El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121
   GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538
   Gujrathi C, 2003, J OTOLARYNGOL, V32, P48, DOI 10.2310/7070.2003.35293
   HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0
   HERMAN JG, 1995, CANCER RES, V55, P4525
   HYAMS VJ, 1971, ANN OTO RHINOL LARYN, V80, P192, DOI 10.1177/000348947108000205
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1
   Katori H, 2005, EJSO, V31, P905, DOI 10.1016/j.ejso.2005.05.014
   Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060
   Kunjoonju JR, 2005, GENE CHROMOSOME CANC, V44, P185, DOI 10.1002/gcc.20230
   LAWSON W, 1995, LARYNGOSCOPE, V105, P282, DOI 10.1288/00005537-199503000-00011
   Lawson W, 2003, LARYNGOSCOPE, V113, P1548, DOI 10.1097/00005537-200309000-00026
   Lydiatt WM, 1998, HEAD NECK-J SCI SPEC, V20, P113, DOI 10.1002/(SICI)1097-0347(199803)20:2<113::AID-HED3>3.3.CO;2-F
   NAGAI H, 1995, CANCER RES, V55, P1752
   Ng IOL, 1999, ORAL ONCOL, V35, P63, DOI 10.1016/S1368-8375(98)00083-9
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x
   Raju U, 2006, CURR GENOMICS, V7, P523, DOI 10.2174/138920206779315719
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1
   STEPHEN JK, 2007, IN PRESS ARCH OTOLAR, V133, P684
   Syrjänen KJ, 2003, J CLIN PATHOL, V56, P174, DOI 10.1136/jcp.56.3.174
   SYRJANEN S, 1987, ACTA OTO-LARYNGOL, V104, P334, DOI 10.3109/00016488709107337
   WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209
   WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520
   Wong TS, 2003, INT J ONCOL, V22, P869
   Wormald PJ, 2003, LARYNGOSCOPE, V113, P867, DOI 10.1097/00005537-200305000-00017
   Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P409, DOI 10.1001/archotol.132.4.409
   Worsham MJ, 2003, ARCH OTOLARYNGOL, V129, P702, DOI 10.1001/archotol.129.7.702
   WORSHAM MJ, IN PRESS ARCH OTOLAR
   Xing EP, 1999, CLIN CANCER RES, V5, P2704
   Yasumatsu R, 2005, HEAD NECK-J SCI SPEC, V27, P44, DOI 10.1002/hed.20115
   Yeh KT, 2003, ONCOL REP, V10, P659
   Yook JI, 1998, ORAL ONCOL, V34, P198, DOI 10.1016/S1368-8375(97)00091-2
NR 47
TC 20
Z9 22
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD OCT
PY 2007
VL 20
IS 10
BP 1019
EP 1027
DI 10.1038/modpathol.3800944
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 212GT
UT WOS:000249583000002
PM 17673925
OA Bronze
DA 2025-01-12
ER

PT J
AU Palomero, T
   Sulis, ML
   Cortina, M
   Real, PJ
   Barnes, K
   Ciofani, M
   Caparros, E
   Buteau, J
   Brown, K
   Perkins, SL
   Bhagat, G
   Agarwal, AM
   Basso, G
   Castillo, M
   Nagase, S
   Cordon-Cardo, C
   Parsons, R
   Zúñiga-Pflücker, JC
   Dominguez, M
   Ferrando, AA
AF Palomero, Teresa
   Sulis, Maria Luisa
   Cortina, Maria
   Real, Pedro J.
   Barnes, Kelly
   Ciofani, Maria
   Caparros, Esther
   Buteau, Jean
   Brown, Kristy
   Perkins, Sherrie L.
   Bhagat, Govind
   Agarwal, Archana M.
   Basso, Giuseppe
   Castillo, Mireia
   Nagase, Satoru
   Cordon-Cardo, Carlos
   Parsons, Ramon
   Zuniga-Pflucker, Juan Carlos
   Dominguez, Maria
   Ferrando, Adolfo A.
TI Mutational loss of PTEN induces resistance to NOTCH1 inhibition in
   T-cell leukemia
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-SECRETASE INHIBITORS; HEMATOPOIETIC
   STEM-CELLS; TUMOR-SUPPRESSOR; C-MYC; EPIGENETIC SILENCERS; DROSOPHILA
   EYE; BREAST-CANCER; PRE-TCR; EXPRESSION
AB Gain-of-function mutations in NOTCH1 are common in T- cell lymphoblastic leukemias and lymphomas ( T- ALL), making this receptor a promising target for drugs such as gamma-secretase inhibitors, which block a proteolytic cleavage required for NOTCH1 activation. However, the enthusiasm for these therapies has been tempered by tumor resistance and the paucity of information on the oncogenic programs regulated by oncogenic NOTCH1. Here we show that NOTCH1 regulates the expression of PTEN ( encoding phosphatase and tensin homolog) and the activity of the phosphoinositol- 3 kinase ( PI3K)-AKT signaling pathway in normal and leukemic T cells. Notch signaling and the PI3K-AKT pathway synergize in vivo in a Drosophila melanogaster model of Notch- induced tumorigenesis, and mutational loss of PTEN is associated with human T- ALL resistance to pharmacological inhibition of NOTCH1. Overall, these findings identify transcriptional control of PTEN and regulation of the PI3K-AKT pathway as key elements of the leukemogenic program activated by NOTCH1 and provide the basis for the design of new therapeutic strategies for T- ALL.
C1 Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.
   Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA.
   Univ Toronto, Sunnybrook Res Inst, Dept Immunol, Toronto, ON M4N 3M5, Canada.
   Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
   Columbia Univ, Med Ctr, Dept Endocrinol, New York, NY 10032 USA.
   Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA.
   Univ Padua, Dept Pediat, Hematooncol Lab, I-35128 Padua, Italy.
   Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Aoba Ku, Sendai, Miyagi 9808574, Japan.
   Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   Inst Neurociencias Alicante, Alicante 03550, Spain.
C3 Columbia University; Columbia University; University of Toronto;
   Sunnybrook Health Science Center; Sunnybrook Research Institute;
   Columbia University; Columbia University; Utah System of Higher
   Education; University of Utah; University of Padua; Tohoku University;
   Columbia University; Consejo Superior de Investigaciones Cientificas
   (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de
   Neurociencias de Alicante (IN)
RP Dominguez, M (通讯作者)，Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.
EM m.dominguez@umh.es; af2196@columbia.edu
RI Caparrós, Esther/AHD-3233-2022; Zuniga-Pflucker, Juan/H-1295-2012;
   Castillo-Martin, Mireia/H-6152-2013; Bhagat, Govind/AAE-9493-2021; Real,
   Pedro/K-2994-2014; Ferrando, Adolfo/Q-7026-2016; Parsons,
   Ramon/KFT-2922-2024; Dominguez, Maria/G-2171-2014
OI Nagase, Satoru/0000-0001-5212-1128; Castillo-Martin,
   Mireia/0000-0001-8926-6013; BASSO, GIUSEPPE/0000-0002-2634-9302;
   Parsons, Ramon/0000-0002-6656-3514; Ciofani, Maria/0000-0001-6472-5260;
   Cortina, Maria/0000-0001-7684-3424; Zuniga-Pflucker, Juan
   Carlos/0000-0003-2538-3178; Dominguez, Maria/0000-0002-3329-7862;
   Bhagat, Govind/0000-0001-6250-048X; Real, Pedro J./0000-0001-7968-5353
FU NCI NIH HHS [R01 CA120196-02, R01 CA082783-08, R01 CA082783-06, R01
   CA082783-07, R01 CA120196, R01 CA082783, CA120196] Funding Source:
   Medline
CR Aggerholm A, 2000, EUR J HAEMATOL, V65, P109, DOI 10.1034/j.1600-0609.2000.90181.x
   Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532
   Chang H, 2006, LEUKEMIA RES, V30, P262, DOI 10.1016/j.leukres.2005.07.008
   Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394
   Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230
   Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234
   DE SB, 1999, NATURE, V398, P518
   deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388
   Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235
   Domínguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402
   Dominguez M, 2006, CANCER RES, V66, P8931, DOI 10.1158/0008-5472.CAN-06-1858
   Doughty CA, 2006, BLOOD, V107, P4458, DOI 10.1182/blood-2005-12-4788
   Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6
   Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1
   Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376
   Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880
   Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495
   Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011
   JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0
   Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5
   Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960
   Påhlman S, 2004, SEMIN CANCER BIOL, V14, P365, DOI 10.1016/j.semcancer.2004.04.016
   Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258
   Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103
   Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031
   Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021
   Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563
   Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890
   Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415
   Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200
   Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0
   Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200
   She QB, 2003, CLIN CANCER RES, V9, P4340
   Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298
   Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054
   Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2
   Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0
   Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5
   Swainson L, 2005, P NATL ACAD SCI USA, V102, P12867, DOI 10.1073/pnas.0503603102
   Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558
   Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096
   Wen CH, 1997, DEVELOPMENT, V124, P4759
   Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Xu Z, 2002, CELL GROWTH DIFFER, V13, P285
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
NR 49
TC 720
Z9 859
U1 1
U2 50
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD OCT
PY 2007
VL 13
IS 10
BP 1203
EP 1210
DI 10.1038/nm1636
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 217XI
UT WOS:000249980200036
PM 17873882
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Bhawal, UK
   Tsukinoki, K
   Sasahira, T
   Sato, F
   Mori, Y
   Muto, N
   Sugiyama, M
   Kuniyasu, H
AF Bhawal, Ujjal Kumar
   Tsukinoki, Keiichi
   Sasahira, Tomonori
   Sato, Fuyuki
   Mori, Yusuke
   Muto, Noriko
   Sugiyama, Masaru
   Kuniyasu, Hiroki
TI Methylation and intratumoural heterogeneity of 14-3-3 σ in oral cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE 14-3-3 sigma; methylation; heterogeneity; oral squamous cell carcinoma;
   cyclinD1
ID EPITHELIAL OVARIAN-CANCER; BREAST-CANCER; SPORADIC BREAST; CPG ISLANDS;
   EARLY EVENT; SIGMA GENE; HYPERMETHYLATION; INACTIVATION; EXPRESSION;
   STRATIFIN
AB 14-3-3 a has been a major G2/M checkpoint control gene and has demonstrated that its inactivation in various cancers occurs mostly by epigenetic hypermethylation, not by genetic change. This study investigated the methylation status and expression of the 14-3-3 a gene in 46 oral squamous cell carcinomas by methylation-specific polymerase chain reaction, reverse transcriptase-polymerase chain reaction, Western blotting and immunohistochemistry. Exons of the p53 gene were examined for mutations by sequencing analysis and CyclinD1 by immunohistochemistry. Methylation of the 14-3-3 a gene was detected in 13% (6/46) of the oral tumours, but not in corresponding adjacent non-malignant and normal gingival tissues. Intratumoural heterogeneity was found in the tumour tissues including three 14-3-3 sigma-methylated samples. Methylation of 14-3-3 sigma was detected in 3 SCC with p53 mutations and 3 with wild-type p53. Our major findings are: (a) methylation of 14-3-3 gene promoter is a rare event in oral cancer; (b) it is not always associated with 14-3-3 protein levels and there is no clear relationship between its methylation and p53 mutation; (c) loss of 14-3-3 a expression is associated with reduced CyclinD1 gene expression.
C1 Kanagawa Dent Coll, Dept Oral Maxillofacial Diagnost Sci, Div Pathol, Yokosuka, Kanagawa 2388580, Japan.
   Kanagawa Dent Coll, Hightech Res Ctr, Yokosuka, Kanagawa 2388580, Japan.
   Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 6348521, Japan.
   Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 0638562, Japan.
   Hiroshima Univ, Fac Dent, Sch Oral Hlth Sci, Dept Oral Hlth Res, Hiroshima 7348553, Japan.
C3 Kanagawa Dental College; Kanagawa Dental College; Nara Medical
   University; Hirosaki University; Hiroshima University
RP Bhawal, UK (通讯作者)，Kanagawa Dent Coll, Dept Oral Maxillofacial Diagnost Sci, Div Pathol, Yokosuka, Kanagawa 2388580, Japan.
EM bhawal2002@yahoo.co.in
RI Mori, Yusuke/C-3302-2014; Sugiyama, Masaru/IZE-3770-2023
CR Akahira J, 2004, CLIN CANCER RES, V10, P2687, DOI 10.1158/1078-0432.CCR-03-0510
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Brambilla E, 1999, CLIN CANCER RES, V5, P243
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   DELLAMBRA E, 1995, J CELL SCI, V108, P3569
   Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Gasco M, 2002, CANCER RES, V62, P2072
   Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6
   Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Kusume T, 1999, CLIN CANCER RES, V5, P4152
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559
   Rosenfeld SA, 2000, ECON DEV Q, V14, P51, DOI 10.1177/089124240001400107
   Sato N, 2003, CANCER RES, V63, P4158
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Suzuki H, 2000, CANCER RES, V60, P4353
   Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134
   Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9
   Wang WF, 1996, J MOL EVOL, V43, P384
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
NR 34
TC 16
Z9 17
U1 0
U2 7
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2007
VL 18
IS 4
BP 817
EP 824
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 214XO
UT WOS:000249771800010
PM 17786341
DA 2025-01-12
ER

PT J
AU Klein, CB
   King, AA
AF Klein, Catherine B.
   King, Audrey A.
TI Genistein genotoxicity: Critical considerations of in vitro exposure
   dose
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE genistein; soy; dose; genotoxicity; carcinogenesis; chemoprevention
ID EPITHELIAL-CELL PROLIFERATION; KINASE INHIBITOR GENISTEIN; OXIDATIVE
   DNA-DAMAGE; BREAST-CANCER RISK; HAMSTER V79 CELLS; PHYSIOLOGICAL
   CONCENTRATIONS; SOY PROTEIN; ISOFLAVONOID GENISTEIN; PHYTO-ESTROGENS;
   GUT MICROFLORA
AB The potential health benefits of soy-derived phytoestrogens include their reported utility as anticarcinogens, cardioprotectants and as hormone replacement alternatives in menopause. Although there is increasing popularity of dietary phytoestrogen supplementation and of vegetarian and vegan diets among adolescents and adults, concerns about potential detrimental or other genotoxic effects persist. While a variety of genotoxic effects of phytoestrogens have been reported in vitro, the concentrations at which such effects occurred were often much higher than the physiologically relevant doses achievable by dietary or pharmacologic intake of soy foods or supplements. This review focuses on in vitro studies of the most abundant soy phytoestrogen, genistein, critically examining dose as a crucial determinant of cellular effects. In consideration of levels of dietary genistein uptake and bioavailability we have defined in vitro concentrations of genistein > 5 mu M as non-physiological, and thus "high" doses, in contrast to much of the previous literature. In doing so, many of the often-cited genotoxic effects of genistein, including apoptosis, cell growth inhibition, topoisomerase inhibition and others become less obvious. Recent cellular, epigenetic and microarray studies are beginning to decipher genistein effects that occur at dietarily relevant low concentrations. In toxicology, the well accepted principle of "the dose defines the poison" applies to many toxicants and can be invoked, as herein, to distinguish genotoxic versus potentially beneficial in vitro effects of natural dietary products such as genistein. (c) 2007 Elsevier Inc. All rights reserved.
C1 NYU, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA.
C3 New York University
RP Klein, CB (通讯作者)，NYU, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.
EM kleinc@env.med.nyu.edu
FU NCI NIH HHS [CA016087] Funding Source: Medline; NIEHS NIH HHS [ES00260]
   Funding Source: Medline
CR Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Allred CD, 2004, CARCINOGENESIS, V25, P1649, DOI 10.1093/carcin/bgh178
   [Anonymous], ENV MOL MUTAGEN
   Baxa DM, 2005, NUTR CANCER, V51, P93, DOI 10.1207/s15327914nc5101_13
   Bektic J, 2004, EUR UROL, V45, P245, DOI 10.1016/j.eururo.2003.09.001
   Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959
   Boos G, 2000, TOXICOL LETT, V116, P7, DOI 10.1016/S0378-4274(00)00192-2
   Borrás C, 2006, FASEB J, V20, P2136, DOI 10.1096/fj.05-5522fje
   Cabanes A, 2004, CARCINOGENESIS, V25, P741, DOI 10.1093/carcin/bgh065
   Choi EJ, 2007, LIFE SCI, V80, P1403, DOI 10.1016/j.lfs.2006.12.031
   Cohen LA, 2000, CARCINOGENESIS, V21, P929, DOI 10.1093/carcin/21.5.929
   Coldham NG, 2002, XENOBIOTICA, V32, P45, DOI 10.1080/00498250110085809
   Das A, 2006, INT J CANCER, V119, P2575, DOI 10.1002/ijc.22228
   Day JK, 2001, NUTR CANCER, V39, P226, DOI 10.1207/S15327914nc392_11
   DAY JK, 2002, GENISTEIN ALTERS MET, V132
   DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1
   Di Virgilio AL, 2004, TOXICOL LETT, V151, P151, DOI 10.1016/j.toxlet.2004.04.005
   Ding H, 2003, BIOCHEM BIOPH RES CO, V305, P950, DOI 10.1016/S0006-291X(03)00873-8
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   El Touny LH, 2006, PROSTATE, V66, P1542, DOI 10.1002/pros.20495
   Eto I, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-20
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009
   Harris DM, 2005, EXP BIOL MED, V230, P558, DOI 10.1177/153537020523000807
   Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089
   Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584
   Hilakivi-Clarke L, 2006, J NUTR, V136, p2697S, DOI 10.1093/jn/136.10.2697S
   Horn-Ross PL, 2001, AM J EPIDEMIOL, V154, P434, DOI 10.1093/aje/154.5.434
   Hung SP, 2005, J CELL BIOCHEM, V96, P1061, DOI 10.1002/jcb.20626
   Hwang CS, 2006, J STEROID BIOCHEM, V101, P246, DOI 10.1016/j.jsbmb.2006.06.020
   Ju YH, 2001, J NUTR, V131, P2957, DOI 10.1093/jn/131.11.2957
   Ju YH, 2006, CARCINOGENESIS, V27, P1292, DOI 10.1093/carcin/bgi370
   Keinan-Boker L, 2004, AM J CLIN NUTR, V79, P282
   Klein CB, 2007, TOXICOL APPL PHARM, V222, P289, DOI 10.1016/j.taap.2006.12.033
   Komissarova EV, 2005, TOXICOL APPL PHARM, V202, P99, DOI 10.1016/j.taap.2004.06.010
   Konstantakopoulos N, 2006, MOL CARCINOGEN, V45, P752, DOI 10.1002/mc.20187
   Kousidou OC, 2006, MINI-REV MED CHEM, V6, P331, DOI 10.2174/138955706776073420
   Kulling SE, 1997, FOOD CHEM TOXICOL, V35, P605, DOI 10.1016/S0278-6915(97)00022-7
   Lutz WK, 2005, TOXICOL SCI, V86, P318, DOI 10.1093/toxsci/kfi200
   Lynch A, 2003, MUTAGENESIS, V18, P345, DOI 10.1093/mutage/geg003
   MARKOVITS J, 1989, CANCER RES, V49, P5111
   Maubach J, 2003, J CHROMATOGR B, V784, P137, DOI 10.1016/S1570-0232(02)00789-4
   McClain RM, 2006, FOOD CHEM TOXICOL, V44, P42, DOI 10.1016/j.fct.2005.06.004
   McIntyre BS, 1998, CELL PROLIFERAT, V31, P35, DOI 10.1046/j.1365-2184.1998.00108.x
   Messina M, 2006, NUTR CANCER, V55, P1, DOI 10.1207/s15327914nc5501_1
   Moore JO, 2006, CARCINOGENESIS, V27, P1627, DOI 10.1093/carcin/bgi367
   Morris SM, 1998, MUTAT RES-FUND MOL M, V405, P41, DOI 10.1016/S0027-5107(98)00126-2
   Mulligan AA, 2007, EUR J CLIN NUTR, V61, P248, DOI 10.1038/sj.ejcn.1602509
   Murata M, 2004, BIOCHEMISTRY-US, V43, P2569, DOI 10.1021/bi035613d
   MURE K, 2006, ENVIRON MOL MUTAGEN, V47, P134
   OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5
   Padilla-Banks E, 2006, ENDOCRINOLOGY, V147, P4871, DOI 10.1210/en.2006-0389
   Polkowski K, 2004, CANCER LETT, V203, P59, DOI 10.1016/j.canlet.2003.08.023
   Ramos S, 2007, J NUTR BIOCHEM, V18, P427, DOI 10.1016/j.jnutbio.2006.11.004
   Rowland IR, 2000, NUTR CANCER, V36, P27, DOI 10.1207/S15327914NC3601_5
   Rüfer CE, 2006, J AGR FOOD CHEM, V54, P2926, DOI 10.1021/jf053112o
   Sacks FM, 2006, CIRCULATION, V113, P1034, DOI 10.1161/CIRCULATIONAHA.106.171052
   Safford B, 2003, REGUL TOXICOL PHARM, V38, P196, DOI 10.1016/S0273-2300(03)00091-6
   Sarkar FH, 2006, MINI-REV MED CHEM, V6, P401, DOI 10.2174/138955706776361439
   Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9
   Setchell KDR, 2002, AM J CLIN NUTR, V76, P447, DOI 10.1093/ajcn/76.2.447
   Shen JC, 2000, MOL CARCINOGEN, V29, P92, DOI 10.1002/1098-2744(200010)29:2<92::AID-MC6>3.0.CO;2-Q
   Singletary K, 2006, ANTICANCER RES, V26, P1039
   Snyder RD, 2003, FOOD CHEM TOXICOL, V41, P1291, DOI 10.1016/S0278-6915(03)00117-0
   Steiner C, 2007, CARCINOGENESIS, V28, P738, DOI 10.1093/carcin/bgl180
   Stopper H, 2005, MUTAT RES-FUND MOL M, V574, P139, DOI 10.1016/j.mrfmmm.2005.01.029
   Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297
   Suzuki K, 2002, INT J CANCER, V99, P846, DOI 10.1002/ijc.10428
   Takahashi Y, 2006, MOL CARCINOGEN, V45, P943, DOI 10.1002/mc.20247
   van Erp-Baart MAJ, 2003, BRIT J NUTR, V89, pS25, DOI 10.1079/BJN2002793
   Wang XY, 2006, J NUTR BIOCHEM, V17, P204, DOI 10.1016/j.jnutbio.2005.07.005
   Wang Y, 2006, RADIAT RES, V166, P73, DOI 10.1667/RR3590.1
   Wei HC, 2002, CANCER LETT, V185, P21, DOI 10.1016/S0304-3835(02)00240-9
   Wiseman H, 2004, AM J CLIN NUTR, V80, P692
   Wu AH, 2002, CARCINOGENESIS, V23, P1491, DOI 10.1093/carcin/23.9.1491
   Wu HJ, 2007, TOXICOL IN VITRO, V21, P335, DOI 10.1016/j.tiv.2006.09.002
   Yoon HS, 2000, BIOCHEM BIOPH RES CO, V276, P151, DOI 10.1006/bbrc.2000.3445
   YU R, 2004, DNA RESP, V3, P235
   YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263
   ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819
NR 81
TC 102
Z9 117
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD OCT 1
PY 2007
VL 224
IS 1
BP 1
EP 11
DI 10.1016/j.taap.2007.06.022
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 214OI
UT WOS:000249747600001
PM 17688899
DA 2025-01-12
ER

PT J
AU Sowinska, A
   Jagodzinski, PP
AF Sowinska, A.
   Jagodzinski, P. P.
TI RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12
   expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell
   lines
SO CANCER LETTERS
LA English
DT Article
DE DNA methyltransferases; CXCL12; breast and pancreatic cancers
ID DNA METHYLTRANSFERASES; CHEMOKINE RECEPTORS; METHYLATION; GENE;
   SURVIVAL; SDF-1
AB It has been recently demonstrated that in colonic carcinoma, CXCL12 expression undergoes epigenetic regulation by methylation of cytosine in cytosine-guanosine (CpG) dinucleotides of the promoter sequence.
   Using lentiviral vectors, we generated stable RNA interference-mediated knockdown of DNMT1 and DNMT3B in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines. Employing reverse transcription real-time quantitative PCR and immunofluorescence analysis, we determined re-expression levels of CXCL12 transcript and protein in these cells. Bisulfite sequencing revealed that the level of promoter demethylation appeared more effective in cells expressing DNMT1 siRNA than in those expressing DNMT3B siRNA, and this correlated with higher expression of CXCL12. Moreover, the combined expression of DNMT1 and DNMT3B siRNAs enhanced promoter demethylation that was associated only with a slight increase of CXCL 12 expression. However, the demethylating agent 5-Aza-2'-deoxycytidine exhibited the strongest effect on promoter demethylation, which correlated with the highest expression level of CXCL12 transcript and protein in MCF-7 and AsPC1 cells.
   Our findings suggest that DNMT1 plays a key role in maintenance of methylation, and DNMT3B may act as an accessory DNA methyltransferase to epigenetically silence CXCL12 expression in MCF-7 and AsPC1 cells. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
C1 Poznan Univ Med Sci, Dept Biochem & Mol Biol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences
RP Jagodzinski, PP (通讯作者)，Poznan Univ Med Sci, Dept Biochem & Mol Biol, 6 Swiecickiego St, PL-60781 Poznan, Poland.
EM pjagodzi@am.poznan.pl
RI Jagodzinski, Pawel/KWV-0637-2024
OI Jagodzinski, Pawel/0000-0002-9046-6802; Sowinska-Seidler,
   Anna/0000-0002-2493-898X
CR Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   García-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016
   Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   LUKER KE, 2005, CANC LETT, V20, P1
   Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Sato N, 2004, CANCER BIOL THER, V4, P33
   Shi HD, 2003, CANCER RES, V63, P2164
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Szabo A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r59
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 27
TC 33
Z9 38
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 18
PY 2007
VL 255
IS 1
BP 153
EP 159
DI 10.1016/j.canlet.2007.04.004
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 210XK
UT WOS:000249488700017
PM 17532557
DA 2025-01-12
ER

PT J
AU Somenzi, G
   Sala, G
   Rossetti, S
   Ren, MQ
   Ghidoni, R
   Sacchi, N
AF Somenzi, Giulia
   Sala, Giusy
   Rossetti, Stefano
   Ren, MingQiang
   Ghidoni, Riccardo
   Sacchi, Nicoletta
TI Disruption of Retinoic Acid Receptor Alpha Reveals the Growth Promoter
   Face of Retinoic Acid
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER CELLS; NUCLEAR RECEPTORS; VITAMIN-A; EXTRACELLULAR
   RELEASE; CARCINOMA-CELLS; BETA-CAROTENE; LUNG-CANCER; KINASE;
   ACTIVATION; EXPRESSION
AB Background. Retinoic acid (RA), the bioactive derivative of Vitamin A, by epigenetically controlling transcription through the RA-receptors (RARs), exerts a potent antiproliferative effect on human cells. However, a number of studies show that RA can also promote cell survival and growth. In the course of one of our studies we observed that disruption of RA-receptor alpha, RAR alpha, abrogates the RA-mediated growth-inhibitory effects and unmasks the growth-promoting face of RA (Ren et al., Mol. Cell. Biol., 2005, 25: 10591). The objective of this study was to investigate whether RA can differentially govern cell growth, in the presence and absence of RAR alpha, through differential regulation of the "rheostat'' comprising ceramide (CER), the sphingolipid with growth-inhibitory activity, and sphingosine-1-phosphate (S1P), the sphingolipid with prosurvival activity. Methodology/Principal Findings. We found that functional inhibition of endogenous RAR alpha in breast cancer cells by using either RAR alpha specific antagonists or a dominant negative RAR alpha mutant hampers on one hand the RA-induced upregulation of neutral sphingomyelinase (nSMase)-mediated CER synthesis, and on the other hand the RA-induced downregulation of sphingosine kinase 1, SK1, pivotal for S1P synthesis. In association with RA inability to regulate the sphingolipid rheostat, cells not only survive, but also grow more in response to RA both in vitro and in vivo. By combining genetic, pharmacological and biochemical approaches, we mechanistically demonstrated that RA-induced growth is, at least in part, due to non-RAR-mediated activation of the SK1-S1P signaling. Conclusions/Significance. In the presence of functional RAR alpha, RA inhibits cell growth by concertedly, and inversely, modulating the CER and S1P synthetic pathways. In the absence of a functional RAR alpha, RA-in a non-RAR-mediated fashion-promotes cell growth by activating the prosurvival S1P signaling. These two distinct, yet integrated processes apparently concur to the growth-promoter effects of RA.
C1 [Sala, Giusy; Ghidoni, Riccardo] Univ Milan, Sch Med, San Paolo Univ Hosp, Biochem & Mol Biol Lab, Milan, Italy.
   [Somenzi, Giulia; Rossetti, Stefano; Ren, MingQiang; Sacchi, Nicoletta] Roswell Pk Canc Inst, Dept Canc Biol, Canc Genet Program, Buffalo, NY 14263 USA.
C3 University of Milan; Roswell Park Comprehensive Cancer Center
RP Ghidoni, R (通讯作者)，Univ Milan, Sch Med, San Paolo Univ Hosp, Biochem & Mol Biol Lab, Milan, Italy.
EM riccardo.ghidoni@unimi.it; nicoletta.sacchi@roswellpark.org
RI Ren, Mingqiang/KHV-8463-2024
OI GHIDONI, RICCARDO/0000-0002-6300-5867
FU MIUR, Italy [PRIN 20011065545]; Cariplo Foundation Award (Italy);
   Roswell Park Alliance Foundation Award; U. S. Army [DAMD 17-02-01-0432];
   Graduate Program of Molecular Medicine, University of Milan, Italy
FX This work was funded by the PRIN 20011065545 grant "Lipids as effectors
   and mediators of growth, differentiation and apoptosis in cancer cells''
   (MIUR, Italy) (RG and NS), a Cariplo Foundation Award (Italy) (RG and
   NS), a Roswell Park Alliance Foundation Award (NS), the U. S. Army DAMD
   17-02-01-0432 (NS), the Graduate Program of Molecular Medicine,
   University of Milan, Italy (G. Somenzi and G. Sala).
CR Albright CD, 2004, J NUTR, V134, P1139, DOI 10.1093/jn/134.5.1139
   Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1
   AMES BN, 1960, J BIOL CHEM, V235, P769
   Anelli V, 2005, J NEUROCHEM, V92, P1204, DOI 10.1111/j.1471-4159.2004.02955.x
   APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129
   Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005
   Bistulfi G, 2006, CANCER RES, V66, P10308, DOI 10.1158/0008-5472.CAN-06-1052
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Decensi A, 2007, NAT CLIN PRACT ONCOL, V4, P64, DOI 10.1038/ncponc0735
   Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329
   Guo XJ, 2002, CANCER RES, V62, P1654
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   HENION PD, 1994, DEV BIOL, V161, P243, DOI 10.1006/dbio.1994.1024
   Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168
   Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200
   KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445
   Khuri FR, 2006, JNCI-J NATL CANCER I, V98, P441, DOI 10.1093/jnci/djj091
   Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200
   Kikuchi K, 2001, BIOORG MED CHEM LETT, V11, P1215, DOI 10.1016/S0960-894X(01)00177-9
   Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033
   Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200
   Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200
   MERRILL AH, 1992, METHOD ENZYMOL, V209, P427
   Mikkelsen S, 1998, CARCINOGENESIS, V19, P663, DOI 10.1093/carcin/19.4.663
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Mollersen L, 2004, CARCINOGENESIS, V25, P149, DOI 10.1093/carcin/bgg176
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182
   Ochoa WF, 2003, BIOCHEMISTRY-US, V42, P8774, DOI 10.1021/bi034713g
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Perry DK, 2000, METHOD ENZYMOL, V312, P22
   Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200
   Pozzi S, 2006, ONCOGENE, V25, P1400, DOI 10.1038/sj.onc.1209173
   REN M, 2005, P AM ASSOC CANC RES, V46, P300
   REN M, 2006, P AM ASSOC CANC RES, V47, P1625
   REN M, 2007, P AM ASSOC CANC RES, V48, P1660
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Ren MQ, 2004, ANTICANCER RES, V24, P2879
   Rexer BN, 2001, CANCER RES, V61, P7065
   ROMAN SD, 1992, CANCER RES, V52, P2236
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050
   SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417
   Sirchia SM, 2002, CANCER RES, V62, P2455
   TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258
   VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N
   VANVELDHOVEN PP, 1995, BIOCHEM MOL BIOL INT, V36, P21
   Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6
   Wang HT, 2001, CANCER RES, V61, P5102
   Zanardi S, 2006, ENDOCR-RELAT CANCER, V13, P51, DOI 10.1677/erc.1.00938
   Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766
NR 52
TC 24
Z9 27
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2007
VL 2
IS 9
AR e836
DI 10.1371/journal.pone.0000836
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V10HQ
UT WOS:000207455500019
PM 17786207
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Buness, A
   Kuner, R
   Ruschhaupt, M
   Poustka, A
   Sültmann, H
   Tresch, A
AF Buness, Andreas
   Kuner, Ruprecht
   Ruschhaupt, Markus
   Poustka, Annemarie
   Sueltmann, Holger
   Tresch, Achim
TI Identification of aberrant chromosomal regions from gene expression
   microarray studies applied to human breast cancer
SO BIOINFORMATICS
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; CLASS-I; P53 STATUS; ARRAY-CGH;
   PATTERNS; TUMORS; PROGNOSIS; AMPLIFICATION; SIGNATURE; PROFILES
AB Motivation: In cancer, chromosomal imbalances like amplifications and deletions, or changes in epigenetic mechanisms like DNA methylation influence the transcriptional activity. These alterations are often not limited to a single gene but affect several genes of the genomic region and may be relevant for the disease status. For example, the ERBB2 amplicon (17q21) in breast cancer is associated with poor patient prognosis. We present a general, unsupervised method for genome-wide gene expression data to systematically detect tumor patients with chromosomal regions of distinct transcriptional activity. The method aims to find expression patterns of adjacent genes with a consistently decreased or increased level of gene expression in tumor samples. Such patterns have been found to be associated with chromosomal aberrations and clinical parameters like tumor grading and thus can be useful for risk stratification or therapy.
   Results: Our approach was applied to 12 independent human breast cancer microarray studies comprising 1422 tumor samples. We prioritized chromosomal regions and genes predominantly found across all studies. The result highlighted not only regions which are well known to be amplified like 17q21 and 11q13, but also others like 8q24 (distal to MYC) and 17q24-q25 which may harbor novel putative oncogenes. Since our approach can be applied to any microarray study it may become a valuable tool for the exploration of transcriptional changes in diverse disease types.
   Availability: The R source codes which implement the method and an exemplary analysis are available at http://www.dkfz.de/mga2/people/buness/CTP/.
   Contact: a.buness@gmx.de
   Supplementary information: Supplementary data are available at Bioinformatics online.
C1 German Canc Res Ctr, Dept Mol Genome Anal, D-69120 Heidelberg, Germany.
   Univ Munich, Inst Med Informat Biometr & Epidemiol, D-81377 Munich, Germany.
   Inst Med Biometry Epidemiiol & Informat, D-55131 Mainz, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); University
   of Munich
RP Buness, A (通讯作者)，German Canc Res Ctr, Dept Mol Genome Anal, D-69120 Heidelberg, Germany.
RI Sultmann, Holger/E-4534-2013
OI Sultmann, Holger/0000-0002-5257-8600
CR Bieche I, 1996, CANCER RES, V56, P3886
   Callagy G, 2005, J PATHOL, V205, P388, DOI 10.1002/path.1694
   Callegaro A, 2006, BIOINFORMATICS, V22, P2658, DOI 10.1093/bioinformatics/btl455
   Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794
   Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102
   Check E, 2005, NATURE, V438, P894, DOI 10.1038/438894a
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Courjal F, 1997, CANCER RES, V57, P4368
   Crawley JJ, 2002, GENOME BIOL, V3
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Hyman E, 2002, CANCER RES, V62, P6240
   Ihaka R., 1996, J Comput Graph Stat, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Ise R, 2005, FEBS LETT, V579, P1732, DOI 10.1016/j.febslet.2005.02.033
   Jain AN, 2001, P NATL ACAD SCI USA, V98, P7952, DOI 10.1073/pnas.151241198
   Jin RX, 2004, PATHOL ONCOL RES, V10, P74, DOI 10.1007/BF02893459
   Kauraniemi P, 2003, AM J PATHOL, V163, P1979, DOI 10.1016/S0002-9440(10)63556-0
   Kauraniemi P, 2001, CANCER RES, V61, P8235
   Lahiri S. N., 2003, RESAMPLING METHODS D
   Levin AM, 2005, BIOINFORMATICS, V21, P2867, DOI 10.1093/bioinformatics/bti417
   Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014
   Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101
   Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
   Madjd Z, 2005, INT J CANCER, V117, P248, DOI 10.1002/ijc.21163
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Myers CL, 2004, BIOINFORMATICS, V20, P3533, DOI 10.1093/bioinformatics/bth440
   Nessling M, 2005, CANCER RES, V65, P439
   Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Prelic A, 2006, BIOINFORMATICS, V22, P1122, DOI 10.1093/bioinformatics/btl060
   Rahnenführer J, 2005, BIOINFORMATICS, V21, P2438, DOI 10.1093/bioinformatics/bti312
   Rennstam K, 2003, CANCER RES, V63, P8861
   Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Staub E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-37
   Tanay Amos, 2002, Bioinformatics, V18 Suppl 1, pS136
   Tibshirani R, 2007, BIOSTATISTICS, V8, P2, DOI 10.1093/biostatistics/kxl005
   Toedling J, 2005, BIOINFORMATICS, V21, P2112, DOI 10.1093/bioinformatics/bti183
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   Zhou Y, 2003, CANCER RES, V63, P5781
NR 48
TC 22
Z9 25
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD SEP 1
PY 2007
VL 23
IS 17
BP 2273
EP 2280
DI 10.1093/bioinformatics/btm340
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA 215OI
UT WOS:000249818500010
PM 17599933
OA Bronze
DA 2025-01-12
ER

PT J
AU Bagadi, SAR
   Prasad, CP
   Srivastava, A
   Prashad, R
   Gupta, SD
   Ralhan, R
AF Bagadi, Sarangadhara Appala Raju
   Prasad, Chandra Prakash
   Srivastava, Anurag
   Prashad, Rajinder
   Gupta, Siddarth Datta
   Ralhan, Ranju
TI Frequent loss of Dab2 protein and infrequent promoter hypermethylation
   in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Dab2/DOC-2; DNA methylation; CpG island; human; breast cancer
ID EPITHELIAL OVARIAN-CANCER; TUMOR-SUPPRESSOR GENE; EXPRESSION; GROWTH;
   MICRORNAS; ADAPTER; DOC-2/DAB2; CELLS; DOC-2/HDAB2; CARCINOMA
AB Disabled-2 (Dab2), a putative tumor suppressor protein, is lost in 80-90% ovarian tumors and ovarian/breast cancer cell lines. The clinical significance of Dab2 protein in breast cancer remains yet unknown. Immunohistochemical analysis of Dab2 protein showed no detectable expression in 67/91 (74%) breast tumors, while all 10 normal tissues showed presence of Dab2 protein. We hypothesized that epigenetic silencing of Dab2 may account for loss of protein in breast cancer. Methylation of Dab2 exon 1, a putative promoter, was analyzed in six breast cancer cell lines and in 54 primary breast tumors by methylation specific PCR. Methylation was observed in MDA-MB-231 and MDA-MB-157 cells and in 6 of 54 (11%) primary breast tumors that also showed loss of Dab2 protein. Expression of Dab2 transcripts was detected in all cell lines except MDA-MB-157. However, none of these six cell lines showed detectable levels of Dab2 protein by western blotting, while non-malignant mammary epithelial cell line MCF 10A showed Dab2 protein expression. To our knowledge this is the first report showing low frequency of Dab2 ( putative) promoter methylation ( 11%) in primary breast tumors. Frequent loss of Dab2 protein ( 74%) suggest that hypermethylation of Dab2 promoter may only be one of the mechanisms accounting for its loss in breast cancer. Further, in silico analysis of Dab2 3'-UTR revealed existence of miRNA complimentary to this region of the gene, suggesting microRNA mediated targeting of Dab2 mRNA might account for loss of the protein in breast cancer.
C1 All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   All India Inst Med Sci, Dept Surg Disciplines, New Delhi 110029, India.
   All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of
   Medical Sciences (AIIMS) New Delhi
RP Ralhan, R (通讯作者)，All India Inst Med Sci, Dept Biochem, Ansari Nagar, New Delhi 110029, India.
EM ralhanr@hotmail.com
RI Bagadi, Sarangadhara appala Raju/IYT-0119-2023; Prasad, Chandra
   Prakash/B-6404-2015
OI Prasad, Chandra Prakash/0000-0002-4911-7483
CR Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003
   Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Elston C., 1998, SYSTEMIC PATHOLOGY B, V3rd, P365
   Enright AJ, 2004, GENOME BIOL, V5
   Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649
   Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789
   Hocevar BA, 1996, P NATL ACAD SCI USA, V93, P7655, DOI 10.1073/pnas.93.15.7655
   Huang Y, 2001, LAB INVEST, V81, P863, DOI 10.1038/labinvest.3780295
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   LAEMMLI UK, 1985, NATURE, V227, P680
   Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403
   Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487
   MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040
   Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769
   Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x
   Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555
   Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x
   Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200
   Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506
   Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075
   SALLES G, 1993, BLOOD, V82, P3539
   Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038
   Sheng ZJ, 2000, GENOMICS, V70, P381, DOI 10.1006/geno.2000.6383
   Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853
   Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103
   Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542
   Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678
   Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481
   Zhou J, 2005, CANCER RES, V65, P6089, DOI 10.1158/0008-5472.CAN-04-3672
   Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200
NR 33
TC 41
Z9 49
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2007
VL 104
IS 3
BP 277
EP 286
DI 10.1007/s10549-006-9422-6
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 202CE
UT WOS:000248878700005
PM 17115114
DA 2025-01-12
ER

PT J
AU Calvisi, DF
   Ladu, S
   Gorden, A
   Farina, M
   Lee, JS
   Conner, EA
   Schroeder, I
   Factor, VM
   Thorgeirsson, SS
AF Calvisi, Diego F.
   Ladu, Sara
   Gorden, Alexis
   Farina, Miriam
   Lee, Ju-Seog
   Conner, Elizabeth A.
   Schroeder, Insa
   Factor, Valentina M.
   Thorgeirsson, Snorri S.
TI Mechanistic and prognostic significance of aberrant methylation in the
   molecular pathogenesis of human hepatocellular carcinoma
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PERICENTROMERIC SATELLITE REGIONS; TUMOR-SUPPRESSOR GENE; DNA
   HYPOMETHYLATION; MICROSATELLITE INSTABILITY; EPIGENETIC INACTIVATION;
   COLORECTAL-CANCER; BREAST-CANCER; LYSYL-OXIDASE; BETA-CATENIN; CPG
   ISLANDS
AB Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, accounting for an estimated 600,000 deaths annually. Aberrant methylation, consisting of DNA hypomethylation and/or promoter gene CpG hypermethylation, is implicated in the development of a variety of solid tumors, including HCC. We analyzed the global levels of DNA methylation as well as the methylation status of 105 putative tumor suppressor genes and found that the extent of genome-wide hypomethylation and CpG hypermethylation correlates with biological features and clinical outcome of HCC patients. We identified activation of Ras and downstream Ras effectors (ERK, AKT, and RAL) due to epigenetic silencing of inhibitors of the Ras pathway in all HCC. Further, selective inactivation of SPRY1 and -2, DAB2, and SOCS4 and -5 genes and inhibitors of angiogenesis (BNIP3, BNIP3L, IGFBP3, and EGLN2) was associated with poor prognosis. Importantly, several epigenetically silenced putative tumor suppressor genes found in HCC were also inactivated in the nontumorous liver. Our results assign both therapeutic and chemopreventive significance to methylation patterns in human HCC and open the possibility of using molecular targets, including those identified in this study, to effectively inhibit HCC development and progression.
C1 NIH, NCI, Canc Res Ctr, Lab Expt Carcinogenesis, Bethesda, MD 20892 USA.
   Univ Sassari, Dept Biomed Sci, Div Expt Pathol & Oncol, I-07100 Sassari, Italy.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); University of Sassari
RP Thorgeirsson, SS (通讯作者)，NCI, Bldg 37,Room 4146A,37 Convent Dr MSC 4262, Bethesda, MD 20892 USA.
EM snorri-thorgeirsson@nih.gov
RI Lee, Ju-Seog/X-1786-2018
OI Lee, Ju-Seog/0000-0002-5666-9753
FU Intramural NIH HHS Funding Source: Medline
CR Atienzar FA, 2006, MUTAT RES-REV MUTAT, V613, P76, DOI 10.1016/j.mrrev.2006.06.001
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6
   Brown KD, 2007, NAT GENET, V39, P289, DOI 10.1038/ng0307-289
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006
   Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014
   Calvisi DF, 2001, CANCER RES, V61, P2085
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Du Y, 2001, CANCER RES, V61, P8094
   Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103
   Elam C, 2005, CANCER RES, V65, P3117, DOI 10.1158/0008-5472.CAN-04-0749
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fransén K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200
   Hellebrekers DMEI, 2006, MOL CANCER THER, V5, P467, DOI 10.1158/1535-7163.MCT-05-0417
   Herman JG, 2005, COLD SH Q B, V70, P329, DOI 10.1101/sqb.2005.70.036
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820
   Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914
   JIANG W, 1989, ONCOGENE, V4, P923
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543
   Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200
   Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400
   Kim M, 2004, NUCLEIC ACIDS RES, V32, P5742, DOI 10.1093/nar/gkh912
   Kirschmann DA, 2002, CANCER RES, V62, P4478
   Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818
   Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481
   Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375
   Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Lim JH, 2004, ONCOGENE, V23, P9427, DOI 10.1038/sj.onc.1208003
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200
   McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371
   Moreno-Bueno G, 2007, CANCER RES, V67, P1927, DOI 10.1158/0008-5472.CAN-06-2687
   Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102
   Piao Z, 2000, INT J ONCOL, V17, P507
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799
   Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Santoni-Rugiu E, 1998, CANCER RES, V58, P123
   Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Uhlmann K, 2003, INT J CANCER, V106, P52, DOI 10.1002/ijc.11175
   Wang SC, 2001, ONCOGENE, V20, P6960, DOI 10.1038/sj.onc.1204873
   Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635
   Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200
NR 76
TC 332
Z9 372
U1 1
U2 19
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2007
VL 117
IS 9
BP 2713
EP 2722
DI 10.1172/JCI31457
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 209JK
UT WOS:000249384600041
PM 17717605
OA Green Published, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Macaluso, M
   Montanari, M
   Noto, PB
   Gregorio, V
   Bronner, C
   Giordano, A
AF Macaluso, Marcella
   Montanari, Micaela
   Noto, Paul Bart
   Gregorio, Valter
   Bronner, Christian
   Giordano, Antonio
TI Epigenetic modulation of estrogen receptor-α by pRb family proteins:: A
   novel mechanism in breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID CELL-CYCLE; ICBP90; GENE; EXPRESSION; COMPLEXES; RB
AB Estrogen receptor-alpha (ER-alpha) plays a crucial role in normal breast development and has also been linked to mammary carcinogenesis and clinical outcome in breast cancer patients. However, ER-alpha gene expression can change during the course of disease and, consequently, therapy resistance can occur. The molecular mechanism governing ER-alpha transcriptional activity and/or silencing is still unclear. Here, we showed that the presence of a specific pRb2/p130 multimolecular complex on the ER-alpha promoter strongly correlates with the methylation status of this gene. Furthermore, we suggested that pRb2/p130 could cooperate with ICBP90 (inverted CCAAT box binding protein of 90 kDa) and DNA methyltransferases in maintaining a specific methylation pattern of ER-alpha gene. The sequence of epigenetic events for establishing and maintaining the silenced state of ER-alpha gene can be locus- or pathway-specific, and the local remodeling of ER-alpha chromatin structure by pRb2/p130 multimolecular complexes may influence its susceptibility to specific DNA methylation. Our novel hypothesis could provide a basis for understanding how the complex pattern of ER-alpha methylation and transcriptional silencing is generated and for understanding the relationship between this pattern and its function during the neoplastic process.
C1 Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.
   Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy.
   Univ Palermo, Dept Oncol, Sect Oncol, Palermo, Italy.
   Univ Louis Pasteur Strasbourg 1, Fac Pharm, Dept Pharmacol & Physicochim, LC1,CNRS,UMR 7175, Illkirch Graffenstaden, France.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; University of Siena; University of Palermo; Centre National
   de la Recherche Scientifique (CNRS); Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg
RP Macaluso, M (通讯作者)，Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.
EM macaluso@temple.edu; Giordano@temple.edu
RI BRONNER, Christian/R-8488-2016; Giordano, Antonio/F-1927-2010
OI BRONNER, Christian/0000-0002-3101-9279; Giordano,
   Antonio/0000-0002-5959-016X
FU NCI NIH HHS [CA060999] Funding Source: Medline
CR Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Brero A, 2006, CURR TOP MICROBIOL, V301, P21
   Bronner C, 2002, ANTICANCER RES, V22, P605
   Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Hopfner R, 2002, ANTICANCER RES, V22, P3165
   Hopfner R, 2001, GENE, V266, P15, DOI 10.1016/S0378-1119(01)00371-7
   Houssami N, 2006, MED J AUSTRALIA, V184, P230, DOI 10.5694/j.1326-5377.2006.tb00208.x
   Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878
   Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194
   Jori FP, 2005, J CELL BIOCHEM, V94, P645, DOI 10.1002/jcb.20315
   La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487
   Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680
   Macaluso M, 2006, CELL DEATH DIFFER, V13, P1515, DOI 10.1038/sj.cdd.4401835
   Macaluso M, 2005, SEMIN ONCOL, V32, P452, DOI 10.1053/j.seminoncol.2005.07.009
   Macaluso M, 2004, TUMORI J, V90, P367, DOI 10.1177/030089160409000401
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068
   Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857
   Oba-Shinjo SM, 2005, MOL BRAIN RES, V140, P25, DOI 10.1016/j.molbrainres.2005.06.015
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhu LA, 2005, EUR J CANCER, V41, P2415, DOI 10.1016/j.ejca.2005.08.009
NR 26
TC 40
Z9 47
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2007
VL 67
IS 16
BP 7731
EP 7737
DI 10.1158/0008-5472.CAN-07-1476
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 200XJ
UT WOS:000248795800023
PM 17699777
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Kovalchuk, O
   Tryndyak, VP
   Montgomery, B
   Boyko, A
   Kutanzi, K
   Zemp, F
   Warbritton, AR
   Latendresse, JR
   Kovalchuk, I
   Beland, FA
   Pogribny, IP
AF Kovalchuk, Olga
   Tryndyak, Volodymyr P.
   Montgomery, Beverly
   Boyko, Alex
   Kutanzi, Kristy
   Zemp, Franz
   Warbritton, Alan R.
   Latendresse, John R.
   Kovalchuk, Igor
   Beland, Frederick A.
   Pogribny, Igor P.
TI Estrogen-induced rat breast carcinogenesis is characterized by
   alterations in DNA methylation, histone modifications and aberrant
   MicroRNA expression
SO CELL CYCLE
LA English
DT Article
DE (17)beta-estradiol; breast carcinogenesis; rat; DNA methylation; histone
   methylation; microRNA
ID GLOBAL DNA; AURORA-A; CANCER; HYPOMETHYLATION; INSTABILITY; PATTERNS;
   DISEASE; CLUSTER
AB Breast cancer is the most common malignancy in women continuing to rise worldwide. Breast cancer emerges through a multi-step process, encompassing progressive changes from a normal cell to hyperplasia (with and without atypia), carcinoma in situ, invasive carcinoma, and metastasis. In the current study, we analyzed the morphological changes and alterations of DNA methylation, histone methylation and microRNA expression during estradiol-17 beta (E-2)-induced mammary carcinogenesis in female August Copenhagen Irish (ACI) rats. E-2-induced breast carcinogenesis in ACI rats provides a physiologically relevant and genetically defined animal model for studying human sporadic breast cancer. The pattern of morphological changes in mammary glands during E-2-induced carcinogenesis was characterized by transition from normal appearing alveolar and ductular hyperplasia to focal hyperplastic areas of atypical glands and ducts accompanied by a rapid and sustained loss of global DNA methylation, LINE-1 hypomethylation, loss of histone H3 lysine 9 and histone H4 lysine 20 trimethylation, and altered microRNAs expression. More importantly, these alterations in the mammary tissue occurred after six weeks of E-2-treatment, whereas the atypical hyperplasia, which represents a putative precursor lesion to mammary carcinoma in this model, was detected only after twelve weeks of exposure, demonstrating clearly that these events are directly associated with the effects of E-2 and are not a consequence of the preexisting preneoplastic lesions. The results of this study show that deregulation of cellular epigenetic processes plays a crucial role in the mechanism of E-2-induced mammary carcinogenesis in ACI rats, especially in the tumor initiation process.
C1 Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 US Food & Drug Administration (FDA); University of Lethbridge
RP Kovalchuk, O (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM olga.kovalchuk@uleth.ca; igor.pogribny@fda.hhs.gov
RI Latendresse, John/A-9215-2009
OI Beland, Frederick/0000-0002-2113-6260; Tryndyak,
   Volodymyr/0000-0002-8319-2954
CR Asada K, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/17142
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800
   Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012
   D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ellsworth DL, 2004, LANCET ONCOL, V5, P753, DOI 10.1016/S1470-2045(04)01653-5
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   FLATAU E, 1983, CANCER RES, V43, P4901
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Hsieh CL, 2003, NAT CELL BIOL, V5, P502, DOI 10.1038/ncb0603-502
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   RAVAL R, 2005, BRIT J CANCER, V92, P162
   Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253
   Seoane J, 2006, CARCINOGENESIS, V27, P2148, DOI 10.1093/carcin/bgl068
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Shull JD, 1997, CARCINOGENESIS, V18, P1595, DOI 10.1093/carcin/18.8.1595
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   YE Y, 2004, BREAST DIS, V14, P69
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
NR 50
TC 95
Z9 124
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD AUG 15
PY 2007
VL 6
IS 16
BP 2010
EP 2018
DI 10.4161/cc.6.16.4549
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 208LL
UT WOS:000249320700010
PM 17700064
OA Bronze
DA 2025-01-12
ER

PT J
AU El-Khoury, V
   Breuzard, G
   Fourré, N
   Dufer, J
AF El-Khoury, V.
   Breuzard, G.
   Fourre, N.
   Dufer, J.
TI The histone deacetylase inhibitor trichostatin A downregulates human
   <i>MDR1 (ABCB1)</i> gene expression by a transcription-dependent
   mechanism in a drug-resistant small cell lung carcinoma cell line model
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE trichostatin A; epigenetics; drug resistance
ID BREAST-CANCER CELLS; FACTOR NF-Y; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN;
   MULTIDRUG-RESISTANCE-1 GENE; CHROMATIN-STRUCTURE; SODIUM-BUTYRATE; DNA
   METHYLATION; NUCLEAR TEXTURE; PROMOTER REGION
AB Tumour drug-resistant ABCBI gene expression is regulated at the chromatin level through epigenetic mechanisms. We examined the effects of the histone deacetylase inhibitor trichostatin A (TSA) on ABCBI gene expression in small cell lung carcinoma (SCLC) drug-sensitive (H69WT) or etoposide-resistant (H69VP) cells. We found that TSA induced an increase in ABCBI expression in drug-sensitive cells, but strongly decreased it in drug-resistant cells. These up- and downregulations occurred at the transcriptional level. Protein synthesis inhibition reduced these modulations, but did not completely suppress them. Differential temporal patterns of histone acetylation were observed at the ABCBI promoter: increase in H4 acetylation in both cell lines, but different H3 acetylation with a progressive increase in H69WT cells but a transient one in H69VP cells. ABCBI regulations were not related with the methylation status of the promoter -50GC, -110GC, and Inr sites, and did not result in further changes to these methylation profiles. Trichostatin A treatment did not modify MBDI binding to the ABCBI promoter and similarly increased PCAF binding in both H69 cell lines. Our results suggest that in H69 drug-resistant SCLC cell line TSA induces downregulation of ABCBI expression through a transcriptional mechanism, independently of promoter methylation, and MBD1 or PCAF recruitment.
C1 Univ Reims, Unite MeDIAN CNRS, UMR 6142, Fac Pharm,IFR 53, F-51096 Reims, France.
C3 Universite de Reims Champagne-Ardenne
RP Dufer, J (通讯作者)，Univ Reims, Unite MeDIAN CNRS, UMR 6142, Fac Pharm,IFR 53, F-51096 Reims, France.
EM jean.dufer@univ-reims.fr
RI breuzard, gilles/C-4735-2013
OI breuzard, gilles/0000-0001-8178-2080
CR Alvelo-Ceron D, 2000, MOL BIOL REP, V27, P61, DOI 10.1023/A:1007156629024
   Ammerpohl O, 2007, BRIT J CANCER, V96, P73, DOI 10.1038/sj.bjc.6603511
   Baker EK, 2004, CANCER BIOL THER, V3, P819, DOI 10.4161/cbt.3.9.1101
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   BROCK I, 1995, CANCER RES, V55, P459
   Castro-Galache MD, 2003, INT J CANCER, V104, P579, DOI 10.1002/ijc.10998
   COSGROVE DE, 1990, BIOCHIM BIOPHYS ACTA, V1087, P80, DOI 10.1016/0167-4781(90)90124-K
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001
   DEHAAN JB, 1986, CANCER RES, V46, P713
   El-Khoury V, 2004, CYTOM PART A, V62A, P109, DOI 10.1002/cyto.a.20088
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Friedman D, 2002, CANCER RES, V62, P3377
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hinnebusch BF, 2003, J GASTROINTEST SURG, V7, P237, DOI 10.1016/S1091-255X(02)00140-3
   HOLZMAYER TA, 1992, J NATL CANCER I, V84, P1486, DOI 10.1093/jnci/84.19.1486
   Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979
   HU ZW, 1993, MOL PHARMACOL, V44, P1105
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5
   Laribee RN, 2001, J IMMUNOL, V167, P5160, DOI 10.4049/jimmunol.167.9.5160
   Li C, 2005, CHINESE MED J-PEKING, V118, P136
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Maehara K, 2002, BIOCHEM BIOPH RES CO, V295, P187, DOI 10.1016/S0006-291X(02)00646-0
   Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040
   Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722
   Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307
   Okamura H, 2004, INT J ONCOL, V25, P1031
   POUPON MF, 1993, J NATL CANCER I, V85, P2023, DOI 10.1093/jnci/85.24.2023
   Savaraj N, 1997, AM J CLIN ONCOL-CANC, V20, P398, DOI 10.1097/00000421-199708000-00016
   Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950
   Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126
   Tanaka H, 2003, CANCER RES, V63, P6942
   Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   Triller N, 2006, LUNG CANCER, V54, P235, DOI 10.1016/j.lungcan.2006.06.019
   Tsurutani J, 2003, INT J CANCER, V104, P238, DOI 10.1002/ijc.10921
   Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yagüe E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200
   Yamada H, 2006, LEUKEMIA RES, V30, P723, DOI 10.1016/j.leukres.2005.09.014
   Yamada T, 2000, CANCER RES, V60, P4761
   Yatouji S, 2007, INT J ONCOL, V30, P1003
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhao SJ, 2003, CANCER RES, V63, P2624
NR 49
TC 47
Z9 59
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 14
PY 2007
VL 97
IS 4
BP 562
EP 573
DI 10.1038/sj.bjc.6603914
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 205OD
UT WOS:000249122700016
PM 17667922
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Pal, S
   Baiocchi, RA
   Byrd, JC
   Grever, MR
   Jacob, ST
   Sif, S
AF Pal, Sharmistha
   Baiocchi, Robert A.
   Byrd, John C.
   Grever, Michael R.
   Jacob, Samson T.
   Sif, Said
TI Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3
   methylation in mantle cell lymphoma
SO EMBO JOURNAL
LA English
DT Article
DE H3R8 and H4R3 methylation; mantle cell lymphoma; miR-92b and miR-96;
   PRMT5; ST7
ID ARGININE METHYLTRANSFERASE PRMT5; TUMOR-SUPPRESSOR GENES; GROUP PROTEIN
   EZH2; GASTRIC-CANCER; BREAST-CANCER; HISTONE; CHROMATIN; COMPLEX;
   IDENTIFICATION; TRANSCRIPTION
AB Protein arginine methyltransferase PRMT5 interacts with human SWI/SNF complexes and methylates histones H3R8 and H4R3. To elucidate the role of PRMT5 in human cancer, we analyzed PRMT5 expression in normal human B lymphocytes and a panel of lymphoid cancer cell lines as well as mantle cell lymphoma (MCL) clinical samples. We show that PRMT5 protein levels are elevated in all cancer cells, including clinical samples examined despite its low rate of transcription and messenger RNA stability. Remarkably, polysome profiling revealed that PRMT5 mRNA is translated more efficiently in Mino and JeKo MCL cells than in normal B cells, and that decreased miR-92b and miR-96 expression augments PRMT5 translation. Consequently, global methylation of H3R8 and H4R3 is increased and is accompanied by repression of suppressor of tumorigenecity 7 (ST7) in lymphoid cancer cells. Furthermore, knockdown of PRMT5 expression reduces proliferation of transformed JeKo and Raji cells. Thus, our studies indicate that aberrant expression of PRMT5 leads to altered epigenetic modification of chromatin, which in turn impacts transcriptional performance of anti-cancer genes and growth of transformed lymphoid cells.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH USA.
   Ohio State Univ, Coll Med, Columbus, OH USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University
RP Sif, S (通讯作者)，Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 1645 Neil Ave, Columbus, OH 43210 USA.
EM sif.1@osu.edu
RI Jacob, Samson/H-3135-2011; Sif, Said/AAE-5554-2019
OI Sif, Said/0000-0001-6268-1145
FU NCI NIH HHS [R01 CA116093, P01 CA101956] Funding Source: Medline
CR Ancelin K, 2006, NAT CELL BIOL, V8, P623, DOI 10.1038/ncb1413
   Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Dacwag CS, 2007, MOL CELL BIOL, V27, P384, DOI 10.1128/MCB.01528-06
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001
   Guezennec X Le, 2006, MOL CELL BIOL, V26, P843
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466
   Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003
   Kim JM, 2005, CLIN CANCER RES, V11, P473
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4
   Moggs JG, 2005, J MOL ENDOCRINOL, V34, P535, DOI 10.1677/jme.1.01677
   Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004
   Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003
   Papp B, 2006, GENE DEV, V20, P2041, DOI 10.1101/gad.388706
   Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531
   Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005
   Slany RK, 2005, HEMATOL ONCOL, V23, P1, DOI 10.1002/hon.739
   Tan CP, 2006, MOL CELL BIOL, V26, P7224, DOI 10.1128/MCB.00473-06
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x
   Wang BB, 2006, MOL CELL, V22, P553, DOI 10.1016/j.molcel.2006.03.034
   Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
NR 33
TC 231
Z9 308
U1 0
U2 39
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD AUG 8
PY 2007
VL 26
IS 15
BP 3558
EP 3569
DI 10.1038/sj.emboj.7601794
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 199DI
UT WOS:000248676000005
PM 17627275
OA Green Published
DA 2025-01-12
ER

PT J
AU Kikuchi, R
   Tsuda, H
   Kanai, Y
   Kasamatsu, T
   Sengoku, K
   Hirohashi, S
   Inazawa, J
   Imoto, I
AF Kikuchi, Ryoko
   Tsuda, Hitoshi
   Kanai, Yae
   Kasamatsu, Takahiro
   Sengoku, Kazuo
   Hirohashi, Setsuo
   Inazawa, Johji
   Imoto, Issei
TI Promoter hypermethylation contributes to frequent inactivation of a
   putative conditional tumor suppressor gene <i>connective tissue growth
   factor</i> in ovarian cancer
SO CANCER RESEARCH
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMA; HUMAN
   BREAST-CANCER; CCN FAMILY; DNA METHYLATION; LUNG-CANCER; EXPRESSION;
   IDENTIFICATION; AMPLIFICATION; METASTASIS
AB Connective tissue growth factor (CTGF) is a secreted protein belonging to the CCN family, members of which are implicated in various biological processes. We identified a homozygous loss of CTGF (6q23.2) in the course of screening a panel of ovarian cancer cell lines for genomic copy number aberrations using in-house array-based comparative genomic hybridization. CTGF mRNA expression was observed in normal ovarian tissue and immortalized ovarian epithelial cells but was reduced in many ovarian cancer cell lines without its homozygous deletion (12 of 23 lines) and restored after treatment with 5-aza 2 '-deoxycytidine. The methylation status around the CTGF CpG island correlated inversely with the expression, and a putative target region for methylation showed promoter activity. CTGF methylation was frequently observed in primary ovarian cancer tissues (39 of 66, 59%) and inversely correlated with CTGF mRNA expression. In an immunohistochemical analysis of primary ovarian cancers, CTGF protein expression was frequently reduced (84 of 103 cases, 82%). Ovarian cancer tended to lack CTGF expression more frequently in the earlier stages (stages I and II) than the advanced stages (stages III and IV). CTGF protein was also differentially expressed among histologic subtypes. Exogenous restoration of CTGF expression or treatment with recombinant CTGF inhibited the growth of ovarian cancer cells lacking its expression, whereas knockdown of endogenous CTGF accelerated growth of ovarian cancer cells with expression of this gene. These results suggest that epigenetic silencing by hypermethylation of the CTGF promoter leads to a loss of CTGF function, which may be a factor in the carcinogenesis of ovarian cancer in a stage-dependent and/or histologic subtype-dependent manner.
C1 Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan.
   Tokyo Med & Dent Univ, Sch Biomed Sci, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan.
   Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan.
   Tokyo Med & Dent Univ, 21st Century Ctr Excellence, Program Mol Destruct & Reconstitut Tooth & Bone, Tokyo, Japan.
   Natl Canc Ctr, Natl Canc Ctr, Res Inst, Div Pathol, Tokyo, Japan.
   Natl Canc Ctr, Div Gynecol, Tokyo, Japan.
   Natl Def Med Coll, Dept Basic Pathol, Saitama, Japan.
   Asahikawa Med Coll, Dept Obstet & Gynecol, Asahikawa, Hokkaido 078, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   National Cancer Center - Japan; National Cancer Center - Japan; National
   Defense Medical College - Japan; Asahikawa Medical College
RP Inazawa, J (通讯作者)，Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.
EM johinaz.cgen@mri.tmd.ac.jp
RI Kanai, Yae/AAE-6987-2019; Imoto, Issei/AAD-5799-2020
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3
   BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X
   Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chiba T, 2005, EUR J CANCER, V41, P1185, DOI 10.1016/j.ejca.2005.02.014
   Chiba T, 2004, J HEPATOL, V41, P436, DOI 10.1016/j.jhep.2004.05.018
   Chien W, 2006, MOL CANCER RES, V4, P591, DOI 10.1158/1541-7786.MCR-06-0029
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Geisler JP, 2003, CANCER-AM CANCER SOC, V98, P2199, DOI 10.1002/cncr.11770
   Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350
   Hayashi H, 2007, HUM GENET, V120, P701, DOI 10.1007/s00439-006-0254-6
   HIRATA J, 1993, INT J CANCER, V55, P521, DOI 10.1002/ijc.2910550332
   Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461
   Imoto I, 2002, CANCER RES, V62, P4860
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437
   Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x
   IWABUCHI H, 1995, CANCER RES, V55, P6172
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018
   KIKUCHI Y, 1986, JNCI-J NATL CANCER I, V77, P1181
   Kolb A, 2003, BIOCHEM BIOPH RES CO, V306, P1099, DOI 10.1016/S0006-291X(03)01104-5
   Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x
   Kubo M, 1998, BRIT J DERMATOL, V139, P192
   Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456
   Lin BR, 2005, GASTROENTEROLOGY, V128, P9, DOI 10.1053/j.gastro.2004.10.007
   Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073
   Moritani NH, 2003, CANCER LETT, V192, P205, DOI 10.1016/S0304-3835(02)00718-8
   Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183
   Nitta M, 2001, GYNECOL ONCOL, V81, P10, DOI 10.1006/gyno.2000.6084
   Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9
   Pan LH, 2002, NEUROL RES, V24, P677, DOI 10.1179/016164102101200573
   Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103
   Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57
   Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15
   Prowse A, 2003, ACS A CLIN ONCOL SER, P49
   Saigusa K, 2007, ONCOGENE, V26, P1110, DOI 10.1038/sj.onc.1210148
   Shakunaga T, 2000, CANCER, V89, P1466, DOI 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G
   Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320
   Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172
   Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200
   Watanabe T, 2001, GYNECOL ONCOL, V81, P172, DOI 10.1006/gyno.2001.6132
   Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
NR 50
TC 68
Z9 78
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2007
VL 67
IS 15
BP 7095
EP 7105
DI 10.1158/0008-5472.CAN-06-4567
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 197BW
UT WOS:000248529300009
PM 17671176
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Di, W
   Guo, SW
AF Di, Wen
   Guo, Sun-Wei
TI The search for genetic variants predisposing women to endometriosis
SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
LA English
DT Article
DE association study; endometriosis; genetics; susceptibility
ID MONOZYGOTIC TWINS; FAMILIAL RISK; EPIGENETIC VARIATION; ABERRANT
   EXPRESSION; COMPLEX TRAITS; BREAST-CANCER; ASSOCIATION; INHERITANCE;
   DISEASE; PAIN
AB Purpose of review
   There is a growing interest in the search for genetic variants that predispose women to endometriosis, yet little headway has been made in the identification of such variants, and published studies are often conflicting. This review evaluates the evidence for a hereditary component in endometriosis, appraises the evidence of linkage and association of genetic polymorphisms and endometriosis, and discusses the implications of this reappraisal for clinical practice and research.
   Recent findings
   The familial aggregation of endometriosis appears to be established although most family studies suffer from various methodological deficiencies, such as failure to control for risk factors and the number of sisters that cases and controls have. The familial aggregation could also be attributed to familial aggregation of risk factors and/or some intermediatory traits that have genetic components. The published association studies are often conflicting, perhaps reflecting these uncertainties.
   Summary
   The search for genetic variants predisposing women to endometriosis has generated a lot of interest, and yet so far it has not shed much light on its pathogenesis. Further genetic epidemiological studies with more solid design and methodological rigor are needed.
C1 Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Obstet & Gynecol Res, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University
RP Guo, SW (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Obstet & Gynecol Res, Shanghai 200025, Peoples R China.
EM hoxa10@gmail.com
RI , 郭孙伟/AAM-8634-2020
CR Altmüller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069
   Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879
   Baird P, 2001, Community Genet, V4, P77, DOI 10.1159/000051161
   BENNETT J. H., 1958, AUSTRALASIAN, V7, P269
   BENNETT JH, 1959, AM J HUM GENET, V11, P169
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Cavalli-Sforza LL., 1981, Cultural transmission and evolution: a quantitative approach
   Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244
   Cheung VG, 2003, COLD SPRING HARB SYM, V68, P403, DOI 10.1101/sqb.2003.68.403
   Chong SY, 2004, CURR OPIN GENET DEV, V14, P692, DOI 10.1016/j.gde.2004.09.001
   Cooper RS, 2003, ANN INTERN MED, V138, P576, DOI 10.7326/0003-4819-138-7-200304010-00014
   Coxhead Dawn, 1993, Journal of Obstetrics and Gynaecology (Abingdon), V13, P42, DOI 10.3109/01443619309151773
   Devlin B, 1997, NATURE, V388, P468, DOI 10.1038/41319
   Dos Reis RM, 1999, J ASSIST REPROD GEN, V16, P500, DOI 10.1023/A:1020559201968
   Edelman GM, 2001, P NATL ACAD SCI USA, V98, P13763, DOI 10.1073/pnas.231499798
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   FREY GH, 1957, AM J OBSTET GYNECOL, V73, P418
   GARDNER GH, 1953, OBSTET GYNECOL, V1, P615
   Garry R, 2006, FERTIL STERIL, V86, P1307, DOI 10.1016/j.fertnstert.2006.06.045
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Guo S, 2005, FERTIL STERIL, V84, pS125, DOI 10.1016/j.fertnstert.2005.07.304
   Guo SW, 2006, GYNECOL OBSTET INVES, V61, P90, DOI 10.1159/000089011
   Guo SW, 2005, MOL HUM REPROD, V11, P729, DOI 10.1093/molehr/gah206
   Guo SW, 2000, HUM HERED, V50, P286, DOI 10.1159/000022931
   Guo SW, 2000, AM J EPIDEMIOL, V151, P1121, DOI 10.1093/oxfordjournals.aje.a010156
   Guo SW, 1999, HUM HERED, V49, P215, DOI 10.1159/000022878
   Guo SW, 1998, AM J HUM GENET, V63, P252, DOI 10.1086/301928
   Hadfield RM, 1997, HUM REPROD UPDATE, V3, P109, DOI 10.1093/humupd/3.2.109
   Hadfield RM, 1997, FERTIL STERIL, V68, P941, DOI 10.1016/S0015-0282(97)00359-2
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Howard F M, 1993, Obstet Gynecol Surv, V48, P357, DOI 10.1097/00006254-199306000-00001
   Husby GK, 2003, ACTA OBSTET GYN SCAN, V82, P649, DOI 10.1034/j.1600-0412.2003.00168.x
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Kashima K, 2004, INT J GYNECOL OBSTET, V84, P61, DOI 10.1016/S0020-7292(03)00340-0
   KENNEDY S, 1995, J ASSIST REPROD GEN, V12, P32, DOI 10.1007/BF02214126
   Kennedy S, 1996, HUM REPROD, V11, P403, DOI 10.1093/HUMREP/11.2.403
   KONINCKX PR, 1994, HUM REPROD, V9, P1001, DOI 10.1093/oxfordjournals.humrep.a138623
   LAMB K, 1986, AM J OBSTET GYNECOL, V154, P596, DOI 10.1016/0002-9378(86)90608-3
   LINDEBAUM S, 1979, SORCERY DIS DANGER N
   MATHEWS JD, 1971, THESIS U MELBOURNE
   MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260
   MOEN M, 1984, ACTA OBSTET GYN SCAN, P25
   Moen MH, 1997, ACTA OBSTET GYN SCAN, V76, P559, DOI 10.3109/00016349709024584
   MOEN MH, 1994, ACTA OBSTET GYN SCAN, V73, P59, DOI 10.3109/00016349409013396
   MOEN MH, 1993, ACTA OBSTET GYN SCAN, V72, P560, DOI 10.3109/00016349309058164
   Ott J., 1999, ANAL HUMAN GENETIC L
   Peaston AE, 2006, MAMM GENOME, V17, P365, DOI 10.1007/s00335-005-0180-2
   Rakyan V, 2003, CURR BIOL, V13, pR6, DOI 10.1016/S0960-9822(02)01377-5
   Rakyan VK, 2006, CURR OPIN GENET DEV, V16, P573, DOI 10.1016/j.gde.2006.09.002
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   Salces I, 2003, ANN HUM BIOL, V30, P176, DOI 10.1080/0301446021000035047
   Salces I, 2001, ANN HUM BIOL, V28, P143
   Schadt EE, 2006, J LIPID RES, V47, P2601, DOI 10.1194/jlr.R600026-JLR200
   SIMPSON JL, 1984, AM J OBSTET GYNECOL, V148, P395, DOI 10.1016/0002-9378(84)90714-2
   SIMPSON JL, 1980, AM J OBSTET GYNECOL, V137, P327, DOI 10.1016/0002-9378(80)90917-5
   Stefanson H, 2002, HUM REPROD, V17, P555, DOI 10.1093/humrep/17.3.555
   Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534
   Treloar SA, 1999, FERTIL STERIL, V71, P701, DOI 10.1016/S0015-0282(98)00540-8
   Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048
   Wu Y, 2005, AM J OBSTET GYNECOL, V193, P371, DOI 10.1016/j.ajog.2005.01.034
   Wu Y, 2006, EPIGENETICS-US, V1, P106, DOI 10.4161/epi.1.2.2766
   Wu Y, 2006, GYNECOL OBSTET INVES, V62, P148, DOI 10.1159/000093130
   Zondervan KT, 2004, HUM REPROD, V19, P448, DOI 10.1093/humrep/deh052
   Zondervan KT, 2002, HUM REPROD, V17, P1415, DOI 10.1093/humrep/17.6.1415
NR 66
TC 31
Z9 33
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-872X
EI 1473-656X
J9 CURR OPIN OBSTET GYN
JI Curr. Opin. Obstet. Gynecol.
PD AUG
PY 2007
VL 19
IS 4
BP 395
EP 401
DI 10.1097/GCO.0b013e328235a5b4
PG 7
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 197NH
UT WOS:000248562000018
PM 17625425
DA 2025-01-12
ER

PT J
AU Versmold, B
   Felsberg, J
   Mikeska, T
   Ehrentraut, D
   Köhler, J
   Hampl, JA
   Röhn, G
   Niederacher, D
   Betz, B
   Hellmich, M
   Pietsch, T
   Schmutzler, RK
   Waha, A
AF Versmold, Beatrix
   Felsberg, Joerg
   Mikeska, Thomas
   Ehrentraut, Denise
   Koehler, Juliane
   Hampl, Juergen A.
   Roehn, Gabriele
   Niederacher, Dieter
   Betz, Beate
   Hellmich, Martin
   Pietsch, Torsten
   Schmutzler, Rita K.
   Waha, Andreas
TI Epigenetic silencing of the candidate tumor suppressor gene PROX1 in
   sporadic breast cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; PROX1; methylation; RT-PCR; expression
ID CPG ISLAND; DNA METHYLATION; HYPERMETHYLATION; EXPRESSION; CARCINOMA
AB Extensive hypermethylation and consecutive transcriptional silencing of turnorsuppressor genes have been documented in multiple tumor entities including breast cancer. In a microarray based genome-wide methylation analysis of five sporadic breast carcinomas we identified a hypermethylated CpG island within the first intron of the prospero related homeobox gene 1 (PROX1). We, therefore, investigated CpG island methylation of PROX 1 in a series of 33 pairs of primary breast cancer and corresponding normal tissue samples by bisulfite sequencing and COBRA analyses. Seventeen of these (52%) breast cancer samples revealed a significant accumulation of methylated CpG sites along with a significant reduction of PROXI transcription compared to normal breast tissues of the same patients. Frequent methylation was also observed in brain metastases from primary breast cancer (21/37 = 57% of cases). Secondary, we analysed 38 brain metastases of primary breast carcinomas and detected a significantly reduced expression of PROXI compared to normal breast tissue (p < 0.001) and primary breast carcinomas (p < 0.05), respectively. Additionally, treatment of breast cancer cell lines with demethylating agents could reactivate PROXI transcription. In summary, we have identified PROXI as a novel target gene that is hypermethylated and transcriptionally silenced in primary and metastatic breast cancer. (c) 2007 Wiley-Liss, Inc.
C1 Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany.
   Univ Cologne, Dept Gynecol & Obstet, Div Mol Gynecooncol, Cologne, Germany.
   Univ Cologne, CMMC, Cologne, Germany.
   Univ Cologne, Dept Neurosurg, Cologne, Germany.
   Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany.
   Univ Dusseldorf, Dept Gynecol & Obstet, D-4000 Dusseldorf, Germany.
C3 University of Bonn; University of Cologne; University of Cologne;
   University of Cologne; University of Cologne; Heinrich Heine University
   Dusseldorf
RP Waha, A (通讯作者)，Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM awaha@uni-bonn.de
RI Mikeska, Thomas/B-4876-2008
OI Mikeska, Thomas/0000-0003-1318-0859
CR Benitez J, 1997, CANCER RES, V57, P4217
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Dammann R, 2001, CANCER RES, V61, P3105
   Dudas J, 2004, ANAT EMBRYOL, V208, P359, DOI 10.1007/s00429-004-0403-4
   Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144
   Evron E, 2001, CANCER RES, V61, P2782
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Hyder SM, 2000, CANCER RES, V60, P3183
   KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294
   Li B, 2001, CANCER RES, V61, P8014
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248
   Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9
   STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844
   Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1
   Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505
   Wittekind C., 2002, TNM Klassifikation maligner Tumoren
   Yan PS, 2001, CANCER RES, V61, P8375
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Zinovieva RD, 1996, GENOMICS, V35, P517, DOI 10.1006/geno.1996.0392
NR 28
TC 59
Z9 70
U1 0
U2 5
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 1
PY 2007
VL 121
IS 3
BP 547
EP 554
DI 10.1002/ijc.22705
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 180ZV
UT WOS:000247407400011
PM 17415710
OA Bronze
DA 2025-01-12
ER

PT J
AU Rivenbark, AG
   Coleman, WB
AF Rivenbark, Ashley G.
   Coleman, William B.
TI Dissecting the molecular mechanisms of cancer through
   bioinformatics-based experimental approaches
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE microarray; bioinformatics; genomics; cancer genetics
ID COMPARATIVE GENOMIC HYBRIDIZATION; PRIMARY BREAST-CANCER; COPY NUMBER;
   ARRAY-CGH; PREDICT SURVIVAL; CDNA MICROARRAYS; GASTRIC-CANCER; GENE;
   EXPRESSION; CLASSIFICATION
AB Cancer is a disease of aberrant gene expression characterized by inappropriate (temporal or quantitative) expression of positive mediators of cell proliferation in conjunction with diminished expression of negative mediators of cell growth. Alteration of the normal balance of these positive and negative mediators leads to the abnormal growth of cells and tissues that typify neoplastic disease. Development of a better understanding of the genetic and epigenetic mechanisms that induce neoplastic transformation and drive the cancer phenotype is essential for continued progress towards the design of practical molecular diagnostics and effective treatment strategies. Over the past decades, molecular techniques that facilitate the assessment of gene expression, identification of gene mutations, and characterization of chromosome abnormalities (numeric and structural) have been established and applied to cancer research. However, many of these techniques are slow and labor-intensive. More recently, high-throughput technologies have emerged that generate large volumes of data related to the genetics and epigenetics of cancer (or other disorders). These advances in molecular genetic technology required the development of sophisticated bioinformatic tools to manage the large datasets generated. The combination of high-throughput molecular assays and bioinformatic-based data mining strategies has significantly impacted our understanding of the molecular pathogenesis of cancer, classification of tumors, and now the management of cancer patients in the clinic. This article will review basic molecular techniques and bioinformatic-based experimental approaches used to dissect the molecular mechanisms of carcinogenesis. J. Cell. Biochem. 101: 1074-1086, 2007. (C) 2007 Wiley-Liss, Inc.
C1 Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr,Curriculum Toxicol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP Coleman, WB (通讯作者)，Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr,Curriculum Toxicol, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM william.coleman@pathology.unc.edu
FU NCI NIH HHS [CA78343] Funding Source: Medline
CR Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   AMISS T, 2006, MOL DIAGNOSTICS CLIN, P31
   Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029
   Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304
   BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113
   Bosserhoff AK, 2000, COMB CHEM HIGH T SCR, V3, P455
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Choi YW, 2007, LUNG CANCER, V55, P43, DOI 10.1016/j.lungcan.2006.09.018
   Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038
   Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   FISHMAN E, 1993, J CLIN EXP NEUROPSYC, V15, P71
   Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048
   Gao F, 2006, CANCER INVEST, V24, P689, DOI 10.1080/07357900600981406
   Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367
   Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664
   Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598
   Hayashi K, 1992, Hum Cell, V5, P180
   HIGHSMITH EW, 2006, MOL DIAGNOSTICS CLIN, P85
   Hippo Y, 2002, CANCER RES, V62, P233
   Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431
   HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208
   IE MS, 2005, CURR OPIN ONCOL, V17, P33
   Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307
   Jain AN, 2001, P NATL ACAD SCI USA, V98, P7952, DOI 10.1073/pnas.151241198
   KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641
   Kleivi K, 2004, CANCER GENET CYTOGEN, V155, P119, DOI 10.1016/j.cancergencyto.2004.03.014
   LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393
   Lonning PE, 2001, ENDOCR-RELAT CANCER, V8, P259, DOI 10.1677/erc.0.0080259
   Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003
   Medvedovic M, 2006, MOLECULAR CARCINOGENESIS AND THE MOLECULAR BIOLOGY OF HUMAN CANCER, P243
   MITELMAN F, 1986, HEREDITAS, V104, P113, DOI 10.1111/j.1601-5223.1986.tb00524.x
   Mohr S, 2002, J CLIN ONCOL, V20, P3165, DOI 10.1200/JCO.2002.12.073
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   NEGRINI M, 1994, CANCER RES, V54, P1331
   NOWELL PC, 1960, SCIENCE, V132, P1497
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   Pusztai L, 2003, ONCOLOGIST, V8, P252, DOI 10.1634/theoncologist.8-3-252
   Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398
   Reid LH, 1996, CANCER RES, V56, P1214
   RICKETTS SL, 2006, MOL DIAGNOSTICS CLIN, P57
   Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914
   ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0
   Russo G, 2003, ONCOGENE, V22, P6497, DOI 10.1038/sj.onc.1206865
   Saramäki OR, 2006, INT J CANCER, V119, P1322, DOI 10.1002/ijc.21976
   Schwaenen C, 2004, P NATL ACAD SCI USA, V101, P1039, DOI 10.1073/pnas.0304717101
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Segal E, 2005, NAT GENET, V37, pS38, DOI 10.1038/ng1561
   Selzer RR, 2005, GENE CHROMOSOME CANC, V44, P305, DOI 10.1002/gcc.20243
   Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   SUMNER AT, 1971, NATURE-NEW BIOL, V232, P31, DOI 10.1038/newbio232031a0
   SUNDAY ME, 1995, AM J PHYSIOL-LUNG C, V269, pL273, DOI 10.1152/ajplung.1995.269.3.L273
   Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998
   TASHIRO F, 1986, BIOCHEM BIOPH RES CO, V138, P858, DOI 10.1016/S0006-291X(86)80575-7
   TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x
   Teuffel O, 2004, LEUKEMIA, V18, P1624, DOI 10.1038/sj.leu.2403462
   Torregrosa D, 1997, CLIN CHIM ACTA, V262, P99, DOI 10.1016/S0009-8981(97)06542-X
   Travis LB, 2006, JNCI-J NATL CANCER I, V98, P15, DOI 10.1093/jnci/djj001
   van Beers EH, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1510
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Veltman JA, 2003, CANCER RES, V63, P2872
   VOLLENWEIDERZERARGUI L, 1986, CANCER-AM CANCER SOC, V57, P1171, DOI 10.1002/1097-0142(19860315)57:6<1171::AID-CNCR2820570618>3.0.CO;2-X
   Wang JB, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-74
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350
   Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6
   Yim SC, 2005, ANAL BIOCHEM, V337, P332, DOI 10.1016/j.ab.2004.11.034
   Zhao HJ, 2006, PLOS MED, V3, P115, DOI 10.1371/journal.pmed.0030013
   Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613
NR 79
TC 8
Z9 8
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 1
PY 2007
VL 101
IS 5
BP 1074
EP 1086
DI 10.1002/jcb.21283
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 199KD
UT WOS:000248693800003
PM 17372928
OA Bronze
DA 2025-01-12
ER

PT J
AU Kuznetsova, EB
   Kekeeva, TV
   Larin, SS
   Zemlyakova, VV
   Babenko, OV
   Nemtsova, MV
   Zaletayev, DV
   Strelnikov, VV
AF Kuznetsova, E. B.
   Kekeeva, T. V.
   Larin, S. S.
   Zemlyakova, V. V.
   Babenko, O. V.
   Nemtsova, M. V.
   Zaletayev, D. V.
   Strelnikov, V. V.
TI Novel markers of gene methylation and expression in breast cancer
SO MOLECULAR BIOLOGY
LA English
DT Article
DE epigenetic regulation of gene expression; breast cancer;
   methylation-sensitive restriction fingerprinting; molecular markers of
   gene methylation and expression
ID TUMOR-SUPPRESSOR GENE; DNA METHYLATION; 14-3-3 SIGMA; HYPERMETHYLATION;
   PROMOTER; INACTIVATION; CELLS; WOMEN; RISK; BIN1
AB An optimized methylation-sensitive restriction fingerprinting technique was used to search for differentially methylated CpG islands in the tumor genome and detected seven genes subject to abnormal epigenetic regulation in breast cancer: SEMA6B, BIN1, VCPIP1, LAMC3, KCNH2, CACNG4, and PSMF1. For each gene, the rate of promoter methylation and changes in expression were estimated in tumor and morphologically intact paired specimens of breast tissue (N = 100). Significant methylation rates of 38, 18, and 8% were found for SEMA6B, BIN1, and LAMC3, respectively. The genes were not methylated in morphologically intact breast tissue. The expression of SEMA6B, BIN1, VCPIP1, LAMC3, KCNH2, CACNG4, and PSMF1 was decreased in 44-94% of tumor specimens by the real-time RT-PCR assay. The most profound changes in SEMA6B and LAMC3 suggest that these genes can be included in biomarker panels for breast cancer diagnosis. Fine methylation mapping of the most frequently methylated CpG islands (SEMA6B, BIN1, and LAMC3) provides a fundamental basis for developing efficient methylation tests for these genes.
C1 Russian Acad Med Sci, Med Genet Res Ctr, Moscow 115478, Russia.
   Sechenov Moscow Med Acad, Inst Mol Med, Minist Hlth & Social Dev Russian Federat, Moscow 119991, Russia.
   Russian Acad Sci, Inst Gene Biol, Moscow 119334, Russia.
C3 Research Centre for Medical Genetics; Russian Academy of Medical
   Sciences; Sechenov First Moscow State Medical University; Ministry of
   Health of the Russian Federation; Russian Academy of Sciences; Institute
   of Gene Biology (IGB) of Russian Academy of Sciences
RP Kuznetsova, EB (通讯作者)，Russian Acad Med Sci, Med Genet Res Ctr, Moscow 115478, Russia.
EM vstrel@list.ru
RI Kuznetsova, Ekaterina/D-1671-2012; Nemtsova, Marina/D-2156-2012;
   Strelnikov, Vladimir/D-1576-2012; Babenko, Olga/D-1652-2012; Zemlyakova,
   Valeria/D-1674-2012; Larin, Sergey/J-6601-2013; Zaletaev,
   Dmitri/E-5331-2010; Kekeeva, Tatiana/D-1647-2012
OI Zaletaev, Dmitri/0000-0002-9323-2673; Strelnikov,
   Vladimir/0000-0001-9283-902X; Kuznetsova, Ekaterina/0000-0001-5825-0430;
   Marina, Nemtsova/0000-0002-2835-5992
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   [Anonymous], 1989, Molecular Cloning, A Laboratory Manual
   Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Clément G, 2004, CANCER RES, V64, P6867, DOI 10.1158/0008-5472.CAN-03-2503
   Dahl C, 2003, BIOGERONTOLOGY, V4, P233, DOI 10.1023/A:1025103319328
   de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225
   Deng Wen-Hui, 2004, Ai Zheng, V23, P1302
   Du Y, 2001, CANCER RES, V61, P8094
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Ge K, 2000, INT J CANCER, V85, P376
   Gonzalgo ML, 1997, CANCER RES, V57, P594
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Melki JR, 1999, CANCER RES, V59, P3730
   Moreau C, 2005, J THERM SPRAY TECHN, V14, P3, DOI 10.1361/10599630522783
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pichert G, 2003, ANN ONCOL, V14, P9, DOI 10.1093/annonc/mdg030
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   Rood BR, 2002, CANCER RES, V62, P3794
   Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Strelnikov VV, 1999, MOL BIOL+, V33, P288
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zemlyakova V. V., 2003, Molekulyarnaya Biologiya (Moscow), V37, P696
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 29
TC 24
Z9 35
U1 1
U2 9
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
EI 1608-3245
J9 MOL BIOL+
JI Mol. Biol.
PD AUG
PY 2007
VL 41
IS 4
BP 562
EP 570
DI 10.1134/S0026893307040061
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 207PS
UT WOS:000249263700006
PM 17936981
DA 2025-01-12
ER

PT J
AU Dahl, E
   Wiesmann, F
   Woenckhaus, M
   Stoehr, R
   Wild, PJ
   Veeck, J
   Knuechell, R
   Klopocki, E
   Sauter, G
   Simon, R
   Wieland, WF
   Walter, B
   Denzinger, S
   Hartmann, A
   Hammerschmied, CG
AF Dahl, E.
   Wiesmann, F.
   Woenckhaus, M.
   Stoehr, R.
   Wild, P. J.
   Veeck, J.
   Knuechell, R.
   Klopocki, E.
   Sauter, G.
   Simon, R.
   Wieland, W. F.
   Walter, B.
   Denzinger, S.
   Hartmann, A.
   Hammerschmied, C. G.
TI Frequent loss of SFRP1 expression in multiple human solid tumours:
   association with aberrant promoter methylation in renal cell carcinoma
SO ONCOGENE
LA English
DT Article
DE loss of SFRP1 in human tumours; renal cell carcinoma; tumour suppressor
   gene; Wnt pathway; SFRP1 methylation; tissue microarray
ID WNT ANTAGONIST SFRP1; BETA-CATENIN; EPIGENETIC INACTIVATION;
   BREAST-CANCER; GENES; TARGET; IDENTIFICATION; NONPAPILLARY; PROGRESSION;
   SUPPRESSOR
AB Oncogenic wingless-related mouse mammary tumour virus (Wnt) signalling, caused by epigenetic inactivation of specific pathway regulators like the putative tumour suppressor secreted frizzled-related protein 1 (SFRP1), may be causally involved in the carcinogenesis of many human solid tumours including breast, colon and kidney cancer. To evaluate the incidence of SFRP1 deficiency in human tumours, we performed a large-scale SFRP1 expression analysis using immunohistochemistry on a comprehensive tissue microarray (TMA) comprising 3448 tumours from 36 organs. This TMA contained 132 different tumour subtypes as well as 26 different normal tissues. Although tumour precursor stages of, for example kidney, colon, endometrium or adrenal gland still exhibited moderate to abundant SFRP1 expression, this expression was frequently lost in the corresponding genuine tumours. We defined nine novel tumour entities with apparent loss of SFRP1 expression, i.e., cancers of the kidney, stomach, small intestine, pancreas, parathyroid, adrenal gland, gall bladder, endometrium and testis. Renal cell carcinoma (RCC) exhibited the highest frequency of SFRP1 loss (89% on mRNA level; 75% on protein level) and was selected for further analysis to investigate the cause of SFRP1 loss in human tumours. We performed expression, mutation and methylation analysis in RCC and their matching normal kidney tissues. SFRP1 promoter methylation was frequently found in RCC (68%, n=38) and was correlated with loss of SFRP1 mRNA expression ( p < 0.05). Although loss of heterozygosity was found in 16% of RCC, structural mutations in the coding or promoter region of the SFRP1 gene were not observed. Our results indicate that loss of SFRP1 expression is a very common event in human cancer, arguing for a fundamental role of aberrant Wnt signalling in the development of solid tumours. In RCC, promoter hypermethylation seems to be the predominant mechanism of SFRP1 gene silencing and may contribute to initiation and progression of this disease.
C1 Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany.
   Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany.
   Univ Regensburg, Dept Urol, D-8400 Regensburg, Germany.
   Univ Zurich, Inst Pathol, Zurich, Switzerland.
   Univ Med Berlin, Charite, Inst Med Genet, Berlin, Germany.
   Univ Hamburg Hosp, Inst Pathol, D-2000 Hamburg, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Regensburg; University of Regensburg; University of Zurich; Berlin
   Institute of Health; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; University of Hamburg;
   University Medical Center Hamburg-Eppendorf
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Stoehr, Robert/D-7504-2011; Veeck, Jurgen/B-9256-2008; Klopocki,
   Eva/B-6823-2017
OI Veeck, Jurgen/0000-0002-2952-6159; Klopocki, Eva/0000-0003-1438-2081
CR Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bohm M, 1997, UROL RES, V25, P161
   Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hoei-Hansen CE, 2004, MOL HUM REPROD, V10, P423, DOI 10.1093/molehr/gah059
   HUGHSON MD, 1993, MODERN PATHOL, V6, P449
   Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098
   Kim YS, 2000, PATHOL INT, V50, P725, DOI 10.1046/j.1440-1827.2000.01111.x
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Li CH, 2006, J DENT RES, V85, P374, DOI 10.1177/154405910608500418
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   MANCILLAJIMENEZ R, 1976, CANCER-AM CANCER SOC, V38, P2469, DOI 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R
   Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   ORTMANN M, 1991, VIRCHOWS ARCH B, V61, P123
   Presti JC, 2002, J UROLOGY, V167, P1464, DOI 10.1016/S0022-5347(05)65346-3
   Reutzel D, 2001, CYTOGENET CELL GENET, V93, P221, DOI 10.1159/000056987
   SCHLEGEL J, 1995, VIRCHOWS ARCH, V426, P223
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   STORKEL S, 1989, VIRCHOWS ARCH B, V56, P237
   Suzuki H, 1997, ONCOLOGY-BASEL, V54, P252
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120
   Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863
   Vainio SJ, 1999, INT J DEV BIOL, V43, P419
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Watanabe H, 2006, PANCREAS, V32, P382, DOI 10.1097/01.mpa.0000221617.89376.38
   Zafrakas M, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-88
   ZANG T, 2000, CHINESE SCI BULL, V45, P1703
   Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268
NR 42
TC 118
Z9 132
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG
PY 2007
VL 26
IS 38
BP 5680
EP 5691
DI 10.1038/sj.onc.1210345
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 200ZS
UT WOS:000248801900015
PM 17353908
DA 2025-01-12
ER

PT J
AU Jin, HC
   Wang, X
   Ying, JM
   Wong, AHY
   Cui, Y
   Srivastava, G
   Shen, ZY
   Li, EM
   Zhang, Q
   Jin, J
   Kupzig, S
   Chan, ATC
   Cullen, PJ
   Tao, Q
AF Jin, Hongchuan
   Wang, Xian
   Ying, Jianming
   Wong, Ada H. Y.
   Cui, Yan
   Srivastava, Gopesh
   Shen, Zhong-Ying
   Li, En-Min
   Zhang, Qian
   Jin, Jie
   Kupzig, Sabine
   Chan, Anthony T. C.
   Cullen, Peter J.
   Tao, Qian
TI Epigenetic silencing of a Ca<SUP>2+</SUP>-regulated Ras
   GTPase-activating protein RASAL defines a new mechanism of Ras
   activation in human cancers
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE calcium; Ras GTPase-activating-like protein; tumorigenesis
ID ABERRANT PROMOTER METHYLATION; CANDIDATE TUMOR-SUPPRESSOR; SQUAMOUS-CELL
   CARCINOMA; STRESS-RESPONSIVE GENE; PROSTATE-CANCER; HDAB2IP GENE; GAP1
   FAMILY; NASOPHARYNGEAL CARCINOMA; EXPRESSION PROFILE; BREAST-CANCER
AB Ras has achieved notoriety as an oncogene aberrantly activated in multiple human tumors. Approximately 30% of all human tumors express an oncogenic form of this GTPase that is locked in an active conformation as a result of being insensitive to Ras GTPaseactivating proteins (GAPs), proteins that normally regulate the inactivation of Ras by enhancing its intrinsic GTPase activity. Besides oncogenic mutations in Ras, signaling by wild-type Ras is also frequently deregulated in tumors through aberrant coupling to activated cell surface receptors. This indicates that alternative mechanisms of aberrant wild-type Ras activation may be involved in tumorigenesis. Here, we describe another mechanism through which aberrant Ras activation is achieved in human cancers. We have established that Ras GTPase-activating-like protein (RASAL), a Ca2+-regulated Ras GAP that decodes the frequency of Ca2+ oscillations, is silenced through CpG methylation in multiple tumors. With the finding that ectopic expression of catalytically active RASAL leads to growth inhibition of these tumor cells by Ras inactivation, we have provided evidence that epigenetically silencing of this Ras GAP represents a mechanism of aberrant Ras activation in certain cancers. Our demonstration that RASAL constitutes a tumor suppressor gene has therefore further emphasized the importance of Ca2+ in the regulation of Ras signaling and has established that deregulation of this pathway is an important step in Ras-mediated tumorigenesis.
C1 Univ Bristol, Henry Wellcome Integrated Signalling Labs, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England.
   Chinese Univ Hong Kong, Canc Epigenet Lab, State Key Lab Oncol S China,Hong Kong Canc Inst, Sir YK Pao Ctr Canc,Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Si, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Shantou Univ, Coll Med, Chinese Univ Hong Kong, Joint Epigenet Grp, Shantou 515041, Peoples R China.
   Peking Univ First Hosp, Dept Urol, Beijing, Peoples R China.
   Inst Urol, Beijing 100034, Peoples R China.
C3 University of Bristol; Chinese University of Hong Kong; Chinese
   University of Hong Kong; University of Hong Kong; Shantou University;
   Peking University
RP Cullen, PJ (通讯作者)，Univ Bristol, Henry Wellcome Integrated Signalling Labs, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England.
EM pete.cullen@bris.ac.uk; qtao@clo.cuhk.edu.hk
RI Yu, Shi-Tong/H-3747-2018; Jin, Hongchuan/C-3686-2009; Wong,
   Ada/LVS-1910-2024; Li, Yuqing/AAR-9383-2021; Chan, Anthony Tak
   Cheung/R-3940-2018; Tao, Qian/T-4743-2018
OI Chan, Anthony Tak Cheung/0000-0002-6912-8091; Cullen,
   Peter/0000-0002-9070-8349; Tao, Qian/0000-0001-5383-4808; Jin,
   Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Allen M, 1998, GENE, V218, P17, DOI 10.1016/S0378-1119(98)00394-1
   BALK SD, 1973, P NATL ACAD SCI USA, V70, P675, DOI 10.1073/pnas.70.3.675
   Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480
   Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003
   Boon LM, 2005, CURR OPIN GENET DEV, V15, P265, DOI 10.1016/j.gde.2005.03.004
   BOYNTON AL, 1976, P NATL ACAD SCI USA, V73, P1651, DOI 10.1073/pnas.73.5.1651
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200
   Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014
   Cozier GE, 2000, J BIOL CHEM, V275, P28261
   Cullen PJ, 2006, CURR OPIN CELL BIOL, V18, P157, DOI 10.1016/j.ceb.2006.02.012
   CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0
   Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808
   Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1
   Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5
   Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236
   Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620
   Fivaz M, 2005, J CELL BIOL, V170, P429, DOI 10.1083/jcb.200409157
   FRIEDMAN E, 1993, NAT GENET, V5, P242, DOI 10.1038/ng1193-242
   Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144
   Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743
   Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105
   Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856
   Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017
   Kratz CP, 2001, GENOMICS, V77, P171, DOI 10.1006/geno.2001.6636
   Kupzig S, 2006, J BIOL CHEM, V281, P9891, DOI 10.1074/jbc.M512802200
   Kupzig S, 2005, P NATL ACAD SCI USA, V102, P7577, DOI 10.1073/pnas.0409611102
   Liu Q, 2005, J CELL BIOL, V170, P183, DOI 10.1083/jcb.200504167
   Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4
   Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X
   Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5
   MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879
   Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003
   Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373
   Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026
   Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X
   Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197
   Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200
   WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386
   Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Yarwood S, 2006, BIOCHEM SOC T, V34, P846, DOI 10.1042/BST0340846
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217
NR 56
TC 104
Z9 125
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 24
PY 2007
VL 104
IS 30
BP 12353
EP 12358
DI 10.1073/pnas.0700153104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 196HK
UT WOS:000248472100023
PM 17640920
OA Green Published
DA 2025-01-12
ER

PT J
AU Basu, I
   Cordovano, G
   Das, I
   Belbin, TJ
   Guha, C
   Schramm, VL
AF Basu, Indranil
   Cordovano, Grace
   Das, Ishita
   Belbin, Thomas J.
   Guha, Chandan
   Schramm, Vern L.
TI A transition state analogue of 5'-methylthioadenosine phosphorylase
   induces apoptosis in head and neck cancers
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PURINE NUCLEOSIDE PHOSPHORYLASE; METHYLTHIOADENOSINE PHOSPHORYLASE;
   5'-METHYLTHIOADENOSINE/S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASE; HOMOZYGOUS
   DELETIONS; POLYAMINE ANALOGS; ESCHERICHIA-COLI; TUMOR-SUPPRESSOR;
   INHIBITORS; 5'-METHYLTHIOADENOSINE; DECARBOXYLASE
AB Methylthio-DADMe-immucillin-A (MT-DADMe-ImmA) is an 86-pM inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP). The sole function of MTAP is to recycle 5'-methylthioadenosine (MTA) to S-adenosylmethionine. Treatment of cultured cells with MT-DADMe-ImmA and MTA inhibited MTAP, increased cellular MTA concentrations, decreased polyamines, and induced apoptosis in FaDu and Cal27, two head and neck squamous cell carcinoma cell lines. The same treatment did not induce apoptosis in normal human fibroblast cell lines (CRL2522 and GM02037) or in MCF7, a breast cancer cell line with an MTAP gene deletion. MT-DADMe-ImmA alone did not induce apoptosis in any cell line, implicating MTA as the active agent. Treatment of sensitive cells caused loss of mitochondrial inner membrane potential, G(2)/M arrest, activation of mitochondria-dependent caspases, and apoptosis. Changes in cellular polyamines and MTA levels occurred in both responsive and nonresponsive cells, suggesting cell-specific epigenetic effects. A survey of aberrant DNA methylation in genomic DNA using a microarray of 12,288 CpG island clones revealed decreased CpG island methylation in treated FaDu cells compared with untreated cells. FaDu tumors in a mouse xenograft model were treated with MT-DADMe-ImmA, resulting in tumor remission. The selective action of MT-DADMe-ImmA on head and neck squamous cell carcinoma cells suggests potential as an agent for treatment of cancers sensitive to reduced CpG island methylation.
C1 Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA.
   Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.
   Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA.
C3 Yeshiva University; Montefiore Medical Center; Albert Einstein College
   of Medicine; Montefiore Medical Center; Albert Einstein College of
   Medicine; Yeshiva University; Montefiore Medical Center; Albert Einstein
   College of Medicine; Yeshiva University
RP Schramm, VL (通讯作者)，Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM vern@aecom.yu.edu
RI ; Belbin, Thomas/JFK-5670-2023
OI Guha, Chandan/0000-0002-1906-2186; Belbin, Thomas/0000-0001-6867-654X
FU NCI NIH HHS [P30 CA013330, CA85953] Funding Source: Medline; NIGMS NIH
   HHS [GM41916] Funding Source: Medline
CR Adrien LR, 2006, CYTOGENET GENOME RES, V114, P16, DOI 10.1159/000091923
   CARTENIFARINA M, 1984, BIOCHIM BIOPHYS ACTA, V805, P158, DOI 10.1016/0167-4889(84)90163-0
   Casero RA, 2005, P W PHARMACOL SOC, V48, P24
   Chattopadhyay S, 2006, MOL CANCER THER, V5, P2549, DOI 10.1158/1535-7163.MCT-06-0313
   Chen ZH, 1996, CANCER RES, V56, P1083
   Chow WA, 2006, CANCER GENET CYTOGEN, V166, P95, DOI 10.1016/j.cancergencyto.2005.10.009
   Christopher SA, 2002, CANCER RES, V62, P6639
   Evans GB, 2005, J MED CHEM, V48, P4679, DOI 10.1021/jm050269z
   FISCHER D, 1976, J CLIN INVEST, V58, P399, DOI 10.1172/JCI108484
   Gaboriau F, 2002, J PHARMACOL TOXICOL, V47, P33, DOI 10.1016/S1056-8719(02)00187-9
   Gandhi V, 2005, BLOOD, V106, P4253, DOI 10.1182/blood-2005-03-1309
   Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454
   Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23
   Karikari CA, 2005, MOL CANCER THER, V4, P1860, DOI 10.1158/1535-7163.MCT-05-0103
   KIM MS, 1993, ANTICANCER RES, V13, P1405
   KLINE PC, 1992, BIOCHEMISTRY-US, V31, P5964, DOI 10.1021/bi00141a003
   KLINE PC, 1995, BIOCHEMISTRY-US, V34, P1153, DOI 10.1021/bi00004a008
   KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033
   MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415
   Meyskens FL, 1999, CLIN CANCER RES, V5, P945
   MITCHELL BS, 1980, ANN INTERN MED, V92, P826, DOI 10.7326/0003-4819-92-6-826
   PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6
   PEGG AE, 1983, METHOD ENZYMOL, V94, P239
   PEGG AE, 1981, BIOCHEM J, V194, P79, DOI 10.1042/bj1940079
   Rinaldo-Matthis A, 2007, BIOCHEMISTRY-US, V46, P659, DOI 10.1021/bi061515r
   Ringia EAT, 2005, CURR TOP MED CHEM, V5, P1237, DOI 10.2174/156802605774463088
   Sauve AA, 2005, MOL CELL, V17, P595, DOI 10.1016/j.molcel.2004.12.032
   Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205
   Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035
   Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876
   Singh V, 2005, BIOCHEMISTRY-US, V44, P11647, DOI 10.1021/bi050863a
   Singh V, 2005, J BIOL CHEM, V280, P18265, DOI 10.1074/jbc.M414472200
   Singh V, 2004, BIOCHEMISTRY-US, V43, P9, DOI 10.1021/bi0358420
   Singh V, 2006, J AM CHEM SOC, V128, P14691, DOI 10.1021/ja065419p
   Subhi AL, 2004, CLIN CANCER RES, V10, P7290, DOI 10.1158/1078-0432.CCR-04-0972
   Wallace HM, 2003, BIOCHEM SOC T, V31, P393, DOI 10.1042/BST0310393
   Wallace HM, 1996, P NUTR SOC, V55, P419, DOI 10.1079/PNS19960039
   Wang XT, 2004, CANCER RES, V64, P1377, DOI 10.1158/0008-5472.CAN-03-2428
   WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X
   WOLFORD RW, 1981, CANCER RES, V41, P3035
NR 40
TC 65
Z9 80
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 20
PY 2007
VL 282
IS 29
BP 21477
EP 21486
DI 10.1074/jbc.M702287200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 190GP
UT WOS:000248047500075
PM 17548352
OA hybrid
DA 2025-01-12
ER

PT J
AU Smith, P
   Nicholson, LJ
   Syed, N
   Payne, A
   Hiller, L
   Garrone, O
   Occelli, M
   Gasco, M
   Crook, T
AF Smith, Paul
   Nicholson, Linda J.
   Syed, Nelofer
   Payne, Annette
   Hiller, Louise
   Garrone, Ornella
   Occelli, Marcella
   Gasco, Milena
   Crook, Tim
TI Epigenetic inactivation implies independent functions for insulin-like
   growth factor binding protein (IGFBP) - Related protein 1 and the
   related IGFBPL1 in inhibiting breast cancer phenotypes
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CELLS; EXPRESSION; GENE; IDENTIFICATION; CARCINOMAS; SIGNATURE; MAC25
AB Purpose: To analyze epigenetic regulation of two related genes, insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) and IGFBPL1, and its significance as a determinant of clinical phenotypes in human breast cancer.
   Experimental Design: We have investigated the expression and epigenetic regulation of IGFBP-rP1 and IGFBPL1 in human breast cancer cell lines and primary and metastatic carcinomas.
   Results: Expression of IGFBP-rP1 and IGFBPL1 is down-regulated in breast cancer cell lines. Aberrant methylation in the CpG islands of each gene correlates well with loss of expression at the mRNA level. Analysis of methylation in DNA isolated from human primary breast tumors showed that methylation in either gene was associated with a worse overall survival (OS; P = 0.008) and disease-free survival (DFS) following surgery (P = 0.04) and worse DFS following adjuvant chemotherapy (P = 0.01). Methylation of IGFBP-rP1 alone was associated with a trend toward decreased OS (P = 0.10) and decreased DFS (P = 0.25). Methylation in IGFBPL1 was clearly associated with worse OS (P = 0.001) and DFS (P < 0.0001). Methylation in either IGFBP-rP1 or IGFBPL1 was significantly associated with nodal disease (P < 0.001).
   Conclusions: Expression of IGFBP-rP1 and IGFBPL1 is regulated by aberrant hypermethylation in breast cancer, implying that inactivation of these genes is involved in the pathogenesis of this malignancy. Analysis of methylation of these genes may have utility in prediction of clinical phenotypes, such as nodal disease and response to chemotherapy.
C1 Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, Chester Beatty Labs, London SW3 6JB, England.
   Kings Coll London, Sch Med, St Thomas Hosp, Rayne Inst,Dept Oncol, London SE1 7EH, England.
   Brunel Univ, Sch Informat Syst Comp & Maths, Uxbridge UB8 3PH, Middx, England.
   Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England.
   Osped Santa Croce & Carle, Dept Med Oncol, Cuneo, Italy.
C3 Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK; University of London; King's College London; Guy's
   & St Thomas' NHS Foundation Trust; Brunel University; University of
   Warwick
RP Crook, T (通讯作者)，Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, Chester Beatty Labs, Mary Jean Mitchell Green Bldg,237 Fulham Rd, London SW3 6JB, England.
EM tim.crook@icr.ac.uk
RI Garrone, Ornella/HHS-9402-2022; Payne, Annette/F-8877-2013
OI Hiller, Louise/0000-0001-8538-9163; Garrone,
   Ornella/0000-0001-7359-5410; Payne, Annette/0000-0002-2009-0141
FU Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source:
   Medline
CR AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149
   Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384
   Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023
   Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772
   Cai Z, 2005, BIOCHEM BIOPH RES CO, V331, P261, DOI 10.1016/j.bbrc.2005.03.163
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   COX DR, 1972, J R STAT SOC B, V34, P187
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937
   Kreike B, 2006, CLIN CANCER RES, V12, P5705, DOI 10.1158/1078-0432.CCR-06-0805
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715
   Nicholson LJ, 2005, MOL THER, V11, P638, DOI 10.1016/j.ymthe.2004.12.010
   OH YM, 1993, J BIOL CHEM, V268, P14964
   Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472
   YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591
NR 18
TC 32
Z9 33
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2007
VL 13
IS 14
BP 4061
EP 4068
DI 10.1158/1078-0432.CCR-06-3052
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 191DO
UT WOS:000248110500006
PM 17634530
DA 2025-01-12
ER

PT J
AU Huang, J
   Zhang, YL
   Teng, XM
   Lin, Y
   Zheng, DL
   Yang, PY
   Han, ZG
AF Huang, Jian
   Zhang, Yun-Li
   Teng, Xiao-Mei
   Lin, Yun
   Zheng, Da-Li
   Yang, Peng-Yuan
   Han, Ze-Guang
TI Down-regulation of SFRP1 as a putative tumor suppressor gene can
   contribute to human hepatocellular carcinoma
SO BMC CANCER
LA English
DT Article
ID FRIZZLED-RELATED PROTEIN-1; WNT ANTAGONIST SFRP1; BETA-CATENIN;
   BREAST-CANCER; PROMOTER HYPERMETHYLATION; PROSTATE-CANCER; EXPRESSION;
   METHYLATION; PATHWAY; GROWTH
AB Background: Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. SFRP1 (the secreted frizzled-related protein 1), a putative tumor suppressor gene mapped onto chromosome 8p12-p11.1, the frequent loss of heterozygosity (LOH) region in human HCC, encodes a Wingless-type (Wnt) signaling antagonist and is frequently inactivated by promoter methylation in many human cancers. However, whether the down-regulation of SFRP1 can contribute to hepatocarcinogenesis still remains unclear.
   Methods: We investigated the expression of SFRP1 through real time RT-PCR and immunohistochemistry staining. The cell growth and colony formation were observed as the overexpression and knockdown of SFRP1. The DNA methylation status within SFRP1 promoter was analyzed through methylation-specific PCR or bisulphate-treated DNA sequencing assays. Loss of heterozygosity was here detected with microsatellite markers.
   Results: SFRP1 was significantly down-regulated in 76.1% (35/46) HCC specimens at mRNA level and in 30% (30/100) HCCs indicated by immunohistochemistry staining, as compared to adjacent non-cancerous livers. The overexpression of SFRP1 can significantly inhibit the cell growth and colony formation of YY-8103, SMMC7721, and Hep3B cells. The RNA interference against the constitutional SFRP1 in the offspring SMMC7721 cells, which were stably transfected by ectopic SFRP1, can markedly promote cell growth of these cells. LOH of both microsatellite markers D8S532 and D8SAC016868 flanking the gene locus was found in 13% (6 of 46 HCCs) and 6.5% (3 of 46 HCCs) of the informative cases, respectively, where 5 of 8 HCC specimens with LOH showed the down-regulation of SFRP1. DNA hypermethylation within SFRP1 promoter was identified in two of three HCC specimens without SFRP1 expression. Moreover, the DNA methylation of SFRP1 promoter was significantly reduced, along with the re-expression of the gene, in those HCC cell lines, Bel7404, QGY7701, and MHCC-H, as treated by DAC.
   Conclusion: Our data suggested that the down-regulation of SFRP1 as a candidate tumor suppressor gene, triggered by the epigenetic and/or genetic events, could contribute to the oncogenesis of HCC.
C1 Fudan Univ, Shanghai Minist Key Lab Dis & Hlth Genom, Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China.
   Fudan Univ, Dept Chem, Shanghai 201203, Peoples R China.
   Jiao Tong Univ, Rui Jin Hosp, Shanghai 200025, Peoples R China.
   Taishan Med Coll, Dept Biochem, Shandong 271000, Peoples R China.
C3 Fudan University; Fudan University; Shanghai Jiao Tong University;
   Shandong First Medical University & Shandong Academy of Medical Sciences
RP Han, ZG (通讯作者)，Fudan Univ, Shanghai Minist Key Lab Dis & Hlth Genom, Chinese Natl Human Genome Ctr Shanghai, 351 Guo Shou Jing Rd, Shanghai 201203, Peoples R China.
EM huangj@chgc.sh.cn; ssmuzhang@hotmail.com; tengxm@chgc.sh.cn;
   liny@chgc.sh.cn; zhengdl@chgc.sh.cn; yangpy@fudan.edu.cn;
   zghan64@hotmail.com
RI Zheng, Dali/J-2973-2019; Yang, Pengyuan/AAH-1016-2020; Zhu,
   Yuyan/ABE-4176-2021
OI Han, Ze-Guang/0000-0002-1018-1752; Zheng, Dali/0000-0003-2345-4040
CR Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740
   Bejsovec A, 2005, CELL, V120, P11, DOI 10.1016/j.cell.2004.12.021
   Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007
   Buim ME, 2005, ONCOLOGY-BASEL, V69, P445, DOI 10.1159/000090984
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Chang Q, 2005, HUM PATHOL, V36, P1265, DOI 10.1016/j.humpath.2005.09.004
   Cui J, 2003, CHINESE MED J-PEKING, V116, P1885
   Cui J, 2003, J GASTROEN HEPATOL, V18, P280, DOI 10.1046/j.1440-1746.2003.02973.x
   Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Ezan J, 2004, CARDIOVASC RES, V63, P731, DOI 10.1016/j.cardiores.2004.05.006
   Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang J, 2006, FEBS LETT, V580, P3571, DOI 10.1016/j.febslet.2006.05.032
   Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83
   Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824
   Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rodriguez J, 2005, NAT NEUROSCI, V8, P1301, DOI 10.1038/nn1547
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Shih YL, 2006, CANCER, V107, P579, DOI 10.1002/cncr.22023
   Shulewitz M, 2006, ONCOGENE, V25, P4361, DOI 10.1038/sj.onc.1209470
   Steelman CA, 2006, FASEB J, V20, P580, DOI 10.1096/fj.05-5125fje
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Wang JS, 2001, CANCER EPIDEM BIOMAR, V10, P143
   Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398
NR 41
TC 71
Z9 81
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 12
PY 2007
VL 7
AR 126
DI 10.1186/1471-2407-7-126
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 197PC
UT WOS:000248566800001
PM 17626620
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lindsey, JC
   Lusher, ME
   Anderton, JA
   Gilbertson, RJ
   Ellison, DW
   Clifford, SC
AF Lindsey, J. C.
   Lusher, M. E.
   Anderton, J. A.
   Gilbertson, R. J.
   Ellison, D. W.
   Clifford, S. C.
TI Epigenetic deregulation of multiple <i>S100</i> gene family members by
   differential hypomethylation and hypermethylation events in
   medulloblastoma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE medulloblastoma; S100; epigenetics; hypomethylation; hypermethylation
ID CALCIUM-BINDING PROTEINS; TUMOR-SUPPRESSOR GENE; DNA METHYLATION;
   BREAST-CANCER; CPG ISLAND; EXPRESSION; METASTASIS; CALCYCLIN; SURVIVAL;
   IDENTIFICATION
AB Deregulated expression of genes encoding members of the S100 family of calcium-binding proteins has been associated with the malignant progression of multiple tumour types. Using a pharmacological expression reactivation approach, we screened 16 S100 genes for evidence of epigenetic regulation in medulloblastoma, the most common malignant brain tumour of childhood. Four family members (S100A2, S100A4, S100A6 and S100A10) demonstrated evidence of upregulated expression in multiple medulloblastoma cell lines, following treatment with the DNA methyltransferase inhibitor, 5'-aza-2'-deoxycytidine. Subsequent analysis revealed methylation of critical CpG sites located within these four genes in an extended cell line panel. Assessment of these genes in the nonneoplastic cerebellum (from which medulloblastomas develop) revealed strong somatic methylation affecting S100A2 and S100A4, whereas S100A6 and S100A10 were unmethylated. Assessed against these normal tissue-specific methylation states, S100A6 and S100A10 demonstrated tumour-specific hypermethylation in medulloblastoma primary tumours (5 out of 40 and 4 out of 35, respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing. Moreover, S100A6 hypermethylation was significantly associated with the aggressive large cell/anaplastic morphophenotype (P = 0.026). In contrast, pro-metastatic S100A4 displayed evidence of hypomethylation relative to the normal cerebellum in a significant proportion primary tumours (7 out of 41, 17%) and cell lines (3 out of 9, 33%), which was associated with its elevated expression. In summary, these data characterise complex patterns of somatic methylation affecting S100 genes in the normal cerebellum and demonstrate their disruption causing epigenetic deregulation of multiple S100 family members in medulloblastoma development. Epigenetic events affecting S100 genes have potential clinical utility and merit further investigation as molecular biomarkers for this disease.
C1 Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA.
C3 Newcastle University - UK; St Jude Children's Research Hospital
RP Clifford, SC (通讯作者)，Newcastle Univ, Sch Med, No Inst Canc Res, Paul O Gorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM c.clifford@ncl.ac.uk
RI Ellison, David/N-4806-2018; Gilbertson, Richard/ABE-1346-2021
OI Clifford, Steve/0000-0003-4893-2184; Gilbertson,
   Richard/0000-0001-7539-9472
CR Arumugam T, 2005, CLIN CANCER RES, V11, P5356, DOI 10.1158/1078-0432.CCR-05-0092
   Choi KS, 2003, FASEB J, V17, P235, DOI 10.1096/fj.02-0697com
   Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Emberley ED, 2004, BIOCHEM CELL BIOL, V82, P508, DOI 10.1139/O04-052
   Feng G, 2001, CANCER RES, V61, P7999
   FILIPEK A, 1993, NEUROREPORT, V4, P383, DOI 10.1097/00001756-199304000-00010
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200
   Giangaspero F., 2000, Pathology and Genetics of Tumours of the Nervous System, P129
   Heizmann CW, 2005, J PEDIATR-US, V147, P731, DOI 10.1016/j.jpeds.2005.08.046
   Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann
   Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613
   Hernan R, 2003, CANCER RES, V63, P140
   HORIKOSHI T, 1992, CANCER RES, V52, P108
   Huang XL, 2003, GENE, V310, P133, DOI 10.1016/S0378-1119(03)00529-8
   JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117
   Langdon JA, 2006, GENE CHROMOSOME CANC, V45, P47, DOI 10.1002/gcc.20262
   Lesniak W, 2000, ACTA NEUROBIOL EXP, V60, P569, DOI 10.55782/ane-2000-1377
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lindsey Janet C, 2005, Neurosurg Focus, V19, pE10, DOI 10.3171/foc.2005.19.5.11
   Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055
   Lusher ME, 2002, CANCER RES, V62, P5906
   Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096
   McManamy CS, 2003, J NEUROPATH EXP NEUR, V62, P627, DOI 10.1093/jnen/62.6.627
   Nakamura N, 1998, CLIN EXP METASTAS, V16, P471
   Namihira M, 2004, FEBS LETT, V572, P184, DOI 10.1016/j.febslet.2004.07.029
   Pantoja C, 2005, CANCER RES, V65, P26
   Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302
   Rehman I, 2004, BRIT J CANCER, V91, P739, DOI 10.1038/sj.bjc.6602034
   Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7
   Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Strathdee G, 2004, BIOCHEM SOC T, V32, P913, DOI 10.1042/BST0320913
   Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747
   Wang GZ, 2006, CANCER RES, V66, P1199, DOI 10.1158/0008-5472.CAN-05-2605
   Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200
   Zimmer DB, 2005, CELL MOL BIOL, V51, P201, DOI 10.1170/T620
NR 40
TC 52
Z9 61
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUL 10
PY 2007
VL 97
IS 2
BP 267
EP 274
DI 10.1038/sj.bjc.6603852
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 190DY
UT WOS:000248039400017
PM 17579622
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhang, CY
   Mao, L
   Li, L
   Tian, Z
   Zhou, XJ
   Zhang, ZY
   Li, J
AF Zhang, Chun-Ye
   Mao, Li
   Li, Lei
   Tian, Zhen
   Zhou, Xiao-Jian
   Zhang, Zhi-Yuan
   Li, Jiang
TI Promoter methylation as a common mechanism for inactivating
   <i>E-cadherin</i> in human salivary gland adenoid cystic carcinoma
SO CANCER
LA English
DT Article
DE E-cadherin; promoter methylation; salivary gland adenoid cystic
   carcinoma; gene inactivation; carcinogenesis
ID SQUAMOUS-CELL CARCINOMAS; LOBULAR BREAST-CANCER; EPIGENETIC
   INACTIVATION; PROTEIN EXPRESSION; THYROID-CARCINOMA; IN-VIVO; GENE;
   HYPERMETHYLATION; RASSF1A; HEAD
AB BACKGROUND. The role of promoter methylation in the inactivation of E-cadherin (E-cad) in salivary gland adenoid cystic carcinoma (ACC) is unknown. The objective of this study was to determine the role and potential clinical implications of promoter methylation of E-cad in salivary gland ACC.
   METHODS. The promoter methylation status of E-cad was determined by using methylation-specific polymerase chain reaction (PCR) analysis in 60 primary salivary gland ACC tissues and 3 ACC cell lines. The level of E-cad protein expression was determined by immunohistochemical analysis of each tumor. E-cad protein and messenger RNA (mRNA) expression levels were examined by immunohistochemical analysis and reverse transcriptase-PCR in 3 ACC cell lines. Associations between molecular alterations and patients' clinicopathologic characteristics were analyzed statistically. E-cad mRNA expression was examined in a 5-azacytidine-treated ACC-2 cell line.
   RESULTS. Promoter methylation of E-cad was detected in 34 of 60 tumors (57%). Of those 34 tumors, 18 tumors (53%) showed no E-cad protein expression, whereas only 5 of the remaining 26 tumors (19%) without E-cad promoter methylation showed no E-cad protein expression (P =.01). Tumors that had E-cad promoter methylation had a significantly higher histologic grade (P =.01) and more perineural invasion (P =.02) compared with tumors that did not have methylation. All 3 ACC cell lines exhibited E-cad promoter methylation and a lack of E-cad mRNA and protein expression, whereas 5-azacytidine restored E-cad mRNA expression in the ACC-2 cell line.
   CONCLUSIONS. E-cad frequently is inactivated in salivary gland ACC through promoter methylation, and E-cad promoter methylation may play a role in tumor cell differentiation and perineural invasion.
C1 Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Oral Pathol,Coll Stomatol, Shanghai 200030, Peoples R China.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
   Univ Texas, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA.
   Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Oral & Maxillofacial Surg,Coll Stomatol, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; Shanghai Jiao Tong University
RP Li, J (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Oral Pathol,Coll Stomatol, Shanghai 200030, Peoples R China.
EM lijiang182000@yahoo.com
RI Zhiyuan, Zhang/AAA-7593-2022; Mao, Li/C-7570-2011
CR [Anonymous], W CHIN J STOMATOL
   COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759
   Dardick I, 1996, COLOR ATLAS TEXT SAL, P149
   del Muro XG, 2000, EUR J CANCER, V36, P357
   Elisei R, 1998, CANCER, V83, P2185, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4
   ELLIS GL, 1996, ATLAS TUMOR PATHOL, V57, P337
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Graziano F, 2004, ANN ONCOL, V15, P489, DOI 10.1093/annonc/mdh108
   GUAN XF, 1996, CHIN J STOMATOL, V3, P74
   HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   Hoteiya T, 1999, J ORAL PATHOL MED, V28, P107
   Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815
   KANAI Y, 1994, JPN J CANCER RES, V85, P1035, DOI 10.1111/j.1349-7006.1994.tb02902.x
   Khan AJ, 2001, INT J CANCER, V96, P149, DOI 10.1002/ijc.1013
   Kim HC, 2002, J KOREAN MED SCI, V17, P23, DOI 10.3346/jkms.2002.17.1.23
   KIM KH, 1994, ARCH OTOLARYNGOL, V120, P721
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Kwon GY, 2005, J KOREAN MED SCI, V20, P242, DOI 10.3346/jkms.2005.20.2.242
   Lee JK, 2004, EXP MOL MED, V36, P165, DOI 10.1038/emm.2004.23
   Li J, 2004, ARCH PATHOL LAB MED, V128, P1385
   Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215
   Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G
   Maruya S, 2004, MODERN PATHOL, V17, P637, DOI 10.1038/modpathol.3800104
   Nakayama S, 2001, INT J CANCER, V93, P667, DOI 10.1002/ijc.1386
   NASCIMENTO AG, 1986, CANCER-AM CANCER SOC, V57, P312, DOI 10.1002/1097-0142(19860115)57:2<312::AID-CNCR2820570220>3.0.CO;2-A
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8
   Rapidis AD, 2005, ORAL ONCOL, V41, P328, DOI 10.1016/j.oraloncology.2004.12.004
   Riese U, 1999, INT J MOL MED, V4, P61
   Saito T, 2003, CANCER-AM CANCER SOC, V97, P1002, DOI 10.1002/cncr.11157
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Sasatomi E, 1996, CANCER, V78, P2101, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2101::AID-CNCR10>3.0.CO;2-2
   Schagdarsurengin U, 2002, CANCER RES, V62, P3698
   Seike M, 2000, CLIN CANCER RES, V6, P4307
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   SPIRO RH, 1974, AM J SURG, V128, P512, DOI 10.1016/0002-9610(74)90265-7
   SPIRO RH, 1979, AM J SURG, V138, P579, DOI 10.1016/0002-9610(79)90423-9
   Sung MW, 2003, ARCH OTOLARYNGOL, V129, P1193, DOI 10.1001/archotol.129.11.1193
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x
   Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139
   Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331
NR 44
TC 38
Z9 43
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUL 1
PY 2007
VL 110
IS 1
BP 87
EP 95
DI 10.1002/cncr.22758
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 180RU
UT WOS:000247384200011
PM 17520682
OA Bronze
DA 2025-01-12
ER

PT J
AU Privette, LM
   González, ME
   Ding, L
   Kleer, CG
   Petty, EM
AF Privette, Lisa M.
   Gonzalez, Maria E.
   Ding, Lei
   Kleer, Celina G.
   Petty, Elizabeth M.
TI Altered expression of the early mitotic checkpoint protein, CHFR, in
   breast cancers:: Implications for tumor suppression
SO CANCER RESEARCH
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; EPIGENETIC INACTIVATION; PROMOTER
   HYPERMETHYLATION; ABERRANT HYPERMETHYLATION; STRESS CHECKPOINT;
   LUNG-CANCER; CPG ISLAND; GENE; CARCINOMA; CHROMOSOME-12
AB Checkpoint with FHA and Ring Finger (CHFR) is hypothesized to mediate a delay in cell cycle progression early in mitosis in response to microtubule stress, independent of the spindle assembly checkpoint. As a potential regulator of cell cycle progression, CHFR naturally becomes an interesting target for understanding cancer cells. In recent years, there has been increasing evidence supporting the role of CHFR as a tumor suppressor, most of which report loss of expression, occasionally due to promoter hypermethylation, in cancers compared with patient-matched normal tissues. We studied both a panel of breast cancer cell lines as well as primary tissue samples from breast cancer patients to investigate CHFR as a relevant tumor suppressor in breast cancer and to determine whether CHFR expression was associated with clinical and pathologic variables. We report that 41% of cell lines and 36% of patient samples showed low or negative CHFR protein expression or staining. In addition, lack of CHFR detection was associated with increased tumor size and weakly correlated with estrogen receptor-negative tumors from patients. To study the effects of low CHFR expression in vitro, we stably expressed a short hairpin RNA construct targeting CHFR in two lines of immortalized human mammary epithelial cells. Notably, decreased CHFR expression resulted in the acquisition of many phenotypes associated with malignant progression, including accelerated growth rates, higher mitotic index, enhanced invasiveness, increased motility, greater aneuploidy, and amplified colony formation in soft agar, further supporting the role of CHFR as a tumor suppressor in breast cancer.
C1 Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Privette, LM (通讯作者)，Univ Michigan, Dept Human Genet, 5220A MSRB3,1150 W Med Ctr, Ann Arbor, MI 48109 USA.
EM epetty@umich.edu
RI Vinnedge, Lisa/H-5869-2019
OI Privette Vinnedge, Lisa/0000-0003-2087-4920
FU National Cancer Institute [R01CA107469] Funding Source: NIH RePORTER;
   National Institute of General Medical Sciences [T32GM007544] Funding
   Source: NIH RePORTER; NCI NIH HHS [R01CA072877, R01CA107469,
   K08CA090876] Funding Source: Medline; NIGMS NIH HHS [5 T32-GM07544]
   Funding Source: Medline
CR Andrieux J, 2002, CANCER GENET CYTOGEN, V137, P68, DOI 10.1016/S0165-4608(02)00554-X
   Aubele M, 2002, ANAL CELL PATHOL, V24, P77, DOI 10.1155/2002/820269
   BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463
   Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658
   Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058
   Chaturvedi P, 2002, CANCER RES, V62, P1797
   Cheung HW, 2005, MOL CARCINOGEN, V43, P237, DOI 10.1002/mc.20106
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019
   Dang C, 2006, CLIN BREAST CANCER, V7, P51, DOI 10.3816/CBC.2006.n.013
   Dohna M, 2000, GENE CHROMOSOME CANC, V28, P145, DOI 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.3.CO;2-Z
   Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161
   Erson AE, 2001, NEOPLASIA, V3, P521, DOI 10.1038/sj.neo.7900187
   ETHIER SP, 1993, CANCER RES, V53, P627
   Fraschini R, 2004, MOL BIOL CELL, V15, P3796, DOI 10.1091/mbc.E04-02-0094
   Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543
   Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2
   Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159
   Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849
   Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Mariatos G, 2003, CANCER RES, V63, P7185
   Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   OGIJ K, 2005, CANCER BIOL THER, V4, P773
   Poole Christopher, 2004, Oncology (Williston Park), V18, P23
   Rutherford S, 2005, LAB INVEST, V85, P1076, DOI 10.1038/labinvest.3700314
   Sakai M, 2005, HEPATO-GASTROENTEROL, V52, P1854
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Sezgin C, 2005, J CHEMOTHERAPY, V17, P96, DOI 10.1179/joc.2005.17.1.96
   Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695
   Shtivelman E, 2003, MOL CANCER RES, V1, P959
   Summers MK, 2005, ONCOGENE, V24, P2589, DOI 10.1038/sj.onc.1208428
   Tokunaga E, 2006, BREAST CANCER RES TR, V97, P199, DOI 10.1007/s10549-005-9112-9
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Van den Eynden GG, 2004, BREAST CANCER RES TR, V85, P13, DOI 10.1023/B:BREA.0000021028.33926.a8
   VANDIEST PJ, 1990, J CLIN PATHOL, V43, P157, DOI 10.1136/jcp.43.2.157
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
NR 41
TC 41
Z9 48
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2007
VL 67
IS 13
BP 6064
EP 6074
DI 10.1158/0008-5472.CAN-06-4109
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 186II
UT WOS:000247772000011
PM 17596595
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Xu, XR
   Gammon, MD
   Zhang, HP
   Wetmur, JG
   Rao, ML
   Teitelbaum, SL
   Britton, JA
   Neugut, AI
   Santella, RM
   Chen, J
AF Xu, Xinran
   Gammon, Marilie D.
   Zhang, Heping
   Wetmur, James G.
   Rao, Manlong
   Teitelbaum, Susan L.
   Britton, Julie A.
   Neugut, Alfred I.
   Santella, Regina M.
   Chen, Jia
TI Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer
   in a population-based study
SO CARCINOGENESIS
LA English
DT Article
ID DIETARY-FOLATE INTAKE; MTHFR POLYMORPHISMS; LONG-ISLAND; ASSOCIATION;
   ALCOHOL; SUSCEPTIBILITY; DNA; MTR
AB One-carbon metabolism facilitates the crosstalk between genetic and epigenetic processes and plays critical roles in both DNA methylation and DNA synthesis, making it a good candidate for studying the risk of breast cancer. We previously reported that polymorphisms in methylenetetrahydrofolate reductase (MTHFR) in one-carbon pathway were associated with breast cancer risk in the population-based Long Island Breast Cancer Study Project. Herein, we systematically investigated putatively functional polymorphisms of seven other one-carbon-metabolizing genes in relation to the breast cancer risk in the same population. Except for a slight indication of increased risk of breast cancer associated with the double repeat (2R) allele in the thymidylate synthase (TYMS) 5'-untranslated region (UTR) (P, trend = 0.07), polymorphisms in the other six genes did not substantially modify the risk of breast cancer, or did they modify the risk associated with dietary intakes of folate and related B vitamins. However, we observed a significant multiplicative interaction between the MTHFR 677C>T and the TYMS 5'-UTR polymorphisms (P = 0.02). We used a recursive partitioning method, RTREE, in an attempt to tease out important or rate-limiting genes encoding these intricately related enzymes. Results from RTREE analyses indicate that MTHFR and TYMS are the two leading rate-limiting enzymes in the pathway, consistent with our epidemiological findings. Our findings underscore the importance of one-carbon metabolism in breast cancer etiology. Although the pathway is a network of interrelated enzymes, redundancy exists; evaluating the rate-limiting enzyme and its interaction with environment and other genes within the same pathway is critical in assessing breast cancer risk.
C1 Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA.
   Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
   Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
   Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Columbia Univ, Dept Epidemiol, New York, NY 10032 USA.
   Columbia Univ, Dept Med, New York, NY 10032 USA.
   Columbia Univ, Dept Environm Hlth Sci, New York, NY 10032 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; University of North Carolina; University of
   North Carolina Chapel Hill; Yale University; Columbia University;
   Columbia University; Columbia University
RP Chen, J (通讯作者)，Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA.
EM jia.chen@mssm.edu
RI Zhang, Heping/JOZ-2696-2023
OI Xu, Xinran/0000-0001-6435-8181; Zhang, Heping/0000-0002-0688-4076
CR [Anonymous], 1989, Applied Logistic Regression
   Baglietto L, 2005, BMJ-BRIT MED J, V331, P807, DOI 10.1136/bmj.38551.446470.06
   Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630
   Chen J, 2004, CANCER EPIDEM BIOMAR, V13, P2247
   Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129
   Cox DG, 2001, BIOINFORMATICS, V17, P738, DOI 10.1093/bioinformatics/17.8.738
   De Marco P, 2001, EUR J PEDIATR SURG, V11, pS14, DOI 10.1055/s-2001-19739
   Feigelson HS, 2003, CANCER EPIDEM BIOMAR, V12, P161
   Försti A, 2004, ONCOL REP, V11, P917
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677
   Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485
   Heil SG, 2001, MOL GENET METAB, V73, P164, DOI 10.1006/mgme.2001.3175
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   Johnson WG, 2004, AM J MED GENET A, V124A, P339, DOI 10.1002/ajmg.a.20505
   Justenhoven C, 2005, CANCER EPIDEM BIOMAR, V14, P3015, DOI 10.1158/1055-9965.EPI-05-0592
   Kalemi TG, 2005, CANCER LETT, V222, P57, DOI 10.1016/j.canlet.2004.11.025
   Kim YI, 2000, NUTR REV, V58, P205
   Le Marchand L, 2004, CANCER EPIDEM BIOMAR, V13, P2071
   Lee SA, 2004, EXP MOL MED, V36, P116, DOI 10.1038/emm.2004.17
   Lewis SJ, 2006, JNCI-J NATL CANCER I, V98, P1607, DOI 10.1093/jnci/djj440
   Machlin LJ., 1991, Handbook of vitamins, V2nd
   MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Rothman KJ, 2008, Modern epidemiology
   Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012
   Semenza JC, 2003, BREAST CANCER RES TR, V77, P217, DOI 10.1023/A:1021843019755
   Seyoum E, 1998, J NUTR, V128, P1956, DOI 10.1093/jn/128.11.1956
   Sharp L, 2002, CANCER LETT, V181, P65, DOI 10.1016/S0304-3835(02)00030-7
   Shrubsole MJ, 2006, CANCER EPIDEM BIOMAR, V15, P586, DOI 10.1158/1055-9965.EPI-05-0576
   Shrubsole MJ, 2004, CANCER EPIDEM BIOMAR, V13, P190, DOI 10.1158/1055-9965.EPI-03-0273
   Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895
   Zhai XJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-138
   Zhang H., 1999, Recursive Partitioning in the Health Sciences
   Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632
NR 35
TC 59
Z9 67
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2007
VL 28
IS 7
BP 1504
EP 1509
DI 10.1093/carcin/bgm061
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 199XX
UT WOS:000248729600019
PM 17372271
DA 2025-01-12
ER

PT J
AU Michelotti, GA
   Brinkley, DM
   Morris, DP
   Smith, MP
   Louie, RJ
   Schwinn, DA
AF Michelotti, Gregory A.
   Brinkley, D. Marshall
   Morris, Daniel P.
   Smith, Michael P.
   Louie, Raphael J.
   Schwinn, Debra A.
TI Epigenetic regulation of human α<sub>1d</sub>-adrenergic receptor gene
   expression:: a role for DNA methylation in Sp1-dependent regulation
SO FASEB JOURNAL
LA English
DT Article
DE transcription; cell-specific; promoter
ID CPG-BINDING-PROTEIN; SUBTYPE MESSENGER-RNAS; DE-NOVO METHYLATION;
   BREAST-CANCER CELLS; LOWER URINARY-TRACT; GROWTH-FACTOR;
   ALPHA(1B)-ADRENERGIC RECEPTOR; CARDIAC-HYPERTROPHY; PROMOTER REGION;
   ALPHA(1)-ADRENERGIC RECEPTORS
AB A growing body of evidence implicates alpha(1)-adrenergic receptors (alpha(1)ARs) as potent regulators of growth pathways. The three alpha(1)AR subtypes (alpha(1a)AR, alpha(1b)AR, alpha(1d)AR) display highly restricted tissue expression that undergoes subtype switching with many pathological stimuli, the mechanistic basis of which remains unknown. To gain insight into transcriptional pathways governing cell-specific regulation of the human alpha(1d)AR subtype, we cloned and characterized the alpha(1d)AR promoter region in two human cellular models that display disparate levels of endogenous alpha(1d)AR expression (SK-N-MC and DU145). Results reveal that alpha(1d)AR basal expression is regulated by Sp1-dependent binding of two promoter-proximal GC boxes, the mutation of which attenuates alpha(1d)AR promoter activity 10-fold. Mechanistically, chromatin immunoprecipitation data demonstrate that Sp1 binding correlates with expression of the endogenous gene in vivo, correlating highly with alpha(1d)AR promoter methylation-dependent silencing of both episomally expressed reporter constructs and the endogenous gene. Further, analysis of methylation status of proximal GC boxes using sodium bisulfite sequencing reveals differential methylation of proximal GC boxes in the two cell lines examined. Together, the data support a mechanism of methylation-dependent disruption of Sp1 binding in a cell-specific manner resulting in repression of basal alpha(1d)AR expression.
C1 Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Med Cardiol & Surg, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Michelotti, GA (通讯作者)，Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA.
EM miche007@mc.duke.edu
RI Smith, Michael-Phillip/ABY-0465-2022; Brinkley, D./AFF-7610-2022
OI Michelotti, Gregory/0000-0002-7908-1979; Schwinn,
   Debra/0000-0002-9696-5231; Louie, Raphael/0000-0003-2429-4499
FU NHLBI NIH HHS [R37 HL049103-11, R37 HL049103-12, R37 HL049103, R37
   HL049103-13, R01 HL049103, HL49103] Funding Source: Medline; NIA NIH HHS
   [R01 AG017566, AG17566] Funding Source: Medline
CR ALLEN KB, 1992, J VASC SURG, V16, P391, DOI 10.1016/0741-5214(92)90372-F
   Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527
   ANYUKHOVSKY EP, 1994, CIRC RES, V74, P937, DOI 10.1161/01.RES.74.5.937
   Aoyama T, 2004, J BIOL CHEM, V279, P28789, DOI 10.1074/jbc.M401273200
   Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229
   Bahouth SW, 2002, MOL PHARMACOL, V61, P379, DOI 10.1124/mol.61.2.379
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6
   BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Brero A, 2006, CURR TOP MICROBIOL, V301, P21
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144
   CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954
   de Mey C, 1998, EUR UROL, V34, P18, DOI 10.1159/000052284
   Doerfler W, 2006, CURR TOP MICROBIOL, V301, P125
   Dunn CJ, 2002, DRUG AGING, V19, P135, DOI 10.2165/00002512-200219020-00004
   Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GAO B, 1994, J BIOL CHEM, V269, P15762
   GAO Y, 1993, APPL SUPERCOND, V1, P131, DOI 10.1016/0964-1807(93)90389-J
   GEE JE, 1992, J BIOL CHEM, V267, P11163
   GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192
   Gonzalez-Cabrera PJ, 2004, ENDOCRINOLOGY, V145, P5157, DOI 10.1210/en.2004-0728
   Gonzalez-Cabrera PJ, 2003, MOL PHARMACOL, V63, P1104, DOI 10.1124/mol.63.5.1104
   Hampel C, 2002, J UROLOGY, V167, P1513, DOI 10.1016/S0022-5347(05)65355-4
   Holmes R, 2006, CYTOGENET GENOME RES, V113, P122, DOI 10.1159/000090823
   Ibarra M, 1997, EUR J PHARMACOL, V322, P221, DOI 10.1016/S0014-2999(97)00092-7
   Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Keffel S, 2000, BIOCHEM BIOPH RES CO, V272, P906, DOI 10.1006/bbrc.2000.2850
   Koshimizu T, 2003, PHARMACOL THERAPEUT, V98, P235, DOI 10.1016/S0163-7258(03)00033-0
   Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Leech CJ, 1996, AM J PHYSIOL-HEART C, V270, pH710, DOI 10.1152/ajpheart.1996.270.2.H710
   LI HT, 1995, CIRCULATION, V92, P918, DOI 10.1161/01.CIR.92.4.918
   Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912
   Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6
   Majumder S, 2006, J CELL BIOCHEM, V97, P1300, DOI 10.1002/jcb.20738
   Malloy BJ, 1998, J UROLOGY, V160, P937, DOI 10.1016/S0022-5347(01)62836-2
   Michelotti GA, 2003, J BIOL CHEM, V278, P8693, DOI 10.1074/jbc.M211986200
   Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9
   MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109
   Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x
   Morris DP, 2005, J BIOL CHEM, V280, P31368, DOI 10.1074/jbc.M501546200
   Morris DP, 2004, MOL PHARMACOL, V66, P843, DOI 10.1124/mol.104.000430
   Mulero-Navarro S, 2006, CARCINOGENESIS, V27, P1099, DOI 10.1093/carcin/bgi344
   Narayan P, 2001, UROLOGY, V57, P466, DOI 10.1016/S0090-4295(00)01042-6
   O'Connell TD, 2001, MOL PHARMACOL, V59, P1225, DOI 10.1124/mol.59.5.1225
   Podgoreanu MV, 2005, J THORAC CARDIOV SUR, V130, P330, DOI 10.1016/j.jtcvs.2004.11.052
   Price D, 2001, EUR UROL, V40, P5, DOI 10.1159/000049889
   Price DT, 2000, J UROLOGY, V164, P2145, DOI 10.1016/S0022-5347(05)66987-X
   PRICE DT, 1994, MOL PHARMACOL, V45, P171
   PRICE DT, 1994, MOL PHARMACOL, V46, P221
   RAMARAO CS, 1992, J BIOL CHEM, V267, P21936
   Razik MA, 1997, J BIOL CHEM, V272, P28237, DOI 10.1074/jbc.272.45.28237
   REILLY PM, 1993, CRIT CARE MED, V21, pS55, DOI 10.1097/00003246-199302001-00011
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839
   Rudner XL, 1999, CIRCULATION, V100, P2336, DOI 10.1161/01.CIR.100.23.2336
   RUFFOLO RR, 1985, PHARMACOL BIOCHEM BE, V22, P827, DOI 10.1016/0091-3057(85)90535-0
   Sado T, 2005, HUM MOL GENET, V14, pR59, DOI 10.1093/hmg/ddi117
   SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134
   Schwinn DA, 2000, BJU INT, V85, P6, DOI 10.1046/j.1464-410X.2000.00061.x
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shibata K, 2003, J BIOL CHEM, V278, P672, DOI 10.1074/jbc.M201375200
   STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Wang GL, 2003, J BIOL CHEM, V278, P40550, DOI 10.1074/jbc.M302879200
   Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x
   Xin XH, 1999, MOL PHARMACOL, V56, P1152, DOI 10.1124/mol.56.6.1152
   Xin XH, 1997, MOL PHARMACOL, V51, P764, DOI 10.1124/mol.51.5.764
   Yun J, 2003, CARDIOVASC RES, V57, P443, DOI 10.1016/S0008-6363(02)00696-X
   Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200
   Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096
   Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
   Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288
NR 79
TC 36
Z9 40
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUL
PY 2007
VL 21
IS 9
BP 1979
EP 1993
DI 10.1096/fj.06-7118com
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 182JG
UT WOS:000247500300008
PM 17384146
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Treilleux, I
   Chapot, B
   Goddard, S
   Pisani, P
   Angèle, S
   Hall, J
AF Treilleux, I.
   Chapot, B.
   Goddard, S.
   Pisani, P.
   Angele, S.
   Hall, J.
TI The molecular causes of low ATM protein expression in breast carcinoma;:
   promoter methylation and levels of the catalytic subunit of
   DNA-dependent protein kinase
SO HISTOPATHOLOGY
LA English
DT Article
DE ataxia telangiectasia; breast tumours; DNA-dependent protein kinase;
   promoter methylation
ID RNA-POLYMERASE-II; ATAXIA-TELANGIECTASIA; GENE-EXPRESSION; ABNORMAL
   EXPRESSION; REPAIR PROTEINS; DOWN-REGULATION; BRCA1 PROMOTER; CANCER;
   CELL; HYPERMETHYLATION
AB Aims: To investigate whether aberrant methylation of the ATM promoter or loss of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) may be the underlying causes of reduced ATM protein levels often seen in breast tumours.
   Methods and results: Methylation-specific polymerase chain reaction was used to determine the ATM promoter status and DNA-PKcs levels were measured by immunohistochemistry. None of the 74 invasive carcinomas (ICs) studied showed ATM promoter hypermethylation, whereas promoter methylation of CDKN2A/p16 (1.8%) and GSTP1 (15.8%) was detected. Of 92 ICs examined, 68 had reduced DNA-PKcs levels, supporting previous findings that alterations in double-strand break repair are associated with breast cancer pathogenesis. Although no association was found between the DNA-PKcs and ATM scores for the series of 92 tissues and 22/24 tissues with normal DNA-PKcs had reduced ATM, 29 tumours showed low expression of both DNA-PKcs and ATM compared with normal tissues.
   Conclusions: No evidence was found that the reduction in ATM protein levels seen in breast carcinoma is the result of epigenetic silencing. However, cross-regulation between DNA-PKcs and ATM may be a possible cause in a subset of tumours and warrants further investigation.
C1 Int Agcy Res Canc, Ctr Reg Leon Berard, F-69372 Lyon, France.
   Int Agcy Res Canc, DNA Repair Grp, F-69372 Lyon, France.
   Int Agcy Res Canc, Descript Epidemiol Prod Grp, F-69372 Lyon, France.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); UNICANCER; Centre Leon Berard; World Health Organization;
   International Agency for Research on Cancer (IARC); World Health
   Organization; International Agency for Research on Cancer (IARC)
RP Hall, J (通讯作者)，Ctr Univ Orsay, Ctr Rech, INSERM, U612,Inst Curie, Bat 110-112, F-91405 Orsay, France.
EM janet.hall@curie.u-psud.fr
RI hall, janet/G-1372-2013
CR Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3
   Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079
   Angèle S, 2003, HISTOPATHOLOGY, V43, P347, DOI 10.1046/j.1365-2559.2003.01713.x
   Angèle S, 2000, CLIN CANCER RES, V6, P3536
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785
   Castellví-Bel S, 1999, HUM MUTAT, V14, P156, DOI 10.1002/(SICI)1098-1004(1999)14:2<156::AID-HUMU7>3.0.CO;2-E
   Chim CS, 2005, LEUKEMIA, V19, P880, DOI 10.1038/sj.leu.2403676
   Cuatrecasas M, 2006, HISTOL HISTOPATHOL, V21, P149, DOI 10.14670/HH-21.149
   Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002
   Ding SL, 2004, BRIT J CANCER, V90, P1995, DOI 10.1038/sj.bjc.6601804
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Gronbæk K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382
   Gueven N, 2006, GENE CHROMOSOME CANC, V45, P61, DOI 10.1002/gcc.20267
   Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261
   Gumy-Pause F, 2006, LEUKEMIA RES, V30, P335, DOI 10.1016/j.leukres.2005.07.012
   Hall J, 2005, CANCER LETT, V227, P105, DOI 10.1016/j.canlet.2004.12.001
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Kairouz R, 1999, J CLIN PATHOL-MOL PA, V52, P252, DOI 10.1136/mp.52.5.252
   LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934
   Luo LP, 1998, CANCER RES, V58, P2293
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Meng ZH, 2004, GENE CHROMOSOME CANC, V41, P214, DOI 10.1002/gcc.20089
   Moll U, 1999, ONCOGENE, V18, P3114, DOI 10.1038/sj.onc.1202640
   Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1
   Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x
   O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Peng YL, 2005, CANCER RES, V65, P1670, DOI 10.1158/0008-5472.CAN-04-3451
   PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449
   Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378
   Sakata KI, 2001, INT J RADIAT ONCOL, V49, P161, DOI 10.1016/S0360-3016(00)01352-3
   Schild-Poulter C, 2003, CANCER RES, V63, P7197
   Shen CY, 2000, CANCER RES, V60, P3884
   Sheppard HM, 2000, BBA-GENE STRUCT EXPR, V1493, P41, DOI 10.1016/S0167-4781(00)00155-X
   Thorstenson YR, 2003, CANCER RES, V63, P3325
   Thorstenson YR, 2001, AM J HUM GENET, V69, P396, DOI 10.1086/321296
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Waha A, 1998, INT J CANCER, V78, P306, DOI 10.1002/(SICI)1097-0215(19981029)78:3<306::AID-IJC8>3.0.CO;2-Z
   Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478
   Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4
NR 43
TC 18
Z9 20
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD JUL
PY 2007
VL 51
IS 1
BP 63
EP 69
DI 10.1111/j.1365-2559.2007.02726.x
PG 7
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 182AH
UT WOS:000247477000007
PM 17593081
DA 2025-01-12
ER

PT J
AU Oh, BK
   Kim, H
   Park, HJ
   Shim, YH
   Choi, J
   Park, C
   Park, YN
AF Oh, Bong-Kyeong
   Kim, Haeryoung
   Park, Hye-Jung
   Shim, Yhong-Hee
   Choi, Jinsub
   Park, Chanil
   Park, Young Nyun
TI DNA methyltransferase expression and DNA methylation in human
   hepatocellular carcinoma and their clinicopathological correlation
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE DNA methylation; DNA methyltransferase; hepatocellular carcinoma
ID PERICENTROMERIC SATELLITE REGIONS; CPG ISLAND HYPERMETHYLATION;
   MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENES; MULTISTEP
   HEPATOCARCINOGENESIS; SPLICE VARIANT; BREAST-CANCER; DE-NOVO; CIRRHOSIS;
   OVEREXPRESSION
AB Aberrant DNA methylation on CpG islands is one of the most consistent epigenetic changes in human cancers, and the methylation process is catalyzed by DNA methyltransferase (DNMT). We evaluated i) the mRNA levels of three DNMTs; DNMT1, DNMT3a and DNMT3b, in 25 hepatocellular carcinomas (HCCs), in their corresponding non-cancerous liver tissues and in 7 normal livers by using realtime reverse transcriptase-polymerase chain reaction; ii) nuclear expression of DNMT1 and DNMT3a proteins in the HCCs by immunohistochemistry, iii) the methylation status of 5 genes; p16, p15, E-cadherin, HIC-1 and RASSF1A in the same tissues, and iv) the relationships between the above results and the clinicopathological characteristics, including prognosis. The differences in mRNA expression levels for DNMT I, DNMT3a and DNMT3b were statistically significant between HCC and normal livers (p < 0.001), HCC and chronic hepatitis (p < 0.001) and HCC and cirrhosis (p < 0.001). An increase in mRNA expression levels of > 4-fold for DNMT3b in HCCs was significantly associated with a poorer overall survival (p=0.027) and shorter metastasis-free survival (p=0.0299). A poorer recurrence-free survival was noted in HCCs with a > 4-fold increase in DNMT3a mRNA (p=0.0120). The average numbers of methylated genes were 0, 1.27, 1.38 and 2.72 for normal livers, chronic hepatitis, cirrhosis and HCCs, respectively, and this progressive increase from normal livers to chronic hepatitis/cirrhosis through HCC may suggest that tumor suppressor gene methylation is an early event in hepatocarcinogenesis. These results first suggest that hepatocarcinogenesis involves an increased expression of DNMT1, DNMT3a and DNMT3b mRNA and a progressive increase in the number of methylated genes from normal liver, chronic hepatitis/cirrhosis to HCC and secondly that an increase in the DNMT3a and DNMT3b mRNA levels in HCCs relative to their non-cancerous tissues may be a predictor of poor survival.
C1 Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea.
   Seoul Natl Univ, Bundang Hosp, Dept Pathol, Songnam 463707, Kyeonggi Do, South Korea.
   Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea.
   Konkuk Univ, Biomol Informat Ctr, Seoul 143701, South Korea.
   Konkuk Univ, Inst Biomed Sci & Technol, Seoul 143701, South Korea.
   Yonsei Univ, Coll Med, Dept Gen Surg, Seoul 120752, South Korea.
   Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21,Inst Gastroenterol, Ctr Chron Metab Dis,ICBIN, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System; Seoul National
   University (SNU); Konkuk University; Konkuk University; Konkuk
   University; Yonsei University; Yonsei University Health System; Yonsei
   University; Yonsei University Health System
RP Park, YN (通讯作者)，Yonsei Univ, Coll Med, Dept Pathol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM young0608@yumc.yonsei.ac.kr
RI Oh, Bong/D-6815-2011; Park, Jun-Beom/I-8201-2019; Park,
   Jihye/AAC-1333-2022; Shim, Yhong-Hee/D-6691-2011
OI Kim, Haeryoung/0000-0002-4205-9081; Shim, Yhong-Hee/0000-0002-8660-4176;
   Park, Young Nyun/0000-0003-0357-7967
CR Arai M, 2006, CANCER-AM CANCER SOC, V106, P2514, DOI 10.1002/cncr.21905
   BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bonfils C, 2000, J BIOL CHEM, V275, P10754, DOI 10.1074/jbc.275.15.10754
   Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5
   Di Gioia S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-89
   Eads CA, 1999, CANCER RES, V59, P2302
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ishiguro A, 2006, J GASTROEN HEPATOL, V21, P1334, DOI 10.1111/j.1440-1746.2006.04137.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338
   Kanai Y, 1997, INT J CANCER, V71, P355
   Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Nagai M, 2003, HEPATOL RES, V26, P186, DOI 10.1016/S1386-6346(03)00091-3
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536
   Oue N, 2001, ONCOL REP, V8, P1085
   Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017
   Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799
   Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507
   Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yang XW, 2001, CANCER RES, V61, P7025
NR 34
TC 161
Z9 195
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUL
PY 2007
VL 20
IS 1
BP 65
EP 73
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 182GK
UT WOS:000247492900009
PM 17549390
DA 2025-01-12
ER

PT J
AU Postovit, LM
   Costa, FF
   Bischof, JM
   Seftor, EA
   Wen, B
   Seftor, REB
   Feinberg, AP
   Soares, MB
   Hendrix, MJC
AF Postovit, Lynne-Marie
   Costa, Fabricio F.
   Bischof, Jared M.
   Seftor, Elisabeth A.
   Wen, Bo
   Seftor, Richard E. B.
   Feinberg, Andrew P.
   Soares, Marcelo Bento
   Hendrix, Mary J. C.
TI The commonality of plasticity underlying multipotent tumor cells and
   embryonic stem cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE melanoma; human embryonic stem cells; epigenetics; nodal
ID METASTATIC MELANOMA-CELLS; GENE-EXPRESSION; VASCULOGENIC MIMICRY;
   MALIGNANT-MELANOMA; DNA METHYLATION; BREAST-CANCER; MICROENVIRONMENT;
   DIFFERENTIATION; PLURIPOTENCY; PATHWAYS
AB Aggressive cancer cells and pluripotent stem cells converge in their capacity for self-renewal, proliferation and plasticity. Recent studies have capitalized on these similarities by demonstrating that tumors arise from specific cancer stem cell populations that, in a manner reminiscent of normal stem cells, are able to both self-renew and give rise to a heterogeneous tumor population. This stem cell like function of aggressive cancer cells is likely attributable to the ectopic expression of embryonic factors such as Nodal and Cancer Testis Specific Antigens (CTAs), which maintain a functional plasticity by promoting pluripotency and immortality. During development, the expression of these embryonic factors is tightly regulated by a dynamic array of mediators, including the spatial and temporal expression of inhibitors such as Lefty, and the epigenetic modulation of the genome. In aggressive cancer cells, particularly melanoma, this balance of regulatory mediators is disrupted, leading to the aberrant expression of pluripotency-associated genes. By exposing aggressive cancer cells to embryonic microenvironments, this balance of regulatory mediators is restored, thereby reprogramming tumor cells to a more benign phenotype. These stern cell-derived mediators, as well as the genes they regulate, provide therapeutic targets designed to specifically differentiate and eradicate aggressive cancers.
C1 Northwestern Univ, Program Canc Biol & Epigenom, Childrens Mem Res Ctr, Feinberg Sch Med, Chicago, IL 60614 USA.
   Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
C3 Northwestern University; Feinberg School of Medicine; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University
RP Hendrix, MJC (通讯作者)，Northwestern Univ, Program Canc Biol & Epigenom, Childrens Mem Res Ctr, Feinberg Sch Med, 2300 Childrens Plaza,Box 222, Chicago, IL 60614 USA.
EM mjchendrix@childrensmemorial.org
RI Feinberg, Andrew/AAY-7666-2020; Costa, Fabricio/M-5309-2017; Wen,
   Bo/P-5332-2019
OI Feinberg, Andrew/0000-0002-8364-1991; Postovit,
   Lynne-Marie/0000-0002-8088-4197; Wen, Bo/0000-0003-0394-7366
FU NCI NIH HHS [R01 CA054358, R37 CA054358-17, CA5902, R37 CA054358]
   Funding Source: Medline
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001
   Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200
   Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095
   Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042
   Costa FF, 2006, CANCER GENET CYTOGEN, V165, P135, DOI 10.1016/j.cancergencyto.2005.07.023
   Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   De S. C., 2004, MOL CELL BIOL, V24, P4781
   DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307
   Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029
   Golan-Mashiach M, 2004, FASEB J, V18, P147, DOI 10.1096/fj.04-2417fje
   HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358
   HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165
   Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092
   Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447
   Hendrix MJC, 2002, CANCER RES, V62, P665
   Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731
   Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   LOTEM J, 2006, ONCOGENE
   Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028
   Mesnard D, 2006, DEVELOPMENT, V133, P2497, DOI 10.1242/dev.02413
   PIERCE GB, 1982, CANCER RES, V42, P1082
   PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608
   Postovit LM, 2006, STEM CELLS, V24, P501, DOI 10.1634/stemcells.2005-0459
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522
   Seftor EA, 2005, CANCER RES, V65, P10164, DOI 10.1158/0008-5472.CAN-05-2497
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Tabibzadeh S, 2006, STEM CELLS, V24, P1998, DOI 10.1634/stemcells.2006-0075
   Takeuchi H, 2003, CANCER RES, V63, P441
   Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778
   Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448
   Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031
   Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553
   Visvader JE, 2006, CANCER RES, V66, P9798, DOI 10.1158/0008-5472.CAN-06-2254
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
NR 52
TC 50
Z9 55
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUL 1
PY 2007
VL 101
IS 4
BP 908
EP 917
DI 10.1002/jcb.21227
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 185EQ
UT WOS:000247694600010
PM 17177292
DA 2025-01-12
ER

PT J
AU Vincent-Salomon, A
   Ganem-Elbaz, C
   Manié, E
   Raynal, V
   Sastre-Garau, X
   Stoppa-Lyonnet, D
   Stern, MH
   Heard, E
AF Vincent-Salomon, Anne
   Ganem-Elbaz, Carine
   Manie, Elodie
   Raynal, Virginie
   Sastre-Garau, Xavier
   Stoppa-Lyonnet, Dominique
   Stern, Marc-Henri
   Heard, Edith
TI X inactive-specific transcript RNA coating and genetic instability of
   the X chromosome in <i>BRCA1</i> breast tumors
SO CANCER RESEARCH
LA English
DT Article
ID XIST RNA; DOSAGE COMPENSATION; CANCER; HETEROCHROMATIN; REPLICATION;
   METHYLATION; MUTATIONS; LOSSES
AB Identification among breast tumors of those arising in a hereditary BRCA1 context remains a medical challenge. Abnormalities in X chromosome copy number and in the epigenetic stability of the inactive X chromosome (Xi) have been proposed to characterize BRCA1 breast tumors. In particular, it has been proposed that loss of BRCA1 function can lead to loss of X inactive-specific transcript (MST) RNA association with the Xi. However, few studies have addressed this issue in a sufficiently large series of BRCA.1 primary tumors. Here we assess X-chromosome status using single-cell (RNA and DNA fluorescence in situ hybridization) and global genomic (array-comparative genomic hybridization and allelotyping) approaches on a series of 11 well-defined BRCA-1 tumors. We show that many or most cells of the tumors contain one or more XIST RNA domains. Furthermore, the number of XIST RNA domains per cell varied considerably even within a single tumor. Frequent X-chromosome allelic and copy number aberrations were found, in agreement with aberrant XIST RNA domain numbers. In summary, by combining multiple approaches to assess the genetics and epigenetics of a large series of BRCA1 primary tumors, we can conclude definitively that BRCAl is not required for XIST RNA coating of the X chromosome. The intraturnoral and intertumoral variability in XIST RNA domain number in BRCA1 tumors correlates with chromosomal genetic abnormalities, including gains, losses, reduplications, and rearrangements of the X-chromosome. Finally, we also show the necessity for combined global and single-cell approaches in the assessment of tumors with such a high degree of heterogeneity.
C1 Inst Curie, CNRS UMR 218, Ctr Rech, F-75248 Paris, France.
   Inst Curie, INSERM U830, F-75248 Paris, France.
   Inst Curie, Dept Tumor Biol, F-75248 Paris, France.
C3 Universite PSL; UNICANCER; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); Universite PSL; UNICANCER; Institut
   Curie; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Universite PSL; Institut Curie
RP Heard, E (通讯作者)，Inst Curie, CNRS UMR 218, Ctr Rech, 26 Rue Ulm, F-75248 Paris, France.
EM marc-henri.stern@curie.fr; edith.heard@curie.fr
RI Heard, Edith/D-7197-2017; Stern, Marc-Henri/A-2728-2011
OI Stern, Marc-Henri/0000-0002-8100-2272; Sastre-Garau,
   Xavier/0000-0001-5992-2083
CR Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Azoulay S, 2005, MODERN PATHOL, V18, P1623, DOI 10.1038/modpathol.3800483
   Chaumeil J, 2006, GENE DEV, V20, P2223, DOI 10.1101/gad.380906
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874
   Heard E, 2005, CURR OPIN GENET DEV, V15, P482, DOI 10.1016/j.gde.2005.08.009
   Heard E, 2006, GENE DEV, V20, P1848, DOI 10.1101/gad.1422906
   Hupé P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418
   Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607
   Jönsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570
   Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053
   Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156
   Neuvial P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-264
   Pageau GJ, 2006, J CELL BIOL, V175, P693, DOI 10.1083/jcb.200602055
   Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128
   Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413
   Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026
NR 25
TC 72
Z9 78
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2007
VL 67
IS 11
BP 5134
EP 5140
DI 10.1158/0008-5472.CAN-07-0465
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 175NS
UT WOS:000247020900013
PM 17545591
DA 2025-01-12
ER

PT J
AU DeAlmeida, VI
   Miao, L
   Ernst, JA
   Koeppen, H
   Polakis, P
   Rubinfeld, B
AF DeAlmeida, Venita I.
   Miao, Li
   Ernst, James A.
   Koeppen, Hartmut
   Polakis, Paul
   Rubinfeld, Bonnee
TI The soluble Wnt receptor Frizzled8CRD-hFc inhibits the growth of
   teratocarcinomas <i>in vivo</i>
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN CANCER-CELLS; EPIGENETIC INACTIVATION; COLORECTAL-CANCER;
   TUMOR-GROWTH; MONOCLONAL-ANTIBODY; BREAST-CANCER; WILMS-TUMORS; TARGET
   GENES; STEM-CELLS; EXPRESSION
AB Wnt signaling is important for normal cell proliferation and differentiation, and mutations in pathway components are associated with human cancers. Recent studies suggest that altered wnt ligand/receptor interactions might also contribute to human tumorigenesis. Therefore, agents that antagonize wnt signaling at the extracellular level would be attractive therapeutics for these cancers. We have generated a soluble wnt receptor comprising the Frizzled8 cysteine-rich domain (CRD) fused to the human Fc domain (F8CRDhFc) that exhibits favorable pharmacologic properties in vivo. Potent antitumor efficacy was shown using the mouse mammary tumor virus-Wnt1 tumor model under dosing conditions that did not produce detectable toxicity in regenerating tissue compartments. In vitro, F8CRDhFc inhibited autocrine writ signaling in the teratoma cell lines PA-1, NTera-2, Tera-2, and NCCIT. In vivo, systemic administration of FSCRDhFc significantly retarded the growth of tumor xenografts derived from two of these cell lines, PA-1 and NTera-2. Pharmacodynamic markers of wnt signaling, identified by gene expression analysis of cultured teratoma cells, were also modulated in the tumor xenografts following treatment with F8CRDhFc. Additionally, these markers could be used as indicators of treatment efficacy and might also be useful in identifying patients that would benefit from the therapeutic agent. This is the first report showing the efficacy of a soluble wnt receptor as an antitumor agent and suggests that further development of wnt antagonists will have utility in treating human cancer.
C1 Genentech Inc, Dept Canc Pathways & Targets, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Prot Chem & Prot Engn, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Rubinfeld, B (通讯作者)，Genentech Inc, Dept Canc Pathways & Targets, 1 DNA Way,MS 40, San Francisco, CA 94080 USA.
EM bonrubin@gene.com
OI Rubinfeld, Bonnee/0000-0001-9861-6775
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601
   Fritsch MK, 2006, PEDIATR DEVEL PATHOL, V9, P115, DOI 10.2350/08-05-0097.1
   Fuchs SY, 2005, CELL CYCLE, V4, P1522
   Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603
   HARRIS RJ, 1990, EUR J BIOCHEM, V194, P611, DOI 10.1111/j.1432-1033.1990.tb15660.x
   He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Ilyas M, 2005, J PATHOL, V205, P130, DOI 10.1002/path.1692
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098
   Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kim SD, 2003, NUMER METH PART D E, V19, P511, DOI 10.1002/num.10061
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4
   Li YH, 2004, ONCOGENE, V23, P9129, DOI 10.1038/sj.onc.1208123
   Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Polakis P, 2000, GENE DEV, V14, P1837
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rubinfeld B, 2006, NAT BIOTECHNOL, V24, P205, DOI 10.1038/nbt1185
   Sarrió D, 2006, HUM PATHOL, V37, P1042, DOI 10.1016/j.humpath.2006.03.003
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432-0436.2005.00015.x
   Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008
   Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498
   You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227
   Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607
   Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103
   Zirn B, 2006, GENE CHROMOSOME CANC, V45, P565, DOI 10.1002/gcc.20319
NR 49
TC 119
Z9 152
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2007
VL 67
IS 11
BP 5371
EP 5379
DI 10.1158/0008-5472.CAN-07-0266
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 175NS
UT WOS:000247020900041
PM 17545618
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Secombe, J
   Eisenman, RN
AF Secombe, Julie
   Eisenman, Robert N.
TI The function and regulation of the JARID1 family of histone H3 lysine 4
   demethylases - The Myc connection
SO CELL CYCLE
LA English
DT Article
DE Jumonji (Jmj); demethylase; Myc; JARID1; Little imaginal discs (Lid)
ID TRANSCRIPTIONAL REGULATION; BREAST-CANCER; DROSOPHILA-MELANOGASTER;
   MENTAL-RETARDATION; ACTIVE GENES; CELL-GROWTH; PHD FINGER; CHROMATIN;
   METHYLATION; PROTEINS
AB Epigenetic regulation of transcription refers to reversible, heritable changes in gene expression that occur in the absence of changes in DNA sequence. A major epigenetic mechanism involves the covalent modification of nucleosomal histones to create binding sites for transcriptional regulators and chromatin remodeling complexes that mediate activation or repression of transcription. While it has been known for a number of years that many histone modifications are reversible, it has only recently been shown that methyl groups are enzymatically removed from lysine residues. Here we discuss the recent characterization of a new class of demethylase enzyme, the JARID1 family, which catalyzes the removal of methyl groups from lysine 4 of histone H3. We summarize recent findings regarding the function of this family of proteins, focusing on our characteriza tion of Little imaginal discs (Lid), the sole JARID1 family protein in Drosophila, which is rate-limiting for Myc-induced cell growth. Finally, we propose models to explain the role of Lid in Myc-mediated growth and discuss the relevance of these findings to human disease and tumor formation.
C1 Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.
C3 Fred Hutchinson Cancer Center
RP Eisenman, RN (通讯作者)，Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,PO Box 19024, Seattle, WA 98109 USA.
EM eisenman@fhcrc.org
FU NCI NIH HHS [R37CA57138] Funding Source: Medline
CR AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4
   ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0
   Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005
   Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0
   FATTAEY AR, 1993, ONCOGENE, V8, P3149
   Forneris F, 2005, J BIOL CHEM, V280, P41360, DOI 10.1074/jbc.M509549200
   Gallant P, 2006, CURR TOP MICROBIOL, V302, P235
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Gildea JJ, 2000, GENETICS, V156, P645
   Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434
   HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Jensen LR, 2005, AM J HUM GENET, V76, P227, DOI 10.1086/427563
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Liang G, 2007, NAT STRUCT MOL BIOL, V14, P243, DOI 10.1038/nsmb1204
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108
   Santos C, 2006, EUR J HUM GENET, V14, P583, DOI 10.1038/sj.ejhg.5201608
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076
   SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200
   Shi XB, 2007, J BIOL CHEM, V282, P2450, DOI 10.1074/jbc.C600286200
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Takeuchi T, 1999, MECH DEVELOP, V86, P29, DOI 10.1016/S0925-4773(99)00100-8
   TAKEUCHI T, 1995, GENE DEV, V9, P1211, DOI 10.1101/gad.9.10.1211
   Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a
   Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
NR 49
TC 72
Z9 85
U1 0
U2 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JUN 1
PY 2007
VL 6
IS 11
BP 1324
EP 1328
DI 10.4161/cc.6.11.4269
PG 5
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 190SZ
UT WOS:000248081700010
PM 17568193
OA Bronze
DA 2025-01-12
ER

PT J
AU Rada-Iglesias, A
   Enroth, S
   Ameur, A
   Koch, CM
   Clelland, GK
   Respuela-Alonso, P
   Wilcox, S
   Dovey, OM
   Ellis, PD
   Langford, CF
   Dunham, I
   Komorowski, J
   Wadelius, C
AF Rada-Iglesias, Alvaro
   Enroth, Stefan
   Ameur, Adam
   Koch, Christoph M.
   Clelland, Gayle K.
   Respuela-Alonso, Patricia
   Wilcox, Sarah
   Dovey, Oliver M.
   Ellis, Peter D.
   Langford, Cordelia F.
   Dunham, Ian
   Komorowski, Jan
   Wadelius, Claes
TI Butyrate mediates decrease of histone acetylation centered on
   transcription start sites and down-regulation of associated genes
SO GENOME RESEARCH
LA English
DT Article
ID BREAST-CANCER CELLS; DEACETYLASE INHIBITORS; SODIUM-BUTYRATE;
   GENOME-WIDE; PERICENTRIC HETEROCHROMATIN; ACETYLTRANSFERASE ACTIVITY;
   TRICHOSTATIN-A; CORE PROMOTER; HEPG2 CELLS; IN-VIVO
AB Butyrate is a histone deacetylase inhibitor (HDACi) with anti-neoplastic properties, which theoretically reactivates epigenetically silenced genes by increasing global histone acetylation. However, recent studies indicate that a similar number or even more genes are down-regulated than up-regulated by this drug. We treated hepatocarcinoma HepG2 cells with butyrate and characterized the levels of acetylation at DNA-bound histones H3 and H4 by ChIP-chip along the ENCODE regions. In contrast to the global increases of histone acetylation, many genomic regions close to transcription start sites were deacetylated after butyrate exposure. In order to validate these findings, we found that both butyrate and trichostatin A treatment resulted in histone deacetylation at selected regions, while nucleosome loss or changes in histone H3 lysine 4 trimethylation (H3K4me3) did not occur in such locations. Furthermore, similar histone deacetylation events were observed when colon adenocarcinoma HT-29 cells were treated with butyrate. In addition, genes with deacetylated promoters were down-regulated by butyrate, and this was mediated at the transcriptional level by affecting RNA polymerase II (POLR2A) initiation/elongation. Finally, the global increase in acetylated histones was preferentially localized to the nuclear periphery, indicating that it might not be associated to euchromatin. Our results are significant for the evaluation of HDACi as anti-tumourogenic drugs, suggesting that previous models of action might need to be revised, and provides an explanation for the frequently observed repression of many genes during HDACi treatment.
C1 Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75105 Uppsala, Sweden.
   Uppsala Univ, Linnaeus Ctr Bioinformat, SE-75105 Uppsala, Sweden.
   Wellcome Trust Sanger Inst, Cambridge, England.
C3 Uppsala University; Uppsala University; Wellcome Trust Sanger Institute
RP Rada-Iglesias, A (通讯作者)，Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75105 Uppsala, Sweden.
EM alvaro.rada@genpat.uu.se; Claes.Wadelius@genpat.uu.se
RI Dunham, Ian/ABE-3179-2021; Enroth, Stefan/C-7396-2009; Komorowski,
   Jan/AAP-1685-2020; Komorowski, Jan/M-2667-2013; Ameur, Adam/E-6207-2011
OI Enroth, Stefan/0000-0002-5056-9137; Komorowski, Jan/0000-0002-0766-8789;
   Koch, Christof/0000-0001-6482-8067; Rada-Iglesias,
   Alvaro/0000-0001-7137-1341; Respuela, Patricia/0000-0002-9719-7860;
   Ameur, Adam/0000-0001-6085-6749; Dunham, Ian/0000-0003-2525-5598
FU NHGRI NIH HHS [5 U01 HG003168, U01 HG003168] Funding Source: Medline
CR Ameur A, 2006, BIOINFORMATICS, V22, P1024, DOI 10.1093/bioinformatics/btl036
   Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100
   Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005
   Bártová E, 2005, J CELL SCI, V118, P5035, DOI 10.1242/jcs.02621
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Daly K, 2006, DNA CELL BIOL, V25, P49, DOI 10.1089/dna.2006.25.49
   Dashwood RH, 2006, CARCINOGENESIS, V27, P344, DOI 10.1093/carcin/bgi253
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   de Ruijter AJM, 2005, EXP CELL RES, V309, P451, DOI 10.1016/j.yexcr.2005.06.024
   Dehm SM, 2004, MOL CELL BIOL, V24, P2296, DOI 10.1128/MCB.24.6.2296-2307.2004
   Dimitri P, 2005, BIOESSAYS, V27, P29, DOI 10.1002/bies.20158
   DONADEL G, 1991, EUR J BIOCHEM, V195, P723, DOI 10.1111/j.1432-1033.1991.tb15759.x
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005
   Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000
   Emanuele S, 2004, EUR J CANCER, V40, P1441, DOI 10.1016/j.ejca.2004.01.039
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gialitakis M, 2006, NUCLEIC ACIDS RES, V34, P765, DOI 10.1093/nar/gkj462
   Gonçalves J, 2005, CLIN CHEM LAB MED, V43, P151, DOI 10.1515/CCLM.2005.025
   Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200
   Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393
   HERUTH DP, 1993, J BIOL CHEM, V268, P20466
   Hirsch CL, 2004, FEBS LETT, V570, P37, DOI 10.1016/j.febslet.2004.06.018
   Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim EH, 2005, ONCOGENE, V24, P6877, DOI 10.1038/sj.onc.1208851
   Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877
   Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787
   Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433
   Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774
   Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400
   Lieb JD, 2005, CELL, V123, P1187, DOI 10.1016/j.cell.2005.12.010
   Lindemann RK, 2004, CELL CYCLE, V3, P779
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8
   Murray JI, 2004, MOL BIOL CELL, V15, P2361, DOI 10.1091/mbc.E03-11-0799
   O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Polioudaki H, 2001, EMBO REP, V2, P920, DOI 10.1093/embo-reports/kve199
   Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242
   Rada-Iglesias A, 2005, HUM MOL GENET, V14, P3435, DOI 10.1093/hmg/ddi378
   Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Ruemmele FM, 2003, GUT, V52, P94, DOI 10.1136/gut.52.1.94
   Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211
   Schübeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520
   Somech R, 2005, J CELL SCI, V118, P4017, DOI 10.1242/jcs.02521
   Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010
   Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441
   Tong X, 2005, J BIOL CHEM, V280, P15503, DOI 10.1074/jbc.M411978200
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202
   Weierich C, 2003, CHROMOSOME RES, V11, P485, DOI 10.1023/A:1025016828544
   Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001
   Zhao YM, 2005, BIOCHEM BIOPH RES CO, V326, P811, DOI 10.1016/j.bbrc.2004.11.118
NR 65
TC 128
Z9 143
U1 0
U2 12
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD JUN
PY 2007
VL 17
IS 6
BP 708
EP 719
DI 10.1101/gr.5540007
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 178NH
UT WOS:000247226900005
PM 17567991
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhang, M
   Wang, Q
   Yuan, W
   Yang, S
   Wang, X
   Yan, JD
   Du, J
   Yin, J
   Gao, SY
   Sun, BC
   Zhu, TH
AF Zhang, Ming
   Wang, Qing
   Yuan, Wei
   Yang, Shuang
   Wang, Xu
   Yan, Ji-Dong
   Du, Jun
   Yin, Jian
   Gao, Song-Yuan
   Sun, Bao-Cun
   Zhu, Tian-Hui
TI Epigenetic regulation of bone morphogenetic protein-6 gene expression in
   breast cancer cells
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE epigenetic regulation; 5-aza-2 '-deoxycytidine (5-aza-dC);
   methylation-sensitive enzyme restriction PCR (MSRE-PCR); bisulfite
   sequencing (BSG); methylation-specific PCR (MSP); estrogen receptor (ER)
ID DNA METHYLATION; PROMOTER METHYLATION; HYPERMETHYLATION; ACTIVATION;
   ESTROGEN; GROWTH; TUMOR
AB Bone morphogenetic protein-6 (BMP-6) is closely correlated with tumor differentiation and skeletal metastasis. Our previous research found that BMP-6 gene expression can be activated dose-dependently by estrogen in estrogen receptor positive (ER+) breast cancer cell line MCF-7. but not in ER negative (ER-) cell line MDA-MB-231. This experiment is designed to investigate the epigenetic regulatory mechanism of the BMP-6 gene expression in breast cancer cell lines MDA-MB-231, MCF-7 and T47D with regard to the methylation status in the 5' flanking region of the human BMP-6 gene. The endogenous level of BNIP-6 mRNA in ER- cell line MDA-MB-231 was relatively lower than that in ER+ MCF-7 and T47D cell lines. After the treatment with 5-aza-2'-deoxycytidine (5-aza-dC, especially in the concentration of 10 mu M), the BMP-6 mRNA expression in MDA-MB-231 was obviously up-regulated. However, 5-aza-dC treatment failed to regulate the expression of BNIP-6 in MCF-7 and T47D cells. Using enzyme restriction PCR (MSRE-PCR), as well as bisulfite sequencing (BSG), methylation of human BNIP-6 gene promoter was detected in MDA-MB-231; while in MCF-7 and T47D, BMP-6 gene promoter remained demethylated status. In 33 breast tumor specimens, promoter methylation of BMP-6 was detected by methylation-specific PCR, hypermethylation of BMP-6 was observed in ER negative cases (16 of 16 cases (100%)), while obviously lower methylation frequency were observed in ER positive cases (3 of 17 cases (18%)), indicating that BMP-6 promoter methylation status is correlated with ER status in breast cancer. (c) 2007 Published by Elsevier Ltd.
C1 Nankai Univ, Coll Med, Mol Med Lab, Tianjin 300071, Peoples R China.
   Tianjin Med Univ, Canc Inst & Hosp, Tianjin 300060, Peoples R China.
C3 Nankai University; Tianjin Medical University
RP Zhu, TH (通讯作者)，Nankai Univ, Coll Med, Mol Med Lab, Tianjin 300071, Peoples R China.
EM zhuth@nankai.edu.cn
RI Zhang, Ming/H-6467-2011; Yin, Jian/JBN-1938-2023
CR Akiyoshi T, 2004, VET PATHOL, V41, P154, DOI 10.1354/vp.41-2-154
   Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891
   Fotovati A, 2006, CLIN CANCER RES, V12, P3010, DOI 10.1158/1078-0432.CCR-05-1962
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Hamdy FC, 1997, CANCER RES, V57, P4427
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   Leung SY, 1999, CANCER RES, V59, P159
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   Maki DD, 2000, AM J NEURORADIOL, V21, P1064
   Matsubayashi H, 2006, CANCER RES, V66, P1208, DOI 10.1158/0008-5472.CAN-05-2664
   Melnikov AA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni092
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Paquette B, 2003, J STEROID BIOCHEM, V87, P65, DOI 10.1016/S0960-0760(03)00386-8
   Perry AS, 2006, ENDOCR-RELAT CANCER, V13, P357, DOI 10.1677/erc.1.01184
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Rudland SDS, 2006, CLIN CANCER RES, V12, P1192, DOI 10.1158/1078-0432.CCR-05-1580
   Schmutte C, 1998, BIOL CHEM, V379, P377
   SHEIKH MS, 1994, INVAS METAST, V14, P329
   Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056
   Sriussadaporn Sutin, 2002, Journal of the Medical Association of Thailand, V85, P327
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tamada H, 2001, J BONE MINER RES, V16, P487, DOI 10.1359/jbmr.2001.16.3.487
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Zhang M, 2005, CHINESE MED J-PEKING, V118, P1629
NR 26
TC 35
Z9 38
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD JUN-JUL
PY 2007
VL 105
IS 1-5
BP 91
EP 97
DI 10.1016/j.jsbmb.2007.01.002
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 210QO
UT WOS:000249470900010
PM 17574840
DA 2025-01-12
ER

PT J
AU Lee, JS
AF Lee, Ji Shin
TI GSTP1 promoter hypermethylation is an early event in breast
   carcinogenesis
SO VIRCHOWS ARCHIV
LA English
DT Article
DE breast; carcinogenesis; methylation; GSTP1
ID GLUTATHIONE-S-TRANSFERASE; DNA METHYLATION; CPG ISLANDS; IN-SITU;
   CANCER; PI; CARCINOMA; GENES; INACTIVATION; PROGRESSION
AB Promoter hypermethylation in precursor lesions of the breast cancer may be biomarkers of cancer risk and targets for cancer chemoprevention. Pi-class glutathione-S-transferases (GSTP1) is inactivated by promoter hypermethylation in invasive breast cancers. However, little is known about epigenetic silencing of GSTP1 gene by promoter hypermethylation in precursor lesions. To determine the significance of GSTP1 promoter hypermethylation in breast carcinogenesis, methylation status of GSTP1 gene was studied by nested methylation-specific polymerase chain reaction, and GSTP1 expression was studied by immunohistochemistry in invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), usual ductal hyperplasia (UDH), and normal breast tissue. GSTP1 promoter hypermethylation was detected in 4/24 (16.7%) of UDH, 18/49 (36.7%) of DCIS, and 14/36 (38.9%) of IDC. No hypermethylation was detected in normal breast tissues. GSTP1 promoter hypermethylation was found to be progressively elevated during breast carcinogenesis (p < 0.01). GSTP1 promoter hypermethylation was associated with loss of GSTP1 expression (p < 0.01 for UDH, p < 0.001 for DCIS and IDC). Our results suggest that GSTP1 promoter hypermethylation is an early event in breast carcinogenesis and appears to functionally silence GSTP1 expression. GSTP1 promoter hypermethylation in the precursor lesions of breast cancer may be used as a target for cancer chemoprevention.
C1 Chonnam Natl Univ, Hwasun Hosp, Hwasuneup 519809, Joellaam Do, South Korea.
   Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju 501746, South Korea.
   Res Inst Med Sci, Kwangju 501746, South Korea.
C3 Chonnam National University; Chonnam National University
RP Lee, JS (通讯作者)，Chonnam Natl Univ, Hwasun Hosp, 160,Ilsim Ri, Hwasuneup 519809, Joellaam Do, South Korea.
EM jshinlee@hanmail.net
FU NCI NIH HHS [P50 CA88843] Funding Source: Medline
CR Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Arpino G, 2005, ANN INTERN MED, V143, P446, DOI 10.7326/0003-4819-143-6-200509200-00009
   BELLAMY COC, 1994, BRIT J CANCER, V69, P183, DOI 10.1038/bjc.1994.31
   Chan QKY, 2005, J MOL DIAGN, V7, P8, DOI 10.1016/S1525-1578(10)60003-7
   Cho MH, 2006, BREAST, V15, P390, DOI 10.1016/j.breast.2005.06.011
   Coles BF, 2003, BIOFACTORS, V17, P115, DOI 10.1002/biof.5520170112
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Esteller M, 1998, CANCER RES, V58, P4515
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Huang JX, 2003, MODERN PATHOL, V16, P558, DOI 10.1097/01.MP.0000071842.83169.5A
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Steele VE, 2005, MUTAT RES-FUND MOL M, V591, P16, DOI 10.1016/j.mrfmmm.2005.04.018
   Tokumaru Y, 2004, CLIN CANCER RES, V10, P5518, DOI 10.1158/1078-0432.CCR-04-0108
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang CW, 2006, CANCER RES, V66, P11649, DOI 10.1158/0008-5472.CAN-06-1645
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
NR 26
TC 51
Z9 59
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD JUN
PY 2007
VL 450
IS 6
BP 637
EP 642
DI 10.1007/s00428-007-0421-8
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 181JU
UT WOS:000247433800004
PM 17479284
DA 2025-01-12
ER

PT J
AU Wu, JJ
   Wang, SH
   Potter, D
   Liu, JC
   Smith, LT
   Wu, YZ
   Huang, THM
   Plass, C
AF Wu, Jiejun
   Wang, Shu-Huei
   Potter, Dustin
   Liu, Joseph C.
   Smith, Laura T.
   Wu, Yue-Zhong
   Huang, Tim H-M
   Plass, Christoph
TI Diverse histone modifications on histone 3 lysine 9 and their relation
   to DNA methylation in specifying gene silencing
SO BMC GENOMICS
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; CPG ISLAND; H3 METHYLTRANSFERASE;
   CHROMATIN-STRUCTURE; BREAST-CANCER; HYPERMETHYLATION; HETEROCHROMATIN;
   TRANSCRIPTION; ARABIDOPSIS; BINDING
AB Background: Previous studies of individual genes have shown that in a self-enforcing way, dimethylation at histone 3 lysine 9 (dimethyl-H3K9) and DNA methylation cooperate to maintain a repressive mode of inactive genes. Less clear is whether this cooperation is generalized in mammalian genomes, such as mouse genome. Here we use epigenomic tools to simultaneously interrogate chromatin modifications and DNA methylation in a mouse leukemia cell line, L1210.
   Results: Histone modifications on H3K9 and DNA methylation in L1210 were profiled by both global CpG island array and custom mouse promoter array analysis. We used chromatin immunoprecipitation microarray (ChIP-chip) to examine acetyl-H3K9 and dimethyl-H3K9. We found that the relative level of acetyl-H3K9 at different chromatin positions has a wider range of distribution than that of dimethyl-H3K9. We then used differential methylation hybridization (DMH) and the restriction landmark genome scanning (RLGS) to analyze the DNA methylation status of the same targets investigated by ChIP-chip. The results of epigenomic profiling, which have been independently confirmed for individual loci, show an inverse relationship between DNA methylation and histone acetylation in regulating gene silencing. In contrast to the previous notion, dimethyl-H3K9 seems to be less distinct in specifying silencing for the genes tested.
   Conclusion: This study demonstrates in L1210 leukemia cells a diverse relationship between histone modifications and DNA methylation in the maintenance of gene silencing. Acetyl-H3K9 shows an inverse relationship between DNA methylation and histone acetylation in regulating gene silencing as expected. However, dimethyl-H3K9 seems to be less distinct in relation to promoter methylation. Meanwhile, a combination of epigenomic tools is of help in understanding the heterogeneity of epigenetic regulation, which may further our vision accumulated from single-gene studies.
C1 Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University
RP Plass, C (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.
EM Jiejun.Wu@osumc.edu; Shu-Huei.Wang@osumc.edu; Dustin.Potter@osumc.edu;
   Joseph.Liu@osumc.edu; Laura.Smith3@osumc.edu; Yue-Zhong.Wu@osumc.edu;
   Tim.Huang@osumc.edu; Christoph.Plass@osumc.edu
RI Plass, Christoph/H-7192-2014
OI Reever, Larson/0000-0002-5692-4793
FU NCI NIH HHS [U54 CA113001, T32 CA106196, P30 CA16058, P01 CA101956,
   P01-CA101956-01, N01-CO-12400, N01CO12400, P30 CA016058] Funding Source:
   Medline
CR Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chang S, 2005, J BIOL CHEM, V280, P796, DOI 10.1074/jbc.M409053200
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Chim CS, 2006, J HUM GENET, V51, P832, DOI 10.1007/s10038-006-0029-x
   Costello Joseph F, 2002, Methods Mol Biol, V200, P53
   Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Gartler SM, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-21
   Hanlon SE, 2004, CURR OPIN GENET DEV, V14, P697, DOI 10.1016/j.gde.2004.09.008
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Padjen K, 2005, MOL CELL BIOL, V25, P4782, DOI 10.1128/MCB.25.11.4782-4791.2005
   Pietrobono R, 2005, HUM MOL GENET, V14, P267, DOI 10.1093/hmg/ddi024
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413
   Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100
   TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G
   Umlauf D, 2004, NAT GENET, V36, P1296, DOI 10.1038/ng1467
   Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011
   Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475
   Wu JJ, 2006, CANCER RES, V66, P6899, DOI 10.1158/0008-5472.CAN-06-0276
   Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200
   Yan PS, 2001, CANCER RES, V61, P8375
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005
   Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048
NR 40
TC 35
Z9 46
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAY 24
PY 2007
VL 8
AR 131
DI 10.1186/1471-2164-8-131
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 175KY
UT WOS:000247013700001
PM 17524140
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU De Luca, A
   Sacchetta, P
   Nieddu, M
   Di Ilio, C
   Favaloro, B
AF De Luca, Antonella
   Sacchetta, Paolo
   Nieddu, Marzia
   Di Ilio, Carmine
   Favaloro, Bartolo
TI Important roles of multiple Sp1 binding sites and epigenetic
   modifications in the regulation of the methionine sulfoxide reductase B1
   (MsrB1) promoter
SO BMC MOLECULAR BIOLOGY
LA English
DT Article
ID CONTROLS DNA METHYLATION; HUMAN BREAST-CANCER; OXIDATIVE STRESS; HISTONE
   DEACETYLASE; SUBSTRATE STEREOSPECIFICITY; REPLICATIVE SENESCENCE;
   ANTIOXIDANT DEFENSE; PROTEIN MECP2; FREE-RADICALS; GENE
AB Background: Methionine sulfoxide reductases (Msrs) are enzymes that catalyze the reduction of oxidized methionine residues. Most organisms that were genetically modified to lack the MsrA gene have shown shortening of their life span. Methionine sulfoxide reductases B (MsrB) proteins codified by three separate genes, named MsrB1, MsrB2, and MsrB3, are included in the Msrs system. To date, the mechanisms responsible for the transcriptional regulation of MsrB genes have not been reported. The aim of this study was to investigate the regulation of MsrB1 selenoprotein levels through transcriptional regulation of the MsrB1 gene in MDA-MB231 and MCF-7 breast carcinoma cell lines.
   Results: A MsrB1 gene promoter is located 169 base pairs upstream from the transcription start site. It contains three Sp1 binding sites which are sufficient for maximal promoter activity in transient transfection experiments.
   High levels of MsrB1 transcript, protein and promoter activity were detected in low metastatic MCF7 human breast cancer cells. On the contrary, very low levels of both MsrB1 transcript and promoter activity were detected in the highly metastatic counterpart MDA-MB231 cells.
   A pivotal role for Sp1 in the constitutive expression of the MsrB1 gene was demonstrated through transient expression of mutant MsrB1 promoter-reporter gene constructs and chromatin immunoprecipitation experiments.
   Since Sp1 is ubiquitously expressed, these sites, while necessary, are not sufficient to explain the patterns of gene expression of MsrB1 in various human breast cancer cells. MDA-MB231 cells can be induced to express MsrB1 by treatment with 5-Aza-2 '-deoxycytidine, a demethylating agent. Therefore, the MsrB1 promoter is controlled by epigenetic modifications.
   Conclusion: The results of this study provide the first insights into the transcriptional regulation of the human MsrB1 gene, including the discovery that the Sp1 transcription factor may play a central role in its expression. We also demonstrated that the MsrB1 promoter activity appears to be controlled by epigenetic modifications such as methylation.
C1 Univ G dAnnunzio, Dept Biomed Sci, Sch Med, Chieti, Italy.
   Univ G dAnnunzio, Unit Gene Regulat, Ctr Excellence Aging, Chieti, Italy.
C3 G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of
   Chieti-Pescara
RP Favaloro, B (通讯作者)，Univ G dAnnunzio, Dept Biomed Sci, Sch Med, Chieti, Italy.
EM atdeluca@unich.it; ps@unich.it; pussolina@yahoo.it; mcpres@unich.it;
   b.favaloro@unich.it
RI Sacchetta, Paolo/E-2928-2010
CR Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647
   Bar-Noy S, 2002, BIOCHEM BIOPH RES CO, V297, P956, DOI 10.1016/S0006-291X(02)02314-8
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632
   BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen C, 2001, J BIOL CHEM, V276, P320, DOI 10.1074/jbc.M007096200
   Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317
   De Luca A, 2006, BIOCHEM J, V393, P321, DOI 10.1042/BJ20050973
   Dressel U, 2000, ANTICANCER RES, V20, P1017
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737
   Hansel A, 2005, BBA-PROTEINS PROTEOM, V1703, P239, DOI 10.1016/j.bbapap.2004.09.010
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kantorow M, 2004, P NATL ACAD SCI USA, V101, P9654, DOI 10.1073/pnas.0403532101
   Kim HY, 2006, BIOCHEMISTRY-US, V45, P13697, DOI 10.1021/bi0611614
   Kim HY, 2005, PLOS BIOL, V3, P2080, DOI 10.1371/journal.pbio.0030375
   Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629
   KOLLMAR R, 1994, J BIOL CHEM, V269, P2252
   LANS MS, 1994, J BIOL CHEM, V269, P14170
   Lee JW, 2006, EXP EYE RES, V82, P816, DOI 10.1016/j.exer.2005.10.003
   Lin XH, 2001, CANCER RES, V61, P8611
   Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783
   Marchetti MA, 2005, INVEST OPHTH VIS SCI, V46, P2107, DOI 10.1167/iovs.05-0018
   Mary J, 2004, EXP GERONTOL, V39, P1117, DOI 10.1016/j.exger.2004.06.008
   Moskovitz J, 2003, P NATL ACAD SCI USA, V100, P7486, DOI 10.1073/pnas.1332607100
   Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003
   Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585
   Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071
   Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167
   Moskovitz J, 2002, BIOCHEM BIOPH RES CO, V290, P62, DOI 10.1006/bbrc.2001.6171
   MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995
   Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Petropoulos I, 2005, BBA-PROTEINS PROTEOM, V1703, P261, DOI 10.1016/j.bbapap.2004.08.018
   Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819
   Picot CR, 2004, FEBS LETT, V558, P74, DOI 10.1016/S0014-5793(03)01530-8
   Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199
   Sagher D, 2006, J BIOL CHEM, V281, P31184, DOI 10.1074/jbc.M606962200
   Saghert D, 2006, P NATL ACAD SCI USA, V103, P8656, DOI 10.1073/pnas.0602826103
   Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004
   Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
   Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005
NR 57
TC 28
Z9 31
U1 2
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2199
J9 BMC MOL BIOL
JI BMC Mol. Biol.
PD MAY 22
PY 2007
VL 8
AR 39
DI 10.1186/1471-2199-8-39
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 175MY
UT WOS:000247018900001
PM 17519015
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Tian, K
   Wang, Y
   Xu, H
AF Tian, K.
   Wang, Y.
   Xu, H.
TI <i>WTH3</i> is a direct target of the p53 protein
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE WTH3 gene; p53-response element; multidrug resistance; apoptosis
ID HUMAN BREAST-CANCER; BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANT;
   DNA METHYLATION; P-GLYCOPROTEIN; GENE FAMILY; CELL-LINES; IN-VIVO;
   APOPTOSIS; IDENTIFICATION
AB Previous results showed that overexpression of the WTH3 gene in multidrug resistance (MDR) cells reduced MDR1 gene expression and converted their resistance to sensitivity to various anticancer drugs. The WTH3 gene promoter was found to be differentially regulated in paired MDR vs non-MDR MCF7 cells owing to epigenetic modifications and transcription factor modulations. To understand further the mechanisms that govern WTH3's differential expression, we uncovered a p53-binding site in its promoter, which indicated that WTH3 could be regulated by the p53 gene. This hypothesis was then tested by different strategies. The resulting data revealed that ( 1) the WTH3 promoter was upregulated by the p53 transgene in diverse host cells; ( 2) there was a correlation between WTH3 expression levels and p53 gene status in a cell line panel; ( 3) a WTH3 promoter region was directly targeted by the p53 protein in vitro and in vivo. In addition, overexpression of the WTH3 gene promoted the apoptotic phenotype in host cells. On the basis of these findings, we believe that the negative role played by the WTH3 gene in MDR development is through its proapoptotic potential that is regulated by multiple mechanisms at the transcription level, and one of these mechanisms is linked to the p53 gene.
C1 SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
   Jilin Univ, Lab Pathobiol, Changchun 130023, Peoples R China.
C3 State University of New York (SUNY) System; Stony Brook University;
   Jilin University
RP Xu, H (通讯作者)，SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
EM hduffy@notes.cc.sunysb.edu
FU NCI NIH HHS [1R01CA090443-01A2, R01 CA090443] Funding Source: Medline
CR Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811
   Adachi K, 2004, ONCOGENE, V23, P7791, DOI 10.1038/sj.onc.1208067
   Antequera F., 1993, Experientia Supplementum (Basel), V64, P169
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75
   CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704
   DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521
   Echard A, 2000, MOL BIOL CELL, V11, P3819, DOI 10.1091/mbc.11.11.3819
   Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580
   ELSTNER E, 1995, CANCER RES, V55, P2822
   GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5
   GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0
   Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200
   Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947
   Li C, 2004, ONCOGENE, V23, P9336, DOI 10.1038/sj.onc.1208114
   Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006
   Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013
   Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855
   Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515
   Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974
   Ramljak D, 2005, MOL CANCER THER, V4, P537, DOI 10.1158/1535-7163.MCT-04-0286
   Righetti SC, 1996, CANCER RES, V56, P689
   Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830
   Schmitt CA, 1999, J PATHOL, V187, P127
   Shan JD, 2000, GENE, V257, P67, DOI 10.1016/S0378-1119(00)00395-4
   Shan JD, 2002, BBA-MOL CELL RES, V1589, P112, DOI 10.1016/S0167-4889(02)00164-7
   Shan JD, 2002, CANCER RES, V62, P290
   SIEGFRIED Z, 1997, CURR BIOL, V7, P305
   Smith ND, 2003, J UROLOGY, V169, P1219, DOI 10.1097/01.ju.0000056085.58221.80
   Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024
   Steer M, 2005, IEEE T MICROW THEORY, V53, P3, DOI 10.1109/TMTT.2004.839957
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   Tian KG, 2005, CANCER RES, V65, P7421, DOI 10.1158/0008-5472.CAN-05-0658
   Xu HP, 2007, CANCER RES, V67, P1239, DOI 10.1158/0008-5472.CAN-06-3688
   Yuan LM, 1999, CANCER RES, V59, P3215
   ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394
NR 44
TC 9
Z9 14
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 21
PY 2007
VL 96
IS 10
BP 1579
EP 1586
DI 10.1038/sj.bjc.6603724
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 168YS
UT WOS:000246560500014
PM 17426708
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Riquelme, E
   Tang, M
   Baez, S
   Diaz, A
   Pruyas, M
   Wistuba, II
   Corvalan, A
AF Riquelme, Erick
   Tang, Moying
   Baez, Sergio
   Diaz, Alfonso
   Pruyas, Martha
   Wistuba, Ignacio I.
   Corvalan, Alejandro
TI Frequent epigenetic inactivation of chromosome 3p candidate tumor
   suppressor genes in gallbladder carcinoma
SO CANCER LETTERS
LA English
DT Article
DE methylation; tumor suppressor genes; gallbladder carcinoma
ID CELL LUNG-CANCER; PROMOTER HYPERMETHYLATION; ALLELOTYPING ANALYSIS;
   HOMOZYGOUS DELETIONS; ISLAND METHYLATION; REVEALS MULTIPLE;
   BREAST-CANCER; ALLELIC LOSS; FHIT GENE; 3P21.3
AB Gallbladder carcinoma (GBC) is a highly malignant neoplasm that represents the leading cause of death for cancer in Chilean females. There is limited information about the molecular abnormalities involved in its pathogenesis. We have identified a number of molecular changes in GBC, including frequent allelic losses at chromosome 3p regions. Four distinct 3p sites (3p12, 3p14.2, 3p21.3 and 3p22-24) with frequent and early allelic losses in the sequential pathogenesis of this neoplasm have been detected. We investigated epigenetic and genetic abnormalities in GBC affecting 6 candidate tumor suppressor genes (TSG) located in chromosome 3p, including DUTT1 (3p12), FHIT(3p14.2), BLU, RASSF1A, SEMA3B and hMLH1 (3p21.3). DNA extracted from frozen tissue obtained from 50 surgical resected GBCs was examined for gene promoter methylation using MSP (methylation-specific PCR) technique after bisulfite treatment in all 6 genes. In addition, we performed PCR-based mutation examination using SSCP in FHIT and RASSF1A genes and loss of heterozygosity (LOH) analysis using microdissected tissue in a subset of tumors for the 3p21.3 region with 8 microsatellite markers. A very high frequency of GBC methylation was detected in SEMA3B (46/50, 92%) and FHIT (33/50, 66%), inter-mediate incidences in BLU (13/50, 26%) and DUTT1 (11/50, 22%) and very low frequencies in RASSF1A (4/50, 8%) and hMLH1 (2/50, 4%). Allelic loss at 3p21.3 was found in nearly half of the GBCs examined. We conclude that epigenetic inactivation by abnormal promoter methylation is a frequent event in chromosome 3p candidate TSGs in GBC pathogenesis, especially affecting genes SEMA3B (3p21.3) and FHIT (3p 14.2). (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Pontificia Univ Catolica Chile, Dept Anat Pathol, Santiago 133202, Chile.
   Hosp Sotero del Rio, Santiago, Chile.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
C3 Pontificia Universidad Catolica de Chile; Universidad de Chile;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Corvalan, A (通讯作者)，Pontificia Univ Catolica Chile, Dept Anat Pathol, 85 Lira St, Santiago 133202, Chile.
EM corvalan@med.puc.cl
RI RIQUELME, ERICK/AAA-6191-2022
OI RIQUELME, ERICK/0000-0002-2696-7995; Corvalan,
   Alejandro/0000-0001-5492-3853
CR ALBORESSAAVEDRA J, 1980, CANCER-AM CANCER SOC, V45, P919, DOI 10.1002/1097-0142(19800301)45:5<919::AID-CNCR2820450514>3.0.CO;2-4
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421
   Esteller M, 2001, CANCER RES, V61, P3225
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fong KM, 1997, CANCER RES, V57, P2256
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   House MG, 2003, ANN SURG ONCOL, V10, P882, DOI 10.1245/ASO.2003.02.014
   Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937
   Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   KNUDSON AG, 1985, CANCER RES, V45, P1437
   Kuroki T, 2003, CANCER RES, V63, P3352
   Lazcano-Ponce EC, 2001, CA-CANCER J CLIN, V51, P349, DOI 10.3322/canjclin.51.6.349
   Lerman MI, 2000, CANCER RES, V60, P6116
   Liu XQ, 2003, INT J CANCER, V106, P60, DOI 10.1002/ijc.11166
   Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716
   Takahashi T, 2004, CLIN CANCER RES, V10, P6126, DOI 10.1158/1078-0432.CCR-04-0579
   Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X
   Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362
   Tse C, 2002, CANCER RES, V62, P542
   Wistuba I I, 1999, J Hepatobiliary Pancreat Surg, V6, P237, DOI 10.1007/s005340050113
   Wistuba II, 2000, CANCER RES, V60, P1949
   Wistuba II, 2004, NAT REV CANCER, V4, P695, DOI 10.1038/nrc1429
   Wistuba II, 2002, AM J PATHOL, V160, P2073, DOI 10.1016/S0002-9440(10)61157-1
   Wistuba II, 2001, CANCER RES, V61, P3795
   Wistuba II, 1998, JAMA-J AM MED ASSOC, V279, P1554, DOI 10.1001/jama.279.19.1554
   Wistuba II, 1997, CANCER RES, V57, P3154
   Wistube II, 2002, BRIT J CANCER, V87, P432, DOI 10.1038/sj.bjc.6600490
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 41
TC 42
Z9 50
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD MAY 18
PY 2007
VL 250
IS 1
BP 100
EP 106
DI 10.1016/j.canlet.2006.09.019
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 164UM
UT WOS:000246260100012
PM 17084965
DA 2025-01-12
ER

PT J
AU Schagdarsurengin, U
   Pfeifer, GP
   Dammann, R
AF Schagdarsurengin, U.
   Pfeifer, G. P.
   Dammann, R.
TI Frequent epigenetic inactivation of <i>cystatin M</i> in breast
   carcinoma
SO ONCOGENE
LA English
DT Article
DE cystatin M; tumour suppressor gene; epigenetic inactivation;
   methylation; breast cancer; CST6
ID CYSTEINE PROTEINASE-INHIBITOR; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR
   GENE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; MALIGNANT PHENOTYPE;
   CANCER; ASSOCIATION; PROGRESSION; EXPRESSION
AB Cystatin M is a potent endogenous inhibitor of lysosomal cysteine proteases. In breast carcinoma, cystatin M expression is frequently downregulated. It has been shown that cystatin M expression suppressed growth and migration of breast cancer cells. We examined the methylation status of the CpG island promoter of cystatin M in four breast cancer cell lines ( MDAMB231, ZR75-1, MCF7 and T47D), in 40 primary breast carcinoma and in corresponding normal tissue probes by combined bisulphite restriction analysis. To investigate the effects of cystatin M expression on the growth of breast carcinoma, cystatin M was transfected in T47D. The cystatin M promoter was highly methylated in all four-breast cancer cell lines. Primary breast tumours were significantly more frequently methylated compared to normal tissue samples ( 60 vs 25%; P = 0.006 Fisher's exact test). Treatment of breast cancer cells with 5-aza-2'-deoxycytidine ( 5-Aza-CdR), reactivated the transcription of cystatin M. Transfection of breast carcinoma cells with cystatin M caused a 30% decrease in colony formation compared to control transfection ( P = 0.002). Our results show that cystatin M is frequently epigenetically inactivated during breast carcinogenesis and cystatin M expression suppresses the growth of breast carcinoma. These data suggest that cystatin M may encode a novel epigenetically inactivated candidate tumour suppressor gene.
C1 Univ Halle Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, D-06097 Halle, Germany.
   City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA USA.
C3 Martin Luther University Halle Wittenberg; City of Hope; Beckman
   Research Institute of City of Hope
RP Dammann, R (通讯作者)，Univ Halle Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, Magdeburger Str 2, D-06097 Halle, Germany.
EM reinhard.dammann@medizin.uni-halle.de
RI Schagdarsurengin, Undraga/AAH-4312-2020
OI Schagdarsurengin, Undraga/0000-0003-0127-4938
FU NCI NIH HHS [CA88873] Funding Source: Medline
CR Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179
   Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   CALKINS CC, 1995, BIOL CHEM H-S, V376, P71
   Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x
   Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763
   Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157
   Henskens YMC, 1996, BIOL CHEM H-S, V377, P71
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Krepela E, 2001, NEOPLASMA, V48, P332
   Lah TT, 1998, BIOL CHEM, V379, P125
   Ni J, 1997, J BIOL CHEM, V272, P10853
   Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Song J, 2006, BIOCHEM BIOPH RES CO, V340, P175, DOI 10.1016/j.bbrc.2005.11.171
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698
   Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388
   Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
NR 31
TC 30
Z9 30
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAY 10
PY 2007
VL 26
IS 21
BP 3089
EP 3094
DI 10.1038/sj.onc.1210107
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 166QX
UT WOS:000246395400014
PM 17099723
DA 2025-01-12
ER

PT J
AU Zhang, Q
   Ying, JM
   Zhang, K
   Li, HY
   Ng, KM
   Zhao, YY
   He, Q
   Yang, XY
   Xin, DQ
   Liao, SK
   Tao, Q
   Jin, J
AF Zhang, Qlan
   Ying, Jianming
   Zhang, Kai
   Li, Hongyu
   Ng, Ka Man
   Zhao, Yayuan
   He, Qun
   Yang, Xinyu
   Xin, Dianqi
   Liao, Shuen-Kuei
   Tao, Qian
   Jin, Jie
TI Aberrant methylation of the 8p22 tumor suppressor gene <i>DLC1</i> in
   renal cell carcinoma
SO CANCER LETTERS
LA English
DT Article
DE methylation; tumor suppressor gene; DLC1 gene; renal; carcinoma
ID HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION;
   CLEAR-CELL; HEPATOCELLULAR-CARCINOMA; CLASSIFICATION; PAPILLARY;
   RASSF1A; KIDNEY; HETEROZYGOSITY
AB Epigenetic mechanisms involving DNA methylation and chromatin remodeling are important in silencing tumor suppressor genes (TSG) in various malignancies, including renal cell carcinoma (RCC). DLC1 (deleted in liver cancer 1)/ARHGAP7 is a recently identified 8p22 candidate TSG. Frequent methylation of the DLC1 promoter with resultant gene silencing has been reported in several tumors, but not in RCC yet. We examined DLC1 promoter methylation in 34 primary RCCs and the corresponding non-malignant tissues, and the correlation of DLC1 methylation with the clinicopathological characteristics of RCC patients. Although DLC1 methylation and downregulation were only detected in one of seven RCC cell lines using methylation-specific PCR (MSP) and semi-quantitative reverse-transcription PCR, we found that the DLC1 promoter was methylated in 35% (12/34) of primary RCC tumors, which was further confirmed by direct sequencing of MSP products and high-resolution bisulfite genomic sequencing. In contrast, only one of the 34 (3%) non-malignant renal tissues had weak methylation. Aberrant DLC1 methylation appeared to be a relatively early event during renal tumorigenesis since 33% of the RCC tumors with pT1 (TNM staging) showed methylation, which is similar to other late stage tumors. Thus, our results demonstrated that DLC1 methylation occurs in a subset of RCC tumors and may play a role in renal carcinogenesis. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.
   Peking Univ, Hosp 1, Dept Urol, Beijing 100871, Peoples R China.
   Peking Univ, Inst Urol, Beijing 100871, Peoples R China.
   Peking Univ, Hlth Sci Ctr, Inst Urol, Dept Pathol, Beijing 100871, Peoples R China.
C3 Chinese University of Hong Kong; Peking University; Peking University;
   Peking University
RP Tao, Q (通讯作者)，Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.
EM qtao@clo.cuhk.edu.hk; jinjie@vip.163.com
RI Jin, Jie/GQH-8572-2022; Zhang, Kaihua/AAD-7882-2022; Tao,
   Qian/T-4743-2018
OI Tao, Qian/0000-0001-5383-4808
CR Bachman KE, 1999, CANCER RES, V59, P798
   Breault JE, 2005, CLIN CANCER RES, V11, P557
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
   Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
   Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827
   Michael A, 2003, LANCET ONCOL, V4, P215, DOI 10.1016/S1470-2045(03)01044-1
   MORITA R, 1991, CANCER RES, V51, P820
   Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371
   Morrissey C, 2001, CANCER RES, V61, P7277
   Ng IOL, 2000, CANCER RES, V60, P6581
   Okuda H, 2006, ONCOGENE, V25, P1733, DOI 10.1038/sj.onc.1209200
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   Sanz-Casla MT, 2003, UROL RES, V31, P159, DOI 10.1007/s00240-003-0308-3
   Schullerus D, 1997, J PATHOL, V183, P151, DOI 10.1002/(SICI)1096-9896(199710)183:2<151::AID-PATH928>3.0.CO;2-R
   SENG TJ, 2006, ONCOGENE
   Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Wong CM, 2003, CANCER RES, V63, P7646
   Yamada D, 2006, INT J CANCER, V118, P916, DOI 10.1002/ijc.21450
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064
   Zambrano NR, 1999, J UROLOGY, V162, P1246, DOI 10.1016/S0022-5347(05)68259-6
NR 37
TC 38
Z9 44
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD MAY 8
PY 2007
VL 249
IS 2
BP 220
EP 226
DI 10.1016/j.canlet.2006.08.019
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 162LM
UT WOS:000246088900011
PM 17029774
DA 2025-01-12
ER

PT J
AU Sandal, T
   Valyi-Nagy, K
   Spencer, VA
   Folberg, R
   Bissell, MJ
   Maniotis, AJ
AF Sandal, Tone
   Valyi-Nagy, Klara
   Spencer, Virginia A.
   Folberg, Robert
   Bissell, Mina J.
   Maniotis, Andrew J.
TI Epigenetic reversion of breast carcinoma phenotype is accompanied by
   changes in DNA sequestration as measured by <i>Alu</i>I restriction
   enzyme
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID EXTRACELLULAR-MATRIX COMPONENTS; MIGRATION-STIMULATING FACTOR;
   FIBRONECTIN ISOFORM; RECIPROCAL INTERACTIONS; MAMMARY EPITHELIUM;
   SIGNALING PATHWAYS; PROTEIN-KINASE; CYCLIC-AMP; CELLS; CANCER
AB The importance of microenvironment and context in regulation of tissue-specific genes is well established. DNA exposure to or the sequestration from nucleases detects differences in higher order chromatin structure in intact cells without disturbing cellular or tissue architecture. To investigate the relationship between chromatin organization and tumor phenotype, we used an established three-dimensional assay in which normal and malignant human breast cells can be easily distinguished by the morphology of the structures they make (acinus-like versus tumor-like, respectively). We show that these phenotypes can be distinguished also by sensitivity to AluI digestion in which the malignant cells resist digestion relative to nonmalignant cells. Treatment of T4-2 breast cancer cells in three-dimensional culture with cAMP analogs or a phosphatidylinositol 3-kinase inhibitor not only reverted their phenotype from nonpolar to polar acinar-like structures but also enhanced chromatin sensitivity to AluI. By using different cAMP analogs, we show that cAMP-induced phenotypic reversion, polarization, and shift in DNA organization act through a cAMP-dependent protein-kinase A-coupled signaling pathway. Importantly, inhibitory antibody to fibronectin produced the same effect. These experiments underscore the concept that modifying the tumor microenvironment can alter the organization of tumor cells and demonstrate that architecture and global chromatin organization are coupled and highly plastic.
C1 Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
   Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; United States Department of
   Energy (DOE); Lawrence Berkeley National Laboratory
RP Maniotis, AJ (通讯作者)，Univ Illinois, Dept Pathol, 840 S Wood St,130 CSN,MC 847, Chicago, IL 60612 USA.
EM amanioti@uic.edu
RI BISSELL, MINA/ABR-7886-2022
OI Valyi-Nagy, Klara/0000-0002-3035-6388
FU NEI NIH HHS [R01 EY010457, EY10457] Funding Source: Medline
CR ASHALL F, 1988, P NATL ACAD SCI USA, V85, P3908, DOI 10.1073/pnas.85.11.3908
   Briand P, 1996, CANCER RES, V56, P2039
   CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507
   Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200
   de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0
   DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144
   DURNING P, 1984, LANCET, V2, P890
   George EL, 1997, BLOOD, V90, P3073, DOI 10.1182/blood.V90.8.3073
   GEORGE EL, 1993, DEVELOPMENT, V119, P1079
   Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359
   Ioachim E, 2005, BJU INT, V95, P655, DOI 10.1111/j.1464-410X.2005.05357.x
   Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1
   KACZMAREK J, 1994, INT J CANCER, V59, P11, DOI 10.1002/ijc.2910590104
   Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275
   Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200
   Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5
   KRYSTOSEK A, 1990, P NATL ACAD SCI USA, V87, P6560, DOI 10.1073/pnas.87.17.6560
   Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103
   Labat-Robert Jacqueline, 2004, Journal de la Societe de Biologie, V198, P287
   Lelièvre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711
   Lin AY, 2005, ARCH PATHOL LAB MED, V129, P884
   Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090
   Maniotis AJ, 2005, AM J PATHOL, V166, P1187, DOI 10.1016/S0002-9440(10)62338-3
   Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849
   Midulla M, 2000, CANCER RES, V60, P164
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184
   PICARDO M, 1991, LANCET, V337, P130, DOI 10.1016/0140-6736(91)90798-T
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Puck TT, 2002, ANN NY ACAD SCI, V968, P122, DOI 10.1111/j.1749-6632.2002.tb04331.x
   Pujuguet P, 2000, J CELL SCI, V113, P849
   Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417
   SCHONBERG S, 1983, EXP CELL RES, V145, P57, DOI 10.1016/S0014-4827(83)80007-X
   Schor SL, 2003, CANCER RES, V63, P8827
   SCHOR SL, 1988, J CELL SCI, V90, P391
   SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606
   WALSH DA, 1968, J BIOL CHEM, V243, P3763
   Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821
   Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x
NR 44
TC 18
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2007
VL 170
IS 5
BP 1739
EP 1749
DI 10.2353/ajpath.2007.060922
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 161XN
UT WOS:000246050400029
PM 17456778
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Ou, JN
   Torrisani, J
   Unterberger, A
   Provençal, N
   Shikimi, K
   Karimi, M
   Ekström, TJ
   Szyf, M
AF Ou, Jing-Ni
   Torrisani, Jerome
   Unterberger, Alexander
   Provencal, Nadine
   Shikimi, Keisuke
   Karimi, Mohsen
   Ekstrom, Tomas J.
   Szyf, Moshe
TI Histone deacetylase inhibitor Trichostatin A induces global and
   gene-specific DNA demethylation in human cancer cell lines
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE histone deacetylase inhibitor; tumor suppressor gene; DNA methylation;
   histone acetylation; hypomethylation; hydroxyurea
ID TUMOR-SUPPRESSOR GENE; ACID RECEPTOR-BETA; RETINOIC ACID;
   CHROMATIN-STRUCTURE; CARCINOMA-CELLS; BREAST-CANCER; METHYLATION;
   BINDING; PROMOTER; 5-AZA-2'-DEOXYCYTIDINE
AB DNA methylation and chromatin structure are two modes of epigenetic control of genome function. Although it is now well established that chromatin silencing could lead to DNA methylation, the relation between chromatin activation and DNA demethylation is unclear. It was generally believed that expression of methylated genes could only be restored by demethylating agents, such as 5-aza-deoxycytidine (5-azaCdR), and that inhibition of histone deacetylation by Trichostatin A (TSA) only activates transcription of unmethylated genes. in this report, we show that increase of histone acetylation by TSA was associated with a significant decrease in global methylation. This global demethylation occurs even when DNA replication is blocked by hydroxyurea, supporting a replication-independent-mechanism of demethylation. TSA also induces histone acetylation, demethylation and expression of the methylated E-CADHERIN and RAR beta 2 genes. However, the genome-wide demethylation induced by TSA does not affect all methylated tumor suppressor genes equally suggesting that induction of acetylation and demethylation by TSA shows some gene selectivity. Taken together, our data provide evidence for a reversible crosstalk between histone acetylation and DNA demethylation, which has significant implications on the use of HDAC inhibitors as therapeutic agents. Crown Copyright (c) 2007 Published by Elsevier Inc. All rights reserved.
C1 McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
   Karolinska Inst, Dept Clin Neurosci, Lab Mol Dev & Tumor Biol, Stockholm, Sweden.
C3 McGill University; Karolinska Institutet
RP Szyf, M (通讯作者)，McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.
EM moshe.szyf@mcgill.ca
RI Torrisani, Jérôme/M-6203-2014; Ekström, Tomas/B-7764-2013
OI Provencal, Nadine/0000-0002-2079-8393
CR Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200
   Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   CLAVERIE JM, 1994, NATURE, V371, P752, DOI 10.1038/371752a0
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029
   Grayson DR, 2005, P NATL ACAD SCI USA, V102, P9341, DOI 10.1073/pnas.0503736102
   Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8
   HENNIG G, 1995, ONCOGENE, V11, P475
   Karimi M., 2006, EXP CELL RES
   Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   LEE XH, 1995, EXP CELL RES, V218, P296, DOI 10.1006/excr.1995.1158
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Ramsahoye Bernard H, 2002, Methods Mol Biol, V200, P9
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064
   Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430
   SHAPIRO GI, 1995, CANCER RES, V55, P6200
   SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090
   Szyf M, 2003, DRUG RESIST UPDATE, V6, P341, DOI 10.1016/j.drup.2003.10.002
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 36
TC 149
Z9 180
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY 1
PY 2007
VL 73
IS 9
BP 1297
EP 1307
DI 10.1016/j.bcp.2006.12.032
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 164TM
UT WOS:000246257300005
PM 17276411
DA 2025-01-12
ER

PT J
AU Ohm, JE
   Baylin, SB
AF Ohm, Joyce E.
   Baylin, Stephen B.
TI Stem cell chromatin patterns - An instructive mechanism for DNA
   hypermethylation?
SO CELL CYCLE
LA English
DT Article
DE epigenetics; stem cells; chromatin; cancer; DNA hypermethylation
ID TUMOR-SUPPRESSOR GENES; HISTONE H3 LYSINE-9; CANCER EPIGENETICS;
   NEUROSPORA-CRASSA; BREAST-CANCER; METHYLATION; POLYCOMB;
   DIFFERENTIATION; IDENTIFICATION; MAINTENANCE
AB Epigenetic gene silencing, and associated promoter CpG island DNA hypermethylation, is an alternative mechanism to mutations by which tumor suppressor genes may be inactivated within a cancer cell. (1-4,5-7) These epigenetic changes are prevalent in all types of cancer, and their appearance may precede genetic changes in premalignant cells and foster the accumulation of additional genetic and epigenetic hits. 8 These epigenetically modified genes constitute important categories of tumor suppressor genes including cell cycle regulators, pro-differentiation factors, and anti-apoptotic genes, 3 and many of these genes are known to play a role in normal development. 9-11 While the silencing of these genes may play an essential role in tumor initiation or progression, the mechanisms underlying the specific targeting of these genes for DNA hypermethylation remains to be determined. The large numbers of epigenetically silenced genes that may be present in any given tumor, and the clustering of silenced genes within single cell pathways, 12 begs the question of whether gene silencing is a series of random events resulting in an enhanced survival of a premalignant clone, or whether silencing is the result of a directed, instructive program for silencing initiation reflective of the cells of origin for tumors. In this regard, the current review stresses the latter hypothesis and the important possibility that the program is linked, at least for silencing of some cancer genes, to the epigenetic control of stem/precursor cell gene expression patterns.
C1 Johns Hopkins Univ, Inst Med, Div Canc Biol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   Johns Hopkins Univ, Inst Med, Program Cellular & Mol Med, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University
RP Baylin, SB (通讯作者)，Bunting Blaustein Canc Res Bldg,1650 Orleans St,S, Baltimore, MD 21213 USA.
EM sbaylin@jhmi.edu
RI Ohm, Joyce/B-1497-2012
OI Ohm, Joyce/0000-0002-7390-8701
FU NCI NIH HHS [R01 CA116160-04, R01 CA043318, R01 CA116160] Funding
   Source: Medline
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6
   ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970
   Burch JBE, 2005, SEMIN CELL DEV BIOL, V16, P71, DOI 10.1016/j.semcdb.2004.10.002
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Furukawa Y, 2002, LEUKEMIA LYMPHOMA, V43, P225, DOI 10.1080/10428190290005973
   Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jackson JP, 2004, CHROMOSOMA, V112, P308, DOI 10.1007/s00412-004-0275-7
   Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   LUND ALM, 2004, CURRENT OPINION GENE, V16, P1
   Malagnac F, 2002, EMBO J, V21, P6842, DOI 10.1093/emboj/cdf687
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4
   PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
NR 48
TC 86
Z9 92
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 1
PY 2007
VL 6
IS 9
BP 1040
EP 1043
DI 10.4161/cc.6.9.4210
PG 4
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 163GV
UT WOS:000246148300008
PM 17457052
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kaz, A
   Kim, YH
   Dzieciatkowskil, S
   Lynch, H
   Watson, P
   Washington, MK
   Lin, L
   Grady, WM
AF Kaz, Andrew
   Kim, Young-Ho
   Dzieciatkowskil, Slavomir
   Lynch, Henry
   Watson, Patrice
   Washington, Mary Kay
   Lin, Li
   Grady, William M.
TI Evidence for the role of aberrant DNA methylation in the pathogenesis of
   Lynch syndrome adenomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE Lynch syndrome; HNPCC; DNA methylation; colon cancer; adenoma
ID NONPOLYPOSIS COLORECTAL-CANCER; CPG ISLAND METHYLATION; MISMATCH REPAIR
   DEFICIENCY; HMLH1 PROMOTER; COLON-CANCER; MICROSATELLITE INSTABILITY;
   BREAST-CANCER; WILD-TYPE; SOMATIC INACTIVATION; MOLECULAR ANALYSIS
AB Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit" mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14(ARF) are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecular pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms. (c) 2007 Wiley-Liss, Inc.
C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
   Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA.
   Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   Samsung Med Ctr, Dept Med, Seoul, South Korea.
   Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea.
   Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA.
   Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA.
   VA Puget Sound Healthcare Syst, R&D Serv, Seattle, WA USA.
C3 Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University
   of Washington; University of Washington Seattle; Sungkyunkwan University
   (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU);
   Creighton University; Vanderbilt University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound
   Health Care System
RP Grady, WM (通讯作者)，Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.
EM wgrady@fhcrc.org
CR Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Cunningham JM, 2001, AM J HUM GENET, V69, P780, DOI 10.1086/323658
   de Abajo AS, 2006, ONCOGENE, V25, P2124, DOI 10.1038/sj.onc.1209233
   Deng GR, 1999, CANCER RES, V59, P2029
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fishbein L, 2005, CANCER GENET CYTOGEN, V157, P181, DOI 10.1016/j.cancergencyto.2004.08.016
   Geisler JP, 2003, EUR J GYNAECOL ONCOL, V24, P361
   Grady WM, 2001, CANCER RES, V61, P900
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043
   Grady WM, 2003, GASTROENTEROLOGY, V124, P1574, DOI 10.1016/S0016-5085(03)00376-7
   HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051
   Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5
   Jass JR, 2002, J GASTROEN HEPATOL, V17, P17, DOI 10.1046/j.1440-1746.2002.02635.x
   Kámory E, 2003, PATHOL ONCOL RES, V9, P236, DOI 10.1007/BF02893384
   Kane MF, 1997, CANCER RES, V57, P808
   Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341
   Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1
   Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108
   Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28
   Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x
   Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234
   McGivern A, 2004, Fam Cancer, V3, P101
   Menigatti M, 2001, GENE CHROMOSOME CANC, V31, P357, DOI 10.1002/gcc.1154
   PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J
   Petko Z, 2005, CLIN CANCER RES, V11, P1203
   Prowse AH, 1997, AM J HUM GENET, V60, P765
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Rowan A, 2005, CLIN GASTROENTEROL H, V3, P1115, DOI 10.1016/S1542-3565(05)00618-X
   Ruteshouser EC, 2005, GENE CHROMOSOME CANC, V43, P172, DOI 10.1002/gcc.20169
   Samowitz WS, 1999, AM J PATHOL, V154, P1637, DOI 10.1016/S0002-9440(10)65418-1
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Shih IM, 2001, CANCER RES, V61, P818
   Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Wagner A, 2003, AM J HUM GENET, V72, P1088, DOI 10.1086/373963
   Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588
   Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296
   Yamamoto H, 2002, GENE CHROMOSOME CANC, V33, P322, DOI 10.1002/gcc.10010
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3
   Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968
NR 53
TC 29
Z9 32
U1 1
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 1
PY 2007
VL 120
IS 9
BP 1922
EP 1929
DI 10.1002/ijc.22544
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 146ZA
UT WOS:000244972000012
PM 17278092
OA Bronze
DA 2025-01-12
ER

PT J
AU de Maat, MFG
   Umetani, N
   Sunami, E
   Turner, RR
   Hoon, DSB
AF de Maat, Michiel F. G.
   Umetani, Naoyuki
   Sunami, Eiji
   Turner, Roderick R.
   Hoon, Dave S. B.
TI Assessment of methviation events durinq colorectal tumor progression by
   absolute quantitative analysis of methylated alleles
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID CPG ISLAND METHYLATION; ABERRANT CRYPT FOCI; DNA METHYLATION;
   MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; PCR ASSAY;
   EPIGENETIC INACTIVATION; GENE-EXPRESSION; CANCER PATIENTS; BREAST-CANCER
AB To date, the epigenetic events involved in the progression of colorectal cancer are not well described. To study, in detail, methylation during colorectal cancer development in high-risk adenomas, we developed an assay combining in situ (on-slide) sodium bisulfite modification (SBM) of paraffin-embedded archival tissue sections with absolute quantitative assessment of methylated alleles (AQAMA). We tested the performance of the assay to detect methylation level differences between paired pre-malignant and malignant colorectal cancer stages. AQAMA assays were used to measure methylation levels at MINT (methylated in tumor) loci MINT1, MINT2, MINT12, and MINT31. Assay performance was verified on cell line DNA and standard cDNA. On-slide SBM, allowing DNA methylation assessment of 1 to 2 mm(2) Of paraffin-embedded archival tissue, was employed. Methylation levels of adenomatous and cancerous components within a single tissue section in 72 colorectal cancer patients were analyzed. AQAMA was verified as accurately assessing CpG island methylation status in cell lines. The correlation between expected and measured cDNA methylation levels was high for all four MINT AQAMA assays (R >= 0.966, P < 0.001). Methylation levels at the four loci increased in 11% and decreased in 36% of specimens comparing paired adenoma and cancer tissues (P < 0.0001 by Kolmogorov-Smirnov test). Single-PCR AQAMA provided accurate methylation level measurement. Variable MINT locus methylation level changes occur during malignant progression of colorectal adenoma. Combining AQAMA with on-slide SBM provides a sensitive assay that allows detailed histology-oriented analysis of DNA methylation levels and may give new, accurate insights into understanding development of epigenetic aberrancies in colorectal cancer progression.
C1 John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   St Johns Hlth Ctr, Dept Surg Pathol, Santa Monica, CA USA.
C3 John Wayne Cancer Institute
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683
CR Afonina IA, 2002, BIOTECHNIQUES, V32, P940, DOI 10.2144/02324pf01
   Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bernard PS, 2002, CLIN CHEM, V48, P1178
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eschrich S, 2005, J CLIN ONCOL, V23, P3526, DOI 10.1200/JCO.2005.00.695
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fujiwara Y, 1999, CANCER RES, V59, P1567
   Harden SV, 2003, CLIN CANCER RES, V9, P1370
   Hawkins N, 2002, GASTROENTEROLOGY, V122, P1376, DOI 10.1053/gast.2002.32997
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hiraoka S, 2006, GASTROENTEROLOGY, V131, P379, DOI 10.1053/j.gastro.2006.04.027
   Jass JR, 2002, SURG CLIN N AM, V82, P891, DOI 10.1016/S0039-6109(02)00047-6
   Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655
   Luo LP, 2005, INT J CANCER, V115, P747, DOI 10.1002/ijc.20936
   Miyashiro I, 2001, CLIN CHEM, V47, P505
   Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Sugai T, 2006, J MOL DIAGN, V8, P193, DOI 10.2353/jmoldx.2006.050052
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689
   Umetani N, 2006, MOL CANCER RES, V4, P303, DOI 10.1158/1541-7786.MCR-05-0199
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wynter CVA, 2006, INT J CANCER, V118, P907, DOI 10.1002/ijc.21363
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
NR 37
TC 25
Z9 30
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY
PY 2007
VL 5
IS 5
BP 461
EP 471
DI 10.1158/1541-7786.MCR-06-0358
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 174DK
UT WOS:000246921200006
PM 17510312
OA Bronze
DA 2025-01-12
ER

PT J
AU Gillman, MW
   Barker, D
   Bier, D
   Cagampang, F
   Challis, J
   Fall, C
   Godfrey, K
   Gluckman, P
   Hanson, M
   Kuh, D
   Nathanielsz, P
   Nestel, P
   Thornburg, KL
AF Gillman, Matthew W.
   Barker, David
   Bier, Dennis
   Cagampang, Felino
   Challis, John
   Fall, Caroline
   Godfrey, Keith
   Gluckman, Peter
   Hanson, Mark
   Kuh, Diana
   Nathanielsz, Peter
   Nestel, Penelope
   Thornburg, Kent L.
TI Meeting Report on the 3rd International Congress on Developmental
   Origins of Health and Disease (DOHaD)
SO PEDIATRIC RESEARCH
LA English
DT Article
ID FETAL-GROWTH RESTRICTION; PREGNANCY WEIGHT-GAIN; BREAST-CANCER RISK;
   LOW-BIRTH-WEIGHT; EPIGENETIC REGULATION; BLOOD-PRESSURE; BODY-SIZE;
   MATERNAL UNDERNUTRITION; GESTATIONAL-AGE; CHILD ADIPOSITY
AB Developmental origins of health and disease (DOHaD) focuses on the earliest stages of human development, and provides a novel paradigm to complement other strategies for lifelong prevention of common chronic health conditions. The 3(rd) International Congress on DOHaD, held in 2005, retained the most popular features from the first two biannual Congresses, while adding a number of innovations, including increased emphasis on implications of DOHaD for the developing world; programs for trainees and young investigators; and new perspectives, including developmental plasticity, influences of social hierarchies, effects of prematurity, and populations in transition. Emerging areas of science included, first, the controversial role. of infant weight gain in predicting adult obesity, diabetes, and cardiovascular disease. Second, in the era of epidemic obesity, pacing attention to the over-nourished fetus is as important as investigating the growth retarded one. Third, environmental toxins appear to have abroad range of long-lasting effects on the developing human. Fourth, epigenetic mechanisms could unite several strands of human and animal observations, and explain how genetically identical individuals raised in similar postnatal environments can nonetheless develop widely differing phenotypes. Improving the environment to which an individual is exposed during development may be as important as any other public health effort to enhance population health world wide.
C1 Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA.
   Harvard Univ, Sch Publ Hlth, Dept Nutr, Harvard Pilgrim Hlth Care, Boston, MA 02215 USA.
   Univ Southampton, Div Dev Origins Hlth & Dis, Southampton SO16 5YA, Hants, England.
   Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA.
   Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada.
   Southampton Gen Hosp, MRC Epidemiol Resource Ctr, Southampton SO16 5YD, Hants, England.
   Univ Auckland, Liggins Inst, Auckland 1, New Zealand.
   Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand.
   UCL Royal Free & UCL Med Sch, Dept Epidemiol & Publ Hlth, MRC Natl Survey Hlth & Dev, London WC1E 6BT, England.
   Univ Texas, Hlth Sci Ctr, Dept Obstet, San Antonio, TX 78229 USA.
   Int Food Policy Res Inst, Washington, DC 20006 USA.
   Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA.
C3 Harvard University; Harvard Medical School; Harvard Pilgrim Health Care;
   Harvard University; Harvard T.H. Chan School of Public Health;
   University of Southampton; Baylor College of Medicine; United States
   Department of Agriculture (USDA); University of Toronto; University of
   Southampton; University of Auckland; University of Auckland; University
   of London; University College London; University of Texas System;
   University of Texas Health Science Center at San Antonio; CGIAR;
   International Food Policy Research Institute (IFPRI); Oregon Health &
   Science University
RP Gillman, MW (通讯作者)，Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.
EM matthew_gillman@hms.harvard.edu
RI Cagampang, Felino/AAG-5141-2019; Kuh, Diana/L-6019-2014; Hanson,
   Mark/AAE-8236-2019; Challis, John/E-7419-2014
OI Cagampang, Felino Ramon/0000-0003-4404-9853; Godfrey,
   Keith/0000-0002-4643-0618; Fall, Caroline/0000-0003-4402-5552; Hanson,
   Mark/0000-0002-6907-613X; Thornburg, Kent/0000-0002-5561-4785;
   Nathanielsz, Peter/0000-0001-8410-6280
FU Medical Research Council [MC_UP_A620_1014, MC_U147585821, MC_U147585827,
   G0400519] Funding Source: Medline; NHLBI NIH HHS [K24 HL 068041] Funding
   Source: Medline; NICHD NIH HHS [R13 HD 051239, P01 HD021350] Funding
   Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400519,
   MC_U147585827, MC_U147585821] Funding Source: UKRI
CR Antonisamy B, 2005, PEDIATR RES, V58, P1022
   Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058
   Armitage JA, 2005, J PHYSIOL-LONDON, V565, P171, DOI 10.1113/jphysiol.2005.084947
   Barker DJP, 2005, NEW ENGL J MED, V353, P1802, DOI 10.1056/NEJMoa044160
   Bergvall N, 2005, PEDIATR RES, V58, P1058
   Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698
   Collins JW, 2005, PEDIATR RES, V58, P1009
   Corvalán C, 2005, PEDIATR RES, V58, P1022
   Crews D, 2006, ENDOCRINOLOGY, V147, pS4, DOI 10.1210/en.2005-1122
   Davies AA, 2005, PEDIATR RES, V58, P1028
   de Assis S, 2005, PEDIATR RES, V58, P1047
   Dunn E, 2005, PEDIATR RES, V58, P1010
   Dziadek M, 2005, PEDIATR RES, V58, P1031
   Giannone PJ, 2005, PEDIATR RES, V58, P1080
   Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187
   Gillman MW, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e221
   Gluckman PD, 2005, P ROY SOC B-BIOL SCI, V272, P671, DOI 10.1098/rspb.2004.3001
   Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292
   Heinonen K, 2005, PEDIATR RES, V58, P1059
   Jansson N, 2005, PEDIATR RES, V58, P1015
   Jensen RI, 2005, PEDIATR RES, V58, P1111
   Jimenez-Chillaron JC, 2005, PEDIATR RES, V58, P1038
   Krishnaveni GV, 2005, PEDIATR RES, V58, P1030
   Lahti J, 2005, PEDIATR RES, V58, P1014
   Lemmen JG, 2005, PEDIATR RES, V58, P1045
   Lillycrop KA, 2005, PEDIATR RES, V58, P1031
   Lumb KJ, 2005, PEDIATR RES, V58, P1080
   Luther JS, 2005, PEDIATR RES, V58, P1015
   McCurdy C, 2005, PEDIATR RES, V58, P1039
   Miles H, 2005, PEDIATR RES, V58, P1016
   Mu JW, 2005, PEDIATR RES, V58, P1063
   Neufeld L, 2005, PEDIATR RES, V58, P1021
   Oken E, 2005, PEDIATR RES, V58, P1127
   Oken E, 2003, OBES RES, V11, P496, DOI 10.1038/oby.2003.69
   Oken E, 2005, OBES RES, V13, P2021, DOI 10.1038/oby.2005.248
   Owen CG, 2005, PEDIATR RES, V58, P1014
   Painter RC, 2005, PEDIATR RES, V58, P1048
   Pierik FH, 2005, PEDIATR RES, V58, P1060
   RADAELLI T, 2005, PEDIAT RES, V58, P1065
   Rahnama F, 2005, PEDIATR RES, V58, P1063
   Raphael D, 2005, PEDIATR RES, V58, P1021
   Rees SM, 2005, PEDIATR RES, V58, P1059
   Rich-Edwards JW, 2005, PEDIATR RES, V58, P1010
   Romundstad PR, 2005, PEDIATR RES, V58, P1048
   Sandovici I, 2005, PEDIATR RES, V58, P1015
   Schack-Nielsen L, 2005, PEDIATR RES, V58, P1034
   Schack-Nielsen L, 2005, PEDIATR RES, V58, P1020
   Schlotz W, 2005, PEDIATR RES, V58, P1014
   Scirica CV, 2005, PEDIATR RES, V58, P1037
   Sharma AJ, 2005, PEDIATR RES, V58, P1038
   Simmons RA, 2005, PEDIATR RES, V58, P1100
   Singhal A, 2004, LANCET, V363, P1642, DOI 10.1016/S0140-6736(04)16210-7
   Snibson K, 2005, PEDIATR RES, V58, P1033
   Stettler N, 2005, CIRCULATION, V111, P1897, DOI 10.1161/01.CIR.0000161797.67671.A7
   Svensson E, 2005, PEDIATR RES, V58, P1048
   Taveras EM, 2005, PEDIATR RES, V58, P1029
   Terry MB, 2005, PEDIATR RES, V58, P1048
   Troisi R, 2005, PEDIATR RES, V58, P1048
   Van den Hove DLA, 2005, PEDIATR RES, V58, P1025
   Vickers MH, 2005, PEDIATR RES, V58, P1128
   Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011
   Webster J, 2005, PEDIATR RES, V58, P1010
   Weiderpass E, 2005, PEDIATR RES, V58, P1049
   Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Zhang YW, 2005, PEDIATR RES, V58, P1047
NR 66
TC 126
Z9 143
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD MAY
PY 2007
VL 61
IS 5
BP 625
EP 629
DI 10.1203/pdr.0b013e3180459fcd
PN 1
PG 5
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 161HJ
UT WOS:000246005100021
PM 17413866
OA Bronze
DA 2025-01-12
ER

PT J
AU Beltran, A
   Parikh, S
   Liu, Y
   Cuevas, BD
   Johnson, GL
   Futscher, BW
   Blancafort, P
AF Beltran, A.
   Parikh, S.
   Liu, Y.
   Cuevas, B. D.
   Johnson, G. L.
   Futscher, B. W.
   Blancafort, P.
TI Re-activation of a dormant tumor suppressor gene maspin by designed
   transcription factors
SO ONCOGENE
LA English
DT Article
DE maspin; SERPINB5; metastatic cells; methylation; zinc-fingers;
   artificial transcription factors
ID ZINC-FINGER DOMAINS; BREAST-CANCER CELLS; DNA-SEQUENCES;
   MAMMALIAN-CELLS; EXPRESSION; RECOGNITION; FAMILY; CONSTRUCTION;
   ANGIOGENESIS; METHYLATION
AB The controlled and specific re-activation of endogenous tumor suppressors in cancer cells represents an important therapeutic strategy to block tumor growth and subsequent progression. Other than ectopic delivery of tumor suppressor-encoded cDNA, there are no therapeutic tools able to specifically re-activate tumor suppressor genes that are silenced in tumor cells. Herein, we describe a novel approach to specifically regulate dormant tumor suppressors in aggressive cancer cells. We have targeted the Mammary Serine Protease Inhibitor (maspin) (SERPINB5) tumor suppressor, which is silenced by transcriptional and aberrant promoter methylation in aggressive epithelial tumors. Maspin is a multifaceted protein, regulating tumor cell homeostasis through inhibition of cell growth, motility and invasion. We have constructed artificial transcription factors (ATFs) made of six zinc-finger (ZF) domains targeted against 18-base pair (bp) unique sequences in the maspin promoter. The ZFs were linked to the activator domain VP64 and delivered in breast tumor cells. We found that the designed ATFs specifically interact with their cognate targets in vitro with high affinity and selectivity. One ATF was able to re-activate maspin in cell lines that comprise a maspin promoter silenced by epigenetic mechanisms. Consistently, we found that this ATF was a powerful inducer of apoptosis and was able to knock down tumor cell invasion in vitro. Moreover, this ATF was able to suppress MDA-MB-231 growth in a xenograft breast cancer model in nude mice. Our work suggests that ATFs could be used in cancer therapeutics as novel molecular switches to re-activate dormant tumor suppressors.
C1 Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ USA.
   Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Arizona Center Cancer Care; University of Arizona; University of Arizona
RP Blancafort, P (通讯作者)，Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
EM pilar_blancafort@med.unc.edu
RI Blancafort, Pilar/K-9029-2012
OI Blancafort, Pilar/0000-0002-3881-7396
FU NCI NIH HHS [R01 CA125273] Funding Source: Medline; NIDDK NIH HHS [R01
   DK037871] Funding Source: Medline; NIGMS NIH HHS [R01 GM030324] Funding
   Source: Medline
CR Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628
   Beltran A, 2006, ASSAY DRUG DEV TECHN, V4, P317, DOI 10.1089/adt.2006.4.317
   Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758
   Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Dreier B, 2005, J BIOL CHEM, V280, P35588, DOI 10.1074/jbc.M506654200
   Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200
   Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Garber K, 2004, NAT BIOTECHNOL, V22, P364, DOI 10.1038/nbt0404-364
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03
   Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568
   Lockett J, 2006, J CELL BIOCHEM, V97, P651, DOI 10.1002/jcb.20721
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   Royer Y, 2004, DNA CELL BIOL, V23, P355, DOI 10.1089/104454904323145245
   Sager R, 1997, ADV EXP MED BIOL, V425, P77
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Seftor REB, 1998, CANCER RES, V58, P5681
   Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758
   Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4
   Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602
   Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x
   Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100
   Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699
   YIN S, 2006, CANCER RES, V15, P4173
   Zardo G, 2005, CELL RES, V15, P679, DOI 10.1038/sj.cr.7290337
   Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006
   Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang WG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-50
   ZHOU Z, 2000, J BIOL CHEM, V9, P6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 40
TC 73
Z9 92
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD APR 26
PY 2007
VL 26
IS 19
BP 2791
EP 2798
DI 10.1038/sj.onc.1210072
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 164CP
UT WOS:000246210600013
PM 17057734
DA 2025-01-12
ER

PT J
AU Sharma, G
   Mirza, S
   Prasad, CP
   Srivastava, A
   Gupta, SD
   Ralhan, R
AF Sharma, Gayatri
   Mirza, Sameer
   Prasad, Chandra P.
   Srivastava, Anurag
   Gupta, Siddhartha Dutta
   Ralhan, Ranju
TI Promoter hypermethylation of <i>p16<SUP>INK4A</SUP></i>,
   <i>p14<SUP>ARF</SUP></i>, <i>CyclinD2</i> and <i>Slit2</i> in serum and
   tumor DNA from breast cancer patients
SO LIFE SCIENCES
LA English
DT Article
DE breast cancer; methylation; serum
ID METHYLATION-SPECIFIC PCR; MULTIPLE GENES; EPIGENETIC INACTIVATION;
   GENOMIC ORGANIZATION; SUPPRESSOR GENES; EXPRESSION; ESTROGEN; FLUID;
   LUNG; METASTASIS
AB Epigenetic mechanisms such as DNA methylation play important role in cancer. Epigenetic alterations involved in the onset and progression of breast cancer may serve as biomarkers for early detection and prediction of disease prognosis. Furthermore, using body fluids such as serum offers a non-invasive method to procure multiple samples for biomarker analyses. The aim of this study to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters. Of the 36 breast cancer patients investigated, 31 (86%) tumors and 30 (83%) paired sera showed methylation of at least one of these 4 genes. Methylation frequencies varied from 27% for CyclinD2, 44% for p16(INK4A), 47% for p14(ARF) to 58% for Slit2. There was concordance between DNA methylation in tumor and paired serum DNA of each gene. This study underscores the potential utility of DNA methylation based screening of serum as a surrogate marker for tumor DNA methylation status of these genes in breast cancer. Further, expression profile of p16(INK4A) could be linked to epigenetic events, thus suggesting this pathway as a potential target for therapeutic strategies based on reversal of epigenetic silencing. (C) 2007 Elsevier Inc. All rights reserved.
C1 All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   All India Inst Med Sci, Dept Surg, New Delhi 110029, India.
   All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of
   Medical Sciences (AIIMS) New Delhi
RP Ralhan, R (通讯作者)，All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
EM ralhanr@rediffmail.com
RI Prasad, Chandra Prakash/B-6404-2015
OI Prasad, Chandra Prakash/0000-0002-4911-7483
CR [Anonymous], 2001, MOL CLONING LAB MANU
   Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   BUCKLEY MF, 1993, ONCOGENE, V8, P2127
   Chopra R, 2001, J CLIN ONCOL, V19, p106S
   Dallol A, 2002, CANCER RES, V62, P5874
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2000, CANCER RES, V60, P129
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibi K, 1998, CANCER RES, V58, P1405
   Holst CR, 2003, CANCER RES, V63, P1596
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Ichikawa D, 2004, ANTICANCER RES, V24, P2477
   *IND COUNC MED RES, 2001, NAT CANC REG PROGR C
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Koike H, 2005, HEPATO-GASTROENTEROL, V52, P1293
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee A, 2004, ARCH PATHOL LAB MED, V128, P1251
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   LEON SA, 1977, CANCER RES, V37, P646
   Leung WK, 2005, BRIT J CANCER, V92, P2190, DOI 10.1038/sj.bjc.6602636
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   LI S, 2006, CANC LETT, V18, P272
   LUKAS J, 1995, ONCOGENE, V10, P2125
   Macaluso M, 2005, SEMIN ONCOL, V32, P452, DOI 10.1053/j.seminoncol.2005.07.009
   Marini A, 2006, J INVEST DERMATOL, V126, P422, DOI 10.1038/sj.jid.5700073
   Marshall Fray F, 2005, J Urol, V173, P1918, DOI 10.1097/01.ju.0000161195.11300.49
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Mitka M, 2003, JAMA-J AM MED ASSOC, V290, P450, DOI 10.1001/jama.290.4.450
   Mori T, 2005, J CLIN ONCOL, V23, P9351, DOI 10.1200/JCO.2005.02.9876
   Mori T, 2006, CANCER RES, V66, P6692, DOI 10.1158/0008-5472.CAN-06-0801
   Müller HM, 2003, CANCER RES, V63, P7641
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   PERTSCHUK LP, 1990, CANCER-AM CANCER SOC, V66, P1663, DOI 10.1002/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C
   PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x
   Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200
   Reynolds PA, 2006, J BIOL CHEM
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Shim YH, 2003, MODERN PATHOL, V16, P430, DOI 10.1097/01.mp.0000066799.99032.A7
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Silva J, 2001, ONCOGENE, V20, P4586, DOI 10.1038/sj.onc.1204617
   SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X
   Stewart CL, 2001, J NEURO-ONCOL, V51, P183, DOI 10.1023/A:1010615822317
   SUZUKI M, 2006, CANC LETT
   Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009
   TAM SW, 1994, ONCOGENE, V9, P2663
   Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   XU L, 1994, CANCER RES, V54, P5262
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 67
TC 84
Z9 100
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD APR 24
PY 2007
VL 80
IS 20
BP 1873
EP 1881
DI 10.1016/j.lfs.2007.02.026
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 166YM
UT WOS:000246417100008
PM 17383681
DA 2025-01-12
ER

PT J
AU Galliher, AJ
   Schiemann, WP
AF Galliher, Amy J.
   Schiemann, William P.
TI Src phosphorylates Tyr<SUP>284</SUP> in TGF-β type II receptor and
   regulates TGF-β stimulation of p38 MAPK during breast cancer cell
   proliferation and invasion
SO CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-BETA; ENHANCES TUMORIGENESIS; SUPPRESSES METASTASIS;
   PROTEIN-KINASE; MAMMARY-GLAND; TUMOR; INTEGRIN; EXPRESSION; INDUCTION;
   MICE
AB Genetic and epigenetic events often negate the cytostatic function of transforming growth factor-beta (TGF-beta) in mammary epithelial cells (MEC), which ultimately enables malignant MECs to proliferate, invade, and metastasize when stimulated by TGF-beta. The molecular mechanisms underlying this phenotypic conversion of TGF-beta function during mammary tumorigenesis remain poorly defined. We previously established alpha(v)beta(3) integrin and Src as essential mediators of mitogen-activated protein kinase (MAPK) activation, invasion, and epithelial-to-mesenchymal transition stimulated by TGF-beta in normal and malignant MECs. Mechanistically, 3 integrin interacted physically with the TGF-beta type II receptor (T beta R II-II), leading to its tyrosine phosphorylation by Src and the initiation of oncogenic signaling by TGF-beta. We now show herein that Src phosphorylated T beta I-II on Y284 both in vitro and in vivo. Interestingly, although the expression of Y284F-T beta R-II mutants in breast cancer cells had no effect on TGF-beta stimulation of Smad2/3, this T beta R-II mutant completely abrogated p38 MAPK activation by TGF-beta. Accordingly, Src-mediated phosphorylation of Y284 coordinated the docking of the SH2 domains of growth factor receptor binding protein 2 (Grb2) and Src homology domain 2 containing (She) T beta R-II, thereby associating these adapter proteins to MAPK activation by TGF-beta. Importantly, Y284F-T beta R-II mutants also abrogated breast cancer cell invasion induced by alpha(v)beta(3) integrin and TGF-beta as well as partially restored their cytostatic response to TGF-beta. Our findings have identified a novel alpha(v)beta(3) integrin/Src/Y284/T beta R-II signaling axis that promotes oncogenic signaling by TGF-beta in malignant MECs and suggest that antagonizing this signaling axis may one day prove beneficial in treating patients with metastatic breast cancers.
C1 Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Schiemann, WP (通讯作者)，Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Room L18-6110,RC1 S Tower,12801 E 17th Ave,POB 65, Aurora, CO 80045 USA.
EM Bill.Schiemann@uchsc.edu
FU NCI NIH HHS [CA 114039, CA 095519] Funding Source: Medline
CR ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871
   Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565
   Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3
   Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   Böttinger EP, 1997, CANCER RES, V57, P5564
   Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44
   Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524
   Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48
   Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859
   Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200
   Kairouz R, 2000, BREAST CANCER RES, V2, P197, DOI 10.1186/bcr54
   Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850
   Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8
   Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7
   SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361
   Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398
   Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899
   Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030
   Tian F, 2003, CANCER RES, V63, P8284
   Vuori K, 1996, MOL CELL BIOL, V16, P2606
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177
   White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025
   WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S
   Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333
NR 32
TC 199
Z9 246
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2007
VL 67
IS 8
BP 3752
EP 3758
DI 10.1158/0008-5472.CAN-06-3851
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 158GL
UT WOS:000245779600037
PM 17440088
DA 2025-01-12
ER

PT J
AU Zhang, YJ
   Wu, HC
   Shen, J
   Ahsan, H
   Tsai, WY
   Yang, HL
   Wang, LY
   Chen, SY
   Chen, CJ
   Santella, RM
AF Zhang, Yu-Jing
   Wu, Hui-Chen
   Shen, Jing
   Ahsan, Habibul
   Tsai, Wei Yann
   Yang, Hwai-l
   Wang, Li-Yu
   Chen, Shu-Yuan
   Chen, Chien-Jen
   Santella, Regina M.
TI Predicting hepatocellular carcinoma by detection of aberrant promoter
   methylation in serum DNA
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HIGH-FREQUENCY; LUNG-CANCER; CPG ISLAND; P16 METHYLATION; BREAST-CANCER;
   P53 MUTATIONS; HYPERMETHYLATION; GENE; PLASMA; INACTIVATION
AB Purpose: Most hepatocellular carcinomas (HCC) are diagnosed at an advanced stage. Hypermethylation of CpG islands in promoter regions is now recognized as an important early event in carcinogenesis and detection of methylated DNA has been suggested as a potential biomarker for early detection of cancer. There are no studies on epigenetic changes in samples from HCC patients before diagnosis. We explored the possible diagnostic value of aberrant promoter hypermethylation of three tumor suppressor genes in serum DNA for early detection of HCC.
   Experimental Design: Aberrant promoter hypermethylation was investigated in DNA isolated from the serum of 50 HCC patients who provided repeated blood samples before diagnosis and 50 controls enrolled in a cancer screen program in Taiwan. Methylation-specific PCR was used to determine the methylation status of p16, p15, and ras association domain family 1A (RASSF1A).
   Results: Among cases, aberrant methylation was found in serum DNA 1 to 9 years before clinical HCC diagnosis. RASSF1A had the highest frequency of hypermethylation with 35 (70%) cases having at least one positive sample compared with 22 (44%) for p16 and 12 (22%) for p15. Six subjects were hypermethylation negative for all three genes. For the 50 controls, promoter hypermethylation was found in three and two subjects for RASSF1A and p16, respectively; none had methylation of p15. A receiver operating characteristic curve that included clinical risk factors (age, HBsAg status, anti - hepatitis C virus status, smoking, and alcohol status) and hypermethylation biomarkers gave an overall predictive accuracy of 89% with sensitivity and specificity 84% and 94%, respectively.
   Conclusions: The analysis of epigenetic changes on RASSF1A, p16, and p15 tumor suppressor genes in serum DNA may be a valuable biomarkers for early detection in populations at high risk of HCC.
C1 Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   Natl Cheng Kung Univ, Dept Stat, Tainan 70101, Taiwan.
   Natl Taiwan Univ, Coll Publ Hlth, Taipei 10764, Taiwan.
   Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   Tzu Chi Univ, Grad Inst Aboriginal Hlth, Hualien, Taiwan.
C3 Columbia University; Columbia University; Columbia University; National
   Cheng Kung University; National Taiwan University; Academia Sinica -
   Taiwan; Tzu Chi University
RP Zhang, YJ (通讯作者)，Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, 701 W 168th St, New York, NY 10032 USA.
EM yz6@columbia.edu
RI Chen, Chien-Jen/N-4723-2019; Wu, Lisa/JPA-4139-2023; Yang,
   Hwai-I/A-9470-2008; Zhang, Yujing/ABB-3590-2021
OI Yang, Hwai-I/0000-0002-3433-942X
FU NCI NIH HHS [P30CA01396] Funding Source: Medline; NIEHS NIH HHS
   [R01ES05116, P30ES09089, P30 ES009089, R01 ES005116] Funding Source:
   Medline
CR Batova A, 1997, CANCER RES, V57, P832
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x
   Chen SY, 2002, INT J CANCER, V99, P14, DOI 10.1002/ijc.10291
   Chu HJ, 2004, J KOREAN MED SCI, V19, P83, DOI 10.3346/jkms.2004.19.1.83
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   De Masi S, 2005, DIGEST LIVER DIS, V37, P260, DOI 10.1016/j.dld.2004.11.005
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Esteller M, 2001, CANCER RES, V61, P3225
   Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392
   Herman JG, 1997, CANCER RES, V57, P837
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hibi K, 2003, CLIN CANCER RES, V9, P1053
   Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1053/jhep.1996.v24.pm0008781327
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   Jackson PE, 2001, CANCER RES, V61, P33
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359
   Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X
   Müller HM, 2003, CANCER RES, V63, P7641
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Santella R. M., 1991, Immunoassays for trace chemical analysis. Monitoring toxic chemicals in humans, food, and the environment., P229
   Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X
   Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755
   Shim YH, 2003, CANCER LETT, V190, P213, DOI 10.1016/S0304-3835(02)00613-4
   Tamori A, 2004, INTERVIROLOGY, V47, P26, DOI 10.1159/000076639
   Toyota M, 2005, SEMIN ONCOL, V32, P521, DOI 10.1053/j.seminoncol.2005.07.003
   Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5<620::AID-IJC5>3.0.CO;2-W
   Wong IHN, 1999, CANCER RES, V59, P71
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   Yeo W, 2005, LIVER INT, V25, P266, DOI 10.1111/j.1478-3231.2005.01084.x
   Zhang YJ, 2005, CANCER LETT, V221, P135, DOI 10.1016/j.canlet.2004.08.028
   Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852
   Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076
   Zhang YJ, 2006, INT J CANCER, V119, P985, DOI 10.1002/ijc.21699
   Zhong S, 2003, CLIN CANCER RES, V9, P3376
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 42
TC 157
Z9 181
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2007
VL 13
IS 8
BP 2378
EP 2384
DI 10.1158/1078-0432.CCR-06-1900
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 159RK
UT WOS:000245883800012
PM 17438096
OA Bronze
DA 2025-01-12
ER

PT J
AU Kubarek, L
   Jagodzinski, PP
AF Kubarek, L.
   Jagodzinski, P. P.
TI Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17
   β-estradoil and tamoxifen is associated with formation of DNA
   methyltransferase 3B4 splice variant in Ishikawa endometrial
   adenocarcinoma cells
SO FEBS LETTERS
LA English
DT Article
DE CXCL12; CXCR4; tamoxifen; 17 beta-estradiol; DNA methyltransferases
ID OVEREXPRESSION; ESTROGEN; HYPOMETHYLATION; INVOLVEMENT; ACTIVATION;
   RECEPTORS
AB Increased risk for the development of endometrial cancer has been associated with unopposed oestrogen exposure, hyperoestrogenic factors, and a history of breast cancer treated long-term with tamoxifen (Tam). Stromal cell-derived factor-1, currently named as CXCL12, is a chemokine that, via binding to CXCR4 receptor, activates several downstream effectors and signalling pathways responsible for proliferation, survival, and migration of cancer cells.
   We observed that 17 beta-estradiol (E2) and tamoxifen (Tam) increase the expression of CXCR4 and CXCL12 transcripts and proteins in oestrogen receptor positive (ER+) but not in negative (ER(-)02) Ishikawa endometrial adenocarcinoma (ISH) cell lines. However, the demethylating agent 5-Aza-2'-deoxycytidine profoundly elevated CXCR4 and CXCL12 expression in both ER+ and ER(-)02 ISH cells. Bisulfite sequencing revealed that E2 and Tam up-regulate expression via demethylation of cytosine in the cytosine-guanosine dinucleotide island of CXCR4 and CXCL12 promoters. We also found that E2 and Tam significantly increased, for several hours, the expression of DNA methyltransferase 3B4 enzymatically inactive splice variant in ER+ but not in ER(-)02 ISH cells.
   Our results suggest that E2 and Tam, through their ability for gene-transcription regulation, change the cellular milieu that maintains the hypermethylated stage of CpG islands of CXCR4 and CXCL12 promoters. (c) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Poznan Univ Med Sci, Dept Biochem & Mol Biol, PL-60781 Poznan, Poland.
C3 Poznan University of Medical Sciences
RP Jagodzinski, PP (通讯作者)，Poznan Univ Med Sci, Dept Biochem & Mol Biol, 6 Swiecickiego St, PL-60781 Poznan, Poland.
EM pjagodzi@am.poznan.pl
RI Jagodzinski, Pawel/KWV-0637-2024
OI Jagodzinski, Pawel/0000-0002-9046-6802
CR Acconcia F, 2006, ENDOCRINOLOGY, V147, P1203, DOI 10.1210/en.2005-1293
   BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Feng Q, 2001, GENE DEV, V15, P827
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Kato H, 2006, INT J CANCER, V118, P1144, DOI 10.1002/ijc.21488
   Li SY, 2005, INT J ONCOL, V27, P1329
   MAKRIGIANNAKIS A, 1995, J CLIN ENDOCR METAB, V80, P185, DOI 10.1210/jc.80.1.185
   Mizokami Y, 2004, INT J CANCER, V110, P652, DOI 10.1002/ijc.20183
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   SABOTA A, 2004, GENOME BIOL, V5, pR59
   Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799
   Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Vilgelm A, 2006, CANCER RES, V66, P3375, DOI 10.1158/0008-5472.CAN-05-4019
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505
   Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   Zlotnik A, 2006, CONTRIB MICROBIOL, V13, P191, DOI 10.1159/000092973
   Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024
NR 24
TC 43
Z9 55
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD APR 3
PY 2007
VL 581
IS 7
BP 1441
EP 1448
DI 10.1016/j.febslet.2007.02.070
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 160CB
UT WOS:000245913300030
PM 17362937
OA Bronze
DA 2025-01-12
ER

PT J
AU Suzuki, M
   Shigematsu, H
   Shames, DS
   Sunaga, N
   Takahashi, T
   Shivapurkar, N
   Iizasa, T
   Minna, JD
   Fujisawa, T
   Gazdar, AF
AF Suzuki, Makoto
   Shigematsu, Hisayuki
   Shames, David S.
   Sunaga, Noriaki
   Takahashi, Takao
   Shivapurkar, Narayan
   Iizasa, Toshihiko
   Minna, John D.
   Fujisawa, Takehiko
   Gazdar, Adi F.
TI Methylation and gene silencing of the Ras-related GTPase gene in lung
   and breast cancers
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
DE RRAD; methylation; lung cancer; breast cancer
ID ABERRANT METHYLATION; DNA METHYLATION; CPG ISLANDS; CELL-LINES; REGIONS;
   MUSCLE; MEMBER; TUMOR; NM23
AB Background: RRAD, a small Ras-related GTPase, is highly expressed in human skeletal muscle, lung, and heart. Although loss of expression of RRAD in breast cancer cells has been reported and it may act as an oncogene, the mechanism of silencing is unknown.
   Methods: We examined (1) mRNA expression of RRAD in lung and breast cancer cell lines using RT-PCR and (2) methylation status of lung and breast cancers.
   Results: Loss of RRAD expression was found in 14 of 20 (70%) NSCLC cell lines, 11 of 11 (100%) SCLC cell lines, and 8 of 10 (80%) breast cancer cell lines; expression was not affected in normal bronchial and mammary epithelial cells. Treatment of 23 expression-negative cell lines with a demethylating agent restored expression in all cases. We developed a methylation-specific assay from the analysis of bisulfite sequencing of the 5' region of RRAD in expression-negative and positive cell lines, which resulted in good concordance between methylation and expression. Primary lung and breast cancers showed hypermethylation in 89 of 214 (42%) and 39 of 63 (62%) cases, respectively. RRAD hypermethylation correlated with smoking history and poorer prognosis in lung adenocarcinomas.
   Conclusions: We conclude that epigenetic silencing of RRAD is a frequent event in lung and breast cancers, and analysis of it may provide novel opportunities for prognosis and therapy of these cancers.
C1 Chiba Univ, Dept Thorac Surg, Grad Sch Med, Chiba, Japan.
   Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA.
C3 Chiba University; University of Texas System; University of Texas
   Dallas; University of Texas Southwestern Medical Center Dallas
RP Suzuki, M (通讯作者)，Chiba Univ, Dept Thorac Surg, Grad Sch Med, Chiba, Japan.
EM smakoto@faculty.chiba-u.jp
RI Gazdar, Adi/F-7496-2010; Minna, John/AAB-1036-2022
OI Shames, David/0000-0002-5900-1177
FU NCI NIH HHS [5U01CA8497102, P50CA70907] Funding Source: Medline
CR Billiard J, 2003, J CELL BIOCHEM, V89, P389, DOI 10.1002/jcb.10514
   Callen DF, 2002, CANCER GENET CYTOGEN, V133, P76, DOI 10.1016/S0165-4608(01)00565-9
   Chen H, 2005, LUNG CANCER, V50, P43, DOI 10.1016/j.lungcan.2005.04.013
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Girard L, 2000, CANCER RES, V60, P4894
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594
   Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111
   Phelps RM, 1996, J CELL BIOCHEM, P32
   REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782
   SATO S, 1994, CANCER RES, V54, P5652
   Suzuki M, 2005, ONCOL REP, V14, P1621
   Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837
   Suzuki M, 2005, BRIT J CANCER, V92, P942, DOI 10.1038/sj.bjc.6602376
   Suzuki M, 2005, LUNG CANCER, V47, P309, DOI 10.1016/j.lungcan.2004.08.006
   Suzuki M, 2005, ONCOGENE, V24, P1302, DOI 10.1038/sj.onc.1208263
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787
   Tseng YH, 2001, CANCER RES, V61, P2071
   Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911
   ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805
   Zöchbauer-Müller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
NR 25
TC 36
Z9 41
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2007
VL 14
IS 4
BP 1397
EP 1404
DI 10.1245/s10434-006-9089-6
PG 8
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 152LA
UT WOS:000245362300021
PM 17195088
DA 2025-01-12
ER

PT J
AU Yamane, K
   Tateishi, K
   Klose, RJ
   Fang, J
   Fabrizio, LA
   Erdjument-Bromage, H
   Taylor-Papadimitriou, J
   Tempst, P
   Zhang, Y
AF Yamane, Kenichi
   Tateishi, Keisuke
   Klose, Robert J.
   Fang, Jia
   Fabrizio, Laura A.
   Erdjument-Bromage, Hediye
   Taylor-Papadimitriou, Joyce
   Tempst, Paul
   Zhang, Yi
TI PLU-1 is an H3K4 dernethylase involved in transcriptional repression and
   breast cancer cell proliferation
SO MOLECULAR CELL
LA English
DT Article
ID DOMAIN-CONTAINING PROTEINS; HISTONE DEMETHYLATION; NUCLEAR-PROTEIN;
   METHYLATION; BINDING; EXPRESSION; GENE; TRIMETHYLATION; POLYCOMB;
   RECEPTOR
AB Posttranslational modification of chromatin by histone methylation has wide-ranging effects on nuclear function, including transcriptional regulation, maintenance of genome integrity, and epigenetic inheritance. The enzymes utilized to place histone methylation marks are well characterized, but the identity of a histone demethylation system remained elusive until recently. The discovery of histone demethylase enzymes capable of directly removing methyl groups from modified lysine residues has demonstrated that histone methylation is a dynamic modification. The most extensive family of histone demethylase enzymes identified so far contains a JmjC domain and catalyzes demethylation through a hydroxylation reaction. Here, we identify PLU-1, a transcriptional repressor implicated in breast cancer, as a histone demethylase enzyme that has the ability to reverse the trimethyl H3K4 modification state. Furthermore, we reveal that PLU-1-mediated H3K4 demethylase activity plays an important role in the proliferative capacity of breast cancer cells through repression of tumor suppressor genes, including BRCA1.
C1 Univ N Carolina, Lineberger Comprehens Canc Ctr, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.
   Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.
   Canc Res UK, Breast Canc Biol Grp, London SE1 9RT, England.
C3 Howard Hughes Medical Institute; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina;
   University of North Carolina Chapel Hill; Memorial Sloan Kettering
   Cancer Center; Cancer Research UK
RP Zhang, Y (通讯作者)，Univ N Carolina, Lineberger Comprehens Canc Ctr, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA.
EM yi_zhang@med.unc.edu
OI Erdjument-Bromage, Hediye/0000-0003-0224-3594; Fang,
   Jia/0000-0001-8583-1652; Zhang, Yi/0000-0002-2789-0811; Tempst,
   Paul/0000-0002-6680-3987
FU NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS
   [GM68804] Funding Source: Medline
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bannowsky A., 2003, EAU UPDATE SERIES, V1, P120, DOI DOI 10.1016/S1570-9124(03)00035-7
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   FATTAEY AR, 1993, ONCOGENE, V8, P3149
   Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300
   Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gildea JJ, 2000, GENETICS, V156, P645
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Heppner GH, 2000, BREAST CANCER RES, V2, P331
   Jensen LR, 2005, AM J HUM GENET, V76, P227, DOI 10.1086/427563
   Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   KLEEBERG U, 1982, J PHARMACOL METHOD, V8, P19, DOI 10.1016/0160-5402(82)90004-3
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Madsen B, 2002, MECH DEVELOP, V119, pS239, DOI 10.1016/S0925-4773(03)00123-0
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3
   Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020
   Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Pulaski BA, 2000, CANCER RES, V60, P2710
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Tan K, 2003, J BIOL CHEM, V278, P20507, DOI 10.1074/jbc.M301994200
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640
   WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153
   Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Zhang L, 2005, EMBO J, V24, P2379, DOI 10.1038/sj.emboj.7600711
   Zhang Y, 2006, NAT STRUCT MOL BIOL, V13, P572, DOI 10.1038/nsmb0706-572
NR 47
TC 387
Z9 484
U1 1
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD MAR 23
PY 2007
VL 25
IS 6
BP 801
EP 812
DI 10.1016/j.molcel.2007.03.001
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 154NI
UT WOS:000245513900006
PM 17363312
OA Bronze
DA 2025-01-12
ER

PT J
AU Evans, MK
   Yu, CR
   Lohani, A
   Mahdi, RM
   Liu, X
   Trzeciak, AR
   Egwuagu, CE
AF Evans, M. K.
   Yu, C-R
   Lohani, A.
   Mahdi, R. M.
   Liu, X.
   Trzeciak, A. R.
   Egwuagu, C. E.
TI Expression of <i>SOCS1</i> and <i>SOCS3</i> genes is differentially
   regulated in breast cancer cells in response to proinflammatory cytokine
   and growth factor signals
SO ONCOGENE
LA English
DT Article
DE breast-cancer cells; SOCS; breast cancer; STAT; BRCA1; DNA
   hypermethylation; interferon
ID ISLAND METHYLATOR PHENOTYPE; DNA-DAMAGE; IFN-GAMMA; BRCA1;
   TRANSCRIPTION; ACTIVATION; CARCINOMA; HYPERMETHYLATION; TUMORIGENESIS;
   COACTIVATOR
AB DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFN gamma, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breast-cancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFN gamma and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFN gamma and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNA-hypermethylation. We further show that the kinetics of SOCS1-mediated feedback inhibition of IFN gamma signaling is comparable to normal breast cells, indicating that the SOCS1 protein in breast-cancer cells is functional. We provide direct evidence that STAT3 pathways are constitutively activated in MCF-7 and HCC1937 cells and may drive the aberrant persistent activation of SOCS genes in breast-cancer cells. Our data therefore suggest that elevated expression of SOCS genes is a specific lesion of breast-cancer cells that may confer resistance to proinflammatory cytokines and trophic factors, by shutting down STAT1/STAT5 signaling that mediate essential functions in the mammary gland.
C1 NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.
   NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Evans, MK (通讯作者)，NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.
EM evansmi@grc.nia.nih.gov; egwuaguc@nei.nih.gov
RI Evans, Michele/AAE-4776-2019
OI Evans, Michele/0000-0002-8546-2831; Yu, Cheng-Rong/0000-0001-7246-0362
FU Intramural NIH HHS Funding Source: Medline
CR Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200
   Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Brender C, 2005, LEUKEMIA, V19, P209, DOI 10.1038/sj.leu.2403610
   Campbell IL, 2005, BRAIN RES REV, V48, P166, DOI 10.1016/j.brainresrev.2004.12.006
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7
   Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536
   Cui JQ, 1998, ONCOL REP, V5, P591
   Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752
   Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195
   He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100
   Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Le Provost F, 2005, BIOCHEM BIOPH RES CO, V338, P1696, DOI 10.1016/j.bbrc.2005.10.138
   Medina D, 2005, ENDOCR-RELAT CANCER, V12, P483, DOI 10.1677/erc.1.00804
   Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018
   Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788
   Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697
   Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115
   Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537
   Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833
   Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
   Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   Yu CR, 2004, J IMMUNOL, V173, P737, DOI 10.4049/jimmunol.173.2.737
NR 33
TC 67
Z9 76
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAR 22
PY 2007
VL 26
IS 13
BP 1941
EP 1948
DI 10.1038/sj.onc.1209993
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 149AE
UT WOS:000245117700011
PM 17001312
DA 2025-01-12
ER

PT J
AU Bianchi, F
   Tagliabue, E
   Ménard, S
   Campiglio, M
AF Bianchi, Francesca
   Tagliabue, Elda
   Menard, Sylvie
   Campiglio, Manuela
TI Fhit expression protects against HER2-driven breast tumor development -:
   Unraveling the molecular interconnections
SO CELL CYCLE
LA English
DT Article
DE Fhit; EGFR; HER2; breast tumors; signaling
ID EPIDERMAL-GROWTH-FACTOR; HISTIDINE TRIAD GENE; LUNG-CANCER;
   CERVICAL-CARCINOMA; CLINICOPATHOLOGICAL SIGNIFICANCE; GASTRIC
   ADENOCARCINOMAS; PROMOTER METHYLATION; DIGESTIVE-TRACT; ERBB RECEPTORS;
   DEFICIENT MICE
AB The tumor suppressor gene FHIT is inactivated by genetic and epigenetic changes, i.e., loss of heterozygosity or promoter hypermethylation, in common human cancers. We recently showed that Fhit protein levels can be regulated by Fhit proteasome degradation mediated by EGF-dependent activation of EGFR family members, including HER2, whose overexpression is linked to poor prognosis in breast cancer. Analysis of a series of 384 human primary breast carcinomas revealed low/absent Fhit protein levels more frequently in HER2-overexpressing tumors. To test for a possible complementation of the FHIT and HER2 genes, tumor incidence was assessed in mice carrying one inactivated Fhit allele (Fhit(+/-)) crossed with FVB/N mice carrying the rat HER2/neu proto-oncogene driven by the mouse mammary tumor virus promoter. All Fhit heterozygous mice developed mammary tumors, whereas when both Fhit alleles (Fhit(+/+)) were present, tumor incidence was reduced in 27% of the mice, which remained tumor-free at twenty months. These findings suggest a protective role for FHIT in HER2-driven mammary tumors. Together, these data argue for the cooperation between Fhit and HER2 in breast carcinogenesis.
C1 Fdn IRCCS, Ist Nazl Tumori, Mol Biol Unit, I-20131 Milan, Italy.
C3 Fondazione IRCCS Istituto Nazionale Tumori Milan
RP Campiglio, M (通讯作者)，Fdn IRCCS, Ist Nazl Tumori, Mol Biol Unit, Via Venezian 1, I-20131 Milan, Italy.
EM manuela.campiglio@istitutotumori.mi.it
RI Bianchi, Francesca/ABD-5518-2020; Tagliabue, Elda/B-9377-2017
OI Bianchi, Francesca/0000-0001-5197-5279; Tagliabue,
   Elda/0000-0001-9877-2903
CR Baffa R, 1998, CANCER RES, V58, P4708
   Baykal C, 2003, INT J GYNECOL CANCER, V13, P192, DOI 10.1046/j.1525-1438.2003.13055.x
   Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438
   Bianchi F, 2006, P NATL ACAD SCI USA, V103, P18981, DOI 10.1073/pnas.0605821103
   Birner P, 2001, CLIN CANCER RES, V7, P1669
   Birrer MJ, 1999, CANCER RES, V59, P5270
   Campiglio M, 2006, J CELL PHYSIOL, V208, P274, DOI 10.1002/jcp.20633
   Campiglio M, 1999, CANCER RES, V59, P3866
   Capuzzi D, 2000, CANCER, V88, P24, DOI 10.1002/(SICI)1097-0142(20000101)88:1<24::AID-CNCR5>3.3.CO;2-N
   Chang KW, 2002, J PATHOL, V196, P300, DOI 10.1002/path.1047
   Chen YJ, 1997, INT J CANCER, V72, P955
   Connolly DC, 2000, CLIN CANCER RES, V6, P3505
   Druck T, 1997, CANCER RES, V57, P504
   Dumon KR, 2001, CANCER RES, V61, P4827
   Eyzaguirre EJ, 1999, MODERN PATHOL, V12, P979
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062
   Greenspan DL, 1997, CANCER RES, V57, P4692
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Hayashi S, 1997, CANCER RES, V57, P1981
   Ingvarsson S, 1999, CANCER RES, V59, P2682
   Ishii H, 2006, CANCER RES, V66, P11287, DOI 10.1158/0008-5472.CAN-06-2503
   Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177
   Krivak TC, 2001, CANCER RES, V61, P4382
   Lee SH, 2001, EXP MOL MED, V33, P124, DOI 10.1038/emm.2001.22
   Lee SH, 2001, BIOCHEM BIOPH RES CO, V284, P850, DOI 10.1006/bbrc.2001.5038
   Luan XD, 1997, ONCOGENE, V15, P79, DOI 10.1038/sj.onc.1201164
   Ménard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E
   Ménard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779
   Negrini M, 1996, CANCER RES, V56, P3173
   Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101
   Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2
   PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x
   Pylkkänen L, 2002, INT J ONCOL, V20, P285
   Ramp U, 2002, J PATHOL, V196, P430, DOI 10.1002/path.1062
   Roa JC, 2006, J GASTROENTEROL, V41, P269, DOI 10.1007/s00535-005-1752-3
   Ross, 1998, Oncologist, V3, P237
   Sauer T, 2005, DIAGN CYTOPATHOL, V33, P228, DOI 10.1002/dc.20338
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sozzi G, 1997, CANCER RES, V57, P5207
   Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8
   Tomizawa Y, 1998, CANCER RES, V58, P5478
   TSENG JE, 1999, AACR P, P184
   Tzahar E, 1996, MOL CELL BIOL, V16, P5276
   Vecchione A, 2004, CLIN CANCER RES, V10, P7607, DOI 10.1158/1078-0432.CCR-04-0341
   Wali A, 2006, MOL CANCER RES, V4, P93, DOI 10.1158/1541-7786.MCR-05-0070
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yang QF, 2001, CLIN CANCER RES, V7, P3869
   Yoshino K, 2000, INT J CANCER, V85, P6, DOI 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.3.CO;2-Y
   Zanesi N, 2005, CANCER RES, V65, P6576, DOI 10.1158/0008-5472.CAN-05-1128
   Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 55
TC 17
Z9 17
U1 0
U2 2
PU LANDES BIOSCIENCE
PI GEORGETOWN
PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAR 15
PY 2007
VL 6
IS 6
BP 643
EP 646
DI 10.4161/cc.6.6.4033
PG 4
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 154HC
UT WOS:000245496500003
PM 17374991
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hansen, NJ
   Wylie, RC
   Phipps, SMO
   Love, WK
   Andrews, LG
   Tollefsbol, TO
AF Hansen, Nathan J.
   Wylie, Rebecca C.
   Phipps, Sharla M. O.
   Love, William K.
   Andrews, Lucy G.
   Tollefsbol, Trygve O.
TI The low-toxicity 9-<i>cis</i> UAB30 novel retinoid down-regulates the
   DNA methyltransferases and has anti-telomerase activity in human breast
   cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE retinoids; breast cancer; 9-cis UAB30 retinoic acid; telomerase
ID ACID RECEPTOR-ALPHA; TUMOR-CELLS; C-MYC; EXPRESSION; GROWTH; INHIBITION;
   INDUCTION; PREVENTION; APOPTOSIS; HTERT
AB Retinoic acids and their derivatives potentiate anticancer effects in breast cancer cells. The aberrant expression of telomerase is critical to the continued proliferation of most cancer cells. Thus, telomerase is an attractive target for chemo-prevention and treatment of breast cancer. 9cUAB30 is a novel synthetic retinoid X receptor-selective retinoic acid (RA) that effectively reduces the tumorigenic phenotype in mouse breast carcinoma with lower toxic effects than natural retinoid treatments. We have assessed 9cUAB30 retinoic acid treatment of human breast cancer cells to determine the potential of this drug as an effective telomerase inhibitor and its application to cancer therapy. 9cUAB30 was found to decrease DNA methyltransferase and telomerase expression in MDA-MB-361, T-47D, and MCF-7 human breast cancer cells and to inhibit the proliferation of these cells. This low-toxicity retinoid also reduced colony formation in soft agar assays in each of these cell types. Combination treatments of 9cUAB30 and all-trans RA proved to be synergistically more effective than either RA alone, further suggesting a possible general epigenetic mechanism that contributes to the anti-telomerase activity of the retinoids. Therefore, the novel retinoid, 9cUAB30, is effective in inhibiting the growth of human breast cancer cells, its anti-cancer effects appear to be related to telomerase inhibition and the mechanism for this process could be mediated through epigenetic modifications.
C1 Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Dept Biol, 175 Campbell Hall,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
FU NCI NIH HHS [R21 CA114019-02, R21 CA114019] Funding Source: Medline
CR Ahmed A, 2001, J AM GERIATR SOC, V49, P1105, DOI 10.1046/j.1532-5415.2001.49217.x
   Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Atigadda VR, 2003, J MED CHEM, V46, P3766, DOI 10.1021/jm030095q
   Cao Y, 2001, FASEB J, V15, P96, DOI 10.1096/fj.01-0447fje
   Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419
   Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X
   Casillas MA, 2003, MOL CELL BIOCHEM, V252, P33, DOI 10.1023/A:1025548623524
   Choi SH, 2000, INT J ONCOL, V17, P971
   Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002
   Czeczuga-Semeniuk E, 2001, CELL MOL BIOL LETT, V6, P925
   Dedieu S, 2006, CELL SIGNAL, V18, P889, DOI 10.1016/j.cellsig.2005.08.001
   Dietze EC, 2003, BIOCHEM BIOPH RES CO, V302, P841, DOI 10.1016/S0006-291X(03)00266-3
   Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174
   Eckhardt Sandor, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P419, DOI 10.2174/1568011024606389
   Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200
   Emionite L, 2004, ANTICANCER RES, V24, P4019
   Farias EF, 2002, CELL GROWTH DIFFER, V13, P335
   Fitzgerald P, 1997, CANCER RES, V57, P2642
   Grubbs CJ, 2003, CANCER LETT, V201, P17, DOI 10.1016/S0304-3835(03)00461-0
   GUDAS LJ, 1994, J BIOL CHEM, V269, P15399
   Guilleret I, 2003, EXP CELL RES, V289, P326, DOI 10.1016/S0014-4827(03)00281-7
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lin F, 2000, CANCER RES, V60, P3271
   Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058
   Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015
   Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790
   Mittal A, 2004, INT J ONCOL, V24, P703
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Muccio DD, 1998, J MED CHEM, V41, P1679, DOI 10.1021/jm970635h
   Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425
   Pendino F, 2006, LEUKEMIA, V20, P599, DOI 10.1038/sj.leu.2404127
   Pendino F, 2003, ONCOGENE, V22, P9142, DOI 10.1038/sj.onc.1207093
   Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998
   Pratt MAC, 2003, J CELL BIOCHEM, V90, P692, DOI 10.1002/jcb.10682
   ROMAN SD, 1992, CANCER RES, V52, P2236
   RUBIN M, 1994, CANCER RES, V54, P6549
   Saretzki G, 2001, CANCER GENE THER, V8, P827, DOI 10.1038/sj.cgt.7700383
   Schneider SM, 2000, CANCER RES, V60, P5479
   SHEIKH MS, 1993, ANTICANCER RES, V13, P1387
   Shen Q, 2003, J MAMMARY GLAND BIOL, V8, P45, DOI 10.1023/A:1025783221557
   Sussman F, 2005, J MED CHEM, V48, P6212, DOI 10.1021/jm050285w
   Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3
   Vivat-Hannah V, 2003, MOL CELL BIOL, V23, P7678, DOI 10.1128/MCB.23.21.7678-7688.2003
   Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598
   Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R
   Xiao XD, 2005, EXP MOL PATHOL, V79, P108, DOI 10.1016/j.yexmp.2005.06.001
   Yang LM, 1999, J MAMMARY GLAND BIOL, V4, P377, DOI 10.1023/A:1018718401126
   Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142
NR 50
TC 23
Z9 32
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2007
VL 30
IS 3
BP 641
EP 650
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 136IO
UT WOS:000244216000012
PM 17273765
DA 2025-01-12
ER

PT J
AU Pageau, GJ
   Hall, LL
   Lawrence, JB
AF Pageau, Gayle J.
   Hall, Lisa L.
   Lawrence, Jeanne B.
TI BRCA1 does not paint the inactive X to localize XIST RNA but may
   contribute to broad changes in cancer that impact XIST and Xi
   heterochromatin
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BRCA-1; XIST; X-inactivation
ID HUMAN BREAST-CANCER; CHROMOSOME INACTIVATION; H2AX PHOSPHORYLATION;
   SEX-CHROMATIN; SC-35 DOMAINS; ACTIVE-X; GENE; CELLS; STABILIZATION;
   INITIATION
AB The BRCA1 tumor suppressor involved in breast and ovarian cancer is linked to several fundamental cell regulatory processes. Recently, it was reported that BRCA1 supports localization of XIST RNA to the inactive X chromosome (Xi) in women. The apparent cytological overlap between BRCA1 and XIST RNA across the Xi raised the possibility a direct role of BRCA1 in localizing XIST. We report here that BRCA1 does not paint the Xi or XIST territory, as do markers of Xi facultative heterochromatin. A smaller BRCA1 accumulation abuts Xi, although this is not exclusive to Xi. In BRCA1 depleted normal and tumor cells, or BRCA1 reconstituted cells, BRCA1 status does not closely correlate with XIST localization, however in a BRCA1 inducible system over-expression correlated strongly with enhanced XIST expression. We confirm frequent loss of an Xi in tumor cells. In addition to mitotic loss of Xi, we find XIST RNA expression or localization frequently become compromised in cultured breast cancer cells, Suggesting Xi heterochromatin may not be fully maintained. We demonstrate that complex epigenetic differences between tumor cell subpopulations can have striking effects on XIST transcription, accumulation, and localization, but this does not strictly correlate with BRCA1. Although BRCA1 can have indirect effects that impact XIST, Our results do not indicate a direct and specific role in XIST RNA regulation. Rather, regulatory factors such as BRCA1 that have broad effects on chromatin or gene regulation can impact XIST RNA and the Xi. We provide preliminary evidence that this may Occur as part of a wider failure of heterochromatin maintenance in some cancers.
C1 Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester
RP Lawrence, JB (通讯作者)，Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.
EM Jeanne.Lawrence@umassmed.edu
OI Pouliot, Gayle/0000-0001-9730-143X; Lawrence, Jeanne/0000-0001-6572-3128
FU NIGMS NIH HHS [GM53234, GM68138] Funding Source: Medline
CR Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0
   BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M
   Chadwick BP, 2005, CHROMOSOMA, V114, P432, DOI 10.1007/s00412-005-0029-1
   Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074
   Chang SC, 2006, FRONT BIOSCI-LANDMRK, V11, P852, DOI 10.2741/1842
   Clemson CM, 2006, P NATL ACAD SCI USA, V103, P7688, DOI 10.1073/pnas.0601069103
   Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259
   Clemson CM, 1998, J CELL BIOL, V142, P13, DOI 10.1083/jcb.142.1.13
   Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773
   de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005
   Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853
   Fang J, 2004, J BIOL CHEM, V279, P52812, DOI 10.1074/jbc.C400493200
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Hall LL, 2002, P NATL ACAD SCI USA, V99, P8677, DOI 10.1073/pnas.132468999
   Hall LL, 2003, SEMIN CELL DEV BIOL, V14, P369, DOI 10.1016/j.semcdb.2003.09.011
   Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200
   Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990
   Jazaeri Amir A, 2004, J Transl Med, V2, P32, DOI 10.1186/1479-5876-2-32
   Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808
   KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D
   LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0
   Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095
   PAGEAU G, 2006, IN PRESS J CELL BIOL
   Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4
   PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   SAVINO A, 1971, ACTA CYTOL, V15, P372
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5
   Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Smith KP, 2004, CHROMOSOMA, V113, P324, DOI 10.1007/s00412-004-0325-1
   Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617
   Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413
   Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004
   Swerdlow AJ, 2001, ANN HUM GENET, V65, P177, DOI 10.1017/S0003480001008569
   Tam R, 2004, J CELL BIOL, V167, P269, DOI 10.1083/jcb.200403128
   Tinker AV, 1998, NUCLEIC ACIDS RES, V26, P2935, DOI 10.1093/nar/26.12.2935
   Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032
   Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   XING Y, 1993, THESIS
   Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635
   Yan OY, 2005, BIOCHEM BIOPH RES CO, V337, P875, DOI 10.1016/j.bbrc.2005.09.122
   Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019
NR 48
TC 48
Z9 54
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR 1
PY 2007
VL 100
IS 4
BP 835
EP 850
DI 10.1002/jcb.21188
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 137HP
UT WOS:000244284000003
PM 17146760
DA 2025-01-12
ER

PT J
AU Rodriguez-Canales, J
   Hanson, JC
   Tangrea, MA
   Erickson, HS
   Albert, PS
   Wallis, BS
   Richardson, AM
   Pinto, PA
   Linehan, WM
   Gillespie, JW
   Merin, MJ
   Libutti, SK
   Woodson, KG
   Emmert-Buck, MR
   Chuaqui, RF
AF Rodriguez-Canales, J.
   Hanson, J. C.
   Tangrea, M. A.
   Erickson, H. S.
   Albert, P. S.
   Wallis, B. S.
   Richardson, A. M.
   Pinto, P. A.
   Linehan, W. M.
   Gillespie, J. W.
   Merin, M. J.
   Libutti, S. K.
   Woodson, K. G.
   Emmert-Buck, M. R.
   Chuaqui, R. F.
TI Identification of a unique epigenetic sub-microenvironment in prostate
   cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE GSTP1; methylation; tumour microenvironment; tumour stroma; prostate
   carcinoma
ID LASER CAPTURE MICRODISSECTION; TUMOR PROGRESSION; INTRAEPITHELIAL
   NEOPLASIA; EPITHELIAL PLASTICITY; PROMOTER METHYLATION; DNA METHYLATION;
   BREAST-CANCER; STROMAL CELLS; GLUTATHIONE; GENE
AB The glutathione S-transferase P1 (GSTP1) gene promoter is methylated in tumour cells in more than 90% of prostate carcinomas. Recently, GSTP1 promoter methylation was identified in tumour-associated stromal cells in addition to the tumour epithelium. To define the extent and location of stromal methylation, epigenetic mapping using pyrosequencing quantification of GSTP1 promoter methylation and an anatomical three-dimensional reconstruction of an entire human prostate specimen with cancer were performed. Normal epithelium and stroma, tumour epithelium, and tumour-associated stromal cells were laser capture-microdissected from multiple locations throughout the gland. As expected, the GSTP1 promoter in both normal epithelium and normal stromal cells distant from the tumour was not methylated and the tumour epithelium showed consistently high levels of promoter methylation throughout. However, tumour-associated stromal cells were found to be methylated only in a localized and distinct anatomical sub-field of the tumour, revealing the presence of an epigenetically unique microenvironment within the cancer. Morphologically, the sub-field consisted of typical, non-reactive stroma, representing a genomic alteration in cells that appeared otherwise histologically normal. Similar epigenetic anatomical mapping of a control prostate gland without cancer showed low background methylation levels in all cell types throughout the specimen. These data suggest that stromal cell methylation can occur in a distinct sub-region of prostate cancer and may have implications for understanding tumour biology and clinical intervention. Published in 2007 by John Wiley & Sons, Ltd.
C1 NCI, NIH, Pathogenet Unit, Pathol Lab,Adv Technol Ctr,Ctr Canc Res, Gaithersburg, MD 20877 USA.
   NCI, NIH, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
   NCI, NIH, Biometr Res Branch, Canc Res Ctr, Bethesda, MD 20892 USA.
   NCI, NIH, Urol Oncol Branch, Canc Res Ctr, Bethesda, MD 20892 USA.
   Sci Applicat Int Corp, Frederick, MD USA.
   NCI, NIH, Pathol Lab, Canc Res Ctr, Bethesda, MD 20892 USA.
   NCI, NIH, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); Science Applications International
   Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI)
RP Emmert-Buck, MR (通讯作者)，NCI, NIH, Pathogenet Unit, Pathol Lab,Adv Technol Ctr,Ctr Canc Res, Rm 109D,8717 Grovemont Circle, Gaithersburg, MD 20877 USA.
EM buckm@mail.nih.gov
RI Gillespie Jr, John/HKM-4991-2023
FU Intramural NIH HHS Funding Source: Medline
CR Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Esteller M, 1998, CANCER RES, V58, P4515
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fend F, 2000, PATHOBIOLOGY, V68, P209, DOI 10.1159/000055925
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113
   Grover AC, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-13
   Grünert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175
   Hanson JA, 2006, JNCI-J NATL CANCER I, V98, P255, DOI 10.1093/jnci/djj051
   Henrique R, 2006, MOL CANCER RES, V4, P1, DOI 10.1158/1541-7786.MCR-05-0113
   Henrique R, 2004, EUR UROL, V46, P660, DOI 10.1016/j.eururo.2004.06.014
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kronz JD, 2001, AM J SURG PATHOL, V25, P1079, DOI 10.1097/00000478-200108000-00014
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Li HR, 2006, CANCER RES, V66, P4079, DOI 10.1158/0008-5472.CAN-05-4264
   Li M, 2003, PROSTATE, V56, P98, DOI 10.1002/pros.10249
   Lin XH, 2001, CANCER RES, V61, P8611
   McNeal JE, 2001, PROSTATE, V49, P48, DOI 10.1002/pros.1117
   MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Olumi AF, 1999, CANCER RES, V59, P5002
   Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5
   Schulz WA, 2006, J CELL MOL MED, V10, P100, DOI 10.1111/j.1582-4934.2006.tb00293.x
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912
   Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001
   Woodson K, 2004, PROSTATE, V60, P25, DOI 10.1002/pros.20013
NR 36
TC 48
Z9 52
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD MAR
PY 2007
VL 211
IS 4
BP 410
EP 419
DI 10.1002/path.2133
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 141YL
UT WOS:000244615000004
PM 17278115
DA 2025-01-12
ER

PT J
AU Chekhun, VF
   Lukyanova, NY
   Kovalchuk, O
   Tryndyak, VP
   Pogribny, IP
AF Chekhun, Vasyl' F.
   Lukyanova, Nataliya Yu.
   Kovalchuk, Olga
   Tryndyak, Volodymyr P.
   Pogribny, Igor P.
TI Epigenetic profiling of multidrug-resistant human MCF-7 breast
   adenocarcinorna cells reveals novel hyper- and hypomethylated targets
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID DNA METHYLATION; CHROMATIN-STRUCTURE; CANCER CELLS; BURKITTS-LYMPHOMA;
   MOLECULAR-BASIS; P-GLYCOPROTEIN; P73; EXPRESSION; APOPTOSIS; DOXORUBICIN
AB The successful treatment of cancer requires a clear understanding of multiple interacting factors involved in the development of drug resistance. Presently, two hypotheses, genetic and epigenetic, have been proposed to explain mechanisms of acquired cancer drug resistance. In the present study, we examined the alterations in epigenetic mechanisms in the drug-resistant MCF-7 human breast cancer cells induced by doxorubicin (DOX) and cisplatin (cisDDP), two chemotherapeutic drugs with different modes of action. Despite this difference, both of the drug-resistant cell lines displayed similar pronounced changes in the global epigenetic landscape showing loss of global DNA methylation, loss of histone H4 lysine 20 trimethylation, increased phosporylation of histone H3 serine 10, and diminished expression of Suv4-20h2 histone methyltransferase compared with parental MCF-7 cells. In addition to global epigenetic changes, the MCF-7/ DOX and MCF-7/cisDDP drug-resistant cells are characterized by extensive alterations in region-specific DNA methylation, as indicated by the appearance of the number of differentially methylated DNA genes. A detailed analysis of hypo- and hypermethylated DNA sequences revealed that the acquisition of drug-resistant phenotype of MCF-7 cells to DOX and cisDDP, in addition to specific alterations induced by a particular drug only, was characterized by three major common mechanisms: dysfunction of genes involved in estrogen metabolism (sulfatase 2 and estrogen receptor alpha), apoptosis (p73, alpha-tubulin, BCL2-antagonist of cell death, tissue transglutaminase 2 and forkhead box protein K1), and cell-cell contact (leptin, stromal cell-derived factor receptor 1, activin A receptor E-cadherin) and showed that two opposing hypo- and hypermethylation processes may enhance and complement each other in the disruption of these pathways. These results provided evidence that epigenetic changes are an important feature of cancer cells with acquired drug-resistant phenotype and may be a crucial contributing factor to its development. Finally, deregulation of similar pathways may explain the existence and provide mechanism of cross-resistance of cancer cells to different types of chemotherapeutic agents.
C1 Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
   RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, Dept Mech Anticanc Therapy, Kiev, Ukraine.
C3 US Food & Drug Administration (FDA); University of Lethbridge; National
   Academy of Sciences Ukraine; Kavetsky Institute of Experimental
   Pathology, Oncology & Radiobiology of NASU
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
RI Lukianova, Nataliia/LTD-8627-2024; Chekhun, Vasyl/A-7124-2015
OI Chekhun, Vasyl/0000-0003-1024-3703; Lukianova,
   Nataliia/0000-0002-3698-3868; Tryndyak, Volodymyr/0000-0002-8319-2954
CR Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   BIEDLER JL, 1994, ANTICANCER DRUG RESI, P1
   Bueso-Ramos C, 2005, J CLIN ONCOL, V23, P3932, DOI 10.1200/JCO.2005.02.998
   Chekhun V F, 2000, Tsitol Genet, V34, P11
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   Corn PG, 1999, CANCER RES, V59, P3352
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823
   Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113
   Francia G, 2005, MOL CANCER THER, V4, P1484, DOI 10.1158/1535-7163.MCT-04-0214
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   GIANCINTI L, 2006, ONCOLOGIST, V11, P1
   Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024
   Gonzalgo ML, 1997, CANCER RES, V57, P594
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gottesman MM, 2006, FEBS LETT, V580, P998, DOI 10.1016/j.febslet.2005.12.060
   Harbottle A, 2001, INT J CANCER, V92, P777, DOI 10.1002/ijc.1283
   Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324
   Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9
   Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3
   Iwasa Y, 2006, GENETICS, V172, P2557, DOI 10.1534/genetics.105.049791
   Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022
   Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931
   Koul S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-16
   Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x
   Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X
   Maier S, 2005, AM J PHARMACOGENOMIC, V5, P223, DOI 10.2165/00129785-200505040-00003
   Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002
   Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470
   Ono Y, 2001, MOL UROL, V5, P25, DOI 10.1089/109153601750124267
   Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001
   Pellegrini F, 2005, CANCER INVEST, V23, P264, DOI 10.1081/CNV-200055970
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515
   Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Roberti A, 2006, J CELL PHYSIOL, V207, P571, DOI 10.1002/jcp.20515
   Robey RW, 2006, CLIN CANCER RES, V12, P1547, DOI 10.1158/1078-0432.CCR-05-1423
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shishova Y V., 2000, Oncology, V2, P11
   Shlapatska LM, 2004, EXP ONCOL, V26, P210
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Stavrovskaya AA, 2000, BIOKHIMIYA, V65, P112
   Steller MD, 2005, MOL CANCER RES, V3, P50
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004
   Tryndyak V, 2006, ANAL BIOCHEM, V356, P202, DOI 10.1016/j.ab.2006.05.019
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235
NR 58
TC 98
Z9 119
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAR
PY 2007
VL 6
IS 3
BP 1089
EP 1098
DI 10.1158/1535-7163.MCT-06-0663
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 148NO
UT WOS:000245082100032
PM 17363502
DA 2025-01-12
ER

PT J
AU Young, DW
   Hassan, MQ
   Yang, XQ
   Galindo, M
   Javed, A
   Zaidi, SK
   Furcinitti, P
   Lapointe, D
   Montecino, M
   Lian, JB
   Stein, JL
   van Wijnen, AJ
   Stein, GS
AF Young, Daniel W.
   Hassan, Mohammad Q.
   Yang, Xiao-Qing
   Galindo, Mario
   Javed, Amjad
   Zaidi, Sayyed K.
   Furcinitti, Paul
   Lapointe, David
   Montecino, Martin
   Lian, Jane B.
   Stein, Janet L.
   van Wijnen, Andre J.
   Stein, Gary S.
TI Mitotic retention of gene expression patterns by the cell
   fate-determining transcription factor Runx2
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE chromatin; epigenetic control; mitosis; cell division
ID CHROMATIN REMODELING COMPLEX; BREAST-CANCER CELLS; DIFFERENTIATION;
   CBFA1; CYCLE; TRANSACTIVATION; ORGANIZATION; RUNX2/CBFA1; DISRUPTION;
   COMPONENTS
AB During cell division, cessation of transcription is coupled with mitotic chromosome condensation. A fundamental biological question is how gene expression patterns are retained during mitosis to ensure the phenotype of progeny cells. We suggest that cell fate-determining transcription factors provide an epigenetic mechanism for the retention of gene expression patterns during cell division. Runx proteins are lineage-specific transcription factors that are essential for hematopoietic, neuronal, gastrointestinal, and osteogenic cell fates. Here we show that Runx2 protein is stable during cell division and remains associated with chromosomes during mitosis through sequence-specific DNA binding. Using siRNA-mediated silencing, mitotic cell synchronization, and expression profiling, we identify Runx2-regulated genes that are modulated postmitotically. Novel target genes involved in cell growth and differentiation were validated by chromatin immunoprecipitation. Importantly, we find that during mitosis, when transcription is shut down, Runx2 selectively occupies target gene promoters, and Runx2 deficiency alters mitotic histone modifications. We conclude that Runx proteins have an active role in retaining phenotype during cell division to support lineage-specific control of gene expression in progeny cells.
C1 Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
   Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA.
   Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA.
   Univ Massachusetts, Sch Med, Informat Serv, Worcester, MA 01655 USA.
   Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion, Chile.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester; University of Massachusetts System;
   University of Massachusetts Worcester; Universidad de Concepcion
RP Stein, GS (通讯作者)，Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
EM gary.stein@umassmed.edu
RI van Wijnen, Andre/AAG-3578-2019; Young, Daniel/HKW-1747-2023; Hassan,
   Mohammad/GZA-7507-2022
OI Zaidi, Kaleem/0000-0001-6664-5168; Javed, Amjad/0000-0002-0847-8266; van
   Wijnen, Andre J./0000-0002-4458-0946; Montecino,
   Martin/0000-0002-6025-0023
FU NCI NIH HHS [P01CA82834, P01 CA082834] Funding Source: Medline; NIAMS
   NIH HHS [AR39588, T32 AR07572, R01 AR039588, T32 AR007572, R01 AR049069,
   P01AR48818, P01 AR048818, AR049069] Funding Source: Medline; NIDDK NIH
   HHS [P30 DK032520, P30 DK32520] Funding Source: Medline
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851
   Barnes GL, 2003, CANCER RES, V63, P2631
   Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233
   Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130
   Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70
   Hovhannisyan H, 2003, MOL CELL BIOL, V23, P1460, DOI 10.1128/MCB.23.4.1460-1469.2003
   Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5
   Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1
   MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7
   Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x
   Neil J, 1999, LEUKEMIA, V13, pS83, DOI 10.1038/sj.leu.2401295
   Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469
   Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669
   Pratap J, 2003, CANCER RES, V63, P5357
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003
   Taniuchi I, 2004, ONCOGENE, V23, P4341, DOI 10.1038/sj.onc.1207671
   Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202
   van der Meijden CMJ, 2002, CANCER RES, V62, P3233
   Vradii D, 2006, J CELL PHYSIOL, V206, P112, DOI 10.1002/jcp.20432
   Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002
   Westendorf JJ, 1999, J CELL BIOCHEM, P51
   Young DW, 2004, J CELL SCI, V117, P4889, DOI 10.1242/jcs.01229
   Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332
   Zaidi SK, 2005, EMBO REP, V6, P128, DOI 10.1038/sj.embor.7400337
   Zaidi SK, 2001, J CELL SCI, V114, P3093
   Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100
   Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2
   Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597
   Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311
NR 48
TC 136
Z9 157
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 27
PY 2007
VL 104
IS 9
BP 3189
EP 3194
DI 10.1073/pnas.0611419104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 142PG
UT WOS:000244661400032
PM 17360627
OA Green Published
DA 2025-01-12
ER

PT J
AU Garcia-Bassets, I
   Kwon, YS
   Telese, F
   Prefontaine, GG
   Hutt, KR
   Cheng, CS
   Ju, BG
   Ohgi, KA
   Wang, J
   Escoubet-Lozach, L
   Rose, DW
   Glass, CK
   Fu, XD
   Rosenfeld, MG
AF Garcia-Bassets, Ivan
   Kwon, Young-Soo
   Telese, Francesca
   Prefontaine, Gratien G.
   Hutt, Kasey R.
   Cheng, Christine S.
   Ju, Bong-Gun
   Ohgi, Kenneth A.
   Wang, Jianxun
   Escoubet-Lozach, Laure
   Rose, David W.
   Glass, Christopher K.
   Fu, Xiang-Dong
   Rosenfeld, Michael G.
TI Histone methylation-dependent mechanisms impose ligand dependency for
   gene activation by nuclear receptors
SO CELL
LA English
DT Article
ID THYROID-HORMONE RECEPTOR; ANDROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION;
   ESTROGEN-RECEPTOR; CO-REPRESSOR; INDEPENDENT ACTIVATION;
   CHROMATIN-STRUCTURE; LYSINE METHYLATION; SIGNALING PATHWAY;
   BREAST-CANCER
AB Nuclear receptors undergo ligand-dependent conformational changes that are required for corepressor-coactivator exchange, but whether there is an actual requirement for specific epigenetic landmarks to impose ligand dependency for gene activation remains unknown. Here we report an unexpected and general strategy that is based on the requirement for specific cohorts of inhibitory histone methyltransferases (HMTs) to impose gene-specific gatekeeper functions that prevent unliganded nuclear receptors and other classes of regulated transcription factors from binding to their target gene promoters and causing constitutive gene activation in the absence of stimulating signals. This strategy, based at least in part on an HMT-dependent inhibitory histone code, imposes a requirement for specific histone demethylases, including LSD1, to permit ligand- and signal-dependent activation of regulated gene expression. These events link an inhibitory methylation component of the histone code to a broadly used strategy that circumvents pathological constitutive gene induction by physiologically regulated transcription factors.
C1 Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Sch Med, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   Howard Hughes Medical Institute; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego
RP Glass, CK (通讯作者)，Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM ckg@ucsd.edu; xdfu@ucsd.edu; mrosenfeld@ucsd.edu
RI Glass, Christopher/AAI-3933-2021; Garcia-Bassets, Ivan/F-5075-2010;
   Telese, Francesca/LDF-9644-2024
OI Garcia-Bassets, Ivan/0000-0002-6941-9585; Telese,
   Francesca/0000-0003-3877-0628
FU NCI NIH HHS [CA52599, R01 CA052599, CA97134, R01 CA097134, CA114184, R33
   CA114184] Funding Source: Medline; NHGRI NIH HHS [HG003119, R01
   HG003119] Funding Source: Medline; NIDDK NIH HHS [R01 DK039949, R37
   DK039949, P30 DK063491, DK39949, DK063491] Funding Source: Medline;
   NINDS NIH HHS [NS34934, R01 NS034934] Funding Source: Medline
CR Andrés ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873
   Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013
   Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3
   Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0
   Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101
   Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004
   Chan C, 2005, J IMMUNOL, V175, P461, DOI 10.4049/jimmunol.175.1.461
   CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0
   CULIG Z, 1994, CANCER RES, V54, P5474
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Du Y, 2001, CANCER RES, V61, P8094
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290
   Forneris F, 2005, J BIOL CHEM, V280, P41360, DOI 10.1074/jbc.M509549200
   Forneris F, 2006, J BIOL CHEM, V281, P35289, DOI 10.1074/jbc.M607411200
   Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599
   Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200
   He LS, 1998, CANCER RES, V58, P4238
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0
   Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kim J, 2005, J MOL ENDOCRINOL, V34, P107, DOI 10.1677/jme.1.01701
   Kim J, 2003, NUCLEIC ACIDS RES, V31, P6741, DOI 10.1093/nar/gkg909
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Kurahashi T, 2005, MOL BIOL CELL, V16, P4705, DOI 10.1091/mbc.E05-05-0470
   Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104
   Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002
   Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469
   Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0
   Métivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101
   Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3
   Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007
   Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556
   Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699
   Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200
   Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998
   Yang XJ, 2003, CURR OPIN GENET DEV, V13, P143, DOI 10.1016/S0959-437X(03)00015-7
   You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454
   Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002
   Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032
   Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6
NR 74
TC 366
Z9 460
U1 1
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD FEB 9
PY 2007
VL 128
IS 3
BP 505
EP 518
DI 10.1016/j.cell.2006.12.038
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 145CK
UT WOS:000244842700017
PM 17289570
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Seng, TJ
   Low, JSW
   Li, H
   Cui, Y
   Goh, HK
   Wong, MLY
   Srivastava, G
   Sidransky, D
   Califano, J
   Steenbergen, RDM
   Rha, SY
   Tan, J
   Hsieh, WS
   Ambinder, RF
   Lin, X
   Chan, ATC
   Tao, Q
AF Seng, T. J.
   Low, J. S. W.
   Li, H.
   Cui, Y.
   Goh, H. K.
   Wong, M. L. Y.
   Srivastava, G.
   Sidransky, D.
   Califano, J.
   Steenbergen, R. D. M.
   Rha, S. Y.
   Tan, J.
   Hsieh, W-S
   Ambinder, R. F.
   Lin, X.
   Chan, A. T. C.
   Tao, Q.
TI The major 8p22 tumor suppressor <i>DLC1</i> is frequently silenced by
   methylation in both endemic and sporadic nasopharyngeal, esophageal, and
   cervical carcinomas, and inhibits tumor cell colony formation
SO ONCOGENE
LA English
DT Article
DE DLC1; 8p22; tumor suppressor gene; methylation; nasopharyngeal
   carcinoma; esophageal carcinoma; cervical carcinoma
ID EPSTEIN-BARR-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; STRESS-RESPONSIVE
   GENE; HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION; P53 GENE;
   EPIGENETIC INACTIVATION; SUSCEPTIBILITY LOCUS; TSLC1 GENE; MULTIPLE
AB Identification of tumor suppressor genes (TSG) silenced by methylation uncovers mechanisms of tumorigenesis and identifies new epigenetic tumor markers for early cancer detection. Both nasopharyngeal carcinoma (NPC) and esophageal carcinoma are major tumors in Southern China and Southeast Asia. Through expression subtraction of NPC, we identified Deleted in Liver Cancer 1 (DLC1)/ARHGAP7 (NM_006094) - an 8p22 TSG as a major downregulated gene. Although expressed in all normal tissues, DLC1 was silenced or downregulated in 11/12 (91%) NPC, 6/15 (40%) esophageal, 5/8 (63%) cervical and 3/9 (33%) breast carcinoma cell lines. No genetic deletion of DLC1 was detected in NPC although a hemizygous deletion at 8p22-11 was found by 1-Mb array-CGH in some cell lines. We then located the functional DLC1 promoter by 5'-RACE and promoter activity assays. This promoter was frequently methylated in all downregulated cell lines and in a large collection of primary tumors including 89% (64/72) NPC (endemic and sporadic types), 51% (48/94) esophageal, 87% (7/8) cervical and 36% (5/14) breast carcinomas, but seldom in paired surgical marginal tissues and not in any normal epithelial tissue. The transcriptional silencing of DLC1 could be reversed by 5-aza-20-deoxycytidine or genetic double knock-out of DNMT1 and DNMT3B. Furthermore, ectopic expression of DLC1 in NPC and esophageal carcinoma cells strongly inhibited their colony formation. We thus found frequent epigenetic silencing of DLC1 in NPC, esophageal and cervical carcinomas, and a high correlation of methylation with its downregulation, suggesting a predominant role of epigenetic inactivation. DLC1 appears to be a major TSG implicated in the pathogenesis of these tumors, and should be further tested as a molecular biomarker in patients with these cancers.
C1 Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China.
   Johns Hopkins Singapore, Biopolis, Singapore, Singapore.
   Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
   Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands.
   Yonsei Univ, Coll Med, Ctr Canc, Seoul 120749, South Korea.
   Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Johns Hopkins
   University; Johns Hopkins Medicine; University of Hong Kong; Johns
   Hopkins University; Johns Hopkins Medicine; Vrije Universiteit
   Amsterdam; Yonsei University; Yonsei University Health System; Johns
   Hopkins University; Johns Hopkins Medicine
RP Tao, Q (通讯作者)，Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China.
EM qtao@clo.cuhk.edu.hk
RI ; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018
OI Rha, Sun Young/0000-0002-2512-4531; Tao, Qian/0000-0001-5383-4808;
   Steenbergen, Renske/0000-0002-2327-9839; Chan, Anthony Tak
   Cheung/0000-0002-6912-8091
FU NCI NIH HHS [P01CA15396] Funding Source: Medline
CR BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422
   Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.0.CO;2-I
   Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048
   Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042
   Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119
   EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Feng BJ, 2002, NAT GENET, V31, P395, DOI 10.1038/ng932
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524
   Gulley ML, 1998, AM J PATHOL, V152, P865
   HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130
   HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x
   Hui ABY, 2003, MOL CARCINOGEN, V38, P170, DOI 10.1002/mc.10156
   Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260
   Kim TM, 2005, CLIN CANCER RES, V11, P79
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Lo KW, 2000, CANCER RES, V60, P3348
   LO KW, 1995, CANCER RES, V55, P2039
   LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0
   Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1
   Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313
   PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755
   SPRUCK CH, 1992, CANCER RES, V52, P4787
   Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445
   Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031
   Steenbergen RDM, 1996, ONCOGENE, V13, P1249
   SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516
   Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Tao Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2672, DOI 10.2741/2000
   Teramoto A, 2004, ONCOL REP, V12, P141
   Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2
   Wang DZM, 1997, CANCER RES, V57, P2478
   Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4
   Wong CM, 2003, CANCER RES, V63, P7646
   Wong ML, 2006, INT J ONCOL, V28, P767
   Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064
   Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217
NR 53
TC 108
Z9 130
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 8
PY 2007
VL 26
IS 6
BP 934
EP 944
DI 10.1038/sj.onc.1209839
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 134DT
UT WOS:000244063800013
PM 16862168
DA 2025-01-12
ER

PT J
AU Nam, JM
   Onodera, Y
   Mazaki, Y
   Miyoshi, H
   Hashimoto, S
   Sabe, H
AF Nam, Jin-Min
   Onodera, Yasuhito
   Mazaki, Yuichi
   Miyoshi, Hiroyuki
   Hashimoto, Shigeru
   Sabe, Hisataka
TI CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated
   breast cancer invasion machinery
SO EMBO JOURNAL
LA English
DT Article
DE AMAP1; breast cancer; invasion; ubiquitination
ID EXTRACELLULAR-MATRIX DEGRADATION; DEPENDENT PROTEASOME PATHWAY;
   GENE-EXPRESSION PROFILES; GROWTH-FACTOR RECEPTORS; TUMOR-CELL INVASION;
   DOWN-REGULATION; TYROSINE KINASES; ADAPTER PROTEIN; EGF RECEPTORS;
   IN-SITU
AB Expression of AMAP1 correlates well with the invasive phenotypes and malignancy of human primary breast carcinomas. AMAP1 recruits its binding proteins, such as cortactin and paxillin, to sites of Arf6 activation to form invadopodia. A mouse ortholog of AMAP1, ASAP1, is known to bind to CIN85, a binding partner of an E3 ligase, Cbl. Here, we found that CIN85 colocalizes with AMAP1 at invadopodia, and binding of AMAP1 with CIN85 is important for the invasive activities of breast cancer cells, including MDA-MB-231. siRNA-mediated silencing of CIN85, as well as Cbl, also inhibited the invasion. We moreover found that AMAP1 is monoubiquitinated, rather than polyubiquitinated, by virtue of Cbl and provide evidence that the ability of AMAP1 to be monoubiquitinated is important for its involvement in invasion. Our results indicate that CIN85, as well as Cbl, which is a well-known suppressor of growth factor receptor signaling, can be positively involved in tumor invasion, and suggest that a complex epigenetic process is involved in AMAP1 function in breast cancer cell invasion.
C1 Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan.
   Kyoto Univ, Grad Sch Biostudies, Kyoto, Japan.
   RIKEN, Tsukuba Inst, BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki, Japan.
C3 Kyoto University; RIKEN
RP Sabe, H (通讯作者)，Osaka Biosci Inst, Dept Mol Biol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.
EM sabe@obi.or.jp
RI Miyoshi, Hiroyuki/G-9808-2013; Hashimoto, Shigeru/D-7138-2012; Sabe,
   Hisataka/A-4066-2012; Nam, Jin-Min/D-6468-2012; Onodera,
   Yasuhito/D-7108-2012
OI Mazaki, Yuichi/0000-0003-4192-0834; Onodera,
   Yasuhito/0000-0002-0064-9016
CR AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742
   Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Bögler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6
   Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827
   Bowden ET, 2001, METHOD CELL BIOL, V63, P613
   Chen H, 2005, P NATL ACAD SCI USA, V102, P2766, DOI 10.1073/pnas.0409719102
   Coopman PJ, 1998, CLIN CANCER RES, V4, P507
   Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789
   d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x
   Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124
   Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056
   Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3
   Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015
   Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983
   Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299
   Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005
   Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1
   Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738
   Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103
   Hashimoto S, 2005, METHOD ENZYMOL, V404, P216, DOI 10.1016/S0076-6879(05)04021-8
   Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101
   Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354
   Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832
   Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x
   Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.e03-09-0683
   Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200
   Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758
   Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001
   Narita T, 2001, CYTOGENET CELL GENET, V93, P133, DOI 10.1159/000056966
   Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588
   Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a
   Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a
   Price JT, 1999, CANCER RES, V59, P5475
   Rizki A, 2004, CANCER CELL, V6, P1, DOI 10.1016/j.ccr.2004.06.019
   Sapi E, 1996, CANCER RES, V56, P5704
   Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762
   Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610
   Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102
   Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a
   Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200
   Tague SE, 2004, P NATL ACAD SCI USA, V101, P9671, DOI 10.1073/pnas.0403531101
   Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147
   Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100
   THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010
   Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303
   Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481
   Zajchowski DA, 2001, CANCER RES, V61, P5168
NR 52
TC 53
Z9 67
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD FEB 7
PY 2007
VL 26
IS 3
BP 647
EP 656
DI 10.1038/sj.emboj.7601534
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 134KS
UT WOS:000244082500002
PM 17255943
OA Green Published
DA 2025-01-12
ER

PT J
AU Wang, ZL
   Yan, PL
   Potter, D
   Eng, CR
   Huang, THM
   Lin, SL
AF Wang, Zailong
   Yan, Pearlly
   Potter, Dustin
   Eng, Charis
   Huang, Tim H-M
   Lin, Shili
TI Heritable clustering and pathway discovery in breast cancer integrating
   epigenetic and phenotypic data
SO BMC BIOINFORMATICS
LA English
DT Article
ID DNA METHYLATION; GENE-EXPRESSION
AB Background: In order to recapitulate tumor progression pathways using epigenetic data, we developed novel clustering and pathway reconstruction algorithms, collectively referred to as heritable clustering. This approach generates a progression model of altered DNA methylation from tumor tissues diagnosed at different developmental stages. The samples act as surrogates for natural progression in breast cancer and allow the algorithm to uncover distinct epigenotypes that describe the molecular events underlying this process. Furthermore, our likelihood-based clustering algorithm has great flexibility, allowing for incomplete epigenotype or clinical phenotype data and also permitting dependencies among variables.
   Results: Using this heritable clustering approach, we analyzed methylation data obtained from 86 primary breast cancers to recapitulate pathways of breast tumor progression. Detailed annotation and interpretation are provided to the optimal pathway recapitulated. The result confirms the previous observation that aggressive tumors tend to exhibit higher levels of promoter hypermethylation.
   Conclusion: Our results indicate that the proposed heritable clustering algorithms are a useful tool for stratifying both methylation and clinical variables of breast cancer. The application to the breast tumor data illustrates that this approach can select meaningful progression models which may aid the interpretation of pathways having biological and clinical significance. Furthermore, the framework allows for other types of biological data, such as microarray gene expression or array CGH data, to be integrated.
C1 Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA.
   Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Stat, Columbus, OH 43210 USA.
   Cleveland Clin Fdn, Cleveland Clin Genomic Med Inst, Cleveland, OH 44195 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; Cleveland
   Clinic Foundation
RP Lin, SL (通讯作者)，Ohio State Univ, Math Biosci Inst, 231 W 18th Ave, Columbus, OH 43210 USA.
EM zailong.wang@yahoo.com; Pearlly.Yan@osumc.edu; Dustin.Potter@osumc.edu;
   engc@ccf.org; Tim.Huang@osumc.edu; shili@stat.ohio-state.edu
RI Yan, Pearlly/E-4339-2011
OI Eng, Charis/0000-0002-3693-5145
FU NCI NIH HHS [P50CA113001, R01CA069065, T32-CA106196-03, R01 CA069065,
   P30CA16058, T32 CA106196, U54 CA113001, P30 CA016058] Funding Source:
   Medline
CR [Anonymous], Modern Information Retrieval: TheConcepts and Technology Behind Search
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Cai L, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r51
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Costello JF, 2005, NAT GENET, V37, P211, DOI 10.1038/ng0305-211
   Datta S, 2003, BIOINFORMATICS, V19, P459, DOI 10.1093/bioinformatics/btg025
   Desper R, 2000, J COMPUT BIOL, V7, P789, DOI 10.1089/10665270050514936
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   Genereux DP, 2005, P NATL ACAD SCI USA, V102, P5802, DOI 10.1073/pnas.0502036102
   Green KA, 2004, CELL MOL LIFE SCI, V61, P1867, DOI 10.1007/s00018-004-3366-y
   Hastie T., 2008, The Elements of Statistical Learning: Data Mining, Inference, and Prediction, P587
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Newton MA, 2002, J AM STAT ASSOC, V97, P931, DOI 10.1198/016214502388618726
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rosen EM, 2005, ENDOCR-RELAT CANCER, V12, P533, DOI 10.1677/erc.1.00972
   Siegmund KD, 2004, BIOINFORMATICS, V20, P1896, DOI 10.1093/bioinformatics/bth176
   VIRE E, 2005, NATURE, V439
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yan PS, 2001, CANCER RES, V61, P8375
   Yoon JP, 2001, J INTELL INF SYST, V17, P241, DOI 10.1023/A:1012861931139
NR 26
TC 6
Z9 9
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD FEB 1
PY 2007
VL 8
AR 38
DI 10.1186/1471-2105-8-38
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 136VK
UT WOS:000244252000001
PM 17270052
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hemminki, K
   Ji, JG
   Försti, A
AF Hemminki, Kari
   Ji, Jianguang
   Foersti, Asta
TI Risks for familial and contralateral breast cancer interact
   multiplicatively and cause a high risk
SO CANCER RESEARCH
LA English
DT Article
ID SUSCEPTIBILITY; EPIDEMIOLOGY
AB The reasons for the high risk of contralateral breast cancer are not understood, although polygenic mechanisms have been suggested to be involved. The nationwide Swedish Family-Cancer Database was used to examine the interaction of the risks for contralateral and familial cancer. Relative risks were separately determined for contralateral and familial breast cancers, and these were tested for additive and multiplicative interactions. The Database contained information on 102,176 first breast cancers. Familial risk for breast cancer was 1.76 and the risk for contralateral breast cancer was 3.40, or 5.80 when extrapolated to two breasts. When women had a family history, the risk for contralateral breast cancer was remarkably high, 5.48, or 9.96 when the risk was extrapolated to two breasts, almost identical with 10.21, which was predicted by the multiplicative model. Although the data do not rule out polygenic mechanisms, they suggest that epigenetic imprinting events may be involved for the contralateral breast cancer.
C1 German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany.
   Karolinska Inst, Ctr Family & Community Med, Huddinge, Sweden.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska
   Institutet
RP Hemminki, K (通讯作者)，German Canc Res Ctr, Div Mol Genet Epidemiol, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
EM k.hemminki@dkfz.de
RI Ji, Jianguang/E-9579-2011
OI Ji, Jianguang/0000-0003-0324-9496
CR [Anonymous], 1996, IARC MON EV CARC RIS
   [Anonymous], 1987, STAT METHODS CANC RE
   Bermejo JL, 2005, JNCI-J NATL CANCER I, V97, P1575, DOI 10.1093/jnci/dji338
   Chen Y, 1999, CANCER EPIDEM BIOMAR, V8, P855
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Frodin JE, 1997, ACTA ONCOL, V36, P465
   Greenland S, 2004, INT J EPIDEMIOL, V33, P1389, DOI 10.1093/ije/dyh276
   Hartman M, 2005, LANCET ONCOL, V6, P377, DOI 10.1016/S1470-2045(05)70174-1
   Hemminki K, 2002, NAT GENET, V32, P233, DOI 10.1038/ng1002-233
   Hemminki K, 2001, MUTAT RES-FUND MOL M, V473, P11, DOI 10.1016/S0027-5107(00)00162-7
   Hemminki K, 2001, ACTA ONCOL, V40, P772
   Johnson N, 2005, LANCET, V366, P1554, DOI 10.1016/S0140-6736(05)67627-1
   Li CI, 2001, J NATL CANCER I, V93, P1008, DOI 10.1093/jnci/93.13.1008
   Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533
   Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Stenmark-Askmalm M, 2001, ACTA ONCOL, V40, P56
   Vaittinen P, 2000, INT J CANCER, V88, P998, DOI 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0
   Zelterman Daniel., 2002, Advanced log-linear models using SAS
NR 20
TC 36
Z9 38
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2007
VL 67
IS 3
BP 868
EP 870
DI 10.1158/0008-5472.CAN-06-3854
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 135EQ
UT WOS:000244137300006
PM 17283115
DA 2025-01-12
ER

PT J
AU Turley, RS
   Finger, EC
   Hempel, N
   How, T
   Fields, TA
   Blobe, GC
AF Turley, Ryan S.
   Finger, Elizabeth C.
   Hempel, Nadine
   How, Tam
   Fields, Timothy A.
   Blobe, Gerard C.
TI The type III transforming growth factor-β receptor as a novel tumor
   suppressor gene in prostate cancer
SO CANCER RESEARCH
LA English
DT Article
ID TGF-BETA; BREAST-CANCER; SOLUBLE BETAGLYCAN; DOWN-REGULATION;
   EXPRESSION; HETEROZYGOSITY; TUMORIGENICITY; MECHANISMS; MEMBRANE;
   PROTEIN
AB The transforming growth factor-beta (TGF-beta) signaling pathway has an important role in regulating normal prostate epithelium, inhibiting proliferation, differentiation, and both androgen deprivation-induced and androgen-independent apoptosis. During prostate cancer formation, most prostate cancer cells become resistant to these homeostatic effects of TGF-beta. Although the loss of expression of either the type I (T beta RI) or type II (T beta RII) TGF-beta receptor has been documented in similar to 30% of prostate cancers, most prostate cancers become TGF-beta resistant without mutation or deletion of T beta RI, T beta RII, or Smads2, 3, and 4, and thus, the mechanism of resistance remains to be defined. Here, we show that type III TGF-beta receptor (T RIII or betaglycan) expression is decreased or lost in the majority of human prostate cancers as compared with benign prostate tissue at both the mRNA and protein level. Loss of T beta RIII expression correlates with advancing tumor stage and a higher probability of prostate-specific antigen (PSA) recurrence, suggesting a role in prostate cancer progression. The loss of T T beta RIII expression is mediated by the loss of heterozygosity at the TGFBR3 genomic locus and epigenetic regulation of the T beta RIII promoter. Functionally, restoring T beta RIII expression in prostate cancer cells potently decreases cell motility and cell invasion through Matrigel in vitro and prostate tumorigenicity in vivo. Taken together, these studies define the loss of T beta RIII expression as a common event in human prostate cancer and suggest that this loss is important for prostate cancer progression through effects on cell motility, invasiveness, and tumorigenicity.
C1 Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Blobe, GC (通讯作者)，Duke Univ, Med Ctr, Dept Med, 221B MSRB Res Dr,Box 2631, Durham, NC 27710 USA.
EM blobe001@mc.duke.edu
RI Hempel, Nadine/F-1700-2014; GAO, JU/AAB-7012-2021; Blobe,
   Gerard/AAJ-5945-2020
OI Hempel, Nadine/0000-0002-5574-8783; Blobe, Gerard/0000-0002-4274-8901
FU NCI NIH HHS [R01 CA 106307] Funding Source: Medline
CR Ahomadegbe JC, 2000, ONCOGENE, V19, P5413, DOI 10.1038/sj.onc.1203914
   Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286
   Bandyopadhyay A, 1999, CANCER RES, V59, P5041
   Bandyopadhyay A, 2005, PROSTATE, V63, P81, DOI 10.1002/pros.20166
   Bandyopadhyay A, 2002, CANCER RES, V62, P4690
   Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200
   BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406
   Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080
   Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195
   Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835
   Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027
   Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585
   ELLIOTT RI, 2005, ANNU REV CELL DEV BI, V21, P659
   Florio P, 2005, EUR J ENDOCRINOL, V152, P277, DOI 10.1530/eje.1.01849
   Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1
   Hsing AY, 1996, CANCER RES, V56, P5146
   Kim IY, 1996, CLIN CANCER RES, V2, P1255
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   LaTulippe E, 2002, CANCER RES, V62, P4499
   Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237
   LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8
   LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557
   LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z
   Luo J, 2001, CANCER RES, V61, P4683
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234
   REPESH LA, 1989, INVAS METAST, V9, P192
   Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003
   Story MT, 1996, J CELL PHYSIOL, V169, P97, DOI 10.1002/(SICI)1097-4652(199610)169:1<97::AID-JCP10>3.0.CO;2-L
   Valster A, 2005, METHODS, V37, P208, DOI 10.1016/j.ymeth.2005.08.001
   WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9
   Welsh JB, 2001, CANCER RES, V61, P5974
   Williams RH, 1996, CLIN CANCER RES, V2, P635
   Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158
NR 40
TC 147
Z9 176
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2007
VL 67
IS 3
BP 1090
EP 1098
DI 10.1158/0008-5472.CAN-06-3117
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 135EQ
UT WOS:000244137300033
PM 17283142
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Hoebeeck, J
   Michels, E
   Menten, B
   Van Roy, N
   Eggert, A
   Schramm, A
   De Preter, K
   Yigit, N
   De Smet, E
   De Paepe, A
   Laureys, G
   Vandesompele, J
   Speleman, F
AF Hoebeeck, Jasmien
   Michels, Evi
   Menten, Bjoern
   Van Roy, Nadine
   Eggert, Angelika
   Schramm, Alexander
   De Preter, Katleen
   Yigit, Nurten
   De Smet, Els
   De Paepe, Anne
   Laureys, Genevieve
   Vandesompele, Jo
   Speleman, Frank
TI High resolution tiling-path BAC array deletion mapping suggests commonly
   involved 3p21-p22 tumor suppressor genes in neuroblastoma and more
   frequent tumors
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE 3p deletion; neuroblastoma; arrayCGH
ID COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-CHROMOSOME 3P21.3; REAL-TIME
   PCR; EPIGENETIC INACTIVATION; EPITHELIAL MALIGNANCIES;
   MYCN-AMPLIFICATION; CGH ANALYSIS; LUNG; EXPRESSION; CANCER
AB The recurrent loss of 3p segments in neuroblastoma suggests the implication of I or more tumor suppressor genes but thus far few efforts have been made to pinpoint their detailed chromosomal position. To achieve this goal, array-based comparative genomic hybridization was performed on a panel of 23 neuroblastoma cell lines and 75 primary tumors using a tiling-path bacterial artificial chromosome array for chromosome 3p. A total of 45 chromosome 3 losses were detected, including whole chromosome losses, large terminal deletions and interstitial deletions. The latter, observed in cell lines as well as a number of distal deletions detected in primary tumors, allowed us to demarcate 3 minimal regions of loss of 3.6 Mb [3p21.31-p21.2, shortest regions of overlap (SRO)1], 1.4 Mb (3p22.3-3p22.2, SRO2) and 3.8 Mb (3p25.3-p25.1, SRO3) in size. The present data significantly extend previous findings and now firmly establish critical regions on 3p implicated in neuroblastoma. Interestingly, the 2 proximal regions coincide with previously defined SROs on 3p21.3 in more frequent tumors including lung and breast cancer. As such, similar tumor suppressor genes may play a critical role in development or progression of a variety of neoplasms, including neuroblastoma. (c) 2006 Wiley-Liss. Inc.
C1 State Univ Ghent Hosp, Ctr Med Genet, MRB, B-9000 Ghent, Belgium.
   Univ Essen Gesamthsch, Childrens Hosp, Dept Pediat Oncol & Hematol, Essen, Germany.
   State Univ Ghent Hosp, Dept Pediat Hematol & Oncol, B-9000 Ghent, Belgium.
C3 Ghent University; Ghent University Hospital; University of Duisburg
   Essen; Ghent University; Ghent University Hospital
RP Speleman, F (通讯作者)，State Univ Ghent Hosp, Ctr Med Genet, MRB, Pintelaan 185, B-9000 Ghent, Belgium.
EM franki.speleman@ugent.be
RI laureys, genevieve/AAG-2390-2021; Eggert, Angelika/AAE-6907-2022;
   Menten, Björn/B-3072-2013; speleman, frank/AAR-5184-2020; Vandesompele,
   Jo/W-3411-2018; De Preter, Katleen/I-7135-2013; Schramm,
   Alexander/G-5688-2010
OI Vandesompele, Jo/0000-0001-6274-0184; Eggert,
   Angelika/0000-0003-3476-8184; De Preter, Katleen/0000-0002-7726-5096;
   Schramm, Alexander/0000-0001-7670-7529; Menten,
   Bjorn/0000-0001-8182-659X
CR Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243
   Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9
   Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255
   Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511
   Breen CJ, 2000, CANCER GENET CYTOGEN, V120, P44, DOI 10.1016/S0165-4608(99)00252-6
   BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134
   Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70
   Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7
   Ejeskär K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297
   Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155
   Hoebeeck J, 2006, INT J CANCER, V119, P624, DOI 10.1002/ijc.21888
   Ji L, 2002, CANCER RES, V62, P2715
   Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101
   Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832
   Luttikhuis MEMO, 2001, BRIT J CANCER, V85, P531, DOI 10.1054/bjoc.2001.1960
   Menten B, 2005, EUR J MED GENET, V48, P301, DOI 10.1016/j.ejmg.2005.04.014
   Menten B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-124
   Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198
   Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569
   Plantaz D, 2001, INT J CANCER, V91, P680, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R
   Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Selzer RR, 2005, GENE CHROMOSOME CANC, V44, P305, DOI 10.1002/gcc.20243
   Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429
   Senchenko VN, 2004, ONCOGENE, V23, P5719, DOI 10.1038/sj.onc.1207760
   Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154
   Van Gele M, 1997, EUR J CANCER, V33, P1979, DOI 10.1016/S0959-8049(97)00289-X
   Van Roy N, 2001, GENE CHROMOSOME CANC, V32, P126, DOI 10.1002/gcc.1174
   Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104
   Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E
   Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2
   Wei MH, 1996, CANCER RES, V56, P1487
NR 38
TC 20
Z9 20
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 1
PY 2007
VL 120
IS 3
BP 533
EP 538
DI 10.1002/ijc.22326
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 117JI
UT WOS:000242869000011
PM 17096344
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, YZ
   Pan, J
   Li, JL
   Lee, JH
   Tunkey, C
   Saraf, K
   Garbe, JC
   Whitley, MZ
   Jelinsky, SA
   Stampfer, MR
   Haney, SA
AF Li, Yizheng
   Pan, Jing
   Li, Jian-Liang
   Lee, Jee Hyung
   Tunkey, Chris
   Saraf, Katie
   Garbe, James C.
   Whitley, Maryann Z.
   Jelinsky, Scott A.
   Stampfer, Martha R.
   Haney, Steven A.
TI Transcriptional changes associated with breast cancer occur as normal
   human mammary epithelial cells overcome senescence barriers and become
   immortalized
SO MOLECULAR CANCER
LA English
DT Article
ID CARCINOMA IN-SITU; TELOMERASE CATALYTIC SUBUNIT; GENE-EXPRESSION
   PATTERNS; DUCTAL CARCINOMAS; DNA METHYLATION; C-MYC; GROWTH; BRCA1;
   IDENTIFICATION; HTERT
AB Background: Human mammary epithelial cells (HMEC) overcome two well-characterized genetic and epigenetic barriers as they progress from primary cells to fully immortalized cell lines in vitro. Finite lifespan HMEC overcome an Rb-mediated stress-associated senescence barrier ( stasis), and a stringent, telomere-length dependent, barrier (agonescence or crisis, depending on p53 status). HMEC that have overcome the second senescence barrier are immortalized.
   Methods: We have characterized pre-stasis, post-selection (post-stasis, with p16 silenced), and fully immortalized HMEC by transcription profiling and RT-PCR. Four pre-stasis and seven post-selection HMEC samples, along with 10 representatives of fully immortalized breast epithelial cell lines, were profiled using Affymetrix U133A/B chips and compared using both supervised and unsupervised clustering. Datasets were validated by RT-PCR for a select set of genes. Quantitative immunofluorescence was used to assess changes in transcriptional regulators associated with the gene expression changes.
   Results: The most dramatic and uniform changes we observed were in a set of about 30 genes that are characterized as a "cancer proliferation cluster," which includes genes expressed during mitosis (CDC2, CDC25, MCM2, PLK1) and following DNA damage. The increased expression of these genes was particularly concordant in the fully immortalized lines. Additional changes were observed in IFN-regulated genes in some post-selection and fully immortalized cultures. Nuclear localization was observed for several transcriptional regulators associated with expression of these genes in post-selection and immortalized HMEC, including Rb, Myc, BRCA1, HDAC3 and SP1.
   Conclusion: Gene expression profiles and cytological changes in related transcriptional regulators indicate that immortalized HMEC resemble non-invasive breast cancers, such as ductal and lobular carcinomas in situ, and are strikingly distinct from finite-lifespan HMEC, particularly with regard to genes involved in proliferation, cell cycle regulation, chromosome structure and the DNA damage response. The comparison of HMEC profiles with lines harboring oncogenic changes (e. g. overexpression of Her-2(neu), loss of p53 expression) identifies genes involved in tissue remodeling as well as proinflamatory cytokines and S100 proteins. Studies on carcinogenesis using immortalized cell lines as starting points or "normal" controls need to account for the significant pre-existing genetic and epigenetic changes inherent in such lines before results can be broadly interpreted.
C1 Wyeth Ayerst Res, Dept Biol Technol, Appl Genomics, Cambridge, MA 02140 USA.
   Wyeth Ayerst Res, Dept Biol Technol, Sect Bioinformat, Cambridge, MA 02140 USA.
   Wyeth Ayerst Res, Dept Biol Technol, Mol Profiling & Biomarker Discovery, Cambridge, MA 02140 USA.
   Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
C3 Pfizer; Pfizer; Pfizer; United States Department of Energy (DOE);
   Lawrence Berkeley National Laboratory
RP Haney, SA (通讯作者)，Wyeth Ayerst Res, Dept Biol Technol, Appl Genomics, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.
EM yli@wyeth.com; jpan@wyeth.com; jlli@wyeth.com;
   jeehyung.lee@novartis.com; ctunkey@crtx.com; ksaraf@wyeth.com;
   jcgarbe@lbl.gov; mwhitley@wyeth.com; sjelinsky@wyeth.com;
   mrstampfer@lbl.gov; shaney@wyeth.com
RI Li, Jian-Liang/AAE-9315-2019; pan, jing/KJL-2220-2024; lee,
   jee-hyung/LKJ-2390-2024
OI Li, Jian-Liang/0000-0002-6487-081X
CR Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752
   Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200
   Baxter NN, 2004, JNCI-J NATL CANCER I, V96, P443, DOI 10.1093/jnci/djh069
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130
   Boland GP, 2004, BRIT J CANCER, V90, P423, DOI 10.1038/sj.bjc.6601534
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301
   BYRNE MC, 2000, CURRENT PROTOCOLS MO
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   CLARK R, 1988, CANCER RES, V48, P4689
   Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260
   Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Deng CX, 2000, BIOESSAYS, V22, P728
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Emberley ED, 2003, CLIN CANCER RES, V9, P2627
   Fabbro M, 2004, EXP CELL RES, V298, P661, DOI 10.1016/j.yexcr.2004.05.004
   Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299
   FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411
   Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523
   Geradts J, 1996, AM J PATHOL, V149, P15
   GILMORE PM, 2004, CANCER RES, V64, P4184
   Goldstein JC, 2005, AGING CELL, V4, P217, DOI 10.1111/j.1474-9726.2005.00163.x
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Hill AA, 2001, GENOME BIOL, V2
   Holst CR, 2003, CANCER RES, V63, P1596
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585
   Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669
   Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504
   Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826
   Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200
   Luker KE, 2001, CANCER RES, V61, P6540
   Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03
   Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Müller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
   Nonet GH, 2001, CANCER RES, V61, P1250
   PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   PIERCE JH, 1991, ONCOGENE, V6, P1189
   Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387
   Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243
   Porter D, 2003, MOL CANCER RES, V1, P362
   Reich M, 2004, BIOINFORMATICS, V20, P1797, DOI 10.1093/bioinformatics/bth138
   Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802
   Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Seth A, 2003, ANTICANCER RES, V23, P2043
   Slonim DK, 2002, NAT GENET, V32, P502, DOI 10.1038/ng1033
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391
   Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667
   Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3
   STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531
   Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   THOMPSON EW, 1994, CLIN EXP METASTAS, V12, P181, DOI 10.1007/BF01753886
   Tsikitis VL, 2006, AM J CLIN ONCOL-CANC, V29, P305, DOI 10.1097/01.coc.0000198740.33617.2f
   Wang B, 1997, ANTICANCER RES, V17, P4387
   Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200
   Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799
   Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   Zhang H, 2004, ONCOGENE, V23, P6193, DOI 10.1038/sj.onc.1207834
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   ZIEGLER EC, 2005, SCI STKE, V284, pRE6
NR 75
TC 48
Z9 55
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JAN 18
PY 2007
VL 6
AR 7
DI 10.1186/1476-4598-6-7
PG 17
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 133NJ
UT WOS:000244019300001
PM 17233903
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Wozniak, RJ
   Klimecki, WT
   Lau, SS
   Feinstein, Y
   Futscher, BW
AF Wozniak, R. J.
   Klimecki, W. T.
   Lau, S. S.
   Feinstein, Y.
   Futscher, B. W.
TI 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone
   methyltransferase and histone H3K9 di-methylation levels are linked to
   tumor suppressor gene reactivation
SO ONCOGENE
LA English
DT Article
DE 5-aza-2 '-deoxycytidine; H3K9 methylation; cytosine methylation; tumor
   suppressor; breast cancer; G9A histone methyltransferase
ID ABERRANT CYTOSINE METHYLATION; RISK MYELODYSPLASTIC SYNDROME;
   CPG-BINDING-PROTEIN; HUMAN BREAST-CANCER; DNA METHYLATION; PROMOTER
   HYPERMETHYLATION; HYPOMETHYLATING AGENT; COLORECTAL-CANCER; BRCA1
   PROMOTER; LUNG-CANCER
AB The epigenetic silencing of tumor suppressor genes is a common event during carcinogenesis, and often involves aberrant DNA methylation and histone modi. cation of gene regulatory regions, resulting in the formation of a transcriptionally repressive chromatin state. Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (DSC3) and MASPIN, which are frequently silenced in this manner in human breast cancer. Treatment of the breast tumor cell lines MDA-MB-231 and UACC 1179 with 5-aza-20-deoxycytidine (5-aza-CdR) induced transcriptional reactivation of both genes in a dose-dependent manner. Importantly, DSC3 and MASPIN reactivation was closely and consistently linked with significant decreases in promoter H3 K9 di-methylation. Moreover, 5-aza-CdR treatment also resulted in global decreases in H3 K9 di-methylation, an effect that was linked to its ability to mediate dose-dependent, post-transcriptional decreases in the key enzyme responsible for this epigenetic modification, G9A. Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells. These results highlight an additional, complimentary mechanism of action for 5-aza-CdR in the reactivation of epigenetically silenced genes, in a manner that is independent of its effects on DNA methylation, further supporting an important role for H3 K9 methylation in the aberrant repression of tumor suppressor genes in human cancer.
C1 Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA.
   Univ Arizona, Arizona Resp Sci Ctr, Tucson, AZ USA.
   Univ Arizona, Arizona Canc Ctr, SW Environm Hlth Sci Ctr Prote Core, Tucson, AZ USA.
C3 University of Arizona; Arizona Center Cancer Care; University of
   Arizona; Arizona Center Cancer Care; University of Arizona
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM bfutscher@azcc.arizona.edu
FU NCI NIH HHS [CA65662, R01 CA065662, T32-CA09213] Funding Source:
   Medline; NIEHS NIH HHS [ES007091, P30 ES06694, P30 ES006694, T32
   ES007091] Funding Source: Medline; PHS HHS [P30023074] Funding Source:
   Medline
CR BAYLIN SB, 1986, CANCER RES, V46, P2917
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bender CM, 1998, CANCER RES, V58, P95
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050
   CREUSOT F, 1982, J BIOL CHEM, V257, P2041
   Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058
   GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218
   Huang C, 2003, CURR OPIN GENET DEV, V13, P246, DOI 10.1016/S0959-437X(03)00054-6
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006
   Kantarjian HM, 2003, CANCER, V98, P522, DOI 10.1002/cncr.11543
   Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602
   KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101
   Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8
   Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224
   Lübbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x
   Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005
   MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076
   MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7
   Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   OTTERSON GA, 1995, ONCOGENE, V11, P1211
   Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   PLIML J, 1964, COLLECT CZECH CHEM C, V29, P2576
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Rosenfeld CS, 2005, SEMIN ONCOL, V32, P465, DOI 10.1053/j.seminoncol.2005.07.002
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010
   Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287
   TAMAME M, 1988, MOL CELL BIOL, V8, P3043, DOI 10.1128/MCB.8.8.3043
   TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403
   Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956
   Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970
NR 65
TC 172
Z9 198
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JAN 4
PY 2007
VL 26
IS 1
BP 77
EP 90
DI 10.1038/sj.onc.1209763
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 122OO
UT WOS:000243236500008
PM 16799634
DA 2025-01-12
ER

PT J
AU Holliday, DL
   Hughes, S
   Shaw, JA
   Walker, RA
   Jones, JL
AF Holliday, Deborah L.
   Hughes, Simon
   Shaw, Jacqueline A.
   Walker, Rosemary A.
   Jones, J. Louise
TI Intrinsic genetic characteristics determine tumor-modifying capacity of
   fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast
   cancer cell invasion
SO BREAST CANCER RESEARCH
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISM; STROMAL CELLS; CORONARY ATHEROSCLEROSIS;
   5A/6A POLYMORPHISM; PROMOTER REGIONS; EPITHELIAL-CELLS; CARCINOMA-CELLS;
   PROGRESSION; EXPRESSION; MICROENVIRONMENT
AB Background Stromal fibroblasts can contribute to tumor invasion through the release of matrix metalloproteinases (MMPs). Population studies have suggested that single nucleotide polymorphisms (SNPs) in MMP genes influence levels of expression and may be associated with breast cancer risk and with disease progression. This study directly examined the impact of MMP SNP genotype on the ability of host fibroblasts to promote tumor cell invasion.
   Methods Primary breast fibroblasts were isolated from patients with (n = 13) or without (n = 19) breast cancer, and their ability to promote breast cancer cell invasion was measured in in vitro invasion assays. Fibroblast invasion-promoting capacity (IPC) was analyzed in relation to donor type (tumor or non-tumor patient), MMP-1, MMP-3, and MMP-9 SNP genotype and MMP activity using independent samples t test and analysis of variance. All statistical tests were two-sided.
   Results Tumor-derived fibroblasts promoted higher levels of invasion than normal fibroblasts (p = 0.041). When IPC was related to genotype, higher levels of IPC were generated by tumor fibroblasts with the high-expressing MMP-3 5A/5A genotype compared with the 5A/6A and 6A/6A genotypes (p = 0.05 and 0.07, respectively), and this was associated with enhanced MMP-3 release. The functional importance of MMP-3 was demonstrated by enhanced invasion in the presence of recombinant MMP-3, whereas reduction occurred in the presence of a specific MMP-3 inhibitor. An inverse relationship was demonstrated between fibroblast IPC and the high-expressing MMP-1 genotype (p = 0.031), but no relationship was seen with MMP-9 SNP status. In contrast, normal fibroblasts showed no variation in IPC in relation to MMP genotype, with MMP-3 5A/5A fibroblasts exhibiting significantly lower levels of IPC than their tumor-derived counterparts (p = 0.04).
   Conclusion This study has shown that tumor-derived fibroblasts exhibit higher levels of IPC than normal fibroblasts and that the MMP-3 5A/5A genotype contributes to this through enhanced MMP-3 release. Despite a high-expressing genotype, normal fibroblasts do not exhibit higher IPC or enhanced MMP release. This suggests that more complex changes occur in tumor-derived fibroblasts, enabling full expression of the MMP SNP genotype and these possibly are epigenetic in nature. The results do suggest that, in women with breast cancer, a high-expressing MMP-3 genotype may promote tumor progression more effectively.
C1 [Holliday, Deborah L.; Hughes, Simon; Jones, J. Louise] John Vane Sci Ctr, Tumor Biol Ctr, CR UK Clin Ctr, Queen Mary Sch Med & Dent,Inst Canc, London EC1M 6BQ, England.
   [Shaw, Jacqueline A.; Walker, Rosemary A.] Univ Leicester, Dept Canc Studies & Mol Med, Breast Canc Res Unit, Leicester LE1 7LX, Leics, England.
C3 University of London; Queen Mary University London; University of
   Leicester
RP Jones, JL (通讯作者)，John Vane Sci Ctr, Tumor Biol Ctr, CR UK Clin Ctr, Queen Mary Sch Med & Dent,Inst Canc, Chaterhouse Square, London EC1M 6BQ, England.
EM Louise.J.Jones@cancer.org.u'
RI Hughes, Simon/B-5217-2008
OI Shaw, Jacqui/0000-0003-4227-503X
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   [Anonymous], 1992, Methods in Lignin Chemistry
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Biondi ML, 2000, CLIN CHEM, V46, P2023
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Blavier L, 2006, CANCER RES, V66, P2691, DOI 10.1158/0008-5472.CAN-05-2919
   Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018
   Crowther M, 2000, BRIT J SURG, V87, P1391, DOI 10.1046/j.1365-2168.2000.01554.x
   Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65
   Dunleavey L, 2000, MATRIX BIOL, V19, P175, DOI 10.1016/S0945-053X(00)00059-7
   Dunleavey L, 2000, ATHEROSCLEROSIS, V151, P587, DOI 10.1016/S0021-9150(00)00443-3
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Fukino K, 2004, CANCER RES, V64, P7231, DOI 10.1158/0008-5472.CAN-04-2866
   Ghilardi G, 2002, CLIN CANCER RES, V8, P3820
   Hannan MA, 2001, CANCER RES, V61, P3627
   Hanson JA, 2006, JNCI-J NATL CANCER I, V98, P255, DOI 10.1093/jnci/djj051
   Heppner KJ, 1996, AM J PATHOL, V149, P273
   Hinoda Y, 2002, INT J CANCER, V102, P526, DOI 10.1002/ijc.10750
   Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086
   HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Jones JL, 2003, J PATHOL, V201, P562, DOI 10.1002/path.1483
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Krippl P, 2004, CLIN CANCER RES, V10, P3518, DOI 10.1158/1078-0432.CCR-04-0010
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Lebret SC, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1656
   Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611
   Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861
   Moinfar F, 2000, CANCER RES, V60, P2562
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429
   Przybylowska K, 2006, BREAST CANCER RES TR, V95, P65, DOI 10.1007/s10549-005-9042-6
   Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066
   Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417
   Rutter JL, 1998, CANCER RES, V58, P5321
   Schor SL, 2001, BREAST CANCER RES, V3, P373, DOI 10.1186/bcr325
   Shekhar MPV, 2001, CANCER RES, V61, P1320
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Wyatt CA, 2002, CANCER RES, V62, P7200
   Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545
   Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055
   Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788
NR 48
TC 40
Z9 43
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2007
VL 9
IS 5
AR R67
DI 10.1186/bcr1775
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 264KI
UT WOS:000253285800016
PM 17922906
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yau, C
   Fedele, V
   Roydasgupta, R
   Fridlyand, J
   Hubbard, A
   Gray, JW
   Chew, K
   Dairkee, SH
   Moore, DH
   Schittulli, F
   Tommasi, S
   Paradiso, A
   Albertson, DG
   Benz, CC
AF Yau, Christina
   Fedele, Vita
   Roydasgupta, Ritu
   Fridlyand, Jane
   Hubbard, Alan
   Gray, Joe W.
   Chew, Karen
   Dairkee, Shanaz H.
   Moore, Dan H.
   Schittulli, Francesco
   Tommasi, Stefania
   Paradiso, Angelo
   Albertson, Donna G.
   Benz, Christopher C.
TI Aging impacts transcriptomes but not genomes of hormone-dependent breast
   cancers
SO BREAST CANCER RESEARCH
LA English
DT Article
ID PROGESTERONE-RECEPTOR LOSS; GENE-EXPRESSION PATTERNS; CELLS IN-VITRO;
   YOUNG AGE; MOLECULAR PORTRAITS; ESTROGEN; SURVIVAL; PROLIFERATION;
   VISUALIZATION; SEGMENTATION
AB Introduction Age is one of the most important risk factors for human malignancies, including breast cancer; in addition, age at diagnosis has been shown to be an independent indicator of breast cancer prognosis. Except for inherited forms of breast cancer, however, there is little genetic or epigenetic understanding of the biological basis linking aging with sporadic breast cancer incidence and its clinical behavior.
   Methods DNA and RNA samples from matched estrogen receptor (ER)-positive sporadic breast cancers diagnosed in either younger (age <= 45 years) or older (age >= 70 years) Caucasian women were analyzed by array comparative genomic hybridization and by expression microarrays. Array comparative genomic hybridization data were analyzed using hierarchical clustering and supervised age cohort comparisons. Expression microarray data were analyzed using hierarchical clustering and gene set enrichment analysis; differential gene expression was also determined by conditional permutation, and an age signature was derived using prediction analysis of microarrays.
   Results Hierarchical clustering of genome-wide copy-number changes in 71 ER-positive DNA samples (27 younger women, 44 older women) demonstrated two age-independent genotypes; one with few genomic changes other than 1q gain/16q loss, and another with amplifications and low-level gains/ losses. Age cohort comparisons showed no significant differences in total or site-specific genomic breaks and amplicon frequencies. Hierarchical clustering of 5.1 K genes variably expressed in 101 ER-positive RNA samples (53 younger women, 48 older women) identified six transcriptome subtypes with an apparent age bias (P < 0.05). Samples with higher expression of a poor outcome-associated proliferation signature were predominantly (65%) younger cases. Supervised analysis identified cancer-associated genes differentially expressed between the cohorts; with younger cases expressing more cell cycle genes and more than threefold higher levels of the growth factor amphiregulin (AREG), and with older cases expressing higher levels of four different homeobox (HOX) genes in addition to ER (ESR1). An age signature validated against two other independent breast cancer datasets proved to have > 80% accuracy in discerning younger from older ER-positive breast cancer cases with characteristic differences in AREG and ESR1 expression.
   Conclusion These findings suggest that epigenetic transcriptome changes, more than genotypic variation, account for age-associated differences in sporadic breast cancer incidence and prognosis.
C1 [Yau, Christina; Hubbard, Alan; Benz, Christopher C.] Buck Inst Age Res, Novato, CA 94945 USA.
   [Fedele, Vita; Roydasgupta, Ritu; Fridlyand, Jane; Gray, Joe W.; Chew, Karen; Moore, Dan H.; Schittulli, Francesco; Albertson, Donna G.; Benz, Christopher C.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   [Dairkee, Shanaz H.; Moore, Dan H.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA.
   [Schittulli, Francesco; Tommasi, Stefania; Paradiso, Angelo] Natl Canc Inst, I-70126 Bari, Italy.
C3 Buck Institute for Research on Aging; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF Helen
   Diller Family Comprehensive Cancer Center; California Pacific Medical
   Center; California Pacific Medical Center Research Institute; IRCCS
   Istituto Tumori Bari Giovanni Paolo II
RP Benz, CC (通讯作者)，Buck Inst Age Res, 8001 Redwood, Novato, CA 94945 USA.
EM cbenz@buckinstitute.org
RI Gray, Joe/AAX-9549-2020; Dairkee, Shanaz/D-6743-2012; paradiso,
   angelo/J-9457-2018; Tommasi, Stefania/J-6732-2012
OI Dairkee, Shanaz/0000-0002-2073-9684; Tommasi,
   Stefania/0000-0002-2157-2978
FU NCI NIH HHS [P50 CA058207, P50-CA58207, P30-CA82103, R01 CA071468,
   R01-CA71468, P30 CA082103] Funding Source: Medline; NIA NIH HHS [R01
   AG020521, R01-AG020521] Funding Source: Medline; National Cancer
   Institute [P30CA082103] Funding Source: NIH RePORTER
CR [Anonymous], DEVCAN PROBABILITY D
   Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249
   Balducci L, 2005, NAT REV CANCER, V5, P655, DOI 10.1038/nrc1675
   Benz Christopher C, 2007, Cancer Res, V67, P4560, DOI 10.1158/0008-5472.CAN-07-1236
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Bortoli S, 2003, GENE, V321, P145, DOI 10.1016/j.gene.2003.08.025
   Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117
   Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104
   Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28
   Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363
   Cui XJ, 2005, J CLIN ONCOL, V23, P7721, DOI 10.1200/JCO.2005.09.004
   Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318
   Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   El Saghir NS, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-194
   Eppenberger-Castori S, 2002, INT J BIOCHEM CELL B, V34, P1318, DOI 10.1016/S1357-2725(02)00052-3
   Ershler WB, 1997, JNCI-J NATL CANCER I, V89, P1489, DOI 10.1093/jnci/89.20.1489
   Figueiredo JC, 2007, BREAST CANCER RES TR, V105, P69, DOI 10.1007/s10549-006-9433-3
   Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96
   Geigl JB, 2004, CANCER RES, V64, P8550, DOI 10.1158/0008-5472.CAN-04-2151
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Han WS, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-82
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   HORWITZ KB, 1978, J BIOL CHEM, V253, P2223
   Hosack DA, 2003, GENOME BIOL, V4, P4, DOI DOI 10.1186/GB-2003-4-6-P4
   Hu YH, 2003, J PROTEOME RES, V2, P405, DOI 10.1021/pr0340227
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   HUEIJEAN H, 2005, BREAST CANC RES TREA, V91, P81
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jayasinghe UW, 2005, ANZ J SURG, V75, P762, DOI 10.1111/j.1445-2197.2005.03515.x
   Kim HJ, 2006, CLIN CANCER RES, V12, p1013S, DOI 10.1158/1078-0432.CCR-05-2128
   Lehman E.L., 1986, TESTING STAT HYPOTHE, V2nd, DOI DOI 10.1093/sysbio/syy020
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000465
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Oh JL, 2006, INT J RADIAT ONCOL, V65, P1345, DOI 10.1016/j.ijrobp.2006.03.028
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Quong J, 2002, BREAST CANCER RES TR, V76, P221, DOI 10.1023/A:1020886801674
   Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4
   Rapiti E, 2005, EUR J CANCER, V41, P1446, DOI 10.1016/j.ejca.2005.02.029
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Rubin E, 2007, CANCER RES, V67, P1527, DOI 10.1158/0008-5472.CAN-06-4283
   Rudolph P, 1999, J PATHOL, V187, P207
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349
   Shoker BS, 1999, J PATHOL, V188, P237
   Smigal C, 2006, CA-CANCER J CLIN, V56, P168, DOI 10.3322/canjclin.56.3.168
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takeda A, 2006, CANCER RES, V66, P6628, DOI 10.1158/0008-5472.CAN-06-0458
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   VANLANDEGHEM AAJ, 1985, CANCER RES, V45, P2900
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Willenbrock H, 2005, BIOINFORMATICS, V21, P4084, DOI 10.1093/bioinformatics/bti677
   DAVID DATABASE
   PREDICTIVE ANAL MICR
   MEDGENE DATABASE
   GSEA SOFTWARE
NR 63
TC 57
Z9 69
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2007
VL 9
IS 5
AR R59
DI 10.1186/bcr1765
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 264KI
UT WOS:000253285800008
PM 17850661
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Feinberg, AP
AF Feinberg, Andrew P.
TI An epigenetic approach to cancer etiology
SO CANCER JOURNAL
LA English
DT Article
DE genomic imprinting; LOI; colorectal cancer
ID GROWTH-FACTOR-II; TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; WILMS-TUMOR;
   FREQUENT LOSS; DNA HYPOMETHYLATION; BREAST-CANCER; NORMAL TISSUE; HUMAN
   GLIOMA; CELL-LINES
AB The practice of clinical oncology historically has been rooted in therapy for established cancers, and over the past decade, early detection of the malignancy has occurred increasingly, allowing an increasing chance of cure by surgical intervention. Cancer prevention has been targeted largely to generic reduction of exposure to environmental carcinogens, such as smoking reduction. However, targeted identification of patients at increased risk and therapeutic tailored intervention in those patients have not taken hold in oncology, despite the enormous success of that approach in preventive cardiology. A paradigm of such a strategy for oncology may be the identification of patients with epigenetic alterations in progenitor cells and intervention before the development of the earliest identifiable neoplasms. We review studies of loss of imprinting of insulin-like growth factor 2 in colorectal cancer as an example of such a target for preventive oncology.
C1 Johns Hopkins Univ, Sch Med, Dept Med, Div Mol Med, Baltimore, MD 21205 USA.
C3 Johns Hopkins University
RP Feinberg, AP (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Med, Div Mol Med, Ross Bldg 1064,720 Rutland Ave, Baltimore, MD 21205 USA.
EM afeinberg@jhmi.edu
RI Feinberg, Andrew/AAY-7666-2020
OI Feinberg, Andrew/0000-0002-8364-1991
FU NCI NIH HHS [R37 CA054358-17, CA65145, R01 CA054358, R37 CA054358]
   Funding Source: Medline
CR Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3
   Astuti D, 2005, BRIT J CANCER, V92, P1574, DOI 10.1038/sj.bjc.6602478
   Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051
   CRUZCORREA M, 2006, ANN M AM GASTR ASS M
   CRUZCORREA M, 2006, ANN M AM ASS CANC RE
   Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cui HM, 2001, CANCER RES, V61, P4947
   Cui HM, 2002, CANCER RES, V62, P6442
   Dupont J, 2003, HORM METAB RES, V35, P740
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Feagins LA, 2006, AM J PHYSIOL-GASTR L, V290, pG871, DOI 10.1152/ajpgi.00383.2005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110
   FEINBERG AP, 1988, CANCER RES, V48, P1159
   GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98
   Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029
   GOETZ SE, 1985, SCIENCE, V228, P187
   GREGER V, 1994, HUM GENET, V94, P491
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jarrard DF, 1995, CLIN CANCER RES, V1, P1471
   Johns LE, 2001, AM J GASTROENTEROL, V96, P2992, DOI 10.1111/j.1572-0241.2001.04677.x
   KAJII T, 1977, NATURE, V268, P633, DOI 10.1038/268633a0
   Kohda M, 2001, MOL CARCINOGEN, V31, P184, DOI 10.1002/mc.1053
   KONDO M, 1995, ONCOGENE, V10, P1193
   LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202
   Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242
   Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034
   Moschos SJ, 2002, ONCOLOGY-BASEL, V63, P317, DOI 10.1159/000066230
   MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440
   Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138
   Nakanishi H, 2004, ONCOL REP, V12, P1273
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94
   Oshimo Y, 2003, INT J ONCOL, V23, P1663
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Percesepe A, 2001, J CLIN ONCOL, V19, P3944, DOI 10.1200/JCO.2001.19.19.3944
   Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Samowitz WS, 2001, GASTROENTEROLOGY, V121, P830, DOI 10.1053/gast.2001.27996
   SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   Uyeno S, 1996, CANCER RES, V56, P5356
   van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3
   VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484
   Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042
   Yan Pearlly S, 2004, Methods Mol Biol, V287, P251
   Yuan JH, 2003, CANCER RES, V63, P4174
   ZHANG YH, 1993, AM J HUM GENET, V53, P113
NR 58
TC 39
Z9 46
U1 0
U2 3
PU JONES AND BARTLETT PUBLISHERS
PI SUDBURY
PA 40 TALL PINE DR, SUDBURY, MA 01776 USA
SN 1528-9117
J9 CANCER J
JI Cancer J.
PD JAN-FEB
PY 2007
VL 13
IS 1
BP 70
EP 74
DI 10.1097/PPO.0b013e31803c6e3b
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 150WV
UT WOS:000245251200011
PM 17464249
DA 2025-01-12
ER

PT J
AU Hasegawa, Y
   Matsubara, A
   Teishima, J
   Seki, M
   Mita, K
   Usui, T
   Oue, N
   Yasui, W
AF Hasegawa, Yasuhisa
   Matsubara, Akio
   Teishima, Jun
   Seki, Mitsuhiro
   Mita, Koji
   Usui, Tsuguru
   Oue, Naohide
   Yasui, Wataru
TI DNA methylation of the <i>RIZ1</i> gene is associated with nuclear
   accumulation of p53 in prostate cancer
SO CANCER SCIENCE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; BREAST-CANCER; CPG
   ISLAND; EXPRESSION; METHYLTRANSFERASE; INACTIVATION; PROTEIN; MUTATIONS;
   THERAPY
AB The retinoblastoma protein-interacting zinc finger gene, RIZ1, is thought to be a tumor suppressor gene. RIZ1 is inactivated by mutation, deletion and DNA methylation in several human cancers. In the present study, the relationship between DNA methylation of RIZ1 and mutation of p53 was investigated in prostate cancer (PCa). In total, 47 cases of node-negative PCa (stages I-III) were analyzed. DNA methylation of the RIZ1 gene was detected in 20 (42.6%) of the 47 PCa tissues by methylation-specific polymerase chain reaction. DNA methylation of the RIZ1 gene was not associated with clinicopathological features. DNA methylation of RIZ1 tended to be present more frequently in PCa specimens with a high Gleason score (16/30, 53.3%) than in those with a low Gleason score (4/17, 23.5%); however, this tendency was not statistically significant (P = 0.0675). Nuclear accumulation of p53 was observed in four (8.5%) of 47 PCa specimens by immunostaining. All four PCa specimens with nuclear accumulation of p53 were stage III disease and showed DNA methylation of RIZ1. However, of the remaining 43 cancers without nuclear accumulation of p53, DNA methylation of RIZ1 was observed in only 16 (37.2%) specimens (P = 0.0272). Of the three PCa cell lines, only the PC3 cell line showed loss of RIZ1 mRNA due to DNA methylation, and this loss was rectified by treatment with a demethylating agent, 5-Aza-2'-deoxycytidine. These results suggest that transcriptional inactivation of RIZ1 by aberrant DNA methylation may contribute to prostate carcinogenesis. Genetic alterations are likely associated with epigenetic alterations in PCa.
C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Urol, Minami Ku, Hiroshima 7348551, Japan.
C3 Hiroshima University; Hiroshima University
RP Yasui, W (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan.
EM wyasui@hiroshima-u.ac.jp
CR Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1
   [Anonymous], TNM CLASSIFICATION M
   BARTEK J, 1990, ONCOGENE, V5, P893
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   BOOKSTEIN R, 1993, CANCER RES, V53, P3369
   BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467
   Casey G, 1996, ONCOGENE, V13, P1971
   Du Y, 2001, CANCER RES, V61, P8094
   Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002
   Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287
   Gleason DF., 1977, UROLOGIC PATHOLOGY P, P171
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   He LS, 1998, CANCER RES, V58, P4238
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4
   Jackson P, 2002, UROL ONCOL, V7, P99, DOI 10.1016/S1078-1439(01)00175-2
   Jarrard DF, 1998, CANCER RES, V58, P5310
   Jiang GL, 2001, CANCER RES, V61, P1796
   Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim KC, 2003, CANCER RES, V63, P7619
   Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2
   Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090
   Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403
   Oue N, 2002, J PATHOL, V198, P55, DOI 10.1002/path.1170
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Piao Z, 2000, CANCER RES, V60, P4701
   Shiina H, 2005, CANCER RES, V65, P2130, DOI 10.1158/0008-5472.CAN-04-3398
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   SUZUKI M, 2006, CANC LETT
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Weith A, 1996, CYTOGENET CELL GENET, V72, P114
NR 35
TC 23
Z9 27
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2007
VL 98
IS 1
BP 32
EP 36
DI 10.1111/j.1349-7006.2006.00338.x
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 108DW
UT WOS:000242221500007
PM 17052263
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Shi, HD
   Guo, JY
   Duff, DJ
   Rahmatpanah, F
   Chitima-Matsiga, R
   Al-Kuhlani, M
   Taylor, KH
   Sjahputera, O
   Andreski, M
   Wooldridge, JE
   Caldwell, CW
AF Shi, Huidong
   Guo, Juyuan
   Duff, Deiter J.
   Rahmatpanah, Farahnaz
   Chitima-Matsiga, Rebecca
   Al-Kuhlani, Mufadhal
   Taylor, Kristen H.
   Sjahputera, Ozy
   Andreski, Melinda
   Wooldridge, James E.
   Caldwell, Charles W.
TI Discovery of novel epigenetic markers in non-Hodgkin's lymphoma
SO CARCINOGENESIS
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; ABERRANT DNA METHYLATION; CELL-LINES; MICROARRAY
   ANALYSIS; BREAST-CANCER; VITAMIN-D; DLC-1; EXPRESSION; PROMOTER;
   HYPERMETHYLATION
AB Non-Hodgkin's lymphoma (NHL) is a group of malignancies with heterogeneous genetic and epigenetic alterations. Discovery of molecular markers that better define NHL should improve diagnosis, prognosis and understanding of the biology. We developed a CpG island DNA microarray for discovery of aberrant methylation targets in cancer, and now apply this method to examine NHL cell lines and primary tumors. This methylation profiling revealed differential patterns in six cell lines originating from different subtypes of NHL. We identified 30 hypermethylated genes in these cell lines and independently confirmed 10 of them. Methylation of 6 of these genes was then further examined in 75 primary NHL specimens composed of four subtypes representing different stages of maturation. Each gene (DLC-1, PCDHGB7, CYP27B1, EFNA5, CCND1 and RAR beta 2) was frequently hypermethylated in these NHLs (87, 78, 61, 53, 40 and 38%, respectively), but not in benign follicular hyperplasia. Although some genes such as DLC-1 and PCDHGB7 were methylated in the vast majority of NHLs, others were differentially methylated in specific subtypes. The methylation of the candidate tumor suppressor gene DLC-1 was detected in a high proportion of primary tumor and plasma DNA samples by using quantitative methylation-specific PCR analysis. This promoter hypermethylation inversely correlated with DLC-1 gene expression in primary NHL samples. Thus, this CpG island microarray is a powerful discovery tool to identify novel methylated genes for further studies of their relevant molecular pathways in NHLs and identification of potential epigenetic biomarkers of disease.
C1 Univ Missouri, Dept Pathol & Anat Sci, Ellis Fischel Canc Ctr, Columbia, MO 65203 USA.
   Univ Iowa, Dept Internal Med, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
C3 University of Missouri System; University of Missouri Columbia;
   University of Iowa
RP Caldwell, CW (通讯作者)，Univ Missouri, Dept Pathol & Anat Sci, Ellis Fischel Canc Ctr, 115 Business Loop I-70 W, Columbia, MO 65203 USA.
EM caldwellc@health.missouri.edu
RI Wooldridge, James/AAA-2466-2021
OI Shi, Huidong/0000-0003-1137-3390; Wooldridge, James/0000-0002-9940-8238;
   Taylor, Kristen/0000-0001-9336-9824
FU NCI NIH HHS [CA100055, CA097880, P50 CA097274] Funding Source: Medline
CR *AM CANC SOC, 2005, AN CANC FACTS FIG
   Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424
   BECKWITH M, 1990, JNCI-J NATL CANCER I, V82, P501, DOI 10.1093/jnci/82.6.501
   Boddy JL, 2005, CLIN CANCER RES, V11, P1394, DOI 10.1158/1078-0432.CCR-04-1237
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Campo E, 1999, SEMIN HEMATOL, V36, P115
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Esteller M, 2003, CLIN IMMUNOL, V109, P80, DOI 10.1016/S1521-6616(03)00208-0
   Esteller M, 2001, CANCER RES, V61, P3225
   Guo JY, 2005, AM J CLIN PATHOL, V124, P430, DOI 10.1309/LCGNV77J464LNFD6
   Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582
   Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237
   Hsu JY, 2001, CANCER RES, V61, P2852
   Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408
   Jaffe E. S., 2001, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
   Jones CD, 2004, J MOL DIAGN, V6, P84, DOI 10.1016/S1525-1578(10)60494-1
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Khorchide M, 2005, J STEROID BIOCHEM, V93, P167, DOI 10.1016/j.jsbmb.2004.12.022
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026
   Liu H, 2004, BLOOD, V104, P2505, DOI 10.1182/blood-2004-02-0483
   Medeiros LJ, 2002, MODERN PATHOL, V15, P556, DOI 10.1038/modpathol.3880562
   Ng IOL, 2000, CANCER RES, V60, P6581
   Pang JCS, 2005, HUM PATHOL, V36, P36, DOI 10.1016/j.humpath.2004.09.021
   Park SW, 2003, INT J ONCOL, V23, P133
   Rossi D, 2004, HAEMATOLOGICA, V89, P154
   Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012
   Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953
   Shi HD, 2003, CANCER RES, V63, P2164
   Shi HD, 2002, CANCER RES, V62, P3214
   Stacchini A, 1999, LEUKEMIA RES, V23, P127, DOI 10.1016/S0145-2126(98)00154-4
   Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716
   Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Welsh J, 2004, AM J CLIN NUTR, V80, p1721S, DOI 10.1093/ajcn/80.6.1721S
   Wong CM, 2003, CANCER RES, V63, P7646
   Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301
   Yan PS, 2001, CANCER RES, V61, P8375
   Yang HY, 2003, CLIN CANCER RES, V9, P4034
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Zelent Arthur, 2005, Cancer Res, V65, P1117, DOI 10.1158/0008-5472.CAN-04-3603
NR 45
TC 72
Z9 79
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2007
VL 28
IS 1
BP 60
EP 70
DI 10.1093/carcin/bgl092
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 120CV
UT WOS:000243062100008
PM 16774933
OA Bronze
DA 2025-01-12
ER

PT J
AU Trtková, K
   Bouchal, J
   Kolár, Z
AF Trtkova, K.
   Bouchal, J.
   Kolar, Z.
TI HISTONE ACETYLATION AND METHYLATION IN THE SIGNALING OF STEROID HORMONE
   RECEPTORS
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Epigenetic modifications; steroid hormone receptors; cellular
   coregulators; prostate cancer
ID HUMAN ANDROGEN RECEPTOR; NUCLEAR-RECEPTOR; PROSTATE-CANCER;
   BREAST-CANCER; ESTROGEN-RECEPTOR; ZINC-FINGER; TRANSCRIPTIONAL
   ACTIVATION; PROTEIN METHYLATION; DNA METHYLATION; PHD FINGER
AB Molecular changes associated with malignancy are extremely complex. Early epigenetic events occuring in the common tumor types such as breast or prostate cancer might determine the subsequent genetic changes leading to tumor development and progression. Covalent modifications of histones play a major role as determiners of epigenetic information and are important in the regulation of gene expression. Acetylation generally corelates with transcriptional activation, while methylation can signal either activation or repression. However, little is known about the interplay of different epigenetic events. Steroid hormones regulate many cellular processes through signal transduction pathways that result in a variety of posttranslational modifications. Such modifications can be triggered by steroid hormones in cooperation with coactivators (p160 family proteins, CBP, p300, p/CAF) and/or corepressors (N-Cor, SMRT, TZF). There is still much to learn about their regulation and the molecular and physiological consequences of these modifications.
C1 [Trtkova, K.] Palacky Univ, Lab Mol Pathol, Fac Med, Olomouc 77515, Czech Republic.
   Palacky Univ, Fac Med, Inst Pathol, Olomouc 77515, Czech Republic.
C3 Palacky University Olomouc; Palacky University Olomouc
RP Trtková, K (通讯作者)，Palacky Univ, Lab Mol Pathol, Fac Med, Hnevotinska 3, Olomouc 77515, Czech Republic.
EM trtkova@post.cz
RI Kolar, Zdenek/A-4597-2008; Bouchal, Jan/JAC-7578-2023
OI Bouchal, Jan/0000-0003-4842-1720; Smesny Trtkova,
   Katerina/0000-0002-6104-8118
FU Czech Ministry of Health [NR9475-3]; Czech Ministry of Education [MSM
   6198959216]
FX We are grateful to Dr. Paul R. Kirk for advice and editorial assistance.
   We acknowledge Ondrej Blaha and Vilem Lukas for figure and manuscript
   preparation. The work was supported by grants NR9475-3 from the Czech
   Ministry of Health and MSM 6198959216 from the Czech Ministry of
   Education.
CR AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4
   Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205
   ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9
   Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5
   Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664
   Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172
   Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200
   Comuzzi B, 2004, J PATHOL, V204, P159, DOI 10.1002/path.1609
   Comuzzi B, 2003, AM J PATHOL, V162, P233, DOI 10.1016/S0002-9440(10)63814-X
   Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a
   Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8
   Debes JD, 2005, CANCER RES, V65, P708
   Debes JD, 2002, CANCER RES, V62, P5632
   Debes JD, 2003, CANCER RES, V63, P7638
   Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2003, CANCER GENET CYTOGEN, V141, P97, DOI 10.1016/S0165-4608(02)00668-4
   FEINBERG AP, 1987, SEMIN SURG ONCOL, V3, P149, DOI 10.1002/ssu.2980030304
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200
   Fronsdal K, 2005, PROSTATE, V62, P299, DOI 10.1002/pros.20140
   Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037
   Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003
   Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200
   Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376
   Giancotti V, 2006, CANCER LETT, V243, P145, DOI 10.1016/j.canlet.2006.01.035
   Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179
   GRANDIEN KFH, 1993, J MOL ENDOCRINOL, V10, P269, DOI 10.1677/jme.0.0100269
   Gregory CW, 2001, CANCER RES, V61, P4315
   Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4
   Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342
   Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858
   He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219
   Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175
   Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6
   Hobish MK, 1998, ORIGINS LIFE EVOL B, V28, P123, DOI 10.1023/A:1006520106159
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Inoue A, 2000, BIOCHEM BIOPH RES CO, V273, P398, DOI 10.1006/bbrc.2000.2953
   Ishizuka M, 2005, BIOCHEM BIOPH RES CO, V331, P1025, DOI 10.1016/j.bbrc.2005.04.024
   Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473
   Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422
   Jarrard DF, 1998, CANCER RES, V58, P5310
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PL, 2003, CURR TOP MICROBIOL, V274, P237
   Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kinoshita H, 2000, CANCER RES, V60, P3623
   Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200
   Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142
   Korkmaz CG, 2004, J ENDOCRINOL, V182, P377, DOI 10.1677/joe.0.1820377
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207
   Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008
   Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002
   LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O
   Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200
   Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Ma H, 1999, MOL CELL BIOL, V19, P6164
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Manning ET, 2001, MOL CELL BIOL, V21, P3876, DOI 10.1128/MCB.21.12.3876-3887.2001
   Marrocco DL, 2007, MOL CANCER THER, V6, P51, DOI 10.1158/1535-7163.MCT-06-0144
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Matousková M, 2006, EXP CELL RES, V312, P1011, DOI 10.1016/j.yexcr.2005.12.010
   Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140
   McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8
   MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085
   Ménard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200
   Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6
   Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101
   Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0
   Peña PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Popov VM, 2007, STEROIDS, V72, P221, DOI 10.1016/j.steroids.2006.12.001
   Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242
   Prins GS, 1998, J UROLOGY, V159, P641, DOI 10.1016/S0022-5347(01)63692-9
   Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556
   Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051
   Rokhlin OW, 2006, MOL CANCER RES, V4, P113, DOI 10.1158/1541-7786.MCR-05-0085
   Romieu-Mourez R, 2002, CANCER RES, V62, P6770
   ROTH SY, 2000, CANCER RES, V60, P5825
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Sartor O, 2002, UROLOGY, V60, P138
   Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Simon JA, 2003, CURR BIOL, V13, pR79, DOI 10.1016/S0960-9822(03)00028-9
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X
   Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325
   Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Tao RH, 2006, MOL CELL ENDOCRINOL, V247, P150, DOI 10.1016/j.mce.2005.12.052
   Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200
   Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652
   Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8
   Toyota M, 2005, SEMIN ONCOL, V32, P521, DOI 10.1053/j.seminoncol.2005.07.003
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200
   Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Wang LG, 2004, ONCOGENE, V23, P5175, DOI 10.1038/sj.onc.1207654
   Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Yan PS, 2001, CANCER RES, V61, P8375
   Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 124
TC 2
Z9 5
U1 0
U2 4
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2007
VL 53
SU S
BP OL930
EP OL942
DI 10.1170/107
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA V10TS
UT WOS:000207486900003
PM 17628895
DA 2025-01-12
ER

PT J
AU Bozhanov, S
   Krasteva, M
   Angelova, S
   Bozhimirov, S
   Georgieva, E
AF Bozhanov, Stefan
   Krasteva, Maria
   Angelova, Svetla
   Bozhimirov, Stanislav
   Georgieva, Elena
TI PCR-SSCP pattern alone is highly predictive of a specific mutation
   within a DNA sequence
SO COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES
LA English
DT Article
DE PCR; SSCP; sequencing; mutation; cancer
ID STRAND CONFORMATION POLYMORPHISM; POLYMERASE-CHAIN-REACTION; POINT
   MUTATIONS; ELECTROPHORESIS; GENE
AB Molecular screening for genetic and epigenetic abnormalities in specific cancer related genes needs rapid and efficient techniques. Of the methods available, most widely used for screening and routine diagnosis is the PCR-SSCP - sequencing analysis. Here we demonstrate that different DNA samples with identical aberrant SSCP pattern show identical nucleotide change after sequencing analysis. This finding was established during a massive screening for mutations in two tumour-suppressor genes (p53 and ATM) in a group of 284 Bulgarian patients overall, 147 of which with breast cancer, 114 with Balkan endemic nephropathy and 23 with colorectal carcinoma. The samples with aberrant electrophoretic behaviour were grouped at equal conditions of SSCP gel electrophoresis according to their mutant pattern and were sequenced in both strands. Sequencing analysis revealed that all samples with identical profile harboured identical nucleotide changes. Reproducibility of this observation was confirmed using different PCR and SSCP electrophoretic devices. On the basis of the obtained results we suggest that the SSCP pattern alone can be used as a diagnostic tool to directly identify specific already characterized genetic abnormalities. Introduction of this approach into scientific and clinical practice will increase considerably the speed of molecular screening analysis.
C1 [Bozhanov, Stefan; Krasteva, Maria; Angelova, Svetla; Bozhimirov, Stanislav; Georgieva, Elena] Bulgarian Acad Sci, Inst Genet, Dept Mol Genet, BU-1113 Sofia, Bulgaria.
C3 Bulgarian Academy of Sciences
RP Bozhanov, S (通讯作者)，Bulgarian Acad Sci, Inst Genet, Dept Mol Genet, Plovdivsko Chaussee 13th Km, BU-1113 Sofia, Bulgaria.
RI Krasteva, Maria/JNR-0409-2023; Georgieva, Elena/O-1674-2019
OI ANGELOVA, SVETLA/0000-0002-9119-6373
CR AHMAD NN, 1995, J MED GENET, V32, P129, DOI 10.1136/jmg.32.2.129
   Atha DH, 1998, ELECTROPHORESIS, V19, P172, DOI 10.1002/elps.1150190207
   Bastos E., 2001, Biotechnologie, Agronomie, Societe et Environnement, V5, P7
   GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513
   HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637
   Krasteva ME, 2006, BIOCHEM BIOPH RES CO, V342, P562, DOI 10.1016/j.bbrc.2006.02.004
   Krasteva ME, 2003, CLIN EXP MED, V3, P173, DOI 10.1007/s10238-003-0022-z
   Kutach LS, 1999, ELECTROPHORESIS, V20, P1204, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1204::AID-ELPS1204>3.0.CO;2-S
   La Farina M, 1998, BIOCHEM BIOPH RES CO, V246, P813
   ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766
   ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8
   PROSSER J, 1993, TRENDS BIOTECHNOL, V11, P238, DOI 10.1016/0167-7799(93)90135-V
   SAVOV A, 1992, NUCLEIC ACIDS RES, V20, P6741, DOI 10.1093/nar/20.24.6741
NR 13
TC 0
Z9 0
U1 0
U2 0
PU PUBL HOUSE BULGARIAN ACAD SCI
PI SOFIA
PA ACADEMICIAN G BONCEV ST, 1113 SOFIA, BULGARIA
SN 1310-1331
J9 CR ACAD BULG SCI
JI C. R. Acad. Bulg. Sci.
PY 2007
VL 60
IS 12
BP 1331
EP 1336
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 255CL
UT WOS:000252634200014
DA 2025-01-12
ER

PT J
AU Fiegl, H
   Elmasry, K
AF Fiegl, Heidi
   Elmasry, Karim
TI Cancer diagnosis, risk assessment and prediction of therapeutic response
   by means of DNA methylation markers
SO DISEASE MARKERS
LA English
DT Article
DE methylation; cancer risk assessment; diagnostics; prediction
ID GENE PROMOTER HYPERMETHYLATION; POLYMERASE-CHAIN-REACTION;
   TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; COLORECTAL-CANCER;
   BREAST-CANCER; PLASMA DNA; PROSTATE-CANCER; BLADDER-CANCER; MULTIPLE
   GENES
AB Epigenetic alterations are heritable changes in gene expression without an accompanying change in primary DNA sequence. Two major mechanisms that cause epigenetic changes are post-translational histone modifications and DNA methylation at cytosine bases within a CpG dinucleotide. Epigenetic defects have turned out to be one of the most common molecular alterations in human neoplasia. Promoter hypermethylation is associated with loss of expression of turnout suppressor genes in cancer. The analysis of aberrant DNA methylation is gaining strength in the fields of cancer risk assessment, diagnosis, and therapy monitoring in different cancer types. These issues are discussed in this review.
C1 UCL, Translat Res Lab, Dept Gynaecol Oncol, Inst Womens Hlth, London W1T 4JF, England.
   Med Univ Innsbruck, Bioctr Innsbruck, Div Cell Biol, Innsbruck, Austria.
C3 University of London; University College London; Medical University of
   Innsbruck
RP Fiegl, H (通讯作者)，UCL, Translat Res Lab, Dept Gynaecol Oncol, Inst Womens Hlth, Windeyer Bldg,46 Cleveland St, London W1T 4JF, England.
EM Heidi.Fiegl@uibk.ac.at
RI Fiegl, Heidi/K-4445-2017
OI Fiegl, Heidi/0000-0002-1236-6806
CR Adorján P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21
   An Q, 2002, CANCER LETT, V188, P109, DOI 10.1016/S0304-3835(02)00496-2
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Balog RP, 2002, ANAL BIOCHEM, V309, P301, DOI 10.1016/S0003-2697(02)00294-4
   Bearzatto A, 2002, CLIN CANCER RES, V8, P3782
   Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625
   Belshaw NJ, 2004, CANCER EPIDEM BIOMAR, V13, P1495
   Chan EC, 2002, CLIN CANCER RES, V8, P3741
   Chan MWY, 2002, CLIN CANCER RES, V8, P464
   Chan MWY, 2004, BIOTECHNOL LETT, V26, P1289, DOI 10.1023/B:BILE.0000044922.43572.2d
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Chu HJ, 2004, J KOREAN MED SCI, V19, P83, DOI 10.3346/jkms.2004.19.1.83
   COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715
   Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   de Fraipont F, 2005, LUNG CANCER, V50, P199, DOI 10.1016/j.lungcan.2005.05.019
   Domínguez G, 2002, CLIN CANCER RES, V8, P980
   Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 1999, CANCER RES, V59, P67
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Giacona MB, 1998, PANCREAS, V17, P89, DOI 10.1097/00006676-199807000-00012
   Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732
   Goessl C, 2000, CANCER RES, V60, P5941
   Gonzalgo ML, 2003, CLIN CANCER RES, V9, P2673
   Gonzalgo ML, 2004, UROLOGY, V63, P414, DOI 10.1016/j.urology.2003.08.039
   Grady WM, 2001, CANCER RES, V61, P900
   Henrique R, 2004, EUR UROL, V46, P660, DOI 10.1016/j.eururo.2004.06.014
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hibi K, 2001, CLIN CANCER RES, V7, P3135
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009
   Hu XC, 2003, ONCOL REP, V10, P1811
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Ichikawa D, 2004, ANTICANCER RES, V24, P2477
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757
   Ito S, 2002, JPN J CANCER RES, V93, P1266, DOI 10.1111/j.1349-7006.2002.tb01233.x
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kanyama Y, 2003, CANCER SCI, V94, P418, DOI 10.1111/j.1349-7006.2003.tb01457.x
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   Koike H, 2005, HEPATO-GASTROENTEROL, V52, P1293
   Koike H, 2004, J SURG ONCOL, V87, P182, DOI 10.1002/jso.20106
   Konno S, 2004, CANCER CYTOPATHOL, V102, P348, DOI 10.1002/cncr.20643
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Kurakawa E, 2001, INT J ONCOL, V19, P277
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X
   Leung WK, 2005, AM J GASTROENTEROL, V100, P2274, DOI 10.1111/j.1572-0241.2005.50412.x
   Leung WK, 2005, BRIT J CANCER, V92, P2190, DOI 10.1038/sj.bjc.6602636
   Leung WK, 2004, CLIN CHEM, V50, P2179, DOI 10.1373/clinchem.2004.039305
   Liu Y, 2003, CARCINOGENESIS, V24, P1897, DOI 10.1093/carcin/bgg169
   Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234
   Matsumoto H, 2003, ANTICANCER RES, V23, P1333
   Mori T, 2005, J CLIN ONCOL, V23, P9351, DOI 10.1200/JCO.2005.02.9876
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Müller HM, 2004, CLIN CHEM, V50, P2171, DOI 10.1373/clinchem.2004.034090
   Nakagawa H, 2001, CANCER RES, V61, P6991
   Nakayama H, 2002, CANCER LETT, V188, P115, DOI 10.1016/S0304-3835(01)00839-4
   Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740
   Olaussen KA, 2005, EUR J CANCER, V41, P2112, DOI 10.1016/j.ejca.2005.06.013
   Petko Z, 2005, CLIN CANCER RES, V11, P1203
   Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Santourlidis S, 1999, PROSTATE, V39, P166
   Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Silva JM, 1999, CANCER RES, V59, P3251
   Soria JC, 2002, CANCER RES, V62, P351
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   Suh CI, 2000, MOL CELL PROBE, V14, P211, DOI 10.1006/mcpr.2000.0307
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   SZE WT, 2002, CLIN CANCER RES, V8, P433
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Usadel H, 2002, CANCER RES, V62, P371
   Valenzuela MT, 2002, EUR UROL, V42, P622, DOI 10.1016/S0302-2838(02)00468-2
   van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898
   Wang YC, 2003, J CLIN INVEST, V111, P887, DOI 10.1172/JCI200315475
   Widschwendter A, 2004, CLIN CANCER RES, V10, P3396, DOI 10.1158/1078-0432.CCR-03-0143
   Wong IHN, 2000, CLIN CANCER RES, V6, P3516
   WONG IHN, CANC RES, V59, P71
   WONG IHN, 1999, CLIN CANCER RES, V9, P1047
   Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139
   Wong TS, 2003, EUR J CANCER, V39, P1881, DOI 10.1016/S0959-8049(03)00428-3
   Zou HZ, 2002, CLIN CANCER RES, V8, P188
NR 100
TC 11
Z9 12
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PY 2007
VL 23
IS 1-2
BP 89
EP 96
DI 10.1155/2007/293138
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA 175GY
UT WOS:000247003100007
PM 17325428
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Ying, JM
   Li, HY
   Murray, P
   Gao, ZF
   Chen, YW
   Wang, YJ
   Lee, KY
   Chan, ATC
   Ambinder, RF
   Srivastava, G
   Tao, Q
AF Ying, Jianming
   Li, Hongyu
   Murray, Paul
   Gao, Zifen
   Chen, Yun-Wen
   Wang, Yajun
   Lee, Kwan Yeung
   Chan, Anthony T. C.
   Ambinder, Richard F.
   Srivastava, Gopesh
   Tao, Qian
TI Tumor-specific methylation of the 8p22 tumor suppressor gene <i>DLC1</i>
   is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types
   of lymphomas
SO EPIGENETICS
LA English
DT Article
DE DLC1; methylation; biomarker; lymphoma; tumor suppressor gene
ID EPSTEIN-BARR-VIRUS; ABERRANT DNA METHYLATION; STRESS-RESPONSIVE GENE;
   HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION; HEMATOPOIETIC
   MALIGNANCIES; HEPATOCELLULAR-CARCINOMA; NASOPHARYNGEAL CARCINOMA;
   FUNDAMENTAL ROLE; SERUM DNA
AB Aberrant promoter methylation is an epigenetic mechanism for silencing tumor suppressor genes (TSG), and is also a biomarker for early cancer diagnosis and prognosis prediction. Recently, we and others identified DLC1 (ARHGAP7) as a functional TSG frequently methylated in multiple carcinomas. Here, we further uncovered DLC1 as one of the up-regulated genes in lymphoma cell lines after pharmacologic demethylation with 5-aza-2 '-deoxycytidine (Aza). Transcriptional silencing and methylation of DLC1 was detected in most Hodgkin (HL) and non-Hodgkin lymphoma (NHL) cell lines, including 4/6 Hodgkin, 4/4 nasal NK/T-cell, 6/6 Burkitt and 5/5 diffuse large B-cell lymphoma cell lines. Aza treatment led to DLC1 promoter demethylation and transcriptional reactivation in silenced cell lines, indicating a methylation-mediated silencing. Aberrant methylation was further detected in 44% (14/37) Hodgkin, 77% (34/44) nasal NK/T-cell and 60-90% of various types of primary NHLs, but not in any normal lymph node or PBMC sample, and is thus tumor-specific. Analysis of microdissected Hodgkin/Reed-Sternberg (HRS) cells from HL cases confirmed the site of methylation as tumor cells. Moreover, DLC1 methylation was detected in 4/14 (29%) serum samples from HL patients. Our results indicate that DLC1 methylation is a frequent event in multiple lymphomagenesis and could serve as a tumor-specific biomarker for future lymphoma diagnosis.
C1 [Chen, Yun-Wen; Srivastava, Gopesh] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Ying, Jianming; Li, Hongyu; Wang, Yajun; Lee, Kwan Yeung; Chan, Anthony T. C.; Tao, Qian] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol,Canc Epigenet Lab, Sir YK Pao Ctr Canc,State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China.
   [Ying, Jianming; Li, Hongyu; Wang, Yajun; Lee, Kwan Yeung; Chan, Anthony T. C.; Tao, Qian] Chinese Univ Hong Kong, Li Ka Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Murray, Paul] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England.
   [Gao, Zifen] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100871, Peoples R China.
   [Tao, Qian] Johns Hopkins Sch Med, Johns Hopkins Singapore & Sidney Kimmel Comprehen, Baltimore, MD USA.
C3 University of Hong Kong; Chinese University of Hong Kong; Chinese
   University of Hong Kong; University of Birmingham; Cancer Research UK;
   Peking University; Johns Hopkins University; Johns Hopkins Medicine
RP Srivastava, G (通讯作者)，Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
EM gopesh@pathology.hku.hk; qtao@clo.cuhk
RI CHEN, YAN/N-4135-2018; Tao, Qian/T-4743-2018; Chan, Anthony Tak
   Cheung/R-3940-2018
OI Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak
   Cheung/0000-0002-6912-8091
CR Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185
   CHEUNG WY, 1993, AM J CLIN PATHOL, V100, P502, DOI 10.1093/ajcp/100.5.502
   Chiang AKS, 1996, INT J CANCER, V68, P285, DOI 10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y
   Claus R, 2005, SEMIN ONCOL, V32, P511, DOI 10.1053/j.seminoncol.2005.07.024
   Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2003, CLIN IMMUNOL, V109, P80, DOI 10.1016/S1521-6616(03)00208-0
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Issa JPJ, 1997, CANCER RES, V57, P1678
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037
   Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1
   Müller HM, 2003, CANCER RES, V63, P7641
   Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313
   Ng IOL, 2000, CANCER RES, V60, P6581
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Shi HD, 2007, CARCINOGENESIS, V28, P60, DOI 10.1093/carcin/bgl092
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   TAO Q, 1995, INT J CANCER, V60, P315, DOI 10.1002/ijc.2910600306
   Winquist E, 2006, INVEST NEW DRUG, V24, P159, DOI 10.1007/s10637-006-5938-1
   Wong CM, 2003, CANCER RES, V63, P7646
   Wong IHN, 1999, CANCER RES, V59, P71
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
   Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291
   Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064
   Zhang Q, 2007, CANCER LETT, V249, P220, DOI 10.1016/j.canlet.2006.08.019
NR 46
TC 24
Z9 29
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JAN-MAR
PY 2007
VL 2
IS 1
BP 15
EP 21
DI 10.4161/epi.2.1.3883
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 306BW
UT WOS:000256223000005
PM 17965626
OA Bronze
DA 2025-01-12
ER

PT J
AU Butcher, DT
   Rodenhiser, DI
AF Butcher, Darci T.
   Rodenhiser, David I.
TI Epigenetic inactivation of BRCA1 is associated with aberrant expression
   of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast
   tumours
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; breast cancer; epigenetics; BRCA1; CTCF; DNMT3b
ID ENHANCER-BLOCKING ACTIVITY; RECEPTOR GENE-EXPRESSION; CARCINOMA IN-SITU;
   CPG METHYLATION; PROMOTER HYPERMETHYLATION; PROTEIN CTCF; CANCER;
   BINDING; ESTROGEN; MECHANISMS
AB We assessed expression of the BRCA1, CTCF and DNMT3b methyltransferase genes along with BRCA1 promoter methylation to better define the epigenetic events involved in BRCA1 inactivation in sporadic breast cancer. These gene expression patterns were determined in 54 sporadic breast tumours by immunohistochemistry and the methylation status of the BRCA1 promoter was evaluated using methylation-specific PCR. We observed significant DNMT3b expression in 80% of the tumours and that 43% of tumours exhibited novel cytoplasmic CTCF expression. Pairwise analyses of gene expression patterns showed that 28/32 tumours; lacked BRCA1 expression and also exhibited cytoplasmic CTCF staining, while 24/32 of these tumours also overexpressed DNMT3b. Furthermore, 86% of the BRCA1 low-expressing tumours were methylated at the BRCA1 promoter and a subset of these tumours displayed both cytoplasmic CTCF and increased DNMT3b expression. Thus, tumour subsets exist that display concurrent decreased BRCA1 expression, BRCA1 promoter methylation, cytoplasmic CTCF expression and with DNMT3b over-expression. We suggest that these altered CTCF and DNMT3b expression patterns represent (a) critical events responsible for the epigenetic inactivation of BRCA1 and (b) a diagnostic signature for epigenetic inactivation of other tumour suppressor genes in sporadic breast tumours. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Western Ontario, London, ON N6A 4L6, Canada.
   London Reg Canc Program, London Hlth Sci Ctr, London, ON N6A 4L6, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); London Health Sciences Centre
RP Rodenhiser, DI (通讯作者)，Univ Western Ontario, Room A4-134,790 Commiss Rd E, London, ON N6A 4L6, Canada.
EM drodenhi@uwo.ca
CR Anderson AE, 2001, BIOTECHNIQUES, V31, P1004, DOI 10.2144/01315bm05
   Aparicio A, 2003, CANCER CHEMOTH PHARM, V51, P231, DOI 10.1007/s00280-002-0563-y
   Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844
   Aulmann S, 2003, BREAST CANCER RES TR, V80, P347, DOI 10.1023/A:1024930404629
   Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729
   Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Bogdani M, 2002, VIRCHOWS ARCH, V440, P274, DOI 10.1007/s004280100526
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Dinesh KPB, 2006, MOL CELL BIOCHEM, V287, P177, DOI 10.1007/s11010-005-9097-z
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dunn KL, 2003, EXP CELL RES, V288, P218, DOI 10.1016/S0014-4827(03)00185-X
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Haines TR, 2001, DEV BIOL, V240, P585, DOI 10.1006/dbio.2001.0504
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042
   Ishida C, 2003, GENE, V310, P151, DOI 10.1016/S0378-1119(03)00545-6
   Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366
   Lübbert M, 2000, CURR TOP MICROBIOL, V249, P135
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   *OHIP, 2002, ONT PHYS GUID REF PA
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540
   RADFORD DM, 1995, CANCER RES, V55, P3399
   Rakha EA, 2004, BRIT J CANCER, V91, P1591, DOI 10.1038/sj.bjc.6602144
   Rasband W., 1997, ImageJ (Image Processing and Analysis in Java)
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Roberts JG, 1999, ANAESTH INTENS CARE, V27, P11, DOI 10.1177/0310057X9902700102
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Tan PH, 2005, MODERN PATHOL, V18, P374, DOI 10.1038/modpathol.3800254
   Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372
   Watanabe D, 2002, MECH DEVELOP, V118, P187, DOI 10.1016/S0925-4773(02)00242-3
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Zhou XL, 2004, BREAST CANCER RES, V6, pR187, DOI 10.1186/bcr774
NR 45
TC 74
Z9 88
U1 1
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JAN
PY 2007
VL 43
IS 1
BP 210
EP 219
DI 10.1016/j.ejca.2006.09.002
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 137RZ
UT WOS:000244311000035
PM 17071074
DA 2025-01-12
ER

PT J
AU Barciszewska, AM
   Murawa, D
   Gawronska, I
   Murawa, P
   Nowak, S
   Barciszewska, MZ
AF Barciszewska, Anna-Maria
   Murawa, Dawid
   Gawronska, Iwona
   Murawa, Pawel
   Nowak, Stanislaw
   Barciszewska, Miroslawa Z.
TI Analysis of 5-methylcytosine in DNA of breast and colon cancer tissues
SO IUBMB LIFE
LA English
DT Article
DE DNA methylation; m(5)C analysis; epigenetics; breast cancer; colon
   cancer; diagnostics
ID GENE-EXPRESSION; METHYLATION; HYPOMETHYLATION; HYPERMETHYLATION;
   PATTERNS; REPEAT; REGION; REPAIR; DAMAGE
AB 5-methylcytosine (m(5)C) can be used as a sensitive marker of progress of the tumor formation induced by the oxidative damage reactions. We have analyzed the amount of m(5)C in DNA of patients with breast and colon cancers. Two dimensional thin layer chromatography (TLC) has been used to monitor 5-methylcytosine level in DNA extracted from cancer tissues. The level of methylation of cytosine at C-5 position in DNA from breast cancer patients correlates well with the malignancy of tumors. Interestingly higher amount of m(5)C in DNA for the breast cancer patients treated with different chemotherapeutics was observed. It suggests an activation of DNA methyltransferase as well as a genomic suppression of the DNA repair genes expression. These differences clearly reflect the health condition of patients and support the global analysis of m(5)C in DNA as a good marker for diagnosis of neoplasia in clinical practice.
C1 [Gawronska, Iwona; Barciszewska, Miroslawa Z.] Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland.
   [Barciszewska, Anna-Maria; Nowak, Stanislaw] Poznan Univ Med Sci, Dept & Clin Neurosurg & Neurotraumatol, Poznan, Poland.
   [Murawa, Dawid; Murawa, Pawel] Wielkopolska Ctr Oncol, Ward Surg Oncol 1, Poznan, Poland.
C3 Polish Academy of Sciences; Institute of Bioorganic Chemistry of the
   Polish Academy of Sciences; Poznan University of Medical Sciences;
   Wielkopolskie Centrum Onkologii
RP Barciszewska, MZ (通讯作者)，Polish Acad Sci, Inst Bioorgan Chem, Noskowskiego 12, PL-61704 Poznan, Poland.
EM Miroslawa.Barciszewska@ibch.poznan.pl
RI Barciszewska, Anna-Maria/J-5978-2018
OI Barciszewska, Anna-Maria/0000-0002-7179-1474
CR Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Boyle P, 2002, BRIT MED BULL, V64, P1, DOI 10.1093/bmb/64.1.1
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464
   Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890
   Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048
   Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Havlis J, 2002, J CHROMATOGR B, V781, P373, DOI 10.1016/S1570-0232(02)00499-3
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hori M, 2003, NUCLEIC ACIDS RES, V31, P1191, DOI 10.1093/nar/gkg223
   Jiricny J, 2002, CURR BIOL, V12, pR846, DOI 10.1016/S0960-9822(02)01350-7
   Johanning GL, 2002, J NUTR, V132, p3814S, DOI 10.1093/jn/132.12.3814S
   Kamiya H, 2002, J BIOCHEM, V132, P551, DOI 10.1093/oxfordjournals.jbchem.a003256
   Lee MP, 2003, ANN NY ACAD SCI, V983, P101, DOI 10.1111/j.1749-6632.2003.tb05965.x
   Mathieu O, 2002, CHROMOSOME RES, V10, P455, DOI 10.1023/A:1020936229771
   Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901
   Nishiyama R, 2005, CANCER BIOL THER, V4, P440
   Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146
   Polyak K, 2002, CURR OPIN ONCOL, V14, P92, DOI 10.1097/00001622-200201000-00016
   Reik W, 2001, ELECTROPHORESIS, V22, P2838, DOI 10.1002/1522-2683(200108)22:14<2838::AID-ELPS2838>3.0.CO;2-M
   Schmitt F, 1997, J BIOL CHEM, V272, P1534, DOI 10.1074/jbc.272.3.1534
   Sharma P, 2005, BREAST CANCER RES, V7, pR634, DOI 10.1186/bcr1203
   Shiraishi M, 2002, BIOL CHEM, V383, P893, DOI 10.1515/BC.2002.096
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zukiel R, 2004, MOL CANCER RES, V2, P196
NR 34
TC 19
Z9 20
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PY 2007
VL 59
IS 12
BP 765
EP 770
DI 10.1080/15216540701697412
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 242HD
UT WOS:000251714500005
PM 18085476
OA Bronze
DA 2025-01-12
ER

PT J
AU McIntyre, GI
AF McIntyre, G. I.
TI Increased cell hydration promotes both tumor growth and metastasis: A
   biochemical mechanism consistent with genetic signatures
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CANCER METASTASIS; BREAST-CANCER; PROGRESSION; GLYCOLYSIS; EXPRESSION;
   WATER
AB It was postulated previously that a progressive increase in cell hydration, induced by successive genetic or epigenetic changes, is the basic mechanism of multistep carcinogenesis, and also that the degree of malignancy increases with the degree of cell hydration. These hypotheses implied that increased cell hydration is a common factor promoting both tumor growth and metastasis, and that metastatic potential increases with the degree of cell hydration. This paper discusses these implications in relation to current concepts of genetic mechanisms determining the acquisition of metastatic potential. It was also postulated previously that the enhancement of metabolic activity by increased cell hydration will increase the ability of tumor cells to compete for nutrients with their normal counterparts. This effect may favor the preferential selection of cells whose genotypes confer the greatest increase in cell hydration and which, on the present hypothesis, would be those with the greatest capacity for metastasis. An important feature of this "common factor" hypothesis is that it suggests a biochemical explanation for DNA-microarray data showing a similarity between the gene expression patterns associated with both tumor growth and metastasis, while the postulated role of genes causing increased cell hydration might explain the apparent acquisition of metastatic potential at an early stage of tumorigenesis. Previous investigations were consistent with the hypothesis that various factors promoting carcinogenesis may do so by increasing cell hydration. A survey of the literature showed that all of these factors also promote cell motility, migration or metastasis, and provided evidence that these effects could be attributed to the associated increase in cell hydration. Methods are suggested for testing the hypothesis, and the paper concludes by emphasizing the need for more research on the biochemistry of cancer, and on the role of water as a biochemical factor of particular importance, not only in carcinogenesis, but in many other aspects of cell biology. (C) 2007 Elsevier Ltd. All rights reserved.
RP McIntyre, GI (通讯作者)，205-640 Dallas Rd, Victoria, BC V8V 1B6, Canada.
EM gimcintyre@pacificcoast.net
CR BECKNER ME, 1990, JNCI-J NATL CANCER I, V82, P1836, DOI 10.1093/jnci/82.23.1836
   Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a
   Chaplin M, 2006, NAT REV MOL CELL BIO, V7, P861, DOI 10.1038/nrm2021
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Gupta PB, 2005, COLD SH Q B, V70, P291, DOI 10.1101/sqb.2005.70.033
   Loitto VM, 2002, J LEUKOCYTE BIOL, V71, P212
   McIntyre GI, 2006, MED HYPOTHESES, V66, P518, DOI 10.1016/j.mehy.2005.09.022
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623, DOI 10.1152/ajpcell.1994.267.6.C1623
   Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   WEINHOUSE S, 1972, CANCER RES, V32, P2007
   Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497
NR 16
TC 12
Z9 15
U1 0
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2007
VL 69
IS 5
BP 1127
EP 1130
DI 10.1016/j.mehy.2007.01.080
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 227LH
UT WOS:000250657700031
PM 17399912
DA 2025-01-12
ER

PT J
AU Torrisani, J
   Unterberger, A
   Tendulkar, SR
   Shikimi, K
   Szyf, M
AF Torrisani, Jerome
   Unterberger, Alexander
   Tendulkar, Sachin R.
   Shikimi, Keisuke
   Szyf, Moshe
TI AUF1 cell cycle variations define genomic DNA methylation by regulation
   of <i>DNMT1 m</i>RNA stability
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID ELEMENT-BINDING PROTEINS; MESSENGER-RNA STABILITY; HU ANTIGEN-R;
   TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; GROWTH-REGULATION; RICH
   ELEMENTS; BREAST-CANCER; METHYLTRANSFERASE; EXPRESSION
AB DNA methylation is a major determinant of epigenetic inheritance. DNA methyltransferase 1 (DNMT1) is the enzyme responsible for the maintenance of DNA methylation patterns during cell division, and deregulated expression of DMMT1 leads to cellular transformation. We show herein that AU-rich element/poly(U)-binding/degradation factor 1 (AUF1)/heterogenous nuclear ribonucleoprotein D interacts with an AU-rich conserved element in the 3' untranslated region of the DNMT1 mRNA and targets it for destabilization by the exosome. AUF1 protein levels are regulated by the cell cycle by the proteasome, resulting in cell cycle-specific destabilization of DNMT1 mRNA. AUF1 knock down leads to increased DNMT1 expression and modifications of cell cycle kinetics, increased DNA methyltransferase activity, and genome hypermethylation. Concurrent AUF1 and DNMT1 knock down abolishes this effect, suggesting that the effects of AUF1 knock down on the cell cycle are mediated at least in part by DNMT1. In this study, we demonstrate a link between AUF1, the RNA degradation machinery, and maintenance of the epigenetic integrity of the cell.
C1 McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
C3 McGill University
RP Szyf, M (通讯作者)，McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.
EM moshe.szyf@mcgill.ca
RI Torrisani, Jérôme/M-6203-2014
FU Wellcome Trust Funding Source: Medline
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6
   Blaxall BC, 2000, MOL CARCINOGEN, V28, P76
   BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460
   Brewer G, 2003, J INTERF CYTOK RES, V23, P553, DOI 10.1089/107999003322485053
   Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973
   Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006
   Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200
   Ding F, 2002, P NATL ACAD SCI USA, V99, P14861, DOI 10.1073/pnas.232565599
   Gouble A, 2002, CANCER RES, V62, P1489
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004
   Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684
   Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406
   Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305
   Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499
   Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699
   Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444
   LIN WT, 2000, J ASSOC INF SYST, V1, P1
   LOFFIN P, 1999, GENE DEV, V13, P1884
   MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327
   MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037
   McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158
   Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200
   Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353
   Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165
   Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138
   Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   Ramsahoye Bernard H, 2002, Methods Mol Biol, V200, P9
   RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595
   ROULEAU J, 1992, J BIOL CHEM, V267, P7368
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003
   Shen ZJ, 2005, NAT IMMUNOL, V6, P1280, DOI 10.1038/ni1266
   Stoecklin G, 2006, EMBO REP, V7, P72, DOI 10.1038/sj.embor.7400572
   SZYF M, 1985, J BIOL CHEM, V260, P8653
   SZYF M, 1991, J BIOL CHEM, V266, P10027
   Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6
   SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4
   Szyf M, 2000, ANN NY ACAD SCI, V910, P156
   Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555
   Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142
   Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346
   Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Yasuda S, 2004, ENDOCRINOLOGY, V145, P1730, DOI 10.1210/en.2003-0862
   ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652
NR 57
TC 40
Z9 52
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JAN
PY 2007
VL 27
IS 1
BP 395
EP 410
DI 10.1128/MCB.01236-06
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 121CX
UT WOS:000243136800031
PM 17030625
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kato, Y
   Salumbides, BC
   Wang, XF
   Qian, DZ
   Williams, S
   Wei, YF
   Sanni, TB
   Atadja, P
   Pili, R
AF Kato, Yukihiko
   Salumbides, Brenda C.
   Wang, Xiao-Fei
   Qian, David Z.
   Williams, Simon
   Wei, Yongfeng
   Sanni, Tolib B.
   Atadja, Peter
   Pili, Roberto
TI Antitumor effect of the histone deacetylase inhibitor LAQ824 in
   combination with 13-<i>cis</i>-retinoic acid in human malignant melanoma
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID SUBEROYLANILIDE HYDROXAMIC ACID; RETINOIC ACID; BREAST-CANCER;
   CELL-DEATH; ACTIN CYTOSKELETON; RECEPTOR BETA-2; GENE-EXPRESSION;
   DOWN-REGULATION; LEUKEMIA-CELLS; UP-REGULATION
AB Resistance to chemotherapy is a major hurdle in the treatment of malignant melanoma. Histone deacetylase (HDAC) inhibitors have been shown to have antitumor activity in different tumor types, including melanoma, and to reverse epigenetic repression of tumor suppressor genes, such as retinoic acid receptor beta (RAR beta). In this study, we tested the antitumor effect of the HDAC inhibitor LAQ824 in combination with 13-cis-retinoic acid (CRA) on two human melanoma cell lines both in vitro and in vivo. Treatment of LAQ824 showed a dose-dependent inhibitory effect on A2058 and HMV-I cell lines in a clonogenic assay. These cell lines were relatively resistance to CRA. On treatment with combination of LAQ824 and CRA, a greater inhibitory effect (up to 98%) was achieved compared with single agents. Lack of RAR beta 2 gene expression was associated with histone acetylation and gene methylation at the promoter level. Treatment with LAQ824 restored retinoid sensitivity by reverting RAR beta 2 epigenetic silencing. The biological effect of LAQ824 was associated with p21 induction in both cell lines but G(2) cell cycle arrest in A2058 and apoptosis in HMV-I cell line. The induction of apoptosis by LAQ824 was associated with increased reactive oxygen species and induction of SM22 gene expression in HMV-I but not in A2058 cell line. Administration of the free radical scavenger L-N-acetylcysteine blocked LAQ824 + CRA- mediated apoptosis in HMV-I cells, suggesting a primary role for reactive oxygen species generation in LAQ824 + CRA-associated lethality. Combination treatment showed 61% and 82% growth inhibition in A2058 and HMV-I tumors, respectively. Greater induction of in vivo apoptosis was observed in the HMV-I but not in the A2058 tumors treated with combination therapy compared with single agents. These results suggest that the HDAC inhibitor LAQ824 has a greater antitumor activity in combination with CRA in melanoma tumors but the degree of induced apoptosis may vary. Combination of HDAC inhibitors and retinoids represents a novel therapeutic approach for malignant melanoma that warrants clinical testing.
C1 Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   Novartis Res Inst, Cambridge, MA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Novartis; Novartis USA
RP Pili, R (通讯作者)，Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg 1M52,1650 Orleans, Baltimore, MD 21231 USA.
EM rpili@jhmi.edu
RI Qian, David/AAL-3441-2021
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105
   Berwick M, 2006, FRONT BIOSCI-LANDMRK, V11, P1244, DOI 10.2741/1877
   Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x
   Burgess AJ, 2001, MOL PHARMACOL, V60, P828
   Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)82148-6
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0
   Demary K, 2001, CANCER LETT, V163, P103, DOI 10.1016/S0304-3835(00)00676-5
   Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600
   DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x
   Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50
   FANG L, 2005, EXPERT OPIN THER TAR, V9, P809
   Florenes VA, 2004, MELANOMA RES, V14, P173, DOI 10.1097/01.cmr.0000129579.49313.26
   Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948
   Goodman A, 2003, MOL BIOL CELL, V14, P2617, DOI 10.1091/mbc.E03-01-0028
   GOODMAN GE, 1986, CANCER TREAT REP, V70, P1023
   GORE L, 2004, J CLIN ONCOL, V22, P3026
   Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148
   Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Jazwinski SM, 2002, ANNU REV MICROBIOL, V56, P769, DOI 10.1146/annurev.micro.56.012302.160830
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kilbridge KL, 2002, J CLIN ONCOL, V20, P1311, DOI 10.1200/JCO.20.5.1311
   Lippman SM, 1997, CANCER CHEMOTHER BIO, V17, P349
   MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7
   MARGOLIN K, 1997, CLIN CANCER RES, V3, P365
   Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158
   MILLWARD MJ, 2004, P AM SOC CLIN ONCOL, V22
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mori T, 2005, J CLIN ONCOL, V23, P9351, DOI 10.1200/JCO.2005.02.9876
   Mork CN, 2005, CURR PHARM DESIGN, V11, P1091, DOI 10.2174/1381612053507567
   Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980
   Pili R, 2001, CANCER RES, V61, P1477
   Place RF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-37
   Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540
   Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069
   Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9
   Remiszewski SW, 2003, J MED CHEM, V46, P4609, DOI 10.1021/jm030235w
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Richtig E, 2005, J CLIN ONCOL, V23, P8655, DOI 10.1200/JCO.2004.00.8128
   Romanski A, 2004, HAEMATOLOGICA, V89, P419
   Rosato RR, 2006, MOL PHARMACOL, V69, P216, DOI 10.1124/mol.105.017145
   Rosato RR, 2005, EXPERT OPIN THER TAR, V9, P809, DOI 10.1517/14728222.9.4.809
   Rosato RR, 2003, CANCER RES, V63, P3637
   Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Spanjaard RA, 1997, CANCER RES, V57, P5122
   Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176
   Wang XF, 2005, CLIN CANCER RES, V11, P3535, DOI 10.1158/1078-0432.CCR-04-1092
   Weisberg E, 2004, LEUKEMIA, V18, P1951, DOI 10.1038/sj.leu.2403519
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Winder SJ, 2003, BIOCHEM J, V375, P287, DOI 10.1042/BJ20030796
   Zhang XD, 2004, MOL CANCER THER, V3, P425
NR 58
TC 51
Z9 61
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JAN
PY 2007
VL 6
IS 1
BP 70
EP 81
DI 10.1158/1535-7163.MCT-06-0125
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 129WC
UT WOS:000243759800008
PM 17237267
OA Bronze
DA 2025-01-12
ER

PT J
AU Yanokura, M
   Banno, K
   Kawaguchi, M
   Hirao, N
   Hirasawa, A
   Susumu, N
   Tsukazaki, K
   Aoki, D
AF Yanokura, Megumi
   Banno, Kouji
   Kawaguchi, Makiko
   Hirao, Nobumaru
   Hirasawa, Akira
   Susumu, Nobuyuki
   Tsukazaki, Katsumi
   Aoki, Daisuke
TI Relationship of aberrant DNA hypermethylation of <i>CHFR</i> with
   sensitivity to taxanes in endometrial cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE CHFR; endometrial cancer; DNA hypermethylation; taxane; chemosensitivity
ID MITOTIC STRESS CHECKPOINT; 5' CPG ISLAND; CHROMOSOMAL INSTABILITY;
   MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; FREQUENT
   HYPERMETHYLATION; EPIGENETIC INACTIVATION; OVARIAN-CANCER;
   BREAST-CANCER; GENE
AB The relationship of aberrant DNA hypermethylation of cell cycle checkpoint genes with the sensitivity of cancer cells to anticancer drugs is a question of current interest. In this study, we investigated the relationship between aberrant hypermethylation of the CHFR (checkpoint with forkhead-associated and ring finger) mitotic checkpoint gene and sensitivity to taxanes in endometrial cancer. Methylation-specific PCR (MSP) indicated aberrant hypermethylation of CHFR in 12.0% (6/50) of endometrial cancer specimens, and suggested that aberrant hypermethylation is significantly more frequent in poorly differentiated adenocarcinoma (G3) (p < 0.05). Of six culture cell lines, SNG-II and HEC108 cells showed aberrant hypermethylation and reduced expression of CHFR. These cells had high sensitivity to taxanes but became resistant after demethylation. Cancer specimens with aberrant hypermethylation of CHFR also exhibited high sensitivity to taxanes. To our knowledge, this study is the first to examine aberrant hypermethylation of CHFR in endometrial cancer, and our results suggest that the methylation status of CHFR may be a new molecular index that will allow design of personalized treatment in endometrial cancer. This may be particularly important in poorly differentiated adenocarcinoma (G3), which is known to have a poor prognosis.
C1 Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University
RP Banno, K (通讯作者)，Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.
EM kbanno@sc.itc.keio.ac.jp
RI Yanokura, Megumi/W-2667-2017; Aoki, Daisuke/E-6650-2014; Banno,
   Kouji/C-9638-2014
CR Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2
   Fraizer GC, 2004, INT J ONCOL, V25, P1631
   Hirasawa A, 2003, CLIN CANCER RES, V9, P5675
   Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101
   Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365
   Kawaguchi M, 2005, ANTICANCER RES, V25, P3547
   Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Susumu- N, 2005, INT J GYNECOL CANCER, V15, P70, DOI 10.1111/j.1048-891x.2005.14424.x
   Suzuki H, 2000, CANCER RES, V60, P4353
   Tokunaga E, 2006, BREAST CANCER RES TR, V97, P199, DOI 10.1007/s10549-005-9112-9
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
NR 17
TC 31
Z9 38
U1 0
U2 4
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2007
VL 17
IS 1
BP 41
EP 48
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 120VJ
UT WOS:000243114100006
PM 17143476
DA 2025-01-12
ER

PT J
AU Arce, C
   Pérez-Plasencia, C
   González-Fierro, A
   de la Cruz-Hernández, E
   Revilla-Vázquez, A
   Chávez-Blanco, A
   Trejo-Becerril, C
   Pérez-Cárdenas, E
   Taja-Chayeb, L
   Bargallo, E
   Villarreal, P
   Ramírez, T
   Vela, T
   Candelaria, M
   Camargo, MF
   Robles, E
   Dueñas-González, A
AF Arce, Claudia
   Perez-Plasencia, Carlos
   Gonzalez-Fierro, Aurora
   de la Cruz-Hernandez, Erick
   Revilla-Vazquez, Alma
   Chavez-Blanco, Alma
   Trejo-Becerril, Catalina
   Perez-Cardenas, Enrique
   Taja-Chayeb, Lucia
   Bargallo, Enrique
   Villarreal, Patricia
   Ramirez, Teresa
   Vela, Teresa
   Candelaria, Myrna
   Camargo, Maria F.
   Robles, Elizabeth
   Duenas-Gonzalez, Alfonso
TI A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant
   Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
SO PLOS ONE
LA English
DT Article
AB Background. Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in cancer therapy. As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating hydralazine, plus the HDAC inhibitor magnesium valproate, were added to neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess their safety and biological efficacy. Methodology. This was a single-arm interventional trial on breast cancer patients (ClinicalTrials.gov Identifier: NCT00395655). After signing informed consent, patients were typed for acetylator phenotype and then treated with hydralazine at 182 mg for rapid-, or 83 mg for slow-acetylators, and magnesium valproate at 30 mg/kg, starting from day -7 until chemotherapy ended, the latter consisting of four cycles of doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every 21 days. Core-needle biopsies were taken from primary breast tumors at diagnosis and at day 8 of treatment with hydralazine and valproate. Main Findings. 16 patients were included and received treatment as planned. All were evaluated for clinical response and toxicity and 15 for pathological response. Treatment was well-tolerated. The most common toxicity was drowsiness grades 1-2. Five (31%) patients had clinical CR and eight (50%) PR for an ORR of 81%. No patient progressed. One of 15 operated patients (6.6%) had pathological CR and 70% had residual disease <3 cm. There was a statistically significant decrease in global 5(m)C content and HDAC activity. Hydralazine and magnesium valproate up- and down-regulated at least 3-fold, 1,091 and 89 genes, respectively. Conclusions. Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors. Doxorubicin and cyclophosphamide treatment is safe, well-tolerated, and appears to increase the efficacy of chemotherapy. A randomized phase III study is ongoing to support the efficacy of so-called epigenetic or transcriptional cancer therapy.
C1 [Perez-Plasencia, Carlos; Gonzalez-Fierro, Aurora; de la Cruz-Hernandez, Erick; Chavez-Blanco, Alma; Trejo-Becerril, Catalina; Perez-Cardenas, Enrique; Taja-Chayeb, Lucia; Camargo, Maria F.; Duenas-Gonzalez, Alfonso] Univ Nacl Autonoma Mexico, Inst Nacl Cancerol INCAN, Inst Invest Biomed, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.
   [Arce, Claudia; Candelaria, Myrna; Robles, Elizabeth] Inst Nacl Cancerol INCAN, Div Invest Clin, Mexico City, DF, Mexico.
   [Revilla-Vazquez, Alma] Univ Nacl Autonoma Mexico, Lab Desarrollo Metodos Analit, FES Cuautitlan, Cuautitlan, Estado Mexico, Mexico.
   [Bargallo, Enrique; Villarreal, Patricia; Ramirez, Teresa] Inst Nacl Cancerol INCAN, Dept Tumores Mamarios, Mexico City, DF, Mexico.
   [Vela, Teresa] Inst Nacl Cancerol INCAN, Dept Patol, Mexico City, DF, Mexico.
C3 Instituto Nacional de Cancerologia (INCAN); Universidad Nacional
   Autonoma de Mexico; Instituto Nacional de Cancerologia (INCAN);
   Universidad Nacional Autonoma de Mexico; Instituto Nacional de
   Cancerologia (INCAN); Instituto Nacional de Cancerologia (INCAN)
RP Dueñas-González, A (通讯作者)，Univ Nacl Autonoma Mexico, Inst Nacl Cancerol INCAN, Inst Invest Biomed, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.
EM alfonso_duenasg@yahoo.com
RI Perez-Cardenas, Enrique/JPW-9339-2023; De la Cruz-Hernandez,
   Erick/E-1487-2019; Arce, Claudia/KOC-2163-2024; Perez-Plasencia,
   Carlos/P-2372-2019
OI Perez-Plasencia, Carlos/0000-0002-8593-8211; Perez-Cardenas,
   Enrique/0000-0002-4896-4111; Revilla Vazquez, Alma
   Luisa/0000-0002-4714-0866
FU CONACyT [SALUD-2002-C01-6579, AVANCE C01-294]; Psicofarma; S. A. de C.
   V., Mexico
FX This work was supported by CONACyT grants SALUD-2002-C01-6579 and AVANCE
   C01-294, and by Psicofarma, S. A. de C. V., Mexico. Sponsors did not
   participate in study design; collection, analysis, and interpretation of
   data; writing of the paper; nor decision to submit it for publication.
CR Acharya S, 2000, J PEDIAT HEMATOL ONC, V22, P62, DOI 10.1097/00043426-200001000-00012
   Angeles E, 2005, LETT DRUG DES DISCOV, V2, P282, DOI 10.2174/1570180054038413
   Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433
   Bonadonna G, 1998, J CLIN ONCOL, V16, P93, DOI 10.1200/JCO.1998.16.1.93
   Bourg V, 2001, ANN ONCOL, V12, P217, DOI 10.1023/A:1008331708395
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Brain E, 1997, BRIT J CANCER, V75, P1360, DOI 10.1038/bjc.1997.230
   Buchholz TA, 2002, CANCER J, V8, P461, DOI 10.1097/00130404-200211000-00010
   Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Castaneda-Hernandez G., 1995, Am J Ther, V2, P57, DOI 10.1097/00045391-199501000-00011
   Chavez-Blanco A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-2
   Chavez-Blanco A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-22
   Claus R, 2005, SEMIN ONCOL, V32, P511, DOI 10.1053/j.seminoncol.2005.07.024
   Cristofanilli M, 2006, CANCER-AM CANCER SOC, V107, P935, DOI 10.1002/cncr.22080
   FERNANDEZSANCHE.M, 1998, MED ONCOL, V23, P171
   Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483
   Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327
   Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002
   GARCIAMANERO G, 2006, BLOOD           0801
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Guerrero KS, 2005, ELECTROPHORESIS, V26, P1057, DOI 10.1002/elps.200410040
   Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799
   Hartsough MT, 2001, CANCER RES, V61, P2320
   Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417
   Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007
   Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187
   Kim MS, 2003, CANCER RES, V63, P7291
   Kitazono M, 2002, CANCER BIOL THER, V1, P665, DOI 10.4161/cbt.317
   Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776
   Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460
   LESSER JM, 1974, DRUG METAB DISPOS, V2, P351
   Li L, 2005, J COMPUT BIOL, V12, P370, DOI 10.1089/cmb.2005.12.370
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Mamelak AJ, 2005, EXP DERMATOL, V14, P336, DOI 10.1111/j.0906-6705.2005.00278.x
   Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021
   Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442
   Modlich O, 2004, CLIN CANCER RES, V10, P6418, DOI 10.1158/1078-0432.CCR-04-1031
   Morrell LE, 1998, CANCER-AM CANCER SOC, V82, P503, DOI 10.1002/(SICI)1097-0142(19980201)82:3<503::AID-CNCR12>3.0.CO;2-5
   Perez-Plasencia C, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-27
   POWLES TJ, 1995, J CLIN ONCOL, V13, P547, DOI 10.1200/JCO.1995.13.3.547
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   REECE PA, 1980, J CHROMATOGR, V181, P427, DOI 10.1016/S0378-4347(00)81145-7
   Rouzier R, 2005, J CLIN ONCOL, V23, P8331, DOI 10.1200/JCO.2005.01.2898
   Rouzier R, 2002, J CLIN ONCOL, V20, P1304, DOI 10.1200/JCO.20.5.1304
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Scholl SM, 1995, EUR J CANCER, V31A, P1969, DOI 10.1016/0959-8049(95)00454-8
   Schover L., 1994, Journal of psychology and human sexuality, V6, P5
   SCHWARTZ GF, 1994, CANCER, V73, P362, DOI 10.1002/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-L
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099
   Shi HD, 2003, CANCER RES, V63, P2164
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Sonnemann J, 2006, INT J ONCOL, V28, P755
   Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Tang Bo, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P283
   Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224
   Wong TWL, 2000, LIFE SCI, V67, pPL1111
   Yan PS, 2001, CANCER RES, V61, P8375
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 70
TC 121
Z9 144
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2006
VL 1
IS 1
AR e98
DI 10.1371/journal.pone.0000098
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V10DB
UT WOS:000207443600097
PM 17183730
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Khalkhali-Ellis, Z
AF Khalkhali-Ellis, Zhila
TI Maspin: The new frontier
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR MASPIN; ABERRANT EXPRESSION; GENE MASPIN; INTESTINAL
   METAPLASIA; SERPIN; HYPOMETHYLATION; CARCINOMA; PROMOTER; CELLS;
   METHYLATION
AB Maspin (mammary serine protease inhibitor) was identified in 1994 by subtractive hybridization analysis of normal mammary tissue and breast cancer cell lines. Subsequently emerging evidence portrays maspin as a multifaceted protein, interacting with diverse group of intercellular and extracellular proteins, regulating cell adhesion motility apoptosis and angiogenesis and critically involved mammary gland development. The tissue-specific expression of maspin is epigenetically controlled and aberrant methylation of maspin promoter is closely associated with maspin gene silencing identification of new tissue sites expressing maspin and novel maspin-binding partners has expanded the horizon for maspin research and promises maspin-based therapeutic approaches for combating cancer. This perspective briefly outlines the past and present strides in deciphering this unique molecule and speculates on new frontiers in maspin research and prospects of maspin as a diagnostic/prognostic indicator in cancer.
C1 Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60614 USA.
C3 Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie
   Comprehensive Cancer Center; Northwestern University; Feinberg School of
   Medicine
RP Khalkhali-Ellis, Z (通讯作者)，Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, 2300 Childrens Plaza,Box 222, Chicago, IL 60614 USA.
EM zellis@childrensmemorial.org
FU NCI NIH HHS [R01 CA075681-10, R01 CA075681, CA 75681] Funding Source:
   Medline
CR Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3
   Bailey CM, 2005, J BIOL CHEM, V280, P34210, DOI 10.1074/jbc.M503523200
   BECK HC, 2006, MOL CELL PROTEO 0420
   Bettstetter M, 2005, J PATHOL, V205, P606, DOI 10.1002/path.1732
   Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200
   Boltze C, 2003, INT J MOL MED, V12, P479
   Cao DF, 2005, J GASTROINTEST CANC, V36, P39, DOI 10.1385/IJGC:36:1:039
   Cella N, 2006, FASEB J, V20, P1510, DOI 10.1096/fj.05-5500fje
   Chen EI, 2005, FASEB J, V19, P1123, DOI 10.1096/fj.04-2970fje
   Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102
   Dokras A, 2002, PLACENTA, V23, P274, DOI 10.1053/plac.2001.0784
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   Fitzgerald M, 2003, NEOPLASIA, V5, P427, DOI 10.1016/S1476-5586(03)80045-3
   Fujisawa K, 2005, LAB INVEST, V85, P214, DOI 10.1038/labinvest.3700214
   Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2
   Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x
   Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03
   LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487
   Li ZG, 2005, ONCOGENE, V24, P2008, DOI 10.1038/sj.onc.1208449
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Maesawa C, 2006, J CLIN PATHOL, V59, P328, DOI 10.1136/jcp.2005.027284
   Marioni G, 2005, HISTOPATHOLOGY, V46, P576, DOI 10.1111/j.1365-2559.2005.02141.x
   Mercatali L, 2006, ANN ONCOL, V17, P424, DOI 10.1093/annonc/mdj109
   Mikus P, 1996, J BIOL CHEM, V271, P10048, DOI 10.1074/jbc.271.17.10048
   Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135
   Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200
   Odero-Marah VA, 2003, CANCER BIOL THER, V2, P398, DOI 10.4161/cbt.2.4.471
   Ogasawara S, 2004, ONCOGENE, V23, P1117, DOI 10.1038/sj.onc.1207211
   PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832
   Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213
   REDDY GP, 2006, J CELL BIOCH
   Reis JS, 2002, VIRCHOWS ARCH, V441, P551, DOI 10.1007/s00428-002-0710-1
   ROSE SL, 2006, GYNECOL ONCOL   0130
   Sager R, 1996, CURR TOP MICROBIOL, V213, P51
   Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269
   Sato N, 2003, CANCER RES, V63, P4158
   Schedel J, 2004, ANN RHEUM DIS, V63, P1205, DOI 10.1136/ard.2003.006312
   Seftor REB, 1998, CANCER RES, V58, P5681
   Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066
   Sheng SJ, 2004, FRONT BIOSCI-LANDMRK, V9, P2733, DOI 10.2741/1432
   Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Sugimoto S, 2004, CANCER LETT, V203, P209, DOI 10.1016/j.canlet.2003.09.010
   Wada K, 2004, J INVEST DERMATOL, V122, P805, DOI 10.1111/j.0022-202X.2004.22308.x
   Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527
   Yang YY, 2006, CLIN EXP PHARMACOL P, V33, P557, DOI 10.1111/j.1440-1681.2006.04408.x
   Yatabe Y, 2004, ONCOGENE, V23, P4041, DOI 10.1038/sj.onc.1207557
   Yin SP, 2005, J BIOL CHEM, V280, P34985, DOI 10.1074/jbc.M503522200
   Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667
   Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zou ZQ, 2002, CLIN CANCER RES, V8, P1172
   Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 57
TC 104
Z9 120
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2006
VL 12
IS 24
BP 7279
EP 7283
DI 10.1158/1078-0432.CCR-06-1589
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 121NT
UT WOS:000243165000012
PM 17189399
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Bianchi, F
   Magnifico, A
   Olgiati, C
   Zanesi, N
   Pekarsky, Y
   Tagliabue, E
   Croce, CM
   Ménard, S
   Campiglio, M
AF Bianchi, Francesca
   Magnifico, Alessandra
   Olgiati, Clelia
   Zanesi, Nicola
   Pekarsky, Yuri
   Tagliabue, Elda
   Croce, Carlo Maria
   Menard, Sylvie
   Campiglio, Manuela
TI FHIT-proteasome degradation caused by mitogenic stimulation of the EGF
   receptor family in cancer cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Fhit phosphorylation proliferation; src; proteasome inhibition
ID GROWTH-FACTOR RECEPTOR; DEFICIENT MICE; BREAST-CANCER; C-SRC; GENE;
   EXPRESSION; APOPTOSIS; UBIQUITIN; THERAPY; PATHWAY
AB The tumor suppressor gene FHIT is inactivated by genetic and epigenetic changes in the majority of common human cancers. The human Fhit protein undergoes phosphorylation on tyrosine residue 114 by Src and related kinases both in vitro and in vivo. Src is a key cytoplasmic tyrosine kinase downstream to several growth factor receptors, including those of the EGF receptor family, which are overexpressed and activated in about one-third of human breast and ovarian carcinomas. However, the biological significance of Fhit phosphorylation by Src has remained elusive. In the present study, we demonstrate that FHIT acts as a checkpoint in cell proliferation mediated by activated tyrosine kinase receptors that recruit Src. Activation of EGF receptor family members induced Fhit phosphorylation by Src and the subsequent proteasome degradation of the phosphorylated Fhit protein. Indeed, the use of the Fhit mutant Y1 14F, which carries a phenylalanine instead of a tyrosine at position 114, unable to be phosphorylated on tyrosine 114 by Src, prevents Fhit degradation. Moreover, Fhit protein reduction is transient and occurs in a specific temporal window. During the signaling pathway of activated tyrosine kinase receptors, the phosphorylation of Fhit induces its degradation and the subsequent reduction in Fhit protein levels allows the transmission of the mitogenic signal; immediately thereafter, Fhit protein levels are restored. Such a scenario would suggest a key role for Fhit in the balance of proliferation/survival/apoptosis signals.
C1 Ohio State Univ, Dept Med Genet, Ctr Comprehens Canc, Columbus, OH 43201 USA.
   Ist Nazl Tumori, Mol Biol Unit, Dept Expt Oncol, I-20133 Milan, Italy.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; Fondazione IRCCS Istituto Nazionale Tumori
   Milan
RP Ménard, S (通讯作者)，Ist Nazl Tumori, Mol Biol Unit, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.
EM sylvie.menard@istitutotumori.mi.it;
   manuela.campiglio@istitutotumori.mi.it
RI menard, sylvie/C-7940-2011; Bianchi, Francesca/ABD-5518-2020; Tagliabue,
   Elda/B-9377-2017
OI Tagliabue, Elda/0000-0001-9877-2903; Bianchi,
   Francesca/0000-0001-5197-5279
CR Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205
   Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55
   Campiglio M, 1999, CANCER RES, V59, P3866
   Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200
   Cavazzoni A, 2004, ONCOGENE, V23, P8439, DOI 10.1038/sj.onc.1207847
   Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098
   Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5
   Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497
   Garrison PN, 2005, BIOCHEMISTRY-US, V44, P6286, DOI 10.1021/bi047670s
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912
   Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441
   MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981
   Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200
   Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081
   Ménard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484
   Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101
   Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2
   Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019
   Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100
   Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898
NR 25
TC 34
Z9 38
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 12
PY 2006
VL 103
IS 50
BP 18981
EP 18986
DI 10.1073/pnas.0605821103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 117PC
UT WOS:000242884200021
PM 17142325
OA Green Published
DA 2025-01-12
ER

PT J
AU Urakami, S
   Shiina, H
   Enokida, H
   Hirata, H
   Kawamoto, K
   Kawakami, T
   Kikuno, N
   Tanaka, Y
   Majid, S
   Nakagawa, M
   Igawa, M
   Dahiya, R
AF Urakami, Shinji
   Shiina, Hiroaki
   Enokida, Hideki
   Hirata, Hiroshi
   Kawamoto, Ken
   Kawakami, Toshifumi
   Kikuno, Nobuyuki
   Tanaka, Yuichiro
   Majid, Shahana
   Nakagawa, Masayuki
   Igawa, Mikio
   Dahiya, Rajvir
TI Wnt antagonist family genes as biomarkers for diagnosis, staging, and
   prognosis of renal cell carcinoma using tumor and serum DNA
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HUMAN PROSTATE-CANCER; PROMOTER-HYPERMETHYLATION; CPG HYPERMETHYLATION;
   BLADDER-CANCER; EPIGENETIC INACTIVATION; ABERRANT METHYLATION; SIGNALING
   PATHWAY; SUPPRESSOR GENES; MULTIPLE GENES; BREAST-CANCER
AB Purpose: We hypothesized that combined methylation analysis of Wnt antagonist genes could serve as a panel of biomarkers for diagnosis, staging, and prognosis in renal cell carcinoma (RCC).
   Experimental Design: Samples (n = 62) of RCC and corresponding normal renal tissue (NRT) were analyzed using methylation-specific PCR for methylation of six Wnt antagonist genes (sFRP-1, sFRP-2, sFRP-4, sFRP-5, Wif-1, and Dkk-3). To increase the sensitivity/specificity of RCC detection, the methylation score (M score) for multigene methylation analysis was developed. Receiver operator characteristic curve analysis was used to determine the optimal sensitivity/specificity of the M score. In addition, the M score was compared with the clinicopathologic outcome. Thirty-three serum DNA samples were also used to investigate the methylation status of Wnt antagonist genes.
   Results: The methylation levels of all Wnt antagonists were significantly higher in RCC than in NRT In multivariate regression analysis, the methylation level of sFRP-1 was a significant independent predictor of RCC, whereas for sFRP-2 and sFRP-4 there was a trend toward significance as independent predictors. The M score of Wnt antagonist genes was significantly higher in RCC than in NRT Overall, the M score had a sensitivity of 79.0% and a specificity of 75.8% (area under the curve, 0.808) as a diagnostic biomarker. In addition, the M score could significantly distinguish grade, pT category, M category, and overall survival of RCC patients. The M score was independent of age and gender in predicting overall survival by the Cox proportional hazards model. In RCC patients, 72.7% of the methylation-specific PCR results had identical methylation in samples of tumor and serum DNA. No serum DNA in normal controls showed aberrant methylation of the Wnt antagonist genes. In addition, the methylation status of Wnt antagonist genes in serum DNA was significantly correlated with tumor grade and stage.
   Conclusions: This is the first report showing that M score analysis of Wnt antagonist genes can serve as an excellent epigenetic biomarker panel for detection, staging, and prognosis of RCC using serum DNA.
C1 Vet Affairs Med Ctr, Urol Res Ctr, San Francisco, CA 94121 USA.
   Univ Calif San Francisco, San Francisco, CA 94121 USA.
   Shimane Univ, Dept Urol, Izumo, Shimane, Japan.
   Kagoshima Univ, Dept Urol, Kagoshima 890, Japan.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   University of California System; University of California San Francisco;
   Shimane University; Kagoshima University
RP Dahiya, R (通讯作者)，Vet Affairs Med Ctr, Urol Res Ctr, 112F,4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NCI NIH HHS [R01CA101844] Funding Source: Medline; NIA NIH HHS
   [R01AG21418] Funding Source: Medline; NIDDK NIH HHS [T32DK07790] Funding
   Source: Medline
CR Bastian PJ, 2005, CLIN CANCER RES, V11, P4037, DOI 10.1158/1078-0432.CCR-04-2446
   Battagli C, 2003, CANCER RES, V63, P8695
   Dahiya R, 1997, INT J CANCER, V72, P762, DOI 10.1002/(SICI)1097-0215(19970904)72:5<762::AID-IJC10>3.0.CO;2-B
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Enokida H, 2006, CANCER-AM CANCER SOC, V106, P79, DOI 10.1002/cncr.21577
   Enokida H, 2005, CLIN CANCER RES, V11, P6582, DOI 10.1158/1078-0432.CCR-05-0658
   Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 2001, CANCER RES, V61, P3225
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Hafez KS, 1997, J UROLOGY, V157, P2067, DOI 10.1016/S0022-5347(01)64675-5
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138
   Jahr S, 2001, CANCER RES, V61, P1659
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Kashyap MK, 2005, BIOMARKERS, V10, P258, DOI 10.1080/13547500500218534
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kawata N, 2005, UROLOGY, V66, P736, DOI 10.1016/j.urology.2005.04.044
   Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lerner SE, 1996, J UROLOGY, V155, P1868, DOI 10.1016/S0022-5347(01)66032-4
   McLaughlin JK, 2000, SEMIN ONCOL, V27, P115
   PORENA M, 1992, J CLIN ULTRASOUND, V20, P395, DOI 10.1002/jcu.1870200606
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Shiina H, 2005, CANCER RES, V65, P2130, DOI 10.1158/0008-5472.CAN-04-3398
   Silva JM, 1999, CANCER RES, V59, P3251
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Walther MM, 1998, J UROLOGY, V159, P718, DOI 10.1016/S0022-5347(01)63709-1
   Zou HZ, 2005, INT J CANCER, V116, P584, DOI 10.1002/ijc.21045
NR 35
TC 124
Z9 139
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 1
PY 2006
VL 12
IS 23
BP 6989
EP 6997
DI 10.1158/1078-0432.CCR-06-1194
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 114UL
UT WOS:000242691000018
PM 17145819
OA hybrid
DA 2025-01-12
ER

PT J
AU Anway, MD
   Leathers, C
   Skinner, MK
AF Anway, Matthew D.
   Leathers, Charles
   Skinner, Michael K.
TI Endocrine disruptor vinclozolin induced epigenetic transgenerational
   adult-onset disease
SO ENDOCRINOLOGY
LA English
DT Article
ID POSTNATAL TESTIS DEVELOPMENT; IN-UTERO EXPOSURE; ENVIRONMENTAL
   ANTIANDROGENS; BREAST-CANCER; RAT; CELLS; MICE; DIETHYLSTILBESTROL;
   EPIDEMIOLOGY; SENSITIVITY
AB The fetal basis of adult disease is poorly understood on a molecular level and cannot be solely attributed to genetic mutations or a single etiology. Embryonic exposure to environmental compounds has been shown to promote various disease states or lesions in the first generation (F1). The current study used the endocrine disruptor vinclozolin (antiandrogenic compound) in a transient embryonic exposure at the time of gonadal sex determination in rats. Adult animals from the F1 generation and all subsequent generations examined (F1-F4) developed a number of disease states or tissue abnormalities including prostate disease, kidney disease, immune system abnormalities, testis abnormalities, and tumor development ( e. g. breast). In addition, a number of blood abnormalities developed including hypercholesterolemia. The incidence or prevalence of these transgenerational disease states was high and consistent across all generations (F1-F4) and, based on data from a previous study, appears to be due in part to epigenetic alterations in the male germ line. The observations demonstrate that an environmental compound, endocrine disruptor, can induce transgenerational disease states or abnormalities, and this suggests a potential epigenetic etiology and molecular basis of adult onset disease.
C1 Washington State Univ, Sch Mol Biosci & Vet Microbiol & Pathol, Ctr Reprod Biol, Pullman, WA 99164 USA.
C3 Washington State University
RP Skinner, MK (通讯作者)，Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA.
EM skinner@mail.wsu.edu
RI Anway, Matthew/B-1480-2008
FU NIEHS NIH HHS [R01 ES012974] Funding Source: Medline
CR Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399
   BAUCK L, 1997, FERRETS RABBITS RODE, P297
   Bjornsson HT, 2004, TRENDS GENET, V20, P350, DOI 10.1016/j.tig.2004.06.009
   Blatt J, 2003, J PEDIAT HEMATOL ONC, V25, P635, DOI 10.1097/00043426-200308000-00009
   Boyle P, 2005, BREAST, V14, P429, DOI 10.1016/j.breast.2005.10.001
   Chang HS, 2006, ENDOCRINOLOGY, V147, P5524, DOI 10.1210/en.2006-0987
   Colbert NKW, 2005, ENVIRON HEALTH PERSP, V113, P700, DOI 10.1289/ehp.7509
   Corwin Elizabeth J, 2004, Biol Res Nurs, V6, P11, DOI 10.1177/1099800404264779
   Cupp AS, 2003, J ANDROL, V24, P736
   Dong H, 2004, BIOCHEMISTRY-US, V43, P15922, DOI 10.1021/bi0482194
   Drake AJ, 2005, AM J PHYSIOL-REG I, V288, pR34, DOI 10.1152/ajpregu.00106.2004
   Durcova-Hills G, 2001, DIFFERENTIATION, V68, P220, DOI 10.1046/j.1432-0436.2001.680409.x
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Euling SY, 2001, SCI TOTAL ENVIRON, V274, P103, DOI 10.1016/S0048-9697(01)00736-7
   Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025
   Foran CM, 2002, TOXICOL SCI, V68, P389, DOI 10.1093/toxsci/68.2.389
   Gill N, 2005, CHEST, V128, P2847, DOI 10.1378/chest.128.4.2847
   Gluckman PD, 2004, PEDIATR RES, V56, P311, DOI 10.1203/01.PDR.0000135998.08025.FB
   GOYAL HO, 1992, ANAT RECORD, V233, P53, DOI 10.1002/ar.1092330108
   Gray LE, 1999, TOXICOL IND HEALTH, V15, P48, DOI 10.1191/074823399678846646
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8
   Heindel JJ, 2005, BIRTH DEFECTS RES A, V73, P131, DOI 10.1002/bdra.20119
   Hellwig J, 2000, REGUL TOXICOL PHARM, V32, P42, DOI 10.1006/rtph.2000.1400
   Hotchkiss AK, 2002, ENVIRON HEALTH PERSP, V110, P435, DOI 10.1289/ehp.02110s3435
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Kaufman JM, 1997, BAILLIERE CLIN ENDOC, V11, P289, DOI 10.1016/S0950-351X(97)80302-3
   KELCE WR, 1994, TOXICOL APPL PHARM, V126, P276, DOI 10.1006/taap.1994.1117
   Ku JH, 2005, INT J ANDROL, V28, P317, DOI 10.1111/j.1365-2605.2005.00560.x
   MAJDIC G, 1995, J ENDOCRINOL, V147, P285, DOI 10.1677/joe.0.1470285
   Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655
   Percy D.H., 2001, PATHOLOGY LAB RODENT, V2nd
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Sajjad Y, 2004, HUM REPROD, V19, P1659, DOI 10.1093/humrep/deh295
   Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080
   Turner KJ, 2003, TOXICOL SCI, V74, P114, DOI 10.1093/toxsci/kfg096
   Uzumcu M, 2004, REPROD TOXICOL, V18, P765, DOI 10.1016/j.reprotox.2004.05.008
   Weiss JR, 2005, CANCER EPIDEM BIOMAR, V14, P20, DOI 10.1158/1055-9965.EPI-05-0414
   Wolf CJ, 2000, TOXICOL SCI, V55, P152, DOI 10.1093/toxsci/55.1.152
   Zambrano E, 2005, J PHYSIOL-LONDON, V566, P225, DOI 10.1113/jphysiol.2005.086462
NR 40
TC 388
Z9 438
U1 1
U2 54
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2006
VL 147
IS 12
BP 5515
EP 5523
DI 10.1210/en.2006-0640
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 105QK
UT WOS:000242047200004
PM 16973726
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Chen, Y
   Toland, AE
   McLennan, J
   Fridlyand, J
   Crawford, B
   Costello, JF
   Ziegler, JL
AF Chen, Ying
   Toland, Amanda E.
   McLennan, Jane
   Fridlyand, Jane
   Crawford, Beth
   Costello, Joseph F.
   Ziegler, John L.
TI Lack of germ-line promoter methylation in <i>BRCA1</i>-negative families
   with familial breast cancer
SO GENETIC TESTING
LA English
DT Article
ID BRCA1 PROMOTER; SPORADIC BREAST; DNA METHYLATION; HYPERMETHYLATION;
   EXPRESSION; REGION; TUMORS; GENE
AB Hereditary breast cancer accounts for about 10% of breast cancer in the United States, but high-penetrance, germ-line mutations in BRCA1 and BRCA2 are responsible for less than half of these high-risk families. Epigenetic modification of DNA by promoter methylation can result in a potentially heritable epimutation that silences the gene. Using a highly sensitive technique, we assayed the BRCA1 gene for promoter methylation among 41 BRCA1-and BRCA2-negative women whose personal and family histories indicated a high risk of BRCA mutations (median prior likelihood = 60%) using the BRCAPro model. DNA from 19 women who were "true negatives" for BRCA mutations served as controls. We found no evidence for promoter methylation among the high-risk women who tested negative for germ-line BRCA mutations. Thus, epimutation is an unlikely explanation for hereditary breast cancer in women who test negative for BRCA mutations.
C1 Univ Calif San Francisco, Ctr Comprehens Canc, Dept Neurol Surg, San Francisco, CA 94143 USA.
   Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Med, Div Human Genet, Columbus, OH 43210 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, Dept Med, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, Canc Risk Program, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; James Cancer Hospital & Solove Research Institute; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University; University of California System; University of
   California San Francisco; UCSF Medical Center; UCSF Helen Diller Family
   Comprehensive Cancer Center; University of California System; University
   of California San Francisco; UCSF Medical Center; UCSF Helen Diller
   Family Comprehensive Cancer Center; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF Helen
   Diller Family Comprehensive Cancer Center
RP Costello, JF (通讯作者)，Univ Calif San Francisco, Ctr Comprehens Canc, Dept Neurol Surg, 2340 Sutter St,Room N225, San Francisco, CA 94143 USA.
EM jcostello@cc.ucsf.edu
RI Roberts, Jayne/G-2458-2011; Toland, Amanda/E-4202-2011
OI Toland, Amanda/0000-0002-0271-1792
CR Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x
   Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
NR 14
TC 21
Z9 22
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1090-6576
J9 GENET TEST
JI Genet. Test.
PD DEC
PY 2006
VL 10
IS 4
BP 281
EP 284
DI 10.1089/gte.2006.10.281
PG 4
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 131TL
UT WOS:000243892800008
PM 17253935
DA 2025-01-12
ER

PT J
AU Menendez, JA
   Vellon, L
   Lupu, R
AF Menendez, Javier A.
   Vellon, Luciano
   Lupu, Ruth
TI DNA topoisomerase IIα (TOP2A) inhibitors up-regulate fatty acid synthase
   gene expression in SK-Br3 breast cancer cells:: <i>In vitro</i> evidence
   for a 'functional amplicon' involving FAS, Her-2/<i>neu</i> and TOP2A
   genes
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE fatty acid synthase; Her-2/neu; erbB-2; chemotherapy; topoisomerase II
   alpha; DNA replication; breast cancer
ID PHARMACOLOGICAL INHIBITION; ONCOGENIC ANTIGEN-519; SYNTHESIS PATHWAY;
   OVEREXPRESSION; MECHANISM; HYPERACTIVITY; AMPLIFICATION; ACTIVATION;
   CARCINOMA; APOPTOSIS
AB Fatty acid synthase (FAS), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in the de novo fatty acid biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas. We recently described that a molecular bi-directional cross-talk between FAS and the Her-2/neu (erbB-2) oncogene is taking place at the level of transcription, translation, and activity in breast cancer cells. Because Her-2/neu has been linked with altered sensitivity to cytotoxic drugs, we envisioned that FAS gene expression may represent a novel predictive molecular factor for breast cancer response to chemotherapy in a Her-2/neu-related manner. We herein evaluated whether chemotherapy-induced cell damage acts in an epigenetic fashion by inducing changes in the transcriptional activation of FAS gene in breast cancer cells. To evaluate this option, FAS- and Her-2/neu-overexpressing SK-Br3 breast cancer cells were transiently transfected with a FAS promoter-reporter construct (FAS-Luciferase) harboring all the elements necessary for high level expression in cancer cells. SK-Br3 cells cultured in the presence of topoisomerase Il alpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions. We failed to observe any significant activation of FAS promoter following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and vincristine. Moreover, the up-regulatory effects of TOP2A inhibitors on the transcriptional activation of FAS gene expression were not significantly decreased when the FAS promoter was damaged at the sterol regulatory element binding protein (SREBP)-binding site. Considering that FAS inhibition produces profound inhibition of DNA replication and S-phase progression in cancer cells, we finally asked whether a crosstalk between TOP2A and FAS could exhibit a Her-2/neu-related bi-directional nature. TOP2A protein levels were decreased during treatment with the anti-Her-2/neu antibody trastuzumab while, concomitantly, FAS promoter activity and FAS protein expression were significantly reduced. Of note, when the expression levels of TOP2A protein were analyzed following exposure of SK-Br3 cells to increasing concentrations of the novel slow-binding FAS inhibitor C75, a dose-dependent reduction in TOP2A expression was observed. Although FAS gene is not physically located in the Her-2/neu-TOP2A amplicon, our present findings strongly suggest that a tight functional association between FAS, Her-2/neu and TOP2A genes is taking place in a subset of breast carcinoma cells.
C1 Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA.
   Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Menendez, JA (通讯作者)，Evanston NW Healthcare Res Inst, Dept Med, 1001 Univ Pl, Evanston, IL 60201 USA.
EM jmenendez@enh.org; r-tupu@northwestern.edu
RI MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016
OI MENENDEZ MENENDEZ, JAVIER ABEL/0000-0001-8733-4561
CR Alò PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108
   Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K
   Baselga J, 1999, SEMIN ONCOL, V26, P78
   Di Leo Angelo, 2003, Clin Breast Cancer, V4, P179
   Harris LN, 2001, CLIN CANCER RES, V7, P1497
   Järvinen TAH, 2003, CYTOPATHOLOGY, V14, P309, DOI 10.1046/j.0956-5507.2003.00105.x
   Järvinen TAH, 2003, BREAST CANCER RES TR, V78, P299, DOI 10.1023/A:1023077507295
   Järvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8
   JAYAKUMAR A, 1994, GENOMICS, V23, P420, DOI 10.1006/geno.1994.1518
   JENSEN V, 1995, J PATHOL, V176, P343, DOI 10.1002/path.1711760405
   KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156
   KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379
   Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897
   Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X
   Kumar-Sinha C, 2003, CANCER RES, V63, P132
   Li JN, 2001, CANCER RES, V61, P1493
   MARTIN AV, 2002, P AM ASSOC CANC RES, V43, P951
   Ménard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779
   Menendez JA, 2004, MOL CARCINOGEN, V41, P164, DOI 10.1002/mc.20054
   Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101
   Menendez JA, 2004, ONCOL REP, V12, P411
   Menendez JA, 2004, INT J ONCOL, V24, P1369
   Menendez JA, 2004, BREAST CANCER RES TR, V84, P183, DOI 10.1023/B:BREA.0000018409.59448.60
   Menendez JA, 2004, INT J ONCOL, V24, P591
   MENENDEZ JA, IN PRESS INT J CANC
   Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115
   Osheroff N, 1998, BBA-GENE STRUCT EXPR, V1400, P1, DOI 10.1016/S0167-4781(98)00123-7
   Oskouian B, 2000, CANCER LETT, V149, P43, DOI 10.1016/S0304-3835(99)00342-0
   Pizer ES, 1998, CANCER RES, V58, P4611
   Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3
   Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975
   THOMPSON BJ, 1981, BIOCHIM BIOPHYS ACTA, V662, P125, DOI 10.1016/0005-2744(81)90232-1
   WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001
   Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831
   Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.3.CO;2-1
   Zhou WB, 2003, CANCER RES, V63, P7330
NR 36
TC 11
Z9 15
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2006
VL 18
IS 6
BP 1081
EP 1087
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 109MZ
UT WOS:000242313700009
PM 17089011
DA 2025-01-12
ER

PT J
AU Rivenbark, AG
   Jones, WD
   Coleman, WB
AF Rivenbark, Ashley G.
   Jones, Wendell D.
   Coleman, William B.
TI DNA methylation-dependent silencing of <i>CST6</i> in human breast
   cancer cell lines
SO LABORATORY INVESTIGATION
LA English
DT Article
DE bisulfite sequencing; breast cancer; CpG island; cystatin M; DNA
   methylation
ID HISTONE DEACETYLASE INHIBITION; CYSTATIN-M; CATHEPSIN-B; PROMOTER
   METHYLATION; GENE-EXPRESSION; IDENTIFICATION; LOCALIZATION; BINDING;
   DEMETHYLATION; SUPPRESSES
AB Cystatin M (CST6) is a candidate breast cancer tumor suppressor that is expressed in normal and premalignant breast epithelium, but not in metastatic breast cancer cell lines. CST6 is subject to epigenetic silencing in MCF-7 breast cancer cells related to methylation of the CpG island that encompasses the CST6 proximal promoter region and exon 1. In the current study, CST6 CpG island methylation and expression status was examined in a panel of breast cancer cell lines. Seven of 12 (58%) cell lines lack detectable expression of CST6 and treatment of these cells with 5-aza-2'-deoxycytidine resulted in a significant increase in CST6 expression, suggesting that the loss of expression may be related to methylation-dependent epigenetic silencing. Bisulfite sequencing of CST6 in a subset of breast cancer cell lines revealed CpG island hypermethylation in CST6-negative cells, and an absence of CpG island methylation in cells that express CST6. The extent of regional methylation was strongly associated with the lack of expression of CST6 among these cell lines. In particular, hypermethylation of the proximal promoter was significantly associated with CST6 gene silencing, and methylation of a number of individual CpGs was found to be statistically correlated with extinction of gene expression. These results establish a strong link between CST6 promoter hypermethylation and loss of CST6 expression in breast cancer cell lines, and suggest that methylation-dependent epigenetic silencing of CST6 may represent an important mechanism for loss of CST6 during breast carcinogenesis in vivo.
C1 Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Curriculum Toxicol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
   Express Analysis, Durham, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill
RP Coleman, WB (通讯作者)，Univ N Carolina, Sch Med, Dept Pathol & Lab Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM william.coleman@pathology.unc.edu
RI Jones, Wendell/JAC-5247-2023
OI Jones, Wendell/0000-0002-9676-5387
FU NCI NIH HHS [CA78343] Funding Source: Medline
CR ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Bender CM, 1998, CANCER RES, V58, P95
   Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Deng GR, 2004, CANCER RES, V64, P2692, DOI 10.1158/0008-5472.CAN-03-3000
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013
   Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270
   HACKETT AJ, 1977, JNCI-J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795
   Harder A, 2004, EUR J CANCER, V40, P2820, DOI 10.1016/j.ejca.2004.07.021
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619
   Keppler D, 2006, CANCER LETT, V235, P159, DOI 10.1016/j.canlet.2005.04.001
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   LASFARGUES EY, 1958, JNCI-J NATL CANCER I, V21, P1131
   LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O
   Lux W, 2005, J THROMB HAEMOST, V3, P1009, DOI 10.1111/j.1538-7836.2005.01276.x
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Nan XS, 1996, MOL CELL BIOL, V16, P414
   Paz MF, 2003, CANCER RES, V63, P1114
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Yano M, 2001, SURG TODAY, V31, P385, DOI 10.1007/s005950170126
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
   Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096
NR 36
TC 40
Z9 45
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD DEC
PY 2006
VL 86
IS 12
BP 1233
EP 1242
DI 10.1038/labinvest.3700485
PG 10
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 111HQ
UT WOS:000242442400004
PM 17043665
OA Bronze
DA 2025-01-12
ER

PT J
AU Sivertsen, S
   Hadar, R
   Elloul, S
   Vintman, L
   Bedrossian, C
   Reich, R
   Davidson, B
AF Sivertsen, Stine
   Hadar, Rivka
   Elloul, Sivan
   Vintman, Lina
   Bedrossian, Carlos
   Reich, Reuven
   Davidson, Ben
TI Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions
   is associated with matrix metalloproteinase, but not with cadherin
   expression
SO LUNG CANCER
LA English
DT Article
DE malignant mesothelioma; cadherins; matrix metalloproteinase; snail;
   effusions
ID FINGER TRANSCRIPTION FACTORS; OVARIAN-CARCINOMA CELLS; BREAST-CANCER
   PATIENTS; REPRESSES E-CADHERIN; N-CADHERIN; IMMUNOHISTOCHEMICAL
   DIAGNOSIS; DIFFERENTIAL EXPRESSION; PERITONEAL MESOTHELIOMA; MESENCHYMAL
   TRANSITIONS; ADHESION MOLECULES
AB Snail, Slug and Sip1 regulate cadherin and protease expression and mediate epithelial-mesenchymal. transition in cancer. We analyzed the expression of cadherins and matrix metalloproteinases (MMP) and their transcriptional regulators in malignant mesothelioma (MM). One hundred and ten MM specimens (86 solid, 24 effusions) and 10 non-malignant effusions with reactive mesothelial cells (RMC) were analyzed for E-cadherin, N-cadherin and P-cadherin protein expression using immunhistochemistry. MM effusions were further analyzed for expression of Snail, Slug, Sip1, E-cadherin, MMP-2, MMP-9, MT1 -MMP (MMP-14) and the MMP inhibitor TIMP-2, and for MMP-2 and MMP-9 activity using RT-PCR, Western blotting, immunhistochemistry and zymography. Results were analyzed for relationship with specimen type (biopsy versus effusion) and anatomic site (pleural versus peritonea[). E-cadherin, N-cadherin and P-cadherin expression was found in 69/110 (63%), 87/110 (79%) and 84/110 (76%) MM cases, respectively. Pleural and peritoneal MM showed comparable expression, but all three cadherins were upregulated in effusions compared to solid tumors (p < 0.001). RMC were uniformly negative for E-cadherin and N-cadherin, and showed P-cadherin expression in 7/10 specimens. Immunohistochemistry localized MMP-2, MMP-9 and TIMP-2 to MM cells in 11/15, 14/15 and 8/15 effusions, respectively. RT-PCR showed direct association between MMP-2 mRNA expression [eve( and the levels of MT1 -MMP (p = 0.027) and TIMP-2 (p = 0.011). Snail protein expression showed positive association with MT1 -MMP (p = 0.016) and TIMP-2 (p = 0.02) mRNA expression, but its expression was unrelated to MMP-2 and MMP-9 expression or activity. Snail, Slug and Sip1 levels did not show inverse association with E-cadherin levels. Our data show that E-cadherin and N-cadherin are selectively expressed in malignant mesothelial cells, and that P-cadherin and N-cadherin are expressed with similar frequency in MM. In agreement with our earlier data for ovarian carcinoma, cadherin expression is upregulated in effusions compared to solid lesions. The increased E-cadherin expression in effusions may be related to lack of negative regulation at the epigenetic level. The relationship between Snail and MMP in MM is uncertain at present. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Oslo, Radiumhosp Rikshosp Med Ctr, Dept Pathol, N-0310 Oslo, Norway.
   Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel.
   Norwegian Amer Hosp, Dept Pathol, Chicago, IL USA.
C3 University of Oslo; Hebrew University of Jerusalem
RP Davidson, B (通讯作者)，Univ Oslo, Radiumhosp Rikshosp Med Ctr, Dept Pathol, N-0310 Oslo, Norway.
EM ben.davidson@radiumhospitalet.no
CR Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Bedrossian CWM, 1998, DIAGN CYTOPATHOL, V19, P131, DOI 10.1002/(SICI)1097-0339(199808)19:2<131::AID-DC14>3.0.CO;2-G
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Britton M, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.30237
   Bukholm IK, 2000, J PATHOL, V190, P15
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Davidson B, 2004, DIAGN CYTOPATHOL, V31, P246, DOI 10.1002/dc.20133
   Davidson B, 2001, AM J SURG PATHOL, V25, P1405, DOI 10.1097/00000478-200111000-00008
   Davidson B, 2004, CLIN CANCER RES, V10, P7335, DOI 10.1158/1078-0432.CCR-04-0183
   Davidson B, 2000, J PATHOL, V192, P460
   DAVIDSON K, 2005, SERIALS LIBR, V49, P89, DOI DOI 10.1300/J123v49n01_04
   Edwards JG, 2003, BRIT J CANCER, V88, P1553, DOI 10.1038/sj.bjc.6600920
   Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946
   Eltabbakh GH, 1999, J SURG ONCOL, V70, P6, DOI 10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X
   Feldman AL, 2003, J CLIN ONCOL, V21, P4560, DOI 10.1200/JCO.2003.04.150
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083
   Han AC, 1997, HUM PATHOL, V28, P641, DOI 10.1016/S0046-8177(97)90171-4
   Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8
   Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017
   Kitazume H, 2000, CANCER CYTOPATHOL, V90, P55, DOI 10.1002/(SICI)1097-0142(20000225)90:1<55::AID-CNCR8>3.0.CO;2-P
   Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   OKA H, 1992, VIRCHOWS ARCH A, V421, P149, DOI 10.1007/BF01607048
   Ordóñez NG, 2003, HUM PATHOL, V34, P749, DOI 10.1016/S0046-8177(03)00285-5
   Ordóñez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001
   Ordóñez NG, 2000, AM J SURG PATHOL, V24, P598, DOI 10.1097/00000478-200004000-00016
   Ordóñez NG, 1999, HUM PATHOL, V30, P313, DOI 10.1016/S0046-8177(99)90011-4
   Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200
   REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618
   Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1
   Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1605::AID-CNCR28>3.0.CO;2-2
   SHIRAYOSHI Y, 1986, EMBO J, V5, P2485, DOI 10.1002/j.1460-2075.1986.tb04525.x
   SIVERTSEN S, IN PRESS ACTA CYTOL
   SOLER AP, 1995, HUM PATHOL, V26, P1363, DOI 10.1016/0046-8177(95)90302-X
   SPIRTAS R, 1988, INT J CANCER, V41, P525, DOI 10.1002/ijc.2910410409
   TAKEICHI M, 1988, DEVELOPMENT, V102, P639
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516
   Yokoyama K, 2003, INT J ONCOL, V22, P891
   Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2
NR 47
TC 37
Z9 47
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD DEC
PY 2006
VL 54
IS 3
BP 309
EP 317
DI 10.1016/j.lungcan.2006.08.010
PG 9
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 111AY
UT WOS:000242424200005
PM 16996643
DA 2025-01-12
ER

PT J
AU Fiskus, W
   Pranpat, M
   Balasis, M
   Herger, B
   Rao, R
   Chinnaiyan, A
   Atadja, P
   Bhalla, K
AF Fiskus, Warren
   Pranpat, Michael
   Balasis, Maria
   Herger, Bryan
   Rao, Rekha
   Chinnaiyan, Arul
   Atadja, Peter
   Bhalla, Kapil
TI Histone deacetylase inhibitors deplete enhancer of zeste 2 and
   associated polycomb repressive complex 2 proteins in human acute
   leukemia cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID AGGRESSIVE BREAST-CANCER; GROUP GENE EZH2; MOUSE DEVELOPMENT; BCR-ABL;
   TRANSCRIPTIONAL REPRESSION; METHYLTRANSFERASE ACTIVITY; MYELOID
   LEUKEMIAS; TARGET GENES; STEM-CELLS; METHYLATION
AB Human enhancer of zeste 2 (EZH2) protein belongs to the multiprotein polycomb repressive complex 2, which also includes suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED). The polycomb repressive complex 2 complex possesses histone methyltransferase activity mediated by the Su(var)3-9, enhancer of zeste, and trithorax domain of EZH2, which methylates histone H3 on lysine (K)-27 (H3K27). In the present studies, we determined that treatment with the hydroxamate histone deacetylase inhibitor LBH589 or LAQ824 depleted the protein levels of EZH2, SUZ12, and EED in the cultured (K562, U937, and HL-60) and primary human acute leukemia cells. This was associated with decreased levels of trimethylated and dimethylated H3K27, with concomitant depletion of the homeobox domain containing HOXA9 and of MEIS1 transcription factors. Knockdown of EZH2 by EZH2 small interfering RNA also depleted SUZ12 and EED, inhibited histone methyltransferase activity, and reduced trimethylated and dimethylated H3K27 levels, with a concomitant loss of clonogenic survival of the cultured acute myelogenous leukemia (AML) cells. EZH2 small interfering RNA sensitized the AML cells to LBH589-mediated depletion of EZH2, SUZ12, and EED; loss of clonogenic survival; and LBH589-induced differentiation of the AML cells. These findings support the rationale to test anti-EZH2 treatment combined with hydroxamate histone deacetylase inhibitors as an antileukemia epigenetic therapy, especially against AML with coexpression of EZH2, HOXA9, and MEIS1 genes.
C1 Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA.
   Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   Novartis Pharmaceut Inc, Cambridge, MA USA.
C3 University System of Georgia; Augusta University; University of Michigan
   System; University of Michigan; Novartis; Novartis USA
RP Bhalla, K (通讯作者)，Med Coll Georgia, Ctr Canc, 1120 15th St,CN2101A, Augusta, GA 30912 USA.
EM kbhalla@mcg.edu
RI Chinnaiyan, Arul/LCE-5288-2024
OI Balasis, Maria/0000-0003-1664-3222; Bhalla, Kapil/0000-0001-5209-5126
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199
   Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625
   Fiskus W, 2006, BLOOD, V108, P645, DOI 10.1182/blood-2005-11-4639
   George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413
   Guo F, 2005, CANCER RES, V65, P10536, DOI 10.1158/0008-5472.CAN-05-1799
   Hernández-Muñoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005
   Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508
   Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5
   Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350
   Lawrence HJ, 2005, LEUKEMIA, V19, P1328, DOI 10.1038/sj.leu.2403816
   Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330
   Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051
   Nimmanapalli R, 2003, CANCER RES, V63, P5126
   Nimmanapalli R, 2002, CANCER RES, V62, P5761
   O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001
   Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Pasini D, 2004, CELL CYCLE, V3, P396
   Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X
   Rössig L, 2005, J EXP MED, V201, P1825, DOI 10.1084/jem.20042097
   Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001
   Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x
   Wermuth PJ, 2005, BLOOD, V105, P1222, DOI 10.1182/blood-2004-03-0802
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 48
TC 101
Z9 121
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2006
VL 5
IS 12
BP 3096
EP 3104
DI 10.1158/1535-7163.MCT-06-0418
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 122UO
UT WOS:000243252800016
PM 17172412
DA 2025-01-12
ER

PT J
AU Leader, JE
   Wang, C
   Fu, M
   Pestell, RG
AF Leader, Jennifer E.
   Wang, Chenguang
   fu, Mao Fu
   Pestell, Richard G.
TI Epigenetic regulation of nuclear steroid receptors
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE nuclear receptors; androgen receptor; estrogen receptor; peroxisome
   proliferator activated receptor; epigenetics; histone
ID HUMAN BREAST-CANCER; GAMMA PPAR-GAMMA; ANDROGEN-RECEPTOR;
   ESTROGEN-RECEPTOR; PROSTATE-CANCER; TRANSCRIPTIONAL COACTIVATOR; HISTONE
   DEACETYLASE-1; BINDING-PROTEINS; GASTRIC-CANCER; CELL-LINES
AB Histone modifier proteins have come to the forefront in the study of gene regulation. It is now known that histone methyltransferases, acetytransferases, kinases, ubiquitinases, deacetylases and demethylases orchestrate expression of target genes by modifying both histone and non-histone proteins. The nuclear receptor (NR) superfamily govern such diverse biological processes as development, physiology and disease, including human cancer. The involvement of NR in complexes with coactivators and corepressors is necessary for regulation of target genes. This review focuses on the newly recognized interactions between the NR and histone modifying enzymes. In addition to regulating histones, the histone modifying proteins directly modify and thereby regulate NR activity. In the same manner that signaling platforms exist within the histone tails that are post-translationally processed by histone modifying proteins, cascades of post-translational modification have been identified within the NR that coordinate their activity. This review focuses on the regulation of the NR estrogen receptor (ER alpha), androgen receptor (AR) and peroxisome proliferator activated receptor-gamma (PPAR gamma), given their role in tumor onset and progression. (c) 2006 Elsevier Inc. All rights reserved.
C1 Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   Georgetown Univ, Interdisciplinary Program Tumor Biol, Washington, DC 20057 USA.
C3 Thomas Jefferson University; Thomas Jefferson University; Georgetown
   University
RP Pestell, RG (通讯作者)，Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.
EM Richard.Pestell@jefferson.edu
RI Pestell, Richard/JQW-3484-2023
FU NCI NIH HHS [R01 CA 70896, 1P30 CA 56036-08, R01 CA 75503, R01 CA
   107382] Funding Source: Medline
CR Beck S, 1999, NAT BIOTECHNOL, V17, P1144, DOI 10.1038/70651
   Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200
   CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   CORTON JC, 2000, ANN REV PHARM TOXICO, P40491
   Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126
   CUI Y, 2006, MOL ENOCRINOL
   Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447
   Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0
   CULIG Z, 1994, CANCER RES, V54, P5474
   Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200
   Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200
   Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200
   Fu MF, 2003, J STEROID BIOCHEM, V85, P133, DOI 10.1016/S0960-0760(03)00223-1
   Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003
   Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002
   Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5
   Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200
   Fuqua SAW, 2000, CANCER RES, V60, P4026
   Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305
   Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754
   HAMM JK, 1999, ANN NY ACAD SCI, V89, P2134
   Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540
   Heaney AP, 2003, J CLIN INVEST, V111, P1381, DOI 10.1172/JCI200316575
   Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070
   Holliday R, 1999, J THEOR BIOL, V200, P339, DOI 10.1006/jtbi.1999.0995
   Hortobagyi GN, 1998, CANCER, V83, P1, DOI 10.1002/(SICI)1097-0142(19980701)83:1<1::AID-CNCR1>3.0.CO;2-X
   Jackson L, 2003, GUT, V52, P1317, DOI 10.1136/gut.52.9.1317
   Jain S, 1998, AM J PATHOL, V153, P349, DOI 10.1016/S0002-9440(10)65577-0
   Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245
   Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674
   Kraus WL, 1999, MOL CELL BIOL, V19, P8123
   Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331
   Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200
   Lee SY, 2003, J IND ENG CHEM, V9, P9
   Lee Y, 1999, J CELL PHYSIOL, V179, P218, DOI 10.1002/(SICI)1097-4652(199905)179:2<218::AID-JCP12>3.0.CO;2-U
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   Nagamine M, 2003, CANCER SCI, V94, P338, DOI 10.1111/j.1349-7006.2003.tb01443.x
   Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012
   Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247
   Sato H, 2000, BRIT J CANCER, V83, P1394, DOI 10.1054/bjoc.2000.1457
   Segawa Y, 2002, PROSTATE, V51, P108, DOI 10.1002/pros.10058
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Takashima T, 2001, INT J ONCOL, V19, P465
   Tilley WD, 1996, CLIN CANCER RES, V2, P277
   Vottero A, 2006, J CLIN ENDOCR METAB, V91, P968, DOI 10.1210/jc.2005-2354
   Wang AG, 2005, BIOL PHARM BULL, V28, P1966, DOI 10.1248/bpb.28.1966
   Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003
   Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200
   Wang JC, 2001, COMP MATER SCI, V21, P9, DOI 10.1016/S0927-0256(00)00212-3
   Wang LX, 2005, DYES PIGMENTS, V65, P15, DOI 10.1016/j.dyepig.2004.05.012
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Yan PS, 2003, CANCER RES, V63, P6178
   YANG T, 2006, TRENDS ENDOCRINOL ME
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510
   Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488
NR 73
TC 69
Z9 77
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV 30
PY 2006
VL 72
IS 11
BP 1589
EP 1596
DI 10.1016/j.bcp.2006.05.024
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 109LR
UT WOS:000242310100026
PM 16844098
DA 2025-01-12
ER

PT J
AU Novak, P
   Jensen, T
   Oshiro, MM
   Wozniak, RJ
   Nouzova, M
   Watts, GS
   Klimecki, WT
   Kim, C
   Futscher, BW
AF Novak, Petr
   Jensen, Taylor
   Oshiro, Marc M.
   Wozniak, Ryan J.
   Nouzova, Marcella
   Watts, George S.
   Klimecki, Walter T.
   Kim, Christina
   Futscher, Bernard W.
TI Epigenetic inactivation of the <i>HOXA</i> gene cluster in breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID CPG-ISLAND; DNA METHYLATION; CELLS; DIFFERENTIATION; EXPRESSION;
   POLYCOMB; TUMORS; P53
AB Using an integrated approach of epigenomic scanning and gene expression profiling, we found aberrant methylation and epigenetic silencing of a small neighborhood of contiguous genes-the HOXA gene cluster in human breast cancer. The observed transcriptional repression was localized to similar to 100 kb of the HOXA gene cluster and did not extend to genes located upstream or downstream of the cluster. Bisulfite sequencing, chromatin immunoprecipitation, and quantitative reverse transcription-PCR analysis confirmed that the loss of expression of the HOXA gene cluster in human breast cancer is closely linked to aberrant DNA methylation and loss of permissive histone modifications in the region. Pharmacologic manipulations showed the importance of these aberrant epigenetic changes in gene silencing and support the hypothesis that aberrant DNA methylation is dominant to histone hypoacetylation. Overall, these data suggest that inactivation of the HOXA gene cluster in breast cancer may represent a new type of genomic lesion-epigenetic microdeletion. We predict that epigenetic microdeletions are common in human cancer and that they functionally resemble genetic microdeletions but are defined by epigenetic inactivation and transcriptional silencing of a relatively small set of contiguous genes along a chromosome, and that this type of genomic lesion is metastable and reversible in a classic epigenetic fashion.
C1 Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
   Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA.
   Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA.
   Univ Arizona, Ctr Surg, Tucson, AZ 85724 USA.
   AS CR, Inst Plant Mol Biol, Ceske Budejovice, Czech Republic.
C3 University of Arizona; Arizona Center Cancer Care; University of
   Arizona; University of Arizona; University of Arizona; Czech Academy of
   Sciences
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.
EM bfutscher@azee.arizona.edu
RI Nouzova, Marcela/AAK-8609-2021; Novak, Petr/A-3059-2013
OI Nouzova, Marcela/0000-0002-4562-1383; Novak, Petr/0000-0002-5068-9681
FU NCI NIH HHS [P30 CA023074, P30CA023074, R33CA091351, R01CA65662,
   CA09213] Funding Source: Medline; NIEHS NIH HHS [P30ES06694, P30
   ES006694, ES007091] Funding Source: Medline
CR Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Wu ZJ, 2004, NAT BIOTECHNOL, V22, P656, DOI 10.1038/nbt0604-656b
   Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007
NR 20
TC 96
Z9 114
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2006
VL 66
IS 22
BP 10664
EP 10670
DI 10.1158/0008-5472.CAN-06-2761
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 108UJ
UT WOS:000242264400006
PM 17090521
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Yan, PS
   Venkataramu, C
   Ibrahim, A
   Liu, JC
   Shen, RLZ
   Diaz, NM
   Centeno, B
   Weber, F
   Leu, YW
   Shapiro, CL
   Eng, C
   Yeatman, TJ
   Huang, THM
AF Yan, Pearlly S.
   Venkataramu, Chinnambally
   Ibrahim, Ashraf
   Liu, Joseph C.
   Shen, Rulong Z.
   Diaz, Nils M.
   Centeno, Barbara
   Weber, Frank
   Leu, Yu-Wei
   Shapiro, Charles L.
   Eng, Charis
   Yeatman, Timothy J.
   Huang, Tim H. -M.
TI Mapping geographic zones of cancer risk with epigenetic biomarkers in
   normal breast tissue
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CPG ISLAND MICROARRAYS; DNA METHYLATION; ALLELIC IMBALANCE; PROMOTER
   HYPERMETHYLATION; LOCAL RECURRENCE; COWDEN-DISEASE; LUNG-CANCER; EARLY
   EVENT; DE-NOVO; CARCINOMAS
AB Purpose: Genetic alterations were previously identified in normal epithelia adjacent to invasive cancers. The aim of this study was to determine DNA methylation in histologically normal tissues from multiple geographic zones adjacent to primary breast tumors.
   Experimental Design: First, methylation status of a 4-kb region of RASSF1A promoter was interrogated using oligonucleoticle-based microarray in 144 samples (primary tumors, 47; adjacent normals, 69; reduction mammoplasty tissues, 28). Second, allelic imbalance (Al)/loss of heterozygosity (LOH) surrounding RASSF1A promoter were analyzed in 30 samples (tumors, 8; adjacent normals, 22). Third, global methylation screening of 49 samples (tumors, 12; adjacent normals, 25; reduction mammoplasty, 12) was done by differential methylation hybridization. Real-time quantitative methylation-specific PCR was used to validate the microarray findings.
   Results: DNA methylation in the core RASSF1A promoter was low in reduction mammoplasty tissues (P = 0.0001) when compared with primary tumors. The adjacent normals had an intermediate level of methylation. The regions surrounding the core were highly methylated in all sample types. Microsatellite markers showed Al/LOH in tumors and some of the adjacent normals. Concurrent Al/LOH and DNA methylation in RASSF1A promoter occurred in two of six tumors. Global methylation screening uncovered genes more methylated in adjacent normals than in reduction mammoplasty tissues. The methylation status of four genes was confirmed by quantitative methylation-specific PCR.
   Conclusions: Our findings suggest a field of methylation changes extending as far as 4 cm from primary tumors. These frequent alterations may explain why normal tissues are at risk for local recurrence and are useful in disease prognostication.
C1 Ohio State Univ, Human Canc Genet Program, Div Human Canc Genet, Columbus, OH 43210 USA.
   Ohio State Univ, Ctr Comprehens Canc, Dept Hematol & Oncol, Columbus, OH 43210 USA.
   Ohio State Univ, Coll Med & Publ Hlth, Dept Pathol, Columbus, OH 43210 USA.
   H Lee Moffit Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL USA.
   Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England.
   Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan.
   Natl Chung Cheng Univ, Inst Mol Biol, Chiayi, Taiwan.
   Cleveland Clin Fdn, Genome Med Inst, Cleveland, OH 44195 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; University
   of Cambridge; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; National Chung Cheng University; National Chung
   Cheng University; Cleveland Clinic Foundation
RP Huang, THM (通讯作者)，Ohio State Univ, Human Canc Genet Program, Div Human Canc Genet, Room 514,420 W 12th Ave, Columbus, OH 43210 USA.
EM tim.huang@osumc.edu
RI Yan, Pearlly/E-4339-2011; Yeatman, Timothy/LJK-6730-2024; Shen,
   Rulong/E-4079-2011; Weber, Frank/A-1883-2012
OI Weber, Frank/0000-0002-0995-667X; Eng, Charis/0000-0002-3693-5145
FU NCI NIH HHS [P30 CA16058, R33 CA 094441, R01 CA098522-03, R01 CA069065,
   U54 CA11300] Funding Source: Medline
CR Aldred MA, 2003, CANCER RES, V63, P2864
   Ballestar E, 2005, PROG MOLEC, V38, P169
   Belinsky SA, 2005, CARCINOGENESIS, V26, P1481, DOI 10.1093/carcin/bgi020
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287
   Boehm D, 2004, HUM MUTAT, V23, P368, DOI 10.1002/humu.20011
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Ellsworth DL, 2004, LANCET ONCOL, V5, P753, DOI 10.1016/S1470-2045(04)01653-5
   Ellsworth DL, 2004, BREAST CANCER RES TR, V88, P131, DOI 10.1007/s10549-004-1424-7
   Ellsworth DL, 2004, ANN SURG ONCOL, V11, P861, DOI 10.1245/ASO.2004.03.024
   Ellsworth RE, 2005, MOL CANCER RES, V3, P71, DOI 10.1158/1541-7786.MCR-04-0180
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Fredriksson I, 2003, BRIT J SURG, V90, P1093, DOI 10.1002/bjs.4206
   Gaston SM, 2005, NAT MED, V11, P95, DOI 10.1038/nm1169
   Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801
   Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582
   Holst CR, 2003, CANCER RES, V63, P1596
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Kaplan J, 2003, J AM COLL SURGEONS, V197, P726, DOI 10.1016/j.jamcollsurg.2003.06.003
   Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907
   Larson PS, 1998, AM J PATHOL, V152, P1591
   Larson PS, 2002, AM J PATHOL, V161, P283, DOI 10.1016/S0002-9440(10)64180-6
   Lehmann U, 2005, CLIN CANCER RES, V11, P3654, DOI 10.1158/1078-0432.CCR-04-2462
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Li Z, 2002, CANCER RES, V62, P1000
   Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639
   Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096
   Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Norton L, 2005, ONCOLOGIST, V10, P370, DOI 10.1634/theoncologist.10-6-370
   Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488
   Pieper U, 2002, BIOCHEMISTRY-US, V41, P5245, DOI 10.1021/bi015687u
   Santoro R, 2005, MOL CELL BIOL, V25, P2539, DOI 10.1128/MCB.25.7.2539-2546.2005
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Thakur N, 2003, J BIOL CHEM, V278, P9514, DOI 10.1074/jbc.M212203200
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Wade PA, 2005, NAT GENET, V37, P212, DOI 10.1038/ng0305-212
   Widschwendter M, 1997, CANCER RES, V57, P4158
   Yan Pearlly S, 2004, Methods Mol Biol, V287, P251
   Yan Pearlly S, 2002, Methods Mol Biol, V200, P87
   Yan PS, 2001, CANCER RES, V61, P8375
   Yan PS, 2003, CANCER RES, V63, P6178
NR 46
TC 161
Z9 177
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD NOV 15
PY 2006
VL 12
IS 22
BP 6626
EP 6636
DI 10.1158/1078-0432.CCR-06-0467
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 108TY
UT WOS:000242263300007
PM 17121881
OA Green Submitted
DA 2025-01-12
ER

PT J
AU van den Boom, J
   Wolter, M
   Blaschke, B
   Knobbe, CB
   Reifenberger, G
AF van den Boom, Joerg
   Wolter, Marietta
   Blaschke, Britta
   Knobbe, Christiane B.
   Reifenberger, Guido
TI Identification of novel genes associated with astrocytoma progression
   using suppression subtractive hybridization and real-time reverse
   transcription-polymerase chain reaction
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE adhesion molecule on glia; astrocytoma; glioblastoma; suppression
   subtractive hybridization; tumor progression
ID RENAL-CELL CARCINOMA; APOLIPOPROTEIN-D; ADHESION MOLECULE; DIFFERENTIAL
   EXPRESSION; BREAST-CANCER; MESSENGER-RNA; LOW-GRADE; AMOG; NA,K-ATPASE;
   PATHWAYS
AB To identify novel genes involved in glioma progression we performed suppression subtractive hybridization combined with cDNA array analysis on 4 patients with primary low-grade gliomas of World Health Organization (WHO) grade II that recurred as secondary glioblastomas (WHO grade IV). Eight genes showing differential expression between primary and recurrent tumors in 3 of the 4 patients were selected for further analysis using real-time reverse transcription on a series of 10 pairs of primary low-grade and recurrent high-grade gliomas as well as 42 astrocytic gliomas of different WHO grades. These analyses revealed that 5 genes, i.e., AMOG (ATP1B2, 17p13.1), APOD (3q26.2-qter), DMXL1 (5q23.1) DRR1 (TU3A, 3p14.2) and PSD3 (KIAA09428/HCA67/EFA6R, 8p22), were expressed at significantly lower levels in secondary glioblastomas as compared to diffuse astrocytomas of WHO grade II. In addition, AMOG, DRR1 and PSD3 transcript levels were significantly lower in primary glioblastomas than in diffuse astrocytomas. Treatment of glioma cell lines with 5-aza-2 '-deoxycytidine and trichostatin A resulted in increased expression of AMOG and APOD transcripts. Sequencing of sodium bisulfite-modified DNA demonstrated AMOG promoter hypermethylation in the glioma cell lines and 1 primary anaplastic astrocytoma with low AMOG expression. Taken together, we identified interesting novel candidate genes that likely contribute to glioma progression and provide first evidence for a role of epigenetic silencing of AMOG in malignant glioma cells. (c) 2006 Wiley-Liss, Inc.
C1 Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany.
C3 Heinrich Heine University Dusseldorf
RP Reifenberger, G (通讯作者)，Univ Dusseldorf, Dept Neuropathol, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM reifenberger@med.uni-duesseldorf.de
RI Reifenberger, Guido/AAE-3599-2019; Knobbe-Thomsen,
   Christiane/D-3116-2019
OI Knobbe-Thomsen, Christiane/0000-0003-1231-0076
CR ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587
   Chen GA, 2002, CLIN CANCER RES, V8, P2298
   Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025
   DIEZITZA I, 1994, AM J PATHOL, V144, P310
   Do Carmo S, 2002, J BIOL CHEM, V277, P5514, DOI 10.1074/jbc.M105057200
   Dropcho EJ, 1996, NEUROLOGY, V47, P684, DOI 10.1212/WNL.47.3.684
   GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165
   Gutmann DH, 2002, ANN NEUROL, V51, P393, DOI 10.1002/ana.10145
   Hemberger M, 2001, P NATL ACAD SCI USA, V98, P13126, DOI 10.1073/pnas.231396598
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010
   Hunter S, 2005, HUM PATHOL, V36, P987, DOI 10.1016/j.humpath.2005.06.018
   Hunter S, 2002, J NEUROPATH EXP NEUR, V61, P275, DOI 10.1093/jnen/61.3.275
   Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2
   Kalman J, 2000, NEUROL RES, V22, P330
   KLEHUES P, 1999, NEHROONCOL, V1, P44
   KLEIHUES P, 2000, WHO CLASSIFICATION T, P22
   Kraemer C, 2000, GENOMICS, V64, P97, DOI 10.1006/geno.1999.6050
   Lecuona E, 1996, BRAIN RES BULL, V40, P167, DOI 10.1016/0361-9230(96)00042-1
   Li C, 2006, PROTEOMICS, V6, P547, DOI 10.1002/pmic.200500256
   Navarro A, 2004, J HISTOCHEM CYTOCHEM, V52, P1031, DOI 10.1369/jhc.3a6213.2004
   Ogawa K, 2005, INT J ONCOL, V27, P417
   Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337
   PAGLIUSI S, 1989, J NEUROSCI RES, V22, P113, DOI 10.1002/jnr.490220202
   Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538
   PROVOST PR, 1991, FEBS LETT, V290, P139, DOI 10.1016/0014-5793(91)81244-3
   Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X
   Reifenberger G, 2004, J MOL MED, V82, P656, DOI 10.1007/s00109-004-0564-x
   Scheidenhelm DK, 2005, MOL CELL BIOL, V25, P3151, DOI 10.1128/MCB.25.8.3151-3162.2005
   Senner V, 2003, NEUROPATH APPL NEURO, V29, P370, DOI 10.1046/j.1365-2990.2003.00473.x
   SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x
   van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3
   Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6
   Wang Y, 2002, J IMMUNOL, V169, P1102, DOI 10.4049/jimmunol.169.2.1102
   Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452
   Zhang DH, 2005, MOL CELL PROTEOMICS, V4, P1686, DOI 10.1074/mcp.M400221-MCP200
NR 36
TC 54
Z9 64
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2006
VL 119
IS 10
BP 2330
EP 2338
DI 10.1002/ijc.22108
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 094EM
UT WOS:000241222300011
PM 16865689
OA Bronze
DA 2025-01-12
ER

PT J
AU Tan, SH
   Ida, H
   Goh, BC
   Hsieh, W
   Loh, M
   Ito, Y
AF Tan, Sing-Huang
   Ida, Hiroshi
   Goh, Boon-Cher
   Hsieh, Wenson
   Loh, Marie
   Ito, Yoshiaki
TI Analyses of promoter hypermethylation for <i>RUNX3</i> and other tumor
   suppressor genes in nasopharyngeal carcinoma
SO ANTICANCER RESEARCH
LA English
DT Article
DE hypermethylation; RUNX3; nasopharyngeal cancer
ID CPG-ISLAND METHYLATION; E-CADHERIN; EPIGENETIC INACTIVATION;
   MICROSATELLITE INSTABILITY; HEPATOCELLULAR-CARCINOMA; PROTEIN
   MISLOCALIZATION; GASTRIC-CARCINOMA; MULTIPLE GENES; BREAST-CANCER;
   IN-SITU
AB Background: Aberrant methylation of cytosine in promoter CpG islands is a recognized contributory process to carcinogenesis. This study explores the methylation profile of RUNX3 in combination with p16, RASSF1A, CDH1 and hMLH1 in nasopharyngeal carcinoma (NPC) patients. Materials and Methods: Genomic DNA was extracted from 19 fresh frozen NPC biopsies, which were then subjected to bisulfite conversion and methylation-specific PCR for analysis of promoter hypermethylation for the five respective genes. Three cell lines, SNU1, RKO and LS174T, were used as controls. Results: The incidences of promoter methylation were as follows: RUNX3 0/19 (0%), p16 6/19 (32%), RASSF1A 13/19 (68%), CDH1 9/19 (47%) and hMLH1 4/19 (21%). Ninety-five percent of the tumor specimens displayed aberrant methylation in at least one of these genes. No significant correlation between methylation status of these genes and clinical parameters was found. Conclusion: Methylation of multiple genes is involved in critical pathways for cancer development in NPC. Promoter hypermethylation for RUNX3 was, however, not present.
C1 Inst Mol & Cell Biol, Mol Oncol RUNX Lab, Proteos 138673, Singapore.
   Johns Hopkins Singapore, Div Biomed Sci, Nanos 138669, Singapore.
   Bioinformat Inst, Singapore 138671, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Institute of
   Molecular & Cell Biology (IMCB); Johns Hopkins University; Johns Hopkins
   Medicine; Agency for Science Technology & Research (A*STAR); A*STAR -
   Bioinformatics Institute (BII)
RP Ito, Y (通讯作者)，Inst Mol & Cell Biol, Mol Oncol RUNX Lab, 61 Biopolis Dr, Proteos 138673, Singapore.
EM itoy@imcb.a-star.edu.sg
OI Loh, Marie/0000-0003-3626-8466
CR Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chan ATC, 2004, SEMIN ONCOL, V31, P794, DOI 10.1053/j.seminoncol.2004.09.008
   Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HO JH, 1978, IARC SCI PUBL, P99
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Horikawa Y, 2003, J UROLOGY, V169, P1541, DOI 10.1097/01.ju.0000046242.55722.1c
   Imamura Y, 2005, ANTICANCER RES, V25, P2627
   Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kao RH, 2002, ANTICANCER RES, V22, P4109
   Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538
   Kwong J, 2002, CLIN CANCER RES, V8, P131
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   LEE J, 1997, CARBOHYDR LETT, V2, P307
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Lo KW, 1996, CANCER RES, V56, P2721
   Lo KW, 2001, CANCER RES, V61, P3877
   Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1
   Oue N, 2003, CANCER SCI, V94, P901, DOI 10.1111/j.1349-7006.2003.tb01373.x
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   SALTOTELLEZ M, 2006, ONCOGENE
   Sato K, 2006, ONCOL REP, V15, P129
   SEOW A, 2004, 6 SING CANC REG
   Shanmugaratnam K, 1978, IARC Sci Publ, P3
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tsao SW, 2003, EUR J CANCER, V39, P524, DOI 10.1016/S0959-8049(02)00494-X
   Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395
   Wong TS, 2003, INT J ONCOL, V22, P869
   Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x
   Zheng J, 2000, Zhonghua Er Bi Yan Hou Ke Za Zhi, V35, P464
   Zheng Z, 1999, HUM PATHOL, V30, P458, DOI 10.1016/S0046-8177(99)90123-5
NR 45
TC 16
Z9 18
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD NOV-DEC
PY 2006
VL 26
IS 6B
BP 4287
EP 4292
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 119UU
UT WOS:000243040300028
PM 17201146
DA 2025-01-12
ER

PT J
AU Montero, AJ
   Díaz-Montero, CM
   Mao, L
   Youssef, EM
   Estecio, M
   Shen, LL
   Issa, JPJ
AF Montero, Alberto J.
   Marcela Diaz-Montero, C.
   Mao, Li
   Youssef, Emile M.
   Estecio, Marcos
   Shen, Lanlan
   Issa, Jean-Pierre J.
TI Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE EGFR; epidermal growth factor receptor; methylation; cancer; decitabine;
   gefitinib; hypomethylating agents
ID EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR EGFR; BREAST-CANCER;
   DINUCLEOTIDE REPEAT; TAMOXIFEN RESISTANCE; METHYLATION ANALYSIS;
   COLORECTAL TUMORS; DNA METHYLATION; FOLIC-ACID; INTRON 1
AB The epidermal growth factor receptor ( EGFR) is a member of the HER/ERB-B family of transmembrane receptor kinases. Overexpression of EGFR confers advantages in cell proliferation, survival, and migration and correlates with decreased survival in multiple solid tumors. However, a proportion of these malignancies have little or no expression of EGFR. CpG island hypermethylation and associated transcriptional silencing are common in solid tumors. The methylation status of the EGFR CpG island was examined in a series of cell lines and tissues. Dense EGFR methylation (90%) was found in the breast cancer cell line CAMA1, and a moderate degree of methylation ( 30 - 50%) was observed in the breast cancer cell lines MB435 and MB453. Transcriptional silencing of EGFR in these cell lines closely correlated with methylation. By contrast, no methylation of the HER-2/ neu CpG island was detected. EGFR hypermethylation was also found in a subset of unselected primary breast (20%), head and neck squamous cell carcinoma (35%), and lung tumors (11%). Treatment with decitabine resulted in the reexpression of EGFR in CAMA1 and MB453. Both cell lines are relatively resistant to killing by the EGFR inhibitor gefitinib. However, after cotreatment with decitabine and gefitinib, a significant effect on the induction of apoptosis was observed. In conclusion, EGFR is hypermethylated and silenced in a subset of solid tumor cell lines and primary tumor specimens, and cotreatment with decitabine and gefitinib has an additive effect only in EGFR methylated breast cancer cell lines.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
   Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
   Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA.
   Novartis Pharmaceut, Early Clin Dev, Oncol Business Unit, Florham Pk, NJ USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Medical University of South
   Carolina; Medical University of South Carolina; Novartis; Novartis USA
RP Issa, JPJ (通讯作者)，Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM jpissa@mdanderson.org
RI Mao, Li/C-7570-2011; Montero, Alberto/AAF-9565-2021
OI Shen, Lanlan/0000-0002-1532-5807; Estecio, Marcos/0000-0002-6874-7413;
   Issa, Jean-Pierre/0000-0003-2258-5030
FU NCI NIH HHS [P50CA100632, R33CA89837, R01CA105346, CA16672] Funding
   Source: Medline
CR Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945
   Buerger H, 2000, CANCER RES, V60, P854
   Buerger H, 2004, J PATHOL, V203, P545, DOI 10.1002/path.1542
   Chi D. D., 1992, Human Molecular Genetics, V1, P135, DOI 10.1093/hmg/1.2.135
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Devereux TR, 1999, CANCER RES, V59, P6087
   Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176
   Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069
   Hiscox S, 2004, CLIN EXP METASTAS, V21, P201, DOI 10.1023/B:CLIN.0000037697.76011.1d
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499
   Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306
   Li B, 2003, CANCER RES, V63, P7443
   Liu WQ, 2003, CLIN CANCER RES, V9, P1009
   Majumdar APN, 2004, FRONT BIOSCI-LANDMRK, V9, P2725, DOI 10.2741/1431
   Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504
   MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722
   Nagothu KK, 2004, AM J PHYSIOL-GASTR L, V287, pG541, DOI 10.1152/ajpgi.00365.2003
   Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3
   Ogino S, 2005, CLIN CANCER RES, V11, P6650, DOI 10.1158/1078-0432.CCR-05-0738
   Ooi A, 2004, MODERN PATHOL, V17, P895, DOI 10.1038/modpathol.3800137
   RIMAWI MFW, 2006, J CLIN ONCOL, P513
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Scartozzi M, 2004, J CLIN ONCOL, V22, P4772, DOI 10.1200/JCO.2004.00.117
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Toyota M, 2000, CANCER RES, V60, P4044
   Treeck O, 2003, BREAST CANCER RES TR, V80, P155, DOI 10.1023/A:1024502107690
   Walker RA, 1999, BREAST CANCER RES TR, V53, P167, DOI 10.1023/A:1006194700667
   Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X
   XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308
   Yano S, 2003, ANTICANCER RES, V23, P3639
   Yarden RI, 2001, J CELL BIOCHEM, P232
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
NR 34
TC 56
Z9 61
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD NOV
PY 2006
VL 5
IS 11
BP 1494
EP 1501
DI 10.4161/cbt.5.11.3299
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 122WA
UT WOS:000243256800015
PM 17369752
OA Bronze
DA 2025-01-12
ER

PT J
AU Hurtubise, A
   Momparler, RL
AF Hurtubise, Annie
   Momparler, Richard L.
TI Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action
   of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE 5-Aza-2'-deoxycytidine; LAQ824; histone deacetylase inhibitor; DNA
   methylation; dose-schedule; breast cancer
ID DNA METHYLATION; 5-AZA-2'-DEOXYCYTIDINE DECITABINE; PHENYLBUTYRATE;
   PHARMACOLOGY; ACETYLATION; COMBINATION; LEUKEMIA; THERAPY; CANCER; GENES
AB Purpose: Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs silenced by aberrant DNA methylation. LAQ824 (LAQ) is a novel inhibitor of histone deacetylase (HDAC) that shows antineoplastic activity and can activate genes that produce cell cycle arrest. Both 5AZA-CdR and LAQ as single agents are currently under clinical investigation in patients with cancer. Previous reports indicate that the "cross-talk" between inhibitors of DNA methylation and HDAC can result in a synergistic activation of silent TSGs. These observations suggest that combination of these inhibitors may be an effective form of epigenetic therapy for breast cancer. The objective of our study was to determine if the combination of 5AZA-CdR and LAQ would show additive or synergistic antineoplastic activity on human MDA-MB-231 and MCF-7 breast carcinoma cells. The antineoplastic activity of these agents was evaluated by clonogenic assay and inhibition of DNA synthesis. Results: The combination produced greater antineoplastic activity for the MDA-MB-231 tumor cells than either agent alone. For the MCF-7 tumor cells, there were signs of antagonism between 5AZA-CdR and LAQ when administered simultaneously. When a sequential schedule (first 5AZA-CdR followed by LAQ) was used, there were no signs of antagonism of the antineoplastic action for the MCF-7 tumor cells. The mechanism of this interaction is probably due to the reduction of progression of MCF-7 tumor cells into S phase by LAQ. This would interfere with the antineoplastic action of 5AZA-CdR, since it is an S phase specific agent. Conclusions: These studies demonstrated the importance of the schedule of administration of 5AZA-CdR and LAQ and may have application for future clinical trials on the treatment of breast cancer with these agents.
C1 Univ Montreal, Hop St Justine, Ctr Rech Pediat, Dept Pharmacol,Serv Hematol Oncol, Montreal, PQ H3T 1C5, Canada.
C3 Universite de Montreal
RP Momparler, RL (通讯作者)，Univ Montreal, Hop St Justine, Ctr Rech Pediat, Dept Pharmacol,Serv Hematol Oncol, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM richard.l.momparler@umontreal.ca
RI Momparler, Richard/AAU-6945-2020
OI Momparler, Richard L/0000-0002-9186-6269
CR Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4
   Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043
   Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Garcia-Manero G, 2005, CANCER INVEST, V23, P635, DOI 10.1080/07357900500283119
   Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   Maslak P, 2006, LEUKEMIA, V20, P212, DOI 10.1038/sj.leu.2404050
   MOMPARLER RL, 1984, CANCER CHEMOTH PHARM, V13, P191, DOI 10.1007/BF00269027
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Momparler RL, 2001, LUNG CANCER, V34, pS111
   Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   Remiszewski SW, 2003, J MED CHEM, V46, P4609, DOI 10.1021/jm030235w
   RICHEL DJ, 1991, BRIT J CANCER, V64, P144, DOI 10.1038/bjc.1991.258
   RIVARD GE, 1981, LEUKEMIA RES, V5, P453, DOI 10.1016/0145-2126(81)90116-8
   Rudek MA, 2005, J CLIN ONCOL, V23, P3906, DOI 10.1200/JCO.2005.07.450
   Sanchez-Gonzalez Blanca, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P937
   Schrump David S, 2002, Clin Lung Cancer, V4, P186, DOI 10.3816/CLC.2002.n.027
   Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371
NR 25
TC 35
Z9 43
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD NOV
PY 2006
VL 58
IS 5
BP 618
EP 625
DI 10.1007/s00280-006-0225-6
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 069YI
UT WOS:000239485000008
PM 16783580
DA 2025-01-12
ER

PT J
AU Bistulfi, G
   Pozzi, S
   Ren, MQ
   Rossetti, S
   Sacchi, N
AF Bistulfi, Gaia
   Pozzi, Silvia
   Ren, MingQiang
   Rossetti, Stefano
   Sacchi, Nicoletta
TI A repressive epigenetic domino effect confers susceptibility to breast
   epithelial cell transformation: Implications for predicting breast
   cancer risk
SO CANCER RESEARCH
LA English
DT Article
ID RETINOIC ACID RECEPTOR; RESPONSE ELEMENT; BINDING-PROTEINS;
   X-CHROMOSOME; EXPRESSION; MORPHOGENESIS; PROMOTER; GENE; ESTERIFICATION;
   SOMITOGENESIS
AB Retinoic acid (RA) is a master epigenetic regulator that plays a pivotal role in both breast morphogenesis and development. Here, we show for the first time that RA, via the RA receptor alpha (RAR alpha), epigenetically regulates in a concerted fashion the transcription of two RA-responsive genes, the RA receptor 2 (RAR beta 2) and the cellular retinol-binding protein 1 (CRBP1). Specifically, an impaired RA signal through RAR alpha in human breast epithelial cells triggers a repressive epigenetic domino effect, involving first RAR beta 2 and second CRBP1. The phenotype acquired by breast epithelial cells clearly implies that the resistance to RA-mediated growth inhibition precedes the acquisition of morphological epithelial transformation, thus supporting the occurrence of sequential transcriptional silencing of first RAR beta 2 and second CRBP1. The identification of this epigenetic network mechanistically linking RAR beta 2 and CRBP1 transcription provides the basis for devising more accurate epigenetic tests for the prediction of breast cancer risk.
C1 Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center
RP Sacchi, N (通讯作者)，Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.
EM nicoletta.sacchi@roswellpark.org
RI Ren, Mingqiang/KHV-8463-2024; Silvia, Pozzi/AAF-9396-2019
CR Andreola F, 2000, BIOCHEM BIOPH RES CO, V279, P920, DOI 10.1006/bbrc.2000.3995
   Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200
   Bean GR, 2005, CANCER EPIDEM BIOMAR, V14, P790, DOI 10.1158/1055-9965.EPI-04-0580
   Blomhoff R, 2006, J NEUROBIOL, V66, P606, DOI 10.1002/neu.20242
   BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174
   Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329
   Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004
   FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352
   Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925
   Heard E, 2005, CURR OPIN GENET DEV, V15, P482, DOI 10.1016/j.gde.2005.08.009
   Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097
   HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9
   Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512
   Kuppumbatti YS, 2001, ONCOGENE, V20, P7413, DOI 10.1038/sj.onc.1204749
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Montesano R, 2002, J CELL SCI, V115, P4419, DOI 10.1242/jcs.00164
   NAPOLI JL, 1995, J STEROID BIOCHEM, V53, P497, DOI 10.1016/0960-0760(95)00096-I
   Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1
   Pozzi S, 2006, ONCOGENE, V25, P1400, DOI 10.1038/sj.onc.1209173
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Rexer BN, 2001, CANCER RES, V61, P7065
   Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694
   Sirchia SM, 2002, CANCER RES, V62, P2455
   SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x
   SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392
   TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258
   Vermot J, 2005, SCIENCE, V308, P563, DOI 10.1126/science.1108363
   Vermot J, 2005, NATURE, V435, P215, DOI 10.1038/nature03488
   Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570
NR 34
TC 24
Z9 28
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2006
VL 66
IS 21
BP 10308
EP 10314
DI 10.1158/0008-5472.CAN-06-1052
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 101ZY
UT WOS:000241781600015
PM 17079450
OA Bronze
DA 2025-01-12
ER

PT J
AU Loree, J
   Koturbash, I
   Kutanzi, K
   Baker, M
   Pogribny, I
   Kovalchuk, O
AF Loree, Jonathan
   Koturbash, Igor
   Kutanzi, Kristy
   Baker, Mike
   Pogribny, Igor
   Kovalchuk, Olga
TI Radiation-induced molecular changes in rat mammary tissue: Possible
   implications for radiation-induced carcinogenesis
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article
DE radiation; mammary tissue; DNA methylation; DNA repair; signaling;
   cellular proliferation; apoptosis
ID PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; INTRACHROMOSOMAL HOMOLOGOUS
   RECOMBINATION; GLOBAL CANCER STATISTICS; BENIGN BREAST DISEASE;
   ATOMIC-BOMB SURVIVORS; BASE EXCISION-REPAIR; DNA METHYLATION;
   IONIZING-RADIATION; CELLS; DAMAGE
AB Purpose: Ionizing radiation is a potent mammary gland carcinogen, yet the exact molecular etiology of radiation-induced breast cancer remains unknown.
   Materials and methods: Our study utilized a rat model of breast carcinogenesis to analyse the molecular and epigenetic changes induced in mammary gland tissue upon exposure to ionizing radiation (IR). Using a methylation-sensitive cytosine extension assay we studied the IR-induced changes in DNA methylation. In parallel, we analysed the expression of proteins involved in DNA methylation, DNA repair and cell proliferation control. Molecular changes were related to cellular proliferation and apoptosis.
   Results: We found that IR led to a loss of genomic cytosine methylation in the exposed mammary tissue. Global DNA hypomethylation was paralleled by reduction in the levels of maintenance (DNMT1) and de novo (DNMT3a and 3b) DNA methyltransferases and methyl-binding protein MeCP2. The observed DNA hypomethylation was linked, at least in part, to activation of DNA repair processes. Concurrently, we observed increased levels of phosphorylated extracellular signal-regulated kinase (p-ERK1/2), phosphorylated AKT kinase (p-AKT), cyclin D1 and proliferating cells nuclear antigen ( PCNA) proteins, suggesting IR alters intra-cellular signaling and cell cycle control mechanisms in mammary tissue. We also noted a significant induction of apoptosis in the exposed tissue 6 hours after irradiation. The observed apoptosis levels were paralleled by the slight elevation of cellular proliferation.
   Conclusions: We have demonstrated that a single exposure to 5 Gy of X rays leads to noticeable epigenetic changes in the rat mammary gland that occurred in the context of activation of DNA damage repair and alterations in the pro-survival growth-stimulatory cellular signaling pathways. The possible cellular repercussions of the observed changes in relationship to breast carcinogenesis are discussed.
C1 Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
   Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AZ USA.
C3 University of Lethbridge; US Food & Drug Administration (FDA)
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, 4401 Univ Dr, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
OI Loree, Jonathan/0000-0001-8189-2132
CR Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064
   AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8
   Bishop AJR, 2000, CANCER RES, V60, P395
   BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890
   Doody MM, 2000, SPINE, V25, P2052
   Ellsworth DL, 2004, LANCET ONCOL, V5, P753, DOI 10.1016/S1470-2045(04)01653-5
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Greene MH, 1997, MAYO CLIN PROC, V72, P54, DOI 10.4065/72.1.54
   HELLGREN D, 1992, MUTAT RES, V284, P37, DOI 10.1016/0027-5107(92)90023-U
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Howe GR, 1996, RADIAT RES, V145, P694, DOI 10.2307/3579360
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeltsch A, 2006, CURR TOP MICROBIOL, V301, P203
   Jenner TJ, 2001, RADIAT RES, V156, P590, DOI 10.1667/0033-7587(2001)156[0590:COBLTR]2.0.CO;2
   Jones BE, 1998, EXTREMOPHILES, V2, P191, DOI 10.1007/s007920050060
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones WD, 2005, IEEE SPECTRUM, V42, P8
   JOSEPHY PD, 2005, MUTATION RES S, V577, pE216
   Koturbash I, 2005, BIOCHEM BIOPH RES CO, V337, P526, DOI 10.1016/j.bbrc.2005.09.084
   Lambert S, 1999, MUTAT RES-DNA REPAIR, V433, P159, DOI 10.1016/S0921-8777(99)00004-X
   Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082
   Liang K, 2003, MOL CANCER THER, V2, P353
   MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679
   Mattsson A, 1997, RADIAT RES, V148, P152, DOI 10.2307/3579572
   Osborne C, 2004, ONCOLOGIST, V9, P361, DOI 10.1634/theoncologist.9-4-361
   Panayiotidis MI, 2004, ANTIOXID REDOX SIGN, V6, P129, DOI 10.1089/152308604771978435
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014
   Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074
   Prise KM, 2001, RADIAT RES, V156, P572, DOI 10.1667/0033-7587(2001)156[0572:AROSOI]2.0.CO;2
   Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002
   Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098
   Ronckers CM, 2005, BREAST CANCER RES, V7, P21, DOI 10.1186/bcr970
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074
   Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3
   Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253
   Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233
   Shackney SE, 2003, ADV ANAT PATHOL, V10, P278, DOI 10.1097/00125480-200309000-00003
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Smith SS, 1998, INT J MOL MED, V1, P147
   Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200
   Söderlund K, 2005, INT J ONCOL, V26, P25
   Sokal RR., 2012, Biometry, V4
   STORM HH, 1992, J NATL CANCER I, V84, P1245, DOI 10.1093/jnci/84.16.1245
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   TURK PW, 1995, CARCINOGENESIS, V16, P1253, DOI 10.1093/carcin/16.5.1253
   Wang T, 2005, J BIOL CHEM, V280, P12593, DOI 10.1074/jbc.M410982200
   West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson SH, 2000, COLD SPRING HARB SYM, V65, P143, DOI 10.1101/sqb.2000.65.143
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Ye Yumei, 2004, Breast Dis, V19, P69
NR 63
TC 58
Z9 77
U1 1
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955-3002
EI 1362-3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD NOV
PY 2006
VL 82
IS 11
BP 805
EP 815
DI 10.1080/09553000600960027
PG 11
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 120KP
UT WOS:000243083900005
PM 17148264
DA 2025-01-12
ER

PT J
AU Sadikovic, B
   Rodenhiser, DI
AF Sadikovic, Bekim
   Rodenhiser, David I.
TI Benzopyrene exposure disrupts DNA methylation and growth dynamics in
   breast cancer cells
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE benzopyrene; DNA methylation; breast cancer; environment; epigenetics
ID POLYCYCLIC AROMATIC-HYDROCARBONS; DIOL EPOXIDE; METHYLTRANSFERASE GENE;
   CYTOSINE METHYLATION; EPITHELIAL-CELLS; ADDUCT FORMATION; RAS GENE; P53;
   EXPRESSION; HYPERMETHYLATION
AB Exposures to environmental carcinogens and unhealthy lifestyle choices increase the incidence of breast cancer. One such compound, benzo(a) pyrene (BaP), leads to covalent DNA modifications and the deregulation of gene expression. To date, these mechanisms of BaP-induced carcinogenesis are poorly understood, particularly in the case of breast cancer. We tested the effects of BaP exposure on cellular growth dynamics and DNA methylation in four breast cancer cell lines since disruptions in DNA methylation lead to deregulated gene expression and the loss of genomic integrity. We observed robust time- and concentration-dependent loss of proliferation, S phase and G2M accumulation and apoptosis in p53 positive MCF-7 and T47-D cells. We observed minimal responses in p53 negative HCC-1086 and MDA MB 231 cells. Furthermore, BaP increased p53 levels in both p53 positive cell lines, as well as p21 levels in MCF-7 cells, an effect that was prevented by the p53-specific inhibitor pifithrin-a. No changes in global levels of DNA methylation levels induced by BaP were detected by the methyl acceptor assay (MAA) in any cell line, however, methylation profiling by AIMS (amplification of intermethylated sites) analysis showed dynamic, sequence-specific hypo- and hypermethylation events in all cell lines. We also identified BaP-induced hypomethylation events at a number of genomic repeats. Our data confirm the p53-specific disruption of the cell cycle as well as the disruption of DNA methylation as a consequence of BaP treatment, thus reinforcing the link between environmental exposures, DNA methylation and breast cancer. (c) 2006 Elsevier Inc. All rights reserved.
C1 Victoria Res Labs, London Reg Canc Program, London Hlth Sci Ctr, London, ON N6A 4L6, Canada.
   Univ Western Ontario, Dept Biochem, London, ON N6A 3K7, Canada.
   Univ Western Ontario, Dept Oncol, London, ON N6A 3K7, Canada.
   Univ Western Ontario, Dept Paediat, London, ON N6A 3K7, Canada.
   EpiGenWestern Res Grp, London, ON, Canada.
C3 Western University (University of Western Ontario); London Health
   Sciences Centre; Western University (University of Western Ontario);
   Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Rodenhiser, DI (通讯作者)，Victoria Res Labs, London Reg Canc Program, London Hlth Sci Ctr, Room A4-134,790 Commissioners Rd E, London, ON N6A 4L6, Canada.
EM drodenhi@uwo.ca
CR Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baskunov VB, 2005, BIOCHEMISTRY-US, V44, P1054, DOI 10.1021/bi048130y
   Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200
   Ciganek M, 2004, SCI TOTAL ENVIRON, V334, P141, DOI 10.1016/j.scitotenv.2004.04.034
   Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837
   Coyle YM, 2004, BREAST CANCER RES TR, V84, P273, DOI 10.1023/B:BREA.0000019964.33963.09
   Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2005, EMBO REP, V6, P624, DOI 10.1038/sj.embor.7400456
   Esteller M, 2001, CANCER RES, V61, P3225
   ESTELLER M, 2006, BRIT J CANCER, V94, P197
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Feng ZH, 2002, J NATL CANCER I, V94, P1527
   Frigola J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e28
   Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S
   Gary RK, 2005, MOL PHARMACEUT, V2, P462, DOI 10.1021/mp050055d
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gorlewska-Roberts K, 2002, ENVIRON MOL MUTAGEN, V39, P184, DOI 10.1002/em.10060
   Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HOLLIDAY R, 1979, BRIT J CANCER, V40, P513, DOI 10.1038/bjc.1979.216
   Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s
   Jeffy BD, 1999, MOL CARCINOGEN, V26, P100, DOI 10.1002/(SICI)1098-2744(199910)26:2<100::AID-MC5>3.0.CO;2-1
   Jeffy BD, 2002, ENVIRON MOL MUTAGEN, V39, P235, DOI 10.1002/em.10051
   Jeffy BD, 2002, CANCER RES, V62, P113
   Jeffy BD, 2000, NEOPLASIA, V2, P460, DOI 10.1038/sj.neo.7900104
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   LIJINSKY W, 1991, MUTAT RES, V259, P251, DOI 10.1016/0165-1218(91)90121-2
   Maier A, 2002, MUTAT RES-GEN TOX EN, V517, P101, DOI 10.1016/S1383-5718(02)00057-8
   MERRICK BA, 1985, CANCER LETT, V29, P139, DOI 10.1016/0304-3835(85)90152-1
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   PRUESSSCHWARTZ D, 1986, CANCER RES, V46, P2697
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799
   Scherer G, 2000, CANCER EPIDEM BIOMAR, V9, P373
   Sparfel L, 2006, CARCINOGENESIS, V27, P656, DOI 10.1093/carcin/bgi256
   Ueng TH, 2004, ARCH ENVIRON CON TOX, V46, P454, DOI 10.1007/s00244-003-2263-y
   VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Walton MI, 2005, MOL CANCER THER, V4, P1369, DOI 10.1158/1535-7163.MCT-04-0341
   Weisenberger DJ, 1999, J BIOL CHEM, V274, P23948, DOI 10.1074/jbc.274.34.23948
   WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7
   WILSON VL, 1984, CARCINOGENESIS, V5, P1027, DOI 10.1093/carcin/5.8.1027
   WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891
   Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052
   Yoon JH, 2001, CANCER RES, V61, P7110
   Zhang N, 2005, J MOL BIOL, V346, P951, DOI 10.1016/j.jmb.2004.12.027
NR 54
TC 105
Z9 121
U1 1
U2 44
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD NOV 1
PY 2006
VL 216
IS 3
BP 458
EP 468
DI 10.1016/j.taap.2006.06.012
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 101MT
UT WOS:000241745600010
PM 16926039
DA 2025-01-12
ER

PT J
AU Takada, H
   Imoto, I
   Tsuda, H
   Nakanishi, Y
   Sakakura, C
   Mitsufuji, S
   Hirohashi, S
   Inazawa, J
AF Takada, H.
   Imoto, I.
   Tsuda, H.
   Nakanishi, Y.
   Sakakura, C.
   Mitsufuji, S.
   Hirohashi, S.
   Inazawa, J.
TI Genomic loss and epigenetic silencing of <i>very-low-density lipoprotein
   receptor</i> involved in gastric carcinogenesis
SO ONCOGENE
LA English
DT Article
DE array-CGH; gastric cancer; VLDLR; homozygous deletion; methylation
ID CANCER CELL-LINES; LUNG-CANCER; HOMOZYGOUS DELETIONS;
   PANCREATIC-CARCINOMA; DNA METHYLATION; VLDL RECEPTOR; BREAST-CANCER; LDL
   RECEPTOR; SHORT ARM; GENE
AB Homozygous loss in the genomic sequence, a mechanism for inactivating tumor-suppressor genes (TSGs) in cancer, has been used as a tag for the identification of novel TSGs, and array-based comparative genomic hybridization (array-CGH) has a great potential for high-throughput identification of this change. We identified a homozygous loss of the very-low-density lipoprotein receptor (VLDLR) gene (9p24.2) from genome-wide screening for copy-number alterations in 32 gastric cancer ( GC) cell lines using array-CGH. Although previous reports demonstrated mRNA or protein expression of VLDLR in various cancers including GC, the association between genomic losses or epigenetic silencing of this gene and carcinogenesis has never been reported before. Homozygous deletion of VLDLR was also seen in primary GCs, albeit infrequently, and about half of GC cell lines showed lost or reduced VLDLR expression. The VLDLR expression was restored in gene-silenced GC cells after treatment with 5-aza 2'-deoxycytidine. According to methylation analyses, hypermethylation of the VLDLR promoter region, which all of GC lines without its expression showed, occurred in some primary GCs. Restoration of VLDLR type I expression in GC cells reduced colony formation. These results suggest that not only the expression of VLDLR but also genetic or epigenetic silencing of this gene may contribute to tumor formation and be involved in gastric carcinogenesis.
C1 Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan.
   Grad Sch Biomed Sci, Tokyo, Japan.
   Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Gastroenterol & Hepatol, Kyoto, Japan.
   Natl Canc Ctr, Res Inst, Div Pathol, Tokyo, Japan.
   Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Digest Surg, Kyoto, Japan.
   Tokyo Med & Dent Univ, COE Program Frontier Res Mol Destruct & Reconstit, Tokyo, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Kyoto Prefectural University of Medicine; National Cancer Center -
   Japan; Kyoto Prefectural University of Medicine; Institute of Science
   Tokyo; Tokyo Medical & Dental University (TMDU)
RP Inazawa, J (通讯作者)，Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.
EM johinaz.cgen@mri.tmd.ac.jp
RI Imoto, Issei/AAD-5799-2020
CR An HX, 1999, CANCER RES, V59, P3941
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Chen T, 2005, WORLD J GASTROENTERO, V11, P2817, DOI 10.3748/wjg.v11.i18.2817
   CHEN WJ, 1990, J BIOL CHEM, V265, P3116
   D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0
   Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E
   Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159
   Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200
   Hiltunen TP, 1998, CIRCULATION, V97, P1079, DOI 10.1161/01.CIR.97.11.1079
   Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x
   Kim SK, 1997, CANCER RES, V57, P400
   Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x
   Nakamura Y, 2000, ARCH PATHOL LAB MED, V124, P119
   Near SE, 2001, J HUM GENET, V46, P490, DOI 10.1007/s100380170051
   Noguchi M, 1997, PATHOL INT, V47, P685, DOI 10.1111/j.1440-1827.1997.tb04442.x
   Reisman DN, 2003, CANCER RES, V63, P560
   SAKAI J, 1994, J BIOL CHEM, V269, P2173
   SAKATA K, 1995, JPN J CANCER RES, V86, P333, DOI 10.1111/j.1349-7006.1995.tb03060.x
   Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200
   Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253
   Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008
   Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072
   Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172
   STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159
   SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119
   Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952
   Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x
   TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747
   TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252
   Tanabe C, 2003, GENE CHROMOSOME CANC, V38, P168, DOI 10.1002/gcc.10269
   Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312
   Vo QN, 2002, HUM PATHOL, V33, P1200, DOI 10.1053/hupa.2002.130108
   Wada Y, 2000, HEART VESSELS, V15, P74, DOI 10.1007/s003800070035
   Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412
   WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3
   Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x
NR 38
TC 29
Z9 35
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT 19
PY 2006
VL 25
IS 49
BP 6554
EP 6562
DI 10.1038/sj.onc.1209657
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 096RS
UT WOS:000241395100012
PM 16715143
DA 2025-01-12
ER

PT J
AU Wu, MY
   Tsai, TF
   Beaudet, AL
AF Wu, Mei-Yi
   Tsai, Ting-Fen
   Beaudet, Arthur L.
TI Deficiency of <i>Rbbp1/Arid4a</i> and <i>Rbbp1l1/Arid4b</i> alters
   epigenetic modifications and suppresses an imprinting defect in the
   PWS/AS domain
SO GENES & DEVELOPMENT
LA English
DT Article
DE Rbbp1/Arid4a; Rbbp1l1/Arid4b; Prader-Willi/Angelman domain; genomic
   imprinting; epigenetic modifications
ID PRADER-WILLI-SYNDROME; RETINOBLASTOMA TUMOR-SUPPRESSOR; HISTONE H3;
   ANGELMAN-SYNDROME; FAMILY PROTEINS; BREAST-CANCER; GROWTH ARREST; ARID
   FAMILY; SNRPN LOCUS; LYSINE 9
AB Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are caused by deficiency of imprinted gene expression from paternal or maternal chromosome 15q11-q13, respectively. Genomic imprinting of the PWS/AS domain is regulated through a bipartite cis-acting imprinting center (PWS-IC/AS-IC) within and upstream of the SNRPN promoter. Here, we show that two Rb-binding protein-related genes, Rbbp1/Arid4a and Rbbp1l1/Arid4b, are involved in the regulation of imprinting of the IC. We recovered these two genes from gene trap mutagenesis selecting for altered expression of an Snrpn-EGFP fusion gene strategy. RBBP1/ARID4A is an Rb-binding protein. RBBP1/ARID4A interacts with RBBP1L1/ARID4B and with the Snrpn promoter, implying that both are part of a protein complex. To further elucidate their roles on regulation of imprinting, we deleted the Rbbp1/Arid4a and Rbbp1l1/Arid4b genes in mice. Combined homozygous deficiency for Rbbp1/Arid4a and heterozygous deficiency for Rbbp1l1/Arid4b altered epigenetic modifications at the PWS-IC with reduced trimethylation of histone H4K20 and H3K9 and reduced DNA methylation, changing the maternal allele toward a more paternal epigenotype. Importantly, mutations of Rbbp1/Arid4a, Rbbp1l1/Arid4b, or Rb suppressed an AS imprinting defect caused by a mutation at the AS-IC. These data identify Rbbp1/Arid4a and Rbbp1l1/Arid4b as new members of epigenetic complexes regulating genomic imprinting at the PWS/AS domain.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan.
C3 Baylor College of Medicine; National Yang Ming Chiao Tung University;
   National Yang Ming Chiao Tung University
RP Beaudet, AL (通讯作者)，Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
EM abeaudet@bcm.tmc.edu
FU NICHD NIH HHS [HD37283, R01 HD037283] Funding Source: Medline
CR Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bressler J, 2001, NAT GENET, V28, P232, DOI 10.1038/90067
   Buiting K, 1999, HUM GENET, V105, P665, DOI 10.1007/s004390051160
   BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395
   Cao JN, 1999, BREAST CANCER RES TR, V53, P279, DOI 10.1023/A:1006115922401
   Cao JN, 2001, J NATL CANCER I, V93, P1159, DOI 10.1093/jnci/93.15.1159
   Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950
   DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0
   Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7
   Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003
   Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655
   FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513
   Fulmer-Smentek SB, 2001, HUM MOL GENET, V10, P645, DOI 10.1093/hmg/10.6.645
   Gabriel JM, 1998, MAMM GENOME, V9, P788, DOI 10.1007/s003359900868
   Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235
   Horsthemke B, 2006, CYTOGENET GENOME RES, V113, P292, DOI 10.1159/000090844
   Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014
   Kantor B, 2006, CYTOGENET GENOME RES, V113, P300, DOI 10.1159/000090845
   Kato MV, 1996, AM J HUM GENET, V59, P1084
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001
   Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520
   Laj A, 1999, MOL CELL BIOL, V19, P6632
   LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233
   Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145
   Perk J, 2002, EMBO J, V21, P5807, DOI 10.1093/emboj/cdf570
   Quina AS, 2006, BIOCHEM PHARMACOL, V72, P1563, DOI 10.1016/j.bcp.2006.06.016
   Saitoh S, 2000, AM J HUM GENET, V66, P1958, DOI 10.1086/302917
   Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009
   Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267
   Takahashi T, 1999, BRIT J CANCER, V81, P342, DOI 10.1038/sj.bjc.6690698
   Tsai TF, 1999, HUM MOL GENET, V8, P1357, DOI 10.1093/hmg/8.8.1357
   Tsai TF, 2003, GENESIS, V37, P151, DOI 10.1002/gene.10237
   Tsai TF, 2002, HUM MOL GENET, V11, P1659, DOI 10.1093/hmg/11.14.1659
   Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013
   Wu MY, 2006, GENESIS, V44, P12, DOI 10.1002/gene.20179
   Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469
   Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25
   Zhu LA, 2005, EUR J CANCER, V41, P2415, DOI 10.1016/j.ejca.2005.08.009
NR 42
TC 76
Z9 96
U1 0
U2 2
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD OCT 15
PY 2006
VL 20
IS 20
BP 2859
EP 2870
DI 10.1101/gad.1452206
PG 12
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 095RB
UT WOS:000241324400010
PM 17043311
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yamada, N
   Hamada, T
   Goto, M
   Tsutsumida, H
   Higashi, M
   Nomoto, M
   Yonezawa, S
AF Yamada, Norishige
   Hamada, Tomofumi
   Goto, Masamichi
   Tsutsumida, Hideaki
   Higashi, Michiyo
   Nomoto, Mitsuharu
   Yonezawa, Suguru
TI <i>MUC2</i> expression is regulated by histone H3 modification and DNA
   methylation in pancreatic cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE pancreas neoplasms; mucin; epigenetics; MUC2; histone modification
ID GENE-EXPRESSION; LYSINE-9 METHYLATION; DEACETYLASE INHIBITORS;
   COLORECTAL-CANCER; CARCINOMA-CELLS; BREAST-CANCER; CHROMATIN; PROMOTER;
   RNA; METHYLTRANSFERASE
AB Mucins are highly glycosylated proteins that play important roles in carcinogenesis. In pancreatic neoplasia, MUC2 mucin has been demonstrated as a tumor suppressor and we have reported that MUC2 is a favorable prognostic factor. Regulation of MUC2 gene expression is known to be controlled by DNA methylation, but the role of histone modification for MUC2 gene expression has yet to be clarified. Herein, we provide the first report that the histone H3 modification of the MUC2 promoter region regulates MUC2 gene expression. To investigate the histone modification and DNA methylation of the promoter region of the MUC2 gene, we treated 2 human pancreatic cancer cell lines, PANC1 (MUC2-negative) and BxPC3 (MUC2-positive) with the DNA methyltransferase inhibitor 5-azacytidine (5-aza), the histone deacetylase inhibitor trichostatin A (TSA), and a combination of these agents. The DNA methylation level of PANC1 cells was decreased by all 3 treatments, whereas histone H3-K4/K9 methylation and H3-K9/K27 acetylation in PANC1 cells was changed to the level in BxPC3 cells by treatment with TSA alone and with the 5-aza/TSA combination. The expression level of MUC2 mRNA in PANC1 cells exhibited a definite increase when treated with TSA and 5-aza/TSA, whereas 5-aza alone induced only a slight increase. Our results suggest that histone H3 modification in the 5' flanking region play an important role in MUC2 gene expression, possibly affecting DNA methylation. An understanding of these intimately correlated epigenetic changes may be of importance for predicting the outcome of patients with pancreatic neoplasms. (c) 2006 Wiley-Liss, Inc.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, Kagoshima 8908544, Japan.
C3 Kagoshima University
RP Goto, M (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.
EM masagoto@m2.kufm.kagoshima-u.ac.jp
RI Goto, Masamichi/B-6535-2009
CR Adsay NV, 2002, MODERN PATHOL, V15, P1087, DOI 10.1097/01.MP.0000028647.98725.8B
   Alvarez-Venegas R, 2005, NUCLEIC ACIDS RES, V33, P5199, DOI 10.1093/nar/gki830
   Aslam F, 2001, CANCER RES, V61, P570
   Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663
   Augenlicht L, 2003, ONCOGENE, V22, P4983, DOI 10.1038/sj.onc.1206521
   Bender J, 2004, CURR OPIN PLANT BIOL, V7, P521, DOI 10.1016/j.pbi.2004.07.003
   Enss ML, 2000, INFLAMM RES, V49, P162, DOI 10.1007/s000110050576
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   Gendrel AV, 2005, CURR OPIN PLANT BIOL, V8, P142, DOI 10.1016/j.pbi.2005.01.007
   Gratchev A, 2001, CANCER LETT, V168, P71, DOI 10.1016/S0304-3835(01)00498-0
   GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x
   Hamada T, 2005, CANCER LETT, V227, P175, DOI 10.1016/j.canlet.2004.11.058
   Hanski C, 1997, LAB INVEST, V77, P685
   Higashi M, 1999, HEPATOLOGY, V30, P1347, DOI 10.1002/hep.510300609
   Ho JJL, 2003, INT J ONCOL, V22, P273
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Ishikawa A, 2004, LAB INVEST, V84, P629, DOI 10.1038/labinvest.3700087
   Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003
   Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101
   Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224
   Meehan RR, 2001, ESSAYS BIOCHEM, V37, P59, DOI 10.1042/bse0370059
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Nakamura A, 2002, J PATHOL, V197, P201, DOI 10.1002/path.1109
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   Recillas-Targa F, 2002, ARCH MED RES, V33, P428, DOI 10.1016/S0188-4409(02)00366-1
   Riede E, 1998, Langenbecks Arch Chir Suppl Kongressbd, V115, P299
   Roessler K, 2005, WORLD J GASTROENTERO, V11, P3182, DOI 10.3748/wjg.v11.i21.3182
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Shi HD, 2003, CANCER RES, V63, P2164
   Siedow A, 2002, TUMOR BIOL, V23, P54, DOI 10.1159/000048689
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tamada S, 2002, PATHOL INT, V52, P713, DOI 10.1046/j.1440-1827.2002.01414.x
   Utsunomiya T, 1998, CLIN CANCER RES, V4, P2605
   Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
   Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   Wolffe AP, 1999, P NATL ACAD SCI USA, V96, P5894, DOI 10.1073/pnas.96.11.5894
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843
   Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2
   Yang XW, 2001, CANCER RES, V61, P7025
   Yonezawa S, 1997, HUM PATHOL, V28, P344, DOI 10.1016/S0046-8177(97)90134-9
   Yonezawa Suguru, 2002, J Hepatobiliary Pancreat Surg, V9, P328, DOI 10.1007/s005340200037
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 57
TC 62
Z9 72
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 15
PY 2006
VL 119
IS 8
BP 1850
EP 1857
DI 10.1002/ijc.22047
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 084EF
UT WOS:000240514100013
PM 16721789
OA Bronze
DA 2025-01-12
ER

PT J
AU Hitchler, MJ
   Wikainapakul, K
   Yu, L
   Powers, K
   Attatippaholkun, W
   Domann, FE
AF Hitchler, Michael J.
   Wikainapakul, Kornwipa
   Yu, Lei
   Powers, Kristy
   Attatippaholkun, Watcharee
   Domann, Frederick E.
TI Epigenetic Regulation of Manganese Superoxide Dismutase Expression in
   Human Breast Cancer Cells
SO EPIGENETICS
LA English
DT Article
DE MnSOD; SOD2; cytosine methylation; breast cancer; histone; chromatin
AB Malignant breast cancer cells often exhibit lower expression and activity of manganese superoxide dismutase (MnSOD) than their normal cell counterparts; however, the mechanism(s) responsible for this change remains unclear. We examined whether SOD2, the gene encoding MnSOD, was epigenetically repressed in breast cancer cell lines by DNA methylation and histone acetylation. RT-PCR analysis of SOD2 mRNA showed the nontumorigenic breast epithelial cell line MCF-10A to have two to three fold higher expression levels than either UACC-893 or MDA-MB-435 breast carcinoma cells. Analysis of a region in the SOD2 promoter by sodium bisulfite genomic sequencing demonstrated significantly higher levels of CpG methylation in both human breast carcinoma cell lines assessed than in MCF-10A cells. CREB binding in vitro to a cognate site derived from this region was repressed by DNA methylation, and CREB binding to the 5' regulatory region of the SOD2 gene in vivo as determined by ChIP was significantly lower in breast carcinoma cells than in MCF-10A. Increased cytosine methylation was also accompanied by a significant decrease in the level of acetylated histones in the same region of the SOD2 promoter. Finally, a causal link between cytosine methylation and transcriptional repression was established by increasing MnSOD mRNA, protein and activity in breast carcinoma cells using the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. These findings indicate that epigenetic silencing of SOD2 constitutes one mechanism
C1 [Domann, Frederick E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Carver Coll Med, Iowa City, IA 52242 USA.
   [Wikainapakul, Kornwipa; Attatippaholkun, Watcharee] Mahidol Univ, Fac Med Technol, Dept Clin Chem, Bangkok 10700, Thailand.
C3 University of Iowa; Mahidol University
RP Domann, FE (通讯作者)，Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Carver Coll Med, Iowa City, IA 52242 USA.
EM frederick-domann@uiowa.edu
OI Domann, Frederick/0000-0002-0489-2179
FU NIH [R01 CA73612]; Royal Golden Jubilee grant from the Thai government; 
   [T32 CA078586]
FX The authors would like to thank Bo James for assistance in preparing
   this manuscript. This work was supported by NIH grant R01 CA73612 to F.
   E. D. M. J. H. received salary support from T32 CA078586. K. W. received
   partial salary support from a Royal Golden Jubilee grant from the Thai
   government.
CR BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8
   BORRELLO S, 1993, MOL ASPECTS MED, V14, P253, DOI 10.1016/0098-2997(93)90012-3
   BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Hermann B, 2005, ARCH SURG-CHICAGO, V140, P1204, DOI 10.1001/archsurg.140.12.1204
   Hodge DR, 2005, CANCER BIOL THER, V4, P585, DOI 10.4161/cbt.4.5.1704
   Hodge DR, 2005, CANCER RES, V65, P6255, DOI 10.1158/0008-5472.CAN-04-4482
   Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6
   Huang YH, 1999, DNA CELL BIOL, V18, P643, DOI 10.1089/104454999315051
   Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x
   Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970
   Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045
   Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455
   Kiningham KK, 2004, BIOCHEM J, V384, P543, DOI 10.1042/BJ20040714
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   LI JJ, 1995, ONCOGENE, V10, P1989
   MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281
   Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164
   Nass SJ, 2000, CANCER RES, V60, P4346
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Ough M, 2004, FREE RADICAL RES, V38, P1223, DOI 10.1080/10715760400017376
   PFEIFER GP, 1985, J BIOL CHEM, V260, P3787
   Porntadavity S, 2001, DNA CELL BIOL, V20, P473, DOI 10.1089/104454901316976109
   Soini Y, 2001, J PATHOL, V195, P156, DOI 10.1002/path.946
   St Clair DK, 2002, METHOD ENZYMOL, V349, P306, DOI 10.1016/S0076-6879(02)49345-7
   SUN Y, 1993, ONCOL RES, V5, P127
   Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265
   Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218
   Zhang N, 1996, BIOCHEM BIOPH RES CO, V220, P171, DOI 10.1006/bbrc.1996.0376
   Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852
NR 37
TC 68
Z9 88
U1 0
U2 10
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD OCT-DEC
PY 2006
VL 1
IS 4
BP 163
EP 171
DI 10.4161/epi.1.4.3401
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA V04NB
UT WOS:000207064000002
PM 17965603
OA Bronze
DA 2025-01-12
ER

PT J
AU Kunze, E
   Wendt, M
   Schlott, T
AF Kunze, Ekkehard
   Wendt, Maike
   Schlott, Thilo
TI Promoter hypermethylation of the 14-3-3 σ, SYK and CAGE-1 genes is
   related to the various phenotypes of urinary bladder carcinomas and
   associated with progression of transitional cell carcinomas
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE urinary bladder; transitional cell carcinomas; squamous cell carcinomas;
   undifferentiated small cell cancers; promoter methylation; 14-3-3 sigma;
   SYK; CAGE-1; PTEN; COX-2; RUNX-3; HIC-1; immunohistochemistry
ID HUMAN BREAST-CANCER; PROTEIN-TYROSINE KINASE; CANCER/TESTIS ANTIGEN;
   NONUROTHELIAL CARCINOMAS; GASTRIC-CARCINOMA; DNA METHYLATION; SIGMA
   GENE; CYCLIN B1; EXPRESSION; FAMILY
AB To explore the significance of epigenetic mechanisms in urinary bladder carcinogenesis mediated by methylation of cytosine in CpG dinucleotides at 5' promoter regions, we analysed the methylation status of a broad panel of different genes in transitional cell carcinomas (TCC) and nonurothelial cancers, among which the 14-3-3 sigma, SYK and CAGE-1 genes were recognised as promising target genes. Using methylation-specific PCR, the rate of DNA hypermethylation proved to be related to the various histopathological cancer subtypes, The higher frequency of promoter methylation of the 14-3-3 sigma (57.1%) and SYK (64.3%) genes in high-grade, high-stage TCC in association with a reduced or even lacking immunohistochemical protein expression than in low-grade, low-stage TCC (28.6% and 42.9%, respectively), indicates that aberrant methylation of these genes plays an essential role in the progression of TCC. The importance of DNA hypermethylation in the conversion of TCC from a low to a high malignant potential was strongly supported by the finding that, unlike superficial low-grade TCC, advanced muscle invasive TCC showed a concurrent promoter methylation of the 14-3-3 sigma, SYK and CAGE-1 genes. Squamous cell carcinomas revealed a peak incidence of hypermethylation of the 14-3-3 sigma gene (80%), and conversely, the lowest methylation frequency of the SYK gene (13.3%). Undifferentiated small cell carcinomas disclosed a promoter methylation of the 14-3-3 sigma, SYK and CAGE-1 genes in only a quarter each for the cases. Although a correlation between the methylation status and gene activity in squamous cell and undifferentiated small cell carcinomas was not observed, the underexpression of the SYK protein products in both cancer types and additionally of the 14-3-3 sigma protein in small cell carcinomas appeared to be related to the aggressive clinical behaviour of both these nonurothelial bladder carcinomas. The relevance of the high frequency of DNA hypermethylation of the CAGE-1 antigen in TCC and squamous cell carcinomas merits further study, particularly in relation to anticancer immunotherapy. The methylation status of the PTEN, COX-2, RUNX-3 and HIC-1 genes was found to be unaltered. In conclusion, the different patterns of aberrant methylation of the 14-3-3 sigma, SYK and CAGE-I genes in the various histopathological cancer types of the urinary bladder point to a role in tumor cell differentiation, resulting in the phenotypical conversion of TCC into nonurothelial carcinomas and in the progression of TCC to a more malignant potential.
C1 Univ Gottingen, Ctr Pathol, Dept Osteopathol & Haematopathol, D-37099 Gottingen, Germany.
   Univ Gottingen, Ctr Pathol, Dept Pathol, D-37099 Gottingen, Germany.
C3 University of Gottingen; University of Gottingen
RP Kunze, E (通讯作者)，Univ Gottingen, Ctr Pathol, Dept Osteopathol & Haematopathol, D-37099 Gottingen, Germany.
EM ekunze@med.uni-goettingen.de
CR Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914
   Cho B, 2002, BIOCHEM BIOPH RES CO, V292, P715, DOI 10.1006/bbrc.2002.6701
   Cho BS, 2003, BIOCHEM BIOPH RES CO, V307, P52, DOI 10.1016/S0006-291X(03)01121-5
   Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x
   Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086
   Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3
   DELLAMBRA E, 1995, J CELL SCI, V108, P3569
   Ding Yong-bin, 2004, Zhonghua Yi Xue Za Zhi, V84, P290
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126
   Gasco M, 2002, CANCER RES, V62, P2072
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Iwata T, 2005, CLIN CANCER RES, V11, P3949, DOI 10.1158/1078-0432.CCR-04-1702
   Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282
   Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171
   Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422
   Knowles MA, 1999, BJU INT, V84, P412
   Kunze E, 2006, INT J MOL MED, V17, P3
   Kunze E, 2002, UROL RES, V30, P66, DOI 10.1007/s00240-001-0232-3
   Kunze E, 1998, EXP TOXICOL PATHOL, V50, P341, DOI 10.1016/S0940-2993(98)80015-8
   Kunze E, 2001, VIRCHOWS ARCH, V439, P609, DOI 10.1007/s004280100429
   KUNZE E, 1998, EINHORN PRESSE, P14
   Kurashige T, 2001, CANCER RES, V61, P4671
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Landry C, 2000, INT J CANCER, V86, P835, DOI 10.1002/(SICI)1097-0215(20000615)86:6<835::AID-IJC12>3.0.CO;2-N
   LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Orntoft TF, 1998, UROL RES, V26, P223, DOI 10.1007/s002400050050
   Park S, 2003, BBA-GENE STRUCT EXPR, V1625, P173, DOI 10.1016/S0167-4781(02)00620-6
   PATARD JJ, 1995, INT J CANCER, V64, P60, DOI 10.1002/ijc.2910640112
   PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507
   Rabbani F, 2000, UROL CLIN N AM, V27, P83, DOI 10.1016/S0094-0143(05)70237-8
   Refenes AN, 1997, NEUROCOMPUTING, V14, P123, DOI 10.1016/S0925-2312(96)00005-7
   Resnick MB, 2002, INT J CANCER, V101, P190, DOI 10.1002/ijc.10585
   Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Suzuki H, 2000, CANCER RES, V60, P4353
   Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9
   Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165
   Wang S, 2004, WORLD J GASTROENTERO, V10, P1815
   Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788
   Yu J, 2003, INT J ONCOL, V22, P1025
   Yuan YF, 2001, CANCER RES, V61, P5558
NR 52
TC 29
Z9 36
U1 0
U2 3
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1107-3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD OCT
PY 2006
VL 18
IS 4
BP 547
EP 557
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 088HV
UT WOS:000240803700003
PM 16964403
DA 2025-01-12
ER

PT J
AU Dokras, A
   Coffin, J
   Field, L
   Frakes, A
   Lee, H
   Madan, A
   Nelson, T
   Ryu, GY
   Yoon, JG
   Madan, A
AF Dokras, Anuja
   Coffin, Jeremy
   Field, Lorie
   Frakes, Amanda
   Lee, Hwahyung
   Madan, Anuradha
   Nelson, Timothy
   Ryu, Gi-Yung
   Yoon, Jae-Geun
   Madan, Anup
TI Epigenetic regulation of maspin expression in the human placenta
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article
DE epigenetic regulation; histone modifications; maspin; placenta; promoter
   methylation
ID BREAST-CANCER CELLS; SUPPRESSOR GENE MASPIN; HISTONE MODIFICATIONS; DNA
   METHYLATION; TRANSCRIPTION; MAMMARY; CHROMATIN; MOTILITY; RECEPTOR
AB Maspin, a tumour suppressor gene, is differentially expressed in the human placenta. Decreased expression of maspin in the first trimester corresponds with the period of maximum trophoblast invasion, suggesting a role in cell invasion and motility. Although methylation of CpG islands regulates maspin expression in cancer cells, the mechanism of maspin regulation in the human placenta is unknown. Our objectives were to determine the role of epigenetic alterations in the regulation of maspin expression in the placenta. Placental samples obtained from 7 to 40 weeks' gestation were used for bisulphite sequencing and chromatin immunoprecipitation (ChIP) PCR. There was no significant change in the methylation indices in the promoter region of maspin throughout gestation. The levels of histone modifications associated with transcriptionally active chromatin were significantly different in placental tissues from second and third trimester relative to those from first trimester. Addition of trichostatin A (TSA) to placental explants increased the maspin mRNA expression (8- to 20-fold), whereas addition of 5-aza-cytidine (5-AzaC) had no effect on maspin expression. Our data suggest that maspin expression in the human placenta is regulated by changes in histone tail modifications. This is the first report of selective histone modifications associated with differential placental gene expression in human gestation.
C1 Univ Iowa, Dept Neurosurg, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA.
   Inst Syst Biol, Seattle, WA USA.
C3 University of Iowa; University of Iowa; Institute for Systems Biology
   (ISB)
RP Madan, A (通讯作者)，Univ Iowa, Dept Neurosurg, 200B,EMRB, Iowa City, IA 52242 USA.
EM anup-madan@uiowa.edu
CR Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200
   BAYLIN SB, 2003, NAT REV CANCER, V6, P107
   Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316
   Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102
   Dokras A, 2002, PLACENTA, V23, P274, DOI 10.1053/plac.2001.0784
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980
   Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395
   Jiang WG, 1997, BIOCHEM BIOPH RES CO, V237, P639, DOI 10.1006/bbrc.1997.7154
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03
   Khalkhali-Ellis Z, 2003, AM J PATHOL, V162, P1411, DOI 10.1016/S0002-9440(10)64274-5
   Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Rajakumar A, 2000, BIOL REPROD, V63, P559, DOI 10.1095/biolreprod63.2.559
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Rose N, 2002, DEV PALEOENVIRON RES, V2, P319
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang WG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-50
   Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 34
TC 42
Z9 47
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 1460-2407
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD OCT
PY 2006
VL 12
IS 10
BP 611
EP 617
DI 10.1093/molehr/gal074
PG 7
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA 086TH
UT WOS:000240695400003
PM 16936308
DA 2025-01-12
ER

PT J
AU Tryndyak, V
   Kovalchuk, O
   Pogribny, IP
AF Tryndyak, Volodymyr
   Kovalchuk, Olga
   Pogribny, Igor P.
TI Identification of differentially methylated sites within unmethylated
   DNA domains in normal and cancer cells
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE DNA methylation; hypermethylation; detection; cancer
ID CPG-ISLANDS; BREAST-CANCER; GENOMIC DNA; HYPOMETHYLATION; GENES;
   AMPLIFICATION; EPIGENETICS; TUMORS; MCRBC; LIVER
AB Altered DNA methylation has been linked to neoplastic cell transformation and is a hallmark of cancer progression. Therefore, the screening for differentially methylated sequences as tumor biomarkers has a significant implication in the clinical setting. To determine the cancer-linked alterations in DNA methylation pattern, we have applied an endonuclease, McrBC, to the existing methylation-sensitive arbitrarily primed polymerase chain reaction (msAP-PCR) method and developed McrBC-msAP-PCR. This modified approach allows detection of differentially methylated sites within unmethylated DNA domains enriched by regulatory sequences and CpG islands. In this method, we used digestion of DNA with the McrBC methylation-sensitive endonuclease to selectively exclude the methylated fraction of DNA, which comprises interspersed and tandem-repeated sequences and exons other than first exons, from analysis. The subsequent digestion of unmethylated DNA fragments with SmaI and HpaII methylation-sensitive restriction endonucleases followed by AP-PCR amplification resulted in the detection of unknown unique sequences associated with cancer-linked methylation changes in genomic DNA. Hypermethylation and hypomethylation are visualized by the increase or decrease in the band intensity of DNA fingerprints. By using this technique, we were able to differentiate clearly, identify, and characterize a number of novel unique DNA sequences with differentially methylated sites in normal and breast cancer cell lines and in normal and rat tumor liver tissues. Published by Elsevier Inc.
C1 Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 US Food & Drug Administration (FDA); University of Lethbridge
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM ipogribny@nctr.fda.gov
OI Tryndyak, Volodymyr/0000-0002-8319-2954
CR Ausubel F. M., 1995, CURRENT PROTOCOLS MO
   COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   FLATAU E, 1983, CANCER RES, V43, P4901
   Frigola J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e28
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426
   Gonzalgo ML, 1997, CANCER RES, V57, P594
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x
   KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lippman Z, 2005, NAT METHODS, V2, P219, DOI 10.1038/nmeth0305-219
   Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545
   Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2
   Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001
   Pogribny IP, 2002, CANCER LETT, V187, P69, DOI 10.1016/S0304-3835(02)00408-1
   Rabinowicz PD, 2003, GENOME RES, V13, P2658, DOI 10.1101/gr.1784803
   RALEIGH EA, 1992, MOL MICROBIOL, V6, P1079, DOI 10.1111/j.1365-2958.1992.tb01546.x
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Rush LJ, 2004, CANCER RES, V64, P2424, DOI 10.1158/0008-5472.CAN-03-2870
   Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799
   Savelyeva L, 2001, CANCER RES, V61, P5179
   SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Toyota M, 1999, CANCER RES, V59, P2307
   Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145
   van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
NR 40
TC 19
Z9 26
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD SEP 15
PY 2006
VL 356
IS 2
BP 202
EP 207
DI 10.1016/j.ab.2006.05.019
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 084HJ
UT WOS:000240523700005
PM 16824473
DA 2025-01-12
ER

PT J
AU Hoque, MO
   Feng, QH
   Toure, P
   Dem, A
   Critchlow, CW
   Hawes, SE
   Wood, T
   Jeronimo, C
   Rosenbaum, E
   Stern, J
   Yu, MJ
   Trink, B
   Kiviat, NB
   Sidransky, D
AF Hoque, Mohammad O.
   Feng, Qinghua
   Toure, Papa
   Dem, Amadou
   Critchlow, Cathy W.
   Hawes, Stephen E.
   Wood, Troy
   Jeronimo, Carmen
   Rosenbaum, Eli
   Stern, Joshua
   Yu, Mujun
   Trink, Barry
   Kiviat, Nancy B.
   Sidransky, David
TI Detection of aberrant methylation of four genes in plasma DNA for the
   detection of breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID LUNG-CANCER; PROMOTER HYPERMETHYLATION; MICROSATELLITE ALTERATIONS;
   SERUM DNA; CERVICAL-CANCER; EARLY-DIAGNOSIS; MULTIPLE GENES; EARLY
   EVENT; TUMOR; CARCINOMA
AB Purpose
   Novel approaches to breast cancer screening are necessary, especially in the developing world where mammography is not feasible. In this study, we explored the hypothesis that blood-based biomarkers have potential for biomarkers for breast cancer.
   Patients and Methods
   We first determined the frequency of aberrant methylation of four candidate genes (APC, GSTP1, Rassf1A, and RAR beta 2) in primary breast cancer tissues from West African women with predominantly advanced cancers. We used a high-throughput DNA methylation assay (quantitative methylation-specific polymerase chain reaction) to examine plasma from 93 women with breast cancer and 76 controls for the presence of four methylated genes. Samples were randomly divided evenly into training and validation data sets. Cutoff values for gene positivity of the plasma-based assay and the gene panel were determined by receiver operating characteristic curves in the training data set and subsequently evaluated as a screening tool in the validation data set.
   Results
   Methylation of at least one gene resulted in a sensitivity of 62% and a specificity of 87%. Moreover, the assay successfully detected 33% (eight of 24) of early-stage tumors.
   Conclusion
   These data suggest that epigenetic markers in plasma may be of interest for detection of breast cancer. Identification of additional breast cancer specific methylated genes with higher prevalence in early stage cancers would improve this approach.
C1 Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, Seattle, WA 98104 USA.
   Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA.
   Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA.
   Univ Dakar, Tumor Inst, Dakar, Senegal.
C3 Harborview Medical Center; University of Washington; University of
   Washington Seattle; Johns Hopkins University; University of Washington;
   University of Washington Seattle
RP Kiviat, NB (通讯作者)，Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, 325 9th Ave, Seattle, WA 98104 USA.
EM nbk@u.washington.edu; dsidrans@jhmi.edu
RI ; Jeronimo, Carmen/H-3284-2013
OI Hoque, Mohammad Obaidul/0000-0001-6701-9978; Jeronimo,
   Carmen/0000-0003-4186-5345
FU NCI NIH HHS [5U01CA 85050, U01-CA84986] Funding Source: Medline
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Chen XQ, 1996, NAT MED, V2, P1033
   CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439
   de Widt-Levert LM, 2003, EUR J SURG ONCOL, V29, P216, DOI 10.1053/ejso.2002.1401
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 1999, CANCER RES, V59, P67
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Goessl C, 1998, CANCER RES, V58, P4728
   Gonzalez R, 2000, ANN ONCOL, V11, P1097, DOI 10.1023/A:1008305412635
   Harden SV, 2003, CLIN CANCER RES, V9, P1370
   Hawes SE, 2003, J INFECT DIS, V188, P555, DOI 10.1086/376996
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805
   Leonhardt H, 2000, J CELL BIOCHEM, P78
   Lo YMD, 2001, BIOMED PHARMACOTHER, V55, P362, DOI 10.1016/S0753-3322(01)00083-X
   Loh WY, 1997, STAT SINICA, V7, P815
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Müller HM, 2003, CANCER RES, V63, P7641
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Ngan RKC, 2001, ANN NY ACAD SCI, V945, P73
   Riddle DL, 1999, PHYS THER, V79, P939, DOI 10.1093/ptj/79.10.939
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Rosenberg K, 1998, J Nurse Midwifery, V43, P394
   SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123
   Sozzi G, 1999, CLIN CANCER RES, V5, P2689
   Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3
   Tsuda H, 2000, BRIT J CANCER, V82, P675
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Usadel H, 2002, CANCER RES, V62, P371
   Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291
   Wong IHN, 1999, CANCER RES, V59, P71
   Yang HJ, 2004, GYNECOL ONCOL, V93, P435, DOI 10.1016/j.ygyno.2004.01.039
NR 41
TC 193
Z9 256
U1 0
U2 24
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 10
PY 2006
VL 24
IS 26
BP 4262
EP 4269
DI 10.1200/JCO.2005.01.3516
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 086AK
UT WOS:000240645300006
PM 16908936
OA Bronze
DA 2025-01-12
ER

PT J
AU Cadieux, B
   Ching, TT
   VandenBerg, SR
   Costello, JF
AF Cadieux, Benoit
   Ching, Tsui-Ting
   VandenBerg, Scott R.
   Costello, Joseph F.
TI Genome-wide hypomethylation in human glioblastomas associated with
   specific copy number alteration, methylenetetrahydrofolate reductase
   allele status, and increased proliferation
SO CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION PATTERNS; CANCER-TESTIS GENES; 5-METHYLCYTOSINE CONTENT;
   CHROMOSOMAL INSTABILITY; COMMON MUTATION; BREAST-CANCER; HUMAN-TUMORS;
   TUMORIGENESIS; CELLS; DISEASE
AB Genome-wide reduction in 5-methylcytosine is an epigenetic hallmark of human tumorigenesis. Experimentally induced hypomethylation in mice promotes genomic instability and is sufficient to initiate tumorigenesis. Here, we report that global hypomethylation is common in primary human glioblastomas [glioblastoma multiforme (GBM)] and can affect up to an estimated 10 million CpG dinucleotides per haploid tumor genome. Demethylation involves satellite 2 (Sat2) pericentromeric DNA at chromosomes 1 and 16, the subtelomeric repeat sequence D4Z4 at chromosomes 4q and 10q, and interspersed AIu elements. Severe hypornethylation of Sat2 sequences is associated with copy number alterations of the adjacent euchromatin, suggesting that hypornethylation may be one factor predisposing to specific genetic alterations commonly occurring in GBMs. An additional apparent consequence of global hypomethylation is reactivation of the cancer-testis antigen MAGEA1 via promoter demethylation, but only in GBMs and GBM cell lines exhibiting a 5-methylcytosine content below a threshold of similar to 50%. Primary GBMs with significant hypomethylation tended to be heterozygous or homozygous for the low-functioning Val allele of the rate-limiting methyl group metabolism gene methylenetetrahydrofolate reductase (MTHFR), or had a deletion encompassing this gene at 1p36. Tumors with severe genomic hypomethylation also had an elevated proliferation index and deletion of the MTHFR gene. These data suggest a model whereby either excessive cell proliferation in the context of inadequate methyl donor production from MTHFR deficiency promotes genomic hypornethylation and further genomic instability, or that MTHFR deficiency-associated demethylation leads to increased proliferative activity in GBM.
C1 Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Costello, JF (通讯作者)，Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, 2340 Sutter,Room N225, San Francisco, CA 94143 USA.
EM jcostello@cc.ucsf.edu
RI Roberts, Jayne/G-2458-2011
OI Ching, Tsui-Ting/0000-0001-7650-1766
FU NCI NIH HHS [R01 CA094971] Funding Source: Medline
CR Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835
   [Anonymous], P NATL ACAD SCI USA
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Beilby J, 2004, EUR J CANCER, V40, P1250, DOI 10.1016/j.ejca.2004.01.026
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   De Smet C, 1999, MOL CELL BIOL, V19, P7327
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8
   Eramo A, 2005, CANCER RES, V65, P11469, DOI 10.1158/0008-5472.CAN-05-1724
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gloria L, 1996, CANCER, V78, P2300, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2300::AID-CNCR5>3.0.CO;2-Q
   Gure AO, 2005, CLIN CANCER RES, V11, P8055, DOI 10.1158/1078-0432.CCR-05-1203
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Heijmans BT, 2003, CANCER RES, V63, P1249
   Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020
   Misra A, 2005, CLIN CANCER RES, V11, P2907, DOI 10.1158/1078-0432.CCR-04-0708
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019
   Prados Michael D., 2000, Seminars in Oncology, V27, P1
   Prak ETL, 2000, NAT REV GENET, V1, P134
   Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Scarcella DL, 1999, CLIN CANCER RES, V5, P335
   Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810
   van Overveld PGM, 2005, ANN NEUROL, V58, P569, DOI 10.1002/ana.20625
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X
NR 50
TC 180
Z9 215
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2006
VL 66
IS 17
BP 8469
EP 8476
DI 10.1158/0008-5472.CAN-06-1547
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 081PL
UT WOS:000240329400023
PM 16951158
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Majumder, S
AF Majumder, Sadhan
TI REST in good times and bad - Roles in tumor suppressor and oncogenic
   activities
SO CELL CYCLE
LA English
DT Article
DE RESTNRSF; epigenetic regulation; neuronal differentiation; chromatin;
   tumor-suppressor activity; oncogenic activity; colon cancer; breast
   cancer; lung cancer; medulloblastoma
ID RESTRICTIVE SILENCER FACTOR; CELL LUNG-CANCER; GENE-EXPRESSION; FACTOR
   NRSF; GLYCINE RECEPTOR; TARGET GENES; TRANSCRIPTION; REST/NRSF;
   REPRESSOR; MEDULLOBLASTOMA
AB The repressor element 1 (RE-1)-silencing transcription factor (REST), also known as the neuron-restrictive silencer factor (NRSF), was originally discovered as a transcriptional repressor of a large number of primarily terminal neuronal differentiation genes in non-neuronal cells and neural stem cells (NSCs). Although REST is expressed in NSCs, its transcription is generally blocked as NSCs undergo differentiation, and it is rarely expressed in terminally differentiated neurons. In support of its function as a transcriptional repressor, REST was found to contain a DNA-binding domain and two repressor domains. The repressor domains were found to associate, directly or indirectly, with a large number of cellular repressor complexes. Thus, REST was considered a major epigenetic regulator controlling chromatin modification. However, REST is expressed in some differentiated neurons, and when bound to a double-stranded small RNA, REST was later found to also function as an activator of its same target neuronal differentiation genes in NSCs. In addition, REST has been found to regulate an evolving array of genes and cellular functions, making it a biological enigma. For example, REST was recently found to have a seemingly paradoxical role in both tumor suppressor activity and oncogenic activity. Current evidence suggests that the diverse cellular context generated by intrinsic factors in the cell, the amount of REST protein present in the cell, the affinity of the REST protein for its specific target gene, and the cellular niche dictate such behavior.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Unit 1006, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Majumder, S (通讯作者)，Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Unit 1006, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM majumder@mdanderson.org
FU NCI NIH HHS [CA97124, CA81255] Funding Source: Medline
CR Andrés ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873
   Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013
   Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015
   Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3
   Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101
   Calderone A, 2003, J NEUROSCI, V23, P2112
   Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839
   Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431
   Cheong A, 2005, MOL CELL, V20, P45, DOI 10.1016/j.molcel.2005.08.030
   CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8
   Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103
   Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032
   Coulson JM, 1999, CANCER RES, V59, P5123
   Coulson JM, 2000, CANCER RES, V60, P1840
   DELLOVADE T, 2006, ANN REV NEUROSCI
   Eberhart CG, 2003, BRAIN PATHOL, V13, P376
   Fogarty MP, 2005, J NEUROBIOL, V64, P458, DOI 10.1002/neu.20166
   Fuller GN, 2005, MOL CANCER THER, V4, P343
   Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X
   Griffith EC, 2001, NEURON, V31, P339, DOI 10.1016/S0896-6273(01)00386-5
   Gurrola-Diaz C, 2003, ONCOGENE, V22, P5636, DOI 10.1038/sj.onc.1206790
   Higashino K, 2003, CANCER SCI, V94, P37, DOI 10.1111/j.1349-7006.2003.tb01349.x
   Hsieh J, 2005, CURR OPIN CELL BIOL, V17, P664, DOI 10.1016/j.ceb.2005.09.002
   Immaneni A, 2000, NUCLEIC ACIDS RES, V28, P3403, DOI 10.1093/nar/28.17.3403
   Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7
   Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891
   Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200
   Knoepfler PS, 2006, CELL CYCLE, V5, P47, DOI 10.4161/cc.5.1.2292
   Koenigsberger C, 2000, P NATL ACAD SCI USA, V97, P2291, DOI 10.1073/pnas.050578797
   Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X
   Kuwahara K, 2003, EMBO J, V22, P6310, DOI 10.1093/emboj/cdg601
   Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565
   Lemonde S, 2004, J NEUROCHEM, V88, P857, DOI 10.1046/j.1471-4159.2003.02223.x
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469
   Lunyak VV, 2005, CELL, V121, P499, DOI 10.1016/j.cell.2005.05.003
   McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X
   Neumann SB, 2004, MOL BRAIN RES, V120, P173, DOI 10.1016/j.molbrainres.2003.10.021
   Nishihara S, 2003, BIOCHEM BIOPH RES CO, V311, P55, DOI 10.1016/j.bbrc.2003.09.158
   Nishimura E, 1996, NEUROSCI LETT, V211, P101, DOI 10.1016/0304-3940(96)12722-1
   Paquette AJ, 2000, P NATL ACAD SCI USA, V97, P12318, DOI 10.1073/pnas.97.22.12318
   Raffel C, 2004, NEOPLASIA, V6, P310, DOI 10.1593/neo.03454
   Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008-5472.CAN-05-0481
   Rutka James T, 2004, Expert Rev Neurother, V4, P879, DOI 10.1586/14737175.4.5.879
   SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435
   Shimojo M, 2004, LIFE SCI, V74, P2213, DOI 10.1016/j.lfs.2003.08.045
   Shimojo M, 1999, MOL CELL BIOL, V19, P6788
   Shimojo M, 2003, MOL CELL BIOL, V23, P9025, DOI 10.1128/MCB.23.24.9025-9031.2003
   Su XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004
   Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006
   Tawadros T, 2005, CELL SIGNAL, V17, P929, DOI 10.1016/j.cellsig.2004.11.013
   van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005
   Watanabe H, 2006, ONCOGENE, V25, P470, DOI 10.1038/sj.onc.1209068
   Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004
   Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033
   Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8
   Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219
NR 57
TC 104
Z9 122
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD SEP 1
PY 2006
VL 5
IS 17
BP 1929
EP 1935
DI 10.4161/cc.5.17.2982
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 089EA
UT WOS:000240861900007
PM 16929174
OA Bronze
DA 2025-01-12
ER

PT J
AU Katoh, M
   Katoh, M
AF Katoh, Masuko
   Katoh, Masaru
TI NUMB is a break of WNT - Notch signaling cycle
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE bioinformatics; comparative genomics; comparative proteomics; WNT;
   Notch; integrome network
ID EVOLUTIONARILY CONSERVED TARGET; COMPARATIVE GENOMICS;
   MOLECULAR-CLONING; GASTRIC-CANCER; UP-REGULATION; GENE; IDENTIFICATION;
   PATHWAY; EXPRESSION; MECHANISM
AB Notch, FGF and WNT signaling pathways cross-talk during embryogenesis, tissue regeneration and carcinogenesis. Notch-ligand binding to Notch receptors leads to the cleavage of Notch receptors and the following nuclear translocation of Notch intracellular domain (NICD) to induce transcriptional activation of Notch target genes. Notch signaling inhibitors, NUMB and NUMB-like (NUMBL), are docking proteins with PTB domain. We searched for the TCF/LEF-binding site within the promoter region of NUMB and NUMBL genes. Because two TCF/LEF-binding sites were identified within human NUMB promoter based on bioinformatics and human intelligence (Humint), comparative integromics analyses on NUMB orthologs were further performed. Chimpanzee NUBM gene, consisting of 13 exons, was identified within NW-115880.1 genome sequence. XM_510045.1 was not the correct coding sequence for chimpanzee NUMB. Chimpanzee NUMB gene was found to encode a 65 1-amino-acid protein showing 99.5, 93.9 and 82.6% total-amino-acid identity with human NUMB, mouse Numb and chicken numb, respectively. Human NUMB mRNA was expressed in placenta, ES cells, neural tissues, trachea, testis, uterus, thymus, coronary artery as well as in a variety of tumors, such as cervical cancer, tong tumor, brain tumor, colorectal and breast cancer. Although distal TCF/LEF-binding site within human NUMB promoter was conserved only among primate NUMB orthologs, proximal TCF/LEF-binding site was conserved among primate and rodent NUMB orthologs. NUMB, JAG 1, FGF 18, FGF20 and SPRY4 are potent targets of the canonical WNT signaling pathway in progenitor cells. NUMB inhibits Notch signaling in progenitor cells to induce differentiation, while JAG I activates Notch signaling in stem cells to maintain self-renewal potential. Because Notch signaling inhibitor NUMB was identified as the safe apparatus for the WNT - Notch signaling cycle, epigenetic silencing, deletion and loss-of-functi on mutation of NUMB gene could lead to carcinogenesis through the dysregulation of the WNT - Notch signaling cycle.
C1 Natl Canc Ctr, Res Inst, Genet & Cell Biol Sect, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   M&M Med BioInformat, Tokyo 1130033, Japan.
C3 National Cancer Center - Japan
RP Katoh, M (通讯作者)，Natl Canc Ctr, Res Inst, Genet & Cell Biol Sect, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM mkatoh@ncc.go.jp
CR Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Garciadiego-Cázares D, 2004, DEVELOPMENT, V131, P4735, DOI 10.1242/dev.01345
   Heller RS, 2003, GENE EXPRESSION, V11, P141, DOI 10.3727/000000003108749035
   KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1016/0270-9139(93)90500-M
   Katoh M, 2006, TECHNOL CANCER RES T, V5, P169, DOI 10.1177/153303460600500208
   Katoh M, 2006, INT J MOL MED, V17, P681
   Katoh M, 2005, INT J ONCOL, V27, P281
   Katoh M, 2005, INT J ONCOL, V26, P1129
   Katoh M, 2005, INT J ONCOL, V26, P1135
   Katoh M, 2005, INT J MOL MED, V15, P749
   Katoh M, 2005, INT J MOL MED, V15, P743
   Katoh M, 2001, INT J ONCOL, V19, P1003
   Katoh M, 2004, INT J ONCOL, V25, P529
   Katoh M, 2002, INT J MOL MED, V10, P677
   Katoh M, 1996, ONCOGENE, V13, P873
   Katoh M, 2005, INT J MOL MED, V15, P533
   Katoh M, 2005, INT J MOL MED, V16, P1103
   Katoh M, 2003, INT J MOL MED, V12, P643
   Katoh M, 2003, INT J ONCOL, V22, P1155
   Katoh M, 2005, INT J ONCOL, V27, P1677
   Katoh M, 2004, CANCER BIOL THER, V3, P566, DOI 10.4161/cbt.3.6.936
   Katoh M, 2002, INT J ONCOL, V21, P1269
   Katoh M, 2005, ONCOL REP, V14, P287
   Katoh M, 2003, INT J MOL MED, V12, P45
   KATOH M, 2005, INT J MOL MED, V14, P747
   Katoh Y, 2006, INT J MOL MED, V17, P529
   Katoh Y, 2006, INT J MOL MED, V17, P391
   Katoh Y, 2005, CANCER BIOL THER, V4, P1050, DOI 10.4161/cbt.4.10.2184
   Katoh Y, 2005, ONCOL REP, V14, P1351
   Katoh Y, 2005, INT J MOL MED, V16, P477
   Katoh Y, 2005, INT J MOL MED, V16, P355
   Katoh Y, 2005, ONCOL REP, V14, P291
   Katoh Y, 2005, INT J MOL MED, V15, P879
   Katoh Y, 2005, INT J MOL MED, V15, P527
   Katoh Y, 2005, INT J ONCOL, V26, P841
   Katoh Y, 2005, INT J MOL MED, V16, P959
   Katoh Y, 2005, INT J ONCOL, V27, P275
   Katoh Y, 2005, INT J MOL MED, V16, P767
   Kirikoshi H, 2001, BIOCHEM BIOPH RES CO, V283, P798, DOI 10.1006/bbrc.2001.4855
   Li JL, 2005, CANCER CELL, V8, P1, DOI 10.1016/j.ccr.2005.06.013
   Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992
   Saitoh T, 2002, INT J ONCOL, V20, P343
   Saitoh T, 2001, INT J ONCOL, V19, P123
   Saitoh T, 2001, BIOCHEM BIOPH RES CO, V284, P1168, DOI 10.1006/bbrc.2001.5105
   SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0
   Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054
   Swain Rajeeb Kumar, 2005, Cell Commun Signal, V3, P12, DOI 10.1186/1478-811X-3-12
   WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530
NR 51
TC 60
Z9 75
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2006
VL 18
IS 3
BP 517
EP 521
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 073LD
UT WOS:000239743500017
PM 16865239
DA 2025-01-12
ER

PT J
AU Ikeda, JI
   Morii, E
   Kimura, H
   Tomita, Y
   Takakuwa, T
   Hasegawa, JI
   Kim, YK
   Miyoshi, Y
   Noguchi, S
   Nishida, T
   Aozasa, K
AF Ikeda, J-i
   Morii, E.
   Kimura, H.
   Tomita, Y.
   Takakuwa, T.
   Hasegawa, J-i
   Kim, Y. K.
   Miyoshi, Y.
   Noguchi, S.
   Nishida, T.
   Aozasa, K.
TI Epigenetic regulation of the expression of the novel stem cell marker
   CDCP 1 in cancer cells
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE CDCP1; methylation; transcriptional regulation; cancer; clinical samples
ID IDENTIFICATION; GENE; BIOLOGY; DOMAIN; TUMORS
AB CDCP1 is a novel stem cell marker that is expressed in several types of cancer. The mechanisms by which CDCP1 expression is regulated, and the clinical implications of this marker, have not been clarified. In this report, we examine the epigenetic-regulation of CDCP1 expression in cell lines and clinical samples from patients with-breast cancer. Many CpG sequences were localized around the transcription initiation site of CDCP1. These CpG motifs were found to be poorly methylated in cell lines with high levels of CDCP1 expression and heavily methylated in cell lines with low levels of CDCP1 expression. The in vitro methylation of CpG sites decreased CDCP1 promoter activity, and the addition of a demethylating reagent restored activity. In 25 breast cancer samples, an inverse correlation was noted between the CDCP1 expression level and the proportion of methylated to nonmethylated CpG sites. Tumours with high-level CDCP1 expression showed higher levels of proliferation, as revealed by immunohistochemical detection of the MIB-1 antigen, than tumours with low-level CDCP1 expression. These findings indicate that the expression of CDCP1 is regulated by methylation of its promoter region in tumours. CDCP1 expression may prove to be useful in the further characterization of cancers. Copyright (c) 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan.
   Osaka Univ, Sch Med, Dept Surg, Suita, Osaka 565, Japan.
   Osaka Univ, Grad Sch Med, Dept Surg Oncol, Suita, Osaka 565, Japan.
C3 Osaka University; Osaka University; Osaka University
RP Morii, E (通讯作者)，Osaka Univ, Grad Sch Med, Dept Pathol, Yamadaoka 2-2, Suita, Osaka 5650871, Japan.
EM morii@patho.med.osaka-u.ac.jp
RI Kim, Jong/AAF-3414-2021
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alleman WG, 2004, CLIN CANCER RES, V10, P7011, DOI 10.1158/1078-0432.CCR-04-0516
   Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019
   Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200
   Bühring HJ, 2004, STEM CELLS, V22, P334, DOI 10.1634/stemcells.22-3-334
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Conze T, 2003, ANN NY ACAD SCI, V996, P222, DOI 10.1111/j.1749-6632.2003.tb03249.x
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Frigola J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e28
   Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jordan CT, 2004, CURR OPIN CELL BIOL, V16, P708, DOI 10.1016/j.ceb.2004.09.002
   Morii E, 2004, J BIOL CHEM, V279, P48923, DOI 10.1074/jbc.M407026200
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566
   Singh SK, 2003, CANCER RES, V63, P5821
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
NR 18
TC 41
Z9 46
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD SEP
PY 2006
VL 210
IS 1
BP 75
EP 84
DI 10.1002/path.2026
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 077OZ
UT WOS:000240040800011
PM 16823897
DA 2025-01-12
ER

PT J
AU Glatz-Krieger, K
   Pache, M
   Tapia, C
   Fuchs, A
   Savic, S
   Glatz, D
   Mihatsch, M
   Meyer, P
AF Glatz-Krieger, Katharina
   Pache, Mona
   Tapia, Coya
   Fuchs, Alain
   Savic, Spasenija
   Glatz, Dieter
   Mihatsch, Michael
   Meyer, Peter
TI Anatomic site-specific patterns of gene copy number gains in skin,
   mucosal, and uveal melanomas detected by fluorescence in situ
   hybridization
SO VIRCHOWS ARCHIV
LA English
DT Article
DE melanoma; fluorescence in situ hybridization; tissue array;
   amplification
ID COMPARATIVE GENOMIC HYBRIDIZATION; METASTATIC BREAST-CANCER; C-MYC;
   MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; MONOCLONAL-ANTIBODY; TISSUE
   MICROARRAYS; BRAF MUTATIONS; CYCLIN D1; OVEREXPRESSION
AB To assess the differences between melanomas of different location and different etiology, 372 malignant melanomas were brought in a tissue microarray format. The collection included 23 acral and 118 non-acral skin melanomas, 9 mucosal melanomas, 100 uveal melanomas, and 122 melanoma metastases. Fluorescence in situ hybridization (FISH) was used to assess copy number changes of the cyclin D1 (CCND1), MDM2, c-myc (MYC), and HER2 genes. FISH analysis revealed distinct differences between melanomas from different locations. CCND1 amplifications were detected in skin melanomas from sites with chronic sun exposure (6 of 32 cases), acral melanomas (4 of 17 cases), and mucosal melanomas (one of ten cases) but not in uveal melanomas. High-level MDM2 amplifications were exclusively present in acral melanomas (2 of 19 cases). MYC copy number gains were detected in 32 of 71 uveal melanomas, five of eight mucosal melanomas, and 6 of 67 melanomas from sites with intermittent sun exposure but not in acral melanomas nor melanomas from sites with chronic sun exposure. Alterations of the MYC gene were associated with advanced tumor stage. There were no high-level HER2 amplifications. Site-specific genetic and epigenetic features may impact the response of melanomas to various anticancer drugs and should be considered in future studies on the molecular pathogenesis of malignant melanomas.
C1 Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland.
   Univ Basel, Eye Clin, CH-4003 Basel, Switzerland.
   Univ Basel, IT Dept, CH-4003 Basel, Switzerland.
C3 University of Basel; University of Basel; University of Basel
RP Glatz-Krieger, K (通讯作者)，Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4031 Basel, Switzerland.
EM Katharina.Glatz@unibas.ch
CR Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622
   Bastian BC, 2000, CANCER RES, V60, P1968
   Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5
   Bastian BC, 2003, ONCOGENE, V22, P3081, DOI 10.1038/sj.onc.1206463
   Bastian BC, 1998, CANCER RES, V58, P2170
   Bodey B, 1997, ANTICANCER RES, V17, P1319
   Bollag Gideon, 2003, Curr Opin Investig Drugs, V4, P1436
   Casorzo L, 2005, MELANOMA RES, V15, P155, DOI 10.1097/00008390-200506000-00003
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329
   Cree IA, 2000, J PATHOL, V191, P112
   Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919
   Edwards RH, 2004, J MED GENET, V41, P270, DOI 10.1136/jmg.2003.016667
   Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941
   Fink-Puches R, 2001, ANTICANCER RES, V21, P2793
   Häusler T, 2005, INT J CANCER, V116, P909, DOI 10.1002/ijc.21086
   Inman JL, 2003, J SURG ONCOL, V84, P82, DOI 10.1002/jso.10297
   Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123
   Mudhar HS, 2004, HISTOPATHOLOGY, V45, P1, DOI 10.1111/j.1365-2559.2004.01874.x
   NATALI PG, 1994, INT J CANCER, V56, P341, DOI 10.1002/ijc.2910560308
   Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679
   Pastorino F, 2003, CLIN CANCER RES, V9, P4595
   Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659
   Persons DL, 2000, ANTICANCER RES, V20, P1965
   Potti Anil, 2003, J Carcinog, V2, P8, DOI 10.1186/1477-3163-2-8
   Ragnarsson-Olding B, 2004, MELANOMA RES, V14, P395, DOI 10.1097/00008390-200410000-00010
   Sasaki Y, 2004, J INVEST DERMATOL, V123, P177, DOI 10.1111/j.0022-202X.2004.22722.x
   Sauter ER, 2002, CANCER RES, V62, P3200
   Shinozaki H, 1996, CLIN CANCER RES, V2, P1155
   Simon R, 2004, METH MOLEC MED, V97, P377
   SINGH AD, 1994, CANCER GENET CYTOGEN, V72, P109, DOI 10.1016/0165-4608(94)90125-2
   Sisley K, 1997, GENE CHROMOSOME CANC, V19, P22, DOI 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2
   SISLEY K, 1992, GENE CHROMOSOME CANC, V5, P197, DOI 10.1002/gcc.2870050304
   Treszl A, 2004, CYTOM PART B-CLIN CY, V60B, P37, DOI 10.1002/cyto.b.20016
   van Dijk M, 2003, GENE CHROMOSOME CANC, V36, P151, DOI 10.1002/gcc.10156
   White VA, 1998, CANCER, V83, P354, DOI 10.1002/(SICI)1097-0142(19980715)83:2<354::AID-CNCR20>3.3.CO;2-C
NR 42
TC 30
Z9 31
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD SEP
PY 2006
VL 449
IS 3
BP 328
EP 333
DI 10.1007/s00428-006-0167-8
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 096NV
UT WOS:000241385000008
PM 16523260
DA 2025-01-12
ER

PT J
AU Reynolds, PA
   Sigaroudinia, M
   Zardo, G
   Wilson, MB
   Benton, GM
   Miller, CJ
   Hong, CB
   Fridlyand, J
   Costello, JF
   Tlsty, TD
AF Reynolds, Paul A.
   Sigaroudinia, Mahvash
   Zardo, Giuseppe
   Wilson, Matthew B.
   Benton, Geoffrey M.
   Miller, Caroline J.
   Hong, Chibo
   Fridlyand, Jane
   Costello, Joseph F.
   Tlsty, Thea D.
TI Tumor suppressor p16<SUP>INK4A</SUP> regulates polycomb-mediated DNA
   hypermethylation in human mammary epithelial cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GROUP PROTEIN EZH2; P16 EXPRESSION; SELF-RENEWAL; METHYLATION; CANCER;
   GENE; GROWTH; SENESCENCE; RECEPTOR; TARGET
AB Alterations in DNA methylation are important in cancer, but the acquisition of these alterations is poorly understood. Using an unbiased global screen for CpG island methylation events, we have identified a non-random pattern of DNA hypermethylation acquired in p16-repressed cells. Interestingly, this pattern included loci located upstream of a number of homeobox genes. Upon removal of p16(INK4A) activity in primary human mammary epithelial cells, polycomb repressors, EZH2 and SUZ12, are upregulated and recruited to HOXA9, a locus expressed during normal breast development and epigenetically silenced in breast cancer. We demonstrate that at this targeted locus, the up-regulation of polycomb repressors is accompanied by the recruitment of DNA methyltransferases and the hypermethylation of DNA, an endpoint, which we show to be dependent on SUZ12 expression. These results demonstrate a causal role of p16INK4A disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression.
C1 Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; University of California San Francisco; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco
RP Tlsty, TD (通讯作者)，Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW501, San Francisco, CA 94143 USA.
EM thea.tlsty@ucsf.edu
RI Zardo, Giuseppe/HSA-9392-2023; Roberts, Jayne/G-2458-2011
OI Reynolds, Paul/0000-0001-8738-1245
FU NCI NIH HHS [R01 CA97214, P50 CA58207] Funding Source: Medline
CR Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224
   [Anonymous], 1993, Resampling-based multiple testing: Examples and methods for p-value adjustment
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717
   Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Costello JF, 2002, NAT GENET, V31, P123, DOI 10.1038/ng0602-123
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Gadd M, 2001, CANCER RES, V61, P8811
   Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Ihaka R., 1996, J Comput Graph Stat, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim MH, 1998, DNA CELL BIOL, V17, P407, DOI 10.1089/dna.1998.17.407
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051
   Meluh PB, 1999, METHOD ENZYMOL, V304, P414
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Nikolova Z, 1998, J CELL SCI, V111, P2741
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2
   Shim YH, 2003, MODERN PATHOL, V16, P430, DOI 10.1097/01.mp.0000066799.99032.A7
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   UNGER MA, 2002, THESIS U PENNSYLVANI
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001
   Wong DJ, 2001, CANCER RES, V61, P8284
NR 58
TC 106
Z9 126
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 25
PY 2006
VL 281
IS 34
BP 24790
EP 24802
DI 10.1074/jbc.M604175200
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 074YF
UT WOS:000239847800075
PM 16766534
OA hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Fulda, S
   Debatin, KM
AF Fulda, S.
   Debatin, K-M
TI 5-aza-2′-deoxycytidine and IFN-γ cooperate to sensitize for
   TRAIL-induced apoptosis by upregulating caspase-8
SO ONCOGENE
LA English
DT Article
DE caspase-8; apoptosis; TRAIL; interferon-gamma; resistance
ID DRUG-INDUCED APOPTOSIS; BREAST-TUMOR CELLS; NEUROBLASTOMA-CELLS; DEATH
   RECEPTOR; INTERFERON-GAMMA; DNA METHYLATION; DECOY RECEPTORS;
   CANCER-THERAPY; CD95 APO-1/FAS; EXPRESSION
AB Resistance of tumors to cytotoxic therapy remains a major obstacle in cancer treatment and is often caused by defects in apoptosis programs. Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors, for example in neuroblastoma or medulloblastoma. Here, we provide for the first time evidence that combined treatment with suboptimal concentrations of the demethylating agent 5-Aza-2'-deoxycytidine (5-dAzaC) and interferon-gamma (IFN-gamma) cooperated to upregulate caspase-8 expression in neuroblastoma and medulloblastoma cells lacking caspase-8. Consequently, activation of caspase-8 and downstream caspases upon addition of TNF-related apoptosis-inducing ligand (TRAIL) was restored by pretreatment with 5-dAzaC and IFN-gamma. Importantly, pretreatment with 5-dAzaC and IFN-gamma acted in concert to significantly enhance TRAIL-induced apoptosis in neuroblastoma and medulloblastoma cells. Inhibition of caspase-8 by dominant-negative caspase-8 or by the relatively specific caspase-8 inhibitior zIETD.fmk inhibited the increase in apoptosis provided by 5-dAzaC and IFN-gamma, indicating that caspase-8 is a key mediator of this sensitization effect. Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.
C1 Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany.
C3 Ulm University
RP Fulda, S (通讯作者)，Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.
EM simone.fulda@uniklinik-ulm.de
RI Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014
OI Fulda, Simone/0000-0002-0459-6417; Debatin,
   Klaus-Michael/0000-0002-8397-1886
CR Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333
   Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Casciano I, 2004, CELL DEATH DIFFER, V11, P131, DOI 10.1038/sj.cdd.4401327
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Eggert A, 2001, CANCER RES, V61, P1314
   Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10
   Fan WM, 1998, ONCOL REP, V5, P1035
   FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464
   Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763
   Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258
   Fulda S, 1997, CANCER RES, V57, P3823
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Fulda S, 2004, VITAM HORM, V67, P275
   Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157
   Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34
   Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200
   Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836
   LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187
   Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401
   Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673
   Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200
   Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523
   Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541
   Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3
   Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840
   Yang XZ, 2003, CANCER RES, V63, P1122
NR 35
TC 84
Z9 93
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD AUG 24
PY 2006
VL 25
IS 37
BP 5125
EP 5133
DI 10.1038/sj.onc.1209518
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 077WZ
UT WOS:000240063700005
PM 16607283
DA 2025-01-12
ER

PT J
AU Wendt, MK
   Johanesen, PA
   Kang-Decker, N
   Binion, DG
   Shah, V
   Dwinell, MB
AF Wendt, M. K.
   Johanesen, P. A.
   Kang-Decker, N.
   Binion, D. G.
   Shah, V.
   Dwinell, M. B.
TI Silencing of epithelial CXCL12 expression by DNA hypermethylation
   promotes colonic carcinoma metastasis
SO ONCOGENE
LA English
DT Article
DE chemokine; intestinal mucosa; epithelial cell; epigenetic
ID CHEMOKINE RECEPTOR CXCR4; FACTOR-I; CPG METHYLATION; BREAST-CANCER;
   CELLS; SDF-1; METHYLTRANSFERASES; LOCALIZATION; LACKING; GROWTH
AB Cellular metastasis is the most detrimental step in carcinoma disease progression, yet the mechanisms that regulate this process are poorly understood. CXCL12 and its receptor CXCR4 are co-expressed in several tissues and cell types throughout the body and play essential roles in development. Disruption of either gene causes embryonic lethality due to similar defects. Post-natally, CXCL12 signaling has a wide range of effects on CXCR4-expressing cells, including the directed migration of leukocytes, lymphocytes and hematopoietic stem cells. Recently, this signaling axis has also been described as an important regulator of directed carcinoma cell metastasis. We show herein that while CXCR4 expression remains consistent, constitutive colonic epithelial expression of CXCL12 is silenced by DNA hypermethylation in primary colorectal carcinomas as well as colorectal carcinoma-derived cell lines. Inhibition of DNA methyltransferase (Dnmt) enzymes with 5-aza-2'-deoxycytidine or genetic ablation of both Dnmt1 and Dnmt3b prevented promoter methylation and restored CXCL12 expression. Re-expression of functional, endogenous CXCL12 in colorectal carcinoma cells dramatically reduced metastatic tumor formation in mice, as well as foci formation in soft agar. Decreased metastasis was correlated with increased caspase activity in cells re-expressing CXCL12. These data constitute the unique observation that silencing CXCL12 within colonic carcinoma cells greatly enhances their metastatic potential.
C1 Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.
   Mayo Clin Fdn, GI Res Unit, Dept Med, Rochester, MN USA.
   Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin; Mayo Clinic; Medical College of Wisconsin
RP Dwinell, MB (通讯作者)，Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM mdwinell@mcw.edu
FU NIDDK NIH HHS [DK062066, DK002808, R01 DK062066, R56 DK062066] Funding
   Source: Medline
CR Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8
   Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Arya M, 2003, CURR MED RES OPIN, V19, P557, DOI 10.1185/030079903125002216
   Begum NA, 1996, BIOCHEM BIOPH RES CO, V229, P864, DOI 10.1006/bbrc.1996.1893
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Derdeyn CA, 1999, AIDS RES HUM RETROV, V15, P1063, DOI 10.1089/088922299310359
   Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359
   Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   García-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016
   Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173
   Haviv YS, 2004, MOL CANCER THER, V3, P687
   Heidemann J, 2004, AM J PHYSIOL-GASTR L, V286, pG1059, DOI 10.1152/ajpgi.00417.2003
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685
   Jubb AM, 2003, ANN NY ACAD SCI, V983, P251, DOI 10.1111/j.1749-6632.2003.tb05980.x
   Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022
   Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978
   Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   PANIS Y, 1990, J HEPATOL, V11, P53, DOI 10.1016/0168-8278(90)90271-R
   Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC
   Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589
   Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004
   Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 45
TC 123
Z9 140
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 17
PY 2006
VL 25
IS 36
BP 4986
EP 4997
DI 10.1038/sj.onc.1209505
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 075XR
UT WOS:000239921300004
PM 16568088
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Conley, BA
   Wright, JJ
   Kummar, S
AF Conley, Barbara A.
   Wright, John J.
   Kummar, Shivaani
TI Targeting epigenetic abnormalities with histone deacetylase inhibitors
SO CANCER
LA English
DT Article
DE histone deacetylase inhibitors; epigenetics; drug development; targeted
   therapeutics
ID SUBEROYLANILIDE HYDROXAMIC ACID; CHRONIC LYMPHOCYTIC-LEUKEMIA;
   TRANS-RETINOIC ACID; BREAST-CANCER CELLS; PHASE-I; DEPSIPEPTIDE
   FR901228; ANTITUMOR-ACTIVITY; INDUCE APOPTOSIS; DOWN-REGULATION;
   CLINICAL-TRIAL
AB BACKGROUND. Alterations in chromosome structure play critical roles in the control of gene transcription. These "epigenetic" alterations include modification of histones and other proteins by acetylation and/or phosphorylation. Normally, these modifications are balanced finely and are highly reversible in normal tissues, but they may be imbalanced and heritable in tumor cells. Histone deacetylase inhibitors increase histone acetylation, thereby modulating the expression of a subset of genes in a coordinated fashion. Several tumor suppressor genes associated with the malignant phenotype are repressed by epigenetic mechanisms in sporadic cancers. Thus, therapy with histone deacetylase inhibitors may alter tumor phenotype to inhibit growth in such tumors.
   METHODS. The authors reviewed the rationale for histone deacetylase inhibitors as potential anticancer agents and reviewed some preclinical and early clinical trial data with various classes of histone deacetylase inhibitors.
   RESULTS. Preclinical and clinical antitumor activity has been observed. Toxicities include fatigue, myelosuppression, and cardiac abnormalities.
   CONCLUSIONS. Histone deacetylase inhibitors have shown promising activity in some solid tumors and hematologic malignancies.
C1 Michigan State Univ, Div Hematol Oncol, Dept Med, Coll Human Med,Clin Ctr B414, E Lansing, MI 48824 USA.
   NCI, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
   NCI, Med Oncol Clin Res Unit, Ctr Canc Res, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
C3 Michigan State University; Michigan State University College of Human
   Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI)
RP Conley, BA (通讯作者)，Michigan State Univ, Div Hematol Oncol, Dept Med, Coll Human Med,Clin Ctr B414, E Lansing, MI 48824 USA.
EM barbara.conley@hc.msu.edu
CR Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794
   Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043
   Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600
   Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589
   Byrd JC, 2005, BLOOD, V105, P959, DOI 10.1182/blood-2004-05-1693
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Camphausen K, 2004, CLIN CANCER RES, V10, P6066, DOI 10.1158/1078-0432.CCR-04-0537
   Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006
   Catley L, 2003, BLOOD, V102, P2615, DOI 10.1182/blood-2003-01-0233
   Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Chung YL, 2004, MOL CANCER THER, V3, P317
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fournel M, 2002, CANCER RES, V62, P4325
   Fuino L, 2003, MOL CANCER THER, V2, P971
   Gabrielli B, 2004, ANN NY ACAD SCI, V1030, P627, DOI 10.1196/annals.1329.073
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Gore L, 2004, J CLIN ONCOL, V22, p201S
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302
   Hsi LC, 2004, CANCER RES, V64, P8778, DOI 10.1158/0008-5472.CAN-04-1867
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   Kitazono M, 2001, J CLIN ENDOCR METAB, V86, P3430, DOI 10.1210/jc.86.7.3430
   Kwon HJ, 2002, INT J CANCER, V97, P290, DOI 10.1002/ijc.1602
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0
   Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532
   Lucas DM, 2004, LEUKEMIA, V18, P1207, DOI 10.1038/sj.leu.2403388
   Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x
   McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3
   Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078-0432.CCR-03-0709
   Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102
   Peart MJ, 2003, CANCER RES, V63, P4460
   Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068
   Plumb JA, 2003, MOL CANCER THER, V2, P721
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069
   Rahmani M, 2005, MOL PHARMACOL, V67, P1166, DOI 10.1124/mol.104.007831
   Rephaeli A, 2005, INT J CANCER, V116, P226, DOI 10.1002/ijc.21030
   Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sakajiri S, 2005, EXP HEMATOL, V33, P53, DOI 10.1016/j.exphem.2004.09.008
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Sasakawa Y, 2005, BIOCHEM PHARMACOL, V69, P603, DOI 10.1016/j.bcp.2004.11.008
   Sato N, 2004, INT J ONCOL, V24, P679
   Sawa H, 2004, ACTA NEUROPATHOL, V107, P523, DOI 10.1007/s00401-004-0841-3
   Schultz BE, 2004, BIOCHEMISTRY-US, V43, P11083, DOI 10.1021/bi0494471
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Trus MR, 2005, LEUKEMIA, V19, P1161, DOI 10.1038/sj.leu.2403773
   Tsurutani J, 2003, INT J CANCER, V104, P238, DOI 10.1002/ijc.10921
   Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010
   Yang XW, 2001, CANCER RES, V61, P7025
   Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737
   Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
NR 68
TC 36
Z9 44
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD AUG 15
PY 2006
VL 107
IS 4
BP 832
EP 840
DI 10.1002/cncr.22064
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 076II
UT WOS:000239950000021
PM 16826577
OA hybrid
DA 2025-01-12
ER

PT J
AU Ai, LB
   Kim, WJ
   Kim, TY
   Fields, CR
   Massoll, NA
   Robertson, KD
   Brown, KD
AF Ai, Lingbao
   Kim, Wan-Ju
   Kim, Tae-You
   Fields, C. Robert
   Massoll, Nicole A.
   Robertson, Keith D.
   Brown, Kevin D.
TI Epigenetic silencing of the tumor suppressor cystatin M occurs during
   breast cancer progression
SO CANCER RESEARCH
LA English
DT Article
ID CYSTEINE PROTEINASE-INHIBITOR; HUMAN CATHEPSIN-B; DNA METHYLATION; CPG
   ISLANDS; PROMOTER HYPERMETHYLATION; MALIGNANT PROGRESSION; ABERRANT
   METHYLATION; ESTROGEN-RECEPTOR; SPORADIC BREAST; M/E EXPRESSION
AB Cystatin M is a secreted inhibitor of lysosomal cysteine proteases. Several lines of evidence indicate that cystatin M is a tumor suppressor important in breast malignancy; however, the mechanism(s) that leads to inactivation of cystatin M during cancer progression is unknown. Inspection of the human cystatin M locus uncovered a large and dense CpG island within the 5' region of this gene (termed CST6). Analysis of cultured human breast tumor lines indicated that cystatin M expression is either undetectable or in low abundance in several lines; however, enhanced gene expression was measured in cells cultured on the DNA demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC). Increased cystatin M expression does not correlate with a cytotoxic response to 5-aza-dC; rather, various molecular approaches indicated that the CST6 gene was aberrantly methylated in these tumor lines as well as in primary breast tumors. Moreover, 60% (12 of 20) of primary tumors analyzed displayed CST6 hypermethylation, indicating that this aberrant characteristic is common in breast malignancies. Finally, preinvasive and invasive breast tumor cells were microdissected from nine archival breast cancer specimens. Of the five tumors displaying CST6 gene methylation, four tumors displayed methylation in both ductal carcinoma in situ and invasive breast carcinoma lesions and reduced expression of cystatin M in these tumors was confirmed by immunohistochemistry. In summary, this study establishes that the tumor suppressor cystatin M is a novel target for epigenetic silencing during mammary tumorigenesis and that this aberrant event can occur before development of invasive breast cancer.
C1 Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Med, Shands Camc Ctr Program Canc Genet Epigenet & Tum, Gainesville, FL 32610 USA.
   Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida
RP Brown, KD (通讯作者)，Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.
EM kdbrown1@ufl.edu
RI Kim, Tae-You/J-2750-2012
OI Robertson, Keith/0000-0002-7508-3328; Ai, Lingbao/0009-0004-8907-8564
FU NCI NIH HHS [R21CA102220, R01CA114229] Funding Source: Medline
CR Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179
   Adamson AW, 2005, MOL BIOL CELL, V16, P1513, DOI 10.1091/mbc.e04-02-0089
   Bachman KE, 1999, CANCER RES, V59, P798
   Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323
   BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223
   BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273
   DICKINSON DP, 1994, GENOMICS, V24, P172, DOI 10.1006/geno.1994.1595
   Dobrovic A, 1997, CANCER RES, V57, P3347
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kane S E, 1990, Semin Cancer Biol, V1, P127
   Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058
   Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086
   Keppler D, 2006, CANCER LETT, V235, P159, DOI 10.1016/j.canlet.2005.04.001
   Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485
   Lah TT, 1998, BIOL CHEM, V379, P125
   Lehmann U, 2002, CANCER RES, V62, P6634
   Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003
   LIOTTA LA, 1991, CANCER RES, V51, pS5054
   MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D
   Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159
   Nass SJ, 2000, CANCER RES, V60, P4346
   Ni J, 1997, J BIOL CHEM, V272, P10853
   Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243
   PRICE JE, 1990, CANCER RES, V50, P717
   Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757
   Schnitt SJ, 1999, SEMIN DIAGN PATHOL, V16, P209
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209
   Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903
   Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   WELLINGS SR, 1975, J NATL CANCER I, V55, P231
   Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322
   Yan SQ, 2003, BIOL CHEM, V384, P845, DOI 10.1515/BC.2003.095
   Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x
   Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x
   Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819
NR 58
TC 73
Z9 82
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2006
VL 66
IS 16
BP 7899
EP 7909
DI 10.1158/0008-5472.CAN-06-0576
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 074QZ
UT WOS:000239828200012
PM 16912163
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Pulukuri, SM
   Rao, JS
AF Pulukuri, S. M.
   Rao, J. S.
TI CpG island promoter methylation and silencing of <i>14-3-3</i>σ gene
   expression in LNCaP and Tramp-C1 prostate cancer cell lines is
   associated with methyl-CpG-binding protein <i>MBD2</i>
SO ONCOGENE
LA English
DT Article
DE CpG methylation; 14-3-3 sigma; MBD2; prostate cancer
ID DNA METHYLATION; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; EPIGENETIC
   INACTIVATION; UPA PROMOTER; HYPERMETHYLATION; CARCINOMA; CHROMATIN;
   MECHANISM; GROWTH
AB 14-3-3 sigma proteins regulate numerous cellular processes that are important to cancer development. One of its biological roles involves G2 cell-cycle arrest following DNA damage. It has also been reported that the loss of 14-3-3 sigma expression via CpG methylation may contribute to malignant transformation by impairing the G2 cell-cycle checkpoint function, thereby allowing an accumulation of genetic defects. However, how the CpG methylation-dependent silencing mechanism works in relation to promoter methylation associated with methyl-CpG-binding proteins (MeCPs) is still unclear. To better understand the mechanism, we first examined the methylation status of the 14-3-3 sigma promoter-associated CpG islands and 14-33 sigma gene expression in a subset of prostate cancer cell lines using methylation-specific PCR (MSP), an HhaI-based DNA methylation assay, and reverse transcription-PCR (RT-PCR). We found that the 14-3-3 sigma expression is lost in LNCaP and Tramp-Cl prostate cancer cell lines and that this expression is restored after treatment with epigenetic silencing modifiers 5-aza-2'-deoxycytidine (5-aza) and trichostatin A (TSA). These results imply transcriptional silencing via promoter-associated CpG methylation. Chromatin immunroprecipitation analysis revealed that methyl-CpG-binding protein 2 (MBD2) is associated preferentially to the methylated CpG island in the 14-3-3 sigma promoter in LNCaP and Tramp-Cl cells but not in 14-3-3 sigma-expressing PC3 and DU145 cells, which contain an unmethylated CpG island in the 14-3-3 sigma promoter region. The 14-3-3 sigma gene silencing because of CpG methylation correlates with binding of MBD2. In addition, the activation of 14-3-3 sigma gene expression by a combination of 5-aza and TSA also involves the release of the MBD2 from the 14-3-3 sigma promoter-methylated CpG island in LNCaP and Tramp-C1 cells. Furthermore, MBD2 knockdown by siRNA stimulated 14-3-3 sigma expression in LNCaP cells. We also investigated whether the loss of 14-3-3 sigma expression in LNCaP and Tramp-Cl cells affects cell proliferation by MTT assays. Interestingly, we observed that 14-3-3 sigma-inactivated LNCaP and Tramp-Cl cells had markedly decreased cell proliferation and protein expression of proliferation cell nuclear antigen (PCNA) after restoration of 14-3-3 sigma expression with 5-aza and TSA treatment. On the other hand, the same treatment did not significantly affect 14-3-3 sigma-active PC3 and DU145 cells, which normally express 14-3-3 sigma. Finally, 14-3-3 sigma knockdown by siRNA resulted in increased proliferation in PC3 and DU145 cells. These findings suggest that the transcriptional silencing of the 14-3-3 sigma gene is caused by promoter CpG island methylation associated with MBD2, and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.
C1 Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA.
   Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA.
C3 University of Illinois System; University of Illinois Peoria; University
   of Illinois System; University of Illinois Peoria
RP Rao, JS (通讯作者)，Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.
EM jsrao@uic.edu
FU NCI NIH HHS [CA 95058, CA 75557, R01 CA092393, CA 116708, CA 92393, R01
   CA116708, R01 CA095058, R01 CA075557] Funding Source: Medline; NINDS NIH
   HHS [NS 47699, R01 NS047699] Funding Source: Medline
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652
   Darwanto A, 2003, CANCER SCI, V94, P442, DOI 10.1111/j.1349-7006.2003.tb01462.x
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171
   Ego T, 2005, ONCOGENE, V24, P1914, DOI 10.1038/sj.onc.1208394
   Esteller M, 2001, CANCER RES, V61, P4689
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   Fujita N, 1999, MOL CELL BIOL, V19, P6415
   Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599
   Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171
   Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787
   Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695
   Lin XH, 2003, CANCER RES, V63, P498
   Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004
   Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371
   Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291
   Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240
   Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5
   Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470
   Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5
   Relchelt J, 2002, J CELL SCI, V115, P2639
   Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Singal R, 2001, CANCER RES, V61, P4820
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tanaka K, 2004, INT J ONCOL, V25, P1591
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777
   Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200
   Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056
   Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200
   Yatabe Y, 2002, ONCOGENE, V21, P8310, DOI 10.1038/sj.onc.1206014
   Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201
   Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200
NR 57
TC 35
Z9 44
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 3
PY 2006
VL 25
IS 33
BP 4559
EP 4572
DI 10.1038/sj.onc.1209462
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 069OG
UT WOS:000239457500006
PM 16786000
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Wolf, I
   O'Kelly, J
   Rubinek, T
   Tong, M
   Nguyen, A
   Lin, BT
   Tai, HH
   Karlan, BY
   Koeffler, HP
AF Wolf, Ido
   O'Kelly, James
   Rubinek, Tamar
   Tong, Min
   Nguyen, Anh
   Lin, Bryan T.
   Tai, Hsin-Hsiung
   Karlan, Beth Y.
   Koeffler, H. Phillip
TI 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human
   breast cancer
SO CANCER RESEARCH
LA English
DT Article
ID CYCLOOXYGENASE-2 EXPRESSION; COX-2 EXPRESSION; AROMATASE; CELLS; GENE;
   CARCINOMA; PROMOTER
AB Prostaglandin E-2 plays a growth-stimulatory role in breast cancer, and the rate-limiting enzyme in its synthesis, cyclo-oxygenase-2, is often overexpressed in these cancers. Little is known about the role of the key prostaglandin catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in breast cancer pathogenesis. Using a pharmacologically based screen for epigenetically silenced genes, we found low levels of 15-PGDH in MDA-MB-231 cells [estrogen receptor (ER) negative] but high levels in MCF-7 cells (ER positive) and observed its up-regulation following demethylation treatment. Further analysis revealed methylation of the 15-PGDH promoter in one breast cancer cell line and 30% of primary tumors. Analysis of 15-PGDH expression revealed low levels in 40% of primary breast tumors and identified a correlation between 15-PGDH and ER expression. Transfection assays showed that transient up-regulation of 15-PGDH levels in MDA-MB-231 cells resulted in a decreased clonal growth, and stable up-regulation significantly decreased the ability of these cells to form tumors in athymic mice. In contrast, transient silencing of 15-PGDH in MCF-7 cells resulted in their enhanced proliferation, and a stable silencing in these cells enhanced cell cycle entry in vitro and tumorigenicity in vivo. Forced expression of 15-PGDH inhibited the ER pathway and silencing of 15-PGDH up-regulated expression of aromatase. In addition, 15-PGDH levels were down-regulated by estrogen but up-regulated by the tumor suppressor gene CAAT/enhancer binding protein alpha. Our results indicate for the first time that 15-PGDH may be a novel tumor suppressor gene in breast cancer, and suggest that this enzyme can modulate the ER pathway.
C1 Univ Calif Los Angeles, Div Hematol Oncol, Cedars Sinai Res Inst, Sch Med, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, Div Endocrinol, Sch Med, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, Div Endocrinol, Womens Canc Res Inst, Los Angeles, CA 90048 USA.
   Reg Med Ctr, Dept Anat Pathol, Tarzana, CA USA.
   Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Cedars Sinai Medical Center; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of California System; University of California Los
   Angeles; University of Kentucky
RP Wolf, I (通讯作者)，Univ Calif Los Angeles, Div Hematol Oncol, Cedars Sinai Res Inst, Sch Med, Davis Bldg 5006,8700 Beverly Blvd, Los Angeles, CA 90048 USA.
EM wolf-i@inter.net.il
RI Lin, Bryan/JJF-9160-2023
FU NHLBI NIH HHS [HL 46296] Funding Source: Medline
CR Backlund MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M411221200
   Brodie AMH, 2001, J STEROID BIOCHEM, V79, P41, DOI 10.1016/S0960-0760(01)00131-5
   Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100
   Díaz-Cruz ES, 2005, J CLIN ENDOCR METAB, V90, P2563, DOI 10.1210/jc.2004-2029
   Ding YF, 2005, CARCINOGENESIS, V26, P65, DOI 10.1093/carcin/bgh277
   ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313, DOI 10.1016/0929-7855(95)00040-W
   Gee JR, 2003, UROL ONCOL-SEMIN O I, V21, P266, DOI 10.1016/S1078-1439(02)00271-5
   Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625
   Greenland KJ, 2000, ENDOCRINOLOGY, V141, P581, DOI 10.1210/en.141.2.581
   Half E, 2002, CANCER RES, V62, P1676
   Liu XH, 1996, CANCER RES, V56, P5125
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Nandy A, 2003, J MOL ENDOCRINOL, V31, P105, DOI 10.1677/jme.0.0310105
   Richards JA, 2002, J STEROID BIOCHEM, V80, P203, DOI 10.1016/S0960-0760(01)00187-X
   Ristimäki A, 2002, CANCER RES, V62, P632
   Tari AM, 2005, LAB INVEST, V85, P1357, DOI 10.1038/labinvest.3700339
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136
   Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101
   Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428
   Zha S, 2004, CANCER LETT, V215, P1, DOI 10.1016/j.canlet.2004.06.014
NR 21
TC 176
Z9 205
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2006
VL 66
IS 15
BP 7818
EP 7823
DI 10.1158/0008-5472.CAN-05-4368
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 069XU
UT WOS:000239483500057
PM 16885386
DA 2025-01-12
ER

PT J
AU Cebrian, A
   Pharoah, PD
   Ahmed, S
   Ropero, S
   Fraga, MF
   Smith, PL
   Conroy, D
   Luben, R
   Perkins, B
   Easton, DF
   Dunning, AM
   Esteller, M
   Ponder, BAJ
AF Cebrian, Arancha
   Pharoah, Paul D.
   Ahmed, Shahana
   Ropero, Santiago
   Fraga, Mario F.
   Smith, Paula L.
   Conroy, Don
   Luben, Robert
   Perkins, Barbara
   Easton, Douglas F.
   Dunning, Alison M.
   Esteller, Manel
   Ponder, Bruce A. J.
TI Genetic variants in epigenetic genes and breast cancer risk
SO CARCINOGENESIS
LA English
DT Article
ID DNA METHYLATION; C-JUN; LUNG-CANCER; TRANSCRIPTION; EXPRESSION; CELLS;
   METHYLTRANSFERASE; IDENTIFICATION; TUMORIGENESIS; ASSOCIATION
AB Epigenetic events, resulting changes in gene expression capacity, are important in tumour progression, and variation in genes involved in epigenetic mechanisms might therefore be important in cancer susceptibility. To evaluate this hypothesis, we examined common variants in 12 genes coding for DNA methyltransferases (DNMT), histone acetyltransferases, histone deacetyltransferases, histone methyltrasferases and methyl-CpG binding domain proteins, for association with breast cancer in a large case-control study (N cases = 4474 and N controls = 4580). We identified 63 single nucleotide polymorphisms (SNPs) that efficiently tag all the known common variants in these genes, and are also expected to tag any unknown SNP in each gene. We found some evidence for association for six SNPs: DNMT3b-c31721t [P (2 df) = 0.007], PRDM2-c99243 t [P (2 df) = 0.03] and t105413c [P-recessive = 0.05], EHMT1-g-9441a [P (2df) = 0.05] and g41451t (P-trend = 0.04), and EHMT2-S237S [P (2df) = 0.04]. The most significant result was for DNMM-c31721t (P-trend = 0.124 after adjusting for multiple testing). However, there were three other results with P < 0.05. The permutation-based probability of this occurring by chance was 0.335. These significant SNPs were genotyped in 75 human cancer cell lines from different tumour types to assess if there was an association between them and six epigenetic measures. No statistically significant association was found. However, a trend was observed: homozygotes for the rare alleles of the EHMT1, EHMT2 and PRDM2 had a mean value for both trimethylation of K9 and K27 of histone H3 remarkably different to the homozygotes for the common alleles. Thus, these preliminary observations suggest the possible existence of a functional consequence of harbouring these genetic variants in histone methyltransferases, and warrant the design of larger epidemiological and biochemical studies to establish the true meaning of these findings.
C1 Univ Cambridge, Strangeways Res Labs, Dept Oncol, Canc Res UK,Human Canc Genet Res Grp, Cambridge CB1 8RN, England.
   Canc Res UK, Strangeways Res Labs, Genet Epidemiol Unit, Cambridge CB1 8RN, England.
   Canc Res UK, Strangeways Res Labs, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.
   Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Madrid, Spain.
C3 Cancer Research UK; University of Cambridge; CRUK Cambridge Institute;
   Cancer Research UK; CRUK Cambridge Institute; University of Cambridge;
   CRUK Cambridge Institute; Cancer Research UK; University of Cambridge;
   Centro Nacional de Investigaciones Oncologicas (CNIO)
RP Cebrian, A (通讯作者)，Univ Cambridge, Strangeways Res Labs, Dept Oncol, Canc Res UK,Human Canc Genet Res Grp, Cambridge CB1 8RN, England.
EM acebrian@iib.uam.es
RI Pharoah, Paul/V-6658-2019; Luben, Robert/KIC-1257-2024; Cebrian,
   Arancha/JMG-6507-2023; Luben, Robert/H-5519-2015; Esteller,
   Manel/L-5956-2014; Fraga, Mario/H-7824-2017
OI Luben, Robert/0000-0002-5088-6343; Dunning, Alison
   Margaret/0000-0001-6651-7166; Esteller, Manel/0000-0003-4490-6093;
   Cebrian Aranda, Arancha/0000-0002-6260-1376; Fraga,
   Mario/0000-0001-8450-2603; Ropero, Santiago/0000-0003-3522-8104
CR ANGUS J, 1995, ONCOGENE, V11, P691
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200
   Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349
   Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337
   Cook AL, 2003, J INVEST DERMATOL, V121, P1150, DOI 10.1046/j.1523-1747.2003.12562.x
   Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6
   EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8
   Farré D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3
   GOODE EL, 2005, P 96 ANN M AM ASS CA
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hong IS, 2004, HUM REPROD, V19, P2192, DOI 10.1093/humrep/deh424
   Houlston RS, 2004, ONCOGENE, V23, P6471, DOI 10.1038/sj.onc.1207951
   Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Ordway JM, 2002, CELL GROWTH DIFFER, V13, P149
   Paz MF, 2003, CANCER RES, V63, P1114
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Seligson D, 2005, INT J ONCOL, V27, P131
   Shen HB, 2002, CANCER RES, V62, P4992
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573
   Weiss C, 2004, CELL CYCLE, V3, P111
   Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281
NR 43
TC 74
Z9 84
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 2006
VL 27
IS 8
BP 1661
EP 1669
DI 10.1093/carcin/bgi375
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 074VY
UT WOS:000239841100017
PM 16501248
OA Bronze
DA 2025-01-12
ER

PT J
AU Tryndyak, VP
   Muskhelishvili, L
   Kovalchuk, O
   Rodriguez-Juarez, R
   Montgomery, B
   Churchwell, MI
   Ross, SA
   Beland, FA
   Pogribny, IP
AF Tryndyak, Volodymyr P.
   Muskhelishvili, Levan
   Kovalchuk, Olga
   Rodriguez-Juarez, Rocio
   Montgomery, Beverly
   Churchwell, Mona I.
   Ross, Sharon A.
   Beland, Frederick A.
   Pogribny, Igor P.
TI Effect of long-term tamoxifen exposure on genotoxic and epigenetic
   changes in rat liver: implications for tamoxifen-induced
   hepatocarcinogenesis
SO CARCINOGENESIS
LA English
DT Article
ID DNA ADDUCT FORMATION; CELL-PROLIFERATION; HEPATIC DNA; GLOBAL DNA;
   METHYLATION; CANCER; HYPOMETHYLATION; EXPRESSION; INDUCTION; GENE
AB Tamoxifen is a non-steroidal anti-estrogen used for the treatment of breast cancer and, more recently, as a chemopreventive agent in healthy women at high risk of developing breast cancer. On the other hand, tamoxifen is a potent hepatocarcinogen in rats, with both tumor-initiating and tumor-promoting properties. There is substantial evidence that hepatic tumors in rats are initiated as a result of formation of tamoxifen-DNA adducts; however, events subsequent to DNA adduct formation are not clear. Recently, it has been demonstrated that genotoxic carcinogens, in addition to exerting genotoxic effects, often cause epigenetic alterations. In the current study, we investigated whether or not the mechanism of tamoxifen-induced hepatocarcinogenesis includes both genotoxic and epigenetic components. Female Fisher 344 rats were fed a 420 p.p.m. tamoxifen diet for 6, 12, 18 or 24 weeks. Hepatic tamoxifen-DNA adduct levels, as assessed by high-performance liquid chromatography and electrospray tandem mass spectrometry, were 580 adducts/10(8) nt at 6 weeks, and increased to similar to 1700 adducts/10(8) nt by 18 weeks. Global liver DNA hypomethylation, as determined by an HpaII-based cytosine extension assay, was increased at all time points, with the maximum increase (similar to 200%) occurring at 6 weeks. Protein expressions of maintenance (DNMT1) DNA methyltransferase and de novo DNA methyltransferases DNMT3a and DNMT3b were decreased at all time points. Likewise, trimethylation of histone H4 lysine 20 was significantly decreased at all time points. In contrast, non-target tissues (i.e. mammary gland, pancreas and spleen) did not show any changes in global DNA methylation or DNA methyltransferase activity. These data indicate the importance of genotoxic and epigenetic alterations in the etiology of tamoxifen-induced hepatocarcinogenesis.
C1 Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
   NCI, Div Canc Prevent, Bethesda, MD 20892 USA.
   Natl Ctr Toxicol Res, Toxicol Pathol Associates, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA); University of Lethbridge; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   US Food & Drug Administration (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
OI Tryndyak, Volodymyr/0000-0002-8319-2954; Beland,
   Frederick/0000-0002-2113-6260
CR [Anonymous], 1971, BIOCHEM J
   BANNASCH P, 1986, CARCINOGENESIS, V7, P689, DOI 10.1093/carcin/7.5.689
   Beland FA, 1999, CARCINOGENESIS, V20, P471, DOI 10.1093/carcin/20.3.471
   Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045
   Besaratinia A, 2005, BIOCHEMISTRY-US, V44, P8418, DOI 10.1021/bi0503753
   Bombail V, 2004, TOXICOL LETT, V149, P51, DOI 10.1016/j.toxlet.2004.01.003
   Carthew P, 1996, CANCER LETT, V106, P163, DOI 10.1016/0304-3835(96)04310-8
   Carthew P, 2001, ARCH TOXICOL, V75, P375, DOI 10.1007/s002040100244
   Chen H, 2004, CARCINOGENESIS, V25, P1779, DOI 10.1093/carcin/bgh161
   Clarke M, 1998, LANCET, V351, P1451
   Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2
   da Costa GG, 2003, CHEM RES TOXICOL, V16, P357, DOI 10.1021/tx020090g
   da Costa GG, 2001, CARCINOGENESIS, V22, P1307, DOI 10.1093/carcin/22.8.1307
   Divi RL, 1999, CANCER RES, V59, P4829
   Dragan YP, 1996, CARCINOGENESIS, V17, P585, DOI 10.1093/carcin/17.3.585
   Dunn BK, 2005, J CLIN ONCOL, V23, P357, DOI 10.1200/JCO.2005.08.028
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   FitzGerald BE, 1996, CARCINOGENESIS, V17, P2703, DOI 10.1093/carcin/17.12.2703
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589
   GREAVES P, 1993, CANCER RES, V53, P3919
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Higashimoto K, 2003, AM J HUM GENET, V73, P948, DOI 10.1086/378595
   Jaffe LF, 2003, ADV CANCER RES, V90, P209, DOI 10.1016/S0065-230X(03)90007-8
   Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031
   Kärki A, 2000, ARCH TOXICOL, V74, P249, DOI 10.1007/s002040000116
   Karpinets TV, 2005, CARCINOGENESIS, V26, P1323, DOI 10.1093/carcin/bgi079
   Kasahara T, 2003, CANCER SCI, V94, P582, DOI 10.1111/j.1349-7006.2003.tb01486.x
   Kimura F, 2003, INT J CANCER, V104, P568, DOI 10.1002/ijc.10988
   McLuckie KIE, 2005, BIOCHEMISTRY-US, V44, P8198, DOI 10.1021/bi047399e
   Moggs JG, 2004, TOXICOL APPL PHARM, V196, P422, DOI 10.1016/j.taap.2004.01.009
   Muskhelishvili L, 1996, AM J PATHOL, V149, P1585
   Phillips DH, 2001, CARCINOGENESIS, V22, P839, DOI 10.1093/carcin/22.6.839
   PHILLIPS DH, 1994, CANCER RES, V54, P5518
   Pitot HC, 2000, ALIMENT PHARM THERAP, V14, P153, DOI 10.1046/j.1365-2036.2000.014s1153.x
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pogribny IP, 2006, MUTAT RES-FUND MOL M, V593, P80, DOI 10.1016/j.mrfmmm.2005.06.028
   Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014
   Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009
   Schild LJ, 2005, MUTAGENESIS, V20, P115, DOI 10.1093/mutage/gei015
   Shibutani S, 1997, BIOCHEMISTRY-US, V36, P13010, DOI 10.1021/bi970243c
   SHIVAPURKAR N, 1984, CARCINOGENESIS, V5, P989, DOI 10.1093/carcin/5.8.989
   Stanley LA, 2001, CANCER LETT, V171, P27, DOI 10.1016/S0304-3835(01)00564-X
   Tao LH, 2004, TOXICOL SCI, V82, P62, DOI 10.1093/toxsci/kfh266
   TERRIER P, 1990, AM J PATHOL, V137, P845
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270
   Watson RE, 2002, TOXICOL SCI, V68, P51, DOI 10.1093/toxsci/68.1.51
   White INH, 1999, CARCINOGENESIS, V20, P1153, DOI 10.1093/carcin/20.7.1153
   Williams GM, 1997, CARCINOGENESIS, V18, P2247, DOI 10.1093/carcin/18.11.2247
   Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102
NR 52
TC 66
Z9 76
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 2006
VL 27
IS 8
BP 1713
EP 1720
DI 10.1093/carcin/bgl050
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 074VY
UT WOS:000239841100023
PM 16632870
OA Bronze
DA 2025-01-12
ER

PT J
AU Carey, N
   La Thangue, NB
AF Carey, Nessa
   La Thangue, Nicholas B.
TI Histone deacetylase inhibitors: gathering pace
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID SYNERGISTICALLY INDUCES APOPTOSIS; SUBEROYLANILIDE HYDROXAMIC ACID;
   MESSENGER-RNA EXPRESSION; POSITIVE BREAST-CANCER; HUMAN GASTRIC-CANCER;
   2 CATALYTIC DOMAINS; HUMAN COLON-CANCER; TRANSCRIPTIONAL REPRESSOR;
   TRICHOSTATIN-A; GLUCOCORTICOID-RECEPTOR
AB Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory proteins are influenced by acetylation. Inhibition of histone deacetylase (HDAC) prompts tumour cells to enter apoptosis and, as a consequence, several HDAC inhibitors have entered clinical trials. It is likely that HDAC inhibitor drugs will provide an important class of new mechanism-based therapeutics for cancer.
C1 Topo Target, Abingdon OX14 4RY, Oxon, England.
   Univ Oxford, Med Sci Div, Nuffield Dept Clin Lab Sci, Lab Canc Biol, Oxford OX3 9DU, England.
C3 University of Oxford
RP La Thangue, NB (通讯作者)，Topo Target, 87A Milton Pk, Abingdon OX14 4RY, Oxon, England.
EM nick.lathangue@ndcls.ox.ac.uk
FU Cancer Research UK [13058] Funding Source: Medline; Medical Research
   Council [G9400953, G0500905] Funding Source: Medline; MRC [G0500905,
   G9400953] Funding Source: UKRI
CR Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Bartling B, 2005, LUNG CANCER-J IASLC, V49, P145, DOI 10.1016/j.lungcan.2005.02.006
   Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018
   Bevins RL, 2005, CANCER RES, V65, P6957, DOI 10.1158/0008-5472.CAN-05-0836
   Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000
   Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433
   Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062
   Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004
   Chiba T, 2004, ONCOLOGY-BASEL, V66, P481, DOI 10.1159/000079503
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392
   Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017
   Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003
   Giannini R, 2005, ANTICANCER RES, V25, P4287
   Glaser KB, 2004, BIOCHEM BIOPH RES CO, V325, P683, DOI 10.1016/j.bbrc.2004.10.082
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567
   Inche AG, 2006, DRUG DISCOV TODAY, V11, P97, DOI 10.1016/S1359-6446(05)03691-3
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kobayashi Y, 2006, ONCOGENE, V25, P512, DOI 10.1038/sj.onc.1209072
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Lee HS, 2004, BIOL PHARM BULL, V27, P1497, DOI 10.1248/bpb.27.1497
   Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200
   Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045
   Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591
   Martínez-Balbás MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662
   Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887
   Matheu A, 2005, J BIOL CHEM, V280, P42433, DOI 10.1074/jbc.M508270200
   McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034
   McLaughlin F, 2003, DRUG DISCOV TODAY, V8, P793, DOI 10.1016/S1359-6446(03)02792-2
   Medina V, 1997, CANCER RES, V57, P3697
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Murphy PJM, 2005, J BIOL CHEM, V280, P33792, DOI 10.1074/jbc.M506997200
   Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395
   Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078-0432.CCR-03-0709
   Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0
   Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368
   Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277
   Rahmani M, 2005, MOL PHARMACOL, V67, P1166, DOI 10.1124/mol.104.007831
   Rahmani M, 2003, CANCER RES, V63, P8420
   Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646
   Sasaki H, 2004, LUNG CANCER, V46, P171, DOI 10.1016/j.lungcan.2004.03.021
   Scanlan MJ, 2002, CANCER RES, V62, P4041
   Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0
   Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x
   Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004
   Vietor I, 2005, J BIOL CHEM, V280, P39795, DOI 10.1074/jbc.M509836200
   Xu YX, 2005, INT J MOL MED, V15, P169
   Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200
   Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x
   Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9
   Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200
   Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195
   Zou H, 2006, BIOCHEM BIOPH RES CO, V341, P45, DOI 10.1016/j.bbrc.2005.12.144
NR 67
TC 107
Z9 139
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD AUG
PY 2006
VL 6
IS 4
BP 369
EP 375
DI 10.1016/j.coph.2006.03.010
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 071ZX
UT WOS:000239643500009
PM 16781195
DA 2025-01-12
ER

PT J
AU Munot, K
   Bell, SM
   Lane, S
   Horgan, K
   Hanby, AM
   Speirs, V
AF Munot, Kailas
   Bell, Sandra M.
   Lane, Sally
   Horgan, Kieran
   Hanby, Andrew M.
   Speirs, Valerie
TI Pattern of expression of genes linked to epigenetic silencing in human
   breast cancer
SO HUMAN PATHOLOGY
LA English
DT Article
DE epigenetics; methylation; breast cancer
ID ESTROGEN-RECEPTOR-BETA; DNA METHYLATION; TUMOR-SUPPRESSOR;
   O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGION; CYCLIN D1;
   ISLAND; PROTEIN; HYPERMETHYLATION; ASSOCIATION
AB Epigenetic mechanisms such as DNA methylation are now recognized to play an important role in neoplasia. The aim of this study is to relate the pattern of expression of multiple cancer genes known to undergo epigenetic inactivation by promoter hypermethylation in breast cancer with histologic and outcome data. We used immunohistochemistry to study expression of the tumor suppressor gene p16, estrogen receptor (ER) alpha, ER beta, progesterone receptor (PR), and the DNA repair gene MGMT (O-6-methylguanine-DNA methyltransferase) in a panel of 200 breast cancers. Methylation-specific polymerase chain reaction was used to confirm MGMT promoter methylation. Loss of expression of MGMT, ER alpha, ER beta, PR, and p16 was observed in 19%, 24%, 13%, 40%, and 50% of cases, respectively. A significant correlation was seen between grade III tumor and loss of expression of ER alpha, ER beta, PR (all P <.0001), and MGMT (P =.04), whereas loss of expression of p 16 was associated with grades I and 11 tumors (P <.001). Cases that expressed 3 or less of the 5 proteins studied had significantly reduced survival (P =.0016). Methylation-specific polymerase chain reaction in a subset of 20 cancers showed DNA methylation associated with the loss of MGMT expression (P <.001). In conclusion, there is silencing of several key genes in breast cancer affecting molecular pathways involved in cell immortalization, DNA repair, and hormonal regulation, and this correlates significantly with risk of cancer-specific death. This expression profile could be linked to epigenetic events, and if so, these pathways have potential as targets for therapeutic strategies based on reversal of epigenetic silencing. (c) 2006 Elsevier Inc. All rights reserved.
C1 St James Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England.
   Leeds Gen Infirm, Breast Unit, Leeds LS9 7TF, W Yorkshire, England.
C3 University of Leeds; Saint James's University Hospital; University of
   Leeds; Leeds General Infirmary
RP Speirs, V (通讯作者)，St James Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England.
EM v.speirs@leeds.ac.uk
RI Speirs, Valerie/ABE-7377-2021; Horgan, Kieran/AAM-1280-2020
OI Bell, Sandra/0000-0002-3022-9864
CR Allred DC, 1998, MODERN PATHOL, V11, P155
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BERNS EMJJ, 1995, BRIT J CANCER, V72, P964, DOI 10.1038/bjc.1995.442
   Brenner AJ, 1996, CLIN CANCER RES, V2, P1993
   CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210
   Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.3.CO;2-3
   Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771
   Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K
   Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739
   Esteller M, 2001, CANCER RES, V61, P3225
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Geradts J, 1996, AM J PATHOL, V149, P15
   Gorgoulis VG, 1998, MOL MED, V4, P807, DOI 10.1007/BF03401773
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Hui R, 2000, CLIN CANCER RES, V6, P2777
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Jackson D P, 1990, Cytopathology, V1, P87, DOI 10.1111/j.1365-2303.1990.tb00333.x
   Jones PA, 1996, CANCER RES, V56, P2463
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Li LC, 2000, BIOCHEM BIOPH RES CO, V275, P682, DOI 10.1006/bbrc.2000.3363
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Marsh KL, 1998, BRIT J CANCER, V77, P1460, DOI 10.1038/bjc.1998.240
   Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R
   Nielsen NH, 2001, CANCER LETT, V163, P59, DOI 10.1016/S0304-3835(00)00674-1
   Osanai T, 2005, JPN J CLIN ONCOL, V35, P121, DOI 10.1093/jjco/hyi036
   Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403
   Preuss I, 1996, CANCER DETECT PREV, V20, P130
   PREUSS I, 1995, INT J CANCER, V61, P321, DOI 10.1002/ijc.2910610308
   Roylance R, 1999, CANCER RES, V59, P1433
   Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1
   RUSH EB, 1995, CANCER LETT, V89, P223, DOI 10.1016/0304-3835(95)03691-O
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z
   Toyota M, 1999, CANCER RES, V59, P2307
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, CANCER RES, V59, P5438
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041
   XU L, 1994, CANCER RES, V54, P5262
   Yan PS, 2001, CANCER RES, V61, P8375
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
NR 45
TC 37
Z9 43
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD AUG
PY 2006
VL 37
IS 8
BP 989
EP 999
DI 10.1016/j.humpath.2006.04.013
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 072SW
UT WOS:000239694300012
PM 16867861
DA 2025-01-12
ER

PT J
AU Loukinov, D
   Ghochikyan, A
   Mkrtichyan, M
   Ichim, TE
   Lobanenkov, VV
   Cribbs, DH
   Agadjanyan, MG
AF Loukinov, Dmitri
   Ghochikyan, Anahit
   Mkrtichyan, Mikayel
   Ichim, Thomas E.
   Lobanenkov, Victor V.
   Cribbs, David H.
   Agadjanyan, Michael G.
TI Antitumor efficacy of DNA vaccination to the epigenetically acting tumor
   promoting transcription factor BORIS and CD80 molecular adjuvant
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BORIS; CT antigens; breast cancer; mammary tumor; vaccine
ID COSTIMULATORY MOLECULES; CANCER/TESTIS ANTIGENS; CANCER-IMMUNOTHERAPY;
   MAMMARY-CARCINOMA; T-LYMPHOCYTES; VACCINES; GENE; EXPRESSION; RESPONSES;
   CTCF
AB Cancer testis (CT) antigens are promising candidates for tumor vaccines due to their immunogenicity and tissue-restricted expression. Recently, we identified a novel cancer testis gene, BORIS, whose expression is restricted to male testis after puberty and is strictly absent in non-malignant female tissue. BOR/Sencodes a DNA-binding protein that shares 11 zing finger (ZF) with transcription factor CTCF and differs at the N- and C-termini. CTCF has been implicated in epigenetic regulation of imprinting, X chromosome inactivation, repression, and activation of cancer testis antigens. BORIS expression has been documented in cancers of diverse histological origin, including, but not limited to breast, prostate, ovary, gastric, liver, endometrial, glia, colon, and esophagus. Interestingly, BORIS induces demethylation and subsequent expression of many cancer-testis genes, including MAGE-A1 and NY-ESO-1, indicating that it is expressed very early in malignancy and might be an attractive candidate for immunotherapy. In this study we tested BORIS as a vaccine in a very aggressive, highly metastatic, and poorly immunogenic murine model of mammary carcinoma. Immunizations with a DNA encoding the mutant form of murine BORIS antigen (pmBORIS lacking DNA-binding function) significantly prolonged survival, and inhibited tumor growth in BALB/c mice inoculated with 4T1 cells. Priming with pmBORIS mixed with molecular adjuvant and boosting with adenoviral vector expressing mBORIS was generally more effective, suggesting that the vaccination protocol could be further optimized. This is the first report demonstrating the feasibility of vaccination with a cancer associated epigenetic regulator for the induction of tumor inhibition.
C1 Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA 92647 USA.
   NIAID, Bethesda, MD USA.
   Oncomune LLC, Miami, FL USA.
   Univ Calif Irvine, Inst Brain Aging & Dementia, Dept Neurol, Irvine, CA 92717 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Allergy & Infectious Diseases (NIAID); University of California System;
   University of California Irvine
RP Agadjanyan, MG (通讯作者)，Inst Mol Med, Dept Mol Immunol, 16371 Gothard St, Huntington Beach, CA 92647 USA.
EM magadjanyan@immed.org
RI Lobanenkov, Victor/ABD-5710-2021
OI Lobanenkov, Victor/0000-0001-6665-3635; Ghochikyan,
   Anahit/0000-0001-5436-0616
CR Browning M., 1997, European Journal of Immunogenetics, V24, P293
   Chen QY, 2004, P NATL ACAD SCI USA, V101, P9363, DOI 10.1073/pnas.0403271101
   Danna EA, 2004, CANCER RES, V64, P2205, DOI 10.1158/0008-5472.CAN-03-2646
   GHOCHIKYAN A, 2006, UNPUB EPIGENETICALLY
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Ikeda H, 2003, CURR PHARM DESIGN, V9, P1133, DOI 10.2174/1381612033454973
   Iwasaki A, 1997, J IMMUNOL, V158, P4591
   Kim JJ, 1997, NAT BIOTECHNOL, V15, P641
   Ko BK, 2003, CLIN CANCER RES, V9, P3222
   Kobie JJ, 2003, CANCER RES, V63, P1860
   Le Poole IC, 2003, EXPERT OPIN INV DRUG, V12, P971, DOI 10.1517/13543784.12.6.971
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   MILLER FR, 1983, INVAS METAST, V3, P22
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Mitsuhashi M, 2004, J LEUKOCYTE BIOL, V76, P322, DOI 10.1189/jlb.1203641
   Miura T, 2000, INFECT IMMUN, V68, P4340, DOI 10.1128/IAI.68.7.4340-4343.2000
   Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234
   Pulaski BA, 1998, CANCER RES, V58, P1486
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297
   Tsuji T, 1997, EUR J IMMUNOL, V27, P782, DOI 10.1002/eji.1830270329
   VANDENEYNDE B, 2004, T CELL DEFINED TUMOR
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x
   Vasilevko V, 2003, CLIN EXP METASTAS, V20, P489, DOI 10.1023/A:1025802610724
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7
   Wang H, 2003, J IMMUNOL, V171, P3823, DOI 10.4049/jimmunol.171.7.3823
   Wu RS, 2001, CANCER IMMUNOL IMMUN, V50, P229, DOI 10.1007/s002620100197
NR 31
TC 36
Z9 41
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 1
PY 2006
VL 98
IS 5
BP 1037
EP 1043
DI 10.1002/jcb.20953
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 067XV
UT WOS:000239336800001
PM 16741971
DA 2025-01-12
ER

PT J
AU Shukla, V
   Coumoul, X
   Cao, L
   Wang, RH
   Xiao, CY
   Xu, XL
   Andò, S
   Yakar, S
   LeRoith, D
   Deng, CX
AF Shukla, Vivek
   Coumoul, Xavier
   Cao, Liu
   Wang, Rui-Hong
   Xiao, Cuiying
   Xu, Xiaoling
   Ando, Sebastiano
   Yakar, Shoshana
   LeRoith, Derek
   Deng, Chuxia
TI Absence of the full-length breast cancer-associated gene-1 leads to
   increased expression of insulin-like growth factor signaling axis
   members
SO CANCER RESEARCH
LA English
DT Article
ID FACTOR BINDING PROTEIN-1; MULTIPLE-MYELOMA CELLS; I IGF-I; TRANSGENIC
   MICE; LIFE-SPAN; RECEPTOR; MIGRATION; BRCA1; P53; ADHESION
AB The breast cancer-associated gene-1 (BRCA1) plays many important functions in multiple biological processes/pathways. Mice homozygous for a targeted deletion of full-length BRCA1 (Brca1(Delta 11/Delta 11)) display both increased tumorigenesis and premature aging, yet molecular mechanisms underlying these defects remain elusive. Here, we show that Brca1 deficiency leads to increased expression of several insulin-like growth factor (IGF) signaling axis members in multiple experimental systems, including BRCA1-deficient mice, primary mammary tumors, and cultured human cells. Furthermore, we provide evidence that activation of IGF signaling by BRCA1 deficiency can also occur in a p53-independent fashion. Our data indicate that BRCA1 interacts with the IRS-1 promoter and inhibits its activity that is associated with epigenetic modification of histone H3 and histone H4 to a transcriptional repression chromatin configuration. We further show that BRCA1-deficient mammary tumor cells exhibit high levels of IRS-1, and acute suppression of Irs-1 using RNA interference significantly inhibits growth of these cells. Those observations provide a molecular insight in understanding both fundamental and therapeutic BRCA1-associated tumorigenesis and aging.
C1 NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
   NIDDKD, Diabet Branch, NIH, Bethesda, MD USA.
   Univ Calabria, Dept Cell Biol, Cosenza, Italy.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of
   Health (NIH) - USA; NIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); University of Calabria
RP Shukla, V (通讯作者)，NIDDKD, Genet Dev & Dis Branch, NIH, Bldg 10-9N105,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM shuklav@mail.nih.gov
RI Yakar, Shoshana/IUN-5716-2023; Xu, Xiaoling/JTT-9808-2023; deng,
   chuxia/N-6713-2016; Coumoul, Xavier/AAR-3649-2020
OI Coumoul, Xavier/0000-0003-2928-9648; Yakar, Shoshana/0000-0002-2352-1330
FU Intramural NIH HHS Funding Source: Medline
CR Abramovitch S, 2003, FEBS LETT, V541, P149, DOI 10.1016/S0014-5793(03)00315-6
   André F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.0.CO;2-D
   ARAKI E, 1991, J BIOL CHEM, V266, P3944
   ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367
   Bachelier R, 2003, ONCOGENE, V22, P528, DOI 10.1038/sj.onc.1206208
   Bähr C, 2005, GROWTH FACTORS, V23, P1, DOI 10.1080/08977190400020229
   Benetos A, 2002, AM J HYPERTENS, V15, P1101, DOI 10.1016/S0895-7061(02)03029-7
   Blüher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223
   Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929
   Campisi J, 2000, IN VIVO, V14, P183
   Campisi J, 2004, NAT MED, V10, P231, DOI 10.1038/nm0304-231
   Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003
   Cozzi R, 2003, J ENDOCRINOL INVEST, V26, P347, DOI 10.1007/BF03345183
   Gay E, 1997, ENDOCRINOLOGY, V138, P2937, DOI 10.1210/en.138.7.2937
   Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1
   Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2
   He Hongpeng, 2003, Briefings in Functional Genomics & Proteomics, V2, P234, DOI 10.1093/bfgp/2.3.234
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298
   Ibrahim YH, 2005, CLIN CANCER RES, V11, p944S
   Kabir-Salmani M, 2004, MOL HUM REPROD, V10, P91, DOI 10.1093/molehr/gah014
   Katic M, 2005, CELL MOL LIFE SCI, V62, P320, DOI 10.1007/s00018-004-4297-y
   Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200
   Kim DS, 2004, CELL SIGNAL, V16, P89, DOI 10.1016/S0898-6568(03)00114-1
   Koda M, 2005, NEOPLASMA, V52, P361
   Kornberg LJ, 2004, INVEST OPHTH VIS SCI, V45, P4463, DOI 10.1167/iovs.03-1201
   Krtolica A, 2002, INT J BIOCHEM CELL B, V34, P1401, DOI 10.1016/S1357-2725(02)00053-5
   Kuro-o M, 2001, TRENDS MOL MED, V7, P179, DOI 10.1016/S1471-4914(01)01921-9
   Lee AV, 2003, HORM METAB RES, V35, P651
   Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319
   Liu JL, 1999, ENDOCRINOLOGY, V140, P5178, DOI 10.1210/en.140.11.5178
   Liu L, 2003, MECH AGEING DEV, V124, P989, DOI 10.1016/j.mad.2003.08.001
   Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404
   Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958
   Martin DC, 1999, J CELL BIOL, V146, P881, DOI 10.1083/jcb.146.4.881
   MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P433, DOI 10.1210/endo-123-1-433
   Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815
   RAJKUMAR K, 1995, ENDOCRINOLOGY, V136, P4029, DOI 10.1210/en.136.9.4029
   Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629
   Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068
   Sjögren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088
   Tai YT, 2003, CANCER RES, V63, P5850
   Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447
   Torrisi R, 2001, BRIT J CANCER, V85, P1838, DOI 10.1054/bjoc.2001.2191
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Urnov FD, 2003, J CELL BIOCHEM, V88, P684, DOI 10.1002/jcb.10397
   Werner H, 2000, MOL GENET METAB, V71, P315, DOI 10.1006/mgme.2000.3044
   Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108
   Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324
   Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5
   Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085
NR 50
TC 40
Z9 46
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2006
VL 66
IS 14
BP 7151
EP 7157
DI 10.1158/0008-5472.CAN-05-4570
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 064QE
UT WOS:000239103400033
PM 16849561
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Flanagan, JM
   Popendikyte, V
   Pozdniakovaite, N
   Sobolev, M
   Assadzadeh, A
   Schumacher, A
   Zangeneh, M
   Lau, L
   Virtanen, C
   Wang, SC
   Petronis, A
AF Flanagan, James M.
   Popendikyte, Violeta
   Pozdniakovaite, Natalija
   Sobolev, Martha
   Assadzadeh, Abbas
   Schumacher, Axel
   Zangeneh, Masood
   Lau, Lynette
   Virtanen, Carl
   Wang, Sun-Chong
   Petronis, Arturas
TI Intra- and interindividual epigenetic variation in human germ cells
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DNA-METHYLATION; CPG ISLANDS; CHROMOSOME BANDS; CDH13 GENE; CHROMATIN;
   MOUSE; INHERITANCE; PROMOTER; RISK; AGE
AB Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins ( PSEN1 and PSEN2), breast cancer ( BRCA1 and BRCA2), myotonic dystrophy ( DM1), and Huntington disease ( HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles ( to 6.8 x 10(-14)). Second, microarray. P = .036 based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.
C1 Ctr Addict & Mental Hlth, Krembil Family Epigenet Lab, Toronto, ON M5T 1R8, Canada.
   Ontario Canc Inst, Microarray Ctr, Toronto, ON M5T 1R8, Canada.
   Inst Biotechnol, Vilnius, Lithuania.
C3 University of Toronto; Centre for Addiction & Mental Health - Canada;
   University of Toronto; University Health Network Toronto; Vilnius
   University
RP Petronis, A (通讯作者)，Ctr Addict & Mental Hlth, Krembil Family Epigenet Lab, 250 Coll St, Toronto, ON M5T 1R8, Canada.
EM arturas_petronis@camh.net
RI Schumacher, Axel/C-6612-2008; zangeneh, masood/ABH-2565-2020; Petronis,
   Art/AAD-4491-2019
OI Zangeneh, Masood/0000-0002-5038-1089; Petronis, Art/0000-0002-4538-1594;
   Flanagan, James/0000-0003-4955-1383
CR Allegrucci C, 2005, REPRODUCTION, V129, P137, DOI 10.1530/rep.1.00360
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Blewitt ME, 2005, P NATL ACAD SCI USA, V102, P7629, DOI 10.1073/pnas.0409375102
   Byrne M, 2003, ARCH GEN PSYCHIAT, V60, P673, DOI 10.1001/archpsyc.60.7.673
   Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2
   Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955
   *CHIMP SEQ AN CONS, 2005, NATURE, V0437
   Chong SY, 2004, CURR OPIN GENET DEV, V14, P692, DOI 10.1016/j.gde.2004.09.001
   Churikov D, 2004, GENOMICS, V84, P745, DOI 10.1016/j.ygeno.2004.06.001
   Churikov D, 2004, CYTOGENET GENOME RES, V105, P203, DOI 10.1159/000078190
   CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510
   Czermin B, 2003, GENETICA, V117, P159, DOI 10.1023/A:1022927725945
   Dudoit S, 2002, GENOME BIOL, V3
   Furey TS, 2003, HUM MOL GENET, V12, P1037, DOI 10.1093/hmg/ddg113
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gisselsson D, 2005, CHROMOSOMA, V114, P118, DOI 10.1007/s00412-005-0343-7
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8
   Hajkova Petra, 2002, Methods Mol Biol, V200, P143
   Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582
   Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5
   Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647
   Hibi K, 2004, BRIT J CANCER, V91, P1139, DOI 10.1038/sj.bjc.6602095
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   JABS EW, 1989, P NATL ACAD SCI USA, V86, P202, DOI 10.1073/pnas.86.1.202
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Kaminsky ZA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni094
   Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368
   Klar AJS, 1998, TRENDS GENET, V14, P299, DOI 10.1016/S0168-9525(98)01535-2
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875
   Malaspina D, 2001, ARCH GEN PSYCHIAT, V58, P361, DOI 10.1001/archpsyc.58.4.361
   Martin DIK, 2005, ANN NY ACAD SCI, V1054, P68, DOI 10.1196/annals.1345.009
   Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656
   Miniou P, 1997, HUM GENET, V99, P738, DOI 10.1007/s004390050441
   Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   Murrell A, 2004, HUM MOL GENET, V13, P247, DOI 10.1093/hmg/ddh013
   Ogama Y, 2004, INT J ONCOL, V25, P685
   Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6
   Polesskaya OO, 2006, J NEUROSCI RES, V83, P362, DOI 10.1002/jnr.20732
   Rakyan V, 2003, CURR BIOL, V13, pR6, DOI 10.1016/S0960-9822(02)01377-5
   Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   Sakai M, 2004, CANCER SCI, V95, P588, DOI 10.1111/j.1349-7006.2004.tb02491.x
   Sandovici I, 2005, HUM MOL GENET, V14, P2135, DOI 10.1093/hmg/ddi218
   Scheid OM, 2003, NAT GENET, V34, P450, DOI 10.1038/ng1210
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Smith A, 2005, MOL BRAIN RES, V135, P225, DOI 10.1016/j.molbrainres.2004.12.025
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077
   Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101
   Widschwendter A, 2004, INT J CANCER, V109, P163, DOI 10.1002/ijc.11706
   Wong AHC, 2005, HUM MOL GENET, V14, pR11, DOI 10.1093/hmg/ddi116
   Yamada Y, 2004, GENOME RES, V14, P247, DOI 10.1101/gr.1351604
   Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Zalensky AO, 2002, J BIOL CHEM, V277, P43474, DOI 10.1074/jbc.M206065200
   ZOGEL C, 2006, EUR J HUM GENET
NR 71
TC 181
Z9 212
U1 0
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUL
PY 2006
VL 79
IS 1
BP 67
EP 84
DI 10.1086/504729
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 053YD
UT WOS:000238341200008
PM 16773567
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Axelson, H
AF Axelson, Hakan
TI Eyeing turnorigenesis:: Notch signaling and epigenetic silencing of
   <i>Rb</i> in <i>Drosophila</i>
SO BIOESSAYS
LA English
DT Article
ID HUMAN BREAST-CANCER; GROWTH; TUMOR; TUMORIGENESIS; NEUROGENESIS;
   MELANOGASTER; ACTIVATION; ENCODES; PATHWAY; HAIRY
AB Notch signaling plays an essential role in the processes of embryogenesis and cellular differentiation, and it is believed that the oncogenic effects of dysregulated Notch signaling are an anomalous reflection of the normal functions of this cascade. Nonetheless, the cellular events associated with oncogenic Notch signaling have thus far remained elusive. In a recent report, Ferres-Marco et al.((1)) described how they used the Drosphila eye as a model system and found that elevated Notch signaling in combination with activation of components of the Polycomb complex of transcriptional repressors led to metastatic growth of tumors through epigenetic silencing of the Rbf gene. Rbf is the Drosophila homologue of the retinoblastoma tumor-suppressor gene (Rb), thus it represents a novel link between Notch signaling, tumor growth and metastasis.
C1 Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden.
C3 Lund University; Skane University Hospital
RP Axelson, H (通讯作者)，Univ Hosp MAS, Dept Lab Med, Div Mol Med, Entrance 78,3rd Floor, SE-20502 Malmo, Sweden.
EM hakan.axelson@med.lu.se
CR Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019
   Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671
   Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548
   Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355
   Domínguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402
   ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B
   Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446
   Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376
   GINIGER E, 1994, DEVELOPMENT, V120, P1385
   Huang DH, 2002, MOL CELL BIOL, V22, P6261, DOI 10.1128/MCB.22.17.6261-6271.2002
   Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5
   Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474
   Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054
   Toba G, 1999, GENETICS, V151, P725
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004
NR 22
TC 3
Z9 4
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0265-9247
J9 BIOESSAYS
JI Bioessays
PD JUL
PY 2006
VL 28
IS 7
BP 692
EP 695
DI 10.1002/bies.20428
PG 4
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA 067SM
UT WOS:000239322900003
PM 16850405
DA 2025-01-12
ER

PT J
AU Ai, LB
   Tao, QA
   Zhong, S
   Fields, CR
   Kim, WJ
   Lee, MW
   Cui, Y
   Brown, KD
   Robertson, KD
AF Ai, Lingbao
   Tao, Qian
   Zhong, Sheng
   Fields, C. Robert
   Kim, Wan-Ju
   Lee, Michael W.
   Cui, Yan
   Brown, Kevin D.
   Robertson, Keith D.
TI Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic
   silencing is a common event in breast cancer
SO CARCINOGENESIS
LA English
DT Article
ID CYCLIN D1; PROMOTER HYPERMETHYLATION; BETA-CATENIN; C-MYC; DNA
   METHYLTRANSFERASES; SIGNALING PATHWAY; SPEMANN ORGANIZER; SECRETED
   PROTEIN; SPORADIC BREAST; RNA EXPRESSION
AB The Wnt signaling pathway is a powerful and prominent oncogenic mechanism dysregulated in numerous cancer types. While evidence from transgenic mouse models and studies of human tumors clearly indicate that this pathway is of likely importance in human breast cancer, few clues as to the exact molecular nature of Wnt dysregulation have been uncovered in this tumor type. Here, we show that the Wnt inhibitory factor-1 (WIF1) gene, which encodes a secreted protein antagonistic to Wnt-dependent signaling, is targeted for epigenetic silencing in human breast cancer. We show that cultured human breast tumor cell lines display absent or low levels of WIF1 expression that are increased when cells are cultured with the DNA demethylating agent 5-aza-2'-deoxycytidine. Furthermore, the WIF1 promoter is aberrantly hypermethylated in these cells as judged by both methylation-specific PCR and bisulfite genomic sequencing. Using a panel of patient-matched breast tumors and normal breast tissue, we show that WIF1 expression is commonly diminished in breast tumors when compared with normal tissue and that this correlates with WIF1 promoter hypermethylation. Analysis of a panel of 24 primary breast tumors determined that the WIF1 promoter is aberrantly methylated in 67% of these tumors, indicating that epigenetic silencing of this gene is a frequent event in human breast cancer. Using an isogenic panel of cell lines proficient or deficient in the DNA methyltransferases (DNMTs) DNMT1 and/or DNMT3B, we show that hypermethylation of the WIF1 promoter is attributable to the cooperative activity of both DNMT1 and DNMT3B. Our findings establish the WIF1 gene as a target for epigenetic silencing in breast cancer and provide a mechanistic link between the dysregulation of Wnt signaling and breast tumorigenesis.
C1 Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Med, Shands Canc Ctr, Program Canc Genet Epigenet & Tumor Virol, Gainesville, FL 32610 USA.
   Chinese Univ Hong Kong, Dept Clin Oncol, Sir YK Pao Canc Ctr, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; Chinese University
   of Hong Kong
RP Robertson, KD (通讯作者)，Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.
EM keithr@ufl.edu
RI Tao, Qian/T-4743-2018
OI Tao, Qian/0000-0001-5383-4808; Ai, Lingbao/0009-0004-8907-8564;
   Robertson, Keith/0000-0002-7508-3328
FU NCI NIH HHS [R21CA102220, R01CA114229, K22CA084535] Funding Source:
   Medline
CR Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703
   Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q
   Gillett CE, 1998, J PATHOL, V184, P396
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   He B, 2005, CANCER RES, V65, P743
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200
   Holst CR, 2003, CANCER RES, V63, P1596
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2
   Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712
   LO PK, 2006, CANC BIOL THER, V5
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282
   Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586
   Nass SJ, 2000, CANCER RES, V60, P4346
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Ozaki S, 2005, ONCOL REP, V14, P1437
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4
   Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010
   Yashima K, 1998, CLIN CANCER RES, V4, P229
   ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695
NR 47
TC 152
Z9 177
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2006
VL 27
IS 7
BP 1341
EP 1348
DI 10.1093/carcin/bgi379
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 061XD
UT WOS:000238906200006
PM 16501252
DA 2025-01-12
ER

PT J
AU Piotrowski, A
   Benetkiewicz, M
   Menzel, U
   de Ståhl, TD
   Mantripragada, K
   Grigelionis, G
   Buckley, PG
   Jankowski, M
   Hoffman, J
   Bala, D
   Srutek, E
   Laskowski, R
   Zegarski, W
   Dumanski, JP
AF Piotrowski, Arkadiusz
   Benetkiewicz, Magdalena
   Menzel, Uwe
   de Stahl, Teresita Diaz
   Mantripragada, Kiran
   Grigelionis, Gintautas
   Buckley, Patrick G.
   Jankowski, Michal
   Hoffman, Jacek
   Bala, Dariusz
   Srutek, Ewa
   Laskowski, Ryszard
   Zegarski, Wojciech
   Dumanski, Jan P.
TI Microarray-based survey of CpG islands identifies concurrent hyper- and
   hypomethylation patterns in tissues derived from patients with breast
   cancer
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; DNA METHYLATION; ARRAY-CGH; CELLS; EXPRESSION;
   REGION; CHROMOSOME-22; NEUROBLASTOMA; ACTIVATION; RESOLUTION
AB Maintenance of CpG island methylation in the genome is crucial for cellular homeostasis and this balance is disrupted in cancer. Our rationale was to compare the methylation of CpG islands in tissues (tumor, healthy breast and blood) from patients with breast cancer. We studied 72 genes in 103 samples using microarray hybridization and bisulfite sequencing. We observed tumor specific hyper- or hypomethylation of five genes; COL9AI, MTIA, MTIJ, HOXA5 and FLJ4S983. A general drop of methylation in COL9AI was apparent in tumors, when compared with blood and healthy breast tissue. Furthermore, one tumor displayed a complete loss of methylation of all five genes, suggesting overall impairment of methylation. The downstream, evolutionary conserved island of HOXA5 showed hypomethylation in 18 tumors and complete methylation in others. This CpG island also displayed a semimethylated state in the majority of normal breast samples, when compared to complete methylation in blood. Distinct methylation patterns were further seen in MTIJ and MTIA, belonging to the metallothionein gene family. The CpG islands of these genes are spaced by 2 kb, which shows selective methylation of two structurally and functionally related genes. The promoters of FLJ45983 and MTIA were methylated above 25% in 18 primary and metastatic tumors. Concurrently, there was also > 10% methylation of healthy breast tissue in 11 and 5 samples, respectively. This suggests that the methylation process for the latter two genes takes place already in normal breast cells. Our results also point to a considerable heterogeneity of epigenetic disturbance in breast cancer. This article contains Supplementary Material available at http://www.interscience.wiley.com/ipages/1045-2257/suppmat. (c) 2006 Wiley-Liss, Inc.
C1 Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden.
   Med Acad Gdansk, Dept Biol & Pharmaceut Bot, PL-80416 Gdansk, Poland.
   Nicholas Copernicus Univ, Clin Surg Oncol, Coll Med, Ctr Oncol, PL-85796 Bydgoszcz, Poland.
   Univ Alabama Birmingham, Sch Med, Dept Genet, Birmingham, AL 35294 USA.
C3 Uppsala University; Fahrenheit Universities; Medical University Gdansk;
   Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum;
   University of Alabama System; University of Alabama Birmingham
RP Piotrowski, A (通讯作者)，Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden.
EM Arek.Piotrowski@genpat.uu.se
RI Zegarski, Wojciech/H-7199-2014; Grigelionis, Gintautas/AAA-1028-2021;
   Piotrowski, Arkadiusz/A-5484-2010
OI Piotrowski, Arkadiusz/0000-0002-0823-0607; Diaz de Stahl,
   Teresita/0000-0001-5933-6623; Dumanski, Jan Piotr/0000-0002-1489-1452;
   Jankowski, Michal/0000-0001-9982-842X
CR Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Buckley PG, 2005, HUM MUTAT, V26, P540, DOI 10.1002/humu.20255
   Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004
   Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   DEBUSTOS C, IN PRESS GENOMICS
   Dhami P, 2005, AM J HUM GENET, V76, P750, DOI 10.1086/429588
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 2001, CANCER RES, V61, P3225
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Grunau C, 2005, GENE CHROMOSOME CANC, V43, P11, DOI 10.1002/gcc.20155
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Gupta A, 2003, CANCER RES, V63, P664
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jin RX, 2004, PATHOL ONCOL RES, V10, P74, DOI 10.1007/BF02893459
   Larochelle C, 1999, DEV DYNAM, V214, P127, DOI 10.1002/(SICI)1097-0177(199902)214:2<127::AID-AJA3>3.0.CO;2-F
   Lim JH, 2005, INT J CANCER, V116, P200, DOI 10.1002/ijc.21007
   Mantripragada KK, 2006, J MED GENET, V43, P28, DOI 10.1136/jmg.2005.033795
   Mantripragada KK, 2004, INT J MOL MED, V13, P273
   Mantripragada KK, 2003, J MOL MED-JMM, V81, P443, DOI 10.1007/s00109-003-0458-3
   Moreau J, 2002, DNA SEQUENCE, V13, P203, DOI 10.1080/10425170290034507
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x
   Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4
   Uhlmann K, 2002, ELECTROPHORESIS, V23, P4072, DOI 10.1002/elps.200290023
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Wilkins JF, 2005, TRENDS GENET, V21, P356, DOI 10.1016/j.tig.2005.04.005
   Yan PS, 2002, METHODS, V27, P162, DOI 10.1016/S1046-2023(02)00070-1
   Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200
NR 44
TC 37
Z9 44
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD JUL
PY 2006
VL 45
IS 7
BP 656
EP 667
DI 10.1002/gcc.20331
PG 12
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 042SH
UT WOS:000237549200004
PM 16575877
DA 2025-01-12
ER

PT J
AU Gebhard, C
   Schwarzfischer, L
   Pham, TH
   Schilling, E
   Klug, M
   Andreesen, R
   Rehli, M
AF Gebhard, Claudia
   Schwarzfischer, Lucia
   Pham, Thu-Hang
   Schilling, Elmar
   Klug, Maja
   Andreesen, Reinhard
   Rehli, Michael
TI Genome-wide profiling of CpG methylation identifies novel targets of
   aberrant hypermethylation in myeloid leukemia
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; DNA-BINDING COLUMN; PROMOTER HYPERMETHYLATION;
   ISLAND METHYLATION; CANCER EPIGENETICS; BREAST-CANCER; EXPRESSION;
   PATTERNS; DISEASE; REGION
AB The methylation of CpG islands is associated with transcriptional repression and, in cancer, leads to the abnormal silencing of tumor suppressor genes. Because aberrant hyper-methylation may be used as a marker for disease, a sensitive method for the global detection of DNA methylation events is of particular importance. We describe a novel and robust technique, called methyl-CpG immunoprecipitation, which allows the unbiased genome-wide profiling of CpG methylation in limited DNA samples. The approach is based on a recombinant, antibody-like protein that efficiently binds native CpG-methylated DNA. In combination with CpG island microarrays, the technique was used to identify > 100 genes with aberrantly methylated CpG islands in three myeloid leukemia cell lines. Interestingly, within all hypermethylation targets, genes involved in transcriptional regulation were significantly overrepresented. More than half of the identified genes were absent in microarray expression studies in either leukemia or normal monocytes, indicating that hypermethylation in cancer may be largely independent of the transcriptional status of the affected gene. Most individually tested genes were also hypermethylated in primary blast cells from acute myeloid leukemia patients, suggesting that our approach can identify novel potential disease markers. The technique may prove useful for genome-wide comparative methylation analysis not only in malignancies.
C1 Univ Hosp, Dept Hematol & Oncol, D-93042 Regensburg, Germany.
C3 University of Regensburg
RP Rehli, M (通讯作者)，Univ Hosp, Dept Hematol & Oncol, D-93042 Regensburg, Germany.
EM michael.rehli@klinik.uni-r.de
RI PHAM, HANG/KCY-9776-2024; Rehli, Michael/E-9093-2011
CR Brock GJR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.24.e123
   Chim CS, 2003, ANN HEMATOL, V82, P738, DOI 10.1007/s00277-003-0744-8
   Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236
   Dahl C, 2003, BIOGERONTOLOGY, V4, P233, DOI 10.1023/A:1025103319328
   Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R
   Dodge JE, 2001, LEUKEMIA RES, V25, P917, DOI 10.1016/S0145-2126(01)00053-4
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Esteller M, 2002, SCIENCE, V297, P1807
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Issa JPJ, 1996, CANCER RES, V56, P973
   JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117
   Kalebic T, 2003, ANN NY ACAD SCI, V983, P278, DOI 10.1111/j.1749-6632.2003.tb05982.x
   Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987
   Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021
   Krause SW, 1996, J LEUKOCYTE BIOL, V60, P540, DOI 10.1002/jlb.60.4.540
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226
   Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888
   Schwab J, 2001, INT IMMUNOL, V13, P705, DOI 10.1093/intimm/13.5.705
   Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913
   Smith RJ, 2003, GENOME RES, V13, P558, DOI 10.1101/gr.781503
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Yan PS, 2001, CANCER RES, V61, P8375
   Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X
   Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387
NR 40
TC 149
Z9 220
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2006
VL 66
IS 12
BP 6118
EP 6128
DI 10.1158/0008-5472.CAN-06-0376
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 054LX
UT WOS:000238379500022
PM 16778185
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Sharma, D
   Saxena, NK
   Davidson, NE
   Vertino, PM
AF Sharma, D
   Saxena, NK
   Davidson, NE
   Vertino, PM
TI Restoration of tamoxifen sensitivity in estrogen receptor-negative
   breast cancer cells: Tamoxifen-bound reactivated ER recruits distinctive
   corepressor complexes
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITION; CPG BINDING-PROTEINS; TRANSCRIPTIONAL
   REPRESSION; DNA METHYLATION; LYSINE 9; IN-VIVO; APOPTOSIS; FAMILY; GENE;
   H3
AB Breast tumors expressing estrogen receptor-alpha (ER) respond well to therapeutic strategies using selective ER modulators, such as tamoxifen. However, similar to 30% of invasive breast cancers are hormone independent because they lack ER expression due to hypermethylation of ER promoter. Treatment of ER-negative breast cancer cells with demethylating agents [5-aza-2'-deoxycytidine (5-aza-dC)] and histone deacetylase (HDAC) inhibitors (tribliostatin A) leads to expression of ER mRNA and functional protein. Here, we examined Whether epigenetically reactivated ER is a target for tamoxifen therapy. Following treatment with trichostatin A and 5-aza-dC, the formerly unresponsive ER-negative MDA-MB-231 breast cancer cells became responsive to tamoxifen. Tamoxifen-mediated inhibition of cell growth in these cells is mediated at least in part by the tamoxifen-bound ER. Tamoxifen-bound reactivated ER induces transcriptional repression at estrogen-responsive genes by ordered recruitment of multiple distinct chromatin-modifying complexes. Using chromatin immunoprecipitation, we show recruitment of two different corepressor complexes to ER-responsive promoters in a mutually exclusive and sequential manner: the nuclear receptor corepressor-HDAC3 complex followed by nucleosome remodeling and histone deacetylation complex. The mechanistic insight provided by this study might help in designing therapeutic strategies directed toward epigenetic mechanisms in the prevention or treatment of breast cancer.
C1 Emory Univ, Winship Canc Inst, Clin C, Sch Med, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Emory University; Emory University; Emory University; Johns Hopkins
   University; Johns Hopkins Medicine
RP Sharma, D (通讯作者)，Emory Univ, Winship Canc Inst, Clin C, Sch Med, Room 4060,1701 Uppergate Dr, Atlanta, GA 30322 USA.
EM dsharma@emory.edu
FU NCI NIH HHS [CA077337, CA88843, R01 CA077337, P50 CA088843, P50
   CA088843-07, P50 CA088843-01, R01 CA077337-02] Funding Source: Medline
CR AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen HM, 1996, J CELL BIOCHEM, V61, P9, DOI 10.1002/(SICI)1097-4644(19960401)61:1<9::AID-JCB2>3.3.CO;2-2
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517
   DUBIK D, 1992, ONCOGENE, V7, P1587
   FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3
   GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538
   Glass CK, 2000, GENE DEV, V14, P121
   Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0
   Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200
   JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580
   JOHNSTON SRD, 1992, ANN ONCOL, V3, P503, DOI 10.1093/oxfordjournals.annonc.a058251
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299
   Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342
   Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502
   Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532
   OSBORNE CK, 1983, CANCER RES, V43, P3583
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999
   PRICE JE, 1990, CANCER RES, V50, P717
   Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446
   Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799
   SHEIKH MS, 1994, INVAS METAST, V14, P329
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1
   Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657
   Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304
   Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892
   UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3
   Yang XW, 2001, CANCER RES, V61, P7025
   Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120
   Zamir I, 1996, MOL CELL BIOL, V16, P5458
   Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200
   Zhang GJ, 1999, CLIN CANCER RES, V5, P2971
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
   Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0
NR 50
TC 175
Z9 207
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2006
VL 66
IS 12
BP 6370
EP 6378
DI 10.1158/0008-5472.CAN-06-0402
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 054LX
UT WOS:000238379500052
PM 16778215
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Veeck, J
   Niederacher, D
   An, H
   Klopocki, E
   Wiesmann, F
   Betz, B
   Galm, O
   Camara, O
   Dürst, M
   Kristiansen, G
   Huszka, C
   Knüchel, R
   Dahl, E
AF Veeck, J.
   Niederacher, D.
   An, H.
   Klopocki, E.
   Wiesmann, F.
   Betz, B.
   Galm, O.
   Camara, O.
   Duerst, M.
   Kristiansen, G.
   Huszka, C.
   Knuechel, R.
   Dahl, E.
TI Aberrant methylation of the Wnt antagonist <i>SFRP1</i> in breast cancer
   is associated with unfavourable prognosis
SO ONCOGENE
LA English
DT Article
DE breast cancer; tumour suppressor gene; Wnt pathway; SFRP1; methylation;
   epigenetics
ID TUMOR-SUPPRESSOR; BETA-CATENIN; PROMOTER HYPERMETHYLATION; EPIGENETIC
   INACTIVATION; COLORECTAL-CANCER; BLADDER-CANCER; OVARIAN-CANCER; COMMON
   EVENT; CYCLIN D1; GENE
AB The canonical Wnt signalling pathway plays a key role during embryogenesis and defects in this pathway have been implicated in the pathogenesis of various types of tumours, including breast cancer. The gene for secreted frizzled-related protein 1 (SFRP1) encodes a soluble Wnt antagonist and is located in a chromosomal region (8p22-p12) that is often deleted in breast cancer. In colon, lung, bladder and ovarian cancer SFRP1 expression is frequently inactivated by promoter methylation. We have previously shown that loss of SFRP1 protein expression is a common event in breast tumours that is associated with poor overall survival in patients with early breast cancer. To investigate the cause of SFRP1 loss in breast cancer, we performed mutation, methylation and expression analysis in human primary breast tumours and breast cell lines. No SFRP1 gene mutations were detected. However, promoter methylation of SFRP1 was frequently observed in both primary breast cancer (61%, n=130) and cell lines analysed by methylation-specific polymerase chain reaction (MSP). We found a tight correlation (P < 0.001) between methylation and loss of SFRP1 expression in primary breast cancer tissue. SFRP1 expression was restored after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Most interestingly, SFRP1 promoter methylation was an independent factor for adverse patient survival in Kaplan-Meier analysis. Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis.
C1 Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany.
   Univ Dusseldorf, Dept Obstet & Gynecol, D-4000 Dusseldorf, Germany.
   Free Univ Berlin, Inst Med Genet, Berlin, Germany.
   Univ Hosp Aachen, Rhein Westfal TH Aachen, Med Clin 4, D-52074 Aachen, Germany.
   Univ Jena, Dept Gynecol, D-6900 Jena, Germany.
   Free Univ Berlin, Inst Pathol, Berlin, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine
   University Dusseldorf; Free University of Berlin; RWTH Aachen
   University; RWTH Aachen University Hospital; Friedrich Schiller
   University of Jena; Free University of Berlin
RP Dahl, E (通讯作者)，Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Klopocki, Eva/B-6823-2017; Veeck, Jurgen/B-9256-2008
OI Klopocki, Eva/0000-0003-1438-2081; An, Han-Xiang/0000-0002-3453-9149;
   Veeck, Jurgen/0000-0002-2952-6159
CR Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263
   Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 2002, J NATL CANCER I, V94, P26
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y
   Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273
   Polakis P, 2000, GENE DEV, V14, P1837
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881
   Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447
NR 40
TC 213
Z9 249
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN 8
PY 2006
VL 25
IS 24
BP 3479
EP 3488
DI 10.1038/sj.onc.1209386
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 055KB
UT WOS:000238448100013
PM 16449975
DA 2025-01-12
ER

PT J
AU Abbosh, PH
   Montgomery, JS
   Starkey, JA
   Novotny, M
   Zuhowski, EG
   Egorin, MJ
   Moseman, AP
   Golas, A
   Brannon, KM
   Balch, C
   Huang, THM
   Nephew, KP
AF Abbosh, Phillip H.
   Montgomery, John S.
   Starkey, Jason A.
   Novotny, Milos
   Zuhowski, Eleanor G.
   Egorin, Merrill J.
   Moseman, Annie P.
   Golas, Adam
   Brannon, Kate M.
   Balch, Curtis
   Huang, Tim H. M.
   Nephew, Kenneth P.
TI Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor
   suppressor genes and reverses the drug-resistant phenotype in cancer
   cells
SO CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION; OVARIAN-CANCER; CISPLATIN RESISTANCE; PROSTATE-CANCER;
   BREAST-CANCER; METHYLTRANSFERASE; PROTEIN; COMPLEX; EZH2; DEACETYLASE
AB Histone modifications and DNA methylation are epigenetic phenomena that play a critical role in many neoplastic processes, including silencing of tumor suppressor genes. One such histone modification, particularly at H3 and H4, is methylation at specific lysine (K) residues. Whereas histone methylation of H3-K9 has been linked to DNA methylation and aberrant gene silencing in cancer cells, no such studies of H3-K27 have been reported. Here, we generated a stable cell line overexpressing a dominant-negative point mutant, H3-K27R, to examine the role of that specific lysine in ovarian cancer. Expression of this construct resulted in loss of methylation at H3-K27, global reduction of DNA methylation, and increased expression of tumor suppressor genes. One of the affected genes, RASSF1, was shown to be a direct target of H3-K27 methylation-mediated silencing. By increasing DNA-platinum adduct formation, indicating increased access of the drug to target DNA sequences, removal of H3-K27 methylation resensitized drug-resistant ovarian cancer cells to the chemotherapeutic agent cisplatin. This increased platinum-DNA access was likely due to relaxation of condensed chromatin. Our results show that overexpression of mutant H3-K27 in mammalian cells represents a novel tool for studying epigenetic mechanisms and the Histone Code Hypothesis in human cancer. Such findings show the significance of H3-K27 methylation as a promising target for epigenetic-based cancer therapies.
C1 Indiana Univ, Sch Med, Bloomington, IN 47405 USA.
   Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
   Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Dept Med, Pittsburgh, PA USA.
   Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; James Cancer Hospital & Solove Research Institute;
   University System of Ohio; Ohio State University
RP Nephew, KP (通讯作者)，Indiana Univ, Sch Med, 302 Jordan Hall,1001 E 3rd St, Bloomington, IN 47405 USA.
EM knephew@indiana.edu
RI Novotný, Michal/M-8654-2019
FU NCI NIH HHS [CA8529, U54CA11300] Funding Source: Medline
CR Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Balch C, 2005, MOL CANCER THER, V4, P1505, DOI 10.1158/1535-7163.MCT-05-0216
   BEHRENS BC, 1987, CANCER RES, V47, P414
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200
   Fishel ML, 2003, MOL CANCER THER, V2, P633
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   FRIEDBERG EC, 1995, DNA REPAIR MUTAGENEI
   Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204
   Giannattasio M, 2005, J BIOL CHEM, V280, P9879, DOI 10.1074/jbc.M414453200
   Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kim MS, 2003, CANCER RES, V63, P7291
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200
   LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0
   Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125
   Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478
   Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4
   PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Plumb JA, 2000, CANCER RES, V60, P6039
   Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1
   Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Stach D, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng002
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200
   Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0
   Whiteside MA, 2004, ONCOGENE, V23, P744, DOI 10.1038/sj.onc.1207164
   Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214
NR 50
TC 87
Z9 102
U1 1
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2006
VL 66
IS 11
BP 5582
EP 5591
DI 10.1158/0008-5472.CAN-05-3575
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 049GC
UT WOS:000238003100010
PM 16740693
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Lai, JP
   Yu, CR
   Moser, CD
   Aderca, I
   Han, T
   Garvey, TD
   Murphy, LM
   Garrity-Par, MM
   Shridhar, V
   Adjei, AA
   Roberts, LR
AF Lai, Jin-Ping
   Yu, Chunrong
   Moser, Catherine D.
   Aderca, Ileana
   Han, Tao
   Garvey, Thomas D.
   Murphy, Linda M.
   Garrity-Par, Megan M.
   Shridhar, Viji
   Adjei, Alex A.
   Roberts, Lewis R.
TI SULF1 inhibits tumor growth and potentiates the effects of histone
   deacetylase inhibitors in hepatocellular carcinoma
SO GASTROENTEROLOGY
LA English
DT Article
ID HUMAN LEUKEMIA-CELLS; BREAST-CANCER CELLS; HEPATOMA-CELLS; MEDIATED
   APOPTOSIS; INDUCE APOPTOSIS; HDAC INHIBITORS; EXPRESSION; BUTYRATE;
   ACID; ACTIVATION
AB Background & Aims: Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide. Improved treatments for advanced HCC are urgently needed. The recently identified human sulfatase 1 enzyme (SULF1) desulfates cell surface heparan sulfate glycosaminoglycans and down-regulates cell growth signaling in HCC cells in vitro. While investigating the epigenetic regulation of SULF1, we discovered that histone H4 acetylation is up-regulated by SULF1 in HCC cells. Histone deacetylase (HDAC) inhibitors reprogram cellular gene expression through the acetylation of nucleosomal histones and promote cell growth arrest and apoptosis. Hence, they are a promising modality for cancer treatment. Methods: To explore the interaction between SULF1 expression and HDAC inhibitor action, we examined the effects of SULF1 expression on HCC cells and xenografts treated with HDAC inhibitors. Results: (1) Forced expression of SULF1 significantly delayed the growth of Huh7 and Hep313 xenografts in nude mice in vivo. (2) SULF1 increased histone H4 acetylation by modulation of cellular HDAC and histone acetyltransferase activities. (3) SULF1 enhanced the induction of apoptosis by the HDAC inhibitors apicidin and scriptaid. (4) SULF1 enhanced the inhibition of tumor growth, migration, and angiogenesis by HDAC inhibitors. We also demonstrate that knockdown of SULF1 with shRNA constructs up-regulates phosphorylation of AKT and Erk and attenuates apicidin-induced apoptosis. The interaction between SULF1 and apicidin was confirmed in vivo in Huh7 and Hep313 xenografts. Conclusions: These results show that SULF1 promotes histone H4 acetylation, potentiates the effects of HDAC inhibitors, and inhibits HCC tumorigenesis.
C1 Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Ctr Basic Res Digest Dis,Div Gastroenterol & Hepa, Rochester, MN 55905 USA.
   Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Oncol, Rochester, MN USA.
   Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Div Expt Pathol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Roberts, LR (通讯作者)，Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Ctr Basic Res Digest Dis,Div Gastroenterol & Hepa, Rochester, MN 55905 USA.
EM roberts.lewis@mayo.edu
RI Lai, Jinping/AAZ-6861-2021; Seal, Sudipta/A-7698-2012
OI Roberts, Lewis/0000-0001-7885-8574
FU NCI NIH HHS [CA100882, CA82862] Funding Source: Medline
CR Abrmofff MD., 2005, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020
   Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1
   Clark AS, 2002, MOL CANCER THER, V1, P707
   Coradini D, 2005, ACTA PHARMACOL SIN, V26, P1025, DOI 10.1111/j.1745-7254.2005.00195.x
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005
   HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329
   Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   Kim JS, 2004, BRIT J HAEMATOL, V124, P166, DOI 10.1046/j.1365-2141.2003.04759.x
   Kim JS, 2001, BIOCHEM BIOPH RES CO, V281, P866, DOI 10.1006/bbrc.2001.4434
   Kim SH, 2004, BIOCHEM BIOPH RES CO, V315, P964, DOI 10.1016/j.bbrc.2004.01.149
   Kruger JS, 2003, MOL CANCER RES, V1, P801
   Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258
   Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043
   Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200
   Li JS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-14
   Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631
   Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897
   Mandal M, 1996, CELL GROWTH DIFFER, V7, P311
   Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   McManus KJ, 2003, MOL CELL BIOL, V23, P7611, DOI 10.1128/MCB.23.21.7611-7627.2003
   Mine N, 2005, DEVELOPMENT, V132, P4317, DOI 10.1242/dev.02030
   Monneret C, 2005, EUR J MED CHEM, V40, P1, DOI 10.1016/j.ejmech.2004.10.001
   Ocker M, 2005, J CANCER RES CLIN, V131, P385, DOI 10.1007/s00432-004-0664-6
   Ogawa K, 2004, J HEPATOL, V40, P278, DOI 10.1016/j.jhep.2003.09.021
   Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200
   Romanski A, 2004, HAEMATOLOGICA, V89, P419
   Rosato RR, 2003, MOL CANCER THER, V2, P1273
   Rosato RR, 2003, CANCER RES, V63, P3637
   Schuchmann M, 2006, ONCOL REP, V15, P227
   Shridhar V, 2002, CANCER RES, V62, P262
   Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 38
TC 60
Z9 65
U1 1
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2006
VL 130
IS 7
BP 2130
EP 2144
DI 10.1053/j.gastro.2006.02.056
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 052CD
UT WOS:000238207500019
PM 16762634
OA Bronze
DA 2025-01-12
ER

PT J
AU Savarese, TM
   Low, HP
   Baik, I
   Strohsnitter, WC
   Hsieh, CC
AF Savarese, Todd M.
   Low, Hoi Pang
   Baik, Inkyung
   Strohsnitter, William C.
   Hsieh, Chung-Cheng
TI Normal breast stem cells, malignant breast stem cells, and the perinatal
   origin of breast cancer
SO STEM CELL REVIEWS
LA English
DT Article
DE breast stem cells; malignant breast stem cells; estrogen; IGF-1;
   birthweight; breast cancer risk; perinatal risk factors for breast
   cancer
AB Both experimental and epidemiological evidence support the concept that the in utero environment can influence an individual's risk of breast cancer in adult life. Recently identified breast stem cells may be the key to understanding the mechanism underlying this phenomenon. It has been theorized that breast cancers arise from breast stem cells. Our emerging view of the characteristics of normal breast stem cells and their link to malignant breast stem cells is reviewed here. It has also been postulated that factors that expand the normal breast stem cell pool in utero would increase the probability that one such cell might undergo an oncogenic mutation or epigenetic change. We dicuss how a number of proposed perinatal determinants of adult breast cancer risk, including (1) in utero estrogen and IGF-1 levels, (2) birthweight, (3) breast density, and (4) early-life mutagen exposure, can be tied together by this "breast stem cell burden" hypothesis.
C1 [Savarese, Todd M.; Baik, Inkyung; Hsieh, Chung-Cheng] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA.
   [Low, Hoi Pang] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA.
   [Strohsnitter, William C.] Tufts Univ New England Med Ctr, Dept Obstet & Gynecol, Boston, MA 02111 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; Tufts Medical Center
RP Hsieh, CC (通讯作者)，Univ Massachusetts, Sch Med, Dept Canc Biol, Div Biostat & Epidemiol, 364 Plantat St,LRB 427, Worcester, MA 01605 USA.
EM chung.hsieh@umassmed.edu
RI Baik, Inkyung/B-6993-2013
OI Baik, Inkyung/0000-0002-9524-4344
FU NCI NIH HHS [CA 90902] Funding Source: Medline
CR Adami HO, 1995, MUTAT RES-FUND MOL M, V333, P29, DOI 10.1016/0027-5107(95)00128-X
   Adami HO, 1998, SEMIN CANCER BIOL, V8, P255, DOI 10.1006/scbi.1998.0077
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Altinkaynak K, 2003, CLIN BIOCHEM, V36, P221, DOI 10.1016/S0009-9120(03)00008-0
   ANBAZHAGAN R, 1991, AM J ANAT, V192, P407, DOI 10.1002/aja.1001920408
   Baik I, 2005, CANCER RES, V65, P358
   Baik I, 2004, CANCER CAUSE CONTROL, V15, P517, DOI 10.1023/B:CACO.0000036450.06092.ce
   Ballen KK, 2001, BONE MARROW TRANSPL, V27, P7, DOI 10.1038/sj.bmt.1702729
   Bartow SA, 1998, J MAMMARY GLAND BIOL, V3, P37, DOI 10.1023/A:1026641401184
   BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501
   Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312
   Byrne C, 1997, J NATL CANCER I, V89, P531, DOI 10.1093/jnci/89.8.531
   BYRNE C, 1995, J NATL CANCER I, V87, P1622, DOI 10.1093/jnci/87.21.1622
   Cerhan JR, 2005, CANCER EPIDEM BIOMAR, V14, P1502, DOI 10.1158/1055-9965.EPI-04-0762
   Chepko G, 2003, TISSUE CELL, V35, P83, DOI 10.1016/S0040-8166(02)00107-6
   Chepko G, 1997, TISSUE CELL, V29, P239, DOI 10.1016/S0040-8166(97)80024-9
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Cohn MA, 1997, FEBS LETT, V403, P181, DOI 10.1016/S0014-5793(97)00050-1
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   DANIEL C, 1971, EXP GERONTOL, V260, P146
   DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53
   DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71
   EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J
   Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797
   HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43
   HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061
   Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1
   HEPPNER GH, 1984, CANCER RES, V44, P2259
   HERCZ P, 1988, EUR J OBSTET GYN R B, V27, P7, DOI 10.1016/S0028-2243(88)80004-2
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901
   Howard BA, 2000, J MAMMARY GLAND BIOL, V5, P119, DOI 10.1023/A:1026487120779
   HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1321, DOI 10.1093/oxfordjournals.aje.a116444
   HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1
   Huss WJ, 2005, CANCER RES, V65, P6640, DOI 10.1158/0008-5472.CAN-04-2548
   KATZ BZ, 1994, INT J CANCER, V59, P684, DOI 10.1002/ijc.2910590517
   Keeling JW, 2000, J PATHOL, V191, P449
   Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032
   Kordon EC, 1998, DEVELOPMENT, V125, P1921
   LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   MILLER AB, 1980, NEW ENGL J MED, V303, P1246, DOI 10.1056/NEJM198011203032130
   Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242
   Palmer JR, 2002, CANCER CAUSE CONTROL, V13, P753, DOI 10.1023/A:1020254711222
   Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011
   Pollak M, 2001, BRIT J CANCER, V85, P428, DOI 10.1054/bjoc.2001.1895
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Potischman N, 1999, CANCER CAUSE CONTROL, V10, P561, DOI 10.1023/A:1008955110868
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558
   Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075
   RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385
   RUDLAND PS, 1988, J CELL SCI, P95
   RUDLAND PS, 1987, CANCER METAST REV, V6, P55, DOI 10.1007/BF00047609
   RUSSO J, 1987, LAB INVEST, V57, P112
   Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007
   SELL S, 1994, LAB INVEST, V70, P6
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Skalkidou A, 2003, PAEDIATR PERINAT EP, V17, P281, DOI 10.1046/j.1365-3016.2003.00494.x
   Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212
   Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O
   SOUTHAM CM, 1961, CANCER-AM CANCER SOC, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O
   SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810
   Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1046/j.1432-0436.1998.6340201.x
   Strohsnitter WC, 2005, EPIDEMIOLOGY, V16, P342, DOI 10.1097/01.ede.0000158741.07645.9b
   TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591
   Tomatis L, 1989, IARC Sci Publ, P1
   Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Tsai YC, 1996, CANCER RES, V56, P402
   Vatten LJ, 2002, BRIT J CANCER, V87, P971, DOI 10.1038/sj.bjc.6600581
   Vatten LJ, 2002, PEDIATRICS, V109, P1131, DOI 10.1542/peds.109.6.1131
   Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625
   WODINSKY ISIDORE, 1967, CANCER CHEMOTHER REP, V51, P415
   Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102
   Yang SW, 2000, J PEDIATR ENDOCR MET, V13, P289
   YEN SSC, 1999, REPROD ENDOCRINOLOGY, P751
   Zeps N, 1996, CELL TISSUE RES, V286, P525, DOI 10.1007/s004410050722
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 84
TC 27
Z9 29
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1550-8943
EI 1558-6804
J9 STEM CELL REV
JI Stem Cell Rev.
PD JUN
PY 2006
VL 2
IS 2
BP 103
EP 109
PG 7
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA V56WX
UT WOS:000203845100005
PM 17237548
DA 2025-01-12
ER

EF